Microinjection	16364460
of	16364460
ritanserin	16364460
into	16364460
the	16364460
CA1	16364460
region	16364460
of	16364460
hippocampus	16364460
improves	16364460
scopolamine	16364460
-	16364460
induced	16364460
amnesia	16364460
in	16364460
adult	16364460
male	16364460
rats	16364460
.	16364460

The	16364460
effect	16364460
of	16364460
ritanserin	16364460
(	16364460
5	16364460
-	16364460
HT2	16364460
antagonist	16364460
)	16364460
on	16364460
scopolamine	16364460
(	16364460
muscarinic	16364460
cholinergic	16364460
antagonist	16364460
)	16364460
-	16364460
induced	16364460
amnesia	16364460
in	16364460
Morris	16364460
water	16364460
maze	16364460
(	16364460
MWM	16364460
)	16364460
was	16364460
investigated	16364460
.	16364460

Rats	16364460
were	16364460
divided	16364460
into	16364460
eight	16364460
groups	16364460
and	16364460
bilaterally	16364460
cannulated	16364460
into	16364460
CA1	16364460
region	16364460
of	16364460
the	16364460
hippocampus	16364460
.	16364460

One	16364460
week	16364460
later	16364460
,	16364460
they	16364460
received	16364460
repeatedly	16364460
vehicles	16364460
(	16364460
saline	16364460
,	16364460
DMSO	16364460
,	16364460
saline	16364460
+	16364460
DMSO	16364460
)	16364460
,	16364460
scopolamine	16364460
(	16364460
2	16364460
microg	16364460
/	16364460
0	16364460
.	16364460
5	16364460
microl	16364460
saline	16364460
/	16364460
side	16364460
;	16364460
30	16364460
min	16364460
before	16364460
training	16364460
)	16364460
,	16364460
ritanserin	16364460
(	16364460
2	16364460
,	16364460
4	16364460
and	16364460
8	16364460
microg	16364460
/	16364460
0	16364460
.	16364460
5	16364460
microl	16364460
DMSO	16364460
/	16364460
side	16364460
;	16364460
20	16364460
min	16364460
before	16364460
training	16364460
)	16364460
and	16364460
scopolamine	16364460
(	16364460
2	16364460
microg	16364460
/	16364460
0	16364460
.	16364460
5	16364460
microl	16364460
;	16364460
30	16364460
min	16364460
before	16364460
ritanserin	16364460
injection	16364460
)	16364460
+	16364460
ritanserin	16364460
(	16364460
4	16364460
microg	16364460
/	16364460
0	16364460
.	16364460
5	16364460
microl	16364460
DMSO	16364460
)	16364460
through	16364460
cannulae	16364460
each	16364460
day	16364460
.	16364460

Animals	16364460
were	16364460
tested	16364460
for	16364460
four	16364460
consecutive	16364460
days	16364460
(	16364460
4	16364460
trial	16364460
/	16364460
day	16364460
)	16364460
in	16364460
MWM	16364460
during	16364460
which	16364460
the	16364460
position	16364460
of	16364460
hidden	16364460
platform	16364460
was	16364460
unchanged	16364460
.	16364460

In	16364460
the	16364460
fifth	16364460
day	16364460
,	16364460
the	16364460
platform	16364460
was	16364460
elevated	16364460
above	16364460
the	16364460
water	16364460
surface	16364460
in	16364460
another	16364460
position	16364460
to	16364460
evaluate	16364460
the	16364460
function	16364460
of	16364460
motor	16364460
,	16364460
motivational	16364460
and	16364460
visual	16364460
systems	16364460
.	16364460

The	16364460
results	16364460
showed	16364460
a	16364460
significant	16364460
increase	16364460
in	16364460
escape	16364460
latencies	16364460
and	16364460
traveled	16364460
distances	16364460
to	16364460
find	16364460
platform	16364460
in	16364460
scopolamine	16364460
-	16364460
treated	16364460
group	16364460
as	16364460
compared	16364460
to	16364460
saline	16364460
group	16364460
.	16364460

Ritanserin	16364460
-	16364460
treated	16364460
rats	16364460
(	16364460
4	16364460
microg	16364460
/	16364460
0	16364460
.	16364460
5	16364460
microl	16364460
/	16364460
side	16364460
)	16364460
showed	16364460
a	16364460
significant	16364460
decrease	16364460
in	16364460
the	16364460
mentioned	16364460
parameters	16364460
as	16364460
compared	16364460
to	16364460
DMSO	16364460
-	16364460
treated	16364460
group	16364460
.	16364460

However	16364460
,	16364460
scopolamine	16364460
and	16364460
ritanserin	16364460
co	16364460
-	16364460
administration	16364460
resulted	16364460
in	16364460
a	16364460
significant	16364460
decrease	16364460
in	16364460
escape	16364460
latencies	16364460
and	16364460
traveled	16364460
distances	16364460
as	16364460
compared	16364460
to	16364460
the	16364460
scopolamine	16364460
-	16364460
treated	16364460
rats	16364460
.	16364460

Our	16364460
findings	16364460
show	16364460
that	16364460
microinjection	16364460
of	16364460
ritanserin	16364460
into	16364460
the	16364460
CA1	16364460
region	16364460
of	16364460
the	16364460
hippocampus	16364460
improves	16364460
the	16364460
scopolamine	16364460
-	16364460
induced	16364460
amnesia	16364460
.	16364460
P2RX7	19160446
:	19160446
A	19160446
bipolar	19160446
and	19160446
unipolar	19160446
disorder	19160446
candidate	19160446
susceptibility	19160446
gene?	19160446
The	19160446
chromosomal	19160446
region	19160446
12q24	19160446
has	19160446
been	19160446
previously	19160446
implicated	19160446
by	19160446
linkage	19160446
studies	19160446
of	19160446
both	19160446
bipolar	19160446
disorder	19160446
and	19160446
unipolar	19160446
mood	19160446
disorder	19160446
and	19160446
we	19160446
have	19160446
reported	19160446
two	19160446
pedigrees	19160446
segregating	19160446
both	19160446
bipolar	19160446
disorder	19160446
and	19160446
Darier	19160446
'	19160446
s	19160446
disease	19160446
that	19160446
show	19160446
linkage	19160446
across	19160446
this	19160446
region	19160446
.	19160446

The	19160446
gene	19160446
P2RX7	19160446
is	19160446
located	19160446
in	19160446
this	19160446
chromosomal	19160446
region	19160446
and	19160446
has	19160446
been	19160446
recently	19160446
reported	19160446
as	19160446
a	19160446
susceptibility	19160446
gene	19160446
for	19160446
bipolar	19160446
disorder	19160446
and	19160446
unipolar	19160446
depression	19160446
.	19160446

The	19160446
non	19160446
-	19160446
synonymous	19160446
SNP	19160446
rs2230912	19160446
(	19160446
resulting	19160446
in	19160446
amino	19160446
-	19160446
acid	19160446
polymorphism	19160446
Q460R	19160446
)	19160446
showed	19160446
the	19160446
strongest	19160446
association	19160446
and	19160446
has	19160446
been	19160446
postulated	19160446
to	19160446
be	19160446
pathogenically	19160446
relevant	19160446
.	19160446

We	19160446
have	19160446
investigated	19160446
this	19160446
gene	19160446
in	19160446
a	19160446
large	19160446
UK	19160446
case	19160446
-	19160446
control	19160446
sample	19160446
(	19160446
bipolar	19160446
I	19160446
disorder	19160446
N	19160446
=	19160446
687	19160446
,	19160446
unipolar	19160446
recurrent	19160446
major	19160446
depression	19160446
N	19160446
=	19160446
1	19160446
,	19160446
036	19160446
,	19160446
controls	19160446
N	19160446
=	19160446
1	19160446
,	19160446
204	19160446
)	19160446
.	19160446

Neither	19160446
rs2230912	19160446
nor	19160446
any	19160446
of	19160446
8	19160446
other	19160446
SNPs	19160446
genotyped	19160446
across	19160446
P2RX7	19160446
was	19160446
found	19160446
to	19160446
be	19160446
associated	19160446
with	19160446
mood	19160446
disorder	19160446
in	19160446
general	19160446
,	19160446
nor	19160446
specifically	19160446
with	19160446
bipolar	19160446
or	19160446
unipolar	19160446
disorder	19160446
.	19160446

Further	19160446
,	19160446
sequencing	19160446
of	19160446
our	19160446
two	19160446
chromosome	19160446
12	19160446
-	19160446
linked	19160446
bipolar	19160446
-	19160446
Darier	19160446
families	19160446
showed	19160446
no	19160446
evidence	19160446
of	19160446
rare	19160446
variants	19160446
at	19160446
P2RX7	19160446
that	19160446
could	19160446
explain	19160446
the	19160446
linkage	19160446
.	19160446

Our	19160446
data	19160446
do	19160446
not	19160446
provide	19160446
support	19160446
for	19160446
rs2230912	19160446
or	19160446
the	19160446
other	19160446
polymorphisms	19160446
studied	19160446
within	19160446
the	19160446
P2RX7	19160446
locus	19160446
,	19160446
being	19160446
involved	19160446
in	19160446
susceptibility	19160446
to	19160446
mood	19160446
disorders	19160446
.	19160446
Pilocarpine	16596970
seizures	16596970
cause	16596970
age	16596970
-	16596970
dependent	16596970
impairment	16596970
in	16596970
auditory	16596970
location	16596970
discrimination	16596970
.	16596970

Children	16596970
who	16596970
have	16596970
status	16596970
epilepticus	16596970
have	16596970
continuous	16596970
or	16596970
rapidly	16596970
repeating	16596970
seizures	16596970
that	16596970
may	16596970
be	16596970
life	16596970
-	16596970
threatening	16596970
and	16596970
may	16596970
cause	16596970
life	16596970
-	16596970
long	16596970
changes	16596970
in	16596970
brain	16596970
and	16596970
behavior	16596970
.	16596970

The	16596970
extent	16596970
to	16596970
which	16596970
status	16596970
epilepticus	16596970
causes	16596970
deficits	16596970
in	16596970
auditory	16596970
discrimination	16596970
is	16596970
unknown	16596970
.	16596970

A	16596970
naturalistic	16596970
auditory	16596970
location	16596970
discrimination	16596970
method	16596970
was	16596970
used	16596970
to	16596970
evaluate	16596970
this	16596970
question	16596970
using	16596970
an	16596970
animal	16596970
model	16596970
of	16596970
status	16596970
epilepticus	16596970
.	16596970

Male	16596970
Sprague	16596970
-	16596970
Dawley	16596970
rats	16596970
were	16596970
injected	16596970
with	16596970
saline	16596970
on	16596970
postnatal	16596970
day	16596970
(	16596970
P	16596970
)	16596970
20	16596970
,	16596970
or	16596970
a	16596970
convulsant	16596970
dose	16596970
of	16596970
pilocarpine	16596970
on	16596970
P20	16596970
or	16596970
P45	16596970
.	16596970

Pilocarpine	16596970
on	16596970
either	16596970
day	16596970
induced	16596970
status	16596970
epilepticus	16596970
;	16596970
status	16596970
epilepticus	16596970
at	16596970
P45	16596970
resulted	16596970
in	16596970
CA3	16596970
cell	16596970
loss	16596970
and	16596970
spontaneous	16596970
seizures	16596970
,	16596970
whereas	16596970
P20	16596970
rats	16596970
had	16596970
no	16596970
cell	16596970
loss	16596970
or	16596970
spontaneous	16596970
seizures	16596970
.	16596970

Mature	16596970
rats	16596970
were	16596970
trained	16596970
with	16596970
sound	16596970
-	16596970
source	16596970
location	16596970
and	16596970
sound	16596970
-	16596970
silence	16596970
discriminations	16596970
.	16596970

Control	16596970
(	16596970
saline	16596970
P20	16596970
)	16596970
rats	16596970
acquired	16596970
both	16596970
discriminations	16596970
immediately	16596970
.	16596970

In	16596970
status	16596970
epilepticus	16596970
(	16596970
P20	16596970
)	16596970
rats	16596970
,	16596970
acquisition	16596970
of	16596970
the	16596970
sound	16596970
-	16596970
source	16596970
location	16596970
discrimination	16596970
was	16596970
moderately	16596970
impaired	16596970
.	16596970

Status	16596970
epilepticus	16596970
(	16596970
P45	16596970
)	16596970
rats	16596970
failed	16596970
to	16596970
acquire	16596970
either	16596970
sound	16596970
-	16596970
source	16596970
location	16596970
or	16596970
sound	16596970
-	16596970
silence	16596970
discriminations	16596970
.	16596970

Status	16596970
epilepticus	16596970
in	16596970
rat	16596970
causes	16596970
an	16596970
age	16596970
-	16596970
dependent	16596970
,	16596970
long	16596970
-	16596970
term	16596970
impairment	16596970
in	16596970
auditory	16596970
discrimination	16596970
.	16596970

This	16596970
impairment	16596970
may	16596970
explain	16596970
one	16596970
cause	16596970
of	16596970
impaired	16596970
auditory	16596970
location	16596970
discrimination	16596970
in	16596970
humans	16596970
.	16596970
The	19394258
first	19394258
founder	19394258
DGUOK	19394258
mutation	19394258
associated	19394258
with	19394258
hepatocerebral	19394258
mitochondrial	19394258
DNA	19394258
depletion	19394258
syndrome	19394258
.	19394258

Deoxyguanosine	19394258
kinase	19394258
(	19394258
dGK	19394258
)	19394258
deficiency	19394258
is	19394258
a	19394258
frequent	19394258
cause	19394258
of	19394258
mitochondrial	19394258
DNA	19394258
depletion	19394258
associated	19394258
with	19394258
a	19394258
hepatocerebral	19394258
phenotype	19394258
.	19394258

In	19394258
this	19394258
study	19394258
,	19394258
we	19394258
describe	19394258
a	19394258
new	19394258
splice	19394258
site	19394258
mutation	19394258
in	19394258
the	19394258
DGUOK	19394258
gene	19394258
and	19394258
the	19394258
clinical	19394258
,	19394258
radiologic	19394258
,	19394258
and	19394258
genetic	19394258
features	19394258
of	19394258
these	19394258
DGUOK	19394258
patients	19394258
.	19394258

This	19394258
new	19394258
DGUOK	19394258
homozygous	19394258
mutation	19394258
(	19394258
c	19394258
.	19394258
444	19394258
-	19394258
62C	19394258
>	19394258
A	19394258
)	19394258
was	19394258
identified	19394258
in	19394258
three	19394258
patients	19394258
from	19394258
two	19394258
North	19394258
-	19394258
African	19394258
consanguineous	19394258
families	19394258
with	19394258
combined	19394258
respiratory	19394258
chain	19394258
deficiencies	19394258
and	19394258
mitochondrial	19394258
DNA	19394258
depletion	19394258
in	19394258
the	19394258
liver	19394258
.	19394258

Brain	19394258
MRIs	19394258
are	19394258
normal	19394258
in	19394258
DGUOK	19394258
patients	19394258
in	19394258
the	19394258
literature	19394258
.	19394258

Interestingly	19394258
,	19394258
we	19394258
found	19394258
subtentorial	19394258
abnormal	19394258
myelination	19394258
and	19394258
moderate	19394258
hyperintensity	19394258
in	19394258
the	19394258
bilateral	19394258
pallidi	19394258
in	19394258
our	19394258
patients	19394258
.	19394258

This	19394258
new	19394258
mutation	19394258
creates	19394258
a	19394258
cryptic	19394258
splice	19394258
site	19394258
in	19394258
intron	19394258
3	19394258
(	19394258
in	19394258
position	19394258
-	19394258
62	19394258
)	19394258
and	19394258
is	19394258
predicted	19394258
to	19394258
result	19394258
in	19394258
a	19394258
larger	19394258
protein	19394258
with	19394258
an	19394258
in	19394258
-	19394258
frame	19394258
insertion	19394258
of	19394258
20	19394258
amino	19394258
acids	19394258
.	19394258

In	19394258
silico	19394258
analysis	19394258
of	19394258
the	19394258
putative	19394258
impact	19394258
of	19394258
the	19394258
insertion	19394258
shows	19394258
serious	19394258
clashes	19394258
in	19394258
protein	19394258
conformation	19394258
:	19394258
this	19394258
insertion	19394258
disrupts	19394258
the	19394258
alpha5	19394258
helix	19394258
of	19394258
the	19394258
dGK	19394258
kinase	19394258
domain	19394258
,	19394258
rendering	19394258
the	19394258
protein	19394258
unable	19394258
to	19394258
bind	19394258
purine	19394258
deoxyribonucleosides	19394258
.	19394258

In	19394258
addition	19394258
,	19394258
a	19394258
common	19394258
haplotype	19394258
that	19394258
segregated	19394258
with	19394258
the	19394258
disease	19394258
in	19394258
both	19394258
families	19394258
was	19394258
detected	19394258
by	19394258
haplotype	19394258
reconstruction	19394258
with	19394258
10	19394258
markers	19394258
(	19394258
microsatellites	19394258
and	19394258
SNPs	19394258
)	19394258
,	19394258
which	19394258
span	19394258
4	19394258
.	19394258
6	19394258
Mb	19394258
of	19394258
DNA	19394258
covering	19394258
the	19394258
DGUOK	19394258
locus	19394258
.	19394258

In	19394258
conclusion	19394258
,	19394258
we	19394258
report	19394258
a	19394258
new	19394258
DGUOK	19394258
splice	19394258
site	19394258
mutation	19394258
that	19394258
provide	19394258
insight	19394258
into	19394258
a	19394258
critical	19394258
protein	19394258
domain	19394258
(	19394258
dGK	19394258
kinase	19394258
domain	19394258
)	19394258
and	19394258
the	19394258
first	19394258
founder	19394258
mutation	19394258
in	19394258
a	19394258
North	19394258
-	19394258
African	19394258
population	19394258
.	19394258
Atypical	20606392
GH	20606392
insensitivity	20606392
syndrome	20606392
and	20606392
severe	20606392
insulin	20606392
-	20606392
like	20606392
growth	20606392
factor	20606392
-	20606392
I	20606392
deficiency	20606392
resulting	20606392
from	20606392
compound	20606392
heterozygous	20606392
mutations	20606392
of	20606392
the	20606392
GH	20606392
receptor	20606392
,	20606392
including	20606392
a	20606392
novel	20606392
frameshift	20606392
mutation	20606392
affecting	20606392
the	20606392
intracellular	20606392
domain	20606392
.	20606392

BACKGROUND	20606392
/	20606392
AIMS	20606392
:	20606392
GH	20606392
insensitivity	20606392
and	20606392
IGF	20606392
deficiency	20606392
may	20606392
result	20606392
from	20606392
aberrations	20606392
of	20606392
the	20606392
GH	20606392
receptor	20606392
(	20606392
GHR	20606392
)	20606392
.	20606392

We	20606392
describe	20606392
a	20606392
4	20606392
-	20606392
year	20606392
-	20606392
old	20606392
child	20606392
with	20606392
modest	20606392
growth	20606392
failure	20606392
and	20606392
normal	20606392
serum	20606392
concentrations	20606392
of	20606392
GH	20606392
-	20606392
binding	20606392
protein	20606392
(	20606392
GHBP	20606392
)	20606392
,	20606392
but	20606392
clinical	20606392
evidence	20606392
of	20606392
GH	20606392
insensitivity	20606392
.	20606392

METHOD	20606392
:	20606392
Serum	20606392
and	20606392
DNA	20606392
samples	20606392
from	20606392
the	20606392
proband	20606392
and	20606392
his	20606392
parents	20606392
were	20606392
analyzed	20606392
.	20606392

RESULTS	20606392
:	20606392
The	20606392
child	20606392
had	20606392
a	20606392
height	20606392
of	20606392
-	20606392
4	20606392
SD	20606392
,	20606392
elevated	20606392
serum	20606392
GH	20606392
concentrations	20606392
,	20606392
abnormally	20606392
low	20606392
serum	20606392
IGF	20606392
-	20606392
I	20606392
and	20606392
IGFBP	20606392
-	20606392
3	20606392
concentrations	20606392
and	20606392
normal	20606392
GHBP	20606392
concentrations	20606392
.	20606392

DNA	20606392
analysis	20606392
revealed	20606392
compound	20606392
heterozygosity	20606392
for	20606392
mutations	20606392
of	20606392
GHR	20606392
,	20606392
including	20606392
a	20606392
previously	20606392
reported	20606392
R211H	20606392
mutation	20606392
and	20606392
a	20606392
novel	20606392
duplication	20606392
of	20606392
a	20606392
nucleotide	20606392
in	20606392
exon	20606392
9	20606392
(	20606392
899dupC	20606392
)	20606392
,	20606392
the	20606392
latter	20606392
resulting	20606392
in	20606392
a	20606392
frameshift	20606392
and	20606392
a	20606392
premature	20606392
stop	20606392
codon	20606392
.	20606392

Treatment	20606392
with	20606392
recombinant	20606392
DNA	20606392
-	20606392
derived	20606392
IGF	20606392
-	20606392
I	20606392
resulted	20606392
in	20606392
growth	20606392
acceleration	20606392
.	20606392

CONCLUSION	20606392
:	20606392
Mutations	20606392
affecting	20606392
the	20606392
intracellular	20606392
domain	20606392
of	20606392
the	20606392
GHR	20606392
can	20606392
result	20606392
in	20606392
GH	20606392
insensitivity	20606392
and	20606392
IGF	20606392
deficiency	20606392
,	20606392
despite	20606392
normal	20606392
serum	20606392
concentrations	20606392
of	20606392
GHBP	20606392
.	20606392

The	20606392
presence	20606392
of	20606392
clinical	20606392
and	20606392
biochemical	20606392
evidence	20606392
of	20606392
GH	20606392
resistance	20606392
is	20606392
sufficient	20606392
to	20606392
consider	20606392
the	20606392
possibility	20606392
of	20606392
aberrations	20606392
of	20606392
the	20606392
GHR	20606392
,	20606392
even	20606392
in	20606392
the	20606392
presence	20606392
of	20606392
normal	20606392
serum	20606392
GHBP	20606392
concentrations	20606392
.	20606392
Safety	20722491
of	20722491
capecitabine	20722491
:	20722491
a	20722491
review	20722491
.	20722491

IMPORTANCE	20722491
OF	20722491
THE	20722491
FIELD	20722491
:	20722491
Fluoropyrimidines	20722491
,	20722491
in	20722491
particular	20722491
5	20722491
-	20722491
fluorouracil	20722491
(	20722491
5	20722491
-	20722491
FU	20722491
)	20722491
,	20722491
have	20722491
been	20722491
the	20722491
mainstay	20722491
of	20722491
treatment	20722491
for	20722491
several	20722491
solid	20722491
tumors	20722491
,	20722491
including	20722491
colorectal	20722491
,	20722491
breast	20722491
and	20722491
head	20722491
and	20722491
neck	20722491
cancers	20722491
,	20722491
for	20722491
>	20722491
40	20722491
years	20722491
.	20722491

AREAS	20722491
COVERED	20722491
IN	20722491
THIS	20722491
REVIEW	20722491
:	20722491
This	20722491
article	20722491
reviews	20722491
the	20722491
pharmacology	20722491
and	20722491
efficacy	20722491
of	20722491
capecitabine	20722491
with	20722491
a	20722491
special	20722491
emphasis	20722491
on	20722491
its	20722491
safety	20722491
.	20722491

WHAT	20722491
THE	20722491
READER	20722491
WILL	20722491
GAIN	20722491
:	20722491
The	20722491
reader	20722491
will	20722491
gain	20722491
better	20722491
insight	20722491
into	20722491
the	20722491
safety	20722491
of	20722491
capecitabine	20722491
in	20722491
special	20722491
populations	20722491
such	20722491
as	20722491
patients	20722491
with	20722491
advanced	20722491
age	20722491
,	20722491
renal	20722491
and	20722491
kidney	20722491
disease	20722491
.	20722491

We	20722491
also	20722491
explore	20722491
different	20722491
dosing	20722491
and	20722491
schedules	20722491
of	20722491
capecitabine	20722491
administration	20722491
.	20722491

TAKE	20722491
HOME	20722491
MESSAGE	20722491
:	20722491
Capecitabine	20722491
is	20722491
an	20722491
oral	20722491
prodrug	20722491
of	20722491
5	20722491
-	20722491
FU	20722491
and	20722491
was	20722491
developed	20722491
to	20722491
fulfill	20722491
the	20722491
need	20722491
for	20722491
a	20722491
more	20722491
convenient	20722491
therapy	20722491
and	20722491
provide	20722491
an	20722491
improved	20722491
safety	20722491
/	20722491
efficacy	20722491
profile	20722491
.	20722491

It	20722491
has	20722491
shown	20722491
promising	20722491
results	20722491
alone	20722491
or	20722491
in	20722491
combination	20722491
with	20722491
other	20722491
chemotherapeutic	20722491
agents	20722491
in	20722491
colorectal	20722491
,	20722491
breast	20722491
,	20722491
pancreaticobiliary	20722491
,	20722491
gastric	20722491
,	20722491
renal	20722491
cell	20722491
and	20722491
head	20722491
and	20722491
neck	20722491
cancers	20722491
.	20722491

The	20722491
most	20722491
commonly	20722491
reported	20722491
toxic	20722491
effects	20722491
of	20722491
capecitabine	20722491
are	20722491
diarrhea	20722491
,	20722491
nausea	20722491
,	20722491
vomiting	20722491
,	20722491
stomatitis	20722491
and	20722491
hand	20722491
-	20722491
foot	20722491
syndrome	20722491
.	20722491

Capecitabine	20722491
has	20722491
a	20722491
well	20722491
-	20722491
established	20722491
safety	20722491
profile	20722491
and	20722491
can	20722491
be	20722491
given	20722491
safely	20722491
to	20722491
patients	20722491
with	20722491
advanced	20722491
age	20722491
,	20722491
hepatic	20722491
and	20722491
renal	20722491
dysfunctions	20722491
.	20722491
Fluoxetine	19914299
improves	19914299
the	19914299
memory	19914299
deficits	19914299
caused	19914299
by	19914299
the	19914299
chemotherapy	19914299
agent	19914299
5	19914299
-	19914299
fluorouracil	19914299
.	19914299

Cancer	19914299
patients	19914299
who	19914299
have	19914299
been	19914299
treated	19914299
with	19914299
systemic	19914299
adjuvant	19914299
chemotherapy	19914299
have	19914299
described	19914299
experiencing	19914299
deteriorations	19914299
in	19914299
cognition	19914299
.	19914299

A	19914299
widely	19914299
used	19914299
chemotherapeutic	19914299
agent	19914299
,	19914299
5	19914299
-	19914299
fluorouracil	19914299
(	19914299
5	19914299
-	19914299
FU	19914299
)	19914299
,	19914299
readily	19914299
crosses	19914299
the	19914299
blood	19914299
-	19914299
brain	19914299
barrier	19914299
and	19914299
so	19914299
could	19914299
have	19914299
a	19914299
direct	19914299
effect	19914299
on	19914299
brain	19914299
function	19914299
.	19914299

In	19914299
particular	19914299
this	19914299
anti	19914299
mitotic	19914299
drug	19914299
could	19914299
reduce	19914299
cell	19914299
proliferation	19914299
in	19914299
the	19914299
neurogenic	19914299
regions	19914299
of	19914299
the	19914299
adult	19914299
brain	19914299
.	19914299

In	19914299
contrast	19914299
reports	19914299
indicate	19914299
that	19914299
hippocampal	19914299
dependent	19914299
neurogenesis	19914299
and	19914299
cognition	19914299
are	19914299
enhanced	19914299
by	19914299
the	19914299
SSRI	19914299
antidepressant	19914299
Fluoxetine	19914299
.	19914299

In	19914299
this	19914299
investigation	19914299
the	19914299
behavioural	19914299
effects	19914299
of	19914299
chronic	19914299
(	19914299
two	19914299
week	19914299
)	19914299
treatment	19914299
with	19914299
5	19914299
-	19914299
FU	19914299
and	19914299
(	19914299
three	19914299
weeks	19914299
)	19914299
with	19914299
Fluoxetine	19914299
either	19914299
separately	19914299
or	19914299
in	19914299
combination	19914299
with	19914299
5	19914299
-	19914299
FU	19914299
were	19914299
tested	19914299
on	19914299
adult	19914299
Lister	19914299
hooded	19914299
rats	19914299
.	19914299

Behavioural	19914299
effects	19914299
were	19914299
tested	19914299
using	19914299
a	19914299
context	19914299
dependent	19914299
conditioned	19914299
emotional	19914299
response	19914299
test	19914299
(	19914299
CER	19914299
)	19914299
which	19914299
showed	19914299
that	19914299
animals	19914299
treated	19914299
with	19914299
5	19914299
-	19914299
FU	19914299
had	19914299
a	19914299
significant	19914299
reduction	19914299
in	19914299
freezing	19914299
time	19914299
compared	19914299
to	19914299
controls	19914299
.	19914299

A	19914299
separate	19914299
group	19914299
of	19914299
animals	19914299
was	19914299
tested	19914299
using	19914299
a	19914299
hippocampal	19914299
dependent	19914299
spatial	19914299
working	19914299
memory	19914299
test	19914299
,	19914299
the	19914299
object	19914299
location	19914299
recognition	19914299
test	19914299
(	19914299
OLR	19914299
)	19914299
.	19914299

Animals	19914299
treated	19914299
only	19914299
with	19914299
5	19914299
-	19914299
FU	19914299
showed	19914299
significant	19914299
deficits	19914299
in	19914299
their	19914299
ability	19914299
to	19914299
carry	19914299
out	19914299
the	19914299
OLR	19914299
task	19914299
but	19914299
co	19914299
administration	19914299
of	19914299
Fluoxetine	19914299
improved	19914299
their	19914299
performance	19914299
.	19914299

5	19914299
-	19914299
FU	19914299
chemotherapy	19914299
caused	19914299
a	19914299
significant	19914299
reduction	19914299
in	19914299
the	19914299
number	19914299
of	19914299
proliferating	19914299
cells	19914299
in	19914299
the	19914299
sub	19914299
granular	19914299
zone	19914299
of	19914299
the	19914299
dentate	19914299
gyrus	19914299
compared	19914299
to	19914299
controls	19914299
.	19914299

This	19914299
reduction	19914299
was	19914299
eliminated	19914299
when	19914299
Fluoxetine	19914299
was	19914299
co	19914299
administered	19914299
with	19914299
5	19914299
-	19914299
FU	19914299
.	19914299

Fluoxetine	19914299
on	19914299
its	19914299
own	19914299
had	19914299
no	19914299
effect	19914299
on	19914299
proliferating	19914299
cell	19914299
number	19914299
or	19914299
behaviour	19914299
.	19914299

These	19914299
findings	19914299
suggest	19914299
that	19914299
5	19914299
-	19914299
FU	19914299
can	19914299
negatively	19914299
affect	19914299
both	19914299
cell	19914299
proliferation	19914299
and	19914299
hippocampal	19914299
dependent	19914299
working	19914299
memory	19914299
and	19914299
that	19914299
these	19914299
deficits	19914299
can	19914299
be	19914299
reversed	19914299
by	19914299
the	19914299
simultaneous	19914299
administration	19914299
of	19914299
the	19914299
antidepressant	19914299
Fluoxetine	19914299
.	19914299
TIEG1	28204828
deficiency	28204828
confers	28204828
enhanced	28204828
myocardial	28204828
protection	28204828
in	28204828
the	28204828
infarcted	28204828
heart	28204828
by	28204828
mediating	28204828
the	28204828
Pten	28204828
/	28204828
Akt	28204828
signalling	28204828
pathway	28204828
.	28204828

The	28204828
transforming	28204828
growth	28204828
factor	28204828
(	28204828
TGF	28204828
)	28204828
-	28204828
b	28204828
-	28204828
inducible	28204828
early	28204828
gene	28204828
-	28204828
1	28204828
(	28204828
TIEG1	28204828
)	28204828
plays	28204828
a	28204828
crucial	28204828
role	28204828
in	28204828
modulating	28204828
cell	28204828
apoptosis	28204828
and	28204828
proliferation	28204828
in	28204828
a	28204828
number	28204828
of	28204828
diseases	28204828
,	28204828
including	28204828
pancreatic	28204828
cancer	28204828
,	28204828
leukaemia	28204828
and	28204828
osteoporosis	28204828
.	28204828

However	28204828
,	28204828
the	28204828
functional	28204828
role	28204828
of	28204828
TIEG1	28204828
in	28204828
the	28204828
heart	28204828
has	28204828
not	28204828
been	28204828
fully	28204828
defined	28204828
.	28204828

In	28204828
this	28204828
study	28204828
,	28204828
we	28204828
first	28204828
investigated	28204828
the	28204828
role	28204828
of	28204828
TIEG1	28204828
in	28204828
ischaemic	28204828
heart	28204828
disease	28204828
.	28204828

For	28204828
in	28204828
vitro	28204828
experiments	28204828
,	28204828
cardiomyocytes	28204828
were	28204828
isolated	28204828
from	28204828
both	28204828
TIEG1	28204828
knockout	28204828
(	28204828
KO	28204828
)	28204828
and	28204828
wile	28204828
-	28204828
type	28204828
(	28204828
WT	28204828
)	28204828
mice	28204828
,	28204828
and	28204828
the	28204828
apoptotic	28204828
ratios	28204828
were	28204828
evaluated	28204828
after	28204828
a	28204828
48	28204828
-	28204828
h	28204828
ischaemic	28204828
insult	28204828
.	28204828

A	28204828
cell	28204828
proliferation	28204828
assay	28204828
was	28204828
performed	28204828
after	28204828
7	28204828
days	28204828
of	28204828
incubation	28204828
under	28204828
normoxic	28204828
conditions	28204828
.	28204828

In	28204828
addition	28204828
,	28204828
the	28204828
angiogenic	28204828
capacity	28204828
of	28204828
endothelial	28204828
cells	28204828
was	28204828
determined	28204828
by	28204828
tube	28204828
formation	28204828
assay	28204828
.	28204828

For	28204828
in	28204828
vivo	28204828
experiments	28204828
,	28204828
a	28204828
model	28204828
of	28204828
myocardial	28204828
infarction	28204828
(	28204828
MI	28204828
)	28204828
was	28204828
established	28204828
using	28204828
both	28204828
TIEG1	28204828
KO	28204828
and	28204828
WT	28204828
mice	28204828
.	28204828

Echocardiography	28204828
was	28204828
performed	28204828
at	28204828
3	28204828
and	28204828
28	28204828
days	28204828
post	28204828
-	28204828
MI	28204828
,	28204828
whereas	28204828
the	28204828
haemodynamics	28204828
test	28204828
was	28204828
performed	28204828
28	28204828
days	28204828
post	28204828
-	28204828
MI	28204828
.	28204828

Histological	28204828
analyses	28204828
of	28204828
apoptosis	28204828
,	28204828
proliferation	28204828
,	28204828
angiogenesis	28204828
and	28204828
infarct	28204828
zone	28204828
assessments	28204828
were	28204828
performed	28204828
using	28204828
terminal	28204828
deoxynucleotidyltransferase	28204828
-	28204828
mediated	28204828
dUTP	28204828
nick	28204828
-	28204828
end	28204828
labelling	28204828
(	28204828
TUNEL	28204828
)	28204828
staining	28204828
,	28204828
BrdU	28204828
immunostaining	28204828
,	28204828
a	28204828
-	28204828
smooth	28204828
muscle	28204828
actin	28204828
(	28204828
a	28204828
-	28204828
SMA	28204828
)	28204828
/	28204828
CD31	28204828
immunostaining	28204828
and	28204828
Masson	28204828
'	28204828
s	28204828
trichrome	28204828
staining	28204828
,	28204828
respectively	28204828
.	28204828

Changes	28204828
in	28204828
the	28204828
expression	28204828
of	28204828
related	28204828
proteins	28204828
caused	28204828
by	28204828
TIEG1	28204828
deficiency	28204828
were	28204828
confirmed	28204828
using	28204828
both	28204828
reverse	28204828
transcription	28204828
-	28204828
quantitative	28204828
polymerase	28204828
chain	28204828
reaction	28204828
(	28204828
RT	28204828
-	28204828
qPCR	28204828
)	28204828
and	28204828
western	28204828
blot	28204828
analysis	28204828
.	28204828

Our	28204828
results	28204828
demonstrated	28204828
that	28204828
the	28204828
absence	28204828
of	28204828
TIEG1	28204828
prevented	28204828
cardiomyocytes	28204828
from	28204828
undergoing	28204828
apoptosis	28204828
and	28204828
promoted	28204828
higher	28204828
proliferation	28204828
;	28204828
it	28204828
stimulated	28204828
the	28204828
proliferation	28204828
of	28204828
endothelial	28204828
cells	28204828
in	28204828
vitro	28204828
and	28204828
in	28204828
vivo	28204828
.	28204828

Improved	28204828
cardiac	28204828
function	28204828
and	28204828
less	28204828
scar	28204828
formation	28204828
were	28204828
observed	28204828
in	28204828
TIEG1	28204828
KO	28204828
mice	28204828
,	28204828
and	28204828
we	28204828
also	28204828
observed	28204828
the	28204828
altered	28204828
expression	28204828
of	28204828
phosphatase	28204828
and	28204828
tensin	28204828
homolog	28204828
(	28204828
Pten	28204828
)	28204828
,	28204828
Akt	28204828
and	28204828
Bcl	28204828
-	28204828
2	28204828
/	28204828
Bax	28204828
,	28204828
as	28204828
well	28204828
as	28204828
vascular	28204828
endothelial	28204828
growth	28204828
factor	28204828
(	28204828
VEGF	28204828
)	28204828
.	28204828

On	28204828
the	28204828
whole	28204828
,	28204828
our	28204828
findings	28204828
indicate	28204828
that	28204828
the	28204828
absence	28204828
of	28204828
TIEG1	28204828
plays	28204828
a	28204828
cardioprotective	28204828
role	28204828
in	28204828
ischaemic	28204828
heart	28204828
disease	28204828
by	28204828
promoting	28204828
changes	28204828
in	28204828
Pten	28204828
/	28204828
Akt	28204828
signalling	28204828
.	28204828
Long	27630165
-	27630165
Lived	27630165
CD4	27630165
+	27630165
IFN	27630165
-	27630165
g	27630165
+	27630165
T	27630165
Cells	27630165
rather	27630165
than	27630165
Short	27630165
-	27630165
Lived	27630165
CD4	27630165
+	27630165
IFN	27630165
-	27630165
g	27630165
+	27630165
IL	27630165
-	27630165
10	27630165
+	27630165
T	27630165
Cells	27630165
Initiate	27630165
Rapid	27630165
IL	27630165
-	27630165
10	27630165
Production	27630165
To	27630165
Suppress	27630165
Anamnestic	27630165
T	27630165
Cell	27630165
Responses	27630165
during	27630165
Secondary	27630165
Malaria	27630165
Infection	27630165
.	27630165

CD4	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
that	27630165
produce	27630165
IFN	27630165
-	27630165
g	27630165
are	27630165
the	27630165
source	27630165
of	27630165
host	27630165
-	27630165
protective	27630165
IL	27630165
-	27630165
10	27630165
during	27630165
primary	27630165
infection	27630165
with	27630165
a	27630165
number	27630165
of	27630165
different	27630165
pathogens	27630165
,	27630165
including	27630165
Plasmodium	27630165
spp	27630165
.	27630165

The	27630165
fate	27630165
of	27630165
these	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
IFN	27630165
-	27630165
g	27630165
(	27630165
+	27630165
)	27630165
IL	27630165
-	27630165
10	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
following	27630165
clearance	27630165
of	27630165
primary	27630165
infection	27630165
and	27630165
their	27630165
subsequent	27630165
influence	27630165
on	27630165
the	27630165
course	27630165
of	27630165
repeated	27630165
infections	27630165
is	27630165
,	27630165
however	27630165
,	27630165
presently	27630165
unknown	27630165
.	27630165

In	27630165
this	27630165
study	27630165
,	27630165
utilizing	27630165
IFN	27630165
-	27630165
g	27630165
-	27630165
yellow	27630165
fluorescent	27630165
protein	27630165
(	27630165
YFP	27630165
)	27630165
and	27630165
IL	27630165
-	27630165
10	27630165
-	27630165
GFP	27630165
dual	27630165
reporter	27630165
mice	27630165
,	27630165
we	27630165
show	27630165
that	27630165
primary	27630165
malaria	27630165
infection	27630165
-	27630165
induced	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
YFP	27630165
(	27630165
+	27630165
)	27630165
GFP	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
have	27630165
limited	27630165
memory	27630165
potential	27630165
,	27630165
do	27630165
not	27630165
stably	27630165
express	27630165
IL	27630165
-	27630165
10	27630165
,	27630165
and	27630165
are	27630165
disproportionately	27630165
lost	27630165
from	27630165
the	27630165
Ag	27630165
-	27630165
experienced	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cell	27630165
memory	27630165
population	27630165
during	27630165
the	27630165
maintenance	27630165
phase	27630165
postinfection	27630165
.	27630165

CD4	27630165
(	27630165
+	27630165
)	27630165
YFP	27630165
(	27630165
+	27630165
)	27630165
GFP	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
generally	27630165
exhibited	27630165
a	27630165
short	27630165
-	27630165
lived	27630165
effector	27630165
rather	27630165
than	27630165
effector	27630165
memory	27630165
T	27630165
cell	27630165
phenotype	27630165
postinfection	27630165
and	27630165
expressed	27630165
high	27630165
levels	27630165
of	27630165
PD	27630165
-	27630165
1	27630165
,	27630165
Lag	27630165
-	27630165
3	27630165
,	27630165
and	27630165
TIGIT	27630165
,	27630165
indicative	27630165
of	27630165
cellular	27630165
exhaustion	27630165
.	27630165

Consistently	27630165
,	27630165
the	27630165
surviving	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
YFP	27630165
(	27630165
+	27630165
)	27630165
GFP	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cell	27630165
-	27630165
derived	27630165
cells	27630165
were	27630165
unresponsive	27630165
and	27630165
failed	27630165
to	27630165
proliferate	27630165
during	27630165
the	27630165
early	27630165
phase	27630165
of	27630165
secondary	27630165
infection	27630165
.	27630165

In	27630165
contrast	27630165
,	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
YFP	27630165
(	27630165
+	27630165
)	27630165
GFP	27630165
(	27630165
-	27630165
)	27630165
T	27630165
cell	27630165
-	27630165
derived	27630165
cells	27630165
expanded	27630165
rapidly	27630165
and	27630165
upregulated	27630165
IL	27630165
-	27630165
10	27630165
expression	27630165
during	27630165
secondary	27630165
infection	27630165
.	27630165

Correspondingly	27630165
,	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
were	27630165
the	27630165
major	27630165
producers	27630165
within	27630165
an	27630165
accelerated	27630165
and	27630165
amplified	27630165
IL	27630165
-	27630165
10	27630165
response	27630165
during	27630165
the	27630165
early	27630165
stage	27630165
of	27630165
secondary	27630165
malaria	27630165
infection	27630165
.	27630165

Notably	27630165
,	27630165
IL	27630165
-	27630165
10	27630165
exerted	27630165
quantitatively	27630165
stronger	27630165
regulatory	27630165
effects	27630165
on	27630165
innate	27630165
and	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cell	27630165
responses	27630165
during	27630165
primary	27630165
and	27630165
secondary	27630165
infections	27630165
,	27630165
respectively	27630165
.	27630165

The	27630165
results	27630165
in	27630165
this	27630165
study	27630165
significantly	27630165
improve	27630165
our	27630165
understanding	27630165
of	27630165
the	27630165
durability	27630165
of	27630165
IL	27630165
-	27630165
10	27630165
-	27630165
producing	27630165
CD4	27630165
(	27630165
+	27630165
)	27630165
T	27630165
cells	27630165
postinfection	27630165
and	27630165
provide	27630165
information	27630165
on	27630165
how	27630165
IL	27630165
-	27630165
10	27630165
may	27630165
contribute	27630165
to	27630165
optimized	27630165
parasite	27630165
control	27630165
and	27630165
prevention	27630165
of	27630165
immune	27630165
-	27630165
mediated	27630165
pathology	27630165
during	27630165
repeated	27630165
malaria	27630165
infections	27630165
.	27630165
Chloroacetaldehyde	17035713
as	17035713
a	17035713
sulfhydryl	17035713
reagent	17035713
:	17035713
the	17035713
role	17035713
of	17035713
critical	17035713
thiol	17035713
groups	17035713
in	17035713
ifosfamide	17035713
nephropathy	17035713
.	17035713

Chloroacetaldehyde	17035713
(	17035713
CAA	17035713
)	17035713
is	17035713
a	17035713
metabolite	17035713
of	17035713
the	17035713
alkylating	17035713
agent	17035713
ifosfamide	17035713
(	17035713
IFO	17035713
)	17035713
and	17035713
putatively	17035713
responsible	17035713
for	17035713
renal	17035713
damage	17035713
following	17035713
anti	17035713
-	17035713
tumor	17035713
therapy	17035713
with	17035713
IFO	17035713
.	17035713

Depletion	17035713
of	17035713
sulfhydryl	17035713
(	17035713
SH	17035713
)	17035713
groups	17035713
has	17035713
been	17035713
reported	17035713
from	17035713
cell	17035713
culture	17035713
,	17035713
animal	17035713
and	17035713
clinical	17035713
studies	17035713
.	17035713

In	17035713
this	17035713
work	17035713
the	17035713
effect	17035713
of	17035713
CAA	17035713
on	17035713
human	17035713
proximal	17035713
tubule	17035713
cells	17035713
in	17035713
primary	17035713
culture	17035713
(	17035713
hRPTEC	17035713
)	17035713
was	17035713
investigated	17035713
.	17035713

Toxicity	17035713
of	17035713
CAA	17035713
was	17035713
determined	17035713
by	17035713
protein	17035713
content	17035713
,	17035713
cell	17035713
number	17035713
,	17035713
LDH	17035713
release	17035713
,	17035713
trypan	17035713
blue	17035713
exclusion	17035713
assay	17035713
and	17035713
caspase	17035713
-	17035713
3	17035713
activity	17035713
.	17035713

Free	17035713
thiols	17035713
were	17035713
measured	17035713
by	17035713
the	17035713
method	17035713
of	17035713
Ellman	17035713
.	17035713

CAA	17035713
reduced	17035713
hRPTEC	17035713
cell	17035713
number	17035713
and	17035713
protein	17035713
,	17035713
induced	17035713
a	17035713
loss	17035713
in	17035713
free	17035713
intracellular	17035713
thiols	17035713
and	17035713
an	17035713
increase	17035713
in	17035713
necrosis	17035713
markers	17035713
.	17035713

CAA	17035713
but	17035713
not	17035713
acrolein	17035713
inhibited	17035713
the	17035713
cysteine	17035713
proteases	17035713
caspase	17035713
-	17035713
3	17035713
,	17035713
caspase	17035713
-	17035713
8	17035713
and	17035713
cathepsin	17035713
B	17035713
.	17035713

Caspase	17035713
activation	17035713
by	17035713
cisplatin	17035713
was	17035713
inhibited	17035713
by	17035713
CAA	17035713
.	17035713

In	17035713
cells	17035713
stained	17035713
with	17035713
fluorescent	17035713
dyes	17035713
targeting	17035713
lysosomes	17035713
,	17035713
CAA	17035713
induced	17035713
an	17035713
increase	17035713
in	17035713
lysosomal	17035713
size	17035713
and	17035713
lysosomal	17035713
leakage	17035713
.	17035713

The	17035713
effects	17035713
of	17035713
CAA	17035713
on	17035713
cysteine	17035713
protease	17035713
activities	17035713
and	17035713
thiols	17035713
could	17035713
be	17035713
reproduced	17035713
in	17035713
cell	17035713
lysate	17035713
.	17035713

Acidification	17035713
,	17035713
which	17035713
slowed	17035713
the	17035713
reaction	17035713
of	17035713
CAA	17035713
with	17035713
thiol	17035713
donors	17035713
,	17035713
could	17035713
also	17035713
attenuate	17035713
effects	17035713
of	17035713
CAA	17035713
on	17035713
necrosis	17035713
markers	17035713
,	17035713
thiol	17035713
depletion	17035713
and	17035713
cysteine	17035713
protease	17035713
inhibition	17035713
in	17035713
living	17035713
cells	17035713
.	17035713

Thus	17035713
,	17035713
CAA	17035713
directly	17035713
reacts	17035713
with	17035713
cellular	17035713
protein	17035713
and	17035713
non	17035713
-	17035713
protein	17035713
thiols	17035713
,	17035713
mediating	17035713
its	17035713
toxicity	17035713
on	17035713
hRPTEC	17035713
.	17035713

This	17035713
effect	17035713
can	17035713
be	17035713
reduced	17035713
by	17035713
acidification	17035713
.	17035713

Therefore	17035713
,	17035713
urinary	17035713
acidification	17035713
could	17035713
be	17035713
an	17035713
option	17035713
to	17035713
prevent	17035713
IFO	17035713
nephropathy	17035713
in	17035713
patients	17035713
.	17035713
Absence	25006961
of	25006961
PKC	25006961
-	25006961
alpha	25006961
attenuates	25006961
lithium	25006961
-	25006961
induced	25006961
nephrogenic	25006961
diabetes	25006961
insipidus	25006961
.	25006961

Lithium	25006961
,	25006961
an	25006961
effective	25006961
antipsychotic	25006961
,	25006961
induces	25006961
nephrogenic	25006961
diabetes	25006961
insipidus	25006961
(	25006961
NDI	25006961
)	25006961
in	25006961
40%	25006961
of	25006961
patients	25006961
.	25006961

The	25006961
decreased	25006961
capacity	25006961
to	25006961
concentrate	25006961
urine	25006961
is	25006961
likely	25006961
due	25006961
to	25006961
lithium	25006961
acutely	25006961
disrupting	25006961
the	25006961
cAMP	25006961
pathway	25006961
and	25006961
chronically	25006961
reducing	25006961
urea	25006961
transporter	25006961
(	25006961
UT	25006961
-	25006961
A1	25006961
)	25006961
and	25006961
water	25006961
channel	25006961
(	25006961
AQP2	25006961
)	25006961
expression	25006961
in	25006961
the	25006961
inner	25006961
medulla	25006961
.	25006961

Targeting	25006961
an	25006961
alternative	25006961
signaling	25006961
pathway	25006961
,	25006961
such	25006961
as	25006961
PKC	25006961
-	25006961
mediated	25006961
signaling	25006961
,	25006961
may	25006961
be	25006961
an	25006961
effective	25006961
method	25006961
of	25006961
treating	25006961
lithium	25006961
-	25006961
induced	25006961
polyuria	25006961
.	25006961

PKC	25006961
-	25006961
alpha	25006961
null	25006961
mice	25006961
(	25006961
PKCa	25006961
KO	25006961
)	25006961
and	25006961
strain	25006961
-	25006961
matched	25006961
wild	25006961
type	25006961
(	25006961
WT	25006961
)	25006961
controls	25006961
were	25006961
treated	25006961
with	25006961
lithium	25006961
for	25006961
0	25006961
,	25006961
3	25006961
or	25006961
5	25006961
days	25006961
.	25006961

WT	25006961
mice	25006961
had	25006961
increased	25006961
urine	25006961
output	25006961
and	25006961
lowered	25006961
urine	25006961
osmolality	25006961
after	25006961
3	25006961
and	25006961
5	25006961
days	25006961
of	25006961
treatment	25006961
whereas	25006961
PKCa	25006961
KO	25006961
mice	25006961
had	25006961
no	25006961
change	25006961
in	25006961
urine	25006961
output	25006961
or	25006961
concentration	25006961
.	25006961

Western	25006961
blot	25006961
analysis	25006961
revealed	25006961
that	25006961
AQP2	25006961
expression	25006961
in	25006961
medullary	25006961
tissues	25006961
was	25006961
lowered	25006961
after	25006961
3	25006961
and	25006961
5	25006961
days	25006961
in	25006961
WT	25006961
mice	25006961
;	25006961
however	25006961
,	25006961
AQP2	25006961
was	25006961
unchanged	25006961
in	25006961
PKCa	25006961
KO	25006961
.	25006961

Similar	25006961
results	25006961
were	25006961
observed	25006961
with	25006961
UT	25006961
-	25006961
A1	25006961
expression	25006961
.	25006961

Animals	25006961
were	25006961
also	25006961
treated	25006961
with	25006961
lithium	25006961
for	25006961
6	25006961
weeks	25006961
.	25006961

Lithium	25006961
-	25006961
treated	25006961
WT	25006961
mice	25006961
had	25006961
19	25006961
-	25006961
fold	25006961
increased	25006961
urine	25006961
output	25006961
whereas	25006961
treated	25006961
PKCa	25006961
KO	25006961
animals	25006961
had	25006961
a	25006961
4	25006961
-	25006961
fold	25006961
increase	25006961
in	25006961
output	25006961
.	25006961

AQP2	25006961
and	25006961
UT	25006961
-	25006961
A1	25006961
expression	25006961
was	25006961
lowered	25006961
in	25006961
6	25006961
week	25006961
lithium	25006961
-	25006961
treated	25006961
WT	25006961
animals	25006961
whereas	25006961
in	25006961
treated	25006961
PKCa	25006961
KO	25006961
mice	25006961
,	25006961
AQP2	25006961
was	25006961
only	25006961
reduced	25006961
by	25006961
2	25006961
-	25006961
fold	25006961
and	25006961
UT	25006961
-	25006961
A1	25006961
expression	25006961
was	25006961
unaffected	25006961
.	25006961

Urinary	25006961
sodium	25006961
,	25006961
potassium	25006961
and	25006961
calcium	25006961
were	25006961
elevated	25006961
in	25006961
lithium	25006961
-	25006961
fed	25006961
WT	25006961
but	25006961
not	25006961
in	25006961
lithium	25006961
-	25006961
fed	25006961
PKCa	25006961
KO	25006961
mice	25006961
.	25006961

Our	25006961
data	25006961
show	25006961
that	25006961
ablation	25006961
of	25006961
PKCa	25006961
preserves	25006961
AQP2	25006961
and	25006961
UT	25006961
-	25006961
A1	25006961
protein	25006961
expression	25006961
and	25006961
localization	25006961
in	25006961
lithium	25006961
-	25006961
induced	25006961
NDI	25006961
,	25006961
and	25006961
prevents	25006961
the	25006961
development	25006961
of	25006961
the	25006961
severe	25006961
polyuria	25006961
associated	25006961
with	25006961
lithium	25006961
therapy	25006961
.	25006961
H3	19825989
histamine	19825989
receptor	19825989
-	19825989
mediated	19825989
activation	19825989
of	19825989
protein	19825989
kinase	19825989
Calpha	19825989
inhibits	19825989
the	19825989
growth	19825989
of	19825989
cholangiocarcinoma	19825989
in	19825989
vitro	19825989
and	19825989
in	19825989
vivo	19825989
.	19825989

Histamine	19825989
regulates	19825989
functions	19825989
via	19825989
four	19825989
receptors	19825989
(	19825989
HRH1	19825989
,	19825989
HRH2	19825989
,	19825989
HRH3	19825989
,	19825989
and	19825989
HRH4	19825989
)	19825989
.	19825989

The	19825989
d	19825989
-	19825989
myo	19825989
-	19825989
inositol	19825989
1	19825989
,	19825989
4	19825989
,	19825989
5	19825989
-	19825989
trisphosphate	19825989
(	19825989
IP	19825989
(	19825989
3	19825989
)	19825989
)	19825989
/	19825989
Ca	19825989
(	19825989
2	19825989
+	19825989
)	19825989
/	19825989
protein	19825989
kinase	19825989
C	19825989
(	19825989
PKC	19825989
)	19825989
/	19825989
mitogen	19825989
-	19825989
activated	19825989
protein	19825989
kinase	19825989
pathway	19825989
regulates	19825989
cholangiocarcinoma	19825989
growth	19825989
.	19825989

We	19825989
evaluated	19825989
the	19825989
role	19825989
of	19825989
HRH3	19825989
in	19825989
the	19825989
regulation	19825989
of	19825989
cholangiocarcinoma	19825989
growth	19825989
.	19825989

Expression	19825989
of	19825989
HRH3	19825989
in	19825989
intrahepatic	19825989
and	19825989
extrahepatic	19825989
cell	19825989
lines	19825989
,	19825989
normal	19825989
cholangiocytes	19825989
,	19825989
and	19825989
human	19825989
tissue	19825989
arrays	19825989
was	19825989
measured	19825989
.	19825989

In	19825989
Mz	19825989
-	19825989
ChA	19825989
-	19825989
1	19825989
cells	19825989
stimulated	19825989
with	19825989
(	19825989
R	19825989
)	19825989
-	19825989
(	19825989
alpha	19825989
)	19825989
-	19825989
(	19825989
-	19825989
)	19825989
-	19825989
methylhistamine	19825989
dihydrobromide	19825989
(	19825989
RAMH	19825989
)	19825989
,	19825989
we	19825989
measured	19825989
(	19825989
a	19825989
)	19825989
cell	19825989
growth	19825989
,	19825989
(	19825989
b	19825989
)	19825989
IP	19825989
(	19825989
3	19825989
)	19825989
and	19825989
cyclic	19825989
AMP	19825989
levels	19825989
,	19825989
and	19825989
(	19825989
c	19825989
)	19825989
phosphorylation	19825989
of	19825989
PKC	19825989
and	19825989
mitogen	19825989
-	19825989
activated	19825989
protein	19825989
kinase	19825989
isoforms	19825989
.	19825989

Localization	19825989
of	19825989
PKCalpha	19825989
was	19825989
visualized	19825989
by	19825989
immunofluorescence	19825989
in	19825989
cell	19825989
smears	19825989
and	19825989
immunoblotting	19825989
for	19825989
PKCalpha	19825989
in	19825989
cytosol	19825989
and	19825989
membrane	19825989
fractions	19825989
.	19825989

Following	19825989
knockdown	19825989
of	19825989
PKCalpha	19825989
,	19825989
Mz	19825989
-	19825989
ChA	19825989
-	19825989
1	19825989
cells	19825989
were	19825989
stimulated	19825989
with	19825989
RAMH	19825989
before	19825989
evaluating	19825989
cell	19825989
growth	19825989
and	19825989
extracellular	19825989
signal	19825989
-	19825989
regulated	19825989
kinase	19825989
(	19825989
ERK	19825989
)	19825989
-	19825989
1	19825989
/	19825989
2	19825989
phosphorylation	19825989
.	19825989

In	19825989
vivo	19825989
experiments	19825989
were	19825989
done	19825989
in	19825989
BALB	19825989
/	19825989
c	19825989
nude	19825989
mice	19825989
.	19825989

Mice	19825989
were	19825989
treated	19825989
with	19825989
saline	19825989
or	19825989
RAMH	19825989
for	19825989
44	19825989
days	19825989
and	19825989
tumor	19825989
volume	19825989
was	19825989
measured	19825989
.	19825989

Tumors	19825989
were	19825989
excised	19825989
and	19825989
evaluated	19825989
for	19825989
proliferation	19825989
,	19825989
apoptosis	19825989
,	19825989
and	19825989
expression	19825989
of	19825989
PKCalpha	19825989
,	19825989
vascular	19825989
endothelial	19825989
growth	19825989
factor	19825989
(	19825989
VEGF	19825989
)	19825989
-	19825989
A	19825989
,	19825989
VEGF	19825989
-	19825989
C	19825989
,	19825989
VEGF	19825989
receptor	19825989
2	19825989
,	19825989
and	19825989
VEGF	19825989
receptor	19825989
3	19825989
.	19825989

HRH3	19825989
expression	19825989
was	19825989
found	19825989
in	19825989
all	19825989
cells	19825989
.	19825989

RAMH	19825989
inhibited	19825989
the	19825989
growth	19825989
of	19825989
cholangiocarcinoma	19825989
cells	19825989
.	19825989

RAMH	19825989
increased	19825989
IP	19825989
(	19825989
3	19825989
)	19825989
levels	19825989
and	19825989
PKCalpha	19825989
phosphorylation	19825989
and	19825989
decreased	19825989
ERK1	19825989
/	19825989
2	19825989
phosphorylation	19825989
.	19825989

RAMH	19825989
induced	19825989
a	19825989
shift	19825989
in	19825989
the	19825989
localization	19825989
of	19825989
PKCalpha	19825989
expression	19825989
from	19825989
the	19825989
cytosolic	19825989
domain	19825989
into	19825989
the	19825989
membrane	19825989
region	19825989
of	19825989
Mz	19825989
-	19825989
ChA	19825989
-	19825989
1	19825989
cells	19825989
.	19825989

Silencing	19825989
of	19825989
PKCalpha	19825989
prevented	19825989
RAMH	19825989
inhibition	19825989
of	19825989
Mz	19825989
-	19825989
ChA	19825989
-	19825989
1	19825989
cell	19825989
growth	19825989
and	19825989
ablated	19825989
RAMH	19825989
effects	19825989
on	19825989
ERK1	19825989
/	19825989
2	19825989
phosphorylation	19825989
.	19825989

In	19825989
vivo	19825989
,	19825989
RAMH	19825989
decreased	19825989
tumor	19825989
growth	19825989
and	19825989
expression	19825989
of	19825989
VEGF	19825989
and	19825989
its	19825989
receptors	19825989
;	19825989
PKCalpha	19825989
expression	19825989
was	19825989
increased	19825989
.	19825989

RAMH	19825989
inhibits	19825989
cholangiocarcinoma	19825989
growth	19825989
by	19825989
PKCalpha	19825989
-	19825989
dependent	19825989
ERK1	19825989
/	19825989
2	19825989
dephosphorylation	19825989
.	19825989

Modulation	19825989
of	19825989
PKCalpha	19825989
by	19825989
histamine	19825989
receptors	19825989
may	19825989
be	19825989
important	19825989
in	19825989
regulating	19825989
cholangiocarcinoma	19825989
growth	19825989
.	19825989
The	17221831
G51S	17221831
purine	17221831
nucleoside	17221831
phosphorylase	17221831
polymorphism	17221831
is	17221831
associated	17221831
with	17221831
cognitive	17221831
decline	17221831
in	17221831
Alzheimer	17221831
'	17221831
s	17221831
disease	17221831
patients	17221831
.	17221831

Alzheimer	17221831
'	17221831
s	17221831
disease	17221831
(	17221831
AD	17221831
)	17221831
is	17221831
a	17221831
polygenic	17221831
and	17221831
multifactorial	17221831
complex	17221831
disease	17221831
,	17221831
whose	17221831
etiopathology	17221831
is	17221831
still	17221831
unclear	17221831
,	17221831
however	17221831
several	17221831
genetic	17221831
factors	17221831
have	17221831
shown	17221831
to	17221831
increase	17221831
the	17221831
risk	17221831
of	17221831
developing	17221831
the	17221831
disease	17221831
.	17221831

Purine	17221831
nucleotides	17221831
and	17221831
nucleosides	17221831
play	17221831
an	17221831
important	17221831
role	17221831
in	17221831
the	17221831
brain	17221831
.	17221831

Besides	17221831
their	17221831
role	17221831
in	17221831
neurotransmission	17221831
and	17221831
neuromodulation	17221831
,	17221831
they	17221831
are	17221831
involved	17221831
in	17221831
trophic	17221831
factor	17221831
release	17221831
,	17221831
apoptosis	17221831
,	17221831
and	17221831
inflammatory	17221831
responses	17221831
.	17221831

These	17221831
mediators	17221831
may	17221831
also	17221831
have	17221831
a	17221831
pivotal	17221831
role	17221831
in	17221831
the	17221831
control	17221831
of	17221831
neurodegenerative	17221831
processes	17221831
associated	17221831
with	17221831
AD	17221831
.	17221831

In	17221831
this	17221831
report	17221831
the	17221831
distribution	17221831
of	17221831
the	17221831
exonic	17221831
G	17221831
/	17221831
A	17221831
single	17221831
nucleotide	17221831
polymorphism	17221831
(	17221831
SNP	17221831
)	17221831
in	17221831
purine	17221831
nucleoside	17221831
phosphorylase	17221831
(	17221831
PNP	17221831
)	17221831
gene	17221831
,	17221831
resulting	17221831
in	17221831
the	17221831
amino	17221831
acid	17221831
substitution	17221831
serine	17221831
to	17221831
glycine	17221831
at	17221831
position	17221831
51	17221831
(	17221831
G51S	17221831
)	17221831
,	17221831
was	17221831
investigated	17221831
in	17221831
a	17221831
large	17221831
population	17221831
of	17221831
AD	17221831
patients	17221831
(	17221831
n	17221831
=	17221831
321	17221831
)	17221831
and	17221831
non	17221831
-	17221831
demented	17221831
control	17221831
(	17221831
n	17221831
=	17221831
208	17221831
)	17221831
.	17221831

The	17221831
PNP	17221831
polymorphism	17221831
distribution	17221831
was	17221831
not	17221831
different	17221831
between	17221831
patients	17221831
and	17221831
controls	17221831
.	17221831

The	17221831
polymorphism	17221831
distribution	17221831
was	17221831
also	17221831
analyzed	17221831
in	17221831
AD	17221831
patients	17221831
stratified	17221831
according	17221831
to	17221831
differential	17221831
progressive	17221831
rate	17221831
of	17221831
cognitive	17221831
decline	17221831
during	17221831
a	17221831
2	17221831
-	17221831
year	17221831
follow	17221831
-	17221831
up	17221831
.	17221831

An	17221831
increased	17221831
representation	17221831
of	17221831
the	17221831
PNP	17221831
AA	17221831
genotype	17221831
was	17221831
observed	17221831
in	17221831
AD	17221831
patients	17221831
with	17221831
fast	17221831
cognitive	17221831
deterioration	17221831
in	17221831
comparison	17221831
with	17221831
that	17221831
from	17221831
patients	17221831
with	17221831
slow	17221831
deterioration	17221831
rate	17221831
.	17221831

Our	17221831
findings	17221831
suggest	17221831
that	17221831
the	17221831
G51S	17221831
PNP	17221831
polymorphism	17221831
is	17221831
associated	17221831
with	17221831
a	17221831
faster	17221831
rate	17221831
of	17221831
cognitive	17221831
decline	17221831
in	17221831
AD	17221831
patients	17221831
,	17221831
highlighting	17221831
the	17221831
important	17221831
role	17221831
of	17221831
purine	17221831
metabolism	17221831
in	17221831
the	17221831
progression	17221831
of	17221831
this	17221831
neurodegenerative	17221831
disorder	17221831
.	17221831
Antithrombotic	20431083
drug	20431083
use	20431083
,	20431083
cerebral	20431083
microbleeds	20431083
,	20431083
and	20431083
intracerebral	20431083
hemorrhage	20431083
:	20431083
a	20431083
systematic	20431083
review	20431083
of	20431083
published	20431083
and	20431083
unpublished	20431083
studies	20431083
.	20431083

BACKGROUND	20431083
AND	20431083
PURPOSE	20431083
:	20431083
Cerebral	20431083
microbleeds	20431083
(	20431083
MB	20431083
)	20431083
are	20431083
potential	20431083
risk	20431083
factors	20431083
for	20431083
intracerebral	20431083
hemorrhage	20431083
(	20431083
ICH	20431083
)	20431083
,	20431083
but	20431083
it	20431083
is	20431083
unclear	20431083
if	20431083
they	20431083
are	20431083
a	20431083
contraindication	20431083
to	20431083
using	20431083
antithrombotic	20431083
drugs	20431083
.	20431083

Insights	20431083
could	20431083
be	20431083
gained	20431083
by	20431083
pooling	20431083
data	20431083
on	20431083
MB	20431083
frequency	20431083
stratified	20431083
by	20431083
antithrombotic	20431083
use	20431083
in	20431083
cohorts	20431083
with	20431083
ICH	20431083
and	20431083
ischemic	20431083
stroke	20431083
(	20431083
IS	20431083
)	20431083
/	20431083
transient	20431083
ischemic	20431083
attack	20431083
(	20431083
TIA	20431083
)	20431083
.	20431083

METHODS	20431083
:	20431083
We	20431083
performed	20431083
a	20431083
systematic	20431083
review	20431083
of	20431083
published	20431083
and	20431083
unpublished	20431083
data	20431083
from	20431083
cohorts	20431083
with	20431083
stroke	20431083
or	20431083
TIA	20431083
to	20431083
compare	20431083
the	20431083
presence	20431083
of	20431083
MB	20431083
in	20431083
:	20431083
(	20431083
1	20431083
)	20431083
antithrombotic	20431083
users	20431083
vs	20431083
nonantithrombotic	20431083
users	20431083
with	20431083
ICH	20431083
;	20431083
(	20431083
2	20431083
)	20431083
antithrombotic	20431083
users	20431083
vs	20431083
nonusers	20431083
with	20431083
IS	20431083
/	20431083
TIA	20431083
;	20431083
and	20431083
(	20431083
3	20431083
)	20431083
ICH	20431083
vs	20431083
ischemic	20431083
events	20431083
stratified	20431083
by	20431083
antithrombotic	20431083
use	20431083
.	20431083

We	20431083
also	20431083
analyzed	20431083
published	20431083
and	20431083
unpublished	20431083
follow	20431083
-	20431083
up	20431083
data	20431083
to	20431083
determine	20431083
the	20431083
risk	20431083
of	20431083
ICH	20431083
in	20431083
antithrombotic	20431083
users	20431083
with	20431083
MB	20431083
.	20431083

RESULTS	20431083
:	20431083
In	20431083
a	20431083
pooled	20431083
analysis	20431083
of	20431083
1460	20431083
ICH	20431083
and	20431083
3817	20431083
IS	20431083
/	20431083
TIA	20431083
,	20431083
MB	20431083
were	20431083
more	20431083
frequent	20431083
in	20431083
ICH	20431083
vs	20431083
IS	20431083
/	20431083
TIA	20431083
in	20431083
all	20431083
treatment	20431083
groups	20431083
,	20431083
but	20431083
the	20431083
excess	20431083
increased	20431083
from	20431083
2	20431083
.	20431083
8	20431083
(	20431083
odds	20431083
ratio	20431083
;	20431083
range	20431083
,	20431083
2	20431083
.	20431083
3	20431083
-	20431083
3	20431083
.	20431083
5	20431083
)	20431083
in	20431083
nonantithrombotic	20431083
users	20431083
to	20431083
5	20431083
.	20431083
7	20431083
(	20431083
range	20431083
,	20431083
3	20431083
.	20431083
4	20431083
-	20431083
9	20431083
.	20431083
7	20431083
)	20431083
in	20431083
antiplatelet	20431083
users	20431083
and	20431083
8	20431083
.	20431083
0	20431083
(	20431083
range	20431083
,	20431083
3	20431083
.	20431083
5	20431083
-	20431083
17	20431083
.	20431083
8	20431083
)	20431083
in	20431083
warfarin	20431083
users	20431083
(	20431083
P	20431083
difference	20431083
=	20431083
0	20431083
.	20431083
01	20431083
)	20431083
.	20431083

There	20431083
was	20431083
also	20431083
an	20431083
excess	20431083
of	20431083
MB	20431083
in	20431083
warfarin	20431083
users	20431083
vs	20431083
nonusers	20431083
with	20431083
ICH	20431083
(	20431083
OR	20431083
,	20431083
2	20431083
.	20431083
7	20431083
;	20431083
95%	20431083
CI	20431083
,	20431083
1	20431083
.	20431083
6	20431083
-	20431083
4	20431083
.	20431083
4	20431083
;	20431083
P	20431083
<	20431083
0	20431083
.	20431083
001	20431083
)	20431083
but	20431083
none	20431083
in	20431083
warfarin	20431083
users	20431083
with	20431083
IS	20431083
/	20431083
TIA	20431083
(	20431083
OR	20431083
,	20431083
1	20431083
.	20431083
3	20431083
;	20431083
95%	20431083
CI	20431083
,	20431083
0	20431083
.	20431083
9	20431083
-	20431083
1	20431083
.	20431083
7	20431083
;	20431083
P	20431083
=	20431083
0	20431083
.	20431083
33	20431083
;	20431083
P	20431083
difference	20431083
=	20431083
0	20431083
.	20431083
01	20431083
)	20431083
.	20431083

There	20431083
was	20431083
a	20431083
smaller	20431083
excess	20431083
of	20431083
MB	20431083
in	20431083
antiplatelet	20431083
users	20431083
vs	20431083
nonusers	20431083
with	20431083
ICH	20431083
(	20431083
OR	20431083
,	20431083
1	20431083
.	20431083
7	20431083
;	20431083
95%	20431083
CI	20431083
,	20431083
1	20431083
.	20431083
3	20431083
-	20431083
2	20431083
.	20431083
3	20431083
;	20431083
P	20431083
<	20431083
0	20431083
.	20431083
001	20431083
)	20431083
,	20431083
but	20431083
findings	20431083
were	20431083
similar	20431083
for	20431083
antiplatelet	20431083
users	20431083
with	20431083
IS	20431083
/	20431083
TIA	20431083
(	20431083
OR	20431083
,	20431083
1	20431083
.	20431083
4	20431083
;	20431083
95%	20431083
CI	20431083
,	20431083
1	20431083
.	20431083
2	20431083
-	20431083
1	20431083
.	20431083
7	20431083
;	20431083
P	20431083
<	20431083
0	20431083
.	20431083
001	20431083
;	20431083
P	20431083
difference	20431083
=	20431083
0	20431083
.	20431083
25	20431083
)	20431083
.	20431083

In	20431083
pooled	20431083
follow	20431083
-	20431083
up	20431083
data	20431083
for	20431083
768	20431083
antithrombotic	20431083
users	20431083
,	20431083
presence	20431083
of	20431083
MB	20431083
at	20431083
baseline	20431083
was	20431083
associated	20431083
with	20431083
a	20431083
substantially	20431083
increased	20431083
risk	20431083
of	20431083
subsequent	20431083
ICH	20431083
(	20431083
OR	20431083
,	20431083
12	20431083
.	20431083
1	20431083
;	20431083
95%	20431083
CI	20431083
,	20431083
3	20431083
.	20431083
4	20431083
-	20431083
42	20431083
.	20431083
5	20431083
;	20431083
P	20431083
<	20431083
0	20431083
.	20431083
001	20431083
)	20431083
.	20431083

CONCLUSIONS	20431083
:	20431083
The	20431083
excess	20431083
of	20431083
MB	20431083
in	20431083
warfarin	20431083
users	20431083
with	20431083
ICH	20431083
compared	20431083
to	20431083
other	20431083
groups	20431083
suggests	20431083
that	20431083
MB	20431083
increase	20431083
the	20431083
risk	20431083
of	20431083
warfarin	20431083
-	20431083
associated	20431083
ICH	20431083
.	20431083

Limited	20431083
prospective	20431083
data	20431083
corroborate	20431083
these	20431083
findings	20431083
,	20431083
but	20431083
larger	20431083
prospective	20431083
studies	20431083
are	20431083
urgently	20431083
required	20431083
.	20431083
Efficacy	19549709
of	19549709
everolimus	19549709
(	19549709
RAD001	19549709
)	19549709
in	19549709
patients	19549709
with	19549709
advanced	19549709
NSCLC	19549709
previously	19549709
treated	19549709
with	19549709
chemotherapy	19549709
alone	19549709
or	19549709
with	19549709
chemotherapy	19549709
and	19549709
EGFR	19549709
inhibitors	19549709
.	19549709

BACKGROUND	19549709
:	19549709
Treatment	19549709
options	19549709
are	19549709
scarce	19549709
in	19549709
pretreated	19549709
advanced	19549709
non	19549709
-	19549709
small	19549709
-	19549709
cell	19549709
lung	19549709
cancer	19549709
(	19549709
NSCLC	19549709
)	19549709
patients	19549709
.	19549709

RAD001	19549709
,	19549709
an	19549709
oral	19549709
inhibitor	19549709
of	19549709
the	19549709
mammalian	19549709
target	19549709
of	19549709
rapamycin	19549709
(	19549709
mTOR	19549709
)	19549709
,	19549709
has	19549709
shown	19549709
phase	19549709
I	19549709
efficacy	19549709
in	19549709
NSCLC	19549709
.	19549709

METHODS	19549709
:	19549709
Stage	19549709
IIIb	19549709
or	19549709
IV	19549709
NSCLC	19549709
patients	19549709
,	19549709
with	19549709
two	19549709
or	19549709
fewer	19549709
prior	19549709
chemotherapy	19549709
regimens	19549709
,	19549709
one	19549709
platinum	19549709
based	19549709
(	19549709
stratum	19549709
1	19549709
)	19549709
or	19549709
both	19549709
chemotherapy	19549709
and	19549709
epidermal	19549709
growth	19549709
factor	19549709
receptor	19549709
tyrosine	19549709
kinase	19549709
inhibitors	19549709
(	19549709
stratum	19549709
2	19549709
)	19549709
,	19549709
received	19549709
RAD001	19549709
10	19549709
mg	19549709
/	19549709
day	19549709
until	19549709
progression	19549709
or	19549709
unacceptable	19549709
toxicity	19549709
.	19549709

Primary	19549709
objective	19549709
was	19549709
overall	19549709
response	19549709
rate	19549709
(	19549709
ORR	19549709
)	19549709
.	19549709

Analyses	19549709
of	19549709
markers	19549709
associated	19549709
with	19549709
the	19549709
mTOR	19549709
pathway	19549709
were	19549709
carried	19549709
out	19549709
on	19549709
archival	19549709
tumor	19549709
from	19549709
a	19549709
subgroup	19549709
using	19549709
immunohistochemistry	19549709
(	19549709
IHC	19549709
)	19549709
and	19549709
direct	19549709
mutation	19549709
sequencing	19549709
.	19549709

RESULTS	19549709
:	19549709
Eighty	19549709
-	19549709
five	19549709
patients	19549709
were	19549709
enrolled	19549709
,	19549709
42	19549709
in	19549709
stratum	19549709
1	19549709
and	19549709
43	19549709
in	19549709
stratum	19549709
.	19549709

ORR	19549709
was	19549709
4	19549709
.	19549709
7%	19549709
(	19549709
7	19549709
.	19549709
1%	19549709
stratum	19549709
1	19549709
;	19549709
2	19549709
.	19549709
3%	19549709
stratum	19549709
2	19549709
)	19549709
.	19549709

Overall	19549709
disease	19549709
control	19549709
rate	19549709
was	19549709
47	19549709
.	19549709
1%	19549709
.	19549709

Median	19549709
progression	19549709
-	19549709
free	19549709
survivals	19549709
(	19549709
PFSs	19549709
)	19549709
were	19549709
2	19549709
.	19549709
6	19549709
(	19549709
stratum	19549709
1	19549709
)	19549709
and	19549709
2	19549709
.	19549709
7	19549709
months	19549709
(	19549709
stratum	19549709
2	19549709
)	19549709
.	19549709

Common	19549709
>	19549709
or	19549709
=	19549709
grade	19549709
3	19549709
events	19549709
were	19549709
fatigue	19549709
,	19549709
dyspnea	19549709
,	19549709
stomatitis	19549709
,	19549709
anemia	19549709
,	19549709
and	19549709
thrombocytopenia	19549709
.	19549709

Pneumonitis	19549709
,	19549709
probably	19549709
or	19549709
possibly	19549709
related	19549709
,	19549709
mainly	19549709
grade	19549709
1	19549709
/	19549709
2	19549709
,	19549709
occurred	19549709
in	19549709
25%	19549709
.	19549709

Cox	19549709
regression	19549709
analysis	19549709
of	19549709
IHC	19549709
scores	19549709
found	19549709
that	19549709
only	19549709
phospho	19549709
AKT	19549709
(	19549709
pAKT	19549709
)	19549709
was	19549709
a	19549709
significant	19549709
independent	19549709
predictor	19549709
of	19549709
worse	19549709
PFS	19549709
.	19549709

CONCLUSIONS	19549709
:	19549709
RAD001	19549709
10	19549709
mg	19549709
/	19549709
day	19549709
was	19549709
well	19549709
tolerated	19549709
,	19549709
showing	19549709
modest	19549709
clinical	19549709
activity	19549709
in	19549709
pretreated	19549709
NSCLC	19549709
.	19549709

Evaluation	19549709
of	19549709
RAD001	19549709
plus	19549709
standard	19549709
therapy	19549709
for	19549709
metastatic	19549709
NSCLC	19549709
continues	19549709
.	19549709
Decreased	27464336
Whole	27464336
-	27464336
Body	27464336
Fat	27464336
Mass	27464336
Produced	27464336
by	27464336
Chronic	27464336
Alcohol	27464336
Consumption	27464336
is	27464336
Associated	27464336
with	27464336
Activation	27464336
of	27464336
S6K1	27464336
-	27464336
Mediated	27464336
Protein	27464336
Synthesis	27464336
and	27464336
Increased	27464336
Autophagy	27464336
in	27464336
Epididymal	27464336
White	27464336
Adipose	27464336
Tissue	27464336
.	27464336

BACKGROUND	27464336
:	27464336
Chronic	27464336
alcohol	27464336
consumption	27464336
leads	27464336
to	27464336
a	27464336
loss	27464336
of	27464336
white	27464336
adipose	27464336
tissue	27464336
(	27464336
WAT	27464336
)	27464336
but	27464336
the	27464336
underlying	27464336
mechanisms	27464336
for	27464336
this	27464336
lipodystrophy	27464336
are	27464336
not	27464336
fully	27464336
elucidated	27464336
.	27464336

This	27464336
study	27464336
tested	27464336
the	27464336
hypothesis	27464336
that	27464336
the	27464336
reduction	27464336
in	27464336
WAT	27464336
mass	27464336
in	27464336
chronic	27464336
alcohol	27464336
-	27464336
fed	27464336
mice	27464336
is	27464336
associated	27464336
with	27464336
a	27464336
decreased	27464336
protein	27464336
synthesis	27464336
specifically	27464336
related	27464336
to	27464336
impaired	27464336
function	27464336
of	27464336
mammalian	27464336
target	27464336
of	27464336
rapamycin	27464336
(	27464336
mTOR	27464336
)	27464336
.	27464336

METHODS	27464336
:	27464336
Adult	27464336
male	27464336
mice	27464336
were	27464336
provided	27464336
an	27464336
alcohol	27464336
-	27464336
containing	27464336
liquid	27464336
diet	27464336
for	27464336
24	27464336
weeks	27464336
or	27464336
an	27464336
isonitrogenous	27464336
isocaloric	27464336
control	27464336
diet	27464336
.	27464336

In	27464336
vivo	27464336
protein	27464336
synthesis	27464336
was	27464336
determined	27464336
at	27464336
this	27464336
time	27464336
and	27464336
thereafter	27464336
epididymal	27464336
WAT	27464336
(	27464336
eWAT	27464336
)	27464336
was	27464336
excised	27464336
for	27464336
analysis	27464336
of	27464336
signal	27464336
transduction	27464336
pathways	27464336
central	27464336
to	27464336
controling	27464336
protein	27464336
synthesis	27464336
and	27464336
degradation	27464336
.	27464336

RESULTS	27464336
:	27464336
While	27464336
chronic	27464336
alcohol	27464336
feeding	27464336
decreased	27464336
whole	27464336
-	27464336
body	27464336
and	27464336
eWAT	27464336
mass	27464336
,	27464336
this	27464336
was	27464336
associated	27464336
with	27464336
a	27464336
discordant	27464336
increase	27464336
in	27464336
protein	27464336
synthesis	27464336
in	27464336
eWAT	27464336
.	27464336

This	27464336
increase	27464336
was	27464336
not	27464336
associated	27464336
with	27464336
a	27464336
change	27464336
in	27464336
mTOR	27464336
,	27464336
4E	27464336
-	27464336
BP1	27464336
,	27464336
Akt	27464336
,	27464336
or	27464336
PRAS40	27464336
phosphorylation	27464336
.	27464336

Instead	27464336
,	27464336
a	27464336
selective	27464336
increase	27464336
in	27464336
phosphorylation	27464336
of	27464336
S6K1	27464336
and	27464336
its	27464336
downstream	27464336
substrates	27464336
,	27464336
S6	27464336
and	27464336
eIF4B	27464336
was	27464336
detected	27464336
in	27464336
alcohol	27464336
-	27464336
fed	27464336
mice	27464336
.	27464336

Alcohol	27464336
also	27464336
increased	27464336
eEF2K	27464336
phosphorylation	27464336
and	27464336
decreased	27464336
eEF2	27464336
phosphorylation	27464336
consistent	27464336
with	27464336
increased	27464336
translation	27464336
elongation	27464336
.	27464336

Alcohol	27464336
increased	27464336
Atg12	27464336
-	27464336
5	27464336
,	27464336
LC3B	27464336
-	27464336
I	27464336
and	27464336
-	27464336
II	27464336
,	27464336
and	27464336
ULK1	27464336
S555	27464336
phosphorylation	27464336
,	27464336
suggesting	27464336
increased	27464336
autophagy	27464336
,	27464336
while	27464336
markers	27464336
of	27464336
apoptosis	27464336
(	27464336
cleaved	27464336
caspase	27464336
-	27464336
3	27464336
and	27464336
-	27464336
9	27464336
,	27464336
and	27464336
PARP	27464336
)	27464336
were	27464336
unchanged	27464336
.	27464336

Lipolytic	27464336
enzymes	27464336
(	27464336
ATGL	27464336
and	27464336
HSL	27464336
phosphorylation	27464336
)	27464336
were	27464336
increased	27464336
and	27464336
lipogenic	27464336
regulators	27464336
(	27464336
PPARgamma	27464336
and	27464336
C	27464336
/	27464336
EBPalpha	27464336
)	27464336
were	27464336
decreased	27464336
in	27464336
eWAT	27464336
by	27464336
alcohol	27464336
.	27464336

Although	27464336
alcohol	27464336
increased	27464336
TNF	27464336
-	27464336
alpha	27464336
,	27464336
IL	27464336
-	27464336
6	27464336
,	27464336
and	27464336
IL	27464336
-	27464336
1beta	27464336
mRNA	27464336
,	27464336
no	27464336
change	27464336
in	27464336
key	27464336
components	27464336
of	27464336
the	27464336
NLRP3	27464336
inflammasome	27464336
(	27464336
NLRP3	27464336
,	27464336
ACS	27464336
,	27464336
and	27464336
cleaved	27464336
caspase	27464336
-	27464336
1	27464336
)	27464336
was	27464336
detected	27464336
suggesting	27464336
alcohol	27464336
did	27464336
not	27464336
increase	27464336
pyroptosis	27464336
.	27464336

Plasma	27464336
insulin	27464336
did	27464336
not	27464336
differ	27464336
between	27464336
groups	27464336
.	27464336

CONCLUSIONS	27464336
:	27464336
These	27464336
results	27464336
demonstrate	27464336
that	27464336
the	27464336
alcohol	27464336
-	27464336
induced	27464336
decrease	27464336
in	27464336
whole	27464336
-	27464336
body	27464336
fat	27464336
mass	27464336
resulted	27464336
in	27464336
part	27464336
from	27464336
activation	27464336
of	27464336
autophagy	27464336
in	27464336
eWAT	27464336
as	27464336
protein	27464336
synthesis	27464336
was	27464336
increased	27464336
and	27464336
mediated	27464336
by	27464336
the	27464336
specific	27464336
increase	27464336
in	27464336
the	27464336
activity	27464336
of	27464336
S6K1	27464336
.	27464336
A	20005218
potential	20005218
regulatory	20005218
single	20005218
nucleotide	20005218
polymorphism	20005218
in	20005218
the	20005218
promoter	20005218
of	20005218
the	20005218
Klotho	20005218
gene	20005218
may	20005218
be	20005218
associated	20005218
with	20005218
essential	20005218
hypertension	20005218
in	20005218
the	20005218
Chinese	20005218
Han	20005218
population	20005218
.	20005218

BACKGROUND	20005218
:	20005218
Mice	20005218
with	20005218
defects	20005218
in	20005218
the	20005218
Klotho	20005218
gene	20005218
exhibit	20005218
multiple	20005218
aging	20005218
phenotypes	20005218
including	20005218
arteriosclerosis	20005218
.	20005218

We	20005218
hypothesised	20005218
that	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
in	20005218
the	20005218
promoter	20005218
region	20005218
of	20005218
the	20005218
human	20005218
Klotho	20005218
gene	20005218
may	20005218
contribute	20005218
to	20005218
the	20005218
prevalence	20005218
of	20005218
Essential	20005218
Hypertension	20005218
(	20005218
EH	20005218
)	20005218
.	20005218

METHODS	20005218
:	20005218
We	20005218
investigate	20005218
whether	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
of	20005218
Klotho	20005218
is	20005218
associated	20005218
with	20005218
EH	20005218
in	20005218
a	20005218
population	20005218
consisting	20005218
of	20005218
215	20005218
patients	20005218
with	20005218
EH	20005218
and	20005218
220	20005218
non	20005218
-	20005218
hypertensive	20005218
subjects	20005218
.	20005218

We	20005218
also	20005218
tested	20005218
whether	20005218
a	20005218
G	20005218
/	20005218
A	20005218
substitution	20005218
at	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
site	20005218
affected	20005218
the	20005218
transcription	20005218
level	20005218
in	20005218
vitro	20005218
through	20005218
the	20005218
dual	20005218
-	20005218
luciferase	20005218
reporter	20005218
assay	20005218
.	20005218

RESULTS	20005218
:	20005218
Differences	20005218
in	20005218
the	20005218
genotype	20005218
distributions	20005218
of	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
between	20005218
the	20005218
EH	20005218
and	20005218
non	20005218
-	20005218
hypertension	20005218
groups	20005218
are	20005218
statistically	20005218
significant	20005218
(	20005218
P	20005218
=	20005218
0	20005218
.	20005218
032	20005218
)	20005218
.	20005218

There	20005218
are	20005218
differential	20005218
effects	20005218
of	20005218
age	20005218
,	20005218
gender	20005218
and	20005218
smoking	20005218
status	20005218
on	20005218
the	20005218
association	20005218
of	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
with	20005218
EH	20005218
;	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
is	20005218
significantly	20005218
associated	20005218
with	20005218
EH	20005218
in	20005218
subjects	20005218
over	20005218
60years	20005218
old	20005218
,	20005218
in	20005218
females	20005218
and	20005218
in	20005218
nonsmokers	20005218
.	20005218

A	20005218
multiple	20005218
logistic	20005218
regression	20005218
analysis	20005218
indicated	20005218
that	20005218
the	20005218
odds	20005218
ratio	20005218
for	20005218
EH	20005218
in	20005218
the	20005218
-	20005218
395A	20005218
allele	20005218
carriers	20005218
as	20005218
compared	20005218
with	20005218
the	20005218
control	20005218
group	20005218
was	20005218
0	20005218
.	20005218
593	20005218
(	20005218
P	20005218
=	20005218
0	20005218
.	20005218
024	20005218
)	20005218
after	20005218
adjusting	20005218
for	20005218
current	20005218
traditional	20005218
risk	20005218
factors	20005218
.	20005218

The	20005218
dual	20005218
-	20005218
luciferase	20005218
reporter	20005218
assay	20005218
revealed	20005218
that	20005218
the	20005218
-	20005218
395A	20005218
carrier	20005218
of	20005218
a	20005218
498	20005218
-	20005218
bp	20005218
DNA	20005218
fragment	20005218
(	20005218
containing	20005218
the	20005218
G	20005218
-	20005218
395A	20005218
site	20005218
)	20005218
upstream	20005218
of	20005218
the	20005218
Klotho	20005218
gene	20005218
has	20005218
higher	20005218
relative	20005218
luciferase	20005218
activity	20005218
than	20005218
the	20005218
-	20005218
395G	20005218
carrier	20005218
.	20005218

CONCLUSIONS	20005218
:	20005218
The	20005218
G	20005218
-	20005218
395A	20005218
polymorphism	20005218
of	20005218
the	20005218
human	20005218
Klotho	20005218
gene	20005218
is	20005218
associated	20005218
with	20005218
EH	20005218
and	20005218
may	20005218
be	20005218
a	20005218
potential	20005218
regulatory	20005218
site	20005218
.	20005218
Protective	18541230
effects	18541230
of	18541230
antithrombin	18541230
on	18541230
puromycin	18541230
aminonucleoside	18541230
nephrosis	18541230
in	18541230
rats	18541230
.	18541230

We	18541230
investigated	18541230
the	18541230
effects	18541230
of	18541230
antithrombin	18541230
,	18541230
a	18541230
plasma	18541230
inhibitor	18541230
of	18541230
coagulation	18541230
factors	18541230
,	18541230
in	18541230
rats	18541230
with	18541230
puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
nephrosis	18541230
,	18541230
which	18541230
is	18541230
an	18541230
experimental	18541230
model	18541230
of	18541230
human	18541230
nephrotic	18541230
syndrome	18541230
.	18541230

Antithrombin	18541230
(	18541230
50	18541230
or	18541230
500	18541230
IU	18541230
/	18541230
kg	18541230
/	18541230
i	18541230
.	18541230
v	18541230
.	18541230
)	18541230
was	18541230
administered	18541230
to	18541230
rats	18541230
once	18541230
a	18541230
day	18541230
for	18541230
10	18541230
days	18541230
immediately	18541230
after	18541230
the	18541230
injection	18541230
of	18541230
puromycin	18541230
aminonucleoside	18541230
(	18541230
50	18541230
mg	18541230
/	18541230
kg	18541230
/	18541230
i	18541230
.	18541230
v	18541230
.	18541230
)	18541230
.	18541230

Treatment	18541230
with	18541230
antithrombin	18541230
attenuated	18541230
the	18541230
puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
hematological	18541230
abnormalities	18541230
.	18541230

Puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
renal	18541230
dysfunction	18541230
and	18541230
hyperlipidemia	18541230
were	18541230
also	18541230
suppressed	18541230
.	18541230

Histopathological	18541230
examination	18541230
revealed	18541230
severe	18541230
renal	18541230
damage	18541230
such	18541230
as	18541230
proteinaceous	18541230
casts	18541230
in	18541230
tubuli	18541230
and	18541230
tubular	18541230
expansion	18541230
in	18541230
the	18541230
kidney	18541230
of	18541230
control	18541230
rats	18541230
,	18541230
while	18541230
an	18541230
improvement	18541230
of	18541230
the	18541230
damage	18541230
was	18541230
seen	18541230
in	18541230
antithrombin	18541230
-	18541230
treated	18541230
rats	18541230
.	18541230

In	18541230
addition	18541230
,	18541230
antithrombin	18541230
treatment	18541230
markedly	18541230
suppressed	18541230
puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
apoptosis	18541230
of	18541230
renal	18541230
tubular	18541230
epithelial	18541230
cells	18541230
.	18541230

Furthermore	18541230
,	18541230
puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
increases	18541230
in	18541230
renal	18541230
cytokine	18541230
content	18541230
were	18541230
also	18541230
decreased	18541230
.	18541230

These	18541230
findings	18541230
suggest	18541230
that	18541230
thrombin	18541230
plays	18541230
an	18541230
important	18541230
role	18541230
in	18541230
the	18541230
pathogenesis	18541230
of	18541230
puromycin	18541230
aminonucleoside	18541230
-	18541230
induced	18541230
nephrotic	18541230
syndrome	18541230
.	18541230

Treatment	18541230
with	18541230
antithrombin	18541230
may	18541230
be	18541230
clinically	18541230
effective	18541230
in	18541230
patients	18541230
with	18541230
nephrotic	18541230
syndrome	18541230
.	18541230
A	28747658
single	28747658
amino	28747658
acid	28747658
substitution	28747658
confers	28747658
B	28747658
-	28747658
cell	28747658
clonogenic	28747658
activity	28747658
to	28747658
the	28747658
HIV	28747658
-	28747658
1	28747658
matrix	28747658
protein	28747658
p17	28747658
.	28747658

Recent	28747658
data	28747658
highlight	28747658
the	28747658
presence	28747658
,	28747658
in	28747658
HIV	28747658
-	28747658
1	28747658
-	28747658
seropositive	28747658
patients	28747658
with	28747658
lymphoma	28747658
,	28747658
of	28747658
p17	28747658
variants	28747658
(	28747658
vp17s	28747658
)	28747658
endowed	28747658
with	28747658
B	28747658
-	28747658
cell	28747658
clonogenicity	28747658
,	28747658
suggesting	28747658
a	28747658
role	28747658
of	28747658
vp17s	28747658
in	28747658
lymphomagenesis	28747658
.	28747658

We	28747658
investigated	28747658
the	28747658
mechanisms	28747658
responsible	28747658
for	28747658
the	28747658
functional	28747658
disparity	28747658
on	28747658
B	28747658
cells	28747658
between	28747658
a	28747658
wild	28747658
-	28747658
type	28747658
p17	28747658
(	28747658
refp17	28747658
)	28747658
and	28747658
a	28747658
vp17	28747658
named	28747658
S75X	28747658
.	28747658

Here	28747658
,	28747658
we	28747658
show	28747658
that	28747658
a	28747658
single	28747658
Arginine	28747658
(	28747658
R	28747658
)	28747658
to	28747658
Glycine	28747658
(	28747658
G	28747658
)	28747658
mutation	28747658
at	28747658
position	28747658
76	28747658
in	28747658
the	28747658
refp17	28747658
backbone	28747658
(	28747658
p17R76G	28747658
)	28747658
,	28747658
as	28747658
in	28747658
the	28747658
S75X	28747658
variant	28747658
,	28747658
is	28747658
per	28747658
se	28747658
sufficient	28747658
to	28747658
confer	28747658
a	28747658
B	28747658
-	28747658
cell	28747658
clonogenic	28747658
potential	28747658
to	28747658
the	28747658
viral	28747658
protein	28747658
and	28747658
modulate	28747658
,	28747658
through	28747658
activation	28747658
of	28747658
the	28747658
PTEN	28747658
/	28747658
PI3K	28747658
/	28747658
Akt	28747658
signaling	28747658
pathway	28747658
,	28747658
different	28747658
molecules	28747658
involved	28747658
in	28747658
apoptosis	28747658
inhibition	28747658
(	28747658
CASP	28747658
-	28747658
9	28747658
,	28747658
CASP	28747658
-	28747658
7	28747658
,	28747658
DFF	28747658
-	28747658
45	28747658
,	28747658
NPM	28747658
,	28747658
YWHAZ	28747658
,	28747658
Src	28747658
,	28747658
PAX2	28747658
,	28747658
MAPK8	28747658
)	28747658
,	28747658
cell	28747658
cycle	28747658
promotion	28747658
and	28747658
cancer	28747658
progression	28747658
(	28747658
CDK1	28747658
,	28747658
CDK2	28747658
,	28747658
CDK8	28747658
,	28747658
CHEK1	28747658
,	28747658
CHEK2	28747658
,	28747658
GSK	28747658
-	28747658
3	28747658
beta	28747658
,	28747658
NPM	28747658
,	28747658
PAK1	28747658
,	28747658
PP2C	28747658
-	28747658
alpha	28747658
)	28747658
.	28747658

Moreover	28747658
,	28747658
the	28747658
only	28747658
R	28747658
to	28747658
G	28747658
mutation	28747658
at	28747658
position	28747658
76	28747658
was	28747658
found	28747658
to	28747658
strongly	28747658
impact	28747658
on	28747658
protein	28747658
folding	28747658
and	28747658
oligomerization	28747658
by	28747658
altering	28747658
the	28747658
hydrogen	28747658
bond	28747658
network	28747658
.	28747658

This	28747658
generates	28747658
a	28747658
conformational	28747658
shift	28747658
in	28747658
the	28747658
p17	28747658
R76G	28747658
mutant	28747658
which	28747658
enables	28747658
a	28747658
functional	28747658
epitope	28747658
(	28747658
s	28747658
)	28747658
,	28747658
masked	28747658
in	28747658
refp17	28747658
,	28747658
to	28747658
elicit	28747658
B	28747658
-	28747658
cell	28747658
growth	28747658
-	28747658
promoting	28747658
signals	28747658
after	28747658
its	28747658
interaction	28747658
with	28747658
a	28747658
still	28747658
unknown	28747658
receptor	28747658
(	28747658
s	28747658
)	28747658
.	28747658

Our	28747658
findings	28747658
offer	28747658
new	28747658
opportunities	28747658
to	28747658
understand	28747658
the	28747658
molecular	28747658
mechanisms	28747658
accounting	28747658
for	28747658
the	28747658
B	28747658
-	28747658
cell	28747658
growth	28747658
-	28747658
promoting	28747658
activity	28747658
of	28747658
vp17s	28747658
.	28747658
Mutation	18179903
analysis	18179903
of	18179903
CHRNA1	18179903
,	18179903
CHRNB1	18179903
,	18179903
CHRND	18179903
,	18179903
and	18179903
RAPSN	18179903
genes	18179903
in	18179903
multiple	18179903
pterygium	18179903
syndrome	18179903
/	18179903
fetal	18179903
akinesia	18179903
patients	18179903
.	18179903

Multiple	18179903
pterygium	18179903
syndromes	18179903
(	18179903
MPS	18179903
)	18179903
comprise	18179903
a	18179903
group	18179903
of	18179903
multiple	18179903
congenital	18179903
anomaly	18179903
disorders	18179903
characterized	18179903
by	18179903
webbing	18179903
(	18179903
pterygia	18179903
)	18179903
of	18179903
the	18179903
neck	18179903
,	18179903
elbows	18179903
,	18179903
and	18179903
/	18179903
or	18179903
knees	18179903
and	18179903
joint	18179903
contractures	18179903
(	18179903
arthrogryposis	18179903
)	18179903
.	18179903

MPS	18179903
are	18179903
phenotypically	18179903
and	18179903
genetically	18179903
heterogeneous	18179903
but	18179903
are	18179903
traditionally	18179903
divided	18179903
into	18179903
prenatally	18179903
lethal	18179903
and	18179903
nonlethal	18179903
(	18179903
Escobar	18179903
)	18179903
types	18179903
.	18179903

Previously	18179903
,	18179903
we	18179903
and	18179903
others	18179903
reported	18179903
that	18179903
recessive	18179903
mutations	18179903
in	18179903
the	18179903
embryonal	18179903
acetylcholine	18179903
receptor	18179903
g	18179903
subunit	18179903
(	18179903
CHRNG	18179903
)	18179903
can	18179903
cause	18179903
both	18179903
lethal	18179903
and	18179903
nonlethal	18179903
MPS	18179903
,	18179903
thus	18179903
demonstrating	18179903
that	18179903
pterygia	18179903
resulted	18179903
from	18179903
fetal	18179903
akinesia	18179903
.	18179903

We	18179903
hypothesized	18179903
that	18179903
mutations	18179903
in	18179903
acetylcholine	18179903
receptor	18179903
-	18179903
related	18179903
genes	18179903
might	18179903
also	18179903
result	18179903
in	18179903
a	18179903
MPS	18179903
/	18179903
fetal	18179903
akinesia	18179903
phenotype	18179903
and	18179903
so	18179903
we	18179903
analyzed	18179903
15	18179903
cases	18179903
of	18179903
lethal	18179903
MPS	18179903
/	18179903
fetal	18179903
akinesia	18179903
without	18179903
CHRNG	18179903
mutations	18179903
for	18179903
mutations	18179903
in	18179903
the	18179903
CHRNA1	18179903
,	18179903
CHRNB1	18179903
,	18179903
CHRND	18179903
,	18179903
and	18179903
rapsyn	18179903
(	18179903
RAPSN	18179903
)	18179903
genes	18179903
.	18179903

No	18179903
CHRNA1	18179903
,	18179903
CHRNB1	18179903
,	18179903
or	18179903
CHRND	18179903
mutations	18179903
were	18179903
detected	18179903
,	18179903
but	18179903
a	18179903
homozygous	18179903
RAPSN	18179903
frameshift	18179903
mutation	18179903
,	18179903
c	18179903
.	18179903
1177	18179903
-	18179903
1178delAA	18179903
,	18179903
was	18179903
identified	18179903
in	18179903
a	18179903
family	18179903
with	18179903
three	18179903
children	18179903
affected	18179903
with	18179903
lethal	18179903
fetal	18179903
akinesia	18179903
sequence	18179903
.	18179903

Previously	18179903
,	18179903
RAPSN	18179903
mutations	18179903
have	18179903
been	18179903
reported	18179903
in	18179903
congenital	18179903
myasthenia	18179903
.	18179903

Functional	18179903
studies	18179903
were	18179903
consistent	18179903
with	18179903
the	18179903
hypothesis	18179903
that	18179903
whereas	18179903
incomplete	18179903
loss	18179903
of	18179903
rapsyn	18179903
function	18179903
may	18179903
cause	18179903
congenital	18179903
myasthenia	18179903
,	18179903
more	18179903
severe	18179903
loss	18179903
of	18179903
function	18179903
can	18179903
result	18179903
in	18179903
a	18179903
lethal	18179903
fetal	18179903
akinesia	18179903
phenotype	18179903
.	18179903
Comparison	15018851
of	15018851
sequential	15018851
cytomegalovirus	15018851
isolates	15018851
in	15018851
a	15018851
patient	15018851
with	15018851
lymphoma	15018851
and	15018851
failing	15018851
antiviral	15018851
therapy	15018851
.	15018851

BACKGROUND	15018851
:	15018851
Long	15018851
-	15018851
term	15018851
anti	15018851
-	15018851
cytomegalovirus	15018851
(	15018851
CMV	15018851
)	15018851
treatments	15018851
in	15018851
immunocompromised	15018851
patients	15018851
are	15018851
hampered	15018851
by	15018851
resistance	15018851
to	15018851
antiviral	15018851
drugs	15018851
.	15018851

Longitudinal	15018851
changes	15018851
in	15018851
the	15018851
resistance	15018851
genotype	15018851
may	15018851
depend	15018851
on	15018851
changes	15018851
in	15018851
selective	15018851
pressure	15018851
and	15018851
the	15018851
complexity	15018851
of	15018851
CMV	15018851
isolates	15018851
.	15018851

OBJECTIVE	15018851
:	15018851
To	15018851
evaluate	15018851
longitudinal	15018851
changes	15018851
in	15018851
the	15018851
CMV	15018851
resistance	15018851
genotype	15018851
and	15018851
phenotype	15018851
along	15018851
with	15018851
strain	15018851
-	15018851
specific	15018851
variability	15018851
in	15018851
a	15018851
patient	15018851
with	15018851
non	15018851
-	15018851
Hodgkin	15018851
'	15018851
s	15018851
lymphoma	15018851
in	15018851
whom	15018851
successive	15018851
anti	15018851
-	15018851
CMV	15018851
treatments	15018851
failed	15018851
.	15018851

STUDY	15018851
DESIGN	15018851
:	15018851
The	15018851
resistance	15018851
phenotype	15018851
and	15018851
genotype	15018851
of	15018851
seven	15018851
CMV	15018851
isolates	15018851
collected	15018851
from	15018851
one	15018851
patient	15018851
during	15018851
a	15018851
2	15018851
-	15018851
year	15018851
follow	15018851
-	15018851
up	15018851
period	15018851
were	15018851
retrospectively	15018851
analysed	15018851
.	15018851

In	15018851
parallel	15018851
,	15018851
we	15018851
used	15018851
glycoprotein	15018851
B	15018851
(	15018851
gB	15018851
)	15018851
genotyping	15018851
,	15018851
and	15018851
a	15018851
-	15018851
and	15018851
UL10	15018851
-	15018851
13	15018851
-	15018851
sequence	15018851
analysis	15018851
to	15018851
study	15018851
CMV	15018851
interstrain	15018851
variability	15018851
.	15018851

RESULTS	15018851
:	15018851
The	15018851
patient	15018851
was	15018851
infected	15018851
by	15018851
at	15018851
least	15018851
three	15018851
CMV	15018851
strains	15018851
plus	15018851
variants	15018851
of	15018851
the	15018851
parental	15018851
strains	15018851
.	15018851

Resistance	15018851
to	15018851
ganciclovir	15018851
,	15018851
cidofovir	15018851
and	15018851
foscarnet	15018851
was	15018851
successively	15018851
detected	15018851
during	15018851
the	15018851
follow	15018851
-	15018851
up	15018851
period	15018851
.	15018851

UL97	15018851
protein	15018851
kinase	15018851
changes	15018851
responsible	15018851
for	15018851
resistance	15018851
to	15018851
ganciclovir	15018851
were	15018851
initially	15018851
detected	15018851
at	15018851
residues	15018851
591	15018851
and	15018851
592	15018851
,	15018851
and	15018851
then	15018851
at	15018851
position	15018851
594	15018851
.	15018851

Decreased	15018851
sensitivity	15018851
to	15018851
foscarnet	15018851
coincided	15018851
with	15018851
the	15018851
appearance	15018851
of	15018851
amino	15018851
acid	15018851
substitution	15018851
N495K	15018851
in	15018851
DNA	15018851
polymerase	15018851
,	15018851
whereas	15018851
cross	15018851
-	15018851
resistance	15018851
to	15018851
ganciclovir	15018851
and	15018851
cidofovir	15018851
was	15018851
due	15018851
to	15018851
the	15018851
L501I	15018851
substitution	15018851
.	15018851

CONCLUSIONS	15018851
:	15018851
The	15018851
CMV	15018851
isolates	15018851
obtained	15018851
from	15018851
our	15018851
patient	15018851
were	15018851
complex	15018851
mixtures	15018851
of	15018851
strains	15018851
.	15018851

Changes	15018851
in	15018851
resistance	15018851
genotypes	15018851
depended	15018851
on	15018851
resistance	15018851
selective	15018851
pressure	15018851
and	15018851
were	15018851
not	15018851
linked	15018851
to	15018851
interstrain	15018851
variation	15018851
.	15018851
Bortezomib	23864035
and	23864035
dexamethasone	23864035
as	23864035
salvage	23864035
therapy	23864035
in	23864035
patients	23864035
with	23864035
relapsed	23864035
/	23864035
refractory	23864035
multiple	23864035
myeloma	23864035
:	23864035
analysis	23864035
of	23864035
long	23864035
-	23864035
term	23864035
clinical	23864035
outcomes	23864035
.	23864035

Bortezomib	23864035
(	23864035
bort	23864035
)	23864035
-	23864035
dexamethasone	23864035
(	23864035
dex	23864035
)	23864035
is	23864035
an	23864035
effective	23864035
therapy	23864035
for	23864035
relapsed	23864035
/	23864035
refractory	23864035
(	23864035
R	23864035
/	23864035
R	23864035
)	23864035
multiple	23864035
myeloma	23864035
(	23864035
MM	23864035
)	23864035
.	23864035

This	23864035
retrospective	23864035
study	23864035
investigated	23864035
the	23864035
combination	23864035
of	23864035
bort	23864035
(	23864035
1	23864035
.	23864035
3	23864035
mg	23864035
/	23864035
m	23864035
(	23864035
2	23864035
)	23864035
on	23864035
days	23864035
1	23864035
,	23864035
4	23864035
,	23864035
8	23864035
,	23864035
and	23864035
11	23864035
every	23864035
3	23864035
weeks	23864035
)	23864035
and	23864035
dex	23864035
(	23864035
20	23864035
mg	23864035
on	23864035
the	23864035
day	23864035
of	23864035
and	23864035
the	23864035
day	23864035
after	23864035
bort	23864035
)	23864035
as	23864035
salvage	23864035
treatment	23864035
in	23864035
85	23864035
patients	23864035
with	23864035
R	23864035
/	23864035
R	23864035
MM	23864035
after	23864035
prior	23864035
autologous	23864035
stem	23864035
cell	23864035
transplantation	23864035
or	23864035
conventional	23864035
chemotherapy	23864035
.	23864035

The	23864035
median	23864035
number	23864035
of	23864035
prior	23864035
lines	23864035
of	23864035
therapy	23864035
was	23864035
2	23864035
.	23864035

Eighty	23864035
-	23864035
seven	23864035
percent	23864035
of	23864035
the	23864035
patients	23864035
had	23864035
received	23864035
immunomodulatory	23864035
drugs	23864035
included	23864035
in	23864035
some	23864035
line	23864035
of	23864035
therapy	23864035
before	23864035
bort	23864035
-	23864035
dex	23864035
.	23864035

The	23864035
median	23864035
number	23864035
of	23864035
bort	23864035
-	23864035
dex	23864035
cycles	23864035
was	23864035
6	23864035
,	23864035
up	23864035
to	23864035
a	23864035
maximum	23864035
of	23864035
12	23864035
cycles	23864035
.	23864035

On	23864035
an	23864035
intention	23864035
-	23864035
to	23864035
-	23864035
treat	23864035
basis	23864035
,	23864035
55	23864035
%	23864035
of	23864035
the	23864035
patients	23864035
achieved	23864035
at	23864035
least	23864035
partial	23864035
response	23864035
,	23864035
including	23864035
19	23864035
%	23864035
CR	23864035
and	23864035
35	23864035
%	23864035
achieved	23864035
at	23864035
least	23864035
very	23864035
good	23864035
partial	23864035
response	23864035
.	23864035

Median	23864035
durations	23864035
of	23864035
response	23864035
,	23864035
time	23864035
to	23864035
next	23864035
therapy	23864035
and	23864035
treatment	23864035
-	23864035
free	23864035
interval	23864035
were	23864035
8	23864035
,	23864035
11	23864035
.	23864035
2	23864035
,	23864035
and	23864035
5	23864035
.	23864035
1	23864035
months	23864035
,	23864035
respectively	23864035
.	23864035

The	23864035
most	23864035
relevant	23864035
adverse	23864035
event	23864035
was	23864035
peripheral	23864035
neuropathy	23864035
,	23864035
which	23864035
occurred	23864035
in	23864035
78	23864035
%	23864035
of	23864035
the	23864035
patients	23864035
(	23864035
grade	23864035
II	23864035
,	23864035
38	23864035
%	23864035
;	23864035
grade	23864035
III	23864035
,	23864035
21	23864035
%	23864035
)	23864035
and	23864035
led	23864035
to	23864035
treatment	23864035
discontinuation	23864035
in	23864035
6	23864035
%	23864035
.	23864035

With	23864035
a	23864035
median	23864035
follow	23864035
up	23864035
of	23864035
22	23864035
months	23864035
,	23864035
median	23864035
time	23864035
to	23864035
progression	23864035
,	23864035
progression	23864035
-	23864035
free	23864035
survival	23864035
(	23864035
PFS	23864035
)	23864035
and	23864035
overall	23864035
survival	23864035
(	23864035
OS	23864035
)	23864035
were	23864035
8	23864035
.	23864035
9	23864035
,	23864035
8	23864035
.	23864035
7	23864035
,	23864035
and	23864035
22	23864035
months	23864035
,	23864035
respectively	23864035
.	23864035

Prolonged	23864035
PFS	23864035
and	23864035
OS	23864035
were	23864035
observed	23864035
in	23864035
patients	23864035
achieving	23864035
CR	23864035
and	23864035
receiving	23864035
bort	23864035
-	23864035
dex	23864035
a	23864035
single	23864035
line	23864035
of	23864035
prior	23864035
therapy	23864035
.	23864035

Bort	23864035
-	23864035
dex	23864035
was	23864035
an	23864035
effective	23864035
salvage	23864035
treatment	23864035
for	23864035
MM	23864035
patients	23864035
,	23864035
particularly	23864035
for	23864035
those	23864035
in	23864035
first	23864035
relapse	23864035
.	23864035
Adenosine	19565319
A	19565319
(	19565319
2A	19565319
)	19565319
receptor	19565319
gene	19565319
(	19565319
ADORA2A	19565319
)	19565319
variants	19565319
may	19565319
increase	19565319
autistic	19565319
symptoms	19565319
and	19565319
anxiety	19565319
in	19565319
autism	19565319
spectrum	19565319
disorder	19565319
.	19565319

Autism	19565319
spectrum	19565319
disorders	19565319
(	19565319
ASDs	19565319
)	19565319
are	19565319
heterogeneous	19565319
disorders	19565319
presenting	19565319
with	19565319
increased	19565319
rates	19565319
of	19565319
anxiety	19565319
.	19565319

The	19565319
adenosine	19565319
A	19565319
(	19565319
2A	19565319
)	19565319
receptor	19565319
gene	19565319
(	19565319
ADORA2A	19565319
)	19565319
is	19565319
associated	19565319
with	19565319
panic	19565319
disorder	19565319
and	19565319
is	19565319
located	19565319
on	19565319
chromosome	19565319
22q11	19565319
.	19565319
23	19565319
.	19565319

Its	19565319
gene	19565319
product	19565319
,	19565319
the	19565319
adenosine	19565319
A	19565319
(	19565319
2A	19565319
)	19565319
receptor	19565319
,	19565319
is	19565319
strongly	19565319
expressed	19565319
in	19565319
the	19565319
caudate	19565319
nucleus	19565319
,	19565319
which	19565319
also	19565319
is	19565319
involved	19565319
in	19565319
ASD	19565319
.	19565319

As	19565319
autistic	19565319
symptoms	19565319
are	19565319
increased	19565319
in	19565319
individuals	19565319
with	19565319
22q11	19565319
.	19565319
2	19565319
deletion	19565319
syndrome	19565319
,	19565319
and	19565319
large	19565319
22q11	19565319
.	19565319
2	19565319
deletions	19565319
and	19565319
duplications	19565319
have	19565319
been	19565319
observed	19565319
in	19565319
ASD	19565319
individuals	19565319
,	19565319
in	19565319
this	19565319
study	19565319
,	19565319
98	19565319
individuals	19565319
with	19565319
ASD	19565319
and	19565319
234	19565319
control	19565319
individuals	19565319
were	19565319
genotyped	19565319
for	19565319
eight	19565319
single	19565319
-	19565319
nucleotide	19565319
polymorphisms	19565319
in	19565319
ADORA2A	19565319
.	19565319

Nominal	19565319
association	19565319
with	19565319
the	19565319
disorder	19565319
was	19565319
observed	19565319
for	19565319
rs2236624	19565319
-	19565319
CC	19565319
,	19565319
and	19565319
phenotypic	19565319
variability	19565319
in	19565319
ASD	19565319
symptoms	19565319
was	19565319
influenced	19565319
by	19565319
rs3761422	19565319
,	19565319
rs5751876	19565319
and	19565319
rs35320474	19565319
.	19565319

In	19565319
addition	19565319
,	19565319
association	19565319
of	19565319
ADORA2A	19565319
variants	19565319
with	19565319
anxiety	19565319
was	19565319
replicated	19565319
for	19565319
individuals	19565319
with	19565319
ASD	19565319
.	19565319

Findings	19565319
point	19565319
toward	19565319
a	19565319
possible	19565319
mediating	19565319
role	19565319
of	19565319
ADORA2A	19565319
variants	19565319
on	19565319
phenotypic	19565319
expression	19565319
in	19565319
ASD	19565319
that	19565319
need	19565319
to	19565319
be	19565319
replicated	19565319
in	19565319
a	19565319
larger	19565319
sample	19565319
.	19565319
Hypoxia	15579441
in	15579441
renal	15579441
disease	15579441
with	15579441
proteinuria	15579441
and	15579441
/	15579441
or	15579441
glomerular	15579441
hypertension	15579441
.	15579441

Despite	15579441
the	15579441
increasing	15579441
need	15579441
to	15579441
identify	15579441
and	15579441
quantify	15579441
tissue	15579441
oxygenation	15579441
at	15579441
the	15579441
cellular	15579441
level	15579441
,	15579441
relatively	15579441
few	15579441
methods	15579441
have	15579441
been	15579441
available	15579441
.	15579441

In	15579441
this	15579441
study	15579441
,	15579441
we	15579441
developed	15579441
a	15579441
new	15579441
hypoxia	15579441
-	15579441
responsive	15579441
reporter	15579441
vector	15579441
using	15579441
a	15579441
hypoxia	15579441
-	15579441
responsive	15579441
element	15579441
of	15579441
the	15579441
5	15579441
'	15579441
vascular	15579441
endothelial	15579441
growth	15579441
factor	15579441
untranslated	15579441
region	15579441
and	15579441
generated	15579441
a	15579441
novel	15579441
hypoxia	15579441
-	15579441
sensing	15579441
transgenic	15579441
rat	15579441
.	15579441

We	15579441
then	15579441
applied	15579441
this	15579441
animal	15579441
model	15579441
to	15579441
the	15579441
detection	15579441
of	15579441
tubulointerstitial	15579441
hypoxia	15579441
in	15579441
the	15579441
diseased	15579441
kidney	15579441
.	15579441

With	15579441
this	15579441
model	15579441
,	15579441
we	15579441
were	15579441
able	15579441
to	15579441
identify	15579441
diffuse	15579441
cortical	15579441
hypoxia	15579441
in	15579441
the	15579441
puromycin	15579441
aminonucleoside	15579441
-	15579441
induced	15579441
nephrotic	15579441
syndrome	15579441
and	15579441
focal	15579441
and	15579441
segmental	15579441
hypoxia	15579441
in	15579441
the	15579441
remnant	15579441
kidney	15579441
model	15579441
.	15579441

Expression	15579441
of	15579441
the	15579441
hypoxia	15579441
-	15579441
responsive	15579441
transgene	15579441
increased	15579441
throughout	15579441
the	15579441
observation	15579441
period	15579441
,	15579441
reaching	15579441
2	15579441
.	15579441
2	15579441
-	15579441
fold	15579441
at	15579441
2	15579441
weeks	15579441
in	15579441
the	15579441
puromycin	15579441
aminonucleoside	15579441
model	15579441
and	15579441
2	15579441
.	15579441
6	15579441
-	15579441
fold	15579441
at	15579441
4	15579441
weeks	15579441
in	15579441
the	15579441
remnant	15579441
kidney	15579441
model	15579441
,	15579441
whereas	15579441
that	15579441
of	15579441
vascular	15579441
endothelial	15579441
growth	15579441
factor	15579441
showed	15579441
a	15579441
mild	15579441
decrease	15579441
,	15579441
reflecting	15579441
distinct	15579441
behaviors	15579441
of	15579441
the	15579441
two	15579441
genes	15579441
.	15579441

The	15579441
degree	15579441
of	15579441
hypoxia	15579441
showed	15579441
a	15579441
positive	15579441
correlation	15579441
with	15579441
microscopic	15579441
tubulointerstitial	15579441
injury	15579441
in	15579441
both	15579441
models	15579441
.	15579441

Finally	15579441
,	15579441
we	15579441
identified	15579441
the	15579441
localization	15579441
of	15579441
proliferating	15579441
cell	15579441
nuclear	15579441
antigen	15579441
-	15579441
positive	15579441
,	15579441
ED	15579441
-	15579441
1	15579441
-	15579441
positive	15579441
,	15579441
and	15579441
terminal	15579441
dUTP	15579441
nick	15579441
-	15579441
end	15579441
labeled	15579441
-	15579441
positive	15579441
cells	15579441
in	15579441
the	15579441
hypoxic	15579441
cortical	15579441
area	15579441
in	15579441
the	15579441
remnant	15579441
kidney	15579441
model	15579441
.	15579441

We	15579441
propose	15579441
here	15579441
a	15579441
possible	15579441
pathological	15579441
tie	15579441
between	15579441
chronic	15579441
tubulointerstitial	15579441
hypoxia	15579441
and	15579441
progressive	15579441
glomerular	15579441
diseases	15579441
.	15579441
Anxiogenic	17975693
potential	17975693
of	17975693
ciprofloxacin	17975693
and	17975693
norfloxacin	17975693
in	17975693
rats	17975693
.	17975693

INTRODUCTION	17975693
:	17975693
The	17975693
possible	17975693
anxiogenic	17975693
effects	17975693
of	17975693
fluoroquinolones	17975693
,	17975693
namely	17975693
ciprofloxacin	17975693
and	17975693
norfloxacin	17975693
,	17975693
were	17975693
investigated	17975693
in	17975693
adult	17975693
Charles	17975693
Foster	17975693
albino	17975693
rats	17975693
of	17975693
either	17975693
sex	17975693
,	17975693
weighing	17975693
150	17975693
-	17975693
200	17975693
g	17975693
.	17975693

METHODS	17975693
:	17975693
The	17975693
drugs	17975693
were	17975693
given	17975693
orally	17975693
,	17975693
in	17975693
doses	17975693
of	17975693
50	17975693
mg	17975693
/	17975693
kg	17975693
for	17975693
five	17975693
consecutive	17975693
days	17975693
and	17975693
the	17975693
experiments	17975693
were	17975693
performed	17975693
on	17975693
the	17975693
fifth	17975693
day	17975693
.	17975693

The	17975693
tests	17975693
included	17975693
open	17975693
-	17975693
field	17975693
exploratory	17975693
behaviour	17975693
,	17975693
elevated	17975693
plus	17975693
maze	17975693
and	17975693
elevated	17975693
zero	17975693
maze	17975693
,	17975693
social	17975693
interaction	17975693
and	17975693
novelty	17975693
-	17975693
suppressed	17975693
feeding	17975693
latency	17975693
behaviour	17975693
.	17975693

RESULTS	17975693
:	17975693
The	17975693
results	17975693
indicate	17975693
that	17975693
ciprofloxacin	17975693
-	17975693
and	17975693
norfloxacin	17975693
-	17975693
treated	17975693
rats	17975693
showed	17975693
anxious	17975693
behaviour	17975693
in	17975693
comparison	17975693
to	17975693
control	17975693
rats	17975693
in	17975693
all	17975693
the	17975693
parameters	17975693
studied	17975693
.	17975693

However	17975693
,	17975693
ciprofloxacin	17975693
-	17975693
and	17975693
norfloxacin	17975693
-	17975693
treated	17975693
rats	17975693
did	17975693
not	17975693
differ	17975693
significantly	17975693
from	17975693
each	17975693
other	17975693
in	17975693
various	17975693
behavioural	17975693
parameters	17975693
.	17975693

CONCLUSION	17975693
:	17975693
The	17975693
present	17975693
experimental	17975693
findings	17975693
substantiate	17975693
the	17975693
clinically	17975693
observed	17975693
anxiogenic	17975693
potential	17975693
of	17975693
ciprofloxacin	17975693
and	17975693
norfloxacin	17975693
.	17975693
Cytochrome	17192049
p4501A1	17192049
gene	17192049
variants	17192049
as	17192049
susceptibility	17192049
marker	17192049
for	17192049
prostate	17192049
cancer	17192049
.	17192049

CYP1A1	17192049
activates	17192049
environmental	17192049
procarcinogens	17192049
and	17192049
catalyzes	17192049
oxidative	17192049
metabolism	17192049
of	17192049
estrogens	17192049
and	17192049
is	17192049
likely	17192049
to	17192049
play	17192049
an	17192049
important	17192049
role	17192049
in	17192049
the	17192049
etiology	17192049
of	17192049
prostate	17192049
cancer	17192049
.	17192049

To	17192049
evaluate	17192049
this	17192049
phenomenon	17192049
,	17192049
the	17192049
association	17192049
between	17192049
two	17192049
single	17192049
nucleotide	17192049
polymorphisms	17192049
(	17192049
A	17192049
to	17192049
G	17192049
transition	17192049
in	17192049
exon7	17192049
leading	17192049
to	17192049
amino	17192049
acid	17192049
substitution	17192049
Ile462Val	17192049
and	17192049
T3801C	17192049
at	17192049
3	17192049
'	17192049
UTR	17192049
)	17192049
of	17192049
CYP1A1	17192049
gene	17192049
in	17192049
prostate	17192049
cancer	17192049
were	17192049
analyzed	17192049
in	17192049
a	17192049
case	17192049
-	17192049
control	17192049
study	17192049
of	17192049
100	17192049
individuals	17192049
in	17192049
South	17192049
Indian	17192049
population	17192049
.	17192049

The	17192049
estimated	17192049
relative	17192049
risk	17192049
was	17192049
significantly	17192049
high	17192049
for	17192049
individuals	17192049
with	17192049
w1	17192049
/	17192049
m1	17192049
genotype	17192049
at	17192049
3	17192049
'	17192049
UTR	17192049
of	17192049
CYP1A1	17192049
gene	17192049
(	17192049
OR	17192049
-	17192049
4	17192049
.	17192049
64	17192049
;	17192049
95%CI	17192049
=	17192049
1	17192049
.	17192049
51	17192049
-	17192049
14	17192049
.	17192049
86	17192049
;	17192049
P	17192049
<	17192049
0	17192049
.	17192049
01	17192049
)	17192049
whereas	17192049
the	17192049
CYP1A1	17192049
Ile	17192049
/	17192049
Val	17192049
genotype	17192049
(	17192049
w2	17192049
/	17192049
m2	17192049
)	17192049
on	17192049
exon	17192049
7	17192049
was	17192049
found	17192049
to	17192049
be	17192049
associated	17192049
with	17192049
a	17192049
decreased	17192049
risk	17192049
for	17192049
prostate	17192049
cancer	17192049
(	17192049
OR	17192049
-	17192049
0	17192049
.	17192049
17	17192049
;	17192049
95%CI	17192049
=	17192049
0	17192049
.	17192049
02	17192049
-	17192049
0	17192049
.	17192049
89	17192049
;	17192049
P	17192049
=	17192049
0	17192049
.	17192049
03	17192049
)	17192049
.	17192049

A	17192049
Stratified	17192049
analysis	17192049
of	17192049
the	17192049
genotypes	17192049
with	17192049
age	17192049
of	17192049
onset	17192049
and	17192049
tumor	17192049
grade	17192049
showed	17192049
the	17192049
w1	17192049
/	17192049
m1	17192049
genotype	17192049
to	17192049
be	17192049
significantly	17192049
associated	17192049
with	17192049
an	17192049
early	17192049
age	17192049
of	17192049
onset	17192049
;	17192049
however	17192049
the	17192049
tumor	17192049
grades	17192049
did	17192049
not	17192049
have	17192049
significant	17192049
association	17192049
with	17192049
the	17192049
variant	17192049
genotypes	17192049
.	17192049

Thus	17192049
the	17192049
present	17192049
study	17192049
indicates	17192049
that	17192049
individuals	17192049
with	17192049
the	17192049
variant	17192049
w1	17192049
/	17192049
m1	17192049
genotype	17192049
exhibit	17192049
an	17192049
increased	17192049
risk	17192049
while	17192049
those	17192049
with	17192049
w2	17192049
/	17192049
m2	17192049
genotype	17192049
exhibit	17192049
a	17192049
decreased	17192049
risk	17192049
for	17192049
prostate	17192049
cancer	17192049
.	17192049
Four	15069170
novel	15069170
mutations	15069170
in	15069170
the	15069170
thiazide	15069170
-	15069170
sensitive	15069170
Na	15069170
-	15069170
Cl	15069170
co	15069170
-	15069170
transporter	15069170
gene	15069170
in	15069170
Japanese	15069170
patients	15069170
with	15069170
Gitelman	15069170
'	15069170
s	15069170
syndrome	15069170
.	15069170

BACKGROUND	15069170
:	15069170
Gitelman	15069170
'	15069170
s	15069170
syndrome	15069170
(	15069170
GS	15069170
)	15069170
is	15069170
an	15069170
autosomal	15069170
recessive	15069170
disorder	15069170
resulting	15069170
from	15069170
inactivating	15069170
mutations	15069170
in	15069170
the	15069170
thiazide	15069170
-	15069170
sensitive	15069170
Na	15069170
-	15069170
Cl	15069170
co	15069170
-	15069170
transporter	15069170
(	15069170
NCCT	15069170
)	15069170
gene	15069170
.	15069170

To	15069170
date	15069170
,	15069170
almost	15069170
90	15069170
mutations	15069170
have	15069170
been	15069170
identified	15069170
.	15069170

It	15069170
is	15069170
possible	15069170
that	15069170
there	15069170
is	15069170
a	15069170
population	15069170
-	15069170
specific	15069170
distribution	15069170
of	15069170
mutations	15069170
.	15069170

In	15069170
this	15069170
study	15069170
,	15069170
we	15069170
analysed	15069170
mutations	15069170
in	15069170
the	15069170
NCCT	15069170
gene	15069170
of	15069170
seven	15069170
Japanese	15069170
patients	15069170
with	15069170
GS	15069170
.	15069170

METHODS	15069170
:	15069170
Peripheral	15069170
blood	15069170
mononuclear	15069170
cells	15069170
were	15069170
isolated	15069170
from	15069170
patients	15069170
with	15069170
GS	15069170
,	15069170
their	15069170
family	15069170
members	15069170
and	15069170
healthy	15069170
control	15069170
subjects	15069170
.	15069170

A	15069170
mutation	15069170
analysis	15069170
of	15069170
the	15069170
NCCT	15069170
gene	15069170
was	15069170
performed	15069170
completely	15069170
by	15069170
direct	15069170
automated	15069170
sequencing	15069170
of	15069170
polymerase	15069170
chain	15069170
reaction	15069170
-	15069170
amplified	15069170
DNA	15069170
products	15069170
.	15069170

In	15069170
patients	15069170
with	15069170
a	15069170
deletion	15069170
or	15069170
splice	15069170
site	15069170
mutation	15069170
,	15069170
we	15069170
undertook	15069170
cDNA	15069170
sequence	15069170
analysis	15069170
.	15069170

RESULTS	15069170
:	15069170
We	15069170
identified	15069170
nine	15069170
mutations	15069170
.	15069170

Five	15069170
of	15069170
them	15069170
[	15069170
c	15069170
.	15069170
185C	15069170
>	15069170
T	15069170
(	15069170
Thr60Met	15069170
)	15069170
,	15069170
c	15069170
.	15069170
1712C	15069170
>	15069170
T	15069170
(	15069170
Ala569Val	15069170
)	15069170
,	15069170
c	15069170
.	15069170
1930C	15069170
>	15069170
T	15069170
(	15069170
Arg642Cys	15069170
)	15069170
,	15069170
c	15069170
.	15069170
2552T	15069170
>	15069170
A	15069170
(	15069170
Leu849His	15069170
)	15069170
and	15069170
c	15069170
.	15069170
1932delC	15069170
]	15069170
have	15069170
been	15069170
reported	15069170
in	15069170
Japanese	15069170
patients	15069170
,	15069170
but	15069170
not	15069170
in	15069170
GS	15069170
patients	15069170
from	15069170
other	15069170
ethnic	15069170
groups	15069170
.	15069170

The	15069170
remaining	15069170
four	15069170
mutations	15069170
[	15069170
c	15069170
.	15069170
7A	15069170
>	15069170
T	15069170
(	15069170
Met1Leu	15069170
)	15069170
,	15069170
c	15069170
.	15069170
1181_1186	15069170
+	15069170
20del26	15069170
,	15069170
c	15069170
.	15069170
1811_1812delAT	15069170
and	15069170
IVS16	15069170
+	15069170
1G	15069170
>	15069170
A	15069170
]	15069170
were	15069170
novel	15069170
.	15069170

In	15069170
cDNA	15069170
derived	15069170
from	15069170
a	15069170
patient	15069170
with	15069170
c	15069170
.	15069170
1181_1186	15069170
+	15069170
20del26	15069170
,	15069170
a	15069170
deletion	15069170
of	15069170
exon	15069170
9	15069170
and	15069170
a	15069170
frameshift	15069170
at	15069170
the	15069170
start	15069170
of	15069170
exon	15069170
10	15069170
were	15069170
observed	15069170
.	15069170

In	15069170
cDNA	15069170
derived	15069170
from	15069170
patients	15069170
with	15069170
IVS16	15069170
+	15069170
1G	15069170
>	15069170
A	15069170
,	15069170
an	15069170
additional	15069170
96	15069170
bp	15069170
insertion	15069170
between	15069170
exons	15069170
16	15069170
and	15069170
17	15069170
was	15069170
observed	15069170
.	15069170

Six	15069170
out	15069170
of	15069170
seven	15069170
patients	15069170
were	15069170
compound	15069170
heterozygotes	15069170
,	15069170
and	15069170
the	15069170
remaining	15069170
one	15069170
carried	15069170
a	15069170
single	15069170
heterozygous	15069170
mutation	15069170
.	15069170

CONCLUSIONS	15069170
:	15069170
We	15069170
found	15069170
four	15069170
novel	15069170
mutations	15069170
in	15069170
the	15069170
NCCT	15069170
gene	15069170
in	15069170
seven	15069170
Japanese	15069170
patients	15069170
with	15069170
GS	15069170
.	15069170

Moreover	15069170
,	15069170
our	15069170
study	15069170
suggests	15069170
that	15069170
the	15069170
distribution	15069170
of	15069170
mutations	15069170
in	15069170
the	15069170
NCCT	15069170
gene	15069170
in	15069170
Japanese	15069170
GS	15069170
patients	15069170
potentially	15069170
differs	15069170
from	15069170
that	15069170
in	15069170
other	15069170
populations	15069170
.	15069170
Autosomal	21903317
dominant	21903317
mutation	21903317
in	21903317
the	21903317
signal	21903317
peptide	21903317
of	21903317
renin	21903317
in	21903317
a	21903317
kindred	21903317
with	21903317
anemia	21903317
,	21903317
hyperuricemia	21903317
,	21903317
and	21903317
CKD	21903317
.	21903317

Homozygous	21903317
or	21903317
compound	21903317
heterozygous	21903317
mutations	21903317
in	21903317
renin	21903317
(	21903317
REN	21903317
)	21903317
cause	21903317
renal	21903317
tubular	21903317
dysgenesis	21903317
,	21903317
which	21903317
is	21903317
characterized	21903317
by	21903317
death	21903317
in	21903317
utero	21903317
due	21903317
to	21903317
kidney	21903317
failure	21903317
and	21903317
pulmonary	21903317
hypoplasia	21903317
.	21903317

The	21903317
phenotype	21903317
resembles	21903317
the	21903317
fetopathy	21903317
caused	21903317
by	21903317
angiotensin	21903317
-	21903317
converting	21903317
enzyme	21903317
inhibitor	21903317
or	21903317
angiotensin	21903317
receptor	21903317
blocker	21903317
intake	21903317
during	21903317
pregnancy	21903317
.	21903317

Recently	21903317
,	21903317
heterozygous	21903317
REN	21903317
mutations	21903317
were	21903317
shown	21903317
to	21903317
result	21903317
in	21903317
early	21903317
-	21903317
onset	21903317
hyperuricemia	21903317
,	21903317
anemia	21903317
,	21903317
and	21903317
chronic	21903317
kidney	21903317
disease	21903317
(	21903317
CKD	21903317
)	21903317
.	21903317

To	21903317
date	21903317
,	21903317
only	21903317
3	21903317
different	21903317
heterozygous	21903317
REN	21903317
mutations	21903317
have	21903317
been	21903317
published	21903317
.	21903317

We	21903317
report	21903317
mutation	21903317
analysis	21903317
of	21903317
the	21903317
REN	21903317
gene	21903317
in	21903317
39	21903317
kindreds	21903317
with	21903317
hyperuricemia	21903317
and	21903317
CKD	21903317
who	21903317
previously	21903317
tested	21903317
negative	21903317
for	21903317
mutations	21903317
in	21903317
the	21903317
UMOD	21903317
(	21903317
uromodulin	21903317
)	21903317
and	21903317
HNF1B	21903317
(	21903317
hepatocyte	21903317
nuclear	21903317
factor	21903317
1b	21903317
)	21903317
genes	21903317
.	21903317

We	21903317
identified	21903317
one	21903317
kindred	21903317
with	21903317
a	21903317
novel	21903317
thymidine	21903317
to	21903317
cytosine	21903317
mutation	21903317
at	21903317
position	21903317
28	21903317
in	21903317
the	21903317
REN	21903317
complementary	21903317
DNA	21903317
,	21903317
corresponding	21903317
to	21903317
a	21903317
tryptophan	21903317
to	21903317
arginine	21903317
substitution	21903317
at	21903317
amino	21903317
acid	21903317
10	21903317
,	21903317
which	21903317
is	21903317
found	21903317
within	21903317
the	21903317
signal	21903317
sequence	21903317
(	21903317
c	21903317
.	21903317
28T	21903317
>	21903317
C	21903317
;	21903317
p	21903317
.	21903317
W10R	21903317
)	21903317
.	21903317

On	21903317
this	21903317
basis	21903317
,	21903317
we	21903317
conclude	21903317
that	21903317
REN	21903317
mutations	21903317
are	21903317
rare	21903317
events	21903317
in	21903317
patients	21903317
with	21903317
CKD	21903317
.	21903317

Within	21903317
the	21903317
kindred	21903317
,	21903317
we	21903317
found	21903317
affected	21903317
individuals	21903317
over	21903317
4	21903317
generations	21903317
who	21903317
carried	21903317
the	21903317
novel	21903317
REN	21903317
mutation	21903317
and	21903317
were	21903317
characterized	21903317
by	21903317
significant	21903317
anemia	21903317
,	21903317
hyperuricemia	21903317
,	21903317
and	21903317
CKD	21903317
.	21903317

Anemia	21903317
was	21903317
severe	21903317
and	21903317
disproportional	21903317
to	21903317
the	21903317
degree	21903317
of	21903317
decreased	21903317
kidney	21903317
function	21903317
.	21903317

Because	21903317
all	21903317
heterozygous	21903317
REN	21903317
mutations	21903317
that	21903317
have	21903317
been	21903317
described	21903317
are	21903317
localized	21903317
in	21903317
the	21903317
signal	21903317
sequence	21903317
,	21903317
screening	21903317
of	21903317
the	21903317
REN	21903317
gene	21903317
for	21903317
patients	21903317
with	21903317
CKD	21903317
with	21903317
hyperuricemia	21903317
and	21903317
anemia	21903317
may	21903317
best	21903317
be	21903317
focused	21903317
on	21903317
sequencing	21903317
of	21903317
exon	21903317
1	21903317
,	21903317
which	21903317
encodes	21903317
the	21903317
signal	21903317
peptide	21903317
.	21903317
A	27999109
Critical	27999109
Role	27999109
for	27999109
the	27999109
Type	27999109
I	27999109
Interferon	27999109
Receptor	27999109
in	27999109
Virus	27999109
-	27999109
Induced	27999109
Autoimmune	27999109
Diabetes	27999109
in	27999109
Rats	27999109
.	27999109

The	27999109
pathogenesis	27999109
of	27999109
human	27999109
type	27999109
1	27999109
diabetes	27999109
,	27999109
characterized	27999109
by	27999109
immune	27999109
-	27999109
mediated	27999109
damage	27999109
of	27999109
insulin	27999109
-	27999109
producing	27999109
b	27999109
-	27999109
cells	27999109
of	27999109
pancreatic	27999109
islets	27999109
,	27999109
may	27999109
involve	27999109
viral	27999109
infection	27999109
.	27999109

Essential	27999109
components	27999109
of	27999109
the	27999109
innate	27999109
immune	27999109
antiviral	27999109
response	27999109
,	27999109
including	27999109
type	27999109
I	27999109
interferon	27999109
(	27999109
IFN	27999109
)	27999109
and	27999109
IFN	27999109
receptor	27999109
-	27999109
mediated	27999109
signaling	27999109
pathways	27999109
,	27999109
are	27999109
candidates	27999109
for	27999109
determining	27999109
susceptibility	27999109
to	27999109
human	27999109
type	27999109
1	27999109
diabetes	27999109
.	27999109

Numerous	27999109
aspects	27999109
of	27999109
human	27999109
type	27999109
1	27999109
diabetes	27999109
pathogenesis	27999109
are	27999109
recapitulated	27999109
in	27999109
the	27999109
LEW	27999109
.	27999109
1WR1	27999109
rat	27999109
model	27999109
.	27999109

Diabetes	27999109
can	27999109
be	27999109
induced	27999109
in	27999109
LEW	27999109
.	27999109
1WR1	27999109
weanling	27999109
rats	27999109
challenged	27999109
with	27999109
virus	27999109
or	27999109
with	27999109
the	27999109
viral	27999109
mimetic	27999109
polyinosinic	27999109
:	27999109
polycytidylic	27999109
acid	27999109
(	27999109
poly	27999109
I	27999109
:	27999109
C	27999109
)	27999109
.	27999109

We	27999109
hypothesized	27999109
that	27999109
disrupting	27999109
the	27999109
cognate	27999109
type	27999109
I	27999109
IFN	27999109
receptor	27999109
(	27999109
type	27999109
I	27999109
IFN	27999109
a	27999109
/	27999109
b	27999109
receptor	27999109
[	27999109
IFNAR	27999109
]	27999109
)	27999109
to	27999109
interrupt	27999109
IFN	27999109
signaling	27999109
would	27999109
prevent	27999109
or	27999109
delay	27999109
the	27999109
development	27999109
of	27999109
virus	27999109
-	27999109
induced	27999109
diabetes	27999109
.	27999109

We	27999109
generated	27999109
IFNAR1	27999109
subunit	27999109
-	27999109
deficient	27999109
LEW	27999109
.	27999109
1WR1	27999109
rats	27999109
using	27999109
CRISPR	27999109
-	27999109
Cas9	27999109
(	27999109
clustered	27999109
regularly	27999109
interspaced	27999109
short	27999109
palindromic	27999109
repeats	27999109
-	27999109
associated	27999109
protein	27999109
9	27999109
)	27999109
genome	27999109
editing	27999109
and	27999109
confirmed	27999109
functional	27999109
disruption	27999109
of	27999109
the	27999109
Ifnar1	27999109
gene	27999109
.	27999109

IFNAR1	27999109
deficiency	27999109
significantly	27999109
delayed	27999109
the	27999109
onset	27999109
and	27999109
frequency	27999109
of	27999109
diabetes	27999109
and	27999109
greatly	27999109
reduced	27999109
the	27999109
intensity	27999109
of	27999109
insulitis	27999109
after	27999109
poly	27999109
I	27999109
:	27999109
C	27999109
treatment	27999109
.	27999109

The	27999109
occurrence	27999109
of	27999109
Kilham	27999109
rat	27999109
virus	27999109
-	27999109
induced	27999109
diabetes	27999109
was	27999109
also	27999109
diminished	27999109
in	27999109
IFNAR1	27999109
-	27999109
deficient	27999109
animals	27999109
.	27999109

These	27999109
findings	27999109
firmly	27999109
establish	27999109
that	27999109
alterations	27999109
in	27999109
innate	27999109
immunity	27999109
influence	27999109
the	27999109
course	27999109
of	27999109
autoimmune	27999109
diabetes	27999109
and	27999109
support	27999109
the	27999109
use	27999109
of	27999109
targeted	27999109
strategies	27999109
to	27999109
limit	27999109
or	27999109
prevent	27999109
the	27999109
development	27999109
of	27999109
type	27999109
1	27999109
diabetes	27999109
.	27999109
Anticonvulsant	16920333
effect	16920333
of	16920333
eslicarbazepine	16920333
acetate	16920333
(	16920333
BIA	16920333
2	16920333
-	16920333
093	16920333
)	16920333
on	16920333
seizures	16920333
induced	16920333
by	16920333
microperfusion	16920333
of	16920333
picrotoxin	16920333
in	16920333
the	16920333
hippocampus	16920333
of	16920333
freely	16920333
moving	16920333
rats	16920333
.	16920333

Eslicarbazepine	16920333
acetate	16920333
(	16920333
BIA	16920333
2	16920333
-	16920333
093	16920333
,	16920333
S	16920333
-	16920333
(	16920333
-	16920333
)	16920333
-	16920333
10	16920333
-	16920333
acetoxy	16920333
-	16920333
10	16920333
,	16920333
11	16920333
-	16920333
dihydro	16920333
-	16920333
5H	16920333
-	16920333
dibenzo	16920333
/	16920333
b	16920333
,	16920333
f	16920333
/	16920333
azepine	16920333
-	16920333
5	16920333
-	16920333
carboxamide	16920333
)	16920333
is	16920333
a	16920333
novel	16920333
antiepileptic	16920333
drug	16920333
,	16920333
now	16920333
in	16920333
Phase	16920333
III	16920333
clinical	16920333
trials	16920333
,	16920333
designed	16920333
with	16920333
the	16920333
aim	16920333
of	16920333
improving	16920333
efficacy	16920333
and	16920333
safety	16920333
in	16920333
comparison	16920333
with	16920333
the	16920333
structurally	16920333
related	16920333
drugs	16920333
carbamazepine	16920333
(	16920333
CBZ	16920333
)	16920333
and	16920333
oxcarbazepine	16920333
(	16920333
OXC	16920333
)	16920333
.	16920333

We	16920333
have	16920333
studied	16920333
the	16920333
effects	16920333
of	16920333
oral	16920333
treatment	16920333
with	16920333
eslicarbazepine	16920333
acetate	16920333
on	16920333
a	16920333
whole	16920333
-	16920333
animal	16920333
model	16920333
in	16920333
which	16920333
partial	16920333
seizures	16920333
can	16920333
be	16920333
elicited	16920333
repeatedly	16920333
on	16920333
different	16920333
days	16920333
without	16920333
changes	16920333
in	16920333
threshold	16920333
or	16920333
seizure	16920333
patterns	16920333
.	16920333

In	16920333
the	16920333
animals	16920333
treated	16920333
with	16920333
threshold	16920333
doses	16920333
of	16920333
picrotoxin	16920333
,	16920333
the	16920333
average	16920333
number	16920333
of	16920333
seizures	16920333
was	16920333
2	16920333
.	16920333
3	16920333
+	16920333
/	16920333
-	16920333
1	16920333
.	16920333
2	16920333
,	16920333
and	16920333
average	16920333
seizure	16920333
duration	16920333
was	16920333
39	16920333
.	16920333
5	16920333
+	16920333
/	16920333
-	16920333
8	16920333
.	16920333
4s	16920333
.	16920333

Pre	16920333
-	16920333
treatment	16920333
with	16920333
a	16920333
dose	16920333
of	16920333
30	16920333
mg	16920333
/	16920333
kg	16920333
2h	16920333
before	16920333
picrotoxin	16920333
microperfusion	16920333
prevented	16920333
seizures	16920333
in	16920333
the	16920333
75%	16920333
of	16920333
the	16920333
rats	16920333
.	16920333

Lower	16920333
doses	16920333
(	16920333
3	16920333
and	16920333
10mg	16920333
/	16920333
kg	16920333
)	16920333
did	16920333
not	16920333
suppress	16920333
seizures	16920333
,	16920333
however	16920333
,	16920333
after	16920333
administration	16920333
of	16920333
10mg	16920333
/	16920333
kg	16920333
,	16920333
significant	16920333
reductions	16920333
in	16920333
seizures	16920333
duration	16920333
(	16920333
24	16920333
.	16920333
3	16920333
+	16920333
/	16920333
-	16920333
6	16920333
.	16920333
8s	16920333
)	16920333
and	16920333
seizure	16920333
number	16920333
(	16920333
1	16920333
.	16920333
6	16920333
+	16920333
/	16920333
-	16920333
0	16920333
.	16920333
34	16920333
)	16920333
were	16920333
found	16920333
.	16920333

No	16920333
adverse	16920333
effects	16920333
of	16920333
eslicarbazepine	16920333
acetate	16920333
were	16920333
observed	16920333
in	16920333
the	16920333
behavioral	16920333
/	16920333
EEG	16920333
patterns	16920333
studied	16920333
,	16920333
including	16920333
sleep	16920333
/	16920333
wakefulness	16920333
cycle	16920333
,	16920333
at	16920333
the	16920333
doses	16920333
studied	16920333
.	16920333
Hypomorphic	19508969
mutations	19508969
in	19508969
meckelin	19508969
(	19508969
MKS3	19508969
/	19508969
TMEM67	19508969
)	19508969
cause	19508969
nephronophthisis	19508969
with	19508969
liver	19508969
fibrosis	19508969
(	19508969
NPHP11	19508969
)	19508969
.	19508969

BACKGROUND	19508969
:	19508969
Nephronophthisis	19508969
(	19508969
NPHP	19508969
)	19508969
,	19508969
a	19508969
rare	19508969
recessive	19508969
cystic	19508969
kidney	19508969
disease	19508969
,	19508969
is	19508969
the	19508969
most	19508969
frequent	19508969
genetic	19508969
cause	19508969
of	19508969
chronic	19508969
renal	19508969
failure	19508969
in	19508969
children	19508969
and	19508969
young	19508969
adults	19508969
.	19508969

Mutations	19508969
in	19508969
nine	19508969
genes	19508969
(	19508969
NPHP1	19508969
-	19508969
9	19508969
)	19508969
have	19508969
been	19508969
identified	19508969
.	19508969

NPHP	19508969
can	19508969
be	19508969
associated	19508969
with	19508969
retinal	19508969
degeneration	19508969
(	19508969
Senior	19508969
-	19508969
Loken	19508969
syndrome	19508969
)	19508969
,	19508969
brainstem	19508969
and	19508969
cerebellar	19508969
anomalies	19508969
(	19508969
Joubert	19508969
syndrome	19508969
)	19508969
,	19508969
or	19508969
liver	19508969
fibrosis	19508969
.	19508969

METHODS	19508969
:	19508969
To	19508969
identify	19508969
a	19508969
causative	19508969
gene	19508969
for	19508969
the	19508969
subset	19508969
of	19508969
patients	19508969
with	19508969
associated	19508969
liver	19508969
fibrosis	19508969
,	19508969
the	19508969
authors	19508969
performed	19508969
a	19508969
genome	19508969
wide	19508969
linkage	19508969
search	19508969
in	19508969
a	19508969
consanguineous	19508969
family	19508969
with	19508969
three	19508969
affected	19508969
patients	19508969
using	19508969
50K	19508969
SNP	19508969
microarrays	19508969
and	19508969
homozygosity	19508969
mapping	19508969
.	19508969

RESULTS	19508969
:	19508969
The	19508969
authors	19508969
obtained	19508969
a	19508969
significant	19508969
maximum	19508969
parametric	19508969
LOD	19508969
(	19508969
logarithm	19508969
of	19508969
odds	19508969
)	19508969
score	19508969
of	19508969
Z	19508969
(	19508969
max	19508969
)	19508969
=	19508969
3	19508969
.	19508969
72	19508969
on	19508969
chromosome	19508969
8q22	19508969
and	19508969
identified	19508969
a	19508969
homozygous	19508969
missense	19508969
mutation	19508969
in	19508969
the	19508969
gene	19508969
MKS3	19508969
/	19508969
TMEM67	19508969
.	19508969

When	19508969
examining	19508969
a	19508969
worldwide	19508969
cohort	19508969
of	19508969
62	19508969
independent	19508969
patients	19508969
with	19508969
NPHP	19508969
and	19508969
associated	19508969
liver	19508969
fibrosis	19508969
we	19508969
identified	19508969
altogether	19508969
four	19508969
novel	19508969
mutations	19508969
(	19508969
p	19508969
.	19508969
W290L	19508969
,	19508969
p	19508969
.	19508969
C615R	19508969
,	19508969
p	19508969
.	19508969
G821S	19508969
,	19508969
and	19508969
p	19508969
.	19508969
G821R	19508969
)	19508969
in	19508969
five	19508969
of	19508969
them	19508969
.	19508969

Mutations	19508969
of	19508969
MKS3	19508969
/	19508969
TMEM67	19508969
,	19508969
found	19508969
recently	19508969
in	19508969
Meckel	19508969
-	19508969
Gruber	19508969
syndrome	19508969
(	19508969
MKS	19508969
)	19508969
type	19508969
3	19508969
and	19508969
Joubert	19508969
syndrome	19508969
(	19508969
JBTS	19508969
)	19508969
type	19508969
6	19508969
,	19508969
are	19508969
predominantly	19508969
truncating	19508969
mutations	19508969
.	19508969

In	19508969
contrast	19508969
,	19508969
the	19508969
mutations	19508969
detected	19508969
here	19508969
in	19508969
patients	19508969
with	19508969
NPHP	19508969
and	19508969
associated	19508969
liver	19508969
fibrosis	19508969
are	19508969
exclusively	19508969
missense	19508969
mutations	19508969
.	19508969

This	19508969
suggests	19508969
that	19508969
they	19508969
may	19508969
represent	19508969
hypomorphic	19508969
alleles	19508969
,	19508969
leading	19508969
to	19508969
a	19508969
milder	19508969
phenotype	19508969
compared	19508969
with	19508969
the	19508969
more	19508969
severe	19508969
MKS	19508969
or	19508969
JBTS	19508969
phenotype	19508969
.	19508969

Additionally	19508969
,	19508969
mutation	19508969
analysis	19508969
for	19508969
MKS3	19508969
/	19508969
TMEM67	19508969
in	19508969
120	19508969
patients	19508969
with	19508969
JBTS	19508969
yielded	19508969
seven	19508969
different	19508969
(	19508969
four	19508969
novel	19508969
)	19508969
mutations	19508969
in	19508969
five	19508969
patients	19508969
,	19508969
four	19508969
of	19508969
whom	19508969
also	19508969
presented	19508969
with	19508969
congenital	19508969
liver	19508969
fibrosis	19508969
.	19508969

CONCLUSIONS	19508969
:	19508969
Hypomorphic	19508969
MKS3	19508969
/	19508969
TMEM67	19508969
mutations	19508969
cause	19508969
NPHP	19508969
with	19508969
liver	19508969
fibrosis	19508969
(	19508969
NPHP11	19508969
)	19508969
.	19508969

This	19508969
is	19508969
the	19508969
first	19508969
report	19508969
of	19508969
MKS3	19508969
mutations	19508969
in	19508969
patients	19508969
with	19508969
no	19508969
vermian	19508969
agenesis	19508969
and	19508969
without	19508969
neurological	19508969
signs	19508969
.	19508969

Thus	19508969
NPHP	19508969
,	19508969
JBTS	19508969
,	19508969
and	19508969
MKS	19508969
represent	19508969
allelic	19508969
disorders	19508969
.	19508969
Genetic	15867855
variants	15867855
of	15867855
the	15867855
T	15867855
-	15867855
cell	15867855
immunoglobulin	15867855
mucin	15867855
1	15867855
but	15867855
not	15867855
the	15867855
T	15867855
-	15867855
cell	15867855
immunoglobulin	15867855
mucin	15867855
3	15867855
gene	15867855
are	15867855
associated	15867855
with	15867855
asthma	15867855
in	15867855
an	15867855
African	15867855
American	15867855
population	15867855
.	15867855

BACKGROUND	15867855
:	15867855
The	15867855
T	15867855
-	15867855
cell	15867855
immunoglobulin	15867855
mucin	15867855
(	15867855
TIM	15867855
)	15867855
proteins	15867855
and	15867855
their	15867855
genetic	15867855
variants	15867855
have	15867855
been	15867855
suggested	15867855
to	15867855
play	15867855
a	15867855
role	15867855
in	15867855
regulating	15867855
allergic	15867855
diseases	15867855
.	15867855

OBJECTIVE	15867855
:	15867855
Genetic	15867855
association	15867855
of	15867855
the	15867855
sequence	15867855
variants	15867855
for	15867855
TIM	15867855
-	15867855
1	15867855
and	15867855
TIM	15867855
-	15867855
3	15867855
genes	15867855
with	15867855
asthma	15867855
in	15867855
an	15867855
African	15867855
American	15867855
population	15867855
was	15867855
investigated	15867855
.	15867855

METHODS	15867855
:	15867855
Both	15867855
case	15867855
-	15867855
control	15867855
and	15867855
family	15867855
-	15867855
based	15867855
association	15867855
analyses	15867855
were	15867855
performed	15867855
for	15867855
a	15867855
total	15867855
of	15867855
7	15867855
polymorphisms	15867855
,	15867855
including	15867855
3	15867855
single	15867855
nucleotide	15867855
polymorphism	15867855
(	15867855
SNPs	15867855
)	15867855
and	15867855
1	15867855
insertion	15867855
/	15867855
deletion	15867855
polymorphism	15867855
in	15867855
the	15867855
TIM	15867855
-	15867855
1	15867855
and	15867855
3	15867855
SNPs	15867855
in	15867855
the	15867855
TIM	15867855
-	15867855
3	15867855
genes	15867855
.	15867855

The	15867855
exposure	15867855
to	15867855
hepatitis	15867855
A	15867855
virus	15867855
as	15867855
judged	15867855
by	15867855
seropositivity	15867855
was	15867855
also	15867855
examined	15867855
.	15867855

RESULTS	15867855
:	15867855
In	15867855
the	15867855
case	15867855
-	15867855
control	15867855
design	15867855
,	15867855
the	15867855
frequencies	15867855
of	15867855
the	15867855
TT	15867855
genotype	15867855
for	15867855
SNP	15867855
rs2277025	15867855
and	15867855
the	15867855
homozygous	15867855
deletion	15867855
variant	15867855
(	15867855
157delMTTTVP	15867855
)	15867855
in	15867855
the	15867855
fourth	15867855
exon	15867855
of	15867855
the	15867855
TIM	15867855
-	15867855
1	15867855
gene	15867855
were	15867855
higher	15867855
among	15867855
patients	15867855
with	15867855
patients	15867855
with	15867855
asthma	15867855
compared	15867855
with	15867855
the	15867855
controls	15867855
(	15867855
odds	15867855
ratio	15867855
[	15867855
OR	15867855
]	15867855
,	15867855
2	15867855
.	15867855
779	15867855
,	15867855
P	15867855
=	15867855
.	15867855
016	15867855
;	15867855
and	15867855
OR	15867855
,	15867855
3	15867855
.	15867855
09	15867855
,	15867855
P	15867855
=	15867855
.	15867855
022	15867855
,	15867855
respectively	15867855
)	15867855
.	15867855

This	15867855
association	15867855
was	15867855
substantiated	15867855
by	15867855
haplotype	15867855
analysis	15867855
of	15867855
these	15867855
and	15867855
2	15867855
additional	15867855
SNPs	15867855
(	15867855
OR	15867855
,	15867855
2	15867855
.	15867855
48	15867855
;	15867855
P	15867855
=	15867855
.	15867855
004	15867855
)	15867855
,	15867855
and	15867855
also	15867855
by	15867855
family	15867855
-	15867855
based	15867855
tests	15867855
for	15867855
the	15867855
allele	15867855
and	15867855
haplotype	15867855
carrying	15867855
157delMTTTVP	15867855
(	15867855
P	15867855
=	15867855
.	15867855
009	15867855
and	15867855
P	15867855
=	15867855
.	15867855
048	15867855
,	15867855
respectively	15867855
)	15867855
.	15867855

Furthermore	15867855
,	15867855
this	15867855
association	15867855
seems	15867855
to	15867855
exist	15867855
even	15867855
in	15867855
the	15867855
hepatitis	15867855
A	15867855
virus	15867855
-	15867855
seronegative	15867855
subjects	15867855
in	15867855
our	15867855
data	15867855
.	15867855

None	15867855
of	15867855
the	15867855
3	15867855
variants	15867855
in	15867855
TIM	15867855
-	15867855
3	15867855
genes	15867855
yielded	15867855
significant	15867855
association	15867855
with	15867855
either	15867855
asthma	15867855
or	15867855
asthma	15867855
-	15867855
related	15867855
phenotypes	15867855
.	15867855

CONCLUSION	15867855
:	15867855
Our	15867855
findings	15867855
suggest	15867855
that	15867855
the	15867855
genetic	15867855
variants	15867855
of	15867855
the	15867855
TIM	15867855
-	15867855
1	15867855
but	15867855
not	15867855
the	15867855
TIM	15867855
-	15867855
3	15867855
gene	15867855
contribute	15867855
to	15867855
asthma	15867855
susceptibility	15867855
in	15867855
this	15867855
African	15867855
-	15867855
American	15867855
population	15867855
.	15867855
Identification	18779591
of	18779591
a	18779591
gain	18779591
-	18779591
of	18779591
-	18779591
function	18779591
mutation	18779591
of	18779591
the	18779591
prolactin	18779591
receptor	18779591
in	18779591
women	18779591
with	18779591
benign	18779591
breast	18779591
tumors	18779591
.	18779591

There	18779591
is	18779591
currently	18779591
no	18779591
known	18779591
genetic	18779591
disease	18779591
linked	18779591
to	18779591
prolactin	18779591
(	18779591
Prl	18779591
)	18779591
or	18779591
its	18779591
receptor	18779591
(	18779591
PrlR	18779591
)	18779591
in	18779591
humans	18779591
.	18779591

Given	18779591
the	18779591
essential	18779591
role	18779591
of	18779591
this	18779591
hormonal	18779591
system	18779591
in	18779591
breast	18779591
physiology	18779591
,	18779591
we	18779591
reasoned	18779591
that	18779591
genetic	18779591
anomalies	18779591
of	18779591
Prl	18779591
/	18779591
PrlR	18779591
genes	18779591
may	18779591
be	18779591
related	18779591
to	18779591
the	18779591
occurrence	18779591
of	18779591
breast	18779591
diseases	18779591
with	18779591
high	18779591
proliferative	18779591
potential	18779591
.	18779591

Multiple	18779591
fibroadenomas	18779591
(	18779591
MFA	18779591
)	18779591
are	18779591
benign	18779591
breast	18779591
tumors	18779591
which	18779591
appear	18779591
most	18779591
frequently	18779591
in	18779591
young	18779591
women	18779591
,	18779591
including	18779591
at	18779591
puberty	18779591
,	18779591
when	18779591
Prl	18779591
has	18779591
well	18779591
-	18779591
recognized	18779591
proliferative	18779591
actions	18779591
on	18779591
the	18779591
breast	18779591
.	18779591

In	18779591
a	18779591
prospective	18779591
study	18779591
involving	18779591
74	18779591
MFA	18779591
patients	18779591
and	18779591
170	18779591
control	18779591
subjects	18779591
,	18779591
we	18779591
identified	18779591
four	18779591
patients	18779591
harboring	18779591
a	18779591
heterozygous	18779591
single	18779591
nucleotide	18779591
polymorphism	18779591
in	18779591
exon	18779591
6	18779591
of	18779591
the	18779591
PrlR	18779591
gene	18779591
,	18779591
encoding	18779591
Ile	18779591
(	18779591
146	18779591
)	18779591
-	18779591
-	18779591
>	18779591
Leu	18779591
substitution	18779591
in	18779591
its	18779591
extracellular	18779591
domain	18779591
.	18779591

This	18779591
sole	18779591
substitution	18779591
was	18779591
sufficient	18779591
to	18779591
confer	18779591
constitutive	18779591
activity	18779591
to	18779591
the	18779591
receptor	18779591
variant	18779591
(	18779591
PrlR	18779591
(	18779591
I146L	18779591
)	18779591
)	18779591
,	18779591
as	18779591
assessed	18779591
in	18779591
three	18779591
reconstituted	18779591
cell	18779591
models	18779591
(	18779591
Ba	18779591
/	18779591
F3	18779591
,	18779591
HEK293	18779591
and	18779591
MCF	18779591
-	18779591
7	18779591
cells	18779591
)	18779591
by	18779591
Prl	18779591
-	18779591
independent	18779591
(	18779591
i	18779591
)	18779591
PrlR	18779591
tyrosine	18779591
phosphorylation	18779591
,	18779591
(	18779591
ii	18779591
)	18779591
activation	18779591
of	18779591
signal	18779591
transducer	18779591
and	18779591
activator	18779591
of	18779591
transcription	18779591
5	18779591
(	18779591
STAT5	18779591
)	18779591
signaling	18779591
,	18779591
(	18779591
iii	18779591
)	18779591
transcriptional	18779591
activity	18779591
toward	18779591
a	18779591
Prl	18779591
-	18779591
responsive	18779591
reporter	18779591
gene	18779591
,	18779591
and	18779591
(	18779591
iv	18779591
)	18779591
cell	18779591
proliferation	18779591
and	18779591
protection	18779591
from	18779591
cell	18779591
death	18779591
.	18779591

Constitutive	18779591
activity	18779591
of	18779591
PrlR	18779591
(	18779591
I146L	18779591
)	18779591
in	18779591
the	18779591
breast	18779591
sample	18779591
from	18779591
a	18779591
patient	18779591
was	18779591
supported	18779591
by	18779591
increased	18779591
STAT5	18779591
signaling	18779591
.	18779591

This	18779591
is	18779591
a	18779591
unique	18779591
description	18779591
of	18779591
a	18779591
functional	18779591
mutation	18779591
of	18779591
the	18779591
PrlR	18779591
associated	18779591
with	18779591
a	18779591
human	18779591
disease	18779591
.	18779591

Hallmarks	18779591
of	18779591
constitutive	18779591
activity	18779591
were	18779591
all	18779591
reversed	18779591
by	18779591
a	18779591
specific	18779591
PrlR	18779591
antagonist	18779591
,	18779591
which	18779591
opens	18779591
potential	18779591
therapeutic	18779591
approaches	18779591
for	18779591
MFA	18779591
,	18779591
or	18779591
any	18779591
other	18779591
disease	18779591
that	18779591
could	18779591
be	18779591
associated	18779591
with	18779591
this	18779591
mutation	18779591
in	18779591
future	18779591
.	18779591
Polymorphic	17277899
Alu	17277899
insertions	17277899
and	17277899
the	17277899
genetic	17277899
structure	17277899
of	17277899
Iberian	17277899
Basques	17277899
.	17277899

Eight	17277899
Alu	17277899
sequences	17277899
(	17277899
ACE	17277899
,	17277899
TPA25	17277899
,	17277899
PV92	17277899
,	17277899
APO	17277899
,	17277899
FXIIIB	17277899
,	17277899
D1	17277899
,	17277899
A25	17277899
and	17277899
B65	17277899
)	17277899
were	17277899
analyzed	17277899
in	17277899
two	17277899
samples	17277899
from	17277899
Navarre	17277899
and	17277899
Guipuzcoa	17277899
provinces	17277899
(	17277899
Basque	17277899
Country	17277899
,	17277899
Spain	17277899
)	17277899
.	17277899

Alu	17277899
data	17277899
for	17277899
other	17277899
European	17277899
,	17277899
Caucasus	17277899
and	17277899
North	17277899
African	17277899
populations	17277899
were	17277899
compiled	17277899
from	17277899
the	17277899
literature	17277899
for	17277899
comparison	17277899
purposes	17277899
to	17277899
assess	17277899
the	17277899
genetic	17277899
relationships	17277899
of	17277899
the	17277899
Basques	17277899
in	17277899
a	17277899
broader	17277899
geographic	17277899
context	17277899
.	17277899

Results	17277899
of	17277899
both	17277899
MDS	17277899
plot	17277899
and	17277899
AMOVA	17277899
revealed	17277899
spatial	17277899
heterogeneity	17277899
among	17277899
these	17277899
three	17277899
population	17277899
clusters	17277899
clearly	17277899
defined	17277899
by	17277899
geography	17277899
.	17277899

On	17277899
the	17277899
contrary	17277899
,	17277899
no	17277899
substantial	17277899
genetic	17277899
heterogeneity	17277899
was	17277899
found	17277899
between	17277899
the	17277899
Basque	17277899
samples	17277899
,	17277899
or	17277899
between	17277899
Basques	17277899
and	17277899
other	17277899
Europeans	17277899
(	17277899
excluding	17277899
Caucasus	17277899
populations	17277899
)	17277899
.	17277899

Moreover	17277899
,	17277899
the	17277899
genetic	17277899
information	17277899
obtained	17277899
from	17277899
Alu	17277899
data	17277899
conflicts	17277899
with	17277899
hypotheses	17277899
linking	17277899
the	17277899
origin	17277899
of	17277899
Basques	17277899
with	17277899
populations	17277899
from	17277899
North	17277899
Africa	17277899
(	17277899
Berbers	17277899
)	17277899
or	17277899
from	17277899
the	17277899
Caucasus	17277899
region	17277899
(	17277899
Georgia	17277899
)	17277899
.	17277899

In	17277899
order	17277899
to	17277899
explain	17277899
the	17277899
reduced	17277899
genetic	17277899
heterogeneity	17277899
detected	17277899
by	17277899
Alu	17277899
insertions	17277899
among	17277899
Basque	17277899
subpopulations	17277899
,	17277899
values	17277899
of	17277899
the	17277899
Wright	17277899
'	17277899
s	17277899
F	17277899
(	17277899
ST	17277899
)	17277899
statistic	17277899
were	17277899
estimated	17277899
for	17277899
both	17277899
Alu	17277899
markers	17277899
and	17277899
a	17277899
set	17277899
of	17277899
short	17277899
tandem	17277899
repeats	17277899
(	17277899
STRs	17277899
)	17277899
in	17277899
terms	17277899
of	17277899
two	17277899
geographical	17277899
scales	17277899
:	17277899
(	17277899
1	17277899
)	17277899
the	17277899
Basque	17277899
Country	17277899
,	17277899
(	17277899
2	17277899
)	17277899
Europe	17277899
(	17277899
including	17277899
Basques	17277899
)	17277899
.	17277899

In	17277899
the	17277899
Basque	17277899
area	17277899
,	17277899
estimates	17277899
of	17277899
Wahlund	17277899
'	17277899
s	17277899
effect	17277899
for	17277899
both	17277899
genetic	17277899
markers	17277899
showed	17277899
no	17277899
statistical	17277899
difference	17277899
between	17277899
Basque	17277899
subpopulations	17277899
.	17277899

However	17277899
,	17277899
when	17277899
this	17277899
analysis	17277899
was	17277899
performed	17277899
on	17277899
a	17277899
European	17277899
scale	17277899
,	17277899
F	17277899
(	17277899
ST	17277899
)	17277899
values	17277899
were	17277899
significantly	17277899
higher	17277899
for	17277899
Alu	17277899
insertions	17277899
than	17277899
for	17277899
STR	17277899
alleles	17277899
.	17277899

From	17277899
these	17277899
results	17277899
,	17277899
we	17277899
suggest	17277899
that	17277899
the	17277899
spatial	17277899
heterogeneity	17277899
of	17277899
the	17277899
Basque	17277899
gene	17277899
pool	17277899
identified	17277899
in	17277899
previous	17277899
polymorphism	17277899
studies	17277899
is	17277899
relatively	17277899
recent	17277899
and	17277899
probably	17277899
caused	17277899
by	17277899
a	17277899
differential	17277899
process	17277899
of	17277899
genetic	17277899
admixture	17277899
with	17277899
non	17277899
-	17277899
Basque	17277899
neighboring	17277899
populations	17277899
modulated	17277899
by	17277899
the	17277899
effect	17277899
of	17277899
a	17277899
linguistic	17277899
barrier	17277899
to	17277899
random	17277899
mating	17277899
.	17277899
Phosphatidylinositol	27798239
4	27798239
-	27798239
kinase	27798239
IIb	27798239
negatively	27798239
regulates	27798239
invadopodia	27798239
formation	27798239
and	27798239
suppresses	27798239
an	27798239
invasive	27798239
cellular	27798239
phenotype	27798239
.	27798239

The	27798239
type	27798239
II	27798239
phosphatidylinositol	27798239
4	27798239
-	27798239
kinase	27798239
(	27798239
PI4KII	27798239
)	27798239
enzymes	27798239
synthesize	27798239
the	27798239
lipid	27798239
phosphatidylinositol	27798239
4	27798239
-	27798239
phosphate	27798239
(	27798239
PI	27798239
(	27798239
4	27798239
)	27798239
P	27798239
)	27798239
,	27798239
which	27798239
has	27798239
been	27798239
detected	27798239
at	27798239
the	27798239
Golgi	27798239
complex	27798239
and	27798239
endosomal	27798239
compartments	27798239
and	27798239
recruits	27798239
clathrin	27798239
adaptors	27798239
.	27798239

Despite	27798239
common	27798239
mechanistic	27798239
similarities	27798239
between	27798239
the	27798239
isoforms	27798239
,	27798239
the	27798239
extent	27798239
of	27798239
their	27798239
redundancy	27798239
is	27798239
unclear	27798239
.	27798239

We	27798239
found	27798239
that	27798239
depletion	27798239
of	27798239
PI4KIIa	27798239
and	27798239
PI4KIIb	27798239
using	27798239
small	27798239
interfering	27798239
RNA	27798239
led	27798239
to	27798239
actin	27798239
remodeling	27798239
.	27798239

Depletion	27798239
of	27798239
PI4KIIb	27798239
also	27798239
induced	27798239
the	27798239
formation	27798239
of	27798239
invadopodia	27798239
containing	27798239
membrane	27798239
type	27798239
I	27798239
matrix	27798239
metalloproteinase	27798239
(	27798239
MT1	27798239
-	27798239
MMP	27798239
)	27798239
.	27798239

Depletion	27798239
of	27798239
PI4KII	27798239
isoforms	27798239
also	27798239
differentially	27798239
affected	27798239
trans	27798239
-	27798239
Golgi	27798239
network	27798239
(	27798239
TGN	27798239
)	27798239
pools	27798239
of	27798239
PI	27798239
(	27798239
4	27798239
)	27798239
P	27798239
and	27798239
post	27798239
-	27798239
TGN	27798239
traffic	27798239
.	27798239

PI4KIIb	27798239
depletion	27798239
caused	27798239
increased	27798239
MT1	27798239
-	27798239
MMP	27798239
trafficking	27798239
to	27798239
invasive	27798239
structures	27798239
at	27798239
the	27798239
plasma	27798239
membrane	27798239
and	27798239
was	27798239
accompanied	27798239
by	27798239
reduced	27798239
colocalization	27798239
of	27798239
MT1	27798239
-	27798239
MMP	27798239
with	27798239
membranes	27798239
containing	27798239
the	27798239
endosomal	27798239
markers	27798239
Rab5	27798239
and	27798239
Rab7	27798239
but	27798239
increased	27798239
localization	27798239
with	27798239
the	27798239
exocytic	27798239
Rab8	27798239
.	27798239

Depletion	27798239
of	27798239
PI4KIIb	27798239
was	27798239
sufficient	27798239
to	27798239
confer	27798239
an	27798239
aggressive	27798239
invasive	27798239
phenotype	27798239
on	27798239
minimally	27798239
invasive	27798239
HeLa	27798239
and	27798239
MCF	27798239
-	27798239
7	27798239
cell	27798239
lines	27798239
.	27798239

Mining	27798239
oncogenomic	27798239
databases	27798239
revealed	27798239
that	27798239
loss	27798239
of	27798239
the	27798239
PI4K2B	27798239
allele	27798239
and	27798239
underexpression	27798239
of	27798239
PI4KIIb	27798239
mRNA	27798239
are	27798239
associated	27798239
with	27798239
human	27798239
cancers	27798239
.	27798239

This	27798239
finding	27798239
supports	27798239
the	27798239
cell	27798239
data	27798239
and	27798239
suggests	27798239
that	27798239
PI4KIIb	27798239
may	27798239
be	27798239
a	27798239
clinically	27798239
significant	27798239
suppressor	27798239
of	27798239
invasion	27798239
.	27798239

We	27798239
propose	27798239
that	27798239
PI4KIIb	27798239
synthesizes	27798239
a	27798239
pool	27798239
of	27798239
PI	27798239
(	27798239
4	27798239
)	27798239
P	27798239
that	27798239
maintains	27798239
MT1	27798239
-	27798239
MMP	27798239
traffic	27798239
in	27798239
the	27798239
degradative	27798239
pathway	27798239
and	27798239
suppresses	27798239
the	27798239
formation	27798239
of	27798239
invadopodia	27798239
.	27798239
Common	17634480
germline	17634480
genetic	17634480
variation	17634480
in	17634480
antioxidant	17634480
defense	17634480
genes	17634480
and	17634480
survival	17634480
after	17634480
diagnosis	17634480
of	17634480
breast	17634480
cancer	17634480
.	17634480

PURPOSE	17634480
:	17634480
The	17634480
prognosis	17634480
of	17634480
breast	17634480
cancer	17634480
varies	17634480
considerably	17634480
among	17634480
individuals	17634480
,	17634480
and	17634480
inherited	17634480
genetic	17634480
factors	17634480
may	17634480
help	17634480
explain	17634480
this	17634480
variability	17634480
.	17634480

Of	17634480
particular	17634480
interest	17634480
are	17634480
genes	17634480
involved	17634480
in	17634480
defense	17634480
against	17634480
reactive	17634480
oxygen	17634480
species	17634480
(	17634480
ROS	17634480
)	17634480
because	17634480
ROS	17634480
are	17634480
thought	17634480
to	17634480
cause	17634480
DNA	17634480
damage	17634480
and	17634480
contribute	17634480
to	17634480
the	17634480
pathogenesis	17634480
of	17634480
cancer	17634480
.	17634480

PATIENTS	17634480
AND	17634480
METHODS	17634480
:	17634480
We	17634480
examined	17634480
associations	17634480
between	17634480
54	17634480
polymorphisms	17634480
that	17634480
tag	17634480
the	17634480
known	17634480
common	17634480
variants	17634480
(	17634480
minor	17634480
allele	17634480
frequency	17634480
>	17634480
0	17634480
.	17634480
05	17634480
)	17634480
in	17634480
10	17634480
genes	17634480
involved	17634480
in	17634480
oxidative	17634480
damage	17634480
repair	17634480
(	17634480
CAT	17634480
,	17634480
SOD1	17634480
,	17634480
SOD2	17634480
,	17634480
GPX1	17634480
,	17634480
GPX4	17634480
,	17634480
GSR	17634480
,	17634480
TXN	17634480
,	17634480
TXN2	17634480
,	17634480
TXNRD1	17634480
,	17634480
and	17634480
TXNRD2	17634480
)	17634480
and	17634480
survival	17634480
in	17634480
4	17634480
,	17634480
470	17634480
women	17634480
with	17634480
breast	17634480
cancer	17634480
.	17634480

RESULTS	17634480
:	17634480
Two	17634480
single	17634480
nucleotide	17634480
polymorphisms	17634480
(	17634480
SNPs	17634480
)	17634480
in	17634480
GPX4	17634480
(	17634480
rs713041	17634480
and	17634480
rs757229	17634480
)	17634480
were	17634480
associated	17634480
with	17634480
all	17634480
-	17634480
cause	17634480
mortality	17634480
even	17634480
after	17634480
adjusting	17634480
for	17634480
multiple	17634480
hypothesis	17634480
testing	17634480
(	17634480
adjusted	17634480
P	17634480
=	17634480
.	17634480
0041	17634480
and	17634480
P	17634480
=	17634480
.	17634480
0035	17634480
)	17634480
.	17634480

These	17634480
SNPs	17634480
are	17634480
correlated	17634480
with	17634480
each	17634480
other	17634480
(	17634480
r2	17634480
=	17634480
0	17634480
.	17634480
61	17634480
)	17634480
.	17634480

GPX4	17634480
rs713041	17634480
is	17634480
located	17634480
near	17634480
the	17634480
selenocysteine	17634480
insertion	17634480
sequence	17634480
element	17634480
in	17634480
the	17634480
GPX4	17634480
3	17634480
'	17634480
untranslated	17634480
region	17634480
,	17634480
and	17634480
the	17634480
rare	17634480
allele	17634480
of	17634480
this	17634480
SNP	17634480
is	17634480
associated	17634480
with	17634480
an	17634480
increased	17634480
risk	17634480
of	17634480
death	17634480
,	17634480
with	17634480
a	17634480
hazard	17634480
ratio	17634480
of	17634480
1	17634480
.	17634480
27	17634480
per	17634480
rare	17634480
allele	17634480
carried	17634480
(	17634480
95%	17634480
CI	17634480
,	17634480
1	17634480
.	17634480
13	17634480
to	17634480
11	17634480
.	17634480
43	17634480
)	17634480
.	17634480

This	17634480
effect	17634480
was	17634480
not	17634480
attenuated	17634480
after	17634480
adjusting	17634480
for	17634480
tumor	17634480
stage	17634480
,	17634480
grade	17634480
,	17634480
or	17634480
estrogen	17634480
receptor	17634480
status	17634480
.	17634480

We	17634480
found	17634480
that	17634480
the	17634480
common	17634480
allele	17634480
is	17634480
preferentially	17634480
expressed	17634480
in	17634480
normal	17634480
lymphocytes	17634480
,	17634480
normal	17634480
breast	17634480
,	17634480
and	17634480
breast	17634480
tumors	17634480
compared	17634480
with	17634480
the	17634480
rare	17634480
allele	17634480
,	17634480
but	17634480
there	17634480
were	17634480
no	17634480
differences	17634480
in	17634480
total	17634480
levels	17634480
of	17634480
GPX4	17634480
mRNA	17634480
across	17634480
genotypes	17634480
.	17634480

CONCLUSION	17634480
:	17634480
These	17634480
data	17634480
provide	17634480
strong	17634480
support	17634480
for	17634480
the	17634480
hypothesis	17634480
that	17634480
common	17634480
variation	17634480
in	17634480
GPX4	17634480
is	17634480
associated	17634480
with	17634480
prognosis	17634480
after	17634480
a	17634480
diagnosis	17634480
of	17634480
breast	17634480
cancer	17634480
.	17634480
A	17549393
novel	17549393
IRF6	17549393
nonsense	17549393
mutation	17549393
(	17549393
Y67X	17549393
)	17549393
in	17549393
a	17549393
German	17549393
family	17549393
with	17549393
Van	17549393
der	17549393
Woude	17549393
syndrome	17549393
.	17549393

Van	17549393
der	17549393
Woude	17549393
syndrome	17549393
(	17549393
VWS	17549393
)	17549393
is	17549393
the	17549393
most	17549393
common	17549393
type	17549393
of	17549393
syndromic	17549393
orofacial	17549393
cleft	17549393
,	17549393
which	17549393
accounts	17549393
for	17549393
approximately	17549393
2%	17549393
of	17549393
all	17549393
cleft	17549393
lip	17549393
and	17549393
palate	17549393
cases	17549393
.	17549393

It	17549393
is	17549393
characterised	17549393
by	17549393
variable	17549393
association	17549393
of	17549393
lower	17549393
lip	17549393
pits	17549393
,	17549393
cleft	17549393
lip	17549393
and	17549393
cleft	17549393
palate	17549393
,	17549393
and	17549393
hypodontia	17549393
.	17549393

VWS	17549393
arises	17549393
as	17549393
the	17549393
result	17549393
of	17549393
mutations	17549393
in	17549393
the	17549393
gene	17549393
encoding	17549393
interferon	17549393
regulatory	17549393
factor	17549393
6	17549393
(	17549393
IRF6	17549393
)	17549393
.	17549393

The	17549393
disorder	17549393
is	17549393
transmitted	17549393
in	17549393
an	17549393
autosomal	17549393
dominant	17549393
manner	17549393
,	17549393
with	17549393
high	17549393
penetrance	17549393
and	17549393
variable	17549393
expressivity	17549393
.	17549393

Very	17549393
recently	17549393
,	17549393
mutations	17549393
of	17549393
the	17549393
IRF6	17549393
gene	17549393
in	17549393
exons	17549393
2	17549393
-	17549393
9	17549393
have	17549393
been	17549393
found	17549393
in	17549393
VWS	17549393
patients	17549393
,	17549393
suggesting	17549393
that	17549393
this	17549393
gene	17549393
plays	17549393
an	17549393
important	17549393
role	17549393
in	17549393
orofacial	17549393
development	17549393
.	17549393

We	17549393
report	17549393
a	17549393
novel	17549393
mutation	17549393
of	17549393
the	17549393
IRF6	17549393
gene	17549393
in	17549393
a	17549393
German	17549393
family	17549393
.	17549393

Five	17549393
out	17549393
of	17549393
the	17549393
12	17549393
persons	17549393
affected	17549393
were	17549393
able	17549393
to	17549393
be	17549393
investigated	17549393
.	17549393

The	17549393
mutation	17549393
produced	17549393
a	17549393
stop	17549393
codon	17549393
within	17549393
exon	17549393
4	17549393
of	17549393
the	17549393
IRF6	17549393
gene	17549393
.	17549393

All	17549393
5	17549393
patients	17549393
were	17549393
heterozygous	17549393
for	17549393
a	17549393
base	17549393
substitution	17549393
c	17549393
.	17549393
201C	17549393
>	17549393
A	17549393
changing	17549393
the	17549393
tyrosine	17549393
codon	17549393
at	17549393
amino	17549393
acid	17549393
position	17549393
67	17549393
into	17549393
a	17549393
stop	17549393
codon	17549393
(	17549393
p	17549393
.	17549393
Y67X	17549393
)	17549393
in	17549393
exon	17549393
4	17549393
.	17549393

The	17549393
premature	17549393
stop	17549393
codon	17549393
was	17549393
responsible	17549393
for	17549393
a	17549393
truncated	17549393
protein	17549393
lacking	17549393
parts	17549393
of	17549393
the	17549393
DNA	17549393
-	17549393
binding	17549393
domain	17549393
and	17549393
the	17549393
complete	17549393
Smad	17549393
-	17549393
interferon	17549393
regulatory	17549393
factor	17549393
-	17549393
binding	17549393
domain	17549393
probably	17549393
essential	17549393
for	17549393
interactions	17549393
with	17549393
the	17549393
Smad	17549393
transcription	17549393
factors	17549393
.	17549393
Late	1353340
-	1353340
onset	1353340
metachromatic	1353340
leukodystrophy	1353340
:	1353340
molecular	1353340
pathology	1353340
in	1353340
two	1353340
siblings	1353340
.	1353340

We	1353340
report	1353340
on	1353340
a	1353340
new	1353340
allele	1353340
at	1353340
the	1353340
arylsulfatase	1353340
A	1353340
(	1353340
ARSA	1353340
)	1353340
locus	1353340
causing	1353340
late	1353340
-	1353340
onset	1353340
metachromatic	1353340
leukodystrophy	1353340
(	1353340
MLD	1353340
)	1353340
.	1353340

In	1353340
that	1353340
allele	1353340
arginine84	1353340
,	1353340
a	1353340
residue	1353340
that	1353340
is	1353340
highly	1353340
conserved	1353340
in	1353340
the	1353340
arylsulfatase	1353340
gene	1353340
family	1353340
,	1353340
is	1353340
replaced	1353340
by	1353340
glutamine	1353340
.	1353340

In	1353340
contrast	1353340
to	1353340
alleles	1353340
that	1353340
cause	1353340
early	1353340
-	1353340
onset	1353340
MLD	1353340
,	1353340
the	1353340
arginine84	1353340
to	1353340
glutamine	1353340
substitution	1353340
is	1353340
associated	1353340
with	1353340
some	1353340
residual	1353340
ARSA	1353340
activity	1353340
.	1353340

A	1353340
comparison	1353340
of	1353340
genotypes	1353340
,	1353340
ARSA	1353340
activities	1353340
,	1353340
and	1353340
clinical	1353340
data	1353340
on	1353340
4	1353340
individuals	1353340
carrying	1353340
the	1353340
allele	1353340
of	1353340
81	1353340
patients	1353340
with	1353340
MLD	1353340
examined	1353340
,	1353340
further	1353340
validates	1353340
the	1353340
concept	1353340
that	1353340
different	1353340
degrees	1353340
of	1353340
residual	1353340
ARSA	1353340
activity	1353340
are	1353340
the	1353340
basis	1353340
of	1353340
phenotypical	1353340
variation	1353340
in	1353340
MLD	1353340
.	1353340
Families	17185386
with	17185386
the	17185386
risk	17185386
allele	17185386
of	17185386
DISC1	17185386
reveal	17185386
a	17185386
link	17185386
between	17185386
schizophrenia	17185386
and	17185386
another	17185386
component	17185386
of	17185386
the	17185386
same	17185386
molecular	17185386
pathway	17185386
,	17185386
NDE1	17185386
.	17185386

We	17185386
have	17185386
previously	17185386
reported	17185386
a	17185386
robust	17185386
association	17185386
between	17185386
an	17185386
allelic	17185386
haplotype	17185386
of	17185386
'	17185386
Disrupted	17185386
in	17185386
Schizophrenia	17185386
1	17185386
'	17185386
(	17185386
DISC1	17185386
)	17185386
and	17185386
schizophrenia	17185386
in	17185386
a	17185386
nationwide	17185386
collection	17185386
of	17185386
Finnish	17185386
schizophrenia	17185386
families	17185386
.	17185386

This	17185386
specific	17185386
DISC1	17185386
allele	17185386
was	17185386
later	17185386
identified	17185386
to	17185386
associate	17185386
with	17185386
visual	17185386
working	17185386
memory	17185386
,	17185386
selectively	17185386
in	17185386
males	17185386
.	17185386

DISC1	17185386
association	17185386
to	17185386
schizophrenia	17185386
has	17185386
since	17185386
been	17185386
replicated	17185386
in	17185386
multiple	17185386
independent	17185386
study	17185386
samples	17185386
from	17185386
different	17185386
populations	17185386
.	17185386

In	17185386
this	17185386
study	17185386
,	17185386
we	17185386
conditioned	17185386
our	17185386
sample	17185386
of	17185386
Finnish	17185386
families	17185386
for	17185386
the	17185386
presence	17185386
of	17185386
the	17185386
Finnish	17185386
tentative	17185386
risk	17185386
allele	17185386
for	17185386
DISC1	17185386
and	17185386
re	17185386
-	17185386
analyzed	17185386
our	17185386
genome	17185386
-	17185386
wide	17185386
scan	17185386
data	17185386
of	17185386
443	17185386
markers	17185386
on	17185386
the	17185386
basis	17185386
of	17185386
this	17185386
stratification	17185386
.	17185386

Two	17185386
additional	17185386
loci	17185386
displayed	17185386
an	17185386
evidence	17185386
of	17185386
linkage	17185386
(	17185386
LOD	17185386
>	17185386
3	17185386
)	17185386
and	17185386
included	17185386
a	17185386
locus	17185386
on	17185386
16p13	17185386
,	17185386
proximal	17185386
to	17185386
the	17185386
gene	17185386
encoding	17185386
NDE1	17185386
,	17185386
which	17185386
has	17185386
been	17185386
shown	17185386
to	17185386
biologically	17185386
interact	17185386
with	17185386
DISC1	17185386
.	17185386

Although	17185386
none	17185386
of	17185386
the	17185386
observed	17185386
linkages	17185386
remained	17185386
significant	17185386
after	17185386
multiple	17185386
test	17185386
correction	17185386
through	17185386
simulation	17185386
,	17185386
further	17185386
analysis	17185386
of	17185386
NDE1	17185386
revealed	17185386
an	17185386
association	17185386
between	17185386
a	17185386
tag	17185386
-	17185386
haplotype	17185386
and	17185386
schizophrenia	17185386
(	17185386
P	17185386
=	17185386
0	17185386
.	17185386
00046	17185386
)	17185386
specific	17185386
to	17185386
females	17185386
,	17185386
which	17185386
proved	17185386
to	17185386
be	17185386
significant	17185386
(	17185386
P	17185386
=	17185386
0	17185386
.	17185386
011	17185386
)	17185386
after	17185386
multiple	17185386
test	17185386
correction	17185386
.	17185386

Our	17185386
finding	17185386
would	17185386
support	17185386
the	17185386
concept	17185386
that	17185386
initial	17185386
gene	17185386
findings	17185386
in	17185386
multifactorial	17185386
diseases	17185386
will	17185386
assist	17185386
in	17185386
the	17185386
identification	17185386
of	17185386
other	17185386
components	17185386
of	17185386
complex	17185386
genetic	17185386
etiology	17185386
.	17185386

Notably	17185386
,	17185386
this	17185386
and	17185386
other	17185386
converging	17185386
lines	17185386
of	17185386
evidence	17185386
underline	17185386
the	17185386
importance	17185386
of	17185386
DISC1	17185386
-	17185386
related	17185386
functional	17185386
pathways	17185386
in	17185386
the	17185386
etiology	17185386
of	17185386
schizophrenia	17185386
.	17185386
CenpH	27993978
regulates	27993978
meiotic	27993978
G2	27993978
/	27993978
M	27993978
transition	27993978
by	27993978
modulating	27993978
the	27993978
APC	27993978
/	27993978
CCdh1	27993978
-	27993978
cyclin	27993978
B1	27993978
pathway	27993978
in	27993978
oocytes	27993978
.	27993978

Meiotic	27993978
resumption	27993978
(	27993978
G2	27993978
/	27993978
M	27993978
transition	27993978
)	27993978
and	27993978
progression	27993978
through	27993978
meiosis	27993978
I	27993978
(	27993978
MI	27993978
)	27993978
are	27993978
two	27993978
key	27993978
stages	27993978
for	27993978
producing	27993978
fertilization	27993978
-	27993978
competent	27993978
eggs	27993978
.	27993978

Here	27993978
,	27993978
we	27993978
report	27993978
that	27993978
CenpH	27993978
,	27993978
a	27993978
component	27993978
of	27993978
the	27993978
kinetochore	27993978
inner	27993978
plate	27993978
,	27993978
is	27993978
responsible	27993978
for	27993978
G2	27993978
/	27993978
M	27993978
transition	27993978
in	27993978
meiotic	27993978
mouse	27993978
oocytes	27993978
.	27993978

Depletion	27993978
of	27993978
CenpH	27993978
by	27993978
morpholino	27993978
injection	27993978
decreased	27993978
cyclin	27993978
B1	27993978
levels	27993978
,	27993978
resulting	27993978
in	27993978
attenuation	27993978
of	27993978
maturation	27993978
-	27993978
promoting	27993978
factor	27993978
(	27993978
MPF	27993978
)	27993978
activation	27993978
,	27993978
and	27993978
severely	27993978
compromised	27993978
meiotic	27993978
resumption	27993978
.	27993978

CenpH	27993978
protects	27993978
cyclin	27993978
B1	27993978
from	27993978
destruction	27993978
by	27993978
competing	27993978
with	27993978
the	27993978
action	27993978
of	27993978
APC	27993978
/	27993978
C	27993978
(	27993978
Cdh1	27993978
)	27993978
Impaired	27993978
G2	27993978
/	27993978
M	27993978
transition	27993978
after	27993978
CenpH	27993978
depletion	27993978
could	27993978
be	27993978
rescued	27993978
by	27993978
expression	27993978
of	27993978
exogenous	27993978
cyclin	27993978
B1	27993978
.	27993978

Unexpectedly	27993978
,	27993978
blocking	27993978
CenpH	27993978
did	27993978
not	27993978
affect	27993978
spindle	27993978
organization	27993978
and	27993978
meiotic	27993978
cell	27993978
cycle	27993978
progression	27993978
after	27993978
germinal	27993978
vesicle	27993978
breakdown	27993978
.	27993978

Our	27993978
findings	27993978
reveal	27993978
a	27993978
novel	27993978
role	27993978
of	27993978
CenpH	27993978
in	27993978
regulating	27993978
meiotic	27993978
G2	27993978
/	27993978
M	27993978
transition	27993978
by	27993978
acting	27993978
via	27993978
the	27993978
APC	27993978
/	27993978
C	27993978
(	27993978
Cdh1	27993978
)	27993978
-	27993978
cyclin	27993978
B1	27993978
pathway	27993978
.	27993978
The	20709368
fibrinogen	20709368
gamma	20709368
10034C	20709368
>	20709368
T	20709368
polymorphism	20709368
is	20709368
not	20709368
associated	20709368
with	20709368
Peripheral	20709368
Arterial	20709368
Disease	20709368
.	20709368

Conversion	20709368
of	20709368
fibrinogen	20709368
to	20709368
fibrin	20709368
plays	20709368
an	20709368
essential	20709368
role	20709368
in	20709368
hemostasis	20709368
and	20709368
results	20709368
in	20709368
stabilization	20709368
of	20709368
the	20709368
fibrin	20709368
clot	20709368
.	20709368

Fibrinogen	20709368
consists	20709368
of	20709368
three	20709368
pairs	20709368
of	20709368
non	20709368
-	20709368
identical	20709368
polypeptide	20709368
chains	20709368
,	20709368
encoded	20709368
by	20709368
different	20709368
genes	20709368
(	20709368
fibrinogen	20709368
alpha	20709368
[	20709368
FGA	20709368
]	20709368
,	20709368
fibrinogen	20709368
beta	20709368
[	20709368
FGB	20709368
]	20709368
and	20709368
fibrinogen	20709368
gamma	20709368
[	20709368
FGG	20709368
]	20709368
)	20709368
.	20709368

A	20709368
functional	20709368
single	20709368
nucleotide	20709368
polymorphism	20709368
(	20709368
SNP	20709368
)	20709368
in	20709368
the	20709368
3	20709368
'	20709368
untranslated	20709368
region	20709368
of	20709368
the	20709368
FGG	20709368
gene	20709368
(	20709368
FGG	20709368
10034C	20709368
>	20709368
T	20709368
,	20709368
rs2066865	20709368
)	20709368
has	20709368
been	20709368
associated	20709368
with	20709368
deep	20709368
venous	20709368
thrombosis	20709368
and	20709368
myocardial	20709368
infarction	20709368
.	20709368

Aim	20709368
of	20709368
the	20709368
present	20709368
study	20709368
was	20709368
to	20709368
analyze	20709368
the	20709368
role	20709368
of	20709368
this	20709368
polymorphism	20709368
in	20709368
peripheral	20709368
arterial	20709368
disease	20709368
(	20709368
PAD	20709368
)	20709368
.	20709368

The	20709368
study	20709368
was	20709368
designed	20709368
as	20709368
case	20709368
-	20709368
control	20709368
study	20709368
including	20709368
891	20709368
patients	20709368
with	20709368
documented	20709368
PAD	20709368
and	20709368
777	20709368
control	20709368
subjects	20709368
.	20709368

FGG	20709368
genotypes	20709368
were	20709368
determined	20709368
by	20709368
exonuclease	20709368
(	20709368
TaqMan	20709368
)	20709368
assays	20709368
.	20709368

FGG	20709368
genotype	20709368
frequencies	20709368
were	20709368
not	20709368
significantly	20709368
different	20709368
between	20709368
PAD	20709368
patients	20709368
(	20709368
CC	20709368
:	20709368
57	20709368
.	20709368
3%	20709368
,	20709368
CT	20709368
:	20709368
36	20709368
.	20709368
7%	20709368
,	20709368
TT	20709368
:	20709368
5	20709368
.	20709368
8%	20709368
)	20709368
and	20709368
control	20709368
subjects	20709368
(	20709368
CC	20709368
:	20709368
60	20709368
.	20709368
9%	20709368
,	20709368
CT	20709368
:	20709368
33	20709368
.	20709368
5%	20709368
,	20709368
TT	20709368
5	20709368
.	20709368
6%	20709368
;	20709368
p	20709368
=	20709368
0	20709368
.	20709368
35	20709368
)	20709368
.	20709368

In	20709368
a	20709368
multivariate	20709368
logistic	20709368
regression	20709368
analysis	20709368
including	20709368
age	20709368
,	20709368
sex	20709368
,	20709368
smoking	20709368
,	20709368
diabetes	20709368
,	20709368
arterial	20709368
hypertension	20709368
and	20709368
hypercholesterolemia	20709368
,	20709368
the	20709368
FGG	20709368
10034	20709368
T	20709368
variant	20709368
was	20709368
not	20709368
significantly	20709368
associated	20709368
with	20709368
the	20709368
presence	20709368
of	20709368
PAD	20709368
(	20709368
Odds	20709368
ratio	20709368
1	20709368
.	20709368
07	20709368
,	20709368
95%	20709368
confidence	20709368
interval	20709368
0	20709368
.	20709368
84	20709368
-	20709368
1	20709368
.	20709368
37	20709368
;	20709368
p	20709368
=	20709368
0	20709368
.	20709368
60	20709368
)	20709368
.	20709368

The	20709368
FGG	20709368
10034C	20709368
>	20709368
T	20709368
polymorphism	20709368
was	20709368
furthermore	20709368
not	20709368
associated	20709368
with	20709368
age	20709368
at	20709368
onset	20709368
of	20709368
PAD	20709368
.	20709368

We	20709368
conclude	20709368
that	20709368
the	20709368
thrombophilic	20709368
FGG	20709368
10034	20709368
T	20709368
gene	20709368
variant	20709368
does	20709368
not	20709368
contribute	20709368
to	20709368
the	20709368
genetic	20709368
susceptibility	20709368
to	20709368
PAD	20709368
.	20709368
Concordance	28068934
between	28068934
PIK3CA	28068934
mutations	28068934
in	28068934
endoscopic	28068934
biopsy	28068934
and	28068934
surgically	28068934
resected	28068934
specimens	28068934
of	28068934
esophageal	28068934
squamous	28068934
cell	28068934
carcinoma	28068934
.	28068934

BACKGROUND	28068934
:	28068934
PIK3CA	28068934
mutations	28068934
are	28068934
expected	28068934
to	28068934
be	28068934
potential	28068934
therapeutic	28068934
targets	28068934
for	28068934
esophageal	28068934
squamous	28068934
cell	28068934
carcinoma	28068934
(	28068934
ESCC	28068934
)	28068934
.	28068934

We	28068934
aimed	28068934
to	28068934
clarify	28068934
the	28068934
concordance	28068934
between	28068934
PIK3CA	28068934
mutations	28068934
detected	28068934
in	28068934
endoscopic	28068934
biopsy	28068934
specimens	28068934
and	28068934
corresponding	28068934
surgically	28068934
resected	28068934
specimens	28068934
.	28068934

METHODS	28068934
:	28068934
We	28068934
examined	28068934
five	28068934
hotspot	28068934
mutations	28068934
in	28068934
the	28068934
PIK3CA	28068934
gene	28068934
(	28068934
E542K	28068934
,	28068934
E545K	28068934
,	28068934
E546K	28068934
,	28068934
H1047R	28068934
,	28068934
and	28068934
H1047L	28068934
)	28068934
in	28068934
formalin	28068934
-	28068934
fixed	28068934
and	28068934
paraffin	28068934
-	28068934
embedded	28068934
tissue	28068934
sections	28068934
of	28068934
paired	28068934
endoscopic	28068934
biopsy	28068934
and	28068934
surgically	28068934
resected	28068934
specimens	28068934
from	28068934
181	28068934
patients	28068934
undergoing	28068934
curative	28068934
resection	28068934
for	28068934
ESCC	28068934
between	28068934
2000	28068934
and	28068934
2011	28068934
using	28068934
a	28068934
Luminex	28068934
technology	28068934
-	28068934
based	28068934
multiplex	28068934
gene	28068934
mutation	28068934
detection	28068934
kit	28068934
.	28068934

RESULTS	28068934
:	28068934
Mutation	28068934
analyses	28068934
were	28068934
successfully	28068934
performed	28068934
for	28068934
both	28068934
endoscopic	28068934
biopsy	28068934
and	28068934
surgically	28068934
resected	28068934
specimens	28068934
in	28068934
all	28068934
the	28068934
cases	28068934
.	28068934

A	28068934
PIK3CA	28068934
mutation	28068934
was	28068934
detected	28068934
in	28068934
either	28068934
type	28068934
of	28068934
specimen	28068934
in	28068934
13	28068934
cases	28068934
(	28068934
7	28068934
.	28068934
2%	28068934
,	28068934
95%	28068934
confidence	28068934
interval	28068934
:	28068934
3	28068934
.	28068934
9	28068934
-	28068934
12	28068934
.	28068934
0	28068934
)	28068934
.	28068934

The	28068934
overall	28068934
concordance	28068934
rate	28068934
,	28068934
positive	28068934
predictive	28068934
value	28068934
,	28068934
and	28068934
negative	28068934
predictive	28068934
value	28068934
were	28068934
98	28068934
.	28068934
3%	28068934
(	28068934
178	28068934
/	28068934
181	28068934
)	28068934
,	28068934
90	28068934
.	28068934
9%	28068934
(	28068934
10	28068934
/	28068934
11	28068934
)	28068934
,	28068934
and	28068934
98	28068934
.	28068934
8%	28068934
(	28068934
168	28068934
/	28068934
170	28068934
)	28068934
,	28068934
respectively	28068934
.	28068934

Among	28068934
patients	28068934
with	28068934
a	28068934
PIK3CA	28068934
mutation	28068934
detected	28068934
in	28068934
both	28068934
types	28068934
of	28068934
specimens	28068934
,	28068934
the	28068934
concordance	28068934
between	28068934
PIK3CA	28068934
mutation	28068934
genotypes	28068934
was	28068934
100%	28068934
.	28068934

There	28068934
were	28068934
three	28068934
cases	28068934
with	28068934
a	28068934
discordant	28068934
mutation	28068934
status	28068934
between	28068934
the	28068934
types	28068934
of	28068934
specimens	28068934
(	28068934
PIK3CA	28068934
mutation	28068934
in	28068934
surgically	28068934
resected	28068934
specimen	28068934
and	28068934
wild	28068934
-	28068934
type	28068934
in	28068934
biopsy	28068934
specimen	28068934
in	28068934
two	28068934
cases	28068934
,	28068934
and	28068934
the	28068934
opposite	28068934
pattern	28068934
in	28068934
one	28068934
case	28068934
)	28068934
,	28068934
suggesting	28068934
possible	28068934
intratumoral	28068934
heterogeneity	28068934
in	28068934
the	28068934
PIK3CA	28068934
mutation	28068934
status	28068934
.	28068934

CONCLUSIONS	28068934
:	28068934
The	28068934
PIK3CA	28068934
mutation	28068934
status	28068934
was	28068934
highly	28068934
concordant	28068934
between	28068934
endoscopic	28068934
biopsy	28068934
and	28068934
surgically	28068934
resected	28068934
specimens	28068934
from	28068934
the	28068934
same	28068934
patient	28068934
,	28068934
suggesting	28068934
that	28068934
endoscopic	28068934
biopsy	28068934
specimens	28068934
can	28068934
be	28068934
clinically	28068934
used	28068934
to	28068934
detect	28068934
PIK3CA	28068934
mutations	28068934
in	28068934
patients	28068934
with	28068934
ESCC	28068934
.	28068934
Paraoxonase	15241482
1	15241482
polymorphisms	15241482
and	15241482
survival	15241482
.	15241482

The	15241482
antioxidant	15241482
enzyme	15241482
paraoxonase	15241482
1	15241482
(	15241482
PON1	15241482
)	15241482
has	15241482
previously	15241482
been	15241482
suggested	15241482
to	15241482
confer	15241482
protection	15241482
against	15241482
coronary	15241482
heart	15241482
disease	15241482
(	15241482
CHD	15241482
)	15241482
,	15241482
one	15241482
of	15241482
the	15241482
main	15241482
causes	15241482
of	15241482
death	15241482
in	15241482
the	15241482
Western	15241482
world	15241482
.	15241482

Two	15241482
coding	15241482
polymorphisms	15241482
,	15241482
55M	15241482
/	15241482
L	15241482
and	15241482
192Q	15241482
/	15241482
R	15241482
,	15241482
and	15241482
a	15241482
promoter	15241482
variant	15241482
,	15241482
-	15241482
107C	15241482
/	15241482
T	15241482
,	15241482
has	15241482
been	15241482
extensively	15241482
studied	15241482
with	15241482
respect	15241482
to	15241482
susceptibility	15241482
to	15241482
CHD	15241482
.	15241482

In	15241482
this	15241482
study	15241482
,	15241482
we	15241482
have	15241482
investigated	15241482
the	15241482
impact	15241482
of	15241482
these	15241482
three	15241482
polymorphisms	15241482
on	15241482
mortality	15241482
using	15241482
a	15241482
sample	15241482
of	15241482
1932	15241482
Danish	15241482
individuals	15241482
aged	15241482
47	15241482
-	15241482
93	15241482
years	15241482
,	15241482
previously	15241482
used	15241482
in	15241482
gene	15241482
-	15241482
longevity	15241482
studies	15241482
.	15241482

A	15241482
cross	15241482
-	15241482
sectional	15241482
study	15241482
comparing	15241482
the	15241482
genotype	15241482
distribution	15241482
of	15241482
the	15241482
three	15241482
polymorphisms	15241482
separately	15241482
as	15241482
well	15241482
as	15241482
the	15241482
haplotype	15241482
distribution	15241482
in	15241482
different	15241482
age	15241482
groups	15241482
did	15241482
not	15241482
reveal	15241482
any	15241482
difference	15241482
.	15241482

However	15241482
,	15241482
a	15241482
longitudinal	15241482
follow	15241482
-	15241482
up	15241482
study	15241482
on	15241482
survival	15241482
in	15241482
the	15241482
same	15241482
sample	15241482
indicated	15241482
that	15241482
192RR	15241482
homozygotes	15241482
have	15241482
a	15241482
poorer	15241482
survival	15241482
compared	15241482
to	15241482
QQ	15241482
homozygotes	15241482
(	15241482
hazard	15241482
rate	15241482
:	15241482
1	15241482
.	15241482
38	15241482
,	15241482
P	15241482
=	15241482
0	15241482
.	15241482
04	15241482
)	15241482
.	15241482

We	15241482
hereafter	15241482
used	15241482
an	15241482
independent	15241482
sample	15241482
of	15241482
541	15241482
Danish	15241482
individuals	15241482
from	15241482
the	15241482
oldest	15241482
cohort	15241482
and	15241482
confirmed	15241482
the	15241482
initial	15241482
findings	15241482
(	15241482
hazard	15241482
rate	15241482
:	15241482
1	15241482
.	15241482
38	15241482
,	15241482
P	15241482
=	15241482
0	15241482
.	15241482
09	15241482
)	15241482
.	15241482

In	15241482
both	15241482
samples	15241482
,	15241482
the	15241482
effect	15241482
was	15241482
most	15241482
pronounced	15241482
in	15241482
women	15241482
.	15241482

Using	15241482
self	15241482
-	15241482
reported	15241482
data	15241482
on	15241482
ischemic	15241482
heart	15241482
disease	15241482
to	15241482
evaluate	15241482
the	15241482
impact	15241482
of	15241482
the	15241482
PON	15241482
192Q	15241482
/	15241482
R	15241482
polymorphism	15241482
on	15241482
susceptibility	15241482
to	15241482
CHD	15241482
,	15241482
we	15241482
found	15241482
only	15241482
a	15241482
nonsignificant	15241482
trend	15241482
of	15241482
192RR	15241482
homozygosity	15241482
in	15241482
women	15241482
being	15241482
a	15241482
risk	15241482
factor	15241482
.	15241482

Our	15241482
results	15241482
thus	15241482
indicates	15241482
that	15241482
PON1	15241482
192RR	15241482
homozygosity	15241482
is	15241482
associated	15241482
with	15241482
increased	15241482
mortality	15241482
in	15241482
women	15241482
in	15241482
the	15241482
second	15241482
half	15241482
of	15241482
life	15241482
and	15241482
that	15241482
this	15241482
increased	15241482
mortality	15241482
is	15241482
possibly	15241482
related	15241482
to	15241482
CHD	15241482
severity	15241482
and	15241482
survival	15241482
after	15241482
CHD	15241482
rather	15241482
than	15241482
susceptibility	15241482
to	15241482
development	15241482
of	15241482
CHD	15241482
.	15241482
The	19721134
antiarrhythmic	19721134
effect	19721134
and	19721134
possible	19721134
ionic	19721134
mechanisms	19721134
of	19721134
pilocarpine	19721134
on	19721134
animal	19721134
models	19721134
.	19721134

This	19721134
study	19721134
was	19721134
designed	19721134
to	19721134
evaluate	19721134
the	19721134
effects	19721134
of	19721134
pilocarpine	19721134
and	19721134
explore	19721134
the	19721134
underlying	19721134
ionic	19721134
mechanism	19721134
,	19721134
using	19721134
both	19721134
aconitine	19721134
-	19721134
induced	19721134
rat	19721134
and	19721134
ouabain	19721134
-	19721134
induced	19721134
guinea	19721134
pig	19721134
arrhythmia	19721134
models	19721134
.	19721134

Confocal	19721134
microscopy	19721134
was	19721134
used	19721134
to	19721134
measure	19721134
intracellular	19721134
free	19721134
-	19721134
calcium	19721134
concentrations	19721134
(	19721134
[	19721134
Ca	19721134
(	19721134
2	19721134
+	19721134
)	19721134
]	19721134
(	19721134
i	19721134
)	19721134
)	19721134
in	19721134
isolated	19721134
myocytes	19721134
.	19721134

The	19721134
current	19721134
data	19721134
showed	19721134
that	19721134
pilocarpine	19721134
significantly	19721134
delayed	19721134
onset	19721134
of	19721134
arrhythmias	19721134
,	19721134
decreased	19721134
the	19721134
time	19721134
course	19721134
of	19721134
ventricular	19721134
tachycardia	19721134
and	19721134
fibrillation	19721134
,	19721134
reduced	19721134
arrhythmia	19721134
score	19721134
,	19721134
and	19721134
increased	19721134
the	19721134
survival	19721134
time	19721134
of	19721134
arrhythmic	19721134
rats	19721134
and	19721134
guinea	19721134
pigs	19721134
.	19721134

[	19721134
Ca	19721134
(	19721134
2	19721134
+	19721134
)	19721134
]	19721134
(	19721134
i	19721134
)	19721134
overload	19721134
induced	19721134
by	19721134
aconitine	19721134
or	19721134
ouabain	19721134
was	19721134
reduced	19721134
in	19721134
isolated	19721134
myocytes	19721134
pretreated	19721134
with	19721134
pilocarpine	19721134
.	19721134

Moreover	19721134
,	19721134
M	19721134
(	19721134
3	19721134
)	19721134
-	19721134
muscarinic	19721134
acetylcholine	19721134
receptor	19721134
(	19721134
mAChR	19721134
)	19721134
antagonist	19721134
4	19721134
-	19721134
DAMP	19721134
(	19721134
4	19721134
-	19721134
diphenylacetoxy	19721134
-	19721134
N	19721134
-	19721134
methylpiperidine	19721134
-	19721134
methiodide	19721134
)	19721134
partially	19721134
abolished	19721134
the	19721134
beneficial	19721134
effects	19721134
of	19721134
pilocarpine	19721134
.	19721134

These	19721134
data	19721134
suggest	19721134
that	19721134
pilocarpine	19721134
produced	19721134
antiarrhythmic	19721134
actions	19721134
on	19721134
arrhythmic	19721134
rat	19721134
and	19721134
guinea	19721134
pig	19721134
models	19721134
induced	19721134
by	19721134
aconitine	19721134
or	19721134
ouabain	19721134
via	19721134
stimulating	19721134
the	19721134
cardiac	19721134
M	19721134
(	19721134
3	19721134
)	19721134
-	19721134
mAChR	19721134
.	19721134

The	19721134
mechanism	19721134
may	19721134
be	19721134
related	19721134
to	19721134
the	19721134
improvement	19721134
of	19721134
Ca	19721134
(	19721134
2	19721134
+	19721134
)	19721134
handling	19721134
.	19721134
Arginase	29183288
1	29183288
deletion	29183288
in	29183288
myeloid	29183288
cells	29183288
affects	29183288
the	29183288
inflammatory	29183288
response	29183288
in	29183288
allergic	29183288
asthma	29183288
,	29183288
but	29183288
not	29183288
lung	29183288
mechanics	29183288
,	29183288
in	29183288
female	29183288
mice	29183288
.	29183288

BACKGROUND	29183288
:	29183288
(	29183288
Over	29183288
-	29183288
)	29183288
expression	29183288
of	29183288
arginase	29183288
may	29183288
limit	29183288
local	29183288
availability	29183288
of	29183288
arginine	29183288
for	29183288
nitric	29183288
oxide	29183288
synthesis	29183288
.	29183288

We	29183288
investigated	29183288
the	29183288
significance	29183288
of	29183288
arginase1	29183288
(	29183288
ARG1	29183288
)	29183288
for	29183288
the	29183288
development	29183288
of	29183288
airway	29183288
hyperresponsiveness	29183288
(	29183288
AHR	29183288
)	29183288
and	29183288
lung	29183288
inflammation	29183288
in	29183288
female	29183288
mice	29183288
with	29183288
ovalbumin	29183288
(	29183288
OVA	29183288
)	29183288
-	29183288
induced	29183288
allergic	29183288
asthma	29183288
.	29183288

METHODS	29183288
:	29183288
Arg1	29183288
was	29183288
ablated	29183288
in	29183288
the	29183288
lung	29183288
by	29183288
crossing	29183288
Arg1	29183288
fl	29183288
/	29183288
fl	29183288
and	29183288
Tie2Cre	29183288
tg	29183288
/	29183288
-	29183288
mice	29183288
.	29183288

OVA	29183288
sensitization	29183288
and	29183288
challenge	29183288
were	29183288
conducted	29183288
,	29183288
and	29183288
AHR	29183288
to	29183288
methacholine	29183288
was	29183288
determined	29183288
using	29183288
the	29183288
Flexivent	29183288
system	29183288
.	29183288

Changes	29183288
in	29183288
gene	29183288
expression	29183288
,	29183288
chemokine	29183288
and	29183288
cytokine	29183288
secretion	29183288
,	29183288
plasma	29183288
IgE	29183288
,	29183288
and	29183288
lung	29183288
histology	29183288
were	29183288
quantified	29183288
using	29183288
RT	29183288
-	29183288
qPCR	29183288
,	29183288
ELISA	29183288
,	29183288
and	29183288
immunohistochemistry	29183288
,	29183288
respectively	29183288
.	29183288

RESULTS	29183288
:	29183288
Arg1	29183288
ablation	29183288
had	29183288
no	29183288
influence	29183288
on	29183288
the	29183288
development	29183288
of	29183288
OVA	29183288
-	29183288
induced	29183288
AHR	29183288
,	29183288
but	29183288
attenuated	29183288
OVA	29183288
-	29183288
induced	29183288
increases	29183288
in	29183288
expression	29183288
of	29183288
Arg2	29183288
and	29183288
Nos2	29183288
,	29183288
Slc7a1	29183288
,	29183288
Slc7a2	29183288
,	29183288
and	29183288
Slc7a7	29183288
(	29183288
arginine	29183288
transporters	29183288
)	29183288
,	29183288
Il4	29183288
,	29183288
Il5	29183288
and	29183288
Il13	29183288
(	29183288
TH2	29183288
-	29183288
type	29183288
cytokines	29183288
)	29183288
,	29183288
Ccl2	29183288
and	29183288
Ccl11	29183288
(	29183288
chemokines	29183288
)	29183288
,	29183288
Ifng	29183288
(	29183288
TH1	29183288
-	29183288
type	29183288
cytokine	29183288
)	29183288
,	29183288
Clca3	29183288
and	29183288
Muc5ac	29183288
(	29183288
goblet	29183288
cell	29183288
markers	29183288
)	29183288
,	29183288
and	29183288
OVA	29183288
-	29183288
specific	29183288
IgE	29183288
.	29183288

Pulmonary	29183288
IL	29183288
-	29183288
10	29183288
protein	29183288
content	29183288
increased	29183288
,	29183288
but	29183288
IL	29183288
-	29183288
4	29183288
,	29183288
IL	29183288
-	29183288
5	29183288
,	29183288
IL	29183288
-	29183288
13	29183288
,	29183288
TNFalpha	29183288
and	29183288
IFNgamma	29183288
content	29183288
,	29183288
and	29183288
lung	29183288
histopathology	29183288
,	29183288
were	29183288
not	29183288
affected	29183288
.	29183288

Arg1	29183288
elimination	29183288
also	29183288
decreased	29183288
number	29183288
and	29183288
tightness	29183288
of	29183288
correlations	29183288
between	29183288
adaptive	29183288
changes	29183288
in	29183288
lung	29183288
function	29183288
and	29183288
inflammatory	29183288
parameters	29183288
in	29183288
OVA	29183288
/	29183288
OVA	29183288
-	29183288
treated	29183288
female	29183288
mice	29183288
.	29183288

OVA	29183288
/	29183288
OVA	29183288
-	29183288
treated	29183288
female	29183288
mice	29183288
mounted	29183288
a	29183288
higher	29183288
OVA	29183288
-	29183288
IgE	29183288
response	29183288
than	29183288
males	29183288
,	29183288
but	29183288
the	29183288
correlation	29183288
between	29183288
lung	29183288
function	29183288
and	29183288
inflammation	29183288
was	29183288
lower	29183288
.	29183288

Arg1	29183288
-	29183288
deficient	29183288
OVA	29183288
/	29183288
OVA	29183288
-	29183288
treated	29183288
females	29183288
differed	29183288
from	29183288
males	29183288
in	29183288
a	29183288
more	29183288
pronounced	29183288
decline	29183288
of	29183288
arginine	29183288
-	29183288
metabolizing	29183288
and	29183288
-	29183288
transporting	29183288
genes	29183288
,	29183288
higher	29183288
plasma	29183288
arginine	29183288
levels	29183288
,	29183288
a	29183288
smaller	29183288
OVA	29183288
-	29183288
specific	29183288
IgE	29183288
response	29183288
,	29183288
and	29183288
no	29183288
improvement	29183288
of	29183288
peripheral	29183288
lung	29183288
function	29183288
.	29183288

CONCLUSION	29183288
:	29183288
Complete	29183288
ablation	29183288
of	29183288
Arg1	29183288
in	29183288
the	29183288
lung	29183288
affects	29183288
mRNA	29183288
abundance	29183288
of	29183288
arginine	29183288
-	29183288
transporting	29183288
and	29183288
-	29183288
metabolizing	29183288
genes	29183288
,	29183288
and	29183288
pro	29183288
-	29183288
inflammatory	29183288
genes	29183288
,	29183288
but	29183288
not	29183288
methacholine	29183288
responsiveness	29183288
or	29183288
accumulation	29183288
of	29183288
inflammatory	29183288
cells	29183288
.	29183288
Valproic	15858223
acid	15858223
I	15858223
:	15858223
time	15858223
course	15858223
of	15858223
lipid	15858223
peroxidation	15858223
biomarkers	15858223
,	15858223
liver	15858223
toxicity	15858223
,	15858223
and	15858223
valproic	15858223
acid	15858223
metabolite	15858223
levels	15858223
in	15858223
rats	15858223
.	15858223

A	15858223
single	15858223
dose	15858223
of	15858223
valproic	15858223
acid	15858223
(	15858223
VPA	15858223
)	15858223
,	15858223
which	15858223
is	15858223
a	15858223
widely	15858223
used	15858223
antiepileptic	15858223
drug	15858223
,	15858223
is	15858223
associated	15858223
with	15858223
oxidative	15858223
stress	15858223
in	15858223
rats	15858223
,	15858223
as	15858223
recently	15858223
demonstrated	15858223
by	15858223
elevated	15858223
levels	15858223
of	15858223
15	15858223
-	15858223
F	15858223
(	15858223
2t	15858223
)	15858223
-	15858223
isoprostane	15858223
(	15858223
15	15858223
-	15858223
F	15858223
(	15858223
2t	15858223
)	15858223
-	15858223
IsoP	15858223
)	15858223
.	15858223

To	15858223
determine	15858223
whether	15858223
there	15858223
was	15858223
a	15858223
temporal	15858223
relationship	15858223
between	15858223
VPA	15858223
-	15858223
associated	15858223
oxidative	15858223
stress	15858223
and	15858223
hepatotoxicity	15858223
,	15858223
adult	15858223
male	15858223
Sprague	15858223
-	15858223
Dawley	15858223
rats	15858223
were	15858223
treated	15858223
ip	15858223
with	15858223
VPA	15858223
(	15858223
500	15858223
mg	15858223
/	15858223
kg	15858223
)	15858223
or	15858223
0	15858223
.	15858223
9%	15858223
saline	15858223
(	15858223
vehicle	15858223
)	15858223
once	15858223
daily	15858223
for	15858223
2	15858223
,	15858223
4	15858223
,	15858223
7	15858223
,	15858223
10	15858223
,	15858223
or	15858223
14	15858223
days	15858223
.	15858223

Oxidative	15858223
stress	15858223
was	15858223
assessed	15858223
by	15858223
determining	15858223
plasma	15858223
and	15858223
liver	15858223
levels	15858223
of	15858223
15	15858223
-	15858223
F	15858223
(	15858223
2t	15858223
)	15858223
-	15858223
IsoP	15858223
,	15858223
lipid	15858223
hydroperoxides	15858223
(	15858223
LPO	15858223
)	15858223
,	15858223
and	15858223
thiobarbituric	15858223
acid	15858223
reactive	15858223
substances	15858223
(	15858223
TBARs	15858223
)	15858223
.	15858223

Plasma	15858223
and	15858223
liver	15858223
15	15858223
-	15858223
F	15858223
(	15858223
2t	15858223
)	15858223
-	15858223
IsoP	15858223
were	15858223
elevated	15858223
and	15858223
reached	15858223
a	15858223
plateau	15858223
after	15858223
day	15858223
2	15858223
of	15858223
VPA	15858223
treatment	15858223
compared	15858223
to	15858223
control	15858223
.	15858223

Liver	15858223
LPO	15858223
levels	15858223
were	15858223
not	15858223
elevated	15858223
until	15858223
day	15858223
7	15858223
of	15858223
treatment	15858223
(	15858223
1	15858223
.	15858223
8	15858223
-	15858223
fold	15858223
versus	15858223
control	15858223
,	15858223
p	15858223
<	15858223
0	15858223
.	15858223
05	15858223
)	15858223
.	15858223

Liver	15858223
and	15858223
plasma	15858223
TBARs	15858223
were	15858223
not	15858223
increased	15858223
until	15858223
14	15858223
days	15858223
(	15858223
2	15858223
-	15858223
fold	15858223
vs	15858223
.	15858223

control	15858223
,	15858223
p	15858223
<	15858223
0	15858223
.	15858223
05	15858223
)	15858223
.	15858223

Liver	15858223
toxicity	15858223
was	15858223
evaluated	15858223
based	15858223
on	15858223
serum	15858223
levels	15858223
of	15858223
alpha	15858223
-	15858223
glutathione	15858223
S	15858223
-	15858223
transferase	15858223
(	15858223
alpha	15858223
-	15858223
GST	15858223
)	15858223
and	15858223
by	15858223
histology	15858223
.	15858223

Serum	15858223
alpha	15858223
-	15858223
GST	15858223
levels	15858223
were	15858223
significantly	15858223
elevated	15858223
by	15858223
day	15858223
4	15858223
,	15858223
which	15858223
corresponded	15858223
to	15858223
hepatotoxicity	15858223
as	15858223
shown	15858223
by	15858223
the	15858223
increasing	15858223
incidence	15858223
of	15858223
inflammation	15858223
of	15858223
the	15858223
liver	15858223
capsule	15858223
,	15858223
necrosis	15858223
,	15858223
and	15858223
steatosis	15858223
throughout	15858223
the	15858223
study	15858223
.	15858223

The	15858223
liver	15858223
levels	15858223
of	15858223
beta	15858223
-	15858223
oxidation	15858223
metabolites	15858223
of	15858223
VPA	15858223
were	15858223
decreased	15858223
by	15858223
day	15858223
14	15858223
,	15858223
while	15858223
the	15858223
levels	15858223
of	15858223
4	15858223
-	15858223
ene	15858223
-	15858223
VPA	15858223
and	15858223
(	15858223
E	15858223
)	15858223
-	15858223
2	15858223
,	15858223
4	15858223
-	15858223
diene	15858223
-	15858223
VPA	15858223
were	15858223
not	15858223
elevated	15858223
throughout	15858223
the	15858223
study	15858223
.	15858223

Overall	15858223
,	15858223
these	15858223
findings	15858223
indicate	15858223
that	15858223
VPA	15858223
treatment	15858223
results	15858223
in	15858223
oxidative	15858223
stress	15858223
,	15858223
as	15858223
measured	15858223
by	15858223
levels	15858223
of	15858223
15	15858223
-	15858223
F	15858223
(	15858223
2t	15858223
)	15858223
-	15858223
IsoP	15858223
,	15858223
which	15858223
precedes	15858223
the	15858223
onset	15858223
of	15858223
necrosis	15858223
,	15858223
steatosis	15858223
,	15858223
and	15858223
elevated	15858223
levels	15858223
of	15858223
serum	15858223
alpha	15858223
-	15858223
GST	15858223
.	15858223
Delineation	16158428
of	16158428
the	16158428
clinical	16158428
phenotype	16158428
associated	16158428
with	16158428
OPHN1	16158428
mutations	16158428
based	16158428
on	16158428
the	16158428
clinical	16158428
and	16158428
neuropsychological	16158428
evaluation	16158428
of	16158428
three	16158428
families	16158428
.	16158428

Recent	16158428
reports	16158428
have	16158428
demonstrated	16158428
that	16158428
mutations	16158428
in	16158428
the	16158428
OPHN1	16158428
gene	16158428
were	16158428
responsible	16158428
for	16158428
a	16158428
syndromic	16158428
rather	16158428
than	16158428
non	16158428
-	16158428
specific	16158428
mental	16158428
retardation	16158428
.	16158428

Abnormalities	16158428
of	16158428
the	16158428
posterior	16158428
fossa	16158428
with	16158428
cerebellar	16158428
hypoplasia	16158428
have	16158428
been	16158428
demonstrated	16158428
in	16158428
all	16158428
male	16158428
patients	16158428
reported	16158428
to	16158428
date	16158428
.	16158428

We	16158428
report	16158428
here	16158428
a	16158428
new	16158428
family	16158428
with	16158428
X	16158428
-	16158428
linked	16158428
mental	16158428
retardation	16158428
due	16158428
to	16158428
mutation	16158428
in	16158428
OPHN1	16158428
and	16158428
present	16158428
unpublished	16158428
data	16158428
about	16158428
two	16158428
families	16158428
previously	16158428
reported	16158428
,	16158428
concerning	16158428
the	16158428
facial	16158428
and	16158428
psychological	16158428
phenotype	16158428
of	16158428
affected	16158428
males	16158428
and	16158428
carrier	16158428
females	16158428
.	16158428

Our	16158428
study	16158428
confirms	16158428
that	16158428
cerebellar	16158428
hypoplasia	16158428
is	16158428
a	16158428
hallmark	16158428
of	16158428
this	16158428
syndrome	16158428
.	16158428

In	16158428
addition	16158428
,	16158428
affected	16158428
males	16158428
display	16158428
facial	16158428
similarities	16158428
that	16158428
can	16158428
help	16158428
the	16158428
diagnosis	16158428
.	16158428

Most	16158428
carrier	16158428
females	16158428
have	16158428
mild	16158428
mental	16158428
retardation	16158428
and	16158428
subtle	16158428
facial	16158428
changes	16158428
.	16158428
Serum	26270232
levels	26270232
of	26270232
chemokines	26270232
CCL4	26270232
and	26270232
CCL5	26270232
in	26270232
cirrhotic	26270232
patients	26270232
indicate	26270232
the	26270232
presence	26270232
of	26270232
hepatocellular	26270232
carcinoma	26270232
.	26270232

BACKGROUND	26270232
:	26270232
Most	26270232
hepatocellular	26270232
carcinomas	26270232
(	26270232
HCCs	26270232
)	26270232
are	26270232
diagnosed	26270232
at	26270232
an	26270232
advanced	26270232
stage	26270232
.	26270232

The	26270232
prognostic	26270232
value	26270232
of	26270232
serum	26270232
tumour	26270232
markers	26270232
alpha	26270232
-	26270232
fetoprotein	26270232
(	26270232
AFP	26270232
)	26270232
and	26270232
des	26270232
-	26270232
gamma	26270232
-	26270232
carboxy	26270232
prothrombin	26270232
(	26270232
DCP	26270232
)	26270232
is	26270232
limited	26270232
.	26270232

The	26270232
aim	26270232
of	26270232
our	26270232
study	26270232
is	26270232
to	26270232
evaluate	26270232
the	26270232
diagnostic	26270232
value	26270232
of	26270232
serum	26270232
growth	26270232
factors	26270232
,	26270232
apoptotic	26270232
and	26270232
inflammatory	26270232
mediators	26270232
of	26270232
cirrhotic	26270232
patients	26270232
with	26270232
and	26270232
without	26270232
HCC	26270232
.	26270232

METHODS	26270232
:	26270232
Serum	26270232
samples	26270232
were	26270232
collected	26270232
from	26270232
cirrhotic	26270232
potential	26270232
liver	26270232
transplant	26270232
patients	26270232
(	26270232
LTx	26270232
)	26270232
with	26270232
(	26270232
n	26270232
=	26270232
61	26270232
)	26270232
and	26270232
without	26270232
HCC	26270232
(	26270232
n	26270232
=	26270232
78	26270232
)	26270232
as	26270232
well	26270232
as	26270232
from	26270232
healthy	26270232
controls	26270232
(	26270232
HCs	26270232
;	26270232
n	26270232
=	26270232
39	26270232
)	26270232
.	26270232

Serum	26270232
concentrations	26270232
of	26270232
CRP	26270232
,	26270232
neopterin	26270232
and	26270232
IL	26270232
-	26270232
6	26270232
as	26270232
markers	26270232
of	26270232
inflammation	26270232
and	26270232
thrombopoietin	26270232
(	26270232
TPO	26270232
)	26270232
,	26270232
GCSF	26270232
,	26270232
FGF	26270232
basic	26270232
and	26270232
VEGF	26270232
,	26270232
HMGB1	26270232
,	26270232
CK	26270232
-	26270232
18	26270232
(	26270232
M65	26270232
)	26270232
and	26270232
CK18	26270232
fragment	26270232
(	26270232
M30	26270232
)	26270232
and	26270232
a	26270232
panel	26270232
of	26270232
proinflammatory	26270232
chemokines	26270232
(	26270232
CCL2	26270232
,	26270232
CCL3	26270232
,	26270232
CCL4	26270232
,	26270232
CCL5	26270232
,	26270232
CXCL5	26270232
and	26270232
IL	26270232
-	26270232
8	26270232
)	26270232
were	26270232
measured	26270232
.	26270232

Chi	26270232
square	26270232
,	26270232
Fisher	26270232
exact	26270232
,	26270232
Mann	26270232
-	26270232
Whitney	26270232
U	26270232
-	26270232
tests	26270232
,	26270232
ROC	26270232
curve	26270232
analysis	26270232
and	26270232
forward	26270232
stepwise	26270232
logistic	26270232
regression	26270232
analyses	26270232
were	26270232
applied	26270232
.	26270232

RESULTS	26270232
:	26270232
Patients	26270232
with	26270232
HCC	26270232
had	26270232
higher	26270232
serum	26270232
TPO	26270232
and	26270232
chemokines	26270232
(	26270232
P	26270232
<	26270232
0	26270232
.	26270232
001	26270232
for	26270232
TPO	26270232
,	26270232
CCL4	26270232
,	26270232
CCL5	26270232
and	26270232
CXCL5	26270232
)	26270232
and	26270232
lower	26270232
CCL2	26270232
(	26270232
P	26270232
=	26270232
0	26270232
.	26270232
008	26270232
)	26270232
levels	26270232
than	26270232
cirrhotic	26270232
patients	26270232
without	26270232
HCC	26270232
.	26270232

Multivariate	26270232
forward	26270232
stepwise	26270232
regression	26270232
analysis	26270232
for	26270232
significant	26270232
parameters	26270232
showed	26270232
that	26270232
among	26270232
the	26270232
studied	26270232
parameters	26270232
CCL4	26270232
and	26270232
CCL5	26270232
(	26270232
P	26270232
=	26270232
0	26270232
.	26270232
001	26270232
)	26270232
are	26270232
diagnostic	26270232
markers	26270232
of	26270232
HCC	26270232
.	26270232

Serum	26270232
levels	26270232
of	26270232
TPO	26270232
and	26270232
chemokines	26270232
were	26270232
lower	26270232
,	26270232
whereas	26270232
M30	26270232
was	26270232
significantly	26270232
higher	26270232
in	26270232
cirrhotic	26270232
patients	26270232
than	26270232
in	26270232
HCs	26270232
.	26270232

CONCLUSIONS	26270232
:	26270232
High	26270232
serum	26270232
levels	26270232
of	26270232
inflammatory	26270232
chemokines	26270232
such	26270232
as	26270232
CCL4	26270232
and	26270232
CCL5	26270232
in	26270232
the	26270232
serum	26270232
of	26270232
cirrhotic	26270232
patients	26270232
indicate	26270232
the	26270232
presence	26270232
of	26270232
HCC	26270232
.	26270232
Over	17345627
-	17345627
expression	17345627
of	17345627
BMP4	17345627
and	17345627
BMP5	17345627
in	17345627
a	17345627
child	17345627
with	17345627
axial	17345627
skeletal	17345627
malformations	17345627
and	17345627
heterotopic	17345627
ossification	17345627
:	17345627
a	17345627
new	17345627
syndrome	17345627
.	17345627

Bone	17345627
morphogenetic	17345627
proteins	17345627
(	17345627
BMPs	17345627
)	17345627
are	17345627
a	17345627
highly	17345627
conserved	17345627
class	17345627
of	17345627
signaling	17345627
molecules	17345627
that	17345627
induce	17345627
ectopic	17345627
cartilage	17345627
and	17345627
bone	17345627
formation	17345627
in	17345627
vivo	17345627
.	17345627

Dysregulated	17345627
expression	17345627
of	17345627
bone	17345627
morphogenetic	17345627
protein	17345627
4	17345627
(	17345627
BMP4	17345627
)	17345627
is	17345627
found	17345627
in	17345627
the	17345627
cells	17345627
of	17345627
patients	17345627
who	17345627
have	17345627
fibrodysplasia	17345627
ossificans	17345627
progressiva	17345627
(	17345627
FOP	17345627
)	17345627
,	17345627
a	17345627
genetic	17345627
disorder	17345627
of	17345627
axial	17345627
and	17345627
appendicular	17345627
skeletal	17345627
malformation	17345627
and	17345627
progressive	17345627
heterotopic	17345627
ossification	17345627
.	17345627

Loss	17345627
of	17345627
function	17345627
mutations	17345627
in	17345627
the	17345627
bone	17345627
morphogenetic	17345627
protein	17345627
5	17345627
(	17345627
bmp5	17345627
)	17345627
gene	17345627
leading	17345627
to	17345627
under	17345627
-	17345627
expression	17345627
of	17345627
BMP5	17345627
cause	17345627
the	17345627
murine	17345627
short	17345627
ear	17345627
syndrome	17345627
,	17345627
characterized	17345627
by	17345627
small	17345627
malformed	17345627
ears	17345627
and	17345627
a	17345627
broad	17345627
range	17345627
of	17345627
axial	17345627
skeletal	17345627
malformations	17345627
.	17345627

We	17345627
found	17345627
features	17345627
reminiscent	17345627
of	17345627
both	17345627
the	17345627
short	17345627
ear	17345627
mouse	17345627
and	17345627
FOP	17345627
in	17345627
a	17345627
child	17345627
with	17345627
malformed	17345627
external	17345627
ears	17345627
,	17345627
multiple	17345627
malformations	17345627
of	17345627
the	17345627
axial	17345627
skeleton	17345627
,	17345627
and	17345627
progressive	17345627
heterotopic	17345627
ossification	17345627
in	17345627
the	17345627
neck	17345627
and	17345627
back	17345627
.	17345627

We	17345627
examined	17345627
BMP	17345627
mRNA	17345627
expression	17345627
in	17345627
transformed	17345627
lymphocytes	17345627
by	17345627
semi	17345627
-	17345627
quantitative	17345627
RT	17345627
-	17345627
PCR	17345627
and	17345627
protein	17345627
expression	17345627
by	17345627
ELISA	17345627
assays	17345627
and	17345627
immunohistochemistry	17345627
.	17345627

Elevated	17345627
levels	17345627
of	17345627
BMP4	17345627
and	17345627
BMP5	17345627
mRNA	17345627
and	17345627
protein	17345627
were	17345627
detected	17345627
in	17345627
the	17345627
patient	17345627
'	17345627
s	17345627
cells	17345627
while	17345627
levels	17345627
of	17345627
BMP2	17345627
mRNA	17345627
were	17345627
unchanged	17345627
.	17345627

Our	17345627
data	17345627
suggest	17345627
that	17345627
dysregulated	17345627
expression	17345627
of	17345627
BMP4	17345627
and	17345627
BMP5	17345627
genes	17345627
is	17345627
associated	17345627
with	17345627
an	17345627
array	17345627
of	17345627
human	17345627
axial	17345627
skeletal	17345627
abnormalities	17345627
similar	17345627
to	17345627
the	17345627
short	17345627
ear	17345627
mouse	17345627
and	17345627
FOP	17345627
.	17345627
The	15673851
activation	15673851
of	15673851
spinal	15673851
N	15673851
-	15673851
methyl	15673851
-	15673851
D	15673851
-	15673851
aspartate	15673851
receptors	15673851
may	15673851
contribute	15673851
to	15673851
degeneration	15673851
of	15673851
spinal	15673851
motor	15673851
neurons	15673851
induced	15673851
by	15673851
neuraxial	15673851
morphine	15673851
after	15673851
a	15673851
noninjurious	15673851
interval	15673851
of	15673851
spinal	15673851
cord	15673851
ischemia	15673851
.	15673851

We	15673851
investigated	15673851
the	15673851
relationship	15673851
between	15673851
the	15673851
degeneration	15673851
of	15673851
spinal	15673851
motor	15673851
neurons	15673851
and	15673851
activation	15673851
of	15673851
N	15673851
-	15673851
methyl	15673851
-	15673851
d	15673851
-	15673851
aspartate	15673851
(	15673851
NMDA	15673851
)	15673851
receptors	15673851
after	15673851
neuraxial	15673851
morphine	15673851
following	15673851
a	15673851
noninjurious	15673851
interval	15673851
of	15673851
aortic	15673851
occlusion	15673851
in	15673851
rats	15673851
.	15673851

Spinal	15673851
cord	15673851
ischemia	15673851
was	15673851
induced	15673851
by	15673851
aortic	15673851
occlusion	15673851
for	15673851
6	15673851
min	15673851
with	15673851
a	15673851
balloon	15673851
catheter	15673851
.	15673851

In	15673851
a	15673851
microdialysis	15673851
study	15673851
,	15673851
10	15673851
muL	15673851
of	15673851
saline	15673851
(	15673851
group	15673851
C	15673851
;	15673851
n	15673851
=	15673851
8	15673851
)	15673851
or	15673851
30	15673851
mug	15673851
of	15673851
morphine	15673851
(	15673851
group	15673851
M	15673851
;	15673851
n	15673851
=	15673851
8	15673851
)	15673851
was	15673851
injected	15673851
intrathecally	15673851
(	15673851
IT	15673851
)	15673851
0	15673851
.	15673851
5	15673851
h	15673851
after	15673851
reflow	15673851
,	15673851
and	15673851
30	15673851
mug	15673851
of	15673851
morphine	15673851
(	15673851
group	15673851
SM	15673851
;	15673851
n	15673851
=	15673851
8	15673851
)	15673851
or	15673851
10	15673851
muL	15673851
of	15673851
saline	15673851
(	15673851
group	15673851
SC	15673851
;	15673851
n	15673851
=	15673851
8	15673851
)	15673851
was	15673851
injected	15673851
IT	15673851
0	15673851
.	15673851
5	15673851
h	15673851
after	15673851
sham	15673851
operation	15673851
.	15673851

Microdialysis	15673851
samples	15673851
were	15673851
collected	15673851
preischemia	15673851
,	15673851
before	15673851
IT	15673851
injection	15673851
,	15673851
and	15673851
at	15673851
2	15673851
,	15673851
4	15673851
,	15673851
8	15673851
,	15673851
24	15673851
,	15673851
and	15673851
48	15673851
h	15673851
of	15673851
reperfusion	15673851
(	15673851
after	15673851
IT	15673851
injection	15673851
)	15673851
.	15673851

Second	15673851
,	15673851
we	15673851
investigated	15673851
the	15673851
effect	15673851
of	15673851
IT	15673851
MK	15673851
-	15673851
801	15673851
(	15673851
30	15673851
mug	15673851
)	15673851
on	15673851
the	15673851
histopathologic	15673851
changes	15673851
in	15673851
the	15673851
spinal	15673851
cord	15673851
after	15673851
morphine	15673851
-	15673851
induced	15673851
spastic	15673851
paraparesis	15673851
.	15673851

After	15673851
IT	15673851
morphine	15673851
,	15673851
the	15673851
cerebrospinal	15673851
fluid	15673851
(	15673851
CSF	15673851
)	15673851
glutamate	15673851
concentration	15673851
was	15673851
increased	15673851
in	15673851
group	15673851
M	15673851
relative	15673851
to	15673851
both	15673851
baseline	15673851
and	15673851
group	15673851
C	15673851
(	15673851
P	15673851
<	15673851
0	15673851
.	15673851
05	15673851
)	15673851
.	15673851

This	15673851
increase	15673851
persisted	15673851
for	15673851
8	15673851
hrs	15673851
.	15673851

IT	15673851
MK	15673851
-	15673851
801	15673851
significantly	15673851
reduced	15673851
the	15673851
number	15673851
of	15673851
dark	15673851
-	15673851
stained	15673851
alpha	15673851
-	15673851
motoneurons	15673851
after	15673851
morphine	15673851
-	15673851
induced	15673851
spastic	15673851
paraparesis	15673851
compared	15673851
with	15673851
the	15673851
saline	15673851
group	15673851
.	15673851

These	15673851
data	15673851
indicate	15673851
that	15673851
IT	15673851
morphine	15673851
induces	15673851
spastic	15673851
paraparesis	15673851
with	15673851
a	15673851
concomitant	15673851
increase	15673851
in	15673851
CSF	15673851
glutamate	15673851
,	15673851
which	15673851
is	15673851
involved	15673851
in	15673851
NMDA	15673851
receptor	15673851
activation	15673851
.	15673851

We	15673851
suggest	15673851
that	15673851
opioids	15673851
may	15673851
be	15673851
neurotoxic	15673851
in	15673851
the	15673851
setting	15673851
of	15673851
spinal	15673851
cord	15673851
ischemia	15673851
via	15673851
NMDA	15673851
receptor	15673851
activation	15673851
.	15673851
Association	16867246
of	16867246
DRD2	16867246
polymorphisms	16867246
and	16867246
chlorpromazine	16867246
-	16867246
induced	16867246
extrapyramidal	16867246
syndrome	16867246
in	16867246
Chinese	16867246
schizophrenic	16867246
patients	16867246
.	16867246

AIM	16867246
:	16867246
Extrapyramidal	16867246
syndrome	16867246
(	16867246
EPS	16867246
)	16867246
is	16867246
most	16867246
commonly	16867246
affected	16867246
by	16867246
typical	16867246
antipsychotic	16867246
drugs	16867246
that	16867246
have	16867246
a	16867246
high	16867246
affinity	16867246
with	16867246
the	16867246
D2	16867246
receptor	16867246
.	16867246

Recently	16867246
,	16867246
many	16867246
research	16867246
groups	16867246
have	16867246
reported	16867246
on	16867246
the	16867246
positive	16867246
relationship	16867246
between	16867246
the	16867246
genetic	16867246
variations	16867246
in	16867246
the	16867246
DRD2	16867246
gene	16867246
and	16867246
the	16867246
therapeutic	16867246
response	16867246
in	16867246
schizophrenia	16867246
patients	16867246
as	16867246
a	16867246
result	16867246
of	16867246
the	16867246
role	16867246
of	16867246
variations	16867246
in	16867246
the	16867246
receptor	16867246
in	16867246
modulating	16867246
receptor	16867246
expression	16867246
.	16867246

In	16867246
this	16867246
study	16867246
,	16867246
we	16867246
evaluate	16867246
the	16867246
role	16867246
DRD2	16867246
plays	16867246
in	16867246
chlorpromazine	16867246
-	16867246
induced	16867246
EPS	16867246
in	16867246
schizophrenic	16867246
patients	16867246
.	16867246

METHODS	16867246
:	16867246
We	16867246
identified	16867246
seven	16867246
SNP	16867246
(	16867246
single	16867246
nucleotide	16867246
polymorphism	16867246
)	16867246
(	16867246
-	16867246
141Cins	16867246
>	16867246
del	16867246
,	16867246
TaqIB	16867246
,	16867246
TaqID	16867246
,	16867246
Ser311Cys	16867246
,	16867246
rs6275	16867246
,	16867246
rs6277	16867246
and	16867246
TaqIA	16867246
)	16867246
in	16867246
the	16867246
DRD2	16867246
gene	16867246
in	16867246
146	16867246
schizophrenic	16867246
inpatients	16867246
(	16867246
59	16867246
with	16867246
EPS	16867246
and	16867246
87	16867246
without	16867246
EPS	16867246
according	16867246
to	16867246
the	16867246
Simpson	16867246
-	16867246
Angus	16867246
Scale	16867246
)	16867246
treated	16867246
with	16867246
chlorpromazine	16867246
after	16867246
8	16867246
weeks	16867246
.	16867246

The	16867246
alleles	16867246
of	16867246
all	16867246
loci	16867246
were	16867246
determined	16867246
by	16867246
PCR	16867246
(	16867246
polymerase	16867246
chain	16867246
reaction	16867246
)	16867246
.	16867246

RESULTS	16867246
:	16867246
Polymorphisms	16867246
TaqID	16867246
,	16867246
Ser311Cys	16867246
and	16867246
rs6277	16867246
were	16867246
not	16867246
polymorphic	16867246
in	16867246
the	16867246
population	16867246
recruited	16867246
in	16867246
the	16867246
present	16867246
study	16867246
.	16867246

No	16867246
statistical	16867246
significance	16867246
was	16867246
found	16867246
in	16867246
the	16867246
allele	16867246
distribution	16867246
of	16867246
-	16867246
141Cins	16867246
>	16867246
del	16867246
,	16867246
TaqIB	16867246
,	16867246
rs6275	16867246
and	16867246
TaqIA	16867246
or	16867246
in	16867246
the	16867246
estimated	16867246
haplotypes	16867246
(	16867246
constituted	16867246
by	16867246
TaqIB	16867246
,	16867246
rs6275	16867246
and	16867246
TaqIA	16867246
)	16867246
in	16867246
linkage	16867246
disequilibrium	16867246
between	16867246
the	16867246
two	16867246
groups	16867246
.	16867246

CONCLUSION	16867246
:	16867246
Our	16867246
results	16867246
did	16867246
not	16867246
lend	16867246
strong	16867246
support	16867246
to	16867246
the	16867246
view	16867246
that	16867246
the	16867246
genetic	16867246
variation	16867246
of	16867246
the	16867246
DRD2	16867246
gene	16867246
plays	16867246
a	16867246
major	16867246
role	16867246
in	16867246
the	16867246
individually	16867246
variable	16867246
adverse	16867246
effect	16867246
induced	16867246
by	16867246
chlorpromazine	16867246
,	16867246
at	16867246
least	16867246
in	16867246
Chinese	16867246
patients	16867246
with	16867246
schizophrenia	16867246
.	16867246

Our	16867246
results	16867246
confirmed	16867246
a	16867246
previous	16867246
study	16867246
on	16867246
the	16867246
relationship	16867246
between	16867246
DRD2	16867246
and	16867246
EPS	16867246
in	16867246
Caucasians	16867246
.	16867246
Does	16309808
domperidone	16309808
potentiate	16309808
mirtazapine	16309808
-	16309808
associated	16309808
restless	16309808
legs	16309808
syndrome?	16309808
There	16309808
is	16309808
now	16309808
evidence	16309808
to	16309808
suggest	16309808
a	16309808
central	16309808
role	16309808
for	16309808
the	16309808
dopaminergic	16309808
system	16309808
in	16309808
restless	16309808
legs	16309808
syndrome	16309808
(	16309808
RLS	16309808
)	16309808
.	16309808

For	16309808
example	16309808
,	16309808
the	16309808
symptoms	16309808
of	16309808
RLS	16309808
can	16309808
be	16309808
dramatically	16309808
improved	16309808
by	16309808
levodopa	16309808
and	16309808
dopamine	16309808
agonists	16309808
,	16309808
whereas	16309808
central	16309808
dopamine	16309808
D2	16309808
receptor	16309808
antagonists	16309808
can	16309808
induce	16309808
or	16309808
aggravate	16309808
RLS	16309808
symptoms	16309808
.	16309808

To	16309808
our	16309808
knowledge	16309808
,	16309808
there	16309808
is	16309808
no	16309808
previous	16309808
report	16309808
regarding	16309808
whether	16309808
domperidone	16309808
,	16309808
a	16309808
peripheral	16309808
dopamine	16309808
D2	16309808
receptor	16309808
antagonist	16309808
,	16309808
can	16309808
also	16309808
induce	16309808
or	16309808
aggravate	16309808
symptoms	16309808
of	16309808
RLS	16309808
.	16309808

Mirtazapine	16309808
,	16309808
the	16309808
first	16309808
noradrenergic	16309808
and	16309808
specific	16309808
serotonergic	16309808
antidepressant	16309808
(	16309808
NaSSA	16309808
)	16309808
,	16309808
has	16309808
been	16309808
associated	16309808
with	16309808
RLS	16309808
in	16309808
several	16309808
recent	16309808
publications	16309808
.	16309808

The	16309808
authors	16309808
report	16309808
here	16309808
a	16309808
depressed	16309808
patient	16309808
comorbid	16309808
with	16309808
postprandial	16309808
dyspepsia	16309808
who	16309808
developed	16309808
RLS	16309808
after	16309808
mirtazapine	16309808
had	16309808
been	16309808
added	16309808
to	16309808
his	16309808
domperidone	16309808
therapy	16309808
.	16309808

Our	16309808
patient	16309808
started	16309808
to	16309808
have	16309808
symptoms	16309808
of	16309808
RLS	16309808
only	16309808
after	16309808
he	16309808
had	16309808
been	16309808
treated	16309808
with	16309808
mirtazapine	16309808
,	16309808
and	16309808
his	16309808
RLS	16309808
symptoms	16309808
resolved	16309808
completely	16309808
upon	16309808
discontinuation	16309808
of	16309808
his	16309808
mirtazapine	16309808
.	16309808

Such	16309808
a	16309808
temporal	16309808
relationship	16309808
between	16309808
the	16309808
use	16309808
of	16309808
mirtazapine	16309808
and	16309808
the	16309808
symptoms	16309808
of	16309808
RLS	16309808
in	16309808
our	16309808
patient	16309808
did	16309808
not	16309808
support	16309808
a	16309808
potentiating	16309808
effect	16309808
of	16309808
domperione	16309808
on	16309808
mirtazapine	16309808
-	16309808
associated	16309808
RLS	16309808
.	16309808

However	16309808
,	16309808
physicians	16309808
should	16309808
be	16309808
aware	16309808
of	16309808
the	16309808
possibility	16309808
that	16309808
mirtazapine	16309808
can	16309808
be	16309808
associated	16309808
with	16309808
RLS	16309808
in	16309808
some	16309808
individuals	16309808
,	16309808
especially	16309808
those	16309808
receiving	16309808
concomitant	16309808
dopamine	16309808
D2	16309808
receptor	16309808
antagonists	16309808
.	16309808
End	11773892
-	11773892
stage	11773892
renal	11773892
disease	11773892
(	11773892
ESRD	11773892
)	11773892
after	11773892
orthotopic	11773892
liver	11773892
transplantation	11773892
(	11773892
OLTX	11773892
)	11773892
using	11773892
calcineurin	11773892
-	11773892
based	11773892
immunotherapy	11773892
:	11773892
risk	11773892
of	11773892
development	11773892
and	11773892
treatment	11773892
.	11773892

BACKGROUND	11773892
:	11773892
The	11773892
calcineurin	11773892
inhibitors	11773892
cyclosporine	11773892
and	11773892
tacrolimus	11773892
are	11773892
both	11773892
known	11773892
to	11773892
be	11773892
nephrotoxic	11773892
.	11773892

Their	11773892
use	11773892
in	11773892
orthotopic	11773892
liver	11773892
transplantation	11773892
(	11773892
OLTX	11773892
)	11773892
has	11773892
dramatically	11773892
improved	11773892
success	11773892
rates	11773892
.	11773892

Recently	11773892
,	11773892
however	11773892
,	11773892
we	11773892
have	11773892
had	11773892
an	11773892
increase	11773892
of	11773892
patients	11773892
who	11773892
are	11773892
presenting	11773892
after	11773892
OLTX	11773892
with	11773892
end	11773892
-	11773892
stage	11773892
renal	11773892
disease	11773892
(	11773892
ESRD	11773892
)	11773892
.	11773892

This	11773892
retrospective	11773892
study	11773892
examines	11773892
the	11773892
incidence	11773892
and	11773892
treatment	11773892
of	11773892
ESRD	11773892
and	11773892
chronic	11773892
renal	11773892
failure	11773892
(	11773892
CRF	11773892
)	11773892
in	11773892
OLTX	11773892
patients	11773892
.	11773892

METHODS	11773892
:	11773892
Patients	11773892
receiving	11773892
an	11773892
OLTX	11773892
only	11773892
from	11773892
June	11773892
1985	11773892
through	11773892
December	11773892
of	11773892
1994	11773892
who	11773892
survived	11773892
6	11773892
months	11773892
postoperatively	11773892
were	11773892
studied	11773892
(	11773892
n	11773892
=	11773892
834	11773892
)	11773892
.	11773892

Our	11773892
prospectively	11773892
collected	11773892
database	11773892
was	11773892
the	11773892
source	11773892
of	11773892
information	11773892
.	11773892

Patients	11773892
were	11773892
divided	11773892
into	11773892
three	11773892
groups	11773892
:	11773892
Controls	11773892
,	11773892
no	11773892
CRF	11773892
or	11773892
ESRD	11773892
,	11773892
n	11773892
=	11773892
748	11773892
;	11773892
CRF	11773892
,	11773892
sustained	11773892
serum	11773892
creatinine	11773892
>	11773892
2	11773892
.	11773892
5	11773892
mg	11773892
/	11773892
dl	11773892
,	11773892
n	11773892
=	11773892
41	11773892
;	11773892
and	11773892
ESRD	11773892
,	11773892
n	11773892
=	11773892
45	11773892
.	11773892

Groups	11773892
were	11773892
compared	11773892
for	11773892
preoperative	11773892
laboratory	11773892
variables	11773892
,	11773892
diagnosis	11773892
,	11773892
postoperative	11773892
variables	11773892
,	11773892
survival	11773892
,	11773892
type	11773892
of	11773892
ESRD	11773892
therapy	11773892
,	11773892
and	11773892
survival	11773892
from	11773892
onset	11773892
of	11773892
ESRD	11773892
.	11773892

RESULTS	11773892
:	11773892
At	11773892
13	11773892
years	11773892
after	11773892
OLTX	11773892
,	11773892
the	11773892
incidence	11773892
of	11773892
severe	11773892
renal	11773892
dysfunction	11773892
was	11773892
18	11773892
.	11773892
1%	11773892
(	11773892
CRF	11773892
8	11773892
.	11773892
6%	11773892
and	11773892
ESRD	11773892
9	11773892
.	11773892
5%	11773892
)	11773892
.	11773892

Compared	11773892
with	11773892
control	11773892
patients	11773892
,	11773892
CRF	11773892
and	11773892
ESRD	11773892
patients	11773892
had	11773892
higher	11773892
preoperative	11773892
serum	11773892
creatinine	11773892
levels	11773892
,	11773892
a	11773892
greater	11773892
percentage	11773892
of	11773892
patients	11773892
with	11773892
hepatorenal	11773892
syndrome	11773892
,	11773892
higher	11773892
percentage	11773892
requirement	11773892
for	11773892
dialysis	11773892
in	11773892
the	11773892
first	11773892
3	11773892
months	11773892
postoperatively	11773892
,	11773892
and	11773892
a	11773892
higher	11773892
1	11773892
-	11773892
year	11773892
serum	11773892
creatinine	11773892
.	11773892

Multivariate	11773892
stepwise	11773892
logistic	11773892
regression	11773892
analysis	11773892
using	11773892
preoperative	11773892
and	11773892
postoperative	11773892
variables	11773892
identified	11773892
that	11773892
an	11773892
increase	11773892
of	11773892
serum	11773892
creatinine	11773892
compared	11773892
with	11773892
average	11773892
at	11773892
1	11773892
year	11773892
,	11773892
3	11773892
months	11773892
,	11773892
and	11773892
4	11773892
weeks	11773892
postoperatively	11773892
were	11773892
independent	11773892
risk	11773892
factors	11773892
for	11773892
the	11773892
development	11773892
of	11773892
CRF	11773892
or	11773892
ESRD	11773892
with	11773892
odds	11773892
ratios	11773892
of	11773892
2	11773892
.	11773892
6	11773892
,	11773892
2	11773892
.	11773892
2	11773892
,	11773892
and	11773892
1	11773892
.	11773892
6	11773892
,	11773892
respectively	11773892
.	11773892

Overall	11773892
survival	11773892
from	11773892
the	11773892
time	11773892
of	11773892
OLTX	11773892
was	11773892
not	11773892
significantly	11773892
different	11773892
among	11773892
groups	11773892
,	11773892
but	11773892
by	11773892
year	11773892
13	11773892
,	11773892
the	11773892
survival	11773892
of	11773892
the	11773892
patients	11773892
who	11773892
had	11773892
ESRD	11773892
was	11773892
only	11773892
28	11773892
.	11773892
2%	11773892
compared	11773892
with	11773892
54	11773892
.	11773892
6%	11773892
in	11773892
the	11773892
control	11773892
group	11773892
.	11773892

Patients	11773892
developing	11773892
ESRD	11773892
had	11773892
a	11773892
6	11773892
-	11773892
year	11773892
survival	11773892
after	11773892
onset	11773892
of	11773892
ESRD	11773892
of	11773892
27%	11773892
for	11773892
the	11773892
patients	11773892
receiving	11773892
hemodialysis	11773892
versus	11773892
71	11773892
.	11773892
4%	11773892
for	11773892
the	11773892
patients	11773892
developing	11773892
ESRD	11773892
who	11773892
subsequently	11773892
received	11773892
kidney	11773892
transplants	11773892
.	11773892

CONCLUSIONS	11773892
:	11773892
Patients	11773892
who	11773892
are	11773892
more	11773892
than	11773892
10	11773892
years	11773892
post	11773892
-	11773892
OLTX	11773892
have	11773892
CRF	11773892
and	11773892
ESRD	11773892
at	11773892
a	11773892
high	11773892
rate	11773892
.	11773892

The	11773892
development	11773892
of	11773892
ESRD	11773892
decreases	11773892
survival	11773892
,	11773892
particularly	11773892
in	11773892
those	11773892
patients	11773892
treated	11773892
with	11773892
dialysis	11773892
only	11773892
.	11773892

Patients	11773892
who	11773892
develop	11773892
ESRD	11773892
have	11773892
a	11773892
higher	11773892
preoperative	11773892
and	11773892
1	11773892
-	11773892
year	11773892
serum	11773892
creatinine	11773892
and	11773892
are	11773892
more	11773892
likely	11773892
to	11773892
have	11773892
hepatorenal	11773892
syndrome	11773892
.	11773892

However	11773892
,	11773892
an	11773892
increase	11773892
of	11773892
serum	11773892
creatinine	11773892
at	11773892
various	11773892
times	11773892
postoperatively	11773892
is	11773892
more	11773892
predictive	11773892
of	11773892
the	11773892
development	11773892
of	11773892
CRF	11773892
or	11773892
ESRD	11773892
.	11773892

New	11773892
strategies	11773892
for	11773892
long	11773892
-	11773892
term	11773892
immunosuppression	11773892
may	11773892
be	11773892
needed	11773892
to	11773892
decrease	11773892
this	11773892
complication	11773892
.	11773892
Alternative	20949073
splicing	20949073
at	20949073
a	20949073
NAGNAG	20949073
acceptor	20949073
site	20949073
as	20949073
a	20949073
novel	20949073
phenotype	20949073
modifier	20949073
.	20949073

Approximately	20949073
30%	20949073
of	20949073
alleles	20949073
causing	20949073
genetic	20949073
disorders	20949073
generate	20949073
premature	20949073
termination	20949073
codons	20949073
(	20949073
PTCs	20949073
)	20949073
,	20949073
which	20949073
are	20949073
usually	20949073
associated	20949073
with	20949073
severe	20949073
phenotypes	20949073
.	20949073

However	20949073
,	20949073
bypassing	20949073
the	20949073
deleterious	20949073
stop	20949073
codon	20949073
can	20949073
lead	20949073
to	20949073
a	20949073
mild	20949073
disease	20949073
outcome	20949073
.	20949073

Splicing	20949073
at	20949073
NAGNAG	20949073
tandem	20949073
splice	20949073
sites	20949073
has	20949073
been	20949073
reported	20949073
to	20949073
result	20949073
in	20949073
insertion	20949073
or	20949073
deletion	20949073
(	20949073
indel	20949073
)	20949073
of	20949073
three	20949073
nucleotides	20949073
.	20949073

We	20949073
identified	20949073
such	20949073
a	20949073
mechanism	20949073
as	20949073
the	20949073
origin	20949073
of	20949073
the	20949073
mild	20949073
to	20949073
asymptomatic	20949073
phenotype	20949073
observed	20949073
in	20949073
cystic	20949073
fibrosis	20949073
patients	20949073
homozygous	20949073
for	20949073
the	20949073
E831X	20949073
mutation	20949073
(	20949073
2623G	20949073
>	20949073
T	20949073
)	20949073
in	20949073
the	20949073
CFTR	20949073
gene	20949073
.	20949073

Analyses	20949073
performed	20949073
on	20949073
nasal	20949073
epithelial	20949073
cell	20949073
mRNA	20949073
detected	20949073
three	20949073
distinct	20949073
isoforms	20949073
,	20949073
a	20949073
considerably	20949073
more	20949073
complex	20949073
situation	20949073
than	20949073
expected	20949073
for	20949073
a	20949073
single	20949073
nucleotide	20949073
substitution	20949073
.	20949073

Structure	20949073
-	20949073
function	20949073
studies	20949073
and	20949073
in	20949073
silico	20949073
analyses	20949073
provided	20949073
the	20949073
first	20949073
experimental	20949073
evidence	20949073
of	20949073
an	20949073
indel	20949073
of	20949073
a	20949073
stop	20949073
codon	20949073
by	20949073
alternative	20949073
splicing	20949073
at	20949073
a	20949073
NAGNAG	20949073
acceptor	20949073
site	20949073
.	20949073

In	20949073
addition	20949073
to	20949073
contributing	20949073
to	20949073
proteome	20949073
plasticity	20949073
,	20949073
alternative	20949073
splicing	20949073
at	20949073
a	20949073
NAGNAG	20949073
tandem	20949073
site	20949073
can	20949073
thus	20949073
remove	20949073
a	20949073
disease	20949073
-	20949073
causing	20949073
UAG	20949073
stop	20949073
codon	20949073
.	20949073

This	20949073
molecular	20949073
study	20949073
reveals	20949073
a	20949073
naturally	20949073
occurring	20949073
mechanism	20949073
where	20949073
the	20949073
effect	20949073
of	20949073
either	20949073
modifier	20949073
genes	20949073
or	20949073
epigenetic	20949073
factors	20949073
could	20949073
be	20949073
suspected	20949073
.	20949073

This	20949073
finding	20949073
is	20949073
of	20949073
importance	20949073
for	20949073
genetic	20949073
counseling	20949073
as	20949073
well	20949073
as	20949073
for	20949073
deciding	20949073
appropriate	20949073
therapeutic	20949073
strategies	20949073
.	20949073
Differential	19889778
impact	19889778
of	19889778
immune	19889778
escape	19889778
mutations	19889778
G145R	19889778
and	19889778
P120T	19889778
on	19889778
the	19889778
replication	19889778
of	19889778
lamivudine	19889778
-	19889778
resistant	19889778
hepatitis	19889778
B	19889778
virus	19889778
e	19889778
antigen	19889778
-	19889778
positive	19889778
and	19889778
-	19889778
negative	19889778
strains	19889778
.	19889778

Immune	19889778
escape	19889778
variants	19889778
of	19889778
the	19889778
hepatitis	19889778
B	19889778
virus	19889778
(	19889778
HBV	19889778
)	19889778
represent	19889778
an	19889778
emerging	19889778
clinical	19889778
challenge	19889778
,	19889778
because	19889778
they	19889778
can	19889778
be	19889778
associated	19889778
with	19889778
vaccine	19889778
escape	19889778
,	19889778
HBV	19889778
reactivation	19889778
,	19889778
and	19889778
failure	19889778
of	19889778
diagnostic	19889778
tests	19889778
.	19889778

Recent	19889778
data	19889778
suggest	19889778
a	19889778
preferential	19889778
selection	19889778
of	19889778
immune	19889778
escape	19889778
mutants	19889778
in	19889778
distinct	19889778
peripheral	19889778
blood	19889778
leukocyte	19889778
compartments	19889778
of	19889778
infected	19889778
individuals	19889778
.	19889778

We	19889778
therefore	19889778
systematically	19889778
analyzed	19889778
the	19889778
functional	19889778
impact	19889778
of	19889778
the	19889778
most	19889778
prevalent	19889778
immune	19889778
escape	19889778
variants	19889778
,	19889778
the	19889778
sG145R	19889778
and	19889778
sP120T	19889778
mutants	19889778
,	19889778
on	19889778
the	19889778
viral	19889778
replication	19889778
efficacy	19889778
and	19889778
antiviral	19889778
drug	19889778
susceptibility	19889778
of	19889778
common	19889778
treatment	19889778
-	19889778
associated	19889778
mutants	19889778
with	19889778
resistance	19889778
to	19889778
lamivudine	19889778
(	19889778
LAM	19889778
)	19889778
and	19889778
/	19889778
or	19889778
HBeAg	19889778
negativity	19889778
.	19889778

Replication	19889778
-	19889778
competent	19889778
HBV	19889778
strains	19889778
with	19889778
sG145R	19889778
or	19889778
sP120T	19889778
and	19889778
LAM	19889778
resistance	19889778
(	19889778
rtM204I	19889778
or	19889778
rtL180M	19889778
/	19889778
rtM204V	19889778
)	19889778
were	19889778
generated	19889778
on	19889778
an	19889778
HBeAg	19889778
-	19889778
positive	19889778
and	19889778
an	19889778
HBeAg	19889778
-	19889778
negative	19889778
background	19889778
with	19889778
precore	19889778
(	19889778
PC	19889778
)	19889778
and	19889778
basal	19889778
core	19889778
promoter	19889778
(	19889778
BCP	19889778
)	19889778
mutants	19889778
.	19889778

The	19889778
sG145R	19889778
mutation	19889778
strongly	19889778
reduced	19889778
HBsAg	19889778
levels	19889778
and	19889778
was	19889778
able	19889778
to	19889778
fully	19889778
restore	19889778
the	19889778
impaired	19889778
replication	19889778
of	19889778
LAM	19889778
-	19889778
resistant	19889778
HBV	19889778
mutants	19889778
to	19889778
the	19889778
levels	19889778
of	19889778
wild	19889778
-	19889778
type	19889778
HBV	19889778
,	19889778
and	19889778
PC	19889778
or	19889778
BCP	19889778
mutations	19889778
further	19889778
enhanced	19889778
viral	19889778
replication	19889778
.	19889778

Although	19889778
the	19889778
sP120T	19889778
substitution	19889778
also	19889778
impaired	19889778
HBsAg	19889778
secretion	19889778
,	19889778
it	19889778
did	19889778
not	19889778
enhance	19889778
the	19889778
replication	19889778
of	19889778
LAM	19889778
-	19889778
resistant	19889778
clones	19889778
.	19889778

However	19889778
,	19889778
the	19889778
concomitant	19889778
occurrence	19889778
of	19889778
HBeAg	19889778
negativity	19889778
(	19889778
PC	19889778
/	19889778
BCP	19889778
)	19889778
,	19889778
sP120T	19889778
,	19889778
and	19889778
LAM	19889778
resistance	19889778
resulted	19889778
in	19889778
the	19889778
restoration	19889778
of	19889778
replication	19889778
to	19889778
levels	19889778
of	19889778
wild	19889778
-	19889778
type	19889778
HBV	19889778
.	19889778

In	19889778
all	19889778
clones	19889778
with	19889778
combined	19889778
immune	19889778
escape	19889778
and	19889778
LAM	19889778
resistance	19889778
mutations	19889778
,	19889778
the	19889778
nucleotide	19889778
analogues	19889778
adefovir	19889778
and	19889778
tenofovir	19889778
remained	19889778
effective	19889778
in	19889778
suppressing	19889778
viral	19889778
replication	19889778
in	19889778
vitro	19889778
.	19889778

These	19889778
findings	19889778
reveal	19889778
the	19889778
differential	19889778
impact	19889778
of	19889778
immune	19889778
escape	19889778
variants	19889778
on	19889778
the	19889778
replication	19889778
and	19889778
drug	19889778
susceptibility	19889778
of	19889778
complex	19889778
HBV	19889778
mutants	19889778
,	19889778
supporting	19889778
the	19889778
need	19889778
of	19889778
close	19889778
surveillance	19889778
and	19889778
treatment	19889778
adjustment	19889778
in	19889778
response	19889778
to	19889778
the	19889778
selection	19889778
of	19889778
distinct	19889778
mutational	19889778
patterns	19889778
.	19889778
Bilateral	19681452
haemorrhagic	19681452
infarction	19681452
of	19681452
the	19681452
globus	19681452
pallidus	19681452
after	19681452
cocaine	19681452
and	19681452
alcohol	19681452
intoxication	19681452
.	19681452

Cocaine	19681452
is	19681452
a	19681452
risk	19681452
factor	19681452
for	19681452
both	19681452
ischemic	19681452
and	19681452
haemorrhagic	19681452
stroke	19681452
.	19681452

We	19681452
present	19681452
the	19681452
case	19681452
of	19681452
a	19681452
31	19681452
-	19681452
year	19681452
-	19681452
old	19681452
man	19681452
with	19681452
bilateral	19681452
ischemia	19681452
of	19681452
the	19681452
globus	19681452
pallidus	19681452
after	19681452
excessive	19681452
alcohol	19681452
and	19681452
intranasal	19681452
cocaine	19681452
use	19681452
.	19681452

Drug	19681452
-	19681452
related	19681452
globus	19681452
pallidus	19681452
infarctions	19681452
are	19681452
most	19681452
often	19681452
associated	19681452
with	19681452
heroin	19681452
.	19681452

Bilateral	19681452
basal	19681452
ganglia	19681452
infarcts	19681452
after	19681452
the	19681452
use	19681452
of	19681452
cocaine	19681452
,	19681452
without	19681452
concurrent	19681452
heroin	19681452
use	19681452
,	19681452
have	19681452
never	19681452
been	19681452
reported	19681452
.	19681452

In	19681452
our	19681452
patient	19681452
,	19681452
transient	19681452
cardiac	19681452
arrhythmia	19681452
or	19681452
respiratory	19681452
dysfunction	19681452
related	19681452
to	19681452
cocaine	19681452
and	19681452
/	19681452
or	19681452
ethanol	19681452
use	19681452
were	19681452
the	19681452
most	19681452
likely	19681452
causes	19681452
of	19681452
cerebral	19681452
hypoperfusion	19681452
.	19681452
Detailed	18657397
spectral	18657397
profile	18657397
analysis	18657397
of	18657397
penicillin	18657397
-	18657397
induced	18657397
epileptiform	18657397
activity	18657397
in	18657397
anesthetized	18657397
rats	18657397
.	18657397

Penicillin	18657397
model	18657397
is	18657397
a	18657397
widely	18657397
used	18657397
experimental	18657397
model	18657397
for	18657397
epilepsy	18657397
research	18657397
.	18657397

In	18657397
the	18657397
present	18657397
study	18657397
we	18657397
aimed	18657397
to	18657397
portray	18657397
a	18657397
detailed	18657397
spectral	18657397
analysis	18657397
of	18657397
penicillin	18657397
-	18657397
induced	18657397
epileptiform	18657397
activity	18657397
in	18657397
comparison	18657397
with	18657397
basal	18657397
brain	18657397
activity	18657397
in	18657397
anesthetized	18657397
Wistar	18657397
rats	18657397
.	18657397

Male	18657397
Wistar	18657397
rats	18657397
were	18657397
anesthetized	18657397
with	18657397
i	18657397
.	18657397
p	18657397
.	18657397

urethane	18657397
and	18657397
connected	18657397
to	18657397
an	18657397
electrocorticogram	18657397
setup	18657397
.	18657397

After	18657397
a	18657397
short	18657397
period	18657397
of	18657397
basal	18657397
activity	18657397
recording	18657397
,	18657397
epileptic	18657397
focus	18657397
was	18657397
induced	18657397
by	18657397
injecting	18657397
400IU	18657397
/	18657397
2	18657397
microl	18657397
penicillin	18657397
-	18657397
G	18657397
potassium	18657397
into	18657397
the	18657397
left	18657397
lateral	18657397
ventricle	18657397
while	18657397
the	18657397
cortical	18657397
activity	18657397
was	18657397
continuously	18657397
recorded	18657397
.	18657397

Basal	18657397
activity	18657397
,	18657397
latent	18657397
period	18657397
and	18657397
the	18657397
penicillin	18657397
-	18657397
induced	18657397
epileptiform	18657397
activity	18657397
periods	18657397
were	18657397
then	18657397
analyzed	18657397
using	18657397
both	18657397
conventional	18657397
methods	18657397
and	18657397
spectral	18657397
analysis	18657397
.	18657397

Spectral	18657397
analyses	18657397
were	18657397
conducted	18657397
by	18657397
dividing	18657397
the	18657397
whole	18657397
spectrum	18657397
into	18657397
different	18657397
frequency	18657397
bands	18657397
including	18657397
delta	18657397
,	18657397
theta	18657397
(	18657397
slow	18657397
and	18657397
fast	18657397
)	18657397
,	18657397
alpha	18657397
-	18657397
sigma	18657397
,	18657397
beta	18657397
(	18657397
1	18657397
and	18657397
2	18657397
)	18657397
and	18657397
gamma	18657397
(	18657397
1	18657397
and	18657397
2	18657397
)	18657397
bands	18657397
.	18657397

Our	18657397
results	18657397
show	18657397
that	18657397
the	18657397
most	18657397
affected	18657397
frequency	18657397
bands	18657397
were	18657397
delta	18657397
,	18657397
theta	18657397
,	18657397
beta	18657397
-	18657397
2	18657397
and	18657397
gamma	18657397
-	18657397
2	18657397
bands	18657397
during	18657397
the	18657397
epileptiform	18657397
activity	18657397
and	18657397
there	18657397
were	18657397
marked	18657397
differences	18657397
in	18657397
terms	18657397
of	18657397
spectral	18657397
densities	18657397
between	18657397
three	18657397
investigated	18657397
episodes	18657397
(	18657397
basal	18657397
activity	18657397
,	18657397
latent	18657397
period	18657397
and	18657397
epileptiform	18657397
activity	18657397
)	18657397
.	18657397

Our	18657397
results	18657397
may	18657397
help	18657397
to	18657397
analyze	18657397
novel	18657397
data	18657397
obtained	18657397
using	18657397
similar	18657397
experimental	18657397
models	18657397
and	18657397
the	18657397
simple	18657397
analysis	18657397
method	18657397
described	18657397
here	18657397
can	18657397
be	18657397
used	18657397
in	18657397
similar	18657397
studies	18657397
to	18657397
investigate	18657397
the	18657397
basic	18657397
neuronal	18657397
mechanism	18657397
of	18657397
this	18657397
or	18657397
other	18657397
types	18657397
of	18657397
experimental	18657397
epilepsies	18657397
.	18657397
Exaggerated	18483878
expression	18483878
of	18483878
inflammatory	18483878
mediators	18483878
in	18483878
vasoactive	18483878
intestinal	18483878
polypeptide	18483878
knockout	18483878
(	18483878
VIP	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
with	18483878
cyclophosphamide	18483878
(	18483878
CYP	18483878
)	18483878
-	18483878
induced	18483878
cystitis	18483878
.	18483878

Vasoactive	18483878
intestinal	18483878
polypeptide	18483878
(	18483878
VIP	18483878
)	18483878
is	18483878
an	18483878
immunomodulatory	18483878
neuropeptide	18483878
distributed	18483878
in	18483878
micturition	18483878
pathways	18483878
.	18483878

VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
exhibit	18483878
altered	18483878
bladder	18483878
function	18483878
and	18483878
neurochemical	18483878
properties	18483878
in	18483878
micturition	18483878
pathways	18483878
after	18483878
cyclophosphamide	18483878
(	18483878
CYP	18483878
)	18483878
-	18483878
induced	18483878
cystitis	18483878
.	18483878

Given	18483878
VIP	18483878
'	18483878
s	18483878
role	18483878
as	18483878
an	18483878
anti	18483878
-	18483878
inflammatory	18483878
mediator	18483878
,	18483878
we	18483878
hypothesized	18483878
that	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
would	18483878
exhibit	18483878
enhanced	18483878
inflammatory	18483878
mediator	18483878
expression	18483878
after	18483878
cystitis	18483878
.	18483878

A	18483878
mouse	18483878
inflammatory	18483878
cytokine	18483878
and	18483878
receptor	18483878
RT2	18483878
profiler	18483878
array	18483878
was	18483878
used	18483878
to	18483878
determine	18483878
regulated	18483878
transcripts	18483878
in	18483878
the	18483878
urinary	18483878
bladder	18483878
of	18483878
wild	18483878
type	18483878
(	18483878
WT	18483878
)	18483878
and	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
with	18483878
or	18483878
without	18483878
CYP	18483878
-	18483878
induced	18483878
cystitis	18483878
(	18483878
150	18483878
mg	18483878
/	18483878
kg	18483878
;	18483878
i	18483878
.	18483878
p	18483878
.	18483878
;	18483878
48	18483878
h	18483878
)	18483878
.	18483878

Four	18483878
binary	18483878
comparisons	18483878
were	18483878
made	18483878
:	18483878
WT	18483878
control	18483878
versus	18483878
CYP	18483878
treatment	18483878
(	18483878
48	18483878
h	18483878
)	18483878
,	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
control	18483878
versus	18483878
CYP	18483878
treatment	18483878
(	18483878
48	18483878
h	18483878
)	18483878
,	18483878
WT	18483878
control	18483878
versus	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
control	18483878
,	18483878
and	18483878
WT	18483878
with	18483878
CYP	18483878
treatment	18483878
(	18483878
48	18483878
h	18483878
)	18483878
versus	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
with	18483878
CYP	18483878
treatment	18483878
(	18483878
48	18483878
h	18483878
)	18483878
.	18483878

The	18483878
genes	18483878
presented	18483878
represent	18483878
(	18483878
1	18483878
)	18483878
greater	18483878
than	18483878
1	18483878
.	18483878
5	18483878
-	18483878
fold	18483878
change	18483878
in	18483878
either	18483878
direction	18483878
and	18483878
(	18483878
2	18483878
)	18483878
the	18483878
p	18483878
value	18483878
is	18483878
less	18483878
than	18483878
0	18483878
.	18483878
05	18483878
for	18483878
the	18483878
comparison	18483878
being	18483878
made	18483878
.	18483878

Several	18483878
regulated	18483878
genes	18483878
were	18483878
validated	18483878
using	18483878
enzyme	18483878
-	18483878
linked	18483878
immunoassays	18483878
including	18483878
IL	18483878
-	18483878
1beta	18483878
and	18483878
CXCL1	18483878
.	18483878

CYP	18483878
treatment	18483878
significantly	18483878
(	18483878
p	18483878
<	18483878
or	18483878
=	18483878
0	18483878
.	18483878
001	18483878
)	18483878
increased	18483878
expression	18483878
of	18483878
CXCL1	18483878
and	18483878
IL	18483878
-	18483878
1beta	18483878
in	18483878
the	18483878
urinary	18483878
bladder	18483878
of	18483878
WT	18483878
and	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
,	18483878
but	18483878
expression	18483878
in	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
with	18483878
CYP	18483878
treatment	18483878
was	18483878
significantly	18483878
(	18483878
p	18483878
<	18483878
or	18483878
=	18483878
0	18483878
.	18483878
001	18483878
)	18483878
greater	18483878
(	18483878
4	18483878
.	18483878
2	18483878
-	18483878
to	18483878
13	18483878
-	18483878
fold	18483878
increase	18483878
)	18483878
than	18483878
that	18483878
observed	18483878
in	18483878
WT	18483878
urinary	18483878
bladder	18483878
(	18483878
3	18483878
.	18483878
6	18483878
-	18483878
to	18483878
5	18483878
-	18483878
fold	18483878
increase	18483878
)	18483878
.	18483878

The	18483878
data	18483878
suggest	18483878
that	18483878
in	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
with	18483878
bladder	18483878
inflammation	18483878
,	18483878
inflammatory	18483878
mediators	18483878
are	18483878
increased	18483878
above	18483878
that	18483878
observed	18483878
in	18483878
WT	18483878
with	18483878
CYP	18483878
.	18483878

This	18483878
shift	18483878
in	18483878
balance	18483878
may	18483878
contribute	18483878
to	18483878
increased	18483878
bladder	18483878
dysfunction	18483878
in	18483878
VIP	18483878
(	18483878
-	18483878
/	18483878
-	18483878
)	18483878
mice	18483878
with	18483878
bladder	18483878
inflammation	18483878
and	18483878
altered	18483878
neurochemical	18483878
expression	18483878
in	18483878
micturition	18483878
pathways	18483878
.	18483878
Seizures	19707748
associated	19707748
with	19707748
levofloxacin	19707748
:	19707748
case	19707748
presentation	19707748
and	19707748
literature	19707748
review	19707748
.	19707748

PURPOSE	19707748
:	19707748
We	19707748
present	19707748
a	19707748
case	19707748
of	19707748
a	19707748
patient	19707748
who	19707748
developed	19707748
seizures	19707748
shortly	19707748
after	19707748
initiating	19707748
treatment	19707748
with	19707748
levofloxacin	19707748
and	19707748
to	19707748
discuss	19707748
the	19707748
potential	19707748
drug	19707748
-	19707748
drug	19707748
interactions	19707748
related	19707748
to	19707748
the	19707748
inhibition	19707748
of	19707748
cytochrome	19707748
P450	19707748
(	19707748
CYP	19707748
)	19707748
1A2	19707748
in	19707748
this	19707748
case	19707748
,	19707748
as	19707748
well	19707748
as	19707748
in	19707748
other	19707748
cases	19707748
,	19707748
of	19707748
levofloxacin	19707748
-	19707748
induced	19707748
seizures	19707748
.	19707748

METHODS	19707748
:	19707748
Several	19707748
biomedical	19707748
databases	19707748
were	19707748
searched	19707748
including	19707748
MEDLINE	19707748
,	19707748
Cochrane	19707748
and	19707748
Ovid	19707748
.	19707748

The	19707748
main	19707748
search	19707748
terms	19707748
utilized	19707748
were	19707748
case	19707748
report	19707748
and	19707748
levofloxacin	19707748
.	19707748

The	19707748
search	19707748
was	19707748
limited	19707748
to	19707748
studies	19707748
published	19707748
in	19707748
English	19707748
.	19707748

RESULTS	19707748
:	19707748
Six	19707748
cases	19707748
of	19707748
levofloxacin	19707748
-	19707748
induced	19707748
seizures	19707748
have	19707748
been	19707748
reported	19707748
in	19707748
the	19707748
literature	19707748
.	19707748

Drug	19707748
-	19707748
drug	19707748
interactions	19707748
related	19707748
to	19707748
the	19707748
inhibition	19707748
of	19707748
CYP1A2	19707748
by	19707748
levofloxacin	19707748
are	19707748
likely	19707748
involved	19707748
in	19707748
the	19707748
clinical	19707748
outcome	19707748
of	19707748
these	19707748
cases	19707748
.	19707748

CONCLUSIONS	19707748
:	19707748
Clinicians	19707748
are	19707748
exhorted	19707748
to	19707748
pay	19707748
close	19707748
attention	19707748
when	19707748
initiating	19707748
levofloxacin	19707748
therapy	19707748
in	19707748
patients	19707748
taking	19707748
medications	19707748
with	19707748
epileptogenic	19707748
properties	19707748
that	19707748
are	19707748
CYP1A2	19707748
substrates	19707748
.	19707748
Takotsubo	24100257
syndrome	24100257
(	24100257
or	24100257
apical	24100257
ballooning	24100257
syndrome	24100257
)	24100257
secondary	24100257
to	24100257
Zolmitriptan	24100257
.	24100257

Takotsubo	24100257
syndrome	24100257
(	24100257
TS	24100257
)	24100257
,	24100257
also	24100257
known	24100257
as	24100257
broken	24100257
heart	24100257
syndrome	24100257
,	24100257
is	24100257
characterized	24100257
by	24100257
left	24100257
ventricle	24100257
apical	24100257
ballooning	24100257
with	24100257
elevated	24100257
cardiac	24100257
biomarkers	24100257
and	24100257
electrocardiographic	24100257
changes	24100257
suggestive	24100257
of	24100257
an	24100257
acute	24100257
coronary	24100257
syndrome	24100257
(	24100257
ie	24100257
,	24100257
ST	24100257
-	24100257
segment	24100257
elevation	24100257
,	24100257
T	24100257
wave	24100257
inversions	24100257
,	24100257
and	24100257
pathologic	24100257
Q	24100257
waves	24100257
)	24100257
.	24100257

We	24100257
report	24100257
a	24100257
case	24100257
of	24100257
54	24100257
-	24100257
year	24100257
-	24100257
old	24100257
woman	24100257
with	24100257
medical	24100257
history	24100257
of	24100257
mitral	24100257
valve	24100257
prolapse	24100257
and	24100257
migraines	24100257
,	24100257
who	24100257
was	24100257
admitted	24100257
to	24100257
the	24100257
hospital	24100257
for	24100257
substernal	24100257
chest	24100257
pain	24100257
and	24100257
electrocardiogram	24100257
demonstrated	24100257
1	24100257
/	24100257
2	24100257
mm	24100257
ST	24100257
-	24100257
segment	24100257
elevation	24100257
in	24100257
leads	24100257
II	24100257
,	24100257
III	24100257
,	24100257
aVF	24100257
,	24100257
V5	24100257
,	24100257
and	24100257
V6	24100257
and	24100257
positive	24100257
troponin	24100257
I	24100257
.	24100257

Emergent	24100257
coronary	24100257
angiogram	24100257
revealed	24100257
normal	24100257
coronary	24100257
arteries	24100257
with	24100257
moderately	24100257
reduced	24100257
left	24100257
ventricular	24100257
ejection	24100257
fraction	24100257
with	24100257
wall	24100257
motion	24100257
abnormalities	24100257
consistent	24100257
with	24100257
TS	24100257
.	24100257

Detailed	24100257
history	24100257
obtained	24100257
retrospectively	24100257
revealed	24100257
that	24100257
the	24100257
patient	24100257
took	24100257
zolmitriptan	24100257
sparingly	24100257
only	24100257
when	24100257
she	24100257
had	24100257
migraines	24100257
.	24100257

But	24100257
before	24100257
this	24100257
event	24100257
,	24100257
she	24100257
was	24100257
taking	24100257
zolmitriptan	24100257
2	24100257
-	24100257
3	24100257
times	24100257
daily	24100257
for	24100257
several	24100257
days	24100257
because	24100257
of	24100257
a	24100257
persistent	24100257
migraine	24100257
headache	24100257
.	24100257

She	24100257
otherwise	24100257
reported	24100257
that	24100257
she	24100257
is	24100257
quite	24100257
active	24100257
,	24100257
rides	24100257
horses	24100257
,	24100257
and	24100257
does	24100257
show	24100257
jumping	24100257
without	24100257
any	24100257
limitations	24100257
in	24100257
her	24100257
physical	24100257
activity	24100257
.	24100257

There	24100257
was	24100257
no	24100257
evidence	24100257
of	24100257
any	24100257
recent	24100257
stress	24100257
or	24100257
status	24100257
migrainosus	24100257
.	24100257

Extensive	24100257
literature	24100257
search	24100257
revealed	24100257
multiple	24100257
cases	24100257
of	24100257
coronary	24100257
artery	24100257
vasospasm	24100257
secondary	24100257
to	24100257
zolmitriptan	24100257
,	24100257
but	24100257
none	24100257
of	24100257
the	24100257
cases	24100257
were	24100257
associated	24100257
with	24100257
TS	24100257
.	24100257
Characterization	16186368
of	16186368
Bietti	16186368
crystalline	16186368
dystrophy	16186368
patients	16186368
with	16186368
CYP4V2	16186368
mutations	16186368
.	16186368

PURPOSE	16186368
:	16186368
Mutations	16186368
of	16186368
the	16186368
CYP4V2	16186368
gene	16186368
,	16186368
a	16186368
novel	16186368
family	16186368
member	16186368
of	16186368
the	16186368
cytochrome	16186368
P450	16186368
genes	16186368
on	16186368
chromosome	16186368
4q35	16186368
,	16186368
have	16186368
recently	16186368
been	16186368
identified	16186368
in	16186368
patients	16186368
with	16186368
Bietti	16186368
crystalline	16186368
dystrophy	16186368
(	16186368
BCD	16186368
)	16186368
.	16186368

The	16186368
aim	16186368
of	16186368
this	16186368
study	16186368
was	16186368
to	16186368
investigate	16186368
the	16186368
spectrum	16186368
of	16186368
mutations	16186368
in	16186368
this	16186368
gene	16186368
in	16186368
BCD	16186368
patients	16186368
from	16186368
Singapore	16186368
,	16186368
and	16186368
to	16186368
characterize	16186368
their	16186368
phenotype	16186368
.	16186368

METHODS	16186368
:	16186368
Nine	16186368
patients	16186368
with	16186368
BCD	16186368
from	16186368
six	16186368
families	16186368
were	16186368
recruited	16186368
into	16186368
the	16186368
study	16186368
.	16186368

The	16186368
11	16186368
exons	16186368
of	16186368
the	16186368
CYP4V2	16186368
gene	16186368
were	16186368
amplified	16186368
from	16186368
genomic	16186368
DNA	16186368
of	16186368
patients	16186368
by	16186368
polymerase	16186368
chain	16186368
reaction	16186368
and	16186368
then	16186368
sequenced	16186368
.	16186368

Detailed	16186368
characterization	16186368
of	16186368
the	16186368
patients	16186368
'	16186368
phenotype	16186368
was	16186368
performed	16186368
with	16186368
fundal	16186368
photography	16186368
,	16186368
visual	16186368
field	16186368
testing	16186368
,	16186368
fundal	16186368
fluorescein	16186368
angiography	16186368
,	16186368
and	16186368
electroretinography	16186368
(	16186368
ERG	16186368
)	16186368
.	16186368

RESULTS	16186368
:	16186368
Three	16186368
pathogenic	16186368
mutations	16186368
were	16186368
identified	16186368
;	16186368
two	16186368
mutations	16186368
,	16186368
S482X	16186368
and	16186368
K386T	16186368
,	16186368
were	16186368
novel	16186368
and	16186368
found	16186368
in	16186368
three	16186368
patients	16186368
.	16186368

The	16186368
third	16186368
mutation	16186368
,	16186368
a	16186368
previously	16186368
identified	16186368
15	16186368
-	16186368
bp	16186368
deletion	16186368
that	16186368
included	16186368
the	16186368
3	16186368
'	16186368
splice	16186368
site	16186368
for	16186368
exon	16186368
7	16186368
,	16186368
was	16186368
found	16186368
in	16186368
all	16186368
nine	16186368
patients	16186368
,	16186368
with	16186368
six	16186368
patients	16186368
carrying	16186368
the	16186368
deletion	16186368
in	16186368
the	16186368
homozygous	16186368
state	16186368
.	16186368

Haplotype	16186368
analysis	16186368
in	16186368
patients	16186368
and	16186368
controls	16186368
indicated	16186368
a	16186368
founder	16186368
effect	16186368
for	16186368
this	16186368
deletion	16186368
mutation	16186368
in	16186368
exon	16186368
7	16186368
.	16186368

Clinical	16186368
heterogeneity	16186368
was	16186368
present	16186368
in	16186368
the	16186368
patients	16186368
.	16186368

Compound	16186368
heterozygotes	16186368
for	16186368
the	16186368
deletion	16186368
in	16186368
exon	16186368
7	16186368
seemed	16186368
to	16186368
have	16186368
more	16186368
severe	16186368
disease	16186368
compared	16186368
to	16186368
patients	16186368
homozygous	16186368
for	16186368
the	16186368
deletion	16186368
.	16186368

There	16186368
was	16186368
good	16186368
correlation	16186368
between	16186368
clinical	16186368
stage	16186368
of	16186368
disease	16186368
and	16186368
ERG	16186368
changes	16186368
,	16186368
but	16186368
age	16186368
did	16186368
not	16186368
correlate	16186368
with	16186368
disease	16186368
severity	16186368
.	16186368

CONCLUSIONS	16186368
:	16186368
This	16186368
study	16186368
identified	16186368
novel	16186368
mutations	16186368
in	16186368
the	16186368
CYP4V2	16186368
gene	16186368
as	16186368
a	16186368
cause	16186368
of	16186368
BCD	16186368
.	16186368

A	16186368
high	16186368
carrier	16186368
frequency	16186368
for	16186368
the	16186368
15	16186368
-	16186368
bp	16186368
deletion	16186368
in	16186368
exon	16186368
7	16186368
may	16186368
exist	16186368
in	16186368
the	16186368
Singapore	16186368
population	16186368
.	16186368

Phenotype	16186368
characterization	16186368
showed	16186368
clinical	16186368
heterogeneity	16186368
,	16186368
and	16186368
age	16186368
did	16186368
not	16186368
correlate	16186368
with	16186368
disease	16186368
severity	16186368
.	16186368
Genetic	17083016
polymorphism	17083016
of	17083016
the	17083016
binding	17083016
domain	17083016
of	17083016
surfactant	17083016
protein	17083016
-	17083016
A2	17083016
increases	17083016
susceptibility	17083016
to	17083016
meningococcal	17083016
disease	17083016
.	17083016

BACKGROUND	17083016
:	17083016
Meningococcal	17083016
disease	17083016
occurs	17083016
after	17083016
colonization	17083016
of	17083016
the	17083016
nasopharynx	17083016
with	17083016
Neisseria	17083016
meningitidis	17083016
.	17083016

Surfactant	17083016
protein	17083016
(	17083016
SP	17083016
)	17083016
-	17083016
A	17083016
and	17083016
SP	17083016
-	17083016
D	17083016
are	17083016
pattern	17083016
-	17083016
recognition	17083016
molecules	17083016
of	17083016
the	17083016
respiratory	17083016
tract	17083016
that	17083016
activate	17083016
inflammatory	17083016
and	17083016
phagocytic	17083016
defences	17083016
after	17083016
binding	17083016
to	17083016
microbial	17083016
sugars	17083016
.	17083016

Variation	17083016
in	17083016
the	17083016
genes	17083016
of	17083016
the	17083016
surfactant	17083016
proteins	17083016
affects	17083016
the	17083016
expression	17083016
and	17083016
function	17083016
of	17083016
these	17083016
molecules	17083016
.	17083016

METHODS	17083016
:	17083016
Allele	17083016
frequencies	17083016
of	17083016
SP	17083016
-	17083016
A1	17083016
,	17083016
SP	17083016
-	17083016
A2	17083016
,	17083016
and	17083016
SP	17083016
-	17083016
D	17083016
were	17083016
determined	17083016
by	17083016
polymerase	17083016
chain	17083016
reaction	17083016
in	17083016
303	17083016
patients	17083016
with	17083016
microbiologically	17083016
proven	17083016
meningococcal	17083016
disease	17083016
,	17083016
including	17083016
18	17083016
patients	17083016
who	17083016
died	17083016
,	17083016
and	17083016
222	17083016
healthy	17083016
control	17083016
subjects	17083016
.	17083016

RESULTS	17083016
:	17083016
Homozygosity	17083016
of	17083016
allele	17083016
1A1	17083016
of	17083016
SP	17083016
-	17083016
A2	17083016
increased	17083016
the	17083016
risk	17083016
of	17083016
meningococcal	17083016
disease	17083016
(	17083016
odds	17083016
ratio	17083016
[	17083016
OR	17083016
]	17083016
,	17083016
7	17083016
.	17083016
4	17083016
;	17083016
95%	17083016
confidence	17083016
interval	17083016
[	17083016
CI	17083016
]	17083016
,	17083016
1	17083016
.	17083016
3	17083016
-	17083016
42	17083016
.	17083016
4	17083016
)	17083016
;	17083016
carriage	17083016
of	17083016
1A5	17083016
reduced	17083016
the	17083016
risk	17083016
(	17083016
OR	17083016
,	17083016
0	17083016
.	17083016
3	17083016
;	17083016
95%	17083016
CI	17083016
,	17083016
0	17083016
.	17083016
1	17083016
-	17083016
0	17083016
.	17083016
97	17083016
)	17083016
.	17083016

An	17083016
analysis	17083016
of	17083016
the	17083016
multiple	17083016
single	17083016
-	17083016
nucleotide	17083016
polymorphisms	17083016
in	17083016
SP	17083016
-	17083016
A	17083016
demonstrated	17083016
that	17083016
homozygosity	17083016
for	17083016
alleles	17083016
encoding	17083016
lysine	17083016
(	17083016
in	17083016
1A1	17083016
)	17083016
rather	17083016
than	17083016
glutamine	17083016
(	17083016
in	17083016
1A5	17083016
)	17083016
at	17083016
amino	17083016
acid	17083016
223	17083016
in	17083016
the	17083016
carbohydrate	17083016
recognition	17083016
domain	17083016
was	17083016
associated	17083016
with	17083016
an	17083016
increased	17083016
risk	17083016
of	17083016
meningococcal	17083016
disease	17083016
(	17083016
OR	17083016
,	17083016
6	17083016
.	17083016
7	17083016
;	17083016
95%	17083016
CI	17083016
,	17083016
1	17083016
.	17083016
4	17083016
-	17083016
31	17083016
.	17083016
5	17083016
)	17083016
.	17083016

Carriage	17083016
of	17083016
alleles	17083016
encoding	17083016
lysine	17083016
at	17083016
residue	17083016
223	17083016
was	17083016
found	17083016
in	17083016
61%	17083016
of	17083016
patients	17083016
who	17083016
died	17083016
,	17083016
compared	17083016
with	17083016
35%	17083016
of	17083016
those	17083016
who	17083016
survived	17083016
(	17083016
OR	17083016
adjusted	17083016
for	17083016
age	17083016
,	17083016
2	17083016
.	17083016
9	17083016
;	17083016
95%	17083016
CI	17083016
,	17083016
1	17083016
.	17083016
1	17083016
-	17083016
7	17083016
.	17083016
7	17083016
)	17083016
.	17083016

Genetic	17083016
variation	17083016
of	17083016
SP	17083016
-	17083016
A1	17083016
and	17083016
SP	17083016
-	17083016
D	17083016
was	17083016
not	17083016
associated	17083016
with	17083016
meningococcal	17083016
disease	17083016
.	17083016

CONCLUSIONS	17083016
:	17083016
Gene	17083016
polymorphism	17083016
resulting	17083016
in	17083016
the	17083016
substitution	17083016
of	17083016
glutamine	17083016
with	17083016
lysine	17083016
at	17083016
residue	17083016
223	17083016
in	17083016
the	17083016
carbohydrate	17083016
recognition	17083016
domain	17083016
of	17083016
SP	17083016
-	17083016
A2	17083016
increases	17083016
susceptibility	17083016
to	17083016
meningococcal	17083016
disease	17083016
,	17083016
as	17083016
well	17083016
as	17083016
the	17083016
risk	17083016
of	17083016
death	17083016
.	17083016
Risk	23952588
factors	23952588
and	23952588
predictors	23952588
of	23952588
levodopa	23952588
-	23952588
induced	23952588
dyskinesia	23952588
among	23952588
multiethnic	23952588
Malaysians	23952588
with	23952588
Parkinson	23952588
'	23952588
s	23952588
disease	23952588
.	23952588

Chronic	23952588
pulsatile	23952588
levodopa	23952588
therapy	23952588
for	23952588
Parkinson	23952588
'	23952588
s	23952588
disease	23952588
(	23952588
PD	23952588
)	23952588
leads	23952588
to	23952588
the	23952588
development	23952588
of	23952588
motor	23952588
fluctuations	23952588
and	23952588
dyskinesia	23952588
.	23952588

We	23952588
studied	23952588
the	23952588
prevalence	23952588
and	23952588
predictors	23952588
of	23952588
levodopa	23952588
-	23952588
induced	23952588
dyskinesia	23952588
among	23952588
multiethnic	23952588
Malaysian	23952588
patients	23952588
with	23952588
PD	23952588
.	23952588

METHODS	23952588
:	23952588
This	23952588
is	23952588
a	23952588
cross	23952588
-	23952588
sectional	23952588
study	23952588
involving	23952588
95	23952588
patients	23952588
with	23952588
PD	23952588
on	23952588
uninterrupted	23952588
levodopa	23952588
therapy	23952588
for	23952588
at	23952588
least	23952588
6	23952588
months	23952588
.	23952588

The	23952588
instrument	23952588
used	23952588
was	23952588
the	23952588
UPDRS	23952588
questionnaires	23952588
.	23952588

The	23952588
predictors	23952588
of	23952588
dyskinesia	23952588
were	23952588
determined	23952588
using	23952588
multivariate	23952588
logistic	23952588
regression	23952588
analysis	23952588
.	23952588

RESULTS	23952588
:	23952588
The	23952588
mean	23952588
age	23952588
was	23952588
65	23952588
.	23952588
6	23952588
+	23952588
8	23952588
.	23952588
5	23952588
years	23952588
.	23952588

The	23952588
mean	23952588
onset	23952588
age	23952588
was	23952588
58	23952588
.	23952588
5	23952588
+	23952588
9	23952588
.	23952588
8	23952588
years	23952588
.	23952588

The	23952588
median	23952588
disease	23952588
duration	23952588
was	23952588
6	23952588
(	23952588
7	23952588
)	23952588
years	23952588
.	23952588

Dyskinesia	23952588
was	23952588
present	23952588
in	23952588
44%	23952588
(	23952588
n	23952588
=	23952588
42	23952588
)	23952588
with	23952588
median	23952588
levodopa	23952588
therapy	23952588
of	23952588
3	23952588
years	23952588
.	23952588

There	23952588
were	23952588
64	23952588
.	23952588
3%	23952588
Chinese	23952588
,	23952588
31%	23952588
Malays	23952588
,	23952588
and	23952588
3	23952588
.	23952588
7%	23952588
Indians	23952588
and	23952588
other	23952588
ethnic	23952588
groups	23952588
.	23952588

Eighty	23952588
-	23952588
one	23952588
percent	23952588
of	23952588
patients	23952588
with	23952588
dyskinesia	23952588
had	23952588
clinical	23952588
fluctuations	23952588
.	23952588

Patients	23952588
with	23952588
dyskinesia	23952588
had	23952588
lower	23952588
onset	23952588
age	23952588
(	23952588
p	23952588
<	23952588
0	23952588
.	23952588
001	23952588
)	23952588
,	23952588
longer	23952588
duration	23952588
of	23952588
levodopa	23952588
therapy	23952588
(	23952588
p	23952588
<	23952588
0	23952588
.	23952588
001	23952588
)	23952588
,	23952588
longer	23952588
disease	23952588
duration	23952588
(	23952588
p	23952588
<	23952588
0	23952588
.	23952588
001	23952588
)	23952588
,	23952588
higher	23952588
total	23952588
daily	23952588
levodopa	23952588
dose	23952588
(	23952588
p	23952588
<	23952588
0	23952588
.	23952588
001	23952588
)	23952588
,	23952588
and	23952588
higher	23952588
total	23952588
UPDRS	23952588
scores	23952588
(	23952588
p	23952588
=	23952588
0	23952588
.	23952588
005	23952588
)	23952588
than	23952588
patients	23952588
without	23952588
dyskinesia	23952588
.	23952588

The	23952588
three	23952588
significant	23952588
predictors	23952588
of	23952588
dyskinesia	23952588
were	23952588
duration	23952588
of	23952588
levodopa	23952588
therapy	23952588
,	23952588
onset	23952588
age	23952588
,	23952588
and	23952588
total	23952588
daily	23952588
levodopa	23952588
dose	23952588
.	23952588

CONCLUSIONS	23952588
:	23952588
The	23952588
prevalence	23952588
of	23952588
levodopa	23952588
-	23952588
induced	23952588
dyskinesia	23952588
in	23952588
our	23952588
patients	23952588
was	23952588
44%	23952588
.	23952588

The	23952588
most	23952588
significant	23952588
predictors	23952588
were	23952588
duration	23952588
of	23952588
levodopa	23952588
therapy	23952588
,	23952588
total	23952588
daily	23952588
levodopa	23952588
dose	23952588
,	23952588
and	23952588
onset	23952588
age	23952588
.	23952588
Novel	19779499
CACNA1S	19779499
mutation	19779499
causes	19779499
autosomal	19779499
dominant	19779499
hypokalemic	19779499
periodic	19779499
paralysis	19779499
in	19779499
a	19779499
South	19779499
American	19779499
family	19779499
.	19779499

Hypokalaemic	19779499
periodic	19779499
paralysis	19779499
(	19779499
HypoPP	19779499
)	19779499
is	19779499
an	19779499
autosomal	19779499
dominant	19779499
disorder	19779499
,	19779499
which	19779499
is	19779499
characterized	19779499
by	19779499
periodic	19779499
attacks	19779499
of	19779499
muscle	19779499
weakness	19779499
associated	19779499
with	19779499
a	19779499
decrease	19779499
in	19779499
the	19779499
serum	19779499
potassium	19779499
level	19779499
.	19779499

A	19779499
major	19779499
disease	19779499
-	19779499
causing	19779499
gene	19779499
for	19779499
HypoPP	19779499
has	19779499
been	19779499
identified	19779499
as	19779499
CACNA1S	19779499
,	19779499
which	19779499
encodes	19779499
the	19779499
skeletal	19779499
muscle	19779499
calcium	19779499
channel	19779499
alpha	19779499
-	19779499
subunit	19779499
with	19779499
four	19779499
transmembrane	19779499
domains	19779499
(	19779499
I	19779499
-	19779499
IV	19779499
)	19779499
,	19779499
each	19779499
with	19779499
six	19779499
transmembrane	19779499
segments	19779499
(	19779499
S1	19779499
-	19779499
S6	19779499
)	19779499
.	19779499

To	19779499
date	19779499
,	19779499
all	19779499
CACNA1S	19779499
mutations	19779499
identified	19779499
in	19779499
HypoPP	19779499
patients	19779499
are	19779499
located	19779499
within	19779499
the	19779499
voltage	19779499
-	19779499
sensor	19779499
S4	19779499
segment	19779499
.	19779499

In	19779499
this	19779499
study	19779499
we	19779499
report	19779499
a	19779499
novel	19779499
CACNA1S	19779499
mutation	19779499
in	19779499
a	19779499
new	19779499
region	19779499
of	19779499
the	19779499
protein	19779499
,	19779499
the	19779499
S3	19779499
segment	19779499
of	19779499
domain	19779499
III	19779499
.	19779499

We	19779499
characterized	19779499
a	19779499
four	19779499
-	19779499
generation	19779499
South	19779499
American	19779499
family	19779499
with	19779499
HypoPP	19779499
.	19779499

Genetic	19779499
analysis	19779499
identified	19779499
a	19779499
novel	19779499
V876E	19779499
mutation	19779499
in	19779499
all	19779499
HypoPP	19779499
patients	19779499
in	19779499
the	19779499
family	19779499
,	19779499
but	19779499
not	19779499
in	19779499
normal	19779499
family	19779499
members	19779499
or	19779499
160	19779499
control	19779499
people	19779499
.	19779499

Clinical	19779499
analysis	19779499
indicates	19779499
that	19779499
mutation	19779499
V876E	19779499
is	19779499
associated	19779499
with	19779499
a	19779499
severe	19779499
outcome	19779499
as	19779499
characterized	19779499
by	19779499
a	19779499
very	19779499
early	19779499
age	19779499
of	19779499
onset	19779499
,	19779499
complete	19779499
penetrance	19779499
and	19779499
a	19779499
severe	19779499
prognosis	19779499
including	19779499
death	19779499
.	19779499

These	19779499
results	19779499
identify	19779499
a	19779499
new	19779499
mutation	19779499
in	19779499
CACNA1S	19779499
and	19779499
expand	19779499
the	19779499
spectrum	19779499
of	19779499
CACNA1S	19779499
mutations	19779499
associated	19779499
with	19779499
HypoPP	19779499
.	19779499
Elevation	20621845
of	20621845
ADAM10	20621845
,	20621845
ADAM17	20621845
,	20621845
MMP	20621845
-	20621845
2	20621845
and	20621845
MMP	20621845
-	20621845
9	20621845
expression	20621845
with	20621845
media	20621845
degeneration	20621845
features	20621845
CaCl2	20621845
-	20621845
induced	20621845
thoracic	20621845
aortic	20621845
aneurysm	20621845
in	20621845
a	20621845
rat	20621845
model	20621845
.	20621845

PURPOSE	20621845
:	20621845
This	20621845
study	20621845
was	20621845
designed	20621845
to	20621845
establish	20621845
a	20621845
rat	20621845
model	20621845
of	20621845
thoracic	20621845
aortic	20621845
aneurysm	20621845
(	20621845
TAA	20621845
)	20621845
by	20621845
calcium	20621845
chloride	20621845
(	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
)	20621845
-	20621845
induced	20621845
arterial	20621845
injury	20621845
and	20621845
to	20621845
explore	20621845
the	20621845
potential	20621845
role	20621845
of	20621845
a	20621845
disintegrin	20621845
and	20621845
metalloproteinase	20621845
(	20621845
ADAM	20621845
)	20621845
,	20621845
matrix	20621845
metalloproteinases	20621845
(	20621845
MMPs	20621845
)	20621845
and	20621845
their	20621845
endogenous	20621845
inhibitors	20621845
(	20621845
TIMPs	20621845
)	20621845
in	20621845
TAA	20621845
formation	20621845
.	20621845

METHODS	20621845
:	20621845
Thoracic	20621845
aorta	20621845
of	20621845
male	20621845
Sprague	20621845
-	20621845
Dawley	20621845
rats	20621845
was	20621845
exposed	20621845
to	20621845
0	20621845
.	20621845
5M	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
or	20621845
normal	20621845
saline	20621845
(	20621845
NaCl	20621845
)	20621845
.	20621845

After	20621845
12weeks	20621845
,	20621845
animals	20621845
were	20621845
euthanized	20621845
,	20621845
and	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
,	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
untreated	20621845
(	20621845
n	20621845
=	20621845
12	20621845
)	20621845
and	20621845
NaCl	20621845
-	20621845
treated	20621845
aortic	20621845
segments	20621845
(	20621845
n	20621845
=	20621845
12	20621845
)	20621845
were	20621845
collected	20621845
for	20621845
histological	20621845
and	20621845
molecular	20621845
assessments	20621845
.	20621845

MMP	20621845
-	20621845
TIMP	20621845
and	20621845
ADAM	20621845
mRNAs	20621845
were	20621845
semi	20621845
-	20621845
quantitatively	20621845
analyzed	20621845
and	20621845
protein	20621845
expressions	20621845
were	20621845
determined	20621845
by	20621845
immunohistochemistry	20621845
.	20621845

RESULTS	20621845
:	20621845
Despite	20621845
similar	20621845
external	20621845
diameters	20621845
among	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
,	20621845
non	20621845
-	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
and	20621845
NaCl	20621845
-	20621845
treated	20621845
segments	20621845
,	20621845
aneurymal	20621845
alteration	20621845
(	20621845
n	20621845
=	20621845
6	20621845
,	20621845
50%	20621845
)	20621845
,	20621845
media	20621845
degeneration	20621845
with	20621845
regional	20621845
disruption	20621845
,	20621845
fragmentation	20621845
of	20621845
elastic	20621845
fiber	20621845
,	20621845
and	20621845
increased	20621845
collagen	20621845
deposition	20621845
(	20621845
n	20621845
=	20621845
12	20621845
,	20621845
100%	20621845
)	20621845
were	20621845
demonstrated	20621845
in	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
segments	20621845
.	20621845

MMP	20621845
-	20621845
2	20621845
,	20621845
MMP	20621845
-	20621845
9	20621845
,	20621845
ADAM	20621845
-	20621845
10	20621845
and	20621845
ADAM	20621845
-	20621845
17	20621845
mRNA	20621845
levels	20621845
were	20621845
increased	20621845
in	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
segments	20621845
(	20621845
all	20621845
p	20621845
<	20621845
0	20621845
.	20621845
01	20621845
)	20621845
,	20621845
with	20621845
trends	20621845
of	20621845
elevation	20621845
in	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
untreated	20621845
segments	20621845
,	20621845
as	20621845
compared	20621845
with	20621845
NaCl	20621845
-	20621845
treated	20621845
segments	20621845
.	20621845

Immunohistochemistry	20621845
displayed	20621845
significantly	20621845
increased	20621845
expressions	20621845
of	20621845
MMP	20621845
-	20621845
2	20621845
,	20621845
MMP	20621845
-	20621845
9	20621845
,	20621845
ADAM	20621845
-	20621845
10	20621845
and	20621845
ADAM	20621845
-	20621845
17	20621845
(	20621845
all	20621845
p	20621845
<	20621845
0	20621845
.	20621845
01	20621845
)	20621845
in	20621845
intima	20621845
and	20621845
media	20621845
for	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
-	20621845
treated	20621845
segments	20621845
.	20621845

TIMP	20621845
mRNA	20621845
and	20621845
tissue	20621845
levels	20621845
did	20621845
not	20621845
differ	20621845
obviously	20621845
among	20621845
the	20621845
three	20621845
aortic	20621845
segments	20621845
.	20621845

CONCLUSION	20621845
:	20621845
This	20621845
study	20621845
establishes	20621845
a	20621845
TAA	20621845
model	20621845
by	20621845
periarterial	20621845
CaCl	20621845
(	20621845
2	20621845
)	20621845
exposure	20621845
in	20621845
rats	20621845
,	20621845
and	20621845
demonstrates	20621845
a	20621845
significant	20621845
elevation	20621845
of	20621845
expression	20621845
of	20621845
MMP	20621845
-	20621845
2	20621845
,	20621845
MMP	20621845
-	20621845
9	20621845
,	20621845
ADAM10	20621845
and	20621845
ADAM17	20621845
in	20621845
the	20621845
pathogenesis	20621845
of	20621845
vascular	20621845
remodeling	20621845
.	20621845
Expanding	18681856
clinical	18681856
spectrum	18681856
of	18681856
non	18681856
-	18681856
autoimmune	18681856
hyperthyroidism	18681856
due	18681856
to	18681856
an	18681856
activating	18681856
germline	18681856
mutation	18681856
,	18681856
p	18681856
.	18681856
M453T	18681856
,	18681856
in	18681856
the	18681856
thyrotropin	18681856
receptor	18681856
gene	18681856
.	18681856

OBJECTIVE	18681856
:	18681856
To	18681856
describe	18681856
clinical	18681856
and	18681856
genetic	18681856
features	18681856
of	18681856
a	18681856
Thai	18681856
family	18681856
with	18681856
non	18681856
-	18681856
autoimmune	18681856
hyperthyroidism	18681856
(	18681856
NAH	18681856
)	18681856
caused	18681856
by	18681856
an	18681856
activating	18681856
germline	18681856
mutation	18681856
in	18681856
the	18681856
thyrotropin	18681856
receptor	18681856
(	18681856
TSHR	18681856
)	18681856
gene	18681856
.	18681856

PATIENTS	18681856
:	18681856
Three	18681856
affected	18681856
individuals	18681856
from	18681856
the	18681856
same	18681856
family	18681856
(	18681856
a	18681856
father	18681856
and	18681856
his	18681856
two	18681856
children	18681856
)	18681856
were	18681856
studied	18681856
.	18681856

Clinical	18681856
and	18681856
imaging	18681856
findings	18681856
were	18681856
reviewed	18681856
and	18681856
compared	18681856
.	18681856

GENETIC	18681856
ANALYSIS	18681856
:	18681856
Genomic	18681856
DNA	18681856
was	18681856
extracted	18681856
from	18681856
peripheral	18681856
blood	18681856
leukocytes	18681856
and	18681856
mutation	18681856
analysis	18681856
of	18681856
the	18681856
entire	18681856
coding	18681856
sequence	18681856
of	18681856
the	18681856
TSHR	18681856
gene	18681856
was	18681856
performed	18681856
in	18681856
both	18681856
children	18681856
and	18681856
their	18681856
parents	18681856
by	18681856
direct	18681856
DNA	18681856
sequencing	18681856
.	18681856

RESULTS	18681856
:	18681856
A	18681856
heterozygous	18681856
germline	18681856
T	18681856
to	18681856
C	18681856
transition	18681856
in	18681856
exon	18681856
10	18681856
of	18681856
the	18681856
TSHR	18681856
gene	18681856
(	18681856
c	18681856
.	18681856
1358T	18681856
-	18681856
-	18681856
>	18681856
C	18681856
)	18681856
resulting	18681856
in	18681856
the	18681856
substitution	18681856
of	18681856
methionine	18681856
(	18681856
ATG	18681856
)	18681856
by	18681856
threonine	18681856
(	18681856
ACG	18681856
)	18681856
at	18681856
codon	18681856
453	18681856
(	18681856
p	18681856
.	18681856
M453T	18681856
)	18681856
was	18681856
identified	18681856
in	18681856
the	18681856
father	18681856
and	18681856
his	18681856
two	18681856
children	18681856
.	18681856

They	18681856
presented	18681856
with	18681856
different	18681856
clinical	18681856
severity	18681856
and	18681856
variable	18681856
age	18681856
of	18681856
onset	18681856
.	18681856

In	18681856
addition	18681856
to	18681856
hyperthyroidism	18681856
,	18681856
ventriculomegaly	18681856
and	18681856
bilateral	18681856
shortening	18681856
of	18681856
the	18681856
fifth	18681856
metacarpal	18681856
bones	18681856
and	18681856
the	18681856
middle	18681856
phalanges	18681856
of	18681856
the	18681856
fifth	18681856
fingers	18681856
were	18681856
consistently	18681856
found	18681856
in	18681856
all	18681856
affected	18681856
individuals	18681856
.	18681856

CONCLUSIONS	18681856
:	18681856
Ventriculomegaly	18681856
and	18681856
bilateral	18681856
shortening	18681856
of	18681856
the	18681856
fifth	18681856
metacarpal	18681856
bones	18681856
and	18681856
the	18681856
middle	18681856
phalanges	18681856
of	18681856
the	18681856
fifth	18681856
fingers	18681856
might	18681856
be	18681856
characteristic	18681856
features	18681856
of	18681856
NAH	18681856
because	18681856
of	18681856
an	18681856
activating	18681856
TSHR	18681856
germline	18681856
mutation	18681856
.	18681856

In	18681856
addition	18681856
,	18681856
the	18681856
shortening	18681856
of	18681856
the	18681856
middle	18681856
phalanges	18681856
of	18681856
the	18681856
fifth	18681856
fingers	18681856
has	18681856
never	18681856
been	18681856
previously	18681856
described	18681856
,	18681856
expanding	18681856
the	18681856
phenotypic	18681856
spectrum	18681856
of	18681856
the	18681856
disease	18681856
.	18681856
Identification	21976953
of	21976953
a	21976953
novel	21976953
FBN1	21976953
gene	21976953
mutation	21976953
in	21976953
a	21976953
Chinese	21976953
family	21976953
with	21976953
Marfan	21976953
syndrome	21976953
.	21976953

PURPOSE	21976953
:	21976953
To	21976953
identify	21976953
the	21976953
mutation	21976953
in	21976953
the	21976953
fibrillin	21976953
-	21976953
1	21976953
gene	21976953
(	21976953
FBN1	21976953
)	21976953
in	21976953
a	21976953
Chinese	21976953
family	21976953
with	21976953
Marfan	21976953
syndrome	21976953
(	21976953
MFS	21976953
)	21976953
.	21976953

METHODS	21976953
:	21976953
Patients	21976953
and	21976953
family	21976953
members	21976953
were	21976953
given	21976953
complete	21976953
physical	21976953
,	21976953
ophthalmic	21976953
,	21976953
and	21976953
cardiovascular	21976953
examinations	21976953
.	21976953

Genomic	21976953
DNA	21976953
was	21976953
extracted	21976953
from	21976953
leukocytes	21976953
of	21976953
venous	21976953
blood	21976953
of	21976953
six	21976953
individuals	21976953
in	21976953
the	21976953
family	21976953
and	21976953
170	21976953
healthy	21976953
Chinese	21976953
individuals	21976953
.	21976953

All	21976953
of	21976953
the	21976953
65	21976953
coding	21976953
exons	21976953
and	21976953
their	21976953
flanking	21976953
intronic	21976953
boundaries	21976953
of	21976953
FBN1	21976953
were	21976953
amplified	21976953
in	21976953
the	21976953
proband	21976953
by	21976953
polymerase	21976953
chain	21976953
reaction	21976953
and	21976953
followed	21976953
by	21976953
direct	21976953
sequencing	21976953
.	21976953

The	21976953
mutation	21976953
identified	21976953
in	21976953
the	21976953
proband	21976953
was	21976953
screened	21976953
in	21976953
the	21976953
other	21976953
family	21976953
members	21976953
and	21976953
the	21976953
170	21976953
healthy	21976953
Chinese	21976953
individuals	21976953
by	21976953
direct	21976953
sequencing	21976953
.	21976953

Protein	21976953
conservation	21976953
analysis	21976953
was	21976953
performed	21976953
in	21976953
six	21976953
species	21976953
using	21976953
an	21976953
online	21976953
ClustalW	21976953
tool	21976953
.	21976953

Protein	21976953
structure	21976953
was	21976953
modeled	21976953
based	21976953
on	21976953
the	21976953
Protein	21976953
data	21976953
bank	21976953
and	21976953
mutated	21976953
in	21976953
DeepView	21976953
v4	21976953
.	21976953
0	21976953
.	21976953
1	21976953
to	21976953
predict	21976953
the	21976953
functional	21976953
consequences	21976953
of	21976953
the	21976953
mutation	21976953
.	21976953

RESULTS	21976953
:	21976953
A	21976953
novel	21976953
heterozygous	21976953
c	21976953
.	21976953
3703T	21976953
>	21976953
C	21976953
change	21976953
in	21976953
exon	21976953
29	21976953
of	21976953
FBN1	21976953
was	21976953
detected	21976953
in	21976953
the	21976953
proband	21976953
,	21976953
which	21976953
resulted	21976953
in	21976953
the	21976953
substitution	21976953
of	21976953
serine	21976953
by	21976953
proline	21976953
at	21976953
codon	21976953
1235	21976953
(	21976953
p	21976953
.	21976953
S1235P	21976953
)	21976953
.	21976953

This	21976953
mutation	21976953
was	21976953
also	21976953
present	21976953
in	21976953
two	21976953
family	21976953
members	21976953
but	21976953
absent	21976953
in	21976953
the	21976953
other	21976953
,	21976953
unaffected	21976953
family	21976953
members	21976953
and	21976953
the	21976953
170	21976953
healthy	21976953
Chinese	21976953
individuals	21976953
.	21976953

The	21976953
mutant	21976953
residue	21976953
located	21976953
in	21976953
the	21976953
calcium	21976953
binding	21976953
epidermal	21976953
growth	21976953
factor	21976953
-	21976953
like	21976953
#	21976953
15	21976953
domain	21976953
is	21976953
highly	21976953
conserved	21976953
among	21976953
mammalian	21976953
species	21976953
and	21976953
could	21976953
probably	21976953
induce	21976953
conformation	21976953
change	21976953
of	21976953
the	21976953
domain	21976953
.	21976953

CONCLUSIONS	21976953
:	21976953
We	21976953
indentified	21976953
a	21976953
novel	21976953
p	21976953
.	21976953
S1235P	21976953
mutation	21976953
in	21976953
FBN1	21976953
,	21976953
which	21976953
is	21976953
the	21976953
causative	21976953
mutation	21976953
for	21976953
MFS	21976953
in	21976953
this	21976953
family	21976953
.	21976953

Our	21976953
result	21976953
expands	21976953
the	21976953
mutation	21976953
spectrum	21976953
of	21976953
FBN1	21976953
and	21976953
contributes	21976953
to	21976953
the	21976953
study	21976953
of	21976953
the	21976953
molecular	21976953
pathogenesis	21976953
of	21976953
Marfan	21976953
syndrome	21976953
.	21976953
CD72	15459183
polymorphisms	15459183
associated	15459183
with	15459183
alternative	15459183
splicing	15459183
modify	15459183
susceptibility	15459183
to	15459183
human	15459183
systemic	15459183
lupus	15459183
erythematosus	15459183
through	15459183
epistatic	15459183
interaction	15459183
with	15459183
FCGR2B	15459183
.	15459183

We	15459183
previously	15459183
reported	15459183
association	15459183
of	15459183
FCGR2B	15459183
-	15459183
Ile232Thr	15459183
with	15459183
systemic	15459183
lupus	15459183
erythematosus	15459183
(	15459183
SLE	15459183
)	15459183
in	15459183
three	15459183
Asian	15459183
populations	15459183
.	15459183

Because	15459183
polymorphism	15459183
of	15459183
CD72	15459183
,	15459183
another	15459183
inhibitory	15459183
receptor	15459183
of	15459183
B	15459183
cells	15459183
,	15459183
was	15459183
associated	15459183
with	15459183
murine	15459183
SLE	15459183
,	15459183
we	15459183
identified	15459183
human	15459183
CD72	15459183
polymorphisms	15459183
,	15459183
tested	15459183
their	15459183
association	15459183
with	15459183
SLE	15459183
and	15459183
examined	15459183
genetic	15459183
interaction	15459183
with	15459183
FCGR2B	15459183
in	15459183
the	15459183
Japanese	15459183
(	15459183
160	15459183
SLE	15459183
,	15459183
277	15459183
controls	15459183
)	15459183
,	15459183
Thais	15459183
(	15459183
87	15459183
SLE	15459183
,	15459183
187	15459183
controls	15459183
)	15459183
and	15459183
Caucasians	15459183
(	15459183
94	15459183
families	15459183
containing	15459183
SLE	15459183
members	15459183
)	15459183
.	15459183

Four	15459183
polymorphisms	15459183
and	15459183
six	15459183
rare	15459183
variations	15459183
were	15459183
detected	15459183
.	15459183

The	15459183
former	15459183
constituted	15459183
two	15459183
major	15459183
haplotypes	15459183
that	15459183
contained	15459183
one	15459183
or	15459183
two	15459183
repeats	15459183
of	15459183
13	15459183
nucleotides	15459183
in	15459183
intron	15459183
8	15459183
(	15459183
designated	15459183
as	15459183
*	15459183
1	15459183
and	15459183
*	15459183
2	15459183
,	15459183
respectively	15459183
)	15459183
.	15459183

Although	15459183
association	15459183
with	15459183
susceptibility	15459183
to	15459183
SLE	15459183
was	15459183
not	15459183
detected	15459183
,	15459183
the	15459183
*	15459183
1	15459183
allele	15459183
was	15459183
significantly	15459183
associated	15459183
with	15459183
nephritis	15459183
among	15459183
the	15459183
Japanese	15459183
patients	15459183
(	15459183
P	15459183
=	15459183
0	15459183
.	15459183
024	15459183
)	15459183
.	15459183

RT	15459183
-	15459183
PCR	15459183
identified	15459183
a	15459183
novel	15459183
alternatively	15459183
spliced	15459183
(	15459183
AS	15459183
)	15459183
transcript	15459183
that	15459183
was	15459183
expressed	15459183
at	15459183
the	15459183
protein	15459183
level	15459183
in	15459183
COS	15459183
-	15459183
7	15459183
transfectants	15459183
.	15459183

The	15459183
ratio	15459183
of	15459183
AS	15459183
/	15459183
common	15459183
isoforms	15459183
was	15459183
strikingly	15459183
increased	15459183
in	15459183
individuals	15459183
with	15459183
*	15459183
2	15459183
/	15459183
*	15459183
2	15459183
genotype	15459183
when	15459183
compared	15459183
with	15459183
*	15459183
1	15459183
/	15459183
*	15459183
1	15459183
(	15459183
P	15459183
=	15459183
0	15459183
.	15459183
000038	15459183
)	15459183
or	15459183
*	15459183
1	15459183
/	15459183
*	15459183
2	15459183
(	15459183
P	15459183
=	15459183
0	15459183
.	15459183
0085	15459183
)	15459183
genotypes	15459183
.	15459183

Using	15459183
the	15459183
two	15459183
Asian	15459183
cohorts	15459183
,	15459183
significant	15459183
association	15459183
of	15459183
FCGR2B	15459183
-	15459183
232Thr	15459183
/	15459183
Thr	15459183
with	15459183
SLE	15459183
was	15459183
observed	15459183
only	15459183
in	15459183
the	15459183
presence	15459183
of	15459183
CD72	15459183
-	15459183
*	15459183
1	15459183
/	15459183
*	15459183
1	15459183
genotype	15459183
(	15459183
OR	15459183
4	15459183
.	15459183
63	15459183
,	15459183
95%	15459183
CI	15459183
1	15459183
.	15459183
47	15459183
-	15459183
14	15459183
.	15459183
6	15459183
,	15459183
P	15459183
=	15459183
0	15459183
.	15459183
009	15459183
versus	15459183
FCGR2B	15459183
-	15459183
232Ile	15459183
/	15459183
Ile	15459183
plus	15459183
CD72	15459183
-	15459183
*	15459183
2	15459183
/	15459183
*	15459183
2	15459183
)	15459183
.	15459183

Minigene	15459183
assays	15459183
demonstrated	15459183
that	15459183
the	15459183
13	15459183
-	15459183
nucleotide	15459183
repeat	15459183
and	15459183
4	15459183
bp	15459183
deletion	15459183
within	15459183
the	15459183
same	15459183
haplotype	15459183
of	15459183
intron	15459183
8	15459183
could	15459183
regulate	15459183
alternative	15459183
splicing	15459183
.	15459183

The	15459183
AS	15459183
isoform	15459183
lacks	15459183
exon	15459183
8	15459183
,	15459183
and	15459183
is	15459183
deduced	15459183
to	15459183
contain	15459183
49	15459183
amino	15459183
acid	15459183
changes	15459183
in	15459183
the	15459183
membrane	15459183
-	15459183
distal	15459183
portion	15459183
of	15459183
the	15459183
extracellular	15459183
domain	15459183
,	15459183
where	15459183
considerable	15459183
amino	15459183
acid	15459183
changes	15459183
are	15459183
known	15459183
in	15459183
CD72	15459183
(	15459183
c	15459183
)	15459183
allele	15459183
associated	15459183
with	15459183
murine	15459183
SLE	15459183
.	15459183

These	15459183
results	15459183
indicated	15459183
that	15459183
the	15459183
presence	15459183
of	15459183
CD72	15459183
-	15459183
*	15459183
2	15459183
allele	15459183
decreases	15459183
risk	15459183
for	15459183
human	15459183
SLE	15459183
conferred	15459183
by	15459183
FCGR2B	15459183
-	15459183
232Thr	15459183
,	15459183
possibly	15459183
by	15459183
increasing	15459183
the	15459183
AS	15459183
isoform	15459183
of	15459183
CD72	15459183
.	15459183
Vaccine	15461822
candidates	15461822
derived	15461822
from	15461822
a	15461822
novel	15461822
infectious	15461822
cDNA	15461822
clone	15461822
of	15461822
an	15461822
American	15461822
genotype	15461822
dengue	15461822
virus	15461822
type	15461822
2	15461822
.	15461822

BACKGROUND	15461822
:	15461822
A	15461822
dengue	15461822
virus	15461822
type	15461822
2	15461822
(	15461822
DEN	15461822
-	15461822
2	15461822
Tonga	15461822
/	15461822
74	15461822
)	15461822
isolated	15461822
from	15461822
a	15461822
1974	15461822
epidemic	15461822
was	15461822
characterized	15461822
by	15461822
mild	15461822
illness	15461822
and	15461822
belongs	15461822
to	15461822
the	15461822
American	15461822
genotype	15461822
of	15461822
DEN	15461822
-	15461822
2	15461822
viruses	15461822
.	15461822

To	15461822
prepare	15461822
a	15461822
vaccine	15461822
candidate	15461822
,	15461822
a	15461822
previously	15461822
described	15461822
30	15461822
nucleotide	15461822
deletion	15461822
(	15461822
Delta30	15461822
)	15461822
in	15461822
the	15461822
3	15461822
'	15461822
untranslated	15461822
region	15461822
of	15461822
DEN	15461822
-	15461822
4	15461822
has	15461822
been	15461822
engineered	15461822
into	15461822
the	15461822
DEN	15461822
-	15461822
2	15461822
isolate	15461822
.	15461822

METHODS	15461822
:	15461822
A	15461822
full	15461822
-	15461822
length	15461822
cDNA	15461822
clone	15461822
was	15461822
generated	15461822
from	15461822
the	15461822
DEN	15461822
-	15461822
2	15461822
virus	15461822
and	15461822
used	15461822
to	15461822
produce	15461822
recombinant	15461822
DEN	15461822
-	15461822
2	15461822
(	15461822
rDEN	15461822
-	15461822
2	15461822
)	15461822
and	15461822
rDEN2Delta30	15461822
.	15461822

Viruses	15461822
were	15461822
evaluated	15461822
for	15461822
replication	15461822
in	15461822
SCID	15461822
mice	15461822
transplanted	15461822
with	15461822
human	15461822
hepatoma	15461822
cells	15461822
(	15461822
SCID	15461822
-	15461822
HuH	15461822
-	15461822
7	15461822
mice	15461822
)	15461822
,	15461822
in	15461822
mosquitoes	15461822
,	15461822
and	15461822
in	15461822
rhesus	15461822
monkeys	15461822
.	15461822

Neutralizing	15461822
antibody	15461822
induction	15461822
and	15461822
protective	15461822
efficacy	15461822
were	15461822
also	15461822
assessed	15461822
in	15461822
rhesus	15461822
monkeys	15461822
.	15461822

RESULTS	15461822
:	15461822
The	15461822
rDEN2Delta30	15461822
virus	15461822
was	15461822
ten	15461822
-	15461822
fold	15461822
reduced	15461822
in	15461822
replication	15461822
in	15461822
SCID	15461822
-	15461822
HuH	15461822
-	15461822
7	15461822
mice	15461822
when	15461822
compared	15461822
to	15461822
the	15461822
parent	15461822
virus	15461822
.	15461822

The	15461822
rDEN	15461822
-	15461822
2	15461822
viruses	15461822
were	15461822
not	15461822
infectious	15461822
for	15461822
Aedes	15461822
mosquitoes	15461822
,	15461822
but	15461822
both	15461822
readily	15461822
infected	15461822
Toxorynchites	15461822
mosquitoes	15461822
.	15461822

In	15461822
rhesus	15461822
monkeys	15461822
,	15461822
rDEN2Delta30	15461822
appeared	15461822
to	15461822
be	15461822
slightly	15461822
attenuated	15461822
when	15461822
compared	15461822
to	15461822
the	15461822
parent	15461822
virus	15461822
as	15461822
measured	15461822
by	15461822
duration	15461822
and	15461822
peak	15461822
of	15461822
viremia	15461822
and	15461822
neutralizing	15461822
antibody	15461822
induction	15461822
.	15461822

A	15461822
derivative	15461822
of	15461822
rDEN2Delta30	15461822
,	15461822
designated	15461822
rDEN2Delta30	15461822
-	15461822
4995	15461822
,	15461822
was	15461822
generated	15461822
by	15461822
incorporation	15461822
of	15461822
a	15461822
point	15461822
mutation	15461822
previously	15461822
identified	15461822
in	15461822
the	15461822
NS3	15461822
gene	15461822
of	15461822
DEN	15461822
-	15461822
4	15461822
and	15461822
was	15461822
found	15461822
to	15461822
be	15461822
more	15461822
attenuated	15461822
than	15461822
rDEN2Delta30	15461822
in	15461822
SCID	15461822
-	15461822
HuH	15461822
-	15461822
7	15461822
mice	15461822
.	15461822

CONCLUSIONS	15461822
:	15461822
The	15461822
rDEN2Delta30	15461822
and	15461822
rDEN2Delta30	15461822
-	15461822
4995	15461822
viruses	15461822
can	15461822
be	15461822
considered	15461822
for	15461822
evaluation	15461822
in	15461822
humans	15461822
and	15461822
for	15461822
inclusion	15461822
in	15461822
a	15461822
tetravalent	15461822
dengue	15461822
vaccine	15461822
.	15461822
The	16167916
effects	16167916
of	16167916
short	16167916
-	16167916
term	16167916
raloxifene	16167916
therapy	16167916
on	16167916
fibrinolysis	16167916
markers	16167916
:	16167916
TAFI	16167916
,	16167916
tPA	16167916
,	16167916
and	16167916
PAI	16167916
-	16167916
1	16167916
.	16167916

BACKGROUND	16167916
:	16167916
Markers	16167916
of	16167916
fibrinolysis	16167916
,	16167916
thrombin	16167916
-	16167916
activatable	16167916
fibrinolysis	16167916
inhibitor	16167916
(	16167916
TAFI	16167916
)	16167916
,	16167916
tissue	16167916
-	16167916
type	16167916
plasminogen	16167916
activator	16167916
(	16167916
tPA	16167916
)	16167916
,	16167916
and	16167916
plasminogen	16167916
activator	16167916
inhibitor	16167916
-	16167916
1	16167916
(	16167916
PAI	16167916
-	16167916
1	16167916
)	16167916
levels	16167916
were	16167916
studied	16167916
for	16167916
the	16167916
evaluation	16167916
of	16167916
short	16167916
-	16167916
term	16167916
effects	16167916
of	16167916
raloxifene	16167916
administration	16167916
in	16167916
postmenopausal	16167916
women	16167916
.	16167916

METHODS	16167916
:	16167916
Thirty	16167916
-	16167916
nine	16167916
postmenopausal	16167916
women	16167916
with	16167916
osteopenia	16167916
or	16167916
osteoporosis	16167916
were	16167916
included	16167916
in	16167916
this	16167916
prospective	16167916
,	16167916
controlled	16167916
clinical	16167916
study	16167916
.	16167916

Twenty	16167916
-	16167916
five	16167916
women	16167916
were	16167916
given	16167916
raloxifene	16167916
hydrochloride	16167916
(	16167916
60	16167916
mg	16167916
/	16167916
day	16167916
)	16167916
plus	16167916
calcium	16167916
(	16167916
500	16167916
mg	16167916
/	16167916
day	16167916
)	16167916
.	16167916

Age	16167916
-	16167916
matched	16167916
controls	16167916
(	16167916
n	16167916
=	16167916
14	16167916
)	16167916
were	16167916
given	16167916
only	16167916
calcium	16167916
.	16167916

Plasma	16167916
TAFI	16167916
,	16167916
tPA	16167916
,	16167916
and	16167916
PAI	16167916
-	16167916
1	16167916
antigen	16167916
levels	16167916
were	16167916
measured	16167916
at	16167916
baseline	16167916
and	16167916
after	16167916
3	16167916
months	16167916
of	16167916
treatment	16167916
by	16167916
commercially	16167916
available	16167916
ELISA	16167916
kits	16167916
.	16167916

Variations	16167916
of	16167916
individuals	16167916
were	16167916
assessed	16167916
by	16167916
Wilcoxon	16167916
'	16167916
s	16167916
test	16167916
.	16167916

Relationship	16167916
between	16167916
those	16167916
markers	16167916
and	16167916
demographic	16167916
characteristics	16167916
were	16167916
investigated	16167916
.	16167916

RESULTS	16167916
:	16167916
Three	16167916
months	16167916
of	16167916
raloxifene	16167916
treatment	16167916
was	16167916
associated	16167916
with	16167916
a	16167916
significant	16167916
decrease	16167916
in	16167916
the	16167916
plasma	16167916
TAFI	16167916
antigen	16167916
concentrations	16167916
(	16167916
16%	16167916
change	16167916
,	16167916
P	16167916
<	16167916
0	16167916
.	16167916
01	16167916
)	16167916
,	16167916
and	16167916
a	16167916
significant	16167916
increase	16167916
in	16167916
tPA	16167916
antigen	16167916
concentrations	16167916
(	16167916
25%	16167916
change	16167916
,	16167916
P	16167916
<	16167916
0	16167916
.	16167916
05	16167916
)	16167916
.	16167916

A	16167916
significant	16167916
correlation	16167916
was	16167916
found	16167916
between	16167916
baseline	16167916
TAFI	16167916
antigen	16167916
concentrations	16167916
and	16167916
the	16167916
duration	16167916
of	16167916
amenorrhea	16167916
(	16167916
P	16167916
<	16167916
0	16167916
.	16167916
05	16167916
;	16167916
r	16167916
=	16167916
0	16167916
.	16167916
33	16167916
)	16167916
.	16167916

CONCLUSION	16167916
:	16167916
We	16167916
suggest	16167916
that	16167916
the	16167916
increased	16167916
risk	16167916
of	16167916
venous	16167916
thromboembolism	16167916
due	16167916
to	16167916
raloxifene	16167916
treatment	16167916
may	16167916
be	16167916
related	16167916
to	16167916
increased	16167916
tPA	16167916
levels	16167916
,	16167916
but	16167916
not	16167916
TAFI	16167916
levels	16167916
.	16167916
NEK2	28101574
serves	28101574
as	28101574
a	28101574
prognostic	28101574
biomarker	28101574
for	28101574
hepatocellular	28101574
carcinoma	28101574
.	28101574

Never	28101574
in	28101574
mitosis	28101574
gene	28101574
A	28101574
(	28101574
NIMA	28101574
)	28101574
-	28101574
related	28101574
kinase	28101574
2	28101574
(	28101574
NEK2	28101574
)	28101574
is	28101574
a	28101574
microtubule	28101574
-	28101574
associated	28101574
protein	28101574
that	28101574
regulates	28101574
spindle	28101574
assembly	28101574
in	28101574
human	28101574
cells	28101574
and	28101574
is	28101574
overexpressed	28101574
in	28101574
various	28101574
malignancies	28101574
.	28101574

However	28101574
,	28101574
the	28101574
role	28101574
of	28101574
NEK2	28101574
in	28101574
hepatocellular	28101574
carcinoma	28101574
(	28101574
HCC	28101574
)	28101574
remains	28101574
undetermined	28101574
.	28101574

We	28101574
performed	28101574
RNA	28101574
-	28101574
seq	28101574
of	28101574
the	28101574
HCC	28101574
cell	28101574
line	28101574
SMMC	28101574
-	28101574
7721	28101574
and	28101574
the	28101574
normal	28101574
liver	28101574
cell	28101574
line	28101574
HL	28101574
-	28101574
7702	28101574
using	28101574
the	28101574
Ion	28101574
Proton	28101574
System	28101574
.	28101574

NEK2	28101574
expression	28101574
was	28101574
detected	28101574
using	28101574
quantitative	28101574
reverse	28101574
transcription	28101574
polymerase	28101574
chain	28101574
reaction	28101574
in	28101574
two	28101574
cell	28101574
lines	28101574
and	28101574
5	28101574
matched	28101574
HCC	28101574
and	28101574
adjacent	28101574
non	28101574
-	28101574
tumorous	28101574
liver	28101574
tissues	28101574
.	28101574

The	28101574
correlation	28101574
between	28101574
survival	28101574
and	28101574
NEK2	28101574
expression	28101574
was	28101574
analyzed	28101574
in	28101574
359	28101574
patients	28101574
with	28101574
HCC	28101574
using	28101574
RNASeqV2	28101574
data	28101574
available	28101574
from	28101574
The	28101574
Cancer	28101574
Genome	28101574
Atlas	28101574
(	28101574
TCGA	28101574
)	28101574
website	28101574
(	28101574
https	28101574
:	28101574
/	28101574
/	28101574
tcga	28101574
-	28101574
data	28101574
.	28101574
nci	28101574
.	28101574
nih	28101574
.	28101574
gov	28101574
/	28101574
tcga	28101574
/	28101574
)	28101574
.	28101574

The	28101574
expression	28101574
of	28101574
NEK2	28101574
,	28101574
phospho	28101574
-	28101574
AKT	28101574
and	28101574
MMP	28101574
-	28101574
2	28101574
was	28101574
evaluated	28101574
by	28101574
immunohistochemistry	28101574
in	28101574
63	28101574
cases	28101574
of	28101574
HCC	28101574
and	28101574
matched	28101574
adjacent	28101574
non	28101574
-	28101574
tumorous	28101574
liver	28101574
tissues	28101574
.	28101574

Relationships	28101574
between	28101574
protein	28101574
expression	28101574
and	28101574
clinicopathological	28101574
parameters	28101574
were	28101574
assessed	28101574
,	28101574
and	28101574
the	28101574
correlations	28101574
between	28101574
NEK2	28101574
with	28101574
phospho	28101574
-	28101574
AKT	28101574
and	28101574
MMP	28101574
-	28101574
2	28101574
expressions	28101574
were	28101574
evaluated	28101574
.	28101574

A	28101574
total	28101574
of	28101574
610	28101574
differentially	28101574
expressed	28101574
genes	28101574
(	28101574
DEGs	28101574
)	28101574
were	28101574
revealed	28101574
in	28101574
the	28101574
transcriptome	28101574
comparison	28101574
,	28101574
297	28101574
of	28101574
which	28101574
were	28101574
upregulated	28101574
and	28101574
313	28101574
were	28101574
downregulated	28101574
in	28101574
HCC	28101574
.	28101574

NEK2	28101574
,	28101574
as	28101574
the	28101574
most	28101574
obviously	28101574
different	28101574
DEG	28101574
in	28101574
cells	28101574
and	28101574
tissues	28101574
from	28101574
the	28101574
RNA	28101574
-	28101574
seq	28101574
data	28101574
,	28101574
was	28101574
listed	28101574
as	28101574
an	28101574
HCC	28101574
candidate	28101574
biomarker	28101574
for	28101574
further	28101574
verification	28101574
.	28101574

NEK2	28101574
was	28101574
overexpressed	28101574
in	28101574
HCC	28101574
cells	28101574
and	28101574
tissues	28101574
(	28101574
P	28101574
=	28101574
0	28101574
.	28101574
002	28101574
,	28101574
P	28101574
=	28101574
0	28101574
.	28101574
013	28101574
)	28101574
and	28101574
HCC	28101574
patients	28101574
with	28101574
a	28101574
high	28101574
expression	28101574
of	28101574
NEK2	28101574
had	28101574
a	28101574
poor	28101574
prognosis	28101574
(	28101574
P	28101574
=	28101574
0	28101574
.	28101574
0145	28101574
)	28101574
.	28101574

Clinical	28101574
analysis	28101574
indicated	28101574
that	28101574
the	28101574
overexpression	28101574
of	28101574
NEK2	28101574
in	28101574
HCC	28101574
was	28101574
significantly	28101574
correlated	28101574
with	28101574
diolame	28101574
complete	28101574
(	28101574
P	28101574
<	28101574
0	28101574
.	28101574
001	28101574
)	28101574
,	28101574
tumor	28101574
nodule	28101574
number	28101574
(	28101574
P	28101574
=	28101574
0	28101574
.	28101574
012	28101574
)	28101574
and	28101574
recurrence	28101574
(	28101574
P	28101574
=	28101574
0	28101574
.	28101574
004	28101574
)	28101574
.	28101574

NEK2	28101574
expression	28101574
was	28101574
positively	28101574
correlated	28101574
with	28101574
the	28101574
expression	28101574
of	28101574
phospho	28101574
-	28101574
AKT	28101574
(	28101574
r	28101574
=	28101574
0	28101574
.	28101574
883	28101574
,	28101574
P	28101574
<	28101574
0	28101574
.	28101574
01	28101574
)	28101574
and	28101574
MMP	28101574
-	28101574
2	28101574
(	28101574
r	28101574
=	28101574
0	28101574
.	28101574
781	28101574
,	28101574
P	28101574
<	28101574
0	28101574
.	28101574
01	28101574
)	28101574
.	28101574

Overexpression	28101574
of	28101574
NEK2	28101574
was	28101574
associated	28101574
with	28101574
clinicopathological	28101574
characteristics	28101574
and	28101574
poor	28101574
patient	28101574
outcomes	28101574
,	28101574
suggesting	28101574
that	28101574
NEK2	28101574
serves	28101574
as	28101574
a	28101574
prognostic	28101574
biomarker	28101574
for	28101574
HCC	28101574
.	28101574

Alteration	28101574
of	28101574
NEK2	28101574
protein	28101574
levels	28101574
may	28101574
contribute	28101574
to	28101574
invasion	28101574
and	28101574
metastasis	28101574
of	28101574
HCC	28101574
,	28101574
which	28101574
may	28101574
occur	28101574
through	28101574
activation	28101574
of	28101574
AKT	28101574
signaling	28101574
and	28101574
promotion	28101574
of	28101574
MMP	28101574
-	28101574
2	28101574
expression	28101574
.	28101574
The	15814629
number	15814629
of	15814629
lymph	15814629
node	15814629
metastases	15814629
in	15814629
gastric	15814629
cancer	15814629
correlates	15814629
with	15814629
the	15814629
angiotensin	15814629
I	15814629
-	15814629
converting	15814629
enzyme	15814629
gene	15814629
insertion	15814629
/	15814629
deletion	15814629
polymorphism	15814629
.	15814629

PURPOSE	15814629
:	15814629
In	15814629
the	15814629
present	15814629
study	15814629
,	15814629
we	15814629
aimed	15814629
to	15814629
substantiate	15814629
the	15814629
putative	15814629
significance	15814629
of	15814629
angiotensin	15814629
I	15814629
-	15814629
converting	15814629
enzyme	15814629
(	15814629
ACE	15814629
)	15814629
on	15814629
gastric	15814629
cancer	15814629
biology	15814629
by	15814629
investigating	15814629
the	15814629
influence	15814629
of	15814629
its	15814629
gene	15814629
polymorphism	15814629
on	15814629
gastric	15814629
cancer	15814629
progression	15814629
.	15814629

EXPERIMENTAL	15814629
DESIGN	15814629
:	15814629
Genomic	15814629
DNA	15814629
was	15814629
purified	15814629
from	15814629
peripheral	15814629
blood	15814629
mononuclear	15814629
cells	15814629
or	15814629
tissue	15814629
specimens	15814629
.	15814629

Amplified	15814629
ACE	15814629
gene	15814629
fragments	15814629
were	15814629
separated	15814629
on	15814629
agarose	15814629
gels	15814629
.	15814629

D	15814629
or	15814629
I	15814629
alleles	15814629
were	15814629
identified	15814629
by	15814629
the	15814629
presence	15814629
of	15814629
190	15814629
-	15814629
or	15814629
490	15814629
-	15814629
bp	15814629
fragments	15814629
,	15814629
respectively	15814629
.	15814629

Local	15814629
expression	15814629
of	15814629
ACE	15814629
was	15814629
investigated	15814629
by	15814629
immunohistochemistry	15814629
.	15814629

RESULTS	15814629
:	15814629
Twenty	15814629
-	15814629
four	15814629
of	15814629
113	15814629
(	15814629
21%	15814629
)	15814629
gastric	15814629
cancer	15814629
patients	15814629
had	15814629
the	15814629
II	15814629
,	15814629
57	15814629
(	15814629
51%	15814629
)	15814629
the	15814629
ID	15814629
,	15814629
and	15814629
32	15814629
(	15814629
28%	15814629
)	15814629
the	15814629
DD	15814629
genotype	15814629
.	15814629

The	15814629
distribution	15814629
of	15814629
the	15814629
ACE	15814629
genotypes	15814629
did	15814629
not	15814629
differ	15814629
significantly	15814629
from	15814629
the	15814629
control	15814629
group	15814629
of	15814629
189	15814629
patients	15814629
without	15814629
gastric	15814629
cancer	15814629
.	15814629

However	15814629
,	15814629
the	15814629
ACE	15814629
genotypes	15814629
correlated	15814629
with	15814629
the	15814629
number	15814629
of	15814629
lymph	15814629
node	15814629
metastases	15814629
and	15814629
the	15814629
Unio	15814629
Internationale	15814629
Contra	15814629
Cancrum	15814629
(	15814629
UICC	15814629
)	15814629
tumor	15814629
stage	15814629
.	15814629

Patients	15814629
with	15814629
the	15814629
II	15814629
genotype	15814629
had	15814629
a	15814629
highly	15814629
significantly	15814629
smaller	15814629
number	15814629
of	15814629
lymph	15814629
node	15814629
metastases	15814629
(	15814629
P	15814629
<	15814629
0	15814629
.	15814629
001	15814629
)	15814629
and	15814629
a	15814629
significantly	15814629
lower	15814629
UICC	15814629
tumor	15814629
stage	15814629
(	15814629
P	15814629
=	15814629
0	15814629
.	15814629
01	15814629
)	15814629
than	15814629
patients	15814629
with	15814629
the	15814629
DD	15814629
genotype	15814629
.	15814629

No	15814629
correlation	15814629
was	15814629
found	15814629
between	15814629
tumor	15814629
type	15814629
,	15814629
tumor	15814629
location	15814629
,	15814629
local	15814629
tumor	15814629
growth	15814629
,	15814629
distant	15814629
metastases	15814629
,	15814629
and	15814629
the	15814629
ACE	15814629
genotype	15814629
.	15814629

The	15814629
expression	15814629
of	15814629
ACE	15814629
in	15814629
gastric	15814629
cancer	15814629
was	15814629
investigated	15814629
by	15814629
immunohistochemistry	15814629
in	15814629
100	15814629
of	15814629
113	15814629
patients	15814629
.	15814629

ACE	15814629
was	15814629
expressed	15814629
by	15814629
endothelial	15814629
cells	15814629
in	15814629
all	15814629
(	15814629
100%	15814629
)	15814629
specimens	15814629
and	15814629
by	15814629
tumor	15814629
cells	15814629
in	15814629
56	15814629
(	15814629
56%	15814629
)	15814629
specimens	15814629
.	15814629

CONCLUSIONS	15814629
:	15814629
Our	15814629
study	15814629
shows	15814629
that	15814629
ACE	15814629
is	15814629
expressed	15814629
locally	15814629
in	15814629
gastric	15814629
cancer	15814629
and	15814629
that	15814629
the	15814629
gene	15814629
polymorphism	15814629
influences	15814629
metastatic	15814629
behavior	15814629
.	15814629
POLG	15122711
mutations	15122711
associated	15122711
with	15122711
Alpers	15122711
'	15122711
syndrome	15122711
and	15122711
mitochondrial	15122711
DNA	15122711
depletion	15122711
.	15122711

Alpers	15122711
'	15122711
syndrome	15122711
is	15122711
a	15122711
fatal	15122711
neurogenetic	15122711
disorder	15122711
first	15122711
described	15122711
more	15122711
than	15122711
70	15122711
years	15122711
ago	15122711
.	15122711

It	15122711
is	15122711
an	15122711
autosomal	15122711
recessive	15122711
,	15122711
developmental	15122711
mitochondrial	15122711
DNA	15122711
depletion	15122711
disorder	15122711
characterized	15122711
by	15122711
deficiency	15122711
in	15122711
mitochondrial	15122711
DNA	15122711
polymerase	15122711
gamma	15122711
(	15122711
POLG	15122711
)	15122711
catalytic	15122711
activity	15122711
,	15122711
refractory	15122711
seizures	15122711
,	15122711
neurodegeneration	15122711
,	15122711
and	15122711
liver	15122711
disease	15122711
.	15122711

In	15122711
two	15122711
unrelated	15122711
pedigrees	15122711
of	15122711
Alpers	15122711
'	15122711
syndrome	15122711
,	15122711
each	15122711
affected	15122711
child	15122711
was	15122711
found	15122711
to	15122711
carry	15122711
a	15122711
homozygous	15122711
mutation	15122711
in	15122711
exon	15122711
17	15122711
of	15122711
the	15122711
POLG	15122711
locus	15122711
that	15122711
led	15122711
to	15122711
a	15122711
Glu873Stop	15122711
mutation	15122711
just	15122711
upstream	15122711
of	15122711
the	15122711
polymerase	15122711
domain	15122711
of	15122711
the	15122711
protein	15122711
.	15122711

In	15122711
addition	15122711
,	15122711
each	15122711
affected	15122711
child	15122711
was	15122711
heterozygous	15122711
for	15122711
the	15122711
G1681A	15122711
mutation	15122711
in	15122711
exon	15122711
7	15122711
that	15122711
led	15122711
to	15122711
an	15122711
Ala467Thr	15122711
substitution	15122711
in	15122711
POLG	15122711
,	15122711
within	15122711
the	15122711
linker	15122711
region	15122711
of	15122711
the	15122711
protein	15122711
.	15122711
Zebrafish	20226780
chordin	20226780
-	20226780
like	20226780
and	20226780
chordin	20226780
are	20226780
functionally	20226780
redundant	20226780
in	20226780
regulating	20226780
patterning	20226780
of	20226780
the	20226780
dorsoventral	20226780
axis	20226780
.	20226780

Chordin	20226780
is	20226780
the	20226780
prototype	20226780
of	20226780
a	20226780
group	20226780
of	20226780
cysteine	20226780
-	20226780
rich	20226780
domain	20226780
-	20226780
containing	20226780
proteins	20226780
that	20226780
bind	20226780
and	20226780
modulate	20226780
signaling	20226780
of	20226780
various	20226780
TGFbeta	20226780
-	20226780
like	20226780
ligands	20226780
.	20226780

Chordin	20226780
-	20226780
like	20226780
1	20226780
and	20226780
2	20226780
(	20226780
CHL1	20226780
and	20226780
2	20226780
)	20226780
are	20226780
two	20226780
members	20226780
of	20226780
this	20226780
group	20226780
that	20226780
have	20226780
been	20226780
described	20226780
in	20226780
human	20226780
,	20226780
mouse	20226780
,	20226780
and	20226780
chick	20226780
.	20226780

However	20226780
,	20226780
in	20226780
vivo	20226780
roles	20226780
for	20226780
CHL1	20226780
and	20226780
2	20226780
in	20226780
early	20226780
development	20226780
are	20226780
unknown	20226780
due	20226780
to	20226780
lack	20226780
of	20226780
loss	20226780
-	20226780
of	20226780
-	20226780
function	20226780
analysis	20226780
.	20226780

Here	20226780
we	20226780
identify	20226780
and	20226780
characterize	20226780
zebrafish	20226780
,	20226780
Danio	20226780
rerio	20226780
,	20226780
CHL	20226780
(	20226780
Chl	20226780
)	20226780
.	20226780

The	20226780
chl	20226780
gene	20226780
is	20226780
on	20226780
a	20226780
region	20226780
of	20226780
chromosome	20226780
21	20226780
syntenic	20226780
with	20226780
the	20226780
area	20226780
of	20226780
murine	20226780
chromosome	20226780
7	20226780
bearing	20226780
the	20226780
CHL2	20226780
gene	20226780
.	20226780

Inability	20226780
to	20226780
identify	20226780
a	20226780
separate	20226780
zebrafish	20226780
gene	20226780
corresponding	20226780
to	20226780
the	20226780
mammalian	20226780
CHL1	20226780
gene	20226780
suggests	20226780
that	20226780
Chl	20226780
may	20226780
serve	20226780
roles	20226780
in	20226780
zebrafish	20226780
distributed	20226780
between	20226780
CHL1	20226780
and	20226780
CHL2	20226780
in	20226780
other	20226780
species	20226780
.	20226780

Chl	20226780
is	20226780
a	20226780
maternal	20226780
factor	20226780
that	20226780
is	20226780
also	20226780
zygotically	20226780
expressed	20226780
later	20226780
in	20226780
development	20226780
and	20226780
has	20226780
spatiotemporal	20226780
expression	20226780
patterns	20226780
that	20226780
differ	20226780
from	20226780
but	20226780
overlap	20226780
those	20226780
of	20226780
zebrafish	20226780
chordin	20226780
(	20226780
Chd	20226780
)	20226780
,	20226780
suggesting	20226780
differences	20226780
but	20226780
also	20226780
possible	20226780
overlap	20226780
in	20226780
developmental	20226780
roles	20226780
of	20226780
the	20226780
two	20226780
proteins	20226780
.	20226780

Chl	20226780
,	20226780
like	20226780
Chd	20226780
,	20226780
dorsalizes	20226780
embryos	20226780
upon	20226780
overexpression	20226780
and	20226780
is	20226780
cleaved	20226780
by	20226780
BMP1	20226780
,	20226780
which	20226780
antagonizes	20226780
this	20226780
activity	20226780
.	20226780

Loss	20226780
-	20226780
of	20226780
-	20226780
function	20226780
experiments	20226780
demonstrate	20226780
that	20226780
Chl	20226780
serves	20226780
as	20226780
a	20226780
BMP	20226780
antagonist	20226780
with	20226780
functions	20226780
that	20226780
overlap	20226780
and	20226780
are	20226780
redundant	20226780
with	20226780
those	20226780
of	20226780
Chd	20226780
in	20226780
forming	20226780
the	20226780
dorsoventral	20226780
axis	20226780
.	20226780
Polymorphic	15599941
forms	15599941
of	15599941
prostate	15599941
specific	15599941
antigen	15599941
and	15599941
their	15599941
interaction	15599941
with	15599941
androgen	15599941
receptor	15599941
trinucleotide	15599941
repeats	15599941
in	15599941
prostate	15599941
cancer	15599941
.	15599941

BACKGROUND	15599941
:	15599941
Recent	15599941
data	15599941
has	15599941
suggested	15599941
that	15599941
polymorphisms	15599941
in	15599941
the	15599941
prostate	15599941
specific	15599941
antigen	15599941
(	15599941
PSA	15599941
)	15599941
may	15599941
increase	15599941
prostate	15599941
cancer	15599941
(	15599941
PC	15599941
)	15599941
risk	15599941
.	15599941

The	15599941
PSA	15599941
gene	15599941
contains	15599941
a	15599941
G	15599941
/	15599941
A	15599941
substitution	15599941
in	15599941
the	15599941
androgen	15599941
response	15599941
element	15599941
(	15599941
ARE	15599941
)	15599941
1	15599941
region	15599941
.	15599941

The	15599941
androgen	15599941
receptor	15599941
(	15599941
AR	15599941
)	15599941
gene	15599941
has	15599941
polymorphic	15599941
regions	15599941
containing	15599941
variable	15599941
length	15599941
glutamine	15599941
and	15599941
glycine	15599941
repeats	15599941
and	15599941
these	15599941
are	15599941
believed	15599941
to	15599941
be	15599941
associated	15599941
with	15599941
PC	15599941
risk	15599941
.	15599941

The	15599941
effect	15599941
on	15599941
PC	15599941
risks	15599941
from	15599941
PSA	15599941
polymorphisms	15599941
alone	15599941
and	15599941
synergistically	15599941
with	15599941
the	15599941
AR	15599941
gene	15599941
was	15599941
examined	15599941
in	15599941
this	15599941
report	15599941
.	15599941

METHODS	15599941
:	15599941
One	15599941
hundred	15599941
PC	15599941
patients	15599941
and	15599941
an	15599941
age	15599941
matched	15599941
cohort	15599941
of	15599941
79	15599941
benign	15599941
prostate	15599941
hyperplasia	15599941
and	15599941
67	15599941
population	15599941
controls	15599941
were	15599941
entered	15599941
in	15599941
this	15599941
study	15599941
.	15599941

DNA	15599941
was	15599941
extracted	15599941
from	15599941
blood	15599941
and	15599941
PSA	15599941
/	15599941
ARE	15599941
promoter	15599941
region	15599941
amplified	15599941
by	15599941
PCR	15599941
.	15599941

PCR	15599941
products	15599941
were	15599941
cut	15599941
with	15599941
Nhe	15599941
1	15599941
restriction	15599941
enzyme	15599941
to	15599941
distinguish	15599941
G	15599941
/	15599941
A	15599941
alleles	15599941
.	15599941

AR	15599941
/	15599941
CAG	15599941
and	15599941
GGC	15599941
repeat	15599941
length	15599941
was	15599941
detected	15599941
by	15599941
automated	15599941
fluorescence	15599941
from	15599941
PCR	15599941
products	15599941
.	15599941

RESULTS	15599941
:	15599941
We	15599941
found	15599941
a	15599941
significantly	15599941
higher	15599941
PSA	15599941
/	15599941
GG	15599941
distribution	15599941
in	15599941
PC	15599941
(	15599941
30%	15599941
)	15599941
than	15599941
either	15599941
benign	15599941
prostatic	15599941
hyperplasia	15599941
(	15599941
BPH	15599941
)	15599941
(	15599941
18%	15599941
)	15599941
or	15599941
population	15599941
controls	15599941
(	15599941
16%	15599941
)	15599941
(	15599941
P	15599941
=	15599941
0	15599941
.	15599941
025	15599941
)	15599941
.	15599941

Furthermore	15599941
the	15599941
GG	15599941
distribution	15599941
within	15599941
cases	15599941
was	15599941
even	15599941
greater	15599941
in	15599941
younger	15599941
men	15599941
(	15599941
<	15599941
65	15599941
years	15599941
;	15599941
42%	15599941
;	15599941
P	15599941
=	15599941
0	15599941
.	15599941
012	15599941
)	15599941
.	15599941

Additionally	15599941
,	15599941
when	15599941
PSA	15599941
genotype	15599941
was	15599941
cross	15599941
classified	15599941
with	15599941
CAG	15599941
repeat	15599941
,	15599941
significantly	15599941
more	15599941
cases	15599941
than	15599941
both	15599941
BPH	15599941
and	15599941
population	15599941
controls	15599941
were	15599941
observed	15599941
to	15599941
have	15599941
a	15599941
short	15599941
(	15599941
<	15599941
22	15599941
)	15599941
CAG	15599941
/	15599941
GG	15599941
genotype	15599941
(	15599941
P	15599941
=	15599941
0	15599941
.	15599941
006	15599941
)	15599941
.	15599941

CONCLUSIONS	15599941
:	15599941
Our	15599941
results	15599941
indicate	15599941
that	15599941
the	15599941
PSA	15599941
/	15599941
ARE	15599941
GG	15599941
genotype	15599941
confers	15599941
an	15599941
increased	15599941
risk	15599941
of	15599941
PC	15599941
especially	15599941
among	15599941
younger	15599941
men	15599941
.	15599941

Moreover	15599941
,	15599941
we	15599941
confirm	15599941
previous	15599941
results	15599941
that	15599941
a	15599941
short	15599941
glutamine	15599941
repeat	15599941
in	15599941
conjunction	15599941
with	15599941
GG	15599941
genotype	15599941
significantly	15599941
increases	15599941
the	15599941
risk	15599941
of	15599941
malignant	15599941
disease	15599941
.	15599941
A	24014394
homozygous	24014394
mutation	24014394
in	24014394
LYRM7	24014394
/	24014394
MZM1L	24014394
associated	24014394
with	24014394
early	24014394
onset	24014394
encephalopathy	24014394
,	24014394
lactic	24014394
acidosis	24014394
,	24014394
and	24014394
severe	24014394
reduction	24014394
of	24014394
mitochondrial	24014394
complex	24014394
III	24014394
activity	24014394
.	24014394

Mutations	24014394
in	24014394
nuclear	24014394
genes	24014394
associated	24014394
with	24014394
defective	24014394
complex	24014394
III	24014394
(	24014394
cIII	24014394
)	24014394
of	24014394
the	24014394
mitochondrial	24014394
respiratory	24014394
chain	24014394
are	24014394
rare	24014394
,	24014394
having	24014394
been	24014394
found	24014394
in	24014394
only	24014394
two	24014394
cIII	24014394
assembly	24014394
factors	24014394
and	24014394
,	24014394
as	24014394
private	24014394
changes	24014394
in	24014394
single	24014394
families	24014394
,	24014394
three	24014394
cIII	24014394
structural	24014394
subunits	24014394
.	24014394

Recently	24014394
,	24014394
human	24014394
LYRM7	24014394
/	24014394
MZM1L	24014394
,	24014394
the	24014394
ortholog	24014394
of	24014394
yeast	24014394
MZM1	24014394
,	24014394
has	24014394
been	24014394
identified	24014394
as	24014394
a	24014394
new	24014394
assembly	24014394
factor	24014394
for	24014394
cIII	24014394
.	24014394

In	24014394
a	24014394
baby	24014394
patient	24014394
with	24014394
early	24014394
onset	24014394
,	24014394
severe	24014394
encephalopathy	24014394
,	24014394
lactic	24014394
acidosis	24014394
and	24014394
profound	24014394
,	24014394
isolated	24014394
cIII	24014394
deficiency	24014394
in	24014394
skeletal	24014394
muscle	24014394
,	24014394
we	24014394
identified	24014394
a	24014394
disease	24014394
-	24014394
segregating	24014394
homozygous	24014394
mutation	24014394
(	24014394
c	24014394
.	24014394
73G	24014394
>	24014394
A	24014394
)	24014394
in	24014394
LYRM7	24014394
/	24014394
MZM1L	24014394
,	24014394
predicting	24014394
a	24014394
drastic	24014394
change	24014394
in	24014394
a	24014394
highly	24014394
conserved	24014394
amino	24014394
-	24014394
acid	24014394
residue	24014394
(	24014394
p	24014394
.	24014394
Asp25Asn	24014394
)	24014394
.	24014394

In	24014394
a	24014394
mzm1D	24014394
yeast	24014394
strain	24014394
,	24014394
the	24014394
expression	24014394
of	24014394
a	24014394
mzm1	24014394
(	24014394
D25N	24014394
)	24014394
mutant	24014394
allele	24014394
caused	24014394
temperature	24014394
-	24014394
sensitive	24014394
respiratory	24014394
growth	24014394
defect	24014394
,	24014394
decreased	24014394
oxygen	24014394
consumption	24014394
,	24014394
impaired	24014394
maturation	24014394
/	24014394
stabilization	24014394
of	24014394
the	24014394
Rieske	24014394
Fe	24014394
-	24014394
S	24014394
protein	24014394
,	24014394
and	24014394
reduced	24014394
complex	24014394
III	24014394
activity	24014394
and	24014394
amount	24014394
.	24014394

LYRM7	24014394
/	24014394
MZM1L	24014394
is	24014394
a	24014394
novel	24014394
disease	24014394
gene	24014394
,	24014394
causing	24014394
cIII	24014394
-	24014394
defective	24014394
,	24014394
early	24014394
onset	24014394
,	24014394
severe	24014394
mitochondrial	24014394
encephalopathy	24014394
.	24014394
cDNA	9647766
sequence	9647766
and	9647766
chromosomal	9647766
localization	9647766
of	9647766
the	9647766
remaining	9647766
three	9647766
human	9647766
nuclear	9647766
encoded	9647766
iron	9647766
sulphur	9647766
protein	9647766
(	9647766
IP	9647766
)	9647766
subunits	9647766
of	9647766
complex	9647766
I	9647766
:	9647766
the	9647766
human	9647766
IP	9647766
fraction	9647766
is	9647766
completed	9647766
.	9647766

NADH	9647766
:	9647766
ubiquinone	9647766
oxidoreductase	9647766
(	9647766
complex	9647766
I	9647766
)	9647766
of	9647766
the	9647766
mitochondrial	9647766
respiratory	9647766
chain	9647766
can	9647766
be	9647766
fragmented	9647766
in	9647766
a	9647766
flavoprotein	9647766
(	9647766
FP	9647766
)	9647766
,	9647766
iron	9647766
-	9647766
sulfur	9647766
protein	9647766
(	9647766
IP	9647766
)	9647766
,	9647766
and	9647766
hydrophobic	9647766
protein	9647766
(	9647766
HP	9647766
)	9647766
subfraction	9647766
.	9647766

The	9647766
IP	9647766
subfraction	9647766
is	9647766
hypothesized	9647766
to	9647766
be	9647766
significant	9647766
,	9647766
since	9647766
it	9647766
contains	9647766
important	9647766
prosthetic	9647766
groups	9647766
highly	9647766
conserved	9647766
among	9647766
species	9647766
.	9647766

We	9647766
cloned	9647766
the	9647766
cDNA	9647766
of	9647766
three	9647766
remaining	9647766
human	9647766
NADH	9647766
:	9647766
ubiquinone	9647766
oxidoreductase	9647766
subunits	9647766
of	9647766
this	9647766
IP	9647766
fraction	9647766
:	9647766
the	9647766
NDUFS2	9647766
(	9647766
49	9647766
kDa	9647766
)	9647766
,	9647766
NDUFS3	9647766
(	9647766
30	9647766
kDa	9647766
)	9647766
,	9647766
and	9647766
NDUFS6	9647766
(	9647766
13	9647766
kDa	9647766
)	9647766
subunits	9647766
.	9647766

All	9647766
presented	9647766
cDNAs	9647766
include	9647766
the	9647766
complete	9647766
open	9647766
reading	9647766
frame	9647766
(	9647766
ORF	9647766
)	9647766
,	9647766
which	9647766
consist	9647766
of	9647766
1392	9647766
,	9647766
795	9647766
,	9647766
and	9647766
375	9647766
base	9647766
pairs	9647766
,	9647766
coding	9647766
for	9647766
463	9647766
,	9647766
264	9647766
,	9647766
and	9647766
124	9647766
amino	9647766
acids	9647766
,	9647766
respectively	9647766
.	9647766

The	9647766
latter	9647766
show	9647766
96	9647766
,	9647766
90	9647766
,	9647766
and	9647766
83%	9647766
homology	9647766
with	9647766
the	9647766
corresponding	9647766
bovine	9647766
translation	9647766
products	9647766
.	9647766

The	9647766
3	9647766
'	9647766
untranslated	9647766
regions	9647766
(	9647766
UTR	9647766
)	9647766
are	9647766
complete	9647766
in	9647766
all	9647766
three	9647766
cDNAs	9647766
.	9647766

Polymerase	9647766
chain	9647766
reaction	9647766
performed	9647766
with	9647766
DNA	9647766
isolated	9647766
from	9647766
somatic	9647766
human	9647766
-	9647766
rodent	9647766
cell	9647766
hybrids	9647766
containing	9647766
defined	9647766
human	9647766
chromosomes	9647766
as	9647766
template	9647766
gave	9647766
a	9647766
human	9647766
-	9647766
specific	9647766
signal	9647766
which	9647766
mapped	9647766
the	9647766
NDUFS2	9647766
and	9647766
NDUFS3	9647766
subunits	9647766
to	9647766
chromosomes	9647766
1	9647766
and	9647766
11	9647766
,	9647766
respectively	9647766
.	9647766

In	9647766
the	9647766
case	9647766
of	9647766
the	9647766
NDUFS6	9647766
subunit	9647766
a	9647766
pseudogene	9647766
may	9647766
be	9647766
present	9647766
since	9647766
signals	9647766
were	9647766
seen	9647766
in	9647766
the	9647766
lanes	9647766
containing	9647766
chromosomes	9647766
5	9647766
and	9647766
6	9647766
.	9647766

The	9647766
NDUFS2	9647766
contains	9647766
a	9647766
highly	9647766
conserved	9647766
protein	9647766
kinase	9647766
C	9647766
phosphorylation	9647766
site	9647766
and	9647766
the	9647766
NDUFS3	9647766
subunit	9647766
contains	9647766
a	9647766
highly	9647766
conserved	9647766
casein	9647766
kinase	9647766
II	9647766
phosphorylation	9647766
site	9647766
which	9647766
make	9647766
them	9647766
strong	9647766
candidates	9647766
for	9647766
future	9647766
mutation	9647766
detection	9647766
studies	9647766
in	9647766
enzymatic	9647766
complex	9647766
I	9647766
-	9647766
deficient	9647766
patients	9647766
.	9647766
The	18366737
FH	18366737
mutation	18366737
database	18366737
:	18366737
an	18366737
online	18366737
database	18366737
of	18366737
fumarate	18366737
hydratase	18366737
mutations	18366737
involved	18366737
in	18366737
the	18366737
MCUL	18366737
(	18366737
HLRCC	18366737
)	18366737
tumor	18366737
syndrome	18366737
and	18366737
congenital	18366737
fumarase	18366737
deficiency	18366737
.	18366737

BACKGROUND	18366737
:	18366737
Fumarate	18366737
hydratase	18366737
(	18366737
HGNC	18366737
approved	18366737
gene	18366737
symbol	18366737
-	18366737
FH	18366737
)	18366737
,	18366737
also	18366737
known	18366737
as	18366737
fumarase	18366737
,	18366737
is	18366737
an	18366737
enzyme	18366737
of	18366737
the	18366737
tricarboxylic	18366737
acid	18366737
(	18366737
TCA	18366737
)	18366737
cycle	18366737
,	18366737
involved	18366737
in	18366737
fundamental	18366737
cellular	18366737
energy	18366737
production	18366737
.	18366737

First	18366737
described	18366737
by	18366737
Zinn	18366737
et	18366737
al	18366737
in	18366737
1986	18366737
,	18366737
deficiency	18366737
of	18366737
FH	18366737
results	18366737
in	18366737
early	18366737
onset	18366737
,	18366737
severe	18366737
encephalopathy	18366737
.	18366737

In	18366737
2002	18366737
,	18366737
the	18366737
Multiple	18366737
Leiomyoma	18366737
Consortium	18366737
identified	18366737
heterozygous	18366737
germline	18366737
mutations	18366737
of	18366737
FH	18366737
in	18366737
patients	18366737
with	18366737
multiple	18366737
cutaneous	18366737
and	18366737
uterine	18366737
leiomyomas	18366737
,	18366737
(	18366737
MCUL	18366737
:	18366737
OMIM	18366737
150800	18366737
)	18366737
.	18366737

In	18366737
some	18366737
families	18366737
renal	18366737
cell	18366737
cancer	18366737
also	18366737
forms	18366737
a	18366737
component	18366737
of	18366737
the	18366737
complex	18366737
and	18366737
as	18366737
such	18366737
has	18366737
been	18366737
described	18366737
as	18366737
hereditary	18366737
leiomyomatosis	18366737
and	18366737
renal	18366737
cell	18366737
cancer	18366737
(	18366737
HLRCC	18366737
:	18366737
OMIM	18366737
605839	18366737
)	18366737
.	18366737

The	18366737
identification	18366737
of	18366737
FH	18366737
as	18366737
a	18366737
tumor	18366737
suppressor	18366737
was	18366737
an	18366737
unexpected	18366737
finding	18366737
and	18366737
following	18366737
the	18366737
identification	18366737
of	18366737
subunits	18366737
of	18366737
succinate	18366737
dehydrogenase	18366737
in	18366737
2000	18366737
and	18366737
2001	18366737
,	18366737
was	18366737
only	18366737
the	18366737
second	18366737
description	18366737
of	18366737
the	18366737
involvement	18366737
of	18366737
an	18366737
enzyme	18366737
of	18366737
intermediary	18366737
metabolism	18366737
in	18366737
tumorigenesis	18366737
.	18366737

DESCRIPTION	18366737
:	18366737
The	18366737
FH	18366737
mutation	18366737
database	18366737
is	18366737
a	18366737
part	18366737
of	18366737
the	18366737
TCA	18366737
cycle	18366737
gene	18366737
mutation	18366737
database	18366737
(	18366737
formerly	18366737
the	18366737
succinate	18366737
dehydrogenase	18366737
gene	18366737
mutation	18366737
database	18366737
)	18366737
and	18366737
is	18366737
based	18366737
on	18366737
the	18366737
Leiden	18366737
Open	18366737
(	18366737
source	18366737
)	18366737
Variation	18366737
Database	18366737
(	18366737
LOVD	18366737
)	18366737
system	18366737
.	18366737

The	18366737
variants	18366737
included	18366737
in	18366737
the	18366737
database	18366737
were	18366737
derived	18366737
from	18366737
the	18366737
published	18366737
literature	18366737
and	18366737
annotated	18366737
to	18366737
conform	18366737
to	18366737
current	18366737
mutation	18366737
nomenclature	18366737
.	18366737

The	18366737
FH	18366737
database	18366737
applies	18366737
HGVS	18366737
nomenclature	18366737
guidelines	18366737
,	18366737
and	18366737
will	18366737
assist	18366737
researchers	18366737
in	18366737
applying	18366737
these	18366737
guidelines	18366737
when	18366737
directly	18366737
submitting	18366737
new	18366737
sequence	18366737
variants	18366737
online	18366737
.	18366737

Since	18366737
the	18366737
first	18366737
molecular	18366737
characterization	18366737
of	18366737
an	18366737
FH	18366737
mutation	18366737
by	18366737
Bourgeron	18366737
et	18366737
al	18366737
in	18366737
1994	18366737
,	18366737
a	18366737
series	18366737
of	18366737
reports	18366737
of	18366737
both	18366737
FH	18366737
deficiency	18366737
patients	18366737
and	18366737
patients	18366737
with	18366737
MCUL	18366737
/	18366737
HLRRC	18366737
have	18366737
described	18366737
107	18366737
variants	18366737
,	18366737
of	18366737
which	18366737
93	18366737
are	18366737
thought	18366737
to	18366737
be	18366737
pathogenic	18366737
.	18366737

The	18366737
most	18366737
common	18366737
type	18366737
of	18366737
mutation	18366737
is	18366737
missense	18366737
(	18366737
57%	18366737
)	18366737
,	18366737
followed	18366737
by	18366737
frameshifts	18366737
&	18366737
nonsense	18366737
(	18366737
27%	18366737
)	18366737
,	18366737
and	18366737
diverse	18366737
deletions	18366737
,	18366737
insertions	18366737
and	18366737
duplications	18366737
.	18366737

Here	18366737
we	18366737
introduce	18366737
an	18366737
online	18366737
database	18366737
detailing	18366737
all	18366737
reported	18366737
FH	18366737
sequence	18366737
variants	18366737
.	18366737

CONCLUSION	18366737
:	18366737
The	18366737
FH	18366737
mutation	18366737
database	18366737
strives	18366737
to	18366737
systematically	18366737
unify	18366737
all	18366737
current	18366737
genetic	18366737
knowledge	18366737
of	18366737
FH	18366737
variants	18366737
.	18366737

We	18366737
believe	18366737
that	18366737
this	18366737
knowledge	18366737
will	18366737
assist	18366737
clinical	18366737
geneticists	18366737
and	18366737
treating	18366737
physicians	18366737
when	18366737
advising	18366737
patients	18366737
and	18366737
their	18366737
families	18366737
,	18366737
will	18366737
provide	18366737
a	18366737
rapid	18366737
and	18366737
convenient	18366737
resource	18366737
for	18366737
research	18366737
scientists	18366737
,	18366737
and	18366737
may	18366737
eventually	18366737
assist	18366737
in	18366737
gaining	18366737
novel	18366737
insights	18366737
into	18366737
FH	18366737
and	18366737
its	18366737
related	18366737
clinical	18366737
syndromes	18366737
.	18366737
Mechanisms	26115410
Underlying	26115410
Latent	26115410
Disease	26115410
Risk	26115410
Associated	26115410
with	26115410
Early	26115410
-	26115410
Life	26115410
Arsenic	26115410
Exposure	26115410
:	26115410
Current	26115410
Research	26115410
Trends	26115410
and	26115410
Scientific	26115410
Gaps	26115410
.	26115410

BACKGROUND	26115410
:	26115410
Millions	26115410
of	26115410
individuals	26115410
worldwide	26115410
,	26115410
particularly	26115410
those	26115410
living	26115410
in	26115410
rural	26115410
and	26115410
developing	26115410
areas	26115410
,	26115410
are	26115410
exposed	26115410
to	26115410
harmful	26115410
levels	26115410
of	26115410
inorganic	26115410
arsenic	26115410
(	26115410
iAs	26115410
)	26115410
in	26115410
their	26115410
drinking	26115410
water	26115410
.	26115410

Inorganic	26115410
As	26115410
exposure	26115410
during	26115410
key	26115410
developmental	26115410
periods	26115410
is	26115410
associated	26115410
with	26115410
a	26115410
variety	26115410
of	26115410
adverse	26115410
health	26115410
effects	26115410
including	26115410
those	26115410
that	26115410
are	26115410
evident	26115410
in	26115410
adulthood	26115410
.	26115410

There	26115410
is	26115410
considerable	26115410
interest	26115410
in	26115410
identifying	26115410
the	26115410
molecular	26115410
mechanisms	26115410
that	26115410
relate	26115410
early	26115410
-	26115410
life	26115410
iAs	26115410
exposure	26115410
to	26115410
the	26115410
development	26115410
of	26115410
these	26115410
latent	26115410
diseases	26115410
,	26115410
particularly	26115410
in	26115410
relationship	26115410
to	26115410
cancer	26115410
.	26115410

OBJECTIVES	26115410
:	26115410
This	26115410
work	26115410
summarizes	26115410
research	26115410
on	26115410
the	26115410
molecular	26115410
mechanisms	26115410
that	26115410
underlie	26115410
the	26115410
increased	26115410
risk	26115410
of	26115410
cancer	26115410
development	26115410
in	26115410
adulthood	26115410
that	26115410
is	26115410
associated	26115410
with	26115410
early	26115410
-	26115410
life	26115410
iAs	26115410
exposure	26115410
.	26115410

DISCUSSION	26115410
:	26115410
Epigenetic	26115410
reprogramming	26115410
that	26115410
imparts	26115410
functional	26115410
changes	26115410
in	26115410
gene	26115410
expression	26115410
,	26115410
the	26115410
development	26115410
of	26115410
cancer	26115410
stem	26115410
cells	26115410
,	26115410
and	26115410
immunomodulation	26115410
are	26115410
plausible	26115410
underlying	26115410
mechanisms	26115410
by	26115410
which	26115410
early	26115410
-	26115410
life	26115410
iAs	26115410
exposure	26115410
elicits	26115410
latent	26115410
carcinogenic	26115410
effects	26115410
.	26115410

CONCLUSIONS	26115410
:	26115410
Evidence	26115410
is	26115410
mounting	26115410
that	26115410
relates	26115410
early	26115410
-	26115410
life	26115410
iAs	26115410
exposure	26115410
and	26115410
cancer	26115410
development	26115410
later	26115410
in	26115410
life	26115410
.	26115410

Future	26115410
research	26115410
should	26115410
include	26115410
animal	26115410
studies	26115410
that	26115410
address	26115410
mechanistic	26115410
hypotheses	26115410
and	26115410
studies	26115410
of	26115410
human	26115410
populations	26115410
that	26115410
integrate	26115410
early	26115410
-	26115410
life	26115410
exposure	26115410
,	26115410
molecular	26115410
alterations	26115410
,	26115410
and	26115410
latent	26115410
disease	26115410
outcomes	26115410
.	26115410
Two	16018252
novel	16018252
mutations	16018252
in	16018252
SRY	16018252
gene	16018252
form	16018252
Chinese	16018252
sex	16018252
reversal	16018252
XY	16018252
females	16018252
.	16018252

The	16018252
SRY	16018252
gene	16018252
(	16018252
sex	16018252
determining	16018252
region	16018252
on	16018252
Y	16018252
chromosome	16018252
)	16018252
acts	16018252
as	16018252
TDF	16018252
and	16018252
is	16018252
required	16018252
for	16018252
regulating	16018252
male	16018252
sex	16018252
determination	16018252
.	16018252

SRY	16018252
represents	16018252
a	16018252
transcription	16018252
factor	16018252
belonging	16018252
to	16018252
the	16018252
superfamily	16018252
of	16018252
genes	16018252
sharing	16018252
the	16018252
HMG	16018252
-	16018252
box	16018252
motif	16018252
(	16018252
high	16018252
-	16018252
mobility	16018252
group	16018252
-	16018252
box	16018252
)	16018252
,	16018252
which	16018252
acts	16018252
as	16018252
DNA	16018252
binding	16018252
region	16018252
.	16018252

Deletion	16018252
and	16018252
inactivating	16018252
mutations	16018252
of	16018252
SRY	16018252
are	16018252
among	16018252
the	16018252
known	16018252
causes	16018252
of	16018252
XY	16018252
sex	16018252
reversal	16018252
.	16018252

Here	16018252
,	16018252
we	16018252
described	16018252
the	16018252
screening	16018252
of	16018252
10	16018252
patients	16018252
who	16018252
presented	16018252
with	16018252
46	16018252
,	16018252
XY	16018252
sex	16018252
reversal	16018252
for	16018252
mutations	16018252
in	16018252
open	16018252
reading	16018252
frame	16018252
(	16018252
ORF	16018252
)	16018252
of	16018252
SRY	16018252
gene	16018252
.	16018252

DNA	16018252
was	16018252
isolated	16018252
from	16018252
blood	16018252
samples	16018252
using	16018252
standard	16018252
techniques	16018252
.	16018252

A	16018252
609	16018252
bp	16018252
fragment	16018252
from	16018252
the	16018252
central	16018252
portion	16018252
of	16018252
the	16018252
SRY	16018252
gene	16018252
was	16018252
amplified	16018252
,	16018252
using	16018252
primers	16018252
XES	16018252
-	16018252
2	16018252
and	16018252
XES	16018252
-	16018252
7	16018252
.	16018252

The	16018252
amplified	16018252
PCR	16018252
fragments	16018252
were	16018252
cloned	16018252
into	16018252
the	16018252
pUCm	16018252
-	16018252
T	16018252
vectors	16018252
,	16018252
and	16018252
direct	16018252
sequencing	16018252
were	16018252
carried	16018252
out	16018252
on	16018252
an	16018252
ABI	16018252
377	16018252
-	16018252
3	16018252
automated	16018252
DNA	16018252
sequencer	16018252
to	16018252
detect	16018252
the	16018252
mutation	16018252
.	16018252

PCR	16018252
-	16018252
restriction	16018252
enzyme	16018252
digestion	16018252
was	16018252
applied	16018252
to	16018252
detect	16018252
the	16018252
results	16018252
of	16018252
DNA	16018252
sequencing	16018252
.	16018252

In	16018252
two	16018252
patients	16018252
,	16018252
de	16018252
novo	16018252
mutations	16018252
led	16018252
to	16018252
an	16018252
amino	16018252
acid	16018252
substitution	16018252
.	16018252

An	16018252
A	16018252
was	16018252
replaced	16018252
by	16018252
a	16018252
G	16018252
in	16018252
codon	16018252
38	16018252
upstream	16018252
of	16018252
the	16018252
5	16018252
'	16018252
border	16018252
outside	16018252
the	16018252
HMG	16018252
box	16018252
of	16018252
the	16018252
SRY	16018252
gene	16018252
,	16018252
resulting	16018252
in	16018252
the	16018252
replacement	16018252
of	16018252
the	16018252
amino	16018252
acid	16018252
glutamate	16018252
by	16018252
glycine	16018252
.	16018252

Another	16018252
heterozygous	16018252
T	16018252
to	16018252
A	16018252
transition	16018252
at	16018252
the	16018252
nucleotide	16018252
position	16018252
+	16018252
387	16018252
which	16018252
encodes	16018252
for	16018252
a	16018252
Tyrosine	16018252
(	16018252
Tyr	16018252
)	16018252
instead	16018252
of	16018252
a	16018252
Term	16018252
,	16018252
whereas	16018252
her	16018252
father	16018252
was	16018252
proven	16018252
to	16018252
have	16018252
the	16018252
wild	16018252
-	16018252
type	16018252
sequence	16018252
.	16018252

These	16018252
point	16018252
mutations	16018252
have	16018252
been	16018252
confirmed	16018252
with	16018252
PCR	16018252
-	16018252
restrict	16018252
enzyme	16018252
method	16018252
.	16018252

As	16018252
demonstrated	16018252
by	16018252
the	16018252
Human	16018252
Gene	16018252
Mutation	16018252
Database	16018252
analysis	16018252
,	16018252
homology	16018252
search	16018252
,	16018252
and	16018252
review	16018252
of	16018252
the	16018252
literature	16018252
,	16018252
these	16018252
two	16018252
mutations	16018252
were	16018252
not	16018252
described	16018252
previously	16018252
and	16018252
brought	16018252
the	16018252
total	16018252
number	16018252
of	16018252
SRY	16018252
gene	16018252
nucleotide	16018252
substitutions	16018252
(	16018252
missense	16018252
/	16018252
nonsense	16018252
)	16018252
to	16018252
45	16018252
.	16018252

These	16018252
findings	16018252
indicated	16018252
that	16018252
these	16018252
amino	16018252
acid	16018252
substitutions	16018252
may	16018252
be	16018252
responsible	16018252
for	16018252
the	16018252
sex	16018252
reversal	16018252
,	16018252
not	16018252
only	16018252
inside	16018252
the	16018252
HMG	16018252
-	16018252
box	16018252
but	16018252
also	16018252
outside	16018252
the	16018252
HMG	16018252
-	16018252
box	16018252
.	16018252

The	16018252
two	16018252
novel	16018252
mutations	16018252
in	16018252
SRY	16018252
gene	16018252
provided	16018252
valuable	16018252
information	16018252
for	16018252
understanding	16018252
the	16018252
molecular	16018252
mechanism	16018252
of	16018252
the	16018252
patient	16018252
with	16018252
46	16018252
,	16018252
XY	16018252
female	16018252
sex	16018252
reversal	16018252
.	16018252
Superoxide	23791840
dismutase	23791840
1	23791840
overexpression	23791840
in	23791840
mice	23791840
abolishes	23791840
maternal	23791840
diabetes	23791840
-	23791840
induced	23791840
endoplasmic	23791840
reticulum	23791840
stress	23791840
in	23791840
diabetic	23791840
embryopathy	23791840
.	23791840

OBJECTIVE	23791840
:	23791840
Both	23791840
oxidative	23791840
stress	23791840
and	23791840
endoplasmic	23791840
reticulum	23791840
stress	23791840
(	23791840
ER	23791840
stress	23791840
)	23791840
are	23791840
causal	23791840
events	23791840
in	23791840
diabetic	23791840
embryopathy	23791840
.	23791840

We	23791840
tested	23791840
whether	23791840
oxidative	23791840
stress	23791840
causes	23791840
ER	23791840
stress	23791840
.	23791840

STUDY	23791840
DESIGN	23791840
:	23791840
Wild	23791840
-	23791840
type	23791840
(	23791840
WT	23791840
)	23791840
and	23791840
superoxide	23791840
dismutase	23791840
1	23791840
(	23791840
SOD1	23791840
)	23791840
-	23791840
overexpressing	23791840
day	23791840
8	23791840
.	23791840
75	23791840
embryos	23791840
from	23791840
nondiabetic	23791840
WT	23791840
control	23791840
with	23791840
SOD1	23791840
transgenic	23791840
male	23791840
and	23791840
diabetic	23791840
WT	23791840
female	23791840
with	23791840
SOD1	23791840
transgenic	23791840
male	23791840
were	23791840
analyzed	23791840
for	23791840
ER	23791840
stress	23791840
markers	23791840
:	23791840
C	23791840
/	23791840
EBP	23791840
-	23791840
homologous	23791840
protein	23791840
(	23791840
CHOP	23791840
)	23791840
,	23791840
calnexin	23791840
,	23791840
eukaryotic	23791840
initiation	23791840
factor	23791840
2a	23791840
(	23791840
eIF2a	23791840
)	23791840
,	23791840
protein	23791840
kinase	23791840
ribonucleic	23791840
acid	23791840
(	23791840
RNA	23791840
)	23791840
-	23791840
like	23791840
ER	23791840
kinase	23791840
(	23791840
PERK	23791840
)	23791840
,	23791840
binding	23791840
immunoglobulin	23791840
protein	23791840
,	23791840
protein	23791840
disulfide	23791840
isomerase	23791840
family	23791840
A	23791840
member	23791840
3	23791840
,	23791840
kinases	23791840
inositol	23791840
-	23791840
requiring	23791840
protein	23791840
-	23791840
1a	23791840
(	23791840
IRE1a	23791840
)	23791840
,	23791840
and	23791840
the	23791840
X	23791840
-	23791840
box	23791840
binding	23791840
protein	23791840
(	23791840
XBP1	23791840
)	23791840
messenger	23791840
RNA	23791840
(	23791840
mRNA	23791840
)	23791840
splicing	23791840
.	23791840

RESULTS	23791840
:	23791840
Maternal	23791840
diabetes	23791840
significantly	23791840
increased	23791840
the	23791840
levels	23791840
of	23791840
CHOP	23791840
,	23791840
calnexin	23791840
,	23791840
phosphorylated	23791840
(	23791840
p	23791840
)	23791840
-	23791840
eIF2a	23791840
,	23791840
p	23791840
-	23791840
PERK	23791840
,	23791840
and	23791840
p	23791840
-	23791840
IRE1a	23791840
;	23791840
triggered	23791840
XBP1	23791840
mRNA	23791840
splicing	23791840
;	23791840
and	23791840
enhanced	23791840
ER	23791840
chaperone	23791840
gene	23791840
expression	23791840
in	23791840
WT	23791840
embryos	23791840
.	23791840

SOD1	23791840
overexpression	23791840
blocked	23791840
these	23791840
diabetes	23791840
-	23791840
induced	23791840
ER	23791840
stress	23791840
markers	23791840
.	23791840

CONCLUSION	23791840
:	23791840
Mitigating	23791840
oxidative	23791840
stress	23791840
via	23791840
SOD1	23791840
overexpression	23791840
blocks	23791840
maternal	23791840
diabetes	23791840
-	23791840
induced	23791840
ER	23791840
stress	23791840
in	23791840
vivo	23791840
.	23791840
The	20401977
human	20401977
AHR	20401977
:	20401977
identification	20401977
of	20401977
single	20401977
nucleotide	20401977
polymorphisms	20401977
from	20401977
six	20401977
ethnic	20401977
populations	20401977
.	20401977

BACKGROUND	20401977
:	20401977
The	20401977
effects	20401977
of	20401977
2	20401977
,	20401977
3	20401977
,	20401977
7	20401977
,	20401977
8	20401977
-	20401977
tetrachlorodibenzo	20401977
-	20401977
p	20401977
-	20401977
dioxin	20401977
and	20401977
related	20401977
dioxin	20401977
-	20401977
like	20401977
chemicals	20401977
are	20401977
mediated	20401977
through	20401977
binding	20401977
-	20401977
dependent	20401977
activation	20401977
of	20401977
the	20401977
cytosolic	20401977
aryl	20401977
hydrocarbon	20401977
receptor	20401977
(	20401977
AHR	20401977
)	20401977
.	20401977

The	20401977
human	20401977
AHR	20401977
is	20401977
a	20401977
low	20401977
-	20401977
affinity	20401977
receptor	20401977
relative	20401977
to	20401977
most	20401977
rodents	20401977
,	20401977
but	20401977
some	20401977
reports	20401977
suggest	20401977
that	20401977
there	20401977
may	20401977
be	20401977
individuals	20401977
with	20401977
polymorphic	20401977
high	20401977
-	20401977
affinity	20401977
receptors	20401977
,	20401977
thereby	20401977
possibly	20401977
increasing	20401977
the	20401977
sensitivity	20401977
to	20401977
dioxins	20401977
in	20401977
such	20401977
people	20401977
.	20401977

METHODS	20401977
:	20401977
Although	20401977
no	20401977
polymorphisms	20401977
have	20401977
been	20401977
reported	20401977
in	20401977
the	20401977
ligand	20401977
binding	20401977
region	20401977
of	20401977
the	20401977
AHR	20401977
in	20401977
the	20401977
over	20401977
100	20401977
reported	20401977
sequences	20401977
,	20401977
we	20401977
sequenced	20401977
108	20401977
additional	20401977
human	20401977
AHR	20401977
genes	20401977
in	20401977
an	20401977
effort	20401977
to	20401977
further	20401977
identify	20401977
single	20401977
single	20401977
nucleotide	20401977
polymorphisms	20401977
(	20401977
SNPs	20401977
)	20401977
within	20401977
the	20401977
open	20401977
reading	20401977
frames	20401977
of	20401977
the	20401977
AHR	20401977
locus	20401977
.	20401977

The	20401977
DNA	20401977
was	20401977
sequenced	20401977
from	20401977
six	20401977
ethnic	20401977
populations	20401977
that	20401977
included	20401977
Japanese	20401977
,	20401977
Chinese	20401977
,	20401977
European	20401977
/	20401977
Caucasian	20401977
,	20401977
African	20401977
-	20401977
American	20401977
,	20401977
South	20401977
East	20401977
Asian	20401977
,	20401977
and	20401977
Hispanic	20401977
.	20401977

RESULTS	20401977
:	20401977
Six	20401977
exonic	20401977
SNPs	20401977
were	20401977
identified	20401977
;	20401977
four	20401977
had	20401977
been	20401977
described	20401977
as	20401977
previously	20401977
reported	20401977
and	20401977
two	20401977
seem	20401977
to	20401977
be	20401977
novel	20401977
.	20401977

Four	20401977
of	20401977
the	20401977
SNPs	20401977
identified	20401977
lead	20401977
to	20401977
amino	20401977
acid	20401977
changes	20401977
in	20401977
the	20401977
AHR	20401977
protein	20401977
and	20401977
two	20401977
of	20401977
the	20401977
SNPs	20401977
lead	20401977
to	20401977
synonymous	20401977
substitutions	20401977
.	20401977

An	20401977
additional	20401977
four	20401977
SNPs	20401977
have	20401977
been	20401977
reported	20401977
elsewhere	20401977
that	20401977
were	20401977
not	20401977
identified	20401977
in	20401977
the	20401977
current	20401977
analysis	20401977
.	20401977

With	20401977
these	20401977
new	20401977
sequences	20401977
,	20401977
more	20401977
than	20401977
200	20401977
human	20401977
AHR	20401977
gene	20401977
sequences	20401977
have	20401977
been	20401977
analyzed	20401977
for	20401977
SNPs	20401977
.	20401977

CONCLUSION	20401977
:	20401977
The	20401977
results	20401977
indicate	20401977
a	20401977
very	20401977
limited	20401977
presence	20401977
of	20401977
polymorphisms	20401977
in	20401977
the	20401977
core	20401977
ligand	20401977
binding	20401977
region	20401977
of	20401977
the	20401977
human	20401977
AHR	20401977
.	20401977

Other	20401977
regions	20401977
,	20401977
such	20401977
as	20401977
the	20401977
transactivation	20401977
domain	20401977
,	20401977
seem	20401977
to	20401977
be	20401977
slightly	20401977
more	20401977
polymorphic	20401977
in	20401977
the	20401977
human	20401977
population	20401977
and	20401977
the	20401977
impact	20401977
on	20401977
functionality	20401977
should	20401977
be	20401977
further	20401977
examined	20401977
.	20401977
A	16157158
Cys	16157158
23	16157158
-	16157158
Ser	16157158
23	16157158
substitution	16157158
in	16157158
the	16157158
5	16157158
-	16157158
HT	16157158
(	16157158
2C	16157158
)	16157158
receptor	16157158
gene	16157158
influences	16157158
body	16157158
weight	16157158
regulation	16157158
in	16157158
females	16157158
with	16157158
seasonal	16157158
affective	16157158
disorder	16157158
:	16157158
an	16157158
Austrian	16157158
-	16157158
Canadian	16157158
collaborative	16157158
study	16157158
.	16157158

Most	16157158
females	16157158
with	16157158
seasonal	16157158
affective	16157158
disorder	16157158
(	16157158
SAD	16157158
)	16157158
exhibit	16157158
atypical	16157158
vegetative	16157158
symptoms	16157158
such	16157158
as	16157158
overeating	16157158
,	16157158
and	16157158
weight	16157158
gain	16157158
when	16157158
depressed	16157158
.	16157158

The	16157158
serotonin	16157158
2C	16157158
receptor	16157158
(	16157158
5	16157158
-	16157158
HT	16157158
(	16157158
2C	16157158
)	16157158
)	16157158
plays	16157158
a	16157158
key	16157158
role	16157158
in	16157158
control	16157158
of	16157158
appetite	16157158
and	16157158
satiety	16157158
.	16157158

A	16157158
5	16157158
-	16157158
HT	16157158
(	16157158
2C	16157158
)	16157158
Cys	16157158
23	16157158
Ser	16157158
substitution	16157158
,	16157158
coded	16157158
for	16157158
by	16157158
a	16157158
single	16157158
nucleotide	16157158
polymorphism	16157158
(	16157158
Cys	16157158
23	16157158
Ser	16157158
)	16157158
within	16157158
the	16157158
5	16157158
-	16157158
HT	16157158
(	16157158
2C	16157158
)	16157158
gene	16157158
,	16157158
has	16157158
been	16157158
shown	16157158
to	16157158
influence	16157158
5	16157158
-	16157158
HT	16157158
(	16157158
2C	16157158
)	16157158
function	16157158
.	16157158

We	16157158
hypothesized	16157158
that	16157158
Cys	16157158
23	16157158
Ser	16157158
influences	16157158
weight	16157158
regulation	16157158
in	16157158
females	16157158
with	16157158
SAD	16157158
.	16157158

Two	16157158
independent	16157158
samples	16157158
from	16157158
Austria	16157158
(	16157158
162	16157158
females	16157158
with	16157158
SAD	16157158
,	16157158
119	16157158
controls	16157158
)	16157158
,	16157158
and	16157158
Canada	16157158
(	16157158
90	16157158
females	16157158
with	16157158
SAD	16157158
,	16157158
42	16157158
controls	16157158
)	16157158
were	16157158
genotyped	16157158
for	16157158
Cys	16157158
23	16157158
Ser	16157158
.	16157158

Influence	16157158
on	16157158
weight	16157158
regulation	16157158
was	16157158
analyzed	16157158
within	16157158
patients	16157158
with	16157158
atypical	16157158
features	16157158
.	16157158

In	16157158
Austrians	16157158
,	16157158
genotype	16157158
distribution	16157158
differed	16157158
between	16157158
patients	16157158
and	16157158
controls	16157158
(	16157158
p	16157158
=	16157158
0	16157158
.	16157158
044	16157158
)	16157158
and	16157158
Cys	16157158
23	16157158
Ser	16157158
was	16157158
associated	16157158
with	16157158
weight	16157158
(	16157158
p	16157158
=	16157158
0	16157158
.	16157158
039	16157158
)	16157158
,	16157158
body	16157158
mass	16157158
index	16157158
(	16157158
BMI	16157158
;	16157158
p	16157158
=	16157158
0	16157158
.	16157158
038	16157158
)	16157158
,	16157158
and	16157158
seasonal	16157158
appetite	16157158
change	16157158
(	16157158
p	16157158
=	16157158
0	16157158
.	16157158
031	16157158
)	16157158
.	16157158

All	16157158
values	16157158
were	16157158
highest	16157158
in	16157158
Cys	16157158
/	16157158
Cys	16157158
,	16157158
intermediate	16157158
in	16157158
Cys	16157158
/	16157158
Ser	16157158
,	16157158
and	16157158
lowest	16157158
in	16157158
Ser	16157158
/	16157158
Ser	16157158
carriers	16157158
.	16157158

In	16157158
Canadian	16157158
patients	16157158
,	16157158
Cys	16157158
23	16157158
Ser	16157158
was	16157158
associated	16157158
with	16157158
minimum	16157158
lifetime	16157158
BMI	16157158
(	16157158
p	16157158
=	16157158
0	16157158
.	16157158
046	16157158
)	16157158
,	16157158
with	16157158
lowest	16157158
values	16157158
in	16157158
Ser	16157158
/	16157158
Ser	16157158
carriers	16157158
.	16157158

Our	16157158
data	16157158
provide	16157158
evidence	16157158
that	16157158
Cys	16157158
23	16157158
Ser	16157158
mediates	16157158
severity	16157158
of	16157158
weight	16157158
regulation	16157158
disturbances	16157158
in	16157158
females	16157158
with	16157158
SAD	16157158
,	16157158
and	16157158
the	16157158
gene	16157158
-	16157158
dose	16157158
effect	16157158
-	16157158
like	16157158
differences	16157158
suggest	16157158
a	16157158
direct	16157158
functional	16157158
role	16157158
of	16157158
Cys	16157158
23	16157158
Ser	16157158
in	16157158
the	16157158
behavioral	16157158
regulation	16157158
of	16157158
body	16157158
weight	16157158
.	16157158
Rab6c	11054569
,	11054569
a	11054569
new	11054569
member	11054569
of	11054569
the	11054569
rab	11054569
gene	11054569
family	11054569
,	11054569
is	11054569
involved	11054569
in	11054569
drug	11054569
resistance	11054569
in	11054569
MCF7	11054569
/	11054569
AdrR	11054569
cells	11054569
.	11054569

A	11054569
new	11054569
Rab6	11054569
homolog	11054569
cDNA	11054569
,	11054569
Rab6c	11054569
,	11054569
was	11054569
discovered	11054569
by	11054569
a	11054569
hypermethylated	11054569
DNA	11054569
fragment	11054569
probe	11054569
that	11054569
was	11054569
isolated	11054569
from	11054569
a	11054569
human	11054569
multidrug	11054569
resistant	11054569
(	11054569
MDR	11054569
)	11054569
breast	11054569
cancer	11054569
cell	11054569
line	11054569
,	11054569
MCF7	11054569
/	11054569
AdrR	11054569
,	11054569
by	11054569
the	11054569
methylation	11054569
sensitive	11054569
-	11054569
representational	11054569
difference	11054569
analysis	11054569
(	11054569
MS	11054569
-	11054569
RDA	11054569
)	11054569
technique	11054569
.	11054569

Rab6c	11054569
was	11054569
found	11054569
to	11054569
be	11054569
under	11054569
-	11054569
expressed	11054569
in	11054569
MCF7	11054569
/	11054569
AdrR	11054569
and	11054569
MES	11054569
-	11054569
SA	11054569
/	11054569
Dx5	11054569
(	11054569
a	11054569
human	11054569
MDR	11054569
uterine	11054569
sarcoma	11054569
cell	11054569
line	11054569
)	11054569
compared	11054569
with	11054569
their	11054569
non	11054569
-	11054569
MDR	11054569
parental	11054569
cell	11054569
lines	11054569
.	11054569

MCF7	11054569
/	11054569
AdrR	11054569
cells	11054569
expressing	11054569
the	11054569
exogenous	11054569
Rab6c	11054569
exhibited	11054569
less	11054569
resistance	11054569
to	11054569
several	11054569
anti	11054569
-	11054569
cancer	11054569
drugs	11054569
,	11054569
such	11054569
as	11054569
doxorubicin	11054569
(	11054569
DOX	11054569
)	11054569
,	11054569
taxol	11054569
,	11054569
vinblastine	11054569
,	11054569
and	11054569
vincristine	11054569
,	11054569
than	11054569
the	11054569
control	11054569
cells	11054569
containing	11054569
the	11054569
empty	11054569
vector	11054569
.	11054569

Flow	11054569
cytometry	11054569
experiments	11054569
confirmed	11054569
that	11054569
the	11054569
transfectants	11054569
'	11054569
diminished	11054569
resistance	11054569
to	11054569
DOX	11054569
was	11054569
caused	11054569
by	11054569
increased	11054569
drug	11054569
accumulation	11054569
induced	11054569
by	11054569
the	11054569
exogenous	11054569
Rab6c	11054569
.	11054569

These	11054569
results	11054569
indicate	11054569
that	11054569
Rab6c	11054569
is	11054569
involved	11054569
in	11054569
drug	11054569
resistance	11054569
in	11054569
MCF7	11054569
/	11054569
AdrR	11054569
cells	11054569
.	11054569
Genome	28650467
-	28650467
wide	28650467
loss	28650467
-	28650467
of	28650467
-	28650467
function	28650467
genetic	28650467
screening	28650467
identifies	28650467
opioid	28650467
receptor	28650467
u1	28650467
as	28650467
a	28650467
key	28650467
regulator	28650467
of	28650467
L	28650467
-	28650467
asparaginase	28650467
resistance	28650467
in	28650467
pediatric	28650467
acute	28650467
lymphoblastic	28650467
leukemia	28650467
.	28650467

L	28650467
-	28650467
asparaginase	28650467
is	28650467
a	28650467
critical	28650467
chemotherapeutic	28650467
agent	28650467
for	28650467
acute	28650467
lymphoblastic	28650467
leukemia	28650467
(	28650467
ALL	28650467
)	28650467
.	28650467

It	28650467
hydrolyzes	28650467
plasma	28650467
asparagine	28650467
into	28650467
aspartate	28650467
and	28650467
NH3	28650467
,	28650467
causing	28650467
asparagine	28650467
deficit	28650467
and	28650467
inhibition	28650467
of	28650467
protein	28650467
synthesis	28650467
and	28650467
eventually	28650467
,	28650467
leukemic	28650467
cell	28650467
death	28650467
.	28650467

However	28650467
,	28650467
patient	28650467
relapse	28650467
often	28650467
occurs	28650467
due	28650467
to	28650467
development	28650467
of	28650467
resistance	28650467
.	28650467

The	28650467
molecular	28650467
mechanism	28650467
by	28650467
which	28650467
ALL	28650467
cells	28650467
acquire	28650467
resistance	28650467
to	28650467
L	28650467
-	28650467
asparaginase	28650467
is	28650467
unknown	28650467
.	28650467

Therefore	28650467
,	28650467
we	28650467
sought	28650467
to	28650467
identify	28650467
genes	28650467
that	28650467
are	28650467
involved	28650467
in	28650467
L	28650467
-	28650467
asparaginase	28650467
resistance	28650467
in	28650467
primary	28650467
leukemic	28650467
cells	28650467
.	28650467

By	28650467
unbiased	28650467
genome	28650467
-	28650467
wide	28650467
RNAi	28650467
screening	28650467
,	28650467
we	28650467
found	28650467
that	28650467
among	28650467
10	28650467
resistant	28650467
ALL	28650467
clones	28650467
,	28650467
six	28650467
hits	28650467
were	28650467
for	28650467
opioid	28650467
receptor	28650467
mu	28650467
1	28650467
(	28650467
oprm1	28650467
)	28650467
,	28650467
two	28650467
hits	28650467
were	28650467
for	28650467
carbonic	28650467
anhydrase	28650467
1	28650467
(	28650467
ca1	28650467
)	28650467
and	28650467
another	28650467
two	28650467
hits	28650467
were	28650467
for	28650467
ubiquitin	28650467
-	28650467
conjugating	28650467
enzyme	28650467
E2C	28650467
(	28650467
ube2c	28650467
)	28650467
.	28650467

We	28650467
also	28650467
found	28650467
that	28650467
OPRM1	28650467
is	28650467
expressed	28650467
in	28650467
all	28650467
leukemic	28650467
cells	28650467
tested	28650467
.	28650467

Specific	28650467
knockdown	28650467
of	28650467
OPRM1	28650467
confers	28650467
L	28650467
-	28650467
asparaginase	28650467
resistance	28650467
,	28650467
validating	28650467
our	28650467
genome	28650467
-	28650467
wide	28650467
retroviral	28650467
shRNA	28650467
library	28650467
screening	28650467
data	28650467
.	28650467

Methadone	28650467
,	28650467
an	28650467
agonist	28650467
of	28650467
OPRM1	28650467
,	28650467
enhances	28650467
the	28650467
sensitivity	28650467
of	28650467
parental	28650467
leukemic	28650467
cells	28650467
,	28650467
but	28650467
not	28650467
OPRM1	28650467
-	28650467
depleted	28650467
cells	28650467
,	28650467
to	28650467
L	28650467
-	28650467
asparaginase	28650467
treatment	28650467
,	28650467
indicating	28650467
that	28650467
OPRM1	28650467
is	28650467
required	28650467
for	28650467
the	28650467
synergistic	28650467
action	28650467
of	28650467
L	28650467
-	28650467
asparaginase	28650467
and	28650467
methadone	28650467
,	28650467
and	28650467
that	28650467
OPRM1	28650467
loss	28650467
promotes	28650467
leukemic	28650467
cell	28650467
survival	28650467
likely	28650467
through	28650467
downregulation	28650467
of	28650467
the	28650467
OPRM1	28650467
-	28650467
mediated	28650467
apoptotic	28650467
pathway	28650467
.	28650467

Consistent	28650467
with	28650467
this	28650467
premise	28650467
,	28650467
patient	28650467
leukemic	28650467
cells	28650467
with	28650467
relatively	28650467
high	28650467
levels	28650467
of	28650467
OPRM1	28650467
are	28650467
more	28650467
sensitive	28650467
to	28650467
L	28650467
-	28650467
asparaginase	28650467
treatment	28650467
compared	28650467
to	28650467
OPRM1	28650467
-	28650467
depleted	28650467
leukemic	28650467
cells	28650467
,	28650467
further	28650467
indicating	28650467
that	28650467
OPRM1	28650467
loss	28650467
has	28650467
a	28650467
crucial	28650467
role	28650467
in	28650467
L	28650467
-	28650467
asparaginase	28650467
resistance	28650467
in	28650467
leukemic	28650467
patients	28650467
.	28650467

Thus	28650467
,	28650467
our	28650467
study	28650467
demonstrates	28650467
for	28650467
the	28650467
first	28650467
time	28650467
,	28650467
a	28650467
novel	28650467
OPRM1	28650467
-	28650467
mediated	28650467
mechanism	28650467
for	28650467
L	28650467
-	28650467
asparaginase	28650467
resistance	28650467
in	28650467
ALL	28650467
,	28650467
and	28650467
identifies	28650467
OPRM1	28650467
as	28650467
a	28650467
functional	28650467
biomarker	28650467
for	28650467
defining	28650467
high	28650467
-	28650467
risk	28650467
subpopulations	28650467
and	28650467
for	28650467
the	28650467
detection	28650467
of	28650467
evolving	28650467
resistant	28650467
clones	28650467
.	28650467

Oprm1	28650467
may	28650467
also	28650467
be	28650467
utilized	28650467
for	28650467
effective	28650467
treatment	28650467
of	28650467
L	28650467
-	28650467
asparaginase	28650467
-	28650467
resistant	28650467
ALL	28650467
.	28650467
Oncogene	28650467
advance	28650467
online	28650467
publication	28650467
,	28650467
26	28650467
June	28650467
2017	28650467
;	28650467
doi	28650467
:	28650467
10	28650467
.	28650467
1038	28650467
/	28650467
onc	28650467
.	28650467
2017	28650467
.	28650467
211	28650467
.	28650467
rTMS	16116131
of	16116131
supplementary	16116131
motor	16116131
area	16116131
modulates	16116131
therapy	16116131
-	16116131
induced	16116131
dyskinesias	16116131
in	16116131
Parkinson	16116131
disease	16116131
.	16116131

The	16116131
neural	16116131
mechanisms	16116131
and	16116131
circuitry	16116131
involved	16116131
in	16116131
levodopa	16116131
-	16116131
induced	16116131
dyskinesia	16116131
are	16116131
unclear	16116131
.	16116131

Using	16116131
repetitive	16116131
transcranial	16116131
magnetic	16116131
stimulation	16116131
(	16116131
rTMS	16116131
)	16116131
over	16116131
the	16116131
supplementary	16116131
motor	16116131
area	16116131
(	16116131
SMA	16116131
)	16116131
in	16116131
a	16116131
group	16116131
of	16116131
patients	16116131
with	16116131
advanced	16116131
Parkinson	16116131
disease	16116131
,	16116131
the	16116131
authors	16116131
investigated	16116131
whether	16116131
modulation	16116131
of	16116131
SMA	16116131
excitability	16116131
may	16116131
result	16116131
in	16116131
a	16116131
modification	16116131
of	16116131
a	16116131
dyskinetic	16116131
state	16116131
induced	16116131
by	16116131
continuous	16116131
apomorphine	16116131
infusion	16116131
.	16116131

rTMS	16116131
at	16116131
1	16116131
Hz	16116131
was	16116131
observed	16116131
to	16116131
markedly	16116131
reduce	16116131
drug	16116131
-	16116131
induced	16116131
dyskinesias	16116131
,	16116131
whereas	16116131
5	16116131
-	16116131
Hz	16116131
rTMS	16116131
induced	16116131
a	16116131
slight	16116131
but	16116131
not	16116131
significant	16116131
increase	16116131
.	16116131
Two	16840830
novel	16840830
mutations	16840830
in	16840830
the	16840830
MEN1	16840830
gene	16840830
in	16840830
subjects	16840830
with	16840830
multiple	16840830
endocrine	16840830
neoplasia	16840830
-	16840830
1	16840830
.	16840830

Multiple	16840830
endocrine	16840830
neoplasia	16840830
type	16840830
1	16840830
(	16840830
MEN1	16840830
)	16840830
is	16840830
characterized	16840830
by	16840830
parathyroid	16840830
,	16840830
enteropancreatic	16840830
endocrine	16840830
and	16840830
pituitary	16840830
adenomas	16840830
as	16840830
well	16840830
as	16840830
germline	16840830
mutation	16840830
of	16840830
the	16840830
MEN1	16840830
gene	16840830
.	16840830

We	16840830
describe	16840830
2	16840830
families	16840830
with	16840830
MEN1	16840830
with	16840830
novel	16840830
mutations	16840830
in	16840830
the	16840830
MEN1	16840830
gene	16840830
.	16840830

One	16840830
family	16840830
was	16840830
of	16840830
Turkish	16840830
origin	16840830
,	16840830
and	16840830
the	16840830
index	16840830
patient	16840830
had	16840830
primary	16840830
hyperparathyroidism	16840830
(	16840830
PHPT	16840830
)	16840830
plus	16840830
a	16840830
prolactinoma	16840830
;	16840830
three	16840830
relatives	16840830
had	16840830
PHPT	16840830
only	16840830
.	16840830

The	16840830
index	16840830
patient	16840830
in	16840830
the	16840830
second	16840830
family	16840830
was	16840830
a	16840830
46	16840830
-	16840830
yr	16840830
-	16840830
old	16840830
woman	16840830
of	16840830
Chinese	16840830
origin	16840830
living	16840830
in	16840830
Taiwan	16840830
.	16840830

This	16840830
patient	16840830
presented	16840830
with	16840830
a	16840830
complaint	16840830
of	16840830
epigastric	16840830
pain	16840830
and	16840830
watery	16840830
diarrhea	16840830
over	16840830
the	16840830
past	16840830
3	16840830
months	16840830
,	16840830
and	16840830
had	16840830
undergone	16840830
subtotal	16840830
parathyroidectomy	16840830
and	16840830
enucleation	16840830
of	16840830
pancreatic	16840830
islet	16840830
cell	16840830
tumor	16840830
about	16840830
10	16840830
yr	16840830
before	16840830
.	16840830

There	16840830
was	16840830
also	16840830
a	16840830
prolactinoma	16840830
.	16840830

Sequence	16840830
analysis	16840830
of	16840830
the	16840830
MEN1	16840830
gene	16840830
from	16840830
leukocyte	16840830
genomic	16840830
DNA	16840830
revealed	16840830
heterozygous	16840830
mutations	16840830
in	16840830
both	16840830
probands	16840830
.	16840830

The	16840830
Turkish	16840830
patient	16840830
and	16840830
her	16840830
affected	16840830
relatives	16840830
all	16840830
had	16840830
a	16840830
heterozygous	16840830
A	16840830
to	16840830
G	16840830
transition	16840830
at	16840830
codon	16840830
557	16840830
(	16840830
AAG	16840830
-	16840830
-	16840830
>	16840830
GAG	16840830
)	16840830
of	16840830
exon	16840830
10	16840830
of	16840830
MEN1	16840830
that	16840830
results	16840830
in	16840830
a	16840830
replacement	16840830
of	16840830
lysine	16840830
by	16840830
glutamic	16840830
acid	16840830
.	16840830

The	16840830
Chinese	16840830
index	16840830
patient	16840830
and	16840830
one	16840830
of	16840830
her	16840830
siblings	16840830
had	16840830
a	16840830
heterozygous	16840830
mutation	16840830
at	16840830
codon	16840830
418	16840830
of	16840830
exon	16840830
9	16840830
(	16840830
GAC	16840830
-	16840830
-	16840830
>	16840830
TAT	16840830
)	16840830
that	16840830
results	16840830
in	16840830
a	16840830
substitution	16840830
of	16840830
aspartic	16840830
acid	16840830
by	16840830
tyrosine	16840830
.	16840830

In	16840830
conclusion	16840830
,	16840830
we	16840830
have	16840830
identified	16840830
2	16840830
novel	16840830
missense	16840830
mutations	16840830
in	16840830
the	16840830
MEN1	16840830
gene	16840830
.	16840830
Sex	20540798
-	20540798
differential	20540798
genetic	20540798
effect	20540798
of	20540798
phosphodiesterase	20540798
4D	20540798
(	20540798
PDE4D	20540798
)	20540798
on	20540798
carotid	20540798
atherosclerosis	20540798
.	20540798

BACKGROUND	20540798
:	20540798
The	20540798
phosphodiesterase	20540798
4D	20540798
(	20540798
PDE4D	20540798
)	20540798
gene	20540798
was	20540798
reported	20540798
as	20540798
a	20540798
susceptibility	20540798
gene	20540798
to	20540798
stroke	20540798
.	20540798

The	20540798
genetic	20540798
effect	20540798
might	20540798
be	20540798
attributed	20540798
to	20540798
its	20540798
role	20540798
in	20540798
modulating	20540798
the	20540798
atherogenic	20540798
process	20540798
in	20540798
the	20540798
carotid	20540798
arteries	20540798
.	20540798

Using	20540798
carotid	20540798
intima	20540798
-	20540798
media	20540798
thickness	20540798
(	20540798
IMT	20540798
)	20540798
and	20540798
plaque	20540798
index	20540798
as	20540798
phenotypes	20540798
,	20540798
the	20540798
present	20540798
study	20540798
sought	20540798
to	20540798
determine	20540798
the	20540798
influence	20540798
of	20540798
this	20540798
gene	20540798
on	20540798
subclinical	20540798
atherosclerosis	20540798
.	20540798

METHODS	20540798
:	20540798
Carotid	20540798
ultrasonography	20540798
was	20540798
performed	20540798
on	20540798
1013	20540798
stroke	20540798
-	20540798
free	20540798
subjects	20540798
who	20540798
participated	20540798
in	20540798
the	20540798
health	20540798
screening	20540798
programs	20540798
(	20540798
age	20540798
52	20540798
.	20540798
6	20540798
+	20540798
/	20540798
-	20540798
12	20540798
.	20540798
2	20540798
;	20540798
47	20540798
.	20540798
6%	20540798
men	20540798
)	20540798
.	20540798

Genotype	20540798
distribution	20540798
was	20540798
compared	20540798
among	20540798
the	20540798
high	20540798
-	20540798
risk	20540798
(	20540798
plaque	20540798
index	20540798
>	20540798
or	20540798
=	20540798
4	20540798
)	20540798
,	20540798
low	20540798
-	20540798
risk	20540798
(	20540798
index	20540798
=	20540798
1	20540798
-	20540798
3	20540798
)	20540798
,	20540798
and	20540798
reference	20540798
(	20540798
index	20540798
=	20540798
0	20540798
)	20540798
groups	20540798
.	20540798

We	20540798
analyzed	20540798
continuous	20540798
IMT	20540798
data	20540798
and	20540798
further	20540798
dichotomized	20540798
IMT	20540798
data	20540798
using	20540798
mean	20540798
plus	20540798
one	20540798
standard	20540798
deviation	20540798
as	20540798
the	20540798
cutoff	20540798
level	20540798
.	20540798

Because	20540798
the	20540798
plaque	20540798
prevalence	20540798
and	20540798
IMT	20540798
values	20540798
displayed	20540798
a	20540798
notable	20540798
difference	20540798
between	20540798
men	20540798
and	20540798
women	20540798
,	20540798
we	20540798
carried	20540798
out	20540798
sex	20540798
-	20540798
specific	20540798
analyses	20540798
in	20540798
addition	20540798
to	20540798
analyzing	20540798
the	20540798
overall	20540798
data	20540798
.	20540798

Rs702553	20540798
at	20540798
the	20540798
PDE4D	20540798
gene	20540798
was	20540798
selected	20540798
because	20540798
it	20540798
conferred	20540798
a	20540798
risk	20540798
for	20540798
young	20540798
stroke	20540798
in	20540798
our	20540798
previous	20540798
report	20540798
.	20540798

Previous	20540798
young	20540798
stroke	20540798
data	20540798
(	20540798
190	20540798
cases	20540798
and	20540798
211	20540798
controls	20540798
)	20540798
with	20540798
an	20540798
additional	20540798
532	20540798
control	20540798
subjects	20540798
without	20540798
ultrasonic	20540798
data	20540798
were	20540798
shown	20540798
as	20540798
a	20540798
cross	20540798
-	20540798
validation	20540798
for	20540798
the	20540798
genetic	20540798
effect	20540798
.	20540798

RESULTS	20540798
:	20540798
In	20540798
the	20540798
overall	20540798
analyses	20540798
,	20540798
the	20540798
rare	20540798
homozygote	20540798
of	20540798
rs702553	20540798
led	20540798
to	20540798
an	20540798
OR	20540798
of	20540798
3	20540798
.	20540798
1	20540798
(	20540798
p	20540798
=	20540798
0	20540798
.	20540798
034	20540798
)	20540798
for	20540798
a	20540798
plaque	20540798
index	20540798
>	20540798
or	20540798
=	20540798
4	20540798
.	20540798

When	20540798
subjects	20540798
were	20540798
stratified	20540798
by	20540798
sex	20540798
,	20540798
the	20540798
genetic	20540798
effect	20540798
was	20540798
only	20540798
evident	20540798
in	20540798
men	20540798
but	20540798
not	20540798
in	20540798
women	20540798
.	20540798

Comparing	20540798
male	20540798
subjects	20540798
with	20540798
plaque	20540798
index	20540798
>	20540798
or	20540798
=	20540798
4	20540798
and	20540798
those	20540798
with	20540798
plaque	20540798
index	20540798
=	20540798
0	20540798
,	20540798
the	20540798
TT	20540798
genotype	20540798
was	20540798
over	20540798
-	20540798
represented	20540798
(	20540798
27	20540798
.	20540798
6%	20540798
vs	20540798
.	20540798

13	20540798
.	20540798
4%	20540798
,	20540798
p	20540798
=	20540798
0	20540798
.	20540798
008	20540798
)	20540798
.	20540798

For	20540798
dichotomized	20540798
IMT	20540798
data	20540798
in	20540798
men	20540798
,	20540798
the	20540798
TT	20540798
genotype	20540798
had	20540798
an	20540798
OR	20540798
of	20540798
2	20540798
.	20540798
1	20540798
(	20540798
p	20540798
=	20540798
0	20540798
.	20540798
032	20540798
)	20540798
for	20540798
a	20540798
thicker	20540798
IMT	20540798
at	20540798
the	20540798
common	20540798
carotid	20540798
artery	20540798
compared	20540798
with	20540798
the	20540798
(	20540798
AA	20540798
+	20540798
AT	20540798
)	20540798
genotypes	20540798
.	20540798

In	20540798
women	20540798
,	20540798
neither	20540798
IMT	20540798
nor	20540798
plaque	20540798
index	20540798
was	20540798
associated	20540798
with	20540798
rs702553	20540798
.	20540798

Similarly	20540798
,	20540798
SNP	20540798
rs702553	20540798
was	20540798
only	20540798
significant	20540798
in	20540798
young	20540798
stroke	20540798
men	20540798
(	20540798
OR	20540798
=	20540798
1	20540798
.	20540798
8	20540798
,	20540798
p	20540798
=	20540798
0	20540798
.	20540798
025	20540798
)	20540798
but	20540798
not	20540798
in	20540798
women	20540798
(	20540798
p	20540798
=	20540798
0	20540798
.	20540798
27	20540798
)	20540798
.	20540798

CONCLUSIONS	20540798
:	20540798
The	20540798
present	20540798
study	20540798
demonstrates	20540798
a	20540798
sex	20540798
-	20540798
differential	20540798
effect	20540798
of	20540798
PDE4D	20540798
on	20540798
IMT	20540798
,	20540798
plaque	20540798
index	20540798
and	20540798
stroke	20540798
,	20540798
which	20540798
highlights	20540798
its	20540798
influence	20540798
on	20540798
various	20540798
aspects	20540798
of	20540798
atherogenesis	20540798
.	20540798
Reduced	27729412
adiponectin	27729412
expression	27729412
after	27729412
high	27729412
-	27729412
fat	27729412
diet	27729412
is	27729412
associated	27729412
with	27729412
selective	27729412
up	27729412
-	27729412
regulation	27729412
of	27729412
ALDH1A1	27729412
and	27729412
further	27729412
retinoic	27729412
acid	27729412
receptor	27729412
signaling	27729412
in	27729412
adipose	27729412
tissue	27729412
.	27729412

Adiponectin	27729412
is	27729412
an	27729412
adipocyte	27729412
-	27729412
derived	27729412
adipokine	27729412
with	27729412
potent	27729412
antidiabetic	27729412
,	27729412
anti	27729412
-	27729412
inflammatory	27729412
,	27729412
and	27729412
antiatherogenic	27729412
activity	27729412
.	27729412

Long	27729412
-	27729412
term	27729412
,	27729412
high	27729412
-	27729412
fat	27729412
diet	27729412
results	27729412
in	27729412
gain	27729412
of	27729412
body	27729412
weight	27729412
,	27729412
adiposity	27729412
,	27729412
further	27729412
inflammatory	27729412
-	27729412
based	27729412
cardiovascular	27729412
diseases	27729412
,	27729412
and	27729412
reduced	27729412
adiponectin	27729412
secretion	27729412
.	27729412

Vitamin	27729412
A	27729412
derivatives	27729412
/	27729412
retinoids	27729412
are	27729412
involved	27729412
in	27729412
several	27729412
of	27729412
these	27729412
processes	27729412
,	27729412
which	27729412
mainly	27729412
take	27729412
place	27729412
in	27729412
white	27729412
adipose	27729412
tissue	27729412
(	27729412
WAT	27729412
)	27729412
.	27729412

In	27729412
this	27729412
study	27729412
,	27729412
we	27729412
examined	27729412
adiponectin	27729412
expression	27729412
as	27729412
a	27729412
function	27729412
of	27729412
dietary	27729412
high	27729412
-	27729412
fat	27729412
and	27729412
high	27729412
-	27729412
vitamin	27729412
A	27729412
conditions	27729412
in	27729412
mice	27729412
.	27729412

A	27729412
decrease	27729412
of	27729412
adiponectin	27729412
expression	27729412
in	27729412
addition	27729412
to	27729412
an	27729412
up	27729412
-	27729412
regulation	27729412
of	27729412
aldehyde	27729412
dehydrogenase	27729412
A1	27729412
(	27729412
ALDH1A1	27729412
)	27729412
,	27729412
retinoid	27729412
signaling	27729412
,	27729412
and	27729412
retinoic	27729412
acid	27729412
response	27729412
element	27729412
signaling	27729412
was	27729412
selectively	27729412
observed	27729412
in	27729412
WAT	27729412
of	27729412
mice	27729412
fed	27729412
a	27729412
normal	27729412
-	27729412
vitamin	27729412
A	27729412
,	27729412
high	27729412
-	27729412
fat	27729412
diet	27729412
.	27729412

Reduced	27729412
adiponectin	27729412
expression	27729412
in	27729412
WAT	27729412
was	27729412
also	27729412
observed	27729412
in	27729412
mice	27729412
fed	27729412
a	27729412
high	27729412
-	27729412
vitamin	27729412
A	27729412
diet	27729412
.	27729412

Adipocyte	27729412
cell	27729412
culture	27729412
revealed	27729412
that	27729412
endogenous	27729412
and	27729412
synthetic	27729412
retinoic	27729412
acid	27729412
receptor	27729412
(	27729412
RAR	27729412
)	27729412
a	27729412
-	27729412
and	27729412
RARg	27729412
-	27729412
selective	27729412
agonists	27729412
,	27729412
as	27729412
well	27729412
as	27729412
a	27729412
synthetic	27729412
retinoid	27729412
X	27729412
receptor	27729412
agonist	27729412
,	27729412
efficiently	27729412
reduced	27729412
adiponectin	27729412
expression	27729412
,	27729412
whereas	27729412
ALDH1A1	27729412
expression	27729412
only	27729412
increased	27729412
with	27729412
RAR	27729412
agonists	27729412
.	27729412

We	27729412
conclude	27729412
that	27729412
reduced	27729412
adiponectin	27729412
expression	27729412
under	27729412
high	27729412
-	27729412
fat	27729412
dietary	27729412
conditions	27729412
is	27729412
dependent	27729412
on	27729412
1	27729412
)	27729412
increased	27729412
ALDH1A1	27729412
expression	27729412
in	27729412
adipocytes	27729412
,	27729412
which	27729412
does	27729412
not	27729412
increase	27729412
all	27729412
-	27729412
trans	27729412
-	27729412
retinoic	27729412
acid	27729412
levels	27729412
;	27729412
2	27729412
)	27729412
further	27729412
RAR	27729412
ligand	27729412
-	27729412
induced	27729412
,	27729412
WAT	27729412
-	27729412
selective	27729412
,	27729412
increased	27729412
retinoic	27729412
acid	27729412
response	27729412
element	27729412
-	27729412
mediated	27729412
signaling	27729412
;	27729412
and	27729412
3	27729412
)	27729412
RAR	27729412
ligand	27729412
-	27729412
dependent	27729412
reduction	27729412
of	27729412
adiponectin	27729412
expression	27729412
.	27729412
-	27729412
Landrier	27729412
,	27729412
J	27729412
.	27729412
-	27729412
F	27729412
.	27729412
,	27729412
Kasiri	27729412
,	27729412
E	27729412
.	27729412
,	27729412
Karkeni	27729412
,	27729412
E	27729412
.	27729412
,	27729412
Mihaly	27729412
,	27729412
J	27729412
.	27729412
,	27729412
Beke	27729412
,	27729412
G	27729412
.	27729412
,	27729412
Weiss	27729412
,	27729412
K	27729412
.	27729412
,	27729412
Lucas	27729412
,	27729412
R	27729412
.	27729412
,	27729412
Aydemir	27729412
,	27729412
G	27729412
.	27729412
,	27729412
Salles	27729412
,	27729412
J	27729412
.	27729412
,	27729412
Walrand	27729412
,	27729412
S	27729412
.	27729412
,	27729412
de	27729412
Lera	27729412
,	27729412
A	27729412
.	27729412

R	27729412
.	27729412
,	27729412
Ruhl	27729412
,	27729412
R	27729412
.	27729412

Reduced	27729412
adiponectin	27729412
expression	27729412
after	27729412
high	27729412
-	27729412
fat	27729412
diet	27729412
is	27729412
associated	27729412
with	27729412
selective	27729412
up	27729412
-	27729412
regulation	27729412
of	27729412
ALDH1A1	27729412
and	27729412
further	27729412
retinoic	27729412
acid	27729412
receptor	27729412
signaling	27729412
in	27729412
adipose	27729412
tissue	27729412
.	27729412
Effect	20428796
of	20428796
the	20428796
abrogation	20428796
of	20428796
TGF	20428796
-	20428796
beta1	20428796
by	20428796
antisense	20428796
oligonucleotides	20428796
on	20428796
the	20428796
expression	20428796
of	20428796
TGF	20428796
-	20428796
beta	20428796
-	20428796
isoforms	20428796
and	20428796
their	20428796
receptors	20428796
I	20428796
and	20428796
II	20428796
in	20428796
isolated	20428796
fibroblasts	20428796
from	20428796
keloid	20428796
scars	20428796
.	20428796

Disequilibrium	20428796
of	20428796
dermal	20428796
wound	20428796
repair	20428796
can	20428796
result	20428796
in	20428796
continued	20428796
accumulation	20428796
of	20428796
ECM	20428796
and	20428796
excessive	20428796
scar	20428796
formation	20428796
.	20428796

In	20428796
susceptible	20428796
genetically	20428796
predisposed	20428796
individuals	20428796
,	20428796
keloid	20428796
formation	20428796
can	20428796
be	20428796
observed	20428796
.	20428796

Keloid	20428796
disease	20428796
represents	20428796
a	20428796
benign	20428796
dermal	20428796
fibroproliferative	20428796
tumor	20428796
that	20428796
is	20428796
unique	20428796
to	20428796
humans	20428796
.	20428796

TGF	20428796
-	20428796
beta	20428796
is	20428796
known	20428796
to	20428796
play	20428796
a	20428796
key	20428796
role	20428796
in	20428796
the	20428796
pathogenesis	20428796
of	20428796
this	20428796
disease	20428796
which	20428796
is	20428796
still	20428796
not	20428796
fully	20428796
understood	20428796
.	20428796

The	20428796
isoforms	20428796
TGF	20428796
-	20428796
beta1	20428796
and	20428796
TGF	20428796
-	20428796
beta2	20428796
have	20428796
profibrotic	20428796
properties	20428796
,	20428796
whereas	20428796
TGF	20428796
-	20428796
beta3	20428796
may	20428796
have	20428796
antifibrotic	20428796
functions	20428796
.	20428796

TGF	20428796
-	20428796
beta	20428796
exerts	20428796
its	20428796
influence	20428796
by	20428796
binding	20428796
to	20428796
type	20428796
I	20428796
and	20428796
type	20428796
II	20428796
TGF	20428796
-	20428796
beta	20428796
receptors	20428796
,	20428796
thereby	20428796
forming	20428796
a	20428796
complex	20428796
and	20428796
activating	20428796
specific	20428796
downstream	20428796
effector	20428796
molecules	20428796
.	20428796

The	20428796
aim	20428796
of	20428796
this	20428796
study	20428796
was	20428796
to	20428796
investigate	20428796
the	20428796
effect	20428796
of	20428796
TGF	20428796
-	20428796
beta1	20428796
targeting	20428796
by	20428796
antisense	20428796
oligonucleotides	20428796
on	20428796
the	20428796
RNA	20428796
synthesis	20428796
and	20428796
protein	20428796
expression	20428796
of	20428796
TGF	20428796
-	20428796
beta	20428796
isoforms	20428796
and	20428796
their	20428796
receptors	20428796
in	20428796
keloid	20428796
-	20428796
derived	20428796
fibroblasts	20428796
.	20428796

In	20428796
tissue	20428796
samples	20428796
with	20428796
normal	20428796
fibroblasts	20428796
(	20428796
NFs	20428796
)	20428796
serving	20428796
as	20428796
control	20428796
samples	20428796
,	20428796
expression	20428796
of	20428796
TGF	20428796
-	20428796
beta1	20428796
and	20428796
-	20428796
beta2	20428796
was	20428796
decreased	20428796
when	20428796
compared	20428796
to	20428796
keloid	20428796
fibroblasts	20428796
(	20428796
KFs	20428796
)	20428796
,	20428796
while	20428796
expression	20428796
of	20428796
TGF	20428796
-	20428796
beta3	20428796
and	20428796
of	20428796
TGF	20428796
-	20428796
betaRII	20428796
was	20428796
significantly	20428796
higher	20428796
in	20428796
NFs	20428796
.	20428796

In	20428796
the	20428796
ELISA	20428796
assay	20428796
,	20428796
abrogation	20428796
of	20428796
TGF	20428796
-	20428796
beta1	20428796
led	20428796
to	20428796
a	20428796
significant	20428796
decrease	20428796
in	20428796
TGF	20428796
-	20428796
beta1	20428796
and	20428796
-	20428796
beta2	20428796
(	20428796
p	20428796
<	20428796
0	20428796
.	20428796
05	20428796
)	20428796
.	20428796

Expression	20428796
of	20428796
TGF	20428796
-	20428796
beta2	20428796
mRNA	20428796
was	20428796
reduced	20428796
.	20428796

Expression	20428796
of	20428796
TGF	20428796
-	20428796
beta3	20428796
mRNA	20428796
revealed	20428796
contrary	20428796
patterns	20428796
in	20428796
KFs	20428796
from	20428796
different	20428796
patients	20428796
while	20428796
expression	20428796
of	20428796
TGF	20428796
-	20428796
betaRI	20428796
was	20428796
found	20428796
to	20428796
be	20428796
equal	20428796
during	20428796
the	20428796
measurement	20428796
period	20428796
.	20428796

TGF	20428796
-	20428796
betaRII	20428796
mRNA	20428796
expression	20428796
was	20428796
increased	20428796
after	20428796
48	20428796
and	20428796
72	20428796
h	20428796
respectively	20428796
.	20428796

There	20428796
is	20428796
growing	20428796
evidence	20428796
for	20428796
a	20428796
regulatory	20428796
mechanism	20428796
between	20428796
TGF	20428796
-	20428796
beta1	20428796
and	20428796
its	20428796
receptors	20428796
.	20428796

Our	20428796
findings	20428796
support	20428796
this	20428796
theory	20428796
by	20428796
suggesting	20428796
interrelations	20428796
between	20428796
the	20428796
different	20428796
TGF	20428796
-	20428796
beta	20428796
isoforms	20428796
and	20428796
their	20428796
receptors	20428796
.	20428796

Abnormal	20428796
response	20428796
of	20428796
KFs	20428796
to	20428796
TGF	20428796
-	20428796
betamight	20428796
reflect	20428796
a	20428796
modification	20428796
in	20428796
the	20428796
regulatory	20428796
pathway	20428796
that	20428796
occurs	20428796
at	20428796
the	20428796
receptor	20428796
level	20428796
or	20428796
during	20428796
intracellular	20428796
trans	20428796
-	20428796
duction	20428796
.	20428796

Improving	20428796
the	20428796
understanding	20428796
of	20428796
TGF	20428796
-	20428796
beta	20428796
in	20428796
keloid	20428796
disease	20428796
could	20428796
lead	20428796
to	20428796
the	20428796
development	20428796
of	20428796
clinically	20428796
useful	20428796
therapeutic	20428796
modalities	20428796
for	20428796
treatment	20428796
of	20428796
keloid	20428796
disease	20428796
or	20428796
even	20428796
allow	20428796
identification	20428796
of	20428796
preventive	20428796
strategies	20428796
.	20428796
TAK1	19536134
is	19536134
an	19536134
essential	19536134
regulator	19536134
of	19536134
BMP	19536134
signalling	19536134
in	19536134
cartilage	19536134
.	19536134

TGFbeta	19536134
activated	19536134
kinase	19536134
1	19536134
(	19536134
TAK1	19536134
)	19536134
,	19536134
a	19536134
member	19536134
of	19536134
the	19536134
MAPKKK	19536134
family	19536134
,	19536134
controls	19536134
diverse	19536134
functions	19536134
ranging	19536134
from	19536134
innate	19536134
and	19536134
adaptive	19536134
immune	19536134
system	19536134
activation	19536134
to	19536134
vascular	19536134
development	19536134
and	19536134
apoptosis	19536134
.	19536134

To	19536134
analyse	19536134
the	19536134
in	19536134
vivo	19536134
function	19536134
of	19536134
TAK1	19536134
in	19536134
cartilage	19536134
,	19536134
we	19536134
generated	19536134
mice	19536134
with	19536134
a	19536134
conditional	19536134
deletion	19536134
of	19536134
Tak1	19536134
driven	19536134
by	19536134
the	19536134
collagen	19536134
2	19536134
promoter	19536134
.	19536134

Tak1	19536134
(	19536134
col2	19536134
)	19536134
mice	19536134
displayed	19536134
severe	19536134
chondrodysplasia	19536134
with	19536134
runting	19536134
,	19536134
impaired	19536134
formation	19536134
of	19536134
secondary	19536134
centres	19536134
of	19536134
ossification	19536134
,	19536134
and	19536134
joint	19536134
abnormalities	19536134
including	19536134
elbow	19536134
dislocation	19536134
and	19536134
tarsal	19536134
fusion	19536134
.	19536134

This	19536134
phenotype	19536134
resembled	19536134
that	19536134
of	19536134
bone	19536134
morphogenetic	19536134
protein	19536134
receptor	19536134
(	19536134
BMPR	19536134
)	19536134
1	19536134
and	19536134
Gdf5	19536134
-	19536134
deficient	19536134
mice	19536134
.	19536134

BMPR	19536134
signalling	19536134
was	19536134
markedly	19536134
impaired	19536134
in	19536134
TAK1	19536134
-	19536134
deficient	19536134
chondrocytes	19536134
as	19536134
evidenced	19536134
by	19536134
reduced	19536134
expression	19536134
of	19536134
known	19536134
BMP	19536134
target	19536134
genes	19536134
as	19536134
well	19536134
as	19536134
reduced	19536134
phosphorylation	19536134
of	19536134
Smad1	19536134
/	19536134
5	19536134
/	19536134
8	19536134
and	19536134
p38	19536134
/	19536134
Jnk	19536134
/	19536134
Erk	19536134
MAP	19536134
kinases	19536134
.	19536134

TAK1	19536134
mediates	19536134
Smad1	19536134
phosphorylation	19536134
at	19536134
C	19536134
-	19536134
terminal	19536134
serine	19536134
residues	19536134
.	19536134

These	19536134
findings	19536134
provide	19536134
the	19536134
first	19536134
in	19536134
vivo	19536134
evidence	19536134
in	19536134
a	19536134
mammalian	19536134
system	19536134
that	19536134
TAK1	19536134
is	19536134
required	19536134
for	19536134
BMP	19536134
signalling	19536134
and	19536134
functions	19536134
as	19536134
an	19536134
upstream	19536134
activating	19536134
kinase	19536134
for	19536134
Smad1	19536134
/	19536134
5	19536134
/	19536134
8	19536134
in	19536134
addition	19536134
to	19536134
its	19536134
known	19536134
role	19536134
in	19536134
regulating	19536134
MAP	19536134
kinase	19536134
pathways	19536134
.	19536134

Our	19536134
experiments	19536134
reveal	19536134
an	19536134
essential	19536134
role	19536134
for	19536134
TAK1	19536134
in	19536134
the	19536134
morphogenesis	19536134
,	19536134
growth	19536134
,	19536134
and	19536134
maintenance	19536134
of	19536134
cartilage	19536134
.	19536134
Promoter	20080916
insertion	20080916
/	20080916
deletion	20080916
in	20080916
the	20080916
IRF5	20080916
gene	20080916
is	20080916
highly	20080916
associated	20080916
with	20080916
susceptibility	20080916
to	20080916
systemic	20080916
lupus	20080916
erythematosus	20080916
in	20080916
distinct	20080916
populations	20080916
,	20080916
but	20080916
exerts	20080916
a	20080916
modest	20080916
effect	20080916
on	20080916
gene	20080916
expression	20080916
in	20080916
peripheral	20080916
blood	20080916
mononuclear	20080916
cells	20080916
.	20080916

OBJECTIVE	20080916
:	20080916
We	20080916
examined	20080916
the	20080916
genetic	20080916
association	20080916
of	20080916
the	20080916
promoter	20080916
insertion	20080916
/	20080916
deletion	20080916
(	20080916
indel	20080916
)	20080916
in	20080916
IRF5	20080916
gene	20080916
with	20080916
systemic	20080916
lupus	20080916
erythematosus	20080916
(	20080916
SLE	20080916
)	20080916
in	20080916
distinct	20080916
populations	20080916
and	20080916
assessed	20080916
its	20080916
role	20080916
in	20080916
gene	20080916
expression	20080916
.	20080916

METHODS	20080916
:	20080916
Four	20080916
IRF5	20080916
polymorphisms	20080916
were	20080916
genotyped	20080916
in	20080916
1488	20080916
SLE	20080916
patients	20080916
and	20080916
1466	20080916
controls	20080916
.	20080916

Gene	20080916
expression	20080916
was	20080916
analyzed	20080916
by	20080916
quantitative	20080916
real	20080916
-	20080916
time	20080916
PCR	20080916
using	20080916
RNA	20080916
from	20080916
peripheral	20080916
blood	20080916
mononuclear	20080916
cells	20080916
(	20080916
PBMC	20080916
)	20080916
.	20080916

RESULTS	20080916
:	20080916
The	20080916
promoter	20080916
indel	20080916
and	20080916
rs2070197	20080916
had	20080916
independent	20080916
genetic	20080916
effects	20080916
,	20080916
which	20080916
accounted	20080916
for	20080916
the	20080916
association	20080916
of	20080916
rs2004640	20080916
and	20080916
rs10954213	20080916
.	20080916

Gene	20080916
expression	20080916
analysis	20080916
revealed	20080916
that	20080916
rs10954213	20080916
exerted	20080916
the	20080916
greatest	20080916
influence	20080916
on	20080916
IRF5	20080916
transcript	20080916
levels	20080916
.	20080916

CONCLUSION	20080916
:	20080916
We	20080916
corroborated	20080916
the	20080916
association	20080916
of	20080916
the	20080916
promoter	20080916
indel	20080916
with	20080916
SLE	20080916
in	20080916
5	20080916
different	20080916
populations	20080916
and	20080916
revealed	20080916
that	20080916
rs10954213	20080916
is	20080916
the	20080916
main	20080916
single	20080916
-	20080916
nucleotide	20080916
polymorphism	20080916
responsible	20080916
for	20080916
altered	20080916
IRF5	20080916
expression	20080916
in	20080916
PBMC	20080916
.	20080916
Tissue	28368537
-	28368537
Specific	28368537
Ablation	28368537
of	28368537
the	28368537
LIF	28368537
Receptor	28368537
in	28368537
the	28368537
Murine	28368537
Uterine	28368537
Epithelium	28368537
Results	28368537
in	28368537
Implantation	28368537
Failure	28368537
.	28368537

The	28368537
cytokine	28368537
leukemia	28368537
inhibitory	28368537
factor	28368537
(	28368537
LIF	28368537
)	28368537
is	28368537
essential	28368537
for	28368537
rendering	28368537
the	28368537
uterus	28368537
receptive	28368537
for	28368537
blastocyst	28368537
implantation	28368537
.	28368537

In	28368537
mice	28368537
,	28368537
LIF	28368537
receptor	28368537
expression	28368537
(	28368537
LIFR	28368537
)	28368537
is	28368537
largely	28368537
restricted	28368537
to	28368537
the	28368537
uterine	28368537
luminal	28368537
epithelium	28368537
(	28368537
LE	28368537
)	28368537
.	28368537

LIF	28368537
,	28368537
secreted	28368537
from	28368537
the	28368537
endometrial	28368537
glands	28368537
(	28368537
GEs	28368537
)	28368537
,	28368537
binds	28368537
to	28368537
the	28368537
LIFR	28368537
,	28368537
activating	28368537
the	28368537
Janus	28368537
kinase	28368537
-	28368537
signal	28368537
transducer	28368537
and	28368537
activation	28368537
of	28368537
transcription	28368537
(	28368537
STAT	28368537
)	28368537
3	28368537
(	28368537
Jak	28368537
-	28368537
Stat3	28368537
)	28368537
signaling	28368537
pathway	28368537
in	28368537
the	28368537
LE	28368537
.	28368537

JAK	28368537
-	28368537
STAT	28368537
activation	28368537
converts	28368537
the	28368537
LE	28368537
to	28368537
a	28368537
receptive	28368537
state	28368537
so	28368537
that	28368537
juxtaposed	28368537
blastocysts	28368537
begin	28368537
to	28368537
implant	28368537
.	28368537

To	28368537
specifically	28368537
delete	28368537
the	28368537
LIFR	28368537
in	28368537
the	28368537
LE	28368537
,	28368537
we	28368537
derived	28368537
a	28368537
line	28368537
of	28368537
mice	28368537
in	28368537
which	28368537
Cre	28368537
recombinase	28368537
was	28368537
inserted	28368537
into	28368537
the	28368537
endogenous	28368537
lactoferrin	28368537
gene	28368537
(	28368537
Ltf	28368537
-	28368537
Cre	28368537
)	28368537
.	28368537

Lactoferrin	28368537
expression	28368537
in	28368537
the	28368537
LE	28368537
is	28368537
induced	28368537
by	28368537
E2	28368537
,	28368537
and	28368537
we	28368537
demonstrate	28368537
that	28368537
Cre	28368537
recombinase	28368537
activity	28368537
is	28368537
restricted	28368537
to	28368537
the	28368537
LE	28368537
and	28368537
GE	28368537
.	28368537

To	28368537
determine	28368537
the	28368537
requirement	28368537
of	28368537
the	28368537
LIFR	28368537
in	28368537
implantation	28368537
,	28368537
we	28368537
derived	28368537
an	28368537
additional	28368537
mouse	28368537
line	28368537
carrying	28368537
a	28368537
conditional	28368537
(	28368537
floxed	28368537
)	28368537
Lifr	28368537
flx	28368537
/	28368537
flx	28368537
gene	28368537
.	28368537

Crossing	28368537
Ltf	28368537
-	28368537
Cre	28368537
mice	28368537
with	28368537
Lifr	28368537
flx	28368537
/	28368537
flx	28368537
mice	28368537
generated	28368537
Lifr	28368537
flx	28368537
/	28368537
D	28368537
:	28368537
Ltf	28368537
Cre	28368537
/	28368537
+	28368537
females	28368537
that	28368537
were	28368537
overtly	28368537
normal	28368537
but	28368537
infertile	28368537
.	28368537

Many	28368537
of	28368537
these	28368537
females	28368537
,	28368537
despite	28368537
repeated	28368537
matings	28368537
,	28368537
did	28368537
not	28368537
become	28368537
pregnant	28368537
.	28368537

Unimplanted	28368537
blastocysts	28368537
were	28368537
recovered	28368537
from	28368537
the	28368537
Lifr	28368537
flx	28368537
/	28368537
D	28368537
:	28368537
Ltf	28368537
Cre	28368537
/	28368537
+	28368537
uteri	28368537
and	28368537
,	28368537
when	28368537
transferred	28368537
to	28368537
wild	28368537
-	28368537
type	28368537
recipients	28368537
,	28368537
implanted	28368537
normally	28368537
,	28368537
indicating	28368537
that	28368537
uterine	28368537
receptivity	28368537
rather	28368537
than	28368537
the	28368537
embryo	28368537
'	28368537
s	28368537
competency	28368537
is	28368537
compromised	28368537
.	28368537

The	28368537
loss	28368537
of	28368537
Lifr	28368537
results	28368537
in	28368537
both	28368537
the	28368537
failure	28368537
for	28368537
STAT3	28368537
to	28368537
translocate	28368537
to	28368537
the	28368537
LE	28368537
nuclei	28368537
and	28368537
a	28368537
reduction	28368537
in	28368537
the	28368537
expression	28368537
of	28368537
the	28368537
LIF	28368537
regulated	28368537
gene	28368537
Msx1	28368537
that	28368537
regulates	28368537
uterine	28368537
receptivity	28368537
.	28368537

These	28368537
results	28368537
reveal	28368537
that	28368537
uterine	28368537
expression	28368537
of	28368537
the	28368537
LIFR	28368537
is	28368537
essential	28368537
for	28368537
embryo	28368537
implantation	28368537
and	28368537
further	28368537
define	28368537
the	28368537
components	28368537
of	28368537
the	28368537
LIF	28368537
signaling	28368537
pathway	28368537
necessary	28368537
for	28368537
effective	28368537
implantation	28368537
.	28368537
Psoriasin	28393239
promotes	28393239
invasion	28393239
,	28393239
aggregation	28393239
and	28393239
survival	28393239
of	28393239
pancreatic	28393239
cancer	28393239
cells	28393239
;	28393239
association	28393239
with	28393239
disease	28393239
progression	28393239
.	28393239

Psoriasin	28393239
(	28393239
S100A7	28393239
)	28393239
is	28393239
an	28393239
11	28393239
-	28393239
kDa	28393239
small	28393239
calcium	28393239
binding	28393239
protein	28393239
initially	28393239
isolated	28393239
from	28393239
psoriatic	28393239
skin	28393239
lesions	28393239
.	28393239

It	28393239
belongs	28393239
to	28393239
the	28393239
S100	28393239
family	28393239
of	28393239
proteins	28393239
which	28393239
play	28393239
an	28393239
important	28393239
role	28393239
in	28393239
a	28393239
range	28393239
of	28393239
cell	28393239
functions	28393239
including	28393239
proliferation	28393239
,	28393239
differentiation	28393239
,	28393239
migration	28393239
and	28393239
apoptosis	28393239
.	28393239

Aberrant	28393239
Psoriasin	28393239
expression	28393239
has	28393239
been	28393239
implicated	28393239
in	28393239
a	28393239
range	28393239
of	28393239
cancers	28393239
and	28393239
is	28393239
often	28393239
associated	28393239
with	28393239
poor	28393239
prognosis	28393239
.	28393239

This	28393239
study	28393239
examined	28393239
the	28393239
role	28393239
of	28393239
Psoriasin	28393239
on	28393239
pancreatic	28393239
cancer	28393239
cell	28393239
functions	28393239
and	28393239
the	28393239
implication	28393239
in	28393239
progression	28393239
of	28393239
the	28393239
disease	28393239
.	28393239

Expression	28393239
of	28393239
Psoriasin	28393239
was	28393239
determined	28393239
in	28393239
a	28393239
cohort	28393239
of	28393239
pancreatic	28393239
tissues	28393239
comprised	28393239
of	28393239
126	28393239
pancreatic	28393239
tumours	28393239
and	28393239
114	28393239
adjacent	28393239
non	28393239
-	28393239
tumour	28393239
pancreatic	28393239
tissues	28393239
.	28393239

Knockdown	28393239
and	28393239
overexpression	28393239
of	28393239
Psoriasin	28393239
in	28393239
pancreatic	28393239
cancer	28393239
cells	28393239
was	28393239
performed	28393239
using	28393239
specifically	28393239
constructed	28393239
plasmids	28393239
,	28393239
which	28393239
either	28393239
had	28393239
anti	28393239
-	28393239
Psoriasin	28393239
ribozyme	28393239
transgene	28393239
or	28393239
the	28393239
full	28393239
length	28393239
human	28393239
Psoriasin	28393239
coding	28393239
sequence	28393239
.	28393239

Psoriasin	28393239
knockdown	28393239
and	28393239
overexpression	28393239
was	28393239
verified	28393239
using	28393239
conventional	28393239
RT	28393239
-	28393239
PCR	28393239
and	28393239
qPCR	28393239
.	28393239

The	28393239
effect	28393239
of	28393239
manipulating	28393239
Psoriasin	28393239
expression	28393239
on	28393239
pancreatic	28393239
cancer	28393239
cell	28393239
functions	28393239
was	28393239
assessed	28393239
using	28393239
several	28393239
in	28393239
vitro	28393239
cell	28393239
function	28393239
assays	28393239
.	28393239

Local	28393239
invasive	28393239
pancreatic	28393239
cancers	28393239
extended	28393239
beyond	28393239
the	28393239
pancreas	28393239
expressed	28393239
higher	28393239
levels	28393239
of	28393239
Psoriasin	28393239
transcripts	28393239
compared	28393239
with	28393239
the	28393239
cancers	28393239
confined	28393239
to	28393239
the	28393239
pancreas	28393239
.	28393239

Primary	28393239
tumours	28393239
with	28393239
distant	28393239
metastases	28393239
exhibited	28393239
a	28393239
reduced	28393239
expression	28393239
of	28393239
Psoriasin	28393239
.	28393239

Psoriasin	28393239
overexpression	28393239
cell	28393239
lines	28393239
exhibited	28393239
significantly	28393239
increased	28393239
growth	28393239
and	28393239
migration	28393239
compared	28393239
to	28393239
control	28393239
cells	28393239
.	28393239

In	28393239
addition	28393239
,	28393239
Psoriasin	28393239
overexpression	28393239
resulted	28393239
in	28393239
increased	28393239
pancreatic	28393239
cancer	28393239
cell	28393239
invasion	28393239
which	28393239
was	28393239
associated	28393239
with	28393239
upregulation	28393239
of	28393239
matrix	28393239
metalloproteinase	28393239
-	28393239
2	28393239
(	28393239
MMP	28393239
-	28393239
2	28393239
)	28393239
and	28393239
MMP	28393239
-	28393239
9	28393239
.	28393239

Overexpression	28393239
of	28393239
Psoriasin	28393239
also	28393239
promoted	28393239
aggregation	28393239
and	28393239
survival	28393239
of	28393239
pancreatic	28393239
cancer	28393239
cells	28393239
when	28393239
they	28393239
lost	28393239
anchorage	28393239
.	28393239

Taken	28393239
together	28393239
,	28393239
higher	28393239
expression	28393239
of	28393239
Psoriasin	28393239
was	28393239
associated	28393239
with	28393239
local	28393239
invasion	28393239
in	28393239
pancreatic	28393239
cancers	28393239
.	28393239

Psoriasin	28393239
expression	28393239
is	28393239
associated	28393239
with	28393239
pancreatic	28393239
cancer	28393239
cell	28393239
growth	28393239
,	28393239
migration	28393239
,	28393239
cell	28393239
-	28393239
matrix	28393239
adhesion	28393239
,	28393239
and	28393239
invasion	28393239
via	28393239
regulation	28393239
of	28393239
MMPs	28393239
.	28393239

As	28393239
such	28393239
,	28393239
the	28393239
proposed	28393239
implications	28393239
of	28393239
Psoriasin	28393239
in	28393239
invasion	28393239
,	28393239
disease	28393239
progression	28393239
and	28393239
as	28393239
a	28393239
potential	28393239
therapeutic	28393239
target	28393239
warrant	28393239
further	28393239
investigation	28393239
.	28393239
Influence	15464247
of	15464247
interleukin	15464247
12B	15464247
(	15464247
IL12B	15464247
)	15464247
polymorphisms	15464247
on	15464247
spontaneous	15464247
and	15464247
treatment	15464247
-	15464247
induced	15464247
recovery	15464247
from	15464247
hepatitis	15464247
C	15464247
virus	15464247
infection	15464247
.	15464247

BACKGROUND	15464247
/	15464247
AIMS	15464247
:	15464247
Interleukin	15464247
-	15464247
12	15464247
(	15464247
IL	15464247
-	15464247
12	15464247
)	15464247
governs	15464247
the	15464247
Th1	15464247
-	15464247
type	15464247
immune	15464247
response	15464247
,	15464247
affecting	15464247
the	15464247
spontaneous	15464247
and	15464247
treatment	15464247
-	15464247
induced	15464247
recovery	15464247
from	15464247
HCV	15464247
-	15464247
infection	15464247
.	15464247

We	15464247
investigated	15464247
whether	15464247
the	15464247
IL12B	15464247
polymorphisms	15464247
within	15464247
the	15464247
promoter	15464247
region	15464247
(	15464247
4	15464247
bp	15464247
insertion	15464247
/	15464247
deletion	15464247
)	15464247
and	15464247
the	15464247
3	15464247
'	15464247
-	15464247
UTR	15464247
(	15464247
1188	15464247
-	15464247
A	15464247
/	15464247
C	15464247
)	15464247
,	15464247
which	15464247
have	15464247
been	15464247
reported	15464247
to	15464247
influence	15464247
IL	15464247
-	15464247
12	15464247
synthesis	15464247
,	15464247
are	15464247
associated	15464247
with	15464247
the	15464247
outcome	15464247
of	15464247
HCV	15464247
infection	15464247
.	15464247

METHODS	15464247
:	15464247
We	15464247
analyzed	15464247
186	15464247
individuals	15464247
with	15464247
spontaneous	15464247
HCV	15464247
clearance	15464247
,	15464247
501	15464247
chronically	15464247
HCV	15464247
infected	15464247
patients	15464247
,	15464247
and	15464247
217	15464247
healthy	15464247
controls	15464247
.	15464247

IL12B	15464247
3	15464247
'	15464247
-	15464247
UTR	15464247
and	15464247
promoter	15464247
genotyping	15464247
was	15464247
performed	15464247
by	15464247
Taqman	15464247
-	15464247
based	15464247
assays	15464247
with	15464247
allele	15464247
-	15464247
specific	15464247
oligonucleotide	15464247
probes	15464247
and	15464247
PCR	15464247
-	15464247
based	15464247
allele	15464247
-	15464247
specific	15464247
DNA	15464247
-	15464247
amplification	15464247
,	15464247
respectively	15464247
.	15464247

RESULTS	15464247
:	15464247
The	15464247
proportion	15464247
of	15464247
IL12B	15464247
promoter	15464247
and	15464247
3	15464247
'	15464247
-	15464247
UTR	15464247
genotypes	15464247
did	15464247
not	15464247
differ	15464247
significantly	15464247
between	15464247
the	15464247
different	15464247
cohorts	15464247
.	15464247

However	15464247
,	15464247
HCV	15464247
genotype	15464247
1	15464247
-	15464247
infected	15464247
patients	15464247
with	15464247
high	15464247
baseline	15464247
viremia	15464247
carrying	15464247
the	15464247
IL12B	15464247
3	15464247
'	15464247
-	15464247
UTR	15464247
1188	15464247
-	15464247
C	15464247
-	15464247
allele	15464247
showed	15464247
significantly	15464247
higher	15464247
sustained	15464247
virologic	15464247
response	15464247
(	15464247
SVR	15464247
)	15464247
rates	15464247
(	15464247
25	15464247
.	15464247
3%	15464247
vs	15464247
.	15464247

46%	15464247
vs	15464247
.	15464247

54	15464247
.	15464247
5%	15464247
for	15464247
A	15464247
/	15464247
A	15464247
,	15464247
A	15464247
/	15464247
C	15464247
and	15464247
C	15464247
/	15464247
C	15464247
)	15464247
due	15464247
to	15464247
reduced	15464247
relapse	15464247
rates	15464247
(	15464247
24	15464247
.	15464247
2%	15464247
vs	15464247
.	15464247

12%	15464247
vs	15464247
.	15464247

zero	15464247
%	15464247
for	15464247
A	15464247
/	15464247
A	15464247
,	15464247
A	15464247
/	15464247
C	15464247
and	15464247
C	15464247
/	15464247
C	15464247
)	15464247
.	15464247

CONCLUSIONS	15464247
:	15464247
IL12B	15464247
3	15464247
'	15464247
-	15464247
UTR	15464247
1188	15464247
-	15464247
C	15464247
-	15464247
allele	15464247
carriers	15464247
appear	15464247
to	15464247
be	15464247
capable	15464247
of	15464247
responding	15464247
more	15464247
efficiently	15464247
to	15464247
antiviral	15464247
combination	15464247
therapy	15464247
as	15464247
a	15464247
consequence	15464247
of	15464247
a	15464247
reduced	15464247
relapse	15464247
rate	15464247
.	15464247

No	15464247
association	15464247
of	15464247
IL12B	15464247
polymorphisms	15464247
and	15464247
self	15464247
-	15464247
limited	15464247
HCV	15464247
infection	15464247
could	15464247
be	15464247
demonstrated	15464247
.	15464247
Neurofibromin	19048115
1	19048115
(	19048115
NF1	19048115
)	19048115
defects	19048115
are	19048115
common	19048115
in	19048115
human	19048115
ovarian	19048115
serous	19048115
carcinomas	19048115
and	19048115
co	19048115
-	19048115
occur	19048115
with	19048115
TP53	19048115
mutations	19048115
.	19048115

Ovarian	19048115
serous	19048115
carcinoma	19048115
(	19048115
OSC	19048115
)	19048115
is	19048115
the	19048115
most	19048115
common	19048115
and	19048115
lethal	19048115
histologic	19048115
type	19048115
of	19048115
ovarian	19048115
epithelial	19048115
malignancy	19048115
.	19048115

Mutations	19048115
of	19048115
TP53	19048115
and	19048115
dysfunction	19048115
of	19048115
the	19048115
Brca1	19048115
and	19048115
/	19048115
or	19048115
Brca2	19048115
tumor	19048115
-	19048115
suppressor	19048115
proteins	19048115
have	19048115
been	19048115
implicated	19048115
in	19048115
the	19048115
molecular	19048115
pathogenesis	19048115
of	19048115
a	19048115
large	19048115
fraction	19048115
of	19048115
OSCs	19048115
,	19048115
but	19048115
frequent	19048115
somatic	19048115
mutations	19048115
in	19048115
other	19048115
well	19048115
-	19048115
established	19048115
tumor	19048115
-	19048115
suppressor	19048115
genes	19048115
have	19048115
not	19048115
been	19048115
identified	19048115
.	19048115

Using	19048115
a	19048115
genome	19048115
-	19048115
wide	19048115
screen	19048115
of	19048115
DNA	19048115
copy	19048115
number	19048115
alterations	19048115
in	19048115
36	19048115
primary	19048115
OSCs	19048115
,	19048115
we	19048115
identified	19048115
two	19048115
tumors	19048115
with	19048115
apparent	19048115
homozygous	19048115
deletions	19048115
of	19048115
the	19048115
NF1	19048115
gene	19048115
.	19048115

Subsequently	19048115
,	19048115
18	19048115
ovarian	19048115
carcinoma	19048115
-	19048115
derived	19048115
cell	19048115
lines	19048115
and	19048115
41	19048115
primary	19048115
OSCs	19048115
were	19048115
evaluated	19048115
for	19048115
NF1	19048115
alterations	19048115
.	19048115

Markedly	19048115
reduced	19048115
or	19048115
absent	19048115
expression	19048115
of	19048115
Nf1	19048115
protein	19048115
was	19048115
observed	19048115
in	19048115
6	19048115
of	19048115
the	19048115
18	19048115
cell	19048115
lines	19048115
,	19048115
and	19048115
using	19048115
the	19048115
protein	19048115
truncation	19048115
test	19048115
and	19048115
sequencing	19048115
of	19048115
cDNA	19048115
and	19048115
genomic	19048115
DNA	19048115
,	19048115
NF1	19048115
mutations	19048115
resulting	19048115
in	19048115
deletion	19048115
of	19048115
exons	19048115
and	19048115
/	19048115
or	19048115
aberrant	19048115
splicing	19048115
of	19048115
NF1	19048115
transcripts	19048115
were	19048115
detected	19048115
in	19048115
5	19048115
of	19048115
the	19048115
6	19048115
cell	19048115
lines	19048115
with	19048115
loss	19048115
of	19048115
NF1	19048115
expression	19048115
.	19048115

Similarly	19048115
,	19048115
NF1	19048115
alterations	19048115
including	19048115
homozygous	19048115
deletions	19048115
and	19048115
splicing	19048115
mutations	19048115
were	19048115
identified	19048115
in	19048115
9	19048115
(	19048115
22%	19048115
)	19048115
of	19048115
41	19048115
primary	19048115
OSCs	19048115
.	19048115

As	19048115
expected	19048115
,	19048115
tumors	19048115
and	19048115
cell	19048115
lines	19048115
with	19048115
NF1	19048115
defects	19048115
lacked	19048115
mutations	19048115
in	19048115
KRAS	19048115
or	19048115
BRAF	19048115
but	19048115
showed	19048115
Ras	19048115
pathway	19048115
activation	19048115
based	19048115
on	19048115
immunohistochemical	19048115
detection	19048115
of	19048115
phosphorylated	19048115
MAPK	19048115
(	19048115
primary	19048115
tumors	19048115
)	19048115
or	19048115
increased	19048115
levels	19048115
of	19048115
GTP	19048115
-	19048115
bound	19048115
Ras	19048115
(	19048115
cell	19048115
lines	19048115
)	19048115
.	19048115

The	19048115
TP53	19048115
tumor	19048115
-	19048115
suppressor	19048115
gene	19048115
was	19048115
mutated	19048115
in	19048115
all	19048115
OSCs	19048115
with	19048115
documented	19048115
NF1	19048115
mutation	19048115
,	19048115
suggesting	19048115
that	19048115
the	19048115
pathways	19048115
regulated	19048115
by	19048115
these	19048115
two	19048115
tumor	19048115
-	19048115
suppressor	19048115
proteins	19048115
often	19048115
cooperate	19048115
in	19048115
the	19048115
development	19048115
of	19048115
ovarian	19048115
carcinomas	19048115
with	19048115
serous	19048115
differentiation	19048115
.	19048115
Drug	16801510
-	16801510
induced	16801510
long	16801510
QT	16801510
syndrome	16801510
in	16801510
injection	16801510
drug	16801510
users	16801510
receiving	16801510
methadone	16801510
:	16801510
high	16801510
frequency	16801510
in	16801510
hospitalized	16801510
patients	16801510
and	16801510
risk	16801510
factors	16801510
.	16801510

BACKGROUND	16801510
:	16801510
Drug	16801510
-	16801510
induced	16801510
long	16801510
QT	16801510
syndrome	16801510
is	16801510
a	16801510
serious	16801510
adverse	16801510
drug	16801510
reaction	16801510
.	16801510

Methadone	16801510
prolongs	16801510
the	16801510
QT	16801510
interval	16801510
in	16801510
vitro	16801510
in	16801510
a	16801510
dose	16801510
-	16801510
dependent	16801510
manner	16801510
.	16801510

In	16801510
the	16801510
inpatient	16801510
setting	16801510
,	16801510
the	16801510
frequency	16801510
of	16801510
QT	16801510
interval	16801510
prolongation	16801510
with	16801510
methadone	16801510
treatment	16801510
,	16801510
its	16801510
dose	16801510
dependence	16801510
,	16801510
and	16801510
the	16801510
importance	16801510
of	16801510
cofactors	16801510
such	16801510
as	16801510
drug	16801510
-	16801510
drug	16801510
interactions	16801510
remain	16801510
unknown	16801510
.	16801510

METHODS	16801510
:	16801510
We	16801510
performed	16801510
a	16801510
systematic	16801510
,	16801510
retrospective	16801510
study	16801510
comparing	16801510
active	16801510
or	16801510
former	16801510
intravenous	16801510
drug	16801510
users	16801510
receiving	16801510
methadone	16801510
and	16801510
those	16801510
not	16801510
receiving	16801510
methadone	16801510
among	16801510
all	16801510
patients	16801510
hospitalized	16801510
over	16801510
a	16801510
5	16801510
-	16801510
year	16801510
period	16801510
in	16801510
a	16801510
tertiary	16801510
care	16801510
hospital	16801510
.	16801510

A	16801510
total	16801510
of	16801510
167	16801510
patients	16801510
receiving	16801510
methadone	16801510
fulfilled	16801510
the	16801510
inclusion	16801510
criteria	16801510
and	16801510
were	16801510
compared	16801510
with	16801510
a	16801510
control	16801510
group	16801510
of	16801510
80	16801510
injection	16801510
drug	16801510
users	16801510
not	16801510
receiving	16801510
methadone	16801510
.	16801510

In	16801510
addition	16801510
to	16801510
methadone	16801510
dose	16801510
,	16801510
15	16801510
demographic	16801510
,	16801510
biological	16801510
,	16801510
and	16801510
pharmacological	16801510
variables	16801510
were	16801510
considered	16801510
as	16801510
potential	16801510
risk	16801510
factors	16801510
for	16801510
QT	16801510
prolongation	16801510
.	16801510

RESULTS	16801510
:	16801510
Among	16801510
167	16801510
methadone	16801510
maintenance	16801510
patients	16801510
,	16801510
the	16801510
prevalence	16801510
of	16801510
QTc	16801510
prolongation	16801510
to	16801510
0	16801510
.	16801510
50	16801510
second	16801510
(	16801510
(	16801510
1	16801510
/	16801510
2	16801510
)	16801510
)	16801510
or	16801510
longer	16801510
was	16801510
16	16801510
.	16801510
2%	16801510
compared	16801510
with	16801510
0%	16801510
in	16801510
80	16801510
control	16801510
subjects	16801510
.	16801510

Six	16801510
patients	16801510
(	16801510
3	16801510
.	16801510
6%	16801510
)	16801510
in	16801510
the	16801510
methadone	16801510
group	16801510
presented	16801510
torsades	16801510
de	16801510
pointes	16801510
.	16801510

QTc	16801510
length	16801510
was	16801510
weakly	16801510
but	16801510
significantly	16801510
associated	16801510
with	16801510
methadone	16801510
daily	16801510
dose	16801510
(	16801510
Spearman	16801510
rank	16801510
correlation	16801510
coefficient	16801510
,	16801510
0	16801510
.	16801510
20	16801510
;	16801510
P	16801510
<	16801510
.	16801510
01	16801510
)	16801510
.	16801510

Multivariate	16801510
regression	16801510
analysis	16801510
allowed	16801510
attribution	16801510
of	16801510
31	16801510
.	16801510
8%	16801510
of	16801510
QTc	16801510
variability	16801510
to	16801510
methadone	16801510
dose	16801510
,	16801510
cytochrome	16801510
P	16801510
-	16801510
450	16801510
3A4	16801510
drug	16801510
-	16801510
drug	16801510
interactions	16801510
,	16801510
hypokalemia	16801510
,	16801510
and	16801510
altered	16801510
liver	16801510
function	16801510
.	16801510

CONCLUSIONS	16801510
:	16801510
QT	16801510
interval	16801510
prolongation	16801510
in	16801510
methadone	16801510
maintenance	16801510
patients	16801510
hospitalized	16801510
in	16801510
a	16801510
tertiary	16801510
care	16801510
center	16801510
is	16801510
a	16801510
frequent	16801510
finding	16801510
.	16801510

Methadone	16801510
dose	16801510
,	16801510
presence	16801510
of	16801510
cytochrome	16801510
P	16801510
-	16801510
450	16801510
3A4	16801510
inhibitors	16801510
,	16801510
potassium	16801510
level	16801510
,	16801510
and	16801510
liver	16801510
function	16801510
contribute	16801510
to	16801510
QT	16801510
prolongation	16801510
.	16801510

Long	16801510
QT	16801510
syndrome	16801510
can	16801510
occur	16801510
with	16801510
low	16801510
doses	16801510
of	16801510
methadone	16801510
.	16801510
Upregulation	26615423
of	26615423
centrosomal	26615423
protein	26615423
55	26615423
is	26615423
associated	26615423
with	26615423
unfavorable	26615423
prognosis	26615423
and	26615423
tumor	26615423
invasion	26615423
in	26615423
epithelial	26615423
ovarian	26615423
carcinoma	26615423
.	26615423

Centrosomal	26615423
protein	26615423
55	26615423
(	26615423
CEP55	26615423
)	26615423
is	26615423
a	26615423
cell	26615423
cycle	26615423
regulator	26615423
implicated	26615423
in	26615423
development	26615423
of	26615423
certain	26615423
cancers	26615423
.	26615423

However	26615423
,	26615423
characteristics	26615423
of	26615423
CEP55	26615423
expression	26615423
and	26615423
its	26615423
clinical	26615423
/	26615423
prognostic	26615423
significance	26615423
are	26615423
unclear	26615423
in	26615423
human	26615423
epithelial	26615423
ovarian	26615423
carcinoma	26615423
(	26615423
EOC	26615423
)	26615423
.	26615423

Therefore	26615423
,	26615423
we	26615423
investigated	26615423
the	26615423
expression	26615423
and	26615423
clinicopathological	26615423
significance	26615423
of	26615423
CEP55	26615423
in	26615423
patients	26615423
with	26615423
EOC	26615423
and	26615423
its	26615423
role	26615423
in	26615423
regulating	26615423
invasion	26615423
and	26615423
metastasis	26615423
of	26615423
ovarian	26615423
cell	26615423
lines	26615423
.	26615423

CEP55	26615423
mRNA	26615423
and	26615423
protein	26615423
expression	26615423
levels	26615423
were	26615423
detected	26615423
by	26615423
quantitative	26615423
real	26615423
-	26615423
time	26615423
PCR	26615423
(	26615423
qRT	26615423
-	26615423
PCR	26615423
)	26615423
,	26615423
Western	26615423
blotting	26615423
,	26615423
and	26615423
immunohistochemistry	26615423
(	26615423
IHC	26615423
)	26615423
.	26615423

Potential	26615423
associations	26615423
of	26615423
CEP55	26615423
expression	26615423
scores	26615423
with	26615423
clinical	26615423
parameters	26615423
and	26615423
patient	26615423
survival	26615423
were	26615423
evaluated	26615423
.	26615423

CEP55	26615423
function	26615423
was	26615423
investigated	26615423
further	26615423
using	26615423
RNA	26615423
interference	26615423
,	26615423
wound	26615423
healing	26615423
assay	26615423
,	26615423
transwell	26615423
assay	26615423
,	26615423
immunofluorescence	26615423
analysis	26615423
,	26615423
qRT	26615423
-	26615423
PCR	26615423
,	26615423
and	26615423
Western	26615423
blotting	26615423
.	26615423

CEP55	26615423
was	26615423
significantly	26615423
upregulated	26615423
in	26615423
ovarian	26615423
cancer	26615423
cell	26615423
lines	26615423
and	26615423
lesions	26615423
compared	26615423
with	26615423
normal	26615423
cells	26615423
and	26615423
adjacent	26615423
noncancerous	26615423
ovarian	26615423
tissues	26615423
.	26615423

In	26615423
the	26615423
213	26615423
EOC	26615423
samples	26615423
,	26615423
CEP55	26615423
protein	26615423
levels	26615423
were	26615423
positively	26615423
correlated	26615423
with	26615423
clinical	26615423
stage	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
lymph	26615423
node	26615423
metastasis	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
intraperitoneal	26615423
metastasis	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
tumor	26615423
recurrence	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
differentiation	26615423
grade	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
residual	26615423
tumor	26615423
size	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
,	26615423
ascites	26615423
see	26615423
tumor	26615423
cells	26615423
(	26615423
P	26615423
=	26615423
0	26615423
.	26615423
020	26615423
)	26615423
,	26615423
and	26615423
serum	26615423
CA153	26615423
level	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
.	26615423

Moreover	26615423
,	26615423
patients	26615423
with	26615423
aberrant	26615423
CEP55	26615423
protein	26615423
expression	26615423
showed	26615423
tendencies	26615423
to	26615423
receive	26615423
neoadjuvant	26615423
chemotherapy	26615423
(	26615423
P	26615423
<	26615423
0	26615423
.	26615423
001	26615423
)	26615423
and	26615423
cytoreductive	26615423
surgery	26615423
(	26615423
P	26615423
=	26615423
0	26615423
.	26615423
020	26615423
)	26615423
.	26615423

By	26615423
contrast	26615423
,	26615423
no	26615423
significant	26615423
correlation	26615423
was	26615423
detected	26615423
between	26615423
the	26615423
protein	26615423
levels	26615423
and	26615423
patient	26615423
age	26615423
,	26615423
histological	26615423
type	26615423
,	26615423
or	26615423
serum	26615423
CA125	26615423
,	26615423
CA199	26615423
,	26615423
CA724	26615423
,	26615423
NSE	26615423
,	26615423
CEA	26615423
,	26615423
and	26615423
b	26615423
-	26615423
HCG	26615423
levels	26615423
.	26615423

Patients	26615423
with	26615423
high	26615423
CEP55	26615423
protein	26615423
expression	26615423
had	26615423
shorter	26615423
overall	26615423
survival	26615423
and	26615423
disease	26615423
-	26615423
free	26615423
survival	26615423
compared	26615423
with	26615423
those	26615423
with	26615423
low	26615423
CEP55	26615423
expression	26615423
.	26615423

Multivariate	26615423
analysis	26615423
implicated	26615423
CEP55	26615423
as	26615423
an	26615423
independent	26615423
prognostic	26615423
indicator	26615423
for	26615423
EOC	26615423
patients	26615423
.	26615423

Additionally	26615423
,	26615423
downregulation	26615423
of	26615423
CEP55	26615423
in	26615423
ovarian	26615423
cancer	26615423
cells	26615423
remarkably	26615423
inhibited	26615423
cellular	26615423
motility	26615423
and	26615423
invasion	26615423
.	26615423

Aberrant	26615423
CEP55	26615423
expression	26615423
may	26615423
predict	26615423
unfavorable	26615423
clinical	26615423
outcomes	26615423
in	26615423
EOC	26615423
patients	26615423
and	26615423
play	26615423
an	26615423
important	26615423
role	26615423
in	26615423
regulating	26615423
invasion	26615423
in	26615423
ovarian	26615423
cancer	26615423
cells	26615423
.	26615423

Thus	26615423
,	26615423
CEP55	26615423
may	26615423
serve	26615423
as	26615423
a	26615423
prognostic	26615423
marker	26615423
and	26615423
therapeutic	26615423
target	26615423
for	26615423
EOC	26615423
.	26615423
Identification	18050247
of	18050247
novel	18050247
susceptibility	18050247
genes	18050247
in	18050247
childhood	18050247
-	18050247
onset	18050247
systemic	18050247
lupus	18050247
erythematosus	18050247
using	18050247
a	18050247
uniquely	18050247
designed	18050247
candidate	18050247
gene	18050247
pathway	18050247
platform	18050247
.	18050247

OBJECTIVE	18050247
:	18050247
Childhood	18050247
-	18050247
onset	18050247
systemic	18050247
lupus	18050247
erythematosus	18050247
(	18050247
SLE	18050247
)	18050247
presents	18050247
a	18050247
unique	18050247
subgroup	18050247
of	18050247
patients	18050247
for	18050247
genetic	18050247
study	18050247
.	18050247

The	18050247
present	18050247
study	18050247
was	18050247
undertaken	18050247
to	18050247
identify	18050247
susceptibility	18050247
genes	18050247
contributing	18050247
to	18050247
SLE	18050247
,	18050247
using	18050247
a	18050247
novel	18050247
candidate	18050247
gene	18050247
pathway	18050247
microarray	18050247
platform	18050247
to	18050247
investigate	18050247
gene	18050247
expression	18050247
in	18050247
patients	18050247
with	18050247
childhood	18050247
-	18050247
onset	18050247
SLE	18050247
and	18050247
both	18050247
of	18050247
their	18050247
parents	18050247
.	18050247

METHODS	18050247
:	18050247
Utilizing	18050247
bioinformatic	18050247
tools	18050247
,	18050247
a	18050247
platform	18050247
of	18050247
9	18050247
,	18050247
412	18050247
single	18050247
-	18050247
nucleotide	18050247
polymorphisms	18050247
(	18050247
SNPs	18050247
)	18050247
from	18050247
1	18050247
,	18050247
204	18050247
genes	18050247
was	18050247
designed	18050247
and	18050247
validated	18050247
.	18050247

Molecular	18050247
inversion	18050247
probes	18050247
and	18050247
high	18050247
-	18050247
throughput	18050247
SNP	18050247
technologies	18050247
were	18050247
used	18050247
for	18050247
assay	18050247
development	18050247
.	18050247

Seven	18050247
hundred	18050247
fifty	18050247
three	18050247
subjects	18050247
,	18050247
corresponding	18050247
to	18050247
251	18050247
full	18050247
trios	18050247
of	18050247
childhood	18050247
-	18050247
onset	18050247
SLE	18050247
families	18050247
,	18050247
were	18050247
genotyped	18050247
and	18050247
analyzed	18050247
using	18050247
transmission	18050247
disequilibrium	18050247
testing	18050247
(	18050247
TDT	18050247
)	18050247
and	18050247
multitest	18050247
corrections	18050247
.	18050247

RESULTS	18050247
:	18050247
Family	18050247
-	18050247
based	18050247
TDT	18050247
showed	18050247
a	18050247
significant	18050247
association	18050247
of	18050247
SLE	18050247
with	18050247
a	18050247
N673S	18050247
polymorphism	18050247
in	18050247
the	18050247
P	18050247
-	18050247
selectin	18050247
gene	18050247
(	18050247
SELP	18050247
)	18050247
(	18050247
P	18050247
=	18050247
5	18050247
.	18050247
74	18050247
x	18050247
10	18050247
(	18050247
-	18050247
6	18050247
)	18050247
)	18050247
and	18050247
a	18050247
C203S	18050247
polymorphism	18050247
in	18050247
the	18050247
interleukin	18050247
-	18050247
1	18050247
receptor	18050247
-	18050247
associated	18050247
kinase	18050247
1	18050247
gene	18050247
(	18050247
IRAK1	18050247
)	18050247
(	18050247
P	18050247
=	18050247
9	18050247
.	18050247
58	18050247
x	18050247
10	18050247
(	18050247
-	18050247
6	18050247
)	18050247
)	18050247
.	18050247

These	18050247
2	18050247
SNPs	18050247
had	18050247
a	18050247
false	18050247
discovery	18050247
rate	18050247
for	18050247
multitest	18050247
correction	18050247
of	18050247
<	18050247
0	18050247
.	18050247
05	18050247
,	18050247
and	18050247
therefore	18050247
a	18050247
>	18050247
95%	18050247
probability	18050247
of	18050247
being	18050247
considered	18050247
as	18050247
proven	18050247
.	18050247

Furthermore	18050247
,	18050247
7	18050247
additional	18050247
SNPs	18050247
showed	18050247
q	18050247
values	18050247
of	18050247
<	18050247
0	18050247
.	18050247
5	18050247
,	18050247
suggesting	18050247
association	18050247
with	18050247
SLE	18050247
and	18050247
providing	18050247
a	18050247
direction	18050247
for	18050247
followup	18050247
studies	18050247
.	18050247

These	18050247
additional	18050247
genes	18050247
notably	18050247
included	18050247
TNFRSF6	18050247
(	18050247
Fas	18050247
)	18050247
and	18050247
IRF5	18050247
,	18050247
supporting	18050247
previous	18050247
findings	18050247
of	18050247
their	18050247
association	18050247
with	18050247
SLE	18050247
pathogenesis	18050247
.	18050247

CONCLUSION	18050247
:	18050247
SELP	18050247
and	18050247
IRAK1	18050247
were	18050247
identified	18050247
as	18050247
novel	18050247
SLE	18050247
-	18050247
associated	18050247
genes	18050247
with	18050247
a	18050247
high	18050247
degree	18050247
of	18050247
significance	18050247
,	18050247
suggesting	18050247
new	18050247
directions	18050247
in	18050247
understanding	18050247
the	18050247
pathogenesis	18050247
of	18050247
SLE	18050247
.	18050247

The	18050247
overall	18050247
design	18050247
and	18050247
results	18050247
of	18050247
this	18050247
study	18050247
demonstrate	18050247
that	18050247
the	18050247
candidate	18050247
gene	18050247
pathway	18050247
microarray	18050247
platform	18050247
used	18050247
provides	18050247
a	18050247
novel	18050247
and	18050247
powerful	18050247
approach	18050247
that	18050247
is	18050247
generally	18050247
applicable	18050247
in	18050247
identifying	18050247
genetic	18050247
foundations	18050247
of	18050247
complex	18050247
diseases	18050247
.	18050247
A	17600377
novel	17600377
compound	17600377
,	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
,	17600377
attenuates	17600377
cognitive	17600377
deficits	17600377
and	17600377
shows	17600377
neuroprotective	17600377
effects	17600377
in	17600377
vitro	17600377
and	17600377
in	17600377
vivo	17600377
dementia	17600377
models	17600377
.	17600377

To	17600377
develop	17600377
a	17600377
novel	17600377
and	17600377
effective	17600377
drug	17600377
that	17600377
could	17600377
enhance	17600377
cognitive	17600377
function	17600377
and	17600377
neuroprotection	17600377
,	17600377
we	17600377
newly	17600377
synthesized	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
by	17600377
the	17600377
esterification	17600377
of	17600377
maltol	17600377
and	17600377
p	17600377
-	17600377
coumaric	17600377
acid	17600377
.	17600377

In	17600377
the	17600377
present	17600377
study	17600377
,	17600377
we	17600377
investigated	17600377
whether	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
could	17600377
improve	17600377
cognitive	17600377
decline	17600377
in	17600377
scopolamine	17600377
-	17600377
injected	17600377
rats	17600377
and	17600377
in	17600377
amyloid	17600377
beta	17600377
peptide	17600377
(	17600377
1	17600377
-	17600377
42	17600377
)	17600377
-	17600377
infused	17600377
rats	17600377
.	17600377

Maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
was	17600377
found	17600377
to	17600377
attenuate	17600377
cognitive	17600377
deficits	17600377
in	17600377
both	17600377
rat	17600377
models	17600377
using	17600377
passive	17600377
avoidance	17600377
test	17600377
and	17600377
to	17600377
reduce	17600377
apoptotic	17600377
cell	17600377
death	17600377
observed	17600377
in	17600377
the	17600377
hippocampus	17600377
of	17600377
the	17600377
amyloid	17600377
beta	17600377
peptide	17600377
(	17600377
1	17600377
-	17600377
42	17600377
)	17600377
-	17600377
infused	17600377
rats	17600377
.	17600377

We	17600377
also	17600377
examined	17600377
the	17600377
neuroprotective	17600377
effects	17600377
of	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
in	17600377
vitro	17600377
using	17600377
SH	17600377
-	17600377
SY5Y	17600377
cells	17600377
.	17600377

Cells	17600377
were	17600377
pretreated	17600377
with	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
,	17600377
before	17600377
exposed	17600377
to	17600377
amyloid	17600377
beta	17600377
peptide	17600377
(	17600377
1	17600377
-	17600377
42	17600377
)	17600377
,	17600377
glutamate	17600377
or	17600377
H2O2	17600377
.	17600377

We	17600377
found	17600377
that	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
significantly	17600377
decreased	17600377
apoptotic	17600377
cell	17600377
death	17600377
and	17600377
reduced	17600377
reactive	17600377
oxygen	17600377
species	17600377
,	17600377
cytochrome	17600377
c	17600377
release	17600377
,	17600377
and	17600377
caspase	17600377
3	17600377
activation	17600377
.	17600377

Taking	17600377
these	17600377
in	17600377
vitro	17600377
and	17600377
in	17600377
vivo	17600377
results	17600377
together	17600377
,	17600377
our	17600377
study	17600377
suggests	17600377
that	17600377
maltolyl	17600377
p	17600377
-	17600377
coumarate	17600377
is	17600377
a	17600377
potentially	17600377
effective	17600377
candidate	17600377
against	17600377
Alzheimer	17600377
'	17600377
s	17600377
disease	17600377
that	17600377
is	17600377
characterized	17600377
by	17600377
wide	17600377
spread	17600377
neuronal	17600377
death	17600377
and	17600377
progressive	17600377
decline	17600377
of	17600377
cognitive	17600377
function	17600377
.	17600377
Anticipation	18470323
in	18470323
familial	18470323
lattice	18470323
corneal	18470323
dystrophy	18470323
type	18470323
I	18470323
with	18470323
R124C	18470323
mutation	18470323
in	18470323
the	18470323
TGFBI	18470323
(	18470323
BIGH3	18470323
)	18470323
gene	18470323
.	18470323

PURPOSE	18470323
:	18470323
To	18470323
report	18470323
the	18470323
clinical	18470323
,	18470323
ophthalmic	18470323
,	18470323
and	18470323
genetic	18470323
characteristics	18470323
for	18470323
lattice	18470323
corneal	18470323
dystrophy	18470323
type	18470323
I	18470323
(	18470323
LCDI	18470323
)	18470323
in	18470323
a	18470323
Chilean	18470323
family	18470323
.	18470323

METHODS	18470323
:	18470323
Six	18470323
affected	18470323
family	18470323
members	18470323
were	18470323
examined	18470323
clinically	18470323
including	18470323
visual	18470323
acuity	18470323
,	18470323
color	18470323
cornea	18470323
photography	18470323
,	18470323
applanation	18470323
tonography	18470323
,	18470323
and	18470323
fundoscopy	18470323
.	18470323

Genomic	18470323
DNA	18470323
was	18470323
extracted	18470323
from	18470323
peripheral	18470323
leukocytes	18470323
from	18470323
six	18470323
affected	18470323
and	18470323
three	18470323
unaffected	18470323
members	18470323
of	18470323
a	18470323
family	18470323
with	18470323
lattice	18470323
corneal	18470323
dystrophy	18470323
type	18470323
I	18470323
.	18470323

Exon	18470323
4	18470323
of	18470323
the	18470323
transforming	18470323
growth	18470323
factor	18470323
-	18470323
induced	18470323
gene	18470323
(	18470323
TGFBI	18470323
)	18470323
was	18470323
screened	18470323
for	18470323
the	18470323
most	18470323
frequent	18470323
mutation	18470323
,	18470323
R124C	18470323
,	18470323
in	18470323
the	18470323
proband	18470323
by	18470323
sequencing	18470323
.	18470323

We	18470323
also	18470323
designed	18470323
a	18470323
rapid	18470323
polymerase	18470323
chain	18470323
reaction	18470323
-	18470323
restriction	18470323
fragment	18470323
length	18470323
polymorphism	18470323
(	18470323
PCR	18470323
-	18470323
RFLP	18470323
)	18470323
method	18470323
to	18470323
analyze	18470323
the	18470323
same	18470323
mutation	18470323
,	18470323
amplifying	18470323
exon	18470323
4	18470323
and	18470323
digesting	18470323
with	18470323
PstI	18470323
restriction	18470323
enzyme	18470323
.	18470323

Using	18470323
this	18470323
strategy	18470323
,	18470323
we	18470323
analyzed	18470323
the	18470323
mutation	18470323
in	18470323
six	18470323
affected	18470323
and	18470323
three	18470323
healthy	18470323
family	18470323
members	18470323
.	18470323

RESULTS	18470323
:	18470323
Three	18470323
generations	18470323
of	18470323
family	18470323
members	18470323
were	18470323
positively	18470323
diagnosed	18470323
with	18470323
lattice	18470323
corneal	18470323
dystrophy	18470323
.	18470323

Six	18470323
participants	18470323
demonstrated	18470323
LCD1	18470323
in	18470323
both	18470323
eyes	18470323
,	18470323
most	18470323
of	18470323
whom	18470323
were	18470323
symmetric	18470323
.	18470323

Age	18470323
at	18470323
onset	18470323
of	18470323
symptoms	18470323
was	18470323
variable	18470323
(	18470323
3	18470323
-	18470323
42	18470323
years	18470323
old	18470323
)	18470323
.	18470323

Moreover	18470323
,	18470323
in	18470323
this	18470323
family	18470323
,	18470323
the	18470323
age	18470323
of	18470323
onset	18470323
of	18470323
the	18470323
disease	18470323
decreased	18470323
in	18470323
succeeding	18470323
generations	18470323
,	18470323
which	18470323
could	18470323
be	18470323
interpreted	18470323
as	18470323
anticipation	18470323
.	18470323

Visual	18470323
acuity	18470323
varied	18470323
from	18470323
1	18470323
.	18470323
0	18470323
to	18470323
0	18470323
.	18470323
13	18470323
.	18470323

Two	18470323
patients	18470323
,	18470323
ages	18470323
69	18470323
and	18470323
44	18470323
years	18470323
old	18470323
,	18470323
demonstrated	18470323
a	18470323
degree	18470323
of	18470323
severity	18470323
""""	18470323
Bad	18470323
""""	18470323
according	18470323
to	18470323
best	18470323
-	18470323
corrected	18470323
vision	18470323
and	18470323
corneal	18470323
commitment	18470323
.	18470323

The	18470323
exon	18470323
4	18470323
sequence	18470323
of	18470323
TGFBI	18470323
of	18470323
the	18470323
proband	18470323
exhibits	18470323
the	18470323
heterozygous	18470323
single	18470323
-	18470323
nucleotide	18470323
mutation	18470323
,	18470323
C417T	18470323
,	18470323
leading	18470323
to	18470323
amino	18470323
acid	18470323
substitution	18470323
(	18470323
R124C	18470323
)	18470323
in	18470323
the	18470323
encoded	18470323
TGF	18470323
-	18470323
induced	18470323
protein	18470323
.	18470323

Using	18470323
PCR	18470323
-	18470323
RFLP	18470323
,	18470323
we	18470323
confirmed	18470323
the	18470323
heterozygous	18470323
mutation	18470323
in	18470323
six	18470323
affected	18470323
family	18470323
members	18470323
and	18470323
excluded	18470323
it	18470323
in	18470323
three	18470323
healthy	18470323
members	18470323
.	18470323

CONCLUSIONS	18470323
:	18470323
The	18470323
R124C	18470323
mutation	18470323
in	18470323
TGFBI	18470323
cosegregated	18470323
with	18470323
LCD	18470323
type	18470323
I	18470323
in	18470323
the	18470323
investigated	18470323
family	18470323
.	18470323

This	18470323
is	18470323
the	18470323
first	18470323
report	18470323
of	18470323
a	18470323
molecular	18470323
analysis	18470323
of	18470323
LCD	18470323
type	18470323
I	18470323
in	18470323
Chilean	18470323
patients	18470323
.	18470323

The	18470323
early	18470323
onset	18470323
affected	18470323
persons	18470323
in	18470323
the	18470323
fourth	18470323
generation	18470323
raises	18470323
the	18470323
possibility	18470323
of	18470323
anticipation	18470323
.	18470323
A	20331935
cross	20331935
-	20331935
sectional	20331935
evaluation	20331935
of	20331935
the	20331935
effect	20331935
of	20331935
risperidone	20331935
and	20331935
selective	20331935
serotonin	20331935
reuptake	20331935
inhibitors	20331935
on	20331935
bone	20331935
mineral	20331935
density	20331935
in	20331935
boys	20331935
.	20331935

OBJECTIVE	20331935
:	20331935
The	20331935
aim	20331935
of	20331935
the	20331935
present	20331935
study	20331935
was	20331935
to	20331935
investigate	20331935
the	20331935
effect	20331935
of	20331935
risperidone	20331935
-	20331935
induced	20331935
hyperprolactinemia	20331935
on	20331935
trabecular	20331935
bone	20331935
mineral	20331935
density	20331935
(	20331935
BMD	20331935
)	20331935
in	20331935
children	20331935
and	20331935
adolescents	20331935
.	20331935

METHOD	20331935
:	20331935
Medically	20331935
healthy	20331935
7	20331935
-	20331935
to	20331935
17	20331935
-	20331935
year	20331935
-	20331935
old	20331935
males	20331935
chronically	20331935
treated	20331935
,	20331935
in	20331935
a	20331935
naturalistic	20331935
setting	20331935
,	20331935
with	20331935
risperidone	20331935
were	20331935
recruited	20331935
for	20331935
this	20331935
cross	20331935
-	20331935
sectional	20331935
study	20331935
through	20331935
child	20331935
psychiatry	20331935
outpatient	20331935
clinics	20331935
between	20331935
November	20331935
2005	20331935
and	20331935
June	20331935
2007	20331935
.	20331935

Anthropometric	20331935
measurements	20331935
and	20331935
laboratory	20331935
testing	20331935
were	20331935
conducted	20331935
.	20331935

The	20331935
clinical	20331935
diagnoses	20331935
were	20331935
based	20331935
on	20331935
chart	20331935
review	20331935
,	20331935
and	20331935
developmental	20331935
and	20331935
treatment	20331935
history	20331935
was	20331935
obtained	20331935
from	20331935
the	20331935
medical	20331935
record	20331935
.	20331935

Volumetric	20331935
BMD	20331935
of	20331935
the	20331935
ultradistal	20331935
radius	20331935
was	20331935
measured	20331935
using	20331935
peripheral	20331935
quantitative	20331935
computed	20331935
tomography	20331935
,	20331935
and	20331935
areal	20331935
BMD	20331935
of	20331935
the	20331935
lumbar	20331935
spine	20331935
was	20331935
estimated	20331935
using	20331935
dual	20331935
-	20331935
energy	20331935
x	20331935
-	20331935
ray	20331935
absorptiometry	20331935
.	20331935

RESULTS	20331935
:	20331935
Hyperprolactinemia	20331935
was	20331935
present	20331935
in	20331935
49%	20331935
of	20331935
83	20331935
boys	20331935
(	20331935
n	20331935
=	20331935
41	20331935
)	20331935
treated	20331935
with	20331935
risperidone	20331935
for	20331935
a	20331935
mean	20331935
of	20331935
2	20331935
.	20331935
9	20331935
years	20331935
.	20331935

Serum	20331935
testosterone	20331935
concentration	20331935
increased	20331935
with	20331935
pubertal	20331935
status	20331935
but	20331935
was	20331935
not	20331935
affected	20331935
by	20331935
hyperprolactinemia	20331935
.	20331935

As	20331935
expected	20331935
,	20331935
bone	20331935
mineral	20331935
content	20331935
and	20331935
BMD	20331935
increased	20331935
with	20331935
sexual	20331935
maturity	20331935
.	20331935

After	20331935
adjusting	20331935
for	20331935
the	20331935
stage	20331935
of	20331935
sexual	20331935
development	20331935
and	20331935
height	20331935
and	20331935
BMI	20331935
z	20331935
scores	20331935
,	20331935
serum	20331935
prolactin	20331935
was	20331935
negatively	20331935
associated	20331935
with	20331935
trabecular	20331935
volumetric	20331935
BMD	20331935
at	20331935
the	20331935
ultradistal	20331935
radius	20331935
(	20331935
P	20331935
<	20331935
.	20331935
03	20331935
)	20331935
.	20331935

Controlling	20331935
for	20331935
relevant	20331935
covariates	20331935
,	20331935
we	20331935
also	20331935
found	20331935
treatment	20331935
with	20331935
selective	20331935
serotonin	20331935
reuptake	20331935
inhibitors	20331935
(	20331935
SSRIs	20331935
)	20331935
to	20331935
be	20331935
associated	20331935
with	20331935
lower	20331935
trabecular	20331935
BMD	20331935
at	20331935
the	20331935
radius	20331935
(	20331935
P	20331935
=	20331935
.	20331935
03	20331935
)	20331935
and	20331935
BMD	20331935
z	20331935
score	20331935
at	20331935
the	20331935
lumbar	20331935
spine	20331935
(	20331935
P	20331935
<	20331935
.	20331935
05	20331935
)	20331935
.	20331935

These	20331935
findings	20331935
became	20331935
more	20331935
marked	20331935
when	20331935
the	20331935
analysis	20331935
was	20331935
restricted	20331935
to	20331935
non	20331935
-	20331935
Hispanic	20331935
white	20331935
patients	20331935
.	20331935

Of	20331935
13	20331935
documented	20331935
fractures	20331935
,	20331935
3	20331935
occurred	20331935
after	20331935
risperidone	20331935
and	20331935
SSRIs	20331935
were	20331935
started	20331935
,	20331935
and	20331935
none	20331935
occurred	20331935
in	20331935
patients	20331935
with	20331935
hyperprolactinemia	20331935
.	20331935

CONCLUSIONS	20331935
:	20331935
This	20331935
is	20331935
the	20331935
first	20331935
study	20331935
to	20331935
link	20331935
risperidone	20331935
-	20331935
induced	20331935
hyperprolactinemia	20331935
and	20331935
SSRI	20331935
treatment	20331935
to	20331935
lower	20331935
BMD	20331935
in	20331935
children	20331935
and	20331935
adolescents	20331935
.	20331935

Future	20331935
research	20331935
should	20331935
evaluate	20331935
the	20331935
longitudinal	20331935
course	20331935
of	20331935
this	20331935
adverse	20331935
event	20331935
to	20331935
determine	20331935
its	20331935
temporal	20331935
stability	20331935
and	20331935
whether	20331935
a	20331935
higher	20331935
fracture	20331935
rate	20331935
ensues	20331935
.	20331935
Behavioral	24911645
and	24911645
neurochemical	24911645
studies	24911645
in	24911645
mice	24911645
pretreated	24911645
with	24911645
garcinielliptone	24911645
FC	24911645
in	24911645
pilocarpine	24911645
-	24911645
induced	24911645
seizures	24911645
.	24911645

Garcinielliptone	24911645
FC	24911645
(	24911645
GFC	24911645
)	24911645
isolated	24911645
from	24911645
hexanic	24911645
fraction	24911645
seed	24911645
extract	24911645
of	24911645
species	24911645
Platonia	24911645
insignis	24911645
Mart	24911645
.	24911645

It	24911645
is	24911645
widely	24911645
used	24911645
in	24911645
folk	24911645
medicine	24911645
to	24911645
treat	24911645
skin	24911645
diseases	24911645
in	24911645
both	24911645
humans	24911645
and	24911645
animals	24911645
as	24911645
well	24911645
as	24911645
the	24911645
seed	24911645
decoction	24911645
has	24911645
been	24911645
used	24911645
to	24911645
treat	24911645
diarrheas	24911645
and	24911645
inflammatory	24911645
diseases	24911645
.	24911645

However	24911645
,	24911645
there	24911645
is	24911645
no	24911645
research	24911645
on	24911645
GFC	24911645
effects	24911645
in	24911645
the	24911645
central	24911645
nervous	24911645
system	24911645
of	24911645
rodents	24911645
.	24911645

The	24911645
present	24911645
study	24911645
aimed	24911645
to	24911645
evaluate	24911645
the	24911645
GFC	24911645
effects	24911645
at	24911645
doses	24911645
of	24911645
25	24911645
,	24911645
50	24911645
or	24911645
75	24911645
mg	24911645
/	24911645
kg	24911645
on	24911645
seizure	24911645
parameters	24911645
to	24911645
determine	24911645
their	24911645
anticonvulsant	24911645
activity	24911645
and	24911645
its	24911645
effects	24911645
on	24911645
amino	24911645
acid	24911645
(	24911645
r	24911645
-	24911645
aminobutyric	24911645
acid	24911645
(	24911645
GABA	24911645
)	24911645
,	24911645
glutamine	24911645
,	24911645
aspartate	24911645
and	24911645
glutathione	24911645
)	24911645
levels	24911645
as	24911645
well	24911645
as	24911645
on	24911645
acetylcholinesterase	24911645
(	24911645
AChE	24911645
)	24911645
activity	24911645
in	24911645
mice	24911645
hippocampus	24911645
after	24911645
seizures	24911645
.	24911645

GFC	24911645
produced	24911645
an	24911645
increased	24911645
latency	24911645
to	24911645
first	24911645
seizure	24911645
,	24911645
at	24911645
doses	24911645
25mg	24911645
/	24911645
kg	24911645
(	24911645
20	24911645
.	24911645
12	24911645
+	24911645
2	24911645
.	24911645
20	24911645
min	24911645
)	24911645
,	24911645
50mg	24911645
/	24911645
kg	24911645
(	24911645
20	24911645
.	24911645
95	24911645
+	24911645
2	24911645
.	24911645
21	24911645
min	24911645
)	24911645
or	24911645
75	24911645
mg	24911645
/	24911645
kg	24911645
(	24911645
23	24911645
.	24911645
43	24911645
+	24911645
1	24911645
.	24911645
99	24911645
min	24911645
)	24911645
when	24911645
compared	24911645
with	24911645
seized	24911645
mice	24911645
.	24911645

In	24911645
addition	24911645
,	24911645
GABA	24911645
content	24911645
of	24911645
mice	24911645
hippocampus	24911645
treated	24911645
with	24911645
GFC75	24911645
plus	24911645
P400	24911645
showed	24911645
an	24911645
increase	24911645
of	24911645
46	24911645
.	24911645
90%	24911645
when	24911645
compared	24911645
with	24911645
seized	24911645
mice	24911645
.	24911645

In	24911645
aspartate	24911645
,	24911645
glutamine	24911645
and	24911645
glutamate	24911645
levels	24911645
detected	24911645
a	24911645
decrease	24911645
of	24911645
5	24911645
.	24911645
21%	24911645
,	24911645
13	24911645
.	24911645
55%	24911645
and	24911645
21	24911645
.	24911645
80%	24911645
,	24911645
respectively	24911645
in	24911645
mice	24911645
hippocampus	24911645
treated	24911645
with	24911645
GFC75	24911645
plus	24911645
P400	24911645
when	24911645
compared	24911645
with	24911645
seized	24911645
mice	24911645
.	24911645

Hippocampus	24911645
mice	24911645
treated	24911645
with	24911645
GFC75	24911645
plus	24911645
P400	24911645
showed	24911645
an	24911645
increase	24911645
in	24911645
AChE	24911645
activity	24911645
(	24911645
63	24911645
.	24911645
30%	24911645
)	24911645
when	24911645
compared	24911645
with	24911645
seized	24911645
mice	24911645
.	24911645

The	24911645
results	24911645
indicate	24911645
that	24911645
GFC	24911645
can	24911645
exert	24911645
anticonvulsant	24911645
activity	24911645
and	24911645
reduce	24911645
the	24911645
frequency	24911645
of	24911645
installation	24911645
of	24911645
pilocarpine	24911645
-	24911645
induced	24911645
status	24911645
epilepticus	24911645
,	24911645
as	24911645
demonstrated	24911645
by	24911645
increase	24911645
in	24911645
latency	24911645
to	24911645
first	24911645
seizure	24911645
and	24911645
decrease	24911645
in	24911645
mortality	24911645
rate	24911645
of	24911645
animals	24911645
.	24911645

In	24911645
conclusion	24911645
,	24911645
our	24911645
data	24911645
suggest	24911645
that	24911645
GFC	24911645
may	24911645
influence	24911645
in	24911645
epileptogenesis	24911645
and	24911645
promote	24911645
anticonvulsant	24911645
actions	24911645
in	24911645
pilocarpine	24911645
model	24911645
by	24911645
modulating	24911645
the	24911645
GABA	24911645
and	24911645
glutamate	24911645
contents	24911645
and	24911645
of	24911645
AChE	24911645
activity	24911645
in	24911645
seized	24911645
mice	24911645
hippocampus	24911645
.	24911645

This	24911645
compound	24911645
may	24911645
be	24911645
useful	24911645
to	24911645
produce	24911645
neuronal	24911645
protection	24911645
and	24911645
it	24911645
can	24911645
be	24911645
considered	24911645
as	24911645
an	24911645
anticonvulsant	24911645
agent	24911645
.	24911645
Gastrointestinal	25979836
hormones	25979836
/	25979836
neurotransmitters	25979836
and	25979836
growth	25979836
factors	25979836
can	25979836
activate	25979836
P21	25979836
activated	25979836
kinase	25979836
2	25979836
in	25979836
pancreatic	25979836
acinar	25979836
cells	25979836
by	25979836
novel	25979836
mechanisms	25979836
.	25979836

P	25979836
-	25979836
21	25979836
-	25979836
activated	25979836
kinases	25979836
(	25979836
PAKs	25979836
)	25979836
are	25979836
serine	25979836
/	25979836
threonine	25979836
kinases	25979836
comprising	25979836
six	25979836
isoforms	25979836
divided	25979836
in	25979836
two	25979836
groups	25979836
,	25979836
group	25979836
-	25979836
I	25979836
(	25979836
PAK1	25979836
-	25979836
3	25979836
)	25979836
/	25979836
group	25979836
-	25979836
II	25979836
(	25979836
PAK4	25979836
-	25979836
6	25979836
)	25979836
which	25979836
play	25979836
important	25979836
roles	25979836
in	25979836
cell	25979836
cytoskeletal	25979836
dynamics	25979836
,	25979836
survival	25979836
,	25979836
secretion	25979836
and	25979836
proliferation	25979836
and	25979836
are	25979836
activated	25979836
by	25979836
diverse	25979836
stimuli	25979836
.	25979836

However	25979836
,	25979836
little	25979836
is	25979836
known	25979836
about	25979836
PAKs	25979836
ability	25979836
to	25979836
be	25979836
activated	25979836
by	25979836
gastrointestinal	25979836
(	25979836
GI	25979836
)	25979836
hormones	25979836
/	25979836
neurotransmitters	25979836
/	25979836
growth	25979836
-	25979836
factors	25979836
.	25979836

We	25979836
used	25979836
rat	25979836
pancreatic	25979836
acini	25979836
to	25979836
explore	25979836
the	25979836
ability	25979836
of	25979836
GI	25979836
-	25979836
hormones	25979836
/	25979836
neurotransmitters	25979836
/	25979836
growth	25979836
-	25979836
factors	25979836
to	25979836
activate	25979836
Group	25979836
-	25979836
I	25979836
-	25979836
PAKs	25979836
and	25979836
the	25979836
signaling	25979836
cascades	25979836
involved	25979836
.	25979836

Only	25979836
PAK2	25979836
was	25979836
present	25979836
in	25979836
acini	25979836
.	25979836

PAK2	25979836
was	25979836
activated	25979836
by	25979836
some	25979836
pancreatic	25979836
growth	25979836
-	25979836
factors	25979836
[	25979836
EGF	25979836
,	25979836
PDGF	25979836
,	25979836
bFGF	25979836
]	25979836
,	25979836
by	25979836
secretagogues	25979836
activating	25979836
phospholipase	25979836
-	25979836
C	25979836
(	25979836
PLC	25979836
)	25979836
[	25979836
CCK	25979836
,	25979836
carbachol	25979836
,	25979836
bombesin	25979836
]	25979836
and	25979836
by	25979836
post	25979836
-	25979836
receptor	25979836
stimulants	25979836
activating	25979836
PKC	25979836
[	25979836
TPA	25979836
]	25979836
,	25979836
but	25979836
not	25979836
agents	25979836
only	25979836
mobilizing	25979836
cellular	25979836
calcium	25979836
or	25979836
increasing	25979836
cyclic	25979836
AMP	25979836
.	25979836

CCK	25979836
-	25979836
activation	25979836
of	25979836
PAK2	25979836
required	25979836
both	25979836
high	25979836
-	25979836
and	25979836
low	25979836
-	25979836
affinity	25979836
-	25979836
CCK1	25979836
-	25979836
receptor	25979836
-	25979836
state	25979836
activation	25979836
.	25979836

It	25979836
was	25979836
partially	25979836
reduced	25979836
by	25979836
PKC	25979836
-	25979836
or	25979836
Src	25979836
-	25979836
inhibition	25979836
,	25979836
but	25979836
not	25979836
with	25979836
PI3K	25979836
-	25979836
inhibitors	25979836
(	25979836
wortmannin	25979836
,	25979836
LY294002	25979836
)	25979836
or	25979836
thapsigargin	25979836
.	25979836

IPA	25979836
-	25979836
3	25979836
,	25979836
which	25979836
prevents	25979836
PAK2	25979836
binding	25979836
to	25979836
small	25979836
-	25979836
GTPases	25979836
partially	25979836
inhibited	25979836
PAK2	25979836
-	25979836
activation	25979836
,	25979836
as	25979836
well	25979836
as	25979836
reduced	25979836
CCK	25979836
-	25979836
induced	25979836
ERK1	25979836
/	25979836
2	25979836
activation	25979836
and	25979836
amylase	25979836
release	25979836
induced	25979836
by	25979836
CCK	25979836
or	25979836
bombesin	25979836
.	25979836

This	25979836
study	25979836
demonstrates	25979836
pancreatic	25979836
acini	25979836
,	25979836
possess	25979836
only	25979836
one	25979836
Group	25979836
-	25979836
I	25979836
-	25979836
PAK	25979836
,	25979836
PAK2	25979836
.	25979836

CCK	25979836
and	25979836
other	25979836
GI	25979836
-	25979836
hormones	25979836
/	25979836
neurotransmitters	25979836
/	25979836
growth	25979836
-	25979836
factors	25979836
activate	25979836
PAK2	25979836
via	25979836
small	25979836
GTPases	25979836
(	25979836
CDC42	25979836
/	25979836
Rac1	25979836
)	25979836
,	25979836
PKC	25979836
and	25979836
SFK	25979836
but	25979836
not	25979836
cytosolic	25979836
calcium	25979836
or	25979836
PI3K	25979836
.	25979836

CCK	25979836
-	25979836
activation	25979836
of	25979836
PAK2	25979836
showed	25979836
several	25979836
novel	25979836
features	25979836
being	25979836
dependent	25979836
on	25979836
both	25979836
receptor	25979836
-	25979836
activation	25979836
states	25979836
,	25979836
having	25979836
PLC	25979836
-	25979836
and	25979836
PKC	25979836
-	25979836
dependent	25979836
/	25979836
independent	25979836
components	25979836
and	25979836
small	25979836
-	25979836
GTPase	25979836
-	25979836
dependent	25979836
/	25979836
independent	25979836
components	25979836
.	25979836

These	25979836
results	25979836
show	25979836
that	25979836
PAK2	25979836
is	25979836
important	25979836
in	25979836
signaling	25979836
cascades	25979836
activated	25979836
by	25979836
numerous	25979836
pancreatic	25979836
stimuli	25979836
which	25979836
mediate	25979836
their	25979836
various	25979836
physiological	25979836
/	25979836
pathophysiological	25979836
responses	25979836
and	25979836
thus	25979836
could	25979836
be	25979836
a	25979836
promising	25979836
target	25979836
for	25979836
the	25979836
development	25979836
of	25979836
therapies	25979836
in	25979836
some	25979836
pancreatic	25979836
disorders	25979836
such	25979836
as	25979836
pancreatitis	25979836
.	25979836

Evaluation	16526029
of	16526029
RGS4	16526029
as	16526029
a	16526029
candidate	16526029
gene	16526029
for	16526029
schizophrenia	16526029
.	16526029

Several	16526029
studies	16526029
have	16526029
suggested	16526029
that	16526029
the	16526029
regulator	16526029
of	16526029
G	16526029
-	16526029
protein	16526029
signaling	16526029
4	16526029
(	16526029
RGS4	16526029
)	16526029
may	16526029
be	16526029
a	16526029
positional	16526029
and	16526029
functional	16526029
candidate	16526029
gene	16526029
for	16526029
schizophrenia	16526029
.	16526029

Three	16526029
single	16526029
nucleotide	16526029
polymorphisms	16526029
(	16526029
SNP	16526029
)	16526029
located	16526029
at	16526029
the	16526029
promoter	16526029
region	16526029
(	16526029
SNP4	16526029
and	16526029
SNP7	16526029
)	16526029
and	16526029
the	16526029
intron	16526029
1	16526029
(	16526029
SNP18	16526029
)	16526029
of	16526029
RGS4	16526029
have	16526029
been	16526029
verified	16526029
in	16526029
different	16526029
ethnic	16526029
groups	16526029
.	16526029

Positive	16526029
results	16526029
have	16526029
been	16526029
reported	16526029
in	16526029
these	16526029
SNPs	16526029
with	16526029
different	16526029
numbers	16526029
of	16526029
SNP	16526029
combinatory	16526029
haplotypes	16526029
.	16526029

In	16526029
this	16526029
study	16526029
,	16526029
these	16526029
three	16526029
SNP	16526029
markers	16526029
were	16526029
genotyped	16526029
in	16526029
218	16526029
schizophrenia	16526029
pedigrees	16526029
of	16526029
Taiwan	16526029
(	16526029
864	16526029
individuals	16526029
)	16526029
for	16526029
association	16526029
analysis	16526029
.	16526029

Among	16526029
these	16526029
three	16526029
SNPs	16526029
,	16526029
neither	16526029
SNP4	16526029
,	16526029
SNP7	16526029
,	16526029
SNP18	16526029
has	16526029
shown	16526029
significant	16526029
association	16526029
with	16526029
schizophrenia	16526029
in	16526029
single	16526029
locus	16526029
association	16526029
analysis	16526029
,	16526029
nor	16526029
any	16526029
compositions	16526029
of	16526029
the	16526029
three	16526029
SNP	16526029
haplotypes	16526029
has	16526029
shown	16526029
significantly	16526029
associations	16526029
with	16526029
the	16526029
DSM	16526029
-	16526029
IV	16526029
diagnosed	16526029
schizophrenia	16526029
.	16526029

Our	16526029
results	16526029
fail	16526029
to	16526029
support	16526029
the	16526029
RGS4	16526029
as	16526029
a	16526029
candidate	16526029
gene	16526029
for	16526029
schizophrenia	16526029
when	16526029
evaluated	16526029
from	16526029
these	16526029
three	16526029
SNP	16526029
markers	16526029
.	16526029
Gastrointestinal	17965424
tolerability	17965424
of	17965424
etoricoxib	17965424
in	17965424
rheumatoid	17965424
arthritis	17965424
patients	17965424
:	17965424
results	17965424
of	17965424
the	17965424
etoricoxib	17965424
vs	17965424
diclofenac	17965424
sodium	17965424
gastrointestinal	17965424
tolerability	17965424
and	17965424
effectiveness	17965424
trial	17965424
(	17965424
EDGE	17965424
-	17965424
II	17965424
)	17965424
.	17965424

OBJECTIVE	17965424
:	17965424
A	17965424
randomised	17965424
,	17965424
double	17965424
-	17965424
blind	17965424
study	17965424
to	17965424
compare	17965424
the	17965424
gastrointestinal	17965424
(	17965424
GI	17965424
)	17965424
tolerability	17965424
,	17965424
safety	17965424
and	17965424
efficacy	17965424
of	17965424
etoricoxib	17965424
and	17965424
diclofenac	17965424
in	17965424
patients	17965424
with	17965424
rheumatoid	17965424
arthritis	17965424
(	17965424
RA	17965424
)	17965424
.	17965424

PATIENTS	17965424
AND	17965424
METHODS	17965424
:	17965424
A	17965424
total	17965424
of	17965424
4086	17965424
patients	17965424
(	17965424
mean	17965424
age	17965424
60	17965424
.	17965424
8	17965424
years	17965424
)	17965424
diagnosed	17965424
with	17965424
RA	17965424
were	17965424
enrolled	17965424
and	17965424
received	17965424
etoricoxib	17965424
90	17965424
mg	17965424
daily	17965424
(	17965424
n	17965424
=	17965424
2032	17965424
)	17965424
or	17965424
diclofenac	17965424
75	17965424
mg	17965424
twice	17965424
daily	17965424
(	17965424
n	17965424
=	17965424
2054	17965424
)	17965424
.	17965424

Use	17965424
of	17965424
gastroprotective	17965424
agents	17965424
and	17965424
low	17965424
-	17965424
dose	17965424
aspirin	17965424
was	17965424
allowed	17965424
.	17965424

The	17965424
prespecified	17965424
primary	17965424
end	17965424
point	17965424
consisted	17965424
of	17965424
the	17965424
cumulative	17965424
rate	17965424
of	17965424
patient	17965424
discontinuations	17965424
due	17965424
to	17965424
clinical	17965424
and	17965424
laboratory	17965424
GI	17965424
adverse	17965424
experiences	17965424
(	17965424
AEs	17965424
)	17965424
.	17965424

General	17965424
safety	17965424
was	17965424
also	17965424
assessed	17965424
,	17965424
including	17965424
adjudicated	17965424
thrombotic	17965424
cardiovascular	17965424
event	17965424
data	17965424
.	17965424

Efficacy	17965424
was	17965424
evaluated	17965424
using	17965424
the	17965424
Patient	17965424
Global	17965424
Assessment	17965424
of	17965424
Disease	17965424
Status	17965424
(	17965424
PGADS	17965424
;	17965424
0	17965424
-	17965424
4	17965424
point	17965424
scale	17965424
)	17965424
.	17965424

RESULTS	17965424
:	17965424
Mean	17965424
(	17965424
SD	17965424
;	17965424
maximum	17965424
)	17965424
duration	17965424
of	17965424
treatment	17965424
was	17965424
19	17965424
.	17965424
3	17965424
(	17965424
10	17965424
.	17965424
3	17965424
;	17965424
32	17965424
.	17965424
9	17965424
)	17965424
and	17965424
19	17965424
.	17965424
1	17965424
(	17965424
10	17965424
.	17965424
4	17965424
;	17965424
33	17965424
.	17965424
1	17965424
)	17965424
months	17965424
in	17965424
the	17965424
etoricoxib	17965424
and	17965424
diclofenac	17965424
groups	17965424
,	17965424
respectively	17965424
.	17965424

The	17965424
cumulative	17965424
discontinuation	17965424
rate	17965424
due	17965424
to	17965424
GI	17965424
AEs	17965424
was	17965424
significantly	17965424
lower	17965424
with	17965424
etoricoxib	17965424
than	17965424
diclofenac	17965424
(	17965424
5	17965424
.	17965424
2	17965424
vs	17965424
8	17965424
.	17965424
5	17965424
events	17965424
per	17965424
100	17965424
patient	17965424
-	17965424
years	17965424
,	17965424
respectively	17965424
;	17965424
hazard	17965424
ratio	17965424
0	17965424
.	17965424
62	17965424
(	17965424
95%	17965424
CI	17965424
:	17965424
0	17965424
.	17965424
47	17965424
,	17965424
0	17965424
.	17965424
81	17965424
;	17965424
p	17965424
<	17965424
or	17965424
=	17965424
0	17965424
.	17965424
001	17965424
)	17965424
)	17965424
.	17965424

The	17965424
incidence	17965424
of	17965424
discontinuations	17965424
for	17965424
hypertension	17965424
-	17965424
related	17965424
and	17965424
oedema	17965424
-	17965424
related	17965424
AEs	17965424
were	17965424
significantly	17965424
higher	17965424
with	17965424
etoricoxib	17965424
(	17965424
2	17965424
.	17965424
5%	17965424
and	17965424
1	17965424
.	17965424
1%	17965424
respectively	17965424
)	17965424
compared	17965424
with	17965424
diclofenac	17965424
(	17965424
1	17965424
.	17965424
5%	17965424
and	17965424
0	17965424
.	17965424
4%	17965424
respectively	17965424
;	17965424
p	17965424
<	17965424
0	17965424
.	17965424
001	17965424
for	17965424
hypertension	17965424
and	17965424
p	17965424
<	17965424
0	17965424
.	17965424
01	17965424
for	17965424
oedema	17965424
)	17965424
.	17965424

Etoricoxib	17965424
and	17965424
diclofenac	17965424
treatment	17965424
resulted	17965424
in	17965424
similar	17965424
efficacy	17965424
(	17965424
PGADS	17965424
mean	17965424
changes	17965424
from	17965424
baseline	17965424
-	17965424
0	17965424
.	17965424
62	17965424
vs	17965424
-	17965424
0	17965424
.	17965424
58	17965424
,	17965424
respectively	17965424
)	17965424
.	17965424

CONCLUSIONS	17965424
:	17965424
Etoricoxib	17965424
90	17965424
mg	17965424
demonstrated	17965424
a	17965424
significantly	17965424
lower	17965424
risk	17965424
for	17965424
discontinuing	17965424
treatment	17965424
due	17965424
to	17965424
GI	17965424
AEs	17965424
compared	17965424
with	17965424
diclofenac	17965424
150	17965424
mg	17965424
.	17965424

Discontinuations	17965424
from	17965424
renovascular	17965424
AEs	17965424
,	17965424
although	17965424
less	17965424
common	17965424
than	17965424
discontinuations	17965424
from	17965424
GI	17965424
AEs	17965424
,	17965424
were	17965424
significantly	17965424
higher	17965424
with	17965424
etoricoxib	17965424
.	17965424
Putative	26411452
Prostate	26411452
Cancer	26411452
Risk	26411452
SNP	26411452
in	26411452
an	26411452
Androgen	26411452
Receptor	26411452
-	26411452
Binding	26411452
Site	26411452
of	26411452
the	26411452
Melanophilin	26411452
Gene	26411452
Illustrates	26411452
Enrichment	26411452
of	26411452
Risk	26411452
SNPs	26411452
in	26411452
Androgen	26411452
Receptor	26411452
Target	26411452
Sites	26411452
.	26411452

Genome	26411452
-	26411452
wide	26411452
association	26411452
studies	26411452
have	26411452
identified	26411452
genomic	26411452
loci	26411452
,	26411452
whose	26411452
single	26411452
-	26411452
nucleotide	26411452
polymorphisms	26411452
(	26411452
SNPs	26411452
)	26411452
predispose	26411452
to	26411452
prostate	26411452
cancer	26411452
(	26411452
PCa	26411452
)	26411452
.	26411452

However	26411452
,	26411452
the	26411452
mechanisms	26411452
of	26411452
most	26411452
of	26411452
these	26411452
variants	26411452
are	26411452
largely	26411452
unknown	26411452
.	26411452

We	26411452
integrated	26411452
chromatin	26411452
-	26411452
immunoprecipitation	26411452
-	26411452
coupled	26411452
sequencing	26411452
and	26411452
microarray	26411452
expression	26411452
profiling	26411452
in	26411452
TMPRSS2	26411452
-	26411452
ERG	26411452
gene	26411452
rearrangement	26411452
positive	26411452
DUCaP	26411452
cells	26411452
with	26411452
the	26411452
GWAS	26411452
PCa	26411452
risk	26411452
SNPs	26411452
catalog	26411452
to	26411452
identify	26411452
disease	26411452
susceptibility	26411452
SNPs	26411452
localized	26411452
within	26411452
functional	26411452
androgen	26411452
receptor	26411452
-	26411452
binding	26411452
sites	26411452
(	26411452
ARBSs	26411452
)	26411452
.	26411452

Among	26411452
the	26411452
48	26411452
GWAS	26411452
index	26411452
risk	26411452
SNPs	26411452
and	26411452
3	26411452
,	26411452
917	26411452
linked	26411452
SNPs	26411452
,	26411452
80	26411452
were	26411452
found	26411452
located	26411452
in	26411452
ARBSs	26411452
.	26411452

Of	26411452
these	26411452
,	26411452
rs11891426	26411452
:	26411452
T	26411452
>	26411452
G	26411452
in	26411452
an	26411452
intron	26411452
of	26411452
the	26411452
melanophilin	26411452
gene	26411452
(	26411452
MLPH	26411452
)	26411452
was	26411452
within	26411452
a	26411452
novel	26411452
putative	26411452
auxiliary	26411452
AR	26411452
-	26411452
binding	26411452
motif	26411452
,	26411452
which	26411452
is	26411452
enriched	26411452
in	26411452
the	26411452
neighborhood	26411452
of	26411452
canonical	26411452
androgen	26411452
-	26411452
responsive	26411452
elements	26411452
.	26411452

T	26411452
>	26411452
G	26411452
exchange	26411452
attenuated	26411452
the	26411452
transcriptional	26411452
activity	26411452
of	26411452
the	26411452
ARBS	26411452
in	26411452
an	26411452
AR	26411452
reporter	26411452
gene	26411452
assay	26411452
.	26411452

The	26411452
expression	26411452
of	26411452
MLPH	26411452
in	26411452
primary	26411452
prostate	26411452
tumors	26411452
was	26411452
significantly	26411452
lower	26411452
in	26411452
those	26411452
with	26411452
the	26411452
G	26411452
compared	26411452
with	26411452
the	26411452
T	26411452
allele	26411452
and	26411452
correlated	26411452
significantly	26411452
with	26411452
AR	26411452
protein	26411452
.	26411452

Higher	26411452
melanophilin	26411452
level	26411452
in	26411452
prostate	26411452
tissue	26411452
of	26411452
patients	26411452
with	26411452
a	26411452
favorable	26411452
PCa	26411452
risk	26411452
profile	26411452
points	26411452
out	26411452
a	26411452
tumor	26411452
-	26411452
suppressive	26411452
effect	26411452
.	26411452

These	26411452
results	26411452
unravel	26411452
a	26411452
hidden	26411452
link	26411452
between	26411452
AR	26411452
and	26411452
a	26411452
functional	26411452
putative	26411452
PCa	26411452
risk	26411452
SNP	26411452
,	26411452
whose	26411452
allele	26411452
alteration	26411452
affects	26411452
androgen	26411452
regulation	26411452
of	26411452
its	26411452
host	26411452
gene	26411452
MLPH	26411452
.	26411452
Cultured	24442316
mycelium	24442316
Cordyceps	24442316
sinensis	24442316
protects	24442316
liver	24442316
sinusoidal	24442316
endothelial	24442316
cells	24442316
in	24442316
acute	24442316
liver	24442316
injured	24442316
mice	24442316
.	24442316

Cultured	24442316
mycelium	24442316
Cordyceps	24442316
sinensis	24442316
(	24442316
CMCS	24442316
)	24442316
was	24442316
widely	24442316
used	24442316
for	24442316
a	24442316
variety	24442316
of	24442316
diseases	24442316
including	24442316
liver	24442316
injury	24442316
,	24442316
the	24442316
current	24442316
study	24442316
aims	24442316
to	24442316
investigate	24442316
the	24442316
protective	24442316
effects	24442316
of	24442316
CMCS	24442316
on	24442316
liver	24442316
sinusoidal	24442316
endothelial	24442316
cells	24442316
(	24442316
LSECs	24442316
)	24442316
in	24442316
acute	24442316
injury	24442316
liver	24442316
and	24442316
related	24442316
action	24442316
mechanisms	24442316
.	24442316

The	24442316
mice	24442316
were	24442316
injected	24442316
intraperitoneally	24442316
with	24442316
lipopolysaccharide	24442316
(	24442316
LPS	24442316
)	24442316
and	24442316
D	24442316
-	24442316
galactosamine	24442316
(	24442316
D	24442316
-	24442316
GalN	24442316
)	24442316
.	24442316

39	24442316
male	24442316
BABL	24442316
/	24442316
c	24442316
mice	24442316
were	24442316
randomly	24442316
divided	24442316
into	24442316
four	24442316
groups	24442316
:	24442316
normal	24442316
control	24442316
,	24442316
model	24442316
control	24442316
,	24442316
CMCS	24442316
treatment	24442316
and	24442316
1	24442316
,	24442316
10	24442316
-	24442316
phenanthroline	24442316
treatment	24442316
groups	24442316
.	24442316

The	24442316
Serum	24442316
liver	24442316
function	24442316
parameters	24442316
including	24442316
alanine	24442316
aminotransferase	24442316
(	24442316
ALT	24442316
)	24442316
and	24442316
aspartate	24442316
aminotransferase	24442316
(	24442316
AST	24442316
)	24442316
levels	24442316
were	24442316
assayed	24442316
with	24442316
the	24442316
commercial	24442316
kit	24442316
.	24442316

The	24442316
inflammation	24442316
and	24442316
scaffold	24442316
structure	24442316
in	24442316
liver	24442316
were	24442316
stained	24442316
with	24442316
hematoxylin	24442316
and	24442316
eosin	24442316
and	24442316
silver	24442316
staining	24442316
respectively	24442316
.	24442316

The	24442316
LSECs	24442316
and	24442316
sub	24442316
-	24442316
endothelial	24442316
basement	24442316
membrane	24442316
were	24442316
observed	24442316
with	24442316
the	24442316
scanning	24442316
and	24442316
transmission	24442316
electronic	24442316
microscope	24442316
.	24442316

The	24442316
protein	24442316
expressions	24442316
of	24442316
intercellular	24442316
adhesion	24442316
molecule	24442316
-	24442316
1	24442316
(	24442316
ICAM	24442316
-	24442316
1	24442316
)	24442316
and	24442316
vascular	24442316
cell	24442316
adhesion	24442316
molecule	24442316
-	24442316
1	24442316
(	24442316
VCAM	24442316
-	24442316
1	24442316
)	24442316
in	24442316
liver	24442316
were	24442316
analyzed	24442316
with	24442316
Western	24442316
blotting	24442316
.	24442316

Expression	24442316
of	24442316
von	24442316
Willebrand	24442316
factor	24442316
(	24442316
vWF	24442316
)	24442316
was	24442316
investigated	24442316
with	24442316
immunofluorescence	24442316
staining	24442316
.	24442316

The	24442316
lipid	24442316
peroxidation	24442316
indicators	24442316
including	24442316
antisuperoxideanion	24442316
(	24442316
ASAFR	24442316
)	24442316
,	24442316
hydroxyl	24442316
free	24442316
radical	24442316
(	24442316
.	24442316
OH	24442316
)	24442316
,	24442316
superoxide	24442316
dismutase	24442316
(	24442316
SOD	24442316
)	24442316
,	24442316
malondialdehyde	24442316
and	24442316
glutathione	24442316
S	24442316
-	24442316
transferase	24442316
(	24442316
GST	24442316
)	24442316
were	24442316
determined	24442316
with	24442316
kits	24442316
,	24442316
and	24442316
matrix	24442316
metalloproteinase	24442316
-	24442316
2	24442316
and	24442316
9	24442316
(	24442316
MMP	24442316
-	24442316
2	24442316
/	24442316
9	24442316
)	24442316
activities	24442316
in	24442316
liver	24442316
were	24442316
analyzed	24442316
with	24442316
gelatin	24442316
zymography	24442316
and	24442316
in	24442316
situ	24442316
fluorescent	24442316
zymography	24442316
respectively	24442316
.	24442316

The	24442316
model	24442316
mice	24442316
had	24442316
much	24442316
higher	24442316
serum	24442316
levels	24442316
of	24442316
ALT	24442316
and	24442316
AST	24442316
than	24442316
the	24442316
normal	24442316
mice	24442316
.	24442316

Compared	24442316
to	24442316
that	24442316
in	24442316
the	24442316
normal	24442316
control	24442316
,	24442316
more	24442316
severe	24442316
liver	24442316
inflammation	24442316
and	24442316
hepatocyte	24442316
apoptosis	24442316
,	24442316
worse	24442316
hepatic	24442316
lipid	24442316
peroxidation	24442316
demonstrated	24442316
by	24442316
the	24442316
increased	24442316
ASAFR	24442316
,	24442316
.	24442316
OH	24442316
and	24442316
MDA	24442316
,	24442316
but	24442316
decreased	24442316
SOD	24442316
and	24442316
GST	24442316
,	24442316
increased	24442316
MMP	24442316
-	24442316
2	24442316
/	24442316
9	24442316
activities	24442316
and	24442316
VCAM	24442316
-	24442316
1	24442316
,	24442316
ICAM	24442316
-	24442316
1	24442316
and	24442316
vWF	24442316
expressions	24442316
,	24442316
which	24442316
revealed	24442316
obvious	24442316
LSEC	24442316
injury	24442316
and	24442316
scaffold	24442316
structure	24442316
broken	24442316
,	24442316
were	24442316
shown	24442316
in	24442316
the	24442316
model	24442316
control	24442316
.	24442316

Compared	24442316
with	24442316
the	24442316
model	24442316
group	24442316
,	24442316
CMCS	24442316
and	24442316
1	24442316
,	24442316
10	24442316
-	24442316
phenanthroline	24442316
significantly	24442316
improved	24442316
serum	24442316
ALT	24442316
/	24442316
AST	24442316
,	24442316
attenuated	24442316
hepatic	24442316
inflammation	24442316
and	24442316
improved	24442316
peroxidative	24442316
injury	24442316
in	24442316
liver	24442316
,	24442316
decreased	24442316
MMP	24442316
-	24442316
2	24442316
/	24442316
9	24442316
activities	24442316
in	24442316
liver	24442316
tissue	24442316
,	24442316
improved	24442316
integration	24442316
of	24442316
scaffold	24442316
structure	24442316
,	24442316
and	24442316
decreased	24442316
protein	24442316
expression	24442316
of	24442316
VCAM	24442316
-	24442316
1	24442316
and	24442316
ICAM	24442316
-	24442316
1	24442316
.	24442316

CMCS	24442316
could	24442316
protect	24442316
LSECs	24442316
from	24442316
injury	24442316
and	24442316
maintain	24442316
the	24442316
microvasculature	24442316
integration	24442316
in	24442316
acute	24442316
injured	24442316
liver	24442316
of	24442316
mice	24442316
induced	24442316
by	24442316
LPS	24442316
/	24442316
D	24442316
-	24442316
GalN	24442316
.	24442316

Its	24442316
action	24442316
mechanism	24442316
was	24442316
associated	24442316
with	24442316
the	24442316
down	24442316
-	24442316
regulation	24442316
of	24442316
MMP	24442316
-	24442316
2	24442316
/	24442316
9	24442316
activities	24442316
and	24442316
inhibition	24442316
of	24442316
peroxidation	24442316
in	24442316
injured	24442316
liver	24442316
.	24442316
Defining	22808010
an	22808010
EPOR	22808010
-	22808010
regulated	22808010
transcriptome	22808010
for	22808010
primary	22808010
progenitors	22808010
,	22808010
including	22808010
Tnfr	22808010
-	22808010
sf13c	22808010
as	22808010
a	22808010
novel	22808010
mediator	22808010
of	22808010
EPO	22808010
-	22808010
dependent	22808010
erythroblast	22808010
formation	22808010
.	22808010

Certain	22808010
concepts	22808010
concerning	22808010
EPO	22808010
/	22808010
EPOR	22808010
action	22808010
modes	22808010
have	22808010
been	22808010
challenged	22808010
by	22808010
in	22808010
vivo	22808010
studies	22808010
:	22808010
Bcl	22808010
-	22808010
x	22808010
levels	22808010
are	22808010
elevated	22808010
in	22808010
maturing	22808010
erythroblasts	22808010
,	22808010
but	22808010
not	22808010
in	22808010
their	22808010
progenitors	22808010
;	22808010
truncated	22808010
EPOR	22808010
alleles	22808010
that	22808010
lack	22808010
a	22808010
major	22808010
p85	22808010
/	22808010
PI3K	22808010
recruitment	22808010
site	22808010
nonetheless	22808010
promote	22808010
polycythemia	22808010
;	22808010
and	22808010
Erk1	22808010
disruption	22808010
unexpectedly	22808010
bolsters	22808010
erythropoiesis	22808010
.	22808010

To	22808010
discover	22808010
novel	22808010
EPO	22808010
/	22808010
EPOR	22808010
action	22808010
routes	22808010
,	22808010
global	22808010
transcriptome	22808010
analyses	22808010
presently	22808010
are	22808010
applied	22808010
to	22808010
interrogate	22808010
EPO	22808010
/	22808010
EPOR	22808010
effects	22808010
on	22808010
primary	22808010
bone	22808010
marrow	22808010
-	22808010
derived	22808010
CFUe	22808010
-	22808010
like	22808010
progenitors	22808010
.	22808010

Overall	22808010
,	22808010
160	22808010
EPO	22808010
/	22808010
EPOR	22808010
target	22808010
transcripts	22808010
were	22808010
significantly	22808010
modulated	22808010
2	22808010
-	22808010
to	22808010
21	22808010
.	22808010
8	22808010
-	22808010
fold	22808010
.	22808010

A	22808010
unique	22808010
set	22808010
of	22808010
EPO	22808010
-	22808010
regulated	22808010
survival	22808010
factors	22808010
included	22808010
Lyl1	22808010
,	22808010
Gas5	22808010
,	22808010
Pim3	22808010
,	22808010
Pim1	22808010
,	22808010
Bim	22808010
,	22808010
Trib3	22808010
and	22808010
Serpina	22808010
3g	22808010
.	22808010

EPO	22808010
/	22808010
EPOR	22808010
-	22808010
modulated	22808010
cell	22808010
cycle	22808010
mediators	22808010
included	22808010
Cdc25a	22808010
,	22808010
Btg3	22808010
,	22808010
Cyclin	22808010
-	22808010
d2	22808010
,	22808010
p27	22808010
-	22808010
kip1	22808010
,	22808010
Cyclin	22808010
-	22808010
g2	22808010
and	22808010
CyclinB1	22808010
-	22808010
IP	22808010
-	22808010
1	22808010
.	22808010

EPO	22808010
regulation	22808010
of	22808010
signal	22808010
transduction	22808010
factors	22808010
was	22808010
also	22808010
interestingly	22808010
complex	22808010
.	22808010

For	22808010
example	22808010
,	22808010
not	22808010
only	22808010
Socs3	22808010
plus	22808010
Socs2	22808010
but	22808010
also	22808010
Spred2	22808010
,	22808010
Spred1	22808010
and	22808010
Eaf1	22808010
were	22808010
EPO	22808010
-	22808010
induced	22808010
as	22808010
negative	22808010
-	22808010
feedback	22808010
components	22808010
.	22808010

Socs2	22808010
,	22808010
plus	22808010
five	22808010
additional	22808010
targets	22808010
,	22808010
further	22808010
proved	22808010
to	22808010
comprise	22808010
new	22808010
EPOR	22808010
/	22808010
Jak2	22808010
/	22808010
Stat5	22808010
response	22808010
genes	22808010
(	22808010
which	22808010
are	22808010
important	22808010
for	22808010
erythropoiesis	22808010
during	22808010
anemia	22808010
)	22808010
.	22808010

Among	22808010
receptors	22808010
,	22808010
an	22808010
atypical	22808010
TNF	22808010
-	22808010
receptor	22808010
Tnfr	22808010
-	22808010
sf13c	22808010
was	22808010
up	22808010
-	22808010
modulated	22808010
>	22808010
5	22808010
-	22808010
fold	22808010
by	22808010
EPO	22808010
.	22808010

Functionally	22808010
,	22808010
Tnfr	22808010
-	22808010
sf13c	22808010
ligation	22808010
proved	22808010
to	22808010
both	22808010
promote	22808010
proerythroblast	22808010
survival	22808010
,	22808010
and	22808010
substantially	22808010
enhance	22808010
erythroblast	22808010
formation	22808010
.	22808010

The	22808010
EPOR	22808010
therefore	22808010
engages	22808010
a	22808010
sophisticated	22808010
set	22808010
of	22808010
transcriptome	22808010
response	22808010
circuits	22808010
,	22808010
with	22808010
Tnfr	22808010
-	22808010
sf13c	22808010
deployed	22808010
as	22808010
one	22808010
novel	22808010
positive	22808010
regulator	22808010
of	22808010
proerythroblast	22808010
formation	22808010
.	22808010
Novel	21080147
CRELD1	21080147
gene	21080147
mutations	21080147
in	21080147
patients	21080147
with	21080147
atrioventricular	21080147
septal	21080147
defect	21080147
.	21080147

BACKGROUND	21080147
:	21080147
Atrioventricular	21080147
septal	21080147
defects	21080147
(	21080147
AVSDs	21080147
)	21080147
occur	21080147
as	21080147
clinical	21080147
defects	21080147
of	21080147
several	21080147
different	21080147
syndromes	21080147
,	21080147
as	21080147
autosomal	21080147
dominant	21080147
defects	21080147
,	21080147
and	21080147
as	21080147
sporadically	21080147
occurring	21080147
malformations	21080147
.	21080147

Consequently	21080147
,	21080147
there	21080147
is	21080147
genetic	21080147
heterogeneity	21080147
,	21080147
but	21080147
until	21080147
recently	21080147
,	21080147
little	21080147
is	21080147
known	21080147
about	21080147
the	21080147
genes	21080147
involving	21080147
in	21080147
the	21080147
pathogenesis	21080147
of	21080147
AVSD	21080147
.	21080147

CRELD1	21080147
gene	21080147
,	21080147
a	21080147
novel	21080147
cell	21080147
adhesion	21080147
molecule	21080147
,	21080147
is	21080147
a	21080147
candidate	21080147
gene	21080147
for	21080147
AVSD	21080147
.	21080147

METHODS	21080147
:	21080147
This	21080147
study	21080147
included	21080147
133	21080147
patients	21080147
with	21080147
AVSD	21080147
and	21080147
200	21080147
healthy	21080147
controls	21080147
.	21080147

Peripheral	21080147
blood	21080147
samples	21080147
were	21080147
collected	21080147
and	21080147
genomic	21080147
DNA	21080147
was	21080147
extracted	21080147
from	21080147
the	21080147
leukocytes	21080147
.	21080147

CRELD1	21080147
was	21080147
amplified	21080147
by	21080147
polymerase	21080147
chain	21080147
reaction	21080147
(	21080147
PCR	21080147
)	21080147
with	21080147
specific	21080147
primers	21080147
.	21080147

The	21080147
sequences	21080147
of	21080147
PCR	21080147
products	21080147
were	21080147
compared	21080147
between	21080147
the	21080147
patients	21080147
and	21080147
controls	21080147
.	21080147

RESULTS	21080147
:	21080147
In	21080147
a	21080147
patient	21080147
,	21080147
a	21080147
C	21080147
-	21080147
to	21080147
-	21080147
G	21080147
transition	21080147
was	21080147
identified	21080147
at	21080147
nucleotide	21080147
857	21080147
in	21080147
exon	21080147
8	21080147
that	21080147
resulted	21080147
in	21080147
a	21080147
substitution	21080147
of	21080147
alanine	21080147
for	21080147
proline	21080147
at	21080147
amino	21080147
acid	21080147
286	21080147
in	21080147
the	21080147
first	21080147
calcium	21080147
-	21080147
binding	21080147
EGF	21080147
domain	21080147
.	21080147

This	21080147
patient	21080147
had	21080147
an	21080147
isolated	21080147
partial	21080147
AVSD	21080147
and	21080147
the	21080147
mutation	21080147
was	21080147
inherited	21080147
from	21080147
her	21080147
mother	21080147
.	21080147

Another	21080147
mutation	21080147
was	21080147
detected	21080147
in	21080147
a	21080147
patient	21080147
with	21080147
a	21080147
partial	21080147
AVSD	21080147
and	21080147
evidence	21080147
of	21080147
Down	21080147
syndrome	21080147
.	21080147

The	21080147
heterozygous	21080147
c	21080147
.	21080147
973G	21080147
>	21080147
A	21080147
transition	21080147
in	21080147
exon	21080147
9	21080147
resulted	21080147
in	21080147
a	21080147
substitution	21080147
of	21080147
lysine	21080147
for	21080147
glutamic	21080147
acid	21080147
at	21080147
amino	21080147
acid	21080147
325	21080147
(	21080147
E325K	21080147
)	21080147
in	21080147
the	21080147
second	21080147
calcium	21080147
-	21080147
binding	21080147
EGF	21080147
domain	21080147
.	21080147

CONCLUSIONS	21080147
:	21080147
Two	21080147
novel	21080147
CRELD1	21080147
mutations	21080147
were	21080147
identified	21080147
in	21080147
the	21080147
calcium	21080147
-	21080147
binding	21080147
EGF	21080147
domain	21080147
in	21080147
patients	21080147
with	21080147
AVSD	21080147
.	21080147

CRELD1	21080147
is	21080147
likely	21080147
to	21080147
be	21080147
an	21080147
AVSD	21080147
-	21080147
susceptibility	21080147
gene	21080147
and	21080147
CRELD1	21080147
mutations	21080147
may	21080147
increase	21080147
the	21080147
risk	21080147
of	21080147
developing	21080147
a	21080147
heart	21080147
defect	21080147
rather	21080147
than	21080147
being	21080147
a	21080147
direct	21080147
causative	21080147
mutation	21080147
.	21080147
The	18165598
differential	18165598
effects	18165598
of	18165598
bupivacaine	18165598
and	18165598
lidocaine	18165598
on	18165598
prostaglandin	18165598
E2	18165598
release	18165598
,	18165598
cyclooxygenase	18165598
gene	18165598
expression	18165598
and	18165598
pain	18165598
in	18165598
a	18165598
clinical	18165598
pain	18165598
model	18165598
.	18165598

BACKGROUND	18165598
:	18165598
In	18165598
addition	18165598
to	18165598
blocking	18165598
nociceptive	18165598
input	18165598
from	18165598
surgical	18165598
sites	18165598
,	18165598
long	18165598
-	18165598
acting	18165598
local	18165598
anesthetics	18165598
might	18165598
directly	18165598
modulate	18165598
inflammation	18165598
.	18165598

In	18165598
the	18165598
present	18165598
study	18165598
,	18165598
we	18165598
describe	18165598
the	18165598
proinflammatory	18165598
effects	18165598
of	18165598
bupivacaine	18165598
on	18165598
local	18165598
prostaglandin	18165598
E2	18165598
(	18165598
PGE2	18165598
)	18165598
production	18165598
and	18165598
cyclooxygenase	18165598
(	18165598
COX	18165598
)	18165598
gene	18165598
expression	18165598
that	18165598
increases	18165598
postoperative	18165598
pain	18165598
in	18165598
human	18165598
subjects	18165598
.	18165598

METHODS	18165598
:	18165598
Subjects	18165598
(	18165598
n	18165598
=	18165598
114	18165598
)	18165598
undergoing	18165598
extraction	18165598
of	18165598
impacted	18165598
third	18165598
molars	18165598
received	18165598
either	18165598
2%	18165598
lidocaine	18165598
or	18165598
0	18165598
.	18165598
5%	18165598
bupivacaine	18165598
before	18165598
surgery	18165598
and	18165598
either	18165598
rofecoxib	18165598
50	18165598
mg	18165598
or	18165598
placebo	18165598
orally	18165598
90	18165598
min	18165598
before	18165598
surgery	18165598
and	18165598
for	18165598
the	18165598
following	18165598
48	18165598
h	18165598
.	18165598

Oral	18165598
mucosal	18165598
biopsies	18165598
were	18165598
taken	18165598
before	18165598
surgery	18165598
and	18165598
48	18165598
h	18165598
after	18165598
surgery	18165598
.	18165598

After	18165598
extraction	18165598
,	18165598
a	18165598
microdialysis	18165598
probe	18165598
was	18165598
placed	18165598
at	18165598
the	18165598
surgical	18165598
site	18165598
for	18165598
PGE2	18165598
and	18165598
thromboxane	18165598
B2	18165598
(	18165598
TXB2	18165598
)	18165598
measurements	18165598
.	18165598

RESULTS	18165598
:	18165598
The	18165598
bupivacaine	18165598
/	18165598
rofecoxib	18165598
group	18165598
reported	18165598
significantly	18165598
less	18165598
pain	18165598
,	18165598
as	18165598
assessed	18165598
by	18165598
a	18165598
visual	18165598
analog	18165598
scale	18165598
,	18165598
compared	18165598
with	18165598
the	18165598
other	18165598
three	18165598
treatment	18165598
groups	18165598
over	18165598
the	18165598
first	18165598
4	18165598
h	18165598
.	18165598

However	18165598
,	18165598
the	18165598
bupivacaine	18165598
/	18165598
placebo	18165598
group	18165598
reported	18165598
significantly	18165598
more	18165598
pain	18165598
at	18165598
24	18165598
h	18165598
and	18165598
PGE2	18165598
levels	18165598
during	18165598
the	18165598
first	18165598
4	18165598
h	18165598
were	18165598
significantly	18165598
higher	18165598
than	18165598
the	18165598
other	18165598
three	18165598
treatment	18165598
groups	18165598
.	18165598

Moreover	18165598
,	18165598
bupivacaine	18165598
significantly	18165598
increased	18165598
COX	18165598
-	18165598
2	18165598
gene	18165598
expression	18165598
at	18165598
48	18165598
h	18165598
as	18165598
compared	18165598
with	18165598
the	18165598
lidocaine	18165598
/	18165598
placebo	18165598
group	18165598
.	18165598

Thromboxane	18165598
levels	18165598
were	18165598
not	18165598
significantly	18165598
affected	18165598
by	18165598
any	18165598
of	18165598
the	18165598
treatments	18165598
,	18165598
indicating	18165598
that	18165598
the	18165598
effects	18165598
seen	18165598
were	18165598
attributable	18165598
to	18165598
inhibition	18165598
of	18165598
COX	18165598
-	18165598
2	18165598
,	18165598
but	18165598
not	18165598
COX	18165598
-	18165598
1	18165598
.	18165598

CONCLUSIONS	18165598
:	18165598
These	18165598
results	18165598
suggest	18165598
that	18165598
bupivacaine	18165598
stimulates	18165598
COX	18165598
-	18165598
2	18165598
gene	18165598
expression	18165598
after	18165598
tissue	18165598
injury	18165598
,	18165598
which	18165598
is	18165598
associated	18165598
with	18165598
higher	18165598
PGE2	18165598
production	18165598
and	18165598
pain	18165598
after	18165598
the	18165598
local	18165598
anesthetic	18165598
effect	18165598
dissipates	18165598
.	18165598
Syncope	17344330
and	17344330
QT	17344330
prolongation	17344330
among	17344330
patients	17344330
treated	17344330
with	17344330
methadone	17344330
for	17344330
heroin	17344330
dependence	17344330
in	17344330
the	17344330
city	17344330
of	17344330
Copenhagen	17344330
.	17344330

BACKGROUND	17344330
:	17344330
Methadone	17344330
is	17344330
prescribed	17344330
to	17344330
heroin	17344330
addicts	17344330
to	17344330
decrease	17344330
illicit	17344330
opioid	17344330
use	17344330
.	17344330

Prolongation	17344330
of	17344330
the	17344330
QT	17344330
interval	17344330
in	17344330
the	17344330
ECG	17344330
of	17344330
patients	17344330
with	17344330
torsade	17344330
de	17344330
pointes	17344330
(	17344330
TdP	17344330
)	17344330
has	17344330
been	17344330
reported	17344330
in	17344330
methadone	17344330
users	17344330
.	17344330

As	17344330
heroin	17344330
addicts	17344330
sometimes	17344330
faint	17344330
while	17344330
using	17344330
illicit	17344330
drugs	17344330
,	17344330
doctors	17344330
might	17344330
attribute	17344330
too	17344330
many	17344330
episodes	17344330
of	17344330
syncope	17344330
to	17344330
illicit	17344330
drug	17344330
use	17344330
and	17344330
thereby	17344330
underestimate	17344330
the	17344330
incidence	17344330
of	17344330
TdP	17344330
in	17344330
this	17344330
special	17344330
population	17344330
,	17344330
and	17344330
the	17344330
high	17344330
mortality	17344330
in	17344330
this	17344330
population	17344330
may	17344330
,	17344330
in	17344330
part	17344330
,	17344330
be	17344330
caused	17344330
by	17344330
the	17344330
proarrhythmic	17344330
effect	17344330
of	17344330
methadone	17344330
.	17344330

METHODS	17344330
:	17344330
In	17344330
this	17344330
cross	17344330
-	17344330
sectional	17344330
study	17344330
interview	17344330
,	17344330
ECGs	17344330
and	17344330
blood	17344330
samples	17344330
were	17344330
collected	17344330
in	17344330
a	17344330
population	17344330
of	17344330
adult	17344330
heroin	17344330
addicts	17344330
treated	17344330
with	17344330
methadone	17344330
or	17344330
buprenorphine	17344330
on	17344330
a	17344330
daily	17344330
basis	17344330
.	17344330

Of	17344330
the	17344330
patients	17344330
at	17344330
the	17344330
Drug	17344330
Addiction	17344330
Service	17344330
in	17344330
the	17344330
municipal	17344330
of	17344330
Copenhagen	17344330
,	17344330
450	17344330
(	17344330
approximately	17344330
52%	17344330
)	17344330
were	17344330
included	17344330
.	17344330

The	17344330
QT	17344330
interval	17344330
was	17344330
estimated	17344330
from	17344330
12	17344330
lead	17344330
ECGs	17344330
.	17344330

All	17344330
participants	17344330
were	17344330
interviewed	17344330
about	17344330
any	17344330
experience	17344330
of	17344330
syncope	17344330
.	17344330

The	17344330
association	17344330
between	17344330
opioid	17344330
dose	17344330
and	17344330
QT	17344330
,	17344330
and	17344330
methadone	17344330
dose	17344330
and	17344330
reporting	17344330
of	17344330
syncope	17344330
was	17344330
assessed	17344330
using	17344330
multivariate	17344330
linear	17344330
regression	17344330
and	17344330
logistic	17344330
regression	17344330
,	17344330
respectively	17344330
.	17344330

RESULTS	17344330
:	17344330
Methadone	17344330
dose	17344330
was	17344330
associated	17344330
with	17344330
longer	17344330
QT	17344330
interval	17344330
of	17344330
0	17344330
.	17344330
140	17344330
ms	17344330
/	17344330
mg	17344330
(	17344330
p	17344330
=	17344330
0	17344330
.	17344330
002	17344330
)	17344330
.	17344330

No	17344330
association	17344330
between	17344330
buprenorphine	17344330
and	17344330
QTc	17344330
was	17344330
found	17344330
.	17344330

Among	17344330
the	17344330
subjects	17344330
treated	17344330
with	17344330
methadone	17344330
,	17344330
28%	17344330
men	17344330
and	17344330
32%	17344330
women	17344330
had	17344330
prolonged	17344330
QTc	17344330
interval	17344330
.	17344330

None	17344330
of	17344330
the	17344330
subjects	17344330
treated	17344330
with	17344330
buprenorphine	17344330
had	17344330
QTc	17344330
interval	17344330
>	17344330
0	17344330
.	17344330
440	17344330
s	17344330
(	17344330
(	17344330
1	17344330
/	17344330
2	17344330
)	17344330
)	17344330
.	17344330

A	17344330
50	17344330
mg	17344330
higher	17344330
methadone	17344330
dose	17344330
was	17344330
associated	17344330
with	17344330
a	17344330
1	17344330
.	17344330
2	17344330
(	17344330
95%	17344330
CI	17344330
1	17344330
.	17344330
1	17344330
to	17344330
1	17344330
.	17344330
4	17344330
)	17344330
times	17344330
higher	17344330
odds	17344330
for	17344330
syncope	17344330
.	17344330

CONCLUSIONS	17344330
:	17344330
Methadone	17344330
is	17344330
associated	17344330
with	17344330
QT	17344330
prolongation	17344330
and	17344330
higher	17344330
reporting	17344330
of	17344330
syncope	17344330
in	17344330
a	17344330
population	17344330
of	17344330
heroin	17344330
addicts	17344330
.	17344330
Clusters	19624920
of	19624920
multidrug	19624920
-	19624920
resistant	19624920
Mycobacterium	19624920
tuberculosis	19624920
cases	19624920
,	19624920
Europe	19624920
.	19624920

Molecular	19624920
surveillance	19624920
of	19624920
multidrug	19624920
-	19624920
resistant	19624920
tuberculosis	19624920
(	19624920
MDR	19624920
TB	19624920
)	19624920
was	19624920
implemented	19624920
in	19624920
Europe	19624920
as	19624920
case	19624920
reporting	19624920
in	19624920
2005	19624920
.	19624920

For	19624920
all	19624920
new	19624920
MDR	19624920
TB	19624920
cases	19624920
detected	19624920
from	19624920
January	19624920
2003	19624920
through	19624920
June	19624920
2007	19624920
,	19624920
countries	19624920
reported	19624920
case	19624920
-	19624920
based	19624920
epidemiologic	19624920
data	19624920
and	19624920
DNA	19624920
fingerprint	19624920
patterns	19624920
of	19624920
MDR	19624920
TB	19624920
strains	19624920
when	19624920
available	19624920
.	19624920

International	19624920
clusters	19624920
were	19624920
detected	19624920
and	19624920
analyzed	19624920
.	19624920

From	19624920
2003	19624920
through	19624920
mid	19624920
-	19624920
2007	19624920
in	19624920
Europe	19624920
,	19624920
2	19624920
,	19624920
494	19624920
cases	19624920
of	19624920
MDR	19624920
TB	19624920
were	19624920
reported	19624920
from	19624920
24	19624920
European	19624920
countries	19624920
.	19624920

Epidemiologic	19624920
and	19624920
molecular	19624920
data	19624920
were	19624920
linked	19624920
for	19624920
593	19624920
(	19624920
39%	19624920
)	19624920
cases	19624920
,	19624920
and	19624920
672	19624920
insertion	19624920
sequence	19624920
6110	19624920
DNA	19624920
fingerprint	19624920
patterns	19624920
were	19624920
reported	19624920
from	19624920
19	19624920
countries	19624920
.	19624920

Of	19624920
these	19624920
patterns	19624920
,	19624920
288	19624920
(	19624920
43%	19624920
)	19624920
belonged	19624920
to	19624920
18	19624920
European	19624920
clusters	19624920
;	19624920
7	19624920
clusters	19624920
(	19624920
242	19624920
/	19624920
288	19624920
cases	19624920
,	19624920
84%	19624920
)	19624920
were	19624920
characterized	19624920
by	19624920
strains	19624920
of	19624920
the	19624920
Beijing	19624920
genotype	19624920
family	19624920
,	19624920
including	19624920
the	19624920
largest	19624920
cluster	19624920
(	19624920
175	19624920
/	19624920
288	19624920
cases	19624920
,	19624920
61%	19624920
)	19624920
.	19624920

Both	19624920
clustering	19624920
and	19624920
the	19624920
Beijing	19624920
genotype	19624920
were	19624920
associated	19624920
with	19624920
strains	19624920
originating	19624920
in	19624920
eastern	19624920
European	19624920
countries	19624920
.	19624920

Molecular	19624920
cluster	19624920
detection	19624920
contributes	19624920
to	19624920
identification	19624920
of	19624920
transmission	19624920
profile	19624920
,	19624920
risk	19624920
factors	19624920
,	19624920
and	19624920
control	19624920
measures	19624920
.	19624920
Association	20801104
study	20801104
of	20801104
polymorphisms	20801104
in	20801104
the	20801104
promoter	20801104
region	20801104
of	20801104
DRD4	20801104
with	20801104
schizophrenia	20801104
,	20801104
depression	20801104
,	20801104
and	20801104
heroin	20801104
addiction	20801104
.	20801104

This	20801104
study	20801104
investigated	20801104
the	20801104
possible	20801104
association	20801104
between	20801104
three	20801104
functional	20801104
polymorphisms	20801104
in	20801104
the	20801104
promoter	20801104
region	20801104
of	20801104
the	20801104
dopamine	20801104
D4	20801104
receptor	20801104
(	20801104
DRD4	20801104
)	20801104
gene	20801104
and	20801104
schizophrenia	20801104
,	20801104
depression	20801104
,	20801104
and	20801104
heroin	20801104
addiction	20801104
.	20801104

Genomic	20801104
DNA	20801104
was	20801104
isolated	20801104
from	20801104
the	20801104
venous	20801104
blood	20801104
leukocytes	20801104
of	20801104
322	20801104
unrelated	20801104
patients	20801104
with	20801104
schizophrenia	20801104
,	20801104
156	20801104
patients	20801104
with	20801104
depression	20801104
,	20801104
300	20801104
patients	20801104
with	20801104
heroin	20801104
addiction	20801104
,	20801104
and	20801104
300	20801104
healthy	20801104
unrelated	20801104
individuals	20801104
.	20801104

Polymorphisms	20801104
in	20801104
the	20801104
promoter	20801104
region	20801104
of	20801104
DRD4	20801104
(	20801104
-	20801104
120	20801104
bp	20801104
duplication	20801104
,	20801104
-	20801104
616C	20801104
/	20801104
G	20801104
,	20801104
and	20801104
-	20801104
521C	20801104
/	20801104
T	20801104
)	20801104
were	20801104
genotyped	20801104
using	20801104
allele	20801104
-	20801104
specific	20801104
polymerase	20801104
chain	20801104
reaction	20801104
analysis	20801104
.	20801104

Genotype	20801104
and	20801104
allele	20801104
were	20801104
analyzed	20801104
using	20801104
SPSS	20801104
11	20801104
.	20801104
5	20801104
software	20801104
.	20801104

Results	20801104
of	20801104
this	20801104
analysis	20801104
indicated	20801104
that	20801104
there	20801104
is	20801104
a	20801104
strong	20801104
finding	20801104
of	20801104
-	20801104
120	20801104
bp	20801104
duplication	20801104
allele	20801104
frequencies	20801104
with	20801104
schizophrenia	20801104
(	20801104
p	20801104
=	20801104
0	20801104
.	20801104
008	20801104
)	20801104
and	20801104
weak	20801104
finding	20801104
with	20801104
-	20801104
1240	20801104
L	20801104
/	20801104
S	20801104
and	20801104
for	20801104
paranoid	20801104
schizophrenia	20801104
(	20801104
p	20801104
=	20801104
0	20801104
.	20801104
022	20801104
)	20801104
.	20801104

Interestingly	20801104
,	20801104
there	20801104
is	20801104
a	20801104
stronger	20801104
finding	20801104
with	20801104
-	20801104
521	20801104
C	20801104
/	20801104
T	20801104
allele	20801104
frequencies	20801104
with	20801104
heroin	20801104
dependence	20801104
(	20801104
p	20801104
=	20801104
0	20801104
.	20801104
0002	20801104
)	20801104
.	20801104

These	20801104
observations	20801104
strongly	20801104
suggest	20801104
that	20801104
the	20801104
-	20801104
120	20801104
-	20801104
bp	20801104
duplication	20801104
polymorphism	20801104
of	20801104
DRD4	20801104
is	20801104
associated	20801104
with	20801104
schizophrenia	20801104
and	20801104
that	20801104
the	20801104
-	20801104
521	20801104
C	20801104
/	20801104
T	20801104
polymorphism	20801104
is	20801104
associated	20801104
with	20801104
heroin	20801104
addiction	20801104
.	20801104
Lack	15200408
of	15200408
major	15200408
involvement	15200408
of	15200408
human	15200408
uroplakin	15200408
genes	15200408
in	15200408
vesicoureteral	15200408
reflux	15200408
:	15200408
implications	15200408
for	15200408
disease	15200408
heterogeneity	15200408
.	15200408

BACKGROUND	15200408
:	15200408
Primary	15200408
vesicoureteral	15200408
reflux	15200408
(	15200408
VUR	15200408
)	15200408
is	15200408
a	15200408
hereditary	15200408
disorder	15200408
characterized	15200408
by	15200408
the	15200408
retrograde	15200408
flow	15200408
of	15200408
urine	15200408
into	15200408
the	15200408
ureters	15200408
and	15200408
kidneys	15200408
.	15200408

It	15200408
affects	15200408
about	15200408
1%	15200408
of	15200408
the	15200408
young	15200408
children	15200408
and	15200408
is	15200408
thus	15200408
one	15200408
of	15200408
the	15200408
most	15200408
common	15200408
hereditary	15200408
diseases	15200408
.	15200408

Its	15200408
associated	15200408
nephropathy	15200408
is	15200408
an	15200408
important	15200408
cause	15200408
of	15200408
end	15200408
-	15200408
stage	15200408
renal	15200408
failure	15200408
in	15200408
children	15200408
and	15200408
adults	15200408
.	15200408

Recent	15200408
studies	15200408
indicate	15200408
that	15200408
genetic	15200408
ablation	15200408
of	15200408
mouse	15200408
uroplakin	15200408
(	15200408
UP	15200408
)	15200408
III	15200408
gene	15200408
,	15200408
which	15200408
encodes	15200408
a	15200408
47	15200408
kD	15200408
urothelial	15200408
-	15200408
specific	15200408
integral	15200408
membrane	15200408
protein	15200408
forming	15200408
urothelial	15200408
plaques	15200408
,	15200408
causes	15200408
VUR	15200408
and	15200408
hydronephrosis	15200408
.	15200408

METHODS	15200408
:	15200408
To	15200408
begin	15200408
to	15200408
determine	15200408
whether	15200408
mutations	15200408
in	15200408
UP	15200408
genes	15200408
might	15200408
play	15200408
a	15200408
role	15200408
in	15200408
human	15200408
VUR	15200408
,	15200408
we	15200408
genotyped	15200408
all	15200408
four	15200408
UP	15200408
genes	15200408
in	15200408
76	15200408
patients	15200408
with	15200408
radiologically	15200408
proven	15200408
primary	15200408
VUR	15200408
by	15200408
polymerase	15200408
chain	15200408
reaction	15200408
(	15200408
PCR	15200408
)	15200408
amplification	15200408
and	15200408
sequencing	15200408
of	15200408
all	15200408
their	15200408
exons	15200408
plus	15200408
50	15200408
to	15200408
150	15200408
bp	15200408
of	15200408
flanking	15200408
intronic	15200408
sequences	15200408
.	15200408

RESULTS	15200408
:	15200408
Eighteen	15200408
single	15200408
nucleotide	15200408
polymorphisms	15200408
(	15200408
SNPs	15200408
)	15200408
were	15200408
identified	15200408
,	15200408
seven	15200408
of	15200408
which	15200408
were	15200408
missense	15200408
,	15200408
with	15200408
no	15200408
truncation	15200408
or	15200408
frame	15200408
shift	15200408
mutations	15200408
.	15200408

Since	15200408
healthy	15200408
relatives	15200408
of	15200408
the	15200408
VUR	15200408
probands	15200408
are	15200408
not	15200408
reliable	15200408
negative	15200408
controls	15200408
for	15200408
VUR	15200408
,	15200408
we	15200408
used	15200408
a	15200408
population	15200408
of	15200408
90	15200408
race	15200408
-	15200408
matched	15200408
,	15200408
healthy	15200408
individuals	15200408
,	15200408
unrelated	15200408
to	15200408
the	15200408
VUR	15200408
patients	15200408
,	15200408
as	15200408
controls	15200408
to	15200408
perform	15200408
an	15200408
association	15200408
study	15200408
.	15200408

Most	15200408
of	15200408
the	15200408
SNPs	15200408
were	15200408
not	15200408
found	15200408
to	15200408
be	15200408
significantly	15200408
associated	15200408
with	15200408
VUR	15200408
.	15200408

However	15200408
,	15200408
SNP1	15200408
of	15200408
UP	15200408
Ia	15200408
gene	15200408
affecting	15200408
a	15200408
C	15200408
to	15200408
T	15200408
conversion	15200408
and	15200408
an	15200408
Ala7Val	15200408
change	15200408
,	15200408
and	15200408
SNP7	15200408
of	15200408
UP	15200408
III	15200408
affecting	15200408
a	15200408
C	15200408
to	15200408
G	15200408
conversion	15200408
and	15200408
a	15200408
Pro154Ala	15200408
change	15200408
,	15200408
were	15200408
marginally	15200408
associated	15200408
with	15200408
VUR	15200408
(	15200408
both	15200408
P	15200408
=	15200408
0	15200408
.	15200408
08	15200408
)	15200408
.	15200408

Studies	15200408
of	15200408
additional	15200408
cases	15200408
yielded	15200408
a	15200408
second	15200408
set	15200408
of	15200408
data	15200408
that	15200408
,	15200408
in	15200408
combination	15200408
with	15200408
the	15200408
first	15200408
set	15200408
,	15200408
confirmed	15200408
a	15200408
weak	15200408
association	15200408
of	15200408
UP	15200408
III	15200408
SNP7	15200408
in	15200408
VUR	15200408
(	15200408
P	15200408
=	15200408
0	15200408
.	15200408
036	15200408
adjusted	15200408
for	15200408
both	15200408
subsets	15200408
of	15200408
cases	15200408
vs	15200408
.	15200408

controls	15200408
)	15200408
.	15200408

CONCLUSION	15200408
:	15200408
Such	15200408
a	15200408
weak	15200408
association	15200408
and	15200408
the	15200408
lack	15200408
of	15200408
families	15200408
with	15200408
simple	15200408
dominant	15200408
Mendelian	15200408
inheritance	15200408
suggest	15200408
that	15200408
missense	15200408
changes	15200408
of	15200408
uroplakin	15200408
genes	15200408
cannot	15200408
play	15200408
a	15200408
dominant	15200408
role	15200408
in	15200408
causing	15200408
VUR	15200408
in	15200408
humans	15200408
,	15200408
although	15200408
they	15200408
may	15200408
be	15200408
weak	15200408
risk	15200408
factors	15200408
contributing	15200408
to	15200408
a	15200408
complex	15200408
polygenic	15200408
disease	15200408
.	15200408

The	15200408
fact	15200408
that	15200408
no	15200408
truncation	15200408
or	15200408
frame	15200408
shift	15200408
mutations	15200408
have	15200408
been	15200408
found	15200408
in	15200408
any	15200408
of	15200408
the	15200408
VUR	15200408
patients	15200408
,	15200408
coupled	15200408
with	15200408
our	15200408
recent	15200408
finding	15200408
that	15200408
some	15200408
breeding	15200408
pairs	15200408
of	15200408
UP	15200408
III	15200408
knockout	15200408
mice	15200408
yield	15200408
litters	15200408
that	15200408
show	15200408
not	15200408
only	15200408
VUR	15200408
,	15200408
but	15200408
also	15200408
severe	15200408
hydronephrosis	15200408
and	15200408
neonatal	15200408
death	15200408
,	15200408
raises	15200408
the	15200408
possibility	15200408
that	15200408
major	15200408
uroplakin	15200408
mutations	15200408
could	15200408
be	15200408
embryonically	15200408
or	15200408
postnatally	15200408
lethal	15200408
in	15200408
humans	15200408
.	15200408
Midline	2422478
B3	2422478
serotonin	2422478
nerves	2422478
in	2422478
rat	2422478
medulla	2422478
are	2422478
involved	2422478
in	2422478
hypotensive	2422478
effect	2422478
of	2422478
methyldopa	2422478
.	2422478

Previous	2422478
experiments	2422478
in	2422478
this	2422478
laboratory	2422478
have	2422478
shown	2422478
that	2422478
microinjection	2422478
of	2422478
methyldopa	2422478
onto	2422478
the	2422478
ventrolateral	2422478
cells	2422478
of	2422478
the	2422478
B3	2422478
serotonin	2422478
neurons	2422478
in	2422478
the	2422478
medulla	2422478
elicits	2422478
a	2422478
hypotensive	2422478
response	2422478
mediated	2422478
by	2422478
a	2422478
projection	2422478
descending	2422478
into	2422478
the	2422478
spinal	2422478
cord	2422478
.	2422478

The	2422478
present	2422478
experiments	2422478
were	2422478
designed	2422478
to	2422478
investigate	2422478
the	2422478
role	2422478
of	2422478
the	2422478
midline	2422478
cells	2422478
of	2422478
the	2422478
B3	2422478
serotonin	2422478
neurons	2422478
in	2422478
the	2422478
medulla	2422478
,	2422478
coinciding	2422478
with	2422478
the	2422478
raphe	2422478
magnus	2422478
.	2422478

In	2422478
spontaneously	2422478
hypertensive	2422478
,	2422478
stroke	2422478
-	2422478
prone	2422478
rats	2422478
,	2422478
microinjection	2422478
of	2422478
methyldopa	2422478
into	2422478
the	2422478
area	2422478
of	2422478
the	2422478
midline	2422478
B3	2422478
serotonin	2422478
cell	2422478
group	2422478
in	2422478
the	2422478
ventral	2422478
medulla	2422478
caused	2422478
a	2422478
potent	2422478
hypotension	2422478
of	2422478
30	2422478
-	2422478
40	2422478
mm	2422478
Hg	2422478
,	2422478
which	2422478
was	2422478
maximal	2422478
2	2422478
-	2422478
3	2422478
h	2422478
after	2422478
administration	2422478
and	2422478
was	2422478
abolished	2422478
by	2422478
the	2422478
serotonin	2422478
neurotoxin	2422478
5	2422478
,	2422478
7	2422478
-	2422478
dihydroxytryptamine	2422478
(	2422478
5	2422478
,	2422478
7	2422478
-	2422478
DHT	2422478
)	2422478
injected	2422478
intracerebroventricularly	2422478
.	2422478

However	2422478
,	2422478
intraspinal	2422478
injection	2422478
of	2422478
5	2422478
,	2422478
7	2422478
-	2422478
DHT	2422478
to	2422478
produce	2422478
a	2422478
more	2422478
selective	2422478
lesion	2422478
of	2422478
only	2422478
descending	2422478
serotonin	2422478
projections	2422478
in	2422478
the	2422478
spinal	2422478
cord	2422478
did	2422478
not	2422478
affect	2422478
this	2422478
hypotension	2422478
.	2422478

Further	2422478
,	2422478
5	2422478
,	2422478
7	2422478
-	2422478
DHT	2422478
lesion	2422478
of	2422478
serotonin	2422478
nerves	2422478
travelling	2422478
in	2422478
the	2422478
median	2422478
forebrain	2422478
bundle	2422478
,	2422478
one	2422478
of	2422478
the	2422478
main	2422478
ascending	2422478
pathways	2422478
from	2422478
the	2422478
B3	2422478
serotonin	2422478
cells	2422478
,	2422478
did	2422478
not	2422478
affect	2422478
the	2422478
fall	2422478
in	2422478
blood	2422478
pressure	2422478
associated	2422478
with	2422478
a	2422478
midline	2422478
B3	2422478
serotonin	2422478
methyldopa	2422478
injection	2422478
.	2422478

It	2422478
is	2422478
concluded	2422478
therefore	2422478
that	2422478
,	2422478
unlike	2422478
the	2422478
ventrolateral	2422478
B3	2422478
cells	2422478
which	2422478
mediate	2422478
a	2422478
methyldopa	2422478
-	2422478
induced	2422478
hypotension	2422478
via	2422478
descending	2422478
projections	2422478
,	2422478
the	2422478
midline	2422478
serotonin	2422478
B3	2422478
cells	2422478
in	2422478
the	2422478
medulla	2422478
contribute	2422478
to	2422478
the	2422478
hypotensive	2422478
action	2422478
of	2422478
methyldopa	2422478
,	2422478
either	2422478
by	2422478
way	2422478
of	2422478
an	2422478
ascending	2422478
projection	2422478
which	2422478
does	2422478
not	2422478
pass	2422478
through	2422478
the	2422478
median	2422478
forebrain	2422478
bundle	2422478
,	2422478
or	2422478
through	2422478
a	2422478
projection	2422478
restricted	2422478
to	2422478
the	2422478
caudal	2422478
brainstem	2422478
.	2422478
A	21219851
novel	21219851
mutation	21219851
screening	21219851
system	21219851
for	21219851
Ehlers	21219851
-	21219851
Danlos	21219851
Syndrome	21219851
,	21219851
vascular	21219851
type	21219851
by	21219851
high	21219851
-	21219851
resolution	21219851
melting	21219851
curve	21219851
analysis	21219851
in	21219851
combination	21219851
with	21219851
small	21219851
amplicon	21219851
genotyping	21219851
using	21219851
genomic	21219851
DNA	21219851
.	21219851

Ehlers	21219851
-	21219851
Danlos	21219851
syndrome	21219851
,	21219851
vascular	21219851
type	21219851
(	21219851
vEDS	21219851
)	21219851
(	21219851
MIM	21219851
#	21219851
130050	21219851
)	21219851
is	21219851
an	21219851
autosomal	21219851
dominant	21219851
disorder	21219851
caused	21219851
by	21219851
type	21219851
III	21219851
procollagen	21219851
gene	21219851
(	21219851
COL3A1	21219851
)	21219851
mutations	21219851
.	21219851

Most	21219851
COL3A1	21219851
mutations	21219851
are	21219851
detected	21219851
by	21219851
using	21219851
total	21219851
RNA	21219851
from	21219851
patient	21219851
-	21219851
derived	21219851
fibroblasts	21219851
,	21219851
which	21219851
requires	21219851
an	21219851
invasive	21219851
skin	21219851
biopsy	21219851
.	21219851

High	21219851
-	21219851
resolution	21219851
melting	21219851
curve	21219851
analysis	21219851
(	21219851
hrMCA	21219851
)	21219851
has	21219851
recently	21219851
been	21219851
developed	21219851
as	21219851
a	21219851
post	21219851
-	21219851
PCR	21219851
mutation	21219851
scanning	21219851
method	21219851
which	21219851
enables	21219851
simple	21219851
,	21219851
rapid	21219851
,	21219851
cost	21219851
-	21219851
effective	21219851
,	21219851
and	21219851
highly	21219851
sensitive	21219851
mutation	21219851
screening	21219851
of	21219851
large	21219851
genes	21219851
.	21219851

We	21219851
established	21219851
a	21219851
hrMCA	21219851
method	21219851
to	21219851
screen	21219851
for	21219851
COL3A1	21219851
mutations	21219851
using	21219851
genomic	21219851
DNA	21219851
.	21219851

PCR	21219851
primers	21219851
pairs	21219851
for	21219851
COL3A1	21219851
(	21219851
52	21219851
amplicons	21219851
)	21219851
were	21219851
designed	21219851
to	21219851
cover	21219851
all	21219851
coding	21219851
regions	21219851
of	21219851
the	21219851
52	21219851
exons	21219851
,	21219851
including	21219851
the	21219851
splicing	21219851
sites	21219851
.	21219851

We	21219851
used	21219851
15	21219851
DNA	21219851
samples	21219851
(	21219851
8	21219851
validation	21219851
samples	21219851
and	21219851
7	21219851
samples	21219851
of	21219851
clinically	21219851
suspected	21219851
vEDS	21219851
patients	21219851
)	21219851
in	21219851
this	21219851
study	21219851
.	21219851

The	21219851
eight	21219851
known	21219851
COL3A1	21219851
mutations	21219851
in	21219851
validation	21219851
samples	21219851
were	21219851
all	21219851
successfully	21219851
detected	21219851
by	21219851
the	21219851
hrMCA	21219851
.	21219851

In	21219851
addition	21219851
,	21219851
we	21219851
identified	21219851
five	21219851
novel	21219851
COL3A1	21219851
mutations	21219851
,	21219851
including	21219851
one	21219851
deletion	21219851
(	21219851
c	21219851
.	21219851
2187delA	21219851
)	21219851
and	21219851
one	21219851
nonsense	21219851
mutation	21219851
(	21219851
c	21219851
.	21219851
2992C	21219851
>	21219851
T	21219851
)	21219851
that	21219851
could	21219851
not	21219851
be	21219851
determined	21219851
by	21219851
the	21219851
conventional	21219851
total	21219851
RNA	21219851
method	21219851
.	21219851

Furthermore	21219851
,	21219851
we	21219851
established	21219851
a	21219851
small	21219851
amplicon	21219851
genotyping	21219851
(	21219851
SAG	21219851
)	21219851
method	21219851
for	21219851
detecting	21219851
three	21219851
high	21219851
frequency	21219851
coding	21219851
-	21219851
region	21219851
SNPs	21219851
(	21219851
rs1800255	21219851
:	21219851
G	21219851
>	21219851
A	21219851
,	21219851
rs1801184	21219851
:	21219851
T	21219851
>	21219851
C	21219851
,	21219851
and	21219851
rs2271683	21219851
:	21219851
A	21219851
>	21219851
G	21219851
)	21219851
in	21219851
COL3A1	21219851
to	21219851
differentiate	21219851
mutations	21219851
before	21219851
sequencing	21219851
.	21219851

The	21219851
use	21219851
of	21219851
hrMCA	21219851
in	21219851
combination	21219851
with	21219851
SAG	21219851
from	21219851
genomic	21219851
DNA	21219851
enables	21219851
rapid	21219851
detection	21219851
of	21219851
COL3A1	21219851
mutations	21219851
with	21219851
high	21219851
efficiency	21219851
and	21219851
specificity	21219851
.	21219851

A	21219851
better	21219851
understanding	21219851
of	21219851
the	21219851
genotype	21219851
-	21219851
phenotype	21219851
correlation	21219851
in	21219851
COL3A1	21219851
using	21219851
this	21219851
method	21219851
will	21219851
lead	21219851
to	21219851
improve	21219851
in	21219851
diagnosis	21219851
and	21219851
treatment	21219851
.	21219851
Quinine	17297207
-	17297207
induced	17297207
arrhythmia	17297207
in	17297207
a	17297207
patient	17297207
with	17297207
severe	17297207
malaria	17297207
.	17297207

It	17297207
was	17297207
reported	17297207
that	17297207
there	17297207
was	17297207
a	17297207
case	17297207
of	17297207
severe	17297207
malaria	17297207
patient	17297207
with	17297207
jaundice	17297207
who	17297207
presented	17297207
with	17297207
arrhythmia	17297207
(	17297207
premature	17297207
ventricular	17297207
contraction	17297207
)	17297207
while	17297207
getting	17297207
quinine	17297207
infusion	17297207
was	17297207
reported	17297207
.	17297207

A	17297207
man	17297207
,	17297207
25	17297207
years	17297207
old	17297207
,	17297207
was	17297207
admitted	17297207
to	17297207
hospital	17297207
with	17297207
high	17297207
fever	17297207
,	17297207
chill	17297207
,	17297207
vomiting	17297207
,	17297207
jaundice	17297207
.	17297207

The	17297207
patient	17297207
was	17297207
fully	17297207
conscious	17297207
,	17297207
blood	17297207
pressure	17297207
120	17297207
/	17297207
80	17297207
mmHg	17297207
,	17297207
pulse	17297207
rate	17297207
100	17297207
x	17297207
/	17297207
minute	17297207
,	17297207
regular	17297207
.	17297207

On	17297207
admission	17297207
,	17297207
laboratory	17297207
examination	17297207
showed	17297207
Plasmodium	17297207
falciparum	17297207
(	17297207
+	17297207
+	17297207
+	17297207
+	17297207
)	17297207
,	17297207
total	17297207
bilirubin	17297207
8	17297207
.	17297207
25	17297207
mg	17297207
/	17297207
dL	17297207
,	17297207
conjugated	17297207
bilirubin	17297207
4	17297207
.	17297207
36	17297207
mg	17297207
/	17297207
dL	17297207
,	17297207
unconjugated	17297207
bilirubin	17297207
3	17297207
.	17297207
89	17297207
mg	17297207
/	17297207
dL	17297207
,	17297207
potassium	17297207
3	17297207
.	17297207
52	17297207
meq	17297207
/	17297207
L	17297207
Patient	17297207
was	17297207
diagnosed	17297207
as	17297207
severe	17297207
malaria	17297207
with	17297207
jaundice	17297207
and	17297207
got	17297207
quinine	17297207
infusion	17297207
in	17297207
dextrose	17297207
5%	17297207
500	17297207
mg	17297207
/	17297207
8	17297207
hour	17297207
.	17297207

On	17297207
the	17297207
second	17297207
day	17297207
the	17297207
patient	17297207
had	17297207
vomitus	17297207
,	17297207
diarrhea	17297207
,	17297207
tinnitus	17297207
,	17297207
loss	17297207
of	17297207
hearing	17297207
.	17297207

After	17297207
30	17297207
hours	17297207
of	17297207
quinine	17297207
infusion	17297207
the	17297207
patient	17297207
felt	17297207
palpitation	17297207
and	17297207
electrocardiography	17297207
(	17297207
ECG	17297207
)	17297207
recording	17297207
showed	17297207
premature	17297207
ventricular	17297207
contraction	17297207
(	17297207
PVC	17297207
)	17297207
>	17297207
5	17297207
x	17297207
/	17297207
minute	17297207
,	17297207
trigemini	17297207
,	17297207
constant	17297207
type	17297207
-	17297207
-	17297207
sinoatrial	17297207
block	17297207
,	17297207
positive	17297207
U	17297207
wave	17297207
.	17297207

He	17297207
was	17297207
treated	17297207
with	17297207
lidocaine	17297207
50	17297207
mg	17297207
intravenously	17297207
followed	17297207
by	17297207
infusion	17297207
1500	17297207
mg	17297207
in	17297207
dextrose	17297207
5%	17297207
/	17297207
24	17297207
hour	17297207
and	17297207
potassium	17297207
aspartate	17297207
tablet	17297207
.	17297207

Quinine	17297207
infusion	17297207
was	17297207
discontinued	17297207
and	17297207
changed	17297207
with	17297207
sulfate	17297207
quinine	17297207
tablets	17297207
.	17297207

Three	17297207
hours	17297207
later	17297207
the	17297207
patient	17297207
felt	17297207
better	17297207
,	17297207
the	17297207
frequency	17297207
of	17297207
PVC	17297207
reduced	17297207
to	17297207
4	17297207
-	17297207
5	17297207
x	17297207
/	17297207
minute	17297207
and	17297207
on	17297207
the	17297207
third	17297207
day	17297207
ECG	17297207
was	17297207
normal	17297207
,	17297207
potassium	17297207
level	17297207
was	17297207
3	17297207
.	17297207
34	17297207
meq	17297207
/	17297207
L	17297207
.	17297207

He	17297207
was	17297207
discharged	17297207
on	17297207
7th	17297207
day	17297207
in	17297207
good	17297207
condition	17297207
.	17297207

Quinine	17297207
,	17297207
like	17297207
quinidine	17297207
,	17297207
is	17297207
a	17297207
chincona	17297207
alkaloid	17297207
that	17297207
has	17297207
anti	17297207
-	17297207
arrhythmic	17297207
property	17297207
,	17297207
although	17297207
it	17297207
also	17297207
pro	17297207
-	17297207
arrhythmic	17297207
that	17297207
can	17297207
cause	17297207
various	17297207
arrhythmias	17297207
,	17297207
including	17297207
severe	17297207
arrhythmia	17297207
such	17297207
as	17297207
multiple	17297207
PVC	17297207
.	17297207

Administration	17297207
of	17297207
parenteral	17297207
quinine	17297207
must	17297207
be	17297207
done	17297207
carefully	17297207
and	17297207
with	17297207
good	17297207
observation	17297207
because	17297207
of	17297207
its	17297207
pro	17297207
-	17297207
arrhythmic	17297207
effect	17297207
,	17297207
especially	17297207
in	17297207
older	17297207
patients	17297207
who	17297207
have	17297207
heart	17297207
diseases	17297207
or	17297207
patients	17297207
with	17297207
electrolyte	17297207
disorder	17297207
(	17297207
hypokalemia	17297207
)	17297207
which	17297207
frequently	17297207
occurs	17297207
due	17297207
to	17297207
vomiting	17297207
and	17297207
or	17297207
diarrhea	17297207
in	17297207
malaria	17297207
cases	17297207
.	17297207
Low	14722929
frequency	14722929
of	14722929
deafness	14722929
-	14722929
associated	14722929
GJB2	14722929
variants	14722929
in	14722929
Kenya	14722929
and	14722929
Sudan	14722929
and	14722929
novel	14722929
GJB2	14722929
variants	14722929
.	14722929

A	14722929
large	14722929
proportion	14722929
of	14722929
non	14722929
-	14722929
syndromic	14722929
autosomal	14722929
recessive	14722929
deafness	14722929
(	14722929
NSARD	14722929
)	14722929
in	14722929
many	14722929
populations	14722929
is	14722929
caused	14722929
by	14722929
variants	14722929
of	14722929
the	14722929
GJB2	14722929
gene	14722929
.	14722929

Here	14722929
,	14722929
the	14722929
frequency	14722929
of	14722929
GJB2	14722929
variants	14722929
was	14722929
studied	14722929
in	14722929
406	14722929
and	14722929
183	14722929
apparently	14722929
unrelated	14722929
children	14722929
from	14722929
Kenya	14722929
and	14722929
Sudan	14722929
,	14722929
respectively	14722929
,	14722929
with	14722929
mostly	14722929
severe	14722929
to	14722929
profound	14722929
non	14722929
-	14722929
syndromic	14722929
deafness	14722929
.	14722929

Nine	14722929
(	14722929
2	14722929
.	14722929
2	14722929
%	14722929
)	14722929
Kenyan	14722929
and	14722929
12	14722929
(	14722929
6	14722929
.	14722929
6	14722929
%	14722929
)	14722929
of	14722929
the	14722929
Sudanese	14722929
children	14722929
only	14722929
were	14722929
carriers	14722929
of	14722929
variants	14722929
within	14722929
the	14722929
coding	14722929
sequence	14722929
of	14722929
the	14722929
GJB2	14722929
gene	14722929
.	14722929

Variants	14722929
in	14722929
the	14722929
5	14722929
'	14722929
-	14722929
adjacent	14722929
region	14722929
were	14722929
detected	14722929
in	14722929
further	14722929
115	14722929
individuals	14722929
.	14722929

A	14722929
total	14722929
of	14722929
10	14722929
novel	14722929
variants	14722929
was	14722929
recognized	14722929
,	14722929
among	14722929
them	14722929
four	14722929
variants	14722929
in	14722929
the	14722929
adjacent	14722929
5	14722929
'	14722929
-	14722929
region	14722929
of	14722929
the	14722929
GJB2	14722929
coding	14722929
exon	14722929
2	14722929
(	14722929
g	14722929
.	14722929
3318	14722929
-	14722929
6T	14722929
>	14722929
A	14722929
,	14722929
g	14722929
.	14722929
3318	14722929
-	14722929
15C	14722929
>	14722929
T	14722929
,	14722929
g	14722929
.	14722929
3318	14722929
-	14722929
34C	14722929
>	14722929
T	14722929
,	14722929
g	14722929
.	14722929
3318	14722929
-	14722929
35T	14722929
>	14722929
G	14722929
)	14722929
,	14722929
a	14722929
6	14722929
base	14722929
-	14722929
pair	14722929
deletion	14722929
(	14722929
g	14722929
.	14722929
3455_3460del	14722929
[	14722929
p	14722929
.	14722929
Asp46_Gln48delinsGlu	14722929
]	14722929
)	14722929
,	14722929
a	14722929
variant	14722929
leading	14722929
to	14722929
a	14722929
stop	14722929
codon	14722929
(	14722929
g	14722929
.	14722929
3512C	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Tyr65X	14722929
]	14722929
)	14722929
,	14722929
synonymous	14722929
variants	14722929
(	14722929
g	14722929
.	14722929
3395C	14722929
>	14722929
T	14722929
[	14722929
p	14722929
.	14722929
Thr26	14722929
]	14722929
,	14722929
g	14722929
.	14722929
3503C	14722929
>	14722929
T	14722929
[	14722929
p	14722929
.	14722929
Asn62	14722929
]	14722929
,	14722929
g	14722929
.	14722929
3627A	14722929
>	14722929
C	14722929
[	14722929
p	14722929
.	14722929
Arg104	14722929
]	14722929
)	14722929
,	14722929
and	14722929
one	14722929
non	14722929
-	14722929
synonymous	14722929
variant	14722929
(	14722929
g	14722929
.	14722929
3816C	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Val167Met	14722929
]	14722929
)	14722929
.	14722929

In	14722929
addition	14722929
,	14722929
the	14722929
previously	14722929
described	14722929
variants	14722929
g	14722929
.	14722929
3352delG	14722929
(	14722929
commonly	14722929
designated	14722929
30delG	14722929
or	14722929
35	14722929
delG	14722929
)	14722929
,	14722929
g	14722929
.	14722929
3426G	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Val37Ile	14722929
]	14722929
,	14722929
g	14722929
.	14722929
3697G	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Arg127His	14722929
]	14722929
,	14722929
g	14722929
.	14722929
3774G	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Val153Ile	14722929
]	14722929
,	14722929
and	14722929
g	14722929
.	14722929
3795G	14722929
>	14722929
A	14722929
[	14722929
p	14722929
.	14722929
Gly160Ser	14722929
]	14722929
were	14722929
identified	14722929
.	14722929

With	14722929
the	14722929
exception	14722929
of	14722929
g	14722929
.	14722929
3318	14722929
-	14722929
34C	14722929
>	14722929
T	14722929
and	14722929
g	14722929
.	14722929
3352delG	14722929
,	14722929
all	14722929
variants	14722929
occurred	14722929
heterozygously	14722929
.	14722929

For	14722929
most	14722929
of	14722929
the	14722929
variants	14722929
identified	14722929
in	14722929
the	14722929
Kenyan	14722929
and	14722929
Sudanese	14722929
study	14722929
population	14722929
,	14722929
a	14722929
causative	14722929
association	14722929
with	14722929
NSARD	14722929
appears	14722929
to	14722929
be	14722929
unlikely	14722929
.	14722929

Compared	14722929
to	14722929
many	14722929
other	14722929
ethnic	14722929
groups	14722929
,	14722929
deafness	14722929
-	14722929
associated	14722929
variants	14722929
of	14722929
the	14722929
coding	14722929
region	14722929
of	14722929
GJB2	14722929
are	14722929
rare	14722929
in	14722929
Sudan	14722929
and	14722929
Kenya	14722929
,	14722929
suggesting	14722929
a	14722929
role	14722929
of	14722929
other	14722929
genetic	14722929
,	14722929
or	14722929
epigenetic	14722929
factors	14722929
as	14722929
a	14722929
cause	14722929
for	14722929
deafness	14722929
in	14722929
these	14722929
countries	14722929
.	14722929
A	20335448
novel	20335448
point	20335448
mutation	20335448
in	20335448
helix	20335448
10	20335448
of	20335448
the	20335448
human	20335448
glucocorticoid	20335448
receptor	20335448
causes	20335448
generalized	20335448
glucocorticoid	20335448
resistance	20335448
by	20335448
disrupting	20335448
the	20335448
structure	20335448
of	20335448
the	20335448
ligand	20335448
-	20335448
binding	20335448
domain	20335448
.	20335448

CONTEXT	20335448
:	20335448
Generalized	20335448
glucocorticoid	20335448
resistance	20335448
syndrome	20335448
is	20335448
a	20335448
rare	20335448
familial	20335448
or	20335448
sporadic	20335448
condition	20335448
characterized	20335448
by	20335448
partial	20335448
insensitivity	20335448
to	20335448
glucocorticoids	20335448
,	20335448
caused	20335448
by	20335448
mutations	20335448
in	20335448
the	20335448
glucocorticoid	20335448
receptor	20335448
(	20335448
GR	20335448
)	20335448
gene	20335448
.	20335448

Most	20335448
of	20335448
the	20335448
reported	20335448
cases	20335448
are	20335448
adults	20335448
,	20335448
demonstrating	20335448
symptoms	20335448
associated	20335448
with	20335448
mineralocorticoid	20335448
and	20335448
/	20335448
or	20335448
adrenal	20335448
androgen	20335448
excess	20335448
caused	20335448
by	20335448
compensatively	20335448
increased	20335448
secretion	20335448
of	20335448
the	20335448
adrenocorticotropic	20335448
hormone	20335448
.	20335448

PATIENT	20335448
:	20335448
We	20335448
identified	20335448
a	20335448
new	20335448
2	20335448
-	20335448
yr	20335448
-	20335448
old	20335448
female	20335448
case	20335448
of	20335448
generalized	20335448
glucocorticoid	20335448
resistance	20335448
syndrome	20335448
.	20335448

The	20335448
patient	20335448
(	20335448
TJ	20335448
)	20335448
presented	20335448
with	20335448
a	20335448
generalized	20335448
seizure	20335448
associated	20335448
with	20335448
hypoglycemia	20335448
and	20335448
hypokalemia	20335448
.	20335448

She	20335448
also	20335448
had	20335448
hypertension	20335448
and	20335448
premature	20335448
pubarche	20335448
,	20335448
whereas	20335448
dexamethasone	20335448
effectively	20335448
suppressed	20335448
these	20335448
clinical	20335448
manifestations	20335448
.	20335448

RESULTS	20335448
:	20335448
The	20335448
patient	20335448
'	20335448
s	20335448
GR	20335448
gene	20335448
had	20335448
a	20335448
heterozygotic	20335448
mutation	20335448
(	20335448
G	20335448
-	20335448
-	20335448
>	20335448
A	20335448
)	20335448
at	20335448
nucleotide	20335448
position	20335448
2141	20335448
(	20335448
exon	20335448
8	20335448
)	20335448
,	20335448
which	20335448
resulted	20335448
in	20335448
substitution	20335448
of	20335448
arginine	20335448
by	20335448
glutamine	20335448
at	20335448
amino	20335448
acid	20335448
position	20335448
714	20335448
in	20335448
the	20335448
ligand	20335448
-	20335448
binding	20335448
domain	20335448
(	20335448
LBD	20335448
)	20335448
of	20335448
the	20335448
GR	20335448
alpha	20335448
.	20335448

Molecular	20335448
analysis	20335448
revealed	20335448
that	20335448
the	20335448
mutant	20335448
receptor	20335448
had	20335448
significantly	20335448
impaired	20335448
transactivation	20335448
activity	20335448
with	20335448
a	20335448
2	20335448
-	20335448
fold	20335448
reduction	20335448
in	20335448
affinity	20335448
to	20335448
ligand	20335448
.	20335448

It	20335448
showed	20335448
attenuated	20335448
transactivation	20335448
of	20335448
the	20335448
activation	20335448
function	20335448
(	20335448
AF	20335448
)	20335448
-	20335448
2	20335448
and	20335448
reduced	20335448
binding	20335448
to	20335448
a	20335448
p160	20335448
nuclear	20335448
receptor	20335448
coactivator	20335448
.	20335448

Computer	20335448
-	20335448
based	20335448
structural	20335448
analysis	20335448
revealed	20335448
that	20335448
replacement	20335448
of	20335448
arginine	20335448
by	20335448
glutamine	20335448
at	20335448
position	20335448
714	20335448
transmitted	20335448
a	20335448
conformational	20335448
change	20335448
to	20335448
the	20335448
LBD	20335448
and	20335448
the	20335448
AF	20335448
-	20335448
2	20335448
transactivation	20335448
surface	20335448
,	20335448
resulting	20335448
in	20335448
a	20335448
decreased	20335448
binding	20335448
affinity	20335448
to	20335448
ligand	20335448
and	20335448
to	20335448
the	20335448
LXXLL	20335448
coactivator	20335448
motif	20335448
.	20335448

CONCLUSIONS	20335448
:	20335448
Dexamethasone	20335448
treatment	20335448
is	20335448
effective	20335448
in	20335448
controlling	20335448
the	20335448
premature	20335448
pubarche	20335448
,	20335448
hypoglycemia	20335448
,	20335448
hypertension	20335448
,	20335448
and	20335448
hypokalemia	20335448
in	20335448
this	20335448
child	20335448
case	20335448
,	20335448
wherein	20335448
arginine	20335448
714	20335448
plays	20335448
a	20335448
key	20335448
role	20335448
in	20335448
the	20335448
proper	20335448
formation	20335448
of	20335448
the	20335448
ligand	20335448
-	20335448
binding	20335448
pocket	20335448
and	20335448
the	20335448
AF	20335448
-	20335448
2	20335448
surface	20335448
of	20335448
the	20335448
GR	20335448
alpha	20335448
LBD	20335448
.	20335448
Inactivation	25622904
of	25622904
Sag	25622904
/	25622904
Rbx2	25622904
/	25622904
Roc2	25622904
e3	25622904
ubiquitin	25622904
ligase	25622904
triggers	25622904
senescence	25622904
and	25622904
inhibits	25622904
kras	25622904
-	25622904
induced	25622904
immortalization	25622904
.	25622904

Our	25622904
recent	25622904
study	25622904
showed	25622904
that	25622904
SAG	25622904
/	25622904
RBX2	25622904
E3	25622904
ubiquitin	25622904
ligase	25622904
regulates	25622904
apoptosis	25622904
and	25622904
vasculogenesis	25622904
by	25622904
promoting	25622904
degradation	25622904
of	25622904
NOXA	25622904
and	25622904
NF1	25622904
,	25622904
and	25622904
co	25622904
-	25622904
operates	25622904
with	25622904
Kras	25622904
to	25622904
promote	25622904
lung	25622904
tumorigenesis	25622904
by	25622904
activating	25622904
NFkappaB	25622904
and	25622904
mTOR	25622904
pathways	25622904
via	25622904
targeted	25622904
degradation	25622904
of	25622904
tumor	25622904
suppressive	25622904
substrates	25622904
including	25622904
IkappaB	25622904
,	25622904
DEPTOR	25622904
,	25622904
p21	25622904
and	25622904
p27	25622904
.	25622904

Here	25622904
we	25622904
investigated	25622904
the	25622904
role	25622904
of	25622904
Sag	25622904
/	25622904
Rbx2	25622904
E3	25622904
ligase	25622904
in	25622904
cellular	25622904
senescence	25622904
and	25622904
immortalization	25622904
of	25622904
mouse	25622904
embryonic	25622904
fibroblasts	25622904
(	25622904
MEFs	25622904
)	25622904
and	25622904
report	25622904
that	25622904
Sag	25622904
is	25622904
required	25622904
for	25622904
proper	25622904
cell	25622904
proliferation	25622904
and	25622904
Kras	25622904
(	25622904
G12D	25622904
)	25622904
-	25622904
induced	25622904
immortalization	25622904
.	25622904

Sag	25622904
inactivation	25622904
by	25622904
genetic	25622904
deletion	25622904
remarkably	25622904
suppresses	25622904
cell	25622904
proliferation	25622904
by	25622904
inducing	25622904
senescence	25622904
,	25622904
which	25622904
is	25622904
associated	25622904
with	25622904
accumulation	25622904
of	25622904
p16	25622904
,	25622904
but	25622904
not	25622904
p53	25622904
.	25622904

Mechanistically	25622904
,	25622904
Sag	25622904
deletion	25622904
caused	25622904
accumulation	25622904
of	25622904
Jun	25622904
-	25622904
B	25622904
,	25622904
a	25622904
substrate	25622904
of	25622904
Sag	25622904
-	25622904
Fbxw7	25622904
E3	25622904
ligase	25622904
and	25622904
a	25622904
transcription	25622904
factor	25622904
that	25622904
drives	25622904
p16	25622904
transcription	25622904
.	25622904

Importantly	25622904
,	25622904
senescence	25622904
triggered	25622904
by	25622904
Sag	25622904
deletion	25622904
can	25622904
be	25622904
largely	25622904
rescued	25622904
by	25622904
simultaneous	25622904
deletion	25622904
of	25622904
Cdkn2a	25622904
,	25622904
the	25622904
p16	25622904
encoding	25622904
gene	25622904
,	25622904
indicating	25622904
its	25622904
causal	25622904
role	25622904
.	25622904

Furthermore	25622904
,	25622904
Kras	25622904
(	25622904
G12D	25622904
)	25622904
-	25622904
induced	25622904
immortalization	25622904
can	25622904
also	25622904
be	25622904
abrogated	25622904
by	25622904
Sag	25622904
deletion	25622904
via	25622904
senescence	25622904
induction	25622904
,	25622904
which	25622904
is	25622904
again	25622904
rescued	25622904
by	25622904
simultaneous	25622904
deletion	25622904
of	25622904
Cdkn2a	25622904
.	25622904

Finally	25622904
,	25622904
we	25622904
found	25622904
that	25622904
Sag	25622904
deletion	25622904
inactivates	25622904
Kras	25622904
(	25622904
G12D	25622904
)	25622904
activity	25622904
and	25622904
block	25622904
the	25622904
MAPK	25622904
signaling	25622904
pathway	25622904
,	25622904
together	25622904
with	25622904
accumulated	25622904
p16	25622904
,	25622904
to	25622904
induce	25622904
senescence	25622904
.	25622904

Taken	25622904
together	25622904
,	25622904
our	25622904
results	25622904
demonstrated	25622904
that	25622904
Sag	25622904
is	25622904
a	25622904
Kras	25622904
(	25622904
G12D	25622904
)	25622904
-	25622904
cooperating	25622904
oncogene	25622904
required	25622904
for	25622904
Kras	25622904
(	25622904
G12D	25622904
)	25622904
-	25622904
induced	25622904
immortalization	25622904
and	25622904
transformation	25622904
,	25622904
and	25622904
targeting	25622904
SAG	25622904
-	25622904
SCF	25622904
E3	25622904
ligase	25622904
may	25622904
,	25622904
therefore	25622904
,	25622904
have	25622904
therapeutic	25622904
value	25622904
for	25622904
senescence	25622904
-	25622904
based	25622904
cancer	25622904
treatment	25622904
.	25622904
In	16112787
vivo	16112787
evidences	16112787
suggesting	16112787
the	16112787
role	16112787
of	16112787
oxidative	16112787
stress	16112787
in	16112787
pathogenesis	16112787
of	16112787
vancomycin	16112787
-	16112787
induced	16112787
nephrotoxicity	16112787
:	16112787
protection	16112787
by	16112787
erdosteine	16112787
.	16112787

The	16112787
aims	16112787
of	16112787
this	16112787
study	16112787
were	16112787
to	16112787
examine	16112787
vancomycin	16112787
(	16112787
VCM	16112787
)	16112787
-	16112787
induced	16112787
oxidative	16112787
stress	16112787
that	16112787
promotes	16112787
production	16112787
of	16112787
reactive	16112787
oxygen	16112787
species	16112787
(	16112787
ROS	16112787
)	16112787
and	16112787
to	16112787
investigate	16112787
the	16112787
role	16112787
of	16112787
erdosteine	16112787
,	16112787
an	16112787
expectorant	16112787
agent	16112787
,	16112787
which	16112787
has	16112787
also	16112787
antioxidant	16112787
properties	16112787
,	16112787
on	16112787
kidney	16112787
tissue	16112787
against	16112787
the	16112787
possible	16112787
VCM	16112787
-	16112787
induced	16112787
renal	16112787
impairment	16112787
in	16112787
rats	16112787
.	16112787

Rats	16112787
were	16112787
divided	16112787
into	16112787
three	16112787
groups	16112787
:	16112787
sham	16112787
,	16112787
VCM	16112787
and	16112787
VCM	16112787
plus	16112787
erdosteine	16112787
.	16112787

VCM	16112787
was	16112787
administrated	16112787
intraperitoneally	16112787
(	16112787
i	16112787
.	16112787
p	16112787
.	16112787
)	16112787
with	16112787
200mgkg	16112787
(	16112787
-	16112787
1	16112787
)	16112787
twice	16112787
daily	16112787
for	16112787
7	16112787
days	16112787
.	16112787

Erdosteine	16112787
was	16112787
administered	16112787
orally	16112787
.	16112787

VCM	16112787
administration	16112787
to	16112787
control	16112787
rats	16112787
significantly	16112787
increased	16112787
renal	16112787
malondialdehyde	16112787
(	16112787
MDA	16112787
)	16112787
and	16112787
urinary	16112787
N	16112787
-	16112787
acetyl	16112787
-	16112787
beta	16112787
-	16112787
d	16112787
-	16112787
glucosaminidase	16112787
(	16112787
NAG	16112787
,	16112787
a	16112787
marker	16112787
of	16112787
renal	16112787
tubular	16112787
injury	16112787
)	16112787
excretion	16112787
but	16112787
decreased	16112787
superoxide	16112787
dismutase	16112787
(	16112787
SOD	16112787
)	16112787
and	16112787
catalase	16112787
(	16112787
CAT	16112787
)	16112787
activities	16112787
.	16112787

Erdosteine	16112787
administration	16112787
with	16112787
VCM	16112787
injections	16112787
caused	16112787
significantly	16112787
decreased	16112787
renal	16112787
MDA	16112787
and	16112787
urinary	16112787
NAG	16112787
excretion	16112787
,	16112787
and	16112787
increased	16112787
SOD	16112787
activity	16112787
,	16112787
but	16112787
not	16112787
CAT	16112787
activity	16112787
in	16112787
renal	16112787
tissue	16112787
when	16112787
compared	16112787
with	16112787
VCM	16112787
alone	16112787
.	16112787

Erdosteine	16112787
showed	16112787
histopathological	16112787
protection	16112787
against	16112787
VCM	16112787
-	16112787
induced	16112787
nephrotoxicity	16112787
.	16112787

There	16112787
were	16112787
a	16112787
significant	16112787
dilatation	16112787
of	16112787
tubular	16112787
lumens	16112787
,	16112787
extensive	16112787
epithelial	16112787
cell	16112787
vacuolization	16112787
,	16112787
atrophy	16112787
,	16112787
desquamation	16112787
,	16112787
and	16112787
necrosis	16112787
in	16112787
VCM	16112787
-	16112787
treated	16112787
rats	16112787
more	16112787
than	16112787
those	16112787
of	16112787
the	16112787
control	16112787
and	16112787
the	16112787
erdosteine	16112787
groups	16112787
.	16112787

Erdosteine	16112787
caused	16112787
a	16112787
marked	16112787
reduction	16112787
in	16112787
the	16112787
extent	16112787
of	16112787
tubular	16112787
damage	16112787
.	16112787

It	16112787
is	16112787
concluded	16112787
that	16112787
oxidative	16112787
tubular	16112787
damage	16112787
plays	16112787
an	16112787
important	16112787
role	16112787
in	16112787
the	16112787
VCM	16112787
-	16112787
induced	16112787
nephrotoxicity	16112787
and	16112787
the	16112787
modulation	16112787
of	16112787
oxidative	16112787
stress	16112787
with	16112787
erdosteine	16112787
reduces	16112787
the	16112787
VCM	16112787
-	16112787
induced	16112787
kidney	16112787
damage	16112787
both	16112787
at	16112787
the	16112787
biochemical	16112787
and	16112787
histological	16112787
levels	16112787
.	16112787
Bone	18310445
morphogenetic	18310445
protein	18310445
-	18310445
4	18310445
interacts	18310445
with	18310445
activin	18310445
and	18310445
GnRH	18310445
to	18310445
modulate	18310445
gonadotrophin	18310445
secretion	18310445
in	18310445
LbetaT2	18310445
gonadotrophs	18310445
.	18310445

We	18310445
have	18310445
shown	18310445
previously	18310445
that	18310445
,	18310445
in	18310445
sheep	18310445
primary	18310445
pituitary	18310445
cells	18310445
,	18310445
bone	18310445
morphogenetic	18310445
proteins	18310445
(	18310445
BMP	18310445
)	18310445
-	18310445
4	18310445
inhibits	18310445
FSHbeta	18310445
mRNA	18310445
expression	18310445
and	18310445
FSH	18310445
release	18310445
.	18310445

In	18310445
contrast	18310445
,	18310445
in	18310445
mouse	18310445
LbetaT2	18310445
gonadotrophs	18310445
,	18310445
others	18310445
have	18310445
shown	18310445
a	18310445
stimulatory	18310445
effect	18310445
of	18310445
BMPs	18310445
on	18310445
basal	18310445
or	18310445
activin	18310445
-	18310445
stimulated	18310445
FSHbeta	18310445
promoter	18310445
-	18310445
driven	18310445
transcription	18310445
.	18310445

As	18310445
a	18310445
species	18310445
comparison	18310445
with	18310445
our	18310445
previous	18310445
results	18310445
,	18310445
we	18310445
used	18310445
LbetaT2	18310445
cells	18310445
to	18310445
investigate	18310445
the	18310445
effects	18310445
of	18310445
BMP	18310445
-	18310445
4	18310445
on	18310445
gonadotrophin	18310445
mRNA	18310445
and	18310445
secretion	18310445
modulated	18310445
by	18310445
activin	18310445
and	18310445
GnRH	18310445
.	18310445

BMP	18310445
-	18310445
4	18310445
alone	18310445
had	18310445
no	18310445
effect	18310445
on	18310445
FSH	18310445
production	18310445
,	18310445
but	18310445
enhanced	18310445
the	18310445
activin	18310445
+	18310445
GnRH	18310445
-	18310445
induced	18310445
stimulation	18310445
of	18310445
FSHbeta	18310445
mRNA	18310445
and	18310445
FSH	18310445
secretion	18310445
,	18310445
without	18310445
any	18310445
effect	18310445
on	18310445
follistatin	18310445
mRNA	18310445
.	18310445

BMP	18310445
-	18310445
4	18310445
reduced	18310445
LHbeta	18310445
mRNA	18310445
up	18310445
-	18310445
regulation	18310445
in	18310445
response	18310445
to	18310445
GnRH	18310445
(	18310445
+	18310445
/	18310445
-	18310445
activin	18310445
)	18310445
and	18310445
decreased	18310445
GnRH	18310445
receptor	18310445
expression	18310445
,	18310445
which	18310445
would	18310445
favour	18310445
FSH	18310445
,	18310445
rather	18310445
than	18310445
LH	18310445
,	18310445
synthesis	18310445
and	18310445
secretion	18310445
.	18310445

In	18310445
contrast	18310445
to	18310445
sheep	18310445
pituitary	18310445
gonadotrophs	18310445
,	18310445
which	18310445
express	18310445
only	18310445
BMP	18310445
receptor	18310445
types	18310445
IA	18310445
(	18310445
BMPRIA	18310445
)	18310445
and	18310445
II	18310445
(	18310445
BMPRII	18310445
)	18310445
,	18310445
LbetaT2	18310445
cells	18310445
also	18310445
express	18310445
BMPRIB	18310445
.	18310445

Smad1	18310445
/	18310445
5	18310445
phosphorylation	18310445
induced	18310445
by	18310445
BMP	18310445
-	18310445
4	18310445
,	18310445
indicating	18310445
activation	18310445
of	18310445
BMP	18310445
signalling	18310445
,	18310445
was	18310445
the	18310445
same	18310445
whether	18310445
BMP	18310445
-	18310445
4	18310445
was	18310445
used	18310445
alone	18310445
or	18310445
combined	18310445
with	18310445
activin	18310445
+	18310445
/	18310445
-	18310445
GnRH	18310445
.	18310445

We	18310445
hypothesized	18310445
that	18310445
activin	18310445
and	18310445
/	18310445
or	18310445
GnRH	18310445
pathways	18310445
may	18310445
be	18310445
modulated	18310445
by	18310445
BMP	18310445
-	18310445
4	18310445
,	18310445
but	18310445
neither	18310445
the	18310445
activin	18310445
-	18310445
stimulated	18310445
phosphorylation	18310445
of	18310445
Smad2	18310445
/	18310445
3	18310445
nor	18310445
the	18310445
GnRH	18310445
-	18310445
induced	18310445
ERK1	18310445
/	18310445
2	18310445
or	18310445
cAMP	18310445
response	18310445
element	18310445
-	18310445
binding	18310445
phosphorylation	18310445
were	18310445
modified	18310445
.	18310445

However	18310445
,	18310445
the	18310445
GnRH	18310445
-	18310445
induced	18310445
activation	18310445
of	18310445
p38	18310445
MAPK	18310445
was	18310445
decreased	18310445
by	18310445
BMP	18310445
-	18310445
4	18310445
.	18310445

This	18310445
was	18310445
associated	18310445
with	18310445
increased	18310445
FSHbeta	18310445
mRNA	18310445
levels	18310445
and	18310445
FSH	18310445
secretion	18310445
,	18310445
but	18310445
decreased	18310445
LHbeta	18310445
mRNA	18310445
levels	18310445
.	18310445

These	18310445
results	18310445
confirm	18310445
1	18310445
.	18310445

BMPs	18310445
as	18310445
important	18310445
modulators	18310445
of	18310445
activin	18310445
and	18310445
/	18310445
or	18310445
GnRH	18310445
-	18310445
stimulated	18310445
gonadotrophin	18310445
synthesis	18310445
and	18310445
release	18310445
and	18310445
2	18310445
.	18310445

important	18310445
species	18310445
differences	18310445
in	18310445
these	18310445
effects	18310445
,	18310445
which	18310445
could	18310445
relate	18310445
to	18310445
differences	18310445
in	18310445
BMP	18310445
receptor	18310445
expression	18310445
in	18310445
gonadotrophs	18310445
.	18310445
Single	16838170
nucleotide	16838170
polymorphisms	16838170
of	16838170
the	16838170
HNF4alpha	16838170
gene	16838170
are	16838170
associated	16838170
with	16838170
the	16838170
conversion	16838170
to	16838170
type	16838170
2	16838170
diabetes	16838170
mellitus	16838170
:	16838170
the	16838170
STOP	16838170
-	16838170
NIDDM	16838170
trial	16838170
.	16838170

Hepatocyte	16838170
nuclear	16838170
factor	16838170
4alpha	16838170
(	16838170
HNF4alpha	16838170
)	16838170
is	16838170
a	16838170
transcription	16838170
factor	16838170
,	16838170
which	16838170
is	16838170
necessary	16838170
for	16838170
normal	16838170
function	16838170
of	16838170
human	16838170
liver	16838170
and	16838170
pancreatic	16838170
islets	16838170
.	16838170

We	16838170
investigated	16838170
whether	16838170
single	16838170
nucleotide	16838170
polymorphisms	16838170
(	16838170
SNPs	16838170
)	16838170
of	16838170
HNF4A	16838170
,	16838170
encoding	16838170
HNF4alpha	16838170
,	16838170
influenced	16838170
the	16838170
conversion	16838170
from	16838170
impaired	16838170
glucose	16838170
tolerance	16838170
(	16838170
IGT	16838170
)	16838170
to	16838170
type	16838170
2	16838170
diabetes	16838170
mellitus	16838170
in	16838170
subjects	16838170
of	16838170
the	16838170
STOP	16838170
-	16838170
NIDDM	16838170
trial	16838170
.	16838170

This	16838170
trial	16838170
aimed	16838170
at	16838170
evaluating	16838170
the	16838170
effect	16838170
of	16838170
acarbose	16838170
compared	16838170
to	16838170
placebo	16838170
in	16838170
the	16838170
prevention	16838170
of	16838170
type	16838170
2	16838170
diabetes	16838170
mellitus	16838170
.	16838170

Eight	16838170
SNPs	16838170
covering	16838170
the	16838170
intragenic	16838170
and	16838170
alternate	16838170
P2	16838170
promoter	16838170
regions	16838170
of	16838170
HNF4A	16838170
were	16838170
genotyped	16838170
in	16838170
study	16838170
samples	16838170
using	16838170
the	16838170
TaqMan	16838170
Allelic	16838170
Discrimination	16838170
Assays	16838170
.	16838170

Three	16838170
SNPs	16838170
in	16838170
the	16838170
P2	16838170
promoter	16838170
region	16838170
(	16838170
rs4810424	16838170
,	16838170
rs1884614	16838170
,	16838170
and	16838170
rs2144908	16838170
)	16838170
were	16838170
in	16838170
almost	16838170
complete	16838170
association	16838170
(	16838170
D	16838170
'	16838170
>	16838170
0	16838170
.	16838170
97	16838170
,	16838170
r	16838170
(	16838170
2	16838170
)	16838170
>	16838170
0	16838170
.	16838170
95	16838170
)	16838170
and	16838170
,	16838170
therefore	16838170
,	16838170
only	16838170
rs4810424	16838170
was	16838170
included	16838170
in	16838170
further	16838170
analyses	16838170
.	16838170

Female	16838170
carriers	16838170
of	16838170
the	16838170
less	16838170
frequent	16838170
C	16838170
allele	16838170
of	16838170
rs4810424	16838170
had	16838170
a	16838170
1	16838170
.	16838170
7	16838170
-	16838170
fold	16838170
elevated	16838170
risk	16838170
[	16838170
95%	16838170
confidence	16838170
interval	16838170
(	16838170
CI	16838170
)	16838170
1	16838170
.	16838170
09	16838170
-	16838170
2	16838170
.	16838170
66	16838170
;	16838170
P	16838170
=	16838170
0	16838170
.	16838170
020	16838170
]	16838170
for	16838170
the	16838170
conversion	16838170
to	16838170
diabetes	16838170
compared	16838170
to	16838170
women	16838170
with	16838170
the	16838170
common	16838170
genotype	16838170
after	16838170
the	16838170
adjustment	16838170
for	16838170
age	16838170
,	16838170
treatment	16838170
group	16838170
(	16838170
placebo	16838170
or	16838170
acarbose	16838170
)	16838170
,	16838170
smoking	16838170
,	16838170
weight	16838170
at	16838170
baseline	16838170
,	16838170
and	16838170
weight	16838170
change	16838170
.	16838170

No	16838170
association	16838170
was	16838170
found	16838170
in	16838170
men	16838170
.	16838170

Haplotype	16838170
analysis	16838170
based	16838170
on	16838170
three	16838170
SNPs	16838170
(	16838170
rs4810424	16838170
,	16838170
rs2071197	16838170
,	16838170
and	16838170
rs3818247	16838170
)	16838170
representing	16838170
the	16838170
linkage	16838170
disequilibrium	16838170
blocks	16838170
in	16838170
our	16838170
study	16838170
population	16838170
indicated	16838170
that	16838170
the	16838170
conversion	16838170
to	16838170
type	16838170
2	16838170
diabetes	16838170
mellitus	16838170
was	16838170
dependent	16838170
on	16838170
the	16838170
number	16838170
of	16838170
risk	16838170
alleles	16838170
in	16838170
different	16838170
haplotypes	16838170
in	16838170
women	16838170
.	16838170

Our	16838170
results	16838170
suggest	16838170
that	16838170
SNPs	16838170
of	16838170
HNF4A	16838170
and	16838170
their	16838170
haplotypes	16838170
predispose	16838170
to	16838170
type	16838170
2	16838170
diabetes	16838170
mellitus	16838170
in	16838170
female	16838170
subjects	16838170
of	16838170
the	16838170
STOP	16838170
-	16838170
NIDDM	16838170
study	16838170
population	16838170
.	16838170
Identification	15086325
of	15086325
three	15086325
F5	15086325
gene	15086325
mutations	15086325
associated	15086325
with	15086325
inherited	15086325
coagulation	15086325
factor	15086325
V	15086325
deficiency	15086325
in	15086325
two	15086325
Chinese	15086325
pedigrees	15086325
.	15086325

To	15086325
investigate	15086325
the	15086325
molecular	15086325
defects	15086325
in	15086325
two	15086325
Chinese	15086325
pedigrees	15086325
with	15086325
inherited	15086325
factor	15086325
V	15086325
(	15086325
FV	15086325
)	15086325
deficiency	15086325
.	15086325

A	15086325
37	15086325
-	15086325
year	15086325
-	15086325
old	15086325
male	15086325
(	15086325
proband	15086325
1	15086325
)	15086325
and	15086325
an	15086325
18	15086325
-	15086325
month	15086325
-	15086325
old	15086325
boy	15086325
(	15086325
proband	15086325
2	15086325
)	15086325
were	15086325
diagnosed	15086325
as	15086325
inherited	15086325
coagulation	15086325
FV	15086325
deficiency	15086325
by	15086325
severely	15086325
reduced	15086325
plasma	15086325
levels	15086325
of	15086325
FV	15086325
activity	15086325
and	15086325
antigen	15086325
.	15086325

All	15086325
25	15086325
exons	15086325
and	15086325
their	15086325
flanking	15086325
sequence	15086325
of	15086325
F5	15086325
gene	15086325
were	15086325
amplified	15086325
by	15086325
polymerase	15086325
chain	15086325
reaction	15086325
(	15086325
PCR	15086325
)	15086325
for	15086325
both	15086325
probands	15086325
and	15086325
the	15086325
PCR	15086325
products	15086325
were	15086325
directly	15086325
sequenced	15086325
.	15086325

Total	15086325
RNA	15086325
was	15086325
extracted	15086325
from	15086325
the	15086325
peripheral	15086325
lymphocytes	15086325
of	15086325
proband	15086325
1	15086325
for	15086325
detecting	15086325
the	15086325
changes	15086325
at	15086325
mRNA	15086325
level	15086325
.	15086325

The	15086325
homozygous	15086325
deletion	15086325
IVS8	15086325
-	15086325
2A	15086325
>	15086325
G	15086325
was	15086325
identified	15086325
in	15086325
the	15086325
F5	15086325
gene	15086325
of	15086325
proband	15086325
1	15086325
and	15086325
complementary	15086325
DNA	15086325
(	15086325
cDNA	15086325
)	15086325
analysis	15086325
revealed	15086325
the	15086325
abolishment	15086325
of	15086325
the	15086325
canonical	15086325
splicing	15086325
site	15086325
by	15086325
the	15086325
mutation	15086325
and	15086325
the	15086325
activation	15086325
of	15086325
the	15086325
cryptic	15086325
acceptor	15086325
site	15086325
24	15086325
bp	15086325
upstream	15086325
instead	15086325
.	15086325

The	15086325
insertion	15086325
introduced	15086325
eight	15086325
additional	15086325
amino	15086325
acids	15086325
(	15086325
AA	15086325
)	15086325
into	15086325
the	15086325
FV	15086325
protein	15086325
.	15086325

Two	15086325
heterozygous	15086325
mutations	15086325
of	15086325
F5	15086325
gene	15086325
were	15086325
discovered	15086325
in	15086325
proband	15086325
2	15086325
.	15086325

The	15086325
2238	15086325
-	15086325
9del	15086325
AG	15086325
in	15086325
exon	15086325
13	15086325
introduced	15086325
a	15086325
premature	15086325
termination	15086325
code	15086325
at	15086325
689	15086325
AA	15086325
and	15086325
the	15086325
substitution	15086325
of	15086325
G6410	15086325
by	15086325
T	15086325
in	15086325
exon	15086325
23	15086325
lead	15086325
to	15086325
the	15086325
missense	15086325
mutation	15086325
Gly2079Val	15086325
.	15086325

Three	15086325
F5	15086325
gene	15086325
mutations	15086325
,	15086325
IVS8	15086325
-	15086325
2A	15086325
>	15086325
G	15086325
,	15086325
2238	15086325
-	15086325
9del	15086325
AG	15086325
and	15086325
G6410T	15086325
,	15086325
have	15086325
been	15086325
identified	15086325
in	15086325
two	15086325
Chinese	15086325
pedigree	15086325
with	15086325
congenital	15086325
FV	15086325
deficiency	15086325
,	15086325
respectively	15086325
.	15086325
Gene	16611040
therapy	16611040
for	16611040
cystic	16611040
fibrosis	16611040
airway	16611040
disease	16611040
-	16611040
is	16611040
clinical	16611040
success	16611040
imminent?	16611040
Cystic	16611040
fibrosis	16611040
(	16611040
CF	16611040
)	16611040
was	16611040
one	16611040
of	16611040
the	16611040
first	16611040
inherited	16611040
disorders	16611040
for	16611040
which	16611040
gene	16611040
therapy	16611040
was	16611040
seriously	16611040
considered	16611040
as	16611040
a	16611040
realistic	16611040
option	16611040
for	16611040
treatment	16611040
,	16611040
and	16611040
as	16611040
such	16611040
,	16611040
it	16611040
has	16611040
long	16611040
provided	16611040
a	16611040
paradigm	16611040
for	16611040
gene	16611040
therapy	16611040
of	16611040
inherited	16611040
diseases	16611040
.	16611040

However	16611040
,	16611040
despite	16611040
the	16611040
cloning	16611040
of	16611040
the	16611040
cystic	16611040
fibrosis	16611040
transmembrane	16611040
conductance	16611040
regulator	16611040
gene	16611040
in	16611040
1989	16611040
,	16611040
over	16611040
15	16611040
years	16611040
later	16611040
a	16611040
practical	16611040
gene	16611040
therapy	16611040
for	16611040
CF	16611040
has	16611040
not	16611040
eventuated	16611040
.	16611040

There	16611040
are	16611040
a	16611040
number	16611040
of	16611040
reasons	16611040
for	16611040
this	16611040
,	16611040
and	16611040
analysis	16611040
of	16611040
the	16611040
specific	16611040
issues	16611040
that	16611040
have	16611040
delayed	16611040
the	16611040
successful	16611040
development	16611040
of	16611040
gene	16611040
therapy	16611040
for	16611040
CF	16611040
also	16611040
provides	16611040
general	16611040
insights	16611040
into	16611040
the	16611040
practical	16611040
complexities	16611040
involved	16611040
in	16611040
the	16611040
development	16611040
of	16611040
gene	16611040
therapy	16611040
for	16611040
inherited	16611040
disorders	16611040
.	16611040

The	16611040
issues	16611040
which	16611040
have	16611040
prevented	16611040
the	16611040
application	16611040
of	16611040
gene	16611040
therapy	16611040
for	16611040
CF	16611040
to	16611040
date	16611040
include	16611040
the	16611040
lack	16611040
of	16611040
suitable	16611040
gene	16611040
delivery	16611040
technologies	16611040
,	16611040
the	16611040
complexities	16611040
of	16611040
the	16611040
interactions	16611040
between	16611040
the	16611040
host	16611040
and	16611040
vector	16611040
,	16611040
the	16611040
biology	16611040
of	16611040
the	16611040
lung	16611040
airways	16611040
,	16611040
and	16611040
the	16611040
nature	16611040
of	16611040
the	16611040
pathology	16611040
found	16611040
in	16611040
individuals	16611040
with	16611040
CF	16611040
.	16611040

We	16611040
will	16611040
discuss	16611040
the	16611040
history	16611040
of	16611040
CF	16611040
gene	16611040
therapy	16611040
with	16611040
specific	16611040
reference	16611040
to	16611040
these	16611040
and	16611040
other	16611040
issues	16611040
that	16611040
pre	16611040
-	16611040
occupy	16611040
the	16611040
field	16611040
at	16611040
present	16611040
:	16611040
namely	16611040
,	16611040
the	16611040
question	16611040
of	16611040
what	16611040
vectors	16611040
appear	16611040
to	16611040
be	16611040
suitable	16611040
for	16611040
airway	16611040
gene	16611040
delivery	16611040
in	16611040
CF	16611040
,	16611040
what	16611040
cells	16611040
must	16611040
be	16611040
targeted	16611040
,	16611040
how	16611040
airway	16611040
epithelium	16611040
defences	16611040
can	16611040
be	16611040
overcome	16611040
or	16611040
eluded	16611040
to	16611040
allow	16611040
efficient	16611040
gene	16611040
delivery	16611040
,	16611040
how	16611040
to	16611040
ensure	16611040
safe	16611040
and	16611040
long	16611040
-	16611040
term	16611040
transgene	16611040
expression	16611040
and	16611040
the	16611040
need	16611040
to	16611040
identify	16611040
relevant	16611040
surrogate	16611040
success	16611040
measures	16611040
that	16611040
can	16611040
be	16611040
used	16611040
to	16611040
assess	16611040
the	16611040
outcome	16611040
of	16611040
gene	16611040
therapy	16611040
in	16611040
CF	16611040
patients	16611040
.	16611040
Amisulpride	16225977
related	16225977
tic	16225977
-	16225977
like	16225977
symptoms	16225977
in	16225977
an	16225977
adolescent	16225977
schizophrenic	16225977
.	16225977

Tic	16225977
disorders	16225977
can	16225977
be	16225977
effectively	16225977
treated	16225977
by	16225977
atypical	16225977
antipsychotics	16225977
such	16225977
as	16225977
risperidone	16225977
,	16225977
olanzapine	16225977
and	16225977
ziprasidone	16225977
.	16225977

However	16225977
,	16225977
there	16225977
are	16225977
two	16225977
case	16225977
reports	16225977
that	16225977
show	16225977
tic	16225977
-	16225977
like	16225977
symptoms	16225977
,	16225977
including	16225977
motor	16225977
and	16225977
phonic	16225977
variants	16225977
,	16225977
occurring	16225977
during	16225977
treatment	16225977
with	16225977
quetiapine	16225977
or	16225977
clozapine	16225977
.	16225977

We	16225977
present	16225977
a	16225977
15	16225977
-	16225977
year	16225977
-	16225977
old	16225977
girl	16225977
schizophrenic	16225977
who	16225977
developed	16225977
frequent	16225977
involuntary	16225977
eye	16225977
-	16225977
blinking	16225977
movements	16225977
after	16225977
5	16225977
months	16225977
of	16225977
amisulpride	16225977
treatment	16225977
(	16225977
1000	16225977
mg	16225977
per	16225977
day	16225977
)	16225977
.	16225977

The	16225977
tic	16225977
-	16225977
like	16225977
symptoms	16225977
resolved	16225977
completely	16225977
after	16225977
we	16225977
reduced	16225977
the	16225977
dose	16225977
of	16225977
amisulpride	16225977
down	16225977
to	16225977
800	16225977
mg	16225977
per	16225977
day	16225977
.	16225977

However	16225977
,	16225977
her	16225977
psychosis	16225977
recurred	16225977
after	16225977
the	16225977
dose	16225977
reduction	16225977
.	16225977

We	16225977
then	16225977
placed	16225977
her	16225977
on	16225977
an	16225977
additional	16225977
100	16225977
mg	16225977
per	16225977
day	16225977
of	16225977
quetiapine	16225977
.	16225977

She	16225977
has	16225977
been	16225977
in	16225977
complete	16225977
remission	16225977
under	16225977
the	16225977
combined	16225977
medications	16225977
for	16225977
more	16225977
than	16225977
one	16225977
year	16225977
and	16225977
maintains	16225977
a	16225977
fair	16225977
role	16225977
function	16225977
.	16225977

No	16225977
more	16225977
tic	16225977
-	16225977
like	16225977
symptoms	16225977
or	16225977
other	16225977
side	16225977
effects	16225977
have	16225977
been	16225977
reported	16225977
.	16225977

Together	16225977
with	16225977
previously	16225977
reported	16225977
cases	16225977
,	16225977
our	16225977
patient	16225977
suggests	16225977
that	16225977
tic	16225977
-	16225977
like	16225977
symptoms	16225977
might	16225977
occur	16225977
in	16225977
certain	16225977
vulnerable	16225977
individuals	16225977
during	16225977
treatment	16225977
with	16225977
atypical	16225977
antipsychotics	16225977
such	16225977
as	16225977
quetiapine	16225977
,	16225977
clozapine	16225977
,	16225977
or	16225977
amisulpride	16225977
.	16225977
Context	23285048
-	23285048
and	23285048
cell	23285048
-	23285048
dependent	23285048
effects	23285048
of	23285048
Delta	23285048
-	23285048
like	23285048
4	23285048
targeting	23285048
in	23285048
the	23285048
bone	23285048
marrow	23285048
microenvironment	23285048
.	23285048

Delta	23285048
-	23285048
like	23285048
4	23285048
(	23285048
Dll4	23285048
)	23285048
is	23285048
a	23285048
ligand	23285048
of	23285048
the	23285048
Notch	23285048
pathway	23285048
family	23285048
which	23285048
has	23285048
been	23285048
widely	23285048
studied	23285048
in	23285048
the	23285048
context	23285048
of	23285048
tumor	23285048
angiogenesis	23285048
,	23285048
its	23285048
blockade	23285048
shown	23285048
to	23285048
result	23285048
in	23285048
non	23285048
-	23285048
productive	23285048
angiogenesis	23285048
and	23285048
halted	23285048
tumor	23285048
growth	23285048
.	23285048

As	23285048
Dll4	23285048
inhibitors	23285048
enter	23285048
the	23285048
clinic	23285048
,	23285048
there	23285048
is	23285048
an	23285048
emerging	23285048
need	23285048
to	23285048
understand	23285048
their	23285048
side	23285048
effects	23285048
,	23285048
namely	23285048
the	23285048
systemic	23285048
consequences	23285048
of	23285048
Dll4	23285048
:	23285048
Notch	23285048
blockade	23285048
in	23285048
tissues	23285048
other	23285048
than	23285048
tumors	23285048
.	23285048

The	23285048
present	23285048
study	23285048
focused	23285048
on	23285048
the	23285048
effects	23285048
of	23285048
systemic	23285048
anti	23285048
-	23285048
Dll4	23285048
targeting	23285048
in	23285048
the	23285048
bone	23285048
marrow	23285048
(	23285048
BM	23285048
)	23285048
microenvironment	23285048
.	23285048

Here	23285048
we	23285048
show	23285048
that	23285048
Dll4	23285048
blockade	23285048
with	23285048
monoclonal	23285048
antibodies	23285048
perturbs	23285048
the	23285048
BM	23285048
vascular	23285048
niche	23285048
of	23285048
sub	23285048
-	23285048
lethally	23285048
irradiated	23285048
mice	23285048
,	23285048
resulting	23285048
in	23285048
increased	23285048
CD31	23285048
(	23285048
+	23285048
)	23285048
,	23285048
VE	23285048
-	23285048
Cadherin	23285048
(	23285048
+	23285048
)	23285048
and	23285048
c	23285048
-	23285048
kit	23285048
(	23285048
+	23285048
)	23285048
vessel	23285048
density	23285048
,	23285048
and	23285048
also	23285048
increased	23285048
megakaryocytes	23285048
,	23285048
whereas	23285048
CD105	23285048
(	23285048
+	23285048
)	23285048
,	23285048
VEGFR3	23285048
(	23285048
+	23285048
)	23285048
,	23285048
SMA	23285048
(	23285048
+	23285048
)	23285048
and	23285048
lectin	23285048
(	23285048
+	23285048
)	23285048
vessel	23285048
density	23285048
remained	23285048
unaltered	23285048
.	23285048

We	23285048
investigated	23285048
also	23285048
the	23285048
expression	23285048
of	23285048
angiocrine	23285048
genes	23285048
upon	23285048
Dll4	23285048
treatment	23285048
in	23285048
vivo	23285048
,	23285048
and	23285048
demonstrate	23285048
that	23285048
IGFbp2	23285048
,	23285048
IGFbp3	23285048
,	23285048
Angpt2	23285048
,	23285048
Dll4	23285048
,	23285048
DHH	23285048
and	23285048
VEGF	23285048
-	23285048
A	23285048
are	23285048
upregulated	23285048
,	23285048
while	23285048
FGF1	23285048
and	23285048
CSF2	23285048
are	23285048
reduced	23285048
.	23285048

In	23285048
vitro	23285048
treatment	23285048
of	23285048
endothelial	23285048
cells	23285048
with	23285048
anti	23285048
-	23285048
Dll4	23285048
reduced	23285048
Akt	23285048
phosphorylation	23285048
while	23285048
maintaining	23285048
similar	23285048
levels	23285048
of	23285048
Erk	23285048
1	23285048
/	23285048
2	23285048
phosphorylation	23285048
.	23285048

Besides	23285048
its	23285048
effects	23285048
in	23285048
the	23285048
BM	23285048
vascular	23285048
niche	23285048
,	23285048
anti	23285048
-	23285048
Dll4	23285048
treatment	23285048
perturbed	23285048
hematopoiesis	23285048
,	23285048
as	23285048
evidenced	23285048
by	23285048
increased	23285048
myeloid	23285048
(	23285048
CD11b	23285048
(	23285048
+	23285048
)	23285048
)	23285048
,	23285048
decreased	23285048
B	23285048
(	23285048
B220	23285048
(	23285048
+	23285048
)	23285048
)	23285048
and	23285048
T	23285048
(	23285048
CD3	23285048
(	23285048
+	23285048
)	23285048
)	23285048
lymphoid	23285048
BM	23285048
content	23285048
of	23285048
treated	23285048
mice	23285048
,	23285048
with	23285048
a	23285048
corresponding	23285048
increase	23285048
in	23285048
myeloid	23285048
circulating	23285048
cells	23285048
.	23285048

Moreover	23285048
,	23285048
anti	23285048
-	23285048
Dll4	23285048
treatment	23285048
also	23285048
increased	23285048
the	23285048
number	23285048
of	23285048
CFU	23285048
-	23285048
M	23285048
and	23285048
-	23285048
G	23285048
colonies	23285048
in	23285048
methylcellulose	23285048
assays	23285048
,	23285048
independently	23285048
of	23285048
Notch1	23285048
.	23285048

Finally	23285048
,	23285048
anti	23285048
-	23285048
Dll4	23285048
treatment	23285048
of	23285048
donor	23285048
BM	23285048
improved	23285048
the	23285048
hematopoietic	23285048
recovery	23285048
of	23285048
lethally	23285048
irradiated	23285048
recipients	23285048
in	23285048
a	23285048
transplant	23285048
setting	23285048
.	23285048

Together	23285048
,	23285048
our	23285048
data	23285048
reveals	23285048
the	23285048
hematopoietic	23285048
(	23285048
BM	23285048
)	23285048
effects	23285048
of	23285048
systemic	23285048
anti	23285048
-	23285048
Dll4	23285048
treatment	23285048
result	23285048
from	23285048
qualitative	23285048
vascular	23285048
changes	23285048
and	23285048
also	23285048
direct	23285048
hematopoietic	23285048
cell	23285048
modulation	23285048
,	23285048
which	23285048
may	23285048
be	23285048
favorable	23285048
in	23285048
a	23285048
transplant	23285048
setting	23285048
.	23285048
Impact	21135151
of	21135151
CCR5delta32	21135151
host	21135151
genetic	21135151
background	21135151
and	21135151
disease	21135151
progression	21135151
on	21135151
HIV	21135151
-	21135151
1	21135151
intrahost	21135151
evolutionary	21135151
processes	21135151
:	21135151
efficient	21135151
hypothesis	21135151
testing	21135151
through	21135151
hierarchical	21135151
phylogenetic	21135151
models	21135151
.	21135151

The	21135151
interplay	21135151
between	21135151
C	21135151
-	21135151
C	21135151
chemokine	21135151
receptor	21135151
type	21135151
5	21135151
(	21135151
CCR5	21135151
)	21135151
host	21135151
genetic	21135151
background	21135151
,	21135151
disease	21135151
progression	21135151
,	21135151
and	21135151
intrahost	21135151
HIV	21135151
-	21135151
1	21135151
evolutionary	21135151
dynamics	21135151
remains	21135151
unclear	21135151
because	21135151
differences	21135151
in	21135151
viral	21135151
evolution	21135151
between	21135151
hosts	21135151
limit	21135151
the	21135151
ability	21135151
to	21135151
draw	21135151
conclusions	21135151
across	21135151
hosts	21135151
stratified	21135151
into	21135151
clinically	21135151
relevant	21135151
populations	21135151
.	21135151

Similar	21135151
inference	21135151
problems	21135151
are	21135151
proliferating	21135151
across	21135151
many	21135151
measurably	21135151
evolving	21135151
pathogens	21135151
for	21135151
which	21135151
intrahost	21135151
sequence	21135151
samples	21135151
are	21135151
readily	21135151
available	21135151
.	21135151

To	21135151
this	21135151
end	21135151
,	21135151
we	21135151
propose	21135151
novel	21135151
hierarchical	21135151
phylogenetic	21135151
models	21135151
(	21135151
HPMs	21135151
)	21135151
that	21135151
incorporate	21135151
fixed	21135151
effects	21135151
to	21135151
test	21135151
for	21135151
differences	21135151
in	21135151
dynamics	21135151
across	21135151
host	21135151
populations	21135151
in	21135151
a	21135151
formal	21135151
statistical	21135151
framework	21135151
employing	21135151
stochastic	21135151
search	21135151
variable	21135151
selection	21135151
and	21135151
model	21135151
averaging	21135151
.	21135151

To	21135151
clarify	21135151
the	21135151
role	21135151
of	21135151
CCR5	21135151
host	21135151
genetic	21135151
background	21135151
and	21135151
disease	21135151
progression	21135151
on	21135151
viral	21135151
evolutionary	21135151
patterns	21135151
,	21135151
we	21135151
obtain	21135151
gp120	21135151
envelope	21135151
sequences	21135151
from	21135151
clonal	21135151
HIV	21135151
-	21135151
1	21135151
variants	21135151
isolated	21135151
at	21135151
multiple	21135151
time	21135151
points	21135151
in	21135151
the	21135151
course	21135151
of	21135151
infection	21135151
from	21135151
populations	21135151
of	21135151
HIV	21135151
-	21135151
1	21135151
-	21135151
infected	21135151
individuals	21135151
who	21135151
only	21135151
harbored	21135151
CCR5	21135151
-	21135151
using	21135151
HIV	21135151
-	21135151
1	21135151
variants	21135151
at	21135151
all	21135151
time	21135151
points	21135151
.	21135151

Presence	21135151
or	21135151
absence	21135151
of	21135151
a	21135151
CCR5	21135151
wt	21135151
/	21135151
DD32	21135151
genotype	21135151
and	21135151
progressive	21135151
or	21135151
long	21135151
-	21135151
term	21135151
nonprogressive	21135151
course	21135151
of	21135151
infection	21135151
stratify	21135151
the	21135151
clinical	21135151
populations	21135151
in	21135151
a	21135151
two	21135151
-	21135151
way	21135151
design	21135151
.	21135151

As	21135151
compared	21135151
with	21135151
the	21135151
standard	21135151
approach	21135151
of	21135151
analyzing	21135151
sequences	21135151
from	21135151
each	21135151
patient	21135151
independently	21135151
,	21135151
the	21135151
HPM	21135151
provides	21135151
more	21135151
efficient	21135151
estimation	21135151
of	21135151
evolutionary	21135151
parameters	21135151
such	21135151
as	21135151
nucleotide	21135151
substitution	21135151
rates	21135151
and	21135151
d	21135151
(	21135151
N	21135151
)	21135151
/	21135151
d	21135151
(	21135151
S	21135151
)	21135151
rate	21135151
ratios	21135151
,	21135151
as	21135151
shown	21135151
by	21135151
significant	21135151
shrinkage	21135151
of	21135151
the	21135151
estimator	21135151
variance	21135151
.	21135151

The	21135151
fixed	21135151
effects	21135151
also	21135151
correct	21135151
for	21135151
nonindependence	21135151
of	21135151
data	21135151
between	21135151
populations	21135151
and	21135151
results	21135151
in	21135151
even	21135151
further	21135151
shrinkage	21135151
of	21135151
individual	21135151
patient	21135151
estimates	21135151
.	21135151

Model	21135151
selection	21135151
suggests	21135151
an	21135151
association	21135151
between	21135151
nucleotide	21135151
substitution	21135151
rate	21135151
and	21135151
disease	21135151
progression	21135151
,	21135151
but	21135151
a	21135151
role	21135151
for	21135151
CCR5	21135151
genotype	21135151
remains	21135151
elusive	21135151
.	21135151

Given	21135151
the	21135151
absence	21135151
of	21135151
clear	21135151
d	21135151
(	21135151
N	21135151
)	21135151
/	21135151
d	21135151
(	21135151
S	21135151
)	21135151
differences	21135151
between	21135151
patient	21135151
groups	21135151
,	21135151
delayed	21135151
onset	21135151
of	21135151
AIDS	21135151
symptoms	21135151
appears	21135151
to	21135151
be	21135151
solely	21135151
associated	21135151
with	21135151
lower	21135151
viral	21135151
replication	21135151
rates	21135151
rather	21135151
than	21135151
with	21135151
differences	21135151
in	21135151
selection	21135151
on	21135151
amino	21135151
acid	21135151
fixation	21135151
.	21135151
Phenylephrine	19957053
but	19957053
not	19957053
ephedrine	19957053
reduces	19957053
frontal	19957053
lobe	19957053
oxygenation	19957053
following	19957053
anesthesia	19957053
-	19957053
induced	19957053
hypotension	19957053
.	19957053

BACKGROUND	19957053
:	19957053
Vasopressor	19957053
agents	19957053
are	19957053
used	19957053
to	19957053
correct	19957053
anesthesia	19957053
-	19957053
induced	19957053
hypotension	19957053
.	19957053

We	19957053
describe	19957053
the	19957053
effect	19957053
of	19957053
phenylephrine	19957053
and	19957053
ephedrine	19957053
on	19957053
frontal	19957053
lobe	19957053
oxygenation	19957053
(	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
)	19957053
following	19957053
anesthesia	19957053
-	19957053
induced	19957053
hypotension	19957053
.	19957053

METHODS	19957053
:	19957053
Following	19957053
induction	19957053
of	19957053
anesthesia	19957053
by	19957053
fentanyl	19957053
(	19957053
0	19957053
.	19957053
15	19957053
mg	19957053
kg	19957053
(	19957053
-	19957053
1	19957053
)	19957053
)	19957053
and	19957053
propofol	19957053
(	19957053
2	19957053
.	19957053
0	19957053
mg	19957053
kg	19957053
(	19957053
-	19957053
1	19957053
)	19957053
)	19957053
,	19957053
13	19957053
patients	19957053
received	19957053
phenylephrine	19957053
(	19957053
0	19957053
.	19957053
1	19957053
mg	19957053
iv	19957053
)	19957053
and	19957053
12	19957053
patients	19957053
received	19957053
ephedrine	19957053
(	19957053
10	19957053
mg	19957053
iv	19957053
)	19957053
to	19957053
restore	19957053
mean	19957053
arterial	19957053
pressure	19957053
(	19957053
MAP	19957053
)	19957053
.	19957053

Heart	19957053
rate	19957053
(	19957053
HR	19957053
)	19957053
,	19957053
MAP	19957053
,	19957053
stroke	19957053
volume	19957053
(	19957053
SV	19957053
)	19957053
,	19957053
cardiac	19957053
output	19957053
(	19957053
CO	19957053
)	19957053
,	19957053
and	19957053
frontal	19957053
lobe	19957053
oxygenation	19957053
(	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
)	19957053
were	19957053
registered	19957053
.	19957053

RESULTS	19957053
:	19957053
Induction	19957053
of	19957053
anesthesia	19957053
was	19957053
followed	19957053
by	19957053
a	19957053
decrease	19957053
in	19957053
MAP	19957053
,	19957053
HR	19957053
,	19957053
SV	19957053
,	19957053
and	19957053
CO	19957053
concomitant	19957053
with	19957053
an	19957053
elevation	19957053
in	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
.	19957053

After	19957053
administration	19957053
of	19957053
phenylephrine	19957053
,	19957053
MAP	19957053
increased	19957053
(	19957053
51	19957053
+	19957053
/	19957053
-	19957053
12	19957053
to	19957053
81	19957053
+	19957053
/	19957053
-	19957053
13	19957053
mmHg	19957053
;	19957053
P	19957053
<	19957053
0	19957053
.	19957053
001	19957053
;	19957053
mean	19957053
+	19957053
/	19957053
-	19957053
SD	19957053
)	19957053
.	19957053

However	19957053
,	19957053
a	19957053
14%	19957053
(	19957053
from	19957053
70	19957053
+	19957053
/	19957053
-	19957053
8%	19957053
to	19957053
60	19957053
+	19957053
/	19957053
-	19957053
7%	19957053
)	19957053
reduction	19957053
in	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
(	19957053
P	19957053
<	19957053
0	19957053
.	19957053
05	19957053
)	19957053
followed	19957053
with	19957053
no	19957053
change	19957053
in	19957053
CO	19957053
(	19957053
3	19957053
.	19957053
7	19957053
+	19957053
/	19957053
-	19957053
1	19957053
.	19957053
1	19957053
to	19957053
3	19957053
.	19957053
4	19957053
+	19957053
/	19957053
-	19957053
0	19957053
.	19957053
9	19957053
l	19957053
min	19957053
(	19957053
-	19957053
1	19957053
)	19957053
)	19957053
.	19957053

The	19957053
administration	19957053
of	19957053
ephedrine	19957053
led	19957053
to	19957053
a	19957053
similar	19957053
increase	19957053
in	19957053
MAP	19957053
(	19957053
53	19957053
+	19957053
/	19957053
-	19957053
9	19957053
to	19957053
79	19957053
+	19957053
/	19957053
-	19957053
8	19957053
mmHg	19957053
;	19957053
P	19957053
<	19957053
0	19957053
.	19957053
001	19957053
)	19957053
,	19957053
restored	19957053
CO	19957053
(	19957053
3	19957053
.	19957053
2	19957053
+	19957053
/	19957053
-	19957053
1	19957053
.	19957053
2	19957053
to	19957053
5	19957053
.	19957053
0	19957053
+	19957053
/	19957053
-	19957053
1	19957053
.	19957053
3	19957053
l	19957053
min	19957053
(	19957053
-	19957053
1	19957053
)	19957053
)	19957053
,	19957053
and	19957053
preserved	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
.	19957053

CONCLUSIONS	19957053
:	19957053
The	19957053
utilization	19957053
of	19957053
phenylephrine	19957053
to	19957053
correct	19957053
hypotension	19957053
induced	19957053
by	19957053
anesthesia	19957053
has	19957053
a	19957053
negative	19957053
impact	19957053
on	19957053
S	19957053
(	19957053
c	19957053
)	19957053
O	19957053
(	19957053
2	19957053
)	19957053
while	19957053
ephedrine	19957053
maintains	19957053
frontal	19957053
lobe	19957053
oxygenation	19957053
potentially	19957053
related	19957053
to	19957053
an	19957053
increase	19957053
in	19957053
CO	19957053
.	19957053
Interleukin	28846666
6	28846666
(	28846666
IL	28846666
-	28846666
6	28846666
)	28846666
and	28846666
Tumor	28846666
Necrosis	28846666
Factor	28846666
alpha	28846666
(	28846666
TNF	28846666
-	28846666
alpha	28846666
)	28846666
Single	28846666
Nucleotide	28846666
Polymorphisms	28846666
(	28846666
SNPs	28846666
)	28846666
,	28846666
Inflammation	28846666
and	28846666
Metabolism	28846666
in	28846666
Gestational	28846666
Diabetes	28846666
Mellitus	28846666
in	28846666
Inner	28846666
Mongolia	28846666
.	28846666

BACKGROUND	28846666
Gestational	28846666
diabetes	28846666
mellitus	28846666
(	28846666
GDM	28846666
)	28846666
is	28846666
common	28846666
all	28846666
over	28846666
the	28846666
world	28846666
.	28846666

GDM	28846666
women	28846666
are	28846666
with	28846666
inflammatory	28846666
and	28846666
metabolisms	28846666
abnormalities	28846666
.	28846666

However	28846666
,	28846666
few	28846666
studies	28846666
have	28846666
focused	28846666
on	28846666
the	28846666
association	28846666
of	28846666
IL	28846666
-	28846666
65	28846666
-	28846666
72C	28846666
/	28846666
G	28846666
and	28846666
TNF	28846666
-	28846666
alpha	28846666
-	28846666
857C	28846666
/	28846666
T	28846666
single	28846666
nucleotide	28846666
polymorphisms	28846666
(	28846666
SNPs	28846666
)	28846666
,	28846666
inflammatory	28846666
biomarkers	28846666
,	28846666
and	28846666
metabolic	28846666
indexes	28846666
in	28846666
women	28846666
with	28846666
GDM	28846666
,	28846666
especially	28846666
in	28846666
the	28846666
Inner	28846666
Mongolia	28846666
population	28846666
.	28846666

The	28846666
aim	28846666
of	28846666
this	28846666
study	28846666
was	28846666
to	28846666
investigate	28846666
the	28846666
associations	28846666
of	28846666
IL	28846666
-	28846666
65	28846666
-	28846666
72C	28846666
/	28846666
G	28846666
and	28846666
TNF	28846666
-	28846666
alpha	28846666
-	28846666
857C	28846666
/	28846666
T	28846666
SNPs	28846666
,	28846666
and	28846666
inflammation	28846666
and	28846666
metabolic	28846666
biomarkers	28846666
in	28846666
women	28846666
with	28846666
GDM	28846666
pregnancies	28846666
.	28846666

MATERIAL	28846666
AND	28846666
METHODS	28846666
Blood	28846666
samples	28846666
and	28846666
placentas	28846666
from	28846666
140	28846666
women	28846666
with	28846666
GDM	28846666
and	28846666
140	28846666
women	28846666
with	28846666
healthy	28846666
pregnancies	28846666
were	28846666
collected	28846666
.	28846666

Matrix	28846666
-	28846666
assisted	28846666
laser	28846666
desorption	28846666
ionization	28846666
time	28846666
of	28846666
flight	28846666
mass	28846666
spectrometry	28846666
(	28846666
MALDI	28846666
-	28846666
TOF	28846666
-	28846666
MS	28846666
)	28846666
and	28846666
MassARRAY	28846666
-	28846666
IPLEX	28846666
were	28846666
performed	28846666
to	28846666
analyze	28846666
IL	28846666
-	28846666
65	28846666
-	28846666
72C	28846666
/	28846666
G	28846666
and	28846666
TNF	28846666
-	28846666
alpha	28846666
-	28846666
857C	28846666
/	28846666
T	28846666
SNPs	28846666
.	28846666

Enzyme	28846666
linked	28846666
immunosorbent	28846666
assay	28846666
(	28846666
ELISA	28846666
)	28846666
was	28846666
performed	28846666
to	28846666
analyze	28846666
inflammatory	28846666
biomarkers	28846666
and	28846666
adipokines	28846666
.	28846666

RESULTS	28846666
Distribution	28846666
frequency	28846666
of	28846666
TNF	28846666
-	28846666
alpha	28846666
-	28846666
857CT	28846666
(	28846666
OR	28846666
=	28846666
3	28846666
.	28846666
316	28846666
,	28846666
95%	28846666
CI	28846666
=	28846666
1	28846666
.	28846666
092	28846666
-	28846666
8	28846666
.	28846666
304	28846666
,	28846666
p	28846666
=	28846666
0	28846666
.	28846666
025	28846666
)	28846666
in	28846666
women	28846666
with	28846666
GDM	28846666
pregnancies	28846666
were	28846666
obviously	28846666
higher	28846666
than	28846666
that	28846666
in	28846666
women	28846666
with	28846666
healthy	28846666
pregnancies	28846666
.	28846666

Women	28846666
with	28846666
GDM	28846666
were	28846666
of	28846666
older	28846666
maternal	28846666
age	28846666
,	28846666
had	28846666
higher	28846666
BMI	28846666
,	28846666
were	28846666
more	28846666
nulliparous	28846666
,	28846666
and	28846666
had	28846666
T2DM	28846666
and	28846666
GDM	28846666
history	28846666
,	28846666
compared	28846666
to	28846666
women	28846666
with	28846666
healthy	28846666
pregnancies	28846666
(	28846666
p	28846666
<	28846666
0	28846666
.	28846666
05	28846666
)	28846666
.	28846666

Inflammatory	28846666
biomarkers	28846666
in	28846666
serum	28846666
(	28846666
hs	28846666
-	28846666
CRP	28846666
,	28846666
IL	28846666
-	28846666
6	28846666
,	28846666
IL	28846666
-	28846666
8	28846666
,	28846666
IL	28846666
-	28846666
6	28846666
/	28846666
IL	28846666
-	28846666
10	28846666
ratio	28846666
)	28846666
and	28846666
placental	28846666
(	28846666
NF	28846666
-	28846666
kappaB	28846666
,	28846666
IL	28846666
-	28846666
6	28846666
,	28846666
IL	28846666
-	28846666
8	28846666
,	28846666
IL	28846666
-	28846666
6	28846666
/	28846666
IL	28846666
-	28846666
10	28846666
ratio	28846666
,	28846666
IL	28846666
-	28846666
1b	28846666
,	28846666
TNF	28846666
-	28846666
alpha	28846666
)	28846666
were	28846666
significantly	28846666
different	28846666
(	28846666
p	28846666
<	28846666
0	28846666
.	28846666
05	28846666
)	28846666
between	28846666
women	28846666
with	28846666
GDM	28846666
and	28846666
women	28846666
with	28846666
healthy	28846666
pregnancies	28846666
.	28846666

Differences	28846666
were	28846666
found	28846666
for	28846666
serum	28846666
FBG	28846666
,	28846666
FINS	28846666
,	28846666
HOMA	28846666
-	28846666
IR	28846666
,	28846666
and	28846666
HOMA	28846666
-	28846666
beta	28846666
,	28846666
and	28846666
placental	28846666
IRS	28846666
-	28846666
1	28846666
,	28846666
IRS	28846666
-	28846666
2	28846666
,	28846666
leptin	28846666
,	28846666
adiponectin	28846666
,	28846666
visfatin	28846666
,	28846666
RBP	28846666
-	28846666
4	28846666
,	28846666
chemerin	28846666
,	28846666
nesfatin	28846666
-	28846666
1	28846666
,	28846666
FATP	28846666
-	28846666
4	28846666
,	28846666
EL	28846666
,	28846666
LPL	28846666
,	28846666
FABP	28846666
-	28846666
1	28846666
,	28846666
FABP	28846666
-	28846666
3	28846666
,	28846666
FABP	28846666
-	28846666
4	28846666
,	28846666
and	28846666
FABP	28846666
-	28846666
5	28846666
.	28846666

CONCLUSIONS	28846666
TNF	28846666
-	28846666
alpha	28846666
-	28846666
857C	28846666
/	28846666
T	28846666
SNP	28846666
,	28846666
hs	28846666
-	28846666
CRP	28846666
,	28846666
IL	28846666
-	28846666
6	28846666
,	28846666
IL	28846666
-	28846666
8	28846666
,	28846666
and	28846666
IL	28846666
-	28846666
6	28846666
/	28846666
IL	28846666
-	28846666
10	28846666
were	28846666
associated	28846666
with	28846666
GDM	28846666
in	28846666
women	28846666
from	28846666
Inner	28846666
Mongolia	28846666
,	28846666
as	28846666
was	28846666
serious	28846666
inflammation	28846666
and	28846666
disordered	28846666
lipid	28846666
and	28846666
glucose	28846666
metabolisms	28846666
.	28846666
Estrogen	17879945
prevents	17879945
cholesteryl	17879945
ester	17879945
accumulation	17879945
in	17879945
macrophages	17879945
induced	17879945
by	17879945
the	17879945
HIV	17879945
protease	17879945
inhibitor	17879945
ritonavir	17879945
.	17879945

Individuals	17879945
with	17879945
HIV	17879945
can	17879945
now	17879945
live	17879945
long	17879945
lives	17879945
with	17879945
drug	17879945
therapy	17879945
that	17879945
often	17879945
includes	17879945
protease	17879945
inhibitors	17879945
such	17879945
as	17879945
ritonavir	17879945
.	17879945

Many	17879945
patients	17879945
,	17879945
however	17879945
,	17879945
develop	17879945
negative	17879945
long	17879945
-	17879945
term	17879945
side	17879945
effects	17879945
such	17879945
as	17879945
premature	17879945
atherosclerosis	17879945
.	17879945

We	17879945
have	17879945
previously	17879945
demonstrated	17879945
that	17879945
ritonavir	17879945
treatment	17879945
increases	17879945
atherosclerotic	17879945
lesion	17879945
formation	17879945
in	17879945
male	17879945
mice	17879945
to	17879945
a	17879945
greater	17879945
extent	17879945
than	17879945
in	17879945
female	17879945
mice	17879945
.	17879945

Furthermore	17879945
,	17879945
peripheral	17879945
blood	17879945
monocytes	17879945
isolated	17879945
from	17879945
ritonavir	17879945
-	17879945
treated	17879945
females	17879945
had	17879945
less	17879945
cholesteryl	17879945
ester	17879945
accumulation	17879945
.	17879945

In	17879945
the	17879945
present	17879945
study	17879945
,	17879945
we	17879945
have	17879945
investigated	17879945
the	17879945
molecular	17879945
mechanisms	17879945
by	17879945
which	17879945
female	17879945
hormones	17879945
influence	17879945
cholesterol	17879945
metabolism	17879945
in	17879945
macrophages	17879945
in	17879945
response	17879945
to	17879945
the	17879945
HIV	17879945
protease	17879945
inhibitor	17879945
ritonavir	17879945
.	17879945

We	17879945
have	17879945
utilized	17879945
the	17879945
human	17879945
monocyte	17879945
cell	17879945
line	17879945
,	17879945
THP	17879945
-	17879945
1	17879945
as	17879945
a	17879945
model	17879945
to	17879945
address	17879945
this	17879945
question	17879945
.	17879945

Briefly	17879945
,	17879945
cells	17879945
were	17879945
differentiated	17879945
for	17879945
72	17879945
h	17879945
with	17879945
100	17879945
nM	17879945
PMA	17879945
to	17879945
obtain	17879945
a	17879945
macrophage	17879945
-	17879945
like	17879945
phenotype	17879945
in	17879945
the	17879945
presence	17879945
or	17879945
absence	17879945
of	17879945
1	17879945
nM	17879945
17beta	17879945
-	17879945
estradiol	17879945
(	17879945
E2	17879945
)	17879945
,	17879945
100	17879945
nM	17879945
progesterone	17879945
or	17879945
vehicle	17879945
(	17879945
0	17879945
.	17879945
01%	17879945
ethanol	17879945
)	17879945
.	17879945

Cells	17879945
were	17879945
then	17879945
treated	17879945
with	17879945
30	17879945
ng	17879945
/	17879945
ml	17879945
ritonavir	17879945
or	17879945
vehicle	17879945
in	17879945
the	17879945
presence	17879945
of	17879945
aggregated	17879945
LDL	17879945
for	17879945
24	17879945
h	17879945
.	17879945

Cell	17879945
extracts	17879945
were	17879945
harvested	17879945
,	17879945
and	17879945
lipid	17879945
or	17879945
total	17879945
RNA	17879945
was	17879945
isolated	17879945
.	17879945

E2	17879945
decreased	17879945
the	17879945
accumulation	17879945
of	17879945
cholesteryl	17879945
esters	17879945
in	17879945
macrophages	17879945
following	17879945
ritonavir	17879945
treatment	17879945
.	17879945

Ritonavir	17879945
increased	17879945
the	17879945
expression	17879945
of	17879945
the	17879945
scavenger	17879945
receptor	17879945
,	17879945
CD36	17879945
mRNA	17879945
,	17879945
responsible	17879945
for	17879945
the	17879945
uptake	17879945
of	17879945
LDL	17879945
.	17879945

Additionally	17879945
,	17879945
ritonavir	17879945
treatment	17879945
selectively	17879945
increased	17879945
the	17879945
relative	17879945
levels	17879945
of	17879945
PPARgamma	17879945
mRNA	17879945
,	17879945
a	17879945
transcription	17879945
factor	17879945
responsible	17879945
for	17879945
the	17879945
regulation	17879945
of	17879945
CD36	17879945
mRNA	17879945
expression	17879945
.	17879945

Treatment	17879945
with	17879945
E2	17879945
,	17879945
however	17879945
,	17879945
failed	17879945
to	17879945
prevent	17879945
these	17879945
increases	17879945
at	17879945
the	17879945
mRNA	17879945
level	17879945
.	17879945

E2	17879945
did	17879945
,	17879945
however	17879945
,	17879945
significantly	17879945
suppress	17879945
CD36	17879945
protein	17879945
levels	17879945
as	17879945
measured	17879945
by	17879945
fluorescent	17879945
immunocytochemistry	17879945
.	17879945

This	17879945
data	17879945
suggests	17879945
that	17879945
E2	17879945
modifies	17879945
the	17879945
expression	17879945
of	17879945
CD36	17879945
at	17879945
the	17879945
level	17879945
of	17879945
protein	17879945
expression	17879945
in	17879945
monocyte	17879945
-	17879945
derived	17879945
macrophages	17879945
resulting	17879945
in	17879945
reduced	17879945
cholesteryl	17879945
ester	17879945
accumulation	17879945
following	17879945
ritonavir	17879945
treatment	17879945
.	17879945
Single	15000256
-	15000256
strand	15000256
conformation	15000256
polymorphism	15000256
analysis	15000256
of	15000256
the	15000256
FMR1	15000256
gene	15000256
in	15000256
autistic	15000256
and	15000256
mentally	15000256
retarded	15000256
children	15000256
in	15000256
Japan	15000256
.	15000256

Fragile	15000256
X	15000256
syndrome	15000256
is	15000256
one	15000256
of	15000256
the	15000256
most	15000256
common	15000256
causes	15000256
of	15000256
mental	15000256
retardation	15000256
in	15000256
males	15000256
,	15000256
and	15000256
patients	15000256
with	15000256
fragile	15000256
X	15000256
syndrome	15000256
occasionally	15000256
develop	15000256
autism	15000256
.	15000256

It	15000256
is	15000256
usually	15000256
caused	15000256
by	15000256
an	15000256
expansion	15000256
of	15000256
the	15000256
trinucleotide	15000256
repeat	15000256
in	15000256
the	15000256
5	15000256
'	15000256
-	15000256
untranslated	15000256
region	15000256
of	15000256
the	15000256
FMR1	15000256
gene	15000256
,	15000256
but	15000256
in	15000256
a	15000256
small	15000256
number	15000256
of	15000256
patients	15000256
deletions	15000256
and	15000256
point	15000256
mutations	15000256
have	15000256
been	15000256
identified	15000256
.	15000256

We	15000256
screened	15000256
all	15000256
17	15000256
exons	15000256
of	15000256
the	15000256
FMR1	15000256
gene	15000256
for	15000256
mutations	15000256
in	15000256
90	15000256
autistic	15000256
or	15000256
mentally	15000256
retarded	15000256
children	15000256
using	15000256
polymerase	15000256
chain	15000256
reaction	15000256
(	15000256
PCR	15000256
)	15000256
-	15000256
single	15000256
strand	15000256
conformation	15000256
polymorphism	15000256
(	15000256
SSCP	15000256
)	15000256
analysis	15000256
.	15000256

No	15000256
mutations	15000256
were	15000256
found	15000256
in	15000256
76	15000256
male	15000256
patients	15000256
.	15000256

However	15000256
,	15000256
one	15000256
female	15000256
patient	15000256
was	15000256
heterozygous	15000256
for	15000256
a	15000256
normal	15000256
allele	15000256
and	15000256
a	15000256
mutant	15000256
allele	15000256
with	15000256
an	15000256
A	15000256
to	15000256
C	15000256
substitution	15000256
at	15000256
nucleotide	15000256
879	15000256
in	15000256
exon	15000256
9	15000256
.	15000256

This	15000256
mutation	15000256
was	15000256
not	15000256
found	15000256
in	15000256
50	15000256
controls	15000256
.	15000256

Reverse	15000256
transcription	15000256
-	15000256
PCR	15000256
revealed	15000256
that	15000256
a	15000256
large	15000256
proportion	15000256
of	15000256
the	15000256
mutant	15000256
transcripts	15000256
were	15000256
spliced	15000256
aberrantly	15000256
,	15000256
causing	15000256
premature	15000256
termination	15000256
of	15000256
the	15000256
protein	15000256
synthesis	15000256
.	15000256

Although	15000256
uncommon	15000256
,	15000256
point	15000256
mutations	15000256
in	15000256
the	15000256
FMR1	15000256
gene	15000256
may	15000256
be	15000256
a	15000256
cause	15000256
of	15000256
autism	15000256
and	15000256
mental	15000256
retardation	15000256
in	15000256
Japanese	15000256
patients	15000256
.	15000256
Homozygously	21750150
deleted	21750150
gene	21750150
DACH1	21750150
regulates	21750150
tumor	21750150
-	21750150
initiating	21750150
activity	21750150
of	21750150
glioma	21750150
cells	21750150
.	21750150

Loss	21750150
or	21750150
reduction	21750150
in	21750150
function	21750150
of	21750150
tumor	21750150
suppressor	21750150
genes	21750150
contributes	21750150
to	21750150
tumorigenesis	21750150
.	21750150

Here	21750150
,	21750150
by	21750150
allelic	21750150
DNA	21750150
copy	21750150
number	21750150
analysis	21750150
using	21750150
single	21750150
-	21750150
nucleotide	21750150
polymorphism	21750150
genotyping	21750150
array	21750150
and	21750150
mass	21750150
spectrometry	21750150
,	21750150
we	21750150
report	21750150
homozygous	21750150
deletion	21750150
in	21750150
glioblastoma	21750150
multiformes	21750150
at	21750150
chromosome	21750150
13q21	21750150
,	21750150
where	21750150
DACH1	21750150
gene	21750150
is	21750150
located	21750150
.	21750150

We	21750150
found	21750150
decreased	21750150
cell	21750150
proliferation	21750150
of	21750150
a	21750150
series	21750150
of	21750150
glioma	21750150
cell	21750150
lines	21750150
by	21750150
forced	21750150
expression	21750150
of	21750150
DACH1	21750150
.	21750150

We	21750150
then	21750150
generated	21750150
U87TR	21750150
-	21750150
Da	21750150
glioma	21750150
cells	21750150
,	21750150
where	21750150
DACH1	21750150
expression	21750150
could	21750150
be	21750150
activated	21750150
by	21750150
exposure	21750150
of	21750150
the	21750150
cells	21750150
to	21750150
doxycycline	21750150
.	21750150

Both	21750150
ex	21750150
vivo	21750150
cellular	21750150
proliferation	21750150
and	21750150
in	21750150
vivo	21750150
growth	21750150
of	21750150
s	21750150
.	21750150
c	21750150
.	21750150

transplanted	21750150
tumors	21750150
in	21750150
mice	21750150
are	21750150
reduced	21750150
in	21750150
U87TR	21750150
-	21750150
Da	21750150
cells	21750150
with	21750150
DACH1	21750150
expression	21750150
(	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
high	21750150
)	21750150
,	21750150
compared	21750150
with	21750150
DACH1	21750150
-	21750150
nonexpressing	21750150
U87TR	21750150
-	21750150
Da	21750150
cells	21750150
(	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
low	21750150
)	21750150
.	21750150

U87	21750150
-	21750150
DACH1	21750150
-	21750150
low	21750150
cells	21750150
form	21750150
spheroids	21750150
with	21750150
CD133	21750150
and	21750150
Nestin	21750150
expression	21750150
in	21750150
serum	21750150
-	21750150
free	21750150
medium	21750150
but	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
high	21750150
cells	21750150
do	21750150
not	21750150
.	21750150

Compared	21750150
with	21750150
spheroid	21750150
-	21750150
forming	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
low	21750150
cells	21750150
,	21750150
adherent	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
high	21750150
cells	21750150
display	21750150
lower	21750150
tumorigenicity	21750150
,	21750150
indicating	21750150
DACH1	21750150
decreases	21750150
the	21750150
number	21750150
of	21750150
tumor	21750150
-	21750150
initiating	21750150
cells	21750150
.	21750150

Gene	21750150
expression	21750150
analysis	21750150
and	21750150
chromatin	21750150
immunoprecipitation	21750150
assay	21750150
reveal	21750150
that	21750150
fibroblast	21750150
growth	21750150
factor	21750150
2	21750150
(	21750150
FGF2	21750150
/	21750150
bFGF	21750150
)	21750150
is	21750150
transcriptionally	21750150
repressed	21750150
by	21750150
DACH1	21750150
,	21750150
especially	21750150
in	21750150
cells	21750150
cultured	21750150
in	21750150
serum	21750150
-	21750150
free	21750150
medium	21750150
.	21750150

Exogenous	21750150
bFGF	21750150
rescues	21750150
spheroid	21750150
-	21750150
forming	21750150
activity	21750150
and	21750150
tumorigenicity	21750150
of	21750150
the	21750150
U87	21750150
-	21750150
DACH1	21750150
-	21750150
high	21750150
cells	21750150
,	21750150
suggesting	21750150
that	21750150
loss	21750150
of	21750150
DACH1	21750150
increases	21750150
the	21750150
number	21750150
of	21750150
tumor	21750150
-	21750150
initiating	21750150
cells	21750150
through	21750150
transcriptional	21750150
activation	21750150
of	21750150
bFGF	21750150
.	21750150

These	21750150
results	21750150
illustrate	21750150
that	21750150
DACH1	21750150
is	21750150
a	21750150
distinctive	21750150
tumor	21750150
suppressor	21750150
,	21750150
which	21750150
does	21750150
not	21750150
only	21750150
suppress	21750150
growth	21750150
of	21750150
tumor	21750150
cells	21750150
but	21750150
also	21750150
regulates	21750150
bFGF	21750150
-	21750150
mediated	21750150
tumor	21750150
-	21750150
initiating	21750150
activity	21750150
of	21750150
glioma	21750150
cells	21750150
.	21750150
Focal	17951029
dermal	17951029
hypoplasia	17951029
resulting	17951029
from	17951029
a	17951029
new	17951029
nonsense	17951029
mutation	17951029
,	17951029
p	17951029
.	17951029
E300X	17951029
,	17951029
in	17951029
the	17951029
PORCN	17951029
gene	17951029
.	17951029

BACKGROUND	17951029
:	17951029
Focal	17951029
dermal	17951029
hypoplasia	17951029
(	17951029
FDH	17951029
)	17951029
(	17951029
OMIM	17951029
305600	17951029
)	17951029
is	17951029
an	17951029
X	17951029
-	17951029
linked	17951029
dominant	17951029
disorder	17951029
of	17951029
ecto	17951029
-	17951029
mesodermal	17951029
development	17951029
.	17951029

Also	17951029
known	17951029
as	17951029
Goltz	17951029
syndrome	17951029
,	17951029
FDH	17951029
presents	17951029
with	17951029
characteristic	17951029
linear	17951029
streaks	17951029
of	17951029
hypoplastic	17951029
dermis	17951029
and	17951029
variable	17951029
abnormalities	17951029
of	17951029
bone	17951029
,	17951029
nails	17951029
,	17951029
hair	17951029
,	17951029
limbs	17951029
,	17951029
teeth	17951029
and	17951029
eyes	17951029
.	17951029

The	17951029
molecular	17951029
basis	17951029
of	17951029
FDH	17951029
involves	17951029
mutations	17951029
in	17951029
the	17951029
PORCN	17951029
gene	17951029
,	17951029
which	17951029
encodes	17951029
an	17951029
enzyme	17951029
that	17951029
allows	17951029
membrane	17951029
targeting	17951029
and	17951029
secretion	17951029
of	17951029
several	17951029
Wnt	17951029
proteins	17951029
critical	17951029
for	17951029
normal	17951029
tissue	17951029
development	17951029
.	17951029

OBJECTIVES	17951029
:	17951029
To	17951029
investigate	17951029
the	17951029
molecular	17951029
basis	17951029
of	17951029
FDH	17951029
in	17951029
a	17951029
2	17951029
-	17951029
year	17951029
-	17951029
old	17951029
Thai	17951029
girl	17951029
who	17951029
presented	17951029
at	17951029
birth	17951029
with	17951029
depressed	17951029
,	17951029
pale	17951029
linear	17951029
scars	17951029
on	17951029
the	17951029
trunk	17951029
and	17951029
limbs	17951029
,	17951029
sparse	17951029
brittle	17951029
hair	17951029
,	17951029
syndactyly	17951029
of	17951029
the	17951029
right	17951029
middle	17951029
and	17951029
ring	17951029
fingers	17951029
,	17951029
dental	17951029
caries	17951029
and	17951029
radiological	17951029
features	17951029
of	17951029
osteopathia	17951029
striata	17951029
.	17951029

METHODS	17951029
:	17951029
Sequencing	17951029
of	17951029
genomic	17951029
DNA	17951029
from	17951029
the	17951029
affected	17951029
individual	17951029
and	17951029
both	17951029
parents	17951029
to	17951029
search	17951029
for	17951029
pathogenic	17951029
mutations	17951029
in	17951029
PORCN	17951029
gene	17951029
.	17951029

RESULTS	17951029
:	17951029
DNA	17951029
sequencing	17951029
disclosed	17951029
a	17951029
heterozygous	17951029
G	17951029
>	17951029
T	17951029
substitution	17951029
at	17951029
nucleotide	17951029
c	17951029
.	17951029
898	17951029
within	17951029
exon	17951029
10	17951029
(	17951029
NM_203475	17951029
.	17951029
1	17951029
)	17951029
,	17951029
converting	17951029
a	17951029
glutamic	17951029
acid	17951029
residue	17951029
(	17951029
GAA	17951029
)	17951029
to	17951029
a	17951029
premature	17951029
termination	17951029
codon	17951029
(	17951029
TAA	17951029
)	17951029
.	17951029

This	17951029
mutation	17951029
,	17951029
designated	17951029
p	17951029
.	17951029
E300X	17951029
,	17951029
was	17951029
not	17951029
detected	17951029
in	17951029
DNA	17951029
from	17951029
either	17951029
parent	17951029
or	17951029
in	17951029
100	17951029
control	17951029
chromosomes	17951029
.	17951029

CONCLUSION	17951029
:	17951029
Identification	17951029
of	17951029
this	17951029
new	17951029
de	17951029
novo	17951029
nonsense	17951029
mutation	17951029
confirms	17951029
the	17951029
diagnosis	17951029
of	17951029
FDH	17951029
in	17951029
this	17951029
child	17951029
and	17951029
highlights	17951029
the	17951029
clinical	17951029
importance	17951029
of	17951029
PORCN	17951029
and	17951029
Wnt	17951029
signalling	17951029
pathways	17951029
in	17951029
embryogenesis	17951029
.	17951029
Human	7905839
mu	7905839
opiate	7905839
receptor	7905839
.	7905839

cDNA	7905839
and	7905839
genomic	7905839
clones	7905839
,	7905839
pharmacologic	7905839
characterization	7905839
and	7905839
chromosomal	7905839
assignment	7905839
.	7905839

A	7905839
human	7905839
mu	7905839
opiate	7905839
receptor	7905839
cDNA	7905839
has	7905839
been	7905839
identified	7905839
from	7905839
a	7905839
cerebral	7905839
cortical	7905839
cDNA	7905839
library	7905839
using	7905839
sequences	7905839
from	7905839
the	7905839
rat	7905839
mu	7905839
opiate	7905839
receptor	7905839
cDNA	7905839
.	7905839

The	7905839
human	7905839
mu	7905839
opiate	7905839
receptor	7905839
(	7905839
h	7905839
mu	7905839
OR1	7905839
)	7905839
shares	7905839
95%	7905839
amino	7905839
acid	7905839
identity	7905839
with	7905839
the	7905839
rat	7905839
sequence	7905839
.	7905839

The	7905839
expressed	7905839
mu	7905839
OR1	7905839
recognized	7905839
tested	7905839
opiate	7905839
drugs	7905839
and	7905839
opioid	7905839
peptides	7905839
in	7905839
a	7905839
sodium	7905839
-	7905839
and	7905839
GTP	7905839
-	7905839
sensitive	7905839
fashion	7905839
with	7905839
affinities	7905839
virtually	7905839
identical	7905839
to	7905839
those	7905839
displayed	7905839
by	7905839
the	7905839
rat	7905839
mu	7905839
opiate	7905839
receptor	7905839
.	7905839

Effects	7905839
on	7905839
cyclic	7905839
AMP	7905839
are	7905839
similar	7905839
to	7905839
those	7905839
noted	7905839
for	7905839
the	7905839
rat	7905839
mu	7905839
opiate	7905839
receptor	7905839
.	7905839

An	7905839
18	7905839
kb	7905839
genomic	7905839
clone	7905839
hybridizing	7905839
with	7905839
the	7905839
h	7905839
mu	7905839
OR1	7905839
cDNA	7905839
contains	7905839
63	7905839
and	7905839
489	7905839
bp	7905839
exonic	7905839
sequences	7905839
flanked	7905839
by	7905839
splice	7905839
donor	7905839
/	7905839
acceptor	7905839
sequences	7905839
.	7905839

Analysis	7905839
of	7905839
hybridization	7905839
to	7905839
DNA	7905839
prepared	7905839
from	7905839
human	7905839
rodent	7905839
hybrid	7905839
cell	7905839
lines	7905839
and	7905839
chromosomal	7905839
in	7905839
situ	7905839
hybridization	7905839
studies	7905839
indicate	7905839
localization	7905839
to	7905839
6q24	7905839
-	7905839
25	7905839
.	7905839

An	7905839
MspI	7905839
polymorphism	7905839
,	7905839
producing	7905839
a	7905839
3	7905839
.	7905839
7	7905839
kb	7905839
band	7905839
,	7905839
may	7905839
prove	7905839
useful	7905839
in	7905839
assessing	7905839
this	7905839
gene	7905839
'	7905839
s	7905839
involvement	7905839
in	7905839
neuropsychiatric	7905839
disorders	7905839
involving	7905839
opiatergic	7905839
systems	7905839
.	7905839
An	28851297
Ag	28851297
-	28851297
globin	28851297
G	28851297
-	28851297
>	28851297
A	28851297
gene	28851297
polymorphism	28851297
associated	28851297
with	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
thalassemia	28851297
globin	28851297
gene	28851297
and	28851297
high	28851297
fetal	28851297
hemoglobin	28851297
production	28851297
.	28851297

BACKGROUND	28851297
:	28851297
Increase	28851297
of	28851297
the	28851297
expression	28851297
of	28851297
g	28851297
-	28851297
globin	28851297
gene	28851297
and	28851297
high	28851297
production	28851297
of	28851297
fetal	28851297
hemoglobin	28851297
(	28851297
HbF	28851297
)	28851297
in	28851297
b	28851297
-	28851297
thalassemia	28851297
patients	28851297
is	28851297
widely	28851297
accepted	28851297
as	28851297
associated	28851297
with	28851297
a	28851297
milder	28851297
or	28851297
even	28851297
asymptomatic	28851297
disease	28851297
.	28851297

The	28851297
search	28851297
for	28851297
HbF	28851297
-	28851297
associated	28851297
polymorphisms	28851297
(	28851297
such	28851297
as	28851297
the	28851297
XmnI	28851297
,	28851297
BCL11A	28851297
and	28851297
MYB	28851297
polymorphisms	28851297
)	28851297
has	28851297
recently	28851297
gained	28851297
great	28851297
attention	28851297
,	28851297
in	28851297
order	28851297
to	28851297
stratify	28851297
b	28851297
-	28851297
thalassemia	28851297
patients	28851297
with	28851297
respect	28851297
to	28851297
expectancy	28851297
of	28851297
the	28851297
first	28851297
transfusion	28851297
,	28851297
need	28851297
for	28851297
annual	28851297
intake	28851297
of	28851297
blood	28851297
,	28851297
response	28851297
to	28851297
HbF	28851297
inducers	28851297
(	28851297
the	28851297
most	28851297
studied	28851297
of	28851297
which	28851297
is	28851297
hydroxyurea	28851297
)	28851297
.	28851297

METHODS	28851297
:	28851297
Ag	28851297
-	28851297
globin	28851297
gene	28851297
sequencing	28851297
was	28851297
performed	28851297
on	28851297
genomic	28851297
DNA	28851297
isolated	28851297
from	28851297
a	28851297
total	28851297
of	28851297
75	28851297
b	28851297
-	28851297
thalassemia	28851297
patients	28851297
,	28851297
including	28851297
31	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
/	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
,	28851297
33	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
/	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
110	28851297
,	28851297
9	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
110	28851297
/	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
110	28851297
,	28851297
one	28851297
b	28851297
(	28851297
0	28851297
)	28851297
IVSI	28851297
-	28851297
1	28851297
/	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
6	28851297
and	28851297
one	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
/	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
6	28851297
.	28851297

RESULTS	28851297
:	28851297
The	28851297
results	28851297
show	28851297
that	28851297
the	28851297
rs368698783	28851297
polymorphism	28851297
is	28851297
present	28851297
in	28851297
b	28851297
-	28851297
thalassemia	28851297
patients	28851297
in	28851297
the	28851297
5	28851297
'	28851297
UTR	28851297
sequence	28851297
(	28851297
+	28851297
25	28851297
)	28851297
of	28851297
the	28851297
Ag	28851297
-	28851297
globin	28851297
gene	28851297
,	28851297
known	28851297
to	28851297
affect	28851297
the	28851297
LYAR	28851297
(	28851297
human	28851297
homologue	28851297
of	28851297
mouse	28851297
Ly	28851297
-	28851297
1	28851297
antibody	28851297
reactive	28851297
clone	28851297
)	28851297
binding	28851297
site	28851297
5	28851297
'	28851297
-	28851297
GGTTAT	28851297
-	28851297
3	28851297
'	28851297
.	28851297

This	28851297
Ag	28851297
(	28851297
+	28851297
25	28851297
G	28851297
-	28851297
>	28851297
A	28851297
)	28851297
polymorphism	28851297
is	28851297
associated	28851297
with	28851297
the	28851297
Gg	28851297
-	28851297
globin	28851297
-	28851297
XmnI	28851297
polymorphism	28851297
and	28851297
both	28851297
are	28851297
linked	28851297
with	28851297
the	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
-	28851297
globin	28851297
gene	28851297
,	28851297
but	28851297
not	28851297
with	28851297
the	28851297
b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
110	28851297
-	28851297
globin	28851297
gene	28851297
.	28851297

In	28851297
agreement	28851297
with	28851297
the	28851297
expectation	28851297
that	28851297
this	28851297
mutation	28851297
alters	28851297
the	28851297
LYAR	28851297
binding	28851297
activity	28851297
,	28851297
we	28851297
found	28851297
that	28851297
the	28851297
Ag	28851297
(	28851297
+	28851297
25	28851297
G	28851297
-	28851297
>	28851297
A	28851297
)	28851297
and	28851297
Gg	28851297
-	28851297
globin	28851297
-	28851297
XmnI	28851297
polymorphisms	28851297
are	28851297
associated	28851297
with	28851297
high	28851297
HbF	28851297
in	28851297
erythroid	28851297
precursor	28851297
cells	28851297
isolated	28851297
from	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
/	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
thalassemia	28851297
patients	28851297
.	28851297

CONCLUSIONS	28851297
:	28851297
As	28851297
a	28851297
potential	28851297
explanation	28851297
of	28851297
our	28851297
findings	28851297
,	28851297
we	28851297
hypothesize	28851297
that	28851297
in	28851297
b	28851297
-	28851297
thalassemia	28851297
the	28851297
Gg	28851297
-	28851297
globin	28851297
-	28851297
XmnI	28851297
/	28851297
Ag	28851297
-	28851297
globin	28851297
-	28851297
(	28851297
G	28851297
-	28851297
>	28851297
A	28851297
)	28851297
genotype	28851297
is	28851297
frequently	28851297
under	28851297
genetic	28851297
linkage	28851297
with	28851297
b	28851297
(	28851297
0	28851297
)	28851297
-	28851297
thalassemia	28851297
mutations	28851297
,	28851297
but	28851297
not	28851297
with	28851297
the	28851297
b	28851297
(	28851297
+	28851297
)	28851297
-	28851297
thalassemia	28851297
mutation	28851297
here	28851297
studied	28851297
(	28851297
i	28851297
.	28851297
e	28851297
.	28851297

b	28851297
(	28851297
+	28851297
)	28851297
IVSI	28851297
-	28851297
110	28851297
)	28851297
and	28851297
that	28851297
this	28851297
genetic	28851297
combination	28851297
has	28851297
been	28851297
selected	28851297
within	28851297
the	28851297
population	28851297
of	28851297
b	28851297
(	28851297
0	28851297
)	28851297
-	28851297
thalassemia	28851297
patients	28851297
,	28851297
due	28851297
to	28851297
functional	28851297
association	28851297
with	28851297
high	28851297
HbF	28851297
.	28851297

Here	28851297
we	28851297
describe	28851297
the	28851297
characterization	28851297
of	28851297
the	28851297
rs368698783	28851297
(	28851297
+	28851297
25	28851297
G	28851297
-	28851297
>	28851297
A	28851297
)	28851297
polymorphism	28851297
of	28851297
the	28851297
Ag	28851297
-	28851297
globin	28851297
gene	28851297
associated	28851297
in	28851297
b	28851297
(	28851297
0	28851297
)	28851297
39	28851297
thalassemia	28851297
patients	28851297
with	28851297
high	28851297
HbF	28851297
in	28851297
erythroid	28851297
precursor	28851297
cells	28851297
.	28851297
Alcohol	27643404
consumption	27643404
and	27643404
prostate	27643404
cancer	27643404
incidence	27643404
and	27643404
progression	27643404
:	27643404
A	27643404
Mendelian	27643404
randomisation	27643404
study	27643404
.	27643404

Prostate	27643404
cancer	27643404
is	27643404
the	27643404
most	27643404
common	27643404
cancer	27643404
in	27643404
men	27643404
in	27643404
developed	27643404
countries	27643404
,	27643404
and	27643404
is	27643404
a	27643404
target	27643404
for	27643404
risk	27643404
reduction	27643404
strategies	27643404
.	27643404

The	27643404
effects	27643404
of	27643404
alcohol	27643404
consumption	27643404
on	27643404
prostate	27643404
cancer	27643404
incidence	27643404
and	27643404
survival	27643404
remain	27643404
unclear	27643404
,	27643404
potentially	27643404
due	27643404
to	27643404
methodological	27643404
limitations	27643404
of	27643404
observational	27643404
studies	27643404
.	27643404

In	27643404
this	27643404
study	27643404
,	27643404
we	27643404
investigated	27643404
the	27643404
associations	27643404
of	27643404
genetic	27643404
variants	27643404
in	27643404
alcohol	27643404
-	27643404
metabolising	27643404
genes	27643404
with	27643404
prostate	27643404
cancer	27643404
incidence	27643404
and	27643404
survival	27643404
.	27643404

We	27643404
analysed	27643404
data	27643404
from	27643404
23	27643404
,	27643404
868	27643404
men	27643404
with	27643404
prostate	27643404
cancer	27643404
and	27643404
23	27643404
,	27643404
051	27643404
controls	27643404
from	27643404
25	27643404
studies	27643404
within	27643404
the	27643404
international	27643404
PRACTICAL	27643404
Consortium	27643404
.	27643404

Study	27643404
-	27643404
specific	27643404
associations	27643404
of	27643404
68	27643404
single	27643404
nucleotide	27643404
polymorphisms	27643404
(	27643404
SNPs	27643404
)	27643404
in	27643404
8	27643404
alcohol	27643404
-	27643404
metabolising	27643404
genes	27643404
(	27643404
Alcohol	27643404
Dehydrogenases	27643404
(	27643404
ADHs	27643404
)	27643404
and	27643404
Aldehyde	27643404
Dehydrogenases	27643404
(	27643404
ALDHs	27643404
)	27643404
)	27643404
with	27643404
prostate	27643404
cancer	27643404
diagnosis	27643404
and	27643404
prostate	27643404
cancer	27643404
-	27643404
specific	27643404
mortality	27643404
,	27643404
by	27643404
grade	27643404
,	27643404
were	27643404
assessed	27643404
using	27643404
logistic	27643404
and	27643404
Cox	27643404
regression	27643404
models	27643404
,	27643404
respectively	27643404
.	27643404

The	27643404
data	27643404
across	27643404
the	27643404
25	27643404
studies	27643404
were	27643404
meta	27643404
-	27643404
analysed	27643404
using	27643404
fixed	27643404
-	27643404
effect	27643404
and	27643404
random	27643404
-	27643404
effects	27643404
models	27643404
.	27643404

We	27643404
found	27643404
little	27643404
evidence	27643404
that	27643404
variants	27643404
in	27643404
alcohol	27643404
metabolising	27643404
genes	27643404
were	27643404
associated	27643404
with	27643404
prostate	27643404
cancer	27643404
diagnosis	27643404
.	27643404

Four	27643404
variants	27643404
in	27643404
two	27643404
genes	27643404
exceeded	27643404
the	27643404
multiple	27643404
testing	27643404
threshold	27643404
for	27643404
associations	27643404
with	27643404
prostate	27643404
cancer	27643404
mortality	27643404
in	27643404
fixed	27643404
-	27643404
effect	27643404
meta	27643404
-	27643404
analyses	27643404
.	27643404

SNPs	27643404
within	27643404
ALDH1A2	27643404
associated	27643404
with	27643404
prostate	27643404
cancer	27643404
mortality	27643404
were	27643404
rs1441817	27643404
(	27643404
fixed	27643404
effects	27643404
hazard	27643404
ratio	27643404
,	27643404
HRfixed	27643404
=	27643404
0	27643404
.	27643404
78	27643404
;	27643404
95%	27643404
confidence	27643404
interval	27643404
(	27643404
95%CI	27643404
)	27643404
:	27643404
0	27643404
.	27643404
66	27643404
,	27643404
0	27643404
.	27643404
91	27643404
;	27643404
p	27643404
values	27643404
=	27643404
0	27643404
.	27643404
002	27643404
)	27643404
;	27643404
rs12910509	27643404
,	27643404
HRfixed	27643404
=	27643404
0	27643404
.	27643404
76	27643404
;	27643404
95%CI	27643404
:	27643404
0	27643404
.	27643404
64	27643404
,	27643404
0	27643404
.	27643404
91	27643404
;	27643404
p	27643404
values	27643404
=	27643404
0	27643404
.	27643404
003	27643404
)	27643404
;	27643404
and	27643404
rs8041922	27643404
(	27643404
HRfixed	27643404
=	27643404
0	27643404
.	27643404
76	27643404
;	27643404
95%CI	27643404
:	27643404
0	27643404
.	27643404
64	27643404
,	27643404
0	27643404
.	27643404
91	27643404
;	27643404
p	27643404
values	27643404
=	27643404
0	27643404
.	27643404
002	27643404
)	27643404
.	27643404

These	27643404
SNPs	27643404
were	27643404
in	27643404
linkage	27643404
disequilibrium	27643404
with	27643404
each	27643404
other	27643404
.	27643404

In	27643404
ALDH1B1	27643404
,	27643404
rs10973794	27643404
(	27643404
HRfixed	27643404
=	27643404
1	27643404
.	27643404
43	27643404
;	27643404
95%CI	27643404
:	27643404
1	27643404
.	27643404
14	27643404
,	27643404
1	27643404
.	27643404
79	27643404
;	27643404
p	27643404
values	27643404
=	27643404
0	27643404
.	27643404
002	27643404
)	27643404
was	27643404
associated	27643404
with	27643404
prostate	27643404
cancer	27643404
mortality	27643404
in	27643404
men	27643404
with	27643404
low	27643404
-	27643404
grade	27643404
prostate	27643404
cancer	27643404
.	27643404

These	27643404
results	27643404
suggest	27643404
that	27643404
alcohol	27643404
consumption	27643404
is	27643404
unlikely	27643404
to	27643404
affect	27643404
prostate	27643404
cancer	27643404
incidence	27643404
,	27643404
but	27643404
it	27643404
may	27643404
influence	27643404
disease	27643404
progression	27643404
.	27643404
Novel	15754732
somatic	15754732
MEN1	15754732
gene	15754732
alterations	15754732
in	15754732
sporadic	15754732
primary	15754732
hyperparathyroidism	15754732
and	15754732
correlation	15754732
with	15754732
clinical	15754732
characteristics	15754732
.	15754732

Primary	15754732
hyperparathyroidism	15754732
(	15754732
pHPT	15754732
)	15754732
is	15754732
a	15754732
common	15754732
endocrine	15754732
disease	15754732
that	15754732
in	15754732
more	15754732
than	15754732
95%	15754732
of	15754732
cases	15754732
is	15754732
sporadic	15754732
and	15754732
only	15754732
in	15754732
some	15754732
cases	15754732
is	15754732
caused	15754732
by	15754732
inherited	15754732
disorders	15754732
,	15754732
isolated	15754732
or	15754732
as	15754732
part	15754732
of	15754732
multiple	15754732
endocrine	15754732
neoplasia	15754732
(	15754732
MEN1	15754732
and	15754732
2	15754732
)	15754732
.	15754732

Somatic	15754732
mutations	15754732
of	15754732
MEN1	15754732
gene	15754732
have	15754732
also	15754732
been	15754732
described	15754732
in	15754732
sporadic	15754732
parathyroid	15754732
tumors	15754732
.	15754732

In	15754732
our	15754732
study	15754732
,	15754732
we	15754732
examined	15754732
the	15754732
presence	15754732
of	15754732
alterations	15754732
in	15754732
MEN1	15754732
gene	15754732
in	15754732
a	15754732
series	15754732
of	15754732
39	15754732
patients	15754732
who	15754732
had	15754732
undergone	15754732
surgery	15754732
for	15754732
sporadic	15754732
pHPT	15754732
(	15754732
35	15754732
with	15754732
parathyroid	15754732
adenoma	15754732
or	15754732
hyperplasia	15754732
,	15754732
4	15754732
with	15754732
a	15754732
carcinoma	15754732
)	15754732
.	15754732

A	15754732
genotype	15754732
-	15754732
phenotype	15754732
correlation	15754732
was	15754732
also	15754732
analysed	15754732
.	15754732

After	15754732
DNA	15754732
extraction	15754732
from	15754732
paraffin	15754732
-	15754732
embedded	15754732
tissues	15754732
,	15754732
we	15754732
amplified	15754732
by	15754732
PCR	15754732
and	15754732
sequenced	15754732
the	15754732
exons	15754732
2	15754732
-	15754732
10	15754732
of	15754732
the	15754732
MEN1	15754732
gene	15754732
.	15754732

Somatic	15754732
MEN1	15754732
mutations	15754732
were	15754732
detected	15754732
in	15754732
6	15754732
of	15754732
the	15754732
35	15754732
patients	15754732
with	15754732
a	15754732
benign	15754732
parathyroid	15754732
lesion	15754732
examined	15754732
(	15754732
17	15754732
.	15754732
1%	15754732
)	15754732
,	15754732
whereas	15754732
no	15754732
alterations	15754732
were	15754732
found	15754732
in	15754732
the	15754732
carcinomas	15754732
.	15754732

Four	15754732
novel	15754732
MEN1	15754732
gene	15754732
mutations	15754732
were	15754732
identified	15754732
as	15754732
follows	15754732
:	15754732
one	15754732
frameshift	15754732
mutation	15754732
(	15754732
222insT	15754732
,	15754732
exon	15754732
2	15754732
)	15754732
,	15754732
one	15754732
frameshift	15754732
deletion	15754732
(	15754732
912delTA	15754732
,	15754732
exon	15754732
5	15754732
)	15754732
,	15754732
one	15754732
in	15754732
-	15754732
frame	15754732
deletion	15754732
(	15754732
835del18	15754732
,	15754732
exon	15754732
4	15754732
)	15754732
and	15754732
one	15754732
missense	15754732
mutation	15754732
(	15754732
P291A	15754732
,	15754732
exon	15754732
6	15754732
)	15754732
.	15754732

In	15754732
addition	15754732
,	15754732
one	15754732
missense	15754732
mutation	15754732
(	15754732
L89R	15754732
,	15754732
exon	15754732
2	15754732
)	15754732
and	15754732
one	15754732
nonsense	15754732
mutation	15754732
(	15754732
Q536X	15754732
,	15754732
exon	15754732
10	15754732
)	15754732
were	15754732
previously	15754732
reported	15754732
.	15754732

Moreover	15754732
,	15754732
two	15754732
polymorphisms	15754732
were	15754732
also	15754732
found	15754732
:	15754732
one	15754732
allele	15754732
carried	15754732
a	15754732
R171Q	15754732
polymorphism	15754732
(	15754732
1	15754732
/	15754732
39	15754732
tumors	15754732
)	15754732
,	15754732
while	15754732
a	15754732
D418D	15754732
polymorphism	15754732
(	15754732
GAC	15754732
/	15754732
GAT	15754732
)	15754732
was	15754732
found	15754732
in	15754732
15	15754732
and	15754732
8	15754732
tumors	15754732
in	15754732
hetero	15754732
(	15754732
CT	15754732
)	15754732
and	15754732
homozygosity	15754732
(	15754732
TT	15754732
)	15754732
,	15754732
respectively	15754732
.	15754732

In	15754732
no	15754732
case	15754732
(	15754732
mutations	15754732
and	15754732
/	15754732
or	15754732
polymorphisms	15754732
)	15754732
did	15754732
we	15754732
find	15754732
a	15754732
genotype	15754732
-	15754732
phenotype	15754732
correlation	15754732
.	15754732

In	15754732
conclusion	15754732
,	15754732
our	15754732
data	15754732
demonstrate	15754732
the	15754732
presence	15754732
of	15754732
somatic	15754732
alterations	15754732
of	15754732
the	15754732
MEN1	15754732
tumor	15754732
suppressor	15754732
gene	15754732
in	15754732
about	15754732
one	15754732
fifth	15754732
of	15754732
benign	15754732
sporadic	15754732
parathyroid	15754732
tumors	15754732
.	15754732

The	15754732
absence	15754732
of	15754732
a	15754732
genotype	15754732
-	15754732
phenotype	15754732
correlation	15754732
,	15754732
however	15754732
,	15754732
suggests	15754732
the	15754732
involvement	15754732
of	15754732
other	15754732
genetic	15754732
/	15754732
epigenetic	15754732
factors	15754732
for	15754732
the	15754732
full	15754732
expression	15754732
of	15754732
the	15754732
disease	15754732
.	15754732
Lack	20651814
of	20651814
association	20651814
between	20651814
ADRA2B	20651814
-	20651814
4825	20651814
gene	20651814
insertion	20651814
/	20651814
deletion	20651814
polymorphism	20651814
and	20651814
migraine	20651814
in	20651814
Chinese	20651814
Han	20651814
population	20651814
.	20651814

OBJECTIVE	20651814
:	20651814
The	20651814
present	20651814
study	20651814
aimed	20651814
to	20651814
estimate	20651814
the	20651814
association	20651814
between	20651814
susceptibility	20651814
to	20651814
migraine	20651814
and	20651814
the	20651814
12	20651814
-	20651814
nucleotide	20651814
insertion	20651814
/	20651814
deletion	20651814
(	20651814
indel	20651814
)	20651814
polymorphism	20651814
in	20651814
promoter	20651814
region	20651814
of	20651814
alpha	20651814
(	20651814
2B	20651814
)	20651814
-	20651814
adrenergic	20651814
receptor	20651814
gene	20651814
(	20651814
ADRA2B	20651814
)	20651814
.	20651814

METHODS	20651814
:	20651814
A	20651814
case	20651814
-	20651814
control	20651814
study	20651814
was	20651814
carried	20651814
out	20651814
in	20651814
Chinese	20651814
Han	20651814
population	20651814
,	20651814
including	20651814
368	20651814
cases	20651814
of	20651814
migraine	20651814
and	20651814
517	20651814
controls	20651814
.	20651814

Genomic	20651814
DNA	20651814
was	20651814
extracted	20651814
from	20651814
blood	20651814
samples	20651814
,	20651814
and	20651814
DNA	20651814
fragments	20651814
containing	20651814
the	20651814
site	20651814
of	20651814
polymorphism	20651814
were	20651814
amplified	20651814
by	20651814
PCR	20651814
.	20651814

Data	20651814
were	20651814
adjusted	20651814
for	20651814
sex	20651814
,	20651814
age	20651814
,	20651814
migraine	20651814
history	20651814
and	20651814
family	20651814
history	20651814
,	20651814
and	20651814
analyzed	20651814
using	20651814
a	20651814
logistic	20651814
regression	20651814
model	20651814
.	20651814

RESULTS	20651814
:	20651814
There	20651814
was	20651814
no	20651814
association	20651814
between	20651814
indel	20651814
polymorphism	20651814
and	20651814
migraine	20651814
,	20651814
at	20651814
either	20651814
the	20651814
allele	20651814
or	20651814
the	20651814
genotype	20651814
level	20651814
.	20651814

CONCLUSION	20651814
:	20651814
These	20651814
findings	20651814
do	20651814
not	20651814
support	20651814
a	20651814
functional	20651814
significance	20651814
of	20651814
ADRA2B	20651814
indel	20651814
polymorphism	20651814
at	20651814
position	20651814
-	20651814
4825	20651814
relative	20651814
to	20651814
the	20651814
start	20651814
codon	20651814
in	20651814
the	20651814
far	20651814
upstream	20651814
region	20651814
of	20651814
the	20651814
promoter	20651814
in	20651814
the	20651814
present	20651814
migraine	20651814
subjects	20651814
.	20651814
Aryl	18410548
hydrocarbon	18410548
receptor	18410548
interacting	18410548
protein	18410548
(	18410548
AIP	18410548
)	18410548
gene	18410548
mutation	18410548
analysis	18410548
in	18410548
children	18410548
and	18410548
adolescents	18410548
with	18410548
sporadic	18410548
pituitary	18410548
adenomas	18410548
.	18410548

OBJECTIVE	18410548
:	18410548
Pituitary	18410548
adenomas	18410548
occur	18410548
rarely	18410548
in	18410548
childhood	18410548
and	18410548
adolescence	18410548
.	18410548

Pituitary	18410548
adenoma	18410548
predisposition	18410548
(	18410548
PAP	18410548
)	18410548
has	18410548
been	18410548
recently	18410548
associated	18410548
with	18410548
germline	18410548
mutations	18410548
in	18410548
the	18410548
aryl	18410548
hydrocarbon	18410548
receptor	18410548
interacting	18410548
protein	18410548
(	18410548
AIP	18410548
)	18410548
gene	18410548
.	18410548

The	18410548
aim	18410548
of	18410548
the	18410548
study	18410548
was	18410548
to	18410548
examine	18410548
the	18410548
proportion	18410548
of	18410548
germline	18410548
AIP	18410548
mutations	18410548
in	18410548
apparently	18410548
sporadic	18410548
paediatric	18410548
pituitary	18410548
adenomas	18410548
.	18410548

DESIGN	18410548
:	18410548
Genomic	18410548
DNA	18410548
was	18410548
analysed	18410548
for	18410548
mutations	18410548
in	18410548
the	18410548
AIP	18410548
gene	18410548
,	18410548
by	18410548
PCR	18410548
amplification	18410548
and	18410548
direct	18410548
sequencing	18410548
.	18410548

PATIENTS	18410548
:	18410548
A	18410548
population	18410548
-	18410548
based	18410548
cohort	18410548
consisting	18410548
of	18410548
36	18410548
apparently	18410548
sporadic	18410548
paediatric	18410548
pituitary	18410548
adenoma	18410548
patients	18410548
,	18410548
referred	18410548
to	18410548
two	18410548
medical	18410548
centres	18410548
in	18410548
Italy	18410548
,	18410548
was	18410548
included	18410548
in	18410548
the	18410548
study	18410548
.	18410548

Patients	18410548
were	18410548
either	18410548
less	18410548
than	18410548
18	18410548
years	18410548
at	18410548
diagnosis	18410548
,	18410548
or	18410548
showed	18410548
clinical	18410548
evidence	18410548
of	18410548
adenoma	18410548
development	18410548
before	18410548
the	18410548
age	18410548
of	18410548
18	18410548
years	18410548
.	18410548

RESULTS	18410548
:	18410548
A	18410548
heterozygous	18410548
in	18410548
-	18410548
frame	18410548
deletion	18410548
Y248del	18410548
(	18410548
c	18410548
.	18410548
742_744delTAC	18410548
)	18410548
was	18410548
identified	18410548
in	18410548
one	18410548
GH	18410548
-	18410548
secreting	18410548
adenoma	18410548
patient	18410548
.	18410548

Loss	18410548
of	18410548
heterozygosity	18410548
(	18410548
LOH	18410548
)	18410548
analysis	18410548
of	18410548
tumour	18410548
DNA	18410548
revealed	18410548
the	18410548
loss	18410548
of	18410548
the	18410548
wild	18410548
-	18410548
type	18410548
allele	18410548
.	18410548

First	18410548
degree	18410548
relatives	18410548
carrying	18410548
the	18410548
mutation	18410548
were	18410548
clinically	18410548
unaffected	18410548
.	18410548

CONCLUSIONS	18410548
:	18410548
While	18410548
mutations	18410548
were	18410548
absent	18410548
in	18410548
non	18410548
-	18410548
GH	18410548
-	18410548
secreting	18410548
adenoma	18410548
patients	18410548
,	18410548
germline	18410548
AIP	18410548
mutations	18410548
can	18410548
be	18410548
found	18410548
in	18410548
children	18410548
and	18410548
adolescents	18410548
with	18410548
GH	18410548
-	18410548
secreting	18410548
tumours	18410548
,	18410548
even	18410548
in	18410548
the	18410548
absence	18410548
of	18410548
family	18410548
history	18410548
.	18410548

The	18410548
present	18410548
study	18410548
reports	18410548
the	18410548
AIP	18410548
mutation	18410548
analysis	18410548
results	18410548
on	18410548
patients	18410548
of	18410548
a	18410548
single	18410548
ethnic	18410548
origin	18410548
.	18410548

Clearly	18410548
,	18410548
further	18410548
studies	18410548
are	18410548
needed	18410548
to	18410548
improve	18410548
our	18410548
knowledge	18410548
on	18410548
the	18410548
role	18410548
of	18410548
AIP	18410548
in	18410548
paediatric	18410548
pituitary	18410548
adenomas	18410548
.	18410548
A	17910065
novel	17910065
missense	17910065
mutation	17910065
in	17910065
the	17910065
paired	17910065
domain	17910065
of	17910065
human	17910065
PAX9	17910065
causes	17910065
oligodontia	17910065
.	17910065

PAX9	17910065
and	17910065
MSX1	17910065
are	17910065
transcription	17910065
factors	17910065
that	17910065
play	17910065
essential	17910065
roles	17910065
in	17910065
craniofacial	17910065
and	17910065
limb	17910065
development	17910065
.	17910065

In	17910065
humans	17910065
,	17910065
mutations	17910065
in	17910065
both	17910065
genes	17910065
are	17910065
associated	17910065
with	17910065
nonsyndromic	17910065
and	17910065
syndromic	17910065
oligodontia	17910065
,	17910065
respectively	17910065
.	17910065

We	17910065
screened	17910065
one	17910065
family	17910065
with	17910065
nonsyndromic	17910065
oligodontia	17910065
for	17910065
mutations	17910065
in	17910065
PAX9	17910065
and	17910065
MSX1	17910065
.	17910065

Single	17910065
stranded	17910065
conformational	17910065
polymorphism	17910065
(	17910065
SSCP	17910065
)	17910065
analysis	17910065
and	17910065
sequencing	17910065
revealed	17910065
a	17910065
novel	17910065
heterozygous	17910065
C139T	17910065
transition	17910065
in	17910065
PAX9	17910065
in	17910065
the	17910065
affected	17910065
members	17910065
of	17910065
the	17910065
family	17910065
.	17910065

There	17910065
were	17910065
no	17910065
mutations	17910065
detected	17910065
in	17910065
the	17910065
entire	17910065
coding	17910065
sequence	17910065
of	17910065
MSX1	17910065
.	17910065

The	17910065
C139T	17910065
mutation	17910065
,	17910065
predicted	17910065
to	17910065
result	17910065
in	17910065
the	17910065
substitution	17910065
of	17910065
an	17910065
arginine	17910065
by	17910065
a	17910065
tryptophan	17910065
(	17910065
R47W	17910065
)	17910065
in	17910065
the	17910065
N	17910065
-	17910065
terminal	17910065
subdomain	17910065
,	17910065
affected	17910065
conserved	17910065
residues	17910065
in	17910065
the	17910065
PAX9	17910065
paired	17910065
domain	17910065
.	17910065

To	17910065
elucidate	17910065
the	17910065
pathogenic	17910065
mechanism	17910065
producing	17910065
oligodontia	17910065
phenotype	17910065
caused	17910065
by	17910065
this	17910065
mutation	17910065
,	17910065
we	17910065
analyzed	17910065
the	17910065
binding	17910065
of	17910065
wild	17910065
-	17910065
type	17910065
and	17910065
mutant	17910065
PAX9	17910065
paired	17910065
domain	17910065
protein	17910065
to	17910065
double	17910065
-	17910065
stranded	17910065
DNA	17910065
targets	17910065
.	17910065

The	17910065
R47W	17910065
mutation	17910065
dramatically	17910065
reduced	17910065
DNA	17910065
binding	17910065
suggesting	17910065
that	17910065
the	17910065
mutant	17910065
protein	17910065
with	17910065
consequent	17910065
haploinsufficiency	17910065
results	17910065
in	17910065
a	17910065
clinical	17910065
phenotype	17910065
.	17910065
Availability	24742750
of	24742750
human	24742750
induced	24742750
pluripotent	24742750
stem	24742750
cell	24742750
-	24742750
derived	24742750
cardiomyocytes	24742750
in	24742750
assessment	24742750
of	24742750
drug	24742750
potential	24742750
for	24742750
QT	24742750
prolongation	24742750
.	24742750

Field	24742750
potential	24742750
duration	24742750
(	24742750
FPD	24742750
)	24742750
in	24742750
human	24742750
-	24742750
induced	24742750
pluripotent	24742750
stem	24742750
cell	24742750
-	24742750
derived	24742750
cardiomyocytes	24742750
(	24742750
hiPS	24742750
-	24742750
CMs	24742750
)	24742750
,	24742750
which	24742750
can	24742750
express	24742750
QT	24742750
interval	24742750
in	24742750
an	24742750
electrocardiogram	24742750
,	24742750
is	24742750
reported	24742750
to	24742750
be	24742750
a	24742750
useful	24742750
tool	24742750
to	24742750
predict	24742750
K	24742750
(	24742750
+	24742750
)	24742750
channel	24742750
and	24742750
Ca	24742750
(	24742750
2	24742750
+	24742750
)	24742750
channel	24742750
blocker	24742750
effects	24742750
on	24742750
QT	24742750
interval	24742750
.	24742750

However	24742750
,	24742750
there	24742750
is	24742750
no	24742750
report	24742750
showing	24742750
that	24742750
this	24742750
technique	24742750
can	24742750
be	24742750
used	24742750
to	24742750
predict	24742750
multichannel	24742750
blocker	24742750
potential	24742750
for	24742750
QT	24742750
prolongation	24742750
.	24742750

The	24742750
aim	24742750
of	24742750
this	24742750
study	24742750
is	24742750
to	24742750
show	24742750
that	24742750
FPD	24742750
from	24742750
MEA	24742750
(	24742750
Multielectrode	24742750
array	24742750
)	24742750
of	24742750
hiPS	24742750
-	24742750
CMs	24742750
can	24742750
detect	24742750
QT	24742750
prolongation	24742750
induced	24742750
by	24742750
multichannel	24742750
blockers	24742750
.	24742750

hiPS	24742750
-	24742750
CMs	24742750
were	24742750
seeded	24742750
onto	24742750
MEA	24742750
and	24742750
FPD	24742750
was	24742750
measured	24742750
for	24742750
2min	24742750
every	24742750
10min	24742750
for	24742750
30min	24742750
after	24742750
drug	24742750
exposure	24742750
for	24742750
the	24742750
vehicle	24742750
and	24742750
each	24742750
drug	24742750
concentration	24742750
.	24742750

IKr	24742750
and	24742750
IKs	24742750
blockers	24742750
concentration	24742750
-	24742750
dependently	24742750
prolonged	24742750
corrected	24742750
FPD	24742750
(	24742750
FPDc	24742750
)	24742750
,	24742750
whereas	24742750
Ca	24742750
(	24742750
2	24742750
+	24742750
)	24742750
channel	24742750
blockers	24742750
concentration	24742750
-	24742750
dependently	24742750
shortened	24742750
FPDc	24742750
.	24742750

Also	24742750
,	24742750
the	24742750
multichannel	24742750
blockers	24742750
Amiodarone	24742750
,	24742750
Paroxetine	24742750
,	24742750
Terfenadine	24742750
and	24742750
Citalopram	24742750
prolonged	24742750
FPDc	24742750
in	24742750
a	24742750
concentration	24742750
dependent	24742750
manner	24742750
.	24742750

Finally	24742750
,	24742750
the	24742750
IKr	24742750
blockers	24742750
,	24742750
Terfenadine	24742750
and	24742750
Citalopram	24742750
,	24742750
which	24742750
are	24742750
reported	24742750
to	24742750
cause	24742750
Torsade	24742750
de	24742750
Pointes	24742750
(	24742750
TdP	24742750
)	24742750
in	24742750
clinical	24742750
practice	24742750
,	24742750
produced	24742750
early	24742750
afterdepolarization	24742750
(	24742750
EAD	24742750
)	24742750
.	24742750

hiPS	24742750
-	24742750
CMs	24742750
using	24742750
MEA	24742750
system	24742750
and	24742750
FPDc	24742750
can	24742750
predict	24742750
the	24742750
effects	24742750
of	24742750
drug	24742750
candidates	24742750
on	24742750
QT	24742750
interval	24742750
.	24742750

This	24742750
study	24742750
also	24742750
shows	24742750
that	24742750
this	24742750
assay	24742750
can	24742750
help	24742750
detect	24742750
EAD	24742750
for	24742750
drugs	24742750
with	24742750
TdP	24742750
potential	24742750
.	24742750
A	17059986
novel	17059986
splicing	17059986
mutation	17059986
in	17059986
SLC12A3	17059986
associated	17059986
with	17059986
Gitelman	17059986
syndrome	17059986
and	17059986
idiopathic	17059986
intracranial	17059986
hypertension	17059986
.	17059986

We	17059986
report	17059986
a	17059986
case	17059986
of	17059986
Gitelman	17059986
syndrome	17059986
(	17059986
GS	17059986
)	17059986
in	17059986
a	17059986
dizygotic	17059986
twin	17059986
who	17059986
presented	17059986
at	17059986
12	17059986
years	17059986
of	17059986
age	17059986
with	17059986
growth	17059986
delay	17059986
,	17059986
metabolic	17059986
alkalosis	17059986
,	17059986
hypomagnesemia	17059986
and	17059986
hypokalemia	17059986
with	17059986
inappropriate	17059986
kaliuresis	17059986
,	17059986
and	17059986
idiopathic	17059986
intracranial	17059986
hypertension	17059986
with	17059986
bilateral	17059986
papilledema	17059986
(	17059986
pseudotumor	17059986
cerebri	17059986
)	17059986
.	17059986

The	17059986
patient	17059986
,	17059986
her	17059986
twin	17059986
sister	17059986
,	17059986
and	17059986
her	17059986
mother	17059986
also	17059986
presented	17059986
with	17059986
cerebral	17059986
cavernous	17059986
malformations	17059986
.	17059986

Based	17059986
on	17059986
the	17059986
early	17059986
onset	17059986
and	17059986
normocalciuria	17059986
,	17059986
Bartter	17059986
syndrome	17059986
was	17059986
diagnosed	17059986
first	17059986
.	17059986

However	17059986
,	17059986
mutation	17059986
analysis	17059986
showed	17059986
that	17059986
the	17059986
proband	17059986
is	17059986
a	17059986
compound	17059986
heterozygote	17059986
for	17059986
2	17059986
mutations	17059986
in	17059986
SLC12A3	17059986
:	17059986
a	17059986
substitution	17059986
of	17059986
serine	17059986
by	17059986
leucine	17059986
at	17059986
amino	17059986
acid	17059986
position	17059986
555	17059986
(	17059986
p	17059986
.	17059986
Ser555Leu	17059986
)	17059986
and	17059986
a	17059986
novel	17059986
guanine	17059986
to	17059986
cytosine	17059986
transition	17059986
at	17059986
the	17059986
5	17059986
'	17059986
splice	17059986
site	17059986
of	17059986
intron	17059986
22	17059986
(	17059986
c	17059986
.	17059986
2633	17059986
+	17059986
1G	17059986
>	17059986
C	17059986
)	17059986
,	17059986
providing	17059986
the	17059986
molecular	17059986
diagnosis	17059986
of	17059986
GS	17059986
.	17059986

These	17059986
mutations	17059986
were	17059986
not	17059986
detected	17059986
in	17059986
200	17059986
normal	17059986
chromosomes	17059986
and	17059986
cosegregated	17059986
within	17059986
the	17059986
family	17059986
.	17059986

Analysis	17059986
of	17059986
complementary	17059986
DNA	17059986
showed	17059986
that	17059986
the	17059986
heterozygous	17059986
nucleotide	17059986
change	17059986
c	17059986
.	17059986
2633	17059986
+	17059986
1G	17059986
>	17059986
C	17059986
caused	17059986
the	17059986
appearance	17059986
of	17059986
2	17059986
RNA	17059986
molecules	17059986
,	17059986
1	17059986
normal	17059986
transcript	17059986
and	17059986
1	17059986
skipping	17059986
the	17059986
entire	17059986
exon	17059986
22	17059986
(	17059986
r	17059986
.	17059986
2521_2634del	17059986
)	17059986
.	17059986

Supplementation	17059986
with	17059986
potassium	17059986
and	17059986
magnesium	17059986
improved	17059986
clinical	17059986
symptoms	17059986
and	17059986
resulted	17059986
in	17059986
catch	17059986
-	17059986
up	17059986
growth	17059986
,	17059986
but	17059986
vision	17059986
remained	17059986
impaired	17059986
.	17059986

Three	17059986
similar	17059986
associations	17059986
of	17059986
Bartter	17059986
syndrome	17059986
/	17059986
GS	17059986
with	17059986
pseudotumor	17059986
cerebri	17059986
were	17059986
found	17059986
in	17059986
the	17059986
literature	17059986
,	17059986
suggesting	17059986
that	17059986
electrolyte	17059986
abnormalities	17059986
and	17059986
secondary	17059986
aldosteronism	17059986
may	17059986
have	17059986
a	17059986
role	17059986
in	17059986
idiopathic	17059986
intracranial	17059986
hypertension	17059986
.	17059986

This	17059986
study	17059986
provides	17059986
further	17059986
evidence	17059986
for	17059986
the	17059986
phenotypical	17059986
heterogeneity	17059986
of	17059986
GS	17059986
and	17059986
its	17059986
association	17059986
with	17059986
severe	17059986
manifestations	17059986
in	17059986
children	17059986
.	17059986

It	17059986
also	17059986
shows	17059986
the	17059986
independent	17059986
segregation	17059986
of	17059986
familial	17059986
cavernomatosis	17059986
and	17059986
GS	17059986
.	17059986
Regulation	28428256
of	28428256
lung	28428256
endothelial	28428256
permeability	28428256
and	28428256
inflammatory	28428256
responses	28428256
by	28428256
prostaglandin	28428256
A2	28428256
:	28428256
role	28428256
of	28428256
EP4	28428256
receptor	28428256
.	28428256

The	28428256
role	28428256
of	28428256
prostaglandin	28428256
A2	28428256
(	28428256
PGA2	28428256
)	28428256
in	28428256
modulation	28428256
of	28428256
vascular	28428256
endothelial	28428256
function	28428256
is	28428256
unknown	28428256
.	28428256

We	28428256
investigated	28428256
effects	28428256
of	28428256
PGA2	28428256
on	28428256
pulmonary	28428256
endothelial	28428256
cell	28428256
(	28428256
EC	28428256
)	28428256
permeability	28428256
and	28428256
inflammatory	28428256
activation	28428256
and	28428256
identified	28428256
a	28428256
receptor	28428256
mediating	28428256
these	28428256
effects	28428256
.	28428256

PGA2	28428256
enhanced	28428256
the	28428256
EC	28428256
barrier	28428256
and	28428256
protected	28428256
against	28428256
barrier	28428256
dysfunction	28428256
caused	28428256
by	28428256
vasoactive	28428256
peptide	28428256
thrombin	28428256
and	28428256
proinflammatory	28428256
bacterial	28428256
wall	28428256
lipopolysaccharide	28428256
(	28428256
LPS	28428256
)	28428256
.	28428256

Receptor	28428256
screening	28428256
using	28428256
pharmacological	28428256
and	28428256
molecular	28428256
inhibitory	28428256
approaches	28428256
identified	28428256
EP4	28428256
as	28428256
a	28428256
novel	28428256
PGA2	28428256
receptor	28428256
.	28428256

EP4	28428256
mediated	28428256
barrier	28428256
-	28428256
protective	28428256
effects	28428256
of	28428256
PGA2	28428256
by	28428256
activating	28428256
Rap1	28428256
/	28428256
Rac1	28428256
GTPase	28428256
and	28428256
protein	28428256
kinase	28428256
A	28428256
targets	28428256
at	28428256
cell	28428256
adhesions	28428256
and	28428256
cytoskeleton	28428256
:	28428256
VE	28428256
-	28428256
cadherin	28428256
,	28428256
p120	28428256
-	28428256
catenin	28428256
,	28428256
ZO	28428256
-	28428256
1	28428256
,	28428256
cortactin	28428256
,	28428256
and	28428256
VASP	28428256
.	28428256

PGA2	28428256
also	28428256
suppressed	28428256
LPS	28428256
-	28428256
induced	28428256
inflammatory	28428256
signaling	28428256
by	28428256
inhibiting	28428256
the	28428256
NFkB	28428256
pathway	28428256
and	28428256
expression	28428256
of	28428256
EC	28428256
adhesion	28428256
molecules	28428256
ICAM1	28428256
and	28428256
VCAM1	28428256
.	28428256

These	28428256
effects	28428256
were	28428256
abolished	28428256
by	28428256
pharmacological	28428256
or	28428256
molecular	28428256
inhibition	28428256
of	28428256
EP4	28428256
.	28428256

In	28428256
vivo	28428256
,	28428256
PGA2	28428256
was	28428256
protective	28428256
in	28428256
two	28428256
distinct	28428256
models	28428256
of	28428256
acute	28428256
lung	28428256
injury	28428256
(	28428256
ALI	28428256
)	28428256
:	28428256
LPS	28428256
-	28428256
induced	28428256
inflammatory	28428256
injury	28428256
and	28428256
two	28428256
-	28428256
hit	28428256
ALI	28428256
caused	28428256
by	28428256
suboptimal	28428256
mechanical	28428256
ventilation	28428256
and	28428256
injection	28428256
of	28428256
thrombin	28428256
receptor	28428256
-	28428256
activating	28428256
peptide	28428256
.	28428256

These	28428256
protective	28428256
effects	28428256
were	28428256
abolished	28428256
in	28428256
mice	28428256
with	28428256
endothelial	28428256
-	28428256
specific	28428256
EP4	28428256
knockout	28428256
.	28428256

The	28428256
results	28428256
suggest	28428256
a	28428256
novel	28428256
role	28428256
for	28428256
the	28428256
PGA2	28428256
-	28428256
EP4	28428256
axis	28428256
in	28428256
vascular	28428256
EC	28428256
protection	28428256
that	28428256
is	28428256
critical	28428256
for	28428256
improvement	28428256
of	28428256
pathological	28428256
states	28428256
associated	28428256
with	28428256
increased	28428256
vascular	28428256
leakage	28428256
and	28428256
inflammation	28428256
.	28428256
Genetic	18457324
polymorphisms	18457324
in	18457324
the	18457324
carbonyl	18457324
reductase	18457324
3	18457324
gene	18457324
CBR3	18457324
and	18457324
the	18457324
NAD	18457324
(	18457324
P	18457324
)	18457324
H	18457324
:	18457324
quinone	18457324
oxidoreductase	18457324
1	18457324
gene	18457324
NQO1	18457324
in	18457324
patients	18457324
who	18457324
developed	18457324
anthracycline	18457324
-	18457324
related	18457324
congestive	18457324
heart	18457324
failure	18457324
after	18457324
childhood	18457324
cancer	18457324
.	18457324

BACKGROUND	18457324
:	18457324
Exposure	18457324
to	18457324
anthracyclines	18457324
as	18457324
part	18457324
of	18457324
cancer	18457324
therapy	18457324
has	18457324
been	18457324
associated	18457324
with	18457324
the	18457324
development	18457324
of	18457324
congestive	18457324
heart	18457324
failure	18457324
(	18457324
CHF	18457324
)	18457324
.	18457324

The	18457324
potential	18457324
role	18457324
of	18457324
genetic	18457324
risk	18457324
factors	18457324
in	18457324
anthracycline	18457324
-	18457324
related	18457324
CHF	18457324
remains	18457324
to	18457324
be	18457324
defined	18457324
.	18457324

Thus	18457324
,	18457324
in	18457324
this	18457324
study	18457324
,	18457324
the	18457324
authors	18457324
examined	18457324
whether	18457324
common	18457324
polymorphisms	18457324
in	18457324
candidate	18457324
genes	18457324
involved	18457324
in	18457324
the	18457324
pharmacodynamics	18457324
of	18457324
anthracyclines	18457324
(	18457324
in	18457324
particular	18457324
,	18457324
the	18457324
nicotinamide	18457324
adenine	18457324
dinucleotide	18457324
phosphate	18457324
:	18457324
quinone	18457324
oxidoreductase	18457324
1	18457324
gene	18457324
NQO1	18457324
and	18457324
the	18457324
carbonyl	18457324
reductase	18457324
3	18457324
gene	18457324
CBR3	18457324
)	18457324
had	18457324
an	18457324
impact	18457324
on	18457324
the	18457324
risk	18457324
of	18457324
anthracycline	18457324
-	18457324
related	18457324
CHF	18457324
.	18457324

METHODS	18457324
:	18457324
A	18457324
nested	18457324
case	18457324
-	18457324
control	18457324
study	18457324
was	18457324
conducted	18457324
within	18457324
a	18457324
cohort	18457324
of	18457324
1979	18457324
patients	18457324
enrolled	18457324
in	18457324
the	18457324
Childhood	18457324
Cancer	18457324
Survivor	18457324
Study	18457324
who	18457324
received	18457324
treatment	18457324
with	18457324
anthracyclines	18457324
and	18457324
had	18457324
available	18457324
DNA	18457324
.	18457324

Thirty	18457324
patients	18457324
with	18457324
CHF	18457324
(	18457324
cases	18457324
)	18457324
and	18457324
115	18457324
matched	18457324
controls	18457324
were	18457324
genotyped	18457324
for	18457324
polymorphisms	18457324
in	18457324
NQO1	18457324
(	18457324
NQO1	18457324
*	18457324
2	18457324
)	18457324
and	18457324
CBR3	18457324
(	18457324
the	18457324
CBR3	18457324
valine	18457324
[	18457324
V	18457324
]	18457324
to	18457324
methionine	18457324
[	18457324
M	18457324
]	18457324
substitution	18457324
at	18457324
position	18457324
244	18457324
[	18457324
V244M	18457324
]	18457324
)	18457324
.	18457324

Enzyme	18457324
activity	18457324
assays	18457324
with	18457324
recombinant	18457324
CBR3	18457324
isoforms	18457324
(	18457324
CBR3	18457324
V244	18457324
and	18457324
CBR3	18457324
M244	18457324
)	18457324
and	18457324
the	18457324
anthracycline	18457324
substrate	18457324
doxorubicin	18457324
were	18457324
used	18457324
to	18457324
investigate	18457324
the	18457324
functional	18457324
impact	18457324
of	18457324
the	18457324
CBR3	18457324
V244M	18457324
polymorphism	18457324
.	18457324

RESULTS	18457324
:	18457324
Multivariate	18457324
analyses	18457324
adjusted	18457324
for	18457324
sex	18457324
and	18457324
primary	18457324
disease	18457324
recurrence	18457324
were	18457324
used	18457324
to	18457324
test	18457324
for	18457324
associations	18457324
between	18457324
the	18457324
candidate	18457324
genetic	18457324
polymorphisms	18457324
(	18457324
NQO1	18457324
*	18457324
2	18457324
and	18457324
CBR3	18457324
V244M	18457324
)	18457324
and	18457324
the	18457324
risk	18457324
of	18457324
CHF	18457324
.	18457324

Analyses	18457324
indicated	18457324
no	18457324
association	18457324
between	18457324
the	18457324
NQO1	18457324
*	18457324
2	18457324
polymorphism	18457324
and	18457324
the	18457324
risk	18457324
of	18457324
anthracycline	18457324
-	18457324
related	18457324
CHF	18457324
(	18457324
odds	18457324
ratio	18457324
[	18457324
OR	18457324
]	18457324
,	18457324
1	18457324
.	18457324
04	18457324
;	18457324
P	18457324
=	18457324
.	18457324
97	18457324
)	18457324
.	18457324

There	18457324
was	18457324
a	18457324
trend	18457324
toward	18457324
an	18457324
association	18457324
between	18457324
the	18457324
CBR3	18457324
V244M	18457324
polymorphism	18457324
and	18457324
the	18457324
risk	18457324
of	18457324
CHF	18457324
(	18457324
OR	18457324
,	18457324
8	18457324
.	18457324
16	18457324
;	18457324
P	18457324
=	18457324
.	18457324
056	18457324
for	18457324
G	18457324
/	18457324
G	18457324
vs	18457324
A	18457324
/	18457324
A	18457324
;	18457324
OR	18457324
,	18457324
5	18457324
.	18457324
44	18457324
;	18457324
P	18457324
=	18457324
.	18457324
092	18457324
for	18457324
G	18457324
/	18457324
A	18457324
vs	18457324
A	18457324
/	18457324
A	18457324
)	18457324
.	18457324

In	18457324
line	18457324
,	18457324
recombinant	18457324
CBR3	18457324
V244	18457324
(	18457324
G	18457324
allele	18457324
)	18457324
synthesized	18457324
2	18457324
.	18457324
6	18457324
-	18457324
fold	18457324
more	18457324
cardiotoxic	18457324
doxorubicinol	18457324
per	18457324
unit	18457324
of	18457324
time	18457324
than	18457324
CBR3	18457324
M244	18457324
(	18457324
A	18457324
allele	18457324
;	18457324
CBR3	18457324
V244	18457324
[	18457324
8	18457324
.	18457324
26	18457324
+	18457324
/	18457324
-	18457324
3	18457324
.	18457324
57	18457324
nmol	18457324
/	18457324
hour	18457324
.	18457324
mg	18457324
]	18457324
vs	18457324
CBR3	18457324
M244	18457324
[	18457324
3	18457324
.	18457324
22	18457324
+	18457324
/	18457324
-	18457324
0	18457324
.	18457324
67	18457324
nmol	18457324
/	18457324
hour	18457324
.	18457324
mg	18457324
]	18457324
;	18457324
P	18457324
=	18457324
.	18457324
01	18457324
)	18457324
.	18457324

CONCLUSIONS	18457324
:	18457324
The	18457324
functional	18457324
CBR3	18457324
V244M	18457324
polymorphism	18457324
may	18457324
have	18457324
an	18457324
impact	18457324
on	18457324
the	18457324
risk	18457324
of	18457324
anthracycline	18457324
-	18457324
related	18457324
CHF	18457324
among	18457324
childhood	18457324
cancer	18457324
survivors	18457324
by	18457324
modulating	18457324
the	18457324
intracardiac	18457324
formation	18457324
of	18457324
cardiotoxic	18457324
anthracycline	18457324
alcohol	18457324
metabolites	18457324
.	18457324

Larger	18457324
confirmatory	18457324
case	18457324
-	18457324
control	18457324
studies	18457324
are	18457324
warranted	18457324
.	18457324
A	17006606
polymorphism	17006606
of	17006606
C	17006606
-	17006606
to	17006606
-	17006606
T	17006606
substitution	17006606
at	17006606
-	17006606
31	17006606
IL1B	17006606
is	17006606
associated	17006606
with	17006606
the	17006606
risk	17006606
of	17006606
advanced	17006606
gastric	17006606
adenocarcinoma	17006606
in	17006606
a	17006606
Japanese	17006606
population	17006606
.	17006606

Proinflammatory	17006606
cytokine	17006606
gene	17006606
polymorphisms	17006606
have	17006606
been	17006606
demonstrated	17006606
to	17006606
associate	17006606
with	17006606
gastric	17006606
cancer	17006606
risk	17006606
,	17006606
of	17006606
which	17006606
IL1B	17006606
-	17006606
31T	17006606
/	17006606
C	17006606
and	17006606
-	17006606
511C	17006606
/	17006606
T	17006606
changes	17006606
have	17006606
been	17006606
well	17006606
investigated	17006606
due	17006606
to	17006606
the	17006606
possibility	17006606
that	17006606
they	17006606
may	17006606
alter	17006606
the	17006606
IL1B	17006606
transcription	17006606
.	17006606

The	17006606
signal	17006606
transduction	17006606
target	17006606
upon	17006606
interleukin	17006606
1	17006606
beta	17006606
(	17006606
IL1beta	17006606
)	17006606
stimulation	17006606
,	17006606
the	17006606
nuclear	17006606
factor	17006606
of	17006606
kappa	17006606
B	17006606
(	17006606
NFkappaB	17006606
)	17006606
activation	17006606
,	17006606
supports	17006606
cancer	17006606
development	17006606
,	17006606
signal	17006606
transduction	17006606
in	17006606
which	17006606
is	17006606
mediated	17006606
by	17006606
FS	17006606
-	17006606
7	17006606
cell	17006606
-	17006606
associated	17006606
cell	17006606
surface	17006606
antigen	17006606
(	17006606
FAS	17006606
)	17006606
signaling	17006606
.	17006606

Based	17006606
on	17006606
recent	17006606
papers	17006606
describing	17006606
the	17006606
prognostic	17006606
roles	17006606
of	17006606
the	17006606
polymorphisms	17006606
and	17006606
the	17006606
NFkappaB	17006606
functions	17006606
on	17006606
cancer	17006606
development	17006606
,	17006606
we	17006606
sought	17006606
to	17006606
determine	17006606
if	17006606
Japanese	17006606
gastric	17006606
cancer	17006606
patients	17006606
were	17006606
affected	17006606
by	17006606
the	17006606
IL1B	17006606
-	17006606
31	17006606
/	17006606
-	17006606
511	17006606
and	17006606
FAS	17006606
-	17006606
670	17006606
polymorphisms	17006606
.	17006606

A	17006606
case	17006606
-	17006606
control	17006606
study	17006606
was	17006606
conducted	17006606
on	17006606
incident	17006606
gastric	17006606
adenocarcinoma	17006606
patients	17006606
(	17006606
n	17006606
=	17006606
271	17006606
)	17006606
and	17006606
age	17006606
-	17006606
gender	17006606
frequency	17006606
-	17006606
matched	17006606
control	17006606
subjects	17006606
(	17006606
n	17006606
=	17006606
271	17006606
)	17006606
.	17006606

We	17006606
observed	17006606
strong	17006606
linkage	17006606
disequilibrium	17006606
between	17006606
the	17006606
T	17006606
allele	17006606
at	17006606
-	17006606
511	17006606
and	17006606
the	17006606
C	17006606
allele	17006606
at	17006606
-	17006606
31	17006606
and	17006606
between	17006606
the	17006606
C	17006606
allele	17006606
at	17006606
-	17006606
511	17006606
and	17006606
the	17006606
T	17006606
allele	17006606
at	17006606
-	17006606
31	17006606
in	17006606
IL1B	17006606
in	17006606
both	17006606
the	17006606
cases	17006606
and	17006606
controls	17006606
(	17006606
R	17006606
(	17006606
2	17006606
)	17006606
=	17006606
0	17006606
.	17006606
94	17006606
)	17006606
.	17006606

Neither	17006606
IL1B	17006606
-	17006606
31	17006606
,	17006606
-	17006606
511	17006606
nor	17006606
FAS	17006606
-	17006606
670	17006606
polymorphisms	17006606
showed	17006606
significantly	17006606
different	17006606
risks	17006606
of	17006606
gastric	17006606
adenocarcinoma	17006606
.	17006606

Though	17006606
FAS	17006606
-	17006606
670	17006606
polymorphisms	17006606
did	17006606
not	17006606
show	17006606
any	17006606
significant	17006606
difference	17006606
,	17006606
the	17006606
proportion	17006606
of	17006606
subjects	17006606
with	17006606
IL1B	17006606
-	17006606
31TT	17006606
(	17006606
or	17006606
IL1B	17006606
-	17006606
511CC	17006606
)	17006606
increased	17006606
according	17006606
to	17006606
stage	17006606
(	17006606
trend	17006606
P	17006606
=	17006606
0	17006606
.	17006606
019	17006606
)	17006606
.	17006606

In	17006606
particular	17006606
,	17006606
subjects	17006606
with	17006606
stage	17006606
IV	17006606
had	17006606
a	17006606
two	17006606
times	17006606
higher	17006606
probability	17006606
of	17006606
having	17006606
either	17006606
IL1B	17006606
-	17006606
31TT	17006606
(	17006606
or	17006606
IL1B	17006606
-	17006606
511CC	17006606
)	17006606
genotype	17006606
compared	17006606
with	17006606
stage	17006606
I	17006606
subjects	17006606
.	17006606

These	17006606
observations	17006606
suggest	17006606
that	17006606
IL1B	17006606
-	17006606
31TT	17006606
and	17006606
IL1B	17006606
-	17006606
511CC	17006606
are	17006606
associated	17006606
with	17006606
disease	17006606
progression	17006606
.	17006606
On	27103577
the	27103577
pivotal	27103577
role	27103577
of	27103577
PPARa	27103577
in	27103577
adaptation	27103577
of	27103577
the	27103577
heart	27103577
to	27103577
hypoxia	27103577
and	27103577
why	27103577
fat	27103577
in	27103577
the	27103577
diet	27103577
increases	27103577
hypoxic	27103577
injury	27103577
.	27103577

The	27103577
role	27103577
of	27103577
peroxisome	27103577
proliferator	27103577
-	27103577
activated	27103577
receptor	27103577
a	27103577
(	27103577
PPARa	27103577
)	27103577
-	27103577
mediated	27103577
metabolic	27103577
remodeling	27103577
in	27103577
cardiac	27103577
adaptation	27103577
to	27103577
hypoxia	27103577
has	27103577
yet	27103577
to	27103577
be	27103577
defined	27103577
.	27103577

Here	27103577
,	27103577
mice	27103577
were	27103577
housed	27103577
in	27103577
hypoxia	27103577
for	27103577
3	27103577
wk	27103577
before	27103577
in	27103577
vivo	27103577
contractile	27103577
function	27103577
was	27103577
measured	27103577
using	27103577
cine	27103577
MRI	27103577
.	27103577

In	27103577
isolated	27103577
,	27103577
perfused	27103577
hearts	27103577
,	27103577
energetics	27103577
were	27103577
measured	27103577
using	27103577
(	27103577
31	27103577
)	27103577
P	27103577
magnetic	27103577
resonance	27103577
spectroscopy	27103577
(	27103577
MRS	27103577
)	27103577
,	27103577
and	27103577
glycolysis	27103577
and	27103577
fatty	27103577
acid	27103577
oxidation	27103577
were	27103577
measured	27103577
using	27103577
[	27103577
(	27103577
3	27103577
)	27103577
H	27103577
]	27103577
labeling	27103577
.	27103577

Compared	27103577
with	27103577
a	27103577
normoxic	27103577
,	27103577
chow	27103577
-	27103577
fed	27103577
control	27103577
mouse	27103577
heart	27103577
,	27103577
hypoxia	27103577
decreased	27103577
PPARa	27103577
expression	27103577
,	27103577
fatty	27103577
acid	27103577
oxidation	27103577
,	27103577
and	27103577
mitochondrial	27103577
uncoupling	27103577
protein	27103577
3	27103577
(	27103577
UCP3	27103577
)	27103577
levels	27103577
,	27103577
while	27103577
increasing	27103577
glycolysis	27103577
,	27103577
all	27103577
of	27103577
which	27103577
served	27103577
to	27103577
maintain	27103577
normal	27103577
ATP	27103577
concentrations	27103577
(	27103577
[	27103577
ATP	27103577
]	27103577
)	27103577
and	27103577
thereby	27103577
,	27103577
ejection	27103577
fractions	27103577
.	27103577

A	27103577
high	27103577
-	27103577
fat	27103577
diet	27103577
increased	27103577
cardiac	27103577
PPARa	27103577
expression	27103577
,	27103577
fatty	27103577
acid	27103577
oxidation	27103577
,	27103577
and	27103577
UCP3	27103577
levels	27103577
with	27103577
decreased	27103577
glycolysis	27103577
.	27103577

Hypoxia	27103577
was	27103577
unable	27103577
to	27103577
alter	27103577
the	27103577
high	27103577
PPARa	27103577
expression	27103577
or	27103577
reverse	27103577
the	27103577
metabolic	27103577
changes	27103577
caused	27103577
by	27103577
the	27103577
high	27103577
-	27103577
fat	27103577
diet	27103577
,	27103577
with	27103577
the	27103577
result	27103577
that	27103577
[	27103577
ATP	27103577
]	27103577
and	27103577
contractile	27103577
function	27103577
decreased	27103577
significantly	27103577
.	27103577

The	27103577
adaptive	27103577
metabolic	27103577
changes	27103577
caused	27103577
by	27103577
hypoxia	27103577
in	27103577
control	27103577
mouse	27103577
hearts	27103577
were	27103577
found	27103577
to	27103577
have	27103577
occurred	27103577
already	27103577
in	27103577
PPARa	27103577
-	27103577
deficient	27103577
(	27103577
PPARa	27103577
(	27103577
-	27103577
/	27103577
-	27103577
)	27103577
)	27103577
mouse	27103577
hearts	27103577
and	27103577
sustained	27103577
function	27103577
in	27103577
hypoxia	27103577
despite	27103577
an	27103577
inability	27103577
for	27103577
further	27103577
metabolic	27103577
remodeling	27103577
.	27103577

We	27103577
conclude	27103577
that	27103577
decreased	27103577
cardiac	27103577
PPARa	27103577
expression	27103577
is	27103577
essential	27103577
for	27103577
adaptive	27103577
metabolic	27103577
remodeling	27103577
in	27103577
hypoxia	27103577
,	27103577
but	27103577
is	27103577
prevented	27103577
by	27103577
dietary	27103577
fat	27103577
.	27103577
-	27103577
Cole	27103577
,	27103577
M	27103577
.	27103577

A	27103577
.	27103577
,	27103577
Abd	27103577
Jamil	27103577
,	27103577
A	27103577
.	27103577

H	27103577
.	27103577
,	27103577
Heather	27103577
,	27103577
L	27103577
.	27103577

C	27103577
.	27103577
,	27103577
Murray	27103577
,	27103577
A	27103577
.	27103577

J	27103577
.	27103577
,	27103577
Sutton	27103577
,	27103577
E	27103577
.	27103577

R	27103577
.	27103577
,	27103577
Slingo	27103577
,	27103577
M	27103577
.	27103577
,	27103577
Sebag	27103577
-	27103577
Montefiore	27103577
,	27103577
L	27103577
.	27103577
,	27103577
Tan	27103577
,	27103577
S	27103577
.	27103577

C	27103577
.	27103577
,	27103577
Aksentijevic	27103577
,	27103577
D	27103577
.	27103577
,	27103577
Gildea	27103577
,	27103577
O	27103577
.	27103577

S	27103577
.	27103577
,	27103577
Stuckey	27103577
,	27103577
D	27103577
.	27103577

J	27103577
.	27103577
,	27103577
Yeoh	27103577
,	27103577
K	27103577
.	27103577

K	27103577
.	27103577
,	27103577
Carr	27103577
,	27103577
C	27103577
.	27103577

A	27103577
.	27103577
,	27103577
Evans	27103577
,	27103577
R	27103577
.	27103577

D	27103577
.	27103577
,	27103577
Aasum	27103577
,	27103577
E	27103577
.	27103577
,	27103577
Schofield	27103577
,	27103577
C	27103577
.	27103577

J	27103577
.	27103577
,	27103577
Ratcliffe	27103577
,	27103577
P	27103577
.	27103577

J	27103577
.	27103577
,	27103577
Neubauer	27103577
,	27103577
S	27103577
.	27103577
,	27103577
Robbins	27103577
,	27103577
P	27103577
.	27103577

A	27103577
.	27103577
,	27103577
Clarke	27103577
,	27103577
K	27103577
.	27103577

On	27103577
the	27103577
pivotal	27103577
role	27103577
of	27103577
PPARa	27103577
in	27103577
adaptation	27103577
of	27103577
the	27103577
heart	27103577
to	27103577
hypoxia	27103577
and	27103577
why	27103577
fat	27103577
in	27103577
the	27103577
diet	27103577
increases	27103577
hypoxic	27103577
injury	27103577
.	27103577
High	19996135
-	19996135
dose	19996135
tranexamic	19996135
Acid	19996135
is	19996135
associated	19996135
with	19996135
nonischemic	19996135
clinical	19996135
seizures	19996135
in	19996135
cardiac	19996135
surgical	19996135
patients	19996135
.	19996135

BACKGROUND	19996135
:	19996135
In	19996135
2	19996135
separate	19996135
centers	19996135
,	19996135
we	19996135
observed	19996135
a	19996135
notable	19996135
increase	19996135
in	19996135
the	19996135
incidence	19996135
of	19996135
postoperative	19996135
convulsive	19996135
seizures	19996135
from	19996135
1	19996135
.	19996135
3%	19996135
to	19996135
3	19996135
.	19996135
8%	19996135
in	19996135
patients	19996135
having	19996135
undergone	19996135
major	19996135
cardiac	19996135
surgical	19996135
procedures	19996135
.	19996135

These	19996135
events	19996135
were	19996135
temporally	19996135
coincident	19996135
with	19996135
the	19996135
initial	19996135
use	19996135
of	19996135
high	19996135
-	19996135
dose	19996135
tranexamic	19996135
acid	19996135
(	19996135
TXA	19996135
)	19996135
therapy	19996135
after	19996135
withdrawal	19996135
of	19996135
aprotinin	19996135
from	19996135
general	19996135
clinical	19996135
usage	19996135
.	19996135

The	19996135
purpose	19996135
of	19996135
this	19996135
review	19996135
was	19996135
to	19996135
perform	19996135
a	19996135
retrospective	19996135
analysis	19996135
to	19996135
examine	19996135
whether	19996135
there	19996135
was	19996135
a	19996135
relation	19996135
between	19996135
TXA	19996135
usage	19996135
and	19996135
seizures	19996135
after	19996135
cardiac	19996135
surgery	19996135
.	19996135

METHODS	19996135
:	19996135
An	19996135
in	19996135
-	19996135
depth	19996135
chart	19996135
review	19996135
was	19996135
undertaken	19996135
in	19996135
all	19996135
24	19996135
patients	19996135
who	19996135
developed	19996135
perioperative	19996135
seizures	19996135
.	19996135

Electroencephalographic	19996135
activity	19996135
was	19996135
recorded	19996135
in	19996135
11	19996135
of	19996135
these	19996135
patients	19996135
,	19996135
and	19996135
all	19996135
patients	19996135
had	19996135
a	19996135
formal	19996135
neurological	19996135
evaluation	19996135
and	19996135
brain	19996135
imaging	19996135
studies	19996135
.	19996135

RESULTS	19996135
:	19996135
Twenty	19996135
-	19996135
one	19996135
of	19996135
the	19996135
24	19996135
patients	19996135
did	19996135
not	19996135
have	19996135
evidence	19996135
of	19996135
new	19996135
cerebral	19996135
ischemic	19996135
injury	19996135
,	19996135
but	19996135
seizures	19996135
were	19996135
likely	19996135
due	19996135
to	19996135
ischemic	19996135
brain	19996135
injury	19996135
in	19996135
3	19996135
patients	19996135
.	19996135

All	19996135
patients	19996135
with	19996135
seizures	19996135
did	19996135
not	19996135
have	19996135
permanent	19996135
neurological	19996135
abnormalities	19996135
.	19996135

All	19996135
24	19996135
patients	19996135
with	19996135
seizures	19996135
received	19996135
high	19996135
doses	19996135
of	19996135
TXA	19996135
intraoperatively	19996135
ranging	19996135
from	19996135
61	19996135
to	19996135
259	19996135
mg	19996135
/	19996135
kg	19996135
,	19996135
had	19996135
a	19996135
mean	19996135
age	19996135
of	19996135
69	19996135
.	19996135
9	19996135
years	19996135
,	19996135
and	19996135
21	19996135
of	19996135
24	19996135
had	19996135
undergone	19996135
open	19996135
chamber	19996135
rather	19996135
than	19996135
coronary	19996135
bypass	19996135
procedures	19996135
.	19996135

All	19996135
but	19996135
one	19996135
patient	19996135
were	19996135
managed	19996135
using	19996135
cardiopulmonary	19996135
bypass	19996135
.	19996135

No	19996135
evidence	19996135
of	19996135
brain	19996135
ischemic	19996135
,	19996135
metabolic	19996135
,	19996135
or	19996135
hyperthermia	19996135
-	19996135
induced	19996135
causes	19996135
for	19996135
their	19996135
seizures	19996135
was	19996135
apparent	19996135
.	19996135

CONCLUSION	19996135
:	19996135
Our	19996135
results	19996135
suggest	19996135
that	19996135
use	19996135
of	19996135
high	19996135
-	19996135
dose	19996135
TXA	19996135
in	19996135
older	19996135
patients	19996135
in	19996135
conjunction	19996135
with	19996135
cardiopulmonary	19996135
bypass	19996135
and	19996135
open	19996135
-	19996135
chamber	19996135
cardiac	19996135
surgery	19996135
is	19996135
associated	19996135
with	19996135
clinical	19996135
seizures	19996135
in	19996135
susceptible	19996135
patients	19996135
.	19996135
Cardioprotective	15233872
effect	15233872
of	15233872
tincture	15233872
of	15233872
Crataegus	15233872
on	15233872
isoproterenol	15233872
-	15233872
induced	15233872
myocardial	15233872
infarction	15233872
in	15233872
rats	15233872
.	15233872

Tincture	15233872
of	15233872
Crataegus	15233872
(	15233872
TCR	15233872
)	15233872
,	15233872
an	15233872
alcoholic	15233872
extract	15233872
of	15233872
the	15233872
berries	15233872
of	15233872
hawthorn	15233872
(	15233872
Crataegus	15233872
oxycantha	15233872
)	15233872
,	15233872
is	15233872
used	15233872
in	15233872
herbal	15233872
and	15233872
homeopathic	15233872
medicine	15233872
.	15233872

The	15233872
present	15233872
study	15233872
was	15233872
done	15233872
to	15233872
investigate	15233872
the	15233872
protective	15233872
effect	15233872
of	15233872
TCR	15233872
on	15233872
experimentally	15233872
induced	15233872
myocardial	15233872
infarction	15233872
in	15233872
rats	15233872
.	15233872

Pretreatment	15233872
of	15233872
TCR	15233872
,	15233872
at	15233872
a	15233872
dose	15233872
of	15233872
0	15233872
.	15233872
5	15233872
mL	15233872
/	15233872
100	15233872
g	15233872
bodyweight	15233872
per	15233872
day	15233872
,	15233872
orally	15233872
for	15233872
30	15233872
days	15233872
,	15233872
prevented	15233872
the	15233872
increase	15233872
in	15233872
lipid	15233872
peroxidation	15233872
and	15233872
activity	15233872
of	15233872
marker	15233872
enzymes	15233872
observed	15233872
in	15233872
isoproterenol	15233872
-	15233872
induced	15233872
rats	15233872
(	15233872
85	15233872
mg	15233872
kg	15233872
(	15233872
-	15233872
1	15233872
)	15233872
s	15233872
.	15233872

c	15233872
.	15233872

for	15233872
2	15233872
days	15233872
at	15233872
an	15233872
interval	15233872
of	15233872
24	15233872
h	15233872
)	15233872
.	15233872

TCR	15233872
prevented	15233872
the	15233872
isoproterenol	15233872
-	15233872
induced	15233872
decrease	15233872
in	15233872
antioxidant	15233872
enzymes	15233872
in	15233872
the	15233872
heart	15233872
and	15233872
increased	15233872
the	15233872
rate	15233872
of	15233872
ADP	15233872
-	15233872
stimulated	15233872
oxygen	15233872
uptake	15233872
and	15233872
respiratory	15233872
coupling	15233872
ratio	15233872
.	15233872

TCR	15233872
protected	15233872
against	15233872
pathological	15233872
changes	15233872
induced	15233872
by	15233872
isoproterenol	15233872
in	15233872
rat	15233872
heart	15233872
.	15233872

The	15233872
results	15233872
show	15233872
that	15233872
pretreatment	15233872
with	15233872
TCR	15233872
may	15233872
be	15233872
useful	15233872
in	15233872
preventing	15233872
the	15233872
damage	15233872
induced	15233872
by	15233872
isoproterenol	15233872
in	15233872
rat	15233872
heart	15233872
.	15233872
Transgelin	26847345
increases	26847345
metastatic	26847345
potential	26847345
of	26847345
colorectal	26847345
cancer	26847345
cells	26847345
in	26847345
vivo	26847345
and	26847345
alters	26847345
expression	26847345
of	26847345
genes	26847345
involved	26847345
in	26847345
cell	26847345
motility	26847345
.	26847345

BACKGROUND	26847345
:	26847345
Transgelin	26847345
is	26847345
an	26847345
actin	26847345
-	26847345
binding	26847345
protein	26847345
that	26847345
promotes	26847345
motility	26847345
in	26847345
normal	26847345
cells	26847345
.	26847345

Although	26847345
the	26847345
role	26847345
of	26847345
transgelin	26847345
in	26847345
cancer	26847345
is	26847345
controversial	26847345
,	26847345
a	26847345
number	26847345
of	26847345
studies	26847345
have	26847345
shown	26847345
that	26847345
elevated	26847345
levels	26847345
correlate	26847345
with	26847345
aggressive	26847345
tumor	26847345
behavior	26847345
,	26847345
advanced	26847345
stage	26847345
,	26847345
and	26847345
poor	26847345
prognosis	26847345
.	26847345

Here	26847345
we	26847345
sought	26847345
to	26847345
determine	26847345
the	26847345
role	26847345
of	26847345
transgelin	26847345
more	26847345
directly	26847345
by	26847345
determining	26847345
whether	26847345
experimental	26847345
manipulation	26847345
of	26847345
transgelin	26847345
levels	26847345
in	26847345
colorectal	26847345
cancer	26847345
(	26847345
CRC	26847345
)	26847345
cells	26847345
led	26847345
to	26847345
changes	26847345
in	26847345
metastatic	26847345
potential	26847345
in	26847345
vivo	26847345
.	26847345

METHODS	26847345
:	26847345
Isogenic	26847345
CRC	26847345
cell	26847345
lines	26847345
that	26847345
differ	26847345
in	26847345
transgelin	26847345
expression	26847345
were	26847345
characterized	26847345
using	26847345
in	26847345
vitro	26847345
assays	26847345
of	26847345
growth	26847345
and	26847345
invasiveness	26847345
and	26847345
a	26847345
mouse	26847345
tail	26847345
vein	26847345
assay	26847345
of	26847345
experimental	26847345
metastasis	26847345
.	26847345

Downstream	26847345
effects	26847345
of	26847345
transgelin	26847345
overexpression	26847345
were	26847345
investigated	26847345
by	26847345
gene	26847345
expression	26847345
profiling	26847345
and	26847345
quantitative	26847345
PCR	26847345
.	26847345

RESULTS	26847345
:	26847345
Stable	26847345
overexpression	26847345
of	26847345
transgelin	26847345
in	26847345
RKO	26847345
cells	26847345
,	26847345
which	26847345
have	26847345
low	26847345
endogenous	26847345
levels	26847345
,	26847345
led	26847345
to	26847345
increased	26847345
invasiveness	26847345
,	26847345
growth	26847345
at	26847345
low	26847345
density	26847345
,	26847345
and	26847345
growth	26847345
in	26847345
soft	26847345
agar	26847345
.	26847345

Overexpression	26847345
also	26847345
led	26847345
to	26847345
an	26847345
increase	26847345
in	26847345
the	26847345
number	26847345
and	26847345
size	26847345
of	26847345
lung	26847345
metastases	26847345
in	26847345
the	26847345
mouse	26847345
tail	26847345
vein	26847345
injection	26847345
model	26847345
.	26847345

Similarly	26847345
,	26847345
attenuation	26847345
of	26847345
transgelin	26847345
expression	26847345
in	26847345
HCT116	26847345
cells	26847345
,	26847345
which	26847345
have	26847345
high	26847345
endogenous	26847345
levels	26847345
,	26847345
decreased	26847345
metastases	26847345
in	26847345
the	26847345
same	26847345
model	26847345
.	26847345

Investigation	26847345
of	26847345
mRNA	26847345
expression	26847345
patterns	26847345
showed	26847345
that	26847345
transgelin	26847345
overexpression	26847345
altered	26847345
the	26847345
levels	26847345
of	26847345
approximately	26847345
250	26847345
other	26847345
transcripts	26847345
,	26847345
with	26847345
over	26847345
-	26847345
representation	26847345
of	26847345
genes	26847345
that	26847345
affect	26847345
function	26847345
of	26847345
actin	26847345
or	26847345
other	26847345
cytoskeletal	26847345
proteins	26847345
.	26847345

Changes	26847345
included	26847345
increases	26847345
in	26847345
HOOK1	26847345
,	26847345
SDCCAG8	26847345
,	26847345
ENAH	26847345
/	26847345
Mena	26847345
,	26847345
and	26847345
TNS1	26847345
and	26847345
decreases	26847345
in	26847345
EMB	26847345
,	26847345
BCL11B	26847345
,	26847345
and	26847345
PTPRD	26847345
.	26847345

CONCLUSIONS	26847345
:	26847345
Increases	26847345
or	26847345
decreases	26847345
in	26847345
transgelin	26847345
levels	26847345
have	26847345
reciprocal	26847345
effects	26847345
on	26847345
tumor	26847345
cell	26847345
behavior	26847345
,	26847345
with	26847345
higher	26847345
expression	26847345
promoting	26847345
metastasis	26847345
.	26847345

Chronic	26847345
overexpression	26847345
influences	26847345
steady	26847345
-	26847345
state	26847345
levels	26847345
of	26847345
mRNAs	26847345
for	26847345
metastasis	26847345
-	26847345
related	26847345
genes	26847345
.	26847345
Vitamin	20415560
E	20415560
reduces	20415560
cardiovascular	20415560
disease	20415560
in	20415560
individuals	20415560
with	20415560
diabetes	20415560
mellitus	20415560
and	20415560
the	20415560
haptoglobin	20415560
2	20415560
-	20415560
2	20415560
genotype	20415560
.	20415560

AIMS	20415560
:	20415560
Individuals	20415560
with	20415560
both	20415560
diabetes	20415560
mellitus	20415560
(	20415560
DM	20415560
)	20415560
and	20415560
the	20415560
Haptoglobin	20415560
(	20415560
Hp	20415560
)	20415560
2	20415560
-	20415560
2	20415560
genotype	20415560
are	20415560
at	20415560
increased	20415560
risk	20415560
of	20415560
cardiovascular	20415560
disease	20415560
.	20415560

As	20415560
the	20415560
antioxidant	20415560
function	20415560
of	20415560
the	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
protein	20415560
is	20415560
impaired	20415560
,	20415560
we	20415560
sought	20415560
to	20415560
test	20415560
the	20415560
pharmacogenomic	20415560
hypothesis	20415560
that	20415560
antioxidant	20415560
vitamin	20415560
E	20415560
supplementation	20415560
would	20415560
provide	20415560
cardiovascular	20415560
protection	20415560
to	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
DM	20415560
individuals	20415560
.	20415560

MATERIALS	20415560
&	20415560
METHODS	20415560
:	20415560
We	20415560
determined	20415560
the	20415560
Hp	20415560
genotype	20415560
on	20415560
DM	20415560
participants	20415560
from	20415560
two	20415560
trials	20415560
(	20415560
HOPE	20415560
and	20415560
ICARE	20415560
)	20415560
and	20415560
assessed	20415560
the	20415560
effect	20415560
of	20415560
vitamin	20415560
E	20415560
by	20415560
Hp	20415560
genotype	20415560
on	20415560
their	20415560
common	20415560
prespecified	20415560
outcome	20415560
,	20415560
the	20415560
composite	20415560
of	20415560
stroke	20415560
,	20415560
myocardial	20415560
infarction	20415560
and	20415560
cardiovascular	20415560
death	20415560
.	20415560

Data	20415560
was	20415560
analyzed	20415560
with	20415560
a	20415560
fixed	20415560
-	20415560
effect	20415560
model	20415560
.	20415560

These	20415560
results	20415560
were	20415560
input	20415560
into	20415560
a	20415560
simulation	20415560
model	20415560
,	20415560
the	20415560
Evidence	20415560
Based	20415560
Medicine	20415560
Integrator	20415560
,	20415560
in	20415560
order	20415560
to	20415560
estimate	20415560
their	20415560
long	20415560
-	20415560
term	20415560
implications	20415560
in	20415560
a	20415560
real	20415560
-	20415560
world	20415560
population	20415560
from	20415560
Kaiser	20415560
Permanente	20415560
(	20415560
CA	20415560
,	20415560
USA	20415560
)	20415560
.	20415560

RESULTS	20415560
:	20415560
Meta	20415560
-	20415560
analysis	20415560
of	20415560
the	20415560
two	20415560
trials	20415560
demonstrated	20415560
a	20415560
significant	20415560
overall	20415560
reduction	20415560
in	20415560
the	20415560
composite	20415560
end	20415560
point	20415560
in	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
DM	20415560
individuals	20415560
with	20415560
vitamin	20415560
E	20415560
(	20415560
odds	20415560
ratio	20415560
:	20415560
0	20415560
.	20415560
58	20415560
;	20415560
95%	20415560
CI	20415560
:	20415560
0	20415560
.	20415560
40	20415560
-	20415560
0	20415560
.	20415560
86	20415560
;	20415560
p	20415560
=	20415560
0	20415560
.	20415560
006	20415560
)	20415560
.	20415560

There	20415560
was	20415560
a	20415560
statistically	20415560
significant	20415560
interaction	20415560
between	20415560
the	20415560
Hp	20415560
genotype	20415560
and	20415560
vitamin	20415560
E	20415560
on	20415560
the	20415560
composite	20415560
end	20415560
point	20415560
.	20415560

In	20415560
these	20415560
trials	20415560
,	20415560
Hp	20415560
typing	20415560
of	20415560
69	20415560
DM	20415560
individuals	20415560
and	20415560
treating	20415560
those	20415560
with	20415560
the	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
with	20415560
vitamin	20415560
E	20415560
prevented	20415560
one	20415560
myocardial	20415560
infarct	20415560
,	20415560
stroke	20415560
or	20415560
cardiovascular	20415560
death	20415560
.	20415560

Lifelong	20415560
administration	20415560
of	20415560
vitamin	20415560
E	20415560
to	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
DM	20415560
individuals	20415560
in	20415560
the	20415560
Kaiser	20415560
population	20415560
would	20415560
increase	20415560
their	20415560
life	20415560
expectancy	20415560
by	20415560
3	20415560
years	20415560
.	20415560

CONCLUSION	20415560
:	20415560
A	20415560
pharmacogenomic	20415560
strategy	20415560
of	20415560
screening	20415560
DM	20415560
individuals	20415560
for	20415560
the	20415560
Hp	20415560
genotype	20415560
and	20415560
treating	20415560
those	20415560
with	20415560
Hp	20415560
2	20415560
-	20415560
2	20415560
with	20415560
vitamin	20415560
E	20415560
appears	20415560
to	20415560
be	20415560
highly	20415560
clinically	20415560
effective	20415560
.	20415560
Clopidogrel	19891556
pharmacogenomics	19891556
and	19891556
risk	19891556
of	19891556
inadequate	19891556
platelet	19891556
inhibition	19891556
:	19891556
US	19891556
FDA	19891556
recommendations	19891556
.	19891556

Antiplatelet	19891556
therapy	19891556
with	19891556
clopidogrel	19891556
is	19891556
the	19891556
current	19891556
standard	19891556
of	19891556
care	19891556
for	19891556
coronary	19891556
artery	19891556
disease	19891556
patients	19891556
undergoing	19891556
a	19891556
percutaneous	19891556
coronary	19891556
intervention	19891556
.	19891556

However	19891556
,	19891556
approximately	19891556
25%	19891556
of	19891556
patients	19891556
experience	19891556
a	19891556
subtherapeutic	19891556
antiplatelet	19891556
response	19891556
.	19891556

Clopidogrel	19891556
is	19891556
a	19891556
prodrug	19891556
that	19891556
undergoes	19891556
hepatic	19891556
biotransformation	19891556
by	19891556
CYP2C19	19891556
into	19891556
its	19891556
active	19891556
metabolite	19891556
.	19891556

Several	19891556
studies	19891556
have	19891556
reported	19891556
that	19891556
,	19891556
compared	19891556
with	19891556
wild	19891556
-	19891556
type	19891556
individuals	19891556
,	19891556
CYP2C19	19891556
variant	19891556
allele	19891556
carriers	19891556
exhibit	19891556
a	19891556
significantly	19891556
lower	19891556
capacity	19891556
to	19891556
metabolize	19891556
clopidogrel	19891556
into	19891556
its	19891556
active	19891556
metabolite	19891556
and	19891556
inhibit	19891556
platelet	19891556
activation	19891556
,	19891556
and	19891556
are	19891556
therefore	19891556
at	19891556
significantly	19891556
higher	19891556
risk	19891556
of	19891556
adverse	19891556
cardiovascular	19891556
events	19891556
.	19891556

Consequently	19891556
,	19891556
the	19891556
US	19891556
FDA	19891556
has	19891556
recently	19891556
changed	19891556
clopidogrel	19891556
'	19891556
s	19891556
prescribing	19891556
information	19891556
to	19891556
highlight	19891556
the	19891556
impact	19891556
of	19891556
CYP2C19	19891556
genotype	19891556
on	19891556
clopidogrel	19891556
pharmacokinetics	19891556
,	19891556
pharmacodynamics	19891556
and	19891556
clinical	19891556
response	19891556
.	19891556

Future	19891556
studies	19891556
remain	19891556
necessary	19891556
to	19891556
develop	19891556
effective	19891556
personalized	19891556
therapeutic	19891556
strategies	19891556
for	19891556
CYP2C19	19891556
variant	19891556
allele	19891556
carriers	19891556
and	19891556
other	19891556
individuals	19891556
at	19891556
risk	19891556
for	19891556
clopidogrel	19891556
nonresponsiveness	19891556
.	19891556
Myc	28368423
enhances	28368423
B	28368423
-	28368423
cell	28368423
receptor	28368423
signaling	28368423
in	28368423
precancerous	28368423
B	28368423
cells	28368423
and	28368423
confers	28368423
resistance	28368423
to	28368423
Btk	28368423
inhibition	28368423
.	28368423

Dysregulation	28368423
of	28368423
the	28368423
oncogenic	28368423
transcription	28368423
factor	28368423
MYC	28368423
induces	28368423
B	28368423
-	28368423
cell	28368423
transformation	28368423
and	28368423
is	28368423
a	28368423
driver	28368423
for	28368423
B	28368423
-	28368423
cell	28368423
non	28368423
-	28368423
Hodgkin	28368423
lymphoma	28368423
(	28368423
B	28368423
-	28368423
NHL	28368423
)	28368423
.	28368423

MYC	28368423
overexpression	28368423
in	28368423
B	28368423
-	28368423
NHL	28368423
is	28368423
associated	28368423
with	28368423
more	28368423
aggressive	28368423
phenotypes	28368423
and	28368423
poor	28368423
prognosis	28368423
.	28368423

Although	28368423
genomic	28368423
studies	28368423
suggest	28368423
a	28368423
link	28368423
between	28368423
MYC	28368423
overexpression	28368423
and	28368423
B	28368423
-	28368423
cell	28368423
receptor	28368423
(	28368423
BCR	28368423
)	28368423
signaling	28368423
molecules	28368423
in	28368423
B	28368423
-	28368423
NHL	28368423
,	28368423
signaling	28368423
pathways	28368423
essential	28368423
to	28368423
Myc	28368423
-	28368423
mediated	28368423
B	28368423
-	28368423
cell	28368423
transformation	28368423
have	28368423
not	28368423
been	28368423
fully	28368423
elucidated	28368423
.	28368423

We	28368423
utilized	28368423
intracellular	28368423
phospho	28368423
-	28368423
flow	28368423
cytometry	28368423
to	28368423
investigate	28368423
the	28368423
relationship	28368423
between	28368423
Myc	28368423
and	28368423
BCR	28368423
signaling	28368423
in	28368423
pre	28368423
-	28368423
malignant	28368423
B	28368423
cells	28368423
.	28368423

Utilizing	28368423
the	28368423
Eu	28368423
-	28368423
myc	28368423
mouse	28368423
model	28368423
,	28368423
where	28368423
Myc	28368423
is	28368423
overexpressed	28368423
specifically	28368423
in	28368423
B	28368423
cells	28368423
,	28368423
both	28368423
basal	28368423
and	28368423
stimulated	28368423
BCR	28368423
signaling	28368423
were	28368423
increased	28368423
in	28368423
precancerous	28368423
B	28368423
lymphocytes	28368423
from	28368423
Eu	28368423
-	28368423
myc	28368423
mice	28368423
compared	28368423
with	28368423
wild	28368423
-	28368423
type	28368423
littermates	28368423
.	28368423

B	28368423
cells	28368423
overexpressing	28368423
Myc	28368423
displayed	28368423
constitutively	28368423
higher	28368423
levels	28368423
of	28368423
activated	28368423
CD79a	28368423
,	28368423
Btk	28368423
,	28368423
Plcg2	28368423
and	28368423
Erk1	28368423
/	28368423
2	28368423
.	28368423

Notably	28368423
,	28368423
Myc	28368423
-	28368423
overexpressing	28368423
B	28368423
cells	28368423
maintained	28368423
elevated	28368423
BCR	28368423
signaling	28368423
despite	28368423
treatment	28368423
with	28368423
ibrutinib	28368423
,	28368423
a	28368423
Bruton	28368423
'	28368423
s	28368423
tyrosine	28368423
kinase	28368423
inhibitor	28368423
.	28368423

Furthermore	28368423
,	28368423
PI3K	28368423
/	28368423
Akt	28368423
pathway	28368423
signaling	28368423
was	28368423
also	28368423
increased	28368423
in	28368423
Eu	28368423
-	28368423
myc	28368423
B	28368423
cells	28368423
,	28368423
and	28368423
this	28368423
increase	28368423
was	28368423
partially	28368423
suppressed	28368423
with	28368423
ibrutinib	28368423
.	28368423

In	28368423
addition	28368423
,	28368423
experiments	28368423
with	28368423
Btk	28368423
-	28368423
null	28368423
B	28368423
cells	28368423
revealed	28368423
off	28368423
-	28368423
target	28368423
effects	28368423
of	28368423
ibrutinib	28368423
on	28368423
BCR	28368423
signaling	28368423
.	28368423

Our	28368423
data	28368423
show	28368423
that	28368423
in	28368423
pre	28368423
-	28368423
malignant	28368423
B	28368423
cells	28368423
,	28368423
Myc	28368423
overexpression	28368423
is	28368423
sufficient	28368423
to	28368423
activate	28368423
BCR	28368423
and	28368423
PI3K	28368423
/	28368423
Akt	28368423
signaling	28368423
pathways	28368423
and	28368423
further	28368423
enhances	28368423
signaling	28368423
following	28368423
BCR	28368423
ligation	28368423
.	28368423

Therefore	28368423
,	28368423
our	28368423
results	28368423
indicate	28368423
that	28368423
precancerous	28368423
B	28368423
cells	28368423
have	28368423
already	28368423
acquired	28368423
enhanced	28368423
survival	28368423
and	28368423
growth	28368423
capabilities	28368423
before	28368423
transformation	28368423
,	28368423
and	28368423
that	28368423
elevated	28368423
MYC	28368423
levels	28368423
confer	28368423
resistance	28368423
to	28368423
pharmacologic	28368423
inhibitors	28368423
of	28368423
BCR	28368423
signaling	28368423
,	28368423
which	28368423
has	28368423
significant	28368423
implications	28368423
for	28368423
B	28368423
-	28368423
NHL	28368423
treatment	28368423
.	28368423
Genetic	18166824
investigation	18166824
of	18166824
four	18166824
meiotic	18166824
genes	18166824
in	18166824
women	18166824
with	18166824
premature	18166824
ovarian	18166824
failure	18166824
.	18166824

OBJECTIVE	18166824
:	18166824
The	18166824
goal	18166824
of	18166824
this	18166824
study	18166824
was	18166824
to	18166824
determine	18166824
whether	18166824
mutations	18166824
of	18166824
meiotic	18166824
genes	18166824
,	18166824
such	18166824
as	18166824
disrupted	18166824
meiotic	18166824
cDNA	18166824
(	18166824
DMC1	18166824
)	18166824
,	18166824
MutS	18166824
homolog	18166824
(	18166824
MSH4	18166824
)	18166824
,	18166824
MSH5	18166824
,	18166824
and	18166824
S	18166824
.	18166824

cerevisiae	18166824
homolog	18166824
(	18166824
SPO11	18166824
)	18166824
,	18166824
were	18166824
associated	18166824
with	18166824
premature	18166824
ovarian	18166824
failure	18166824
(	18166824
POF	18166824
)	18166824
.	18166824

DESIGN	18166824
:	18166824
Case	18166824
-	18166824
control	18166824
study	18166824
.	18166824

METHODS	18166824
:	18166824
Blood	18166824
sampling	18166824
,	18166824
karyotype	18166824
,	18166824
hormonal	18166824
dosage	18166824
,	18166824
ultrasound	18166824
,	18166824
and	18166824
ovarian	18166824
biopsy	18166824
were	18166824
carried	18166824
out	18166824
on	18166824
most	18166824
patients	18166824
.	18166824

However	18166824
,	18166824
the	18166824
main	18166824
outcome	18166824
measure	18166824
was	18166824
the	18166824
sequencing	18166824
of	18166824
genomic	18166824
DNA	18166824
from	18166824
peripheral	18166824
blood	18166824
samples	18166824
of	18166824
41	18166824
women	18166824
with	18166824
POF	18166824
and	18166824
36	18166824
fertile	18166824
women	18166824
(	18166824
controls	18166824
)	18166824
.	18166824

RESULTS	18166824
:	18166824
A	18166824
single	18166824
heterozygous	18166824
missense	18166824
mutation	18166824
,	18166824
substitution	18166824
of	18166824
a	18166824
cytosine	18166824
residue	18166824
with	18166824
thymidine	18166824
in	18166824
exon	18166824
2	18166824
of	18166824
MSH5	18166824
,	18166824
was	18166824
found	18166824
in	18166824
two	18166824
Caucasian	18166824
women	18166824
in	18166824
whom	18166824
POF	18166824
developed	18166824
at	18166824
18	18166824
and	18166824
36	18166824
years	18166824
of	18166824
age	18166824
.	18166824

This	18166824
mutation	18166824
resulted	18166824
in	18166824
replacement	18166824
of	18166824
a	18166824
non	18166824
-	18166824
polar	18166824
amino	18166824
acid	18166824
(	18166824
proline	18166824
)	18166824
with	18166824
a	18166824
polar	18166824
amino	18166824
acid	18166824
(	18166824
serine	18166824
)	18166824
at	18166824
position	18166824
29	18166824
(	18166824
P29S	18166824
)	18166824
.	18166824

Neither	18166824
36	18166824
control	18166824
women	18166824
nor	18166824
39	18166824
other	18166824
patients	18166824
with	18166824
POF	18166824
possessed	18166824
this	18166824
genetic	18166824
perturbation	18166824
.	18166824

Another	18166824
POF	18166824
patient	18166824
of	18166824
African	18166824
origin	18166824
showed	18166824
a	18166824
homozygous	18166824
nucleotide	18166824
change	18166824
in	18166824
the	18166824
tenth	18166824
of	18166824
DMC1	18166824
gene	18166824
that	18166824
led	18166824
to	18166824
an	18166824
alteration	18166824
of	18166824
the	18166824
amino	18166824
acid	18166824
composition	18166824
of	18166824
the	18166824
protein	18166824
(	18166824
M200V	18166824
)	18166824
.	18166824

CONCLUSIONS	18166824
:	18166824
The	18166824
symptoms	18166824
of	18166824
infertility	18166824
observed	18166824
in	18166824
the	18166824
DMC1	18166824
homozygote	18166824
mutation	18166824
carrier	18166824
and	18166824
in	18166824
both	18166824
patients	18166824
with	18166824
a	18166824
heterozygous	18166824
substitution	18166824
in	18166824
exon	18166824
2	18166824
of	18166824
the	18166824
MSH5	18166824
gene	18166824
provide	18166824
indirect	18166824
evidence	18166824
of	18166824
the	18166824
role	18166824
of	18166824
genes	18166824
involved	18166824
in	18166824
meiotic	18166824
recombination	18166824
in	18166824
the	18166824
regulation	18166824
of	18166824
ovarian	18166824
function	18166824
.	18166824

MSH5	18166824
and	18166824
DMC1	18166824
mutations	18166824
may	18166824
be	18166824
one	18166824
explanation	18166824
for	18166824
POF	18166824
,	18166824
albeit	18166824
uncommon	18166824
.	18166824
Nicotine	15991002
antagonizes	15991002
caffeine	15991002
-	15991002
but	15991002
not	15991002
pentylenetetrazole	15991002
-	15991002
induced	15991002
anxiogenic	15991002
effect	15991002
in	15991002
mice	15991002
.	15991002

RATIONALE	15991002
:	15991002
Nicotine	15991002
and	15991002
caffeine	15991002
are	15991002
widely	15991002
consumed	15991002
licit	15991002
psychoactive	15991002
drugs	15991002
worldwide	15991002
.	15991002

Epidemiological	15991002
studies	15991002
showed	15991002
that	15991002
they	15991002
were	15991002
generally	15991002
used	15991002
concurrently	15991002
.	15991002

Although	15991002
some	15991002
studies	15991002
in	15991002
experimental	15991002
animals	15991002
indicate	15991002
clear	15991002
pharmacological	15991002
interactions	15991002
between	15991002
them	15991002
,	15991002
no	15991002
studies	15991002
have	15991002
shown	15991002
a	15991002
specific	15991002
interaction	15991002
on	15991002
anxiety	15991002
responses	15991002
.	15991002

OBJECTIVES	15991002
:	15991002
The	15991002
present	15991002
study	15991002
investigates	15991002
the	15991002
effects	15991002
of	15991002
nicotine	15991002
on	15991002
anxiety	15991002
induced	15991002
by	15991002
caffeine	15991002
and	15991002
another	15991002
anxiogenic	15991002
drug	15991002
,	15991002
pentylenetetrazole	15991002
,	15991002
in	15991002
mice	15991002
.	15991002

The	15991002
elevated	15991002
plus	15991002
-	15991002
maze	15991002
(	15991002
EPM	15991002
)	15991002
test	15991002
was	15991002
used	15991002
to	15991002
evaluate	15991002
the	15991002
effects	15991002
of	15991002
drugs	15991002
on	15991002
anxiety	15991002
.	15991002

METHODS	15991002
:	15991002
Adult	15991002
male	15991002
Swiss	15991002
Webster	15991002
mice	15991002
(	15991002
25	15991002
-	15991002
32	15991002
g	15991002
)	15991002
were	15991002
given	15991002
nicotine	15991002
(	15991002
0	15991002
.	15991002
05	15991002
-	15991002
0	15991002
.	15991002
25	15991002
mg	15991002
/	15991002
kg	15991002
s	15991002
.	15991002
c	15991002
.	15991002
)	15991002
or	15991002
saline	15991002
10	15991002
min	15991002
before	15991002
caffeine	15991002
(	15991002
70	15991002
mg	15991002
/	15991002
kg	15991002
i	15991002
.	15991002
p	15991002
.	15991002
)	15991002
or	15991002
pentylenetetrazole	15991002
(	15991002
15	15991002
and	15991002
30	15991002
mg	15991002
/	15991002
kg	15991002
i	15991002
.	15991002
p	15991002
.	15991002
)	15991002
injections	15991002
.	15991002

After	15991002
15	15991002
min	15991002
,	15991002
mice	15991002
were	15991002
evaluated	15991002
for	15991002
their	15991002
open	15991002
-	15991002
and	15991002
closed	15991002
-	15991002
arm	15991002
time	15991002
and	15991002
entries	15991002
on	15991002
the	15991002
EPM	15991002
for	15991002
a	15991002
10	15991002
-	15991002
min	15991002
session	15991002
.	15991002

Locomotor	15991002
activity	15991002
was	15991002
recorded	15991002
for	15991002
individual	15991002
groups	15991002
by	15991002
using	15991002
the	15991002
same	15991002
treatment	15991002
protocol	15991002
with	15991002
the	15991002
EPM	15991002
test	15991002
.	15991002

RESULTS	15991002
:	15991002
Nicotine	15991002
(	15991002
0	15991002
.	15991002
05	15991002
-	15991002
0	15991002
.	15991002
25	15991002
mg	15991002
/	15991002
kg	15991002
)	15991002
itself	15991002
did	15991002
not	15991002
produce	15991002
any	15991002
significant	15991002
effect	15991002
in	15991002
the	15991002
EPM	15991002
test	15991002
,	15991002
whereas	15991002
caffeine	15991002
(	15991002
70	15991002
mg	15991002
/	15991002
kg	15991002
)	15991002
and	15991002
pentylenetetrazole	15991002
(	15991002
30	15991002
mg	15991002
/	15991002
kg	15991002
)	15991002
produced	15991002
an	15991002
anxiogenic	15991002
effect	15991002
,	15991002
apparent	15991002
with	15991002
decreases	15991002
in	15991002
open	15991002
-	15991002
arm	15991002
time	15991002
and	15991002
entry	15991002
.	15991002

Nicotine	15991002
(	15991002
0	15991002
.	15991002
25	15991002
mg	15991002
/	15991002
kg	15991002
)	15991002
pretreatment	15991002
blocked	15991002
the	15991002
caffeine	15991002
-	15991002
but	15991002
not	15991002
pentylenetetrazole	15991002
-	15991002
induced	15991002
anxiety	15991002
.	15991002

Administration	15991002
of	15991002
each	15991002
drug	15991002
and	15991002
their	15991002
combinations	15991002
did	15991002
not	15991002
produce	15991002
any	15991002
effect	15991002
on	15991002
locomotor	15991002
activity	15991002
.	15991002

CONCLUSIONS	15991002
:	15991002
Our	15991002
results	15991002
suggest	15991002
that	15991002
the	15991002
antagonistic	15991002
effect	15991002
of	15991002
nicotine	15991002
on	15991002
caffeine	15991002
-	15991002
induced	15991002
anxiety	15991002
is	15991002
specific	15991002
to	15991002
caffeine	15991002
,	15991002
instead	15991002
of	15991002
a	15991002
non	15991002
-	15991002
specific	15991002
anxiolytic	15991002
effect	15991002
.	15991002

Thus	15991002
,	15991002
it	15991002
may	15991002
extend	15991002
the	15991002
current	15991002
findings	15991002
on	15991002
the	15991002
interaction	15991002
between	15991002
nicotine	15991002
and	15991002
caffeine	15991002
.	15991002
Behavioral	17194457
effects	17194457
of	17194457
pubertal	17194457
anabolic	17194457
androgenic	17194457
steroid	17194457
exposure	17194457
in	17194457
male	17194457
rats	17194457
with	17194457
low	17194457
serotonin	17194457
.	17194457

The	17194457
goal	17194457
of	17194457
this	17194457
study	17194457
was	17194457
to	17194457
assess	17194457
the	17194457
interactive	17194457
effects	17194457
of	17194457
chronic	17194457
anabolic	17194457
androgenic	17194457
steroid	17194457
(	17194457
AAS	17194457
)	17194457
exposure	17194457
and	17194457
brain	17194457
serotonin	17194457
(	17194457
5	17194457
-	17194457
hydroxytryptamine	17194457
,	17194457
5	17194457
-	17194457
HT	17194457
)	17194457
depletion	17194457
on	17194457
behavior	17194457
of	17194457
pubertal	17194457
male	17194457
rats	17194457
.	17194457

Serotonin	17194457
was	17194457
depleted	17194457
beginning	17194457
on	17194457
postnatal	17194457
day	17194457
26	17194457
with	17194457
parachlorophenylalanine	17194457
(	17194457
PCPA	17194457
100	17194457
mg	17194457
/	17194457
kg	17194457
,	17194457
every	17194457
other	17194457
day	17194457
)	17194457
;	17194457
controls	17194457
received	17194457
saline	17194457
.	17194457

At	17194457
puberty	17194457
(	17194457
P40	17194457
)	17194457
,	17194457
half	17194457
the	17194457
PCPA	17194457
-	17194457
treated	17194457
rats	17194457
and	17194457
half	17194457
the	17194457
saline	17194457
-	17194457
treated	17194457
rats	17194457
began	17194457
treatment	17194457
with	17194457
testosterone	17194457
(	17194457
T	17194457
,	17194457
5	17194457
mg	17194457
/	17194457
kg	17194457
,	17194457
5	17194457
days	17194457
/	17194457
week	17194457
)	17194457
.	17194457

Behavioral	17194457
measures	17194457
included	17194457
locomotion	17194457
,	17194457
irritability	17194457
,	17194457
copulation	17194457
,	17194457
partner	17194457
preference	17194457
,	17194457
and	17194457
aggression	17194457
.	17194457

Animals	17194457
were	17194457
tested	17194457
for	17194457
aggression	17194457
in	17194457
their	17194457
home	17194457
cage	17194457
,	17194457
both	17194457
with	17194457
and	17194457
without	17194457
physical	17194457
provocation	17194457
(	17194457
mild	17194457
tail	17194457
pinch	17194457
)	17194457
.	17194457

Brain	17194457
levels	17194457
of	17194457
5	17194457
-	17194457
HT	17194457
and	17194457
its	17194457
metabolite	17194457
,	17194457
5	17194457
-	17194457
hydroxyindoleacetic	17194457
acid	17194457
(	17194457
5	17194457
-	17194457
HIAA	17194457
)	17194457
,	17194457
were	17194457
determined	17194457
using	17194457
HPLC	17194457
.	17194457

PCPA	17194457
significantly	17194457
and	17194457
substantially	17194457
depleted	17194457
5	17194457
-	17194457
HT	17194457
and	17194457
5	17194457
-	17194457
HIAA	17194457
in	17194457
all	17194457
brain	17194457
regions	17194457
examined	17194457
.	17194457

Chronic	17194457
T	17194457
treatment	17194457
significantly	17194457
decreased	17194457
5	17194457
-	17194457
HT	17194457
and	17194457
5	17194457
-	17194457
HIAA	17194457
in	17194457
certain	17194457
brain	17194457
areas	17194457
,	17194457
but	17194457
to	17194457
a	17194457
much	17194457
lesser	17194457
extent	17194457
than	17194457
PCPA	17194457
.	17194457

Chronic	17194457
exposure	17194457
to	17194457
PCPA	17194457
alone	17194457
significantly	17194457
decreased	17194457
locomotor	17194457
activity	17194457
and	17194457
increased	17194457
irritability	17194457
but	17194457
had	17194457
no	17194457
effect	17194457
on	17194457
sexual	17194457
behavior	17194457
,	17194457
partner	17194457
preference	17194457
,	17194457
or	17194457
aggression	17194457
.	17194457

T	17194457
alone	17194457
had	17194457
no	17194457
effect	17194457
on	17194457
locomotion	17194457
,	17194457
irritability	17194457
,	17194457
or	17194457
sexual	17194457
behavior	17194457
but	17194457
increased	17194457
partner	17194457
preference	17194457
and	17194457
aggression	17194457
.	17194457

The	17194457
most	17194457
striking	17194457
effect	17194457
of	17194457
combining	17194457
T	17194457
+	17194457
PCPA	17194457
was	17194457
a	17194457
significant	17194457
increase	17194457
in	17194457
attack	17194457
frequency	17194457
as	17194457
well	17194457
as	17194457
a	17194457
significant	17194457
decrease	17194457
in	17194457
the	17194457
latency	17194457
to	17194457
attack	17194457
,	17194457
particularly	17194457
following	17194457
physical	17194457
provocation	17194457
.	17194457

Based	17194457
on	17194457
these	17194457
data	17194457
,	17194457
it	17194457
can	17194457
be	17194457
speculated	17194457
that	17194457
pubertal	17194457
AAS	17194457
users	17194457
with	17194457
low	17194457
central	17194457
5	17194457
-	17194457
HT	17194457
may	17194457
be	17194457
especially	17194457
prone	17194457
to	17194457
exhibit	17194457
aggressive	17194457
behavior	17194457
.	17194457
DNA	16843501
damage	16843501
and	16843501
repair	16843501
in	16843501
gastric	16843501
cancer	16843501
-	16843501
-	16843501
a	16843501
correlation	16843501
with	16843501
the	16843501
hOGG1	16843501
and	16843501
RAD51	16843501
genes	16843501
polymorphisms	16843501
.	16843501

The	16843501
cell	16843501
'	16843501
s	16843501
susceptibility	16843501
to	16843501
mutagens	16843501
and	16843501
its	16843501
ability	16843501
to	16843501
repair	16843501
DNA	16843501
lesions	16843501
are	16843501
important	16843501
for	16843501
cancer	16843501
induction	16843501
,	16843501
promotion	16843501
and	16843501
progression	16843501
.	16843501

Both	16843501
the	16843501
mutagens	16843501
'	16843501
sensitivity	16843501
and	16843501
the	16843501
efficacy	16843501
of	16843501
DNA	16843501
repair	16843501
may	16843501
be	16843501
affected	16843501
by	16843501
variation	16843501
in	16843501
several	16843501
genes	16843501
,	16843501
including	16843501
DNA	16843501
repair	16843501
genes	16843501
.	16843501

The	16843501
hOGG1	16843501
gene	16843501
encodes	16843501
glycosylase	16843501
of	16843501
base	16843501
excision	16843501
repair	16843501
and	16843501
RAD51	16843501
specifies	16843501
a	16843501
key	16843501
protein	16843501
in	16843501
homologues	16843501
recombination	16843501
repair	16843501
.	16843501

Both	16843501
can	16843501
be	16843501
involved	16843501
in	16843501
the	16843501
repair	16843501
of	16843501
oxidative	16843501
DNA	16843501
lesions	16843501
,	16843501
which	16843501
can	16843501
contribute	16843501
to	16843501
stomach	16843501
cancer	16843501
.	16843501

In	16843501
the	16843501
present	16843501
work	16843501
we	16843501
determined	16843501
the	16843501
level	16843501
of	16843501
basal	16843501
and	16843501
oxidative	16843501
DNA	16843501
damage	16843501
and	16843501
the	16843501
kinetics	16843501
of	16843501
removal	16843501
of	16843501
DNA	16843501
damage	16843501
induced	16843501
by	16843501
hydrogen	16843501
peroxide	16843501
in	16843501
peripheral	16843501
blood	16843501
lymphocytes	16843501
of	16843501
30	16843501
gastric	16843501
cancer	16843501
patients	16843501
and	16843501
30	16843501
healthy	16843501
individuals	16843501
.	16843501

The	16843501
metrics	16843501
from	16843501
DNA	16843501
damage	16843501
and	16843501
repair	16843501
study	16843501
were	16843501
correlated	16843501
with	16843501
the	16843501
genotypes	16843501
of	16843501
common	16843501
polymorphisms	16843501
of	16843501
the	16843501
hOGG1	16843501
and	16843501
RAD51	16843501
genes	16843501
:	16843501
a	16843501
G	16843501
-	16843501
-	16843501
>	16843501
C	16843501
transversion	16843501
at	16843501
1245	16843501
position	16843501
of	16843501
the	16843501
hOGG1	16843501
gene	16843501
producing	16843501
a	16843501
Ser	16843501
-	16843501
-	16843501
>	16843501
Cys	16843501
substitution	16843501
at	16843501
the	16843501
codon	16843501
326	16843501
(	16843501
the	16843501
Ser326Cys	16843501
polymorphism	16843501
)	16843501
and	16843501
a	16843501
G	16843501
-	16843501
-	16843501
>	16843501
C	16843501
substitution	16843501
at	16843501
position	16843501
135	16843501
(	16843501
5	16843501
'	16843501
-	16843501
untranslated	16843501
region	16843501
)	16843501
of	16843501
the	16843501
RAD51	16843501
gene	16843501
(	16843501
the	16843501
G135C	16843501
polymorphism	16843501
)	16843501
.	16843501

DNA	16843501
damage	16843501
and	16843501
repair	16843501
were	16843501
evaluated	16843501
by	16843501
alkaline	16843501
single	16843501
cell	16843501
gel	16843501
electrophoresis	16843501
(	16843501
comet	16843501
assay	16843501
)	16843501
assisted	16843501
by	16843501
DNA	16843501
repair	16843501
enzymes	16843501
:	16843501
endonuclease	16843501
III	16843501
(	16843501
Nth	16843501
)	16843501
and	16843501
formamidopyrimidine	16843501
-	16843501
DNA	16843501
glycosylase	16843501
(	16843501
Fpg	16843501
)	16843501
,	16843501
preferentially	16843501
recognizing	16843501
oxidized	16843501
DNA	16843501
bases	16843501
.	16843501

The	16843501
genotypes	16843501
of	16843501
the	16843501
polymorphism	16843501
were	16843501
determined	16843501
by	16843501
restriction	16843501
fragment	16843501
length	16843501
polymorphism	16843501
PCR	16843501
.	16843501

We	16843501
observed	16843501
a	16843501
strong	16843501
association	16843501
between	16843501
gastric	16843501
cancer	16843501
occurrence	16843501
,	16843501
impaired	16843501
DNA	16843501
repair	16843501
in	16843501
human	16843501
lymphocytes	16843501
and	16843501
the	16843501
G	16843501
/	16843501
C	16843501
genotype	16843501
of	16843501
the	16843501
G135C	16843501
polymorphism	16843501
of	16843501
the	16843501
RAD51	16843501
gene	16843501
.	16843501

Moreover	16843501
,	16843501
there	16843501
was	16843501
a	16843501
strong	16843501
correlation	16843501
between	16843501
that	16843501
genotype	16843501
and	16843501
stomach	16843501
cancer	16843501
occurrence	16843501
in	16843501
subjects	16843501
with	16843501
high	16843501
level	16843501
of	16843501
oxidatively	16843501
damaged	16843501
DNA	16843501
.	16843501

We	16843501
did	16843501
not	16843501
observe	16843501
any	16843501
correlation	16843501
between	16843501
the	16843501
Ser1245Cys	16843501
polymorphism	16843501
of	16843501
the	16843501
hOGG1	16843501
gene	16843501
and	16843501
gastric	16843501
cancer	16843501
,	16843501
including	16843501
subjects	16843501
with	16843501
impaired	16843501
DNA	16843501
repair	16843501
and	16843501
/	16843501
or	16843501
high	16843501
levels	16843501
of	16843501
endogenous	16843501
oxidative	16843501
DNA	16843501
lesions	16843501
.	16843501

Therefore	16843501
,	16843501
our	16843501
result	16843501
suggest	16843501
that	16843501
the	16843501
G135C	16843501
polymorphism	16843501
of	16843501
the	16843501
RAD51	16843501
gene	16843501
may	16843501
be	16843501
linked	16843501
with	16843501
gastric	16843501
cancer	16843501
by	16843501
the	16843501
modulation	16843501
of	16843501
the	16843501
cellular	16843501
response	16843501
to	16843501
oxidative	16843501
stress	16843501
and	16843501
this	16843501
polymorphism	16843501
may	16843501
be	16843501
a	16843501
useful	16843501
additional	16843501
marker	16843501
in	16843501
this	16843501
disease	16843501
along	16843501
with	16843501
the	16843501
genetic	16843501
or	16843501
/	16843501
and	16843501
environmental	16843501
indicators	16843501
of	16843501
oxidative	16843501
stress	16843501
.	16843501
Ca2	15184369
+	15184369
dependence	15184369
of	15184369
the	15184369
Ca2	15184369
+	15184369
-	15184369
selective	15184369
TRPV6	15184369
channel	15184369
.	15184369

Microfluorimetry	15184369
and	15184369
patch	15184369
-	15184369
clamp	15184369
experiments	15184369
were	15184369
performed	15184369
on	15184369
TRPV6	15184369
-	15184369
expressing	15184369
HEK	15184369
cells	15184369
to	15184369
determine	15184369
whether	15184369
this	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
-	15184369
sensing	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
channel	15184369
is	15184369
constitutively	15184369
active	15184369
.	15184369

Intact	15184369
cells	15184369
loaded	15184369
with	15184369
fura	15184369
-	15184369
2	15184369
had	15184369
an	15184369
elevated	15184369
intracellular	15184369
free	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
concentration	15184369
(	15184369
(	15184369
i	15184369
)	15184369
)	15184369
,	15184369
which	15184369
decreased	15184369
to	15184369
the	15184369
same	15184369
level	15184369
such	15184369
as	15184369
in	15184369
non	15184369
-	15184369
transfected	15184369
cells	15184369
if	15184369
external	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
was	15184369
chelated	15184369
by	15184369
EGTA	15184369
.	15184369

Whole	15184369
cell	15184369
recordings	15184369
from	15184369
non	15184369
-	15184369
transfected	15184369
HEK	15184369
cells	15184369
and	15184369
cells	15184369
expressing	15184369
human	15184369
TRPV6	15184369
revealed	15184369
the	15184369
presence	15184369
of	15184369
a	15184369
basal	15184369
inward	15184369
current	15184369
in	15184369
both	15184369
types	15184369
of	15184369
cells	15184369
when	15184369
the	15184369
internal	15184369
solution	15184369
contained	15184369
0	15184369
.	15184369
1	15184369
mm	15184369
EGTA	15184369
and	15184369
100	15184369
nm	15184369
(	15184369
i	15184369
)	15184369
or	15184369
if	15184369
the	15184369
cytosolic	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
buffering	15184369
remained	15184369
undisturbed	15184369
in	15184369
perforated	15184369
patch	15184369
-	15184369
clamp	15184369
experiments	15184369
.	15184369

If	15184369
recombinantly	15184369
expressed	15184369
TRPV6	15184369
forms	15184369
open	15184369
channels	15184369
,	15184369
one	15184369
would	15184369
expect	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
-	15184369
induced	15184369
current	15184369
inhibition	15184369
,	15184369
because	15184369
TRPV6	15184369
is	15184369
negatively	15184369
regulated	15184369
by	15184369
internal	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
.	15184369

However	15184369
,	15184369
dialyzing	15184369
solutions	15184369
with	15184369
high	15184369
such	15184369
as	15184369
1	15184369
microm	15184369
into	15184369
TRPV6	15184369
-	15184369
expressing	15184369
cells	15184369
did	15184369
not	15184369
block	15184369
the	15184369
basal	15184369
inward	15184369
current	15184369
,	15184369
which	15184369
was	15184369
not	15184369
different	15184369
from	15184369
the	15184369
recordings	15184369
from	15184369
non	15184369
-	15184369
transfected	15184369
cells	15184369
.	15184369

In	15184369
contrast	15184369
,	15184369
dialyzing	15184369
0	15184369
.	15184369
5	15184369
mm	15184369
EGTA	15184369
into	15184369
TRPV6	15184369
-	15184369
expressing	15184369
cells	15184369
readily	15184369
activated	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
inward	15184369
currents	15184369
,	15184369
which	15184369
were	15184369
undetectable	15184369
in	15184369
non	15184369
-	15184369
transfected	15184369
cells	15184369
.	15184369

Interestingly	15184369
,	15184369
monovalent	15184369
cations	15184369
permeated	15184369
the	15184369
TRPV6	15184369
channels	15184369
under	15184369
conditions	15184369
where	15184369
no	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
permeation	15184369
was	15184369
detectable	15184369
,	15184369
indicating	15184369
that	15184369
divalent	15184369
cations	15184369
block	15184369
TRPV6	15184369
channels	15184369
from	15184369
the	15184369
extracellular	15184369
side	15184369
.	15184369

Like	15184369
human	15184369
TRPV6	15184369
,	15184369
the	15184369
truncated	15184369
human	15184369
TRPV6	15184369
(	15184369
Delta695	15184369
-	15184369
725	15184369
)	15184369
,	15184369
which	15184369
lacks	15184369
the	15184369
C	15184369
-	15184369
terminal	15184369
domain	15184369
required	15184369
for	15184369
Ca	15184369
(	15184369
2	15184369
+	15184369
)	15184369
-	15184369
calmodulin	15184369
binding	15184369
,	15184369
does	15184369
not	15184369
form	15184369
constitutive	15184369
active	15184369
channels	15184369
,	15184369
whereas	15184369
the	15184369
human	15184369
TRPV6	15184369
(	15184369
D542A	15184369
)	15184369
,	15184369
carrying	15184369
a	15184369
point	15184369
mutation	15184369
in	15184369
the	15184369
presumed	15184369
pore	15184369
region	15184369
,	15184369
does	15184369
not	15184369
function	15184369
as	15184369
a	15184369
channel	15184369
.	15184369

In	15184369
summary	15184369
,	15184369
no	15184369
constitutive	15184369
open	15184369
TRPV6	15184369
channels	15184369
were	15184369
detected	15184369
in	15184369
patch	15184369
-	15184369
clamp	15184369
experiments	15184369
from	15184369
transfected	15184369
HEK	15184369
cells	15184369
.	15184369

However	15184369
,	15184369
channel	15184369
activity	15184369
is	15184369
highly	15184369
regulated	15184369
by	15184369
intracellular	15184369
and	15184369
extracellular	15184369
divalent	15184369
cations	15184369
.	15184369
Memory	16574713
function	16574713
and	16574713
serotonin	16574713
transporter	16574713
promoter	16574713
gene	16574713
polymorphism	16574713
in	16574713
ecstasy	16574713
(	16574713
MDMA	16574713
)	16574713
users	16574713
.	16574713

Although	16574713
3	16574713
,	16574713
4	16574713
-	16574713
methylenedioxymethamphetamine	16574713
(	16574713
MDMA	16574713
or	16574713
ecstasy	16574713
)	16574713
has	16574713
been	16574713
shown	16574713
to	16574713
damage	16574713
brain	16574713
serotonin	16574713
(	16574713
5	16574713
-	16574713
HT	16574713
)	16574713
neurons	16574713
in	16574713
animals	16574713
and	16574713
possibly	16574713
humans	16574713
,	16574713
little	16574713
is	16574713
known	16574713
about	16574713
the	16574713
long	16574713
-	16574713
term	16574713
consequences	16574713
of	16574713
MDMA	16574713
-	16574713
induced	16574713
5	16574713
-	16574713
HT	16574713
neurotoxic	16574713
lesions	16574713
on	16574713
functions	16574713
in	16574713
which	16574713
5	16574713
-	16574713
HT	16574713
is	16574713
involved	16574713
,	16574713
such	16574713
as	16574713
cognitive	16574713
function	16574713
.	16574713

Because	16574713
5	16574713
-	16574713
HT	16574713
transporters	16574713
play	16574713
a	16574713
key	16574713
element	16574713
in	16574713
the	16574713
regulation	16574713
of	16574713
synaptic	16574713
5	16574713
-	16574713
HT	16574713
transmission	16574713
it	16574713
may	16574713
be	16574713
important	16574713
to	16574713
control	16574713
for	16574713
the	16574713
potential	16574713
covariance	16574713
effect	16574713
of	16574713
a	16574713
polymorphism	16574713
in	16574713
the	16574713
5	16574713
-	16574713
HT	16574713
transporter	16574713
promoter	16574713
gene	16574713
region	16574713
(	16574713
5	16574713
-	16574713
HTTLPR	16574713
)	16574713
when	16574713
studying	16574713
the	16574713
effects	16574713
of	16574713
MDMA	16574713
as	16574713
well	16574713
as	16574713
cognitive	16574713
functioning	16574713
.	16574713

The	16574713
aim	16574713
of	16574713
the	16574713
study	16574713
was	16574713
to	16574713
investigate	16574713
the	16574713
effects	16574713
of	16574713
moderate	16574713
and	16574713
heavy	16574713
MDMA	16574713
use	16574713
on	16574713
cognitive	16574713
function	16574713
,	16574713
as	16574713
well	16574713
as	16574713
the	16574713
effects	16574713
of	16574713
long	16574713
-	16574713
term	16574713
abstention	16574713
from	16574713
MDMA	16574713
,	16574713
in	16574713
subjects	16574713
genotyped	16574713
for	16574713
5	16574713
-	16574713
HTTLPR	16574713
.	16574713

A	16574713
second	16574713
aim	16574713
of	16574713
the	16574713
study	16574713
was	16574713
to	16574713
determine	16574713
whether	16574713
these	16574713
effects	16574713
differ	16574713
for	16574713
females	16574713
and	16574713
males	16574713
.	16574713

Fifteen	16574713
moderate	16574713
MDMA	16574713
users	16574713
(	16574713
<	16574713
55	16574713
lifetime	16574713
tablets	16574713
)	16574713
,	16574713
22	16574713
heavy	16574713
MDMA	16574713
+	16574713
users	16574713
(	16574713
>	16574713
55	16574713
lifetime	16574713
tablets	16574713
)	16574713
,	16574713
16	16574713
ex	16574713
-	16574713
MDMA	16574713
+	16574713
users	16574713
(	16574713
last	16574713
tablet	16574713
>	16574713
1	16574713
year	16574713
ago	16574713
)	16574713
and	16574713
13	16574713
controls	16574713
were	16574713
compared	16574713
on	16574713
a	16574713
battery	16574713
of	16574713
neuropsychological	16574713
tests	16574713
.	16574713

DNA	16574713
from	16574713
peripheral	16574713
nuclear	16574713
blood	16574713
cells	16574713
was	16574713
genotyped	16574713
for	16574713
5	16574713
-	16574713
HTTLPR	16574713
using	16574713
standard	16574713
polymerase	16574713
chain	16574713
reaction	16574713
methods	16574713
.	16574713
A	16574713
significant	16574713
group	16574713
effect	16574713
was	16574713
observed	16574713
only	16574713
on	16574713
memory	16574713
function	16574713
tasks	16574713
(	16574713
p	16574713
=	16574713
0	16574713
.	16574713
04	16574713
)	16574713
but	16574713
not	16574713
on	16574713
reaction	16574713
times	16574713
(	16574713
p	16574713
=	16574713
0	16574713
.	16574713
61	16574713
)	16574713
or	16574713
attention	16574713
/	16574713
executive	16574713
functioning	16574713
(	16574713
p	16574713
=	16574713
0	16574713
.	16574713
59	16574713
)	16574713
.	16574713

Heavy	16574713
and	16574713
ex	16574713
-	16574713
MDMA	16574713
+	16574713
users	16574713
performed	16574713
significantly	16574713
poorer	16574713
on	16574713
memory	16574713
tasks	16574713
than	16574713
controls	16574713
.	16574713

In	16574713
contrast	16574713
,	16574713
no	16574713
evidence	16574713
of	16574713
memory	16574713
impairment	16574713
was	16574713
observed	16574713
in	16574713
moderate	16574713
MDMA	16574713
users	16574713
.	16574713

No	16574713
significant	16574713
effect	16574713
of	16574713
5	16574713
-	16574713
HTTLPR	16574713
or	16574713
gender	16574713
was	16574713
observed	16574713
.	16574713

While	16574713
the	16574713
use	16574713
of	16574713
MDMA	16574713
in	16574713
quantities	16574713
that	16574713
may	16574713
be	16574713
considered	16574713
""""	16574713
moderate	16574713
""""	16574713
is	16574713
not	16574713
associated	16574713
with	16574713
impaired	16574713
memory	16574713
functioning	16574713
,	16574713
heavy	16574713
use	16574713
of	16574713
MDMA	16574713
use	16574713
may	16574713
lead	16574713
to	16574713
long	16574713
lasting	16574713
memory	16574713
impairments	16574713
.	16574713

No	16574713
effect	16574713
of	16574713
5	16574713
-	16574713
HTTLPR	16574713
or	16574713
gender	16574713
on	16574713
memory	16574713
function	16574713
or	16574713
MDMA	16574713
use	16574713
was	16574713
observed	16574713
.	16574713
Effects	18507837
of	18507837
common	18507837
germline	18507837
genetic	18507837
variation	18507837
in	18507837
cell	18507837
cycle	18507837
control	18507837
genes	18507837
on	18507837
breast	18507837
cancer	18507837
survival	18507837
:	18507837
results	18507837
from	18507837
a	18507837
population	18507837
-	18507837
based	18507837
cohort	18507837
.	18507837

INTRODUCTION	18507837
:	18507837
Somatic	18507837
alterations	18507837
have	18507837
been	18507837
shown	18507837
to	18507837
correlate	18507837
with	18507837
breast	18507837
cancer	18507837
prognosis	18507837
and	18507837
survival	18507837
,	18507837
but	18507837
less	18507837
is	18507837
known	18507837
about	18507837
the	18507837
effects	18507837
of	18507837
common	18507837
inherited	18507837
genetic	18507837
variation	18507837
.	18507837

Of	18507837
particular	18507837
interest	18507837
are	18507837
genes	18507837
involved	18507837
in	18507837
cell	18507837
cycle	18507837
pathways	18507837
,	18507837
which	18507837
regulate	18507837
cell	18507837
division	18507837
.	18507837

METHODS	18507837
:	18507837
We	18507837
examined	18507837
associations	18507837
between	18507837
common	18507837
germline	18507837
genetic	18507837
variation	18507837
in	18507837
13	18507837
genes	18507837
involved	18507837
in	18507837
cell	18507837
cycle	18507837
control	18507837
(	18507837
CCND1	18507837
,	18507837
CCND2	18507837
,	18507837
CCND3	18507837
,	18507837
CCNE1	18507837
,	18507837
CDK2	18507837
[	18507837
p33	18507837
]	18507837
,	18507837
CDK4	18507837
,	18507837
CDK6	18507837
,	18507837
CDKN1A	18507837
[	18507837
p21	18507837
,	18507837
Cip1	18507837
]	18507837
,	18507837
CDKN1B	18507837
[	18507837
p27	18507837
,	18507837
Kip1	18507837
]	18507837
,	18507837
CDKN2A	18507837
[	18507837
p16	18507837
]	18507837
,	18507837
CDKN2B	18507837
[	18507837
p15	18507837
]	18507837
,	18507837
CDKN2C	18507837
[	18507837
p18	18507837
]	18507837
,	18507837
and	18507837
CDKN2D	18507837
[	18507837
p19	18507837
]	18507837
)	18507837
and	18507837
survival	18507837
among	18507837
women	18507837
diagnosed	18507837
with	18507837
invasive	18507837
breast	18507837
cancer	18507837
participating	18507837
in	18507837
the	18507837
SEARCH	18507837
(	18507837
Studies	18507837
of	18507837
Epidemiology	18507837
and	18507837
Risk	18507837
factors	18507837
in	18507837
Cancer	18507837
Heredity	18507837
)	18507837
breast	18507837
cancer	18507837
study	18507837
.	18507837

DNA	18507837
from	18507837
up	18507837
to	18507837
4	18507837
,	18507837
470	18507837
women	18507837
was	18507837
genotyped	18507837
for	18507837
85	18507837
polymorphisms	18507837
that	18507837
tag	18507837
the	18507837
known	18507837
common	18507837
polymorphisms	18507837
(	18507837
minor	18507837
allele	18507837
frequency	18507837
>	18507837
0	18507837
.	18507837
05	18507837
)	18507837
in	18507837
the	18507837
genes	18507837
.	18507837

The	18507837
genotypes	18507837
of	18507837
each	18507837
polymorphism	18507837
were	18507837
tested	18507837
for	18507837
association	18507837
with	18507837
survival	18507837
using	18507837
Cox	18507837
regression	18507837
analysis	18507837
.	18507837

RESULTS	18507837
:	18507837
The	18507837
rare	18507837
allele	18507837
of	18507837
the	18507837
tagging	18507837
single	18507837
nucleotide	18507837
polymorphism	18507837
(	18507837
SNP	18507837
)	18507837
rs2479717	18507837
is	18507837
associated	18507837
with	18507837
an	18507837
increased	18507837
risk	18507837
of	18507837
death	18507837
(	18507837
hazard	18507837
ratio	18507837
=	18507837
1	18507837
.	18507837
26	18507837
per	18507837
rare	18507837
allele	18507837
carried	18507837
,	18507837
95%	18507837
confidence	18507837
interval	18507837
:	18507837
1	18507837
.	18507837
12	18507837
to	18507837
1	18507837
.	18507837
42	18507837
;	18507837
P	18507837
=	18507837
0	18507837
.	18507837
0001	18507837
)	18507837
,	18507837
which	18507837
was	18507837
not	18507837
attenuated	18507837
after	18507837
adjusting	18507837
for	18507837
tumour	18507837
stage	18507837
,	18507837
grade	18507837
,	18507837
and	18507837
treatment	18507837
.	18507837

This	18507837
SNP	18507837
is	18507837
part	18507837
of	18507837
a	18507837
large	18507837
linkage	18507837
disequilibrium	18507837
block	18507837
,	18507837
which	18507837
contains	18507837
CCND3	18507837
,	18507837
BYSL	18507837
,	18507837
TRFP	18507837
,	18507837
USP49	18507837
,	18507837
C6ofr49	18507837
,	18507837
FRS3	18507837
,	18507837
and	18507837
PGC	18507837
.	18507837

We	18507837
evaluated	18507837
the	18507837
association	18507837
of	18507837
survival	18507837
and	18507837
somatic	18507837
expression	18507837
of	18507837
these	18507837
genes	18507837
in	18507837
breast	18507837
tumours	18507837
using	18507837
expression	18507837
microarray	18507837
data	18507837
from	18507837
seven	18507837
published	18507837
datasets	18507837
.	18507837

Elevated	18507837
expression	18507837
of	18507837
the	18507837
C6orf49	18507837
transcript	18507837
was	18507837
associated	18507837
with	18507837
breast	18507837
cancer	18507837
survival	18507837
,	18507837
adding	18507837
biological	18507837
interest	18507837
to	18507837
the	18507837
finding	18507837
.	18507837

CONCLUSION	18507837
:	18507837
It	18507837
is	18507837
possible	18507837
that	18507837
CCND3	18507837
rs2479717	18507837
,	18507837
or	18507837
another	18507837
variant	18507837
it	18507837
tags	18507837
,	18507837
is	18507837
associated	18507837
with	18507837
prognosis	18507837
after	18507837
a	18507837
diagnosis	18507837
of	18507837
breast	18507837
cancer	18507837
.	18507837

Further	18507837
study	18507837
is	18507837
required	18507837
to	18507837
validate	18507837
this	18507837
finding	18507837
.	18507837
Disruption	17304550
of	17304550
a	17304550
synaptotagmin	17304550
(	17304550
SYT14	17304550
)	17304550
associated	17304550
with	17304550
neurodevelopmental	17304550
abnormalities	17304550
.	17304550

We	17304550
report	17304550
cytogenetic	17304550
and	17304550
molecular	17304550
studies	17304550
of	17304550
a	17304550
de	17304550
novo	17304550
,	17304550
apparently	17304550
balanced	17304550
t	17304550
(	17304550
1	17304550
;	17304550
3	17304550
)	17304550
(	17304550
q32	17304550
.	17304550
1	17304550
;	17304550
q25	17304550
.	17304550
1	17304550
)	17304550
identified	17304550
in	17304550
a	17304550
12	17304550
-	17304550
year	17304550
-	17304550
old	17304550
female	17304550
(	17304550
designated	17304550
DGAP128	17304550
)	17304550
with	17304550
cerebral	17304550
atrophy	17304550
,	17304550
macrocephaly	17304550
seizures	17304550
,	17304550
and	17304550
developmental	17304550
delay	17304550
.	17304550

A	17304550
combination	17304550
of	17304550
fluorescence	17304550
in	17304550
situ	17304550
hybridization	17304550
(	17304550
FISH	17304550
)	17304550
and	17304550
Southern	17304550
blot	17304550
analysis	17304550
demonstrated	17304550
disruption	17304550
of	17304550
a	17304550
synaptotagmin	17304550
gene	17304550
(	17304550
SYT14	17304550
)	17304550
at	17304550
the	17304550
1q32	17304550
breakpoint	17304550
.	17304550

Expression	17304550
of	17304550
SYT14	17304550
in	17304550
human	17304550
brain	17304550
was	17304550
confirmed	17304550
using	17304550
Northern	17304550
analysis	17304550
.	17304550

Because	17304550
members	17304550
of	17304550
the	17304550
synaptotagmin	17304550
family	17304550
of	17304550
proteins	17304550
function	17304550
as	17304550
sensors	17304550
that	17304550
link	17304550
changes	17304550
in	17304550
calcium	17304550
levels	17304550
with	17304550
a	17304550
variety	17304550
of	17304550
biological	17304550
processes	17304550
,	17304550
including	17304550
neurotransmission	17304550
and	17304550
hormone	17304550
-	17304550
responsiveness	17304550
,	17304550
SYT14	17304550
is	17304550
an	17304550
intriguing	17304550
candidate	17304550
gene	17304550
for	17304550
the	17304550
abnormal	17304550
development	17304550
in	17304550
this	17304550
child	17304550
.	17304550

This	17304550
is	17304550
the	17304550
first	17304550
known	17304550
constitutional	17304550
rearrangement	17304550
of	17304550
SYT14	17304550
,	17304550
and	17304550
further	17304550
systematic	17304550
genetic	17304550
analysis	17304550
and	17304550
clinical	17304550
studies	17304550
of	17304550
DGAP128	17304550
may	17304550
offer	17304550
unique	17304550
insights	17304550
into	17304550
the	17304550
role	17304550
of	17304550
SYT14	17304550
in	17304550
neurodevelopment	17304550
.	17304550
Atorvastatin	16820346
prevented	16820346
and	16820346
reversed	16820346
dexamethasone	16820346
-	16820346
induced	16820346
hypertension	16820346
in	16820346
the	16820346
rat	16820346
.	16820346

To	16820346
assess	16820346
the	16820346
antioxidant	16820346
effects	16820346
of	16820346
atorvastatin	16820346
(	16820346
atorva	16820346
)	16820346
on	16820346
dexamethasone	16820346
(	16820346
dex	16820346
)	16820346
-	16820346
induced	16820346
hypertension	16820346
,	16820346
60	16820346
male	16820346
Sprague	16820346
-	16820346
Dawley	16820346
rats	16820346
were	16820346
treated	16820346
with	16820346
atorva	16820346
30	16820346
mg	16820346
/	16820346
kg	16820346
/	16820346
day	16820346
or	16820346
tap	16820346
water	16820346
for	16820346
15	16820346
days	16820346
.	16820346

Dex	16820346
increased	16820346
systolic	16820346
blood	16820346
pressure	16820346
(	16820346
SBP	16820346
)	16820346
from	16820346
109	16820346
+	16820346
/	16820346
-	16820346
1	16820346
.	16820346
8	16820346
to	16820346
135	16820346
+	16820346
/	16820346
-	16820346
0	16820346
.	16820346
6	16820346
mmHg	16820346
and	16820346
plasma	16820346
superoxide	16820346
(	16820346
5711	16820346
+	16820346
/	16820346
-	16820346
284	16820346
.	16820346
9	16820346
saline	16820346
,	16820346
7931	16820346
+	16820346
/	16820346
-	16820346
392	16820346
.	16820346
8	16820346
U	16820346
/	16820346
ml	16820346
dex	16820346
,	16820346
P	16820346
<	16820346
0	16820346
.	16820346
001	16820346
)	16820346
.	16820346

In	16820346
this	16820346
prevention	16820346
study	16820346
,	16820346
SBP	16820346
in	16820346
the	16820346
atorva	16820346
+	16820346
dex	16820346
group	16820346
was	16820346
increased	16820346
from	16820346
115	16820346
+	16820346
/	16820346
-	16820346
0	16820346
.	16820346
4	16820346
to	16820346
124	16820346
+	16820346
/	16820346
-	16820346
1	16820346
.	16820346
5	16820346
mmHg	16820346
,	16820346
but	16820346
this	16820346
was	16820346
significantly	16820346
lower	16820346
than	16820346
in	16820346
the	16820346
dex	16820346
-	16820346
only	16820346
group	16820346
(	16820346
P	16820346
'	16820346
<	16820346
0	16820346
.	16820346
05	16820346
)	16820346
.	16820346

Atorva	16820346
reversed	16820346
dex	16820346
-	16820346
induced	16820346
hypertension	16820346
(	16820346
129	16820346
+	16820346
/	16820346
-	16820346
0	16820346
.	16820346
6	16820346
mmHg	16820346
,	16820346
vs	16820346
.	16820346

135	16820346
+	16820346
/	16820346
-	16820346
0	16820346
.	16820346
6	16820346
mmHg	16820346
P	16820346
'	16820346
<	16820346
0	16820346
.	16820346
05	16820346
)	16820346
and	16820346
decreased	16820346
plasma	16820346
superoxide	16820346
(	16820346
7931	16820346
+	16820346
/	16820346
-	16820346
392	16820346
.	16820346
8	16820346
dex	16820346
,	16820346
1187	16820346
+	16820346
/	16820346
-	16820346
441	16820346
.	16820346
2	16820346
atorva	16820346
+	16820346
dex	16820346
,	16820346
P	16820346
<	16820346
0	16820346
.	16820346
0001	16820346
)	16820346
.	16820346

Plasma	16820346
nitrate	16820346
/	16820346
nitrite	16820346
(	16820346
NOx	16820346
)	16820346
was	16820346
decreased	16820346
in	16820346
dex	16820346
-	16820346
treated	16820346
rats	16820346
compared	16820346
to	16820346
saline	16820346
-	16820346
treated	16820346
rats	16820346
(	16820346
11	16820346
.	16820346
2	16820346
+	16820346
/	16820346
-	16820346
1	16820346
.	16820346
08	16820346
microm	16820346
,	16820346
15	16820346
.	16820346
3	16820346
+	16820346
/	16820346
-	16820346
1	16820346
.	16820346
17	16820346
microm	16820346
,	16820346
respectively	16820346
,	16820346
P	16820346
<	16820346
0	16820346
.	16820346
05	16820346
)	16820346
.	16820346

Atorva	16820346
affected	16820346
neither	16820346
plasma	16820346
NOx	16820346
nor	16820346
thymus	16820346
weight	16820346
.	16820346

Thus	16820346
,	16820346
atorvastatin	16820346
prevented	16820346
and	16820346
reversed	16820346
dexamethasone	16820346
-	16820346
induced	16820346
hypertension	16820346
in	16820346
the	16820346
rat	16820346
.	16820346
Comparison	19234905
of	19234905
unilateral	19234905
pallidotomy	19234905
and	19234905
subthalamotomy	19234905
findings	19234905
in	19234905
advanced	19234905
idiopathic	19234905
Parkinson	19234905
'	19234905
s	19234905
disease	19234905
.	19234905

A	19234905
prospective	19234905
,	19234905
randomized	19234905
,	19234905
double	19234905
-	19234905
blind	19234905
pilot	19234905
study	19234905
to	19234905
compare	19234905
the	19234905
results	19234905
of	19234905
stereotactic	19234905
unilateral	19234905
pallidotomy	19234905
and	19234905
subthalamotomy	19234905
in	19234905
advanced	19234905
idiopathic	19234905
Parkinson	19234905
'	19234905
s	19234905
disease	19234905
(	19234905
PD	19234905
)	19234905
refractory	19234905
to	19234905
medical	19234905
treatment	19234905
was	19234905
designed	19234905
.	19234905

Ten	19234905
consecutive	19234905
patients	19234905
(	19234905
mean	19234905
age	19234905
,	19234905
58	19234905
.	19234905
4	19234905
+	19234905
/	19234905
-	19234905
6	19234905
.	19234905
8	19234905
years	19234905
;	19234905
7	19234905
men	19234905
,	19234905
3	19234905
women	19234905
)	19234905
with	19234905
similar	19234905
characteristics	19234905
at	19234905
the	19234905
duration	19234905
of	19234905
disease	19234905
(	19234905
mean	19234905
disease	19234905
time	19234905
,	19234905
8	19234905
.	19234905
4	19234905
+	19234905
/	19234905
-	19234905
3	19234905
.	19234905
5	19234905
years	19234905
)	19234905
,	19234905
disabling	19234905
motor	19234905
fluctuations	19234905
(	19234905
Hoehn	19234905
_	19234905
Yahr	19234905
stage	19234905
3	19234905
-	19234905
5	19234905
in	19234905
off	19234905
-	19234905
drug	19234905
phases	19234905
)	19234905
and	19234905
levodopa	19234905
-	19234905
induced	19234905
dyskinesias	19234905
were	19234905
selected	19234905
.	19234905

All	19234905
patients	19234905
had	19234905
bilateral	19234905
symptoms	19234905
and	19234905
their	19234905
levodopa	19234905
equivalent	19234905
dosing	19234905
were	19234905
analysed	19234905
.	19234905

Six	19234905
patients	19234905
were	19234905
operated	19234905
on	19234905
in	19234905
the	19234905
globus	19234905
pallidus	19234905
interna	19234905
(	19234905
GPi	19234905
)	19234905
and	19234905
four	19234905
in	19234905
the	19234905
subthalamic	19234905
nucleus	19234905
(	19234905
STN	19234905
)	19234905
.	19234905

Clinical	19234905
evaluation	19234905
included	19234905
the	19234905
use	19234905
of	19234905
the	19234905
Unified	19234905
Parkinson	19234905
'	19234905
s	19234905
Disease	19234905
Rating	19234905
Scale	19234905
(	19234905
UPDRS	19234905
)	19234905
,	19234905
Hoehn_Yahr	19234905
score	19234905
and	19234905
Schwab	19234905
England	19234905
activities	19234905
of	19234905
daily	19234905
living	19234905
(	19234905
ADL	19234905
)	19234905
score	19234905
in	19234905
'	19234905
on	19234905
'	19234905
-	19234905
and	19234905
'	19234905
off	19234905
'	19234905
-	19234905
drug	19234905
conditions	19234905
before	19234905
surgery	19234905
and	19234905
6	19234905
months	19234905
after	19234905
surgery	19234905
.	19234905

There	19234905
was	19234905
statistically	19234905
significant	19234905
improvement	19234905
in	19234905
all	19234905
contralateral	19234905
major	19234905
parkinsonian	19234905
motor	19234905
signs	19234905
in	19234905
all	19234905
patients	19234905
followed	19234905
for	19234905
6	19234905
months	19234905
.	19234905

Levodopa	19234905
equivalent	19234905
daily	19234905
intake	19234905
was	19234905
significantly	19234905
reduced	19234905
in	19234905
the	19234905
STN	19234905
group	19234905
.	19234905

Changes	19234905
in	19234905
UPDRS	19234905
,	19234905
Hoehn	19234905
_	19234905
Yahr	19234905
and	19234905
Schwab	19234905
England	19234905
ADL	19234905
scores	19234905
were	19234905
similar	19234905
in	19234905
both	19234905
groups	19234905
.	19234905

Cognitive	19234905
functions	19234905
were	19234905
unchanged	19234905
in	19234905
both	19234905
groups	19234905
.	19234905

Complications	19234905
were	19234905
observed	19234905
in	19234905
two	19234905
patients	19234905
:	19234905
one	19234905
had	19234905
a	19234905
left	19234905
homonymous	19234905
hemianopsia	19234905
after	19234905
pallidotomy	19234905
and	19234905
another	19234905
one	19234905
developed	19234905
left	19234905
hemiballistic	19234905
movements	19234905
3	19234905
days	19234905
after	19234905
subthalamotomy	19234905
which	19234905
partly	19234905
improved	19234905
within	19234905
1	19234905
month	19234905
with	19234905
Valproate	19234905
1000	19234905
mg	19234905
/	19234905
day	19234905
.	19234905

The	19234905
findings	19234905
of	19234905
this	19234905
study	19234905
suggest	19234905
that	19234905
lesions	19234905
of	19234905
the	19234905
unilateral	19234905
STN	19234905
and	19234905
GPi	19234905
are	19234905
equally	19234905
effective	19234905
treatment	19234905
for	19234905
patients	19234905
with	19234905
advanced	19234905
PD	19234905
refractory	19234905
to	19234905
medical	19234905
treatment	19234905
.	19234905
Cholecystokinin	24309294
-	24309294
octapeptide	24309294
restored	24309294
morphine	24309294
-	24309294
induced	24309294
hippocampal	24309294
long	24309294
-	24309294
term	24309294
potentiation	24309294
impairment	24309294
in	24309294
rats	24309294
.	24309294

Cholecystokinin	24309294
-	24309294
octapeptide	24309294
(	24309294
CCK	24309294
-	24309294
8	24309294
)	24309294
,	24309294
which	24309294
is	24309294
a	24309294
typical	24309294
brain	24309294
-	24309294
gut	24309294
peptide	24309294
,	24309294
exerts	24309294
a	24309294
wide	24309294
range	24309294
of	24309294
biological	24309294
activities	24309294
on	24309294
the	24309294
central	24309294
nervous	24309294
system	24309294
.	24309294

We	24309294
have	24309294
previously	24309294
reported	24309294
that	24309294
CCK	24309294
-	24309294
8	24309294
significantly	24309294
alleviated	24309294
morphine	24309294
-	24309294
induced	24309294
amnesia	24309294
and	24309294
reversed	24309294
spine	24309294
density	24309294
decreases	24309294
in	24309294
the	24309294
CA1	24309294
region	24309294
of	24309294
the	24309294
hippocampus	24309294
in	24309294
morphine	24309294
-	24309294
treated	24309294
animals	24309294
.	24309294

Here	24309294
,	24309294
we	24309294
investigated	24309294
the	24309294
effects	24309294
of	24309294
CCK	24309294
-	24309294
8	24309294
on	24309294
long	24309294
-	24309294
term	24309294
potentiation	24309294
(	24309294
LTP	24309294
)	24309294
in	24309294
the	24309294
lateral	24309294
perforant	24309294
path	24309294
(	24309294
LPP	24309294
)	24309294
-	24309294
granule	24309294
cell	24309294
synapse	24309294
of	24309294
rat	24309294
dentate	24309294
gyrus	24309294
(	24309294
DG	24309294
)	24309294
in	24309294
acute	24309294
saline	24309294
or	24309294
morphine	24309294
-	24309294
treated	24309294
rats	24309294
.	24309294

Population	24309294
spikes	24309294
(	24309294
PS	24309294
)	24309294
,	24309294
which	24309294
were	24309294
evoked	24309294
by	24309294
stimulation	24309294
of	24309294
the	24309294
LPP	24309294
,	24309294
were	24309294
recorded	24309294
in	24309294
the	24309294
DG	24309294
region	24309294
.	24309294

Acute	24309294
morphine	24309294
(	24309294
30mg	24309294
/	24309294
kg	24309294
,	24309294
s	24309294
.	24309294
c	24309294
.	24309294
)	24309294
treatment	24309294
significantly	24309294
attenuated	24309294
hippocampal	24309294
LTP	24309294
and	24309294
CCK	24309294
-	24309294
8	24309294
(	24309294
1ug	24309294
,	24309294
i	24309294
.	24309294
c	24309294
.	24309294
v	24309294
.	24309294
)	24309294
restored	24309294
the	24309294
amplitude	24309294
of	24309294
PS	24309294
that	24309294
was	24309294
attenuated	24309294
by	24309294
morphine	24309294
injection	24309294
.	24309294

Furthermore	24309294
,	24309294
microinjection	24309294
of	24309294
CCK	24309294
-	24309294
8	24309294
(	24309294
0	24309294
.	24309294
1	24309294
and	24309294
1ug	24309294
,	24309294
i	24309294
.	24309294
c	24309294
.	24309294
v	24309294
.	24309294
)	24309294
also	24309294
significantly	24309294
augmented	24309294
hippocampal	24309294
LTP	24309294
in	24309294
saline	24309294
-	24309294
treated	24309294
(	24309294
1ml	24309294
/	24309294
kg	24309294
,	24309294
s	24309294
.	24309294
c	24309294
.	24309294
)	24309294
rats	24309294
.	24309294

Pre	24309294
-	24309294
treatment	24309294
of	24309294
the	24309294
CCK2	24309294
receptor	24309294
antagonist	24309294
L	24309294
-	24309294
365	24309294
,	24309294
260	24309294
(	24309294
10ug	24309294
,	24309294
i	24309294
.	24309294
c	24309294
.	24309294
v	24309294
)	24309294
reversed	24309294
the	24309294
effects	24309294
of	24309294
CCK	24309294
-	24309294
8	24309294
,	24309294
but	24309294
the	24309294
CCK1	24309294
receptor	24309294
antagonist	24309294
L	24309294
-	24309294
364	24309294
,	24309294
718	24309294
(	24309294
10ug	24309294
,	24309294
i	24309294
.	24309294
c	24309294
.	24309294
v	24309294
)	24309294
did	24309294
not	24309294
.	24309294

The	24309294
present	24309294
results	24309294
demonstrate	24309294
that	24309294
CCK	24309294
-	24309294
8	24309294
attenuates	24309294
the	24309294
effect	24309294
of	24309294
morphine	24309294
on	24309294
hippocampal	24309294
LTP	24309294
through	24309294
CCK2	24309294
receptors	24309294
and	24309294
suggest	24309294
an	24309294
ameliorative	24309294
function	24309294
of	24309294
CCK	24309294
-	24309294
8	24309294
on	24309294
morphine	24309294
-	24309294
induced	24309294
memory	24309294
impairment	24309294
.	24309294
Distinct	16541406
patterns	16541406
of	16541406
germ	16541406
-	16541406
line	16541406
deletions	16541406
in	16541406
MLH1	16541406
and	16541406
MSH2	16541406
:	16541406
the	16541406
implication	16541406
of	16541406
Alu	16541406
repetitive	16541406
element	16541406
in	16541406
the	16541406
genetic	16541406
etiology	16541406
of	16541406
Lynch	16541406
syndrome	16541406
(	16541406
HNPCC	16541406
)	16541406
.	16541406

A	16541406
relatively	16541406
high	16541406
frequency	16541406
of	16541406
germ	16541406
-	16541406
line	16541406
genomic	16541406
rearrangements	16541406
in	16541406
MLH1	16541406
and	16541406
MSH2	16541406
has	16541406
been	16541406
reported	16541406
among	16541406
Lynch	16541406
Syndrome	16541406
(	16541406
HNPCC	16541406
)	16541406
patients	16541406
from	16541406
different	16541406
ethnic	16541406
populations	16541406
.	16541406

To	16541406
investigate	16541406
the	16541406
underlying	16541406
molecular	16541406
mechanisms	16541406
,	16541406
we	16541406
characterized	16541406
the	16541406
DNA	16541406
breakpoints	16541406
of	16541406
11	16541406
germ	16541406
-	16541406
line	16541406
deletions	16541406
,	16541406
six	16541406
for	16541406
MLH1	16541406
and	16541406
five	16541406
for	16541406
MSH2	16541406
.	16541406

Distinct	16541406
deletion	16541406
patterns	16541406
were	16541406
found	16541406
for	16541406
the	16541406
two	16541406
genes	16541406
.	16541406

The	16541406
five	16541406
cases	16541406
of	16541406
MSH2	16541406
deletions	16541406
result	16541406
exclusively	16541406
from	16541406
intragenic	16541406
unequal	16541406
recombination	16541406
mediated	16541406
by	16541406
repetitive	16541406
Alu	16541406
sequences	16541406
.	16541406

In	16541406
contrast	16541406
,	16541406
five	16541406
out	16541406
of	16541406
the	16541406
six	16541406
MLH1	16541406
deletions	16541406
are	16541406
due	16541406
to	16541406
recombinations	16541406
involving	16541406
sequences	16541406
of	16541406
no	16541406
significant	16541406
homology	16541406
(	16541406
P	16541406
=	16541406
0	16541406
.	16541406
015	16541406
)	16541406
.	16541406

A	16541406
detailed	16541406
analysis	16541406
of	16541406
the	16541406
DNA	16541406
breakpoints	16541406
in	16541406
the	16541406
two	16541406
genes	16541406
,	16541406
previously	16541406
characterized	16541406
by	16541406
other	16541406
groups	16541406
,	16541406
validated	16541406
the	16541406
observation	16541406
that	16541406
Alu	16541406
-	16541406
mediated	16541406
unequal	16541406
recombination	16541406
is	16541406
the	16541406
main	16541406
type	16541406
of	16541406
deletion	16541406
in	16541406
MSH2	16541406
(	16541406
n	16541406
=	16541406
34	16541406
)	16541406
,	16541406
but	16541406
not	16541406
in	16541406
MLH1	16541406
(	16541406
n	16541406
=	16541406
21	16541406
)	16541406
(	16541406
P	16541406
<	16541406
0	16541406
.	16541406
0001	16541406
)	16541406
.	16541406

Plotting	16541406
the	16541406
distribution	16541406
of	16541406
known	16541406
DNA	16541406
breakpoints	16541406
among	16541406
the	16541406
introns	16541406
of	16541406
the	16541406
two	16541406
genes	16541406
showed	16541406
that	16541406
,	16541406
the	16541406
highest	16541406
breakpoint	16541406
density	16541406
is	16541406
co	16541406
-	16541406
localized	16541406
with	16541406
the	16541406
highest	16541406
Alu	16541406
density	16541406
.	16541406

Our	16541406
study	16541406
suggests	16541406
that	16541406
Alu	16541406
is	16541406
a	16541406
promoting	16541406
factor	16541406
for	16541406
the	16541406
genomic	16541406
recombinations	16541406
in	16541406
both	16541406
MLH1	16541406
and	16541406
MSH2	16541406
,	16541406
and	16541406
the	16541406
local	16541406
Alu	16541406
density	16541406
may	16541406
be	16541406
involved	16541406
in	16541406
shaping	16541406
the	16541406
deletion	16541406
pattern	16541406
.	16541406
Vitamin	19789368
D	19789368
receptor	19789368
expression	19789368
is	19789368
associated	19789368
with	19789368
PIK3CA	19789368
and	19789368
KRAS	19789368
mutations	19789368
in	19789368
colorectal	19789368
cancer	19789368
.	19789368

Vitamin	19789368
D	19789368
is	19789368
associated	19789368
with	19789368
decreased	19789368
risks	19789368
of	19789368
various	19789368
cancers	19789368
,	19789368
including	19789368
colon	19789368
cancer	19789368
.	19789368

The	19789368
vitamin	19789368
D	19789368
receptor	19789368
(	19789368
VDR	19789368
)	19789368
is	19789368
a	19789368
transcription	19789368
factor	19789368
,	19789368
which	19789368
plays	19789368
an	19789368
important	19789368
role	19789368
in	19789368
cellular	19789368
differentiation	19789368
and	19789368
inhibition	19789368
of	19789368
proliferation	19789368
.	19789368

A	19789368
link	19789368
between	19789368
VDR	19789368
and	19789368
the	19789368
RAS	19789368
-	19789368
mitogen	19789368
-	19789368
activated	19789368
protein	19789368
kinase	19789368
(	19789368
MAPK	19789368
)	19789368
or	19789368
phosphatidylinositol	19789368
3	19789368
-	19789368
kinase	19789368
(	19789368
PI3K	19789368
)	19789368
-	19789368
AKT	19789368
pathway	19789368
has	19789368
been	19789368
suggested	19789368
.	19789368

However	19789368
,	19789368
the	19789368
prognostic	19789368
role	19789368
of	19789368
VDR	19789368
expression	19789368
or	19789368
its	19789368
relationship	19789368
with	19789368
PIK3CA	19789368
or	19789368
KRAS	19789368
mutation	19789368
remains	19789368
uncertain	19789368
.	19789368

Among	19789368
619	19789368
colorectal	19789368
cancers	19789368
in	19789368
two	19789368
prospective	19789368
cohort	19789368
studies	19789368
,	19789368
233	19789368
(	19789368
38%	19789368
)	19789368
tumors	19789368
showed	19789368
VDR	19789368
overexpression	19789368
by	19789368
immunohistochemistry	19789368
.	19789368

We	19789368
analyzed	19789368
for	19789368
PIK3CA	19789368
and	19789368
KRAS	19789368
mutations	19789368
and	19789368
LINE	19789368
-	19789368
1	19789368
methylation	19789368
by	19789368
Pyrosequencing	19789368
,	19789368
microsatellite	19789368
instability	19789368
(	19789368
MSI	19789368
)	19789368
,	19789368
and	19789368
DNA	19789368
methylation	19789368
(	19789368
epigenetic	19789368
changes	19789368
)	19789368
in	19789368
eight	19789368
CpG	19789368
island	19789368
methylator	19789368
phenotype	19789368
(	19789368
CIMP	19789368
)	19789368
-	19789368
specific	19789368
promoters	19789368
[	19789368
CACNA1G	19789368
,	19789368
CDKN2A	19789368
(	19789368
p16	19789368
)	19789368
,	19789368
CRABP1	19789368
,	19789368
IGF2	19789368
,	19789368
MLH1	19789368
,	19789368
NEUROG1	19789368
,	19789368
RUNX3	19789368
,	19789368
and	19789368
SOCS1	19789368
]	19789368
by	19789368
MethyLight	19789368
(	19789368
real	19789368
-	19789368
time	19789368
PCR	19789368
)	19789368
.	19789368

VDR	19789368
overexpression	19789368
was	19789368
significantly	19789368
associated	19789368
with	19789368
KRAS	19789368
mutation	19789368
(	19789368
odds	19789368
ratio	19789368
,	19789368
1	19789368
.	19789368
55	19789368
;	19789368
95%	19789368
confidence	19789368
interval	19789368
,	19789368
1	19789368
.	19789368
11	19789368
-	19789368
2	19789368
.	19789368
16	19789368
)	19789368
and	19789368
PIK3CA	19789368
mutation	19789368
(	19789368
odds	19789368
ratio	19789368
,	19789368
2	19789368
.	19789368
17	19789368
;	19789368
95%	19789368
confidence	19789368
interval	19789368
,	19789368
1	19789368
.	19789368
36	19789368
-	19789368
3	19789368
.	19789368
47	19789368
)	19789368
,	19789368
both	19789368
of	19789368
which	19789368
persisted	19789368
in	19789368
multivariate	19789368
logistic	19789368
regression	19789368
analysis	19789368
.	19789368

VDR	19789368
was	19789368
not	19789368
independently	19789368
associated	19789368
with	19789368
body	19789368
mass	19789368
index	19789368
,	19789368
family	19789368
history	19789368
of	19789368
colorectal	19789368
cancer	19789368
,	19789368
tumor	19789368
location	19789368
(	19789368
colon	19789368
versus	19789368
rectum	19789368
)	19789368
,	19789368
stage	19789368
,	19789368
tumor	19789368
grade	19789368
,	19789368
signet	19789368
ring	19789368
cells	19789368
,	19789368
CIMP	19789368
,	19789368
MSI	19789368
,	19789368
LINE	19789368
-	19789368
1	19789368
hypomethylation	19789368
,	19789368
BRAF	19789368
,	19789368
p53	19789368
,	19789368
p21	19789368
,	19789368
beta	19789368
-	19789368
catenin	19789368
,	19789368
or	19789368
cyclooxygenase	19789368
-	19789368
2	19789368
.	19789368

VDR	19789368
expression	19789368
was	19789368
not	19789368
significantly	19789368
related	19789368
with	19789368
patient	19789368
survival	19789368
,	19789368
prognosis	19789368
,	19789368
or	19789368
clinical	19789368
outcome	19789368
.	19789368

In	19789368
conclusion	19789368
,	19789368
VDR	19789368
overexpression	19789368
in	19789368
colorectal	19789368
cancer	19789368
is	19789368
independently	19789368
associated	19789368
with	19789368
PIK3CA	19789368
and	19789368
KRAS	19789368
mutations	19789368
.	19789368

Our	19789368
data	19789368
support	19789368
potential	19789368
interactions	19789368
between	19789368
the	19789368
VDR	19789368
,	19789368
RAS	19789368
-	19789368
MAPK	19789368
and	19789368
PI3K	19789368
-	19789368
AKT	19789368
pathways	19789368
,	19789368
and	19789368
possible	19789368
influence	19789368
by	19789368
KRAS	19789368
or	19789368
PIK3CA	19789368
mutation	19789368
on	19789368
therapy	19789368
or	19789368
chemoprevention	19789368
targeting	19789368
VDR	19789368
.	19789368
Identification	15807692
of	15807692
novel	15807692
type	15807692
VII	15807692
collagen	15807692
gene	15807692
mutations	15807692
resulting	15807692
in	15807692
severe	15807692
recessive	15807692
dystrophic	15807692
epidermolysis	15807692
bullosa	15807692
.	15807692

In	15807692
this	15807692
work	15807692
,	15807692
we	15807692
studied	15807692
the	15807692
proband	15807692
in	15807692
a	15807692
small	15807692
nuclear	15807692
family	15807692
of	15807692
Chinese	15807692
and	15807692
Dutch	15807692
/	15807692
German	15807692
descent	15807692
and	15807692
identified	15807692
two	15807692
novel	15807692
mutations	15807692
in	15807692
the	15807692
type	15807692
VII	15807692
collagen	15807692
gene	15807692
leading	15807692
to	15807692
recessive	15807692
dystrophic	15807692
epidermolysis	15807692
bullosa	15807692
,	15807692
Hallopeau	15807692
-	15807692
Siemens	15807692
variant	15807692
(	15807692
HS	15807692
-	15807692
RDEB	15807692
)	15807692
.	15807692

The	15807692
maternal	15807692
mutation	15807692
is	15807692
a	15807692
single	15807692
base	15807692
pair	15807692
deletion	15807692
of	15807692
a	15807692
cytosine	15807692
nucleotide	15807692
in	15807692
exon	15807692
26	15807692
,	15807692
designated	15807692
3472delC	15807692
,	15807692
resulting	15807692
in	15807692
a	15807692
frameshift	15807692
and	15807692
a	15807692
premature	15807692
termination	15807692
codon	15807692
(	15807692
PTC	15807692
)	15807692
within	15807692
the	15807692
same	15807692
exon	15807692
,	15807692
7	15807692
bp	15807692
downstream	15807692
of	15807692
the	15807692
site	15807692
of	15807692
the	15807692
mutation	15807692
.	15807692

The	15807692
paternal	15807692
mutation	15807692
is	15807692
a	15807692
G	15807692
-	15807692
-	15807692
>	15807692
A	15807692
transition	15807692
located	15807692
at	15807692
the	15807692
5	15807692
'	15807692
donor	15807692
splice	15807692
site	15807692
within	15807692
intron	15807692
51	15807692
,	15807692
designated	15807692
IVS51	15807692
+	15807692
1G	15807692
-	15807692
-	15807692
>	15807692
A	15807692
.	15807692

This	15807692
mutation	15807692
leads	15807692
to	15807692
the	15807692
activation	15807692
of	15807692
a	15807692
cryptic	15807692
splice	15807692
site	15807692
,	15807692
32	15807692
bp	15807692
downstream	15807692
of	15807692
the	15807692
mutation	15807692
site	15807692
and	15807692
to	15807692
subsequent	15807692
aberrant	15807692
out	15807692
-	15807692
of	15807692
-	15807692
frame	15807692
splicing	15807692
,	15807692
resulting	15807692
in	15807692
two	15807692
alternative	15807692
mRNA	15807692
transcripts	15807692
and	15807692
a	15807692
downstream	15807692
PTC	15807692
.	15807692

To	15807692
our	15807692
knowledge	15807692
,	15807692
these	15807692
two	15807692
mutations	15807692
have	15807692
not	15807692
been	15807692
previously	15807692
reported	15807692
.	15807692

These	15807692
findings	15807692
extend	15807692
the	15807692
body	15807692
of	15807692
evidence	15807692
for	15807692
compound	15807692
heterozygous	15807692
mutations	15807692
leading	15807692
to	15807692
HS	15807692
-	15807692
RDEB	15807692
and	15807692
provide	15807692
the	15807692
basis	15807692
for	15807692
prenatal	15807692
diagnosis	15807692
in	15807692
this	15807692
family	15807692
.	15807692
Detection	21130517
of	21130517
EGFR	21130517
mutations	21130517
in	21130517
plasma	21130517
DNA	21130517
from	21130517
lung	21130517
cancer	21130517
patients	21130517
by	21130517
mass	21130517
spectrometry	21130517
genotyping	21130517
is	21130517
predictive	21130517
of	21130517
tumor	21130517
EGFR	21130517
status	21130517
and	21130517
response	21130517
to	21130517
EGFR	21130517
inhibitors	21130517
.	21130517

AIMS	21130517
:	21130517
EGFR	21130517
mutations	21130517
now	21130517
guide	21130517
the	21130517
clinical	21130517
use	21130517
of	21130517
EGFR	21130517
-	21130517
targeted	21130517
therapy	21130517
in	21130517
lung	21130517
cancer	21130517
.	21130517

However	21130517
,	21130517
standard	21130517
EGFR	21130517
mutation	21130517
analysis	21130517
requires	21130517
a	21130517
minimum	21130517
amount	21130517
of	21130517
tumor	21130517
tissue	21130517
,	21130517
which	21130517
may	21130517
not	21130517
be	21130517
available	21130517
in	21130517
certain	21130517
situations	21130517
.	21130517

In	21130517
this	21130517
study	21130517
,	21130517
we	21130517
combined	21130517
a	21130517
mass	21130517
spectrometry	21130517
genotyping	21130517
assay	21130517
(	21130517
Sequenom	21130517
)	21130517
with	21130517
a	21130517
mutant	21130517
-	21130517
enriched	21130517
PCR	21130517
(	21130517
ME	21130517
-	21130517
PCR	21130517
)	21130517
to	21130517
detect	21130517
EGFR	21130517
mutations	21130517
in	21130517
free	21130517
plasma	21130517
DNA	21130517
from	21130517
patients	21130517
with	21130517
lung	21130517
cancer	21130517
.	21130517

METHOD	21130517
:	21130517
DNAs	21130517
were	21130517
extracted	21130517
from	21130517
31	21130517
plasma	21130517
samples	21130517
from	21130517
31	21130517
patients	21130517
and	21130517
analyzed	21130517
by	21130517
both	21130517
methods	21130517
for	21130517
EGFR	21130517
Exon	21130517
19	21130517
deletion	21130517
and	21130517
EGFR	21130517
L858R	21130517
mutation	21130517
.	21130517

Results	21130517
in	21130517
plasma	21130517
DNA	21130517
samples	21130517
were	21130517
compared	21130517
with	21130517
EGFR	21130517
mutation	21130517
status	21130517
obtained	21130517
in	21130517
tumor	21130517
DNA	21130517
(	21130517
18	21130517
/	21130517
31	21130517
EGFR	21130517
mutant	21130517
)	21130517
.	21130517

The	21130517
relationship	21130517
of	21130517
EGFR	21130517
mutation	21130517
status	21130517
in	21130517
tumor	21130517
and	21130517
/	21130517
or	21130517
plasma	21130517
samples	21130517
to	21130517
overall	21130517
survival	21130517
was	21130517
assessed	21130517
.	21130517

RESULTS	21130517
:	21130517
The	21130517
EGFR	21130517
mutation	21130517
status	21130517
in	21130517
plasma	21130517
DNA	21130517
was	21130517
identical	21130517
to	21130517
the	21130517
primary	21130517
tumor	21130517
in	21130517
61%	21130517
of	21130517
patients	21130517
(	21130517
19	21130517
/	21130517
31	21130517
)	21130517
.	21130517

By	21130517
mass	21130517
spectrometry	21130517
genotyping	21130517
,	21130517
the	21130517
plasma	21130517
samples	21130517
contained	21130517
mutant	21130517
DNA	21130517
corresponding	21130517
to	21130517
5	21130517
/	21130517
14	21130517
EGFR	21130517
Exon	21130517
19	21130517
deletions	21130517
and	21130517
3	21130517
/	21130517
4	21130517
EGFR	21130517
L858R	21130517
mutations	21130517
previously	21130517
diagnosed	21130517
in	21130517
the	21130517
matched	21130517
tumors	21130517
.	21130517

Two	21130517
samples	21130517
were	21130517
positive	21130517
in	21130517
plasma	21130517
DNA	21130517
but	21130517
negative	21130517
in	21130517
primary	21130517
tumor	21130517
tissue	21130517
.	21130517

Results	21130517
were	21130517
similar	21130517
for	21130517
samples	21130517
studied	21130517
by	21130517
ME	21130517
-	21130517
PCR	21130517
.	21130517

For	21130517
patients	21130517
treated	21130517
with	21130517
erlotinib	21130517
,	21130517
overall	21130517
survival	21130517
was	21130517
correlated	21130517
with	21130517
the	21130517
presence	21130517
of	21130517
EGFR	21130517
mutation	21130517
in	21130517
plasma	21130517
and	21130517
/	21130517
or	21130517
tumor	21130517
tissue	21130517
(	21130517
p	21130517
=	21130517
0	21130517
.	21130517
002	21130517
)	21130517
,	21130517
with	21130517
the	21130517
two	21130517
patients	21130517
positive	21130517
only	21130517
in	21130517
plasma	21130517
DNA	21130517
showing	21130517
responses	21130517
and	21130517
favorable	21130517
outcomes	21130517
.	21130517

CONCLUSION	21130517
:	21130517
The	21130517
detection	21130517
of	21130517
EGFR	21130517
mutations	21130517
in	21130517
plasma	21130517
DNA	21130517
samples	21130517
by	21130517
mass	21130517
spectrometry	21130517
genotyping	21130517
and	21130517
ME	21130517
-	21130517
PCR	21130517
is	21130517
feasible	21130517
.	21130517

A	21130517
positive	21130517
EGFR	21130517
result	21130517
in	21130517
plasma	21130517
DNA	21130517
has	21130517
a	21130517
high	21130517
predictive	21130517
value	21130517
for	21130517
tumor	21130517
EGFR	21130517
status	21130517
and	21130517
for	21130517
favorable	21130517
clinical	21130517
course	21130517
on	21130517
EGFR	21130517
-	21130517
targeted	21130517
therapy	21130517
and	21130517
could	21130517
therefore	21130517
be	21130517
useful	21130517
in	21130517
guiding	21130517
clinical	21130517
decisions	21130517
in	21130517
patients	21130517
with	21130517
insufficient	21130517
or	21130517
unavailable	21130517
tumor	21130517
specimens	21130517
.	21130517
Dynamic	28604678
subunit	28604678
turnover	28604678
in	28604678
ESCRT	28604678
-	28604678
III	28604678
assemblies	28604678
is	28604678
regulated	28604678
by	28604678
Vps4	28604678
to	28604678
mediate	28604678
membrane	28604678
remodelling	28604678
during	28604678
cytokinesis	28604678
.	28604678

The	28604678
endosomal	28604678
sorting	28604678
complex	28604678
required	28604678
for	28604678
transport	28604678
(	28604678
ESCRT	28604678
)	28604678
-	28604678
III	28604678
mediates	28604678
membrane	28604678
fission	28604678
in	28604678
fundamental	28604678
cellular	28604678
processes	28604678
,	28604678
including	28604678
cytokinesis	28604678
.	28604678

ESCRT	28604678
-	28604678
III	28604678
is	28604678
thought	28604678
to	28604678
form	28604678
persistent	28604678
filaments	28604678
that	28604678
over	28604678
time	28604678
increase	28604678
their	28604678
curvature	28604678
to	28604678
constrict	28604678
membranes	28604678
.	28604678

Unexpectedly	28604678
,	28604678
we	28604678
found	28604678
that	28604678
ESCRT	28604678
-	28604678
III	28604678
at	28604678
the	28604678
midbody	28604678
of	28604678
human	28604678
cells	28604678
rapidly	28604678
turns	28604678
over	28604678
subunits	28604678
with	28604678
cytoplasmic	28604678
pools	28604678
while	28604678
gradually	28604678
forming	28604678
larger	28604678
assemblies	28604678
.	28604678

ESCRT	28604678
-	28604678
III	28604678
turnover	28604678
depended	28604678
on	28604678
the	28604678
ATPase	28604678
VPS4	28604678
,	28604678
which	28604678
accumulated	28604678
at	28604678
the	28604678
midbody	28604678
simultaneously	28604678
with	28604678
ESCRT	28604678
-	28604678
III	28604678
subunits	28604678
,	28604678
and	28604678
was	28604678
required	28604678
for	28604678
assembly	28604678
of	28604678
functional	28604678
ESCRT	28604678
-	28604678
III	28604678
structures	28604678
.	28604678

In	28604678
vitro	28604678
,	28604678
the	28604678
Vps2	28604678
/	28604678
Vps24	28604678
subunits	28604678
of	28604678
ESCRT	28604678
-	28604678
III	28604678
formed	28604678
side	28604678
-	28604678
by	28604678
-	28604678
side	28604678
filaments	28604678
with	28604678
Snf7	28604678
and	28604678
inhibited	28604678
further	28604678
polymerization	28604678
,	28604678
but	28604678
the	28604678
growth	28604678
inhibition	28604678
was	28604678
alleviated	28604678
by	28604678
the	28604678
addition	28604678
of	28604678
Vps4	28604678
and	28604678
ATP	28604678
.	28604678

High	28604678
-	28604678
speed	28604678
atomic	28604678
force	28604678
microscopy	28604678
further	28604678
revealed	28604678
highly	28604678
dynamic	28604678
arrays	28604678
of	28604678
growing	28604678
and	28604678
shrinking	28604678
ESCRT	28604678
-	28604678
III	28604678
spirals	28604678
in	28604678
the	28604678
presence	28604678
of	28604678
Vps4	28604678
.	28604678

Continuous	28604678
ESCRT	28604678
-	28604678
III	28604678
remodelling	28604678
by	28604678
subunit	28604678
turnover	28604678
might	28604678
facilitate	28604678
shape	28604678
adaptions	28604678
to	28604678
variable	28604678
membrane	28604678
geometries	28604678
,	28604678
with	28604678
broad	28604678
implications	28604678
for	28604678
diverse	28604678
cellular	28604678
processes	28604678
.	28604678
Acute	18439803
effects	18439803
of	18439803
N	18439803
-	18439803
(	18439803
2	18439803
-	18439803
propylpentanoyl	18439803
)	18439803
urea	18439803
on	18439803
hippocampal	18439803
amino	18439803
acid	18439803
neurotransmitters	18439803
in	18439803
pilocarpine	18439803
-	18439803
induced	18439803
seizure	18439803
in	18439803
rats	18439803
.	18439803

The	18439803
present	18439803
study	18439803
aimed	18439803
to	18439803
investigate	18439803
the	18439803
anticonvulsant	18439803
activity	18439803
as	18439803
well	18439803
as	18439803
the	18439803
effects	18439803
on	18439803
the	18439803
level	18439803
of	18439803
hippocampal	18439803
amino	18439803
acid	18439803
neurotransmitters	18439803
(	18439803
glutamate	18439803
,	18439803
aspartate	18439803
,	18439803
glycine	18439803
and	18439803
GABA	18439803
)	18439803
of	18439803
N	18439803
-	18439803
(	18439803
2	18439803
-	18439803
propylpentanoyl	18439803
)	18439803
urea	18439803
(	18439803
VPU	18439803
)	18439803
in	18439803
comparison	18439803
to	18439803
its	18439803
parent	18439803
compound	18439803
,	18439803
valproic	18439803
acid	18439803
(	18439803
VPA	18439803
)	18439803
.	18439803

VPU	18439803
was	18439803
more	18439803
potent	18439803
than	18439803
VPA	18439803
,	18439803
exhibiting	18439803
the	18439803
median	18439803
effective	18439803
dose	18439803
(	18439803
ED	18439803
(	18439803
50	18439803
)	18439803
)	18439803
of	18439803
49	18439803
mg	18439803
/	18439803
kg	18439803
in	18439803
protecting	18439803
rats	18439803
against	18439803
pilocarpine	18439803
-	18439803
induced	18439803
seizure	18439803
whereas	18439803
the	18439803
corresponding	18439803
value	18439803
for	18439803
VPA	18439803
was	18439803
322	18439803
mg	18439803
/	18439803
kg	18439803
.	18439803

In	18439803
vivo	18439803
microdialysis	18439803
demonstrated	18439803
that	18439803
an	18439803
intraperitoneal	18439803
administration	18439803
of	18439803
pilocarpine	18439803
induced	18439803
a	18439803
pronounced	18439803
increment	18439803
of	18439803
hippocampal	18439803
glutamate	18439803
and	18439803
aspartate	18439803
whereas	18439803
no	18439803
significant	18439803
change	18439803
was	18439803
observed	18439803
on	18439803
the	18439803
level	18439803
of	18439803
glycine	18439803
and	18439803
GABA	18439803
.	18439803

Pretreatment	18439803
with	18439803
either	18439803
VPU	18439803
(	18439803
50	18439803
and	18439803
100	18439803
mg	18439803
/	18439803
kg	18439803
)	18439803
or	18439803
VPA	18439803
(	18439803
300	18439803
and	18439803
600	18439803
mg	18439803
/	18439803
kg	18439803
)	18439803
completely	18439803
abolished	18439803
pilocarpine	18439803
-	18439803
evoked	18439803
increases	18439803
in	18439803
extracellular	18439803
glutamate	18439803
and	18439803
aspartate	18439803
.	18439803

In	18439803
addition	18439803
,	18439803
a	18439803
statistically	18439803
significant	18439803
reduction	18439803
was	18439803
also	18439803
observed	18439803
on	18439803
the	18439803
level	18439803
of	18439803
GABA	18439803
and	18439803
glycine	18439803
but	18439803
less	18439803
than	18439803
a	18439803
drastic	18439803
reduction	18439803
of	18439803
glutamate	18439803
and	18439803
aspartate	18439803
level	18439803
.	18439803

Based	18439803
on	18439803
the	18439803
finding	18439803
that	18439803
VPU	18439803
and	18439803
VPA	18439803
could	18439803
protect	18439803
the	18439803
animals	18439803
against	18439803
pilocarpine	18439803
-	18439803
induced	18439803
seizure	18439803
it	18439803
is	18439803
suggested	18439803
that	18439803
the	18439803
reduction	18439803
of	18439803
inhibitory	18439803
amino	18439803
acid	18439803
neurotransmitters	18439803
was	18439803
comparatively	18439803
minor	18439803
and	18439803
offset	18439803
by	18439803
a	18439803
pronounced	18439803
reduction	18439803
of	18439803
glutamate	18439803
and	18439803
aspartate	18439803
.	18439803

Therefore	18439803
,	18439803
like	18439803
VPA	18439803
,	18439803
the	18439803
finding	18439803
that	18439803
VPU	18439803
could	18439803
drastically	18439803
reduce	18439803
pilocarpine	18439803
-	18439803
induced	18439803
increases	18439803
in	18439803
glutamate	18439803
and	18439803
aspartate	18439803
should	18439803
account	18439803
,	18439803
at	18439803
least	18439803
partly	18439803
,	18439803
for	18439803
its	18439803
anticonvulsant	18439803
activity	18439803
observed	18439803
in	18439803
pilocarpine	18439803
-	18439803
induced	18439803
seizure	18439803
in	18439803
experimental	18439803
animals	18439803
.	18439803

Some	18439803
other	18439803
mechanism	18439803
than	18439803
those	18439803
being	18439803
reported	18439803
herein	18439803
should	18439803
be	18439803
further	18439803
investigated	18439803
.	18439803
Carrier	16152606
frequency	16152606
of	16152606
mutation	16152606
657del5	16152606
in	16152606
the	16152606
NBS1	16152606
gene	16152606
in	16152606
a	16152606
population	16152606
of	16152606
Polish	16152606
pediatric	16152606
patients	16152606
with	16152606
sporadic	16152606
lymphoid	16152606
malignancies	16152606
.	16152606

Nijmegen	16152606
breakage	16152606
syndrome	16152606
(	16152606
NBS	16152606
)	16152606
is	16152606
a	16152606
human	16152606
autosomal	16152606
recessive	16152606
disease	16152606
characterized	16152606
by	16152606
genomic	16152606
instability	16152606
and	16152606
enhanced	16152606
cancer	16152606
predisposition	16152606
,	16152606
in	16152606
particular	16152606
to	16152606
lymphoma	16152606
and	16152606
leukemia	16152606
.	16152606

Recently	16152606
,	16152606
significantly	16152606
higher	16152606
frequencies	16152606
of	16152606
heterozygous	16152606
carriers	16152606
of	16152606
the	16152606
Slavic	16152606
founder	16152606
NBS1	16152606
mutation	16152606
,	16152606
657del5	16152606
,	16152606
were	16152606
found	16152606
in	16152606
Russian	16152606
children	16152606
with	16152606
sporadic	16152606
lymphoid	16152606
malignancies	16152606
,	16152606
and	16152606
in	16152606
Polish	16152606
adults	16152606
with	16152606
non	16152606
-	16152606
Hodgkin	16152606
lymphoma	16152606
(	16152606
NHL	16152606
)	16152606
.	16152606

In	16152606
addition	16152606
,	16152606
the	16152606
substitution	16152606
643C	16152606
>	16152606
T	16152606
(	16152606
R215W	16152606
)	16152606
has	16152606
also	16152606
been	16152606
found	16152606
in	16152606
excess	16152606
among	16152606
children	16152606
with	16152606
acute	16152606
lymphoblastic	16152606
leukemia	16152606
(	16152606
ALL	16152606
)	16152606
.	16152606

In	16152606
an	16152606
attempt	16152606
to	16152606
asses	16152606
the	16152606
contribution	16152606
of	16152606
both	16152606
mutations	16152606
to	16152606
the	16152606
development	16152606
of	16152606
sporadic	16152606
lymphoid	16152606
malignancies	16152606
,	16152606
we	16152606
analyzed	16152606
DNA	16152606
samples	16152606
from	16152606
a	16152606
large	16152606
group	16152606
of	16152606
Polish	16152606
pediatric	16152606
patients	16152606
.	16152606

The	16152606
NBS1	16152606
mutation	16152606
657del5	16152606
on	16152606
one	16152606
allele	16152606
was	16152606
found	16152606
in	16152606
3	16152606
of	16152606
270	16152606
patients	16152606
with	16152606
ALL	16152606
and	16152606
2	16152606
of	16152606
212	16152606
children	16152606
and	16152606
adolescents	16152606
with	16152606
NHL	16152606
;	16152606
no	16152606
carrier	16152606
was	16152606
found	16152606
among	16152606
63	16152606
patients	16152606
with	16152606
Hodgkin	16152606
lymphoma	16152606
(	16152606
HL	16152606
)	16152606
.	16152606

No	16152606
carriers	16152606
of	16152606
the	16152606
variant	16152606
R215W	16152606
were	16152606
detected	16152606
in	16152606
any	16152606
studied	16152606
group	16152606
.	16152606

The	16152606
relative	16152606
frequency	16152606
of	16152606
the	16152606
657del5	16152606
mutation	16152606
was	16152606
calculated	16152606
from	16152606
a	16152606
total	16152606
of	16152606
6	16152606
,	16152606
984	16152606
controls	16152606
matched	16152606
by	16152606
place	16152606
of	16152606
patient	16152606
residence	16152606
,	16152606
of	16152606
whom	16152606
42	16152606
were	16152606
found	16152606
to	16152606
be	16152606
carriers	16152606
(	16152606
frequency	16152606
=	16152606
0	16152606
.	16152606
006	16152606
)	16152606
.	16152606

In	16152606
the	16152606
analyzed	16152606
population	16152606
with	16152606
malignancies	16152606
,	16152606
an	16152606
increased	16152606
odds	16152606
ratio	16152606
for	16152606
the	16152606
occurrence	16152606
of	16152606
mutation	16152606
657del5	16152606
was	16152606
found	16152606
in	16152606
comparison	16152606
with	16152606
the	16152606
control	16152606
Polish	16152606
population	16152606
(	16152606
OR	16152606
range	16152606
1	16152606
.	16152606
48	16152606
-	16152606
1	16152606
.	16152606
85	16152606
,	16152606
95%	16152606
confidence	16152606
interval	16152606
1	16152606
.	16152606
18	16152606
-	16152606
2	16152606
.	16152606
65	16152606
)	16152606
.	16152606

This	16152606
finding	16152606
indicates	16152606
that	16152606
the	16152606
frequency	16152606
of	16152606
the	16152606
mutation	16152606
carriers	16152606
was	16152606
indeed	16152606
increased	16152606
in	16152606
patients	16152606
with	16152606
ALL	16152606
and	16152606
NHL	16152606
(	16152606
p	16152606
<	16152606
0	16152606
.	16152606
05	16152606
)	16152606
.	16152606

Nonetheless	16152606
,	16152606
NBS1	16152606
gene	16152606
heterozygosity	16152606
is	16152606
not	16152606
a	16152606
major	16152606
risk	16152606
factor	16152606
for	16152606
lymphoid	16152606
malignancies	16152606
in	16152606
childhood	16152606
and	16152606
adolescence	16152606
.	16152606
TNFR	22711886
-	22711886
associated	22711886
factor	22711886
2	22711886
deficiency	22711886
in	22711886
B	22711886
lymphocytes	22711886
predisposes	22711886
to	22711886
chronic	22711886
lymphocytic	22711886
leukemia	22711886
/	22711886
small	22711886
lymphocytic	22711886
lymphoma	22711886
in	22711886
mice	22711886
.	22711886

We	22711886
have	22711886
previously	22711886
shown	22711886
that	22711886
transgenic	22711886
(	22711886
tg	22711886
)	22711886
mice	22711886
expressing	22711886
in	22711886
B	22711886
lymphocytes	22711886
both	22711886
BCL	22711886
-	22711886
2	22711886
and	22711886
a	22711886
TNFR	22711886
-	22711886
associated	22711886
factor	22711886
2	22711886
(	22711886
TRAF2	22711886
)	22711886
mutant	22711886
lacking	22711886
the	22711886
really	22711886
interesting	22711886
new	22711886
gene	22711886
and	22711886
zinc	22711886
finger	22711886
domains	22711886
(	22711886
TRAF2DN	22711886
)	22711886
develop	22711886
small	22711886
lymphocytic	22711886
lymphoma	22711886
and	22711886
chronic	22711886
lymphocytic	22711886
leukemia	22711886
with	22711886
high	22711886
incidence	22711886
(	22711886
Zapata	22711886
et	22711886
al	22711886
.	22711886

2004	22711886
.	22711886

Proc	22711886
.	22711886

Nat	22711886
.	22711886

Acad	22711886
.	22711886

Sci	22711886
.	22711886

USA	22711886
101	22711886
:	22711886
16600	22711886
-	22711886
16605	22711886
)	22711886
.	22711886

Further	22711886
analysis	22711886
of	22711886
the	22711886
expression	22711886
of	22711886
TRAF2	22711886
and	22711886
TRAF2DN	22711886
in	22711886
purified	22711886
B	22711886
cells	22711886
demonstrated	22711886
that	22711886
expression	22711886
of	22711886
both	22711886
endogenous	22711886
TRAF2	22711886
and	22711886
tg	22711886
TRAF2DN	22711886
was	22711886
negligible	22711886
in	22711886
Traf2DN	22711886
-	22711886
tg	22711886
B	22711886
cells	22711886
compared	22711886
with	22711886
wild	22711886
-	22711886
type	22711886
mice	22711886
.	22711886

This	22711886
was	22711886
the	22711886
result	22711886
of	22711886
proteasome	22711886
-	22711886
dependent	22711886
degradation	22711886
,	22711886
and	22711886
rendered	22711886
TRAF2DN	22711886
B	22711886
cells	22711886
as	22711886
bona	22711886
fide	22711886
TRAF2	22711886
-	22711886
deficient	22711886
B	22711886
cells	22711886
.	22711886

Similar	22711886
to	22711886
B	22711886
cells	22711886
with	22711886
targeted	22711886
Traf2	22711886
deletion	22711886
,	22711886
Traf2DN	22711886
-	22711886
tg	22711886
mice	22711886
show	22711886
expanded	22711886
marginal	22711886
zone	22711886
B	22711886
cell	22711886
population	22711886
and	22711886
have	22711886
constitutive	22711886
p100	22711886
NF	22711886
-	22711886
kappaB2	22711886
processing	22711886
.	22711886

Also	22711886
,	22711886
TRAF3	22711886
,	22711886
X	22711886
-	22711886
linked	22711886
inhibitor	22711886
of	22711886
apoptosis	22711886
,	22711886
and	22711886
Bcl	22711886
-	22711886
X	22711886
(	22711886
L	22711886
)	22711886
expression	22711886
levels	22711886
were	22711886
increased	22711886
,	22711886
whereas	22711886
cellular	22711886
inhibitors	22711886
of	22711886
apoptosis	22711886
1	22711886
and	22711886
2	22711886
levels	22711886
were	22711886
drastically	22711886
reduced	22711886
compared	22711886
with	22711886
those	22711886
found	22711886
in	22711886
wild	22711886
-	22711886
type	22711886
B	22711886
cells	22711886
.	22711886

Moreover	22711886
,	22711886
consistent	22711886
with	22711886
previous	22711886
results	22711886
,	22711886
we	22711886
also	22711886
show	22711886
that	22711886
TRAF2	22711886
was	22711886
required	22711886
for	22711886
efficient	22711886
JNK	22711886
and	22711886
ERK	22711886
activation	22711886
in	22711886
response	22711886
to	22711886
CD40	22711886
engagement	22711886
.	22711886

However	22711886
,	22711886
TRAF2	22711886
was	22711886
deleterious	22711886
for	22711886
BCR	22711886
-	22711886
mediated	22711886
activation	22711886
of	22711886
these	22711886
kinases	22711886
.	22711886

In	22711886
contrast	22711886
,	22711886
TRAF2	22711886
deficiency	22711886
had	22711886
no	22711886
effect	22711886
on	22711886
CD40	22711886
-	22711886
mediated	22711886
p38	22711886
MAPK	22711886
activation	22711886
but	22711886
significantly	22711886
reduced	22711886
BCR	22711886
-	22711886
mediated	22711886
p38	22711886
activation	22711886
.	22711886

Finally	22711886
,	22711886
we	22711886
further	22711886
confirm	22711886
that	22711886
TRAF2	22711886
was	22711886
required	22711886
for	22711886
CD40	22711886
-	22711886
mediated	22711886
proliferation	22711886
,	22711886
but	22711886
its	22711886
absence	22711886
relieved	22711886
B	22711886
cells	22711886
of	22711886
the	22711886
need	22711886
for	22711886
B	22711886
cell	22711886
activating	22711886
factor	22711886
for	22711886
survival	22711886
.	22711886

Altogether	22711886
,	22711886
our	22711886
results	22711886
suggest	22711886
that	22711886
TRAF2	22711886
deficiency	22711886
cooperates	22711886
with	22711886
BCL	22711886
-	22711886
2	22711886
in	22711886
promoting	22711886
chronic	22711886
lymphocytic	22711886
leukemia	22711886
/	22711886
small	22711886
lymphocytic	22711886
lymphoma	22711886
in	22711886
mice	22711886
,	22711886
possibly	22711886
by	22711886
specifically	22711886
enforcing	22711886
marginal	22711886
zone	22711886
B	22711886
cell	22711886
accumulation	22711886
,	22711886
increasing	22711886
X	22711886
-	22711886
linked	22711886
inhibitor	22711886
of	22711886
apoptosis	22711886
expression	22711886
,	22711886
and	22711886
rendering	22711886
B	22711886
cells	22711886
independent	22711886
of	22711886
B	22711886
cell	22711886
activating	22711886
factor	22711886
for	22711886
survival	22711886
.	22711886
Association	20105310
of	20105310
adipocyte	20105310
genes	20105310
with	20105310
ASP	20105310
expression	20105310
:	20105310
a	20105310
microarray	20105310
analysis	20105310
of	20105310
subcutaneous	20105310
and	20105310
omental	20105310
adipose	20105310
tissue	20105310
in	20105310
morbidly	20105310
obese	20105310
subjects	20105310
.	20105310

BACKGROUND	20105310
:	20105310
Prevalence	20105310
of	20105310
obesity	20105310
is	20105310
increasing	20105310
to	20105310
pandemic	20105310
proportions	20105310
.	20105310

However	20105310
,	20105310
obese	20105310
subjects	20105310
differ	20105310
in	20105310
insulin	20105310
resistance	20105310
,	20105310
adipokine	20105310
production	20105310
and	20105310
co	20105310
-	20105310
morbidities	20105310
.	20105310

Based	20105310
on	20105310
fasting	20105310
plasma	20105310
analysis	20105310
,	20105310
obese	20105310
subjects	20105310
were	20105310
grouped	20105310
as	20105310
Low	20105310
Acylation	20105310
Stimulating	20105310
protein	20105310
(	20105310
ASP	20105310
)	20105310
and	20105310
Triglyceride	20105310
(	20105310
TG	20105310
)	20105310
(	20105310
LAT	20105310
)	20105310
vs	20105310
High	20105310
ASP	20105310
and	20105310
TG	20105310
(	20105310
HAT	20105310
)	20105310
.	20105310

Subcutaneous	20105310
(	20105310
SC	20105310
)	20105310
and	20105310
omental	20105310
(	20105310
OM	20105310
)	20105310
adipose	20105310
tissues	20105310
(	20105310
n	20105310
=	20105310
21	20105310
)	20105310
were	20105310
analysed	20105310
by	20105310
microarray	20105310
,	20105310
and	20105310
biologic	20105310
pathways	20105310
in	20105310
lipid	20105310
metabolism	20105310
and	20105310
inflammation	20105310
were	20105310
specifically	20105310
examined	20105310
.	20105310

METHODS	20105310
:	20105310
LAT	20105310
and	20105310
HAT	20105310
groups	20105310
were	20105310
matched	20105310
in	20105310
age	20105310
,	20105310
obesity	20105310
,	20105310
insulin	20105310
,	20105310
and	20105310
glucose	20105310
,	20105310
and	20105310
had	20105310
similar	20105310
expression	20105310
of	20105310
insulin	20105310
-	20105310
related	20105310
genes	20105310
(	20105310
InsR	20105310
,	20105310
IRS	20105310
-	20105310
1	20105310
)	20105310
.	20105310

ASP	20105310
related	20105310
genes	20105310
tended	20105310
to	20105310
be	20105310
increased	20105310
in	20105310
the	20105310
HAT	20105310
group	20105310
and	20105310
were	20105310
correlated	20105310
(	20105310
factor	20105310
B	20105310
,	20105310
adipsin	20105310
,	20105310
complement	20105310
C3	20105310
,	20105310
p	20105310
<	20105310
0	20105310
.	20105310
01	20105310
each	20105310
)	20105310
.	20105310

Differences	20105310
between	20105310
LAT	20105310
and	20105310
HAT	20105310
group	20105310
were	20105310
almost	20105310
exclusively	20105310
in	20105310
SC	20105310
tissue	20105310
,	20105310
with	20105310
little	20105310
difference	20105310
in	20105310
OM	20105310
tissue	20105310
.	20105310

Increased	20105310
C5L2	20105310
(	20105310
p	20105310
<	20105310
0	20105310
.	20105310
01	20105310
)	20105310
,	20105310
an	20105310
ASP	20105310
receptor	20105310
,	20105310
in	20105310
HAT	20105310
suggests	20105310
a	20105310
compensatory	20105310
ASP	20105310
pathway	20105310
,	20105310
associated	20105310
with	20105310
increased	20105310
TG	20105310
storage	20105310
.	20105310

RESULTS	20105310
:	20105310
HAT	20105310
adipose	20105310
tissue	20105310
demonstrated	20105310
increased	20105310
lipid	20105310
related	20105310
genes	20105310
for	20105310
storage	20105310
(	20105310
CD36	20105310
,	20105310
DGAT1	20105310
,	20105310
DGAT2	20105310
,	20105310
SCD1	20105310
,	20105310
FASN	20105310
,	20105310
and	20105310
LPL	20105310
)	20105310
,	20105310
lipolysis	20105310
(	20105310
HSL	20105310
,	20105310
CES1	20105310
,	20105310
perilipin	20105310
)	20105310
,	20105310
fatty	20105310
acid	20105310
binding	20105310
proteins	20105310
(	20105310
FABP1	20105310
,	20105310
FABP3	20105310
)	20105310
and	20105310
adipocyte	20105310
differentiation	20105310
markers	20105310
(	20105310
CEBPalpha	20105310
,	20105310
CEBPbeta	20105310
,	20105310
PPARgamma	20105310
)	20105310
.	20105310

By	20105310
contrast	20105310
,	20105310
oxidation	20105310
related	20105310
genes	20105310
were	20105310
decreased	20105310
(	20105310
AMPK	20105310
,	20105310
UCP1	20105310
,	20105310
CPT1	20105310
,	20105310
FABP7	20105310
)	20105310
.	20105310

HAT	20105310
subjects	20105310
had	20105310
increased	20105310
anti	20105310
-	20105310
inflammatory	20105310
genes	20105310
TGFB1	20105310
,	20105310
TIMP1	20105310
,	20105310
TIMP3	20105310
,	20105310
and	20105310
TIMP4	20105310
while	20105310
proinflammatory	20105310
PIG7	20105310
and	20105310
MMP2	20105310
were	20105310
also	20105310
significantly	20105310
increased	20105310
;	20105310
all	20105310
genes	20105310
,	20105310
p	20105310
<	20105310
0	20105310
.	20105310
025	20105310
.	20105310

CONCLUSION	20105310
:	20105310
Taken	20105310
together	20105310
,	20105310
the	20105310
profile	20105310
of	20105310
C5L2	20105310
receptor	20105310
,	20105310
ASP	20105310
gene	20105310
expression	20105310
and	20105310
metabolic	20105310
factors	20105310
in	20105310
adipose	20105310
tissue	20105310
from	20105310
morbidly	20105310
obese	20105310
HAT	20105310
subjects	20105310
suggests	20105310
a	20105310
compensatory	20105310
response	20105310
associated	20105310
with	20105310
the	20105310
increased	20105310
plasma	20105310
ASP	20105310
and	20105310
TG	20105310
.	20105310
MHC	21695597
region	21695597
and	21695597
risk	21695597
of	21695597
systemic	21695597
lupus	21695597
erythematosus	21695597
in	21695597
African	21695597
American	21695597
women	21695597
.	21695597

The	21695597
major	21695597
histocompatibility	21695597
complex	21695597
(	21695597
MHC	21695597
)	21695597
on	21695597
chromosome	21695597
6p21	21695597
is	21695597
a	21695597
key	21695597
contributor	21695597
to	21695597
the	21695597
genetic	21695597
basis	21695597
of	21695597
systemic	21695597
lupus	21695597
erythematosus	21695597
(	21695597
SLE	21695597
)	21695597
.	21695597

Although	21695597
SLE	21695597
affects	21695597
African	21695597
Americans	21695597
disproportionately	21695597
compared	21695597
to	21695597
European	21695597
Americans	21695597
,	21695597
there	21695597
has	21695597
been	21695597
no	21695597
comprehensive	21695597
analysis	21695597
of	21695597
the	21695597
MHC	21695597
region	21695597
in	21695597
relationship	21695597
to	21695597
SLE	21695597
in	21695597
African	21695597
Americans	21695597
.	21695597

We	21695597
conducted	21695597
a	21695597
screening	21695597
of	21695597
the	21695597
MHC	21695597
region	21695597
for	21695597
1	21695597
,	21695597
536	21695597
single	21695597
nucleotide	21695597
polymorphisms	21695597
(	21695597
SNPs	21695597
)	21695597
and	21695597
the	21695597
deletion	21695597
of	21695597
the	21695597
C4A	21695597
gene	21695597
in	21695597
a	21695597
SLE	21695597
case	21695597
-	21695597
control	21695597
study	21695597
(	21695597
380	21695597
cases	21695597
,	21695597
765	21695597
age	21695597
-	21695597
matched	21695597
controls	21695597
)	21695597
nested	21695597
within	21695597
the	21695597
prospective	21695597
Black	21695597
Women	21695597
'	21695597
s	21695597
Health	21695597
Study	21695597
.	21695597

We	21695597
also	21695597
genotyped	21695597
1	21695597
,	21695597
509	21695597
ancestral	21695597
informative	21695597
markers	21695597
throughout	21695597
the	21695597
genome	21695597
to	21695597
estimate	21695597
European	21695597
ancestry	21695597
to	21695597
control	21695597
for	21695597
population	21695597
stratification	21695597
due	21695597
to	21695597
population	21695597
admixture	21695597
.	21695597

The	21695597
most	21695597
strongly	21695597
associated	21695597
SNP	21695597
with	21695597
SLE	21695597
was	21695597
the	21695597
rs9271366	21695597
(	21695597
odds	21695597
ratio	21695597
,	21695597
OR	21695597
=	21695597
1	21695597
.	21695597
70	21695597
,	21695597
p	21695597
=	21695597
5	21695597
.	21695597
6	21695597
10	21695597
(	21695597
-	21695597
5	21695597
)	21695597
)	21695597
near	21695597
the	21695597
HLA	21695597
-	21695597
DRB1	21695597
gene	21695597
.	21695597

Conditional	21695597
haplotype	21695597
analysis	21695597
revealed	21695597
three	21695597
other	21695597
SNPs	21695597
,	21695597
rs204890	21695597
(	21695597
OR	21695597
=	21695597
1	21695597
.	21695597
86	21695597
,	21695597
p	21695597
=	21695597
1	21695597
.	21695597
2	21695597
10	21695597
(	21695597
-	21695597
4	21695597
)	21695597
)	21695597
,	21695597
rs2071349	21695597
(	21695597
OR	21695597
=	21695597
1	21695597
.	21695597
53	21695597
,	21695597
p	21695597
=	21695597
1	21695597
.	21695597
0	21695597
10	21695597
(	21695597
-	21695597
3	21695597
)	21695597
)	21695597
,	21695597
and	21695597
rs2844580	21695597
(	21695597
OR	21695597
=	21695597
1	21695597
.	21695597
43	21695597
,	21695597
p	21695597
=	21695597
1	21695597
.	21695597
3	21695597
10	21695597
(	21695597
-	21695597
3	21695597
)	21695597
)	21695597
,	21695597
to	21695597
be	21695597
associated	21695597
with	21695597
SLE	21695597
independent	21695597
of	21695597
the	21695597
rs9271366	21695597
SNP	21695597
.	21695597

In	21695597
univariate	21695597
analysis	21695597
,	21695597
the	21695597
OR	21695597
for	21695597
the	21695597
C4A	21695597
deletion	21695597
was	21695597
1	21695597
.	21695597
38	21695597
,	21695597
p	21695597
=	21695597
0	21695597
.	21695597
075	21695597
,	21695597
but	21695597
after	21695597
simultaneous	21695597
adjustment	21695597
for	21695597
the	21695597
other	21695597
four	21695597
SNPs	21695597
the	21695597
odds	21695597
ratio	21695597
was	21695597
1	21695597
.	21695597
01	21695597
,	21695597
p	21695597
=	21695597
0	21695597
.	21695597
98	21695597
.	21695597

A	21695597
genotype	21695597
score	21695597
combining	21695597
the	21695597
four	21695597
newly	21695597
identified	21695597
SNPs	21695597
showed	21695597
an	21695597
additive	21695597
risk	21695597
according	21695597
to	21695597
the	21695597
number	21695597
of	21695597
high	21695597
-	21695597
risk	21695597
alleles	21695597
(	21695597
OR	21695597
=	21695597
1	21695597
.	21695597
67	21695597
per	21695597
high	21695597
-	21695597
risk	21695597
allele	21695597
,	21695597
p	21695597
<	21695597
0	21695597
.	21695597
0001	21695597
)	21695597
.	21695597

Our	21695597
strongest	21695597
signal	21695597
,	21695597
the	21695597
rs9271366	21695597
SNP	21695597
,	21695597
was	21695597
also	21695597
associated	21695597
with	21695597
higher	21695597
risk	21695597
of	21695597
SLE	21695597
in	21695597
a	21695597
previous	21695597
Chinese	21695597
genome	21695597
-	21695597
wide	21695597
association	21695597
study	21695597
(	21695597
GWAS	21695597
)	21695597
.	21695597

In	21695597
addition	21695597
,	21695597
two	21695597
SNPs	21695597
found	21695597
in	21695597
a	21695597
GWAS	21695597
of	21695597
European	21695597
ancestry	21695597
women	21695597
were	21695597
confirmed	21695597
in	21695597
our	21695597
study	21695597
,	21695597
indicating	21695597
that	21695597
African	21695597
Americans	21695597
share	21695597
some	21695597
genetic	21695597
risk	21695597
factors	21695597
for	21695597
SLE	21695597
with	21695597
European	21695597
and	21695597
Chinese	21695597
subjects	21695597
.	21695597

In	21695597
summary	21695597
,	21695597
we	21695597
found	21695597
four	21695597
independent	21695597
signals	21695597
in	21695597
the	21695597
MHC	21695597
region	21695597
associated	21695597
with	21695597
risk	21695597
of	21695597
SLE	21695597
in	21695597
African	21695597
American	21695597
women	21695597
.	21695597
Polymorphic	17959715
MLH1	17959715
and	17959715
risk	17959715
of	17959715
cancer	17959715
after	17959715
methylating	17959715
chemotherapy	17959715
for	17959715
Hodgkin	17959715
lymphoma	17959715
.	17959715

BACKGROUND	17959715
AND	17959715
OBJECTIVE	17959715
:	17959715
Methylating	17959715
agents	17959715
are	17959715
effective	17959715
chemotherapy	17959715
agents	17959715
for	17959715
Hodgkin	17959715
lymphoma	17959715
,	17959715
but	17959715
are	17959715
associated	17959715
with	17959715
the	17959715
development	17959715
of	17959715
second	17959715
primary	17959715
cancers	17959715
.	17959715

Cytotoxicity	17959715
of	17959715
methylating	17959715
agents	17959715
is	17959715
mediated	17959715
primarily	17959715
by	17959715
the	17959715
DNA	17959715
mismatch	17959715
repair	17959715
(	17959715
MMR	17959715
)	17959715
system	17959715
.	17959715

Loss	17959715
of	17959715
MLH1	17959715
,	17959715
a	17959715
major	17959715
component	17959715
of	17959715
DNA	17959715
MMR	17959715
,	17959715
results	17959715
in	17959715
tolerance	17959715
to	17959715
the	17959715
cytotoxic	17959715
effects	17959715
of	17959715
methylating	17959715
agents	17959715
and	17959715
persistence	17959715
of	17959715
mutagenised	17959715
cells	17959715
at	17959715
high	17959715
risk	17959715
of	17959715
malignant	17959715
transformation	17959715
.	17959715

We	17959715
hypothesised	17959715
that	17959715
a	17959715
common	17959715
substitution	17959715
in	17959715
the	17959715
basal	17959715
promoter	17959715
of	17959715
MLH1	17959715
(	17959715
position	17959715
-	17959715
93	17959715
,	17959715
rs1800734	17959715
)	17959715
modifies	17959715
the	17959715
risk	17959715
of	17959715
cancer	17959715
after	17959715
methylating	17959715
chemotherapy	17959715
.	17959715

METHODS	17959715
:	17959715
133	17959715
patients	17959715
who	17959715
developed	17959715
cancer	17959715
following	17959715
chemotherapy	17959715
and	17959715
/	17959715
or	17959715
radiotherapy	17959715
(	17959715
n	17959715
=	17959715
133	17959715
)	17959715
,	17959715
420	17959715
patients	17959715
diagnosed	17959715
with	17959715
de	17959715
novo	17959715
myeloid	17959715
leukaemia	17959715
,	17959715
242	17959715
patients	17959715
diagnosed	17959715
with	17959715
primary	17959715
Hodgkin	17959715
lymphoma	17959715
,	17959715
and	17959715
1177	17959715
healthy	17959715
controls	17959715
were	17959715
genotyped	17959715
for	17959715
the	17959715
MLH1	17959715
-	17959715
93	17959715
polymorphism	17959715
by	17959715
allelic	17959715
discrimination	17959715
polymerase	17959715
chain	17959715
reaction	17959715
(	17959715
PCR	17959715
)	17959715
and	17959715
restriction	17959715
fragment	17959715
length	17959715
polymorphism	17959715
assay	17959715
.	17959715

Odds	17959715
ratios	17959715
and	17959715
95%	17959715
confidence	17959715
intervals	17959715
for	17959715
cancer	17959715
risk	17959715
by	17959715
MLH1	17959715
-	17959715
93	17959715
polymorphism	17959715
status	17959715
,	17959715
and	17959715
stratified	17959715
by	17959715
previous	17959715
exposure	17959715
to	17959715
methylating	17959715
chemotherapy	17959715
,	17959715
were	17959715
calculated	17959715
using	17959715
unconditional	17959715
logistic	17959715
regression	17959715
.	17959715

RESULTS	17959715
:	17959715
Carrier	17959715
frequency	17959715
of	17959715
the	17959715
MLH1	17959715
-	17959715
93	17959715
variant	17959715
was	17959715
higher	17959715
in	17959715
patients	17959715
who	17959715
developed	17959715
therapy	17959715
related	17959715
acute	17959715
myeloid	17959715
leukaemia	17959715
(	17959715
t	17959715
-	17959715
AML	17959715
)	17959715
(	17959715
75	17959715
.	17959715
0%	17959715
,	17959715
n	17959715
=	17959715
12	17959715
)	17959715
or	17959715
breast	17959715
cancer	17959715
(	17959715
53	17959715
.	17959715
3%	17959715
.	17959715

n	17959715
=	17959715
15	17959715
)	17959715
after	17959715
methylating	17959715
chemotherapy	17959715
for	17959715
Hodgkin	17959715
lymphoma	17959715
compared	17959715
to	17959715
patients	17959715
without	17959715
previous	17959715
methylating	17959715
exposure	17959715
(	17959715
t	17959715
-	17959715
AML	17959715
,	17959715
30	17959715
.	17959715
4%	17959715
,	17959715
n	17959715
=	17959715
69	17959715
;	17959715
breast	17959715
cancer	17959715
patients	17959715
,	17959715
27	17959715
.	17959715
2%	17959715
,	17959715
n	17959715
=	17959715
22	17959715
)	17959715
.	17959715

The	17959715
MLH1	17959715
-	17959715
93	17959715
variant	17959715
allele	17959715
was	17959715
also	17959715
over	17959715
-	17959715
represented	17959715
in	17959715
t	17959715
-	17959715
AML	17959715
cases	17959715
when	17959715
compared	17959715
to	17959715
de	17959715
novo	17959715
AML	17959715
cases	17959715
(	17959715
36	17959715
.	17959715
9%	17959715
,	17959715
n	17959715
=	17959715
420	17959715
)	17959715
and	17959715
healthy	17959715
controls	17959715
(	17959715
36	17959715
.	17959715
3%	17959715
,	17959715
n	17959715
=	17959715
952	17959715
)	17959715
,	17959715
and	17959715
was	17959715
associated	17959715
with	17959715
a	17959715
significantly	17959715
increased	17959715
risk	17959715
of	17959715
developing	17959715
t	17959715
-	17959715
AML	17959715
(	17959715
odds	17959715
ratio	17959715
5	17959715
.	17959715
31	17959715
,	17959715
95%	17959715
confidence	17959715
interval	17959715
1	17959715
.	17959715
40	17959715
to	17959715
20	17959715
.	17959715
15	17959715
)	17959715
,	17959715
but	17959715
only	17959715
in	17959715
patients	17959715
previously	17959715
treated	17959715
with	17959715
a	17959715
methylating	17959715
agent	17959715
.	17959715

CONCLUSIONS	17959715
:	17959715
These	17959715
data	17959715
support	17959715
the	17959715
hypothesis	17959715
that	17959715
the	17959715
common	17959715
polymorphism	17959715
at	17959715
position	17959715
-	17959715
93	17959715
in	17959715
the	17959715
core	17959715
promoter	17959715
of	17959715
MLH1	17959715
defines	17959715
a	17959715
risk	17959715
allele	17959715
for	17959715
the	17959715
development	17959715
of	17959715
cancer	17959715
after	17959715
methylating	17959715
chemotherapy	17959715
for	17959715
Hodgkin	17959715
lymphoma	17959715
.	17959715

However	17959715
,	17959715
replication	17959715
of	17959715
this	17959715
finding	17959715
in	17959715
larger	17959715
studies	17959715
is	17959715
suggested	17959715
.	17959715
Genetic	16506214
variation	16506214
in	16506214
the	16506214
COX	16506214
-	16506214
2	16506214
gene	16506214
and	16506214
the	16506214
association	16506214
with	16506214
prostate	16506214
cancer	16506214
risk	16506214
.	16506214

COX	16506214
-	16506214
2	16506214
is	16506214
a	16506214
key	16506214
enzyme	16506214
in	16506214
the	16506214
conversion	16506214
of	16506214
arachidonic	16506214
acid	16506214
to	16506214
prostaglandins	16506214
.	16506214

The	16506214
prostaglandins	16506214
produced	16506214
by	16506214
COX	16506214
-	16506214
2	16506214
are	16506214
involved	16506214
in	16506214
inflammation	16506214
and	16506214
pain	16506214
response	16506214
in	16506214
different	16506214
tissues	16506214
in	16506214
the	16506214
body	16506214
.	16506214

Accumulating	16506214
evidence	16506214
from	16506214
epidemiologic	16506214
studies	16506214
,	16506214
chemical	16506214
carcinogen	16506214
-	16506214
induced	16506214
rodent	16506214
models	16506214
and	16506214
clinical	16506214
trials	16506214
indicate	16506214
that	16506214
COX	16506214
-	16506214
2	16506214
plays	16506214
a	16506214
role	16506214
in	16506214
human	16506214
carcinogenesis	16506214
and	16506214
is	16506214
overexpressed	16506214
in	16506214
prostate	16506214
cancer	16506214
tissue	16506214
.	16506214

We	16506214
examined	16506214
whether	16506214
sequence	16506214
variants	16506214
in	16506214
the	16506214
COX	16506214
-	16506214
2	16506214
gene	16506214
are	16506214
associated	16506214
with	16506214
prostate	16506214
cancer	16506214
risk	16506214
.	16506214

We	16506214
analyzed	16506214
a	16506214
large	16506214
population	16506214
-	16506214
based	16506214
case	16506214
-	16506214
control	16506214
study	16506214
,	16506214
cancer	16506214
prostate	16506214
in	16506214
Sweden	16506214
(	16506214
CAPS	16506214
)	16506214
consisting	16506214
of	16506214
1	16506214
,	16506214
378	16506214
cases	16506214
and	16506214
782	16506214
controls	16506214
.	16506214

We	16506214
evaluated	16506214
16	16506214
single	16506214
nucleotide	16506214
polymorphisms	16506214
(	16506214
SNPs	16506214
)	16506214
spanning	16506214
the	16506214
entire	16506214
COX	16506214
-	16506214
2	16506214
gene	16506214
in	16506214
94	16506214
subjects	16506214
of	16506214
the	16506214
control	16506214
group	16506214
.	16506214

Five	16506214
SNPs	16506214
had	16506214
a	16506214
minor	16506214
allele	16506214
frequency	16506214
of	16506214
more	16506214
than	16506214
5%	16506214
in	16506214
our	16506214
study	16506214
population	16506214
and	16506214
these	16506214
were	16506214
genotyped	16506214
in	16506214
all	16506214
case	16506214
patients	16506214
and	16506214
control	16506214
subjects	16506214
and	16506214
gene	16506214
-	16506214
specific	16506214
haplotypes	16506214
were	16506214
constructed	16506214
.	16506214

A	16506214
statistically	16506214
significant	16506214
difference	16506214
in	16506214
allele	16506214
frequency	16506214
between	16506214
cases	16506214
and	16506214
controls	16506214
was	16506214
observed	16506214
for	16506214
2	16506214
of	16506214
the	16506214
SNPs	16506214
(	16506214
+	16506214
3100	16506214
T	16506214
/	16506214
G	16506214
and	16506214
+	16506214
8365	16506214
C	16506214
/	16506214
T	16506214
)	16506214
,	16506214
with	16506214
an	16506214
odds	16506214
ratio	16506214
of	16506214
0	16506214
.	16506214
78	16506214
(	16506214
95%	16506214
CI	16506214
=	16506214
0	16506214
.	16506214
64	16506214
-	16506214
0	16506214
.	16506214
96	16506214
)	16506214
and	16506214
0	16506214
.	16506214
65	16506214
(	16506214
95%	16506214
CI	16506214
=	16506214
0	16506214
.	16506214
45	16506214
-	16506214
0	16506214
.	16506214
94	16506214
)	16506214
respectively	16506214
.	16506214

In	16506214
the	16506214
haplotype	16506214
analysis	16506214
,	16506214
1	16506214
haplotype	16506214
carrying	16506214
the	16506214
variant	16506214
allele	16506214
from	16506214
both	16506214
+	16506214
3100	16506214
T	16506214
/	16506214
G	16506214
and	16506214
+	16506214
8365	16506214
C	16506214
/	16506214
T	16506214
,	16506214
with	16506214
a	16506214
population	16506214
frequency	16506214
of	16506214
3%	16506214
,	16506214
was	16506214
also	16506214
significantly	16506214
associated	16506214
with	16506214
decreased	16506214
risk	16506214
of	16506214
prostate	16506214
cancer	16506214
(	16506214
p	16506214
=	16506214
0	16506214
.	16506214
036	16506214
,	16506214
global	16506214
simulated	16506214
p	16506214
-	16506214
value	16506214
=	16506214
0	16506214
.	16506214
046	16506214
)	16506214
.	16506214

This	16506214
study	16506214
supports	16506214
the	16506214
hypothesis	16506214
that	16506214
inflammation	16506214
is	16506214
involved	16506214
in	16506214
prostate	16506214
carcinogenesis	16506214
and	16506214
that	16506214
sequence	16506214
variation	16506214
within	16506214
the	16506214
COX	16506214
-	16506214
2	16506214
gene	16506214
influence	16506214
the	16506214
risk	16506214
of	16506214
prostate	16506214
cancer	16506214
.	16506214
Glutamatergic	20558148
neurotransmission	20558148
mediated	20558148
by	20558148
NMDA	20558148
receptors	20558148
in	20558148
the	20558148
inferior	20558148
colliculus	20558148
can	20558148
modulate	20558148
haloperidol	20558148
-	20558148
induced	20558148
catalepsy	20558148
.	20558148

The	20558148
inferior	20558148
colliculus	20558148
(	20558148
IC	20558148
)	20558148
is	20558148
primarily	20558148
involved	20558148
in	20558148
the	20558148
processing	20558148
of	20558148
auditory	20558148
information	20558148
,	20558148
but	20558148
it	20558148
is	20558148
distinguished	20558148
from	20558148
other	20558148
auditory	20558148
nuclei	20558148
in	20558148
the	20558148
brainstem	20558148
by	20558148
its	20558148
connections	20558148
with	20558148
structures	20558148
of	20558148
the	20558148
motor	20558148
system	20558148
.	20558148

Functional	20558148
evidence	20558148
relating	20558148
the	20558148
IC	20558148
to	20558148
motor	20558148
behavior	20558148
derives	20558148
from	20558148
experiments	20558148
showing	20558148
that	20558148
activation	20558148
of	20558148
the	20558148
IC	20558148
by	20558148
electrical	20558148
stimulation	20558148
or	20558148
excitatory	20558148
amino	20558148
acid	20558148
microinjection	20558148
causes	20558148
freezing	20558148
,	20558148
escape	20558148
-	20558148
like	20558148
behavior	20558148
,	20558148
and	20558148
immobility	20558148
.	20558148

However	20558148
,	20558148
the	20558148
nature	20558148
of	20558148
this	20558148
immobility	20558148
is	20558148
still	20558148
unclear	20558148
.	20558148

The	20558148
present	20558148
study	20558148
examined	20558148
the	20558148
influence	20558148
of	20558148
excitatory	20558148
amino	20558148
acid	20558148
-	20558148
mediated	20558148
mechanisms	20558148
in	20558148
the	20558148
IC	20558148
on	20558148
the	20558148
catalepsy	20558148
induced	20558148
by	20558148
the	20558148
dopamine	20558148
receptor	20558148
blocker	20558148
haloperidol	20558148
administered	20558148
systemically	20558148
(	20558148
1	20558148
or	20558148
0	20558148
.	20558148
5	20558148
mg	20558148
/	20558148
kg	20558148
)	20558148
in	20558148
rats	20558148
.	20558148

Haloperidol	20558148
-	20558148
induced	20558148
catalepsy	20558148
was	20558148
challenged	20558148
with	20558148
prior	20558148
intracollicular	20558148
microinjections	20558148
of	20558148
glutamate	20558148
NMDA	20558148
receptor	20558148
antagonists	20558148
,	20558148
MK	20558148
-	20558148
801	20558148
(	20558148
15	20558148
or	20558148
30	20558148
mmol	20558148
/	20558148
0	20558148
.	20558148
5	20558148
microl	20558148
)	20558148
and	20558148
AP7	20558148
(	20558148
10	20558148
or	20558148
20	20558148
nmol	20558148
/	20558148
0	20558148
.	20558148
5	20558148
microl	20558148
)	20558148
,	20558148
or	20558148
of	20558148
the	20558148
NMDA	20558148
receptor	20558148
agonist	20558148
N	20558148
-	20558148
methyl	20558148
-	20558148
d	20558148
-	20558148
aspartate	20558148
(	20558148
NMDA	20558148
,	20558148
20	20558148
or	20558148
30	20558148
nmol	20558148
/	20558148
0	20558148
.	20558148
5	20558148
microl	20558148
)	20558148
.	20558148

The	20558148
results	20558148
showed	20558148
that	20558148
intracollicular	20558148
microinjection	20558148
of	20558148
MK	20558148
-	20558148
801	20558148
and	20558148
AP7	20558148
previous	20558148
to	20558148
systemic	20558148
injections	20558148
of	20558148
haloperidol	20558148
significantly	20558148
attenuated	20558148
the	20558148
catalepsy	20558148
,	20558148
as	20558148
indicated	20558148
by	20558148
a	20558148
reduced	20558148
latency	20558148
to	20558148
step	20558148
down	20558148
from	20558148
a	20558148
horizontal	20558148
bar	20558148
.	20558148

Accordingly	20558148
,	20558148
intracollicular	20558148
microinjection	20558148
of	20558148
NMDA	20558148
increased	20558148
the	20558148
latency	20558148
to	20558148
step	20558148
down	20558148
the	20558148
bar	20558148
.	20558148

These	20558148
findings	20558148
suggest	20558148
that	20558148
glutamate	20558148
-	20558148
mediated	20558148
mechanisms	20558148
in	20558148
the	20558148
neural	20558148
circuits	20558148
at	20558148
the	20558148
IC	20558148
level	20558148
influence	20558148
haloperidol	20558148
-	20558148
induced	20558148
catalepsy	20558148
and	20558148
participate	20558148
in	20558148
the	20558148
regulation	20558148
of	20558148
motor	20558148
activity	20558148
.	20558148
Antioxidant	24587916
effects	24587916
of	24587916
bovine	24587916
lactoferrin	24587916
on	24587916
dexamethasone	24587916
-	24587916
induced	24587916
hypertension	24587916
in	24587916
rat	24587916
.	24587916

Dexamethasone	24587916
-	24587916
(	24587916
Dex	24587916
-	24587916
)	24587916
induced	24587916
hypertension	24587916
is	24587916
associated	24587916
with	24587916
enhanced	24587916
oxidative	24587916
stress	24587916
.	24587916

Lactoferrin	24587916
(	24587916
LF	24587916
)	24587916
is	24587916
an	24587916
iron	24587916
-	24587916
binding	24587916
glycoprotein	24587916
with	24587916
antihypertensive	24587916
properties	24587916
.	24587916

In	24587916
this	24587916
study	24587916
,	24587916
we	24587916
investigated	24587916
the	24587916
effect	24587916
of	24587916
chronic	24587916
administration	24587916
of	24587916
LF	24587916
on	24587916
oxidative	24587916
stress	24587916
and	24587916
hypertension	24587916
upon	24587916
Dex	24587916
administration	24587916
.	24587916

Male	24587916
Wistar	24587916
rats	24587916
were	24587916
treated	24587916
by	24587916
Dex	24587916
(	24587916
30	24587916
u	24587916
g	24587916
/	24587916
kg	24587916
/	24587916
day	24587916
subcutaneously	24587916
)	24587916
or	24587916
saline	24587916
for	24587916
14	24587916
days	24587916
.	24587916

Oral	24587916
bovine	24587916
LF	24587916
(	24587916
30	24587916
,	24587916
100	24587916
,	24587916
300	24587916
mg	24587916
/	24587916
kg	24587916
)	24587916
was	24587916
given	24587916
from	24587916
day	24587916
8	24587916
to	24587916
14	24587916
in	24587916
a	24587916
reversal	24587916
study	24587916
.	24587916

In	24587916
a	24587916
prevention	24587916
study	24587916
,	24587916
rats	24587916
received	24587916
4	24587916
days	24587916
of	24587916
LF	24587916
treatment	24587916
followed	24587916
by	24587916
Dex	24587916
and	24587916
continued	24587916
during	24587916
the	24587916
test	24587916
period	24587916
.	24587916

Systolic	24587916
blood	24587916
pressure	24587916
(	24587916
SBP	24587916
)	24587916
was	24587916
measured	24587916
using	24587916
tail	24587916
-	24587916
cuff	24587916
method	24587916
.	24587916

Thymus	24587916
weight	24587916
was	24587916
used	24587916
as	24587916
a	24587916
marker	24587916
of	24587916
glucocorticoid	24587916
activity	24587916
.	24587916

Plasma	24587916
hydrogen	24587916
peroxide	24587916
(	24587916
H2O2	24587916
)	24587916
concentration	24587916
and	24587916
ferric	24587916
reducing	24587916
antioxidant	24587916
power	24587916
(	24587916
FRAP	24587916
)	24587916
value	24587916
were	24587916
determined	24587916
.	24587916

Dexamethasone	24587916
significantly	24587916
increased	24587916
SBP	24587916
and	24587916
plasma	24587916
H2O2	24587916
level	24587916
and	24587916
decreased	24587916
thymus	24587916
and	24587916
body	24587916
weights	24587916
.	24587916

LF	24587916
lowered	24587916
(	24587916
P	24587916
<	24587916
0	24587916
.	24587916
01	24587916
)	24587916
and	24587916
dose	24587916
dependently	24587916
prevented	24587916
(	24587916
P	24587916
<	24587916
0	24587916
.	24587916
001	24587916
)	24587916
Dex	24587916
-	24587916
induced	24587916
hypertension	24587916
.	24587916

LF	24587916
prevented	24587916
body	24587916
weight	24587916
loss	24587916
and	24587916
significantly	24587916
reduced	24587916
the	24587916
elevated	24587916
plasma	24587916
H2O2	24587916
and	24587916
increased	24587916
FRAP	24587916
values	24587916
.	24587916

Chronic	24587916
administration	24587916
of	24587916
LF	24587916
strongly	24587916
reduced	24587916
the	24587916
blood	24587916
pressure	24587916
and	24587916
production	24587916
of	24587916
ROS	24587916
and	24587916
improved	24587916
antioxidant	24587916
capacity	24587916
in	24587916
Dex	24587916
-	24587916
induced	24587916
hypertension	24587916
,	24587916
suggesting	24587916
the	24587916
role	24587916
of	24587916
inhibition	24587916
of	24587916
oxidative	24587916
stress	24587916
as	24587916
another	24587916
mechanism	24587916
of	24587916
antihypertensive	24587916
action	24587916
of	24587916
LF	24587916
.	24587916
Role	27860244
of	27860244
protein	27860244
arginine	27860244
methyltransferase	27860244
5	27860244
in	27860244
inflammation	27860244
and	27860244
migration	27860244
of	27860244
fibroblast	27860244
-	27860244
like	27860244
synoviocytes	27860244
in	27860244
rheumatoid	27860244
arthritis	27860244
.	27860244

To	27860244
probe	27860244
the	27860244
role	27860244
of	27860244
protein	27860244
arginine	27860244
methyltransferase	27860244
5	27860244
(	27860244
PRMT5	27860244
)	27860244
in	27860244
regulating	27860244
inflammation	27860244
,	27860244
cell	27860244
proliferation	27860244
,	27860244
migration	27860244
and	27860244
invasion	27860244
of	27860244
fibroblast	27860244
-	27860244
like	27860244
synoviocytes	27860244
(	27860244
FLSs	27860244
)	27860244
from	27860244
patients	27860244
with	27860244
rheumatoid	27860244
arthritis	27860244
(	27860244
RA	27860244
)	27860244
.	27860244

FLSs	27860244
were	27860244
separated	27860244
from	27860244
synovial	27860244
tissues	27860244
(	27860244
STs	27860244
)	27860244
from	27860244
patients	27860244
with	27860244
RA	27860244
and	27860244
osteoarthritis	27860244
(	27860244
OA	27860244
)	27860244
.	27860244

An	27860244
inhibitor	27860244
of	27860244
PRMT5	27860244
(	27860244
EPZ015666	27860244
)	27860244
and	27860244
short	27860244
interference	27860244
RNA	27860244
(	27860244
siRNA	27860244
)	27860244
against	27860244
PRMT5	27860244
were	27860244
used	27860244
to	27860244
inhibit	27860244
PRMT5	27860244
expression	27860244
.	27860244

The	27860244
standard	27860244
of	27860244
protein	27860244
was	27860244
measured	27860244
by	27860244
Western	27860244
blot	27860244
or	27860244
immunofluorescence	27860244
.	27860244

The	27860244
excretion	27860244
and	27860244
genetic	27860244
expression	27860244
of	27860244
inflammatory	27860244
factors	27860244
were	27860244
,	27860244
respectively	27860244
,	27860244
estimated	27860244
by	27860244
enzyme	27860244
-	27860244
linked	27860244
immunosorbent	27860244
assay	27860244
(	27860244
ELISA	27860244
)	27860244
and	27860244
real	27860244
-	27860244
time	27860244
polymerase	27860244
chain	27860244
reaction	27860244
(	27860244
PCR	27860244
)	27860244
.	27860244

Migration	27860244
and	27860244
invasion	27860244
in	27860244
vitro	27860244
were	27860244
detected	27860244
by	27860244
Boyden	27860244
chamber	27860244
assay	27860244
.	27860244

FLSs	27860244
proliferation	27860244
was	27860244
detected	27860244
by	27860244
BrdU	27860244
incorporation	27860244
.	27860244

Increased	27860244
PRMT5	27860244
was	27860244
discovered	27860244
in	27860244
STs	27860244
and	27860244
FLSs	27860244
from	27860244
patients	27860244
with	27860244
RA	27860244
.	27860244

In	27860244
RA	27860244
FLSs	27860244
,	27860244
the	27860244
level	27860244
of	27860244
PRMT5	27860244
was	27860244
up	27860244
-	27860244
regulated	27860244
by	27860244
stimulation	27860244
with	27860244
IL	27860244
-	27860244
1b	27860244
and	27860244
TNF	27860244
-	27860244
a	27860244
.	27860244

Inhibition	27860244
of	27860244
PRMT5	27860244
by	27860244
EPZ015666	27860244
and	27860244
siRNA	27860244
-	27860244
mediated	27860244
knockdown	27860244
reduced	27860244
IL	27860244
-	27860244
6	27860244
and	27860244
IL	27860244
-	27860244
8	27860244
production	27860244
,	27860244
and	27860244
proliferation	27860244
of	27860244
RA	27860244
FLSs	27860244
.	27860244

In	27860244
addition	27860244
,	27860244
inhibition	27860244
of	27860244
PRMT5	27860244
decreased	27860244
in	27860244
vitro	27860244
migration	27860244
and	27860244
invasion	27860244
of	27860244
RA	27860244
FLSs	27860244
.	27860244

Furthermore	27860244
,	27860244
EPZ015666	27860244
restrained	27860244
the	27860244
phosphorylation	27860244
of	27860244
IkB	27860244
kinaseb	27860244
and	27860244
IkBa	27860244
,	27860244
as	27860244
well	27860244
as	27860244
nucleus	27860244
transsituation	27860244
of	27860244
p65	27860244
as	27860244
well	27860244
as	27860244
AKT	27860244
in	27860244
FLSs	27860244
.	27860244

PRMT5	27860244
regulated	27860244
the	27860244
production	27860244
of	27860244
inflammatory	27860244
factors	27860244
,	27860244
cell	27860244
proliferation	27860244
,	27860244
migration	27860244
and	27860244
invasion	27860244
of	27860244
RA	27860244
FLS	27860244
,	27860244
which	27860244
was	27860244
mediated	27860244
by	27860244
the	27860244
NF	27860244
-	27860244
kB	27860244
and	27860244
AKT	27860244
pathways	27860244
.	27860244

Our	27860244
data	27860244
suggested	27860244
that	27860244
targeting	27860244
PRMT5	27860244
to	27860244
prevent	27860244
synovial	27860244
inflammation	27860244
and	27860244
destruction	27860244
might	27860244
be	27860244
a	27860244
promising	27860244
therapy	27860244
for	27860244
RA	27860244
.	27860244
Protein	19672862
kinase	19672862
C	19672862
alpha	19672862
-	19672862
dependent	19672862
signaling	19672862
mediates	19672862
endometrial	19672862
cancer	19672862
cell	19672862
growth	19672862
and	19672862
tumorigenesis	19672862
.	19672862

Endometrial	19672862
cancer	19672862
is	19672862
the	19672862
most	19672862
common	19672862
invasive	19672862
gynecologic	19672862
malignancy	19672862
,	19672862
yet	19672862
molecular	19672862
mechanisms	19672862
and	19672862
signaling	19672862
pathways	19672862
underlying	19672862
its	19672862
etiology	19672862
and	19672862
pathophysiology	19672862
remain	19672862
poorly	19672862
characterized	19672862
.	19672862

We	19672862
sought	19672862
to	19672862
define	19672862
a	19672862
functional	19672862
role	19672862
for	19672862
the	19672862
protein	19672862
kinase	19672862
C	19672862
(	19672862
PKC	19672862
)	19672862
isoform	19672862
,	19672862
PKCalpha	19672862
,	19672862
in	19672862
an	19672862
established	19672862
cell	19672862
model	19672862
of	19672862
endometrial	19672862
adenocarcinoma	19672862
.	19672862

Ishikawa	19672862
cells	19672862
depleted	19672862
of	19672862
PKCalpha	19672862
protein	19672862
grew	19672862
slower	19672862
,	19672862
formed	19672862
fewer	19672862
colonies	19672862
in	19672862
anchorage	19672862
-	19672862
independent	19672862
growth	19672862
assays	19672862
and	19672862
exhibited	19672862
impaired	19672862
xenograft	19672862
tumor	19672862
formation	19672862
in	19672862
nude	19672862
mice	19672862
.	19672862

Consistent	19672862
with	19672862
impaired	19672862
growth	19672862
,	19672862
PKCalpha	19672862
knockdown	19672862
increased	19672862
levels	19672862
of	19672862
the	19672862
cyclin	19672862
-	19672862
dependent	19672862
kinase	19672862
(	19672862
CDK	19672862
)	19672862
inhibitors	19672862
p21	19672862
(	19672862
Cip1	19672862
/	19672862
WAF1	19672862
)	19672862
(	19672862
p21	19672862
)	19672862
and	19672862
p27	19672862
(	19672862
Kip1	19672862
)	19672862
(	19672862
p27	19672862
)	19672862
.	19672862

Despite	19672862
the	19672862
absence	19672862
of	19672862
functional	19672862
phosphatase	19672862
and	19672862
tensin	19672862
homolog	19672862
(	19672862
PTEN	19672862
)	19672862
protein	19672862
in	19672862
Ishikawa	19672862
cells	19672862
,	19672862
PKCalpha	19672862
knockdown	19672862
reduced	19672862
Akt	19672862
phosphorylation	19672862
at	19672862
serine	19672862
473	19672862
and	19672862
concomitantly	19672862
inhibited	19672862
phosphorylation	19672862
of	19672862
the	19672862
Akt	19672862
target	19672862
,	19672862
glycogen	19672862
synthase	19672862
kinase	19672862
-	19672862
3beta	19672862
(	19672862
GSK	19672862
-	19672862
3beta	19672862
)	19672862
.	19672862

PKCalpha	19672862
knockdown	19672862
also	19672862
resulted	19672862
in	19672862
decreased	19672862
basal	19672862
ERK	19672862
phosphorylation	19672862
and	19672862
attenuated	19672862
ERK	19672862
activation	19672862
following	19672862
EGF	19672862
stimulation	19672862
.	19672862

p21	19672862
and	19672862
p27	19672862
expression	19672862
was	19672862
not	19672862
increased	19672862
by	19672862
treatment	19672862
of	19672862
Ishikawa	19672862
cells	19672862
with	19672862
ERK	19672862
and	19672862
Akt	19672862
inhibitors	19672862
,	19672862
suggesting	19672862
that	19672862
PKCalpha	19672862
regulates	19672862
CDK	19672862
expression	19672862
independently	19672862
of	19672862
Akt	19672862
and	19672862
ERK	19672862
.	19672862

Immunohistochemical	19672862
analysis	19672862
of	19672862
Grade	19672862
1	19672862
endometrioid	19672862
adenocarcinoma	19672862
revealed	19672862
aberrant	19672862
PKCalpha	19672862
expression	19672862
,	19672862
with	19672862
foci	19672862
of	19672862
elevated	19672862
PKCalpha	19672862
staining	19672862
,	19672862
not	19672862
observed	19672862
in	19672862
normal	19672862
endometrium	19672862
.	19672862

These	19672862
studies	19672862
demonstrate	19672862
a	19672862
critical	19672862
role	19672862
for	19672862
PKCalpha	19672862
signaling	19672862
in	19672862
endometrial	19672862
tumorigenesis	19672862
by	19672862
regulating	19672862
expression	19672862
of	19672862
CDK	19672862
inhibitors	19672862
p21	19672862
and	19672862
p27	19672862
and	19672862
activation	19672862
of	19672862
Akt	19672862
and	19672862
ERK	19672862
-	19672862
dependent	19672862
proliferative	19672862
pathways	19672862
.	19672862

Thus	19672862
,	19672862
targeting	19672862
PKCalpha	19672862
may	19672862
provide	19672862
novel	19672862
therapeutic	19672862
options	19672862
in	19672862
endometrial	19672862
tumors	19672862
.	19672862
Common	15668505
BRCA2	15668505
variants	15668505
and	15668505
modification	15668505
of	15668505
breast	15668505
and	15668505
ovarian	15668505
cancer	15668505
risk	15668505
in	15668505
BRCA1	15668505
mutation	15668505
carriers	15668505
.	15668505

The	15668505
HH	15668505
genotype	15668505
of	15668505
the	15668505
nonconservative	15668505
amino	15668505
acid	15668505
substitution	15668505
polymorphism	15668505
N372H	15668505
in	15668505
the	15668505
BRCA2	15668505
gene	15668505
was	15668505
reported	15668505
to	15668505
be	15668505
associated	15668505
with	15668505
a	15668505
1	15668505
.	15668505
3	15668505
-	15668505
to	15668505
1	15668505
.	15668505
5	15668505
-	15668505
fold	15668505
increase	15668505
in	15668505
risk	15668505
of	15668505
both	15668505
breast	15668505
and	15668505
ovarian	15668505
cancer	15668505
.	15668505

As	15668505
these	15668505
studies	15668505
concerned	15668505
sporadic	15668505
cancer	15668505
cases	15668505
,	15668505
we	15668505
investigated	15668505
whether	15668505
N372H	15668505
and	15668505
another	15668505
common	15668505
variant	15668505
located	15668505
in	15668505
the	15668505
5	15668505
'	15668505
-	15668505
untranslated	15668505
region	15668505
(	15668505
203G	15668505
>	15668505
A	15668505
)	15668505
of	15668505
the	15668505
BRCA2	15668505
gene	15668505
modify	15668505
breast	15668505
or	15668505
ovarian	15668505
cancer	15668505
risk	15668505
in	15668505
BRCA1	15668505
mutation	15668505
carriers	15668505
.	15668505

The	15668505
study	15668505
includes	15668505
778	15668505
women	15668505
carrying	15668505
a	15668505
BRCA1	15668505
germ	15668505
-	15668505
line	15668505
mutation	15668505
belonging	15668505
to	15668505
403	15668505
families	15668505
.	15668505

The	15668505
two	15668505
BRCA2	15668505
variants	15668505
were	15668505
analyzed	15668505
by	15668505
the	15668505
TaqMan	15668505
allelic	15668505
discrimination	15668505
technique	15668505
.	15668505

Genotypes	15668505
were	15668505
analyzed	15668505
by	15668505
disease	15668505
-	15668505
free	15668505
survival	15668505
analysis	15668505
using	15668505
a	15668505
Cox	15668505
proportional	15668505
hazards	15668505
model	15668505
.	15668505

We	15668505
found	15668505
no	15668505
evidence	15668505
of	15668505
a	15668505
significant	15668505
modification	15668505
of	15668505
breast	15668505
cancer	15668505
penetrance	15668505
in	15668505
BRCA1	15668505
mutation	15668505
carriers	15668505
by	15668505
either	15668505
polymorphism	15668505
.	15668505

In	15668505
respect	15668505
of	15668505
ovarian	15668505
cancer	15668505
risk	15668505
,	15668505
we	15668505
also	15668505
saw	15668505
no	15668505
effect	15668505
with	15668505
the	15668505
N372H	15668505
variant	15668505
but	15668505
we	15668505
did	15668505
observe	15668505
a	15668505
borderline	15668505
association	15668505
with	15668505
the	15668505
5	15668505
'	15668505
-	15668505
untranslated	15668505
region	15668505
203A	15668505
allele	15668505
(	15668505
hazard	15668505
ratio	15668505
,	15668505
1	15668505
.	15668505
43	15668505
;	15668505
CI	15668505
,	15668505
1	15668505
.	15668505
01	15668505
-	15668505
2	15668505
.	15668505
00	15668505
)	15668505
.	15668505

In	15668505
contrast	15668505
to	15668505
the	15668505
result	15668505
of	15668505
Healey	15668505
et	15668505
al	15668505
.	15668505

on	15668505
newborn	15668505
females	15668505
and	15668505
adult	15668505
female	15668505
controls	15668505
,	15668505
we	15668505
found	15668505
no	15668505
departure	15668505
from	15668505
Hardy	15668505
-	15668505
Weinberg	15668505
equilibrium	15668505
in	15668505
the	15668505
distribution	15668505
of	15668505
N372H	15668505
alleles	15668505
for	15668505
our	15668505
female	15668505
BRCA1	15668505
carriers	15668505
.	15668505

We	15668505
conclude	15668505
that	15668505
if	15668505
these	15668505
single	15668505
-	15668505
nucleotide	15668505
polymorphisms	15668505
do	15668505
modify	15668505
the	15668505
risk	15668505
of	15668505
cancer	15668505
in	15668505
BRCA1	15668505
mutation	15668505
carriers	15668505
,	15668505
their	15668505
effects	15668505
are	15668505
not	15668505
significantly	15668505
larger	15668505
than	15668505
that	15668505
of	15668505
N372H	15668505
previously	15668505
observed	15668505
in	15668505
the	15668505
general	15668505
population	15668505
.	15668505
New	15770495
mutations	15770495
,	15770495
hotspots	15770495
,	15770495
and	15770495
founder	15770495
effects	15770495
in	15770495
Brazilian	15770495
patients	15770495
with	15770495
steroid	15770495
5alpha	15770495
-	15770495
reductase	15770495
deficiency	15770495
type	15770495
2	15770495
.	15770495

Mutations	15770495
of	15770495
the	15770495
steroid	15770495
5alpha	15770495
-	15770495
reductase	15770495
type	15770495
2	15770495
(	15770495
SRD5A2	15770495
)	15770495
gene	15770495
in	15770495
46	15770495
,	15770495
XY	15770495
subjects	15770495
cause	15770495
masculinization	15770495
defects	15770495
of	15770495
varying	15770495
degrees	15770495
,	15770495
due	15770495
to	15770495
reduced	15770495
or	15770495
impaired	15770495
enzymatic	15770495
activity	15770495
.	15770495

In	15770495
this	15770495
study	15770495
,	15770495
sequence	15770495
abnormalities	15770495
of	15770495
the	15770495
SRD5A2	15770495
gene	15770495
were	15770495
assessed	15770495
by	15770495
polymerase	15770495
chain	15770495
reaction	15770495
with	15770495
specific	15770495
primers	15770495
and	15770495
automated	15770495
sequencing	15770495
analysis	15770495
in	15770495
DNA	15770495
samples	15770495
from	15770495
20	15770495
patients	15770495
with	15770495
suspected	15770495
steroid	15770495
5alpha	15770495
-	15770495
reductase	15770495
type	15770495
2	15770495
deficiency	15770495
from	15770495
18	15770495
Brazilian	15770495
families	15770495
.	15770495

Eleven	15770495
subjects	15770495
presented	15770495
SRD5A2	15770495
homozygous	15770495
single	15770495
-	15770495
base	15770495
mutations	15770495
(	15770495
two	15770495
first	15770495
cousins	15770495
and	15770495
four	15770495
unrelated	15770495
patients	15770495
with	15770495
G183S	15770495
,	15770495
two	15770495
with	15770495
R246W	15770495
,	15770495
one	15770495
with	15770495
del642T	15770495
,	15770495
one	15770495
with	15770495
G196S	15770495
,	15770495
and	15770495
one	15770495
with	15770495
217_218insC	15770495
plus	15770495
the	15770495
A49T	15770495
variant	15770495
in	15770495
heterozygosis	15770495
)	15770495
,	15770495
whereas	15770495
four	15770495
were	15770495
compound	15770495
heterozygotes	15770495
(	15770495
one	15770495
with	15770495
Q126R	15770495
/	15770495
IVS3	15770495
+	15770495
1G	15770495
>	15770495
A	15770495
,	15770495
one	15770495
with	15770495
Q126R	15770495
/	15770495
del418T	15770495
,	15770495
and	15770495
two	15770495
brothers	15770495
with	15770495
Q126R	15770495
/	15770495
G158R	15770495
)	15770495
.	15770495

Three	15770495
patients	15770495
were	15770495
heterozygous	15770495
for	15770495
A207D	15770495
,	15770495
G196S	15770495
,	15770495
and	15770495
R266W	15770495
substitutions	15770495
.	15770495

The	15770495
V89L	15770495
polymorphism	15770495
was	15770495
found	15770495
in	15770495
heterozygosis	15770495
in	15770495
one	15770495
of	15770495
them	15770495
(	15770495
with	15770495
A207D	15770495
)	15770495
and	15770495
in	15770495
one	15770495
case	15770495
with	15770495
an	15770495
otherwise	15770495
normal	15770495
gene	15770495
sequence	15770495
.	15770495

The	15770495
A49T	15770495
variant	15770495
was	15770495
also	15770495
detected	15770495
in	15770495
heterozygosis	15770495
in	15770495
the	15770495
second	15770495
case	15770495
without	15770495
other	15770495
sequencing	15770495
abnormalities	15770495
.	15770495

Four	15770495
patients	15770495
harbor	15770495
yet	15770495
non	15770495
-	15770495
described	15770495
SRD5A2	15770495
gene	15770495
mutations	15770495
:	15770495
a	15770495
single	15770495
nucleotide	15770495
deletion	15770495
(	15770495
del642T	15770495
)	15770495
,	15770495
a	15770495
G158R	15770495
amino	15770495
acid	15770495
substitution	15770495
,	15770495
a	15770495
splice	15770495
junction	15770495
mutation	15770495
(	15770495
IVS3	15770495
+	15770495
1G	15770495
>	15770495
A	15770495
)	15770495
,	15770495
and	15770495
the	15770495
insertion	15770495
of	15770495
a	15770495
cytosine	15770495
(	15770495
217_218insC	15770495
)	15770495
occurring	15770495
at	15770495
a	15770495
CCCC	15770495
motif	15770495
.	15770495

This	15770495
is	15770495
the	15770495
first	15770495
report	15770495
of	15770495
a	15770495
single	15770495
-	15770495
nucleotide	15770495
insertion	15770495
in	15770495
the	15770495
coding	15770495
sequence	15770495
of	15770495
the	15770495
SRD5A2	15770495
gene	15770495
.	15770495

In	15770495
addition	15770495
to	15770495
these	15770495
new	15770495
mutations	15770495
,	15770495
this	15770495
investigation	15770495
reveals	15770495
the	15770495
prevalence	15770495
of	15770495
G183S	15770495
substitution	15770495
among	15770495
a	15770495
subset	15770495
of	15770495
African	15770495
-	15770495
Brazilian	15770495
patients	15770495
and	15770495
presents	15770495
evidences	15770495
of	15770495
the	15770495
recurrence	15770495
of	15770495
already	15770495
known	15770495
mutations	15770495
.	15770495
Effects	24709919
of	24709919
ginsenosides	24709919
on	24709919
opioid	24709919
-	24709919
induced	24709919
hyperalgesia	24709919
in	24709919
mice	24709919
.	24709919

Opioid	24709919
-	24709919
induced	24709919
hyperalgesia	24709919
(	24709919
OIH	24709919
)	24709919
is	24709919
characterized	24709919
by	24709919
nociceptive	24709919
sensitization	24709919
caused	24709919
by	24709919
the	24709919
cessation	24709919
of	24709919
chronic	24709919
opioid	24709919
use	24709919
.	24709919

OIH	24709919
can	24709919
limit	24709919
the	24709919
clinical	24709919
use	24709919
of	24709919
opioid	24709919
analgesics	24709919
and	24709919
complicate	24709919
withdrawal	24709919
from	24709919
opioid	24709919
addiction	24709919
.	24709919

In	24709919
this	24709919
study	24709919
,	24709919
we	24709919
investigated	24709919
the	24709919
effects	24709919
of	24709919
Re	24709919
,	24709919
Rg1	24709919
,	24709919
and	24709919
Rb1	24709919
ginsenosides	24709919
,	24709919
the	24709919
bioactive	24709919
components	24709919
of	24709919
ginseng	24709919
,	24709919
on	24709919
OIH	24709919
.	24709919

OIH	24709919
was	24709919
achieved	24709919
in	24709919
mice	24709919
after	24709919
subcutaneous	24709919
administration	24709919
of	24709919
morphine	24709919
for	24709919
7	24709919
consecutive	24709919
days	24709919
three	24709919
times	24709919
per	24709919
day	24709919
.	24709919

During	24709919
withdrawal	24709919
(	24709919
days	24709919
8	24709919
and	24709919
9	24709919
)	24709919
,	24709919
these	24709919
mice	24709919
were	24709919
administered	24709919
Re	24709919
,	24709919
Rg1	24709919
,	24709919
or	24709919
Rb1	24709919
intragastrically	24709919
two	24709919
times	24709919
per	24709919
day	24709919
.	24709919

On	24709919
the	24709919
test	24709919
day	24709919
(	24709919
day	24709919
10	24709919
)	24709919
,	24709919
mice	24709919
were	24709919
subjected	24709919
to	24709919
the	24709919
thermal	24709919
sensitivity	24709919
test	24709919
and	24709919
the	24709919
acetic	24709919
acid	24709919
-	24709919
induced	24709919
writhing	24709919
test	24709919
.	24709919

Re	24709919
(	24709919
300	24709919
mg	24709919
/	24709919
kg	24709919
)	24709919
inhibited	24709919
OIH	24709919
in	24709919
both	24709919
the	24709919
thermal	24709919
sensitivity	24709919
test	24709919
and	24709919
the	24709919
acetic	24709919
acid	24709919
-	24709919
induced	24709919
writhing	24709919
test	24709919
.	24709919

However	24709919
,	24709919
the	24709919
Rg1	24709919
and	24709919
Rb1	24709919
ginsenosides	24709919
failed	24709919
to	24709919
prevent	24709919
OIH	24709919
in	24709919
either	24709919
test	24709919
.	24709919

Furthermore	24709919
,	24709919
Rg1	24709919
showed	24709919
a	24709919
tendency	24709919
to	24709919
aggravate	24709919
OIH	24709919
in	24709919
the	24709919
acetic	24709919
acid	24709919
-	24709919
induced	24709919
writhing	24709919
test	24709919
.	24709919

Our	24709919
data	24709919
suggested	24709919
that	24709919
the	24709919
ginsenoside	24709919
Re	24709919
,	24709919
but	24709919
not	24709919
Rg1	24709919
or	24709919
Rb1	24709919
,	24709919
may	24709919
contribute	24709919
toward	24709919
reversal	24709919
of	24709919
OIH	24709919
.	24709919
Association	20523265
study	20523265
of	20523265
complement	20523265
factor	20523265
H	20523265
,	20523265
C2	20523265
,	20523265
CFB	20523265
,	20523265
and	20523265
C3	20523265
and	20523265
age	20523265
-	20523265
related	20523265
macular	20523265
degeneration	20523265
in	20523265
a	20523265
Han	20523265
Chinese	20523265
population	20523265
.	20523265

PURPOSE	20523265
:	20523265
Genes	20523265
in	20523265
the	20523265
complement	20523265
pathway	20523265
,	20523265
including	20523265
complement	20523265
factor	20523265
H	20523265
(	20523265
CFH	20523265
)	20523265
,	20523265
C2	20523265
/	20523265
BF	20523265
,	20523265
and	20523265
C3	20523265
,	20523265
have	20523265
been	20523265
reported	20523265
to	20523265
be	20523265
associated	20523265
with	20523265
age	20523265
-	20523265
related	20523265
macular	20523265
degeneration	20523265
(	20523265
AMD	20523265
)	20523265
.	20523265

Genetic	20523265
variants	20523265
,	20523265
single	20523265
-	20523265
nucleotide	20523265
polymorphisms	20523265
(	20523265
SNPs	20523265
)	20523265
,	20523265
in	20523265
these	20523265
genes	20523265
were	20523265
geno	20523265
-	20523265
typed	20523265
for	20523265
a	20523265
case	20523265
-	20523265
control	20523265
association	20523265
study	20523265
in	20523265
a	20523265
mainland	20523265
Han	20523265
Chinese	20523265
population	20523265
.	20523265

METHODS	20523265
:	20523265
One	20523265
hundred	20523265
and	20523265
fifty	20523265
-	20523265
eight	20523265
patients	20523265
with	20523265
wet	20523265
AMD	20523265
,	20523265
80	20523265
patients	20523265
with	20523265
soft	20523265
drusen	20523265
,	20523265
and	20523265
220	20523265
matched	20523265
control	20523265
subjects	20523265
were	20523265
recruited	20523265
among	20523265
Han	20523265
Chinese	20523265
in	20523265
mainland	20523265
China	20523265
.	20523265

Seven	20523265
SNPs	20523265
in	20523265
CFH	20523265
and	20523265
two	20523265
SNPs	20523265
in	20523265
C2	20523265
,	20523265
CFB	20523265
'	20523265
,	20523265
and	20523265
C3	20523265
were	20523265
genotyped	20523265
using	20523265
the	20523265
ABI	20523265
SNaPshot	20523265
method	20523265
.	20523265

A	20523265
deletion	20523265
of	20523265
84	20523265
,	20523265
682	20523265
base	20523265
pairs	20523265
covering	20523265
the	20523265
CFHR1	20523265
and	20523265
CFHR3	20523265
genes	20523265
was	20523265
detected	20523265
by	20523265
direct	20523265
polymerase	20523265
chain	20523265
reaction	20523265
and	20523265
gel	20523265
electrophoresis	20523265
.	20523265

RESULTS	20523265
:	20523265
Four	20523265
SNPs	20523265
,	20523265
including	20523265
rs3753394	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0276	20523265
)	20523265
,	20523265
rs800292	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0266	20523265
)	20523265
,	20523265
rs1061170	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
00514	20523265
)	20523265
,	20523265
and	20523265
rs1329428	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0089	20523265
)	20523265
,	20523265
in	20523265
CFH	20523265
showed	20523265
a	20523265
significant	20523265
association	20523265
with	20523265
wet	20523265
AMD	20523265
in	20523265
the	20523265
cohort	20523265
of	20523265
this	20523265
study	20523265
.	20523265

A	20523265
haplotype	20523265
containing	20523265
these	20523265
four	20523265
SNPs	20523265
(	20523265
CATA	20523265
)	20523265
significantly	20523265
increased	20523265
protection	20523265
of	20523265
wet	20523265
AMD	20523265
with	20523265
a	20523265
P	20523265
value	20523265
of	20523265
0	20523265
.	20523265
0005	20523265
and	20523265
an	20523265
odds	20523265
ratio	20523265
of	20523265
0	20523265
.	20523265
29	20523265
(	20523265
95%	20523265
confidence	20523265
interval	20523265
:	20523265
0	20523265
.	20523265
15	20523265
-	20523265
0	20523265
.	20523265
60	20523265
)	20523265
.	20523265

Unlike	20523265
in	20523265
other	20523265
populations	20523265
,	20523265
rs2274700	20523265
and	20523265
rs1410996	20523265
did	20523265
not	20523265
show	20523265
a	20523265
significant	20523265
association	20523265
with	20523265
AMD	20523265
in	20523265
the	20523265
Chinese	20523265
population	20523265
of	20523265
this	20523265
study	20523265
.	20523265

None	20523265
of	20523265
the	20523265
SNPs	20523265
in	20523265
CFH	20523265
showed	20523265
a	20523265
significant	20523265
association	20523265
with	20523265
drusen	20523265
,	20523265
and	20523265
none	20523265
of	20523265
the	20523265
SNPs	20523265
in	20523265
CFH	20523265
,	20523265
C2	20523265
,	20523265
CFB	20523265
,	20523265
and	20523265
C3	20523265
showed	20523265
a	20523265
significant	20523265
association	20523265
with	20523265
either	20523265
wet	20523265
AMD	20523265
or	20523265
drusen	20523265
in	20523265
the	20523265
cohort	20523265
of	20523265
this	20523265
study	20523265
.	20523265

The	20523265
CFHR1	20523265
and	20523265
CFHR3	20523265
deletion	20523265
was	20523265
not	20523265
polymorphic	20523265
in	20523265
the	20523265
Chinese	20523265
population	20523265
and	20523265
was	20523265
not	20523265
associated	20523265
with	20523265
wet	20523265
AMD	20523265
or	20523265
drusen	20523265
.	20523265

CONCLUSION	20523265
:	20523265
This	20523265
study	20523265
showed	20523265
that	20523265
SNPs	20523265
rs3753394	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0276	20523265
)	20523265
,	20523265
rs800292	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0266	20523265
)	20523265
,	20523265
rs1061170	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
00514	20523265
)	20523265
,	20523265
and	20523265
rs1329428	20523265
(	20523265
P	20523265
=	20523265
0	20523265
.	20523265
0089	20523265
)	20523265
,	20523265
but	20523265
not	20523265
rs7535263	20523265
,	20523265
rs1410996	20523265
,	20523265
or	20523265
rs2274700	20523265
,	20523265
in	20523265
CFH	20523265
were	20523265
significantly	20523265
associated	20523265
with	20523265
wet	20523265
AMD	20523265
in	20523265
a	20523265
mainland	20523265
Han	20523265
Chinese	20523265
population	20523265
.	20523265

This	20523265
study	20523265
showed	20523265
that	20523265
CFH	20523265
was	20523265
more	20523265
likely	20523265
to	20523265
be	20523265
AMD	20523265
susceptibility	20523265
gene	20523265
at	20523265
Chr	20523265
.	20523265
1q31	20523265
based	20523265
on	20523265
the	20523265
finding	20523265
that	20523265
the	20523265
CFHR1	20523265
and	20523265
CFHR3	20523265
deletion	20523265
was	20523265
not	20523265
polymorphic	20523265
in	20523265
the	20523265
cohort	20523265
of	20523265
this	20523265
study	20523265
,	20523265
and	20523265
none	20523265
of	20523265
the	20523265
SNPs	20523265
that	20523265
were	20523265
significantly	20523265
associated	20523265
with	20523265
AMD	20523265
in	20523265
a	20523265
white	20523265
population	20523265
in	20523265
C2	20523265
,	20523265
CFB	20523265
,	20523265
and	20523265
C3	20523265
genes	20523265
showed	20523265
a	20523265
significant	20523265
association	20523265
with	20523265
AMD	20523265
.	20523265
Seven	27840894
novel	27840894
and	27840894
six	27840894
de	27840894
novo	27840894
PHEX	27840894
gene	27840894
mutations	27840894
in	27840894
patients	27840894
with	27840894
hypophosphatemic	27840894
rickets	27840894
.	27840894

Inactivating	27840894
mutations	27840894
in	27840894
phosphate	27840894
-	27840894
regulating	27840894
gene	27840894
with	27840894
homologies	27840894
to	27840894
endopeptidase	27840894
on	27840894
the	27840894
X	27840894
chromosome	27840894
(	27840894
PHEX	27840894
)	27840894
have	27840894
been	27840894
identified	27840894
as	27840894
a	27840894
cause	27840894
of	27840894
X	27840894
-	27840894
linked	27840894
hypophosphatemic	27840894
rickets	27840894
(	27840894
XLH	27840894
;	27840894
OMIM	27840894
307800	27840894
)	27840894
.	27840894

In	27840894
the	27840894
present	27840894
study	27840894
,	27840894
we	27840894
enrolled	27840894
43	27840894
patients	27840894
from	27840894
18	27840894
unrelated	27840894
families	27840894
clinically	27840894
diagnosed	27840894
with	27840894
hypophosphatemic	27840894
rickets	27840894
and	27840894
250	27840894
healthy	27840894
controls	27840894
.	27840894

For	27840894
each	27840894
available	27840894
individual	27840894
,	27840894
all	27840894
22	27840894
exons	27840894
with	27840894
their	27840894
exon	27840894
-	27840894
intron	27840894
boundaries	27840894
of	27840894
the	27840894
PHEX	27840894
gene	27840894
were	27840894
directly	27840894
sequenced	27840894
.	27840894

The	27840894
levels	27840894
of	27840894
serum	27840894
fibroblast	27840894
growth	27840894
factor	27840894
23	27840894
(	27840894
FGF23	27840894
)	27840894
were	27840894
measured	27840894
as	27840894
well	27840894
.	27840894

Sequencing	27840894
analysis	27840894
detected	27840894
17	27840894
different	27840894
PHEX	27840894
gene	27840894
mutations	27840894
,	27840894
and	27840894
7	27840894
of	27840894
these	27840894
were	27840894
identified	27840894
as	27840894
novel	27840894
:	27840894
3	27840894
missense	27840894
mutations	27840894
,	27840894
including	27840894
c	27840894
.	27840894
304G	27840894
>	27840894
A	27840894
(	27840894
p	27840894
.	27840894
Gly102Arg	27840894
)	27840894
in	27840894
exon	27840894
3	27840894
,	27840894
c	27840894
.	27840894
229T	27840894
>	27840894
C	27840894
(	27840894
p	27840894
.	27840894
Cys77Arg	27840894
)	27840894
in	27840894
exon	27840894
3	27840894
and	27840894
c	27840894
.	27840894
824T	27840894
>	27840894
C	27840894
(	27840894
p	27840894
.	27840894
Leu275Pro	27840894
)	27840894
in	27840894
exon	27840894
7	27840894
;	27840894
2	27840894
deletion	27840894
mutations	27840894
,	27840894
including	27840894
c	27840894
.	27840894
528delT	27840894
(	27840894
p	27840894
.	27840894
Glu177LysfsX44	27840894
)	27840894
in	27840894
exon	27840894
5	27840894
and	27840894
c	27840894
.	27840894
1234delA	27840894
(	27840894
p	27840894
.	27840894
Ser412ValfsX12	27840894
)	27840894
in	27840894
exon	27840894
11	27840894
;	27840894
and	27840894
2	27840894
alternative	27840894
splicing	27840894
mutations	27840894
,	27840894
including	27840894
c	27840894
.	27840894
436_436	27840894
+	27840894
1delAG	27840894
in	27840894
intron	27840894
4	27840894
at	27840894
splicing	27840894
donor	27840894
sites	27840894
and	27840894
c	27840894
.	27840894
1483	27840894
-	27840894
1G	27840894
>	27840894
C	27840894
in	27840894
intron	27840894
13	27840894
at	27840894
splicing	27840894
acceptor	27840894
sites	27840894
.	27840894

Moreover	27840894
,	27840894
6	27840894
mutations	27840894
were	27840894
proven	27840894
to	27840894
be	27840894
de	27840894
novo	27840894
in	27840894
6	27840894
sporadic	27840894
cases	27840894
and	27840894
the	27840894
probands	27840894
were	27840894
all	27840894
females	27840894
.	27840894

No	27840894
mutations	27840894
were	27840894
found	27840894
in	27840894
the	27840894
250	27840894
healthy	27840894
controls	27840894
.	27840894

The	27840894
serum	27840894
levels	27840894
of	27840894
FGF23	27840894
varied	27840894
widely	27840894
among	27840894
the	27840894
patients	27840894
with	27840894
XLH	27840894
,	27840894
and	27840894
no	27840894
significant	27840894
difference	27840894
was	27840894
found	27840894
when	27840894
compared	27840894
with	27840894
those	27840894
of	27840894
the	27840894
healthy	27840894
controls	27840894
.	27840894

On	27840894
the	27840894
whole	27840894
,	27840894
the	27840894
findings	27840894
of	27840894
this	27840894
study	27840894
provide	27840894
new	27840894
insight	27840894
into	27840894
the	27840894
spectrum	27840894
of	27840894
PHEX	27840894
mutations	27840894
and	27840894
provide	27840894
potential	27840894
evidence	27840894
of	27840894
a	27840894
critical	27840894
domain	27840894
in	27840894
PHEX	27840894
protein	27840894
.	27840894

In	27840894
addition	27840894
,	27840894
the	27840894
finding	27840894
of	27840894
an	27840894
overlap	27840894
of	27840894
the	27840894
serum	27840894
FGF23	27840894
levels	27840894
between	27840894
the	27840894
patients	27840894
with	27840894
XLH	27840894
and	27840894
the	27840894
healthy	27840894
controls	27840894
indicates	27840894
its	27840894
limited	27840894
diagnostic	27840894
value	27840894
in	27840894
XLH	27840894
.	27840894
Hepatocyte	10491763
nuclear	10491763
factor	10491763
-	10491763
6	10491763
:	10491763
associations	10491763
between	10491763
genetic	10491763
variability	10491763
and	10491763
type	10491763
II	10491763
diabetes	10491763
and	10491763
between	10491763
genetic	10491763
variability	10491763
and	10491763
estimates	10491763
of	10491763
insulin	10491763
secretion	10491763
.	10491763

The	10491763
transcription	10491763
factor	10491763
hepatocyte	10491763
nuclear	10491763
factor	10491763
(	10491763
HNF	10491763
)	10491763
-	10491763
6	10491763
is	10491763
an	10491763
upstream	10491763
regulator	10491763
of	10491763
several	10491763
genes	10491763
involved	10491763
in	10491763
the	10491763
pathogenesis	10491763
of	10491763
maturity	10491763
-	10491763
onset	10491763
diabetes	10491763
of	10491763
the	10491763
young	10491763
.	10491763

We	10491763
therefore	10491763
tested	10491763
the	10491763
hypothesis	10491763
that	10491763
variability	10491763
in	10491763
the	10491763
HNF	10491763
-	10491763
6	10491763
gene	10491763
is	10491763
associated	10491763
with	10491763
subsets	10491763
of	10491763
Type	10491763
II	10491763
(	10491763
non	10491763
-	10491763
insulin	10491763
-	10491763
dependent	10491763
)	10491763
diabetes	10491763
mellitus	10491763
and	10491763
estimates	10491763
of	10491763
insulin	10491763
secretion	10491763
in	10491763
glucose	10491763
tolerant	10491763
subjects	10491763
.	10491763

We	10491763
cloned	10491763
the	10491763
coding	10491763
region	10491763
as	10491763
well	10491763
as	10491763
the	10491763
intron	10491763
-	10491763
exon	10491763
boundaries	10491763
of	10491763
the	10491763
HNF	10491763
-	10491763
6	10491763
gene	10491763
.	10491763

We	10491763
then	10491763
examined	10491763
them	10491763
on	10491763
genomic	10491763
DNA	10491763
in	10491763
six	10491763
MODY	10491763
probands	10491763
without	10491763
mutations	10491763
in	10491763
the	10491763
MODY1	10491763
,	10491763
MODY3	10491763
and	10491763
MODY4	10491763
genes	10491763
and	10491763
in	10491763
54	10491763
patients	10491763
with	10491763
late	10491763
-	10491763
onset	10491763
Type	10491763
II	10491763
diabetes	10491763
by	10491763
combined	10491763
single	10491763
strand	10491763
conformational	10491763
polymorphism	10491763
-	10491763
heteroduplex	10491763
analysis	10491763
followed	10491763
by	10491763
direct	10491763
sequencing	10491763
of	10491763
identified	10491763
variants	10491763
.	10491763

An	10491763
identified	10491763
missense	10491763
variant	10491763
was	10491763
examined	10491763
in	10491763
association	10491763
studies	10491763
and	10491763
genotype	10491763
-	10491763
phenotype	10491763
studies	10491763
.	10491763

We	10491763
identified	10491763
two	10491763
silent	10491763
and	10491763
one	10491763
missense	10491763
(	10491763
Pro75	10491763
Ala	10491763
)	10491763
variant	10491763
.	10491763

In	10491763
an	10491763
association	10491763
study	10491763
the	10491763
allelic	10491763
frequency	10491763
of	10491763
the	10491763
Pro75Ala	10491763
polymorphism	10491763
was	10491763
3	10491763
.	10491763
2%	10491763
(	10491763
95%	10491763
confidence	10491763
interval	10491763
,	10491763
1	10491763
.	10491763
9	10491763
-	10491763
4	10491763
.	10491763
5	10491763
)	10491763
in	10491763
330	10491763
patients	10491763
with	10491763
Type	10491763
II	10491763
diabetes	10491763
mellitus	10491763
compared	10491763
with	10491763
4	10491763
.	10491763
2%	10491763
(	10491763
2	10491763
.	10491763
4	10491763
-	10491763
6	10491763
.	10491763
0	10491763
)	10491763
in	10491763
238	10491763
age	10491763
-	10491763
matched	10491763
glucose	10491763
tolerant	10491763
control	10491763
subjects	10491763
.	10491763

Moreover	10491763
,	10491763
in	10491763
studies	10491763
of	10491763
238	10491763
middle	10491763
-	10491763
aged	10491763
glucose	10491763
tolerant	10491763
subjects	10491763
,	10491763
of	10491763
226	10491763
glucose	10491763
tolerant	10491763
offspring	10491763
of	10491763
Type	10491763
II	10491763
diabetic	10491763
patients	10491763
and	10491763
of	10491763
367	10491763
young	10491763
healthy	10491763
subjects	10491763
,	10491763
the	10491763
carriers	10491763
of	10491763
the	10491763
polymorphism	10491763
did	10491763
not	10491763
differ	10491763
from	10491763
non	10491763
-	10491763
carriers	10491763
in	10491763
glucose	10491763
induced	10491763
serum	10491763
insulin	10491763
or	10491763
C	10491763
-	10491763
peptide	10491763
responses	10491763
.	10491763

Mutations	10491763
in	10491763
the	10491763
coding	10491763
region	10491763
of	10491763
the	10491763
HNF	10491763
-	10491763
6	10491763
gene	10491763
are	10491763
not	10491763
associated	10491763
with	10491763
Type	10491763
II	10491763
diabetes	10491763
or	10491763
with	10491763
changes	10491763
in	10491763
insulin	10491763
responses	10491763
to	10491763
glucose	10491763
among	10491763
the	10491763
Caucasians	10491763
examined	10491763
.	10491763
Pethidine	9672936
-	9672936
associated	9672936
seizure	9672936
in	9672936
a	9672936
healthy	9672936
adolescent	9672936
receiving	9672936
pethidine	9672936
for	9672936
postoperative	9672936
pain	9672936
control	9672936
.	9672936

A	9672936
healthy	9672936
17	9672936
-	9672936
year	9672936
-	9672936
old	9672936
male	9672936
received	9672936
standard	9672936
intermittent	9672936
doses	9672936
of	9672936
pethidine	9672936
via	9672936
a	9672936
patient	9672936
-	9672936
controlled	9672936
analgesia	9672936
(	9672936
PCA	9672936
)	9672936
pump	9672936
for	9672936
management	9672936
of	9672936
postoperative	9672936
pain	9672936
control	9672936
.	9672936

Twenty	9672936
-	9672936
three	9672936
h	9672936
postoperatively	9672936
he	9672936
developed	9672936
a	9672936
brief	9672936
self	9672936
-	9672936
limited	9672936
seizure	9672936
.	9672936

Both	9672936
plasma	9672936
pethidine	9672936
and	9672936
norpethidine	9672936
were	9672936
elevated	9672936
in	9672936
the	9672936
range	9672936
associated	9672936
with	9672936
clinical	9672936
manifestations	9672936
of	9672936
central	9672936
nervous	9672936
system	9672936
excitation	9672936
.	9672936

No	9672936
other	9672936
risk	9672936
factors	9672936
for	9672936
CNS	9672936
toxicity	9672936
were	9672936
identified	9672936
.	9672936

This	9672936
method	9672936
allowed	9672936
frequent	9672936
self	9672936
-	9672936
dosing	9672936
of	9672936
pethidine	9672936
at	9672936
short	9672936
time	9672936
intervals	9672936
and	9672936
rapid	9672936
accumulation	9672936
of	9672936
pethidine	9672936
and	9672936
norpethidine	9672936
.	9672936

The	9672936
routine	9672936
use	9672936
of	9672936
pethidine	9672936
via	9672936
PCA	9672936
even	9672936
for	9672936
a	9672936
brief	9672936
postoperative	9672936
analgesia	9672936
should	9672936
be	9672936
reconsidered	9672936
.	9672936
Smoking	19841052
of	19841052
crack	19841052
cocaine	19841052
as	19841052
a	19841052
risk	19841052
factor	19841052
for	19841052
HIV	19841052
infection	19841052
among	19841052
people	19841052
who	19841052
use	19841052
injection	19841052
drugs	19841052
.	19841052

BACKGROUND	19841052
:	19841052
Little	19841052
is	19841052
known	19841052
about	19841052
the	19841052
possible	19841052
role	19841052
that	19841052
smoking	19841052
crack	19841052
cocaine	19841052
has	19841052
on	19841052
the	19841052
incidence	19841052
of	19841052
HIV	19841052
infection	19841052
.	19841052

Given	19841052
the	19841052
increasing	19841052
use	19841052
of	19841052
crack	19841052
cocaine	19841052
,	19841052
we	19841052
sought	19841052
to	19841052
examine	19841052
whether	19841052
use	19841052
of	19841052
this	19841052
illicit	19841052
drug	19841052
has	19841052
become	19841052
a	19841052
risk	19841052
factor	19841052
for	19841052
HIV	19841052
infection	19841052
.	19841052

METHODS	19841052
:	19841052
We	19841052
included	19841052
data	19841052
from	19841052
people	19841052
participating	19841052
in	19841052
the	19841052
Vancouver	19841052
Injection	19841052
Drug	19841052
Users	19841052
Study	19841052
who	19841052
reported	19841052
injecting	19841052
illicit	19841052
drugs	19841052
at	19841052
least	19841052
once	19841052
in	19841052
the	19841052
month	19841052
before	19841052
enrolment	19841052
,	19841052
lived	19841052
in	19841052
the	19841052
greater	19841052
Vancouver	19841052
area	19841052
,	19841052
were	19841052
HIV	19841052
-	19841052
negative	19841052
at	19841052
enrolment	19841052
and	19841052
completed	19841052
at	19841052
least	19841052
1	19841052
follow	19841052
-	19841052
up	19841052
study	19841052
visit	19841052
.	19841052

To	19841052
determine	19841052
whether	19841052
the	19841052
risk	19841052
of	19841052
HIV	19841052
seroconversion	19841052
among	19841052
daily	19841052
smokers	19841052
of	19841052
crack	19841052
cocaine	19841052
changed	19841052
over	19841052
time	19841052
,	19841052
we	19841052
used	19841052
Cox	19841052
proportional	19841052
hazards	19841052
regression	19841052
and	19841052
divided	19841052
the	19841052
study	19841052
into	19841052
3	19841052
periods	19841052
:	19841052
May	19841052
1	19841052
,	19841052
1996	19841052
-	19841052
Nov	19841052
.	19841052

30	19841052
,	19841052
1999	19841052
(	19841052
period	19841052
1	19841052
)	19841052
,	19841052
Dec	19841052
.	19841052

1	19841052
,	19841052
1999	19841052
-	19841052
Nov	19841052
.	19841052

30	19841052
,	19841052
2002	19841052
(	19841052
period	19841052
2	19841052
)	19841052
,	19841052
and	19841052
Dec	19841052
.	19841052

1	19841052
,	19841052
2002	19841052
-	19841052
Dec	19841052
.	19841052

30	19841052
,	19841052
2005	19841052
(	19841052
period	19841052
3	19841052
)	19841052
.	19841052

RESULTS	19841052
:	19841052
Overall	19841052
,	19841052
1048	19841052
eligible	19841052
injection	19841052
drug	19841052
users	19841052
were	19841052
included	19841052
in	19841052
our	19841052
study	19841052
.	19841052

Of	19841052
these	19841052
,	19841052
137	19841052
acquired	19841052
HIV	19841052
infection	19841052
during	19841052
follow	19841052
-	19841052
up	19841052
.	19841052

The	19841052
mean	19841052
proportion	19841052
of	19841052
participants	19841052
who	19841052
reported	19841052
daily	19841052
smoking	19841052
of	19841052
crack	19841052
cocaine	19841052
increased	19841052
from	19841052
11	19841052
.	19841052
6%	19841052
in	19841052
period	19841052
1	19841052
to	19841052
39	19841052
.	19841052
7%	19841052
in	19841052
period	19841052
3	19841052
.	19841052

After	19841052
adjusting	19841052
for	19841052
potential	19841052
confounders	19841052
,	19841052
we	19841052
found	19841052
that	19841052
the	19841052
risk	19841052
of	19841052
HIV	19841052
seroconversion	19841052
among	19841052
participants	19841052
who	19841052
were	19841052
daily	19841052
smokers	19841052
of	19841052
crack	19841052
cocaine	19841052
increased	19841052
over	19841052
time	19841052
(	19841052
period	19841052
1	19841052
:	19841052
hazard	19841052
ratio	19841052
[	19841052
HR	19841052
]	19841052
1	19841052
.	19841052
03	19841052
,	19841052
95%	19841052
confidence	19841052
interval	19841052
[	19841052
CI	19841052
]	19841052
0	19841052
.	19841052
57	19841052
-	19841052
1	19841052
.	19841052
85	19841052
;	19841052
period	19841052
2	19841052
:	19841052
HR	19841052
1	19841052
.	19841052
68	19841052
,	19841052
95%	19841052
CI	19841052
1	19841052
.	19841052
01	19841052
-	19841052
2	19841052
.	19841052
80	19841052
;	19841052
and	19841052
period	19841052
3	19841052
:	19841052
HR	19841052
2	19841052
.	19841052
74	19841052
,	19841052
95%	19841052
CI	19841052
1	19841052
.	19841052
06	19841052
-	19841052
7	19841052
.	19841052
11	19841052
)	19841052
.	19841052

INTERPRETATION	19841052
:	19841052
Smoking	19841052
of	19841052
crack	19841052
cocaine	19841052
was	19841052
found	19841052
to	19841052
be	19841052
an	19841052
independent	19841052
risk	19841052
factor	19841052
for	19841052
HIV	19841052
seroconversion	19841052
among	19841052
people	19841052
who	19841052
were	19841052
injection	19841052
drug	19841052
users	19841052
.	19841052

This	19841052
finding	19841052
points	19841052
to	19841052
the	19841052
urgent	19841052
need	19841052
for	19841052
evidence	19841052
-	19841052
based	19841052
public	19841052
health	19841052
initiatives	19841052
targeted	19841052
at	19841052
people	19841052
who	19841052
smoke	19841052
crack	19841052
cocaine	19841052
.	19841052
Common	15755837
dihydrofolate	15755837
reductase	15755837
19	15755837
-	15755837
base	15755837
pair	15755837
deletion	15755837
allele	15755837
:	15755837
a	15755837
novel	15755837
risk	15755837
factor	15755837
for	15755837
preterm	15755837
delivery	15755837
.	15755837

BACKGROUND	15755837
:	15755837
Folate	15755837
is	15755837
critical	15755837
for	15755837
cell	15755837
division	15755837
,	15755837
a	15755837
major	15755837
feature	15755837
of	15755837
in	15755837
utero	15755837
development	15755837
.	15755837

Dihydrofolate	15755837
reductase	15755837
(	15755837
DHFR	15755837
)	15755837
is	15755837
required	15755837
to	15755837
convert	15755837
the	15755837
folic	15755837
acid	15755837
used	15755837
in	15755837
supplements	15755837
and	15755837
for	15755837
food	15755837
fortification	15755837
and	15755837
the	15755837
dihydrofolate	15755837
produced	15755837
by	15755837
thymidylate	15755837
synthase	15755837
during	15755837
DNA	15755837
synthesis	15755837
to	15755837
the	15755837
reduced	15755837
folate	15755837
forms	15755837
used	15755837
by	15755837
the	15755837
cell	15755837
.	15755837

OBJECTIVE	15755837
:	15755837
We	15755837
aimed	15755837
to	15755837
determine	15755837
whether	15755837
a	15755837
common	15755837
,	15755837
recently	15755837
discovered	15755837
deletion	15755837
polymorphism	15755837
in	15755837
the	15755837
DHFR	15755837
gene	15755837
is	15755837
a	15755837
risk	15755837
factor	15755837
for	15755837
preterm	15755837
delivery	15755837
or	15755837
low	15755837
birth	15755837
weight	15755837
.	15755837

DESIGN	15755837
:	15755837
We	15755837
studied	15755837
324	15755837
pregnant	15755837
women	15755837
from	15755837
Camden	15755837
,	15755837
NJ	15755837
.	15755837

Folate	15755837
intake	15755837
was	15755837
computed	15755837
from	15755837
folate	15755837
supplement	15755837
intake	15755837
plus	15755837
the	15755837
mean	15755837
of	15755837
two	15755837
24	15755837
-	15755837
h	15755837
recalls	15755837
completed	15755837
during	15755837
the	15755837
course	15755837
of	15755837
pregnancy	15755837
.	15755837

Genomic	15755837
DNA	15755837
was	15755837
extracted	15755837
from	15755837
the	15755837
women	15755837
'	15755837
s	15755837
leukocytes	15755837
and	15755837
genotyped	15755837
.	15755837

RESULTS	15755837
:	15755837
Women	15755837
with	15755837
a	15755837
deletion	15755837
allele	15755837
had	15755837
a	15755837
significantly	15755837
greater	15755837
risk	15755837
of	15755837
preterm	15755837
delivery	15755837
[	15755837
adjusted	15755837
odds	15755837
ratio	15755837
(	15755837
AOR	15755837
)	15755837
:	15755837
3	15755837
.	15755837
0	15755837
;	15755837
95%	15755837
CI	15755837
:	15755837
1	15755837
.	15755837
0	15755837
,	15755837
8	15755837
.	15755837
8	15755837
;	15755837
P	15755837
<	15755837
0	15755837
.	15755837
05	15755837
]	15755837
than	15755837
did	15755837
those	15755837
without	15755837
a	15755837
deletion	15755837
allele	15755837
.	15755837

Women	15755837
with	15755837
both	15755837
a	15755837
DHFR	15755837
deletion	15755837
allele	15755837
and	15755837
low	15755837
folate	15755837
intake	15755837
(	15755837
<	15755837
400	15755837
microg	15755837
/	15755837
d	15755837
from	15755837
diet	15755837
plus	15755837
supplements	15755837
)	15755837
had	15755837
a	15755837
significantly	15755837
greater	15755837
risk	15755837
of	15755837
preterm	15755837
delivery	15755837
(	15755837
AOR	15755837
:	15755837
5	15755837
.	15755837
5	15755837
;	15755837
95%	15755837
CI	15755837
:	15755837
1	15755837
.	15755837
5	15755837
,	15755837
20	15755837
.	15755837
4	15755837
;	15755837
P	15755837
=	15755837
0	15755837
.	15755837
01	15755837
)	15755837
and	15755837
a	15755837
significantly	15755837
greater	15755837
risk	15755837
of	15755837
having	15755837
an	15755837
infant	15755837
with	15755837
a	15755837
low	15755837
birth	15755837
weight	15755837
(	15755837
AOR	15755837
:	15755837
8	15755837
.	15755837
3	15755837
;	15755837
95%	15755837
CI	15755837
:	15755837
1	15755837
.	15755837
8	15755837
,	15755837
38	15755837
.	15755837
6	15755837
;	15755837
P	15755837
=	15755837
0	15755837
.	15755837
01	15755837
)	15755837
than	15755837
did	15755837
women	15755837
without	15755837
a	15755837
deletion	15755837
allele	15755837
and	15755837
with	15755837
a	15755837
folate	15755837
intake	15755837
>	15755837
/	15755837
=	15755837
400	15755837
microg	15755837
/	15755837
d	15755837
.	15755837

CONCLUSIONS	15755837
:	15755837
The	15755837
DHFR	15755837
19	15755837
-	15755837
base	15755837
pair	15755837
deletion	15755837
allele	15755837
may	15755837
be	15755837
a	15755837
risk	15755837
factor	15755837
for	15755837
preterm	15755837
delivery	15755837
.	15755837

In	15755837
the	15755837
presence	15755837
of	15755837
low	15755837
dietary	15755837
folate	15755837
,	15755837
the	15755837
allele	15755837
may	15755837
also	15755837
be	15755837
a	15755837
risk	15755837
factor	15755837
for	15755837
low	15755837
birth	15755837
weight	15755837
.	15755837

This	15755837
may	15755837
be	15755837
a	15755837
gene	15755837
-	15755837
environment	15755837
interaction	15755837
.	15755837
Nefiracetam	8829135
(	8829135
DM	8829135
-	8829135
9384	8829135
)	8829135
reverses	8829135
apomorphine	8829135
-	8829135
induced	8829135
amnesia	8829135
of	8829135
a	8829135
passive	8829135
avoidance	8829135
response	8829135
:	8829135
delayed	8829135
emergence	8829135
of	8829135
the	8829135
memory	8829135
retention	8829135
effects	8829135
.	8829135

Nefiracetam	8829135
is	8829135
a	8829135
novel	8829135
pyrrolidone	8829135
derivative	8829135
which	8829135
attenuates	8829135
scopolamine	8829135
-	8829135
induced	8829135
learning	8829135
and	8829135
post	8829135
-	8829135
training	8829135
consolidation	8829135
deficits	8829135
.	8829135

Given	8829135
that	8829135
apomorphine	8829135
inhibits	8829135
passive	8829135
avoidance	8829135
retention	8829135
when	8829135
given	8829135
during	8829135
training	8829135
or	8829135
in	8829135
a	8829135
defined	8829135
10	8829135
-	8829135
12h	8829135
post	8829135
-	8829135
training	8829135
period	8829135
,	8829135
we	8829135
evaluated	8829135
the	8829135
ability	8829135
of	8829135
nefiracetam	8829135
to	8829135
attenuate	8829135
amnesia	8829135
induced	8829135
by	8829135
dopaminergic	8829135
agonism	8829135
.	8829135

A	8829135
step	8829135
-	8829135
down	8829135
passive	8829135
avoidance	8829135
paradigm	8829135
was	8829135
employed	8829135
and	8829135
nefiracetam	8829135
(	8829135
3	8829135
mg	8829135
/	8829135
kg	8829135
)	8829135
and	8829135
apomorphine	8829135
(	8829135
0	8829135
.	8829135
5	8829135
mg	8829135
/	8829135
kg	8829135
)	8829135
were	8829135
given	8829135
alone	8829135
or	8829135
in	8829135
combination	8829135
during	8829135
training	8829135
and	8829135
at	8829135
the	8829135
10	8829135
-	8829135
12h	8829135
post	8829135
-	8829135
training	8829135
period	8829135
of	8829135
consolidation	8829135
.	8829135

Co	8829135
-	8829135
administration	8829135
of	8829135
nefiracetam	8829135
and	8829135
apomorphine	8829135
during	8829135
training	8829135
or	8829135
10h	8829135
thereafter	8829135
produced	8829135
no	8829135
significant	8829135
anti	8829135
-	8829135
amnesic	8829135
effect	8829135
.	8829135

However	8829135
,	8829135
administration	8829135
of	8829135
nefiracetam	8829135
during	8829135
training	8829135
completely	8829135
reversed	8829135
the	8829135
amnesia	8829135
induced	8829135
by	8829135
apomorphine	8829135
at	8829135
the	8829135
10h	8829135
post	8829135
-	8829135
training	8829135
time	8829135
and	8829135
the	8829135
converse	8829135
was	8829135
also	8829135
true	8829135
.	8829135

These	8829135
effects	8829135
were	8829135
not	8829135
mediated	8829135
by	8829135
a	8829135
dopaminergic	8829135
mechanism	8829135
as	8829135
nefiracetam	8829135
,	8829135
at	8829135
millimolar	8829135
concentrations	8829135
,	8829135
failed	8829135
to	8829135
displace	8829135
either	8829135
[	8829135
3H	8829135
]	8829135
SCH	8829135
23390	8829135
or	8829135
[	8829135
3H	8829135
]	8829135
spiperone	8829135
binding	8829135
from	8829135
D1	8829135
or	8829135
D2	8829135
dopamine	8829135
receptor	8829135
subtypes	8829135
,	8829135
respectively	8829135
.	8829135

It	8829135
is	8829135
suggested	8829135
that	8829135
nefiracetam	8829135
augments	8829135
molecular	8829135
processes	8829135
in	8829135
the	8829135
early	8829135
stages	8829135
of	8829135
events	8829135
which	8829135
ultimately	8829135
lead	8829135
to	8829135
consolidation	8829135
of	8829135
memory	8829135
.	8829135
Angiotensin	28660748
II	28660748
subtype	28660748
1a	28660748
receptor	28660748
signaling	28660748
in	28660748
resident	28660748
hepatic	28660748
macrophages	28660748
induces	28660748
liver	28660748
metastasis	28660748
formation	28660748
.	28660748

Liver	28660748
metastases	28660748
from	28660748
colorectal	28660748
cancer	28660748
(	28660748
CRC	28660748
)	28660748
are	28660748
a	28660748
clinically	28660748
significant	28660748
problem	28660748
.	28660748

The	28660748
renin	28660748
-	28660748
angiotensin	28660748
system	28660748
is	28660748
involved	28660748
in	28660748
tumor	28660748
growth	28660748
and	28660748
metastases	28660748
.	28660748

This	28660748
study	28660748
was	28660748
designed	28660748
to	28660748
evaluate	28660748
the	28660748
role	28660748
of	28660748
angiotensin	28660748
II	28660748
subtype	28660748
receptor	28660748
1a	28660748
(	28660748
AT1a	28660748
)	28660748
in	28660748
the	28660748
formation	28660748
of	28660748
liver	28660748
metastasis	28660748
in	28660748
CRC	28660748
.	28660748

A	28660748
model	28660748
of	28660748
liver	28660748
metastasis	28660748
was	28660748
developed	28660748
by	28660748
intrasplenic	28660748
injection	28660748
of	28660748
mouse	28660748
colon	28660748
cancer	28660748
(	28660748
CMT	28660748
-	28660748
93	28660748
)	28660748
into	28660748
AT1a	28660748
knockout	28660748
mice	28660748
(	28660748
AT1aKO	28660748
)	28660748
and	28660748
wild	28660748
-	28660748
type	28660748
(	28660748
C57BL	28660748
/	28660748
6	28660748
)	28660748
mice	28660748
(	28660748
WT	28660748
)	28660748
.	28660748

Compared	28660748
with	28660748
WT	28660748
mice	28660748
,	28660748
the	28660748
liver	28660748
weight	28660748
and	28660748
liver	28660748
metastatic	28660748
rate	28660748
were	28660748
significantly	28660748
lower	28660748
in	28660748
AT1aKO	28660748
.	28660748

The	28660748
mRNA	28660748
levels	28660748
of	28660748
CD31	28660748
,	28660748
transforming	28660748
growth	28660748
factor	28660748
-	28660748
b1	28660748
(	28660748
TGF	28660748
-	28660748
b1	28660748
)	28660748
,	28660748
and	28660748
F4	28660748
/	28660748
80	28660748
were	28660748
suppressed	28660748
in	28660748
AT1aKO	28660748
compared	28660748
with	28660748
WT	28660748
.	28660748

Double	28660748
immunofluorescence	28660748
analysis	28660748
showed	28660748
that	28660748
the	28660748
number	28660748
of	28660748
accumulated	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
expressing	28660748
TGF	28660748
-	28660748
b1	28660748
in	28660748
metastatic	28660748
areas	28660748
was	28660748
higher	28660748
in	28660748
WT	28660748
than	28660748
in	28660748
AT1aKO	28660748
.	28660748

The	28660748
AT1aKO	28660748
bone	28660748
marrow	28660748
(	28660748
BM	28660748
)	28660748
(	28660748
AT1aKO	28660748
-	28660748
BM	28660748
)	28660748
>	28660748
WT	28660748
showed	28660748
suppressed	28660748
formation	28660748
of	28660748
liver	28660748
metastasis	28660748
compared	28660748
with	28660748
WT	28660748
-	28660748
BM	28660748
>	28660748
WT	28660748
.	28660748

However	28660748
,	28660748
the	28660748
formation	28660748
of	28660748
metastasis	28660748
was	28660748
further	28660748
suppressed	28660748
in	28660748
WT	28660748
-	28660748
BM	28660748
>	28660748
AT1aKO	28660748
compared	28660748
with	28660748
AT1aKO	28660748
-	28660748
BM	28660748
>	28660748
WT	28660748
.	28660748

In	28660748
addition	28660748
,	28660748
accumulated	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
in	28660748
the	28660748
liver	28660748
metastasis	28660748
were	28660748
not	28660748
BM	28660748
-	28660748
derived	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
,	28660748
but	28660748
mainly	28660748
resident	28660748
hepatic	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
,	28660748
and	28660748
these	28660748
resident	28660748
hepatic	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
were	28660748
positive	28660748
for	28660748
TGF	28660748
-	28660748
b1	28660748
.	28660748

Angiotensin	28660748
II	28660748
enhanced	28660748
TGF	28660748
-	28660748
b1	28660748
expression	28660748
in	28660748
Kupffer	28660748
cells	28660748
.	28660748

Treatment	28660748
of	28660748
WT	28660748
with	28660748
clodronate	28660748
liposomes	28660748
suppressed	28660748
liver	28660748
metastasis	28660748
by	28660748
diminishing	28660748
TGF	28660748
-	28660748
b1	28660748
(	28660748
+	28660748
)	28660748
F4	28660748
/	28660748
80	28660748
(	28660748
+	28660748
)	28660748
cells	28660748
accumulation	28660748
.	28660748

The	28660748
formation	28660748
of	28660748
liver	28660748
metastasis	28660748
correlated	28660748
with	28660748
collagen	28660748
deposition	28660748
in	28660748
the	28660748
metastatic	28660748
area	28660748
,	28660748
which	28660748
was	28660748
dependent	28660748
on	28660748
AT1a	28660748
signaling	28660748
.	28660748

These	28660748
results	28660748
suggested	28660748
that	28660748
resident	28660748
hepatic	28660748
macrophages	28660748
induced	28660748
liver	28660748
metastasis	28660748
formation	28660748
by	28660748
induction	28660748
of	28660748
TGF	28660748
-	28660748
b1	28660748
through	28660748
AT1a	28660748
signaling	28660748
.	28660748
Isoproterenol	18808529
induces	18808529
primary	18808529
loss	18808529
of	18808529
dystrophin	18808529
in	18808529
rat	18808529
hearts	18808529
:	18808529
correlation	18808529
with	18808529
myocardial	18808529
injury	18808529
.	18808529

The	18808529
mechanism	18808529
of	18808529
isoproterenol	18808529
-	18808529
induced	18808529
myocardial	18808529
damage	18808529
is	18808529
unknown	18808529
,	18808529
but	18808529
a	18808529
mismatch	18808529
of	18808529
oxygen	18808529
supply	18808529
vs	18808529
.	18808529

demand	18808529
following	18808529
coronary	18808529
hypotension	18808529
and	18808529
myocardial	18808529
hyperactivity	18808529
is	18808529
the	18808529
best	18808529
explanation	18808529
for	18808529
the	18808529
complex	18808529
morphological	18808529
alterations	18808529
observed	18808529
.	18808529

Severe	18808529
alterations	18808529
in	18808529
the	18808529
structural	18808529
integrity	18808529
of	18808529
the	18808529
sarcolemma	18808529
of	18808529
cardiomyocytes	18808529
have	18808529
been	18808529
demonstrated	18808529
to	18808529
be	18808529
caused	18808529
by	18808529
isoproterenol	18808529
.	18808529

Taking	18808529
into	18808529
account	18808529
that	18808529
the	18808529
sarcolemmal	18808529
integrity	18808529
is	18808529
stabilized	18808529
by	18808529
the	18808529
dystrophin	18808529
-	18808529
glycoprotein	18808529
complex	18808529
(	18808529
DGC	18808529
)	18808529
that	18808529
connects	18808529
actin	18808529
and	18808529
laminin	18808529
in	18808529
contractile	18808529
machinery	18808529
and	18808529
extracellular	18808529
matrix	18808529
and	18808529
by	18808529
integrins	18808529
,	18808529
this	18808529
study	18808529
tests	18808529
the	18808529
hypothesis	18808529
that	18808529
isoproterenol	18808529
affects	18808529
sarcolemmal	18808529
stability	18808529
through	18808529
changes	18808529
in	18808529
the	18808529
DGC	18808529
and	18808529
integrins	18808529
.	18808529

We	18808529
found	18808529
different	18808529
sensitivity	18808529
of	18808529
the	18808529
DGC	18808529
and	18808529
integrin	18808529
to	18808529
isoproterenol	18808529
subcutaneous	18808529
administration	18808529
.	18808529

Immunofluorescent	18808529
staining	18808529
revealed	18808529
that	18808529
dystrophin	18808529
is	18808529
the	18808529
most	18808529
sensitive	18808529
among	18808529
the	18808529
structures	18808529
connecting	18808529
the	18808529
actin	18808529
in	18808529
the	18808529
cardiomyocyte	18808529
cytoskeleton	18808529
and	18808529
the	18808529
extracellular	18808529
matrix	18808529
.	18808529

The	18808529
sarcomeric	18808529
actin	18808529
dissolution	18808529
occurred	18808529
after	18808529
the	18808529
reduction	18808529
or	18808529
loss	18808529
of	18808529
dystrophin	18808529
.	18808529

Subsequently	18808529
,	18808529
after	18808529
lysis	18808529
of	18808529
myofilaments	18808529
,	18808529
gamma	18808529
-	18808529
sarcoglycan	18808529
,	18808529
beta	18808529
-	18808529
dystroglycan	18808529
,	18808529
beta1	18808529
-	18808529
integrin	18808529
,	18808529
and	18808529
laminin	18808529
alpha	18808529
-	18808529
2	18808529
expressions	18808529
were	18808529
reduced	18808529
followed	18808529
by	18808529
their	18808529
breakdown	18808529
,	18808529
as	18808529
epiphenomena	18808529
of	18808529
the	18808529
myocytolytic	18808529
process	18808529
.	18808529

In	18808529
conclusion	18808529
,	18808529
administration	18808529
of	18808529
isoproterenol	18808529
to	18808529
rats	18808529
results	18808529
in	18808529
primary	18808529
loss	18808529
of	18808529
dystrophin	18808529
,	18808529
the	18808529
most	18808529
sensitive	18808529
among	18808529
the	18808529
structural	18808529
proteins	18808529
that	18808529
form	18808529
the	18808529
DGC	18808529
that	18808529
connects	18808529
the	18808529
extracellular	18808529
matrix	18808529
and	18808529
the	18808529
cytoskeleton	18808529
in	18808529
cardiomyocyte	18808529
.	18808529

These	18808529
changes	18808529
,	18808529
related	18808529
to	18808529
ischaemic	18808529
injury	18808529
,	18808529
explain	18808529
the	18808529
severe	18808529
alterations	18808529
in	18808529
the	18808529
structural	18808529
integrity	18808529
of	18808529
the	18808529
sarcolemma	18808529
of	18808529
cardiomyocytes	18808529
and	18808529
hence	18808529
severe	18808529
and	18808529
irreversible	18808529
injury	18808529
induced	18808529
by	18808529
isoproterenol	18808529
.	18808529
The	24477591
-	24477591
930A	24477591
>	24477591
G	24477591
polymorphism	24477591
of	24477591
the	24477591
CYBA	24477591
gene	24477591
is	24477591
associated	24477591
with	24477591
premature	24477591
coronary	24477591
artery	24477591
disease	24477591
.	24477591

A	24477591
case	24477591
-	24477591
control	24477591
study	24477591
and	24477591
gene	24477591
-	24477591
risk	24477591
factors	24477591
interactions	24477591
.	24477591

Reactive	24477591
oxygen	24477591
species	24477591
(	24477591
ROS	24477591
)	24477591
are	24477591
involved	24477591
in	24477591
the	24477591
pathogenesis	24477591
of	24477591
atherosclerosis	24477591
and	24477591
coronary	24477591
artery	24477591
disease	24477591
(	24477591
CAD	24477591
)	24477591
.	24477591

NADPH	24477591
oxidases	24477591
are	24477591
the	24477591
main	24477591
source	24477591
of	24477591
ROS	24477591
in	24477591
the	24477591
vasculature	24477591
.	24477591

p22phox	24477591
is	24477591
a	24477591
critical	24477591
component	24477591
of	24477591
vascular	24477591
NADPH	24477591
oxidases	24477591
and	24477591
is	24477591
encoded	24477591
by	24477591
the	24477591
CYBA	24477591
(	24477591
cytochrome	24477591
b245	24477591
alpha	24477591
)	24477591
gene	24477591
.	24477591

The	24477591
-	24477591
930A	24477591
>	24477591
G	24477591
CYBA	24477591
polymorphism	24477591
(	24477591
rs9932581	24477591
:	24477591
A	24477591
>	24477591
G	24477591
)	24477591
modulates	24477591
the	24477591
activity	24477591
of	24477591
the	24477591
CYBA	24477591
promoter	24477591
,	24477591
and	24477591
influences	24477591
CYBA	24477591
transcriptional	24477591
activity	24477591
.	24477591

The	24477591
aim	24477591
of	24477591
the	24477591
present	24477591
study	24477591
was	24477591
to	24477591
analyze	24477591
a	24477591
possible	24477591
association	24477591
between	24477591
the	24477591
-	24477591
930A	24477591
>	24477591
G	24477591
polymorphism	24477591
and	24477591
CAD	24477591
and	24477591
to	24477591
search	24477591
for	24477591
gene	24477591
-	24477591
traditional	24477591
risk	24477591
factors	24477591
interactions	24477591
.	24477591

480	24477591
subjects	24477591
were	24477591
studied	24477591
:	24477591
240	24477591
patients	24477591
with	24477591
premature	24477591
CAD	24477591
,	24477591
240	24477591
age	24477591
and	24477591
sex	24477591
matched	24477591
blood	24477591
donors	24477591
.	24477591

The	24477591
-	24477591
930A	24477591
>	24477591
G	24477591
polymorphism	24477591
was	24477591
genotyped	24477591
using	24477591
the	24477591
TaqMan	24477591
-	24477591
Pre	24477591
-	24477591
designed	24477591
SNP	24477591
Genotyping	24477591
Assay	24477591
(	24477591
Applied	24477591
Biosystems	24477591
)	24477591
.	24477591

The	24477591
-	24477591
930G	24477591
allele	24477591
carrier	24477591
state	24477591
was	24477591
a	24477591
risk	24477591
factor	24477591
for	24477591
CAD	24477591
(	24477591
OR	24477591
2	24477591
.	24477591
03	24477591
,	24477591
95%	24477591
CI	24477591
1	24477591
.	24477591
21	24477591
-	24477591
3	24477591
.	24477591
44	24477591
,	24477591
P	24477591
=	24477591
0	24477591
.	24477591
007	24477591
)	24477591
.	24477591

A	24477591
synergistic	24477591
effect	24477591
of	24477591
the	24477591
-	24477591
930G	24477591
allele	24477591
with	24477591
overweight	24477591
/	24477591
obesity	24477591
(	24477591
BMI	24477591
-	24477591
-	24477591
25	24477591
)	24477591
and	24477591
cigarette	24477591
smoking	24477591
was	24477591
found	24477591
.	24477591

The	24477591
estimated	24477591
CAD	24477591
risk	24477591
for	24477591
BMI	24477591
-	24477591
-	24477591
25	24477591
and	24477591
the	24477591
-	24477591
930G	24477591
allele	24477591
interaction	24477591
was	24477591
about	24477591
160%	24477591
greater	24477591
than	24477591
that	24477591
predicted	24477591
by	24477591
assuming	24477591
additivity	24477591
of	24477591
the	24477591
effects	24477591
,	24477591
and	24477591
about	24477591
40%	24477591
greater	24477591
for	24477591
interaction	24477591
of	24477591
cigarette	24477591
smoking	24477591
and	24477591
the	24477591
-	24477591
930G	24477591
allele	24477591
.	24477591

Overweight	24477591
/	24477591
obesity	24477591
was	24477591
a	24477591
risk	24477591
factor	24477591
for	24477591
CAD	24477591
only	24477591
in	24477591
the	24477591
-	24477591
930G	24477591
allele	24477591
carriers	24477591
(	24477591
P	24477591
<	24477591
10	24477591
(	24477591
-	24477591
10	24477591
)	24477591
)	24477591
but	24477591
not	24477591
in	24477591
the	24477591
AA	24477591
homozygotes	24477591
(	24477591
P	24477591
=	24477591
1	24477591
.	24477591
00	24477591
)	24477591
.	24477591

In	24477591
conclusion	24477591
the	24477591
-	24477591
930A	24477591
>	24477591
G	24477591
CYBA	24477591
polymorphism	24477591
is	24477591
associated	24477591
with	24477591
CAD	24477591
in	24477591
the	24477591
Polish	24477591
population	24477591
.	24477591

The	24477591
-	24477591
930G	24477591
allele	24477591
carriers	24477591
are	24477591
particularly	24477591
at	24477591
risk	24477591
of	24477591
consequences	24477591
of	24477591
obesity	24477591
and	24477591
tobacco	24477591
smoke	24477591
exposure	24477591
.	24477591
Segregation	16277682
of	16277682
a	16277682
M404V	16277682
mutation	16277682
of	16277682
the	16277682
p62	16277682
/	16277682
sequestosome	16277682
1	16277682
(	16277682
p62	16277682
/	16277682
SQSTM1	16277682
)	16277682
gene	16277682
with	16277682
polyostotic	16277682
Paget	16277682
'	16277682
s	16277682
disease	16277682
of	16277682
bone	16277682
in	16277682
an	16277682
Italian	16277682
family	16277682
.	16277682

Mutations	16277682
of	16277682
the	16277682
p62	16277682
/	16277682
Sequestosome	16277682
1	16277682
gene	16277682
(	16277682
p62	16277682
/	16277682
SQSTM1	16277682
)	16277682
account	16277682
for	16277682
both	16277682
sporadic	16277682
and	16277682
familial	16277682
forms	16277682
of	16277682
Paget	16277682
'	16277682
s	16277682
disease	16277682
of	16277682
bone	16277682
(	16277682
PDB	16277682
)	16277682
.	16277682

We	16277682
originally	16277682
described	16277682
a	16277682
methionine	16277682
-	16277682
-	16277682
>	16277682
valine	16277682
substitution	16277682
at	16277682
codon	16277682
404	16277682
(	16277682
M404V	16277682
)	16277682
of	16277682
exon	16277682
8	16277682
,	16277682
in	16277682
the	16277682
ubiquitin	16277682
protein	16277682
-	16277682
binding	16277682
domain	16277682
of	16277682
p62	16277682
/	16277682
SQSTM1	16277682
gene	16277682
in	16277682
an	16277682
Italian	16277682
PDB	16277682
patient	16277682
.	16277682

The	16277682
collection	16277682
of	16277682
data	16277682
from	16277682
the	16277682
patient	16277682
'	16277682
s	16277682
pedigree	16277682
provided	16277682
evidence	16277682
for	16277682
a	16277682
familial	16277682
form	16277682
of	16277682
PDB	16277682
.	16277682

Extension	16277682
of	16277682
the	16277682
genetic	16277682
analysis	16277682
to	16277682
other	16277682
relatives	16277682
in	16277682
this	16277682
family	16277682
demonstrated	16277682
segregation	16277682
of	16277682
the	16277682
M404V	16277682
mutation	16277682
with	16277682
the	16277682
polyostotic	16277682
PDB	16277682
phenotype	16277682
and	16277682
provided	16277682
the	16277682
identification	16277682
of	16277682
six	16277682
asymptomatic	16277682
gene	16277682
carriers	16277682
.	16277682

DNA	16277682
for	16277682
mutational	16277682
analysis	16277682
of	16277682
the	16277682
exon	16277682
8	16277682
coding	16277682
sequence	16277682
was	16277682
obtained	16277682
from	16277682
22	16277682
subjects	16277682
,	16277682
4	16277682
PDB	16277682
patients	16277682
and	16277682
18	16277682
clinically	16277682
unaffected	16277682
members	16277682
.	16277682

Of	16277682
the	16277682
five	16277682
clinically	16277682
ascertained	16277682
affected	16277682
members	16277682
of	16277682
the	16277682
family	16277682
,	16277682
four	16277682
possessed	16277682
the	16277682
M404V	16277682
mutation	16277682
and	16277682
exhibited	16277682
the	16277682
polyostotic	16277682
form	16277682
of	16277682
PDB	16277682
,	16277682
except	16277682
one	16277682
patient	16277682
with	16277682
a	16277682
single	16277682
X	16277682
-	16277682
ray	16277682
-	16277682
assessed	16277682
skeletal	16277682
localization	16277682
and	16277682
one	16277682
with	16277682
a	16277682
polyostotic	16277682
disease	16277682
who	16277682
had	16277682
died	16277682
several	16277682
years	16277682
before	16277682
the	16277682
DNA	16277682
analysis	16277682
.	16277682

By	16277682
both	16277682
reconstitution	16277682
and	16277682
mutational	16277682
analysis	16277682
of	16277682
the	16277682
pedigree	16277682
,	16277682
six	16277682
unaffected	16277682
subjects	16277682
were	16277682
shown	16277682
to	16277682
bear	16277682
the	16277682
M404V	16277682
mutation	16277682
,	16277682
representing	16277682
potential	16277682
asymptomatic	16277682
gene	16277682
carriers	16277682
whose	16277682
circulating	16277682
levels	16277682
of	16277682
alkaline	16277682
phosphatase	16277682
were	16277682
recently	16277682
assessed	16277682
as	16277682
still	16277682
within	16277682
the	16277682
normal	16277682
range	16277682
.	16277682

Taken	16277682
together	16277682
,	16277682
these	16277682
results	16277682
support	16277682
a	16277682
genotype	16277682
-	16277682
phenotype	16277682
correlation	16277682
between	16277682
the	16277682
M404V	16277682
mutation	16277682
in	16277682
the	16277682
p62	16277682
/	16277682
SQSTM1	16277682
gene	16277682
and	16277682
a	16277682
polyostotic	16277682
form	16277682
of	16277682
PDB	16277682
in	16277682
this	16277682
family	16277682
.	16277682

The	16277682
high	16277682
penetrance	16277682
of	16277682
the	16277682
PDB	16277682
trait	16277682
in	16277682
this	16277682
family	16277682
together	16277682
with	16277682
the	16277682
study	16277682
of	16277682
the	16277682
asymptomatic	16277682
gene	16277682
carriers	16277682
will	16277682
allow	16277682
us	16277682
to	16277682
confirm	16277682
the	16277682
proposed	16277682
genotype	16277682
-	16277682
phenotype	16277682
correlation	16277682
and	16277682
to	16277682
evaluate	16277682
the	16277682
potential	16277682
use	16277682
of	16277682
mutational	16277682
analysis	16277682
of	16277682
the	16277682
p62	16277682
/	16277682
SQSTM1	16277682
gene	16277682
in	16277682
the	16277682
early	16277682
detection	16277682
of	16277682
relatives	16277682
at	16277682
risk	16277682
for	16277682
PDB	16277682
.	16277682
Osteogenesis	19208385
imperfecta	19208385
type	19208385
III	19208385
with	19208385
intracranial	19208385
hemorrhage	19208385
and	19208385
brachydactyly	19208385
associated	19208385
with	19208385
mutations	19208385
in	19208385
exon	19208385
49	19208385
of	19208385
COL1A2	19208385
.	19208385

Osteogenesis	19208385
imperfecta	19208385
(	19208385
OI	19208385
)	19208385
is	19208385
a	19208385
heritable	19208385
bone	19208385
disorder	19208385
characterized	19208385
by	19208385
fractures	19208385
with	19208385
minimal	19208385
trauma	19208385
.	19208385

Intracranial	19208385
hemorrhage	19208385
has	19208385
been	19208385
reported	19208385
in	19208385
a	19208385
small	19208385
number	19208385
of	19208385
OI	19208385
patients	19208385
.	19208385

Here	19208385
we	19208385
describe	19208385
three	19208385
patients	19208385
,	19208385
a	19208385
boy	19208385
(	19208385
aged	19208385
15	19208385
years	19208385
)	19208385
and	19208385
two	19208385
girls	19208385
(	19208385
aged	19208385
17	19208385
and	19208385
7	19208385
years	19208385
)	19208385
with	19208385
OI	19208385
type	19208385
III	19208385
who	19208385
suffered	19208385
intracranial	19208385
hemorrhage	19208385
and	19208385
in	19208385
addition	19208385
had	19208385
brachydactyly	19208385
and	19208385
nail	19208385
hypoplasia	19208385
.	19208385

In	19208385
all	19208385
of	19208385
these	19208385
patients	19208385
,	19208385
OI	19208385
was	19208385
caused	19208385
by	19208385
glycine	19208385
mutations	19208385
affecting	19208385
exon	19208385
49	19208385
of	19208385
the	19208385
COL1A2	19208385
gene	19208385
,	19208385
which	19208385
codes	19208385
for	19208385
the	19208385
most	19208385
carboxy	19208385
-	19208385
terminal	19208385
part	19208385
of	19208385
the	19208385
triple	19208385
-	19208385
helical	19208385
domain	19208385
of	19208385
the	19208385
collagen	19208385
type	19208385
I	19208385
alpha	19208385
2	19208385
chain	19208385
.	19208385

These	19208385
observations	19208385
suggest	19208385
that	19208385
mutations	19208385
in	19208385
this	19208385
region	19208385
of	19208385
the	19208385
collagen	19208385
type	19208385
I	19208385
alpha	19208385
2	19208385
chain	19208385
carry	19208385
a	19208385
high	19208385
risk	19208385
of	19208385
abnormal	19208385
limb	19208385
development	19208385
and	19208385
intracranial	19208385
bleeding	19208385
.	19208385
SLURP1	20854438
mutation	20854438
-	20854438
impaired	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
in	20854438
a	20854438
family	20854438
with	20854438
mal	20854438
de	20854438
Meleda	20854438
.	20854438

BACKGROUND	20854438
:	20854438
Mal	20854438
de	20854438
Meleda	20854438
(	20854438
MDM	20854438
)	20854438
is	20854438
palmoplantar	20854438
erythrokeratoderma	20854438
with	20854438
an	20854438
autosomal	20854438
recessive	20854438
inheritance	20854438
and	20854438
is	20854438
caused	20854438
by	20854438
a	20854438
mutation	20854438
in	20854438
the	20854438
gene	20854438
encoding	20854438
SLURP	20854438
-	20854438
1	20854438
(	20854438
lymphocyte	20854438
antigen	20854438
6	20854438
/	20854438
urokinase	20854438
-	20854438
type	20854438
plasminogen	20854438
activator	20854438
receptor	20854438
related	20854438
protein	20854438
-	20854438
1	20854438
)	20854438
.	20854438

SLURP	20854438
-	20854438
1	20854438
is	20854438
an	20854438
allosteric	20854438
agonist	20854438
to	20854438
the	20854438
nicotinic	20854438
acetylcholine	20854438
receptor	20854438
(	20854438
nAchR	20854438
)	20854438
and	20854438
it	20854438
regulates	20854438
epidermal	20854438
homeostasis	20854438
.	20854438

In	20854438
addition	20854438
,	20854438
murine	20854438
studies	20854438
have	20854438
shown	20854438
that	20854438
nAchR	20854438
signalling	20854438
is	20854438
important	20854438
for	20854438
the	20854438
regulation	20854438
of	20854438
T	20854438
-	20854438
cell	20854438
function	20854438
.	20854438

Among	20854438
the	20854438
family	20854438
members	20854438
,	20854438
patients	20854438
with	20854438
the	20854438
homozygous	20854438
SLURP1	20854438
(	20854438
previously	20854438
known	20854438
as	20854438
ARS	20854438
component	20854438
B	20854438
)	20854438
mutation	20854438
are	20854438
prone	20854438
to	20854438
melanoma	20854438
and	20854438
viral	20854438
infection	20854438
,	20854438
which	20854438
might	20854438
link	20854438
to	20854438
defective	20854438
T	20854438
-	20854438
cell	20854438
function	20854438
as	20854438
well	20854438
as	20854438
a	20854438
derangement	20854438
of	20854438
epidermal	20854438
homeostasis	20854438
.	20854438

OBJECTIVES	20854438
:	20854438
To	20854438
investigate	20854438
the	20854438
association	20854438
of	20854438
the	20854438
SLURP1	20854438
gene	20854438
mutation	20854438
with	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
in	20854438
a	20854438
Taiwanese	20854438
family	20854438
with	20854438
MDM	20854438
.	20854438

To	20854438
test	20854438
that	20854438
SLURP	20854438
-	20854438
1	20854438
is	20854438
essential	20854438
for	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
.	20854438

METHODS	20854438
:	20854438
Human	20854438
peripheral	20854438
blood	20854438
mononuclear	20854438
cells	20854438
(	20854438
PBMCs	20854438
)	20854438
were	20854438
isolated	20854438
from	20854438
a	20854438
Taiwanese	20854438
MDM	20854438
family	20854438
bearing	20854438
the	20854438
G	20854438
to	20854438
A	20854438
substitution	20854438
in	20854438
nucleotide	20854438
256	20854438
in	20854438
the	20854438
SLURP1	20854438
gene	20854438
,	20854438
corresponding	20854438
to	20854438
a	20854438
glycine	20854438
to	20854438
arginine	20854438
substitution	20854438
at	20854438
amino	20854438
acid	20854438
86	20854438
(	20854438
G86R	20854438
)	20854438
in	20854438
the	20854438
SLURP	20854438
-	20854438
1	20854438
protein	20854438
.	20854438

PBMCs	20854438
from	20854438
homozygotes	20854438
and	20854438
wild	20854438
-	20854438
type	20854438
controls	20854438
were	20854438
stimulated	20854438
with	20854438
anti	20854438
-	20854438
CD3	20854438
/	20854438
anti	20854438
-	20854438
CD28	20854438
antibodies	20854438
and	20854438
the	20854438
level	20854438
of	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
was	20854438
determined	20854438
by	20854438
the	20854438
stimulation	20854438
index	20854438
.	20854438

RESULTS	20854438
:	20854438
PBMCs	20854438
with	20854438
the	20854438
heterozygous	20854438
and	20854438
homozygous	20854438
SLURP	20854438
-	20854438
1	20854438
G86R	20854438
mutation	20854438
had	20854438
defective	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
.	20854438

This	20854438
was	20854438
restored	20854438
by	20854438
the	20854438
addition	20854438
of	20854438
0	20854438
5	20854438
ug	20854438
mL	20854438
(	20854438
-	20854438
1	20854438
)	20854438
recombinant	20854438
human	20854438
SLURP	20854438
-	20854438
1	20854438
protein	20854438
.	20854438

CONCLUSIONS	20854438
:	20854438
Patients	20854438
with	20854438
MDM	20854438
with	20854438
the	20854438
homozygous	20854438
SLURP	20854438
-	20854438
1	20854438
G86R	20854438
mutation	20854438
may	20854438
have	20854438
an	20854438
impaired	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
.	20854438

The	20854438
presence	20854438
of	20854438
wild	20854438
-	20854438
type	20854438
SLURP	20854438
-	20854438
1	20854438
is	20854438
essential	20854438
for	20854438
normal	20854438
T	20854438
-	20854438
cell	20854438
activation	20854438
.	20854438
Molecular	20583543
diagnosis	20583543
of	20583543
46	20583543
,	20583543
XY	20583543
DSD	20583543
and	20583543
identification	20583543
of	20583543
a	20583543
novel	20583543
8	20583543
nucleotide	20583543
deletion	20583543
in	20583543
exon	20583543
1	20583543
of	20583543
the	20583543
SRD5A2	20583543
gene	20583543
.	20583543

Phenotypic	20583543
presentation	20583543
of	20583543
46	20583543
,	20583543
XY	20583543
DSD	20583543
depends	20583543
on	20583543
the	20583543
underlying	20583543
defects	20583543
.	20583543

Defect	20583543
in	20583543
androgen	20583543
action	20583543
on	20583543
the	20583543
target	20583543
tissues	20583543
or	20583543
production	20583543
of	20583543
active	20583543
metabolite	20583543
share	20583543
common	20583543
morphological	20583543
features	20583543
.	20583543

Molecular	20583543
study	20583543
may	20583543
help	20583543
differentiating	20583543
these	20583543
abnormalities	20583543
with	20583543
precision	20583543
.	20583543

Mutational	20583543
analysis	20583543
of	20583543
androgen	20583543
receptor	20583543
(	20583543
AR	20583543
)	20583543
and	20583543
SRD5A2	20583543
genes	20583543
was	20583543
performed	20583543
in	20583543
29	20583543
patients	20583543
with	20583543
46	20583543
,	20583543
XY	20583543
DSD	20583543
,	20583543
by	20583543
PCR	20583543
-	20583543
SSCP	20583543
.	20583543

The	20583543
amplicons	20583543
that	20583543
showed	20583543
an	20583543
aberrant	20583543
migration	20583543
in	20583543
SSCP	20583543
were	20583543
subjected	20583543
to	20583543
sequencing	20583543
.	20583543

Interestingly	20583543
,	20583543
six	20583543
patients	20583543
from	20583543
4	20583543
unrelated	20583543
families	20583543
(	20583543
a	20583543
pair	20583543
of	20583543
sibs	20583543
,	20583543
uncle	20583543
/	20583543
nephew	20583543
and	20583543
other	20583543
two	20583543
isolated	20583543
)	20583543
were	20583543
identified	20583543
with	20583543
mutations	20583543
in	20583543
SRD5A2	20583543
gene	20583543
.	20583543

In	20583543
five	20583543
patients	20583543
p	20583543
.	20583543
R246Q	20583543
missense	20583543
mutation	20583543
was	20583543
detected	20583543
,	20583543
of	20583543
which	20583543
four	20583543
were	20583543
homozygous	20583543
and	20583543
one	20583543
was	20583543
compound	20583543
heterozygous	20583543
:	20583543
g	20583543
.	20583543
80_87delT	20583543
CGCGAAG	20583543
(	20583543
p	20583543
.	20583543
A27fsX132	20583543
)	20583543
and	20583543
p	20583543
.	20583543
R246Q	20583543
.	20583543

Another	20583543
patient	20583543
with	20583543
isolated	20583543
micropenis	20583543
harbored	20583543
a	20583543
heterozygous	20583543
p	20583543
.	20583543
G196S	20583543
missense	20583543
mutation	20583543
.	20583543

No	20583543
AR	20583543
gene	20583543
mutation	20583543
was	20583543
detected	20583543
.	20583543

In	20583543
conclusion	20583543
,	20583543
our	20583543
study	20583543
suggests	20583543
that	20583543
p	20583543
.	20583543
R246Q	20583543
mutation	20583543
is	20583543
common	20583543
amongst	20583543
patients	20583543
with	20583543
SRD5A2	20583543
gene	20583543
defect	20583543
from	20583543
the	20583543
Northern	20583543
states	20583543
of	20583543
India	20583543
.	20583543

Also	20583543
,	20583543
it	20583543
records	20583543
a	20583543
novel	20583543
deletion	20583543
in	20583543
exon	20583543
1	20583543
of	20583543
SRD5A2	20583543
gene	20583543
in	20583543
a	20583543
patient	20583543
with	20583543
severe	20583543
hypospadias	20583543
.	20583543
People	15817013
aged	15817013
over	15817013
75	15817013
in	15817013
atrial	15817013
fibrillation	15817013
on	15817013
warfarin	15817013
:	15817013
the	15817013
rate	15817013
of	15817013
major	15817013
hemorrhage	15817013
and	15817013
stroke	15817013
in	15817013
more	15817013
than	15817013
500	15817013
patient	15817013
-	15817013
years	15817013
of	15817013
follow	15817013
-	15817013
up	15817013
.	15817013

OBJECTIVES	15817013
:	15817013
To	15817013
determine	15817013
the	15817013
incidence	15817013
of	15817013
major	15817013
hemorrhage	15817013
and	15817013
stroke	15817013
in	15817013
people	15817013
aged	15817013
76	15817013
and	15817013
older	15817013
with	15817013
atrial	15817013
fibrillation	15817013
on	15817013
adjusted	15817013
-	15817013
dose	15817013
warfarin	15817013
who	15817013
had	15817013
been	15817013
recently	15817013
been	15817013
admitted	15817013
to	15817013
hospital	15817013
.	15817013

DESIGN	15817013
:	15817013
A	15817013
retrospective	15817013
observational	15817013
cohort	15817013
study	15817013
.	15817013

SETTING	15817013
:	15817013
A	15817013
major	15817013
healthcare	15817013
network	15817013
involving	15817013
four	15817013
tertiary	15817013
hospitals	15817013
.	15817013

PARTICIPANTS	15817013
:	15817013
Two	15817013
hundred	15817013
thirty	15817013
-	15817013
five	15817013
patients	15817013
aged	15817013
76	15817013
and	15817013
older	15817013
admitted	15817013
to	15817013
a	15817013
major	15817013
healthcare	15817013
network	15817013
between	15817013
July	15817013
1	15817013
,	15817013
2001	15817013
,	15817013
and	15817013
June	15817013
30	15817013
,	15817013
2002	15817013
,	15817013
with	15817013
atrial	15817013
fibrillation	15817013
on	15817013
warfarin	15817013
were	15817013
enrolled	15817013
.	15817013

MEASUREMENTS	15817013
:	15817013
Information	15817013
regarding	15817013
major	15817013
bleeding	15817013
episodes	15817013
,	15817013
strokes	15817013
,	15817013
and	15817013
warfarin	15817013
use	15817013
was	15817013
obtained	15817013
from	15817013
patients	15817013
,	15817013
relatives	15817013
,	15817013
primary	15817013
physicians	15817013
,	15817013
and	15817013
medical	15817013
records	15817013
.	15817013

RESULTS	15817013
:	15817013
Two	15817013
hundred	15817013
twenty	15817013
-	15817013
eight	15817013
patients	15817013
(	15817013
42%	15817013
men	15817013
)	15817013
with	15817013
a	15817013
mean	15817013
age	15817013
of	15817013
81	15817013
.	15817013
1	15817013
(	15817013
range	15817013
76	15817013
-	15817013
94	15817013
)	15817013
were	15817013
included	15817013
in	15817013
the	15817013
analysis	15817013
.	15817013

Total	15817013
follow	15817013
-	15817013
up	15817013
on	15817013
warfarin	15817013
was	15817013
530	15817013
years	15817013
(	15817013
mean	15817013
28	15817013
months	15817013
)	15817013
.	15817013

There	15817013
were	15817013
53	15817013
major	15817013
hemorrhages	15817013
,	15817013
for	15817013
an	15817013
annual	15817013
rate	15817013
of	15817013
10	15817013
.	15817013
0%	15817013
,	15817013
including	15817013
24	15817013
(	15817013
45	15817013
.	15817013
3%	15817013
)	15817013
life	15817013
-	15817013
threatening	15817013
and	15817013
five	15817013
(	15817013
9	15817013
.	15817013
4%	15817013
)	15817013
fatal	15817013
bleeds	15817013
.	15817013

The	15817013
annual	15817013
stroke	15817013
rate	15817013
after	15817013
initiation	15817013
of	15817013
warfarin	15817013
was	15817013
2	15817013
.	15817013
6%	15817013
.	15817013

CONCLUSION	15817013
:	15817013
The	15817013
rate	15817013
of	15817013
major	15817013
hemorrhage	15817013
was	15817013
high	15817013
in	15817013
this	15817013
old	15817013
,	15817013
frail	15817013
group	15817013
,	15817013
but	15817013
excluding	15817013
fatalities	15817013
,	15817013
resulted	15817013
in	15817013
no	15817013
long	15817013
-	15817013
term	15817013
sequelae	15817013
,	15817013
and	15817013
the	15817013
stroke	15817013
rate	15817013
on	15817013
warfarin	15817013
was	15817013
low	15817013
,	15817013
demonstrating	15817013
how	15817013
effective	15817013
warfarin	15817013
treatment	15817013
is	15817013
.	15817013
Apomorphine	11009181
:	11009181
an	11009181
underutilized	11009181
therapy	11009181
for	11009181
Parkinson	11009181
'	11009181
s	11009181
disease	11009181
.	11009181

Apomorphine	11009181
was	11009181
the	11009181
first	11009181
dopaminergic	11009181
drug	11009181
ever	11009181
used	11009181
to	11009181
treat	11009181
symptoms	11009181
of	11009181
Parkinson	11009181
'	11009181
s	11009181
disease	11009181
.	11009181

While	11009181
powerful	11009181
antiparkinsonian	11009181
effects	11009181
had	11009181
been	11009181
observed	11009181
as	11009181
early	11009181
as	11009181
1951	11009181
,	11009181
the	11009181
potential	11009181
of	11009181
treating	11009181
fluctuating	11009181
Parkinson	11009181
'	11009181
s	11009181
disease	11009181
by	11009181
subcutaneous	11009181
administration	11009181
of	11009181
apomorphine	11009181
has	11009181
only	11009181
recently	11009181
become	11009181
the	11009181
subject	11009181
of	11009181
systematic	11009181
study	11009181
.	11009181

A	11009181
number	11009181
of	11009181
small	11009181
scale	11009181
clinical	11009181
trials	11009181
have	11009181
unequivocally	11009181
shown	11009181
that	11009181
intermittent	11009181
subcutaneous	11009181
apomorphine	11009181
injections	11009181
produce	11009181
antiparkinsonian	11009181
benefit	11009181
close	11009181
if	11009181
not	11009181
identical	11009181
to	11009181
that	11009181
seen	11009181
with	11009181
levodopa	11009181
and	11009181
that	11009181
apomorphine	11009181
rescue	11009181
injections	11009181
can	11009181
reliably	11009181
revert	11009181
off	11009181
-	11009181
periods	11009181
even	11009181
in	11009181
patients	11009181
with	11009181
complex	11009181
on	11009181
-	11009181
off	11009181
motor	11009181
swings	11009181
.	11009181

Continuous	11009181
subcutaneous	11009181
apomorphine	11009181
infusions	11009181
can	11009181
reduce	11009181
daily	11009181
off	11009181
-	11009181
time	11009181
by	11009181
more	11009181
than	11009181
50%	11009181
in	11009181
this	11009181
group	11009181
of	11009181
patients	11009181
,	11009181
which	11009181
appears	11009181
to	11009181
be	11009181
a	11009181
stronger	11009181
effect	11009181
than	11009181
that	11009181
generally	11009181
seen	11009181
with	11009181
add	11009181
-	11009181
on	11009181
therapy	11009181
with	11009181
oral	11009181
dopamine	11009181
agonists	11009181
or	11009181
COMT	11009181
inhibitors	11009181
.	11009181

Extended	11009181
follow	11009181
-	11009181
up	11009181
studies	11009181
of	11009181
up	11009181
to	11009181
8	11009181
years	11009181
have	11009181
demonstrated	11009181
long	11009181
-	11009181
term	11009181
persistence	11009181
of	11009181
apomorphine	11009181
efficacy	11009181
.	11009181

In	11009181
addition	11009181
,	11009181
there	11009181
is	11009181
convincing	11009181
clinical	11009181
evidence	11009181
that	11009181
monotherapy	11009181
with	11009181
continuous	11009181
subcutaneous	11009181
apomorphine	11009181
infusions	11009181
is	11009181
associated	11009181
with	11009181
marked	11009181
reductions	11009181
of	11009181
preexisting	11009181
levodopa	11009181
-	11009181
induced	11009181
dyskinesias	11009181
.	11009181

The	11009181
main	11009181
side	11009181
effects	11009181
of	11009181
subcutaneous	11009181
apomorphine	11009181
treatment	11009181
are	11009181
related	11009181
to	11009181
cutaneous	11009181
tolerability	11009181
problems	11009181
,	11009181
whereas	11009181
sedation	11009181
and	11009181
psychiatric	11009181
complications	11009181
play	11009181
a	11009181
lesser	11009181
role	11009181
.	11009181

Given	11009181
the	11009181
marked	11009181
degree	11009181
of	11009181
efficacy	11009181
of	11009181
subcutaneous	11009181
apomorphine	11009181
treatment	11009181
in	11009181
fluctuating	11009181
Parkinson	11009181
'	11009181
s	11009181
disease	11009181
,	11009181
this	11009181
approach	11009181
seems	11009181
to	11009181
deserve	11009181
more	11009181
widespread	11009181
clinical	11009181
use	11009181
.	11009181
Interleukin	21615796
-	21615796
17F	21615796
gene	21615796
polymorphism	21615796
in	21615796
patients	21615796
with	21615796
chronic	21615796
immune	21615796
thrombocytopenia	21615796
.	21615796

INTRODUCTION	21615796
:	21615796
IL	21615796
-	21615796
17F	21615796
is	21615796
a	21615796
novel	21615796
inflammatory	21615796
cytokine	21615796
and	21615796
plays	21615796
an	21615796
important	21615796
role	21615796
in	21615796
some	21615796
autoimmune	21615796
diseases	21615796
.	21615796

We	21615796
investigated	21615796
the	21615796
association	21615796
between	21615796
chronic	21615796
ITP	21615796
and	21615796
the	21615796
frequency	21615796
of	21615796
the	21615796
single	21615796
-	21615796
nucleotide	21615796
polymorphism	21615796
rs763780	21615796
(	21615796
7488T	21615796
/	21615796
C	21615796
)	21615796
,	21615796
which	21615796
causes	21615796
a	21615796
His	21615796
-	21615796
to	21615796
-	21615796
Arg	21615796
substitution	21615796
at	21615796
amino	21615796
acid	21615796
161	21615796
.	21615796

PATIENTS	21615796
AND	21615796
METHODS	21615796
:	21615796
We	21615796
examined	21615796
102	21615796
patients	21615796
(	21615796
men	21615796
/	21615796
women	21615796
,	21615796
40	21615796
/	21615796
62	21615796
;	21615796
median	21615796
age	21615796
,	21615796
42	21615796
)	21615796
diagnosed	21615796
with	21615796
chronic	21615796
ITP	21615796
and	21615796
188	21615796
healthy	21615796
controls	21615796
(	21615796
men	21615796
/	21615796
women	21615796
,	21615796
78	21615796
/	21615796
110	21615796
;	21615796
median	21615796
age	21615796
,	21615796
38	21615796
)	21615796
.	21615796

Genotyping	21615796
was	21615796
determined	21615796
by	21615796
the	21615796
polymerase	21615796
chain	21615796
reaction	21615796
-	21615796
restriction	21615796
fragment	21615796
length	21615796
polymorphism	21615796
(	21615796
PCR	21615796
-	21615796
RFLP	21615796
)	21615796
technique	21615796
.	21615796

RESULTS	21615796
:	21615796
Compared	21615796
with	21615796
the	21615796
control	21615796
group	21615796
,	21615796
patients	21615796
with	21615796
chronic	21615796
ITP	21615796
had	21615796
a	21615796
significantly	21615796
lower	21615796
frequency	21615796
of	21615796
the	21615796
IL	21615796
-	21615796
17F	21615796
7488CC	21615796
genotype	21615796
(	21615796
0%	21615796
vs	21615796
.	21615796

4	21615796
.	21615796
8%	21615796
,	21615796
P	21615796
<	21615796
0	21615796
.	21615796
05	21615796
)	21615796
.	21615796

The	21615796
number	21615796
of	21615796
IL	21615796
-	21615796
17F	21615796
7488C	21615796
alleles	21615796
among	21615796
the	21615796
patients	21615796
with	21615796
chronic	21615796
ITP	21615796
was	21615796
also	21615796
significantly	21615796
lower	21615796
than	21615796
in	21615796
the	21615796
control	21615796
group	21615796
(	21615796
8	21615796
.	21615796
7%	21615796
vs	21615796
.	21615796

15	21615796
.	21615796
2%	21615796
OR	21615796
=	21615796
0	21615796
.	21615796
48	21615796
,	21615796
95%CI	21615796
=	21615796
0	21615796
.	21615796
27	21615796
-	21615796
0	21615796
.	21615796
84	21615796
,	21615796
P	21615796
=	21615796
0	21615796
.	21615796
016	21615796
)	21615796
.	21615796

Furthermore	21615796
,	21615796
patients	21615796
with	21615796
the	21615796
IL	21615796
-	21615796
17F	21615796
7488TT	21615796
genotype	21615796
showed	21615796
a	21615796
severe	21615796
thrombocytopenic	21615796
state	21615796
(	21615796
platelet	21615796
count	21615796
<	21615796
10	21615796
10	21615796
(	21615796
9	21615796
)	21615796
/	21615796
L	21615796
)	21615796
at	21615796
diagnosis	21615796
than	21615796
those	21615796
with	21615796
the	21615796
IL	21615796
-	21615796
17F	21615796
7488TC	21615796
genotype	21615796
(	21615796
20	21615796
.	21615796
9%	21615796
vs	21615796
.	21615796

0%	21615796
,	21615796
P	21615796
=	21615796
0	21615796
.	21615796
04	21615796
)	21615796
.	21615796

CONCLUSION	21615796
:	21615796
These	21615796
findings	21615796
suggest	21615796
that	21615796
the	21615796
IL	21615796
-	21615796
17F	21615796
7488	21615796
T	21615796
allele	21615796
is	21615796
significantly	21615796
associated	21615796
with	21615796
the	21615796
development	21615796
of	21615796
chronic	21615796
ITP	21615796
,	21615796
suggesting	21615796
a	21615796
role	21615796
for	21615796
IL	21615796
-	21615796
17F	21615796
in	21615796
the	21615796
pathogenesis	21615796
of	21615796
chronic	21615796
ITP	21615796
.	21615796
Identification	26684240
of	26684240
the	26684240
BRAF	26684240
V600E	26684240
mutation	26684240
in	26684240
gastroenteropancreatic	26684240
neuroendocrine	26684240
tumors	26684240
.	26684240

Genomic	26684240
profiles	26684240
of	26684240
gastroenteropancreatic	26684240
neuroendocrine	26684240
tumors	26684240
(	26684240
GEP	26684240
-	26684240
NETs	26684240
)	26684240
are	26684240
still	26684240
insufficiently	26684240
understood	26684240
,	26684240
and	26684240
the	26684240
genetic	26684240
alterations	26684240
associated	26684240
with	26684240
drug	26684240
responses	26684240
have	26684240
not	26684240
been	26684240
studied	26684240
.	26684240

Here	26684240
,	26684240
we	26684240
performed	26684240
whole	26684240
exome	26684240
sequencing	26684240
of	26684240
12	26684240
GEP	26684240
-	26684240
NETs	26684240
from	26684240
patients	26684240
enrolled	26684240
in	26684240
a	26684240
nonrandomized	26684240
,	26684240
open	26684240
-	26684240
labeled	26684240
,	26684240
single	26684240
-	26684240
center	26684240
phase	26684240
II	26684240
study	26684240
for	26684240
pazopanib	26684240
,	26684240
and	26684240
integrated	26684240
our	26684240
results	26684240
with	26684240
previously	26684240
published	26684240
results	26684240
on	26684240
pancreas	26684240
(	26684240
n	26684240
=	26684240
12	26684240
)	26684240
and	26684240
small	26684240
intestine	26684240
NETs	26684240
(	26684240
n	26684240
=	26684240
50	26684240
)	26684240
.	26684240

The	26684240
mean	26684240
numbers	26684240
of	26684240
somatic	26684240
mutations	26684240
in	26684240
each	26684240
case	26684240
varied	26684240
widely	26684240
from	26684240
20	26684240
to	26684240
4682	26684240
.	26684240

Among	26684240
12	26684240
GEP	26684240
-	26684240
NETs	26684240
,	26684240
eight	26684240
showed	26684240
mutations	26684240
of	26684240
more	26684240
than	26684240
one	26684240
cancer	26684240
-	26684240
related	26684240
gene	26684240
,	26684240
including	26684240
TP53	26684240
,	26684240
CNBD1	26684240
,	26684240
RB1	26684240
,	26684240
APC	26684240
,	26684240
BCOR	26684240
,	26684240
BRAF	26684240
,	26684240
CTNNB1	26684240
,	26684240
EGFR	26684240
,	26684240
EP300	26684240
,	26684240
ERBB3	26684240
,	26684240
KDM6A	26684240
,	26684240
KRAS	26684240
,	26684240
MGA	26684240
,	26684240
MLL3	26684240
,	26684240
PTEN	26684240
,	26684240
RASA1	26684240
,	26684240
SMARCB1	26684240
,	26684240
SPEN	26684240
,	26684240
TBC1D12	26684240
,	26684240
and	26684240
VHL	26684240
.	26684240

TP53	26684240
was	26684240
recurrently	26684240
mutated	26684240
in	26684240
three	26684240
cases	26684240
,	26684240
whereas	26684240
CNBD1	26684240
and	26684240
RB1	26684240
mutations	26684240
were	26684240
identified	26684240
in	26684240
two	26684240
cases	26684240
.	26684240

Three	26684240
GEP	26684240
-	26684240
NET	26684240
patients	26684240
with	26684240
TP53	26684240
mutations	26684240
demonstrated	26684240
a	26684240
durable	26684240
response	26684240
and	26684240
one	26684240
small	26684240
intestinal	26684240
grade	26684240
(	26684240
G	26684240
)	26684240
1	26684240
NET	26684240
patient	26684240
with	26684240
BRAF	26684240
V600E	26684240
mutation	26684240
showed	26684240
progression	26684240
after	26684240
pazopanib	26684240
treatment	26684240
.	26684240

We	26684240
found	26684240
BRAF	26684240
V600E	26684240
(	26684240
G1	26684240
NET	26684240
from	26684240
rectum	26684240
and	26684240
two	26684240
G3	26684240
NETs	26684240
from	26684240
colon	26684240
)	26684240
and	26684240
BRAF	26684240
G593S	26684240
(	26684240
G2	26684240
NET	26684240
from	26684240
pancreas	26684240
)	26684240
missense	26684240
mutations	26684240
(	26684240
9	26684240
.	26684240
1%	26684240
)	26684240
in	26684240
an	26684240
independent	26684240
cohort	26684240
of	26684240
44	26684240
GEP	26684240
-	26684240
NETs	26684240
from	26684240
the	26684240
rectum	26684240
(	26684240
n	26684240
=	26684240
26	26684240
)	26684240
,	26684240
colon	26684240
(	26684240
n	26684240
=	26684240
7	26684240
)	26684240
,	26684240
pancreas	26684240
(	26684240
n	26684240
=	26684240
4	26684240
)	26684240
,	26684240
small	26684240
intestine	26684240
(	26684240
n	26684240
=	26684240
3	26684240
)	26684240
,	26684240
stomach	26684240
(	26684240
n	26684240
=	26684240
3	26684240
)	26684240
and	26684240
appendix	26684240
(	26684240
n	26684240
=	26684240
1	26684240
)	26684240
by	26684240
Sanger	26684240
sequencing	26684240
.	26684240

All	26684240
tumor	26684240
specimens	26684240
were	26684240
obtained	26684240
before	26684240
chemotherapy	26684240
.	26684240

In	26684240
conclusion	26684240
,	26684240
BRAF	26684240
V600E	26684240
mutation	26684240
is	26684240
likely	26684240
to	26684240
result	26684240
in	26684240
resistance	26684240
to	26684240
pazopanib	26684240
but	26684240
may	26684240
be	26684240
a	26684240
potentianally	26684240
actionable	26684240
mutation	26684240
in	26684240
metastatic	26684240
GEP	26684240
-	26684240
NETs	26684240
patients	26684240
.	26684240
A	21325775
novel	21325775
apolipoprotein	21325775
E	21325775
mutation	21325775
,	21325775
ApoE	21325775
Osaka	21325775
(	21325775
Arg158	21325775
Pro	21325775
)	21325775
,	21325775
in	21325775
a	21325775
dyslipidemic	21325775
patient	21325775
with	21325775
lipoprotein	21325775
glomerulopathy	21325775
.	21325775

Lipoprotein	21325775
glomerulopathy	21325775
(	21325775
LPG	21325775
)	21325775
is	21325775
a	21325775
rare	21325775
disease	21325775
characterized	21325775
by	21325775
the	21325775
presence	21325775
of	21325775
thrombuslike	21325775
deposition	21325775
in	21325775
markedly	21325775
dilated	21325775
glomerular	21325775
capillaries	21325775
and	21325775
is	21325775
often	21325775
accompanied	21325775
by	21325775
an	21325775
increased	21325775
serum	21325775
apolipoprotein	21325775
E	21325775
(	21325775
apoE	21325775
)	21325775
level	21325775
.	21325775

Several	21325775
gene	21325775
mutations	21325775
of	21325775
apoE	21325775
have	21325775
been	21325775
reported	21325775
to	21325775
be	21325775
associated	21325775
with	21325775
LPG	21325775
.	21325775

In	21325775
the	21325775
current	21325775
study	21325775
,	21325775
we	21325775
report	21325775
an	21325775
LPG	21325775
patient	21325775
with	21325775
a	21325775
novel	21325775
apoE	21325775
mutation	21325775
,	21325775
apoE	21325775
Osaka	21325775
.	21325775

The	21325775
patient	21325775
was	21325775
a	21325775
45	21325775
-	21325775
year	21325775
-	21325775
old	21325775
man	21325775
who	21325775
was	21325775
hospitalized	21325775
due	21325775
to	21325775
nephrotic	21325775
syndrome	21325775
.	21325775

Light	21325775
and	21325775
electron	21325775
microscopic	21325775
observations	21325775
of	21325775
renal	21325775
biopsy	21325775
clearly	21325775
showed	21325775
characteristic	21325775
findings	21325775
of	21325775
LPG	21325775
,	21325775
including	21325775
lamellate	21325775
thrombi	21325775
in	21325775
the	21325775
lumen	21325775
of	21325775
dilated	21325775
glomerular	21325775
capillaries	21325775
.	21325775

His	21325775
apoE	21325775
phenotype	21325775
was	21325775
apoE3	21325775
/	21325775
2	21325775
and	21325775
he	21325775
had	21325775
mild	21325775
dyslipidemia	21325775
with	21325775
a	21325775
mid	21325775
-	21325775
band	21325775
on	21325775
polyacrylamide	21325775
gel	21325775
electrophoresis	21325775
.	21325775

It	21325775
is	21325775
intriguing	21325775
that	21325775
the	21325775
serum	21325775
apoE	21325775
level	21325775
was	21325775
within	21325775
normal	21325775
limits	21325775
.	21325775

We	21325775
determined	21325775
the	21325775
sequence	21325775
of	21325775
the	21325775
apoE	21325775
gene	21325775
using	21325775
direct	21325775
sequencing	21325775
of	21325775
the	21325775
polymerase	21325775
chain	21325775
reaction	21325775
(	21325775
PCR	21325775
)	21325775
products	21325775
.	21325775

ApoE	21325775
gene	21325775
analysis	21325775
showed	21325775
a	21325775
nucleotide	21325775
substitution	21325775
of	21325775
G	21325775
to	21325775
C	21325775
at	21325775
codon	21325775
158	21325775
of	21325775
exon	21325775
4	21325775
.	21325775

This	21325775
mutation	21325775
denoted	21325775
an	21325775
amino	21325775
acid	21325775
substitution	21325775
of	21325775
arginine	21325775
residue	21325775
for	21325775
the	21325775
proline	21325775
residue	21325775
at	21325775
position	21325775
158	21325775
of	21325775
apoE	21325775
.	21325775

The	21325775
result	21325775
of	21325775
PCR	21325775
associated	21325775
with	21325775
restriction	21325775
fragment	21325775
length	21325775
polymorphism	21325775
analysis	21325775
also	21325775
suggested	21325775
that	21325775
this	21325775
mutation	21325775
is	21325775
heterozygous	21325775
.	21325775

It	21325775
is	21325775
possible	21325775
that	21325775
apoE	21325775
Osaka	21325775
mutation	21325775
causes	21325775
a	21325775
conformational	21325775
change	21325775
of	21325775
apoE	21325775
protein	21325775
and	21325775
affects	21325775
the	21325775
interaction	21325775
between	21325775
abnormal	21325775
apoE	21325775
-	21325775
containing	21325775
lipoproteins	21325775
and	21325775
the	21325775
endothelial	21325775
cells	21325775
of	21325775
glomerular	21325775
capillaries	21325775
.	21325775

The	21325775
precise	21325775
mechanism	21325775
of	21325775
LPG	21325775
related	21325775
with	21325775
apoE	21325775
Osaka	21325775
,	21325775
however	21325775
,	21325775
remains	21325775
to	21325775
be	21325775
elucidated	21325775
.	21325775
Hemodynamic	19067809
parameters	19067809
and	19067809
heart	19067809
rate	19067809
variability	19067809
during	19067809
a	19067809
tilt	19067809
test	19067809
in	19067809
relation	19067809
to	19067809
gene	19067809
polymorphism	19067809
of	19067809
renin	19067809
-	19067809
angiotensin	19067809
and	19067809
serotonin	19067809
system	19067809
.	19067809

PURPOSE	19067809
:	19067809
The	19067809
aim	19067809
of	19067809
the	19067809
study	19067809
was	19067809
to	19067809
evaluate	19067809
the	19067809
renin	19067809
-	19067809
angiotensin	19067809
system	19067809
and	19067809
serotonin	19067809
transporter	19067809
gene	19067809
polymorphisms	19067809
in	19067809
relation	19067809
to	19067809
hemodynamic	19067809
parameters	19067809
and	19067809
heart	19067809
rate	19067809
variability	19067809
during	19067809
a	19067809
head	19067809
-	19067809
up	19067809
tilt	19067809
test	19067809
(	19067809
HUT	19067809
)	19067809
in	19067809
patients	19067809
with	19067809
vasovagal	19067809
syncope	19067809
.	19067809

METHODS	19067809
:	19067809
DNA	19067809
was	19067809
collected	19067809
from	19067809
191	19067809
patients	19067809
(	19067809
mean	19067809
age	19067809
44	19067809
+	19067809
/	19067809
-	19067809
18	19067809
years	19067809
,	19067809
61	19067809
men	19067809
,	19067809
130	19067809
women	19067809
)	19067809
.	19067809

The	19067809
following	19067809
gene	19067809
polymorphisms	19067809
were	19067809
determined	19067809
in	19067809
genomic	19067809
DNA	19067809
:	19067809
angiotensin	19067809
-	19067809
converting	19067809
enzyme	19067809
insertion	19067809
/	19067809
deletion	19067809
polymorphism	19067809
(	19067809
I	19067809
/	19067809
D	19067809
ACE	19067809
)	19067809
,	19067809
angiotensinogen	19067809
gene	19067809
polymorphism	19067809
(	19067809
M	19067809
235	19067809
)	19067809
,	19067809
angiotensin	19067809
II	19067809
receptor	19067809
type	19067809
1	19067809
(	19067809
ATR1	19067809
)	19067809
polymorphism	19067809
(	19067809
A	19067809
11666C	19067809
)	19067809
,	19067809
and	19067809
polymorphism	19067809
of	19067809
serotonin	19067809
transporter	19067809
gene	19067809
(	19067809
5HTTLPR	19067809
)	19067809
.	19067809
Heart	19067809
rate	19067809
variability	19067809
during	19067809
HUT	19067809
was	19067809
assessed	19067809
in	19067809
5	19067809
-	19067809
minute	19067809
intervals	19067809
by	19067809
low	19067809
frequency	19067809
,	19067809
high	19067809
frequency	19067809
,	19067809
standard	19067809
deviation	19067809
of	19067809
the	19067809
normal	19067809
-	19067809
to	19067809
-	19067809
normal	19067809
(	19067809
SDNN	19067809
)	19067809
,	19067809
and	19067809
root	19067809
mean	19067809
square	19067809
successive	19067809
difference	19067809
parameters	19067809
.	19067809

RESULTS	19067809
:	19067809
AA	19067809
genotype	19067809
of	19067809
A	19067809
1166C	19067809
polymorphism	19067809
was	19067809
associated	19067809
with	19067809
lower	19067809
minimal	19067809
systolic	19067809
blood	19067809
pressure	19067809
(	19067809
SBP	19067809
)	19067809
and	19067809
diastolic	19067809
blood	19067809
pressure	19067809
(	19067809
DBP	19067809
)	19067809
during	19067809
HUT	19067809
compared	19067809
with	19067809
other	19067809
genotypes	19067809
(	19067809
minimal	19067809
SBP	19067809
:	19067809
AA	19067809
59	19067809
.	19067809
6	19067809
+	19067809
/	19067809
-	19067809
21	19067809
,	19067809
8	19067809
,	19067809
AC	19067809
79	19067809
.	19067809
9	19067809
+	19067809
/	19067809
-	19067809
22	19067809
.	19067809
7	19067809
,	19067809
CC	19067809
65	19067809
.	19067809
4	19067809
+	19067809
/	19067809
-	19067809
22	19067809
.	19067809
7	19067809
mmHg	19067809
,	19067809
P	19067809
=	19067809
0	19067809
.	19067809
007	19067809
)	19067809
,	19067809
(	19067809
minimal	19067809
DBP	19067809
:	19067809
AA	19067809
36	19067809
.	19067809
4	19067809
+	19067809
/	19067809
-	19067809
22	19067809
.	19067809
7	19067809
,	19067809
AC	19067809
52	19067809
.	19067809
3	19067809
+	19067809
/	19067809
-	19067809
22	19067809
.	19067809
9	19067809
,	19067809
CC	19067809
45	19067809
.	19067809
4	19067809
+	19067809
/	19067809
-	19067809
19	19067809
.	19067809
5	19067809
mmHg	19067809
,	19067809
P	19067809
=	19067809
0	19067809
.	19067809
007	19067809
)	19067809
.	19067809
AA	19067809
genotype	19067809
was	19067809
also	19067809
associated	19067809
with	19067809
higher	19067809
SDNN	19067809
compared	19067809
to	19067809
other	19067809
genotypes	19067809
in	19067809
the	19067809
early	19067809
phase	19067809
of	19067809
HUT	19067809
(	19067809
SDNN	19067809
in	19067809
5	19067809
minutes	19067809
of	19067809
tilt	19067809
:	19067809
AA	19067809
59	19067809
.	19067809
7	19067809
+	19067809
/	19067809
-	19067809
24	19067809
.	19067809
6	19067809
,	19067809
AC	19067809
50	19067809
.	19067809
6	19067809
+	19067809
/	19067809
-	19067809
20	19067809
.	19067809
6	19067809
,	19067809
CC	19067809
46	19067809
.	19067809
0	19067809
+	19067809
/	19067809
-	19067809
13	19067809
.	19067809
2	19067809
,	19067809
P	19067809
=	19067809
0	19067809
.	19067809
01	19067809
)	19067809
and	19067809
at	19067809
syncope	19067809
occurrence	19067809
(	19067809
SDNN	19067809
:	19067809
AA	19067809
71	19067809
.	19067809
0	19067809
+	19067809
/	19067809
-	19067809
20	19067809
.	19067809
9	19067809
,	19067809
AC	19067809
58	19067809
.	19067809
2	19067809
+	19067809
/	19067809
-	19067809
17	19067809
.	19067809
9	19067809
,	19067809
CC	19067809
58	19067809
+	19067809
/	19067809
-	19067809
10	19067809
,	19067809
P	19067809
=	19067809
0	19067809
.	19067809
04	19067809
)	19067809
CONCLUSION	19067809
:	19067809
AA	19067809
genotype	19067809
of	19067809
A	19067809
1166C	19067809
polymorphism	19067809
in	19067809
the	19067809
ATR1	19067809
gene	19067809
may	19067809
be	19067809
associated	19067809
with	19067809
hypotension	19067809
and	19067809
decline	19067809
in	19067809
sympathetic	19067809
tone	19067809
during	19067809
HUT	19067809
.	19067809

Its	19067809
role	19067809
in	19067809
genetic	19067809
predisposition	19067809
to	19067809
vasovagal	19067809
syncope	19067809
cannot	19067809
be	19067809
excluded	19067809
.	19067809
Founder	10788334
mutations	10788334
in	10788334
the	10788334
BRCA1	10788334
gene	10788334
in	10788334
Polish	10788334
families	10788334
with	10788334
breast	10788334
-	10788334
ovarian	10788334
cancer	10788334
.	10788334

We	10788334
have	10788334
undertaken	10788334
a	10788334
hospital	10788334
-	10788334
based	10788334
study	10788334
,	10788334
to	10788334
identify	10788334
possible	10788334
BRCA1	10788334
and	10788334
BRCA2	10788334
founder	10788334
mutations	10788334
in	10788334
the	10788334
Polish	10788334
population	10788334
.	10788334

The	10788334
study	10788334
group	10788334
consisted	10788334
of	10788334
66	10788334
Polish	10788334
families	10788334
with	10788334
cancer	10788334
who	10788334
have	10788334
at	10788334
least	10788334
three	10788334
related	10788334
females	10788334
affected	10788334
with	10788334
breast	10788334
or	10788334
ovarian	10788334
cancer	10788334
and	10788334
who	10788334
had	10788334
cancer	10788334
diagnosed	10788334
,	10788334
in	10788334
at	10788334
least	10788334
one	10788334
of	10788334
the	10788334
three	10788334
affected	10788334
females	10788334
,	10788334
at	10788334
age	10788334
<	10788334
50	10788334
years	10788334
.	10788334

A	10788334
total	10788334
of	10788334
26	10788334
families	10788334
had	10788334
both	10788334
breast	10788334
and	10788334
ovarian	10788334
cancers	10788334
,	10788334
4	10788334
families	10788334
had	10788334
ovarian	10788334
cancers	10788334
only	10788334
,	10788334
and	10788334
36	10788334
families	10788334
had	10788334
breast	10788334
cancers	10788334
only	10788334
.	10788334

Genomic	10788334
DNA	10788334
was	10788334
prepared	10788334
from	10788334
the	10788334
peripheral	10788334
blood	10788334
leukocytes	10788334
of	10788334
at	10788334
least	10788334
one	10788334
affected	10788334
woman	10788334
from	10788334
each	10788334
family	10788334
.	10788334

The	10788334
entire	10788334
coding	10788334
region	10788334
of	10788334
BRCA1	10788334
and	10788334
BRCA2	10788334
was	10788334
screened	10788334
for	10788334
the	10788334
presence	10788334
of	10788334
germline	10788334
mutations	10788334
,	10788334
by	10788334
use	10788334
of	10788334
SSCP	10788334
followed	10788334
by	10788334
direct	10788334
sequencing	10788334
of	10788334
observed	10788334
variants	10788334
.	10788334

Mutations	10788334
were	10788334
found	10788334
in	10788334
35	10788334
(	10788334
53%	10788334
)	10788334
of	10788334
the	10788334
66	10788334
families	10788334
studied	10788334
.	10788334

All	10788334
but	10788334
one	10788334
of	10788334
the	10788334
mutations	10788334
were	10788334
detected	10788334
within	10788334
the	10788334
BRCA1	10788334
gene	10788334
.	10788334

BRCA1	10788334
abnormalities	10788334
were	10788334
identified	10788334
in	10788334
all	10788334
four	10788334
families	10788334
with	10788334
ovarian	10788334
cancer	10788334
only	10788334
,	10788334
in	10788334
67%	10788334
of	10788334
27	10788334
families	10788334
with	10788334
both	10788334
breast	10788334
and	10788334
ovarian	10788334
cancer	10788334
,	10788334
and	10788334
in	10788334
34%	10788334
of	10788334
35	10788334
families	10788334
with	10788334
breast	10788334
cancer	10788334
only	10788334
.	10788334

The	10788334
single	10788334
family	10788334
with	10788334
a	10788334
BRCA2	10788334
mutation	10788334
had	10788334
the	10788334
breast	10788334
-	10788334
ovarian	10788334
cancer	10788334
syndrome	10788334
.	10788334

Seven	10788334
distinct	10788334
mutations	10788334
were	10788334
identified	10788334
;	10788334
five	10788334
of	10788334
these	10788334
occurred	10788334
in	10788334
two	10788334
or	10788334
more	10788334
families	10788334
.	10788334

In	10788334
total	10788334
,	10788334
recurrent	10788334
mutations	10788334
were	10788334
found	10788334
in	10788334
33	10788334
(	10788334
94%	10788334
)	10788334
of	10788334
the	10788334
35	10788334
families	10788334
with	10788334
detected	10788334
mutations	10788334
.	10788334

Three	10788334
BRCA1	10788334
abnormalities	10788334
-	10788334
5382insC	10788334
,	10788334
C61G	10788334
,	10788334
and	10788334
4153delA	10788334
-	10788334
accounted	10788334
for	10788334
51%	10788334
,	10788334
20%	10788334
,	10788334
and	10788334
11%	10788334
of	10788334
the	10788334
identified	10788334
mutations	10788334
,	10788334
respectively	10788334
.	10788334
Allelic	16046395
expression	16046395
imbalance	16046395
of	16046395
human	16046395
mu	16046395
opioid	16046395
receptor	16046395
(	16046395
OPRM1	16046395
)	16046395
caused	16046395
by	16046395
variant	16046395
A118G	16046395
.	16046395

As	16046395
a	16046395
primary	16046395
target	16046395
for	16046395
opioid	16046395
drugs	16046395
and	16046395
peptides	16046395
,	16046395
the	16046395
mu	16046395
opioid	16046395
receptor	16046395
(	16046395
OPRM1	16046395
)	16046395
plays	16046395
a	16046395
key	16046395
role	16046395
in	16046395
pain	16046395
perception	16046395
and	16046395
addiction	16046395
.	16046395

Genetic	16046395
variants	16046395
of	16046395
OPRM1	16046395
have	16046395
been	16046395
implicated	16046395
in	16046395
predisposition	16046395
to	16046395
drug	16046395
addiction	16046395
,	16046395
in	16046395
particular	16046395
the	16046395
single	16046395
nucleotide	16046395
polymorphism	16046395
A118G	16046395
,	16046395
leading	16046395
to	16046395
an	16046395
N40D	16046395
substitution	16046395
,	16046395
with	16046395
an	16046395
allele	16046395
frequency	16046395
of	16046395
10	16046395
-	16046395
32%	16046395
,	16046395
and	16046395
uncertain	16046395
functions	16046395
.	16046395

We	16046395
have	16046395
measured	16046395
allele	16046395
-	16046395
specific	16046395
mRNA	16046395
expression	16046395
of	16046395
OPRM1	16046395
in	16046395
human	16046395
autopsy	16046395
brain	16046395
tissues	16046395
,	16046395
using	16046395
A118G	16046395
as	16046395
a	16046395
marker	16046395
.	16046395

In	16046395
8	16046395
heterozygous	16046395
samples	16046395
measured	16046395
,	16046395
the	16046395
A118	16046395
mRNA	16046395
allele	16046395
was	16046395
1	16046395
.	16046395
5	16046395
-	16046395
2	16046395
.	16046395
5	16046395
-	16046395
fold	16046395
more	16046395
abundant	16046395
than	16046395
the	16046395
G118	16046395
allele	16046395
.	16046395

Transfection	16046395
into	16046395
Chinese	16046395
hamster	16046395
ovary	16046395
cells	16046395
of	16046395
a	16046395
cDNA	16046395
representing	16046395
only	16046395
the	16046395
coding	16046395
region	16046395
of	16046395
OPRM1	16046395
,	16046395
carrying	16046395
adenosine	16046395
,	16046395
guanosine	16046395
,	16046395
cytidine	16046395
,	16046395
and	16046395
thymidine	16046395
in	16046395
position	16046395
118	16046395
,	16046395
resulted	16046395
in	16046395
1	16046395
.	16046395
5	16046395
-	16046395
fold	16046395
lower	16046395
mRNA	16046395
levels	16046395
only	16046395
for	16046395
OPRM1	16046395
-	16046395
G118	16046395
,	16046395
and	16046395
more	16046395
than	16046395
10	16046395
-	16046395
fold	16046395
lower	16046395
OPRM1	16046395
protein	16046395
levels	16046395
,	16046395
measured	16046395
by	16046395
Western	16046395
blotting	16046395
and	16046395
receptor	16046395
binding	16046395
assay	16046395
.	16046395

After	16046395
transfection	16046395
and	16046395
inhibition	16046395
of	16046395
transcription	16046395
with	16046395
actinomycin	16046395
D	16046395
,	16046395
analysis	16046395
of	16046395
mRNA	16046395
turnover	16046395
failed	16046395
to	16046395
reveal	16046395
differences	16046395
in	16046395
mRNA	16046395
stability	16046395
between	16046395
A118	16046395
and	16046395
G118	16046395
alleles	16046395
,	16046395
indicating	16046395
a	16046395
defect	16046395
in	16046395
transcription	16046395
or	16046395
mRNA	16046395
maturation	16046395
.	16046395

These	16046395
results	16046395
indicate	16046395
that	16046395
OPRM1	16046395
-	16046395
G118	16046395
is	16046395
a	16046395
functional	16046395
variant	16046395
with	16046395
deleterious	16046395
effects	16046395
on	16046395
both	16046395
mRNA	16046395
and	16046395
protein	16046395
yield	16046395
.	16046395

Clarifying	16046395
the	16046395
functional	16046395
relevance	16046395
of	16046395
polymorphisms	16046395
associated	16046395
with	16046395
susceptibility	16046395
to	16046395
a	16046395
complex	16046395
disorder	16046395
such	16046395
as	16046395
drug	16046395
addiction	16046395
provides	16046395
a	16046395
foundation	16046395
for	16046395
clinical	16046395
association	16046395
studies	16046395
.	16046395
Peroxisomal	16412238
proliferator	16412238
activated	16412238
receptor	16412238
-	16412238
gamma	16412238
deficiency	16412238
in	16412238
a	16412238
Canadian	16412238
kindred	16412238
with	16412238
familial	16412238
partial	16412238
lipodystrophy	16412238
type	16412238
3	16412238
(	16412238
FPLD3	16412238
)	16412238
.	16412238

BACKGROUND	16412238
:	16412238
Familial	16412238
partial	16412238
lipodystrophy	16412238
(	16412238
Dunnigan	16412238
)	16412238
type	16412238
3	16412238
(	16412238
FPLD3	16412238
,	16412238
Mendelian	16412238
Inheritance	16412238
in	16412238
Man	16412238
[	16412238
MIM	16412238
]	16412238
604367	16412238
)	16412238
results	16412238
from	16412238
heterozygous	16412238
mutations	16412238
in	16412238
PPARG	16412238
encoding	16412238
peroxisomal	16412238
proliferator	16412238
-	16412238
activated	16412238
receptor	16412238
-	16412238
gamma	16412238
.	16412238

Both	16412238
dominant	16412238
-	16412238
negative	16412238
and	16412238
haploinsufficiency	16412238
mechanisms	16412238
have	16412238
been	16412238
suggested	16412238
for	16412238
this	16412238
condition	16412238
.	16412238

METHODS	16412238
:	16412238
We	16412238
present	16412238
a	16412238
Canadian	16412238
FPLD3	16412238
kindred	16412238
with	16412238
an	16412238
affected	16412238
mother	16412238
who	16412238
had	16412238
loss	16412238
of	16412238
fat	16412238
on	16412238
arms	16412238
and	16412238
legs	16412238
,	16412238
but	16412238
no	16412238
increase	16412238
in	16412238
facial	16412238
,	16412238
neck	16412238
,	16412238
suprascapular	16412238
or	16412238
abdominal	16412238
fat	16412238
.	16412238

She	16412238
had	16412238
profound	16412238
insulin	16412238
resistance	16412238
,	16412238
diabetes	16412238
,	16412238
severe	16412238
hypertriglyceridemia	16412238
and	16412238
relapsing	16412238
pancreatitis	16412238
,	16412238
while	16412238
her	16412238
pre	16412238
-	16412238
pubescent	16412238
daughter	16412238
had	16412238
normal	16412238
fat	16412238
distribution	16412238
but	16412238
elevated	16412238
plasma	16412238
triglycerides	16412238
and	16412238
C	16412238
-	16412238
peptide	16412238
and	16412238
depressed	16412238
high	16412238
-	16412238
density	16412238
lipoprotein	16412238
cholesterol	16412238
.	16412238

RESULTS	16412238
:	16412238
The	16412238
mother	16412238
and	16412238
daughter	16412238
were	16412238
each	16412238
heterozygous	16412238
for	16412238
PPARG	16412238
nonsense	16412238
mutation	16412238
Y355X	16412238
,	16412238
whose	16412238
protein	16412238
product	16412238
in	16412238
vitro	16412238
was	16412238
transcriptionally	16412238
inactive	16412238
with	16412238
no	16412238
dominant	16412238
-	16412238
negative	16412238
activity	16412238
against	16412238
the	16412238
wild	16412238
-	16412238
type	16412238
receptor	16412238
.	16412238

In	16412238
addition	16412238
the	16412238
mutant	16412238
protein	16412238
appeared	16412238
to	16412238
be	16412238
markedly	16412238
unstable	16412238
.	16412238

CONCLUSION	16412238
:	16412238
Taken	16412238
together	16412238
with	16412238
previous	16412238
studies	16412238
of	16412238
human	16412238
PPARG	16412238
mutations	16412238
,	16412238
these	16412238
findings	16412238
suggest	16412238
that	16412238
PPAR	16412238
-	16412238
gamma	16412238
deficiency	16412238
due	16412238
either	16412238
to	16412238
haploinsufficiency	16412238
or	16412238
to	16412238
substantial	16412238
activity	16412238
loss	16412238
due	16412238
to	16412238
dominant	16412238
negative	16412238
interference	16412238
of	16412238
the	16412238
normal	16412238
allele	16412238
product	16412238
'	16412238
s	16412238
function	16412238
can	16412238
each	16412238
contribute	16412238
to	16412238
the	16412238
FPLD3	16412238
phenotype	16412238
.	16412238
Cytostatic	20828385
and	20828385
anti	20828385
-	20828385
angiogenic	20828385
effects	20828385
of	20828385
temsirolimus	20828385
in	20828385
refractory	20828385
mantle	20828385
cell	20828385
lymphoma	20828385
.	20828385

Mantle	20828385
cell	20828385
lymphoma	20828385
(	20828385
MCL	20828385
)	20828385
is	20828385
a	20828385
rare	20828385
and	20828385
aggressive	20828385
type	20828385
of	20828385
B	20828385
-	20828385
cell	20828385
non	20828385
-	20828385
Hodgkin	20828385
'	20828385
s	20828385
lymphoma	20828385
.	20828385

Patients	20828385
become	20828385
progressively	20828385
refractory	20828385
to	20828385
conventional	20828385
chemotherapy	20828385
,	20828385
and	20828385
their	20828385
prognosis	20828385
is	20828385
poor	20828385
.	20828385

However	20828385
,	20828385
a	20828385
38%	20828385
remission	20828385
rate	20828385
has	20828385
been	20828385
recently	20828385
reported	20828385
in	20828385
refractory	20828385
MCL	20828385
treated	20828385
with	20828385
temsirolimus	20828385
,	20828385
a	20828385
mTOR	20828385
inhibitor	20828385
.	20828385
Here	20828385
we	20828385
had	20828385
the	20828385
opportunity	20828385
to	20828385
study	20828385
a	20828385
case	20828385
of	20828385
refractory	20828385
MCL	20828385
who	20828385
had	20828385
tumor	20828385
regression	20828385
two	20828385
months	20828385
after	20828385
temsirolimus	20828385
treatment	20828385
,	20828385
and	20828385
a	20828385
progression	20828385
-	20828385
free	20828385
survival	20828385
of	20828385
10	20828385
months	20828385
.	20828385

In	20828385
this	20828385
case	20828385
,	20828385
lymph	20828385
node	20828385
biopsies	20828385
were	20828385
performed	20828385
before	20828385
and	20828385
six	20828385
months	20828385
after	20828385
temsirolimus	20828385
therapy	20828385
.	20828385

Comparison	20828385
of	20828385
the	20828385
two	20828385
biopsies	20828385
showed	20828385
that	20828385
temsirolimus	20828385
inhibited	20828385
tumor	20828385
cell	20828385
proliferation	20828385
through	20828385
cell	20828385
cycle	20828385
arrest	20828385
,	20828385
but	20828385
did	20828385
not	20828385
induce	20828385
any	20828385
change	20828385
in	20828385
the	20828385
number	20828385
of	20828385
apoptotic	20828385
tumor	20828385
cells	20828385
.	20828385

Apart	20828385
from	20828385
this	20828385
cytostatic	20828385
effect	20828385
,	20828385
temsirolimus	20828385
had	20828385
an	20828385
antiangiogenic	20828385
effect	20828385
with	20828385
decrease	20828385
of	20828385
tumor	20828385
microvessel	20828385
density	20828385
and	20828385
of	20828385
VEGF	20828385
expression	20828385
.	20828385

Moreover	20828385
,	20828385
numerous	20828385
patchy	20828385
,	20828385
well	20828385
-	20828385
limited	20828385
fibrotic	20828385
areas	20828385
,	20828385
compatible	20828385
with	20828385
post	20828385
-	20828385
necrotic	20828385
tissue	20828385
repair	20828385
,	20828385
were	20828385
found	20828385
after	20828385
6	20828385
-	20828385
month	20828385
temsirolimus	20828385
therapy	20828385
.	20828385

Thus	20828385
,	20828385
temsirolimus	20828385
reduced	20828385
tumor	20828385
burden	20828385
through	20828385
associated	20828385
cytostatic	20828385
and	20828385
anti	20828385
-	20828385
angiogenic	20828385
effects	20828385
.	20828385
This	20828385
dual	20828385
effect	20828385
of	20828385
temsirolimus	20828385
on	20828385
tumor	20828385
tissue	20828385
could	20828385
contribute	20828385
to	20828385
its	20828385
recently	20828385
reported	20828385
efficiency	20828385
in	20828385
refractory	20828385
MCL	20828385
resistant	20828385
to	20828385
conventional	20828385
chemotherapy	20828385
.	20828385
Rapid	19319147
reversal	19319147
of	19319147
anticoagulation	19319147
reduces	19319147
hemorrhage	19319147
volume	19319147
in	19319147
a	19319147
mouse	19319147
model	19319147
of	19319147
warfarin	19319147
-	19319147
associated	19319147
intracerebral	19319147
hemorrhage	19319147
.	19319147

Warfarin	19319147
-	19319147
associated	19319147
intracerebral	19319147
hemorrhage	19319147
(	19319147
W	19319147
-	19319147
ICH	19319147
)	19319147
is	19319147
a	19319147
severe	19319147
type	19319147
of	19319147
stroke	19319147
.	19319147

There	19319147
is	19319147
no	19319147
consensus	19319147
on	19319147
the	19319147
optimal	19319147
treatment	19319147
for	19319147
W	19319147
-	19319147
ICH	19319147
.	19319147

Using	19319147
a	19319147
mouse	19319147
model	19319147
,	19319147
we	19319147
tested	19319147
whether	19319147
the	19319147
rapid	19319147
reversal	19319147
of	19319147
anticoagulation	19319147
using	19319147
human	19319147
prothrombin	19319147
complex	19319147
concentrate	19319147
(	19319147
PCC	19319147
)	19319147
can	19319147
reduce	19319147
hemorrhagic	19319147
blood	19319147
volume	19319147
.	19319147

Male	19319147
CD	19319147
-	19319147
1	19319147
mice	19319147
were	19319147
treated	19319147
with	19319147
warfarin	19319147
(	19319147
2	19319147
mg	19319147
/	19319147
kg	19319147
over	19319147
24	19319147
h	19319147
)	19319147
,	19319147
resulting	19319147
in	19319147
a	19319147
mean	19319147
(	19319147
+	19319147
/	19319147
-	19319147
s	19319147
.	19319147
d	19319147
.	19319147
)	19319147
International	19319147
Normalized	19319147
Ratio	19319147
of	19319147
3	19319147
.	19319147
5	19319147
+	19319147
/	19319147
-	19319147
0	19319147
.	19319147
9	19319147
.	19319147

First	19319147
,	19319147
we	19319147
showed	19319147
that	19319147
an	19319147
intravenous	19319147
administration	19319147
of	19319147
human	19319147
PCC	19319147
rapidly	19319147
reversed	19319147
anticoagulation	19319147
in	19319147
mice	19319147
.	19319147

Second	19319147
,	19319147
a	19319147
stereotactic	19319147
injection	19319147
of	19319147
collagenase	19319147
was	19319147
administered	19319147
to	19319147
induce	19319147
hemorrhage	19319147
in	19319147
the	19319147
right	19319147
striatum	19319147
.	19319147

Forty	19319147
-	19319147
five	19319147
minutes	19319147
later	19319147
,	19319147
the	19319147
animals	19319147
were	19319147
randomly	19319147
treated	19319147
with	19319147
PCC	19319147
(	19319147
100	19319147
U	19319147
/	19319147
kg	19319147
)	19319147
or	19319147
saline	19319147
i	19319147
.	19319147
v	19319147
.	19319147

(	19319147
n	19319147
=	19319147
12	19319147
per	19319147
group	19319147
)	19319147
.	19319147

Twenty	19319147
-	19319147
four	19319147
hours	19319147
after	19319147
hemorrhage	19319147
induction	19319147
,	19319147
hemorrhagic	19319147
blood	19319147
volume	19319147
was	19319147
quantified	19319147
using	19319147
a	19319147
photometric	19319147
hemoglobin	19319147
assay	19319147
.	19319147

The	19319147
mean	19319147
hemorrhagic	19319147
blood	19319147
volume	19319147
was	19319147
reduced	19319147
in	19319147
PCC	19319147
-	19319147
treated	19319147
animals	19319147
(	19319147
6	19319147
.	19319147
5	19319147
+	19319147
/	19319147
-	19319147
3	19319147
.	19319147
1	19319147
microL	19319147
)	19319147
compared	19319147
with	19319147
saline	19319147
controls	19319147
(	19319147
15	19319147
.	19319147
3	19319147
+	19319147
/	19319147
-	19319147
11	19319147
.	19319147
2	19319147
microL	19319147
,	19319147
P	19319147
=	19319147
0	19319147
.	19319147
015	19319147
)	19319147
.	19319147

In	19319147
the	19319147
saline	19319147
group	19319147
,	19319147
45%	19319147
of	19319147
the	19319147
mice	19319147
developed	19319147
large	19319147
hematomas	19319147
(	19319147
i	19319147
.	19319147
e	19319147
.	19319147
,	19319147
>	19319147
15	19319147
microL	19319147
)	19319147
.	19319147

In	19319147
contrast	19319147
,	19319147
such	19319147
extensive	19319147
lesions	19319147
were	19319147
never	19319147
found	19319147
in	19319147
the	19319147
PCC	19319147
group	19319147
.	19319147

We	19319147
provide	19319147
experimental	19319147
data	19319147
suggesting	19319147
PCC	19319147
to	19319147
be	19319147
an	19319147
effective	19319147
acute	19319147
treatment	19319147
for	19319147
W	19319147
-	19319147
ICH	19319147
in	19319147
terms	19319147
of	19319147
reducing	19319147
hemorrhagic	19319147
blood	19319147
volume	19319147
.	19319147

Future	19319147
studies	19319147
are	19319147
needed	19319147
to	19319147
assess	19319147
the	19319147
therapeutic	19319147
potential	19319147
emerging	19319147
from	19319147
our	19319147
finding	19319147
for	19319147
human	19319147
W	19319147
-	19319147
ICH	19319147
.	19319147
Role	26102294
of	26102294
stress	26102294
-	26102294
activated	26102294
OCT4A	26102294
in	26102294
the	26102294
cell	26102294
fate	26102294
decisions	26102294
of	26102294
embryonal	26102294
carcinoma	26102294
cells	26102294
treated	26102294
with	26102294
etoposide	26102294
.	26102294

Tumor	26102294
cellular	26102294
senescence	26102294
induced	26102294
by	26102294
genotoxic	26102294
treatments	26102294
has	26102294
recently	26102294
been	26102294
found	26102294
to	26102294
be	26102294
paradoxically	26102294
linked	26102294
to	26102294
the	26102294
induction	26102294
of	26102294
""""	26102294
stemness	26102294
.	26102294
""""	26102294
This	26102294
observation	26102294
is	26102294
critical	26102294
as	26102294
it	26102294
directly	26102294
impinges	26102294
upon	26102294
the	26102294
response	26102294
of	26102294
tumors	26102294
to	26102294
current	26102294
chemo	26102294
-	26102294
radio	26102294
-	26102294
therapy	26102294
treatment	26102294
regimens	26102294
.	26102294

Previously	26102294
,	26102294
we	26102294
showed	26102294
that	26102294
following	26102294
etoposide	26102294
(	26102294
ETO	26102294
)	26102294
treatment	26102294
embryonal	26102294
carcinoma	26102294
PA	26102294
-	26102294
1	26102294
cells	26102294
undergo	26102294
a	26102294
p53	26102294
-	26102294
dependent	26102294
upregulation	26102294
of	26102294
OCT4A	26102294
and	26102294
p21Cip1	26102294
(	26102294
governing	26102294
self	26102294
-	26102294
renewal	26102294
and	26102294
regulating	26102294
cell	26102294
cycle	26102294
inhibition	26102294
and	26102294
senescence	26102294
,	26102294
respectively	26102294
)	26102294
.	26102294

Here	26102294
we	26102294
report	26102294
further	26102294
detail	26102294
on	26102294
the	26102294
relationship	26102294
between	26102294
these	26102294
and	26102294
other	26102294
critical	26102294
cell	26102294
-	26102294
fate	26102294
regulators	26102294
.	26102294

PA	26102294
-	26102294
1	26102294
cells	26102294
treated	26102294
with	26102294
ETO	26102294
display	26102294
highly	26102294
heterogeneous	26102294
increases	26102294
in	26102294
OCT4A	26102294
and	26102294
p21Cip1	26102294
indicative	26102294
of	26102294
dis	26102294
-	26102294
adaptation	26102294
catastrophe	26102294
.	26102294

Silencing	26102294
OCT4A	26102294
suppresses	26102294
p21Cip1	26102294
,	26102294
changes	26102294
cell	26102294
cycle	26102294
regulation	26102294
and	26102294
subsequently	26102294
suppresses	26102294
terminal	26102294
senescence	26102294
;	26102294
p21Cip1	26102294
-	26102294
silencing	26102294
did	26102294
not	26102294
affect	26102294
OCT4A	26102294
expression	26102294
or	26102294
cellular	26102294
phenotype	26102294
.	26102294

SOX2	26102294
and	26102294
NANOG	26102294
expression	26102294
did	26102294
not	26102294
change	26102294
following	26102294
ETO	26102294
treatment	26102294
suggesting	26102294
a	26102294
dissociation	26102294
of	26102294
OCT4A	26102294
from	26102294
its	26102294
pluripotency	26102294
function	26102294
.	26102294

Instead	26102294
,	26102294
ETO	26102294
-	26102294
induced	26102294
OCT4A	26102294
was	26102294
concomitant	26102294
with	26102294
activation	26102294
of	26102294
AMPK	26102294
,	26102294
a	26102294
key	26102294
component	26102294
of	26102294
metabolic	26102294
stress	26102294
and	26102294
autophagy	26102294
regulation	26102294
.	26102294

p16ink4a	26102294
,	26102294
the	26102294
inducer	26102294
of	26102294
terminal	26102294
senescence	26102294
,	26102294
underwent	26102294
autophagic	26102294
sequestration	26102294
in	26102294
the	26102294
cytoplasm	26102294
of	26102294
ETO	26102294
-	26102294
treated	26102294
cells	26102294
,	26102294
allowing	26102294
alternative	26102294
cell	26102294
fates	26102294
.	26102294

Accordingly	26102294
,	26102294
failure	26102294
of	26102294
autophagy	26102294
was	26102294
accompanied	26102294
by	26102294
an	26102294
accumulation	26102294
of	26102294
p16ink4a	26102294
,	26102294
nuclear	26102294
disintegration	26102294
,	26102294
and	26102294
loss	26102294
of	26102294
cell	26102294
recovery	26102294
.	26102294

Together	26102294
,	26102294
these	26102294
findings	26102294
imply	26102294
that	26102294
OCT4A	26102294
induction	26102294
following	26102294
DNA	26102294
damage	26102294
in	26102294
PA	26102294
-	26102294
1	26102294
cells	26102294
,	26102294
performs	26102294
a	26102294
cell	26102294
stress	26102294
,	26102294
rather	26102294
than	26102294
self	26102294
-	26102294
renewal	26102294
,	26102294
function	26102294
by	26102294
moderating	26102294
the	26102294
expression	26102294
of	26102294
p21Cip1	26102294
,	26102294
which	26102294
alongside	26102294
AMPK	26102294
helps	26102294
to	26102294
then	26102294
regulate	26102294
autophagy	26102294
.	26102294

Moreover	26102294
,	26102294
this	26102294
data	26102294
indicates	26102294
that	26102294
exhaustion	26102294
of	26102294
autophagy	26102294
,	26102294
through	26102294
persistent	26102294
DNA	26102294
damage	26102294
,	26102294
is	26102294
the	26102294
cause	26102294
of	26102294
terminal	26102294
cellular	26102294
senescence	26102294
.	26102294
Cisplatin	27172902
induces	27172902
tolerogenic	27172902
dendritic	27172902
cells	27172902
in	27172902
response	27172902
to	27172902
TLR	27172902
agonists	27172902
via	27172902
the	27172902
abundant	27172902
production	27172902
of	27172902
IL	27172902
-	27172902
10	27172902
,	27172902
thereby	27172902
promoting	27172902
Th2	27172902
-	27172902
and	27172902
Tr1	27172902
-	27172902
biased	27172902
T	27172902
-	27172902
cell	27172902
immunity	27172902
.	27172902

Although	27172902
many	27172902
advantageous	27172902
roles	27172902
of	27172902
cisplatin	27172902
(	27172902
cis	27172902
-	27172902
diamminedichloroplatinum	27172902
(	27172902
II	27172902
)	27172902
,	27172902
CDDP	27172902
)	27172902
have	27172902
been	27172902
reported	27172902
in	27172902
cancer	27172902
therapy	27172902
,	27172902
the	27172902
immunomodulatory	27172902
roles	27172902
of	27172902
cisplatin	27172902
in	27172902
the	27172902
phenotypic	27172902
and	27172902
functional	27172902
alterations	27172902
of	27172902
dendritic	27172902
cells	27172902
(	27172902
DCs	27172902
)	27172902
are	27172902
poorly	27172902
understood	27172902
.	27172902

Here	27172902
,	27172902
we	27172902
investigated	27172902
the	27172902
effect	27172902
of	27172902
cisplatin	27172902
on	27172902
the	27172902
functionality	27172902
of	27172902
DCs	27172902
and	27172902
the	27172902
changes	27172902
in	27172902
signaling	27172902
pathways	27172902
activated	27172902
upon	27172902
toll	27172902
-	27172902
like	27172902
receptor	27172902
(	27172902
TLR	27172902
)	27172902
stimulation	27172902
.	27172902

Cisplatin	27172902
-	27172902
treated	27172902
DCs	27172902
down	27172902
-	27172902
regulated	27172902
the	27172902
expression	27172902
of	27172902
cell	27172902
surface	27172902
molecules	27172902
(	27172902
CD80	27172902
,	27172902
CD86	27172902
,	27172902
MHC	27172902
class	27172902
I	27172902
and	27172902
II	27172902
)	27172902
and	27172902
up	27172902
-	27172902
regulated	27172902
endocytic	27172902
capacity	27172902
in	27172902
a	27172902
dose	27172902
-	27172902
dependent	27172902
manner	27172902
.	27172902

Upon	27172902
stimulation	27172902
with	27172902
various	27172902
TLR	27172902
agonists	27172902
,	27172902
cisplatin	27172902
-	27172902
treated	27172902
DCs	27172902
showed	27172902
markedly	27172902
increased	27172902
IL	27172902
-	27172902
10	27172902
production	27172902
through	27172902
activation	27172902
of	27172902
the	27172902
p38	27172902
MAPK	27172902
and	27172902
NF	27172902
-	27172902
kappaB	27172902
signaling	27172902
pathways	27172902
without	27172902
altering	27172902
the	27172902
levels	27172902
of	27172902
TNF	27172902
-	27172902
alpha	27172902
and	27172902
IL	27172902
-	27172902
12p70	27172902
,	27172902
indicating	27172902
the	27172902
cisplatin	27172902
-	27172902
mediated	27172902
induction	27172902
of	27172902
tolerogenic	27172902
DCs	27172902
.	27172902

This	27172902
effect	27172902
was	27172902
dependent	27172902
on	27172902
the	27172902
production	27172902
of	27172902
IL	27172902
-	27172902
10	27172902
from	27172902
DCs	27172902
,	27172902
as	27172902
neither	27172902
DCs	27172902
isolated	27172902
from	27172902
IL	27172902
-	27172902
10	27172902
-	27172902
/	27172902
-	27172902
mice	27172902
nor	27172902
IL	27172902
-	27172902
10	27172902
-	27172902
neutralized	27172902
DCs	27172902
generated	27172902
tolerogenic	27172902
DCs	27172902
.	27172902

Interestingly	27172902
,	27172902
DCs	27172902
that	27172902
were	27172902
co	27172902
-	27172902
treated	27172902
with	27172902
cisplatin	27172902
and	27172902
lipopolysaccharide	27172902
(	27172902
LPS	27172902
)	27172902
exhibited	27172902
a	27172902
decreased	27172902
immunostimulatory	27172902
capacity	27172902
for	27172902
inducing	27172902
the	27172902
proliferation	27172902
of	27172902
Th1	27172902
-	27172902
and	27172902
Th17	27172902
-	27172902
type	27172902
T	27172902
cells	27172902
;	27172902
instead	27172902
,	27172902
these	27172902
DCs	27172902
contributed	27172902
to	27172902
Th2	27172902
-	27172902
type	27172902
T	27172902
cell	27172902
immunity	27172902
.	27172902

Furthermore	27172902
,	27172902
in	27172902
vitro	27172902
and	27172902
in	27172902
vivo	27172902
investigations	27172902
revealed	27172902
a	27172902
unique	27172902
T	27172902
cell	27172902
population	27172902
,	27172902
IL	27172902
-	27172902
10	27172902
-	27172902
producing	27172902
CD3	27172902
+	27172902
CD4	27172902
+	27172902
LAG	27172902
-	27172902
3	27172902
+	27172902
CD49b	27172902
+	27172902
CD25	27172902
-	27172902
Foxp3	27172902
-	27172902
Tr1	27172902
cells	27172902
,	27172902
that	27172902
was	27172902
significantly	27172902
increased	27172902
without	27172902
altering	27172902
the	27172902
Foxp3	27172902
+	27172902
regulatory	27172902
T	27172902
cell	27172902
population	27172902
.	27172902

Taken	27172902
together	27172902
,	27172902
our	27172902
results	27172902
suggest	27172902
that	27172902
cisplatin	27172902
induces	27172902
immune	27172902
-	27172902
suppressive	27172902
tolerogenic	27172902
DCs	27172902
in	27172902
TLR	27172902
agonist	27172902
-	27172902
induced	27172902
inflammatory	27172902
conditions	27172902
via	27172902
abundant	27172902
IL	27172902
-	27172902
10	27172902
production	27172902
,	27172902
thereby	27172902
skewing	27172902
Th	27172902
cell	27172902
differentiation	27172902
towards	27172902
Th2	27172902
and	27172902
Tr1	27172902
cells	27172902
.	27172902

This	27172902
relationship	27172902
may	27172902
provide	27172902
cancer	27172902
cells	27172902
with	27172902
an	27172902
opportunity	27172902
to	27172902
evade	27172902
the	27172902
immune	27172902
system	27172902
.	27172902

Leukemia	25277705
inhibitory	25277705
factor	25277705
protects	25277705
the	25277705
lung	25277705
during	25277705
respiratory	25277705
syncytial	25277705
viral	25277705
infection	25277705
.	25277705

BACKGROUND	25277705
:	25277705
Respiratory	25277705
syncytial	25277705
virus	25277705
(	25277705
RSV	25277705
)	25277705
infects	25277705
the	25277705
lung	25277705
epithelium	25277705
where	25277705
it	25277705
stimulates	25277705
the	25277705
production	25277705
of	25277705
numerous	25277705
host	25277705
cytokines	25277705
that	25277705
are	25277705
associated	25277705
with	25277705
disease	25277705
burden	25277705
and	25277705
acute	25277705
lung	25277705
injury	25277705
.	25277705

Characterizing	25277705
the	25277705
host	25277705
cytokine	25277705
response	25277705
to	25277705
RSV	25277705
infection	25277705
,	25277705
the	25277705
regulation	25277705
of	25277705
host	25277705
cytokines	25277705
and	25277705
the	25277705
impact	25277705
of	25277705
neutralizing	25277705
an	25277705
RSV	25277705
-	25277705
inducible	25277705
cytokine	25277705
during	25277705
infection	25277705
were	25277705
undertaken	25277705
in	25277705
this	25277705
study	25277705
.	25277705

METHODS	25277705
:	25277705
A549	25277705
,	25277705
primary	25277705
human	25277705
small	25277705
airway	25277705
epithelial	25277705
(	25277705
SAE	25277705
)	25277705
cells	25277705
and	25277705
wild	25277705
-	25277705
type	25277705
,	25277705
TIR	25277705
-	25277705
domain	25277705
-	25277705
containing	25277705
adapter	25277705
-	25277705
inducing	25277705
interferon	25277705
-	25277705
b	25277705
(	25277705
Trif	25277705
)	25277705
and	25277705
mitochondrial	25277705
antiviral	25277705
-	25277705
signaling	25277705
protein	25277705
(	25277705
Mavs	25277705
)	25277705
knockout	25277705
(	25277705
KO	25277705
)	25277705
mice	25277705
were	25277705
infected	25277705
with	25277705
RSV	25277705
and	25277705
cytokine	25277705
responses	25277705
were	25277705
investigated	25277705
by	25277705
ELISA	25277705
,	25277705
multiplex	25277705
analysis	25277705
and	25277705
qPCR	25277705
.	25277705

Neutralizing	25277705
anti	25277705
-	25277705
leukemia	25277705
inhibitory	25277705
factor	25277705
(	25277705
LIF	25277705
)	25277705
IgG	25277705
or	25277705
control	25277705
IgG	25277705
was	25277705
administered	25277705
to	25277705
a	25277705
group	25277705
of	25277705
wild	25277705
-	25277705
type	25277705
animals	25277705
prior	25277705
to	25277705
RSV	25277705
infection	25277705
.	25277705

RESULTS	25277705
AND	25277705
DISCUSSION	25277705
:	25277705
RSV	25277705
-	25277705
infected	25277705
A549	25277705
and	25277705
SAE	25277705
cells	25277705
release	25277705
a	25277705
network	25277705
of	25277705
cytokines	25277705
,	25277705
including	25277705
newly	25277705
identified	25277705
RSV	25277705
-	25277705
inducible	25277705
cytokines	25277705
LIF	25277705
,	25277705
migration	25277705
inhibitory	25277705
factor	25277705
(	25277705
MIF	25277705
)	25277705
,	25277705
stem	25277705
cell	25277705
factor	25277705
(	25277705
SCF	25277705
)	25277705
,	25277705
CCL27	25277705
,	25277705
CXCL12	25277705
and	25277705
stem	25277705
cell	25277705
growth	25277705
factor	25277705
beta	25277705
(	25277705
SCGF	25277705
-	25277705
b	25277705
)	25277705
.	25277705

These	25277705
RSV	25277705
-	25277705
inducible	25277705
cytokines	25277705
were	25277705
also	25277705
observed	25277705
in	25277705
the	25277705
airways	25277705
of	25277705
mice	25277705
during	25277705
an	25277705
infection	25277705
.	25277705

To	25277705
identify	25277705
the	25277705
regulation	25277705
of	25277705
RSV	25277705
inducible	25277705
cytokines	25277705
,	25277705
Mavs	25277705
and	25277705
Trif	25277705
deficient	25277705
animals	25277705
were	25277705
infected	25277705
with	25277705
RSV	25277705
.	25277705

In	25277705
vivo	25277705
induction	25277705
of	25277705
airway	25277705
IL	25277705
-	25277705
1b	25277705
,	25277705
IL	25277705
-	25277705
4	25277705
,	25277705
IL	25277705
-	25277705
5	25277705
,	25277705
IL	25277705
-	25277705
6	25277705
,	25277705
IL	25277705
-	25277705
12	25277705
(	25277705
p40	25277705
)	25277705
,	25277705
IFN	25277705
-	25277705
g	25277705
,	25277705
CCL2	25277705
,	25277705
CCL5	25277705
,	25277705
CCL3	25277705
,	25277705
CXCL1	25277705
,	25277705
IP	25277705
-	25277705
10	25277705
/	25277705
CXCL10	25277705
,	25277705
IL	25277705
-	25277705
22	25277705
,	25277705
MIG	25277705
/	25277705
CXCL9	25277705
and	25277705
MIF	25277705
were	25277705
dependent	25277705
on	25277705
Mavs	25277705
expression	25277705
in	25277705
mice	25277705
.	25277705

Loss	25277705
of	25277705
Trif	25277705
expression	25277705
in	25277705
mice	25277705
altered	25277705
the	25277705
RSV	25277705
induction	25277705
of	25277705
IL	25277705
-	25277705
1b	25277705
,	25277705
IL	25277705
-	25277705
5	25277705
,	25277705
CXCL12	25277705
,	25277705
MIF	25277705
,	25277705
LIF	25277705
,	25277705
CXCL12	25277705
and	25277705
IFN	25277705
-	25277705
g	25277705
.	25277705

Silencing	25277705
of	25277705
retinoic	25277705
acid	25277705
-	25277705
inducible	25277705
gene	25277705
-	25277705
1	25277705
(	25277705
RIG	25277705
-	25277705
I	25277705
)	25277705
expression	25277705
in	25277705
A549	25277705
cells	25277705
had	25277705
a	25277705
greater	25277705
impact	25277705
on	25277705
RSV	25277705
-	25277705
inducible	25277705
cytokines	25277705
than	25277705
melanoma	25277705
differentiation	25277705
-	25277705
associated	25277705
protein	25277705
5	25277705
(	25277705
MDA5	25277705
)	25277705
and	25277705
laboratory	25277705
of	25277705
genetics	25277705
and	25277705
physiology	25277705
2	25277705
(	25277705
LGP2	25277705
)	25277705
,	25277705
and	25277705
Trif	25277705
expression	25277705
.	25277705

To	25277705
evaluate	25277705
the	25277705
role	25277705
of	25277705
LIF	25277705
in	25277705
the	25277705
airways	25277705
during	25277705
RSV	25277705
infection	25277705
,	25277705
animals	25277705
were	25277705
treated	25277705
with	25277705
neutralizing	25277705
anti	25277705
-	25277705
LIF	25277705
IgG	25277705
,	25277705
which	25277705
enhanced	25277705
RSV	25277705
pathology	25277705
observed	25277705
with	25277705
increased	25277705
airspace	25277705
protein	25277705
content	25277705
,	25277705
apoptosis	25277705
and	25277705
airway	25277705
hyperresponsiveness	25277705
compared	25277705
to	25277705
control	25277705
IgG	25277705
treatment	25277705
.	25277705

CONCLUSIONS	25277705
:	25277705
RSV	25277705
infection	25277705
in	25277705
the	25277705
epithelium	25277705
induces	25277705
a	25277705
network	25277705
of	25277705
immune	25277705
factors	25277705
to	25277705
counter	25277705
infection	25277705
,	25277705
primarily	25277705
in	25277705
a	25277705
RIG	25277705
-	25277705
I	25277705
dependent	25277705
manner	25277705
.	25277705

Expression	25277705
of	25277705
LIF	25277705
protects	25277705
the	25277705
lung	25277705
from	25277705
lung	25277705
injury	25277705
and	25277705
enhanced	25277705
pathology	25277705
during	25277705
RSV	25277705
infection	25277705
.	25277705
Assessment	17491223
of	17491223
a	17491223
new	17491223
non	17491223
-	17491223
invasive	17491223
index	17491223
of	17491223
cardiac	17491223
performance	17491223
for	17491223
detection	17491223
of	17491223
dobutamine	17491223
-	17491223
induced	17491223
myocardial	17491223
ischemia	17491223
.	17491223

BACKGROUND	17491223
:	17491223
Electrocardiography	17491223
has	17491223
a	17491223
very	17491223
low	17491223
sensitivity	17491223
in	17491223
detecting	17491223
dobutamine	17491223
-	17491223
induced	17491223
myocardial	17491223
ischemia	17491223
.	17491223

OBJECTIVES	17491223
:	17491223
To	17491223
assess	17491223
the	17491223
added	17491223
diagnostic	17491223
value	17491223
of	17491223
a	17491223
new	17491223
cardiac	17491223
performance	17491223
index	17491223
(	17491223
dP	17491223
/	17491223
dtejc	17491223
)	17491223
measurement	17491223
,	17491223
based	17491223
on	17491223
brachial	17491223
artery	17491223
flow	17491223
changes	17491223
,	17491223
as	17491223
compared	17491223
to	17491223
standard	17491223
12	17491223
-	17491223
lead	17491223
ECG	17491223
,	17491223
for	17491223
detecting	17491223
dobutamine	17491223
-	17491223
induced	17491223
myocardial	17491223
ischemia	17491223
,	17491223
using	17491223
Tc99m	17491223
-	17491223
Sestamibi	17491223
single	17491223
-	17491223
photon	17491223
emission	17491223
computed	17491223
tomography	17491223
as	17491223
the	17491223
gold	17491223
standard	17491223
of	17491223
comparison	17491223
to	17491223
assess	17491223
the	17491223
presence	17491223
or	17491223
absence	17491223
of	17491223
ischemia	17491223
.	17491223

METHODS	17491223
:	17491223
The	17491223
study	17491223
group	17491223
comprised	17491223
40	17491223
patients	17491223
undergoing	17491223
Sestamibi	17491223
-	17491223
SPECT	17491223
/	17491223
dobutamine	17491223
stress	17491223
test	17491223
.	17491223

Simultaneous	17491223
measurements	17491223
of	17491223
ECG	17491223
and	17491223
brachial	17491223
artery	17491223
dP	17491223
/	17491223
dtejc	17491223
were	17491223
performed	17491223
at	17491223
each	17491223
dobutamine	17491223
level	17491223
.	17491223

In	17491223
19	17491223
of	17491223
the	17491223
40	17491223
patients	17491223
perfusion	17491223
defects	17491223
compatible	17491223
with	17491223
ischemia	17491223
were	17491223
detected	17491223
on	17491223
SPECT	17491223
.	17491223

The	17491223
increase	17491223
in	17491223
dP	17491223
/	17491223
dtejc	17491223
during	17491223
infusion	17491223
of	17491223
dobutamine	17491223
in	17491223
this	17491223
group	17491223
was	17491223
severely	17491223
impaired	17491223
as	17491223
compared	17491223
to	17491223
the	17491223
non	17491223
-	17491223
ischemic	17491223
group	17491223
.	17491223

dP	17491223
/	17491223
dtejc	17491223
outcome	17491223
was	17491223
combined	17491223
with	17491223
the	17491223
ECG	17491223
results	17491223
,	17491223
giving	17491223
an	17491223
ECG	17491223
-	17491223
enhanced	17491223
value	17491223
,	17491223
and	17491223
compared	17491223
to	17491223
ECG	17491223
alone	17491223
.	17491223

RESULTS	17491223
:	17491223
The	17491223
sensitivity	17491223
improved	17491223
dramatically	17491223
from	17491223
16%	17491223
to	17491223
79%	17491223
,	17491223
positive	17491223
predictive	17491223
value	17491223
increased	17491223
from	17491223
60%	17491223
to	17491223
68%	17491223
and	17491223
negative	17491223
predictive	17491223
value	17491223
from	17491223
54%	17491223
to	17491223
78%	17491223
,	17491223
and	17491223
specificity	17491223
decreased	17491223
from	17491223
90%	17491223
to	17491223
67%	17491223
.	17491223

CONCLUSIONS	17491223
:	17491223
If	17491223
ECG	17491223
alone	17491223
is	17491223
used	17491223
for	17491223
specificity	17491223
,	17491223
the	17491223
combination	17491223
with	17491223
dP	17491223
/	17491223
dtejc	17491223
improved	17491223
the	17491223
sensitivity	17491223
of	17491223
the	17491223
test	17491223
and	17491223
could	17491223
be	17491223
a	17491223
cost	17491223
-	17491223
savings	17491223
alternative	17491223
to	17491223
cardiac	17491223
imaging	17491223
or	17491223
perfusion	17491223
studies	17491223
to	17491223
detect	17491223
myocardial	17491223
ischemia	17491223
,	17491223
especially	17491223
in	17491223
patients	17491223
unable	17491223
to	17491223
exercise	17491223
.	17491223
Two	15749661
novel	15749661
mutations	15749661
,	15749661
L490R	15749661
and	15749661
V561X	15749661
,	15749661
of	15749661
the	15749661
transferrin	15749661
receptor	15749661
2	15749661
gene	15749661
in	15749661
Japanese	15749661
patients	15749661
with	15749661
hemochromatosis	15749661
.	15749661

BACKGROUND	15749661
AND	15749661
OBJECTIVES	15749661
:	15749661
The	15749661
low	15749661
prevalence	15749661
of	15749661
the	15749661
C282Y	15749661
mutation	15749661
of	15749661
the	15749661
HFE	15749661
gene	15749661
in	15749661
Japan	15749661
means	15749661
that	15749661
the	15749661
genetic	15749661
background	15749661
of	15749661
hemochromatosis	15749661
in	15749661
Japanese	15749661
patients	15749661
remains	15749661
unclear	15749661
.	15749661

In	15749661
a	15749661
previous	15749661
report	15749661
,	15749661
we	15749661
showed	15749661
that	15749661
3	15749661
patients	15749661
from	15749661
one	15749661
family	15749661
had	15749661
an	15749661
AVAQ	15749661
594	15749661
-	15749661
597	15749661
deletion	15749661
of	15749661
the	15749661
transferrin	15749661
receptor	15749661
(	15749661
TfR2	15749661
)	15749661
gene	15749661
.	15749661

This	15749661
suggests	15749661
that	15749661
the	15749661
TfR2	15749661
gene	15749661
is	15749661
involved	15749661
in	15749661
hemochromatosis	15749661
in	15749661
Japanese	15749661
patients	15749661
.	15749661

DESIGN	15749661
AND	15749661
METHODS	15749661
:	15749661
Nine	15749661
patients	15749661
clinically	15749661
diagnosed	15749661
with	15749661
hemochromatosis	15749661
were	15749661
included	15749661
in	15749661
the	15749661
study	15749661
.	15749661

DNA	15749661
was	15749661
extracted	15749661
from	15749661
whole	15749661
blood	15749661
samples	15749661
collected	15749661
with	15749661
informed	15749661
consent	15749661
.	15749661

The	15749661
HFE	15749661
and	15749661
TfR2	15749661
genes	15749661
were	15749661
analyzed	15749661
by	15749661
sequencing	15749661
the	15749661
coding	15749661
region	15749661
and	15749661
splicing	15749661
sites	15749661
.	15749661

RESULTS	15749661
:	15749661
There	15749661
were	15749661
no	15749661
mutations	15749661
in	15749661
the	15749661
HFE	15749661
gene	15749661
.	15749661

In	15749661
the	15749661
TfR2	15749661
gene	15749661
,	15749661
2	15749661
novel	15749661
mutations	15749661
,	15749661
1469T	15749661
-	15749661
>	15749661
G	15749661
(	15749661
L490R	15749661
)	15749661
and	15749661
1665delC	15749661
(	15749661
V561X	15749661
)	15749661
,	15749661
were	15749661
found	15749661
in	15749661
2	15749661
patients	15749661
.	15749661

A	15749661
known	15749661
variation	15749661
,	15749661
714C	15749661
-	15749661
>	15749661
(	15749661
I238M	15749661
)	15749661
,	15749661
was	15749661
also	15749661
found	15749661
in	15749661
the	15749661
patient	15749661
with	15749661
L490R	15749661
.	15749661

The	15749661
patient	15749661
homozygous	15749661
for	15749661
both	15749661
L490R	15749661
and	15749661
I238M	15749661
presented	15749661
with	15749661
a	15749661
mild	15749661
manifestation	15749661
of	15749661
hemochromatosis	15749661
at	15749661
the	15749661
age	15749661
of	15749661
41	15749661
years	15749661
.	15749661

His	15749661
liver	15749661
was	15749661
cirrhotic	15749661
with	15749661
parenchymal	15749661
iron	15749661
deposits	15749661
and	15749661
the	15749661
result	15749661
of	15749661
a	15749661
glucose	15749661
tolerance	15749661
test	15749661
was	15749661
compatible	15749661
with	15749661
diabetes	15749661
mellitus	15749661
.	15749661

The	15749661
patient	15749661
homozygous	15749661
for	15749661
V561X	15749661
had	15749661
severe	15749661
iron	15749661
overload	15749661
with	15749661
the	15749661
triad	15749661
of	15749661
cirrhosis	15749661
,	15749661
diabetes	15749661
mellitus	15749661
and	15749661
skin	15749661
pigmentation	15749661
at	15749661
the	15749661
age	15749661
of	15749661
58	15749661
years	15749661
.	15749661

INTERPRETATION	15749661
AND	15749661
CONCLUSIONS	15749661
:	15749661
Taken	15749661
together	15749661
with	15749661
the	15749661
previous	15749661
report	15749661
,	15749661
5	15749661
of	15749661
our	15749661
12	15749661
patients	15749661
with	15749661
hemochromatosis	15749661
manifesting	15749661
in	15749661
middle	15749661
age	15749661
had	15749661
mutations	15749661
in	15749661
the	15749661
TfR2	15749661
gene	15749661
.	15749661

Thus	15749661
,	15749661
TfR2	15749661
plays	15749661
a	15749661
role	15749661
in	15749661
the	15749661
pathogenesis	15749661
of	15749661
hemochromatosis	15749661
in	15749661
Japan	15749661
.	15749661
Endothelial	24623966
NADPH	24623966
oxidase	24623966
4	24623966
mediates	24623966
vascular	24623966
endothelial	24623966
growth	24623966
factor	24623966
receptor	24623966
2	24623966
-	24623966
induced	24623966
intravitreal	24623966
neovascularization	24623966
in	24623966
a	24623966
rat	24623966
model	24623966
of	24623966
retinopathy	24623966
of	24623966
prematurity	24623966
.	24623966

PURPOSE	24623966
:	24623966
NADPH	24623966
oxidase	24623966
-	24623966
generated	24623966
reactive	24623966
oxygen	24623966
species	24623966
(	24623966
ROS	24623966
)	24623966
are	24623966
implicated	24623966
in	24623966
angiogenesis	24623966
.	24623966

Isoforms	24623966
of	24623966
NADPH	24623966
oxidase	24623966
NOX1	24623966
,	24623966
NOX2	24623966
,	24623966
and	24623966
NOX4	24623966
are	24623966
reported	24623966
to	24623966
be	24623966
expressed	24623966
in	24623966
endothelial	24623966
cells	24623966
(	24623966
ECs	24623966
)	24623966
.	24623966

Of	24623966
these	24623966
,	24623966
NOX1	24623966
and	24623966
NOX2	24623966
have	24623966
been	24623966
reported	24623966
to	24623966
contribute	24623966
to	24623966
intravitreal	24623966
neovascularization	24623966
(	24623966
IVNV	24623966
)	24623966
in	24623966
oxygen	24623966
-	24623966
induced	24623966
retinopathy	24623966
(	24623966
OIR	24623966
)	24623966
models	24623966
.	24623966

In	24623966
this	24623966
study	24623966
,	24623966
we	24623966
tested	24623966
the	24623966
hypothesis	24623966
that	24623966
the	24623966
isoform	24623966
NOX4	24623966
in	24623966
ECs	24623966
contributed	24623966
to	24623966
vascular	24623966
endothelial	24623966
growth	24623966
factor	24623966
(	24623966
VEGF	24623966
)	24623966
-	24623966
induced	24623966
angiogenesis	24623966
and	24623966
IVNV	24623966
.	24623966

METHODS	24623966
:	24623966
Isoforms	24623966
of	24623966
NADPH	24623966
oxidase	24623966
MRNA	24623966
were	24623966
measured	24623966
in	24623966
several	24623966
types	24623966
of	24623966
cultured	24623966
vascular	24623966
ecs	24623966
:	24623966
human	24623966
retinal	24623966
microvascular	24623966
ECs	24623966
(	24623966
hRMVECs	24623966
)	24623966
,	24623966
choroidal	24623966
ECs	24623966
(	24623966
CECs	24623966
)	24623966
,	24623966
and	24623966
human	24623966
umbilical	24623966
vascular	24623966
ECs	24623966
(	24623966
HUVECs	24623966
)	24623966
using	24623966
real	24623966
-	24623966
time	24623966
PCR	24623966
.	24623966

Newborn	24623966
rat	24623966
pups	24623966
and	24623966
dams	24623966
were	24623966
placed	24623966
into	24623966
an	24623966
OIR	24623966
model	24623966
that	24623966
cycled	24623966
oxygen	24623966
concentration	24623966
between	24623966
50%	24623966
and	24623966
10%	24623966
every	24623966
24	24623966
h	24623966
for	24623966
14	24623966
days	24623966
,	24623966
and	24623966
then	24623966
were	24623966
placed	24623966
in	24623966
room	24623966
air	24623966
(	24623966
RA	24623966
)	24623966
for	24623966
an	24623966
additional	24623966
4	24623966
days	24623966
(	24623966
rat	24623966
OIR	24623966
model	24623966
)	24623966
.	24623966

NOX4	24623966
expression	24623966
in	24623966
retinal	24623966
lysates	24623966
from	24623966
the	24623966
RA	24623966
-	24623966
raised	24623966
pups	24623966
at	24623966
postnatal	24623966
day	24623966
0	24623966
(	24623966
P0	24623966
)	24623966
,	24623966
P14	24623966
,	24623966
and	24623966
P18	24623966
was	24623966
determined	24623966
with	24623966
western	24623966
blots	24623966
.	24623966

STAT3	24623966
activation	24623966
was	24623966
determined	24623966
as	24623966
the	24623966
ratio	24623966
of	24623966
phosphorylated	24623966
STAT3	24623966
to	24623966
total	24623966
STAT3	24623966
with	24623966
western	24623966
blot	24623966
analysis	24623966
of	24623966
retinal	24623966
lysates	24623966
from	24623966
pups	24623966
raised	24623966
in	24623966
RA	24623966
or	24623966
from	24623966
the	24623966
rat	24623966
OIR	24623966
model	24623966
at	24623966
P18	24623966
.	24623966

Semiquantitative	24623966
assessment	24623966
of	24623966
the	24623966
density	24623966
of	24623966
NOX4	24623966
colabeling	24623966
with	24623966
lectin	24623966
-	24623966
stained	24623966
retinal	24623966
ECs	24623966
was	24623966
determined	24623966
by	24623966
immunolabeling	24623966
of	24623966
retinal	24623966
cryosections	24623966
from	24623966
P18	24623966
pups	24623966
in	24623966
OIR	24623966
or	24623966
in	24623966
RA	24623966
.	24623966

In	24623966
hRMVECs	24623966
transfected	24623966
with	24623966
NOX4	24623966
siRNA	24623966
and	24623966
treated	24623966
with	24623966
VEGF	24623966
or	24623966
control	24623966
,	24623966
1	24623966
)	24623966
ROS	24623966
generation	24623966
was	24623966
measured	24623966
using	24623966
the	24623966
5	24623966
-	24623966
(	24623966
and	24623966
-	24623966
6	24623966
)	24623966
-	24623966
chloromethyl	24623966
-	24623966
2	24623966
'	24623966
,	24623966
7	24623966
'	24623966
-	24623966
dichlorodihydrofluorescein	24623966
diacetate	24623966
,	24623966
acetyl	24623966
ester	24623966
fluorescence	24623966
assay	24623966
and	24623966
2	24623966
)	24623966
phosphorylated	24623966
VEGF	24623966
receptor	24623966
2	24623966
and	24623966
STAT3	24623966
,	24623966
and	24623966
total	24623966
VEGFR2	24623966
and	24623966
STAT3	24623966
were	24623966
measured	24623966
in	24623966
western	24623966
blot	24623966
analyses	24623966
.	24623966

VEGF	24623966
-	24623966
stimulated	24623966
hRMVEC	24623966
proliferation	24623966
was	24623966
measured	24623966
following	24623966
transfection	24623966
with	24623966
NOX4	24623966
siRNA	24623966
or	24623966
STAT3	24623966
siRNA	24623966
,	24623966
or	24623966
respective	24623966
controls	24623966
.	24623966

RESULTS	24623966
:	24623966
NOX4	24623966
was	24623966
the	24623966
most	24623966
prevalent	24623966
isoform	24623966
of	24623966
NADPH	24623966
oxidase	24623966
in	24623966
vascular	24623966
ECs	24623966
.	24623966

NOX4	24623966
expression	24623966
in	24623966
retinal	24623966
lysates	24623966
was	24623966
significantly	24623966
decreased	24623966
during	24623966
development	24623966
in	24623966
RA	24623966
.	24623966

Compared	24623966
to	24623966
RA	24623966
,	24623966
the	24623966
expression	24623966
of	24623966
retinal	24623966
NOX4	24623966
increased	24623966
at	24623966
P18	24623966
.	24623966

At	24623966
p18	24623966
OIR	24623966
,	24623966
semiquantitative	24623966
assessment	24623966
of	24623966
the	24623966
density	24623966
of	24623966
lectin	24623966
and	24623966
NOX4	24623966
colabeling	24623966
in	24623966
retinal	24623966
vascular	24623966
ECs	24623966
was	24623966
greater	24623966
in	24623966
retinal	24623966
cryosections	24623966
and	24623966
activated	24623966
STAT3	24623966
was	24623966
greater	24623966
in	24623966
retinal	24623966
lysates	24623966
when	24623966
compared	24623966
to	24623966
the	24623966
RA	24623966
-	24623966
raised	24623966
pups	24623966
.	24623966

In	24623966
cultured	24623966
hRMVECs	24623966
,	24623966
knockdown	24623966
of	24623966
NOX4	24623966
by	24623966
siRNA	24623966
transfection	24623966
inhibited	24623966
VEGF	24623966
-	24623966
induced	24623966
ROS	24623966
generation	24623966
.	24623966

VEGF	24623966
induced	24623966
a	24623966
physical	24623966
interaction	24623966
of	24623966
phosphorylated	24623966
-	24623966
VEGFR2	24623966
and	24623966
NOX4	24623966
.	24623966

Knockdown	24623966
of	24623966
NOX4	24623966
:	24623966
1	24623966
)	24623966
reduced	24623966
VEGFR2	24623966
activation	24623966
but	24623966
did	24623966
not	24623966
abolish	24623966
it	24623966
and	24623966
2	24623966
)	24623966
abolished	24623966
STAT3	24623966
activation	24623966
in	24623966
response	24623966
to	24623966
VEGF	24623966
.	24623966

Knockdown	24623966
of	24623966
either	24623966
NOX4	24623966
or	24623966
STAT3	24623966
inhibited	24623966
VEGF	24623966
-	24623966
induced	24623966
EC	24623966
proliferation	24623966
.	24623966

CONCLUSIONS	24623966
:	24623966
Our	24623966
data	24623966
suggest	24623966
that	24623966
in	24623966
a	24623966
model	24623966
representative	24623966
of	24623966
human	24623966
retinopathy	24623966
of	24623966
prematurity	24623966
,	24623966
NOX4	24623966
was	24623966
increased	24623966
at	24623966
a	24623966
time	24623966
point	24623966
when	24623966
IVNV	24623966
developed	24623966
.	24623966

VEGF	24623966
-	24623966
activated	24623966
NOX4	24623966
led	24623966
to	24623966
an	24623966
interaction	24623966
between	24623966
VEGF	24623966
-	24623966
activated	24623966
VEGFR2	24623966
and	24623966
NOX4	24623966
that	24623966
mediated	24623966
EC	24623966
proliferation	24623966
via	24623966
activation	24623966
of	24623966
STAT3	24623966
.	24623966

Altogether	24623966
,	24623966
our	24623966
results	24623966
suggest	24623966
that	24623966
NOX4	24623966
may	24623966
regulate	24623966
VEGFR2	24623966
-	24623966
mediated	24623966
IVNV	24623966
through	24623966
activated	24623966
STAT3	24623966
.	24623966
MDMA	16574712
polydrug	16574712
users	16574712
show	16574712
process	16574712
-	16574712
specific	16574712
central	16574712
executive	16574712
impairments	16574712
coupled	16574712
with	16574712
impaired	16574712
social	16574712
and	16574712
emotional	16574712
judgement	16574712
processes	16574712
.	16574712

In	16574712
recent	16574712
years	16574712
working	16574712
memory	16574712
deficits	16574712
have	16574712
been	16574712
reported	16574712
in	16574712
users	16574712
of	16574712
MDMA	16574712
(	16574712
3	16574712
,	16574712
4	16574712
-	16574712
methylenedioxymethamphetamine	16574712
,	16574712
ecstasy	16574712
)	16574712
.	16574712

The	16574712
current	16574712
study	16574712
aimed	16574712
to	16574712
assess	16574712
the	16574712
impact	16574712
of	16574712
MDMA	16574712
use	16574712
on	16574712
three	16574712
separate	16574712
central	16574712
executive	16574712
processes	16574712
(	16574712
set	16574712
shifting	16574712
,	16574712
inhibition	16574712
and	16574712
memory	16574712
updating	16574712
)	16574712
and	16574712
also	16574712
on	16574712
""""	16574712
prefrontal	16574712
""""	16574712
mediated	16574712
social	16574712
and	16574712
emotional	16574712
judgement	16574712
processes	16574712
.	16574712

Fifteen	16574712
polydrug	16574712
ecstasy	16574712
users	16574712
and	16574712
15	16574712
polydrug	16574712
non	16574712
-	16574712
ecstasy	16574712
user	16574712
controls	16574712
completed	16574712
a	16574712
general	16574712
drug	16574712
use	16574712
questionnaire	16574712
,	16574712
the	16574712
Brixton	16574712
Spatial	16574712
Anticipation	16574712
task	16574712
(	16574712
set	16574712
shifting	16574712
)	16574712
,	16574712
Backward	16574712
Digit	16574712
Span	16574712
procedure	16574712
(	16574712
memory	16574712
updating	16574712
)	16574712
,	16574712
Inhibition	16574712
of	16574712
Return	16574712
(	16574712
inhibition	16574712
)	16574712
,	16574712
an	16574712
emotional	16574712
intelligence	16574712
scale	16574712
,	16574712
the	16574712
Tromso	16574712
Social	16574712
Intelligence	16574712
Scale	16574712
and	16574712
the	16574712
Dysexecutive	16574712
Questionnaire	16574712
(	16574712
DEX	16574712
)	16574712
.	16574712

Compared	16574712
with	16574712
MDMA	16574712
-	16574712
free	16574712
polydrug	16574712
controls	16574712
,	16574712
MDMA	16574712
polydrug	16574712
users	16574712
showed	16574712
impairments	16574712
in	16574712
set	16574712
shifting	16574712
and	16574712
memory	16574712
updating	16574712
,	16574712
and	16574712
also	16574712
in	16574712
social	16574712
and	16574712
emotional	16574712
judgement	16574712
processes	16574712
.	16574712

The	16574712
latter	16574712
two	16574712
deficits	16574712
remained	16574712
significant	16574712
after	16574712
controlling	16574712
for	16574712
other	16574712
drug	16574712
use	16574712
.	16574712

These	16574712
data	16574712
lend	16574712
further	16574712
support	16574712
to	16574712
the	16574712
proposal	16574712
that	16574712
cognitive	16574712
processes	16574712
mediated	16574712
by	16574712
the	16574712
prefrontal	16574712
cortex	16574712
may	16574712
be	16574712
impaired	16574712
by	16574712
recreational	16574712
ecstasy	16574712
use	16574712
.	16574712
Successful	16000134
therapy	16000134
with	16000134
argatroban	16000134
for	16000134
superior	16000134
mesenteric	16000134
vein	16000134
thrombosis	16000134
in	16000134
a	16000134
patient	16000134
with	16000134
congenital	16000134
antithrombin	16000134
deficiency	16000134
.	16000134

A	16000134
38	16000134
-	16000134
year	16000134
-	16000134
old	16000134
woman	16000134
was	16000134
admitted	16000134
with	16000134
superior	16000134
mesenteric	16000134
vein	16000134
(	16000134
SMV	16000134
)	16000134
thrombosis	16000134
,	16000134
which	16000134
was	16000134
refractory	16000134
to	16000134
anticoagulation	16000134
therapy	16000134
.	16000134

The	16000134
plasma	16000134
antithrombin	16000134
activity	16000134
was	16000134
decreased	16000134
and	16000134
hardly	16000134
compensated	16000134
by	16000134
concentrated	16000134
antithrombin	16000134
preparation	16000134
due	16000134
to	16000134
high	16000134
consumption	16000134
rate	16000134
.	16000134

However	16000134
,	16000134
successful	16000134
anticoagulation	16000134
was	16000134
achieved	16000134
by	16000134
administration	16000134
of	16000134
direct	16000134
thrombin	16000134
inhibitor	16000134
,	16000134
argatroban	16000134
.	16000134

Family	16000134
studies	16000134
of	16000134
antithrombin	16000134
activity	16000134
revealed	16000134
that	16000134
she	16000134
had	16000134
type	16000134
I	16000134
congenital	16000134
antithrombin	16000134
deficiency	16000134
.	16000134

A	16000134
novel	16000134
heterozygous	16000134
mutation	16000134
in	16000134
the	16000134
gene	16000134
for	16000134
antithrombin	16000134
(	16000134
single	16000134
nucleotide	16000134
T	16000134
insertion	16000134
at	16000134
7916	16000134
and	16000134
7917	16000134
,	16000134
Glu	16000134
272	16000134
to	16000134
stop	16000134
in	16000134
exon	16000134
4	16000134
)	16000134
was	16000134
identified	16000134
.	16000134

Argatroban	16000134
administration	16000134
would	16000134
be	16000134
effective	16000134
in	16000134
the	16000134
treatment	16000134
of	16000134
congenital	16000134
antithrombin	16000134
deficiency	16000134
with	16000134
SMV	16000134
thrombosis	16000134
.	16000134
Mutational	21054465
analysis	21054465
of	21054465
CYP2C8	21054465
in	21054465
hypertensive	21054465
patients	21054465
using	21054465
denaturing	21054465
high	21054465
performance	21054465
liquid	21054465
chromatography	21054465
.	21054465

WHAT	21054465
IS	21054465
KNOWN	21054465
AND	21054465
OBJECTIVE	21054465
:	21054465
CYP2C8	21054465
is	21054465
involved	21054465
in	21054465
the	21054465
cytochrome	21054465
P450	21054465
(	21054465
CYP	21054465
)	21054465
epoxygenase	21054465
pathway	21054465
.	21054465

Arachidonic	21054465
acid	21054465
metabolites	21054465
such	21054465
as	21054465
epoxyeicosatrienenoic	21054465
acids	21054465
and	21054465
hydroxyeicosatetrenoic	21054465
acids	21054465
,	21054465
produced	21054465
may	21054465
have	21054465
a	21054465
role	21054465
in	21054465
hypertension	21054465
.	21054465

We	21054465
aimed	21054465
to	21054465
develop	21054465
a	21054465
medium	21054465
through	21054465
-	21054465
put	21054465
method	21054465
for	21054465
screening	21054465
samples	21054465
of	21054465
known	21054465
and	21054465
new	21054465
mutations	21054465
of	21054465
CYP2C8	21054465
using	21054465
denaturing	21054465
high	21054465
performance	21054465
liquid	21054465
chromatography	21054465
(	21054465
DHPLC	21054465
)	21054465
.	21054465

METHODS	21054465
:	21054465
DNA	21054465
samples	21054465
from	21054465
200	21054465
subjects	21054465
(	21054465
hypertensive	21054465
patients	21054465
and	21054465
healthy	21054465
controls	21054465
)	21054465
were	21054465
screened	21054465
for	21054465
SNPs	21054465
in	21054465
CYP2C8	21054465
using	21054465
DHPLC	21054465
.	21054465

Genotypes	21054465
and	21054465
allelic	21054465
frequencies	21054465
of	21054465
CYP2C8	21054465
between	21054465
the	21054465
healthy	21054465
controls	21054465
and	21054465
patients	21054465
with	21054465
hypertension	21054465
were	21054465
compared	21054465
.	21054465

RESULTS	21054465
AND	21054465
DISCUSSIONS	21054465
:	21054465
Six	21054465
variants	21054465
were	21054465
detected	21054465
and	21054465
two	21054465
were	21054465
new	21054465
;	21054465
T	21054465
deletion	21054465
at	21054465
5063	21054465
and	21054465
substitution	21054465
of	21054465
C	21054465
to	21054465
T	21054465
at	21054465
33468	21054465
in	21054465
exon	21054465
8	21054465
.	21054465

Differences	21054465
in	21054465
variant	21054465
frequencies	21054465
were	21054465
detected	21054465
between	21054465
the	21054465
controls	21054465
and	21054465
hypertensive	21054465
patients	21054465
.	21054465

The	21054465
controls	21054465
have	21054465
significantly	21054465
higher	21054465
prevalence	21054465
of	21054465
C35322C	21054465
compared	21054465
to	21054465
the	21054465
patients	21054465
.	21054465

The	21054465
functional	21054465
significance	21054465
of	21054465
the	21054465
SNP	21054465
at	21054465
35322	21054465
requires	21054465
further	21054465
study	21054465
.	21054465

Having	21054465
homozygous	21054465
C35322C	21054465
could	21054465
be	21054465
a	21054465
protective	21054465
factor	21054465
for	21054465
hypertension	21054465
.	21054465

WHAT	21054465
IS	21054465
NEW	21054465
AND	21054465
CONCLUSION	21054465
:	21054465
Denaturing	21054465
high	21054465
performance	21054465
liquid	21054465
chromatography	21054465
is	21054465
useful	21054465
for	21054465
population	21054465
screening	21054465
to	21054465
identify	21054465
new	21054465
and	21054465
existing	21054465
SNPs	21054465
.	21054465

A	21054465
higher	21054465
frequency	21054465
of	21054465
the	21054465
C35322T	21054465
SNP	21054465
was	21054465
observed	21054465
among	21054465
hypertensive	21054465
patients	21054465
than	21054465
control	21054465
subjects	21054465
.	21054465

This	21054465
potentially	21054465
important	21054465
observation	21054465
requires	21054465
confirmation	21054465
and	21054465
the	21054465
clinical	21054465
significance	21054465
assessed	21054465
.	21054465
Voltage	27941998
-	27941998
Dependent	27941998
Anion	27941998
Channel	27941998
1	27941998
(	27941998
VDAC1	27941998
)	27941998
Participates	27941998
the	27941998
Apoptosis	27941998
of	27941998
the	27941998
Mitochondrial	27941998
Dysfunction	27941998
in	27941998
Desminopathy	27941998
.	27941998

Desminopathies	27941998
caused	27941998
by	27941998
the	27941998
mutation	27941998
in	27941998
the	27941998
gene	27941998
coding	27941998
for	27941998
desmin	27941998
are	27941998
genetically	27941998
protein	27941998
aggregation	27941998
myopathies	27941998
.	27941998

Mitochondrial	27941998
dysfunction	27941998
is	27941998
one	27941998
of	27941998
pathological	27941998
changes	27941998
in	27941998
the	27941998
desminopathies	27941998
at	27941998
the	27941998
earliest	27941998
stage	27941998
.	27941998

The	27941998
molecular	27941998
mechanisms	27941998
of	27941998
mitochondria	27941998
dysfunction	27941998
in	27941998
desminopathies	27941998
remain	27941998
exclusive	27941998
.	27941998

VDAC1	27941998
regulates	27941998
mitochondrial	27941998
uptake	27941998
across	27941998
the	27941998
outer	27941998
membrane	27941998
and	27941998
mitochondrial	27941998
outer	27941998
membrane	27941998
permeabilization	27941998
(	27941998
MOMP	27941998
)	27941998
.	27941998

Relationships	27941998
between	27941998
desminopathies	27941998
and	27941998
Voltage	27941998
-	27941998
dependent	27941998
anion	27941998
channel	27941998
1	27941998
(	27941998
VDAC1	27941998
)	27941998
remain	27941998
unclear	27941998
.	27941998

Here	27941998
we	27941998
successfully	27941998
constructed	27941998
the	27941998
desminopathy	27941998
rat	27941998
model	27941998
,	27941998
evaluated	27941998
with	27941998
conventional	27941998
stains	27941998
,	27941998
containing	27941998
hematoxylin	27941998
and	27941998
eosin	27941998
(	27941998
HE	27941998
)	27941998
,	27941998
Gomori	27941998
Trichrome	27941998
(	27941998
MGT	27941998
)	27941998
,	27941998
(	27941998
PAS	27941998
)	27941998
,	27941998
red	27941998
oil	27941998
(	27941998
ORO	27941998
)	27941998
,	27941998
NADH	27941998
-	27941998
TR	27941998
,	27941998
SDH	27941998
staining	27941998
and	27941998
immunohistochemistry	27941998
.	27941998

Immunofluorescence	27941998
results	27941998
showed	27941998
that	27941998
VDAC1	27941998
was	27941998
accumulated	27941998
in	27941998
the	27941998
desmin	27941998
highly	27941998
stained	27941998
area	27941998
of	27941998
muscle	27941998
fibers	27941998
of	27941998
desminopathy	27941998
patients	27941998
or	27941998
desminopathy	27941998
rat	27941998
model	27941998
compared	27941998
to	27941998
the	27941998
normal	27941998
ones	27941998
.	27941998

Meanwhile	27941998
apoptosis	27941998
related	27941998
proteins	27941998
bax	27941998
and	27941998
ATF2	27941998
were	27941998
involved	27941998
in	27941998
desminopathy	27941998
patients	27941998
and	27941998
desminopathy	27941998
rat	27941998
model	27941998
,	27941998
but	27941998
not	27941998
bcl	27941998
-	27941998
2	27941998
,	27941998
bcl	27941998
-	27941998
xl	27941998
or	27941998
HK2	27941998
.	27941998
VDAC1	27941998
and	27941998
desmin	27941998
are	27941998
closely	27941998
relevant	27941998
in	27941998
the	27941998
tissue	27941998
splices	27941998
of	27941998
deminopathies	27941998
patients	27941998
and	27941998
rats	27941998
with	27941998
desminopathy	27941998
at	27941998
protein	27941998
lever	27941998
.	27941998

Moreover	27941998
,	27941998
apoptotic	27941998
proteins	27941998
are	27941998
also	27941998
involved	27941998
in	27941998
the	27941998
desminopathies	27941998
,	27941998
like	27941998
bax	27941998
,	27941998
ATF2	27941998
,	27941998
but	27941998
not	27941998
bcl	27941998
-	27941998
2	27941998
,	27941998
bcl	27941998
-	27941998
xl	27941998
or	27941998
HK2	27941998
.	27941998

This	27941998
pathological	27941998
analysis	27941998
presents	27941998
the	27941998
correlation	27941998
between	27941998
VDAC1	27941998
and	27941998
desmin	27941998
,	27941998
and	27941998
apoptosis	27941998
related	27941998
proteins	27941998
are	27941998
correlated	27941998
in	27941998
the	27941998
desminopathy	27941998
.	27941998

Furthermore	27941998
,	27941998
we	27941998
provide	27941998
a	27941998
rat	27941998
model	27941998
of	27941998
desminopathy	27941998
for	27941998
the	27941998
investigation	27941998
of	27941998
desmin	27941998
related	27941998
myopathy	27941998
.	27941998
The	23949582
cytogenetic	23949582
action	23949582
of	23949582
ifosfamide	23949582
,	23949582
mesna	23949582
,	23949582
and	23949582
their	23949582
combination	23949582
on	23949582
peripheral	23949582
rabbit	23949582
lymphocytes	23949582
:	23949582
an	23949582
in	23949582
vivo	23949582
/	23949582
in	23949582
vitro	23949582
cytogenetic	23949582
study	23949582
.	23949582

Ifosfamide	23949582
(	23949582
IFO	23949582
)	23949582
is	23949582
an	23949582
alkylating	23949582
nitrogen	23949582
mustard	23949582
,	23949582
administrated	23949582
as	23949582
an	23949582
antineoplasmic	23949582
agent	23949582
.	23949582

It	23949582
is	23949582
characterized	23949582
by	23949582
its	23949582
intense	23949582
urotoxic	23949582
action	23949582
,	23949582
leading	23949582
to	23949582
hemorrhagic	23949582
cystitis	23949582
.	23949582

This	23949582
side	23949582
effect	23949582
of	23949582
IFO	23949582
raises	23949582
the	23949582
requirement	23949582
for	23949582
the	23949582
co	23949582
-	23949582
administration	23949582
with	23949582
sodium	23949582
2	23949582
-	23949582
sulfanylethanesulfonate	23949582
(	23949582
Mesna	23949582
)	23949582
aiming	23949582
to	23949582
avoid	23949582
or	23949582
minimize	23949582
this	23949582
effect	23949582
.	23949582

IFO	23949582
and	23949582
Mesna	23949582
were	23949582
administrated	23949582
separately	23949582
on	23949582
rabbit	23949582
'	23949582
s	23949582
lymphocytes	23949582
in	23949582
vivo	23949582
,	23949582
which	23949582
were	23949582
later	23949582
developed	23949582
in	23949582
vitro	23949582
.	23949582

Cytogenetic	23949582
markers	23949582
for	23949582
sister	23949582
chromatid	23949582
exchanges	23949582
(	23949582
SCEs	23949582
)	23949582
,	23949582
proliferation	23949582
rate	23949582
index	23949582
(	23949582
PRI	23949582
)	23949582
and	23949582
Mitotic	23949582
Index	23949582
were	23949582
recorded	23949582
.	23949582

Mesna	23949582
'	23949582
s	23949582
action	23949582
,	23949582
in	23949582
conjunction	23949582
with	23949582
IFO	23949582
reduces	23949582
the	23949582
frequency	23949582
of	23949582
SCEs	23949582
,	23949582
in	23949582
comparison	23949582
with	23949582
the	23949582
SCEs	23949582
recordings	23949582
obtained	23949582
when	23949582
IFO	23949582
is	23949582
administered	23949582
alone	23949582
.	23949582

In	23949582
addition	23949582
to	23949582
this	23949582
,	23949582
when	23949582
high	23949582
concentrations	23949582
of	23949582
Mesna	23949582
were	23949582
administered	23949582
alone	23949582
significant	23949582
reductions	23949582
of	23949582
the	23949582
PRI	23949582
were	23949582
noted	23949582
,	23949582
than	23949582
with	23949582
IFO	23949582
acting	23949582
at	23949582
the	23949582
same	23949582
concentration	23949582
on	23949582
the	23949582
lymphocytes	23949582
.	23949582

Mesna	23949582
significantly	23949582
reduces	23949582
IFO	23949582
'	23949582
s	23949582
genotoxicity	23949582
,	23949582
while	23949582
when	23949582
administered	23949582
in	23949582
high	23949582
concentrations	23949582
it	23949582
acts	23949582
in	23949582
an	23949582
inhibitory	23949582
fashion	23949582
on	23949582
the	23949582
cytostatic	23949582
action	23949582
of	23949582
the	23949582
drug	23949582
.	23949582
Two	21904390
novel	21904390
mutations	21904390
of	21904390
the	21904390
PAX6	21904390
gene	21904390
causing	21904390
different	21904390
phenotype	21904390
in	21904390
a	21904390
cohort	21904390
of	21904390
Chinese	21904390
patients	21904390
.	21904390

PURPOSE	21904390
:	21904390
Aniridia	21904390
(	21904390
AN	21904390
)	21904390
is	21904390
a	21904390
rare	21904390
congenital	21904390
panocular	21904390
disorder	21904390
caused	21904390
by	21904390
the	21904390
mutations	21904390
of	21904390
the	21904390
paired	21904390
box	21904390
homeotic	21904390
gene	21904390
6	21904390
(	21904390
PAX6	21904390
)	21904390
gene	21904390
.	21904390

The	21904390
PAX6	21904390
gene	21904390
is	21904390
also	21904390
involved	21904390
in	21904390
other	21904390
anterior	21904390
segment	21904390
malformations	21904390
including	21904390
Peters	21904390
anomaly	21904390
.	21904390

We	21904390
studied	21904390
the	21904390
PAX6	21904390
gene	21904390
mutations	21904390
in	21904390
a	21904390
cohort	21904390
of	21904390
affected	21904390
individuals	21904390
with	21904390
different	21904390
clinical	21904390
phenotype	21904390
including	21904390
AN	21904390
,	21904390
coloboma	21904390
of	21904390
iris	21904390
and	21904390
choroid	21904390
,	21904390
or	21904390
anterior	21904390
segment	21904390
malformations	21904390
.	21904390

PATIENTS	21904390
AND	21904390
METHODS	21904390
:	21904390
Six	21904390
unrelated	21904390
families	21904390
and	21904390
10	21904390
sporadic	21904390
patients	21904390
were	21904390
examined	21904390
clinically	21904390
.	21904390

After	21904390
informed	21904390
consent	21904390
was	21904390
obtained	21904390
,	21904390
genomic	21904390
DNA	21904390
was	21904390
extracted	21904390
from	21904390
the	21904390
venous	21904390
blood	21904390
of	21904390
all	21904390
participants	21904390
.	21904390

Mutation	21904390
screening	21904390
of	21904390
all	21904390
exons	21904390
of	21904390
the	21904390
PAX6	21904390
gene	21904390
was	21904390
performed	21904390
by	21904390
direct	21904390
sequencing	21904390
of	21904390
PCR	21904390
-	21904390
amplified	21904390
DNA	21904390
fragments	21904390
.	21904390

Multiplex	21904390
ligation	21904390
-	21904390
dependent	21904390
probe	21904390
amplification	21904390
(	21904390
MLPA	21904390
)	21904390
was	21904390
performed	21904390
to	21904390
detect	21904390
large	21904390
deletions	21904390
.	21904390

RESULTS	21904390
:	21904390
By	21904390
clinical	21904390
examination	21904390
,	21904390
the	21904390
patients	21904390
and	21904390
the	21904390
pedigrees	21904390
were	21904390
divided	21904390
into	21904390
the	21904390
following	21904390
three	21904390
groups	21904390
:	21904390
AN	21904390
,	21904390
coloboma	21904390
of	21904390
iris	21904390
and	21904390
choroids	21904390
,	21904390
and	21904390
the	21904390
anterior	21904390
segment	21904390
malformations	21904390
including	21904390
peters	21904390
anomaly	21904390
.	21904390

Sequencing	21904390
of	21904390
the	21904390
PAX6	21904390
gene	21904390
,	21904390
three	21904390
intragenic	21904390
mutations	21904390
including	21904390
a	21904390
novel	21904390
heterozygous	21904390
splicing	21904390
-	21904390
site	21904390
mutations	21904390
c	21904390
.	21904390
357	21904390
-	21904390
3C	21904390
>	21904390
G	21904390
(	21904390
p	21904390
.	21904390
Ser119fsX	21904390
)	21904390
were	21904390
identified	21904390
in	21904390
the	21904390
patients	21904390
of	21904390
the	21904390
AN	21904390
group	21904390
.	21904390

A	21904390
novel	21904390
missense	21904390
mutation	21904390
c	21904390
.	21904390
643T	21904390
>	21904390
C	21904390
(	21904390
p	21904390
.	21904390
S216P	21904390
)	21904390
was	21904390
detected	21904390
in	21904390
the	21904390
anterior	21904390
segment	21904390
malformation	21904390
group	21904390
.	21904390

The	21904390
mutation	21904390
p	21904390
.	21904390
S216P	21904390
located	21904390
in	21904390
the	21904390
homeodomain	21904390
region	21904390
of	21904390
the	21904390
PAX6	21904390
caused	21904390
the	21904390
phenotype	21904390
of	21904390
Peters	21904390
anomaly	21904390
in	21904390
family	21904390
A6	21904390
with	21904390
different	21904390
expressing	21904390
.	21904390

Through	21904390
MLPA	21904390
analysis	21904390
,	21904390
a	21904390
large	21904390
deletion	21904390
including	21904390
the	21904390
whole	21904390
PAX6	21904390
gene	21904390
and	21904390
DKFZ	21904390
p686k1684	21904390
gene	21904390
was	21904390
detected	21904390
in	21904390
one	21904390
sporadic	21904390
patient	21904390
from	21904390
the	21904390
AN	21904390
group	21904390
.	21904390

Neither	21904390
intragenic	21904390
mutation	21904390
nor	21904390
large	21904390
deletion	21904390
was	21904390
identified	21904390
in	21904390
the	21904390
group	21904390
with	21904390
coloboma	21904390
of	21904390
iris	21904390
and	21904390
choroid	21904390
.	21904390

CONCLUSION	21904390
:	21904390
Our	21904390
findings	21904390
further	21904390
confirmed	21904390
that	21904390
different	21904390
kind	21904390
of	21904390
mutations	21904390
might	21904390
cause	21904390
different	21904390
ocular	21904390
phenotype	21904390
,	21904390
and	21904390
clearly	21904390
clinical	21904390
phenotype	21904390
classification	21904390
might	21904390
increase	21904390
the	21904390
mutation	21904390
detection	21904390
rate	21904390
of	21904390
the	21904390
PAX6	21904390
gene	21904390
.	21904390
Polymorphisms	16252083
of	16252083
the	16252083
DNA	16252083
mismatch	16252083
repair	16252083
gene	16252083
HMSH2	16252083
in	16252083
breast	16252083
cancer	16252083
occurence	16252083
and	16252083
progression	16252083
.	16252083

The	16252083
response	16252083
of	16252083
the	16252083
cell	16252083
to	16252083
DNA	16252083
damage	16252083
and	16252083
its	16252083
ability	16252083
to	16252083
maintain	16252083
genomic	16252083
stability	16252083
by	16252083
DNA	16252083
repair	16252083
are	16252083
crucial	16252083
in	16252083
preventing	16252083
cancer	16252083
initiation	16252083
and	16252083
progression	16252083
.	16252083

Therefore	16252083
,	16252083
polymorphism	16252083
of	16252083
DNA	16252083
repair	16252083
genes	16252083
may	16252083
affect	16252083
the	16252083
process	16252083
of	16252083
carcinogenesis	16252083
.	16252083

The	16252083
importance	16252083
of	16252083
genetic	16252083
variability	16252083
of	16252083
the	16252083
components	16252083
of	16252083
mismatch	16252083
repair	16252083
(	16252083
MMR	16252083
)	16252083
genes	16252083
is	16252083
well	16252083
documented	16252083
in	16252083
colorectal	16252083
cancer	16252083
,	16252083
but	16252083
little	16252083
is	16252083
known	16252083
about	16252083
its	16252083
role	16252083
in	16252083
breast	16252083
cancer	16252083
.	16252083

hMSH2	16252083
is	16252083
one	16252083
of	16252083
the	16252083
crucial	16252083
proteins	16252083
of	16252083
MMR	16252083
.	16252083

We	16252083
performed	16252083
a	16252083
case	16252083
-	16252083
control	16252083
study	16252083
to	16252083
test	16252083
the	16252083
association	16252083
between	16252083
two	16252083
polymorphisms	16252083
in	16252083
the	16252083
hMSH2	16252083
gene	16252083
:	16252083
an	16252083
A	16252083
-	16252083
-	16252083
>	16252083
G	16252083
transition	16252083
at	16252083
127	16252083
position	16252083
producing	16252083
an	16252083
Asn	16252083
-	16252083
-	16252083
>	16252083
Ser	16252083
substitution	16252083
at	16252083
codon	16252083
127	16252083
(	16252083
the	16252083
Asn127Ser	16252083
polymorphism	16252083
)	16252083
and	16252083
a	16252083
G	16252083
-	16252083
-	16252083
>	16252083
A	16252083
transition	16252083
at	16252083
1032	16252083
position	16252083
resulting	16252083
in	16252083
a	16252083
Gly	16252083
-	16252083
-	16252083
>	16252083
Asp	16252083
change	16252083
at	16252083
codon	16252083
322	16252083
(	16252083
the	16252083
Gly322Asp	16252083
polymorphism	16252083
)	16252083
and	16252083
breast	16252083
cancer	16252083
risk	16252083
and	16252083
cancer	16252083
progression	16252083
.	16252083

Genotypes	16252083
were	16252083
determined	16252083
in	16252083
DNA	16252083
from	16252083
peripheral	16252083
blood	16252083
lymphocytes	16252083
of	16252083
150	16252083
breast	16252083
cancer	16252083
patients	16252083
and	16252083
150	16252083
age	16252083
-	16252083
matched	16252083
women	16252083
(	16252083
controls	16252083
)	16252083
by	16252083
restriction	16252083
fragment	16252083
length	16252083
polymorphism	16252083
and	16252083
allele	16252083
-	16252083
specific	16252083
PCR	16252083
.	16252083

We	16252083
did	16252083
not	16252083
observe	16252083
any	16252083
correlation	16252083
between	16252083
studied	16252083
polymorphisms	16252083
and	16252083
breast	16252083
cancer	16252083
progression	16252083
evaluated	16252083
by	16252083
node	16252083
-	16252083
metastasis	16252083
,	16252083
tumor	16252083
size	16252083
and	16252083
Bloom	16252083
-	16252083
Richardson	16252083
grading	16252083
.	16252083

A	16252083
strong	16252083
association	16252083
between	16252083
breast	16252083
cancer	16252083
occurrence	16252083
and	16252083
the	16252083
Gly	16252083
/	16252083
Gly	16252083
phenotype	16252083
of	16252083
the	16252083
Gly322Asp	16252083
polymorphism	16252083
(	16252083
odds	16252083
ratio	16252083
8	16252083
.	16252083
39	16252083
;	16252083
95%	16252083
confidence	16252083
interval	16252083
1	16252083
.	16252083
44	16252083
-	16252083
48	16252083
.	16252083
8	16252083
)	16252083
was	16252083
found	16252083
.	16252083

Therefore	16252083
,	16252083
MMR	16252083
may	16252083
play	16252083
a	16252083
role	16252083
in	16252083
the	16252083
breast	16252083
carcinogenesis	16252083
and	16252083
the	16252083
Gly322Asp	16252083
polymorphism	16252083
of	16252083
the	16252083
hMSH2	16252083
gene	16252083
may	16252083
be	16252083
considered	16252083
as	16252083
a	16252083
potential	16252083
marker	16252083
in	16252083
breast	16252083
cancer	16252083
.	16252083
Vitamin	15820770
D	15820770
-	15820770
binding	15820770
protein	15820770
gene	15820770
polymorphism	15820770
association	15820770
with	15820770
IA	15820770
-	15820770
2	15820770
autoantibodies	15820770
in	15820770
type	15820770
1	15820770
diabetes	15820770
.	15820770

BACKGROUND	15820770
:	15820770
Vitamin	15820770
D	15820770
-	15820770
binding	15820770
protein	15820770
(	15820770
DBP	15820770
)	15820770
is	15820770
the	15820770
main	15820770
systemic	15820770
transporter	15820770
of	15820770
1	15820770
.	15820770
25	15820770
(	15820770
OH	15820770
)	15820770
2D3	15820770
and	15820770
is	15820770
essential	15820770
for	15820770
its	15820770
cellular	15820770
endocytosis	15820770
.	15820770

There	15820770
are	15820770
two	15820770
known	15820770
polymorphisms	15820770
in	15820770
exon	15820770
11	15820770
of	15820770
the	15820770
DBP	15820770
gene	15820770
resulting	15820770
in	15820770
amino	15820770
acid	15820770
variants	15820770
:	15820770
GAT	15820770
-	15820770
-	15820770
>	15820770
GAG	15820770
substitution	15820770
replaces	15820770
aspartic	15820770
acid	15820770
by	15820770
glutamic	15820770
acid	15820770
in	15820770
codon	15820770
416	15820770
;	15820770
and	15820770
ACG	15820770
-	15820770
-	15820770
>	15820770
AAG	15820770
substitution	15820770
in	15820770
codon	15820770
420	15820770
leads	15820770
to	15820770
an	15820770
exchange	15820770
of	15820770
threonine	15820770
for	15820770
lysine	15820770
.	15820770

These	15820770
DBP	15820770
variants	15820770
lead	15820770
to	15820770
differences	15820770
in	15820770
the	15820770
affinity	15820770
for	15820770
1	15820770
.	15820770
25	15820770
(	15820770
OH	15820770
)	15820770
2D3	15820770
.	15820770

Correlations	15820770
between	15820770
DBP	15820770
alleles	15820770
and	15820770
type	15820770
1	15820770
diabetes	15820770
have	15820770
been	15820770
described	15820770
in	15820770
different	15820770
populations	15820770
.	15820770

Therefore	15820770
,	15820770
we	15820770
investigated	15820770
the	15820770
polymorphism	15820770
in	15820770
codon	15820770
416	15820770
of	15820770
the	15820770
DBP	15820770
gene	15820770
for	15820770
an	15820770
association	15820770
with	15820770
autoimmune	15820770
markers	15820770
of	15820770
type	15820770
1	15820770
diabetes	15820770
.	15820770

DESIGN	15820770
AND	15820770
METHODS	15820770
:	15820770
The	15820770
present	15820770
analysis	15820770
was	15820770
a	15820770
case	15820770
control	15820770
study	15820770
.	15820770

110	15820770
patients	15820770
,	15820770
68	15820770
controls	15820770
,	15820770
and	15820770
115	15820770
first	15820770
-	15820770
degree	15820770
relatives	15820770
were	15820770
genotyped	15820770
for	15820770
the	15820770
DBP	15820770
polymorphism	15820770
in	15820770
codon	15820770
416	15820770
.	15820770

DNA	15820770
typing	15820770
of	15820770
DBP	15820770
locus	15820770
was	15820770
performed	15820770
by	15820770
the	15820770
PCR	15820770
-	15820770
restriction	15820770
fragment	15820770
length	15820770
polymorphism	15820770
method	15820770
(	15820770
RFLP	15820770
)	15820770
.	15820770

RESULTS	15820770
:	15820770
The	15820770
frequencies	15820770
of	15820770
the	15820770
Asp	15820770
/	15820770
Glu	15820770
and	15820770
Glu	15820770
/	15820770
Glu	15820770
were	15820770
significantly	15820770
increased	15820770
in	15820770
diabetic	15820770
subjects	15820770
with	15820770
detectable	15820770
IA	15820770
-	15820770
2	15820770
antibodies	15820770
(	15820770
P	15820770
<	15820770
0	15820770
.	15820770
01	15820770
)	15820770
.	15820770

On	15820770
the	15820770
contrary	15820770
,	15820770
the	15820770
DBP	15820770
Glu	15820770
-	15820770
containing	15820770
genotype	15820770
was	15820770
not	15820770
accompanied	15820770
by	15820770
differences	15820770
in	15820770
the	15820770
prevalence	15820770
of	15820770
GAD65	15820770
antibodies	15820770
.	15820770

These	15820770
finding	15820770
supports	15820770
a	15820770
role	15820770
of	15820770
the	15820770
vitamin	15820770
D	15820770
endocrine	15820770
system	15820770
in	15820770
the	15820770
autoimmune	15820770
process	15820770
of	15820770
type	15820770
1	15820770
diabetes	15820770
.	15820770
Deletion	28346429
of	28346429
endothelial	28346429
cell	28346429
-	28346429
specific	28346429
liver	28346429
kinase	28346429
B1	28346429
increases	28346429
angiogenesis	28346429
and	28346429
tumor	28346429
growth	28346429
via	28346429
vascular	28346429
endothelial	28346429
growth	28346429
factor	28346429
.	28346429

Liver	28346429
kinase	28346429
B1	28346429
(	28346429
LKB1	28346429
)	28346429
is	28346429
a	28346429
serine	28346429
/	28346429
threonine	28346429
protein	28346429
kinase	28346429
ubiquitously	28346429
expressed	28346429
in	28346429
mammalian	28346429
cells	28346429
.	28346429

It	28346429
was	28346429
first	28346429
identified	28346429
in	28346429
Peutz	28346429
-	28346429
Jeghers	28346429
syndrome	28346429
as	28346429
a	28346429
tumor	28346429
suppressor	28346429
gene	28346429
.	28346429

Whether	28346429
endothelial	28346429
LKB1	28346429
regulates	28346429
angiogenesis	28346429
and	28346429
tumor	28346429
growth	28346429
is	28346429
unknown	28346429
.	28346429

In	28346429
this	28346429
study	28346429
,	28346429
we	28346429
generated	28346429
endothelial	28346429
cell	28346429
-	28346429
specific	28346429
LKB1	28346429
-	28346429
knockout	28346429
(	28346429
LKB1	28346429
(	28346429
endo	28346429
-	28346429
/	28346429
-	28346429
)	28346429
)	28346429
mice	28346429
by	28346429
crossbreeding	28346429
vascular	28346429
endothelial	28346429
-	28346429
cadherin	28346429
-	28346429
Cre	28346429
mice	28346429
with	28346429
LKB1	28346429
(	28346429
flox	28346429
/	28346429
flox	28346429
)	28346429
mice	28346429
.	28346429

Vascular	28346429
endothelial	28346429
growth	28346429
factor	28346429
(	28346429
VEGF	28346429
)	28346429
level	28346429
was	28346429
highly	28346429
co	28346429
-	28346429
stained	28346429
in	28346429
endothelial	28346429
cells	28346429
but	28346429
not	28346429
in	28346429
macrophages	28346429
in	28346429
LKB1	28346429
(	28346429
endo	28346429
-	28346429
/	28346429
-	28346429
)	28346429
mice	28346429
.	28346429

Consistently	28346429
,	28346429
LKB1	28346429
(	28346429
endo	28346429
-	28346429
/	28346429
-	28346429
)	28346429
mouse	28346429
tissues	28346429
including	28346429
the	28346429
lung	28346429
,	28346429
skin	28346429
,	28346429
kidney	28346429
and	28346429
liver	28346429
showed	28346429
increased	28346429
vascular	28346429
permeability	28346429
.	28346429

Tumors	28346429
implanted	28346429
in	28346429
LKB1	28346429
(	28346429
endo	28346429
-	28346429
/	28346429
-	28346429
)	28346429
mice	28346429
but	28346429
not	28346429
macrophage	28346429
-	28346429
specific	28346429
LKB1	28346429
-	28346429
knockout	28346429
mice	28346429
grew	28346429
faster	28346429
and	28346429
showed	28346429
enhanced	28346429
vascular	28346429
permeability	28346429
and	28346429
increased	28346429
angiogenesis	28346429
as	28346429
compared	28346429
with	28346429
those	28346429
implanted	28346429
in	28346429
wild	28346429
-	28346429
type	28346429
mice	28346429
.	28346429

Injection	28346429
of	28346429
VEGF	28346429
-	28346429
neutralizing	28346429
antibody	28346429
but	28346429
not	28346429
the	28346429
isotype	28346429
-	28346429
matched	28346429
control	28346429
antibody	28346429
decreased	28346429
endothelial	28346429
-	28346429
cell	28346429
angiogenesis	28346429
and	28346429
tumor	28346429
growth	28346429
in	28346429
vivo	28346429
.	28346429

Furthermore	28346429
,	28346429
LKB1	28346429
deletion	28346429
enhanced	28346429
mouse	28346429
retinal	28346429
and	28346429
cell	28346429
angiogenesis	28346429
,	28346429
and	28346429
knockdown	28346429
of	28346429
VEGF	28346429
by	28346429
small	28346429
-	28346429
interfering	28346429
RNA	28346429
decreased	28346429
endothelial	28346429
cell	28346429
proliferation	28346429
and	28346429
migration	28346429
.	28346429

Re	28346429
-	28346429
expression	28346429
of	28346429
LKB1	28346429
or	28346429
knockdown	28346429
of	28346429
VEGF	28346429
receptor	28346429
2	28346429
decreased	28346429
the	28346429
overproliferation	28346429
and	28346429
-	28346429
migration	28346429
observed	28346429
in	28346429
LKB1	28346429
(	28346429
endo	28346429
-	28346429
/	28346429
-	28346429
)	28346429
cells	28346429
.	28346429

Mechanistically	28346429
,	28346429
LKB1	28346429
could	28346429
bind	28346429
to	28346429
the	28346429
VEGF	28346429
transcription	28346429
factor	28346429
,	28346429
specificity	28346429
protein	28346429
1	28346429
(	28346429
Sp1	28346429
)	28346429
,	28346429
which	28346429
then	28346429
inhibited	28346429
the	28346429
binding	28346429
of	28346429
Sp1	28346429
to	28346429
the	28346429
VEGF	28346429
promoter	28346429
to	28346429
reduce	28346429
VEGF	28346429
expression	28346429
.	28346429

Endothelial	28346429
LKB1	28346429
may	28346429
regulate	28346429
endothelial	28346429
angiogenesis	28346429
and	28346429
tumor	28346429
growth	28346429
by	28346429
modulating	28346429
Sp1	28346429
-	28346429
mediated	28346429
VEGF	28346429
expression	28346429
.	28346429
Urinary	15130900
bladder	15130900
cancer	15130900
in	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
:	15130900
risks	15130900
and	15130900
relation	15130900
to	15130900
cyclophosphamide	15130900
.	15130900

OBJECTIVE	15130900
:	15130900
To	15130900
assess	15130900
and	15130900
characterise	15130900
the	15130900
risk	15130900
of	15130900
bladder	15130900
cancer	15130900
,	15130900
and	15130900
its	15130900
relation	15130900
to	15130900
cyclophosphamide	15130900
,	15130900
in	15130900
patients	15130900
with	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
.	15130900

METHODS	15130900
:	15130900
In	15130900
the	15130900
population	15130900
based	15130900
,	15130900
nationwide	15130900
Swedish	15130900
Inpatient	15130900
Register	15130900
a	15130900
cohort	15130900
of	15130900
1065	15130900
patients	15130900
with	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
,	15130900
1969	15130900
-	15130900
95	15130900
,	15130900
was	15130900
identified	15130900
.	15130900

Through	15130900
linkage	15130900
with	15130900
the	15130900
Swedish	15130900
Cancer	15130900
Register	15130900
,	15130900
all	15130900
subjects	15130900
in	15130900
this	15130900
cohort	15130900
diagnosed	15130900
with	15130900
bladder	15130900
cancer	15130900
were	15130900
identified	15130900
.	15130900

Nested	15130900
within	15130900
the	15130900
cohort	15130900
,	15130900
a	15130900
matched	15130900
case	15130900
-	15130900
control	15130900
study	15130900
was	15130900
performed	15130900
to	15130900
estimate	15130900
the	15130900
association	15130900
between	15130900
cyclophosphamide	15130900
and	15130900
bladder	15130900
cancer	15130900
using	15130900
odds	15130900
ratios	15130900
(	15130900
ORs	15130900
)	15130900
as	15130900
relative	15130900
risk	15130900
.	15130900

In	15130900
the	15130900
cohort	15130900
the	15130900
cumulative	15130900
risk	15130900
of	15130900
bladder	15130900
cancer	15130900
after	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
,	15130900
and	15130900
the	15130900
relative	15130900
prevalence	15130900
of	15130900
a	15130900
history	15130900
of	15130900
bladder	15130900
cancer	15130900
at	15130900
the	15130900
time	15130900
of	15130900
diagnosis	15130900
of	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
,	15130900
were	15130900
also	15130900
estimated	15130900
.	15130900

RESULTS	15130900
:	15130900
The	15130900
median	15130900
cumulative	15130900
doses	15130900
of	15130900
cyclophosphamide	15130900
among	15130900
cases	15130900
(	15130900
n	15130900
=	15130900
11	15130900
)	15130900
and	15130900
controls	15130900
(	15130900
n	15130900
=	15130900
25	15130900
)	15130900
were	15130900
113	15130900
g	15130900
and	15130900
25	15130900
g	15130900
,	15130900
respectively	15130900
.	15130900

The	15130900
risk	15130900
of	15130900
bladder	15130900
cancer	15130900
doubled	15130900
for	15130900
every	15130900
10	15130900
g	15130900
increment	15130900
in	15130900
cyclophosphamide	15130900
(	15130900
OR	15130900
=	15130900
2	15130900
.	15130900
0	15130900
,	15130900
95%	15130900
confidence	15130900
interval	15130900
(	15130900
CI	15130900
)	15130900
0	15130900
.	15130900
8	15130900
to	15130900
4	15130900
.	15130900
9	15130900
)	15130900
.	15130900

Treatment	15130900
duration	15130900
longer	15130900
than	15130900
1	15130900
year	15130900
was	15130900
associated	15130900
with	15130900
an	15130900
eightfold	15130900
increased	15130900
risk	15130900
(	15130900
OR	15130900
=	15130900
7	15130900
.	15130900
7	15130900
,	15130900
95%	15130900
CI	15130900
0	15130900
.	15130900
9	15130900
to	15130900
69	15130900
)	15130900
.	15130900

The	15130900
absolute	15130900
risk	15130900
for	15130900
bladder	15130900
cancer	15130900
in	15130900
the	15130900
cohort	15130900
reached	15130900
10%	15130900
16	15130900
years	15130900
after	15130900
diagnosis	15130900
of	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
,	15130900
and	15130900
a	15130900
history	15130900
of	15130900
bladder	15130900
cancer	15130900
was	15130900
(	15130900
non	15130900
-	15130900
significantly	15130900
)	15130900
twice	15130900
as	15130900
common	15130900
as	15130900
expected	15130900
at	15130900
the	15130900
time	15130900
of	15130900
diagnosis	15130900
of	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
.	15130900

CONCLUSION	15130900
:	15130900
The	15130900
results	15130900
indicate	15130900
a	15130900
dose	15130900
-	15130900
response	15130900
relationship	15130900
between	15130900
cyclophosphamide	15130900
and	15130900
the	15130900
risk	15130900
of	15130900
bladder	15130900
cancer	15130900
,	15130900
high	15130900
cumulative	15130900
risks	15130900
in	15130900
the	15130900
entire	15130900
cohort	15130900
,	15130900
and	15130900
also	15130900
the	15130900
possibility	15130900
of	15130900
risk	15130900
factors	15130900
operating	15130900
even	15130900
before	15130900
Wegener	15130900
'	15130900
s	15130900
granulomatosis	15130900
.	15130900
Mutation	19276632
analysis	19276632
of	19276632
FOXF2	19276632
in	19276632
patients	19276632
with	19276632
disorders	19276632
of	19276632
sex	19276632
development	19276632
(	19276632
DSD	19276632
)	19276632
in	19276632
combination	19276632
with	19276632
cleft	19276632
palate	19276632
.	19276632

In	19276632
contrast	19276632
to	19276632
disorders	19276632
of	19276632
sexual	19276632
differentiation	19276632
caused	19276632
by	19276632
lack	19276632
of	19276632
androgen	19276632
production	19276632
or	19276632
inhibited	19276632
androgen	19276632
action	19276632
,	19276632
defects	19276632
affecting	19276632
development	19276632
of	19276632
the	19276632
bipotent	19276632
genital	19276632
anlagen	19276632
have	19276632
rarely	19276632
been	19276632
investigated	19276632
in	19276632
humans	19276632
.	19276632

We	19276632
have	19276632
previously	19276632
documented	19276632
that	19276632
the	19276632
transcription	19276632
factor	19276632
FOXF2	19276632
is	19276632
highly	19276632
expressed	19276632
in	19276632
human	19276632
foreskin	19276632
.	19276632

Moreover	19276632
,	19276632
Foxf2	19276632
knockout	19276632
mice	19276632
present	19276632
with	19276632
cleft	19276632
palate	19276632
in	19276632
combination	19276632
with	19276632
hypoplasia	19276632
of	19276632
the	19276632
genital	19276632
tubercle	19276632
.	19276632

We	19276632
hypothesized	19276632
that	19276632
humans	19276632
with	19276632
disorders	19276632
of	19276632
sex	19276632
development	19276632
(	19276632
DSD	19276632
)	19276632
in	19276632
combination	19276632
with	19276632
cleft	19276632
palate	19276632
could	19276632
have	19276632
mutations	19276632
in	19276632
the	19276632
FOXF2	19276632
gene	19276632
.	19276632

Eighteen	19276632
children	19276632
with	19276632
DSD	19276632
and	19276632
cleft	19276632
palate	19276632
were	19276632
identified	19276632
in	19276632
the	19276632
L	19276632
beck	19276632
DSD	19276632
database	19276632
(	19276632
about	19276632
1	19276632
,	19276632
500	19276632
entries	19276632
)	19276632
.	19276632

Genomic	19276632
DNA	19276632
sequence	19276632
analysis	19276632
of	19276632
the	19276632
FOXF2	19276632
gene	19276632
was	19276632
performed	19276632
and	19276632
compared	19276632
with	19276632
10	19276632
normal	19276632
female	19276632
and	19276632
10	19276632
normal	19276632
male	19276632
controls	19276632
,	19276632
respectively	19276632
.	19276632

Two	19276632
heterozygous	19276632
DNA	19276632
sequence	19276632
variations	19276632
were	19276632
solely	19276632
present	19276632
in	19276632
one	19276632
single	19276632
patient	19276632
each	19276632
but	19276632
in	19276632
none	19276632
of	19276632
the	19276632
20	19276632
normal	19276632
controls	19276632
:	19276632
a	19276632
duplication	19276632
of	19276632
GCC	19276632
(	19276632
c	19276632
.	19276632
97GCC	19276632
[	19276632
9	19276632
]	19276632
+	19276632
[	19276632
10	19276632
]	19276632
)	19276632
resulting	19276632
in	19276632
an	19276632
extra	19276632
alanine	19276632
within	19276632
exon	19276632
1	19276632
and	19276632
a	19276632
25	19276632
*	19276632
G	19276632
>	19276632
A	19276632
substitution	19276632
in	19276632
the	19276632
3	19276632
'	19276632
-	19276632
untranslated	19276632
region	19276632
.	19276632

Two	19276632
patients	19276632
carried	19276632
a	19276632
c	19276632
.	19276632
262G	19276632
>	19276632
A	19276632
sequence	19276632
variation	19276632
predicting	19276632
for	19276632
an	19276632
Ala88Thr	19276632
exchange	19276632
which	19276632
was	19276632
also	19276632
detected	19276632
in	19276632
2	19276632
normal	19276632
controls	19276632
.	19276632

Two	19276632
silent	19276632
mutations	19276632
,	19276632
c	19276632
.	19276632
1272C	19276632
>	19276632
T	19276632
(	19276632
Ser424Ser	19276632
)	19276632
and	19276632
c	19276632
.	19276632
1284T	19276632
>	19276632
C	19276632
(	19276632
Tyr428Tyr	19276632
)	19276632
,	19276632
respectively	19276632
,	19276632
occurred	19276632
in	19276632
the	19276632
coding	19276632
region	19276632
of	19276632
exon	19276632
2	19276632
,	19276632
again	19276632
in	19276632
both	19276632
patients	19276632
and	19276632
normal	19276632
controls	19276632
.	19276632

In	19276632
conclusion	19276632
,	19276632
the	19276632
majority	19276632
of	19276632
the	19276632
detected	19276632
sequence	19276632
alterations	19276632
were	19276632
polymorphisms	19276632
without	19276632
obvious	19276632
functional	19276632
relevance	19276632
.	19276632

However	19276632
,	19276632
it	19276632
cannot	19276632
be	19276632
excluded	19276632
that	19276632
the	19276632
2	19276632
unique	19276632
DNA	19276632
sequence	19276632
alterations	19276632
could	19276632
have	19276632
affected	19276632
FOXF2	19276632
on	19276632
the	19276632
mRNA	19276632
or	19276632
protein	19276632
level	19276632
thus	19276632
contributing	19276632
to	19276632
the	19276632
observed	19276632
disturbances	19276632
in	19276632
genital	19276632
and	19276632
palate	19276632
development	19276632
.	19276632
Melanocortin	19463742
-	19463742
4	19463742
receptor	19463742
activation	19463742
inhibits	19463742
c	19463742
-	19463742
Jun	19463742
N	19463742
-	19463742
terminal	19463742
kinase	19463742
activity	19463742
and	19463742
promotes	19463742
insulin	19463742
signaling	19463742
.	19463742

The	19463742
melanocortin	19463742
system	19463742
is	19463742
crucial	19463742
to	19463742
regulation	19463742
of	19463742
energy	19463742
homeostasis	19463742
.	19463742

The	19463742
melanocortin	19463742
receptor	19463742
type	19463742
4	19463742
(	19463742
MC4R	19463742
)	19463742
modulates	19463742
insulin	19463742
signaling	19463742
via	19463742
effects	19463742
on	19463742
c	19463742
-	19463742
Jun	19463742
N	19463742
-	19463742
terminal	19463742
kinase	19463742
(	19463742
JNK	19463742
)	19463742
.	19463742

The	19463742
melanocortin	19463742
agonist	19463742
NDP	19463742
-	19463742
MSH	19463742
dose	19463742
-	19463742
dependently	19463742
inhibited	19463742
JNK	19463742
activity	19463742
in	19463742
HEK293	19463742
cells	19463742
stably	19463742
expressing	19463742
the	19463742
human	19463742
MC4R	19463742
;	19463742
effects	19463742
were	19463742
reversed	19463742
by	19463742
melanocortin	19463742
receptor	19463742
antagonist	19463742
.	19463742

NDP	19463742
-	19463742
MSH	19463742
time	19463742
-	19463742
and	19463742
dose	19463742
-	19463742
dependently	19463742
inhibited	19463742
IRS	19463742
-	19463742
1	19463742
(	19463742
ser307	19463742
)	19463742
phosphorylation	19463742
,	19463742
effects	19463742
also	19463742
reversed	19463742
by	19463742
a	19463742
specific	19463742
melanocortin	19463742
receptor	19463742
antagonist	19463742
.	19463742

NDP	19463742
-	19463742
MSH	19463742
augmented	19463742
insulin	19463742
-	19463742
stimulated	19463742
AKT	19463742
phosphorylation	19463742
in	19463742
vitro	19463742
.	19463742

The	19463742
melanocortin	19463742
agonist	19463742
melanotan	19463742
II	19463742
increased	19463742
insulin	19463742
-	19463742
stimulated	19463742
AKT	19463742
phosphorylation	19463742
in	19463742
the	19463742
rat	19463742
hypothalamus	19463742
in	19463742
vivo	19463742
.	19463742

NDP	19463742
-	19463742
MSH	19463742
increased	19463742
insulin	19463742
-	19463742
stimulated	19463742
glucose	19463742
uptake	19463742
in	19463742
hypothalamic	19463742
GT1	19463742
-	19463742
1	19463742
cells	19463742
.	19463742

The	19463742
current	19463742
study	19463742
shows	19463742
that	19463742
the	19463742
melanocortinergic	19463742
system	19463742
interacts	19463742
with	19463742
insulin	19463742
signaling	19463742
via	19463742
novel	19463742
effects	19463742
on	19463742
JNK	19463742
activity	19463742
.	19463742
Recovery	18503483
of	18503483
tacrolimus	18503483
-	18503483
associated	18503483
brachial	18503483
neuritis	18503483
after	18503483
conversion	18503483
to	18503483
everolimus	18503483
in	18503483
a	18503483
pediatric	18503483
renal	18503483
transplant	18503483
recipient	18503483
-	18503483
-	18503483
case	18503483
report	18503483
and	18503483
review	18503483
of	18503483
the	18503483
literature	18503483
.	18503483

TAC	18503483
has	18503483
been	18503483
shown	18503483
to	18503483
be	18503483
a	18503483
potent	18503483
immunosuppressive	18503483
agent	18503483
for	18503483
solid	18503483
organ	18503483
transplantation	18503483
in	18503483
pediatrics	18503483
.	18503483

Neurotoxicity	18503483
is	18503483
a	18503483
potentially	18503483
serious	18503483
toxic	18503483
effect	18503483
.	18503483

It	18503483
is	18503483
characterized	18503483
by	18503483
encephalopathy	18503483
,	18503483
headaches	18503483
,	18503483
seizures	18503483
,	18503483
or	18503483
neurological	18503483
deficits	18503483
.	18503483

Here	18503483
,	18503483
we	18503483
describe	18503483
an	18503483
eight	18503483
-	18503483
and	18503483
-	18503483
a	18503483
-	18503483
half	18503483
-	18503483
yr	18503483
-	18503483
old	18503483
male	18503483
renal	18503483
transplant	18503483
recipient	18503483
with	18503483
right	18503483
BN	18503483
.	18503483

MRI	18503483
demonstrated	18503483
hyperintense	18503483
T2	18503483
signals	18503483
in	18503483
the	18503483
cervical	18503483
cord	18503483
and	18503483
right	18503483
brachial	18503483
plexus	18503483
roots	18503483
indicative	18503483
of	18503483
both	18503483
myelitis	18503483
and	18503483
right	18503483
brachial	18503483
plexitis	18503483
.	18503483

Symptoms	18503483
persisted	18503483
for	18503483
three	18503483
months	18503483
despite	18503483
TAC	18503483
dose	18503483
reduction	18503483
,	18503483
administration	18503483
of	18503483
IVIG	18503483
and	18503483
four	18503483
doses	18503483
of	18503483
methylprednisolone	18503483
pulse	18503483
therapy	18503483
.	18503483

Improvement	18503483
and	18503483
eventually	18503483
full	18503483
recovery	18503483
only	18503483
occurred	18503483
after	18503483
TAC	18503483
was	18503483
completely	18503483
discontinued	18503483
and	18503483
successfully	18503483
replaced	18503483
by	18503483
everolimus	18503483
.	18503483
A	21126715
Taiwanese	21126715
boy	21126715
with	21126715
congenital	21126715
generalized	21126715
lipodystrophy	21126715
caused	21126715
by	21126715
homozygous	21126715
Ile262fs	21126715
mutation	21126715
in	21126715
the	21126715
BSCL2	21126715
gene	21126715
.	21126715

Congenital	21126715
generalized	21126715
lipodystrophy	21126715
(	21126715
CGL	21126715
)	21126715
is	21126715
a	21126715
rare	21126715
autosomal	21126715
recessive	21126715
disease	21126715
that	21126715
is	21126715
characterized	21126715
by	21126715
a	21126715
near	21126715
-	21126715
complete	21126715
absence	21126715
of	21126715
adipose	21126715
tissue	21126715
from	21126715
birth	21126715
or	21126715
early	21126715
infancy	21126715
.	21126715

Mutations	21126715
in	21126715
the	21126715
BSCL2	21126715
gene	21126715
are	21126715
known	21126715
to	21126715
result	21126715
in	21126715
CGL2	21126715
,	21126715
a	21126715
more	21126715
severe	21126715
phenotype	21126715
than	21126715
CGL1	21126715
,	21126715
with	21126715
earlier	21126715
onset	21126715
,	21126715
more	21126715
extensive	21126715
fat	21126715
loss	21126715
and	21126715
biochemical	21126715
changes	21126715
,	21126715
more	21126715
severe	21126715
intellectual	21126715
impairment	21126715
,	21126715
and	21126715
more	21126715
severe	21126715
cardiomyopathy	21126715
.	21126715

We	21126715
report	21126715
a	21126715
3	21126715
-	21126715
month	21126715
-	21126715
old	21126715
Taiwanese	21126715
boy	21126715
with	21126715
initial	21126715
presentation	21126715
of	21126715
a	21126715
lack	21126715
of	21126715
subcutaneous	21126715
fat	21126715
,	21126715
prominent	21126715
musculature	21126715
,	21126715
generalized	21126715
eruptive	21126715
xanthomas	21126715
,	21126715
and	21126715
extreme	21126715
hypertriglyceridemia	21126715
.	21126715

Absence	21126715
of	21126715
mechanical	21126715
adipose	21126715
tissue	21126715
in	21126715
the	21126715
orbits	21126715
and	21126715
scalp	21126715
was	21126715
revealed	21126715
by	21126715
head	21126715
magnetic	21126715
resonance	21126715
imaging	21126715
.	21126715

Hepatomegaly	21126715
was	21126715
noticed	21126715
,	21126715
and	21126715
histological	21126715
examination	21126715
of	21126715
a	21126715
liver	21126715
biopsy	21126715
specimen	21126715
suggested	21126715
severe	21126715
hepatic	21126715
steatosis	21126715
and	21126715
periportal	21126715
necrosis	21126715
.	21126715

However	21126715
,	21126715
echocardiography	21126715
indicated	21126715
no	21126715
sign	21126715
of	21126715
cardiomyopathy	21126715
and	21126715
he	21126715
showed	21126715
no	21126715
distinct	21126715
intellectual	21126715
impairment	21126715
that	21126715
interfered	21126715
with	21126715
daily	21126715
life	21126715
.	21126715

About	21126715
1	21126715
year	21126715
later	21126715
,	21126715
abdominal	21126715
computed	21126715
tomography	21126715
revealed	21126715
enlargement	21126715
of	21126715
kidneys	21126715
.	21126715

He	21126715
had	21126715
a	21126715
homozygous	21126715
insertion	21126715
of	21126715
a	21126715
nucleotide	21126715
,	21126715
783insG	21126715
(	21126715
Ile262fs	21126715
mutation	21126715
)	21126715
,	21126715
in	21126715
exon	21126715
7	21126715
of	21126715
the	21126715
BSCL2	21126715
gene	21126715
.	21126715

We	21126715
reviewed	21126715
the	21126715
genotype	21126715
of	21126715
CGL	21126715
cases	21126715
from	21126715
Japan	21126715
,	21126715
India	21126715
,	21126715
China	21126715
and	21126715
Taiwan	21126715
,	21126715
and	21126715
found	21126715
that	21126715
BSCL2	21126715
is	21126715
a	21126715
major	21126715
causative	21126715
gene	21126715
for	21126715
CGL	21126715
in	21126715
Asian	21126715
.	21126715
Pleomorphic	28259923
adenoma	28259923
gene	28259923
like	28259923
-	28259923
2	28259923
induces	28259923
epithelial	28259923
-	28259923
mesenchymal	28259923
transition	28259923
via	28259923
Wnt	28259923
/	28259923
b	28259923
-	28259923
catenin	28259923
signaling	28259923
pathway	28259923
in	28259923
human	28259923
colorectal	28259923
adenocarcinoma	28259923
.	28259923

Epithelial	28259923
-	28259923
mesenchymal	28259923
transition	28259923
(	28259923
EMT	28259923
)	28259923
is	28259923
a	28259923
critical	28259923
step	28259923
in	28259923
the	28259923
acquisition	28259923
of	28259923
metastatic	28259923
and	28259923
invasive	28259923
power	28259923
for	28259923
tumor	28259923
cells	28259923
.	28259923

Colorectal	28259923
adenocarcinoma	28259923
(	28259923
CRC	28259923
)	28259923
is	28259923
a	28259923
common	28259923
cancer	28259923
where	28259923
metastasis	28259923
is	28259923
directly	28259923
linked	28259923
to	28259923
patient	28259923
survival	28259923
.	28259923

Recent	28259923
studies	28259923
show	28259923
that	28259923
pleomorphic	28259923
adenoma	28259923
gene	28259923
like	28259923
-	28259923
2	28259923
(	28259923
PLAGL2	28259923
)	28259923
could	28259923
induce	28259923
tumor	28259923
EMT	28259923
and	28259923
is	28259923
an	28259923
independent	28259923
predictive	28259923
factor	28259923
associated	28259923
with	28259923
poor	28259923
prognosis	28259923
in	28259923
cancer	28259923
.	28259923

In	28259923
the	28259923
present	28259923
study	28259923
,	28259923
we	28259923
confirmed	28259923
the	28259923
role	28259923
of	28259923
PLAGL2	28259923
in	28259923
the	28259923
prognosis	28259923
of	28259923
CRC	28259923
patients	28259923
and	28259923
provide	28259923
molecular	28259923
evidence	28259923
of	28259923
PLAGL2	28259923
promoted	28259923
EMT	28259923
in	28259923
CRC	28259923
cell	28259923
line	28259923
SW480	28259923
.	28259923

We	28259923
found	28259923
that	28259923
PLAGL2	28259923
expression	28259923
was	28259923
upregulated	28259923
in	28259923
the	28259923
paraffin	28259923
-	28259923
embedded	28259923
CRC	28259923
tissues	28259923
compared	28259923
to	28259923
borderline	28259923
or	28259923
benign	28259923
tissues	28259923
.	28259923

Experimental	28259923
EMT	28259923
induced	28259923
by	28259923
PLAGL2	28259923
plasmid	28259923
transfection	28259923
proved	28259923
PLAGL2	28259923
protein	28259923
overexpression	28259923
could	28259923
enhance	28259923
the	28259923
cell	28259923
scratch	28259923
wound	28259923
-	28259923
healing	28259923
and	28259923
transwell	28259923
ability	28259923
and	28259923
significantly	28259923
upregulated	28259923
mesenchymal	28259923
marker	28259923
proteins	28259923
,	28259923
N	28259923
-	28259923
cadherin	28259923
and	28259923
vimentin	28259923
and	28259923
concurrently	28259923
downregulated	28259923
epithelial	28259923
marker	28259923
of	28259923
E	28259923
-	28259923
cadherin	28259923
.	28259923

Subsequently	28259923
,	28259923
through	28259923
western	28259923
blot	28259923
assay	28259923
,	28259923
we	28259923
found	28259923
that	28259923
PLAGL2	28259923
could	28259923
activate	28259923
the	28259923
wnt	28259923
-	28259923
signaling	28259923
component	28259923
b	28259923
-	28259923
catenin	28259923
in	28259923
the	28259923
nuclei	28259923
.	28259923

More	28259923
CRC	28259923
cell	28259923
metastasis	28259923
to	28259923
the	28259923
lungs	28259923
was	28259923
observed	28259923
when	28259923
the	28259923
PLAGL2	28259923
overexpressing	28259923
SW480	28259923
cells	28259923
were	28259923
injected	28259923
into	28259923
the	28259923
tail	28259923
vein	28259923
of	28259923
rats	28259923
,	28259923
compared	28259923
with	28259923
the	28259923
cell	28259923
control	28259923
and	28259923
PLAGL2	28259923
silence	28259923
group	28259923
.	28259923

Our	28259923
findings	28259923
indicated	28259923
that	28259923
PLAGL2	28259923
might	28259923
be	28259923
a	28259923
very	28259923
upstream	28259923
key	28259923
molecule	28259923
regulating	28259923
EMT	28259923
involved	28259923
in	28259923
Wnt	28259923
/	28259923
b	28259923
-	28259923
catenin	28259923
signaling	28259923
pathway	28259923
.	28259923
Calcium	28518143
sensing	28518143
receptor	28518143
protects	28518143
high	28518143
glucose	28518143
-	28518143
induced	28518143
energy	28518143
metabolism	28518143
disorder	28518143
via	28518143
blocking	28518143
gp78	28518143
-	28518143
ubiquitin	28518143
proteasome	28518143
pathway	28518143
.	28518143

Diabetic	28518143
cardiomyopathy	28518143
(	28518143
DCM	28518143
)	28518143
is	28518143
a	28518143
major	28518143
complication	28518143
and	28518143
fatal	28518143
cause	28518143
of	28518143
the	28518143
patients	28518143
with	28518143
diabetes	28518143
.	28518143

The	28518143
calcium	28518143
sensing	28518143
receptor	28518143
(	28518143
CaSR	28518143
)	28518143
is	28518143
a	28518143
G	28518143
protein	28518143
-	28518143
coupled	28518143
receptor	28518143
,	28518143
which	28518143
is	28518143
involved	28518143
in	28518143
maintaining	28518143
calcium	28518143
homeostasis	28518143
,	28518143
regulating	28518143
cell	28518143
proliferation	28518143
and	28518143
apoptosis	28518143
,	28518143
and	28518143
so	28518143
on	28518143
.	28518143

In	28518143
our	28518143
previous	28518143
study	28518143
,	28518143
we	28518143
found	28518143
that	28518143
CaSR	28518143
expression	28518143
,	28518143
intracellular	28518143
calcium	28518143
levels	28518143
and	28518143
cardiac	28518143
function	28518143
were	28518143
all	28518143
significantly	28518143
decreased	28518143
in	28518143
DCM	28518143
rats	28518143
;	28518143
however	28518143
,	28518143
the	28518143
exact	28518143
mechanism	28518143
are	28518143
not	28518143
clear	28518143
yet	28518143
.	28518143

The	28518143
present	28518143
study	28518143
revealed	28518143
the	28518143
protective	28518143
role	28518143
of	28518143
CaSR	28518143
in	28518143
myocardial	28518143
energy	28518143
metabolism	28518143
disorder	28518143
induced	28518143
by	28518143
high	28518143
glucose	28518143
(	28518143
HG	28518143
)	28518143
as	28518143
well	28518143
as	28518143
the	28518143
underlying	28518143
mechanism	28518143
.	28518143

Here	28518143
,	28518143
we	28518143
demonstrated	28518143
that	28518143
HG	28518143
decreased	28518143
the	28518143
expression	28518143
of	28518143
CaSR	28518143
,	28518143
mitochondrial	28518143
fusion	28518143
proteins	28518143
(	28518143
Mfn1	28518143
,	28518143
Mfn2	28518143
)	28518143
,	28518143
cell	28518143
gap	28518143
junction	28518143
related	28518143
proteins	28518143
(	28518143
Cx43	28518143
,	28518143
beta	28518143
-	28518143
catenin	28518143
,	28518143
N	28518143
-	28518143
cadherin	28518143
)	28518143
,	28518143
and	28518143
intracellular	28518143
ATP	28518143
concentration	28518143
.	28518143

In	28518143
contrast	28518143
,	28518143
HG	28518143
increased	28518143
extracellular	28518143
ATP	28518143
concentration	28518143
,	28518143
the	28518143
expression	28518143
of	28518143
gp78	28518143
,	28518143
mitochondrial	28518143
fission	28518143
proteins	28518143
(	28518143
Fis1	28518143
,	28518143
Drp1	28518143
)	28518143
,	28518143
and	28518143
the	28518143
ubiquitination	28518143
levels	28518143
of	28518143
Mfn1	28518143
,	28518143
Mfn2	28518143
and	28518143
Cx43	28518143
.	28518143

Moreover	28518143
,	28518143
CaSR	28518143
agonist	28518143
and	28518143
gp78	28518143
-	28518143
siRNA	28518143
significantly	28518143
reduced	28518143
the	28518143
above	28518143
changes	28518143
.	28518143

Taken	28518143
together	28518143
,	28518143
these	28518143
results	28518143
suggest	28518143
that	28518143
HG	28518143
induces	28518143
myocardial	28518143
energy	28518143
metabolism	28518143
disorder	28518143
via	28518143
decrease	28518143
of	28518143
CaSR	28518143
expression	28518143
,	28518143
and	28518143
activation	28518143
of	28518143
gp78	28518143
-	28518143
ubiquitin	28518143
proteasome	28518143
system	28518143
.	28518143

In	28518143
turn	28518143
,	28518143
these	28518143
effects	28518143
disrupt	28518143
the	28518143
structure	28518143
and	28518143
function	28518143
of	28518143
the	28518143
mitochondria	28518143
and	28518143
the	28518143
cell	28518143
gap	28518143
junction	28518143
,	28518143
result	28518143
in	28518143
the	28518143
reduced	28518143
ATP	28518143
synthesis	28518143
and	28518143
the	28518143
increased	28518143
ATP	28518143
leakage	28518143
.	28518143

Stimulation	28518143
of	28518143
CaSR	28518143
significantly	28518143
attenuates	28518143
HG	28518143
-	28518143
induced	28518143
abnormal	28518143
myocardial	28518143
energy	28518143
metabolism	28518143
,	28518143
suggesting	28518143
CaSR	28518143
would	28518143
be	28518143
a	28518143
promising	28518143
potential	28518143
therapeutic	28518143
target	28518143
for	28518143
DCM	28518143
.	28518143
Mutations	17595233
in	17595233
pattern	17595233
recognition	17595233
receptor	17595233
genes	17595233
modulate	17595233
seroreactivity	17595233
to	17595233
microbial	17595233
antigens	17595233
in	17595233
patients	17595233
with	17595233
inflammatory	17595233
bowel	17595233
disease	17595233
.	17595233

BACKGROUND	17595233
AND	17595233
AIMS	17595233
:	17595233
A	17595233
number	17595233
of	17595233
antibodies	17595233
against	17595233
microbial	17595233
epitopes	17595233
or	17595233
self	17595233
-	17595233
antigens	17595233
have	17595233
been	17595233
associated	17595233
with	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
.	17595233

The	17595233
development	17595233
of	17595233
antibodies	17595233
reflects	17595233
a	17595233
loss	17595233
of	17595233
tolerance	17595233
to	17595233
intestinal	17595233
bacteria	17595233
that	17595233
underlies	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
,	17595233
resulting	17595233
in	17595233
an	17595233
exaggerated	17595233
adaptive	17595233
immune	17595233
response	17595233
to	17595233
these	17595233
bacteria	17595233
.	17595233

It	17595233
was	17595233
hypothesised	17595233
that	17595233
the	17595233
development	17595233
of	17595233
antimicrobial	17595233
antibodies	17595233
is	17595233
influenced	17595233
by	17595233
the	17595233
presence	17595233
of	17595233
genetic	17595233
variants	17595233
in	17595233
pattern	17595233
recognition	17595233
receptor	17595233
genes	17595233
.	17595233

The	17595233
aim	17595233
of	17595233
this	17595233
study	17595233
was	17595233
therefore	17595233
to	17595233
investigate	17595233
the	17595233
influence	17595233
of	17595233
mutations	17595233
in	17595233
these	17595233
innate	17595233
immune	17595233
receptor	17595233
genes	17595233
(	17595233
nucleotide	17595233
oligomerisation	17595233
domain	17595233
(	17595233
NOD	17595233
)	17595233
2	17595233
/	17595233
caspase	17595233
recruitment	17595233
domain	17595233
(	17595233
CARD	17595233
)	17595233
15	17595233
,	17595233
NOD1	17595233
/	17595233
CARD4	17595233
,	17595233
TUCAN	17595233
/	17595233
CARDINAL	17595233
/	17595233
CARD8	17595233
,	17595233
Toll	17595233
-	17595233
like	17595233
receptor	17595233
(	17595233
TLR	17595233
)	17595233
4	17595233
,	17595233
TLR2	17595233
,	17595233
TLR1	17595233
and	17595233
TLR6	17595233
)	17595233
on	17595233
the	17595233
development	17595233
of	17595233
antimicrobial	17595233
and	17595233
antiglycan	17595233
antibodies	17595233
in	17595233
inflammatory	17595233
bowel	17595233
disease	17595233
(	17595233
IBD	17595233
)	17595233
.	17595233

Materials	17595233
and	17595233
METHODS	17595233
:	17595233
A	17595233
cohort	17595233
of	17595233
1163	17595233
unrelated	17595233
patients	17595233
with	17595233
IBD	17595233
(	17595233
874	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
,	17595233
259	17595233
ulcerative	17595233
colitis	17595233
,	17595233
30	17595233
indeterminate	17595233
colitis	17595233
)	17595233
and	17595233
312	17595233
controls	17595233
were	17595233
analysed	17595233
for	17595233
anti	17595233
-	17595233
Saccharomyces	17595233
cerevisiae	17595233
antibodies	17595233
(	17595233
gASCA	17595233
)	17595233
IgG	17595233
,	17595233
anti	17595233
-	17595233
laminaribioside	17595233
antibodies	17595233
(	17595233
ALCA	17595233
)	17595233
IgG	17595233
,	17595233
anti	17595233
-	17595233
chitobioside	17595233
antibodies	17595233
(	17595233
ACCA	17595233
)	17595233
IgA	17595233
,	17595233
anti	17595233
-	17595233
mannobioside	17595233
antibodies	17595233
(	17595233
AMCA	17595233
)	17595233
IgG	17595233
and	17595233
outer	17595233
membrane	17595233
porin	17595233
(	17595233
Omp	17595233
)	17595233
IgA	17595233
and	17595233
were	17595233
genotyped	17595233
for	17595233
variants	17595233
in	17595233
NOD2	17595233
/	17595233
CARD15	17595233
,	17595233
TUCAN	17595233
/	17595233
CARDINAL	17595233
/	17595233
CARD8	17595233
,	17595233
NOD1	17595233
/	17595233
CARD4	17595233
,	17595233
TLR4	17595233
,	17595233
TLR1	17595233
,	17595233
TLR2	17595233
and	17595233
TLR6	17595233
.	17595233

RESULTS	17595233
:	17595233
When	17595233
compared	17595233
with	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
patients	17595233
without	17595233
CARD15	17595233
mutations	17595233
,	17595233
the	17595233
presence	17595233
of	17595233
at	17595233
least	17595233
one	17595233
CARD15	17595233
variant	17595233
in	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
patients	17595233
more	17595233
frequently	17595233
led	17595233
to	17595233
gASCA	17595233
positivity	17595233
(	17595233
66	17595233
.	17595233
1%	17595233
versus	17595233
51	17595233
.	17595233
5%	17595233
,	17595233
p	17595233
<	17595233
0	17595233
.	17595233
0001	17595233
)	17595233
and	17595233
ALCA	17595233
positivity	17595233
(	17595233
43	17595233
.	17595233
3%	17595233
versus	17595233
34	17595233
.	17595233
9%	17595233
,	17595233
p	17595233
=	17595233
0	17595233
.	17595233
018	17595233
)	17595233
and	17595233
higher	17595233
gASCA	17595233
titers	17595233
(	17595233
85	17595233
.	17595233
7	17595233
versus	17595233
51	17595233
.	17595233
8	17595233
ELISA	17595233
units	17595233
,	17595233
p	17595233
<	17595233
0	17595233
.	17595233
0001	17595233
)	17595233
,	17595233
independent	17595233
of	17595233
ileal	17595233
involvement	17595233
.	17595233

A	17595233
gene	17595233
dosage	17595233
effect	17595233
,	17595233
with	17595233
increasing	17595233
gASCA	17595233
and	17595233
ALCA	17595233
positivity	17595233
for	17595233
patients	17595233
carrying	17595233
none	17595233
,	17595233
one	17595233
and	17595233
two	17595233
CARD15	17595233
variants	17595233
,	17595233
respectively	17595233
,	17595233
was	17595233
seen	17595233
for	17595233
both	17595233
markers	17595233
.	17595233

Similarly	17595233
,	17595233
Crohn	17595233
'	17595233
s	17595233
disease	17595233
patients	17595233
carrying	17595233
NOD1	17595233
/	17595233
CARD4	17595233
indel	17595233
had	17595233
a	17595233
higher	17595233
prevalence	17595233
of	17595233
gASCA	17595233
antibodies	17595233
than	17595233
wild	17595233
-	17595233
type	17595233
patients	17595233
(	17595233
63	17595233
.	17595233
8%	17595233
versus	17595233
55	17595233
.	17595233
2%	17595233
,	17595233
p	17595233
=	17595233
0	17595233
.	17595233
014	17595233
)	17595233
,	17595233
also	17595233
with	17595233
a	17595233
gene	17595233
dosage	17595233
effect	17595233
.	17595233

An	17595233
opposite	17595233
effect	17595233
was	17595233
observed	17595233
for	17595233
the	17595233
TLR4	17595233
D299G	17595233
and	17595233
TLR2	17595233
P631H	17595233
variants	17595233
,	17595233
with	17595233
a	17595233
lower	17595233
prevalence	17595233
of	17595233
ACCA	17595233
antibodies	17595233
(	17595233
23	17595233
.	17595233
4%	17595233
versus	17595233
35%	17595233
,	17595233
p	17595233
=	17595233
0	17595233
.	17595233
013	17595233
)	17595233
and	17595233
Omp	17595233
antibodies	17595233
(	17595233
20	17595233
.	17595233
5%	17595233
versus	17595233
34	17595233
.	17595233
6%	17595233
,	17595233
p	17595233
=	17595233
0	17595233
.	17595233
009	17595233
)	17595233
,	17595233
respectively	17595233
.	17595233

CONCLUSION	17595233
:	17595233
Variants	17595233
in	17595233
innate	17595233
immune	17595233
receptor	17595233
genes	17595233
were	17595233
found	17595233
to	17595233
influence	17595233
antibody	17595233
formation	17595233
against	17595233
microbial	17595233
epitopes	17595233
.	17595233

In	17595233
this	17595233
respect	17595233
,	17595233
it	17595233
is	17595233
intriguing	17595233
that	17595233
an	17595233
opposite	17595233
effect	17595233
of	17595233
CARD15	17595233
and	17595233
TLR4	17595233
variants	17595233
was	17595233
observed	17595233
.	17595233

These	17595233
findings	17595233
may	17595233
contribute	17595233
to	17595233
an	17595233
understanding	17595233
of	17595233
the	17595233
aetiology	17595233
of	17595233
the	17595233
seroreactivity	17595233
observed	17595233
in	17595233
IBD	17595233
.	17595233
Serotonin	20705401
6	20705401
receptor	20705401
gene	20705401
is	20705401
associated	20705401
with	20705401
methamphetamine	20705401
-	20705401
induced	20705401
psychosis	20705401
in	20705401
a	20705401
Japanese	20705401
population	20705401
.	20705401

BACKGROUND	20705401
:	20705401
Altered	20705401
serotonergic	20705401
neural	20705401
transmission	20705401
is	20705401
hypothesized	20705401
to	20705401
be	20705401
a	20705401
susceptibility	20705401
factor	20705401
for	20705401
psychotic	20705401
disorders	20705401
such	20705401
as	20705401
schizophrenia	20705401
.	20705401

The	20705401
serotonin	20705401
6	20705401
(	20705401
5	20705401
-	20705401
HT6	20705401
)	20705401
receptor	20705401
is	20705401
therapeutically	20705401
targeted	20705401
by	20705401
several	20705401
second	20705401
generation	20705401
antipsychotics	20705401
,	20705401
such	20705401
as	20705401
clozapine	20705401
and	20705401
olanzapine	20705401
,	20705401
and	20705401
d	20705401
-	20705401
amphetamine	20705401
-	20705401
induced	20705401
hyperactivity	20705401
in	20705401
rats	20705401
is	20705401
corrected	20705401
with	20705401
the	20705401
use	20705401
of	20705401
a	20705401
selective	20705401
5	20705401
-	20705401
HT6	20705401
receptor	20705401
antagonist	20705401
.	20705401

In	20705401
addition	20705401
,	20705401
the	20705401
disrupted	20705401
prepulse	20705401
inhibition	20705401
induced	20705401
by	20705401
d	20705401
-	20705401
amphetamine	20705401
or	20705401
phencyclidine	20705401
was	20705401
restored	20705401
by	20705401
5	20705401
-	20705401
HT6	20705401
receptor	20705401
antagonist	20705401
in	20705401
an	20705401
animal	20705401
study	20705401
using	20705401
rats	20705401
.	20705401

These	20705401
animal	20705401
models	20705401
were	20705401
considered	20705401
to	20705401
reflect	20705401
the	20705401
positive	20705401
symptoms	20705401
of	20705401
schizophrenia	20705401
,	20705401
and	20705401
the	20705401
above	20705401
evidence	20705401
suggests	20705401
that	20705401
altered	20705401
5	20705401
-	20705401
HT6	20705401
receptors	20705401
are	20705401
involved	20705401
in	20705401
the	20705401
pathophysiology	20705401
of	20705401
psychotic	20705401
disorders	20705401
.	20705401

The	20705401
symptoms	20705401
of	20705401
methamphetamine	20705401
(	20705401
METH	20705401
)	20705401
-	20705401
induced	20705401
psychosis	20705401
are	20705401
similar	20705401
to	20705401
those	20705401
of	20705401
paranoid	20705401
type	20705401
schizophrenia	20705401
.	20705401

Therefore	20705401
,	20705401
we	20705401
conducted	20705401
an	20705401
analysis	20705401
of	20705401
the	20705401
association	20705401
of	20705401
the	20705401
5	20705401
-	20705401
HT6	20705401
gene	20705401
(	20705401
HTR6	20705401
)	20705401
with	20705401
METH	20705401
-	20705401
induced	20705401
psychosis	20705401
.	20705401

METHOD	20705401
:	20705401
Using	20705401
five	20705401
tagging	20705401
SNPs	20705401
(	20705401
rs6693503	20705401
,	20705401
rs1805054	20705401
,	20705401
rs4912138	20705401
,	20705401
rs3790757	20705401
and	20705401
rs9659997	20705401
)	20705401
,	20705401
we	20705401
conducted	20705401
a	20705401
genetic	20705401
association	20705401
analysis	20705401
of	20705401
case	20705401
-	20705401
control	20705401
samples	20705401
(	20705401
197	20705401
METH	20705401
-	20705401
induced	20705401
psychosis	20705401
patients	20705401
and	20705401
337	20705401
controls	20705401
)	20705401
in	20705401
the	20705401
Japanese	20705401
population	20705401
.	20705401

The	20705401
age	20705401
and	20705401
sex	20705401
of	20705401
the	20705401
control	20705401
subjects	20705401
did	20705401
not	20705401
differ	20705401
from	20705401
those	20705401
of	20705401
the	20705401
methamphetamine	20705401
dependence	20705401
patients	20705401
.	20705401

RESULTS	20705401
:	20705401
rs6693503	20705401
was	20705401
associated	20705401
with	20705401
METH	20705401
-	20705401
induced	20705401
psychosis	20705401
patients	20705401
in	20705401
the	20705401
allele	20705401
/	20705401
genotype	20705401
-	20705401
wise	20705401
analysis	20705401
.	20705401

Moreover	20705401
,	20705401
this	20705401
association	20705401
remained	20705401
significant	20705401
after	20705401
Bonferroni	20705401
correction	20705401
.	20705401

In	20705401
the	20705401
haplotype	20705401
-	20705401
wise	20705401
analysis	20705401
,	20705401
we	20705401
detected	20705401
an	20705401
association	20705401
between	20705401
two	20705401
markers	20705401
(	20705401
rs6693503	20705401
and	20705401
rs1805054	20705401
)	20705401
and	20705401
three	20705401
markers	20705401
(	20705401
rs6693503	20705401
,	20705401
rs1805054	20705401
and	20705401
rs4912138	20705401
)	20705401
in	20705401
HTR6	20705401
and	20705401
METH	20705401
-	20705401
induced	20705401
psychosis	20705401
patients	20705401
,	20705401
respectively	20705401
.	20705401

CONCLUSION	20705401
:	20705401
HTR6	20705401
may	20705401
play	20705401
an	20705401
important	20705401
role	20705401
in	20705401
the	20705401
pathophysiology	20705401
of	20705401
METH	20705401
-	20705401
induced	20705401
psychosis	20705401
in	20705401
the	20705401
Japanese	20705401
population	20705401
.	20705401
Growth	19207031
hormone	19207031
dose	19207031
in	19207031
growth	19207031
hormone	19207031
-	19207031
deficient	19207031
adults	19207031
is	19207031
not	19207031
associated	19207031
with	19207031
IGF	19207031
-	19207031
1	19207031
gene	19207031
polymorphisms	19207031
.	19207031

AIMS	19207031
:	19207031
Several	19207031
SNPs	19207031
and	19207031
a	19207031
microsatellite	19207031
cytosine	19207031
-	19207031
adenine	19207031
repeat	19207031
promoter	19207031
polymorphism	19207031
of	19207031
the	19207031
IGF	19207031
-	19207031
1	19207031
gene	19207031
have	19207031
been	19207031
reported	19207031
to	19207031
be	19207031
associated	19207031
with	19207031
circulating	19207031
IGF	19207031
-	19207031
1	19207031
serum	19207031
concentrations	19207031
.	19207031

Variance	19207031
in	19207031
IGF	19207031
-	19207031
1	19207031
concentrations	19207031
due	19207031
to	19207031
genetic	19207031
variations	19207031
may	19207031
affect	19207031
different	19207031
response	19207031
to	19207031
growth	19207031
hormone	19207031
(	19207031
GH	19207031
)	19207031
treatment	19207031
,	19207031
resulting	19207031
in	19207031
different	19207031
individually	19207031
required	19207031
GH	19207031
-	19207031
doses	19207031
in	19207031
GH	19207031
-	19207031
deficient	19207031
patients	19207031
.	19207031

The	19207031
aim	19207031
of	19207031
this	19207031
study	19207031
was	19207031
to	19207031
test	19207031
if	19207031
the	19207031
IGF	19207031
-	19207031
1	19207031
gene	19207031
polymorphisms	19207031
are	19207031
associated	19207031
with	19207031
the	19207031
GH	19207031
-	19207031
dose	19207031
of	19207031
GH	19207031
-	19207031
deficient	19207031
adults	19207031
.	19207031

MATERIALS	19207031
&	19207031
METHODS	19207031
:	19207031
A	19207031
total	19207031
of	19207031
nine	19207031
tagging	19207031
SNPs	19207031
,	19207031
five	19207031
additionally	19207031
selected	19207031
SNPs	19207031
and	19207031
a	19207031
cytosine	19207031
-	19207031
adenine	19207031
repeat	19207031
polymorphism	19207031
were	19207031
determined	19207031
in	19207031
133	19207031
German	19207031
adult	19207031
patients	19207031
(	19207031
66	19207031
men	19207031
,	19207031
67	19207031
women	19207031
;	19207031
mean	19207031
age	19207031
45	19207031
.	19207031
4	19207031
years	19207031
+	19207031
/	19207031
-	19207031
13	19207031
.	19207031
1	19207031
standard	19207031
deviation	19207031
;	19207031
majority	19207031
Caucasian	19207031
)	19207031
with	19207031
GH	19207031
-	19207031
deficiency	19207031
(	19207031
GHD	19207031
)	19207031
of	19207031
different	19207031
origin	19207031
,	19207031
derived	19207031
from	19207031
the	19207031
prospective	19207031
Pfizer	19207031
International	19207031
Metabolic	19207031
Study	19207031
(	19207031
KIMS	19207031
)	19207031
Pharmacogenetics	19207031
Study	19207031
.	19207031

Patients	19207031
received	19207031
GH	19207031
-	19207031
treatment	19207031
for	19207031
12	19207031
months	19207031
with	19207031
finished	19207031
dose	19207031
-	19207031
titration	19207031
of	19207031
GH	19207031
and	19207031
centralized	19207031
IGF	19207031
-	19207031
1	19207031
measurements	19207031
.	19207031

GH	19207031
-	19207031
dose	19207031
after	19207031
1	19207031
year	19207031
of	19207031
treatment	19207031
,	19207031
IGF	19207031
-	19207031
1	19207031
concentrations	19207031
,	19207031
IGF	19207031
-	19207031
1	19207031
-	19207031
standard	19207031
deviation	19207031
score	19207031
(	19207031
SDS	19207031
)	19207031
,	19207031
the	19207031
IGF	19207031
-	19207031
1	19207031
:	19207031
GH	19207031
ratio	19207031
and	19207031
anthropometric	19207031
data	19207031
were	19207031
analyzed	19207031
by	19207031
genotype	19207031
.	19207031

RESULTS	19207031
:	19207031
Except	19207031
for	19207031
rs1019731	19207031
,	19207031
which	19207031
showed	19207031
a	19207031
significant	19207031
difference	19207031
of	19207031
IGF	19207031
-	19207031
1	19207031
-	19207031
SDS	19207031
by	19207031
genotypes	19207031
(	19207031
p	19207031
=	19207031
0	19207031
.	19207031
02	19207031
)	19207031
,	19207031
all	19207031
polymorphisms	19207031
showed	19207031
no	19207031
associations	19207031
with	19207031
the	19207031
GH	19207031
-	19207031
doses	19207031
,	19207031
IGF	19207031
-	19207031
1	19207031
concentrations	19207031
,	19207031
IGF	19207031
-	19207031
1	19207031
-	19207031
SDS	19207031
and	19207031
IGF	19207031
-	19207031
1	19207031
:	19207031
GH	19207031
ratio	19207031
after	19207031
adjusting	19207031
for	19207031
the	19207031
confounding	19207031
variables	19207031
gender	19207031
,	19207031
age	19207031
and	19207031
BMI	19207031
.	19207031

CONCLUSION	19207031
:	19207031
IGF	19207031
-	19207031
1	19207031
gene	19207031
polymorphisms	19207031
were	19207031
not	19207031
associated	19207031
with	19207031
the	19207031
responsiveness	19207031
to	19207031
exogenous	19207031
GH	19207031
in	19207031
GHD	19207031
.	19207031

Therefore	19207031
,	19207031
genetic	19207031
variations	19207031
of	19207031
the	19207031
IGF	19207031
-	19207031
1	19207031
gene	19207031
seem	19207031
not	19207031
to	19207031
be	19207031
major	19207031
influencing	19207031
factors	19207031
of	19207031
the	19207031
GH	19207031
-	19207031
IGF	19207031
-	19207031
axis	19207031
causing	19207031
variable	19207031
response	19207031
to	19207031
exogenous	19207031
GH	19207031
-	19207031
treatment	19207031
.	19207031
Fine	15459975
mapping	15459975
and	15459975
identification	15459975
of	15459975
a	15459975
candidate	15459975
gene	15459975
SSH1	15459975
in	15459975
disseminated	15459975
superficial	15459975
actinic	15459975
porokeratosis	15459975
.	15459975

Disseminated	15459975
superficial	15459975
actinic	15459975
porokeratosis	15459975
(	15459975
DSAP	15459975
)	15459975
is	15459975
an	15459975
uncommon	15459975
autosomal	15459975
dominant	15459975
chronic	15459975
keratinization	15459975
disorder	15459975
,	15459975
characterized	15459975
by	15459975
multiple	15459975
superficial	15459975
keratotic	15459975
lesions	15459975
surrounded	15459975
by	15459975
a	15459975
slightly	15459975
raised	15459975
keratotic	15459975
border	15459975
.	15459975

Thus	15459975
far	15459975
,	15459975
although	15459975
two	15459975
loci	15459975
for	15459975
DSAP	15459975
have	15459975
been	15459975
identified	15459975
,	15459975
the	15459975
genetic	15459975
basis	15459975
and	15459975
pathogenesis	15459975
of	15459975
this	15459975
disorder	15459975
have	15459975
not	15459975
been	15459975
elucidated	15459975
yet	15459975
.	15459975

In	15459975
this	15459975
study	15459975
,	15459975
we	15459975
performed	15459975
a	15459975
genome	15459975
-	15459975
wide	15459975
linkage	15459975
analysis	15459975
in	15459975
three	15459975
Chinese	15459975
affected	15459975
families	15459975
and	15459975
localized	15459975
the	15459975
gene	15459975
in	15459975
an	15459975
8	15459975
.	15459975
0	15459975
cM	15459975
interval	15459975
defined	15459975
by	15459975
D12S330	15459975
and	15459975
D12S354	15459975
on	15459975
chromosome	15459975
12	15459975
.	15459975

Upon	15459975
screening	15459975
30	15459975
candidate	15459975
genes	15459975
,	15459975
we	15459975
identified	15459975
a	15459975
missense	15459975
mutation	15459975
,	15459975
p	15459975
.	15459975
Ser63Asn	15459975
in	15459975
SSH1	15459975
in	15459975
one	15459975
family	15459975
,	15459975
a	15459975
frameshift	15459975
mutation	15459975
,	15459975
p	15459975
.	15459975
Ser19CysfsX24	15459975
in	15459975
an	15459975
alternative	15459975
variant	15459975
(	15459975
isoform	15459975
f	15459975
)	15459975
of	15459975
SSH1	15459975
in	15459975
another	15459975
family	15459975
,	15459975
and	15459975
a	15459975
frameshift	15459975
mutation	15459975
,	15459975
p	15459975
.	15459975
Pro27ProfsX54	15459975
in	15459975
the	15459975
same	15459975
alternative	15459975
variant	15459975
in	15459975
one	15459975
non	15459975
-	15459975
familial	15459975
case	15459975
with	15459975
DSAP	15459975
.	15459975

SSH1	15459975
encodes	15459975
a	15459975
phosphatase	15459975
that	15459975
plays	15459975
a	15459975
pivotal	15459975
role	15459975
in	15459975
actin	15459975
dynamics	15459975
.	15459975

Our	15459975
data	15459975
suggested	15459975
that	15459975
cytoskeleton	15459975
disorganization	15459975
in	15459975
epidermal	15459975
cells	15459975
is	15459975
likely	15459975
associated	15459975
with	15459975
the	15459975
pathogenesis	15459975
of	15459975
DSAP	15459975
.	15459975
Atorvastatin	28260077
protects	28260077
against	28260077
contrast	28260077
-	28260077
induced	28260077
nephropathy	28260077
via	28260077
anti	28260077
-	28260077
apoptosis	28260077
by	28260077
the	28260077
upregulation	28260077
of	28260077
Hsp27	28260077
in	28260077
vivo	28260077
and	28260077
in	28260077
vitro	28260077
.	28260077

Contrast	28260077
-	28260077
induced	28260077
nephropathy	28260077
(	28260077
CIN	28260077
)	28260077
is	28260077
an	28260077
iatrogenic	28260077
acute	28260077
renal	28260077
failure	28260077
occurring	28260077
following	28260077
the	28260077
intravascular	28260077
injection	28260077
of	28260077
iodinated	28260077
radiographic	28260077
contrast	28260077
medium	28260077
.	28260077

However	28260077
,	28260077
the	28260077
regulatory	28260077
mechanisms	28260077
for	28260077
CIN	28260077
remain	28260077
to	28260077
be	28260077
fully	28260077
elucidated	28260077
.	28260077

The	28260077
present	28260077
study	28260077
aimed	28260077
to	28260077
investigate	28260077
whether	28260077
atorvastatin	28260077
protects	28260077
against	28260077
CIN	28260077
via	28260077
anti	28260077
-	28260077
apoptotic	28260077
effects	28260077
by	28260077
the	28260077
upregulation	28260077
of	28260077
Hsp27	28260077
in	28260077
vivo	28260077
and	28260077
in	28260077
vitro	28260077
.	28260077

To	28260077
determine	28260077
whether	28260077
atorvastatin	28260077
attenuated	28260077
CIN	28260077
,	28260077
the	28260077
inflammatory	28260077
response	28260077
and	28260077
apoptosis	28260077
in	28260077
vivo	28260077
and	28260077
in	28260077
vitro	28260077
,	28260077
a	28260077
rat	28260077
model	28260077
of	28260077
iopamidol	28260077
-	28260077
induced	28260077
CIN	28260077
was	28260077
used	28260077
,	28260077
and	28260077
human	28260077
embryonic	28260077
proximal	28260077
tubule	28260077
(	28260077
HK2	28260077
)	28260077
cell	28260077
damage	28260077
was	28260077
assessed	28260077
.	28260077

The	28260077
rats	28260077
were	28260077
assigned	28260077
into	28260077
four	28260077
groups	28260077
(	28260077
n	28260077
=	28260077
10	28260077
per	28260077
group	28260077
)	28260077
,	28260077
as	28260077
follows	28260077
:	28260077
Control	28260077
rats	28260077
;	28260077
rats	28260077
+	28260077
atorvastatin	28260077
;	28260077
rats	28260077
+	28260077
iopamidol	28260077
;	28260077
rats	28260077
+	28260077
iopamidol	28260077
+	28260077
atorvastatin	28260077
.	28260077

In	28260077
vitro	28260077
,	28260077
the	28260077
HK2	28260077
cells	28260077
were	28260077
treated	28260077
with	28260077
iopamidol	28260077
in	28260077
the	28260077
presence	28260077
or	28260077
absence	28260077
of	28260077
atorvastatin	28260077
,	28260077
heat	28260077
shock	28260077
protein	28260077
(	28260077
Hsp	28260077
)	28260077
27	28260077
small	28260077
interfering	28260077
(	28260077
si	28260077
)	28260077
RNA	28260077
or	28260077
pcDNA3	28260077
.	28260077
1	28260077
-	28260077
Hsp27	28260077
.	28260077

The	28260077
renal	28260077
tissues	28260077
were	28260077
examined	28260077
histopathologically	28260077
and	28260077
collected	28260077
for	28260077
western	28260077
blot	28260077
analysis	28260077
.	28260077

The	28260077
results	28260077
showed	28260077
that	28260077
atorvastatin	28260077
ameliorated	28260077
the	28260077
apoptosis	28260077
and	28260077
deterioration	28260077
of	28260077
renal	28260077
function	28260077
(	28260077
P	28260077
<	28260077
0	28260077
.	28260077
05	28260077
)	28260077
.	28260077

Furthermore	28260077
,	28260077
atorvastatin	28260077
reduced	28260077
the	28260077
iopamidol	28260077
-	28260077
induced	28260077
activity	28260077
of	28260077
B	28260077
cell	28260077
lymphoma	28260077
-	28260077
2	28260077
(	28260077
Bcl	28260077
-	28260077
2	28260077
)	28260077
-	28260077
associated	28260077
X	28260077
protein	28260077
(	28260077
Bax	28260077
)	28260077
/	28260077
caspase	28260077
-	28260077
3	28260077
and	28260077
increased	28260077
the	28260077
expression	28260077
of	28260077
Bcl	28260077
-	28260077
2	28260077
in	28260077
vivo	28260077
and	28260077
in	28260077
vitro	28260077
.	28260077

Notably	28260077
,	28260077
following	28260077
treatment	28260077
with	28260077
Hsp27	28260077
siRNA	28260077
or	28260077
pcDNA3	28260077
.	28260077
1	28260077
-	28260077
Hsp27	28260077
,	28260077
it	28260077
was	28260077
found	28260077
that	28260077
iopamidol	28260077
enhanced	28260077
or	28260077
weakened	28260077
the	28260077
upregulation	28260077
of	28260077
Bax	28260077
/	28260077
caspase	28260077
-	28260077
3	28260077
and	28260077
downregulation	28260077
of	28260077
Bcl	28260077
-	28260077
2	28260077
in	28260077
the	28260077
HK2	28260077
cells	28260077
,	28260077
respectively	28260077
.	28260077

The	28260077
results	28260077
of	28260077
the	28260077
present	28260077
study	28260077
suggested	28260077
that	28260077
atorvastatin	28260077
protected	28260077
against	28260077
contrast	28260077
-	28260077
induced	28260077
renal	28260077
tubular	28260077
cell	28260077
apoptosis	28260077
through	28260077
the	28260077
upregulation	28260077
of	28260077
Hsp27	28260077
in	28260077
vivo	28260077
and	28260077
in	28260077
vitro	28260077
.	28260077
Possible	16720068
neuroleptic	16720068
malignant	16720068
syndrome	16720068
related	16720068
to	16720068
concomitant	16720068
treatment	16720068
with	16720068
paroxetine	16720068
and	16720068
alprazolam	16720068
.	16720068

A	16720068
74	16720068
-	16720068
year	16720068
-	16720068
old	16720068
man	16720068
with	16720068
depressive	16720068
symptoms	16720068
was	16720068
admitted	16720068
to	16720068
a	16720068
psychiatric	16720068
hospital	16720068
due	16720068
to	16720068
insomnia	16720068
,	16720068
loss	16720068
of	16720068
appetite	16720068
,	16720068
exhaustion	16720068
,	16720068
and	16720068
agitation	16720068
.	16720068

Medical	16720068
treatment	16720068
was	16720068
initiated	16720068
at	16720068
a	16720068
daily	16720068
dose	16720068
of	16720068
20	16720068
mg	16720068
paroxetine	16720068
and	16720068
1	16720068
.	16720068
2	16720068
mg	16720068
alprazolam	16720068
.	16720068

On	16720068
the	16720068
10th	16720068
day	16720068
of	16720068
paroxetine	16720068
and	16720068
alprazolam	16720068
treatment	16720068
,	16720068
the	16720068
patient	16720068
exhibited	16720068
marked	16720068
psychomotor	16720068
retardation	16720068
,	16720068
disorientation	16720068
,	16720068
and	16720068
severe	16720068
muscle	16720068
rigidity	16720068
with	16720068
tremors	16720068
.	16720068

The	16720068
patient	16720068
had	16720068
a	16720068
fever	16720068
(	16720068
38	16720068
.	16720068
2	16720068
degrees	16720068
C	16720068
)	16720068
,	16720068
fluctuating	16720068
blood	16720068
pressure	16720068
(	16720068
between	16720068
165	16720068
/	16720068
90	16720068
and	16720068
130	16720068
/	16720068
70	16720068
mg	16720068
mm	16720068
Hg	16720068
)	16720068
,	16720068
and	16720068
severe	16720068
extrapyramidal	16720068
symptoms	16720068
.	16720068

Laboratory	16720068
tests	16720068
showed	16720068
an	16720068
elevation	16720068
of	16720068
creatine	16720068
phosphokinase	16720068
(	16720068
2218	16720068
IU	16720068
/	16720068
L	16720068
)	16720068
,	16720068
aspartate	16720068
aminotransferase	16720068
(	16720068
134	16720068
IU	16720068
/	16720068
L	16720068
)	16720068
,	16720068
alanine	16720068
aminotransferase	16720068
(	16720068
78	16720068
IU	16720068
/	16720068
L	16720068
)	16720068
,	16720068
and	16720068
BUN	16720068
(	16720068
27	16720068
.	16720068
9	16720068
mg	16720068
/	16720068
ml	16720068
)	16720068
levels	16720068
.	16720068

The	16720068
patient	16720068
received	16720068
bromocriptine	16720068
and	16720068
diazepam	16720068
to	16720068
treat	16720068
his	16720068
symptoms	16720068
.	16720068

7	16720068
days	16720068
later	16720068
,	16720068
the	16720068
fever	16720068
disappeared	16720068
and	16720068
the	16720068
patient	16720068
'	16720068
s	16720068
serum	16720068
CPK	16720068
levels	16720068
were	16720068
normalized	16720068
(	16720068
175	16720068
IU	16720068
/	16720068
L	16720068
)	16720068
.	16720068

This	16720068
patient	16720068
presented	16720068
with	16720068
symptoms	16720068
of	16720068
neuroleptic	16720068
malignant	16720068
syndrome	16720068
(	16720068
NMS	16720068
)	16720068
,	16720068
thus	16720068
demonstrating	16720068
that	16720068
NMS	16720068
-	16720068
like	16720068
symptoms	16720068
can	16720068
occur	16720068
after	16720068
combined	16720068
paroxetine	16720068
and	16720068
alprazolam	16720068
treatment	16720068
.	16720068

The	16720068
adverse	16720068
drug	16720068
reaction	16720068
score	16720068
obtained	16720068
by	16720068
the	16720068
Naranjo	16720068
algorithm	16720068
was	16720068
6	16720068
in	16720068
our	16720068
case	16720068
,	16720068
indicating	16720068
a	16720068
probable	16720068
relationship	16720068
between	16720068
the	16720068
patient	16720068
'	16720068
s	16720068
NMS	16720068
-	16720068
like	16720068
adverse	16720068
symptoms	16720068
and	16720068
the	16720068
combined	16720068
treatment	16720068
used	16720068
in	16720068
this	16720068
case	16720068
.	16720068

The	16720068
involvement	16720068
of	16720068
physiologic	16720068
and	16720068
environmental	16720068
aspects	16720068
specific	16720068
to	16720068
this	16720068
patient	16720068
was	16720068
suspected	16720068
.	16720068

Several	16720068
risk	16720068
factors	16720068
for	16720068
NMS	16720068
should	16720068
be	16720068
noted	16720068
in	16720068
elderly	16720068
depressive	16720068
patients	16720068
whose	16720068
symptoms	16720068
often	16720068
include	16720068
dehydration	16720068
,	16720068
agitation	16720068
,	16720068
malnutrition	16720068
,	16720068
and	16720068
exhaustion	16720068
.	16720068

Careful	16720068
therapeutic	16720068
intervention	16720068
is	16720068
necessary	16720068
in	16720068
cases	16720068
involving	16720068
elderly	16720068
patients	16720068
who	16720068
suffer	16720068
from	16720068
depression	16720068
.	16720068
Whole	27930654
-	27930654
Organism	27930654
Developmental	27930654
Expression	27930654
Profiling	27930654
Identifies	27930654
RAB	27930654
-	27930654
28	27930654
as	27930654
a	27930654
Novel	27930654
Ciliary	27930654
GTPase	27930654
Associated	27930654
with	27930654
the	27930654
BBSome	27930654
and	27930654
Intraflagellar	27930654
Transport	27930654
.	27930654

Primary	27930654
cilia	27930654
are	27930654
specialised	27930654
sensory	27930654
and	27930654
developmental	27930654
signalling	27930654
devices	27930654
extending	27930654
from	27930654
the	27930654
surface	27930654
of	27930654
most	27930654
eukaryotic	27930654
cells	27930654
.	27930654

Defects	27930654
in	27930654
these	27930654
organelles	27930654
cause	27930654
inherited	27930654
human	27930654
disorders	27930654
(	27930654
ciliopathies	27930654
)	27930654
such	27930654
as	27930654
retinitis	27930654
pigmentosa	27930654
and	27930654
Bardet	27930654
-	27930654
Biedl	27930654
syndrome	27930654
(	27930654
BBS	27930654
)	27930654
,	27930654
frequently	27930654
affecting	27930654
many	27930654
physiological	27930654
and	27930654
developmental	27930654
processes	27930654
across	27930654
multiple	27930654
organs	27930654
.	27930654

Cilium	27930654
formation	27930654
,	27930654
maintenance	27930654
and	27930654
function	27930654
depend	27930654
on	27930654
intracellular	27930654
transport	27930654
systems	27930654
such	27930654
as	27930654
intraflagellar	27930654
transport	27930654
(	27930654
IFT	27930654
)	27930654
,	27930654
which	27930654
is	27930654
driven	27930654
by	27930654
kinesin	27930654
-	27930654
2	27930654
and	27930654
IFT	27930654
-	27930654
dynein	27930654
motors	27930654
and	27930654
regulated	27930654
by	27930654
the	27930654
Bardet	27930654
-	27930654
Biedl	27930654
syndrome	27930654
(	27930654
BBS	27930654
)	27930654
cargo	27930654
-	27930654
adaptor	27930654
protein	27930654
complex	27930654
,	27930654
or	27930654
BBSome	27930654
.	27930654

To	27930654
identify	27930654
new	27930654
cilium	27930654
-	27930654
associated	27930654
genes	27930654
,	27930654
we	27930654
employed	27930654
the	27930654
nematode	27930654
C	27930654
.	27930654

elegans	27930654
,	27930654
where	27930654
ciliogenesis	27930654
occurs	27930654
within	27930654
a	27930654
short	27930654
timespan	27930654
during	27930654
late	27930654
embryogenesis	27930654
when	27930654
most	27930654
sensory	27930654
neurons	27930654
differentiate	27930654
.	27930654

Using	27930654
whole	27930654
-	27930654
organism	27930654
RNA	27930654
-	27930654
Seq	27930654
libraries	27930654
,	27930654
we	27930654
discovered	27930654
a	27930654
signature	27930654
expression	27930654
profile	27930654
highly	27930654
enriched	27930654
for	27930654
transcripts	27930654
of	27930654
known	27930654
ciliary	27930654
proteins	27930654
,	27930654
including	27930654
FAM	27930654
-	27930654
161	27930654
(	27930654
FAM161A	27930654
orthologue	27930654
)	27930654
,	27930654
CCDC	27930654
-	27930654
104	27930654
(	27930654
CCDC104	27930654
)	27930654
,	27930654
and	27930654
RPI	27930654
-	27930654
1	27930654
(	27930654
RP1	27930654
/	27930654
RP1L1	27930654
)	27930654
,	27930654
which	27930654
we	27930654
confirm	27930654
are	27930654
cilium	27930654
-	27930654
localised	27930654
in	27930654
worms	27930654
.	27930654

From	27930654
a	27930654
list	27930654
of	27930654
185	27930654
candidate	27930654
ciliary	27930654
genes	27930654
,	27930654
we	27930654
uncover	27930654
orthologues	27930654
of	27930654
human	27930654
MAP9	27930654
,	27930654
YAP	27930654
,	27930654
CCDC149	27930654
,	27930654
and	27930654
RAB28	27930654
as	27930654
conserved	27930654
cilium	27930654
-	27930654
associated	27930654
components	27930654
.	27930654

Further	27930654
analyses	27930654
of	27930654
C	27930654
.	27930654

elegans	27930654
RAB	27930654
-	27930654
28	27930654
,	27930654
recently	27930654
associated	27930654
with	27930654
autosomal	27930654
-	27930654
recessive	27930654
cone	27930654
-	27930654
rod	27930654
dystrophy	27930654
,	27930654
reveal	27930654
that	27930654
this	27930654
small	27930654
GTPase	27930654
is	27930654
exclusively	27930654
expressed	27930654
in	27930654
ciliated	27930654
neurons	27930654
where	27930654
it	27930654
dynamically	27930654
associates	27930654
with	27930654
IFT	27930654
trains	27930654
.	27930654

Whereas	27930654
inactive	27930654
GDP	27930654
-	27930654
bound	27930654
RAB	27930654
-	27930654
28	27930654
displays	27930654
no	27930654
IFT	27930654
movement	27930654
and	27930654
diffuse	27930654
localisation	27930654
,	27930654
GTP	27930654
-	27930654
bound	27930654
(	27930654
activated	27930654
)	27930654
RAB	27930654
-	27930654
28	27930654
concentrates	27930654
at	27930654
the	27930654
periciliary	27930654
membrane	27930654
in	27930654
a	27930654
BBSome	27930654
-	27930654
dependent	27930654
manner	27930654
and	27930654
undergoes	27930654
bidirectional	27930654
IFT	27930654
.	27930654

Functional	27930654
analyses	27930654
reveal	27930654
that	27930654
whilst	27930654
cilium	27930654
structure	27930654
,	27930654
sensory	27930654
function	27930654
and	27930654
IFT	27930654
are	27930654
seemingly	27930654
normal	27930654
in	27930654
a	27930654
rab	27930654
-	27930654
28	27930654
null	27930654
allele	27930654
,	27930654
overexpression	27930654
of	27930654
predicted	27930654
GDP	27930654
or	27930654
GTP	27930654
locked	27930654
variants	27930654
of	27930654
RAB	27930654
-	27930654
28	27930654
perturbs	27930654
cilium	27930654
and	27930654
sensory	27930654
pore	27930654
morphogenesis	27930654
and	27930654
function	27930654
.	27930654

Collectively	27930654
,	27930654
our	27930654
findings	27930654
present	27930654
a	27930654
new	27930654
approach	27930654
for	27930654
identifying	27930654
ciliary	27930654
proteins	27930654
,	27930654
and	27930654
unveil	27930654
RAB28	27930654
,	27930654
a	27930654
GTPase	27930654
most	27930654
closely	27930654
related	27930654
to	27930654
the	27930654
BBS	27930654
protein	27930654
RABL4	27930654
/	27930654
IFT27	27930654
,	27930654
as	27930654
an	27930654
IFT	27930654
-	27930654
associated	27930654
cargo	27930654
with	27930654
BBSome	27930654
-	27930654
dependent	27930654
cell	27930654
autonomous	27930654
and	27930654
non	27930654
-	27930654
autonomous	27930654
functions	27930654
at	27930654
the	27930654
ciliary	27930654
base	27930654
.	27930654
Compound	15064320
heterozygous	15064320
mutations	15064320
in	15064320
the	15064320
SRD5A2	15064320
gene	15064320
exon	15064320
4	15064320
in	15064320
a	15064320
male	15064320
pseudohermaphrodite	15064320
patient	15064320
of	15064320
Chinese	15064320
origin	15064320
.	15064320

The	15064320
goal	15064320
of	15064320
this	15064320
study	15064320
was	15064320
to	15064320
perform	15064320
5	15064320
-	15064320
alpha	15064320
-	15064320
reductase	15064320
type	15064320
2	15064320
gene	15064320
(	15064320
SRD5A2	15064320
)	15064320
analysis	15064320
in	15064320
a	15064320
male	15064320
pseudohermaphrodite	15064320
(	15064320
MPH	15064320
)	15064320
patient	15064320
with	15064320
normal	15064320
testosterone	15064320
(	15064320
T	15064320
)	15064320
production	15064320
and	15064320
normal	15064320
androgen	15064320
receptor	15064320
(	15064320
AR	15064320
)	15064320
gene	15064320
coding	15064320
sequences	15064320
.	15064320

A	15064320
patient	15064320
of	15064320
Chinese	15064320
origin	15064320
with	15064320
ambiguous	15064320
genitalia	15064320
at	15064320
14	15064320
months	15064320
,	15064320
a	15064320
46	15064320
,	15064320
XY	15064320
karyotype	15064320
,	15064320
and	15064320
normal	15064320
T	15064320
secretion	15064320
under	15064320
human	15064320
chorionic	15064320
gonadotropin	15064320
(	15064320
hCG	15064320
)	15064320
stimulation	15064320
underwent	15064320
a	15064320
gonadectomy	15064320
at	15064320
20	15064320
months	15064320
.	15064320

Exons	15064320
1	15064320
-	15064320
8	15064320
of	15064320
the	15064320
AR	15064320
gene	15064320
and	15064320
exons	15064320
1	15064320
-	15064320
5	15064320
of	15064320
the	15064320
SRD5A2	15064320
gene	15064320
were	15064320
sequenced	15064320
from	15064320
peripheral	15064320
blood	15064320
DNA	15064320
.	15064320

AR	15064320
gene	15064320
coding	15064320
sequences	15064320
were	15064320
normal	15064320
.	15064320

SRD5A2	15064320
gene	15064320
analysis	15064320
revealed	15064320
2	15064320
consecutive	15064320
mutations	15064320
in	15064320
exon	15064320
4	15064320
,	15064320
each	15064320
located	15064320
in	15064320
a	15064320
different	15064320
allele	15064320
:	15064320
1	15064320
)	15064320
a	15064320
T	15064320
nucleotide	15064320
deletion	15064320
,	15064320
which	15064320
predicts	15064320
a	15064320
frameshift	15064320
mutation	15064320
from	15064320
codon	15064320
219	15064320
,	15064320
and	15064320
2	15064320
)	15064320
a	15064320
missense	15064320
mutation	15064320
at	15064320
codon	15064320
227	15064320
,	15064320
where	15064320
the	15064320
substitution	15064320
of	15064320
guanine	15064320
(	15064320
CGA	15064320
)	15064320
by	15064320
adenine	15064320
(	15064320
CAA	15064320
)	15064320
predicts	15064320
a	15064320
glutamine	15064320
replacement	15064320
of	15064320
arginine	15064320
(	15064320
R227Q	15064320
)	15064320
.	15064320

Testes	15064320
located	15064320
in	15064320
the	15064320
inguinal	15064320
canal	15064320
showed	15064320
a	15064320
normal	15064320
morphology	15064320
for	15064320
age	15064320
.	15064320

The	15064320
patient	15064320
was	15064320
a	15064320
compound	15064320
heterozygote	15064320
for	15064320
SRD5A2	15064320
mutations	15064320
,	15064320
carrying	15064320
2	15064320
mutations	15064320
in	15064320
exon	15064320
4	15064320
.	15064320

The	15064320
patient	15064320
showed	15064320
an	15064320
R227Q	15064320
mutation	15064320
that	15064320
has	15064320
been	15064320
described	15064320
in	15064320
an	15064320
Asian	15064320
population	15064320
and	15064320
MPH	15064320
patients	15064320
,	15064320
along	15064320
with	15064320
a	15064320
novel	15064320
frameshift	15064320
mutation	15064320
,	15064320
Tdel219	15064320
.	15064320

Testis	15064320
morphology	15064320
showed	15064320
that	15064320
,	15064320
during	15064320
early	15064320
infancy	15064320
,	15064320
the	15064320
5	15064320
-	15064320
alpha	15064320
-	15064320
reductase	15064320
enzyme	15064320
deficiency	15064320
may	15064320
not	15064320
have	15064320
affected	15064320
interstitial	15064320
or	15064320
tubular	15064320
development	15064320
.	15064320
A	17003357
haplotype	17003357
-	17003357
based	17003357
analysis	17003357
of	17003357
the	17003357
PTPN22	17003357
locus	17003357
in	17003357
type	17003357
1	17003357
diabetes	17003357
.	17003357

A	17003357
recent	17003357
addition	17003357
to	17003357
the	17003357
list	17003357
of	17003357
widely	17003357
confirmed	17003357
type	17003357
1	17003357
diabetes	17003357
risk	17003357
loci	17003357
is	17003357
the	17003357
PTPN22	17003357
gene	17003357
encoding	17003357
a	17003357
lymphoid	17003357
-	17003357
specific	17003357
phosphatase	17003357
(	17003357
Lyp	17003357
)	17003357
.	17003357

However	17003357
,	17003357
evidence	17003357
supporting	17003357
a	17003357
role	17003357
for	17003357
PTPN22	17003357
in	17003357
type	17003357
1	17003357
diabetes	17003357
derives	17003357
entirely	17003357
from	17003357
the	17003357
study	17003357
of	17003357
just	17003357
one	17003357
coding	17003357
single	17003357
nucleotide	17003357
polymorphism	17003357
,	17003357
1858C	17003357
/	17003357
T	17003357
.	17003357

In	17003357
the	17003357
current	17003357
study	17003357
,	17003357
the	17003357
haplotype	17003357
structure	17003357
of	17003357
the	17003357
PTPN22	17003357
region	17003357
was	17003357
determined	17003357
,	17003357
and	17003357
individual	17003357
haplotypes	17003357
were	17003357
tested	17003357
for	17003357
association	17003357
with	17003357
type	17003357
1	17003357
diabetes	17003357
in	17003357
family	17003357
-	17003357
based	17003357
tests	17003357
.	17003357

The	17003357
1858T	17003357
risk	17003357
allele	17003357
occurred	17003357
on	17003357
only	17003357
a	17003357
single	17003357
haplotype	17003357
that	17003357
was	17003357
strongly	17003357
associated	17003357
with	17003357
type	17003357
1	17003357
diabetes	17003357
(	17003357
P	17003357
=	17003357
7	17003357
.	17003357
9	17003357
x	17003357
10	17003357
(	17003357
-	17003357
5	17003357
)	17003357
)	17003357
.	17003357

After	17003357
controlling	17003357
for	17003357
the	17003357
effects	17003357
of	17003357
this	17003357
allele	17003357
,	17003357
two	17003357
other	17003357
haplotypes	17003357
were	17003357
observed	17003357
to	17003357
be	17003357
weakly	17003357
associated	17003357
with	17003357
type	17003357
1	17003357
diabetes	17003357
(	17003357
P	17003357
<	17003357
0	17003357
.	17003357
05	17003357
)	17003357
.	17003357

Sequencing	17003357
of	17003357
the	17003357
coding	17003357
region	17003357
of	17003357
PTPN22	17003357
on	17003357
these	17003357
haplotypes	17003357
revealed	17003357
a	17003357
novel	17003357
variant	17003357
(	17003357
2250G	17003357
/	17003357
C	17003357
)	17003357
predicted	17003357
to	17003357
result	17003357
in	17003357
a	17003357
nonsynonymous	17003357
amino	17003357
acid	17003357
substitution	17003357
.	17003357

Analysis	17003357
of	17003357
PTPN22	17003357
transcripts	17003357
from	17003357
a	17003357
subject	17003357
heterozygous	17003357
for	17003357
this	17003357
variant	17003357
indicated	17003357
that	17003357
it	17003357
interfered	17003357
with	17003357
normal	17003357
mRNA	17003357
splicing	17003357
,	17003357
resulting	17003357
in	17003357
a	17003357
premature	17003357
termination	17003357
codon	17003357
after	17003357
exon	17003357
17	17003357
.	17003357

These	17003357
results	17003357
support	17003357
the	17003357
conclusion	17003357
that	17003357
the	17003357
1858C	17003357
/	17003357
T	17003357
allele	17003357
is	17003357
the	17003357
major	17003357
risk	17003357
variant	17003357
for	17003357
type	17003357
1	17003357
diabetes	17003357
in	17003357
the	17003357
PTPN22	17003357
locus	17003357
,	17003357
but	17003357
they	17003357
suggest	17003357
that	17003357
additional	17003357
infrequent	17003357
coding	17003357
variants	17003357
at	17003357
PTPN22	17003357
may	17003357
also	17003357
contribute	17003357
to	17003357
type	17003357
1	17003357
diabetes	17003357
risk	17003357
.	17003357
Sepsis	25218136
-	25218136
induced	25218136
changes	25218136
in	25218136
amino	25218136
acid	25218136
transporters	25218136
and	25218136
leucine	25218136
signaling	25218136
via	25218136
mTOR	25218136
in	25218136
skeletal	25218136
muscle	25218136
.	25218136

The	25218136
present	25218136
study	25218136
tested	25218136
the	25218136
hypothesis	25218136
that	25218136
sepsis	25218136
-	25218136
induced	25218136
leucine	25218136
(	25218136
Leu	25218136
)	25218136
resistance	25218136
in	25218136
skeletal	25218136
muscle	25218136
is	25218136
associated	25218136
with	25218136
a	25218136
down	25218136
-	25218136
regulation	25218136
of	25218136
amino	25218136
acid	25218136
transporters	25218136
important	25218136
in	25218136
regulating	25218136
Leu	25218136
flux	25218136
or	25218136
an	25218136
impairment	25218136
in	25218136
the	25218136
formation	25218136
of	25218136
the	25218136
Leu	25218136
-	25218136
sensitive	25218136
mTOR	25218136
-	25218136
Ragulator	25218136
complex	25218136
.	25218136

Sepsis	25218136
in	25218136
adult	25218136
male	25218136
rats	25218136
decreased	25218136
basal	25218136
protein	25218136
synthesis	25218136
in	25218136
gastrocnemius	25218136
,	25218136
associated	25218136
with	25218136
a	25218136
reduction	25218136
in	25218136
mTOR	25218136
activation	25218136
as	25218136
indicated	25218136
by	25218136
decreased	25218136
4E	25218136
-	25218136
BP1	25218136
and	25218136
S6K1	25218136
phosphorylation	25218136
.	25218136

The	25218136
ability	25218136
of	25218136
oral	25218136
Leu	25218136
to	25218136
increase	25218136
protein	25218136
synthesis	25218136
and	25218136
mTOR	25218136
kinase	25218136
after	25218136
1	25218136
h	25218136
was	25218136
largely	25218136
prevented	25218136
in	25218136
sepsis	25218136
.	25218136

Sepsis	25218136
increased	25218136
CAT1	25218136
,	25218136
LAT2	25218136
and	25218136
SNAT2	25218136
mRNA	25218136
content	25218136
two	25218136
-	25218136
to	25218136
fourfold	25218136
,	25218136
but	25218136
only	25218136
the	25218136
protein	25218136
content	25218136
for	25218136
CAT1	25218136
(	25218136
20	25218136
%	25218136
decrease	25218136
)	25218136
differed	25218136
significantly	25218136
.	25218136

Conversely	25218136
,	25218136
sepsis	25218136
decreased	25218136
the	25218136
proton	25218136
-	25218136
assisted	25218136
amino	25218136
acid	25218136
transporter	25218136
(	25218136
PAT	25218136
)	25218136
-	25218136
2	25218136
mRNA	25218136
by	25218136
60	25218136
%	25218136
,	25218136
but	25218136
without	25218136
a	25218136
coordinate	25218136
change	25218136
in	25218136
PAT2	25218136
protein	25218136
.	25218136

There	25218136
was	25218136
no	25218136
sepsis	25218136
or	25218136
Leu	25218136
effect	25218136
on	25218136
the	25218136
protein	25218136
content	25218136
for	25218136
RagA	25218136
-	25218136
D	25218136
,	25218136
LAMTOR	25218136
-	25218136
1	25218136
and	25218136
-	25218136
2	25218136
,	25218136
raptor	25218136
,	25218136
Rheb	25218136
or	25218136
mTOR	25218136
in	25218136
muscle	25218136
.	25218136

The	25218136
binding	25218136
of	25218136
mTOR	25218136
,	25218136
PRAS40	25218136
and	25218136
RagC	25218136
to	25218136
raptor	25218136
did	25218136
not	25218136
differ	25218136
for	25218136
control	25218136
and	25218136
septic	25218136
muscle	25218136
in	25218136
the	25218136
basal	25218136
condition	25218136
;	25218136
however	25218136
,	25218136
the	25218136
Leu	25218136
-	25218136
induced	25218136
decrease	25218136
in	25218136
PRAS40	25218136
raptor	25218136
and	25218136
increase	25218136
in	25218136
RagC	25218136
raptor	25218136
seen	25218136
in	25218136
control	25218136
muscle	25218136
was	25218136
absent	25218136
in	25218136
sepsis	25218136
.	25218136

The	25218136
intracellular	25218136
Leu	25218136
concentration	25218136
was	25218136
increased	25218136
in	25218136
septic	25218136
muscle	25218136
,	25218136
compared	25218136
to	25218136
basal	25218136
control	25218136
conditions	25218136
,	25218136
and	25218136
oral	25218136
Leu	25218136
further	25218136
increased	25218136
the	25218136
intracellular	25218136
Leu	25218136
concentration	25218136
similarly	25218136
in	25218136
both	25218136
control	25218136
and	25218136
septic	25218136
rats	25218136
.	25218136

Hence	25218136
,	25218136
while	25218136
alterations	25218136
in	25218136
select	25218136
amino	25218136
acid	25218136
transporters	25218136
are	25218136
not	25218136
associated	25218136
with	25218136
development	25218136
of	25218136
sepsis	25218136
-	25218136
induced	25218136
Leu	25218136
resistance	25218136
,	25218136
the	25218136
Leu	25218136
-	25218136
stimulated	25218136
binding	25218136
of	25218136
raptor	25218136
with	25218136
RagC	25218136
and	25218136
the	25218136
recruitment	25218136
of	25218136
mTOR	25218136
/	25218136
raptor	25218136
to	25218136
the	25218136
endosome	25218136
-	25218136
lysosomal	25218136
compartment	25218136
may	25218136
partially	25218136
explain	25218136
the	25218136
inability	25218136
of	25218136
Leu	25218136
to	25218136
fully	25218136
activate	25218136
mTOR	25218136
and	25218136
muscle	25218136
protein	25218136
synthesis	25218136
.	25218136
Identification	18385794
of	18385794
novel	18385794
mutations	18385794
and	18385794
sequence	18385794
variants	18385794
in	18385794
the	18385794
SOX2	18385794
and	18385794
CHX10	18385794
genes	18385794
in	18385794
patients	18385794
with	18385794
anophthalmia	18385794
/	18385794
microphthalmia	18385794
.	18385794

PURPOSE	18385794
:	18385794
Mutations	18385794
in	18385794
the	18385794
SOX2	18385794
and	18385794
CHX10	18385794
genes	18385794
have	18385794
been	18385794
reported	18385794
in	18385794
patients	18385794
with	18385794
anophthalmia	18385794
and	18385794
/	18385794
or	18385794
microphthalmia	18385794
.	18385794

In	18385794
this	18385794
study	18385794
,	18385794
we	18385794
evaluated	18385794
34	18385794
anophthalmic	18385794
/	18385794
microphthalmic	18385794
patient	18385794
DNA	18385794
samples	18385794
(	18385794
two	18385794
sets	18385794
of	18385794
siblings	18385794
included	18385794
)	18385794
for	18385794
mutations	18385794
and	18385794
sequence	18385794
variants	18385794
in	18385794
SOX2	18385794
and	18385794
CHX10	18385794
.	18385794

METHODS	18385794
:	18385794
Conformational	18385794
sensitive	18385794
gel	18385794
electrophoresis	18385794
(	18385794
CSGE	18385794
)	18385794
was	18385794
used	18385794
for	18385794
the	18385794
initial	18385794
SOX2	18385794
and	18385794
CHX10	18385794
screening	18385794
of	18385794
34	18385794
affected	18385794
individuals	18385794
(	18385794
two	18385794
sets	18385794
of	18385794
siblings	18385794
)	18385794
,	18385794
five	18385794
unaffected	18385794
family	18385794
members	18385794
,	18385794
and	18385794
80	18385794
healthy	18385794
controls	18385794
.	18385794

Patient	18385794
samples	18385794
containing	18385794
heteroduplexes	18385794
were	18385794
selected	18385794
for	18385794
sequence	18385794
analysis	18385794
.	18385794

Base	18385794
pair	18385794
changes	18385794
in	18385794
SOX2	18385794
and	18385794
CHX10	18385794
were	18385794
confirmed	18385794
by	18385794
sequencing	18385794
bidirectionally	18385794
in	18385794
patient	18385794
samples	18385794
.	18385794

RESULTS	18385794
:	18385794
Two	18385794
novel	18385794
heterozygous	18385794
mutations	18385794
and	18385794
two	18385794
sequence	18385794
variants	18385794
(	18385794
one	18385794
known	18385794
)	18385794
in	18385794
SOX2	18385794
were	18385794
identified	18385794
in	18385794
this	18385794
cohort	18385794
.	18385794

Mutation	18385794
c	18385794
.	18385794
310	18385794
G	18385794
>	18385794
T	18385794
(	18385794
p	18385794
.	18385794

Glu104X	18385794
)	18385794
,	18385794
found	18385794
in	18385794
one	18385794
patient	18385794
,	18385794
was	18385794
in	18385794
the	18385794
region	18385794
encoding	18385794
the	18385794
high	18385794
mobility	18385794
group	18385794
(	18385794
HMG	18385794
)	18385794
DNA	18385794
-	18385794
binding	18385794
domain	18385794
and	18385794
resulted	18385794
in	18385794
a	18385794
change	18385794
from	18385794
glutamic	18385794
acid	18385794
to	18385794
a	18385794
stop	18385794
codon	18385794
.	18385794

The	18385794
second	18385794
mutation	18385794
,	18385794
noted	18385794
in	18385794
two	18385794
affected	18385794
siblings	18385794
,	18385794
was	18385794
a	18385794
single	18385794
nucleotide	18385794
deletion	18385794
c	18385794
.	18385794
549delC	18385794
(	18385794
p	18385794
.	18385794

Pro184ArgfsX19	18385794
)	18385794
in	18385794
the	18385794
region	18385794
encoding	18385794
the	18385794
activation	18385794
domain	18385794
,	18385794
resulting	18385794
in	18385794
a	18385794
frameshift	18385794
and	18385794
premature	18385794
termination	18385794
of	18385794
the	18385794
coding	18385794
sequence	18385794
.	18385794

The	18385794
shortened	18385794
protein	18385794
products	18385794
may	18385794
result	18385794
in	18385794
the	18385794
loss	18385794
of	18385794
function	18385794
.	18385794

In	18385794
addition	18385794
,	18385794
a	18385794
novel	18385794
nucleotide	18385794
substitution	18385794
c	18385794
.	18385794
*	18385794
557G	18385794
>	18385794
A	18385794
was	18385794
identified	18385794
in	18385794
the	18385794
3	18385794
'	18385794
-	18385794
untranslated	18385794
region	18385794
in	18385794
one	18385794
patient	18385794
.	18385794

The	18385794
relationship	18385794
between	18385794
the	18385794
nucleotide	18385794
change	18385794
and	18385794
the	18385794
protein	18385794
function	18385794
is	18385794
indeterminate	18385794
.	18385794

A	18385794
known	18385794
single	18385794
nucleotide	18385794
polymorphism	18385794
(	18385794
c	18385794
.	18385794

*	18385794
469	18385794
C	18385794
>	18385794
A	18385794
,	18385794
SNP	18385794
rs11915160	18385794
)	18385794
was	18385794
also	18385794
detected	18385794
in	18385794
2	18385794
of	18385794
the	18385794
34	18385794
patients	18385794
.	18385794

Screening	18385794
of	18385794
CHX10	18385794
identified	18385794
two	18385794
synonymous	18385794
sequence	18385794
variants	18385794
,	18385794
c	18385794
.	18385794
471	18385794
C	18385794
>	18385794
T	18385794
(	18385794
p	18385794
.	18385794
Ser157Ser	18385794
,	18385794
rs35435463	18385794
)	18385794
and	18385794
c	18385794
.	18385794
579	18385794
G	18385794
>	18385794
A	18385794
(	18385794
p	18385794
.	18385794

Gln193Gln	18385794
,	18385794
novel	18385794
SNP	18385794
)	18385794
,	18385794
and	18385794
one	18385794
non	18385794
-	18385794
synonymous	18385794
sequence	18385794
variant	18385794
,	18385794
c	18385794
.	18385794
871	18385794
G	18385794
>	18385794
A	18385794
(	18385794
p	18385794
.	18385794

Asp291Asn	18385794
,	18385794
novel	18385794
SNP	18385794
)	18385794
.	18385794

The	18385794
non	18385794
-	18385794
synonymous	18385794
polymorphism	18385794
was	18385794
also	18385794
present	18385794
in	18385794
healthy	18385794
controls	18385794
,	18385794
suggesting	18385794
non	18385794
-	18385794
causality	18385794
.	18385794

CONCLUSIONS	18385794
:	18385794
These	18385794
results	18385794
support	18385794
the	18385794
role	18385794
of	18385794
SOX2	18385794
in	18385794
ocular	18385794
development	18385794
.	18385794

Loss	18385794
of	18385794
SOX2	18385794
function	18385794
results	18385794
in	18385794
severe	18385794
eye	18385794
malformation	18385794
.	18385794

CHX10	18385794
was	18385794
not	18385794
implicated	18385794
with	18385794
microphthalmia	18385794
/	18385794
anophthalmia	18385794
in	18385794
our	18385794
patient	18385794
cohort	18385794
.	18385794
Combination	27509880
of	27509880
the	27509880
histone	27509880
deacetylase	27509880
inhibitor	27509880
depsipeptide	27509880
and	27509880
5	27509880
-	27509880
fluorouracil	27509880
upregulates	27509880
major	27509880
histocompatibility	27509880
complex	27509880
class	27509880
II	27509880
and	27509880
p21	27509880
genes	27509880
and	27509880
activates	27509880
caspase	27509880
-	27509880
3	27509880
/	27509880
7	27509880
in	27509880
human	27509880
colon	27509880
cancer	27509880
HCT	27509880
-	27509880
116	27509880
cells	27509880
.	27509880

Epigenetic	27509880
anticancer	27509880
drugs	27509880
such	27509880
as	27509880
histone	27509880
deacetylase	27509880
(	27509880
HDAC	27509880
)	27509880
inhibitors	27509880
have	27509880
been	27509880
combined	27509880
with	27509880
existing	27509880
anticancer	27509880
drugs	27509880
for	27509880
synergistic	27509880
or	27509880
additive	27509880
effects	27509880
.	27509880

In	27509880
the	27509880
present	27509880
study	27509880
,	27509880
we	27509880
found	27509880
that	27509880
a	27509880
very	27509880
low	27509880
concentration	27509880
of	27509880
depsipeptide	27509880
,	27509880
an	27509880
HDAC	27509880
inhibitor	27509880
,	27509880
potentiated	27509880
the	27509880
antitumor	27509880
activity	27509880
of	27509880
5	27509880
-	27509880
fluorouracil	27509880
(	27509880
5	27509880
-	27509880
FU	27509880
)	27509880
in	27509880
a	27509880
human	27509880
colon	27509880
cancer	27509880
cell	27509880
model	27509880
using	27509880
HCT	27509880
-	27509880
116	27509880
,	27509880
HT29	27509880
,	27509880
and	27509880
SW48	27509880
cells	27509880
via	27509880
the	27509880
inhibition	27509880
of	27509880
colony	27509880
formation	27509880
ability	27509880
or	27509880
cellular	27509880
viability	27509880
.	27509880

Exposure	27509880
to	27509880
a	27509880
combination	27509880
of	27509880
5	27509880
-	27509880
FU	27509880
(	27509880
1	27509880
.	27509880
75	27509880
uM	27509880
)	27509880
and	27509880
1	27509880
nM	27509880
depsipeptide	27509880
for	27509880
24	27509880
and	27509880
48	27509880
h	27509880
resulted	27509880
in	27509880
a	27509880
3	27509880
-	27509880
to	27509880
4	27509880
-	27509880
fold	27509880
increase	27509880
in	27509880
activated	27509880
caspase	27509880
-	27509880
3	27509880
/	27509880
7	27509880
,	27509880
while	27509880
5	27509880
-	27509880
FU	27509880
alone	27509880
failed	27509880
to	27509880
activate	27509880
caspase	27509880
-	27509880
3	27509880
/	27509880
7	27509880
.	27509880

Microarray	27509880
and	27509880
subsequent	27509880
gene	27509880
ontology	27509880
analyses	27509880
revealed	27509880
that	27509880
compared	27509880
to	27509880
5	27509880
-	27509880
FU	27509880
or	27509880
depsipeptide	27509880
alone	27509880
,	27509880
the	27509880
combination	27509880
treatment	27509880
of	27509880
5	27509880
-	27509880
FU	27509880
and	27509880
depsipeptide	27509880
upregulated	27509880
genes	27509880
related	27509880
to	27509880
cell	27509880
death	27509880
and	27509880
the	27509880
apoptotic	27509880
process	27509880
consistent	27509880
with	27509880
the	27509880
inhibition	27509880
of	27509880
colony	27509880
formation	27509880
and	27509880
caspase	27509880
-	27509880
3	27509880
/	27509880
7	27509880
activation	27509880
.	27509880

These	27509880
analyses	27509880
indicated	27509880
marked	27509880
upregulation	27509880
of	27509880
antigen	27509880
processing	27509880
and	27509880
presentation	27509880
of	27509880
peptide	27509880
or	27509880
polysaccharide	27509880
antigen	27509880
via	27509880
major	27509880
histocompatibility	27509880
complex	27509880
(	27509880
MHC	27509880
)	27509880
class	27509880
(	27509880
GO	27509880
:	27509880
0002504	27509880
)	27509880
and	27509880
MHC	27509880
protein	27509880
complex	27509880
(	27509880
GO	27509880
:	27509880
0042611	27509880
)	27509880
.	27509880

Compared	27509880
with	27509880
vehicle	27509880
controls	27509880
,	27509880
the	27509880
cells	27509880
treated	27509880
with	27509880
the	27509880
combination	27509880
of	27509880
5	27509880
-	27509880
FU	27509880
and	27509880
depsipeptide	27509880
showed	27509880
marked	27509880
induction	27509880
(	27509880
3	27509880
-	27509880
to	27509880
8	27509880
.	27509880
5	27509880
-	27509880
fold	27509880
)	27509880
of	27509880
expression	27509880
of	27509880
MHC	27509880
class	27509880
II	27509880
genes	27509880
,	27509880
but	27509880
not	27509880
of	27509880
MHC	27509880
class	27509880
I	27509880
genes	27509880
.	27509880

Furthermore	27509880
,	27509880
our	27509880
global	27509880
analysis	27509880
of	27509880
gene	27509880
expression	27509880
,	27509880
which	27509880
was	27509880
focused	27509880
on	27509880
genes	27509880
involved	27509880
in	27509880
the	27509880
molecular	27509880
regulation	27509880
of	27509880
MHC	27509880
class	27509880
II	27509880
genes	27509880
,	27509880
showed	27509880
enhancement	27509880
of	27509880
pro	27509880
-	27509880
apoptotic	27509880
PCAF	27509880
and	27509880
CIITA	27509880
after	27509880
the	27509880
combination	27509880
of	27509880
5	27509880
-	27509880
FU	27509880
and	27509880
depsipeptide	27509880
.	27509880

These	27509880
results	27509880
may	27509880
indicate	27509880
a	27509880
closer	27509880
relationship	27509880
between	27509880
elevation	27509880
of	27509880
MHC	27509880
class	27509880
II	27509880
expression	27509880
and	27509880
cellular	27509880
apoptosis	27509880
induced	27509880
by	27509880
the	27509880
combination	27509880
of	27509880
depsipeptide	27509880
and	27509880
5	27509880
-	27509880
FU	27509880
.	27509880

To	27509880
the	27509880
best	27509880
of	27509880
our	27509880
knowledge	27509880
,	27509880
this	27509880
is	27509880
the	27509880
first	27509880
study	27509880
to	27509880
report	27509880
that	27509880
the	27509880
combination	27509880
of	27509880
5	27509880
-	27509880
FU	27509880
and	27509880
depsipeptide	27509880
induces	27509880
human	27509880
colon	27509880
cancer	27509880
cell	27509880
apoptosis	27509880
in	27509880
a	27509880
concerted	27509880
manner	27509880
with	27509880
the	27509880
induction	27509880
of	27509880
MHC	27509880
class	27509880
II	27509880
gene	27509880
expression	27509880
.	27509880
MOL1	26991973
is	26991973
required	26991973
for	26991973
cambium	26991973
homeostasis	26991973
in	26991973
Arabidopsis	26991973
.	26991973

Plants	26991973
maintain	26991973
pools	26991973
of	26991973
pluripotent	26991973
stem	26991973
cells	26991973
which	26991973
allow	26991973
them	26991973
to	26991973
constantly	26991973
produce	26991973
new	26991973
tissues	26991973
and	26991973
organs	26991973
.	26991973

Stem	26991973
cell	26991973
homeostasis	26991973
in	26991973
shoot	26991973
and	26991973
root	26991973
tips	26991973
depends	26991973
on	26991973
negative	26991973
regulation	26991973
by	26991973
ligand	26991973
-	26991973
receptor	26991973
pairs	26991973
of	26991973
the	26991973
CLE	26991973
peptide	26991973
and	26991973
leucine	26991973
-	26991973
rich	26991973
repeat	26991973
receptor	26991973
-	26991973
like	26991973
kinase	26991973
(	26991973
LRR	26991973
-	26991973
RLK	26991973
)	26991973
families	26991973
.	26991973

However	26991973
,	26991973
regulation	26991973
of	26991973
the	26991973
cambium	26991973
,	26991973
the	26991973
stem	26991973
cell	26991973
niche	26991973
required	26991973
for	26991973
lateral	26991973
growth	26991973
of	26991973
shoots	26991973
and	26991973
roots	26991973
,	26991973
is	26991973
poorly	26991973
characterized	26991973
.	26991973

Here	26991973
we	26991973
show	26991973
that	26991973
the	26991973
LRR	26991973
-	26991973
RLK	26991973
MOL1	26991973
is	26991973
necessary	26991973
for	26991973
cambium	26991973
homeostasis	26991973
in	26991973
Arabidopsis	26991973
thaliana	26991973
.	26991973

By	26991973
employing	26991973
promoter	26991973
reporter	26991973
lines	26991973
,	26991973
we	26991973
reveal	26991973
that	26991973
MOL1	26991973
is	26991973
active	26991973
in	26991973
a	26991973
domain	26991973
that	26991973
is	26991973
distinct	26991973
from	26991973
the	26991973
domain	26991973
of	26991973
the	26991973
positively	26991973
acting	26991973
CLE41	26991973
/	26991973
PXY	26991973
signaling	26991973
module	26991973
.	26991973

In	26991973
particular	26991973
,	26991973
we	26991973
show	26991973
that	26991973
MOL1	26991973
acts	26991973
in	26991973
an	26991973
opposing	26991973
manner	26991973
to	26991973
the	26991973
CLE41	26991973
/	26991973
PXY	26991973
module	26991973
and	26991973
that	26991973
changing	26991973
the	26991973
domain	26991973
or	26991973
level	26991973
of	26991973
MOL1	26991973
expression	26991973
both	26991973
result	26991973
in	26991973
disturbed	26991973
cambium	26991973
organization	26991973
.	26991973

Underlining	26991973
discrete	26991973
roles	26991973
of	26991973
MOL1	26991973
and	26991973
PXY	26991973
,	26991973
both	26991973
LRR	26991973
-	26991973
RLKs	26991973
are	26991973
not	26991973
able	26991973
to	26991973
replace	26991973
each	26991973
other	26991973
when	26991973
their	26991973
expression	26991973
domains	26991973
are	26991973
interchanged	26991973
.	26991973

Furthermore	26991973
,	26991973
MOL1	26991973
but	26991973
not	26991973
PXY	26991973
is	26991973
able	26991973
to	26991973
rescue	26991973
CLV1	26991973
deficiency	26991973
in	26991973
the	26991973
shoot	26991973
apical	26991973
meristem	26991973
.	26991973

By	26991973
identifying	26991973
genes	26991973
mis	26991973
-	26991973
expressed	26991973
in	26991973
mol1	26991973
mutants	26991973
,	26991973
we	26991973
demonstrate	26991973
that	26991973
MOL1	26991973
represses	26991973
genes	26991973
associated	26991973
with	26991973
stress	26991973
-	26991973
related	26991973
ethylene	26991973
and	26991973
jasmonic	26991973
acid	26991973
hormone	26991973
signaling	26991973
pathways	26991973
which	26991973
have	26991973
known	26991973
roles	26991973
in	26991973
coordinating	26991973
lateral	26991973
growth	26991973
of	26991973
the	26991973
Arabidopsis	26991973
stem	26991973
.	26991973

Our	26991973
findings	26991973
provide	26991973
evidence	26991973
that	26991973
common	26991973
regulatory	26991973
mechanisms	26991973
in	26991973
different	26991973
plant	26991973
stem	26991973
cell	26991973
niches	26991973
are	26991973
adapted	26991973
to	26991973
specific	26991973
niche	26991973
anatomies	26991973
and	26991973
emphasize	26991973
the	26991973
importance	26991973
of	26991973
a	26991973
complex	26991973
spatial	26991973
organization	26991973
of	26991973
intercellular	26991973
signaling	26991973
cascades	26991973
for	26991973
a	26991973
strictly	26991973
bidirectional	26991973
tissue	26991973
production	26991973
.	26991973
R58fs	18945288
mutation	18945288
in	18945288
the	18945288
HGD	18945288
gene	18945288
in	18945288
a	18945288
family	18945288
with	18945288
alkaptonuria	18945288
in	18945288
the	18945288
UAE	18945288
.	18945288

This	18945288
study	18945288
was	18945288
conducted	18945288
to	18945288
determine	18945288
the	18945288
prevalence	18945288
of	18945288
alkaptonuria	18945288
in	18945288
the	18945288
UAE	18945288
population	18945288
and	18945288
to	18945288
identify	18945288
the	18945288
genotype	18945288
of	18945288
affected	18945288
individuals	18945288
.	18945288

In	18945288
a	18945288
3	18945288
stage	18945288
sampling	18945288
technique	18945288
2981	18945288
pupils	18945288
from	18945288
Government	18945288
schools	18945288
in	18945288
Al	18945288
Ain	18945288
and	18945288
private	18945288
schools	18945288
in	18945288
Dubai	18945288
were	18945288
selected	18945288
to	18945288
take	18945288
part	18945288
in	18945288
the	18945288
study	18945288
,	18945288
of	18945288
whom	18945288
2857	18945288
provided	18945288
urine	18945288
samples	18945288
.	18945288

Urine	18945288
collected	18945288
was	18945288
analysed	18945288
for	18945288
homogentisic	18945288
acid	18945288
by	18945288
gas	18945288
chromatography	18945288
-	18945288
mass	18945288
spectrometry	18945288
.	18945288

Genomic	18945288
DNA	18945288
was	18945288
isolated	18945288
from	18945288
the	18945288
white	18945288
blood	18945288
cells	18945288
of	18945288
all	18945288
family	18945288
members	18945288
of	18945288
the	18945288
affected	18945288
case	18945288
following	18945288
standard	18945288
established	18945288
protocols	18945288
.	18945288

Specific	18945288
PRC	18945288
primers	18945288
were	18945288
designed	18945288
to	18945288
amplify	18945288
all	18945288
14	18945288
exons	18945288
of	18945288
the	18945288
HGD	18945288
gene	18945288
with	18945288
the	18945288
flanking	18945288
intronic	18945288
sequences	18945288
including	18945288
the	18945288
splice	18945288
site	18945288
sequences	18945288
.	18945288

2857	18945288
children	18945288
returned	18945288
a	18945288
viable	18945288
urine	18945288
sample	18945288
,	18945288
of	18945288
which	18945288
one	18945288
was	18945288
highly	18945288
positive	18945288
for	18945288
homogentisic	18945288
acid	18945288
.	18945288

All	18945288
12	18945288
members	18945288
of	18945288
this	18945288
girl	18945288
'	18945288
s	18945288
family	18945288
were	18945288
studied	18945288
and	18945288
one	18945288
,	18945288
a	18945288
22	18945288
year	18945288
old	18945288
brother	18945288
,	18945288
was	18945288
found	18945288
to	18945288
excrete	18945288
HGA	18945288
.	18945288

Another	18945288
,	18945288
a	18945288
sister	18945288
who	18945288
had	18945288
not	18945288
provided	18945288
a	18945288
urine	18945288
sample	18945288
,	18945288
was	18945288
discovered	18945288
by	18945288
genetic	18945288
testing	18945288
.	18945288

There	18945288
were	18945288
no	18945288
complaints	18945288
of	18945288
joint	18945288
pain	18945288
or	18945288
other	18945288
symptoms	18945288
in	18945288
any	18945288
member	18945288
of	18945288
this	18945288
family	18945288
.	18945288

Parents	18945288
were	18945288
first	18945288
cousins	18945288
.	18945288

We	18945288
found	18945288
a	18945288
single	18945288
nucleotide	18945288
deletion	18945288
c	18945288
.	18945288
342delA	18945288
,	18945288
located	18945288
in	18945288
exon	18945288
3	18945288
,	18945288
which	18945288
resulted	18945288
in	18945288
a	18945288
frameshift	18945288
at	18945288
amino	18945288
acid	18945288
position	18945288
58	18945288
(	18945288
p	18945288
.	18945288
Arg58fs	18945288
or	18945288
p	18945288
.	18945288
R58fs	18945288
)	18945288
.	18945288

Alkaptonuria	18945288
may	18945288
be	18945288
more	18945288
common	18945288
than	18945288
it	18945288
is	18945288
thought	18945288
to	18945288
be	18945288
with	18945288
an	18945288
allele	18945288
prevalence	18945288
estimated	18945288
at	18945288
0	18945288
.	18945288
0107	18945288
(	18945288
95%	18945288
CI	18945288
0	18945288
.	18945288
000392	18945288
-	18945288
0	18945288
.	18945288
03473	18945288
)	18945288
.	18945288

The	18945288
R58fs	18945288
mutation	18945288
is	18945288
old	18945288
,	18945288
perhaps	18945288
having	18945288
occurred	18945288
several	18945288
thousand	18945288
years	18945288
ago	18945288
,	18945288
and	18945288
has	18945288
spread	18945288
over	18945288
a	18945288
large	18945288
geographical	18945288
area	18945288
.	18945288
5	16369751
-	16369751
Fluorouracil	16369751
cardiotoxicity	16369751
induced	16369751
by	16369751
alpha	16369751
-	16369751
fluoro	16369751
-	16369751
beta	16369751
-	16369751
alanine	16369751
.	16369751

Cardiotoxicity	16369751
is	16369751
a	16369751
rare	16369751
complication	16369751
occurring	16369751
during	16369751
5	16369751
-	16369751
fluorouracil	16369751
(	16369751
5	16369751
-	16369751
FU	16369751
)	16369751
treatment	16369751
for	16369751
malignancies	16369751
.	16369751

We	16369751
herein	16369751
report	16369751
the	16369751
case	16369751
of	16369751
a	16369751
70	16369751
-	16369751
year	16369751
-	16369751
old	16369751
man	16369751
with	16369751
5	16369751
-	16369751
FU	16369751
-	16369751
induced	16369751
cardiotoxicity	16369751
,	16369751
in	16369751
whom	16369751
a	16369751
high	16369751
serum	16369751
level	16369751
of	16369751
alpha	16369751
-	16369751
fluoro	16369751
-	16369751
beta	16369751
-	16369751
alanine	16369751
(	16369751
FBAL	16369751
)	16369751
was	16369751
observed	16369751
.	16369751

The	16369751
patient	16369751
,	16369751
who	16369751
had	16369751
unresectable	16369751
colon	16369751
cancer	16369751
metastases	16369751
to	16369751
the	16369751
liver	16369751
and	16369751
lung	16369751
,	16369751
was	16369751
referred	16369751
to	16369751
us	16369751
for	16369751
chemotherapy	16369751
from	16369751
an	16369751
affiliated	16369751
hospital	16369751
;	16369751
he	16369751
had	16369751
no	16369751
cardiac	16369751
history	16369751
.	16369751

After	16369751
admission	16369751
,	16369751
the	16369751
patient	16369751
received	16369751
a	16369751
continuous	16369751
intravenous	16369751
infusion	16369751
of	16369751
5	16369751
-	16369751
FU	16369751
(	16369751
1000	16369751
mg	16369751
/	16369751
day	16369751
)	16369751
,	16369751
during	16369751
which	16369751
precordial	16369751
pain	16369751
with	16369751
right	16369751
bundle	16369751
branch	16369751
block	16369751
occurred	16369751
concomitantly	16369751
with	16369751
a	16369751
high	16369751
serum	16369751
FBAL	16369751
concentration	16369751
of	16369751
1955	16369751
ng	16369751
/	16369751
ml	16369751
.	16369751

Both	16369751
the	16369751
precordial	16369751
pain	16369751
and	16369751
the	16369751
electrocardiographic	16369751
changes	16369751
disappeared	16369751
spontaneously	16369751
after	16369751
the	16369751
discontinuation	16369751
of	16369751
5	16369751
-	16369751
FU	16369751
.	16369751

As	16369751
the	16369751
precordial	16369751
pain	16369751
in	16369751
this	16369751
patient	16369751
was	16369751
considered	16369751
to	16369751
have	16369751
been	16369751
due	16369751
to	16369751
5	16369751
-	16369751
FU	16369751
-	16369751
induced	16369751
cardiotoxicity	16369751
,	16369751
the	16369751
administration	16369751
of	16369751
5	16369751
-	16369751
FU	16369751
was	16369751
abandoned	16369751
.	16369751

Instead	16369751
,	16369751
oral	16369751
administration	16369751
of	16369751
S	16369751
-	16369751
1	16369751
(	16369751
a	16369751
derivative	16369751
of	16369751
5	16369751
-	16369751
FU	16369751
)	16369751
,	16369751
at	16369751
200	16369751
mg	16369751
/	16369751
day	16369751
twice	16369751
a	16369751
week	16369751
,	16369751
was	16369751
instituted	16369751
,	16369751
because	16369751
S	16369751
-	16369751
1	16369751
has	16369751
a	16369751
strong	16369751
inhibitory	16369751
effect	16369751
on	16369751
dihydropyrimidine	16369751
dehydrogenase	16369751
,	16369751
which	16369751
catalyzes	16369751
the	16369751
degradative	16369751
of	16369751
5	16369751
-	16369751
FU	16369751
into	16369751
FBAL	16369751
.	16369751

The	16369751
serum	16369751
FBAL	16369751
concentration	16369751
subsequently	16369751
decreased	16369751
to	16369751
352	16369751
ng	16369751
/	16369751
ml	16369751
,	16369751
the	16369751
same	16369751
as	16369751
the	16369751
value	16369751
measured	16369751
on	16369751
the	16369751
first	16369751
day	16369751
of	16369751
S	16369751
-	16369751
1	16369751
administration	16369751
.	16369751

Thereafter	16369751
,	16369751
no	16369751
cardiac	16369751
symptoms	16369751
were	16369751
observed	16369751
.	16369751

The	16369751
patient	16369751
achieved	16369751
a	16369751
partial	16369751
response	16369751
6	16369751
months	16369751
after	16369751
the	16369751
initiation	16369751
of	16369751
the	16369751
S	16369751
-	16369751
1	16369751
treatment	16369751
.	16369751

The	16369751
experience	16369751
of	16369751
this	16369751
case	16369751
,	16369751
together	16369751
with	16369751
a	16369751
review	16369751
of	16369751
the	16369751
literature	16369751
,	16369751
suggests	16369751
that	16369751
FBAL	16369751
is	16369751
related	16369751
to	16369751
5	16369751
-	16369751
FU	16369751
-	16369751
induced	16369751
cardiotoxicity	16369751
.	16369751

S	16369751
-	16369751
1	16369751
may	16369751
be	16369751
administered	16369751
safely	16369751
to	16369751
patients	16369751
with	16369751
5	16369751
-	16369751
FU	16369751
-	16369751
induced	16369751
cardiotoxicity	16369751
.	16369751
Hypoglycemic	28487437
Effect	28487437
of	28487437
Combined	28487437
Ghrelin	28487437
and	28487437
Glucagon	28487437
Receptor	28487437
Blockade	28487437
.	28487437

Glucagon	28487437
receptor	28487437
(	28487437
GcgR	28487437
)	28487437
blockade	28487437
has	28487437
been	28487437
proposed	28487437
as	28487437
an	28487437
alternative	28487437
to	28487437
insulin	28487437
monotherapy	28487437
for	28487437
treating	28487437
type	28487437
1	28487437
diabetes	28487437
since	28487437
deletion	28487437
or	28487437
inhibition	28487437
of	28487437
GcgRs	28487437
corrects	28487437
hyperglycemia	28487437
in	28487437
models	28487437
of	28487437
diabetes	28487437
.	28487437

The	28487437
factors	28487437
regulating	28487437
glycemia	28487437
in	28487437
a	28487437
setting	28487437
devoid	28487437
of	28487437
insulin	28487437
and	28487437
glucagon	28487437
function	28487437
remain	28487437
unclear	28487437
but	28487437
may	28487437
include	28487437
the	28487437
hormone	28487437
ghrelin	28487437
.	28487437

Not	28487437
only	28487437
is	28487437
ghrelin	28487437
release	28487437
controlled	28487437
by	28487437
glucose	28487437
but	28487437
also	28487437
ghrelin	28487437
has	28487437
many	28487437
actions	28487437
that	28487437
can	28487437
raise	28487437
or	28487437
reduce	28487437
falls	28487437
in	28487437
blood	28487437
glucose	28487437
level	28487437
.	28487437

Here	28487437
,	28487437
we	28487437
tested	28487437
the	28487437
hypothesis	28487437
that	28487437
ghrelin	28487437
rises	28487437
to	28487437
prevent	28487437
hypoglycemia	28487437
in	28487437
the	28487437
absence	28487437
of	28487437
glucagon	28487437
function	28487437
.	28487437

Both	28487437
GcgR	28487437
knockout	28487437
(	28487437
Gcgr	28487437
(	28487437
-	28487437
/	28487437
-	28487437
)	28487437
)	28487437
mice	28487437
and	28487437
db	28487437
/	28487437
db	28487437
mice	28487437
that	28487437
were	28487437
administered	28487437
GcgR	28487437
monoclonal	28487437
antibody	28487437
displayed	28487437
lower	28487437
blood	28487437
glucose	28487437
levels	28487437
accompanied	28487437
by	28487437
elevated	28487437
plasma	28487437
ghrelin	28487437
levels	28487437
.	28487437

Although	28487437
treatment	28487437
with	28487437
the	28487437
pancreatic	28487437
b	28487437
-	28487437
cell	28487437
toxin	28487437
streptozotocin	28487437
induced	28487437
hyperglycemia	28487437
and	28487437
raised	28487437
plasma	28487437
ghrelin	28487437
levels	28487437
in	28487437
wild	28487437
-	28487437
type	28487437
mice	28487437
,	28487437
hyperglycemia	28487437
was	28487437
averted	28487437
in	28487437
similarly	28487437
treated	28487437
Gcgr	28487437
(	28487437
-	28487437
/	28487437
-	28487437
)	28487437
mice	28487437
and	28487437
the	28487437
plasma	28487437
ghrelin	28487437
level	28487437
was	28487437
further	28487437
increased	28487437
.	28487437

Notably	28487437
,	28487437
administration	28487437
of	28487437
a	28487437
ghrelin	28487437
receptor	28487437
antagonist	28487437
further	28487437
reduced	28487437
blood	28487437
glucose	28487437
levels	28487437
into	28487437
the	28487437
markedly	28487437
hypoglycemic	28487437
range	28487437
in	28487437
overnight	28487437
-	28487437
fasted	28487437
,	28487437
streptozotocin	28487437
-	28487437
treated	28487437
Gcgr	28487437
(	28487437
-	28487437
/	28487437
-	28487437
)	28487437
mice	28487437
.	28487437

A	28487437
lowered	28487437
blood	28487437
glucose	28487437
level	28487437
also	28487437
was	28487437
observed	28487437
in	28487437
overnight	28487437
-	28487437
fasted	28487437
,	28487437
streptozotocin	28487437
-	28487437
treated	28487437
ghrelin	28487437
receptor	28487437
-	28487437
null	28487437
mice	28487437
that	28487437
were	28487437
administered	28487437
GcgR	28487437
monoclonal	28487437
antibody	28487437
.	28487437

These	28487437
data	28487437
suggest	28487437
that	28487437
when	28487437
glucagon	28487437
activity	28487437
is	28487437
blocked	28487437
in	28487437
the	28487437
setting	28487437
of	28487437
type	28487437
1	28487437
diabetes	28487437
,	28487437
the	28487437
plasma	28487437
ghrelin	28487437
level	28487437
rises	28487437
,	28487437
preventing	28487437
hypoglycemia	28487437
.	28487437
Star	28151486
-	28151486
PAP	28151486
,	28151486
a	28151486
poly	28151486
(	28151486
A	28151486
)	28151486
polymerase	28151486
,	28151486
functions	28151486
as	28151486
a	28151486
tumor	28151486
suppressor	28151486
in	28151486
an	28151486
orthotopic	28151486
human	28151486
breast	28151486
cancer	28151486
model	28151486
.	28151486

Star	28151486
-	28151486
PAP	28151486
is	28151486
a	28151486
noncanonical	28151486
poly	28151486
(	28151486
A	28151486
)	28151486
polymerase	28151486
and	28151486
required	28151486
for	28151486
the	28151486
expression	28151486
of	28151486
a	28151486
select	28151486
set	28151486
of	28151486
mRNAs	28151486
.	28151486

However	28151486
,	28151486
the	28151486
pathological	28151486
role	28151486
of	28151486
Star	28151486
-	28151486
PAP	28151486
in	28151486
cancer	28151486
largely	28151486
remains	28151486
unknown	28151486
.	28151486

In	28151486
this	28151486
study	28151486
,	28151486
we	28151486
observed	28151486
decreased	28151486
expression	28151486
of	28151486
Star	28151486
-	28151486
PAP	28151486
in	28151486
breast	28151486
cancer	28151486
cell	28151486
lines	28151486
and	28151486
tissues	28151486
.	28151486

Ectopic	28151486
Star	28151486
-	28151486
PAP	28151486
expression	28151486
inhibited	28151486
proliferation	28151486
as	28151486
well	28151486
as	28151486
colony	28151486
-	28151486
forming	28151486
ability	28151486
of	28151486
breast	28151486
cancer	28151486
cells	28151486
.	28151486

In	28151486
breast	28151486
cancer	28151486
patients	28151486
,	28151486
high	28151486
levels	28151486
of	28151486
Star	28151486
-	28151486
PAP	28151486
correlated	28151486
with	28151486
an	28151486
improved	28151486
prognosis	28151486
.	28151486

Moreover	28151486
,	28151486
by	28151486
regulating	28151486
the	28151486
expression	28151486
of	28151486
BIK	28151486
(	28151486
BCL2	28151486
-	28151486
interacting	28151486
killer	28151486
)	28151486
,	28151486
Star	28151486
-	28151486
PAP	28151486
induced	28151486
apoptosis	28151486
of	28151486
breast	28151486
cancer	28151486
cells	28151486
through	28151486
the	28151486
mitochondrial	28151486
pathway	28151486
.	28151486

The	28151486
growth	28151486
of	28151486
breast	28151486
cancer	28151486
xenografts	28151486
in	28151486
NOD	28151486
/	28151486
SCID	28151486
mice	28151486
was	28151486
also	28151486
inhibited	28151486
by	28151486
the	28151486
doxycycline	28151486
-	28151486
induced	28151486
Star	28151486
-	28151486
PAP	28151486
overexpression	28151486
.	28151486

Furthermore	28151486
,	28151486
Star	28151486
-	28151486
PAP	28151486
sensitized	28151486
breast	28151486
cancer	28151486
cells	28151486
to	28151486
chemotherapy	28151486
drugs	28151486
both	28151486
in	28151486
vitro	28151486
and	28151486
in	28151486
vivo	28151486
.	28151486

In	28151486
mammary	28151486
epithelial	28151486
cells	28151486
,	28151486
Star	28151486
-	28151486
PAP	28151486
knockdown	28151486
partially	28151486
transformed	28151486
these	28151486
cells	28151486
and	28151486
induced	28151486
them	28151486
to	28151486
undergo	28151486
epithelial	28151486
-	28151486
mesenchymal	28151486
transition	28151486
(	28151486
EMT	28151486
)	28151486
.	28151486

These	28151486
findings	28151486
suggested	28151486
that	28151486
Star	28151486
-	28151486
PAP	28151486
possesses	28151486
tumor	28151486
-	28151486
suppressing	28151486
activity	28151486
and	28151486
can	28151486
be	28151486
a	28151486
valuable	28151486
target	28151486
for	28151486
developing	28151486
new	28151486
cancer	28151486
therapeutic	28151486
strategies	28151486
.	28151486
Chronic	24842192
treatment	24842192
with	24842192
metformin	24842192
suppresses	24842192
toll	24842192
-	24842192
like	24842192
receptor	24842192
4	24842192
signaling	24842192
and	24842192
attenuates	24842192
left	24842192
ventricular	24842192
dysfunction	24842192
following	24842192
myocardial	24842192
infarction	24842192
.	24842192

Acute	24842192
treatment	24842192
with	24842192
metformin	24842192
has	24842192
a	24842192
protective	24842192
effect	24842192
in	24842192
myocardial	24842192
infarction	24842192
by	24842192
suppression	24842192
of	24842192
inflammatory	24842192
responses	24842192
due	24842192
to	24842192
activation	24842192
of	24842192
AMP	24842192
-	24842192
activated	24842192
protein	24842192
kinase	24842192
(	24842192
AMPK	24842192
)	24842192
.	24842192

In	24842192
the	24842192
present	24842192
study	24842192
,	24842192
the	24842192
effect	24842192
of	24842192
chronic	24842192
pre	24842192
-	24842192
treatment	24842192
with	24842192
metformin	24842192
on	24842192
cardiac	24842192
dysfunction	24842192
and	24842192
toll	24842192
-	24842192
like	24842192
receptor	24842192
4	24842192
(	24842192
TLR4	24842192
)	24842192
activities	24842192
following	24842192
myocardial	24842192
infarction	24842192
and	24842192
their	24842192
relation	24842192
with	24842192
AMPK	24842192
were	24842192
assessed	24842192
.	24842192

Male	24842192
Wistar	24842192
rats	24842192
were	24842192
randomly	24842192
assigned	24842192
to	24842192
one	24842192
of	24842192
5	24842192
groups	24842192
(	24842192
n	24842192
=	24842192
6	24842192
)	24842192
:	24842192
normal	24842192
control	24842192
and	24842192
groups	24842192
were	24842192
injected	24842192
isoproterenol	24842192
after	24842192
chronic	24842192
pre	24842192
-	24842192
treatment	24842192
with	24842192
0	24842192
,	24842192
25	24842192
,	24842192
50	24842192
,	24842192
or	24842192
100mg	24842192
/	24842192
kg	24842192
of	24842192
metformin	24842192
twice	24842192
daily	24842192
for	24842192
14	24842192
days	24842192
.	24842192

Isoproterenol	24842192
(	24842192
100mg	24842192
/	24842192
kg	24842192
)	24842192
was	24842192
injected	24842192
subcutaneously	24842192
on	24842192
the	24842192
13th	24842192
and	24842192
14th	24842192
days	24842192
to	24842192
induce	24842192
acute	24842192
myocardial	24842192
infarction	24842192
.	24842192

Isoproterenol	24842192
alone	24842192
decreased	24842192
left	24842192
ventricular	24842192
systolic	24842192
pressure	24842192
and	24842192
myocardial	24842192
contractility	24842192
indexed	24842192
as	24842192
LVdp	24842192
/	24842192
dtmax	24842192
and	24842192
LVdp	24842192
/	24842192
dtmin	24842192
.	24842192

The	24842192
left	24842192
ventricular	24842192
dysfunction	24842192
was	24842192
significantly	24842192
lower	24842192
in	24842192
the	24842192
groups	24842192
treated	24842192
with	24842192
25	24842192
and	24842192
50mg	24842192
/	24842192
kg	24842192
of	24842192
metformin	24842192
.	24842192

Metfromin	24842192
markedly	24842192
lowered	24842192
isoproterenol	24842192
-	24842192
induced	24842192
elevation	24842192
in	24842192
the	24842192
levels	24842192
of	24842192
TLR4	24842192
mRNA	24842192
,	24842192
myeloid	24842192
differentiation	24842192
protein	24842192
88	24842192
(	24842192
MyD88	24842192
)	24842192
,	24842192
tumor	24842192
necrosis	24842192
factor	24842192
-	24842192
alpha	24842192
(	24842192
TNF	24842192
-	24842192
a	24842192
)	24842192
,	24842192
and	24842192
interleukin	24842192
6	24842192
(	24842192
IL	24842192
-	24842192
6	24842192
)	24842192
in	24842192
the	24842192
heart	24842192
tissues	24842192
.	24842192

Similar	24842192
changes	24842192
were	24842192
also	24842192
seen	24842192
in	24842192
the	24842192
serum	24842192
levels	24842192
of	24842192
TNF	24842192
-	24842192
a	24842192
and	24842192
IL	24842192
-	24842192
6	24842192
.	24842192

However	24842192
,	24842192
the	24842192
lower	24842192
doses	24842192
of	24842192
25	24842192
and	24842192
50mg	24842192
/	24842192
kg	24842192
were	24842192
more	24842192
effective	24842192
than	24842192
100mg	24842192
/	24842192
kg	24842192
.	24842192

Phosphorylated	24842192
AMPKa	24842192
(	24842192
p	24842192
-	24842192
AMPK	24842192
)	24842192
in	24842192
the	24842192
myocardium	24842192
was	24842192
significantly	24842192
elevated	24842192
by	24842192
25mg	24842192
/	24842192
kg	24842192
of	24842192
metformin	24842192
,	24842192
slightly	24842192
by	24842192
50mg	24842192
/	24842192
kg	24842192
,	24842192
but	24842192
not	24842192
by	24842192
100mg	24842192
/	24842192
kg	24842192
.	24842192

Chronic	24842192
pre	24842192
-	24842192
treatment	24842192
with	24842192
metformin	24842192
reduces	24842192
post	24842192
-	24842192
myocardial	24842192
infarction	24842192
cardiac	24842192
dysfunction	24842192
and	24842192
suppresses	24842192
inflammatory	24842192
responses	24842192
,	24842192
possibly	24842192
through	24842192
inhibition	24842192
of	24842192
TLR4	24842192
activities	24842192
.	24842192

This	24842192
mechanism	24842192
can	24842192
be	24842192
considered	24842192
as	24842192
a	24842192
target	24842192
to	24842192
protect	24842192
infarcted	24842192
myocardium	24842192
.	24842192
Identification	18046082
of	18046082
apolipoprotein	18046082
E	18046082
Guangzhou	18046082
(	18046082
arginine	18046082
150	18046082
proline	18046082
)	18046082
,	18046082
a	18046082
new	18046082
variant	18046082
associated	18046082
with	18046082
lipoprotein	18046082
glomerulopathy	18046082
.	18046082

BACKGROUND	18046082
/	18046082
AIMS	18046082
:	18046082
Lipoprotein	18046082
glomerulopathy	18046082
(	18046082
LPG	18046082
)	18046082
is	18046082
a	18046082
rare	18046082
disease	18046082
characterized	18046082
by	18046082
thrombus	18046082
-	18046082
like	18046082
substances	18046082
in	18046082
markedly	18046082
dilated	18046082
glomerular	18046082
capillaries	18046082
and	18046082
elevated	18046082
plasma	18046082
levels	18046082
of	18046082
apolipoprotein	18046082
E	18046082
(	18046082
apoE	18046082
)	18046082
.	18046082

Previous	18046082
studies	18046082
have	18046082
shown	18046082
that	18046082
genetic	18046082
disorders	18046082
of	18046082
apoE	18046082
may	18046082
contribute	18046082
to	18046082
the	18046082
pathogenesis	18046082
of	18046082
LPG	18046082
,	18046082
but	18046082
LPG	18046082
may	18046082
not	18046082
be	18046082
caused	18046082
by	18046082
apoE	18046082
gene	18046082
mutations	18046082
in	18046082
Chinese	18046082
patients	18046082
.	18046082

This	18046082
study	18046082
investigated	18046082
the	18046082
association	18046082
of	18046082
a	18046082
new	18046082
variant	18046082
of	18046082
apoE	18046082
with	18046082
LPG	18046082
in	18046082
a	18046082
Chinese	18046082
family	18046082
.	18046082

METHODS	18046082
:	18046082
The	18046082
apoE	18046082
gene	18046082
in	18046082
a	18046082
family	18046082
with	18046082
4	18046082
LPG	18046082
patients	18046082
was	18046082
sequenced	18046082
.	18046082

The	18046082
polymerase	18046082
chain	18046082
reaction	18046082
product	18046082
of	18046082
coding	18046082
region	18046082
of	18046082
apoE	18046082
exon	18046082
4	18046082
was	18046082
cloned	18046082
into	18046082
pMD	18046082
18	18046082
-	18046082
T	18046082
vector	18046082
and	18046082
then	18046082
sequenced	18046082
.	18046082

RESULTS	18046082
:	18046082
A	18046082
novel	18046082
point	18046082
mutation	18046082
in	18046082
exon	18046082
4	18046082
of	18046082
the	18046082
apoE	18046082
gene	18046082
was	18046082
identified	18046082
in	18046082
all	18046082
4	18046082
LPG	18046082
patients	18046082
and	18046082
1	18046082
asymptomatic	18046082
family	18046082
member	18046082
.	18046082

Sequence	18046082
analysis	18046082
confirmed	18046082
a	18046082
nucleotide	18046082
G	18046082
to	18046082
C	18046082
point	18046082
mutation	18046082
in	18046082
exon	18046082
4	18046082
(	18046082
base	18046082
308	18046082
)	18046082
of	18046082
the	18046082
apoE	18046082
gene	18046082
in	18046082
all	18046082
patients	18046082
and	18046082
the	18046082
asymptomatic	18046082
family	18046082
member	18046082
.	18046082

This	18046082
missense	18046082
mutation	18046082
denotes	18046082
amino	18046082
acid	18046082
substitution	18046082
of	18046082
the	18046082
proline	18046082
residue	18046082
for	18046082
arginine	18046082
residue	18046082
at	18046082
position	18046082
150	18046082
of	18046082
apoE	18046082
.	18046082

Those	18046082
patients	18046082
were	18046082
all	18046082
heterozygotes	18046082
with	18046082
apoE	18046082
Guangzhou	18046082
.	18046082

One	18046082
of	18046082
2	18046082
grandsons	18046082
was	18046082
a	18046082
heterozygous	18046082
carrier	18046082
of	18046082
apoE	18046082
Guangzhou	18046082
,	18046082
although	18046082
he	18046082
did	18046082
not	18046082
have	18046082
proteinuria	18046082
.	18046082

CONCLUSION	18046082
:	18046082
The	18046082
results	18046082
of	18046082
this	18046082
study	18046082
suggest	18046082
that	18046082
apoE	18046082
(	18046082
arginine	18046082
150	18046082
proline	18046082
)	18046082
is	18046082
a	18046082
novel	18046082
apoE	18046082
variant	18046082
that	18046082
etiologically	18046082
related	18046082
to	18046082
LPG	18046082
.	18046082

This	18046082
variant	18046082
(	18046082
apoE	18046082
Guangzhou	18046082
)	18046082
may	18046082
cause	18046082
a	18046082
marked	18046082
molecular	18046082
conformational	18046082
change	18046082
of	18046082
the	18046082
apoE	18046082
and	18046082
thus	18046082
impair	18046082
its	18046082
binding	18046082
ability	18046082
to	18046082
lipids	18046082
.	18046082
A	17033686
two	17033686
base	17033686
pair	17033686
deletion	17033686
in	17033686
the	17033686
PQBP1	17033686
gene	17033686
is	17033686
associated	17033686
with	17033686
microphthalmia	17033686
,	17033686
microcephaly	17033686
,	17033686
and	17033686
mental	17033686
retardation	17033686
.	17033686

X	17033686
-	17033686
linked	17033686
mental	17033686
retardation	17033686
has	17033686
been	17033686
traditionally	17033686
divided	17033686
into	17033686
syndromic	17033686
(	17033686
S	17033686
-	17033686
XLMR	17033686
)	17033686
and	17033686
non	17033686
-	17033686
syndromic	17033686
forms	17033686
(	17033686
NS	17033686
-	17033686
XLMR	17033686
)	17033686
,	17033686
although	17033686
the	17033686
borderlines	17033686
between	17033686
these	17033686
phenotypes	17033686
begin	17033686
to	17033686
vanish	17033686
and	17033686
mutations	17033686
in	17033686
a	17033686
single	17033686
gene	17033686
,	17033686
for	17033686
example	17033686
PQBP1	17033686
,	17033686
can	17033686
cause	17033686
S	17033686
-	17033686
XLMR	17033686
as	17033686
well	17033686
as	17033686
NS	17033686
-	17033686
XLMR	17033686
.	17033686

Here	17033686
,	17033686
we	17033686
report	17033686
two	17033686
maternal	17033686
cousins	17033686
with	17033686
an	17033686
apparently	17033686
X	17033686
-	17033686
linked	17033686
phenotype	17033686
of	17033686
mental	17033686
retardation	17033686
(	17033686
MR	17033686
)	17033686
,	17033686
microphthalmia	17033686
,	17033686
choroid	17033686
coloboma	17033686
,	17033686
microcephaly	17033686
,	17033686
renal	17033686
hypoplasia	17033686
,	17033686
and	17033686
spastic	17033686
paraplegia	17033686
.	17033686

By	17033686
multipoint	17033686
linkage	17033686
analysis	17033686
with	17033686
markers	17033686
spanning	17033686
the	17033686
entire	17033686
X	17033686
-	17033686
chromosome	17033686
we	17033686
mapped	17033686
the	17033686
disease	17033686
locus	17033686
to	17033686
a	17033686
28	17033686
-	17033686
Mb	17033686
interval	17033686
between	17033686
Xp11	17033686
.	17033686
4	17033686
and	17033686
Xq12	17033686
,	17033686
including	17033686
the	17033686
BCOR	17033686
gene	17033686
.	17033686

A	17033686
missense	17033686
mutation	17033686
in	17033686
BCOR	17033686
was	17033686
described	17033686
in	17033686
a	17033686
family	17033686
with	17033686
Lenz	17033686
microphthalmia	17033686
syndrome	17033686
,	17033686
a	17033686
phenotype	17033686
showing	17033686
substantial	17033686
overlapping	17033686
features	17033686
with	17033686
that	17033686
described	17033686
in	17033686
the	17033686
two	17033686
cousins	17033686
.	17033686

However	17033686
,	17033686
no	17033686
mutation	17033686
in	17033686
the	17033686
BCOR	17033686
gene	17033686
was	17033686
found	17033686
in	17033686
both	17033686
patients	17033686
.	17033686

Subsequent	17033686
mutation	17033686
analysis	17033686
of	17033686
PQBP1	17033686
,	17033686
located	17033686
within	17033686
the	17033686
delineated	17033686
linkage	17033686
interval	17033686
in	17033686
Xp11	17033686
.	17033686
23	17033686
,	17033686
revealed	17033686
a	17033686
2	17033686
-	17033686
bp	17033686
deletion	17033686
,	17033686
c	17033686
.	17033686
461_462delAG	17033686
,	17033686
that	17033686
cosegregated	17033686
with	17033686
the	17033686
disease	17033686
.	17033686

Notably	17033686
,	17033686
the	17033686
same	17033686
mutation	17033686
is	17033686
associated	17033686
with	17033686
the	17033686
Hamel	17033686
cerebropalatocardiac	17033686
syndrome	17033686
,	17033686
another	17033686
form	17033686
of	17033686
S	17033686
-	17033686
XLMR	17033686
.	17033686

Haplotype	17033686
analysis	17033686
suggests	17033686
a	17033686
germline	17033686
mosaicism	17033686
of	17033686
the	17033686
2	17033686
-	17033686
bp	17033686
deletion	17033686
in	17033686
the	17033686
maternal	17033686
grandmother	17033686
of	17033686
both	17033686
affected	17033686
individuals	17033686
.	17033686

In	17033686
summary	17033686
,	17033686
our	17033686
findings	17033686
demonstrate	17033686
for	17033686
the	17033686
first	17033686
time	17033686
that	17033686
mutations	17033686
in	17033686
PQBP1	17033686
are	17033686
associated	17033686
with	17033686
an	17033686
S	17033686
-	17033686
XLMR	17033686
phenotype	17033686
including	17033686
microphthalmia	17033686
,	17033686
thereby	17033686
further	17033686
extending	17033686
the	17033686
clinical	17033686
spectrum	17033686
of	17033686
phenotypes	17033686
associated	17033686
with	17033686
PQBP1	17033686
mutations	17033686
.	17033686
Genetic	16418600
investigation	16418600
of	16418600
the	16418600
TSPYL1	16418600
gene	16418600
in	16418600
sudden	16418600
infant	16418600
death	16418600
syndrome	16418600
.	16418600

BACKGROUND	16418600
:	16418600
Sudden	16418600
infant	16418600
death	16418600
syndrome	16418600
(	16418600
SIDS	16418600
)	16418600
constitutes	16418600
the	16418600
most	16418600
frequent	16418600
cause	16418600
of	16418600
death	16418600
in	16418600
the	16418600
postperinatal	16418600
period	16418600
in	16418600
Germany	16418600
.	16418600

Recently	16418600
,	16418600
a	16418600
lethal	16418600
phenotype	16418600
characterized	16418600
by	16418600
sudden	16418600
infant	16418600
death	16418600
with	16418600
dysgenesis	16418600
of	16418600
the	16418600
testes	16418600
syndrome	16418600
(	16418600
SIDDT	16418600
)	16418600
was	16418600
identified	16418600
to	16418600
be	16418600
caused	16418600
by	16418600
loss	16418600
of	16418600
function	16418600
mutations	16418600
in	16418600
the	16418600
TSPYL1	16418600
gene	16418600
.	16418600

PURPOSE	16418600
:	16418600
The	16418600
study	16418600
'	16418600
s	16418600
purpose	16418600
was	16418600
to	16418600
reveal	16418600
a	16418600
possible	16418600
role	16418600
of	16418600
TSPYL1	16418600
in	16418600
SIDS	16418600
.	16418600

METHODS	16418600
:	16418600
DNA	16418600
samples	16418600
of	16418600
126	16418600
SIDS	16418600
cases	16418600
and	16418600
261	16418600
controls	16418600
were	16418600
investigated	16418600
.	16418600

RESULTS	16418600
:	16418600
We	16418600
found	16418600
five	16418600
sequence	16418600
variations	16418600
,	16418600
each	16418600
of	16418600
them	16418600
causing	16418600
an	16418600
amino	16418600
acid	16418600
substitution	16418600
.	16418600

No	16418600
Hardy	16418600
Weinberg	16418600
disequilibrium	16418600
and	16418600
no	16418600
significant	16418600
difference	16418600
in	16418600
allele	16418600
frequencies	16418600
between	16418600
patients	16418600
and	16418600
controls	16418600
were	16418600
observed	16418600
for	16418600
any	16418600
variation	16418600
.	16418600

In	16418600
one	16418600
female	16418600
patient	16418600
a	16418600
p	16418600
.	16418600
F366L	16418600
amino	16418600
acid	16418600
polymorphism	16418600
was	16418600
found	16418600
heterozygous	16418600
,	16418600
which	16418600
could	16418600
not	16418600
be	16418600
displayed	16418600
in	16418600
controls	16418600
.	16418600

A	16418600
pathogenic	16418600
implication	16418600
of	16418600
this	16418600
substitution	16418600
,	16418600
which	16418600
is	16418600
conserved	16418600
in	16418600
primates	16418600
and	16418600
rodents	16418600
,	16418600
cannot	16418600
be	16418600
ruled	16418600
out	16418600
completely	16418600
.	16418600

Because	16418600
SIDDT	16418600
is	16418600
the	16418600
result	16418600
of	16418600
homozygous	16418600
TSPYL1	16418600
mutations	16418600
,	16418600
this	16418600
heterozygous	16418600
exchange	16418600
cannot	16418600
solely	16418600
explain	16418600
the	16418600
sudden	16418600
death	16418600
in	16418600
this	16418600
child	16418600
.	16418600

The	16418600
reported	16418600
mutation	16418600
associated	16418600
with	16418600
SIDDT	16418600
(	16418600
457_458insG	16418600
)	16418600
was	16418600
not	16418600
detectable	16418600
in	16418600
our	16418600
cohort	16418600
.	16418600

CONCLUSION	16418600
:	16418600
No	16418600
association	16418600
of	16418600
sequence	16418600
variations	16418600
in	16418600
the	16418600
TSPYL1	16418600
gene	16418600
and	16418600
SIDS	16418600
has	16418600
been	16418600
found	16418600
in	16418600
a	16418600
German	16418600
cohort	16418600
.	16418600

Genetic	16418600
analysis	16418600
of	16418600
TSPYL1	16418600
seems	16418600
to	16418600
be	16418600
of	16418600
limited	16418600
significance	16418600
in	16418600
the	16418600
differential	16418600
diagnosis	16418600
of	16418600
SIDS	16418600
without	16418600
dysgenesis	16418600
of	16418600
the	16418600
testes	16418600
.	16418600
High	18674790
fat	18674790
diet	18674790
-	18674790
fed	18674790
obese	18674790
rats	18674790
are	18674790
highly	18674790
sensitive	18674790
to	18674790
doxorubicin	18674790
-	18674790
induced	18674790
cardiotoxicity	18674790
.	18674790

Often	18674790
,	18674790
chemotherapy	18674790
by	18674790
doxorubicin	18674790
(	18674790
Adriamycin	18674790
)	18674790
is	18674790
limited	18674790
due	18674790
to	18674790
life	18674790
threatening	18674790
cardiotoxicity	18674790
in	18674790
patients	18674790
during	18674790
and	18674790
posttherapy	18674790
.	18674790

Recently	18674790
,	18674790
we	18674790
have	18674790
shown	18674790
that	18674790
moderate	18674790
diet	18674790
restriction	18674790
remarkably	18674790
protects	18674790
against	18674790
doxorubicin	18674790
-	18674790
induced	18674790
cardiotoxicity	18674790
.	18674790

This	18674790
cardioprotection	18674790
is	18674790
accompanied	18674790
by	18674790
decreased	18674790
cardiac	18674790
oxidative	18674790
stress	18674790
and	18674790
triglycerides	18674790
and	18674790
increased	18674790
cardiac	18674790
fatty	18674790
-	18674790
acid	18674790
oxidation	18674790
,	18674790
ATP	18674790
synthesis	18674790
,	18674790
and	18674790
upregulated	18674790
JAK	18674790
/	18674790
STAT3	18674790
pathway	18674790
.	18674790

In	18674790
the	18674790
current	18674790
study	18674790
,	18674790
we	18674790
investigated	18674790
whether	18674790
a	18674790
physiological	18674790
intervention	18674790
by	18674790
feeding	18674790
40%	18674790
high	18674790
fat	18674790
diet	18674790
(	18674790
HFD	18674790
)	18674790
,	18674790
which	18674790
induces	18674790
obesity	18674790
in	18674790
male	18674790
Sprague	18674790
-	18674790
Dawley	18674790
rats	18674790
(	18674790
250	18674790
-	18674790
275	18674790
g	18674790
)	18674790
,	18674790
sensitizes	18674790
to	18674790
doxorubicin	18674790
-	18674790
induced	18674790
cardiotoxicity	18674790
.	18674790

A	18674790
LD	18674790
(	18674790
10	18674790
)	18674790
dose	18674790
(	18674790
8	18674790
mg	18674790
doxorubicin	18674790
/	18674790
kg	18674790
,	18674790
ip	18674790
)	18674790
administered	18674790
on	18674790
day	18674790
43	18674790
of	18674790
the	18674790
HFD	18674790
feeding	18674790
regimen	18674790
led	18674790
to	18674790
higher	18674790
cardiotoxicity	18674790
,	18674790
cardiac	18674790
dysfunction	18674790
,	18674790
lipid	18674790
peroxidation	18674790
,	18674790
and	18674790
80%	18674790
mortality	18674790
in	18674790
the	18674790
obese	18674790
(	18674790
OB	18674790
)	18674790
rats	18674790
in	18674790
the	18674790
absence	18674790
of	18674790
any	18674790
significant	18674790
renal	18674790
or	18674790
hepatic	18674790
toxicity	18674790
.	18674790

Doxorubicin	18674790
toxicokinetics	18674790
studies	18674790
revealed	18674790
no	18674790
change	18674790
in	18674790
accumulation	18674790
of	18674790
doxorubicin	18674790
and	18674790
doxorubicinol	18674790
(	18674790
toxic	18674790
metabolite	18674790
)	18674790
in	18674790
the	18674790
normal	18674790
diet	18674790
-	18674790
fed	18674790
(	18674790
ND	18674790
)	18674790
and	18674790
OB	18674790
hearts	18674790
.	18674790

Mechanistic	18674790
studies	18674790
revealed	18674790
that	18674790
OB	18674790
rats	18674790
are	18674790
sensitized	18674790
due	18674790
to	18674790
:	18674790
(	18674790
1	18674790
)	18674790
higher	18674790
oxyradical	18674790
stress	18674790
leading	18674790
to	18674790
upregulation	18674790
of	18674790
uncoupling	18674790
proteins	18674790
2	18674790
and	18674790
3	18674790
,	18674790
(	18674790
2	18674790
)	18674790
downregulation	18674790
of	18674790
cardiac	18674790
peroxisome	18674790
proliferators	18674790
activated	18674790
receptor	18674790
-	18674790
alpha	18674790
,	18674790
(	18674790
3	18674790
)	18674790
decreased	18674790
plasma	18674790
adiponectin	18674790
levels	18674790
,	18674790
(	18674790
4	18674790
)	18674790
decreased	18674790
cardiac	18674790
fatty	18674790
-	18674790
acid	18674790
oxidation	18674790
(	18674790
666	18674790
.	18674790
9	18674790
+	18674790
/	18674790
-	18674790
14	18674790
.	18674790
0	18674790
nmol	18674790
/	18674790
min	18674790
/	18674790
g	18674790
heart	18674790
in	18674790
ND	18674790
versus	18674790
400	18674790
.	18674790
2	18674790
+	18674790
/	18674790
-	18674790
11	18674790
.	18674790
8	18674790
nmol	18674790
/	18674790
min	18674790
/	18674790
g	18674790
heart	18674790
in	18674790
OB	18674790
)	18674790
,	18674790
(	18674790
5	18674790
)	18674790
decreased	18674790
mitochondrial	18674790
AMP	18674790
-	18674790
alpha2	18674790
protein	18674790
kinase	18674790
,	18674790
and	18674790
(	18674790
6	18674790
)	18674790
86%	18674790
drop	18674790
in	18674790
cardiac	18674790
ATP	18674790
levels	18674790
accompanied	18674790
by	18674790
decreased	18674790
ATP	18674790
/	18674790
ADP	18674790
ratio	18674790
after	18674790
doxorubicin	18674790
administration	18674790
.	18674790

Decreased	18674790
cardiac	18674790
erythropoietin	18674790
and	18674790
increased	18674790
SOCS3	18674790
further	18674790
downregulated	18674790
the	18674790
cardioprotective	18674790
JAK	18674790
/	18674790
STAT3	18674790
pathway	18674790
.	18674790

In	18674790
conclusion	18674790
,	18674790
HFD	18674790
-	18674790
induced	18674790
obese	18674790
rats	18674790
are	18674790
highly	18674790
sensitized	18674790
to	18674790
doxorubicin	18674790
-	18674790
induced	18674790
cardiotoxicity	18674790
by	18674790
substantially	18674790
downregulating	18674790
cardiac	18674790
mitochondrial	18674790
ATP	18674790
generation	18674790
,	18674790
increasing	18674790
oxidative	18674790
stress	18674790
and	18674790
downregulating	18674790
the	18674790
JAK	18674790
/	18674790
STAT3	18674790
pathway	18674790
.	18674790
Risks	17255138
and	17255138
benefits	17255138
of	17255138
COX	17255138
-	17255138
2	17255138
inhibitors	17255138
vs	17255138
non	17255138
-	17255138
selective	17255138
NSAIDs	17255138
:	17255138
does	17255138
their	17255138
cardiovascular	17255138
risk	17255138
exceed	17255138
their	17255138
gastrointestinal	17255138
benefit?	17255138
A	17255138
retrospective	17255138
cohort	17255138
study	17255138
.	17255138

OBJECTIVES	17255138
:	17255138
The	17255138
risk	17255138
of	17255138
acute	17255138
myocardial	17255138
infarction	17255138
(	17255138
AMI	17255138
)	17255138
with	17255138
COX	17255138
-	17255138
2	17255138
inhibitors	17255138
may	17255138
offset	17255138
their	17255138
gastrointestinal	17255138
(	17255138
GI	17255138
)	17255138
benefit	17255138
compared	17255138
with	17255138
non	17255138
-	17255138
selective	17255138
(	17255138
NS	17255138
)	17255138
non	17255138
-	17255138
steroidal	17255138
anti	17255138
-	17255138
inflammatory	17255138
drugs	17255138
(	17255138
NSAIDs	17255138
)	17255138
.	17255138

We	17255138
aimed	17255138
to	17255138
compare	17255138
the	17255138
risks	17255138
of	17255138
hospitalization	17255138
for	17255138
AMI	17255138
and	17255138
GI	17255138
bleeding	17255138
among	17255138
elderly	17255138
patients	17255138
using	17255138
COX	17255138
-	17255138
2	17255138
inhibitors	17255138
,	17255138
NS	17255138
-	17255138
NSAIDs	17255138
and	17255138
acetaminophen	17255138
.	17255138

METHODS	17255138
:	17255138
We	17255138
conducted	17255138
a	17255138
retrospective	17255138
cohort	17255138
study	17255138
using	17255138
administrative	17255138
data	17255138
of	17255138
patients	17255138
>	17255138
or	17255138
=	17255138
65	17255138
years	17255138
of	17255138
age	17255138
who	17255138
filled	17255138
a	17255138
prescription	17255138
for	17255138
NSAID	17255138
or	17255138
acetaminophen	17255138
during	17255138
1999	17255138
-	17255138
2002	17255138
.	17255138

Outcomes	17255138
were	17255138
compared	17255138
using	17255138
Cox	17255138
regression	17255138
models	17255138
with	17255138
time	17255138
-	17255138
dependent	17255138
exposures	17255138
.	17255138

RESULTS	17255138
:	17255138
Person	17255138
-	17255138
years	17255138
of	17255138
exposure	17255138
among	17255138
non	17255138
-	17255138
users	17255138
of	17255138
aspirin	17255138
were	17255138
:	17255138
75	17255138
,	17255138
761	17255138
to	17255138
acetaminophen	17255138
,	17255138
42	17255138
,	17255138
671	17255138
to	17255138
rofecoxib	17255138
65	17255138
,	17255138
860	17255138
to	17255138
celecoxib	17255138
,	17255138
and	17255138
37	17255138
,	17255138
495	17255138
to	17255138
NS	17255138
-	17255138
NSAIDs	17255138
.	17255138

Among	17255138
users	17255138
of	17255138
aspirin	17255138
,	17255138
they	17255138
were	17255138
:	17255138
14	17255138
,	17255138
671	17255138
to	17255138
rofecoxib	17255138
,	17255138
22	17255138
,	17255138
875	17255138
to	17255138
celecoxib	17255138
,	17255138
9	17255138
,	17255138
832	17255138
to	17255138
NS	17255138
-	17255138
NSAIDs	17255138
and	17255138
38	17255138
,	17255138
048	17255138
to	17255138
acetaminophen	17255138
.	17255138

Among	17255138
non	17255138
-	17255138
users	17255138
of	17255138
aspirin	17255138
,	17255138
the	17255138
adjusted	17255138
hazard	17255138
ratios	17255138
(	17255138
95%	17255138
confidence	17255138
interval	17255138
)	17255138
of	17255138
hospitalization	17255138
for	17255138
AMI	17255138
/	17255138
GI	17255138
vs	17255138
the	17255138
acetaminophen	17255138
(	17255138
with	17255138
no	17255138
aspirin	17255138
)	17255138
group	17255138
were	17255138
:	17255138
rofecoxib	17255138
1	17255138
.	17255138
27	17255138
(	17255138
1	17255138
.	17255138
13	17255138
,	17255138
1	17255138
.	17255138
42	17255138
)	17255138
,	17255138
celecoxib	17255138
0	17255138
.	17255138
93	17255138
(	17255138
0	17255138
.	17255138
83	17255138
,	17255138
1	17255138
.	17255138
03	17255138
)	17255138
,	17255138
naproxen	17255138
1	17255138
.	17255138
59	17255138
(	17255138
1	17255138
.	17255138
31	17255138
,	17255138
1	17255138
.	17255138
93	17255138
)	17255138
,	17255138
diclofenac	17255138
1	17255138
.	17255138
17	17255138
(	17255138
0	17255138
.	17255138
99	17255138
,	17255138
1	17255138
.	17255138
38	17255138
)	17255138
and	17255138
ibuprofen	17255138
1	17255138
.	17255138
05	17255138
(	17255138
0	17255138
.	17255138
74	17255138
,	17255138
1	17255138
.	17255138
51	17255138
)	17255138
.	17255138

Among	17255138
users	17255138
of	17255138
aspirin	17255138
,	17255138
they	17255138
were	17255138
:	17255138
rofecoxib	17255138
1	17255138
.	17255138
73	17255138
(	17255138
1	17255138
.	17255138
52	17255138
,	17255138
1	17255138
.	17255138
98	17255138
)	17255138
,	17255138
celecoxib	17255138
1	17255138
.	17255138
34	17255138
(	17255138
1	17255138
.	17255138
19	17255138
,	17255138
1	17255138
.	17255138
52	17255138
)	17255138
,	17255138
ibuprofen	17255138
1	17255138
.	17255138
51	17255138
(	17255138
0	17255138
.	17255138
95	17255138
,	17255138
2	17255138
.	17255138
41	17255138
)	17255138
,	17255138
diclofenac	17255138
1	17255138
.	17255138
69	17255138
(	17255138
1	17255138
.	17255138
35	17255138
,	17255138
2	17255138
.	17255138
10	17255138
)	17255138
,	17255138
naproxen	17255138
1	17255138
.	17255138
35	17255138
(	17255138
0	17255138
.	17255138
97	17255138
,	17255138
1	17255138
.	17255138
88	17255138
)	17255138
and	17255138
acetaminophen	17255138
1	17255138
.	17255138
29	17255138
(	17255138
1	17255138
.	17255138
17	17255138
,	17255138
1	17255138
.	17255138
42	17255138
)	17255138
.	17255138

CONCLUSION	17255138
:	17255138
Among	17255138
non	17255138
-	17255138
users	17255138
of	17255138
aspirin	17255138
,	17255138
naproxen	17255138
seemed	17255138
to	17255138
carry	17255138
the	17255138
highest	17255138
risk	17255138
for	17255138
AMI	17255138
/	17255138
GI	17255138
bleeding	17255138
.	17255138

The	17255138
AMI	17255138
/	17255138
GI	17255138
toxicity	17255138
of	17255138
celecoxib	17255138
was	17255138
similar	17255138
to	17255138
that	17255138
of	17255138
acetaminophen	17255138
and	17255138
seemed	17255138
to	17255138
be	17255138
better	17255138
than	17255138
those	17255138
of	17255138
rofecoxib	17255138
and	17255138
NS	17255138
-	17255138
NSAIDs	17255138
.	17255138

Among	17255138
users	17255138
of	17255138
aspirin	17255138
,	17255138
both	17255138
celecoxib	17255138
and	17255138
naproxen	17255138
seemed	17255138
to	17255138
be	17255138
the	17255138
least	17255138
toxic	17255138
.	17255138
In	20973483
vivo	20973483
characterization	20973483
of	20973483
a	20973483
dual	20973483
adenosine	20973483
A2A	20973483
/	20973483
A1	20973483
receptor	20973483
antagonist	20973483
in	20973483
animal	20973483
models	20973483
of	20973483
Parkinson	20973483
'	20973483
s	20973483
disease	20973483
.	20973483

The	20973483
in	20973483
vivo	20973483
characterization	20973483
of	20973483
a	20973483
dual	20973483
adenosine	20973483
A	20973483
(	20973483
2A	20973483
)	20973483
/	20973483
A	20973483
(	20973483
1	20973483
)	20973483
receptor	20973483
antagonist	20973483
in	20973483
several	20973483
animal	20973483
models	20973483
of	20973483
Parkinson	20973483
'	20973483
s	20973483
disease	20973483
is	20973483
described	20973483
.	20973483

Discovery	20973483
and	20973483
scale	20973483
-	20973483
up	20973483
syntheses	20973483
of	20973483
compound	20973483
1	20973483
are	20973483
described	20973483
in	20973483
detail	20973483
,	20973483
highlighting	20973483
optimization	20973483
steps	20973483
that	20973483
increased	20973483
the	20973483
overall	20973483
yield	20973483
of	20973483
1	20973483
from	20973483
10	20973483
.	20973483
0%	20973483
to	20973483
30	20973483
.	20973483
5%	20973483
.	20973483

Compound	20973483
1	20973483
is	20973483
a	20973483
potent	20973483
A	20973483
(	20973483
2A	20973483
)	20973483
/	20973483
A	20973483
(	20973483
1	20973483
)	20973483
receptor	20973483
antagonist	20973483
in	20973483
vitro	20973483
(	20973483
A	20973483
(	20973483
2A	20973483
)	20973483
K	20973483
(	20973483
i	20973483
)	20973483
=	20973483
4	20973483
.	20973483
1	20973483
nM	20973483
;	20973483
A	20973483
(	20973483
1	20973483
)	20973483
K	20973483
(	20973483
i	20973483
)	20973483
=	20973483
17	20973483
.	20973483
0	20973483
nM	20973483
)	20973483
that	20973483
has	20973483
excellent	20973483
activity	20973483
,	20973483
after	20973483
oral	20973483
administration	20973483
,	20973483
across	20973483
a	20973483
number	20973483
of	20973483
animal	20973483
models	20973483
of	20973483
Parkinson	20973483
'	20973483
s	20973483
disease	20973483
including	20973483
mouse	20973483
and	20973483
rat	20973483
models	20973483
of	20973483
haloperidol	20973483
-	20973483
induced	20973483
catalepsy	20973483
,	20973483
mouse	20973483
model	20973483
of	20973483
reserpine	20973483
-	20973483
induced	20973483
akinesia	20973483
,	20973483
rat	20973483
6	20973483
-	20973483
hydroxydopamine	20973483
(	20973483
6	20973483
-	20973483
OHDA	20973483
)	20973483
lesion	20973483
model	20973483
of	20973483
drug	20973483
-	20973483
induced	20973483
rotation	20973483
,	20973483
and	20973483
MPTP	20973483
-	20973483
treated	20973483
non	20973483
-	20973483
human	20973483
primate	20973483
model	20973483
.	20973483
Coincidence	17671735
of	17671735
mutations	17671735
in	17671735
different	17671735
connexin	17671735
genes	17671735
in	17671735
Hungarian	17671735
patients	17671735
.	17671735

Mutations	17671735
in	17671735
the	17671735
GJB2	17671735
gene	17671735
are	17671735
the	17671735
most	17671735
common	17671735
cause	17671735
of	17671735
hereditary	17671735
prelingual	17671735
sensorineural	17671735
hearing	17671735
impairment	17671735
in	17671735
Europe	17671735
.	17671735

Several	17671735
studies	17671735
indicate	17671735
that	17671735
different	17671735
members	17671735
of	17671735
the	17671735
connexin	17671735
protein	17671735
family	17671735
interact	17671735
to	17671735
form	17671735
gap	17671735
junctions	17671735
in	17671735
the	17671735
inner	17671735
ear	17671735
.	17671735

Mutations	17671735
in	17671735
different	17671735
connexin	17671735
genes	17671735
may	17671735
accumulate	17671735
and	17671735
,	17671735
consequently	17671735
lead	17671735
to	17671735
hearing	17671735
impairment	17671735
.	17671735

Therefore	17671735
,	17671735
we	17671735
screened	17671735
47	17671735
Hungarian	17671735
GJB2	17671735
-	17671735
heterozygous	17671735
(	17671735
one	17671735
mutation	17671735
in	17671735
coding	17671735
exon	17671735
of	17671735
the	17671735
GJB2	17671735
gene	17671735
)	17671735
patients	17671735
with	17671735
hearing	17671735
impairment	17671735
for	17671735
DNA	17671735
changes	17671735
in	17671735
two	17671735
further	17671735
connexin	17671735
genes	17671735
(	17671735
GJB6	17671735
and	17671735
GJB3	17671735
)	17671735
and	17671735
in	17671735
the	17671735
5	17671735
'	17671735
non	17671735
-	17671735
coding	17671735
region	17671735
of	17671735
GJB2	17671735
including	17671735
the	17671735
splice	17671735
sites	17671735
.	17671735

Eleven	17671735
out	17671735
of	17671735
47	17671735
GJB2	17671735
-	17671735
heterozygous	17671735
patients	17671735
analyzed	17671735
carried	17671735
the	17671735
splice	17671735
site	17671735
mutation	17671735
-	17671735
3170G	17671735
>	17671735
A	17671735
in	17671735
the	17671735
5	17671735
'	17671735
UTR	17671735
region	17671735
of	17671735
GJB2	17671735
.	17671735

One	17671735
out	17671735
of	17671735
these	17671735
11	17671735
patients	17671735
showed	17671735
homozygous	17671735
-	17671735
3170G	17671735
>	17671735
A	17671735
genotype	17671735
in	17671735
combination	17671735
with	17671735
p	17671735
.	17671735
R127H	17671735
.	17671735

Next	17671735
to	17671735
the	17671735
GJB2	17671735
mutations	17671735
we	17671735
noted	17671735
2	17671735
cases	17671735
of	17671735
deletion	17671735
in	17671735
GJB6	17671735
[	17671735
Delta	17671735
(	17671735
GJB6	17671735
-	17671735
D13S1830	17671735
)	17671735
]	17671735
and	17671735
3	17671735
(	17671735
2	17671735
new	17671735
and	17671735
1	17671735
described	17671735
)	17671735
base	17671735
substitutions	17671735
in	17671735
GJB3	17671735
[	17671735
c	17671735
.	17671735
357C	17671735
>	17671735
T	17671735
,	17671735
c	17671735
.	17671735
798C	17671735
>	17671735
T	17671735
and	17671735
c	17671735
.	17671735
94C	17671735
>	17671735
T	17671735
(	17671735
p	17671735
.	17671735
R32W	17671735
)	17671735
]	17671735
which	17671735
are	17671735
unlikely	17671735
disease	17671735
-	17671735
causing	17671735
.	17671735

Our	17671735
results	17671735
suggest	17671735
the	17671735
importance	17671735
of	17671735
routine	17671735
screening	17671735
for	17671735
the	17671735
rather	17671735
frequent	17671735
-	17671735
3170G	17671735
>	17671735
A	17671735
mutation	17671735
(	17671735
in	17671735
addition	17671735
to	17671735
c	17671735
.	17671735
35delG	17671735
)	17671735
in	17671735
patients	17671735
with	17671735
hearing	17671735
impairment	17671735
.	17671735
Tumor	16575011
thymidylate	16575011
synthase	16575011
1494del6	16575011
genotype	16575011
as	16575011
a	16575011
prognostic	16575011
factor	16575011
in	16575011
colorectal	16575011
cancer	16575011
patients	16575011
receiving	16575011
fluorouracil	16575011
-	16575011
based	16575011
adjuvant	16575011
treatment	16575011
.	16575011

PURPOSE	16575011
:	16575011
The	16575011
purpose	16575011
of	16575011
this	16575011
study	16575011
was	16575011
to	16575011
analyze	16575011
the	16575011
value	16575011
of	16575011
germline	16575011
and	16575011
tumor	16575011
thymidylate	16575011
synthase	16575011
(	16575011
TS	16575011
)	16575011
genotyping	16575011
as	16575011
a	16575011
prognostic	16575011
marker	16575011
in	16575011
a	16575011
series	16575011
of	16575011
colorectal	16575011
cancer	16575011
patients	16575011
receiving	16575011
adjuvant	16575011
fluorouracil	16575011
(	16575011
FU	16575011
)	16575011
-	16575011
based	16575011
treatment	16575011
.	16575011

PATIENTS	16575011
AND	16575011
METHODS	16575011
:	16575011
One	16575011
hundred	16575011
twenty	16575011
-	16575011
nine	16575011
colorectal	16575011
cancer	16575011
patients	16575011
homogeneously	16575011
treated	16575011
with	16575011
FU	16575011
plus	16575011
levamisole	16575011
or	16575011
leucovorin	16575011
in	16575011
the	16575011
adjuvant	16575011
setting	16575011
were	16575011
included	16575011
.	16575011

TS	16575011
enhancer	16575011
region	16575011
,	16575011
3R	16575011
G	16575011
>	16575011
C	16575011
single	16575011
nucleotide	16575011
polymorphism	16575011
(	16575011
SNP	16575011
)	16575011
,	16575011
and	16575011
TS	16575011
1494del6	16575011
polymorphisms	16575011
were	16575011
assessed	16575011
in	16575011
both	16575011
fresh	16575011
-	16575011
frozen	16575011
normal	16575011
mucosa	16575011
and	16575011
tumor	16575011
.	16575011

Mutational	16575011
analyses	16575011
of	16575011
TS	16575011
and	16575011
allelic	16575011
imbalances	16575011
were	16575011
studied	16575011
in	16575011
all	16575011
primary	16575011
tumors	16575011
and	16575011
in	16575011
18	16575011
additional	16575011
metachronic	16575011
metastases	16575011
.	16575011

TS	16575011
protein	16575011
immunostaining	16575011
was	16575011
assessed	16575011
in	16575011
an	16575011
expanded	16575011
series	16575011
of	16575011
214	16575011
tumors	16575011
.	16575011

Multivariate	16575011
Cox	16575011
models	16575011
were	16575011
adjusted	16575011
for	16575011
stage	16575011
,	16575011
differentiation	16575011
,	16575011
and	16575011
location	16575011
.	16575011

RESULTS	16575011
:	16575011
Tumor	16575011
genotyping	16575011
(	16575011
frequency	16575011
of	16575011
allelic	16575011
loss	16575011
,	16575011
26%	16575011
)	16575011
showed	16575011
that	16575011
the	16575011
3R	16575011
/	16575011
3R	16575011
genotype	16575011
was	16575011
associated	16575011
with	16575011
a	16575011
better	16575011
outcome	16575011
(	16575011
hazard	16575011
ratio	16575011
[	16575011
HR	16575011
]	16575011
=	16575011
0	16575011
.	16575011
38	16575011
;	16575011
95%	16575011
CI	16575011
,	16575011
0	16575011
.	16575011
16	16575011
to	16575011
0	16575011
.	16575011
93	16575011
;	16575011
P	16575011
=	16575011
.	16575011
020	16575011
for	16575011
the	16575011
recessive	16575011
model	16575011
)	16575011
.	16575011

3R	16575011
G	16575011
>	16575011
C	16575011
SNP	16575011
genotyping	16575011
did	16575011
not	16575011
add	16575011
prognostic	16575011
information	16575011
.	16575011

Tumor	16575011
TS	16575011
1494del6	16575011
allele	16575011
(	16575011
frequency	16575011
of	16575011
allelic	16575011
loss	16575011
,	16575011
36%	16575011
)	16575011
was	16575011
protective	16575011
(	16575011
for	16575011
each	16575011
allele	16575011
with	16575011
the	16575011
deletion	16575011
,	16575011
based	16575011
on	16575011
an	16575011
additive	16575011
model	16575011
,	16575011
HR	16575011
=	16575011
0	16575011
.	16575011
42	16575011
;	16575011
95%	16575011
CI	16575011
,	16575011
0	16575011
.	16575011
22	16575011
to	16575011
0	16575011
.	16575011
82	16575011
;	16575011
P	16575011
=	16575011
.	16575011
0034	16575011
)	16575011
.	16575011

Both	16575011
polymorphisms	16575011
were	16575011
in	16575011
strong	16575011
linkage	16575011
disequilibrium	16575011
(	16575011
D	16575011
'	16575011
=	16575011
0	16575011
.	16575011
71	16575011
,	16575011
P	16575011
<	16575011
.	16575011
001	16575011
)	16575011
,	16575011
and	16575011
the	16575011
3R	16575011
/	16575011
-	16575011
6	16575011
base	16575011
pair	16575011
(	16575011
bp	16575011
)	16575011
haplotype	16575011
showed	16575011
a	16575011
significant	16575011
overall	16575011
survival	16575011
benefit	16575011
compared	16575011
with	16575011
the	16575011
most	16575011
prevalent	16575011
haplotype	16575011
2R	16575011
/	16575011
+	16575011
6bp	16575011
(	16575011
HR	16575011
=	16575011
0	16575011
.	16575011
42	16575011
;	16575011
95%	16575011
CI	16575011
,	16575011
0	16575011
.	16575011
20	16575011
to	16575011
0	16575011
.	16575011
85	16575011
;	16575011
P	16575011
=	16575011
.	16575011
017	16575011
)	16575011
.	16575011

No	16575011
TS	16575011
point	16575011
mutation	16575011
was	16575011
detected	16575011
in	16575011
primary	16575011
tumors	16575011
or	16575011
metastases	16575011
.	16575011

TS	16575011
protein	16575011
immunostaining	16575011
was	16575011
not	16575011
associated	16575011
with	16575011
survival	16575011
or	16575011
any	16575011
of	16575011
the	16575011
genotypes	16575011
analyzed	16575011
.	16575011

CONCLUSION	16575011
:	16575011
Tumor	16575011
TS	16575011
1494del6	16575011
genotype	16575011
may	16575011
be	16575011
a	16575011
prognostic	16575011
factor	16575011
in	16575011
FU	16575011
-	16575011
based	16575011
adjuvant	16575011
treatment	16575011
of	16575011
colorectal	16575011
cancer	16575011
patients	16575011
.	16575011
Permeability	20588063
,	20588063
ultrastructural	20588063
changes	20588063
,	20588063
and	20588063
distribution	20588063
of	20588063
novel	20588063
proteins	20588063
in	20588063
the	20588063
glomerular	20588063
barrier	20588063
in	20588063
early	20588063
puromycin	20588063
aminonucleoside	20588063
nephrosis	20588063
.	20588063

BACKGROUND	20588063
/	20588063
AIMS	20588063
:	20588063
It	20588063
is	20588063
still	20588063
unclear	20588063
what	20588063
happens	20588063
in	20588063
the	20588063
glomerulus	20588063
when	20588063
proteinuria	20588063
starts	20588063
.	20588063

Using	20588063
puromycin	20588063
aminonucleoside	20588063
nephrosis	20588063
(	20588063
PAN	20588063
)	20588063
rats	20588063
,	20588063
we	20588063
studied	20588063
early	20588063
ultrastructural	20588063
and	20588063
permeability	20588063
changes	20588063
in	20588063
relation	20588063
to	20588063
the	20588063
expression	20588063
of	20588063
the	20588063
podocyte	20588063
-	20588063
associated	20588063
molecules	20588063
nephrin	20588063
,	20588063
a	20588063
-	20588063
actinin	20588063
,	20588063
dendrin	20588063
,	20588063
and	20588063
plekhh2	20588063
,	20588063
the	20588063
last	20588063
two	20588063
of	20588063
which	20588063
were	20588063
only	20588063
recently	20588063
discovered	20588063
in	20588063
podocytes	20588063
.	20588063

METHODS	20588063
:	20588063
Using	20588063
immune	20588063
stainings	20588063
,	20588063
semiquantitative	20588063
measurement	20588063
was	20588063
performed	20588063
under	20588063
the	20588063
electron	20588063
microscope	20588063
.	20588063

Permeability	20588063
was	20588063
assessed	20588063
using	20588063
isolated	20588063
kidney	20588063
perfusion	20588063
with	20588063
tracers	20588063
.	20588063

Possible	20588063
effects	20588063
of	20588063
ACE	20588063
inhibition	20588063
were	20588063
tested	20588063
.	20588063

RESULTS	20588063
:	20588063
By	20588063
day	20588063
2	20588063
,	20588063
some	20588063
patchy	20588063
foot	20588063
process	20588063
effacement	20588063
,	20588063
but	20588063
no	20588063
proteinuria	20588063
,	20588063
appeared	20588063
.	20588063

The	20588063
amount	20588063
of	20588063
nephrin	20588063
was	20588063
reduced	20588063
in	20588063
both	20588063
diseased	20588063
and	20588063
normal	20588063
areas	20588063
.	20588063

The	20588063
other	20588063
proteins	20588063
showed	20588063
few	20588063
changes	20588063
,	20588063
which	20588063
were	20588063
limited	20588063
to	20588063
diseased	20588063
areas	20588063
.	20588063

By	20588063
day	20588063
4	20588063
,	20588063
foot	20588063
process	20588063
effacement	20588063
was	20588063
complete	20588063
and	20588063
proteinuria	20588063
appeared	20588063
in	20588063
parallel	20588063
with	20588063
signs	20588063
of	20588063
size	20588063
barrier	20588063
damage	20588063
.	20588063

Nephrin	20588063
decreased	20588063
further	20588063
,	20588063
while	20588063
dendrin	20588063
and	20588063
plekhh2	20588063
also	20588063
decreased	20588063
but	20588063
a	20588063
-	20588063
actinin	20588063
remained	20588063
unchanged	20588063
.	20588063

ACE	20588063
inhibition	20588063
had	20588063
no	20588063
significant	20588063
protective	20588063
effect	20588063
.	20588063

CONCLUSIONS	20588063
:	20588063
PAN	20588063
glomeruli	20588063
already	20588063
showed	20588063
significant	20588063
pathology	20588063
by	20588063
day	20588063
4	20588063
,	20588063
despite	20588063
relatively	20588063
mild	20588063
proteinuria	20588063
.	20588063

This	20588063
was	20588063
preceded	20588063
by	20588063
altered	20588063
nephrin	20588063
expression	20588063
,	20588063
supporting	20588063
its	20588063
pivotal	20588063
role	20588063
in	20588063
podocyte	20588063
morphology	20588063
.	20588063

The	20588063
novel	20588063
proteins	20588063
dendrin	20588063
and	20588063
plekhh2	20588063
were	20588063
both	20588063
reduced	20588063
,	20588063
suggesting	20588063
roles	20588063
in	20588063
PAN	20588063
,	20588063
whereas	20588063
a	20588063
-	20588063
actinin	20588063
was	20588063
unchanged	20588063
.	20588063
Intronic	16849419
deletions	16849419
in	16849419
the	16849419
SLC34A3	16849419
gene	16849419
cause	16849419
hereditary	16849419
hypophosphatemic	16849419
rickets	16849419
with	16849419
hypercalciuria	16849419
.	16849419

CONTEXT	16849419
:	16849419
Hereditary	16849419
hypophosphatemic	16849419
rickets	16849419
with	16849419
hypercalciuria	16849419
(	16849419
HHRH	16849419
)	16849419
is	16849419
a	16849419
rare	16849419
metabolic	16849419
disorder	16849419
,	16849419
characterized	16849419
by	16849419
hypophosphatemia	16849419
and	16849419
rickets	16849419
/	16849419
osteomalacia	16849419
with	16849419
increased	16849419
serum	16849419
1	16849419
,	16849419
25	16849419
-	16849419
dihydroxyvitamin	16849419
D	16849419
[	16849419
1	16849419
,	16849419
25	16849419
-	16849419
(	16849419
OH	16849419
)	16849419
(	16849419
2	16849419
)	16849419
D	16849419
]	16849419
resulting	16849419
in	16849419
hypercalciuria	16849419
.	16849419

OBJECTIVE	16849419
:	16849419
Our	16849419
objective	16849419
was	16849419
to	16849419
determine	16849419
whether	16849419
mutations	16849419
in	16849419
the	16849419
SLC34A3	16849419
gene	16849419
,	16849419
which	16849419
encodes	16849419
sodium	16849419
-	16849419
phosphate	16849419
cotransporter	16849419
type	16849419
IIc	16849419
,	16849419
are	16849419
responsible	16849419
for	16849419
the	16849419
occurrence	16849419
of	16849419
HHRH	16849419
.	16849419

DESIGN	16849419
AND	16849419
SETTING	16849419
:	16849419
Mutation	16849419
analysis	16849419
of	16849419
exons	16849419
and	16849419
adjacent	16849419
introns	16849419
in	16849419
the	16849419
SLC34A3	16849419
gene	16849419
was	16849419
conducted	16849419
at	16849419
an	16849419
academic	16849419
research	16849419
laboratory	16849419
and	16849419
medical	16849419
center	16849419
.	16849419

PATIENTS	16849419
OR	16849419
OTHER	16849419
PARTICIPANTS	16849419
:	16849419
Members	16849419
of	16849419
two	16849419
unrelated	16849419
families	16849419
with	16849419
HHRH	16849419
participated	16849419
in	16849419
the	16849419
study	16849419
.	16849419

RESULTS	16849419
:	16849419
Two	16849419
affected	16849419
siblings	16849419
in	16849419
one	16849419
family	16849419
were	16849419
homozygous	16849419
for	16849419
a	16849419
101	16849419
-	16849419
bp	16849419
deletion	16849419
in	16849419
intron	16849419
9	16849419
.	16849419

Haplotype	16849419
analysis	16849419
of	16849419
the	16849419
SLC34A3	16849419
locus	16849419
in	16849419
the	16849419
family	16849419
showed	16849419
that	16849419
the	16849419
two	16849419
deletions	16849419
are	16849419
on	16849419
different	16849419
haplotypes	16849419
.	16849419

An	16849419
unrelated	16849419
individual	16849419
with	16849419
HHRH	16849419
was	16849419
a	16849419
compound	16849419
heterozygote	16849419
for	16849419
an	16849419
85	16849419
-	16849419
bp	16849419
deletion	16849419
in	16849419
intron	16849419
10	16849419
and	16849419
a	16849419
G	16849419
-	16849419
to	16849419
-	16849419
A	16849419
substitution	16849419
at	16849419
the	16849419
last	16849419
nucleotide	16849419
in	16849419
exon	16849419
7	16849419
.	16849419

The	16849419
intron	16849419
9	16849419
deletion	16849419
(	16849419
and	16849419
likely	16849419
the	16849419
other	16849419
two	16849419
mutations	16849419
)	16849419
identified	16849419
in	16849419
this	16849419
study	16849419
causes	16849419
aberrant	16849419
RNA	16849419
splicing	16849419
.	16849419

Sequence	16849419
analysis	16849419
of	16849419
the	16849419
deleted	16849419
regions	16849419
revealed	16849419
the	16849419
presence	16849419
of	16849419
direct	16849419
repeats	16849419
of	16849419
homologous	16849419
sequences	16849419
.	16849419

CONCLUSION	16849419
:	16849419
HHRH	16849419
is	16849419
caused	16849419
by	16849419
biallelic	16849419
mutations	16849419
in	16849419
the	16849419
SLC34A3	16849419
gene	16849419
.	16849419

Haplotype	16849419
analysis	16849419
suggests	16849419
that	16849419
the	16849419
two	16849419
intron	16849419
9	16849419
deletions	16849419
arose	16849419
independently	16849419
.	16849419

The	16849419
identification	16849419
of	16849419
three	16849419
independent	16849419
deletions	16849419
in	16849419
introns	16849419
9	16849419
and	16849419
10	16849419
suggests	16849419
that	16849419
the	16849419
SLC34A3	16849419
gene	16849419
may	16849419
be	16849419
susceptible	16849419
to	16849419
unequal	16849419
crossing	16849419
over	16849419
because	16849419
of	16849419
sequence	16849419
misalignment	16849419
during	16849419
meiosis	16849419
.	16849419
The	24588023
association	24588023
between	24588023
tranexamic	24588023
acid	24588023
and	24588023
convulsive	24588023
seizures	24588023
after	24588023
cardiac	24588023
surgery	24588023
:	24588023
a	24588023
multivariate	24588023
analysis	24588023
in	24588023
11	24588023
529	24588023
patients	24588023
.	24588023

Because	24588023
of	24588023
a	24588023
lack	24588023
of	24588023
contemporary	24588023
data	24588023
regarding	24588023
seizures	24588023
after	24588023
cardiac	24588023
surgery	24588023
,	24588023
we	24588023
undertook	24588023
a	24588023
retrospective	24588023
analysis	24588023
of	24588023
prospectively	24588023
collected	24588023
data	24588023
from	24588023
11	24588023
529	24588023
patients	24588023
in	24588023
whom	24588023
cardiopulmonary	24588023
bypass	24588023
was	24588023
used	24588023
from	24588023
January	24588023
2004	24588023
to	24588023
December	24588023
2010	24588023
.	24588023

A	24588023
convulsive	24588023
seizure	24588023
was	24588023
defined	24588023
as	24588023
a	24588023
transient	24588023
episode	24588023
of	24588023
disturbed	24588023
brain	24588023
function	24588023
characterised	24588023
by	24588023
abnormal	24588023
involuntary	24588023
motor	24588023
movements	24588023
.	24588023

Multivariate	24588023
regression	24588023
analysis	24588023
was	24588023
performed	24588023
to	24588023
identify	24588023
independent	24588023
predictors	24588023
of	24588023
postoperative	24588023
seizures	24588023
.	24588023

A	24588023
total	24588023
of	24588023
100	24588023
(	24588023
0	24588023
.	24588023
9%	24588023
)	24588023
patients	24588023
developed	24588023
postoperative	24588023
convulsive	24588023
seizures	24588023
.	24588023

Generalised	24588023
and	24588023
focal	24588023
seizures	24588023
were	24588023
identified	24588023
in	24588023
68	24588023
and	24588023
32	24588023
patients	24588023
,	24588023
respectively	24588023
.	24588023

The	24588023
median	24588023
(	24588023
IQR	24588023
[	24588023
range	24588023
]	24588023
)	24588023
time	24588023
after	24588023
surgery	24588023
when	24588023
the	24588023
seizure	24588023
occurred	24588023
was	24588023
7	24588023
(	24588023
6	24588023
-	24588023
12	24588023
[	24588023
1	24588023
-	24588023
216	24588023
]	24588023
)	24588023
h	24588023
and	24588023
8	24588023
(	24588023
6	24588023
-	24588023
11	24588023
[	24588023
4	24588023
-	24588023
18	24588023
]	24588023
)	24588023
h	24588023
,	24588023
respectively	24588023
.	24588023

Epileptiform	24588023
findings	24588023
on	24588023
electroencephalography	24588023
were	24588023
seen	24588023
in	24588023
19	24588023
patients	24588023
.	24588023

Independent	24588023
predictors	24588023
of	24588023
postoperative	24588023
seizures	24588023
included	24588023
age	24588023
,	24588023
female	24588023
sex	24588023
,	24588023
redo	24588023
cardiac	24588023
surgery	24588023
,	24588023
calcification	24588023
of	24588023
ascending	24588023
aorta	24588023
,	24588023
congestive	24588023
heart	24588023
failure	24588023
,	24588023
deep	24588023
hypothermic	24588023
circulatory	24588023
arrest	24588023
,	24588023
duration	24588023
of	24588023
aortic	24588023
cross	24588023
-	24588023
clamp	24588023
and	24588023
tranexamic	24588023
acid	24588023
.	24588023

When	24588023
tested	24588023
in	24588023
a	24588023
multivariate	24588023
regression	24588023
analysis	24588023
,	24588023
tranexamic	24588023
acid	24588023
was	24588023
a	24588023
strong	24588023
independent	24588023
predictor	24588023
of	24588023
seizures	24588023
(	24588023
OR	24588023
14	24588023
.	24588023
3	24588023
,	24588023
95%	24588023
CI	24588023
5	24588023
.	24588023
5	24588023
-	24588023
36	24588023
.	24588023
7	24588023
;	24588023
p	24588023
<	24588023
0	24588023
.	24588023
001	24588023
)	24588023
.	24588023

Patients	24588023
with	24588023
convulsive	24588023
seizures	24588023
had	24588023
2	24588023
.	24588023
5	24588023
times	24588023
higher	24588023
in	24588023
-	24588023
hospital	24588023
mortality	24588023
rates	24588023
and	24588023
twice	24588023
the	24588023
length	24588023
of	24588023
hospital	24588023
stay	24588023
compared	24588023
with	24588023
patients	24588023
without	24588023
convulsive	24588023
seizures	24588023
.	24588023

Mean	24588023
(	24588023
IQR	24588023
[	24588023
range	24588023
]	24588023
)	24588023
length	24588023
of	24588023
stay	24588023
in	24588023
the	24588023
intensive	24588023
care	24588023
unit	24588023
was	24588023
115	24588023
(	24588023
49	24588023
-	24588023
228	24588023
[	24588023
32	24588023
-	24588023
481	24588023
]	24588023
)	24588023
h	24588023
in	24588023
patients	24588023
with	24588023
convulsive	24588023
seizures	24588023
compared	24588023
with	24588023
26	24588023
(	24588023
22	24588023
-	24588023
69	24588023
[	24588023
14	24588023
-	24588023
1080	24588023
]	24588023
)	24588023
h	24588023
in	24588023
patients	24588023
without	24588023
seizures	24588023
(	24588023
p	24588023
<	24588023
0	24588023
.	24588023
001	24588023
)	24588023
.	24588023

Convulsive	24588023
seizures	24588023
are	24588023
a	24588023
serious	24588023
postoperative	24588023
complication	24588023
after	24588023
cardiac	24588023
surgery	24588023
.	24588023

As	24588023
tranexamic	24588023
acid	24588023
is	24588023
the	24588023
only	24588023
modifiable	24588023
factor	24588023
,	24588023
its	24588023
administration	24588023
,	24588023
particularly	24588023
in	24588023
doses	24588023
exceeding	24588023
80	24588023
mg	24588023
.	24588023
kg	24588023
(	24588023
-	24588023
1	24588023
)	24588023
,	24588023
should	24588023
be	24588023
weighed	24588023
against	24588023
the	24588023
risk	24588023
of	24588023
postoperative	24588023
seizures	24588023
.	24588023
A	28416580
TSPO	28416580
ligand	28416580
attenuates	28416580
brain	28416580
injury	28416580
after	28416580
intracerebral	28416580
hemorrhage	28416580
.	28416580

Intracerebral	28416580
hemorrhage	28416580
(	28416580
ICH	28416580
)	28416580
is	28416580
a	28416580
devastating	28416580
disease	28416580
without	28416580
effective	28416580
treatment	28416580
.	28416580

After	28416580
ICH	28416580
,	28416580
the	28416580
immediate	28416580
infiltration	28416580
of	28416580
leukocytes	28416580
and	28416580
activation	28416580
of	28416580
microglia	28416580
are	28416580
accompanied	28416580
by	28416580
a	28416580
rapid	28416580
up	28416580
-	28416580
regulation	28416580
of	28416580
the	28416580
18	28416580
-	28416580
kDa	28416580
translocator	28416580
protein	28416580
(	28416580
TSPO	28416580
)	28416580
.	28416580

TSPO	28416580
ligands	28416580
have	28416580
shown	28416580
anti	28416580
-	28416580
inflammatory	28416580
and	28416580
neuroprotective	28416580
properties	28416580
in	28416580
models	28416580
of	28416580
CNS	28416580
injury	28416580
.	28416580

In	28416580
this	28416580
study	28416580
,	28416580
we	28416580
determined	28416580
the	28416580
impact	28416580
of	28416580
a	28416580
TSPO	28416580
ligand	28416580
,	28416580
etifoxine	28416580
,	28416580
on	28416580
brain	28416580
injury	28416580
and	28416580
inflammation	28416580
in	28416580
2	28416580
mouse	28416580
models	28416580
of	28416580
ICH	28416580
.	28416580

TSPO	28416580
was	28416580
up	28416580
-	28416580
regulated	28416580
in	28416580
Iba1	28416580
(	28416580
+	28416580
)	28416580
cells	28416580
from	28416580
brains	28416580
of	28416580
patients	28416580
with	28416580
ICH	28416580
and	28416580
in	28416580
CD11b	28416580
(	28416580
+	28416580
)	28416580
CD45	28416580
(	28416580
int	28416580
)	28416580
cells	28416580
from	28416580
mice	28416580
subjected	28416580
to	28416580
collagenase	28416580
-	28416580
induced	28416580
ICH	28416580
.	28416580

Etifoxine	28416580
significantly	28416580
reduced	28416580
neurodeficits	28416580
and	28416580
perihematomal	28416580
brain	28416580
edema	28416580
after	28416580
ICH	28416580
induction	28416580
by	28416580
injection	28416580
of	28416580
either	28416580
autologous	28416580
blood	28416580
or	28416580
collagenase	28416580
.	28416580

In	28416580
collagenase	28416580
-	28416580
induced	28416580
ICH	28416580
mice	28416580
,	28416580
the	28416580
protection	28416580
of	28416580
etifoxine	28416580
was	28416580
associated	28416580
with	28416580
reduced	28416580
leukocyte	28416580
infiltration	28416580
into	28416580
the	28416580
brain	28416580
and	28416580
microglial	28416580
production	28416580
of	28416580
IL	28416580
-	28416580
6	28416580
and	28416580
TNF	28416580
-	28416580
a	28416580
.	28416580

Etifoxine	28416580
improved	28416580
blood	28416580
-	28416580
brain	28416580
barrier	28416580
integrity	28416580
and	28416580
diminished	28416580
cell	28416580
death	28416580
.	28416580

Notably	28416580
,	28416580
the	28416580
protective	28416580
effect	28416580
of	28416580
etifoxine	28416580
was	28416580
abolished	28416580
in	28416580
mice	28416580
depleted	28416580
of	28416580
microglia	28416580
by	28416580
using	28416580
a	28416580
colony	28416580
-	28416580
stimulating	28416580
factor	28416580
1	28416580
receptor	28416580
inhibitor	28416580
.	28416580

These	28416580
results	28416580
indicate	28416580
that	28416580
the	28416580
TSPO	28416580
ligand	28416580
etifoxine	28416580
attenuates	28416580
brain	28416580
injury	28416580
and	28416580
inflammation	28416580
after	28416580
ICH	28416580
.	28416580

TSPO	28416580
may	28416580
be	28416580
a	28416580
viable	28416580
therapeutic	28416580
target	28416580
that	28416580
requires	28416580
further	28416580
investigations	28416580
in	28416580
ICH	28416580
.	28416580
-	28416580
Li	28416580
,	28416580
M	28416580
.	28416580
,	28416580
Ren	28416580
,	28416580
H	28416580
.	28416580
,	28416580
Sheth	28416580
,	28416580
K	28416580
.	28416580

N	28416580
.	28416580
,	28416580
Shi	28416580
,	28416580
F	28416580
.	28416580
-	28416580
D	28416580
.	28416580
,	28416580
Liu	28416580
,	28416580
Q	28416580
.	28416580

A	28416580
TSPO	28416580
ligand	28416580
attenuates	28416580
brain	28416580
injury	28416580
after	28416580
intracerebral	28416580
hemorrhage	28416580
.	28416580
Mechanisms	16810074
of	16810074
hypertension	16810074
induced	16810074
by	16810074
nitric	16810074
oxide	16810074
(	16810074
NO	16810074
)	16810074
deficiency	16810074
:	16810074
focus	16810074
on	16810074
venous	16810074
function	16810074
.	16810074

Loss	16810074
of	16810074
endothelial	16810074
cell	16810074
-	16810074
derived	16810074
nitric	16810074
oxide	16810074
(	16810074
NO	16810074
)	16810074
in	16810074
hypertension	16810074
is	16810074
a	16810074
hallmark	16810074
of	16810074
arterial	16810074
dysfunction	16810074
.	16810074

Experimental	16810074
hypertension	16810074
created	16810074
by	16810074
the	16810074
removal	16810074
of	16810074
NO	16810074
,	16810074
however	16810074
,	16810074
involves	16810074
mechanisms	16810074
in	16810074
addition	16810074
to	16810074
decreased	16810074
arterial	16810074
vasodilator	16810074
activity	16810074
.	16810074

These	16810074
include	16810074
augmented	16810074
endothelin	16810074
-	16810074
1	16810074
(	16810074
ET	16810074
-	16810074
1	16810074
)	16810074
release	16810074
,	16810074
increased	16810074
sympathetic	16810074
nervous	16810074
system	16810074
activity	16810074
,	16810074
and	16810074
elevated	16810074
tissue	16810074
oxidative	16810074
stress	16810074
.	16810074

We	16810074
hypothesized	16810074
that	16810074
increased	16810074
venous	16810074
smooth	16810074
muscle	16810074
(	16810074
venomotor	16810074
)	16810074
tone	16810074
plays	16810074
a	16810074
role	16810074
in	16810074
Nomega	16810074
-	16810074
nitro	16810074
-	16810074
L	16810074
-	16810074
arginine	16810074
(	16810074
LNNA	16810074
)	16810074
hypertension	16810074
through	16810074
these	16810074
mechanisms	16810074
.	16810074

Rats	16810074
were	16810074
treated	16810074
with	16810074
the	16810074
NO	16810074
synthase	16810074
inhibitor	16810074
LNNA	16810074
(	16810074
0	16810074
.	16810074
5	16810074
g	16810074
/	16810074
L	16810074
in	16810074
drinking	16810074
water	16810074
)	16810074
for	16810074
2	16810074
weeks	16810074
.	16810074

Mean	16810074
arterial	16810074
pressure	16810074
of	16810074
conscious	16810074
rats	16810074
was	16810074
119	16810074
+	16810074
/	16810074
-	16810074
2	16810074
mm	16810074
Hg	16810074
in	16810074
control	16810074
and	16810074
194	16810074
+	16810074
/	16810074
-	16810074
5	16810074
mm	16810074
Hg	16810074
in	16810074
LNNA	16810074
rats	16810074
(	16810074
P	16810074
<	16810074
0	16810074
.	16810074
05	16810074
)	16810074
.	16810074

Carotid	16810074
arteries	16810074
and	16810074
vena	16810074
cava	16810074
were	16810074
removed	16810074
for	16810074
measurement	16810074
of	16810074
isometric	16810074
contraction	16810074
.	16810074

Maximal	16810074
contraction	16810074
to	16810074
norepinephrine	16810074
was	16810074
modestly	16810074
reduced	16810074
in	16810074
arteries	16810074
from	16810074
LNNA	16810074
compared	16810074
with	16810074
control	16810074
rats	16810074
whereas	16810074
the	16810074
maximum	16810074
contraction	16810074
to	16810074
ET	16810074
-	16810074
1	16810074
was	16810074
significantly	16810074
reduced	16810074
(	16810074
54%	16810074
control	16810074
)	16810074
.	16810074

Maximum	16810074
contraction	16810074
of	16810074
vena	16810074
cava	16810074
to	16810074
norepinephrine	16810074
(	16810074
37%	16810074
control	16810074
)	16810074
also	16810074
was	16810074
reduced	16810074
but	16810074
no	16810074
change	16810074
in	16810074
response	16810074
to	16810074
ET	16810074
-	16810074
1	16810074
was	16810074
observed	16810074
.	16810074

Mean	16810074
circulatory	16810074
filling	16810074
pressure	16810074
,	16810074
an	16810074
in	16810074
vivo	16810074
measure	16810074
of	16810074
venomotor	16810074
tone	16810074
,	16810074
was	16810074
not	16810074
elevated	16810074
in	16810074
LNNA	16810074
hypertension	16810074
at	16810074
1	16810074
or	16810074
2	16810074
weeks	16810074
after	16810074
LNNA	16810074
.	16810074

The	16810074
superoxide	16810074
scavenger	16810074
tempol	16810074
(	16810074
30	16810074
,	16810074
100	16810074
,	16810074
and	16810074
300	16810074
micromol	16810074
kg	16810074
(	16810074
-	16810074
1	16810074
)	16810074
,	16810074
IV	16810074
)	16810074
did	16810074
not	16810074
change	16810074
arterial	16810074
pressure	16810074
in	16810074
control	16810074
rats	16810074
but	16810074
caused	16810074
a	16810074
dose	16810074
-	16810074
dependent	16810074
decrease	16810074
in	16810074
LNNA	16810074
rats	16810074
(	16810074
-	16810074
18	16810074
+	16810074
/	16810074
-	16810074
8	16810074
,	16810074
-	16810074
26	16810074
+	16810074
/	16810074
-	16810074
15	16810074
,	16810074
and	16810074
-	16810074
54	16810074
+	16810074
/	16810074
-	16810074
11	16810074
mm	16810074
Hg	16810074
)	16810074
.	16810074

Similarly	16810074
,	16810074
ganglionic	16810074
blockade	16810074
with	16810074
hexamethonium	16810074
caused	16810074
a	16810074
significantly	16810074
greater	16810074
fall	16810074
in	16810074
LNNA	16810074
hypertensive	16810074
rats	16810074
(	16810074
76	16810074
+	16810074
/	16810074
-	16810074
9	16810074
mm	16810074
Hg	16810074
)	16810074
compared	16810074
with	16810074
control	16810074
rats	16810074
(	16810074
35	16810074
+	16810074
/	16810074
-	16810074
10	16810074
mm	16810074
Hg	16810074
)	16810074
.	16810074

Carotid	16810074
arteries	16810074
,	16810074
vena	16810074
cava	16810074
,	16810074
and	16810074
sympathetic	16810074
ganglia	16810074
from	16810074
LNNA	16810074
rats	16810074
had	16810074
higher	16810074
basal	16810074
levels	16810074
of	16810074
superoxide	16810074
compared	16810074
with	16810074
those	16810074
from	16810074
control	16810074
rats	16810074
.	16810074

These	16810074
data	16810074
suggest	16810074
that	16810074
while	16810074
NO	16810074
deficiency	16810074
increases	16810074
oxidative	16810074
stress	16810074
and	16810074
sympathetic	16810074
activity	16810074
in	16810074
both	16810074
arterial	16810074
and	16810074
venous	16810074
vessels	16810074
,	16810074
the	16810074
impact	16810074
on	16810074
veins	16810074
does	16810074
not	16810074
make	16810074
a	16810074
major	16810074
contribution	16810074
to	16810074
this	16810074
form	16810074
of	16810074
hypertension	16810074
.	16810074
Necrotising	24671324
fasciitis	24671324
after	24671324
bortezomib	24671324
and	24671324
dexamethasone	24671324
-	24671324
containing	24671324
regimen	24671324
in	24671324
an	24671324
elderly	24671324
patient	24671324
of	24671324
Waldenstrom	24671324
macroglobulinaemia	24671324
.	24671324

Bortezomib	24671324
and	24671324
high	24671324
-	24671324
dose	24671324
dexamethasone	24671324
-	24671324
containing	24671324
regimens	24671324
are	24671324
considered	24671324
to	24671324
be	24671324
generally	24671324
tolerable	24671324
with	24671324
few	24671324
severe	24671324
bacterial	24671324
infections	24671324
in	24671324
patients	24671324
with	24671324
B	24671324
-	24671324
cell	24671324
malignancies	24671324
.	24671324

However	24671324
,	24671324
information	24671324
is	24671324
limited	24671324
concerning	24671324
the	24671324
safety	24671324
of	24671324
the	24671324
regimen	24671324
in	24671324
elderly	24671324
patients	24671324
.	24671324

We	24671324
report	24671324
a	24671324
case	24671324
of	24671324
a	24671324
76	24671324
-	24671324
year	24671324
-	24671324
old	24671324
man	24671324
with	24671324
Waldenstrom	24671324
macroglobulinaemia	24671324
who	24671324
suffered	24671324
necrotising	24671324
fasciitis	24671324
without	24671324
neutropenia	24671324
after	24671324
the	24671324
combination	24671324
treatment	24671324
with	24671324
bortezomib	24671324
,	24671324
high	24671324
-	24671324
dose	24671324
dexamethasone	24671324
and	24671324
rituximab	24671324
.	24671324

Despite	24671324
immediate	24671324
intravenous	24671324
antimicrobial	24671324
therapy	24671324
,	24671324
he	24671324
succumbed	24671324
23	24671324
h	24671324
after	24671324
the	24671324
onset	24671324
.	24671324

Physicians	24671324
should	24671324
recognise	24671324
the	24671324
possibility	24671324
of	24671324
fatal	24671324
bacterial	24671324
infections	24671324
related	24671324
to	24671324
bortezomib	24671324
plus	24671324
high	24671324
-	24671324
dose	24671324
dexamethasone	24671324
in	24671324
elderly	24671324
patients	24671324
,	24671324
and	24671324
we	24671324
believe	24671324
this	24671324
case	24671324
warrants	24671324
further	24671324
investigation	24671324
.	24671324
The	19759529
glycine	19759529
transporter	19759529
-	19759529
1	19759529
inhibitor	19759529
SSR103800	19759529
displays	19759529
a	19759529
selective	19759529
and	19759529
specific	19759529
antipsychotic	19759529
-	19759529
like	19759529
profile	19759529
in	19759529
normal	19759529
and	19759529
transgenic	19759529
mice	19759529
.	19759529

Schizophrenia	19759529
has	19759529
been	19759529
initially	19759529
associated	19759529
with	19759529
dysfunction	19759529
in	19759529
dopamine	19759529
neurotransmission	19759529
.	19759529

However	19759529
,	19759529
the	19759529
observation	19759529
that	19759529
antagonists	19759529
of	19759529
the	19759529
glutamate	19759529
N	19759529
-	19759529
methyl	19759529
-	19759529
D	19759529
-	19759529
aspartate	19759529
(	19759529
NMDA	19759529
)	19759529
receptor	19759529
produce	19759529
schizophrenic	19759529
-	19759529
like	19759529
symptoms	19759529
in	19759529
humans	19759529
has	19759529
led	19759529
to	19759529
the	19759529
idea	19759529
of	19759529
a	19759529
dysfunctioning	19759529
of	19759529
the	19759529
glutamatergic	19759529
system	19759529
via	19759529
its	19759529
NMDA	19759529
receptor	19759529
.	19759529

As	19759529
a	19759529
result	19759529
,	19759529
there	19759529
is	19759529
a	19759529
growing	19759529
interest	19759529
in	19759529
the	19759529
development	19759529
of	19759529
pharmacological	19759529
agents	19759529
with	19759529
potential	19759529
antipsychotic	19759529
properties	19759529
that	19759529
enhance	19759529
the	19759529
activity	19759529
of	19759529
the	19759529
glutamatergic	19759529
system	19759529
via	19759529
a	19759529
modulation	19759529
of	19759529
the	19759529
NMDA	19759529
receptor	19759529
.	19759529

Among	19759529
them	19759529
are	19759529
glycine	19759529
transporter	19759529
-	19759529
1	19759529
(	19759529
GlyT1	19759529
)	19759529
inhibitors	19759529
such	19759529
as	19759529
SSR103800	19759529
,	19759529
which	19759529
indirectly	19759529
enhance	19759529
NMDA	19759529
receptor	19759529
function	19759529
by	19759529
increasing	19759529
the	19759529
glycine	19759529
(	19759529
a	19759529
co	19759529
-	19759529
agonist	19759529
for	19759529
the	19759529
NMDA	19759529
receptor	19759529
)	19759529
levels	19759529
in	19759529
the	19759529
synapse	19759529
.	19759529

This	19759529
study	19759529
aimed	19759529
at	19759529
investigating	19759529
the	19759529
potential	19759529
antipsychotic	19759529
-	19759529
like	19759529
properties	19759529
of	19759529
SSR103800	19759529
,	19759529
with	19759529
a	19759529
particular	19759529
focus	19759529
on	19759529
models	19759529
of	19759529
hyperactivity	19759529
,	19759529
involving	19759529
either	19759529
drug	19759529
challenge	19759529
(	19759529
ie	19759529
,	19759529
amphetamine	19759529
and	19759529
MK	19759529
-	19759529
801	19759529
)	19759529
or	19759529
transgenic	19759529
mice	19759529
(	19759529
ie	19759529
,	19759529
NMDA	19759529
Nr1	19759529
(	19759529
neo	19759529
-	19759529
/	19759529
-	19759529
)	19759529
and	19759529
DAT	19759529
(	19759529
-	19759529
/	19759529
-	19759529
)	19759529
)	19759529
.	19759529

Results	19759529
showed	19759529
that	19759529
SSR103800	19759529
(	19759529
10	19759529
-	19759529
30	19759529
mg	19759529
/	19759529
kg	19759529
p	19759529
.	19759529
o	19759529
.	19759529
)	19759529
blocked	19759529
hyperactivity	19759529
induced	19759529
by	19759529
the	19759529
non	19759529
-	19759529
competitive	19759529
NMDA	19759529
receptor	19759529
antagonist	19759529
,	19759529
MK	19759529
-	19759529
801	19759529
and	19759529
partially	19759529
reversed	19759529
spontaneous	19759529
hyperactivity	19759529
of	19759529
NMDA	19759529
Nr1	19759529
(	19759529
neo	19759529
-	19759529
/	19759529
-	19759529
)	19759529
mice	19759529
.	19759529

In	19759529
contrast	19759529
,	19759529
SSR103800	19759529
failed	19759529
to	19759529
affect	19759529
hyperactivity	19759529
induced	19759529
by	19759529
amphetamine	19759529
or	19759529
naturally	19759529
observed	19759529
in	19759529
dopamine	19759529
transporter	19759529
(	19759529
DAT	19759529
(	19759529
-	19759529
/	19759529
-	19759529
)	19759529
)	19759529
knockout	19759529
mice	19759529
(	19759529
10	19759529
-	19759529
30	19759529
mg	19759529
/	19759529
kg	19759529
p	19759529
.	19759529
o	19759529
.	19759529
)	19759529
.	19759529

Importantly	19759529
,	19759529
both	19759529
classical	19759529
(	19759529
haloperidol	19759529
)	19759529
and	19759529
atypical	19759529
(	19759529
olanzapine	19759529
,	19759529
clozapine	19759529
and	19759529
aripiprazole	19759529
)	19759529
antipsychotics	19759529
were	19759529
effective	19759529
in	19759529
all	19759529
these	19759529
models	19759529
of	19759529
hyperactivity	19759529
.	19759529

However	19759529
,	19759529
unlike	19759529
these	19759529
latter	19759529
,	19759529
SSR103800	19759529
did	19759529
not	19759529
produce	19759529
catalepsy	19759529
(	19759529
retention	19759529
on	19759529
the	19759529
bar	19759529
test	19759529
)	19759529
up	19759529
to	19759529
30	19759529
mg	19759529
/	19759529
kg	19759529
p	19759529
.	19759529
o	19759529
.	19759529

Together	19759529
these	19759529
findings	19759529
show	19759529
that	19759529
the	19759529
GlyT1	19759529
inhibitor	19759529
,	19759529
SSR103800	19759529
,	19759529
produces	19759529
antipsychotic	19759529
-	19759529
like	19759529
effects	19759529
,	19759529
which	19759529
differ	19759529
from	19759529
those	19759529
observed	19759529
with	19759529
compounds	19759529
primarily	19759529
targeting	19759529
the	19759529
dopaminergic	19759529
system	19759529
,	19759529
and	19759529
has	19759529
a	19759529
reduced	19759529
side	19759529
-	19759529
effect	19759529
potential	19759529
as	19759529
compared	19759529
with	19759529
these	19759529
latter	19759529
drugs	19759529
.	19759529
Atrial	15042318
fibrillation	15042318
following	15042318
chemotherapy	15042318
for	15042318
stage	15042318
IIIE	15042318
diffuse	15042318
large	15042318
B	15042318
-	15042318
cell	15042318
gastric	15042318
lymphoma	15042318
in	15042318
a	15042318
patient	15042318
with	15042318
myotonic	15042318
dystrophy	15042318
(	15042318
Steinert	15042318
'	15042318
s	15042318
disease	15042318
)	15042318
.	15042318

The	15042318
authors	15042318
describe	15042318
the	15042318
unusual	15042318
association	15042318
between	15042318
diffuse	15042318
B	15042318
-	15042318
cell	15042318
gastric	15042318
lymphoma	15042318
and	15042318
myotonic	15042318
dystrophy	15042318
,	15042318
the	15042318
most	15042318
common	15042318
form	15042318
of	15042318
adult	15042318
muscular	15042318
dystrophy	15042318
,	15042318
and	15042318
sudden	15042318
atrial	15042318
fibrillation	15042318
following	15042318
one	15042318
cycle	15042318
of	15042318
doxorubicin	15042318
-	15042318
based	15042318
chemotherapy	15042318
in	15042318
the	15042318
same	15042318
patient	15042318
.	15042318

Atrial	15042318
fibrillation	15042318
or	15042318
other	15042318
cardiac	15042318
arrhythmias	15042318
are	15042318
unusual	15042318
complications	15042318
in	15042318
patients	15042318
treated	15042318
with	15042318
chemotherapy	15042318
.	15042318

The	15042318
cardiac	15042318
toxicity	15042318
intrinsically	15042318
associated	15042318
with	15042318
the	15042318
aggressive	15042318
chemotherapy	15042318
employed	15042318
could	15042318
function	15042318
as	15042318
a	15042318
triggering	15042318
factor	15042318
for	15042318
the	15042318
arrhythmia	15042318
in	15042318
the	15042318
predisposed	15042318
myocardium	15042318
of	15042318
this	15042318
patient	15042318
.	15042318
NOTCH1	27084744
and	27084744
SOX10	27084744
are	27084744
Essential	27084744
for	27084744
Proliferation	27084744
and	27084744
Radiation	27084744
Resistance	27084744
of	27084744
Cancer	27084744
Stem	27084744
-	27084744
Like	27084744
Cells	27084744
in	27084744
Adenoid	27084744
Cystic	27084744
Carcinoma	27084744
.	27084744

PURPOSE	27084744
:	27084744
Although	27084744
the	27084744
existence	27084744
of	27084744
cancer	27084744
stem	27084744
cells	27084744
(	27084744
CSC	27084744
)	27084744
in	27084744
adenoid	27084744
cystic	27084744
carcinoma	27084744
(	27084744
ACC	27084744
)	27084744
has	27084744
been	27084744
proposed	27084744
,	27084744
lack	27084744
of	27084744
assays	27084744
for	27084744
their	27084744
propagation	27084744
and	27084744
uncertainty	27084744
about	27084744
molecular	27084744
markers	27084744
prevented	27084744
their	27084744
characterization	27084744
.	27084744

Our	27084744
objective	27084744
was	27084744
to	27084744
isolate	27084744
CSC	27084744
from	27084744
ACC	27084744
and	27084744
provide	27084744
insight	27084744
into	27084744
signaling	27084744
pathways	27084744
that	27084744
support	27084744
their	27084744
propagation	27084744
.	27084744

EXPERIMENTAL	27084744
DESIGN	27084744
:	27084744
To	27084744
isolate	27084744
CSC	27084744
from	27084744
ACC	27084744
and	27084744
characterize	27084744
them	27084744
,	27084744
we	27084744
used	27084744
ROCK	27084744
inhibitor	27084744
-	27084744
supplemented	27084744
cell	27084744
culture	27084744
,	27084744
immunomagnetic	27084744
cell	27084744
sorting	27084744
,	27084744
andin	27084744
vitro	27084744
/	27084744
in	27084744
vivoassays	27084744
for	27084744
CSC	27084744
viability	27084744
and	27084744
tumorigenicity	27084744
.	27084744

RESULTS	27084744
:	27084744
We	27084744
identified	27084744
in	27084744
ACC	27084744
CD133	27084744
-	27084744
positive	27084744
CSC	27084744
that	27084744
expressed	27084744
NOTCH1	27084744
and	27084744
SOX10	27084744
,	27084744
formed	27084744
spheroids	27084744
,	27084744
and	27084744
initiated	27084744
tumors	27084744
in	27084744
nude	27084744
mice	27084744
.	27084744

CD133	27084744
(	27084744
+	27084744
)	27084744
ACC	27084744
cells	27084744
produced	27084744
activated	27084744
NOTCH1	27084744
(	27084744
N1ICD	27084744
)	27084744
and	27084744
generated	27084744
CD133	27084744
(	27084744
-	27084744
)	27084744
cells	27084744
that	27084744
expressed	27084744
JAG1	27084744
as	27084744
well	27084744
as	27084744
neural	27084744
differentiation	27084744
factors	27084744
NR2F1	27084744
,	27084744
NR2F2	27084744
,	27084744
and	27084744
p27Kip1	27084744
.	27084744

Knockdowns	27084744
of	27084744
NOTCH1	27084744
,	27084744
SOX10	27084744
,	27084744
and	27084744
their	27084744
common	27084744
effector	27084744
FABP7	27084744
had	27084744
negative	27084744
effects	27084744
on	27084744
each	27084744
other	27084744
,	27084744
inhibited	27084744
spheroidogenesis	27084744
,	27084744
and	27084744
induced	27084744
cell	27084744
death	27084744
pointing	27084744
at	27084744
their	27084744
essential	27084744
roles	27084744
in	27084744
CSC	27084744
maintenance	27084744
.	27084744

Downstream	27084744
effects	27084744
of	27084744
FABP7	27084744
knockdown	27084744
included	27084744
suppression	27084744
of	27084744
a	27084744
broad	27084744
spectrum	27084744
of	27084744
genes	27084744
involved	27084744
in	27084744
proliferation	27084744
,	27084744
ribosome	27084744
biogenesis	27084744
,	27084744
and	27084744
metabolism	27084744
.	27084744

Among	27084744
proliferation	27084744
-	27084744
linked	27084744
NOTCH1	27084744
/	27084744
FABP7	27084744
targets	27084744
,	27084744
we	27084744
identified	27084744
SKP2	27084744
and	27084744
its	27084744
substrate	27084744
p27Kip1	27084744
.	27084744

A	27084744
g	27084744
-	27084744
secretase	27084744
inhibitor	27084744
,	27084744
DAPT	27084744
,	27084744
selectively	27084744
depleted	27084744
CD133	27084744
(	27084744
+	27084744
)	27084744
cells	27084744
,	27084744
suppressed	27084744
N1ICD	27084744
and	27084744
SKP2	27084744
,	27084744
induced	27084744
p27Kip1	27084744
,	27084744
inhibited	27084744
ACC	27084744
growthin	27084744
vivo	27084744
,	27084744
and	27084744
sensitized	27084744
CD133	27084744
(	27084744
+	27084744
)	27084744
cells	27084744
to	27084744
radiation	27084744
.	27084744

CONCLUSIONS	27084744
:	27084744
These	27084744
results	27084744
establish	27084744
in	27084744
the	27084744
majority	27084744
of	27084744
ACC	27084744
the	27084744
presence	27084744
of	27084744
a	27084744
previously	27084744
uncharacterized	27084744
population	27084744
of	27084744
CD133	27084744
(	27084744
+	27084744
)	27084744
cells	27084744
with	27084744
neural	27084744
stem	27084744
properties	27084744
,	27084744
which	27084744
are	27084744
driven	27084744
by	27084744
SOX10	27084744
,	27084744
NOTCH1	27084744
,	27084744
and	27084744
FABP7	27084744
.	27084744

Sensitivity	27084744
of	27084744
these	27084744
cells	27084744
to	27084744
Notch	27084744
inhibition	27084744
and	27084744
their	27084744
dependence	27084744
on	27084744
SKP2	27084744
offer	27084744
new	27084744
opportunities	27084744
for	27084744
targeted	27084744
ACC	27084744
therapies	27084744
.	27084744
The	26449539
impact	26449539
of	26449539
PPARa	26449539
activation	26449539
on	26449539
whole	26449539
genome	26449539
gene	26449539
expression	26449539
in	26449539
human	26449539
precision	26449539
cut	26449539
liver	26449539
slices	26449539
.	26449539

BACKGROUND	26449539
:	26449539
Studies	26449539
in	26449539
mice	26449539
have	26449539
shown	26449539
that	26449539
PPARa	26449539
is	26449539
an	26449539
important	26449539
regulator	26449539
of	26449539
lipid	26449539
metabolism	26449539
in	26449539
liver	26449539
and	26449539
key	26449539
transcription	26449539
factor	26449539
involved	26449539
in	26449539
the	26449539
adaptive	26449539
response	26449539
to	26449539
fasting	26449539
.	26449539

However	26449539
,	26449539
much	26449539
less	26449539
is	26449539
known	26449539
about	26449539
the	26449539
role	26449539
of	26449539
PPARa	26449539
in	26449539
human	26449539
liver	26449539
.	26449539

METHODS	26449539
:	26449539
Here	26449539
we	26449539
set	26449539
out	26449539
to	26449539
study	26449539
the	26449539
function	26449539
of	26449539
PPARa	26449539
in	26449539
human	26449539
liver	26449539
via	26449539
analysis	26449539
of	26449539
whole	26449539
genome	26449539
gene	26449539
regulation	26449539
in	26449539
human	26449539
liver	26449539
slices	26449539
treated	26449539
with	26449539
the	26449539
PPARa	26449539
agonist	26449539
Wy14643	26449539
.	26449539

RESULTS	26449539
:	26449539
Quantitative	26449539
PCR	26449539
indicated	26449539
that	26449539
PPARa	26449539
is	26449539
well	26449539
expressed	26449539
in	26449539
human	26449539
liver	26449539
and	26449539
human	26449539
liver	26449539
slices	26449539
and	26449539
that	26449539
the	26449539
classical	26449539
PPARa	26449539
targets	26449539
PLIN2	26449539
,	26449539
VLDLR	26449539
,	26449539
ANGPTL4	26449539
,	26449539
CPT1A	26449539
and	26449539
PDK4	26449539
are	26449539
robustly	26449539
induced	26449539
by	26449539
PPARa	26449539
activation	26449539
.	26449539

Transcriptomics	26449539
analysis	26449539
indicated	26449539
that	26449539
617	26449539
genes	26449539
were	26449539
upregulated	26449539
and	26449539
665	26449539
genes	26449539
were	26449539
downregulated	26449539
by	26449539
PPARa	26449539
activation	26449539
(	26449539
q	26449539
value	26449539
<	26449539
0	26449539
.	26449539
05	26449539
)	26449539
.	26449539

Many	26449539
genes	26449539
induced	26449539
by	26449539
PPARa	26449539
activation	26449539
were	26449539
involved	26449539
in	26449539
lipid	26449539
metabolism	26449539
(	26449539
ACSL5	26449539
,	26449539
AGPAT9	26449539
,	26449539
FADS1	26449539
,	26449539
SLC27A4	26449539
)	26449539
,	26449539
xenobiotic	26449539
metabolism	26449539
(	26449539
POR	26449539
,	26449539
ABCC2	26449539
,	26449539
CYP3A5	26449539
)	26449539
or	26449539
the	26449539
unfolded	26449539
protein	26449539
response	26449539
,	26449539
whereas	26449539
most	26449539
of	26449539
the	26449539
downregulated	26449539
genes	26449539
were	26449539
involved	26449539
in	26449539
immune	26449539
-	26449539
related	26449539
pathways	26449539
.	26449539

Among	26449539
the	26449539
most	26449539
highly	26449539
repressed	26449539
genes	26449539
upon	26449539
PPARa	26449539
activation	26449539
were	26449539
several	26449539
chemokines	26449539
(	26449539
e	26449539
.	26449539
g	26449539
.	26449539

CXCL9	26449539
-	26449539
11	26449539
,	26449539
CCL8	26449539
,	26449539
CX3CL1	26449539
,	26449539
CXCL6	26449539
)	26449539
,	26449539
interferon	26449539
g	26449539
-	26449539
induced	26449539
genes	26449539
(	26449539
e	26449539
.	26449539
g	26449539
.	26449539

IFITM1	26449539
,	26449539
IFIT1	26449539
,	26449539
IFIT2	26449539
,	26449539
IFIT3	26449539
)	26449539
and	26449539
numerous	26449539
other	26449539
immune	26449539
-	26449539
related	26449539
genes	26449539
(	26449539
e	26449539
.	26449539
g	26449539
.	26449539

TLR3	26449539
,	26449539
NOS2	26449539
,	26449539
and	26449539
LCN2	26449539
)	26449539
.	26449539

Comparative	26449539
analysis	26449539
of	26449539
gene	26449539
regulation	26449539
by	26449539
Wy14643	26449539
between	26449539
human	26449539
liver	26449539
slices	26449539
and	26449539
primary	26449539
human	26449539
hepatocytes	26449539
showed	26449539
that	26449539
down	26449539
-	26449539
regulation	26449539
of	26449539
gene	26449539
expression	26449539
by	26449539
PPARa	26449539
is	26449539
much	26449539
better	26449539
captured	26449539
by	26449539
liver	26449539
slices	26449539
as	26449539
compared	26449539
to	26449539
primary	26449539
hepatocytes	26449539
.	26449539

In	26449539
particular	26449539
,	26449539
PPARa	26449539
activation	26449539
markedly	26449539
suppressed	26449539
immunity	26449539
/	26449539
inflammation	26449539
-	26449539
related	26449539
genes	26449539
in	26449539
human	26449539
liver	26449539
slices	26449539
but	26449539
not	26449539
in	26449539
primary	26449539
hepatocytes	26449539
.	26449539

Finally	26449539
,	26449539
several	26449539
putative	26449539
new	26449539
target	26449539
genes	26449539
of	26449539
PPARa	26449539
were	26449539
identified	26449539
that	26449539
were	26449539
commonly	26449539
induced	26449539
by	26449539
PPARa	26449539
activation	26449539
in	26449539
the	26449539
two	26449539
human	26449539
liver	26449539
model	26449539
systems	26449539
,	26449539
including	26449539
TSKU	26449539
,	26449539
RHOF	26449539
,	26449539
CA12	26449539
and	26449539
VSIG10L	26449539
.	26449539

CONCLUSION	26449539
:	26449539
Our	26449539
paper	26449539
demonstrates	26449539
the	26449539
suitability	26449539
and	26449539
superiority	26449539
of	26449539
human	26449539
liver	26449539
slices	26449539
over	26449539
primary	26449539
hepatocytes	26449539
for	26449539
studying	26449539
the	26449539
functional	26449539
role	26449539
of	26449539
PPARa	26449539
in	26449539
human	26449539
liver	26449539
.	26449539

Our	26449539
data	26449539
underscore	26449539
the	26449539
major	26449539
role	26449539
of	26449539
PPARa	26449539
in	26449539
regulation	26449539
of	26449539
hepatic	26449539
lipid	26449539
and	26449539
xenobiotic	26449539
metabolism	26449539
in	26449539
human	26449539
liver	26449539
and	26449539
reveal	26449539
a	26449539
marked	26449539
immuno	26449539
-	26449539
suppressive	26449539
/	26449539
anti	26449539
-	26449539
inflammatory	26449539
effect	26449539
of	26449539
PPARa	26449539
in	26449539
human	26449539
liver	26449539
slices	26449539
that	26449539
may	26449539
be	26449539
therapeutically	26449539
relevant	26449539
for	26449539
non	26449539
-	26449539
alcoholic	26449539
fatty	26449539
liver	26449539
disease	26449539
.	26449539
Curcumin	18593936
decreases	18593936
specificity	18593936
protein	18593936
expression	18593936
in	18593936
bladder	18593936
cancer	18593936
cells	18593936
.	18593936

Curcumin	18593936
is	18593936
the	18593936
active	18593936
component	18593936
of	18593936
tumeric	18593936
,	18593936
and	18593936
this	18593936
polyphenolic	18593936
compound	18593936
has	18593936
been	18593936
extensively	18593936
investigated	18593936
as	18593936
an	18593936
anticancer	18593936
drug	18593936
that	18593936
modulates	18593936
multiple	18593936
pathways	18593936
and	18593936
genes	18593936
.	18593936

In	18593936
this	18593936
study	18593936
,	18593936
10	18593936
to	18593936
25	18593936
micromol	18593936
/	18593936
L	18593936
curcumin	18593936
inhibited	18593936
253JB	18593936
-	18593936
V	18593936
and	18593936
KU7	18593936
bladder	18593936
cancer	18593936
cell	18593936
growth	18593936
,	18593936
and	18593936
this	18593936
was	18593936
accompanied	18593936
by	18593936
induction	18593936
of	18593936
apoptosis	18593936
and	18593936
decreased	18593936
expression	18593936
of	18593936
the	18593936
proapoptotic	18593936
protein	18593936
survivin	18593936
and	18593936
the	18593936
angiogenic	18593936
proteins	18593936
vascular	18593936
endothelial	18593936
growth	18593936
factor	18593936
(	18593936
VEGF	18593936
)	18593936
and	18593936
VEGF	18593936
receptor	18593936
1	18593936
(	18593936
VEGFR1	18593936
)	18593936
.	18593936

Because	18593936
expression	18593936
of	18593936
survivin	18593936
,	18593936
VEGF	18593936
,	18593936
and	18593936
VEGFR1	18593936
are	18593936
dependent	18593936
on	18593936
specificity	18593936
protein	18593936
(	18593936
Sp	18593936
)	18593936
transcription	18593936
factors	18593936
,	18593936
we	18593936
also	18593936
investigated	18593936
the	18593936
effects	18593936
of	18593936
curcumin	18593936
on	18593936
Sp	18593936
protein	18593936
expression	18593936
as	18593936
an	18593936
underlying	18593936
mechanism	18593936
for	18593936
the	18593936
apoptotic	18593936
and	18593936
antiangiogenic	18593936
activity	18593936
of	18593936
this	18593936
compound	18593936
.	18593936

The	18593936
results	18593936
show	18593936
that	18593936
curcumin	18593936
induced	18593936
proteasome	18593936
-	18593936
dependent	18593936
down	18593936
-	18593936
regulation	18593936
of	18593936
Sp1	18593936
,	18593936
Sp3	18593936
,	18593936
and	18593936
Sp4	18593936
in	18593936
253JB	18593936
-	18593936
V	18593936
and	18593936
KU7	18593936
cells	18593936
.	18593936

Moreover	18593936
,	18593936
using	18593936
RNA	18593936
interference	18593936
with	18593936
small	18593936
inhibitory	18593936
RNAs	18593936
for	18593936
Sp1	18593936
,	18593936
Sp3	18593936
,	18593936
and	18593936
Sp4	18593936
,	18593936
we	18593936
observed	18593936
that	18593936
curcumin	18593936
-	18593936
dependent	18593936
inhibition	18593936
of	18593936
nuclear	18593936
factor	18593936
kappaB	18593936
(	18593936
NF	18593936
-	18593936
kappaB	18593936
)	18593936
-	18593936
dependent	18593936
genes	18593936
,	18593936
such	18593936
as	18593936
bcl	18593936
-	18593936
2	18593936
,	18593936
survivin	18593936
,	18593936
and	18593936
cyclin	18593936
D1	18593936
,	18593936
was	18593936
also	18593936
due	18593936
,	18593936
in	18593936
part	18593936
,	18593936
to	18593936
loss	18593936
of	18593936
Sp	18593936
proteins	18593936
.	18593936

Curcumin	18593936
also	18593936
decreased	18593936
bladder	18593936
tumor	18593936
growth	18593936
in	18593936
athymic	18593936
nude	18593936
mice	18593936
bearing	18593936
KU7	18593936
cells	18593936
as	18593936
xenografts	18593936
and	18593936
this	18593936
was	18593936
accompanied	18593936
by	18593936
decreased	18593936
Sp1	18593936
,	18593936
Sp3	18593936
,	18593936
and	18593936
Sp4	18593936
protein	18593936
levels	18593936
in	18593936
tumors	18593936
.	18593936

These	18593936
results	18593936
show	18593936
for	18593936
the	18593936
first	18593936
time	18593936
that	18593936
one	18593936
of	18593936
the	18593936
underlying	18593936
mechanisms	18593936
of	18593936
action	18593936
of	18593936
curcumin	18593936
as	18593936
a	18593936
cancer	18593936
chemotherapeutic	18593936
agent	18593936
is	18593936
due	18593936
,	18593936
in	18593936
part	18593936
,	18593936
to	18593936
decreased	18593936
expression	18593936
of	18593936
Sp	18593936
transcription	18593936
factors	18593936
in	18593936
bladder	18593936
cancer	18593936
cells	18593936
.	18593936
Study	19101703
of	19101703
a	19101703
Taiwanese	19101703
family	19101703
with	19101703
oculopharyngeal	19101703
muscular	19101703
dystrophy	19101703
.	19101703

BACKGROUND	19101703
:	19101703
Oculopharyngeal	19101703
muscular	19101703
dystrophy	19101703
(	19101703
OPMD	19101703
)	19101703
is	19101703
a	19101703
late	19101703
onset	19101703
autosomal	19101703
dominant	19101703
muscle	19101703
disorder	19101703
.	19101703

OPMD	19101703
is	19101703
caused	19101703
by	19101703
a	19101703
short	19101703
trinucleotide	19101703
repeat	19101703
expansion	19101703
encoding	19101703
an	19101703
expanded	19101703
polyalanine	19101703
tract	19101703
in	19101703
the	19101703
polyadenylate	19101703
binding	19101703
-	19101703
protein	19101703
nuclear	19101703
1	19101703
(	19101703
PABPN1	19101703
)	19101703
gene	19101703
.	19101703

We	19101703
identified	19101703
and	19101703
characterized	19101703
a	19101703
PABPN1	19101703
mutation	19101703
in	19101703
a	19101703
Taiwanese	19101703
family	19101703
with	19101703
OPMD	19101703
.	19101703

METHODS	19101703
:	19101703
The	19101703
phenotypic	19101703
and	19101703
genotypic	19101703
characteristics	19101703
of	19101703
all	19101703
subjects	19101703
were	19101703
evaluated	19101703
in	19101703
a	19101703
Taiwanese	19101703
OPMD	19101703
family	19101703
.	19101703

Genetic	19101703
alterations	19101703
in	19101703
the	19101703
PABPN1	19101703
gene	19101703
were	19101703
identified	19101703
using	19101703
PCR	19101703
and	19101703
DNA	19101703
sequencing	19101703
.	19101703

RESULTS	19101703
:	19101703
Ten	19101703
subjects	19101703
with	19101703
OPMD	19101703
(	19101703
6	19101703
symptomatic	19101703
and	19101703
4	19101703
asymptomatic	19101703
)	19101703
within	19101703
the	19101703
Taiwanese	19101703
family	19101703
carried	19101703
a	19101703
novel	19101703
mutation	19101703
in	19101703
the	19101703
PABPN1	19101703
gene	19101703
.	19101703

The	19101703
normal	19101703
(	19101703
GCG	19101703
)	19101703
6	19101703
(	19101703
GCA	19101703
)	19101703
3GCG	19101703
sequence	19101703
was	19101703
replaced	19101703
by	19101703
(	19101703
GCG	19101703
)	19101703
6	19101703
(	19101703
GCA	19101703
)	19101703
(	19101703
GCG	19101703
)	19101703
4	19101703
(	19101703
GCA	19101703
)	19101703
3GCG	19101703
due	19101703
to	19101703
an	19101703
insertion	19101703
of	19101703
(	19101703
GCG	19101703
)	19101703
4GCA	19101703
into	19101703
the	19101703
normal	19101703
allele	19101703
in	19101703
the	19101703
Taiwanese	19101703
OPMD	19101703
subjects	19101703
.	19101703

CONCLUSIONS	19101703
:	19101703
In	19101703
contrast	19101703
to	19101703
a	19101703
single	19101703
GCG	19101703
expansion	19101703
in	19101703
most	19101703
of	19101703
OPMD	19101703
patients	19101703
in	19101703
the	19101703
literature	19101703
,	19101703
an	19101703
insertion	19101703
of	19101703
(	19101703
GCG	19101703
)	19101703
4GCA	19101703
in	19101703
the	19101703
PABPN1	19101703
gene	19101703
was	19101703
found	19101703
in	19101703
the	19101703
Taiwanese	19101703
OPMD	19101703
subjects	19101703
.	19101703

The	19101703
identification	19101703
of	19101703
this	19101703
mutation	19101703
appears	19101703
to	19101703
support	19101703
the	19101703
molecular	19101703
mechanism	19101703
of	19101703
unequal	19101703
cross	19101703
-	19101703
over	19101703
of	19101703
two	19101703
PABPN1	19101703
alleles	19101703
.	19101703
A	17177139
novel	17177139
mutation	17177139
(	17177139
E333D	17177139
)	17177139
in	17177139
the	17177139
thyroid	17177139
hormone	17177139
beta	17177139
receptor	17177139
causing	17177139
resistance	17177139
to	17177139
thyroid	17177139
hormone	17177139
syndrome	17177139
.	17177139

Resistance	17177139
to	17177139
thyroid	17177139
hormone	17177139
(	17177139
RTH	17177139
)	17177139
is	17177139
an	17177139
inherited	17177139
syndrome	17177139
characterized	17177139
by	17177139
elevated	17177139
serum	17177139
thyroid	17177139
hormones	17177139
(	17177139
TH	17177139
)	17177139
,	17177139
failure	17177139
to	17177139
suppress	17177139
pituitary	17177139
thyroid	17177139
stimulating	17177139
hormone	17177139
(	17177139
TSH	17177139
)	17177139
secretion	17177139
,	17177139
and	17177139
variable	17177139
peripheral	17177139
tissue	17177139
responsiveness	17177139
to	17177139
TH	17177139
.	17177139

The	17177139
disorder	17177139
is	17177139
associated	17177139
with	17177139
diverse	17177139
mutations	17177139
in	17177139
the	17177139
thyroid	17177139
hormone	17177139
beta	17177139
receptor	17177139
(	17177139
TRbeta	17177139
)	17177139
.	17177139

Here	17177139
,	17177139
we	17177139
report	17177139
a	17177139
novel	17177139
natural	17177139
RTH	17177139
mutation	17177139
(	17177139
E333D	17177139
)	17177139
located	17177139
in	17177139
the	17177139
large	17177139
carboxy	17177139
-	17177139
terminal	17177139
ligand	17177139
binding	17177139
domain	17177139
of	17177139
TRbeta	17177139
.	17177139

The	17177139
mutation	17177139
was	17177139
identified	17177139
in	17177139
a	17177139
22	17177139
-	17177139
year	17177139
-	17177139
old	17177139
French	17177139
woman	17177139
coming	17177139
to	17177139
medical	17177139
attention	17177139
because	17177139
of	17177139
an	17177139
increasing	17177139
overweight	17177139
.	17177139

Biochemical	17177139
tests	17177139
showed	17177139
elevated	17177139
free	17177139
thyroxine	17177139
(	17177139
T4	17177139
:	17177139
20	17177139
.	17177139
8	17177139
pg	17177139
/	17177139
ml	17177139
(	17177139
normal	17177139
,	17177139
8	17177139
.	17177139
5	17177139
-	17177139
18	17177139
)	17177139
)	17177139
and	17177139
triiodothyronine	17177139
(	17177139
T3	17177139
:	17177139
5	17177139
.	17177139
7	17177139
pg	17177139
/	17177139
ml	17177139
(	17177139
normal	17177139
,	17177139
1	17177139
.	17177139
4	17177139
-	17177139
4	17177139
)	17177139
)	17177139
in	17177139
the	17177139
serum	17177139
,	17177139
together	17177139
with	17177139
an	17177139
inappropriately	17177139
nonsuppressed	17177139
TSH	17177139
level	17177139
of	17177139
4	17177139
.	17177139
7	17177139
mU	17177139
/	17177139
ml	17177139
(	17177139
normal	17177139
,	17177139
0	17177139
.	17177139
4	17177139
-	17177139
4	17177139
)	17177139
.	17177139

Her	17177139
father	17177139
and	17177139
her	17177139
brother	17177139
'	17177139
s	17177139
serum	17177139
tests	17177139
also	17177139
showed	17177139
biochemical	17177139
abnormalities	17177139
consistent	17177139
with	17177139
RTH	17177139
.	17177139

Direct	17177139
sequencing	17177139
of	17177139
the	17177139
TRbeta	17177139
gene	17177139
revealed	17177139
a	17177139
heterozygous	17177139
transition	17177139
1284A	17177139
>	17177139
C	17177139
in	17177139
exon	17177139
9	17177139
resulting	17177139
in	17177139
substitution	17177139
of	17177139
glutamic	17177139
acid	17177139
333	17177139
by	17177139
aspartic	17177139
acid	17177139
residue	17177139
(	17177139
E333D	17177139
)	17177139
.	17177139

Further	17177139
functional	17177139
analyses	17177139
of	17177139
the	17177139
novel	17177139
TRbeta	17177139
mutant	17177139
were	17177139
conducted	17177139
.	17177139

We	17177139
found	17177139
that	17177139
the	17177139
E333D	17177139
mutation	17177139
neither	17177139
significantly	17177139
affected	17177139
the	17177139
affinity	17177139
of	17177139
the	17177139
receptor	17177139
for	17177139
T3	17177139
nor	17177139
modified	17177139
heterodimer	17177139
formation	17177139
with	17177139
retinoid	17177139
X	17177139
receptor	17177139
(	17177139
RXR	17177139
)	17177139
when	17177139
bound	17177139
to	17177139
DNA	17177139
.	17177139

However	17177139
,	17177139
in	17177139
transient	17177139
transfection	17177139
assays	17177139
,	17177139
the	17177139
E333D	17177139
TRbeta	17177139
mutant	17177139
exhibited	17177139
impaired	17177139
transcriptional	17177139
regulation	17177139
on	17177139
two	17177139
distinct	17177139
positively	17177139
regulated	17177139
thyroid	17177139
response	17177139
elements	17177139
(	17177139
F2	17177139
-	17177139
and	17177139
DR4	17177139
-	17177139
TREs	17177139
)	17177139
as	17177139
well	17177139
as	17177139
on	17177139
the	17177139
negatively	17177139
regulated	17177139
human	17177139
TSHalpha	17177139
promoter	17177139
.	17177139

Moreover	17177139
,	17177139
a	17177139
dominant	17177139
inhibition	17177139
of	17177139
the	17177139
wild	17177139
-	17177139
type	17177139
TRbeta	17177139
counterpart	17177139
transactivation	17177139
function	17177139
was	17177139
observed	17177139
on	17177139
both	17177139
a	17177139
positive	17177139
(	17177139
F2	17177139
-	17177139
TRE	17177139
)	17177139
and	17177139
a	17177139
negative	17177139
(	17177139
TSHalpha	17177139
)	17177139
promoter	17177139
.	17177139

These	17177139
results	17177139
strongly	17177139
suggest	17177139
that	17177139
the	17177139
E333D	17177139
TRbeta	17177139
mutation	17177139
is	17177139
responsible	17177139
for	17177139
the	17177139
RTH	17177139
phenotype	17177139
in	17177139
the	17177139
proposita	17177139
'	17177139
s	17177139
family	17177139
.	17177139
Cloning	7668252
of	7668252
human	7668252
very	7668252
-	7668252
long	7668252
-	7668252
chain	7668252
acyl	7668252
-	7668252
coenzyme	7668252
A	7668252
dehydrogenase	7668252
and	7668252
molecular	7668252
characterization	7668252
of	7668252
its	7668252
deficiency	7668252
in	7668252
two	7668252
patients	7668252
.	7668252

Two	7668252
overlapping	7668252
cDNA	7668252
clones	7668252
(	7668252
1	7668252
,	7668252
991	7668252
bp	7668252
and	7668252
736	7668252
bp	7668252
,	7668252
respectively	7668252
)	7668252
encoding	7668252
the	7668252
precursor	7668252
of	7668252
human	7668252
mitochondrial	7668252
very	7668252
-	7668252
long	7668252
-	7668252
chain	7668252
acyl	7668252
-	7668252
coenzyme	7668252
A	7668252
dehydrogenase	7668252
(	7668252
VLCAD	7668252
)	7668252
were	7668252
cloned	7668252
and	7668252
sequenced	7668252
.	7668252

The	7668252
cDNA	7668252
inserts	7668252
of	7668252
these	7668252
clones	7668252
together	7668252
encompass	7668252
a	7668252
region	7668252
of	7668252
2	7668252
,	7668252
177	7668252
bases	7668252
,	7668252
encoding	7668252
the	7668252
entire	7668252
protein	7668252
of	7668252
655	7668252
amino	7668252
acids	7668252
,	7668252
including	7668252
a	7668252
40	7668252
-	7668252
amino	7668252
acid	7668252
leader	7668252
peptide	7668252
and	7668252
a	7668252
615	7668252
-	7668252
amino	7668252
acid	7668252
mature	7668252
polypeptide	7668252
.	7668252

PCR	7668252
-	7668252
amplified	7668252
VLCAD	7668252
cDNAs	7668252
were	7668252
sequenced	7668252
in	7668252
cultured	7668252
fibroblasts	7668252
from	7668252
two	7668252
VLCAD	7668252
-	7668252
deficient	7668252
patients	7668252
.	7668252

In	7668252
both	7668252
patients	7668252
,	7668252
a	7668252
105	7668252
-	7668252
bp	7668252
deletion	7668252
encompassing	7668252
bases	7668252
1078	7668252
-	7668252
1182	7668252
in	7668252
VLCAD	7668252
cDNA	7668252
was	7668252
identified	7668252
.	7668252

The	7668252
deletion	7668252
seems	7668252
to	7668252
occur	7668252
due	7668252
to	7668252
exon	7668252
skipping	7668252
during	7668252
processing	7668252
of	7668252
VLCAD	7668252
pre	7668252
-	7668252
mRNA	7668252
.	7668252

This	7668252
is	7668252
the	7668252
first	7668252
demonstration	7668252
of	7668252
a	7668252
mutation	7668252
causing	7668252
VLCAD	7668252
deficiency	7668252
.	7668252

Quantitative	7668252
cDNA	7668252
expression	7668252
of	7668252
normal	7668252
human	7668252
VLCAD	7668252
was	7668252
performed	7668252
in	7668252
the	7668252
patients	7668252
fibroblasts	7668252
,	7668252
using	7668252
vaccinia	7668252
viral	7668252
system	7668252
,	7668252
which	7668252
demonstrated	7668252
that	7668252
the	7668252
deficiency	7668252
of	7668252
the	7668252
normal	7668252
VLCAD	7668252
protein	7668252
causes	7668252
impaired	7668252
long	7668252
-	7668252
chain	7668252
fatty	7668252
acid	7668252
beta	7668252
-	7668252
oxidation	7668252
activity	7668252
in	7668252
the	7668252
patients	7668252
fibroblasts	7668252
.	7668252

In	7668252
patient	7668252
fibroblasts	7668252
,	7668252
raising	7668252
VLCAD	7668252
activity	7668252
to	7668252
approximately	7668252
20%	7668252
of	7668252
normal	7668252
control	7668252
fibroblast	7668252
activity	7668252
raised	7668252
palmitic	7668252
acid	7668252
beta	7668252
-	7668252
oxidation	7668252
flux	7668252
to	7668252
the	7668252
level	7668252
found	7668252
in	7668252
control	7668252
fibroblasts	7668252
,	7668252
which	7668252
may	7668252
offer	7668252
important	7668252
information	7668252
for	7668252
the	7668252
rational	7668252
design	7668252
of	7668252
future	7668252
somatic	7668252
gene	7668252
therapy	7668252
for	7668252
VLCAD	7668252
deficiency	7668252
.	7668252
Haplotype	15523499
structure	15523499
of	15523499
the	15523499
beta	15523499
adrenergic	15523499
receptor	15523499
genes	15523499
in	15523499
US	15523499
Caucasians	15523499
and	15523499
African	15523499
Americans	15523499
.	15523499

The	15523499
beta	15523499
-	15523499
adrenergic	15523499
receptors	15523499
(	15523499
beta	15523499
-	15523499
AR	15523499
)	15523499
are	15523499
G	15523499
protein	15523499
-	15523499
coupled	15523499
receptors	15523499
activated	15523499
by	15523499
epinephrine	15523499
and	15523499
norepinephrine	15523499
and	15523499
are	15523499
involved	15523499
in	15523499
a	15523499
variety	15523499
of	15523499
their	15523499
physiological	15523499
functions	15523499
.	15523499

Previously	15523499
,	15523499
three	15523499
beta	15523499
-	15523499
AR	15523499
genes	15523499
(	15523499
ADRB1	15523499
,	15523499
ADRB2	15523499
and	15523499
ADRB3	15523499
)	15523499
were	15523499
resequenced	15523499
,	15523499
identifying	15523499
polymorphisms	15523499
that	15523499
were	15523499
used	15523499
in	15523499
genetic	15523499
association	15523499
studies	15523499
of	15523499
cardiovascular	15523499
and	15523499
metabolic	15523499
disorders	15523499
.	15523499

These	15523499
studies	15523499
have	15523499
produced	15523499
intriguing	15523499
but	15523499
inconsistent	15523499
results	15523499
,	15523499
potentially	15523499
because	15523499
the	15523499
known	15523499
functional	15523499
variants	15523499
:	15523499
ADRB1	15523499
Arg389Gly	15523499
and	15523499
Gly49Ser	15523499
,	15523499
ADRB2	15523499
Arg16Gly	15523499
and	15523499
Gln27Glu	15523499
,	15523499
and	15523499
ADRB3	15523499
Arg64Trp	15523499
provided	15523499
an	15523499
incomplete	15523499
picture	15523499
of	15523499
the	15523499
total	15523499
functional	15523499
diversity	15523499
at	15523499
these	15523499
genes	15523499
.	15523499

Therefore	15523499
,	15523499
we	15523499
created	15523499
marker	15523499
panels	15523499
for	15523499
each	15523499
beta	15523499
-	15523499
AR	15523499
gene	15523499
that	15523499
included	15523499
the	15523499
known	15523499
functional	15523499
markers	15523499
and	15523499
also	15523499
other	15523499
markers	15523499
evenly	15523499
spaced	15523499
and	15523499
with	15523499
sufficient	15523499
density	15523499
to	15523499
identify	15523499
haplotype	15523499
block	15523499
structure	15523499
and	15523499
to	15523499
maximize	15523499
haplotype	15523499
diversity	15523499
.	15523499

A	15523499
total	15523499
of	15523499
27	15523499
markers	15523499
were	15523499
genotyped	15523499
in	15523499
96	15523499
US	15523499
Caucasians	15523499
and	15523499
96	15523499
African	15523499
Americans	15523499
.	15523499

In	15523499
both	15523499
populations	15523499
and	15523499
for	15523499
each	15523499
gene	15523499
,	15523499
a	15523499
single	15523499
block	15523499
with	15523499
little	15523499
evidence	15523499
of	15523499
historical	15523499
recombination	15523499
was	15523499
observed	15523499
.	15523499

For	15523499
each	15523499
gene	15523499
,	15523499
haplotype	15523499
captured	15523499
most	15523499
of	15523499
the	15523499
information	15523499
content	15523499
of	15523499
each	15523499
functional	15523499
locus	15523499
,	15523499
even	15523499
if	15523499
that	15523499
locus	15523499
was	15523499
not	15523499
genotyped	15523499
,	15523499
and	15523499
presumably	15523499
haplotype	15523499
would	15523499
capture	15523499
the	15523499
signal	15523499
from	15523499
unknown	15523499
functional	15523499
loci	15523499
whose	15523499
alleles	15523499
are	15523499
of	15523499
moderate	15523499
abundance	15523499
.	15523499

This	15523499
study	15523499
demonstrates	15523499
the	15523499
utility	15523499
of	15523499
using	15523499
beta	15523499
-	15523499
AR	15523499
gene	15523499
haplotype	15523499
maps	15523499
and	15523499
marker	15523499
panels	15523499
as	15523499
tools	15523499
for	15523499
linkage	15523499
studies	15523499
on	15523499
beta	15523499
-	15523499
AR	15523499
function	15523499
.	15523499
Association	20708777
of	20708777
DNA	20708777
polymorphisms	20708777
within	20708777
the	20708777
CYP11B2	20708777
/	20708777
CYP11B1	20708777
locus	20708777
and	20708777
postoperative	20708777
hypertension	20708777
risk	20708777
in	20708777
the	20708777
patients	20708777
with	20708777
aldosterone	20708777
-	20708777
producing	20708777
adenomas	20708777
.	20708777

OBJECTIVES	20708777
:	20708777
Hypertension	20708777
often	20708777
persists	20708777
after	20708777
adrenalectomy	20708777
for	20708777
primary	20708777
aldosteronism	20708777
.	20708777

Traditional	20708777
factors	20708777
associated	20708777
with	20708777
postoperative	20708777
hypertension	20708777
were	20708777
evaluated	20708777
,	20708777
but	20708777
whether	20708777
genetic	20708777
determinants	20708777
were	20708777
involved	20708777
remains	20708777
poorly	20708777
understood	20708777
.	20708777

The	20708777
aim	20708777
of	20708777
this	20708777
study	20708777
was	20708777
to	20708777
investigate	20708777
the	20708777
association	20708777
of	20708777
DNA	20708777
polymorphisms	20708777
within	20708777
steroid	20708777
synthesis	20708777
genes	20708777
(	20708777
CYP11B2	20708777
,	20708777
CYP11B1	20708777
)	20708777
and	20708777
the	20708777
postoperative	20708777
resolution	20708777
of	20708777
hypertension	20708777
in	20708777
Chinese	20708777
patients	20708777
undergoing	20708777
adrenalectomy	20708777
for	20708777
aldosterone	20708777
-	20708777
producing	20708777
adenomas	20708777
(	20708777
APA	20708777
)	20708777
.	20708777

METHODS	20708777
:	20708777
Ninety	20708777
-	20708777
three	20708777
patients	20708777
with	20708777
APA	20708777
were	20708777
assessed	20708777
for	20708777
postoperative	20708777
resolution	20708777
of	20708777
hypertension	20708777
.	20708777

All	20708777
patients	20708777
were	20708777
genotyped	20708777
for	20708777
rs1799998	20708777
(	20708777
C	20708777
-	20708777
344	20708777
T	20708777
)	20708777
,	20708777
intron	20708777
2	20708777
conversion	20708777
,	20708777
rs4539	20708777
(	20708777
A2718G	20708777
)	20708777
within	20708777
CYP11B2	20708777
and	20708777
rs6410	20708777
(	20708777
G22	20708777
5A	20708777
)	20708777
,	20708777
rs6387	20708777
(	20708777
A2803G	20708777
)	20708777
within	20708777
CYP11B1	20708777
.	20708777

The	20708777
associations	20708777
between	20708777
CYPB11B2	20708777
/	20708777
CYP11B1	20708777
polymorphisms	20708777
and	20708777
persistent	20708777
postoperative	20708777
hypertension	20708777
were	20708777
assessed	20708777
by	20708777
multivariate	20708777
analysis	20708777
.	20708777

RESULTS	20708777
:	20708777
CYP11B2	20708777
-	20708777
CYP11B1	20708777
haplotype	20708777
was	20708777
associated	20708777
with	20708777
persistent	20708777
postoperative	20708777
hypertension	20708777
in	20708777
Chinese	20708777
patients	20708777
undergoing	20708777
adrenalectomy	20708777
with	20708777
APA	20708777
(	20708777
P	20708777
=	20708777
.	20708777
006	20708777
)	20708777
.	20708777

Specifically	20708777
,	20708777
the	20708777
rs4539	20708777
(	20708777
AA	20708777
)	20708777
polymorphism	20708777
was	20708777
associated	20708777
with	20708777
persistent	20708777
postoperative	20708777
hypertension	20708777
(	20708777
P	20708777
=	20708777
.	20708777
002	20708777
)	20708777
.	20708777

Multivariate	20708777
logistic	20708777
regression	20708777
revealed	20708777
the	20708777
common	20708777
haplotypes	20708777
H1	20708777
(	20708777
AGACT	20708777
)	20708777
,	20708777
H2	20708777
(	20708777
AGAWT	20708777
)	20708777
,	20708777
and	20708777
H3	20708777
(	20708777
AGAWC	20708777
)	20708777
were	20708777
associated	20708777
with	20708777
the	20708777
persistent	20708777
postoperative	20708777
hypertension	20708777
(	20708777
P	20708777
=	20708777
.	20708777
01	20708777
,	20708777
0	20708777
.	20708777
03	20708777
,	20708777
0	20708777
.	20708777
005	20708777
after	20708777
Bonferroni	20708777
correction	20708777
)	20708777
.	20708777

Additional	20708777
predictors	20708777
of	20708777
persistent	20708777
postoperative	20708777
hypertension	20708777
included	20708777
duration	20708777
of	20708777
hypertension	20708777
(	20708777
P	20708777
<	20708777
.	20708777
0005	20708777
)	20708777
,	20708777
family	20708777
history	20708777
of	20708777
hypertension	20708777
(	20708777
P	20708777
=	20708777
.	20708777
001	20708777
)	20708777
,	20708777
and	20708777
elevated	20708777
systolic	20708777
blood	20708777
pressure	20708777
(	20708777
P	20708777
=	20708777
.	20708777
015	20708777
)	20708777
.	20708777

CONCLUSIONS	20708777
:	20708777
The	20708777
rs4539	20708777
(	20708777
AA	20708777
)	20708777
,	20708777
H1	20708777
,	20708777
H2	20708777
,	20708777
and	20708777
H3	20708777
are	20708777
genetic	20708777
predictors	20708777
for	20708777
postoperative	20708777
persistence	20708777
of	20708777
hypertension	20708777
for	20708777
Chinese	20708777
patients	20708777
treated	20708777
by	20708777
adrenalectomy	20708777
with	20708777
APA	20708777
.	20708777

DNA	20708777
polymorphisms	20708777
at	20708777
CYP11B2	20708777
/	20708777
B1	20708777
locus	20708777
may	20708777
confer	20708777
susceptibility	20708777
to	20708777
postoperative	20708777
hypertension	20708777
of	20708777
patients	20708777
with	20708777
APA	20708777
.	20708777
Analysis	17065198
of	17065198
skin	17065198
cancer	17065198
risk	17065198
factors	17065198
in	17065198
immunosuppressed	17065198
renal	17065198
transplant	17065198
patients	17065198
shows	17065198
high	17065198
levels	17065198
of	17065198
UV	17065198
-	17065198
specific	17065198
tandem	17065198
CC	17065198
to	17065198
TT	17065198
mutations	17065198
of	17065198
the	17065198
p53	17065198
gene	17065198
.	17065198

Immunosuppressed	17065198
renal	17065198
transplant	17065198
recipients	17065198
(	17065198
RTRs	17065198
)	17065198
are	17065198
predisposed	17065198
to	17065198
non	17065198
-	17065198
melanoma	17065198
skin	17065198
cancers	17065198
(	17065198
NMSCs	17065198
)	17065198
,	17065198
predominantly	17065198
squamous	17065198
cell	17065198
carcinomas	17065198
(	17065198
SCCs	17065198
)	17065198
.	17065198

We	17065198
have	17065198
analyzed	17065198
skin	17065198
lesions	17065198
from	17065198
RTRs	17065198
with	17065198
aggressive	17065198
tumors	17065198
for	17065198
p53	17065198
gene	17065198
modifications	17065198
,	17065198
the	17065198
presence	17065198
of	17065198
Human	17065198
Papillomas	17065198
Virus	17065198
(	17065198
HPV	17065198
)	17065198
DNA	17065198
in	17065198
relation	17065198
to	17065198
the	17065198
p53	17065198
codon	17065198
72	17065198
genotype	17065198
and	17065198
polymorphisms	17065198
of	17065198
the	17065198
XPD	17065198
repair	17065198
gene	17065198
.	17065198

We	17065198
detected	17065198
24	17065198
p53	17065198
mutations	17065198
in	17065198
15	17065198
/	17065198
25	17065198
(	17065198
60%	17065198
)	17065198
NMSCs	17065198
,	17065198
1	17065198
deletion	17065198
and	17065198
23	17065198
base	17065198
substitutions	17065198
,	17065198
the	17065198
majority	17065198
(	17065198
78%	17065198
)	17065198
being	17065198
UV	17065198
-	17065198
specific	17065198
C	17065198
to	17065198
T	17065198
transitions	17065198
at	17065198
bipyrimidine	17065198
sites	17065198
.	17065198

Importantly	17065198
,	17065198
35%	17065198
(	17065198
6	17065198
/	17065198
17	17065198
)	17065198
are	17065198
tandem	17065198
mutations	17065198
,	17065198
including	17065198
4	17065198
UV	17065198
signature	17065198
CC	17065198
to	17065198
TT	17065198
transitions	17065198
possibly	17065198
linked	17065198
to	17065198
modulated	17065198
DNA	17065198
repair	17065198
caused	17065198
by	17065198
the	17065198
immunosuppressive	17065198
drug	17065198
cyclosporin	17065198
A	17065198
(	17065198
CsA	17065198
)	17065198
.	17065198

We	17065198
found	17065198
8	17065198
p53	17065198
mutations	17065198
in	17065198
7	17065198
/	17065198
17	17065198
(	17065198
41%	17065198
)	17065198
precancerous	17065198
actinic	17065198
keratosis	17065198
(	17065198
AK	17065198
)	17065198
,	17065198
suggesting	17065198
that	17065198
p53	17065198
mutations	17065198
are	17065198
early	17065198
events	17065198
in	17065198
RTR	17065198
skin	17065198
carcinogenesis	17065198
.	17065198

Immunohistochemical	17065198
analysis	17065198
shows	17065198
a	17065198
good	17065198
correlation	17065198
between	17065198
p53	17065198
accumulation	17065198
and	17065198
mutations	17065198
.	17065198

HPV	17065198
DNA	17065198
was	17065198
detected	17065198
in	17065198
78%	17065198
of	17065198
skin	17065198
lesions	17065198
(	17065198
60%	17065198
Basal	17065198
Cell	17065198
Carcinomas	17065198
,	17065198
82%AK	17065198
and	17065198
79%	17065198
SCCs	17065198
)	17065198
.	17065198

Thus	17065198
,	17065198
immunosuppression	17065198
has	17065198
increased	17065198
the	17065198
risk	17065198
of	17065198
infections	17065198
by	17065198
HPVs	17065198
,	17065198
predominantly	17065198
epidermodysplasia	17065198
verruciformis	17065198
,	17065198
speculated	17065198
to	17065198
play	17065198
a	17065198
role	17065198
in	17065198
skin	17065198
cancer	17065198
development	17065198
.	17065198

No	17065198
association	17065198
is	17065198
found	17065198
between	17065198
HPV	17065198
status	17065198
and	17065198
p53	17065198
mutation	17065198
.	17065198

Moreover	17065198
,	17065198
p53	17065198
codon	17065198
72	17065198
or	17065198
frequencies	17065198
of	17065198
three	17065198
XPD	17065198
genotypes	17065198
of	17065198
RTRs	17065198
are	17065198
comparable	17065198
with	17065198
control	17065198
populations	17065198
.	17065198

The	17065198
p53	17065198
mutation	17065198
spectrum	17065198
,	17065198
presenting	17065198
a	17065198
high	17065198
level	17065198
of	17065198
CC	17065198
to	17065198
TT	17065198
mutations	17065198
,	17065198
shows	17065198
that	17065198
the	17065198
UV	17065198
component	17065198
of	17065198
sunlight	17065198
is	17065198
the	17065198
major	17065198
risk	17065198
factor	17065198
and	17065198
modulated	17065198
DNA	17065198
repair	17065198
by	17065198
immunosuppressive	17065198
drug	17065198
treatment	17065198
may	17065198
be	17065198
significant	17065198
in	17065198
the	17065198
skin	17065198
carcinogenesis	17065198
of	17065198
RTRs	17065198
.	17065198
Tumor	15583840
associated	15583840
antigen	15583840
recognition	15583840
by	15583840
autologous	15583840
serum	15583840
in	15583840
patients	15583840
with	15583840
breast	15583840
cancer	15583840
.	15583840

Breast	15583840
cancer	15583840
accounts	15583840
for	15583840
30	15583840
-	15583840
40%	15583840
of	15583840
all	15583840
deaths	15583840
from	15583840
cancers	15583840
in	15583840
females	15583840
.	15583840

In	15583840
an	15583840
effort	15583840
to	15583840
identify	15583840
tumor	15583840
associated	15583840
antigens	15583840
that	15583840
may	15583840
be	15583840
useful	15583840
for	15583840
immunotherapy	15583840
,	15583840
we	15583840
utilized	15583840
serological	15583840
analysis	15583840
of	15583840
recombinant	15583840
cDNA	15583840
expression	15583840
libraries	15583840
(	15583840
SEREX	15583840
)	15583840
technique	15583840
to	15583840
identify	15583840
breast	15583840
cancer	15583840
-	15583840
associated	15583840
antigens	15583840
.	15583840

SEREX	15583840
screening	15583840
of	15583840
cDNA	15583840
expression	15583840
libraries	15583840
derived	15583840
from	15583840
3	15583840
breast	15583840
cancer	15583840
patients	15583840
identified	15583840
a	15583840
total	15583840
of	15583840
88	15583840
positive	15583840
clones	15583840
(	15583840
bcg	15583840
-	15583840
1	15583840
to	15583840
bcg	15583840
-	15583840
88	15583840
)	15583840
,	15583840
including	15583840
27	15583840
hitherto	15583840
unknown	15583840
sequences	15583840
.	15583840

The	15583840
cDNA	15583840
sequences	15583840
and	15583840
mRNA	15583840
expression	15583840
patterns	15583840
were	15583840
characterized	15583840
.	15583840

Seroreactivity	15583840
of	15583840
the	15583840
SEREX	15583840
clones	15583840
were	15583840
determined	15583840
in	15583840
sera	15583840
from	15583840
75	15583840
breast	15583840
cancer	15583840
patients	15583840
,	15583840
75	15583840
colon	15583840
cancer	15583840
patients	15583840
,	15583840
and	15583840
25	15583840
healthy	15583840
donors	15583840
.	15583840

Expression	15583840
analysis	15583840
on	15583840
a	15583840
cDNA	15583840
panel	15583840
from	15583840
17	15583840
different	15583840
normal	15583840
tissues	15583840
by	15583840
reverse	15583840
transcription	15583840
-	15583840
PCR	15583840
(	15583840
RT	15583840
-	15583840
PCR	15583840
)	15583840
revealed	15583840
tissue	15583840
restricted	15583840
mRNA	15583840
expression	15583840
of	15583840
2	15583840
of	15583840
the	15583840
27	15583840
unknown	15583840
antigens	15583840
.	15583840

Bcg	15583840
-	15583840
72	15583840
is	15583840
expressed	15583840
only	15583840
in	15583840
breast	15583840
,	15583840
prostate	15583840
and	15583840
thymus	15583840
,	15583840
while	15583840
bcg	15583840
-	15583840
84	15583840
is	15583840
expressed	15583840
at	15583840
moderate	15583840
levels	15583840
in	15583840
testis	15583840
,	15583840
spleen	15583840
and	15583840
breast	15583840
.	15583840

The	15583840
other	15583840
25	15583840
unknown	15583840
antigens	15583840
were	15583840
expressed	15583840
in	15583840
most	15583840
other	15583840
tissues	15583840
.	15583840

Serologic	15583840
assay	15583840
revealed	15583840
that	15583840
7	15583840
out	15583840
of	15583840
the	15583840
88	15583840
clones	15583840
showed	15583840
reactivity	15583840
to	15583840
at	15583840
least	15583840
one	15583840
serum	15583840
from	15583840
either	15583840
75	15583840
breast	15583840
or	15583840
75	15583840
colon	15583840
cancer	15583840
patients	15583840
.	15583840

These	15583840
clones	15583840
did	15583840
not	15583840
react	15583840
with	15583840
sera	15583840
from	15583840
a	15583840
panel	15583840
of	15583840
25	15583840
healthy	15583840
adult	15583840
individuals	15583840
.	15583840

Our	15583840
results	15583840
demonstrate	15583840
the	15583840
utility	15583840
of	15583840
the	15583840
SEREX	15583840
approach	15583840
for	15583840
the	15583840
identification	15583840
of	15583840
potential	15583840
tumor	15583840
associated	15583840
antigens	15583840
in	15583840
human	15583840
breast	15583840
cancer	15583840
.	15583840
The	21163864
M235T	21163864
polymorphism	21163864
of	21163864
the	21163864
angiotensinogen	21163864
gene	21163864
in	21163864
South	21163864
Indian	21163864
patients	21163864
of	21163864
hypertrophic	21163864
cardiomyopathy	21163864
.	21163864

INTRODUCTION	21163864
:	21163864
Hypertrophic	21163864
cardiomyopathy	21163864
(	21163864
HCM	21163864
)	21163864
is	21163864
a	21163864
complex	21163864
disorder	21163864
and	21163864
genetically	21163864
transmitted	21163864
cardiac	21163864
disease	21163864
with	21163864
a	21163864
diverse	21163864
clinical	21163864
course	21163864
.	21163864

The	21163864
objective	21163864
of	21163864
the	21163864
present	21163864
study	21163864
was	21163864
to	21163864
examine	21163864
the	21163864
association	21163864
of	21163864
the	21163864
T704C	21163864
polymorphism	21163864
of	21163864
exon	21163864
2	21163864
of	21163864
the	21163864
angiotensinogen	21163864
(	21163864
AGT	21163864
)	21163864
gene	21163864
with	21163864
HCM	21163864
in	21163864
a	21163864
South	21163864
Indian	21163864
population	21163864
from	21163864
Andhra	21163864
Pradesh	21163864
.	21163864

Subjects	21163864
and	21163864
methods	21163864
.	21163864

One	21163864
-	21163864
hundred	21163864
and	21163864
fifty	21163864
HCM	21163864
(	21163864
90	21163864
sporadic	21163864
hypertrophic	21163864
cardiomyopathy	21163864
[	21163864
SHCM	21163864
]	21163864
and	21163864
60	21163864
familial	21163864
hypertrophic	21163864
cardiomyopathy	21163864
[	21163864
FHCM	21163864
]	21163864
)	21163864
patients	21163864
and	21163864
165	21163864
age	21163864
-	21163864
and	21163864
sex	21163864
-	21163864
matched	21163864
normal	21163864
healthy	21163864
controls	21163864
without	21163864
known	21163864
hypertension	21163864
and	21163864
left	21163864
ventricular	21163864
hypertrophy	21163864
were	21163864
included	21163864
in	21163864
the	21163864
study	21163864
.	21163864

DNA	21163864
was	21163864
isolated	21163864
from	21163864
peripheral	21163864
leukocytes	21163864
and	21163864
the	21163864
region	21163864
of	21163864
interest	21163864
in	21163864
the	21163864
AGT	21163864
gene	21163864
bearing	21163864
a	21163864
missense	21163864
mutation	21163864
methionine	21163864
to	21163864
threonine	21163864
substitution	21163864
at	21163864
codon	21163864
235	21163864
(	21163864
M235T	21163864
)	21163864
of	21163864
exon	21163864
2	21163864
,	21163864
was	21163864
amplified	21163864
by	21163864
polymerase	21163864
chain	21163864
reaction	21163864
(	21163864
PCR	21163864
)	21163864
.	21163864

The	21163864
PCR	21163864
products	21163864
were	21163864
subjected	21163864
to	21163864
restriction	21163864
digestion	21163864
with	21163864
the	21163864
enzyme	21163864
SfaNI	21163864
.	21163864

RESULTS	21163864
:	21163864
Significant	21163864
differences	21163864
were	21163864
detected	21163864
in	21163864
genotypic	21163864
distribution	21163864
(	21163864
p	21163864
=	21163864
0	21163864
.	21163864
04	21163864
)	21163864
as	21163864
well	21163864
as	21163864
the	21163864
allelic	21163864
frequency	21163864
(	21163864
p	21163864
=	21163864
0	21163864
.	21163864
003	21163864
)	21163864
between	21163864
the	21163864
SHCM	21163864
patients	21163864
and	21163864
controls	21163864
.	21163864

The	21163864
polymorphism	21163864
did	21163864
not	21163864
show	21163864
any	21163864
association	21163864
with	21163864
FHCM	21163864
.	21163864

CONCLUSION	21163864
:	21163864
Our	21163864
results	21163864
suggest	21163864
that	21163864
the	21163864
T	21163864
allele	21163864
of	21163864
the	21163864
AGT	21163864
gene	21163864
is	21163864
significantly	21163864
associated	21163864
with	21163864
SHCM	21163864
in	21163864
a	21163864
South	21163864
Indian	21163864
population	21163864
from	21163864
Andhra	21163864
Pradesh	21163864
.	21163864

However	21163864
,	21163864
we	21163864
did	21163864
not	21163864
find	21163864
significant	21163864
association	21163864
of	21163864
this	21163864
polymorphism	21163864
with	21163864
FHCM	21163864
.	21163864
Gankyrin	28777492
induces	28777492
STAT3	28777492
activation	28777492
in	28777492
tumor	28777492
microenvironment	28777492
and	28777492
sorafenib	28777492
resistance	28777492
in	28777492
hepatocellular	28777492
carcinoma	28777492
.	28777492

Most	28777492
hepatocellular	28777492
carcinomas	28777492
(	28777492
HCC	28777492
)	28777492
develop	28777492
as	28777492
a	28777492
result	28777492
of	28777492
chronic	28777492
liver	28777492
inflammation	28777492
.	28777492

We	28777492
have	28777492
shown	28777492
that	28777492
the	28777492
oncoprotein	28777492
gankyrin	28777492
is	28777492
critical	28777492
for	28777492
inflammation	28777492
-	28777492
induced	28777492
tumorigenesis	28777492
in	28777492
the	28777492
colon	28777492
.	28777492

Although	28777492
the	28777492
in	28777492
vitro	28777492
function	28777492
of	28777492
gankyrin	28777492
is	28777492
well	28777492
known	28777492
,	28777492
its	28777492
role	28777492
in	28777492
vivo	28777492
remains	28777492
to	28777492
be	28777492
elucidated	28777492
.	28777492

We	28777492
investigated	28777492
the	28777492
effect	28777492
of	28777492
gankyrin	28777492
in	28777492
the	28777492
tumor	28777492
microenvironment	28777492
of	28777492
mice	28777492
with	28777492
liver	28777492
parenchymal	28777492
cell	28777492
-	28777492
specific	28777492
gankyrin	28777492
ablation	28777492
(	28777492
Alb	28777492
-	28777492
Cre	28777492
;	28777492
gankyrin	28777492
(	28777492
f	28777492
/	28777492
f	28777492
)	28777492
)	28777492
and	28777492
gankyrin	28777492
deletion	28777492
both	28777492
in	28777492
liver	28777492
parenchymal	28777492
and	28777492
non	28777492
-	28777492
parenchymal	28777492
cells	28777492
(	28777492
Mx1	28777492
-	28777492
Cre	28777492
;	28777492
gankyrin	28777492
(	28777492
f	28777492
/	28777492
f	28777492
)	28777492
)	28777492
.	28777492

Gankyrin	28777492
upregulates	28777492
vascular	28777492
endothelial	28777492
growth	28777492
factor	28777492
expression	28777492
in	28777492
tumor	28777492
cells	28777492
.	28777492

Gankyrin	28777492
binds	28777492
to	28777492
Src	28777492
homology	28777492
2	28777492
domain	28777492
-	28777492
containing	28777492
protein	28777492
tyrosine	28777492
phosphatase	28777492
-	28777492
1	28777492
(	28777492
SHP	28777492
-	28777492
1	28777492
)	28777492
,	28777492
mainly	28777492
expressed	28777492
in	28777492
liver	28777492
non	28777492
-	28777492
parenchymal	28777492
cells	28777492
,	28777492
resulting	28777492
in	28777492
phosphorylation	28777492
and	28777492
activation	28777492
of	28777492
signal	28777492
transducer	28777492
and	28777492
activator	28777492
of	28777492
transcription	28777492
3	28777492
(	28777492
STAT3	28777492
)	28777492
.	28777492

Gankyrin	28777492
deficiency	28777492
in	28777492
non	28777492
-	28777492
parenchymal	28777492
cells	28777492
,	28777492
but	28777492
not	28777492
in	28777492
parenchymal	28777492
cells	28777492
,	28777492
reduced	28777492
STAT3	28777492
activity	28777492
,	28777492
interleukin	28777492
(	28777492
IL	28777492
)	28777492
-	28777492
6	28777492
production	28777492
,	28777492
and	28777492
cancer	28777492
stem	28777492
cell	28777492
marker	28777492
(	28777492
Bmi1	28777492
and	28777492
epithelial	28777492
cell	28777492
adhesion	28777492
molecule	28777492
[	28777492
EpCAM	28777492
]	28777492
)	28777492
expression	28777492
,	28777492
leading	28777492
to	28777492
attenuated	28777492
tumorigenic	28777492
potential	28777492
.	28777492

Chronic	28777492
inflammation	28777492
enhances	28777492
gankyrin	28777492
expression	28777492
in	28777492
the	28777492
human	28777492
liver	28777492
.	28777492

Gankyrin	28777492
expression	28777492
in	28777492
the	28777492
tumor	28777492
microenvironment	28777492
is	28777492
negatively	28777492
correlated	28777492
with	28777492
progression	28777492
-	28777492
free	28777492
survival	28777492
in	28777492
patients	28777492
undergoing	28777492
sorafenib	28777492
treatment	28777492
for	28777492
HCC	28777492
.	28777492

Thus	28777492
,	28777492
gankyrin	28777492
appears	28777492
to	28777492
play	28777492
a	28777492
critical	28777492
oncogenic	28777492
function	28777492
in	28777492
tumor	28777492
microenvironment	28777492
and	28777492
may	28777492
be	28777492
a	28777492
potential	28777492
target	28777492
for	28777492
developing	28777492
therapeutic	28777492
and	28777492
preventive	28777492
strategies	28777492
against	28777492
HCC	28777492
.	28777492
Effects	15266215
of	15266215
the	15266215
cyclooxygenase	15266215
-	15266215
2	15266215
specific	15266215
inhibitor	15266215
valdecoxib	15266215
versus	15266215
nonsteroidal	15266215
antiinflammatory	15266215
agents	15266215
and	15266215
placebo	15266215
on	15266215
cardiovascular	15266215
thrombotic	15266215
events	15266215
in	15266215
patients	15266215
with	15266215
arthritis	15266215
.	15266215

There	15266215
have	15266215
been	15266215
concerns	15266215
that	15266215
the	15266215
risk	15266215
of	15266215
cardiovascular	15266215
thrombotic	15266215
events	15266215
may	15266215
be	15266215
higher	15266215
with	15266215
cyclooxygenase	15266215
(	15266215
COX	15266215
)	15266215
-	15266215
2	15266215
-	15266215
specific	15266215
inhibitors	15266215
than	15266215
nonselective	15266215
nonsteroidal	15266215
antiinflammatory	15266215
drugs	15266215
(	15266215
NSAIDs	15266215
)	15266215
.	15266215

We	15266215
evaluated	15266215
cardiovascular	15266215
event	15266215
data	15266215
for	15266215
valdecoxib	15266215
,	15266215
a	15266215
new	15266215
COX	15266215
-	15266215
2	15266215
-	15266215
specific	15266215
inhibitor	15266215
in	15266215
approximately	15266215
8000	15266215
patients	15266215
with	15266215
osteoarthritis	15266215
and	15266215
rheumatoid	15266215
arthritis	15266215
treated	15266215
with	15266215
this	15266215
agent	15266215
in	15266215
randomized	15266215
clinical	15266215
trials	15266215
.	15266215

The	15266215
incidence	15266215
of	15266215
cardiovascular	15266215
thrombotic	15266215
events	15266215
(	15266215
cardiac	15266215
,	15266215
cerebrovascular	15266215
and	15266215
peripheral	15266215
vascular	15266215
,	15266215
or	15266215
arterial	15266215
thrombotic	15266215
)	15266215
was	15266215
determined	15266215
by	15266215
analyzing	15266215
pooled	15266215
valdecoxib	15266215
(	15266215
10	15266215
-	15266215
80	15266215
mg	15266215
daily	15266215
)	15266215
,	15266215
nonselective	15266215
NSAID	15266215
(	15266215
diclofenac	15266215
75	15266215
mg	15266215
bid	15266215
,	15266215
ibuprofen	15266215
800	15266215
mg	15266215
tid	15266215
,	15266215
or	15266215
naproxen	15266215
500	15266215
mg	15266215
bid	15266215
)	15266215
and	15266215
placebo	15266215
data	15266215
from	15266215
10	15266215
randomized	15266215
osteoarthritis	15266215
and	15266215
rheumatoid	15266215
arthritis	15266215
trials	15266215
that	15266215
were	15266215
6	15266215
-	15266215
52	15266215
weeks	15266215
in	15266215
duration	15266215
.	15266215

The	15266215
incidence	15266215
rates	15266215
of	15266215
events	15266215
were	15266215
determined	15266215
in	15266215
all	15266215
patients	15266215
(	15266215
n	15266215
=	15266215
7934	15266215
)	15266215
and	15266215
in	15266215
users	15266215
of	15266215
low	15266215
-	15266215
dose	15266215
(	15266215
<	15266215
or	15266215
=	15266215
325	15266215
mg	15266215
daily	15266215
)	15266215
aspirin	15266215
(	15266215
n	15266215
=	15266215
1051	15266215
)	15266215
and	15266215
nonusers	15266215
of	15266215
aspirin	15266215
(	15266215
n	15266215
=	15266215
6883	15266215
)	15266215
.	15266215

Crude	15266215
and	15266215
exposure	15266215
-	15266215
adjusted	15266215
incidences	15266215
of	15266215
thrombotic	15266215
events	15266215
were	15266215
similar	15266215
for	15266215
valdecoxib	15266215
,	15266215
NSAIDs	15266215
,	15266215
and	15266215
placebo	15266215
.	15266215

The	15266215
risk	15266215
of	15266215
serious	15266215
thrombotic	15266215
events	15266215
was	15266215
also	15266215
similar	15266215
for	15266215
each	15266215
valdecoxib	15266215
dose	15266215
.	15266215

Thrombotic	15266215
risk	15266215
was	15266215
consistently	15266215
higher	15266215
for	15266215
users	15266215
of	15266215
aspirin	15266215
users	15266215
than	15266215
nonusers	15266215
of	15266215
aspirin	15266215
(	15266215
placebo	15266215
,	15266215
1	15266215
.	15266215
4%	15266215
vs	15266215
.	15266215

0%	15266215
;	15266215
valdecoxib	15266215
,	15266215
1	15266215
.	15266215
7%	15266215
vs	15266215
.	15266215

0	15266215
.	15266215
2%	15266215
;	15266215
NSAIDs	15266215
,	15266215
1	15266215
.	15266215
9%	15266215
vs	15266215
.	15266215

0	15266215
.	15266215
5%	15266215
)	15266215
.	15266215

The	15266215
rates	15266215
of	15266215
events	15266215
in	15266215
users	15266215
of	15266215
aspirin	15266215
were	15266215
similar	15266215
for	15266215
all	15266215
3	15266215
treatment	15266215
groups	15266215
and	15266215
across	15266215
valdecoxib	15266215
doses	15266215
.	15266215

Short	15266215
-	15266215
and	15266215
intermediate	15266215
-	15266215
term	15266215
treatment	15266215
with	15266215
therapeutic	15266215
(	15266215
10	15266215
or	15266215
20	15266215
mg	15266215
daily	15266215
)	15266215
and	15266215
supratherapeutic	15266215
(	15266215
40	15266215
or	15266215
80	15266215
mg	15266215
daily	15266215
)	15266215
valdecoxib	15266215
doses	15266215
was	15266215
not	15266215
associated	15266215
with	15266215
an	15266215
increased	15266215
incidence	15266215
of	15266215
thrombotic	15266215
events	15266215
relative	15266215
to	15266215
nonselective	15266215
NSAIDs	15266215
or	15266215
placebo	15266215
in	15266215
osteoarthritis	15266215
and	15266215
rheumatoid	15266215
arthritis	15266215
patients	15266215
in	15266215
controlled	15266215
clinical	15266215
trials	15266215
.	15266215
Metallothionein	27184800
-	27184800
1	27184800
as	27184800
a	27184800
biomarker	27184800
of	27184800
altered	27184800
redox	27184800
metabolism	27184800
in	27184800
hepatocellular	27184800
carcinoma	27184800
cells	27184800
exposed	27184800
to	27184800
sorafenib	27184800
.	27184800

BACKGROUND	27184800
:	27184800
Sorafenib	27184800
,	27184800
a	27184800
kinase	27184800
inhibitor	27184800
active	27184800
against	27184800
various	27184800
solid	27184800
tumours	27184800
,	27184800
induces	27184800
oxidative	27184800
stress	27184800
and	27184800
ferroptosis	27184800
,	27184800
a	27184800
new	27184800
form	27184800
of	27184800
oxidative	27184800
necrosis	27184800
,	27184800
in	27184800
some	27184800
cancer	27184800
cells	27184800
.	27184800

Clinically	27184800
-	27184800
applicable	27184800
biomarkers	27184800
that	27184800
reflect	27184800
the	27184800
impact	27184800
of	27184800
sorafenib	27184800
on	27184800
the	27184800
redox	27184800
metabolism	27184800
of	27184800
cancer	27184800
cells	27184800
are	27184800
lacking	27184800
.	27184800

METHODS	27184800
:	27184800
We	27184800
used	27184800
gene	27184800
expression	27184800
microarrays	27184800
,	27184800
real	27184800
-	27184800
time	27184800
PCR	27184800
,	27184800
immunoblot	27184800
,	27184800
protein	27184800
-	27184800
specific	27184800
ELISA	27184800
,	27184800
and	27184800
gene	27184800
reporter	27184800
constructs	27184800
encoding	27184800
the	27184800
enzyme	27184800
luciferase	27184800
to	27184800
study	27184800
the	27184800
response	27184800
of	27184800
a	27184800
panel	27184800
of	27184800
cancer	27184800
cells	27184800
to	27184800
sorafenib	27184800
.	27184800

Tumour	27184800
explants	27184800
prepared	27184800
from	27184800
surgical	27184800
hepatocellular	27184800
carcinoma	27184800
(	27184800
HCC	27184800
)	27184800
samples	27184800
and	27184800
serum	27184800
samples	27184800
obtained	27184800
from	27184800
HCC	27184800
patients	27184800
receiving	27184800
sorafenib	27184800
were	27184800
also	27184800
used	27184800
.	27184800

RESULTS	27184800
:	27184800
We	27184800
observed	27184800
that	27184800
genes	27184800
of	27184800
the	27184800
metallothionein	27184800
-	27184800
1	27184800
(	27184800
MT1	27184800
)	27184800
family	27184800
are	27184800
induced	27184800
in	27184800
the	27184800
HCC	27184800
cell	27184800
line	27184800
Huh7	27184800
exposed	27184800
to	27184800
sorafenib	27184800
.	27184800

Sorafenib	27184800
increased	27184800
the	27184800
expression	27184800
of	27184800
MT1G	27184800
mRNA	27184800
in	27184800
a	27184800
panel	27184800
of	27184800
human	27184800
cancer	27184800
cells	27184800
,	27184800
an	27184800
effect	27184800
that	27184800
was	27184800
not	27184800
observed	27184800
with	27184800
eight	27184800
other	27184800
clinically	27184800
-	27184800
approved	27184800
kinase	27184800
inhibitors	27184800
.	27184800

We	27184800
identified	27184800
the	27184800
minimal	27184800
region	27184800
of	27184800
the	27184800
MT1G	27184800
promoter	27184800
that	27184800
confers	27184800
inducibility	27184800
by	27184800
sorafenib	27184800
to	27184800
a	27184800
133	27184800
base	27184800
pair	27184800
region	27184800
containing	27184800
an	27184800
Anti	27184800
-	27184800
oxidant	27184800
Response	27184800
Element	27184800
(	27184800
ARE	27184800
)	27184800
and	27184800
showed	27184800
the	27184800
essential	27184800
role	27184800
of	27184800
the	27184800
transcription	27184800
factor	27184800
NRF2	27184800
(	27184800
Nuclear	27184800
factor	27184800
erythroid	27184800
2	27184800
-	27184800
Related	27184800
Factor	27184800
2	27184800
)	27184800
.	27184800

We	27184800
examined	27184800
the	27184800
clinical	27184800
relevance	27184800
of	27184800
our	27184800
findings	27184800
by	27184800
analysing	27184800
the	27184800
regulation	27184800
of	27184800
MT1G	27184800
in	27184800
five	27184800
tumour	27184800
explants	27184800
prepared	27184800
from	27184800
surgical	27184800
HCC	27184800
samples	27184800
.	27184800

Finally	27184800
,	27184800
we	27184800
showed	27184800
that	27184800
the	27184800
protein	27184800
levels	27184800
of	27184800
MT1	27184800
increase	27184800
in	27184800
the	27184800
serum	27184800
of	27184800
some	27184800
HCC	27184800
patients	27184800
receiving	27184800
sorafenib	27184800
,	27184800
and	27184800
found	27184800
an	27184800
association	27184800
with	27184800
reduced	27184800
overall	27184800
survival	27184800
.	27184800

CONCLUSION	27184800
:	27184800
These	27184800
findings	27184800
indicate	27184800
that	27184800
MT1	27184800
constitute	27184800
a	27184800
biomarker	27184800
adapted	27184800
for	27184800
exploring	27184800
the	27184800
impact	27184800
of	27184800
sorafenib	27184800
on	27184800
the	27184800
redox	27184800
metabolism	27184800
of	27184800
cancer	27184800
cells	27184800
.	27184800
Familial	21042587
glucocorticoid	21042587
receptor	21042587
haploinsufficiency	21042587
by	21042587
non	21042587
-	21042587
sense	21042587
mediated	21042587
mRNA	21042587
decay	21042587
,	21042587
adrenal	21042587
hyperplasia	21042587
and	21042587
apparent	21042587
mineralocorticoid	21042587
excess	21042587
.	21042587

Primary	21042587
glucocorticoid	21042587
resistance	21042587
(	21042587
OMIM	21042587
138040	21042587
)	21042587
is	21042587
a	21042587
rare	21042587
hereditary	21042587
disease	21042587
that	21042587
causes	21042587
a	21042587
generalized	21042587
partial	21042587
insensitivity	21042587
to	21042587
glucocorticoid	21042587
action	21042587
,	21042587
due	21042587
to	21042587
genetic	21042587
alterations	21042587
of	21042587
the	21042587
glucocorticoid	21042587
receptor	21042587
(	21042587
GR	21042587
)	21042587
.	21042587

Investigation	21042587
of	21042587
adrenal	21042587
incidentalomas	21042587
led	21042587
to	21042587
the	21042587
discovery	21042587
of	21042587
a	21042587
family	21042587
(	21042587
eight	21042587
affected	21042587
individuals	21042587
spanning	21042587
three	21042587
generations	21042587
)	21042587
,	21042587
prone	21042587
to	21042587
cortisol	21042587
resistance	21042587
,	21042587
bilateral	21042587
adrenal	21042587
hyperplasia	21042587
,	21042587
arterial	21042587
hypertension	21042587
and	21042587
hypokalemia	21042587
.	21042587

This	21042587
phenotype	21042587
exacerbated	21042587
over	21042587
time	21042587
,	21042587
cosegregates	21042587
with	21042587
the	21042587
first	21042587
heterozygous	21042587
nonsense	21042587
mutation	21042587
p	21042587
.	21042587
R469	21042587
[	21042587
R	21042587
,	21042587
X	21042587
]	21042587
reported	21042587
to	21042587
date	21042587
for	21042587
the	21042587
GR	21042587
,	21042587
replacing	21042587
an	21042587
arginine	21042587
(	21042587
CGA	21042587
)	21042587
by	21042587
a	21042587
stop	21042587
(	21042587
TGA	21042587
)	21042587
at	21042587
amino	21042587
-	21042587
acid	21042587
469	21042587
in	21042587
the	21042587
second	21042587
zinc	21042587
finger	21042587
of	21042587
the	21042587
DNA	21042587
-	21042587
binding	21042587
domain	21042587
of	21042587
the	21042587
receptor	21042587
.	21042587

In	21042587
vitro	21042587
,	21042587
this	21042587
mutation	21042587
leads	21042587
to	21042587
a	21042587
truncated	21042587
50	21042587
-	21042587
kDa	21042587
GR	21042587
lacking	21042587
hormone	21042587
and	21042587
DNA	21042587
binding	21042587
capacity	21042587
,	21042587
devoid	21042587
of	21042587
hormone	21042587
-	21042587
dependent	21042587
nuclear	21042587
translocation	21042587
and	21042587
transactivation	21042587
properties	21042587
.	21042587

In	21042587
the	21042587
proband	21042587
'	21042587
s	21042587
fibroblasts	21042587
,	21042587
we	21042587
provided	21042587
evidence	21042587
for	21042587
the	21042587
lack	21042587
of	21042587
expression	21042587
of	21042587
the	21042587
defective	21042587
allele	21042587
in	21042587
vivo	21042587
.	21042587

The	21042587
absence	21042587
of	21042587
detectable	21042587
mutated	21042587
GR	21042587
mRNA	21042587
was	21042587
accompanied	21042587
by	21042587
a	21042587
50%	21042587
reduction	21042587
in	21042587
wild	21042587
type	21042587
GR	21042587
transcript	21042587
and	21042587
protein	21042587
.	21042587

This	21042587
reduced	21042587
GR	21042587
expression	21042587
leads	21042587
to	21042587
a	21042587
significantly	21042587
below	21042587
-	21042587
normal	21042587
induction	21042587
of	21042587
glucocorticoid	21042587
-	21042587
induced	21042587
target	21042587
genes	21042587
,	21042587
FKBP5	21042587
in	21042587
fibroblasts	21042587
.	21042587

We	21042587
demonstrated	21042587
that	21042587
the	21042587
molecular	21042587
mechanisms	21042587
of	21042587
glucocorticoid	21042587
signaling	21042587
dysfunction	21042587
involved	21042587
GR	21042587
haploinsufficiency	21042587
due	21042587
to	21042587
the	21042587
selective	21042587
degradation	21042587
of	21042587
the	21042587
mutated	21042587
GR	21042587
transcript	21042587
through	21042587
a	21042587
nonsense	21042587
-	21042587
mediated	21042587
mRNA	21042587
Decay	21042587
that	21042587
was	21042587
experimentally	21042587
validated	21042587
on	21042587
emetine	21042587
-	21042587
treated	21042587
propositus	21042587
'	21042587
fibroblasts	21042587
.	21042587

GR	21042587
haploinsufficiency	21042587
leads	21042587
to	21042587
hypertension	21042587
due	21042587
to	21042587
illicit	21042587
occupation	21042587
of	21042587
renal	21042587
mineralocorticoid	21042587
receptor	21042587
by	21042587
elevated	21042587
cortisol	21042587
rather	21042587
than	21042587
to	21042587
increased	21042587
mineralocorticoid	21042587
production	21042587
reported	21042587
in	21042587
primary	21042587
glucocorticoid	21042587
resistance	21042587
.	21042587

Indeed	21042587
,	21042587
apparent	21042587
mineralocorticoid	21042587
excess	21042587
was	21042587
demonstrated	21042587
by	21042587
a	21042587
decrease	21042587
in	21042587
urinary	21042587
tetrahydrocortisone	21042587
-	21042587
tetrahydrocortisol	21042587
ratio	21042587
in	21042587
affected	21042587
patients	21042587
,	21042587
revealing	21042587
reduced	21042587
glucocorticoid	21042587
degradation	21042587
by	21042587
renal	21042587
activity	21042587
of	21042587
the	21042587
11b	21042587
-	21042587
hydroxysteroid	21042587
dehydrogenase	21042587
type	21042587
2	21042587
,	21042587
a	21042587
GR	21042587
regulated	21042587
gene	21042587
.	21042587

We	21042587
propose	21042587
thus	21042587
that	21042587
GR	21042587
haploinsufficiency	21042587
compromises	21042587
glucocorticoid	21042587
sensitivity	21042587
and	21042587
may	21042587
represent	21042587
a	21042587
novel	21042587
genetic	21042587
cause	21042587
of	21042587
subclinical	21042587
hypercortisolism	21042587
,	21042587
incidentally	21042587
revealed	21042587
bilateral	21042587
adrenal	21042587
hyperplasia	21042587
and	21042587
mineralocorticoid	21042587
-	21042587
independent	21042587
hypertension	21042587
.	21042587
Genetic	16410744
alterations	16410744
in	16410744
primary	16410744
glioblastomas	16410744
in	16410744
Japan	16410744
.	16410744

Current	16410744
knowledge	16410744
of	16410744
genetic	16410744
alterations	16410744
in	16410744
glioblastomas	16410744
is	16410744
based	16410744
largely	16410744
on	16410744
genetic	16410744
analyses	16410744
of	16410744
tumors	16410744
from	16410744
mainly	16410744
caucasian	16410744
patients	16410744
in	16410744
the	16410744
United	16410744
States	16410744
and	16410744
Europe	16410744
.	16410744

In	16410744
the	16410744
present	16410744
study	16410744
,	16410744
screening	16410744
for	16410744
several	16410744
key	16410744
genetic	16410744
alterations	16410744
was	16410744
performed	16410744
on	16410744
77	16410744
primary	16410744
(	16410744
de	16410744
novo	16410744
)	16410744
glioblastomas	16410744
in	16410744
Japanese	16410744
patients	16410744
.	16410744

SSCP	16410744
followed	16410744
by	16410744
DNA	16410744
sequencing	16410744
revealed	16410744
TP53	16410744
mutations	16410744
in	16410744
16	16410744
of	16410744
73	16410744
(	16410744
22%	16410744
)	16410744
glioblastomas	16410744
and	16410744
PTEN	16410744
mutations	16410744
in	16410744
13	16410744
of	16410744
63	16410744
(	16410744
21%	16410744
)	16410744
cases	16410744
analyzed	16410744
.	16410744

Polymerase	16410744
chain	16410744
reaction	16410744
(	16410744
PCR	16410744
)	16410744
showed	16410744
EGFR	16410744
amplification	16410744
in	16410744
25	16410744
of	16410744
77	16410744
(	16410744
32%	16410744
)	16410744
cases	16410744
and	16410744
p16	16410744
homozygous	16410744
deletion	16410744
in	16410744
32	16410744
of	16410744
77	16410744
(	16410744
42%	16410744
)	16410744
cases	16410744
.	16410744

Quantitative	16410744
microsatellite	16410744
analysis	16410744
revealed	16410744
LOH	16410744
10q	16410744
in	16410744
41	16410744
of	16410744
59	16410744
(	16410744
69%	16410744
)	16410744
glioblastomas	16410744
.	16410744

The	16410744
frequencies	16410744
of	16410744
these	16410744
genetic	16410744
alterations	16410744
were	16410744
similar	16410744
to	16410744
those	16410744
reported	16410744
for	16410744
primary	16410744
glioblastomas	16410744
at	16410744
the	16410744
population	16410744
level	16410744
in	16410744
Switzerland	16410744
.	16410744

As	16410744
previously	16410744
observed	16410744
for	16410744
glioblastomas	16410744
in	16410744
Europe	16410744
,	16410744
there	16410744
was	16410744
a	16410744
positive	16410744
association	16410744
between	16410744
EGFR	16410744
amplification	16410744
and	16410744
p16	16410744
deletion	16410744
(	16410744
p	16410744
=	16410744
0	16410744
.	16410744
009	16410744
)	16410744
,	16410744
whereas	16410744
there	16410744
was	16410744
an	16410744
inverse	16410744
association	16410744
between	16410744
TP53	16410744
mutations	16410744
and	16410744
p16	16410744
deletion	16410744
(	16410744
p	16410744
=	16410744
0	16410744
.	16410744
049	16410744
)	16410744
in	16410744
glioblastomas	16410744
in	16410744
Japan	16410744
.	16410744

Multivariate	16410744
analyses	16410744
showed	16410744
that	16410744
radiotherapy	16410744
was	16410744
significantly	16410744
predictive	16410744
for	16410744
longer	16410744
survival	16410744
of	16410744
glioblastoma	16410744
patients	16410744
(	16410744
p	16410744
=	16410744
0	16410744
.	16410744
002	16410744
)	16410744
.	16410744

SSCP	16410744
followed	16410744
by	16410744
DNA	16410744
sequencing	16410744
of	16410744
the	16410744
kinase	16410744
domain	16410744
(	16410744
exons	16410744
18	16410744
-	16410744
21	16410744
)	16410744
of	16410744
the	16410744
EGFR	16410744
gene	16410744
revealed	16410744
mutations	16410744
in	16410744
2	16410744
ou	16410744
of	16410744
69	16410744
(	16410744
3%	16410744
)	16410744
glioblastomas	16410744
in	16410744
Japan	16410744
and	16410744
in	16410744
4	16410744
of	16410744
81	16410744
(	16410744
5%	16410744
)	16410744
glioblastomas	16410744
in	16410744
Switzerland	16410744
.	16410744

The	16410744
allele	16410744
frequencies	16410744
of	16410744
polymorphisms	16410744
at	16410744
codon	16410744
787	16410744
CAG	16410744
/	16410744
CAA	16410744
(	16410744
Gln	16410744
/	16410744
Gln	16410744
)	16410744
in	16410744
glioblastomas	16410744
in	16410744
Japan	16410744
were	16410744
G	16410744
/	16410744
G	16410744
(	16410744
82	16410744
.	16410744
4%	16410744
)	16410744
,	16410744
G	16410744
/	16410744
A	16410744
(	16410744
10	16410744
.	16410744
8%	16410744
)	16410744
,	16410744
A	16410744
/	16410744
A	16410744
(	16410744
6	16410744
.	16410744
8%	16410744
)	16410744
,	16410744
corresponding	16410744
to	16410744
G	16410744
0	16410744
.	16410744
878	16410744
versus	16410744
A	16410744
0	16410744
.	16410744
122	16410744
,	16410744
significantly	16410744
different	16410744
from	16410744
those	16410744
in	16410744
glioblastomas	16410744
in	16410744
Switzerland	16410744
:	16410744
G	16410744
/	16410744
G	16410744
(	16410744
27	16410744
.	16410744
2%	16410744
)	16410744
,	16410744
G	16410744
/	16410744
A	16410744
(	16410744
28	16410744
.	16410744
4%	16410744
)	16410744
,	16410744
A	16410744
/	16410744
A	16410744
(	16410744
44	16410744
.	16410744
4%	16410744
)	16410744
,	16410744
corresponding	16410744
to	16410744
G	16410744
0	16410744
.	16410744
414	16410744
versus	16410744
A	16410744
0	16410744
.	16410744
586	16410744
(	16410744
p	16410744
<	16410744
0	16410744
.	16410744
0001	16410744
)	16410744
.	16410744

These	16410744
results	16410744
suggest	16410744
that	16410744
primary	16410744
glioblastomas	16410744
in	16410744
Japan	16410744
show	16410744
genetic	16410744
alterations	16410744
similar	16410744
to	16410744
those	16410744
in	16410744
Switzerland	16410744
,	16410744
suggesting	16410744
a	16410744
similar	16410744
molecular	16410744
basis	16410744
in	16410744
caucasians	16410744
and	16410744
Asians	16410744
,	16410744
despite	16410744
different	16410744
genetic	16410744
backgrounds	16410744
,	16410744
including	16410744
different	16410744
status	16410744
of	16410744
a	16410744
polymorphism	16410744
in	16410744
the	16410744
EGFR	16410744
gene	16410744
.	16410744
Large	20143913
deletion	20143913
involving	20143913
exon	20143913
5	20143913
of	20143913
the	20143913
arylsulfatase	20143913
B	20143913
gene	20143913
caused	20143913
apparent	20143913
homozygosity	20143913
in	20143913
a	20143913
mucopolysaccharidosis	20143913
type	20143913
VI	20143913
patient	20143913
.	20143913

Apparent	20143913
homozygosity	20143913
for	20143913
the	20143913
mutation	20143913
p	20143913
.	20143913
R315X	20143913
present	20143913
on	20143913
exon	20143913
5	20143913
of	20143913
the	20143913
arylsulfatase	20143913
B	20143913
(	20143913
ARSB	20143913
)	20143913
gene	20143913
in	20143913
a	20143913
mucopolysaccharidosis	20143913
type	20143913
VI	20143913
patient	20143913
was	20143913
solved	20143913
in	20143913
this	20143913
study	20143913
by	20143913
further	20143913
testing	20143913
for	20143913
a	20143913
second	20143913
mutation	20143913
.	20143913

Patient	20143913
cDNA	20143913
analysis	20143913
revealed	20143913
that	20143913
the	20143913
entire	20143913
exon	20143913
5	20143913
of	20143913
the	20143913
ARSB	20143913
gene	20143913
was	20143913
lacking	20143913
;	20143913
this	20143913
new	20143913
mutation	20143913
was	20143913
identified	20143913
as	20143913
c	20143913
.	20143913
899	20143913
-	20143913
1142del	20143913
.	20143913

As	20143913
the	20143913
genomic	20143913
DNA	20143913
sequencing	20143913
excluded	20143913
the	20143913
presence	20143913
of	20143913
splicing	20143913
mutations	20143913
,	20143913
polymerase	20143913
chain	20143913
reaction	20143913
analysis	20143913
was	20143913
performed	20143913
for	20143913
polymorphisms	20143913
listed	20143913
in	20143913
the	20143913
NCBI	20143913
SNP	20143913
database	20143913
for	20143913
the	20143913
ARSB	20143913
gene	20143913
.	20143913

This	20143913
allowed	20143913
the	20143913
mutation	20143913
at	20143913
the	20143913
genomic	20143913
DNA	20143913
level	20143913
to	20143913
be	20143913
identified	20143913
as	20143913
g	20143913
.	20143913
99367	20143913
-	20143913
102002del	20143913
;	20143913
this	20143913
gross	20143913
deletion	20143913
,	20143913
involving	20143913
the	20143913
entire	20143913
exon	20143913
5	20143913
of	20143913
the	20143913
gene	20143913
and	20143913
parts	20143913
of	20143913
introns	20143913
4	20143913
and	20143913
5	20143913
led	20143913
to	20143913
a	20143913
frameshift	20143913
starting	20143913
at	20143913
amino	20143913
acid	20143913
300	20143913
and	20143913
resulting	20143913
in	20143913
a	20143913
protein	20143913
with	20143913
39%	20143913
amino	20143913
acids	20143913
different	20143913
from	20143913
the	20143913
normal	20143913
enzyme	20143913
.	20143913

We	20143913
stress	20143913
that	20143913
extensive	20143913
DNA	20143913
analysis	20143913
needs	20143913
to	20143913
be	20143913
performed	20143913
in	20143913
case	20143913
of	20143913
apparent	20143913
homozygosity	20143913
to	20143913
avoid	20143913
potential	20143913
errors	20143913
in	20143913
genetic	20143913
counseling	20143913
.	20143913
Nijmegen	15033202
breakage	15033202
syndrome	15033202
in	15033202
13%	15033202
of	15033202
age	15033202
-	15033202
matched	15033202
Czech	15033202
children	15033202
with	15033202
primary	15033202
microcephaly	15033202
.	15033202

The	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
is	15033202
a	15033202
rare	15033202
autosomal	15033202
recessive	15033202
chromosomal	15033202
instability	15033202
disorder	15033202
characterized	15033202
by	15033202
early	15033202
growth	15033202
retardation	15033202
,	15033202
congenital	15033202
microcephaly	15033202
,	15033202
immunodeficiency	15033202
,	15033202
borderline	15033202
mental	15033202
development	15033202
,	15033202
and	15033202
a	15033202
high	15033202
tendency	15033202
to	15033202
lymphoreticular	15033202
malignancies	15033202
.	15033202

Most	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
patients	15033202
are	15033202
of	15033202
Slavonic	15033202
origin	15033202
,	15033202
and	15033202
all	15033202
of	15033202
them	15033202
known	15033202
so	15033202
far	15033202
carry	15033202
a	15033202
founder	15033202
homozygous	15033202
5	15033202
nucleotide	15033202
deletion	15033202
in	15033202
the	15033202
NBS1	15033202
gene	15033202
.	15033202

Microcephaly	15033202
was	15033202
present	15033202
in	15033202
100%	15033202
of	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
patients	15033202
in	15033202
a	15033202
recent	15033202
large	15033202
international	15033202
cooperative	15033202
study	15033202
.	15033202

The	15033202
frequency	15033202
of	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
among	15033202
children	15033202
with	15033202
primary	15033202
microcephaly	15033202
was	15033202
not	15033202
known	15033202
.	15033202

Early	15033202
correct	15033202
diagnosis	15033202
of	15033202
the	15033202
syndrome	15033202
is	15033202
crucial	15033202
for	15033202
appropriate	15033202
preventive	15033202
care	15033202
and	15033202
therapy	15033202
.	15033202

We	15033202
tested	15033202
67	15033202
Czech	15033202
patients	15033202
of	15033202
different	15033202
ages	15033202
with	15033202
simple	15033202
microcephaly	15033202
for	15033202
the	15033202
presence	15033202
of	15033202
the	15033202
most	15033202
common	15033202
mutation	15033202
in	15033202
the	15033202
NBS1	15033202
gene	15033202
.	15033202

Three	15033202
new	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
cases	15033202
were	15033202
detected	15033202
in	15033202
this	15033202
cohort	15033202
,	15033202
representing	15033202
4	15033202
.	15033202
5%	15033202
of	15033202
the	15033202
cohort	15033202
.	15033202

All	15033202
these	15033202
newly	15033202
diagnosed	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
patients	15033202
were	15033202
younger	15033202
than	15033202
10	15033202
months	15033202
at	15033202
the	15033202
time	15033202
of	15033202
diagnosis	15033202
.	15033202

They	15033202
were	15033202
all	15033202
born	15033202
within	15033202
a	15033202
2	15033202
.	15033202
5	15033202
-	15033202
year	15033202
period	15033202
.	15033202

Twenty	15033202
-	15033202
three	15033202
of	15033202
the	15033202
67	15033202
children	15033202
in	15033202
the	15033202
cohort	15033202
were	15033202
born	15033202
within	15033202
this	15033202
2	15033202
.	15033202
5	15033202
-	15033202
year	15033202
period	15033202
,	15033202
representing	15033202
a	15033202
13%	15033202
incidence	15033202
of	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
.	15033202

Frequency	15033202
of	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
heterozygotes	15033202
among	15033202
infants	15033202
in	15033202
the	15033202
Czech	15033202
Republic	15033202
is	15033202
1	15033202
:	15033202
130	15033202
-	15033202
158	15033202
and	15033202
the	15033202
birth	15033202
rate	15033202
is	15033202
90	15033202
,	15033202
000	15033202
per	15033202
year	15033202
,	15033202
therefore	15033202
in	15033202
the	15033202
time	15033202
span	15033202
of	15033202
2	15033202
.	15033202
5	15033202
years	15033202
,	15033202
three	15033202
new	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
homozygotes	15033202
are	15033202
expected	15033202
to	15033202
be	15033202
born	15033202
.	15033202

Therefore	15033202
we	15033202
assume	15033202
that	15033202
by	15033202
DNA	15033202
testing	15033202
of	15033202
Czech	15033202
primary	15033202
microcephalic	15033202
children	15033202
it	15033202
is	15033202
possible	15033202
to	15033202
detect	15033202
all	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
patients	15033202
to	15033202
be	15033202
expected	15033202
.	15033202

The	15033202
age	15033202
at	15033202
correct	15033202
diagnosis	15033202
was	15033202
lowered	15033202
from	15033202
7	15033202
.	15033202
1	15033202
years	15033202
at	15033202
the	15033202
time	15033202
before	15033202
DNA	15033202
testing	15033202
,	15033202
to	15033202
well	15033202
under	15033202
1	15033202
year	15033202
of	15033202
age	15033202
.	15033202

All	15033202
new	15033202
Nijmegen	15033202
breakage	15033202
syndrome	15033202
patients	15033202
could	15033202
receive	15033202
appropriate	15033202
preventive	15033202
care	15033202
,	15033202
which	15033202
should	15033202
significantly	15033202
improve	15033202
their	15033202
life	15033202
expectancy	15033202
and	15033202
prognosis	15033202
.	15033202
CTR9	24036311
/	24036311
PAF1c	24036311
regulates	24036311
molecular	24036311
lineage	24036311
identity	24036311
,	24036311
histone	24036311
H3K36	24036311
trimethylation	24036311
and	24036311
genomic	24036311
imprinting	24036311
during	24036311
preimplantation	24036311
development	24036311
.	24036311

Genome	24036311
-	24036311
wide	24036311
epigenetic	24036311
reprogramming	24036311
is	24036311
required	24036311
for	24036311
successful	24036311
preimplantation	24036311
development	24036311
.	24036311

Inappropriate	24036311
or	24036311
deficient	24036311
chromatin	24036311
regulation	24036311
can	24036311
result	24036311
in	24036311
defective	24036311
lineage	24036311
specification	24036311
and	24036311
loss	24036311
of	24036311
genomic	24036311
imprinting	24036311
,	24036311
compromising	24036311
normal	24036311
development	24036311
.	24036311

Here	24036311
we	24036311
report	24036311
that	24036311
two	24036311
members	24036311
of	24036311
the	24036311
RNA	24036311
polymerase	24036311
II	24036311
associated	24036311
factor	24036311
,	24036311
homolog	24036311
(	24036311
Saccharomyces	24036311
cerevisiae	24036311
)	24036311
complex	24036311
(	24036311
PAF1	24036311
complex	24036311
)	24036311
components	24036311
,	24036311
Ctr9	24036311
and	24036311
Rtf1	24036311
,	24036311
are	24036311
required	24036311
during	24036311
mammalian	24036311
preimplantation	24036311
development	24036311
.	24036311

We	24036311
demonstrate	24036311
that	24036311
Ctr9	24036311
-	24036311
deficient	24036311
embryos	24036311
fail	24036311
to	24036311
correctly	24036311
specify	24036311
lineages	24036311
at	24036311
the	24036311
blastocyst	24036311
stage	24036311
.	24036311

Expression	24036311
of	24036311
some	24036311
lineage	24036311
specific	24036311
factors	24036311
is	24036311
markedly	24036311
reduced	24036311
in	24036311
Ctr9	24036311
knockdown	24036311
embryos	24036311
,	24036311
including	24036311
Eomes	24036311
,	24036311
Elf5	24036311
and	24036311
Sox2	24036311
,	24036311
while	24036311
others	24036311
are	24036311
inappropriately	24036311
expressed	24036311
(	24036311
Oct4	24036311
,	24036311
Nanog	24036311
,	24036311
Gata6	24036311
,	24036311
Fgf4	24036311
and	24036311
Sox17	24036311
)	24036311
.	24036311

We	24036311
also	24036311
show	24036311
that	24036311
several	24036311
imprinted	24036311
genes	24036311
(	24036311
Mest	24036311
,	24036311
Peg3	24036311
,	24036311
Snrpn	24036311
and	24036311
Meg3	24036311
)	24036311
are	24036311
aberrantly	24036311
expressed	24036311
although	24036311
allele	24036311
specific	24036311
DNA	24036311
methylation	24036311
is	24036311
not	24036311
altered	24036311
.	24036311

We	24036311
document	24036311
a	24036311
loss	24036311
of	24036311
histone	24036311
H3	24036311
lysine	24036311
36	24036311
trimethylation	24036311
(	24036311
H3K36me3	24036311
)	24036311
in	24036311
Ctr9	24036311
-	24036311
deficient	24036311
embryos	24036311
and	24036311
confirm	24036311
that	24036311
knockdown	24036311
of	24036311
either	24036311
Setd2	24036311
or	24036311
Rtf1	24036311
results	24036311
in	24036311
similar	24036311
phenotypes	24036311
.	24036311

These	24036311
findings	24036311
show	24036311
that	24036311
the	24036311
PAF1	24036311
complex	24036311
is	24036311
required	24036311
for	24036311
mammalian	24036311
development	24036311
,	24036311
likely	24036311
through	24036311
regulation	24036311
of	24036311
H3K36me3	24036311
,	24036311
and	24036311
indicate	24036311
functional	24036311
conservation	24036311
of	24036311
the	24036311
PAF1	24036311
complex	24036311
from	24036311
yeast	24036311
to	24036311
mammals	24036311
in	24036311
vivo	24036311
.	24036311
Salidroside	30836660
Ameliorates	30836660
Renal	30836660
Interstitial	30836660
Fibrosis	30836660
by	30836660
Inhibiting	30836660
the	30836660
TLR4	30836660
/	30836660
NF	30836660
-	30836660
kappaB	30836660
and	30836660
MAPK	30836660
Signaling	30836660
Pathways	30836660
.	30836660

Salidroside	30836660
(	30836660
Sal	30836660
)	30836660
is	30836660
an	30836660
active	30836660
ingredient	30836660
that	30836660
is	30836660
isolated	30836660
from	30836660
Rhodiola	30836660
rosea	30836660
,	30836660
which	30836660
has	30836660
been	30836660
reported	30836660
to	30836660
have	30836660
anti	30836660
-	30836660
inflammatory	30836660
activities	30836660
and	30836660
a	30836660
renal	30836660
protective	30836660
effect	30836660
.	30836660

However	30836660
,	30836660
the	30836660
role	30836660
of	30836660
Sal	30836660
on	30836660
renal	30836660
fibrosis	30836660
has	30836660
not	30836660
yet	30836660
been	30836660
elucidated	30836660
.	30836660

Here	30836660
,	30836660
the	30836660
purpose	30836660
of	30836660
the	30836660
current	30836660
study	30836660
is	30836660
to	30836660
test	30836660
the	30836660
protective	30836660
effects	30836660
of	30836660
Sal	30836660
against	30836660
renal	30836660
interstitial	30836660
fibrosis	30836660
(	30836660
RIF	30836660
)	30836660
,	30836660
and	30836660
to	30836660
explore	30836660
the	30836660
underlying	30836660
mechanisms	30836660
using	30836660
both	30836660
in	30836660
vivo	30836660
and	30836660
in	30836660
vitro	30836660
models	30836660
.	30836660

In	30836660
this	30836660
study	30836660
,	30836660
we	30836660
establish	30836660
the	30836660
unilateral	30836660
ureteric	30836660
obstruction	30836660
(	30836660
UUO	30836660
)	30836660
or	30836660
folic	30836660
acid	30836660
(	30836660
FA	30836660
)	30836660
-	30836660
induced	30836660
mice	30836660
renal	30836660
interstitial	30836660
fibrosis	30836660
in	30836660
vivo	30836660
and	30836660
the	30836660
transforming	30836660
growth	30836660
factor	30836660
(	30836660
TGF	30836660
)	30836660
-	30836660
beta1	30836660
-	30836660
stimulated	30836660
human	30836660
proximal	30836660
tubular	30836660
epithelial	30836660
cell	30836660
(	30836660
HK	30836660
-	30836660
2	30836660
)	30836660
model	30836660
in	30836660
vitro	30836660
.	30836660

The	30836660
levels	30836660
of	30836660
kidney	30836660
functional	30836660
parameters	30836660
and	30836660
inflammatory	30836660
cytokines	30836660
in	30836660
serum	30836660
are	30836660
examined	30836660
.	30836660

The	30836660
degree	30836660
of	30836660
renal	30836660
damage	30836660
and	30836660
fibrosis	30836660
is	30836660
determined	30836660
by	30836660
histological	30836660
assessment	30836660
.	30836660

Immunohistochemistry	30836660
and	30836660
western	30836660
blotting	30836660
are	30836660
used	30836660
to	30836660
determine	30836660
the	30836660
mechanisms	30836660
of	30836660
Sal	30836660
against	30836660
RIF	30836660
.	30836660

Our	30836660
results	30836660
show	30836660
that	30836660
treatment	30836660
with	30836660
Sal	30836660
can	30836660
ameliorate	30836660
tubular	30836660
injury	30836660
and	30836660
deposition	30836660
of	30836660
the	30836660
extracellular	30836660
matrix	30836660
(	30836660
ECM	30836660
)	30836660
components	30836660
(	30836660
including	30836660
collagen	30836660
SH	30836660
and	30836660
collagen	30836660
I	30836660
)	30836660
.	30836660

Furthermore	30836660
,	30836660
Sal	30836660
administration	30836660
significantly	30836660
suppresses	30836660
epithelial	30836660
-	30836660
mesenchymal	30836660
transition	30836660
(	30836660
EMT	30836660
)	30836660
,	30836660
as	30836660
evidenced	30836660
by	30836660
a	30836660
decreased	30836660
expression	30836660
of	30836660
alpha	30836660
-	30836660
SMA	30836660
,	30836660
vimentin	30836660
,	30836660
TGF	30836660
-	30836660
beta1	30836660
,	30836660
snail	30836660
,	30836660
slug	30836660
,	30836660
and	30836660
a	30836660
largely	30836660
restored	30836660
expression	30836660
of	30836660
E	30836660
-	30836660
cadherin	30836660
.	30836660

Additionally	30836660
,	30836660
Sal	30836660
also	30836660
reduces	30836660
the	30836660
levels	30836660
of	30836660
serum	30836660
biochemical	30836660
markers	30836660
(	30836660
serum	30836660
creatinine	30836660
,	30836660
Scr	30836660
;	30836660
blood	30836660
urea	30836660
nitrogen	30836660
,	30836660
BUN	30836660
;	30836660
and	30836660
uric	30836660
acid	30836660
,	30836660
UA	30836660
)	30836660
and	30836660
decreases	30836660
the	30836660
release	30836660
of	30836660
inflammatory	30836660
cytokines	30836660
(	30836660
IL	30836660
-	30836660
1beta	30836660
,	30836660
IL	30836660
-	30836660
6	30836660
,	30836660
TNF	30836660
-	30836660
alpha	30836660
)	30836660
.	30836660

Further	30836660
study	30836660
revealed	30836660
that	30836660
the	30836660
effect	30836660
of	30836660
Sal	30836660
on	30836660
renal	30836660
interstitial	30836660
fibrosis	30836660
is	30836660
associated	30836660
with	30836660
the	30836660
lower	30836660
expression	30836660
of	30836660
TLR4	30836660
,	30836660
p	30836660
-	30836660
IkappaBalpha	30836660
,	30836660
p	30836660
-	30836660
NF	30836660
-	30836660
kappaB	30836660
and	30836660
mitogen	30836660
-	30836660
activated	30836660
protein	30836660
kinases	30836660
(	30836660
MAPK	30836660
)	30836660
,	30836660
both	30836660
in	30836660
vivo	30836660
and	30836660
in	30836660
vitro	30836660
.	30836660

In	30836660
conclusion	30836660
,	30836660
Sal	30836660
treatment	30836660
improves	30836660
kidney	30836660
function	30836660
,	30836660
ameliorates	30836660
the	30836660
deposition	30836660
of	30836660
the	30836660
ECM	30836660
components	30836660
and	30836660
relieves	30836660
the	30836660
protein	30836660
levels	30836660
of	30836660
EMT	30836660
markers	30836660
in	30836660
mouse	30836660
kidneys	30836660
and	30836660
HK	30836660
-	30836660
2	30836660
cells	30836660
.	30836660

Furthermore	30836660
,	30836660
Sal	30836660
treatment	30836660
significantly	30836660
decreases	30836660
the	30836660
release	30836660
of	30836660
inflammatory	30836660
cytokines	30836660
and	30836660
inhibits	30836660
the	30836660
TLR4	30836660
/	30836660
NF	30836660
-	30836660
kappaB	30836660
and	30836660
MAPK	30836660
signaling	30836660
pathways	30836660
.	30836660

Collectively	30836660
,	30836660
these	30836660
results	30836660
suggest	30836660
that	30836660
the	30836660
administration	30836660
of	30836660
Sal	30836660
could	30836660
be	30836660
a	30836660
novel	30836660
therapeutic	30836660
strategy	30836660
in	30836660
treating	30836660
renal	30836660
fibrosis	30836660
.	30836660
Neuregulin	19306381
-	19306381
1	19306381
beta	19306381
and	19306381
neuregulin	19306381
-	19306381
1	19306381
alpha	19306381
differentially	19306381
affect	19306381
the	19306381
migration	19306381
and	19306381
invasion	19306381
of	19306381
malignant	19306381
peripheral	19306381
nerve	19306381
sheath	19306381
tumor	19306381
cells	19306381
.	19306381

Malignant	19306381
peripheral	19306381
nerve	19306381
sheath	19306381
tumors	19306381
(	19306381
MPNSTs	19306381
)	19306381
are	19306381
the	19306381
most	19306381
common	19306381
malignancy	19306381
associated	19306381
with	19306381
neurofibromatosis	19306381
Type	19306381
1	19306381
(	19306381
NF1	19306381
)	19306381
.	19306381

These	19306381
Schwann	19306381
cell	19306381
lineage	19306381
-	19306381
derived	19306381
sarcomas	19306381
aggressively	19306381
invade	19306381
adjacent	19306381
nerve	19306381
and	19306381
soft	19306381
tissue	19306381
,	19306381
frequently	19306381
precluding	19306381
surgical	19306381
resection	19306381
.	19306381

Little	19306381
is	19306381
known	19306381
regarding	19306381
the	19306381
mechanisms	19306381
underlying	19306381
this	19306381
invasive	19306381
behavior	19306381
.	19306381

We	19306381
have	19306381
shown	19306381
that	19306381
MPNSTs	19306381
express	19306381
neuregulin	19306381
-	19306381
1	19306381
(	19306381
NRG	19306381
-	19306381
1	19306381
)	19306381
beta	19306381
isoforms	19306381
,	19306381
which	19306381
promote	19306381
Schwann	19306381
cell	19306381
migration	19306381
during	19306381
development	19306381
,	19306381
and	19306381
NRG	19306381
-	19306381
1	19306381
alpha	19306381
isoforms	19306381
,	19306381
whose	19306381
effects	19306381
on	19306381
Schwann	19306381
cells	19306381
are	19306381
poorly	19306381
understood	19306381
.	19306381

Hypothesizing	19306381
that	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
and	19306381
/	19306381
or	19306381
NRG	19306381
-	19306381
1	19306381
alpha	19306381
promote	19306381
MPNST	19306381
invasion	19306381
,	19306381
we	19306381
found	19306381
that	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
promoted	19306381
MPNST	19306381
migration	19306381
in	19306381
a	19306381
substrate	19306381
-	19306381
specific	19306381
manner	19306381
,	19306381
markedly	19306381
enhancing	19306381
migration	19306381
on	19306381
laminin	19306381
but	19306381
not	19306381
on	19306381
collagen	19306381
type	19306381
I	19306381
or	19306381
fibronectin	19306381
.	19306381

The	19306381
NRG	19306381
-	19306381
1	19306381
receptors	19306381
erbB3	19306381
and	19306381
erbB4	19306381
were	19306381
present	19306381
in	19306381
MPNST	19306381
invadopodia	19306381
(	19306381
processes	19306381
mediating	19306381
invasion	19306381
)	19306381
,	19306381
partially	19306381
colocalized	19306381
with	19306381
focal	19306381
adhesion	19306381
kinase	19306381
and	19306381
the	19306381
laminin	19306381
receptor	19306381
beta	19306381
(	19306381
1	19306381
)	19306381
-	19306381
integrin	19306381
and	19306381
coimmunoprecipitated	19306381
with	19306381
beta	19306381
(	19306381
1	19306381
)	19306381
-	19306381
integrin	19306381
.	19306381

NRG	19306381
-	19306381
1	19306381
beta	19306381
stimulated	19306381
human	19306381
and	19306381
murine	19306381
MPNST	19306381
cell	19306381
migration	19306381
and	19306381
invasion	19306381
in	19306381
a	19306381
concentration	19306381
-	19306381
dependent	19306381
manner	19306381
in	19306381
three	19306381
-	19306381
dimensional	19306381
migration	19306381
assays	19306381
,	19306381
acting	19306381
as	19306381
a	19306381
chemotactic	19306381
factor	19306381
.	19306381

Both	19306381
baseline	19306381
and	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
-	19306381
induced	19306381
migration	19306381
were	19306381
erbB	19306381
-	19306381
dependent	19306381
and	19306381
required	19306381
the	19306381
action	19306381
of	19306381
MEK	19306381
1	19306381
/	19306381
2	19306381
,	19306381
SAPK	19306381
/	19306381
JNK	19306381
,	19306381
PI	19306381
-	19306381
3	19306381
kinase	19306381
,	19306381
Src	19306381
family	19306381
kinases	19306381
and	19306381
ROCK	19306381
-	19306381
I	19306381
/	19306381
II	19306381
.	19306381

In	19306381
contrast	19306381
,	19306381
NRG	19306381
-	19306381
1	19306381
alpha	19306381
had	19306381
no	19306381
effect	19306381
on	19306381
the	19306381
migration	19306381
and	19306381
invasion	19306381
of	19306381
some	19306381
MPNST	19306381
lines	19306381
and	19306381
inhibited	19306381
the	19306381
migration	19306381
of	19306381
others	19306381
.	19306381

While	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
potently	19306381
and	19306381
persistently	19306381
activated	19306381
Erk	19306381
1	19306381
/	19306381
2	19306381
,	19306381
SAPK	19306381
/	19306381
JNK	19306381
,	19306381
Akt	19306381
and	19306381
Src	19306381
family	19306381
kinases	19306381
,	19306381
NRG	19306381
-	19306381
1	19306381
alpha	19306381
did	19306381
not	19306381
activate	19306381
Akt	19306381
and	19306381
activated	19306381
these	19306381
other	19306381
kinases	19306381
with	19306381
kinetics	19306381
distinct	19306381
from	19306381
those	19306381
evident	19306381
in	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
-	19306381
stimulated	19306381
cells	19306381
.	19306381

These	19306381
findings	19306381
suggest	19306381
that	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
enhances	19306381
MPNST	19306381
migration	19306381
and	19306381
that	19306381
NRG	19306381
-	19306381
1	19306381
beta	19306381
and	19306381
NRG	19306381
-	19306381
1	19306381
alpha	19306381
differentially	19306381
modulate	19306381
this	19306381
process	19306381
.	19306381
Critical	23069675
role	23069675
of	23069675
neuronal	23069675
pentraxin	23069675
1	23069675
in	23069675
mitochondria	23069675
-	23069675
mediated	23069675
hypoxic	23069675
-	23069675
ischemic	23069675
neuronal	23069675
injury	23069675
.	23069675

Developing	23069675
brain	23069675
is	23069675
highly	23069675
susceptible	23069675
to	23069675
hypoxic	23069675
-	23069675
ischemic	23069675
(	23069675
HI	23069675
)	23069675
injury	23069675
leading	23069675
to	23069675
severe	23069675
neurological	23069675
disabilities	23069675
in	23069675
surviving	23069675
infants	23069675
and	23069675
children	23069675
.	23069675

Previously	23069675
,	23069675
we	23069675
have	23069675
reported	23069675
induction	23069675
of	23069675
neuronal	23069675
pentraxin	23069675
1	23069675
(	23069675
NP1	23069675
)	23069675
,	23069675
a	23069675
novel	23069675
neuronal	23069675
protein	23069675
of	23069675
long	23069675
-	23069675
pentraxin	23069675
family	23069675
,	23069675
following	23069675
HI	23069675
neuronal	23069675
injury	23069675
.	23069675

Here	23069675
,	23069675
we	23069675
investigated	23069675
how	23069675
this	23069675
specific	23069675
signal	23069675
is	23069675
propagated	23069675
to	23069675
cause	23069675
the	23069675
HI	23069675
neuronal	23069675
death	23069675
.	23069675

We	23069675
used	23069675
wild	23069675
-	23069675
type	23069675
(	23069675
WT	23069675
)	23069675
and	23069675
NP1	23069675
knockout	23069675
(	23069675
NP1	23069675
-	23069675
KO	23069675
)	23069675
mouse	23069675
hippocampal	23069675
cultures	23069675
,	23069675
modeled	23069675
in	23069675
vitro	23069675
following	23069675
exposure	23069675
to	23069675
oxygen	23069675
glucose	23069675
deprivation	23069675
(	23069675
OGD	23069675
)	23069675
,	23069675
and	23069675
in	23069675
vivo	23069675
neonatal	23069675
(	23069675
P9	23069675
-	23069675
10	23069675
)	23069675
mouse	23069675
model	23069675
of	23069675
HI	23069675
brain	23069675
injury	23069675
.	23069675

Our	23069675
results	23069675
show	23069675
induction	23069675
of	23069675
NP1	23069675
in	23069675
primary	23069675
hippocampal	23069675
neurons	23069675
following	23069675
OGD	23069675
exposure	23069675
(	23069675
4	23069675
-	23069675
8	23069675
h	23069675
)	23069675
and	23069675
in	23069675
the	23069675
ipsilateral	23069675
hippocampal	23069675
CA1	23069675
and	23069675
CA3	23069675
regions	23069675
at	23069675
24	23069675
-	23069675
48	23069675
h	23069675
post	23069675
-	23069675
HI	23069675
compared	23069675
to	23069675
the	23069675
contralateral	23069675
side	23069675
.	23069675

We	23069675
also	23069675
found	23069675
increased	23069675
PTEN	23069675
activity	23069675
concurrent	23069675
with	23069675
OGD	23069675
time	23069675
-	23069675
dependent	23069675
(	23069675
4	23069675
-	23069675
8	23069675
h	23069675
)	23069675
dephosphorylation	23069675
of	23069675
Akt	23069675
(	23069675
Ser473	23069675
)	23069675
and	23069675
GSK	23069675
-	23069675
3b	23069675
(	23069675
Ser9	23069675
)	23069675
.	23069675

OGD	23069675
also	23069675
caused	23069675
a	23069675
time	23069675
-	23069675
dependent	23069675
decrease	23069675
in	23069675
the	23069675
phosphorylation	23069675
of	23069675
Bad	23069675
(	23069675
Ser136	23069675
)	23069675
,	23069675
and	23069675
Bax	23069675
protein	23069675
levels	23069675
.	23069675

Immunofluorescence	23069675
staining	23069675
and	23069675
subcellular	23069675
fractionation	23069675
analyses	23069675
revealed	23069675
increased	23069675
mitochondrial	23069675
translocation	23069675
of	23069675
Bad	23069675
and	23069675
Bax	23069675
proteins	23069675
from	23069675
cytoplasm	23069675
following	23069675
OGD	23069675
(	23069675
4	23069675
h	23069675
)	23069675
and	23069675
simultaneously	23069675
increased	23069675
release	23069675
of	23069675
Cyt	23069675
C	23069675
from	23069675
mitochondria	23069675
followed	23069675
by	23069675
activation	23069675
of	23069675
caspase	23069675
-	23069675
3	23069675
.	23069675

NP1	23069675
protein	23069675
was	23069675
immunoprecipitated	23069675
with	23069675
Bad	23069675
and	23069675
Bax	23069675
proteins	23069675
;	23069675
OGD	23069675
caused	23069675
increased	23069675
interactions	23069675
of	23069675
NP1	23069675
with	23069675
Bad	23069675
and	23069675
Bax	23069675
,	23069675
thereby	23069675
,	23069675
facilitating	23069675
their	23069675
mitochondrial	23069675
translocation	23069675
and	23069675
dissipation	23069675
of	23069675
mitochondrial	23069675
membrane	23069675
potential	23069675
(	23069675
D	23069675
(	23069675
m	23069675
)	23069675
)	23069675
.	23069675

This	23069675
NP1	23069675
induction	23069675
preceded	23069675
the	23069675
increased	23069675
mitochondrial	23069675
release	23069675
of	23069675
cytochrome	23069675
C	23069675
(	23069675
Cyt	23069675
C	23069675
)	23069675
into	23069675
the	23069675
cytosol	23069675
,	23069675
activation	23069675
of	23069675
caspase	23069675
-	23069675
3	23069675
and	23069675
OGD	23069675
time	23069675
-	23069675
dependent	23069675
cell	23069675
death	23069675
in	23069675
WT	23069675
primary	23069675
hippocampal	23069675
neurons	23069675
.	23069675

In	23069675
contrast	23069675
,	23069675
in	23069675
NP1	23069675
-	23069675
KO	23069675
neurons	23069675
there	23069675
was	23069675
no	23069675
translocation	23069675
of	23069675
Bad	23069675
and	23069675
Bax	23069675
from	23069675
cytosol	23069675
to	23069675
the	23069675
mitochondria	23069675
,	23069675
and	23069675
no	23069675
evidence	23069675
of	23069675
D	23069675
(	23069675
m	23069675
)	23069675
loss	23069675
,	23069675
increased	23069675
Cyt	23069675
C	23069675
release	23069675
and	23069675
caspase	23069675
-	23069675
3	23069675
activation	23069675
following	23069675
OGD	23069675
;	23069675
which	23069675
resulted	23069675
in	23069675
significantly	23069675
reduced	23069675
neuronal	23069675
death	23069675
.	23069675

Our	23069675
results	23069675
indicate	23069675
a	23069675
regulatory	23069675
role	23069675
of	23069675
NP1	23069675
in	23069675
Bad	23069675
/	23069675
Bax	23069675
-	23069675
dependent	23069675
mitochondrial	23069675
release	23069675
of	23069675
Cyt	23069675
C	23069675
and	23069675
caspase	23069675
-	23069675
3	23069675
activation	23069675
.	23069675

Together	23069675
our	23069675
findings	23069675
demonstrate	23069675
a	23069675
novel	23069675
mechanism	23069675
by	23069675
which	23069675
NP1	23069675
regulates	23069675
mitochondria	23069675
-	23069675
driven	23069675
hippocampal	23069675
cell	23069675
death	23069675
;	23069675
suggesting	23069675
NP1	23069675
as	23069675
a	23069675
potential	23069675
therapeutic	23069675
target	23069675
against	23069675
HI	23069675
brain	23069675
injury	23069675
in	23069675
neonates	23069675
.	23069675
Repeated	27866394
otilonium	27866394
bromide	27866394
administration	27866394
prevents	27866394
neurotransmitter	27866394
changes	27866394
in	27866394
colon	27866394
of	27866394
rats	27866394
underwent	27866394
to	27866394
wrap	27866394
restraint	27866394
stress	27866394
.	27866394

Otilonium	27866394
bromide	27866394
(	27866394
OB	27866394
)	27866394
is	27866394
a	27866394
spasmolytic	27866394
drug	27866394
successfully	27866394
used	27866394
for	27866394
the	27866394
treatment	27866394
of	27866394
irritable	27866394
bowel	27866394
syndrome	27866394
(	27866394
IBS	27866394
)	27866394
.	27866394

Its	27866394
efficacy	27866394
has	27866394
been	27866394
attributed	27866394
to	27866394
the	27866394
block	27866394
of	27866394
L	27866394
-	27866394
and	27866394
T	27866394
-	27866394
type	27866394
Ca	27866394
(	27866394
2	27866394
+	27866394
)	27866394
channels	27866394
and	27866394
muscarinic	27866394
and	27866394
tachykinin	27866394
receptors	27866394
in	27866394
the	27866394
smooth	27866394
muscle	27866394
.	27866394

Furthermore	27866394
,	27866394
in	27866394
healthy	27866394
rats	27866394
,	27866394
repeated	27866394
OB	27866394
administration	27866394
modified	27866394
neurotransmitter	27866394
expression	27866394
and	27866394
function	27866394
suggesting	27866394
other	27866394
mechanisms	27866394
of	27866394
action	27866394
.	27866394

On	27866394
this	27866394
basis	27866394
,	27866394
we	27866394
investigated	27866394
whether	27866394
repeated	27866394
OB	27866394
treatment	27866394
prevented	27866394
the	27866394
functional	27866394
and	27866394
neurochemical	27866394
changes	27866394
observed	27866394
in	27866394
the	27866394
colon	27866394
of	27866394
rats	27866394
underwent	27866394
to	27866394
wrap	27866394
restrain	27866394
stress	27866394
(	27866394
WRS	27866394
)	27866394
a	27866394
psychosocial	27866394
stressor	27866394
considered	27866394
suitable	27866394
to	27866394
reproduce	27866394
the	27866394
main	27866394
IBS	27866394
signs	27866394
and	27866394
symptoms	27866394
.	27866394

In	27866394
control	27866394
,	27866394
WRS	27866394
and	27866394
OB	27866394
/	27866394
WRS	27866394
rats	27866394
functional	27866394
parameters	27866394
were	27866394
measured	27866394
in	27866394
vivo	27866394
and	27866394
morphological	27866394
investigations	27866394
were	27866394
done	27866394
ex	27866394
vivo	27866394
in	27866394
the	27866394
colon	27866394
.	27866394

The	27866394
results	27866394
showed	27866394
that	27866394
OB	27866394
counteracts	27866394
most	27866394
of	27866394
the	27866394
neurotransmitters	27866394
changes	27866394
caused	27866394
by	27866394
WRS	27866394
.	27866394

In	27866394
particular	27866394
,	27866394
the	27866394
drug	27866394
prevents	27866394
the	27866394
decrease	27866394
in	27866394
SP	27866394
-	27866394
,	27866394
NK1r	27866394
-	27866394
,	27866394
nNOS	27866394
-	27866394
,	27866394
VIP	27866394
-	27866394
,	27866394
and	27866394
S100b	27866394
-	27866394
immunoreactivity	27866394
(	27866394
IR	27866394
)	27866394
and	27866394
the	27866394
increase	27866394
in	27866394
CGRP	27866394
-	27866394
,	27866394
and	27866394
CRF1r	27866394
-	27866394
IR	27866394
.	27866394

On	27866394
the	27866394
contrary	27866394
,	27866394
OB	27866394
does	27866394
not	27866394
affect	27866394
the	27866394
increase	27866394
in	27866394
CRF2r	27866394
-	27866394
IR	27866394
neurons	27866394
observed	27866394
in	27866394
WRS	27866394
rats	27866394
and	27866394
does	27866394
not	27866394
interfere	27866394
with	27866394
the	27866394
mild	27866394
mucosal	27866394
inflammation	27866394
due	27866394
to	27866394
WRS	27866394
.	27866394

Finally	27866394
,	27866394
OB	27866394
per	27866394
se	27866394
increases	27866394
the	27866394
Mr2	27866394
expression	27866394
in	27866394
the	27866394
muscle	27866394
wall	27866394
and	27866394
decreases	27866394
the	27866394
number	27866394
of	27866394
the	27866394
myenteric	27866394
ChAT	27866394
-	27866394
IR	27866394
neurons	27866394
.	27866394

Functional	27866394
findings	27866394
show	27866394
a	27866394
significantly	27866394
reduction	27866394
in	27866394
the	27866394
number	27866394
of	27866394
spontaneous	27866394
abdominal	27866394
contraction	27866394
in	27866394
OB	27866394
treated	27866394
rats	27866394
.	27866394

The	27866394
ability	27866394
of	27866394
OB	27866394
to	27866394
block	27866394
L	27866394
-	27866394
type	27866394
Ca	27866394
(	27866394
2	27866394
+	27866394
)	27866394
channels	27866394
,	27866394
also	27866394
expressed	27866394
by	27866394
enteric	27866394
neurons	27866394
,	27866394
might	27866394
represent	27866394
a	27866394
possible	27866394
mechanism	27866394
through	27866394
which	27866394
OB	27866394
exerts	27866394
its	27866394
actions	27866394
.	27866394
Lack	20682662
of	20682662
association	20682662
of	20682662
C	20682662
-	20682662
C	20682662
chemokine	20682662
receptor	20682662
5	20682662
DD32	20682662
deletion	20682662
status	20682662
with	20682662
rheumatoid	20682662
arthritis	20682662
,	20682662
systemic	20682662
lupus	20682662
erythematosus	20682662
,	20682662
lupus	20682662
nephritis	20682662
,	20682662
and	20682662
disease	20682662
severity	20682662
.	20682662

OBJECTIVE	20682662
:	20682662
C	20682662
-	20682662
C	20682662
chemokine	20682662
receptor	20682662
5	20682662
(	20682662
CCR5	20682662
)	20682662
plays	20682662
an	20682662
important	20682662
role	20682662
in	20682662
inflammation	20682662
.	20682662

A	20682662
32	20682662
base	20682662
-	20682662
pair	20682662
(	20682662
DD32	20682662
)	20682662
deletion	20682662
in	20682662
the	20682662
CCR5	20682662
gene	20682662
leads	20682662
to	20682662
a	20682662
nonfunctional	20682662
receptor	20682662
.	20682662

This	20682662
deletion	20682662
has	20682662
been	20682662
reported	20682662
to	20682662
have	20682662
a	20682662
protective	20682662
effect	20682662
on	20682662
the	20682662
development	20682662
and	20682662
progression	20682662
of	20682662
several	20682662
autoimmune	20682662
diseases	20682662
.	20682662

We	20682662
investigated	20682662
whether	20682662
the	20682662
DD32	20682662
deletion	20682662
is	20682662
associated	20682662
with	20682662
disease	20682662
susceptibility	20682662
in	20682662
a	20682662
population	20682662
of	20682662
patients	20682662
with	20682662
rheumatoid	20682662
arthritis	20682662
(	20682662
RA	20682662
)	20682662
,	20682662
systemic	20682662
lupus	20682662
erythematosus	20682662
(	20682662
SLE	20682662
)	20682662
,	20682662
and	20682662
lupus	20682662
nephritis	20682662
(	20682662
LN	20682662
)	20682662
;	20682662
and	20682662
whether	20682662
it	20682662
is	20682662
associated	20682662
with	20682662
disease	20682662
severity	20682662
.	20682662

METHODS	20682662
:	20682662
DNA	20682662
samples	20682662
from	20682662
405	20682662
RA	20682662
patients	20682662
,	20682662
97	20682662
SLE	20682662
patients	20682662
,	20682662
113	20682662
LN	20682662
patients	20682662
,	20682662
and	20682662
431	20682662
healthy	20682662
controls	20682662
were	20682662
genotyped	20682662
for	20682662
the	20682662
CCR5	20682662
DD32	20682662
deletion	20682662
.	20682662

Differences	20682662
in	20682662
genotype	20682662
frequencies	20682662
were	20682662
tested	20682662
between	20682662
patients	20682662
and	20682662
controls	20682662
.	20682662

Association	20682662
of	20682662
genotypes	20682662
with	20682662
disease	20682662
severity	20682662
was	20682662
analyzed	20682662
.	20682662

RESULTS	20682662
:	20682662
Genotype	20682662
frequencies	20682662
of	20682662
each	20682662
group	20682662
were	20682662
in	20682662
Hardy	20682662
-	20682662
Weinberg	20682662
equilibrium	20682662
.	20682662

The	20682662
genotype	20682662
frequencies	20682662
of	20682662
patients	20682662
did	20682662
not	20682662
differ	20682662
significantly	20682662
from	20682662
controls	20682662
(	20682662
CCR5	20682662
/	20682662
DD32	20682662
,	20682662
DD32	20682662
/	20682662
DD32	20682662
:	20682662
RA	20682662
18	20682662
.	20682662
3%	20682662
and	20682662
1	20682662
.	20682662
2%	20682662
,	20682662
respectively	20682662
;	20682662
SLE	20682662
17	20682662
.	20682662
5%	20682662
and	20682662
2	20682662
.	20682662
1%	20682662
;	20682662
LN	20682662
13	20682662
.	20682662
3%	20682662
and	20682662
1	20682662
.	20682662
8%	20682662
;	20682662
controls	20682662
20	20682662
.	20682662
0%	20682662
and	20682662
2	20682662
.	20682662
8%	20682662
)	20682662
.	20682662

However	20682662
,	20682662
there	20682662
was	20682662
a	20682662
trend	20682662
for	20682662
lower	20682662
DD32	20682662
deletion	20682662
allele	20682662
frequency	20682662
in	20682662
LN	20682662
patients	20682662
compared	20682662
to	20682662
controls	20682662
(	20682662
p	20682662
=	20682662
0	20682662
.	20682662
08	20682662
)	20682662
.	20682662

There	20682662
was	20682662
no	20682662
significant	20682662
association	20682662
between	20682662
the	20682662
CCR5	20682662
status	20682662
and	20682662
disease	20682662
severity	20682662
in	20682662
RA	20682662
,	20682662
SLE	20682662
,	20682662
or	20682662
LN	20682662
.	20682662

CONCLUSION	20682662
:	20682662
Although	20682662
an	20682662
association	20682662
with	20682662
LN	20682662
cannot	20682662
be	20682662
excluded	20682662
,	20682662
the	20682662
CCR5	20682662
DD32	20682662
deletion	20682662
does	20682662
not	20682662
seem	20682662
to	20682662
be	20682662
a	20682662
disease	20682662
susceptibility	20682662
genotype	20682662
for	20682662
RA	20682662
,	20682662
SLE	20682662
,	20682662
or	20682662
LN	20682662
.	20682662

No	20682662
significant	20682662
effect	20682662
of	20682662
the	20682662
DD32	20682662
deletion	20682662
on	20682662
disease	20682662
severity	20682662
was	20682662
demonstrated	20682662
.	20682662
Cocaine	20477932
causes	20477932
memory	20477932
and	20477932
learning	20477932
impairments	20477932
in	20477932
rats	20477932
:	20477932
involvement	20477932
of	20477932
nuclear	20477932
factor	20477932
kappa	20477932
B	20477932
and	20477932
oxidative	20477932
stress	20477932
,	20477932
and	20477932
prevention	20477932
by	20477932
topiramate	20477932
.	20477932

Different	20477932
mechanisms	20477932
have	20477932
been	20477932
suggested	20477932
for	20477932
cocaine	20477932
toxicity	20477932
including	20477932
an	20477932
increase	20477932
in	20477932
oxidative	20477932
stress	20477932
but	20477932
the	20477932
association	20477932
between	20477932
oxidative	20477932
status	20477932
in	20477932
the	20477932
brain	20477932
and	20477932
cocaine	20477932
induced	20477932
-	20477932
behaviour	20477932
is	20477932
poorly	20477932
understood	20477932
.	20477932

Nuclear	20477932
factor	20477932
kappa	20477932
B	20477932
(	20477932
NFkappaB	20477932
)	20477932
is	20477932
a	20477932
sensor	20477932
of	20477932
oxidative	20477932
stress	20477932
and	20477932
participates	20477932
in	20477932
memory	20477932
formation	20477932
that	20477932
could	20477932
be	20477932
involved	20477932
in	20477932
drug	20477932
toxicity	20477932
and	20477932
addiction	20477932
mechanisms	20477932
.	20477932

Therefore	20477932
NFkappaB	20477932
activity	20477932
,	20477932
oxidative	20477932
stress	20477932
,	20477932
neuronal	20477932
nitric	20477932
oxide	20477932
synthase	20477932
(	20477932
nNOS	20477932
)	20477932
activity	20477932
,	20477932
spatial	20477932
learning	20477932
and	20477932
memory	20477932
as	20477932
well	20477932
as	20477932
the	20477932
effect	20477932
of	20477932
topiramate	20477932
,	20477932
a	20477932
previously	20477932
proposed	20477932
therapy	20477932
for	20477932
cocaine	20477932
addiction	20477932
,	20477932
were	20477932
evaluated	20477932
in	20477932
an	20477932
experimental	20477932
model	20477932
of	20477932
cocaine	20477932
administration	20477932
in	20477932
rats	20477932
.	20477932

NFkappaB	20477932
activity	20477932
was	20477932
decreased	20477932
in	20477932
the	20477932
frontal	20477932
cortex	20477932
of	20477932
cocaine	20477932
treated	20477932
rats	20477932
,	20477932
as	20477932
well	20477932
as	20477932
GSH	20477932
concentration	20477932
and	20477932
glutathione	20477932
peroxidase	20477932
activity	20477932
in	20477932
the	20477932
hippocampus	20477932
,	20477932
whereas	20477932
nNOS	20477932
activity	20477932
in	20477932
the	20477932
hippocampus	20477932
was	20477932
increased	20477932
.	20477932

Memory	20477932
retrieval	20477932
of	20477932
experiences	20477932
acquired	20477932
prior	20477932
to	20477932
cocaine	20477932
administration	20477932
was	20477932
impaired	20477932
and	20477932
negatively	20477932
correlated	20477932
with	20477932
NFkappaB	20477932
activity	20477932
in	20477932
the	20477932
frontal	20477932
cortex	20477932
.	20477932

In	20477932
contrast	20477932
,	20477932
learning	20477932
of	20477932
new	20477932
tasks	20477932
was	20477932
enhanced	20477932
and	20477932
correlated	20477932
with	20477932
the	20477932
increase	20477932
of	20477932
nNOS	20477932
activity	20477932
and	20477932
the	20477932
decrease	20477932
of	20477932
glutathione	20477932
peroxidase	20477932
.	20477932

These	20477932
results	20477932
provide	20477932
evidence	20477932
for	20477932
a	20477932
possible	20477932
mechanistic	20477932
role	20477932
of	20477932
oxidative	20477932
and	20477932
nitrosative	20477932
stress	20477932
and	20477932
NFkappaB	20477932
in	20477932
the	20477932
alterations	20477932
induced	20477932
by	20477932
cocaine	20477932
.	20477932

Topiramate	20477932
prevented	20477932
all	20477932
the	20477932
alterations	20477932
observed	20477932
,	20477932
showing	20477932
novel	20477932
neuroprotective	20477932
properties	20477932
.	20477932
D90A	12442272
-	12442272
SOD1	12442272
mediated	12442272
amyotrophic	12442272
lateral	12442272
sclerosis	12442272
:	12442272
a	12442272
single	12442272
founder	12442272
for	12442272
all	12442272
cases	12442272
with	12442272
evidence	12442272
for	12442272
a	12442272
Cis	12442272
-	12442272
acting	12442272
disease	12442272
modifier	12442272
in	12442272
the	12442272
recessive	12442272
haplotype	12442272
.	12442272

More	12442272
than	12442272
100	12442272
different	12442272
heterozygous	12442272
mutations	12442272
in	12442272
copper	12442272
/	12442272
zinc	12442272
superoxide	12442272
dismutase	12442272
(	12442272
SOD1	12442272
)	12442272
have	12442272
been	12442272
found	12442272
in	12442272
patients	12442272
with	12442272
amyotrophic	12442272
lateral	12442272
sclerosis	12442272
(	12442272
ALS	12442272
)	12442272
,	12442272
a	12442272
fatal	12442272
neurodegenerative	12442272
disease	12442272
.	12442272

Uniquely	12442272
,	12442272
D90A	12442272
-	12442272
SOD1	12442272
has	12442272
been	12442272
identified	12442272
in	12442272
recessive	12442272
,	12442272
dominant	12442272
and	12442272
apparently	12442272
sporadic	12442272
pedigrees	12442272
.	12442272

The	12442272
phenotype	12442272
of	12442272
homozygotes	12442272
is	12442272
stereotyped	12442272
with	12442272
an	12442272
extended	12442272
survival	12442272
,	12442272
whereas	12442272
that	12442272
of	12442272
affected	12442272
heterozygotes	12442272
varies	12442272
.	12442272

The	12442272
frequency	12442272
of	12442272
D90A	12442272
-	12442272
SOD1	12442272
is	12442272
50	12442272
times	12442272
higher	12442272
in	12442272
Scandinavia	12442272
(	12442272
2	12442272
.	12442272
5%	12442272
)	12442272
than	12442272
elsewhere	12442272
,	12442272
though	12442272
ALS	12442272
prevalence	12442272
is	12442272
not	12442272
raised	12442272
there	12442272
.	12442272

Our	12442272
earlier	12442272
study	12442272
indicated	12442272
separate	12442272
founders	12442272
for	12442272
recessive	12442272
and	12442272
dominant	12442272
/	12442272
sporadic	12442272
ALS	12442272
and	12442272
we	12442272
proposed	12442272
a	12442272
disease	12442272
-	12442272
modifying	12442272
factor	12442272
linked	12442272
to	12442272
the	12442272
recessive	12442272
mutation	12442272
.	12442272

Here	12442272
we	12442272
have	12442272
doubled	12442272
our	12442272
sample	12442272
set	12442272
and	12442272
employed	12442272
novel	12442272
markers	12442272
to	12442272
characterise	12442272
the	12442272
mutation	12442272
'	12442272
s	12442272
origin	12442272
and	12442272
localise	12442272
any	12442272
modifying	12442272
factor	12442272
.	12442272

Linkage	12442272
disequilibrium	12442272
analysis	12442272
indicates	12442272
that	12442272
D90A	12442272
homozygotes	12442272
and	12442272
heterozygotes	12442272
share	12442272
a	12442272
rare	12442272
haplotype	12442272
and	12442272
are	12442272
all	12442272
descended	12442272
from	12442272
a	12442272
single	12442272
ancient	12442272
founder	12442272
(	12442272
alpha	12442272
0	12442272
.	12442272
974	12442272
)	12442272
c	12442272
.	12442272
895	12442272
generations	12442272
ago	12442272
.	12442272

Homozygotes	12442272
arose	12442272
subsequently	12442272
only	12442272
c	12442272
.	12442272
63	12442272
generations	12442272
ago	12442272
(	12442272
alpha	12442272
0	12442272
.	12442272
878	12442272
)	12442272
.	12442272

Recombination	12442272
has	12442272
reduced	12442272
the	12442272
region	12442272
shared	12442272
by	12442272
recessive	12442272
kindreds	12442272
to	12442272
97	12442272
-	12442272
265	12442272
kb	12442272
around	12442272
SOD1	12442272
,	12442272
excluding	12442272
all	12442272
neighbouring	12442272
genes	12442272
.	12442272

We	12442272
propose	12442272
that	12442272
a	12442272
cis	12442272
-	12442272
acting	12442272
regulatory	12442272
polymorphism	12442272
has	12442272
arisen	12442272
close	12442272
to	12442272
D90A	12442272
-	12442272
SOD1	12442272
in	12442272
the	12442272
recessive	12442272
founder	12442272
,	12442272
which	12442272
decreases	12442272
ALS	12442272
susceptibility	12442272
in	12442272
heterozygotes	12442272
and	12442272
slows	12442272
disease	12442272
progression	12442272
.	12442272
Spirulina	28075473
lipopolysaccharides	28075473
inhibit	28075473
tumor	28075473
growth	28075473
in	28075473
a	28075473
Toll	28075473
-	28075473
like	28075473
receptor	28075473
4	28075473
-	28075473
dependent	28075473
manner	28075473
by	28075473
altering	28075473
the	28075473
cytokine	28075473
milieu	28075473
from	28075473
interleukin	28075473
-	28075473
17	28075473
/	28075473
interleukin	28075473
-	28075473
23	28075473
to	28075473
interferon	28075473
-	28075473
g	28075473
.	28075473

Th17	28075473
cells	28075473
and	28075473
the	28075473
cytokine	28075473
they	28075473
produce	28075473
,	28075473
interleukin	28075473
(	28075473
IL	28075473
)	28075473
-	28075473
17	28075473
,	28075473
play	28075473
an	28075473
important	28075473
role	28075473
in	28075473
tumor	28075473
progression	28075473
in	28075473
humans	28075473
and	28075473
in	28075473
mice	28075473
.	28075473

IL	28075473
-	28075473
6	28075473
and	28075473
IL	28075473
-	28075473
23	28075473
are	28075473
critical	28075473
cytokines	28075473
for	28075473
the	28075473
differentiation	28075473
and	28075473
propagation	28075473
of	28075473
Th17	28075473
cells	28075473
,	28075473
respectively	28075473
.	28075473

Bacterial	28075473
lipopolysaccharides	28075473
(	28075473
LPS	28075473
)	28075473
are	28075473
known	28075473
to	28075473
stimulate	28075473
immune	28075473
cells	28075473
to	28075473
produce	28075473
such	28075473
inflammatory	28075473
cytokines	28075473
.	28075473

Contrary	28075473
to	28075473
Escherichia	28075473
coli	28075473
(	28075473
E	28075473
.	28075473

coli	28075473
)	28075473
LPS	28075473
,	28075473
LPS	28075473
from	28075473
Spirulina	28075473
has	28075473
low	28075473
toxicity	28075473
and	28075473
barely	28075473
induces	28075473
in	28075473
vivo	28075473
production	28075473
of	28075473
IL	28075473
-	28075473
6	28075473
and	28075473
IL	28075473
-	28075473
23	28075473
in	28075473
mice	28075473
.	28075473

We	28075473
examined	28075473
the	28075473
antitumor	28075473
effects	28075473
of	28075473
Spirulina	28075473
LPS	28075473
compared	28075473
to	28075473
E	28075473
.	28075473

coli	28075473
LPS	28075473
in	28075473
an	28075473
MH134	28075473
hepatoma	28075473
model	28075473
.	28075473

Administration	28075473
of	28075473
Spirulina	28075473
LPS	28075473
suppressed	28075473
tumor	28075473
growth	28075473
in	28075473
C3H	28075473
/	28075473
HeN	28075473
mice	28075473
,	28075473
but	28075473
not	28075473
in	28075473
Toll	28075473
-	28075473
like	28075473
receptor	28075473
4	28075473
(	28075473
TLR4	28075473
)	28075473
-	28075473
mutant	28075473
C3H	28075473
/	28075473
HeJ	28075473
mice	28075473
,	28075473
by	28075473
reducing	28075473
serum	28075473
levels	28075473
of	28075473
IL	28075473
-	28075473
17	28075473
and	28075473
IL	28075473
-	28075473
23	28075473
,	28075473
while	28075473
increasing	28075473
interferon	28075473
(	28075473
IFN	28075473
)	28075473
-	28075473
g	28075473
levels	28075473
.	28075473

The	28075473
antitumor	28075473
activity	28075473
and	28075473
IFN	28075473
-	28075473
g	28075473
production	28075473
were	28075473
mediated	28075473
by	28075473
T	28075473
cells	28075473
.	28075473

Moreover	28075473
,	28075473
in	28075473
vitro	28075473
experiments	28075473
showed	28075473
that	28075473
Spirulina	28075473
LPS	28075473
impaired	28075473
the	28075473
antigen	28075473
-	28075473
presenting	28075473
function	28075473
that	28075473
supports	28075473
the	28075473
generation	28075473
of	28075473
IL	28075473
-	28075473
17	28075473
-	28075473
producing	28075473
cells	28075473
in	28075473
a	28075473
toll	28075473
-	28075473
like	28075473
receptor	28075473
(	28075473
TLR	28075473
)	28075473
4	28075473
-	28075473
dependent	28075473
manner	28075473
.	28075473

Of	28075473
note	28075473
,	28075473
injection	28075473
of	28075473
anti	28075473
-	28075473
IL	28075473
-	28075473
17	28075473
antibody	28075473
in	28075473
tumor	28075473
-	28075473
bearing	28075473
C3H	28075473
/	28075473
HeN	28075473
mice	28075473
in	28075473
the	28075473
absence	28075473
of	28075473
Spirulina	28075473
LPS	28075473
markedly	28075473
suppressed	28075473
tumor	28075473
growth	28075473
and	28075473
augmented	28075473
IFN	28075473
-	28075473
g	28075473
responses	28075473
.	28075473

Thus	28075473
,	28075473
our	28075473
results	28075473
support	28075473
the	28075473
notion	28075473
that	28075473
IFN	28075473
-	28075473
g	28075473
and	28075473
IL	28075473
-	28075473
17	28075473
/	28075473
IL	28075473
-	28075473
23	28075473
mutually	28075473
regulate	28075473
Th17	28075473
and	28075473
Th1	28075473
responses	28075473
in	28075473
tumor	28075473
-	28075473
bearing	28075473
hosts	28075473
,	28075473
and	28075473
Spirulina	28075473
LPS	28075473
modulates	28075473
the	28075473
balance	28075473
of	28075473
the	28075473
IFN	28075473
-	28075473
g	28075473
-	28075473
IL	28075473
-	28075473
17	28075473
/	28075473
IL	28075473
-	28075473
23	28075473
axis	28075473
towards	28075473
IFN	28075473
-	28075473
g	28075473
production	28075473
,	28075473
which	28075473
leads	28075473
to	28075473
tumor	28075473
inhibition	28075473
.	28075473

Furthermore	28075473
,	28075473
Spirulina	28075473
LPS	28075473
effectively	28075473
inhibited	28075473
the	28075473
spontaneous	28075473
development	28075473
of	28075473
mammary	28075473
tumors	28075473
.	28075473

This	28075473
study	28075473
has	28075473
important	28075473
implications	28075473
for	28075473
the	28075473
exploitation	28075473
of	28075473
TLR	28075473
-	28075473
based	28075473
immunomodulators	28075473
for	28075473
cancer	28075473
immunotherapy	28075473
.	28075473
Myotonic	9294109
dystrophy	9294109
protein	9294109
kinase	9294109
is	9294109
involved	9294109
in	9294109
the	9294109
modulation	9294109
of	9294109
the	9294109
Ca2	9294109
+	9294109
homeostasis	9294109
in	9294109
skeletal	9294109
muscle	9294109
cells	9294109
.	9294109

Myotonic	9294109
dystrophy	9294109
(	9294109
DM	9294109
)	9294109
,	9294109
the	9294109
most	9294109
prevalent	9294109
muscular	9294109
disorder	9294109
in	9294109
adults	9294109
,	9294109
is	9294109
caused	9294109
by	9294109
(	9294109
CTG	9294109
)	9294109
n	9294109
-	9294109
repeat	9294109
expansion	9294109
in	9294109
a	9294109
gene	9294109
encoding	9294109
a	9294109
protein	9294109
kinase	9294109
(	9294109
DM	9294109
protein	9294109
kinase	9294109
;	9294109
DMPK	9294109
)	9294109
and	9294109
involves	9294109
changes	9294109
in	9294109
cytoarchitecture	9294109
and	9294109
ion	9294109
homeostasis	9294109
.	9294109

To	9294109
obtain	9294109
clues	9294109
to	9294109
the	9294109
normal	9294109
biological	9294109
role	9294109
of	9294109
DMPK	9294109
in	9294109
cellular	9294109
ion	9294109
homeostasis	9294109
,	9294109
we	9294109
have	9294109
compared	9294109
the	9294109
resting	9294109
[	9294109
Ca2	9294109
+	9294109
]	9294109
i	9294109
,	9294109
the	9294109
amplitude	9294109
and	9294109
shape	9294109
of	9294109
depolarization	9294109
-	9294109
induced	9294109
Ca2	9294109
+	9294109
transients	9294109
,	9294109
and	9294109
the	9294109
content	9294109
of	9294109
ATP	9294109
-	9294109
driven	9294109
ion	9294109
pumps	9294109
in	9294109
cultured	9294109
skeletal	9294109
muscle	9294109
cells	9294109
of	9294109
wild	9294109
-	9294109
type	9294109
and	9294109
DMPK	9294109
[	9294109
-	9294109
/	9294109
-	9294109
]	9294109
knockout	9294109
mice	9294109
.	9294109

In	9294109
vitro	9294109
-	9294109
differentiated	9294109
DMPK	9294109
[	9294109
-	9294109
/	9294109
-	9294109
]	9294109
myotubes	9294109
exhibit	9294109
a	9294109
higher	9294109
resting	9294109
[	9294109
Ca2	9294109
+	9294109
]	9294109
i	9294109
than	9294109
do	9294109
wild	9294109
-	9294109
type	9294109
myotubes	9294109
because	9294109
of	9294109
an	9294109
altered	9294109
open	9294109
probability	9294109
of	9294109
voltage	9294109
-	9294109
dependent	9294109
l	9294109
-	9294109
type	9294109
Ca2	9294109
+	9294109
and	9294109
Na	9294109
+	9294109
channels	9294109
.	9294109

The	9294109
mutant	9294109
myotubes	9294109
exhibit	9294109
smaller	9294109
and	9294109
slower	9294109
Ca2	9294109
+	9294109
responses	9294109
upon	9294109
triggering	9294109
by	9294109
acetylcholine	9294109
or	9294109
high	9294109
external	9294109
K	9294109
+	9294109
.	9294109

In	9294109
addition	9294109
,	9294109
we	9294109
observed	9294109
that	9294109
these	9294109
Ca2	9294109
+	9294109
transients	9294109
partially	9294109
result	9294109
from	9294109
an	9294109
influx	9294109
of	9294109
extracellular	9294109
Ca2	9294109
+	9294109
through	9294109
the	9294109
l	9294109
-	9294109
type	9294109
Ca2	9294109
+	9294109
channel	9294109
.	9294109

Neither	9294109
the	9294109
content	9294109
nor	9294109
the	9294109
activity	9294109
of	9294109
Na	9294109
+	9294109
/	9294109
K	9294109
+	9294109
ATPase	9294109
and	9294109
sarcoplasmic	9294109
reticulum	9294109
Ca2	9294109
+	9294109
-	9294109
ATPase	9294109
are	9294109
affected	9294109
by	9294109
DMPK	9294109
absence	9294109
.	9294109

In	9294109
conclusion	9294109
,	9294109
our	9294109
data	9294109
suggest	9294109
that	9294109
DMPK	9294109
is	9294109
involved	9294109
in	9294109
modulating	9294109
the	9294109
initial	9294109
events	9294109
of	9294109
excitation	9294109
-	9294109
contraction	9294109
coupling	9294109
in	9294109
skeletal	9294109
muscle	9294109
.	9294109
Mutations	8755918
associated	8755918
with	8755918
variant	8755918
phenotypes	8755918
in	8755918
ataxia	8755918
-	8755918
telangiectasia	8755918
.	8755918

We	8755918
have	8755918
identified	8755918
14	8755918
families	8755918
with	8755918
ataxia	8755918
-	8755918
telangiectasia	8755918
(	8755918
A	8755918
-	8755918
T	8755918
)	8755918
in	8755918
which	8755918
mutation	8755918
of	8755918
the	8755918
ATM	8755918
gene	8755918
is	8755918
associated	8755918
with	8755918
a	8755918
less	8755918
severe	8755918
clinical	8755918
and	8755918
cellular	8755918
phenotype	8755918
(	8755918
approximately	8755918
10%	8755918
-	8755918
15%	8755918
of	8755918
A	8755918
-	8755918
T	8755918
families	8755918
identified	8755918
in	8755918
the	8755918
United	8755918
Kingdom	8755918
)	8755918
.	8755918

In	8755918
10	8755918
of	8755918
these	8755918
families	8755918
,	8755918
all	8755918
the	8755918
homozygotes	8755918
have	8755918
a	8755918
137	8755918
-	8755918
bp	8755918
insertion	8755918
in	8755918
their	8755918
cDNA	8755918
caused	8755918
by	8755918
a	8755918
point	8755918
mutation	8755918
in	8755918
a	8755918
sequence	8755918
resembling	8755918
a	8755918
splice	8755918
-	8755918
donor	8755918
site	8755918
.	8755918

The	8755918
second	8755918
A	8755918
-	8755918
T	8755918
allele	8755918
has	8755918
a	8755918
different	8755918
mutation	8755918
in	8755918
each	8755918
patient	8755918
.	8755918

We	8755918
show	8755918
that	8755918
the	8755918
less	8755918
severe	8755918
phenotype	8755918
in	8755918
these	8755918
patients	8755918
is	8755918
caused	8755918
by	8755918
some	8755918
degree	8755918
of	8755918
normal	8755918
splicing	8755918
,	8755918
which	8755918
occurs	8755918
as	8755918
an	8755918
alternative	8755918
product	8755918
from	8755918
the	8755918
insertion	8755918
-	8755918
containing	8755918
allele	8755918
.	8755918

The	8755918
level	8755918
of	8755918
the	8755918
137	8755918
-	8755918
bp	8755918
PCR	8755918
product	8755918
containing	8755918
the	8755918
insertion	8755918
was	8755918
lowest	8755918
in	8755918
two	8755918
patients	8755918
who	8755918
showed	8755918
a	8755918
later	8755918
onset	8755918
of	8755918
cerebellar	8755918
ataxia	8755918
.	8755918

A	8755918
further	8755918
four	8755918
families	8755918
who	8755918
do	8755918
not	8755918
have	8755918
this	8755918
insertion	8755918
have	8755918
been	8755918
identified	8755918
.	8755918

Mutations	8755918
detected	8755918
in	8755918
two	8755918
of	8755918
four	8755918
of	8755918
these	8755918
are	8755918
missense	8755918
mutations	8755918
,	8755918
normally	8755918
rare	8755918
in	8755918
A	8755918
-	8755918
T	8755918
patients	8755918
.	8755918

The	8755918
demonstration	8755918
of	8755918
mutations	8755918
giving	8755918
rise	8755918
to	8755918
a	8755918
slightly	8755918
milder	8755918
phenotype	8755918
in	8755918
A	8755918
-	8755918
T	8755918
raises	8755918
the	8755918
interesting	8755918
question	8755918
of	8755918
what	8755918
range	8755918
of	8755918
phenotypes	8755918
might	8755918
occur	8755918
in	8755918
individuals	8755918
in	8755918
whom	8755918
both	8755918
mutations	8755918
are	8755918
milder	8755918
.	8755918

One	8755918
possibility	8755918
might	8755918
be	8755918
that	8755918
individuals	8755918
who	8755918
are	8755918
compound	8755918
heterozygotes	8755918
for	8755918
ATM	8755918
mutations	8755918
are	8755918
more	8755918
common	8755918
than	8755918
we	8755918
realize	8755918
.	8755918
Omitting	18544179
fentanyl	18544179
reduces	18544179
nausea	18544179
and	18544179
vomiting	18544179
,	18544179
without	18544179
increasing	18544179
pain	18544179
,	18544179
after	18544179
sevoflurane	18544179
for	18544179
day	18544179
surgery	18544179
.	18544179

BACKGROUND	18544179
AND	18544179
OBJECTIVE	18544179
:	18544179
Despite	18544179
advantages	18544179
of	18544179
induction	18544179
and	18544179
maintenance	18544179
of	18544179
anaesthesia	18544179
with	18544179
sevoflurane	18544179
,	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
occurs	18544179
frequently	18544179
.	18544179

Fentanyl	18544179
is	18544179
a	18544179
commonly	18544179
used	18544179
supplement	18544179
that	18544179
may	18544179
contribute	18544179
to	18544179
this	18544179
,	18544179
although	18544179
it	18544179
may	18544179
also	18544179
improve	18544179
analgesia	18544179
.	18544179

METHODS	18544179
:	18544179
This	18544179
double	18544179
-	18544179
blind	18544179
study	18544179
examined	18544179
the	18544179
incidence	18544179
and	18544179
severity	18544179
of	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
and	18544179
pain	18544179
in	18544179
the	18544179
first	18544179
24	18544179
h	18544179
after	18544179
sevoflurane	18544179
anaesthesia	18544179
in	18544179
216	18544179
adult	18544179
day	18544179
surgery	18544179
patients	18544179
.	18544179

Patients	18544179
were	18544179
randomly	18544179
allocated	18544179
to	18544179
either	18544179
receive	18544179
or	18544179
not	18544179
receive	18544179
1	18544179
1	18544179
fentanyl	18544179
,	18544179
while	18544179
a	18544179
third	18544179
group	18544179
received	18544179
dexamethasone	18544179
in	18544179
addition	18544179
to	18544179
fentanyl	18544179
.	18544179

RESULTS	18544179
:	18544179
Omission	18544179
of	18544179
fentanyl	18544179
did	18544179
not	18544179
reduce	18544179
the	18544179
overall	18544179
incidence	18544179
of	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
,	18544179
but	18544179
did	18544179
reduce	18544179
the	18544179
incidence	18544179
of	18544179
vomiting	18544179
and	18544179
/	18544179
or	18544179
moderate	18544179
to	18544179
severe	18544179
nausea	18544179
prior	18544179
to	18544179
discharge	18544179
from	18544179
20%	18544179
and	18544179
17%	18544179
with	18544179
fentanyl	18544179
and	18544179
fentanyl	18544179
-	18544179
dexamethasone	18544179
,	18544179
respectively	18544179
,	18544179
to	18544179
5%	18544179
(	18544179
P	18544179
=	18544179
0	18544179
.	18544179
013	18544179
)	18544179
.	18544179

Antiemetic	18544179
requirements	18544179
were	18544179
reduced	18544179
from	18544179
24%	18544179
and	18544179
31%	18544179
to	18544179
7%	18544179
(	18544179
P	18544179
=	18544179
0	18544179
.	18544179
0012	18544179
)	18544179
.	18544179

Dexamethasone	18544179
had	18544179
no	18544179
significant	18544179
effect	18544179
on	18544179
the	18544179
incidence	18544179
or	18544179
severity	18544179
of	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
.	18544179

Combining	18544179
the	18544179
two	18544179
fentanyl	18544179
groups	18544179
revealed	18544179
further	18544179
significant	18544179
benefits	18544179
from	18544179
the	18544179
avoidance	18544179
of	18544179
opioids	18544179
,	18544179
reducing	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
and	18544179
nausea	18544179
prior	18544179
to	18544179
discharge	18544179
from	18544179
35%	18544179
and	18544179
33%	18544179
to	18544179
22%	18544179
and	18544179
19%	18544179
(	18544179
P	18544179
=	18544179
0	18544179
.	18544179
049	18544179
and	18544179
P	18544179
=	18544179
0	18544179
.	18544179
035	18544179
)	18544179
,	18544179
respectively	18544179
,	18544179
while	18544179
nausea	18544179
in	18544179
the	18544179
first	18544179
24	18544179
h	18544179
was	18544179
decreased	18544179
from	18544179
42%	18544179
to	18544179
27%	18544179
(	18544179
P	18544179
=	18544179
0	18544179
.	18544179
034	18544179
)	18544179
.	18544179

Pain	18544179
severity	18544179
and	18544179
analgesic	18544179
requirements	18544179
were	18544179
unaffected	18544179
by	18544179
the	18544179
omission	18544179
of	18544179
fentanyl	18544179
.	18544179

Fentanyl	18544179
did	18544179
reduce	18544179
minor	18544179
intraoperative	18544179
movement	18544179
but	18544179
had	18544179
no	18544179
sevoflurane	18544179
-	18544179
sparing	18544179
effect	18544179
and	18544179
increased	18544179
respiratory	18544179
depression	18544179
,	18544179
hypotension	18544179
and	18544179
bradycardia	18544179
.	18544179

CONCLUSION	18544179
:	18544179
As	18544179
fentanyl	18544179
exacerbated	18544179
postoperative	18544179
nausea	18544179
and	18544179
vomiting	18544179
without	18544179
an	18544179
improvement	18544179
in	18544179
postoperative	18544179
pain	18544179
and	18544179
also	18544179
had	18544179
adverse	18544179
cardiorespiratory	18544179
effects	18544179
,	18544179
it	18544179
appears	18544179
to	18544179
be	18544179
an	18544179
unnecessary	18544179
and	18544179
possibly	18544179
detrimental	18544179
supplement	18544179
to	18544179
sevoflurane	18544179
in	18544179
day	18544179
surgery	18544179
.	18544179
Aconitine	24840785
-	24840785
induced	24840785
Ca2	24840785
+	24840785
overload	24840785
causes	24840785
arrhythmia	24840785
and	24840785
triggers	24840785
apoptosis	24840785
through	24840785
p38	24840785
MAPK	24840785
signaling	24840785
pathway	24840785
in	24840785
rats	24840785
.	24840785

Aconitine	24840785
is	24840785
a	24840785
major	24840785
bioactive	24840785
diterpenoid	24840785
alkaloid	24840785
with	24840785
high	24840785
content	24840785
derived	24840785
from	24840785
herbal	24840785
aconitum	24840785
plants	24840785
.	24840785

Emerging	24840785
evidence	24840785
indicates	24840785
that	24840785
voltage	24840785
-	24840785
dependent	24840785
Na	24840785
(	24840785
+	24840785
)	24840785
channels	24840785
have	24840785
pivotal	24840785
roles	24840785
in	24840785
the	24840785
cardiotoxicity	24840785
of	24840785
aconitine	24840785
.	24840785

However	24840785
,	24840785
no	24840785
reports	24840785
are	24840785
available	24840785
on	24840785
the	24840785
role	24840785
of	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
in	24840785
aconitine	24840785
poisoning	24840785
.	24840785

In	24840785
this	24840785
study	24840785
,	24840785
we	24840785
explored	24840785
the	24840785
importance	24840785
of	24840785
pathological	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
signaling	24840785
in	24840785
aconitine	24840785
poisoning	24840785
in	24840785
vitro	24840785
and	24840785
in	24840785
vivo	24840785
.	24840785

We	24840785
found	24840785
that	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
overload	24840785
lead	24840785
to	24840785
accelerated	24840785
beating	24840785
rhythm	24840785
in	24840785
adult	24840785
rat	24840785
ventricular	24840785
myocytes	24840785
and	24840785
caused	24840785
arrhythmia	24840785
in	24840785
conscious	24840785
freely	24840785
moving	24840785
rats	24840785
.	24840785

To	24840785
investigate	24840785
effects	24840785
of	24840785
aconitine	24840785
on	24840785
myocardial	24840785
injury	24840785
,	24840785
we	24840785
performed	24840785
cytotoxicity	24840785
assay	24840785
in	24840785
neonatal	24840785
rat	24840785
ventricular	24840785
myocytes	24840785
(	24840785
NRVMs	24840785
)	24840785
,	24840785
as	24840785
well	24840785
as	24840785
measured	24840785
lactate	24840785
dehydrogenase	24840785
level	24840785
in	24840785
the	24840785
culture	24840785
medium	24840785
of	24840785
NRVMs	24840785
and	24840785
activities	24840785
of	24840785
serum	24840785
cardiac	24840785
enzymes	24840785
in	24840785
rats	24840785
.	24840785

The	24840785
results	24840785
showed	24840785
that	24840785
aconitine	24840785
resulted	24840785
in	24840785
myocardial	24840785
injury	24840785
and	24840785
reduced	24840785
NRVMs	24840785
viability	24840785
dose	24840785
-	24840785
dependently	24840785
.	24840785

To	24840785
confirm	24840785
the	24840785
pro	24840785
-	24840785
apoptotic	24840785
effects	24840785
,	24840785
we	24840785
performed	24840785
flow	24840785
cytometric	24840785
detection	24840785
,	24840785
cardiac	24840785
histology	24840785
,	24840785
transmission	24840785
electron	24840785
microscopy	24840785
and	24840785
terminal	24840785
deoxynucleotidyl	24840785
transferase	24840785
-	24840785
mediated	24840785
dUTP	24840785
-	24840785
biotin	24840785
nick	24840785
end	24840785
labeling	24840785
assay	24840785
.	24840785

The	24840785
results	24840785
showed	24840785
that	24840785
aconitine	24840785
stimulated	24840785
apoptosis	24840785
time	24840785
-	24840785
dependently	24840785
.	24840785

The	24840785
expression	24840785
analysis	24840785
of	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
handling	24840785
proteins	24840785
demonstrated	24840785
that	24840785
aconitine	24840785
promoted	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
overload	24840785
through	24840785
the	24840785
expression	24840785
regulation	24840785
of	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
handling	24840785
proteins	24840785
.	24840785

The	24840785
expression	24840785
analysis	24840785
of	24840785
apoptosis	24840785
-	24840785
related	24840785
proteins	24840785
revealed	24840785
that	24840785
pro	24840785
-	24840785
apoptotic	24840785
protein	24840785
expression	24840785
was	24840785
upregulated	24840785
,	24840785
and	24840785
anti	24840785
-	24840785
apoptotic	24840785
protein	24840785
BCL	24840785
-	24840785
2	24840785
expression	24840785
was	24840785
downregulated	24840785
.	24840785

Furthermore	24840785
,	24840785
increased	24840785
phosphorylation	24840785
of	24840785
MAPK	24840785
family	24840785
members	24840785
,	24840785
especially	24840785
the	24840785
P	24840785
-	24840785
P38	24840785
/	24840785
P38	24840785
ratio	24840785
was	24840785
found	24840785
in	24840785
cardiac	24840785
tissues	24840785
.	24840785

Hence	24840785
,	24840785
our	24840785
results	24840785
suggest	24840785
that	24840785
aconitine	24840785
significantly	24840785
aggravates	24840785
Ca	24840785
(	24840785
2	24840785
+	24840785
)	24840785
overload	24840785
and	24840785
causes	24840785
arrhythmia	24840785
and	24840785
finally	24840785
promotes	24840785
apoptotic	24840785
development	24840785
via	24840785
phosphorylation	24840785
of	24840785
P38	24840785
mitogen	24840785
-	24840785
activated	24840785
protein	24840785
kinase	24840785
.	24840785
Coenzyme	20510337
Q10	20510337
treatment	20510337
ameliorates	20510337
acute	20510337
cisplatin	20510337
nephrotoxicity	20510337
in	20510337
mice	20510337
.	20510337

The	20510337
nephroprotective	20510337
effect	20510337
of	20510337
coenzyme	20510337
Q10	20510337
was	20510337
investigated	20510337
in	20510337
mice	20510337
with	20510337
acute	20510337
renal	20510337
injury	20510337
induced	20510337
by	20510337
a	20510337
single	20510337
i	20510337
.	20510337
p	20510337
.	20510337

injection	20510337
of	20510337
cisplatin	20510337
(	20510337
5	20510337
mg	20510337
/	20510337
kg	20510337
)	20510337
.	20510337

Coenzyme	20510337
Q10	20510337
treatment	20510337
(	20510337
10	20510337
mg	20510337
/	20510337
kg	20510337
/	20510337
day	20510337
,	20510337
i	20510337
.	20510337
p	20510337
.	20510337
)	20510337
was	20510337
applied	20510337
for	20510337
6	20510337
consecutive	20510337
days	20510337
,	20510337
starting	20510337
1	20510337
day	20510337
before	20510337
cisplatin	20510337
administration	20510337
.	20510337

Coenzyme	20510337
Q10	20510337
significantly	20510337
reduced	20510337
blood	20510337
urea	20510337
nitrogen	20510337
and	20510337
serum	20510337
creatinine	20510337
levels	20510337
which	20510337
were	20510337
increased	20510337
by	20510337
cisplatin	20510337
.	20510337

Coenzyme	20510337
Q10	20510337
significantly	20510337
compensated	20510337
deficits	20510337
in	20510337
the	20510337
antioxidant	20510337
defense	20510337
mechanisms	20510337
(	20510337
reduced	20510337
glutathione	20510337
level	20510337
and	20510337
superoxide	20510337
dismutase	20510337
activity	20510337
)	20510337
,	20510337
suppressed	20510337
lipid	20510337
peroxidation	20510337
,	20510337
decreased	20510337
the	20510337
elevations	20510337
of	20510337
tumor	20510337
necrosis	20510337
factor	20510337
-	20510337
alpha	20510337
,	20510337
nitric	20510337
oxide	20510337
and	20510337
platinum	20510337
ion	20510337
concentration	20510337
,	20510337
and	20510337
attenuated	20510337
the	20510337
reductions	20510337
of	20510337
selenium	20510337
and	20510337
zinc	20510337
ions	20510337
in	20510337
renal	20510337
tissue	20510337
resulted	20510337
from	20510337
cisplatin	20510337
administration	20510337
.	20510337

Also	20510337
,	20510337
histopathological	20510337
renal	20510337
tissue	20510337
damage	20510337
mediated	20510337
by	20510337
cisplatin	20510337
was	20510337
ameliorated	20510337
by	20510337
coenzyme	20510337
Q10	20510337
treatment	20510337
.	20510337

Immunohistochemical	20510337
analysis	20510337
revealed	20510337
that	20510337
coenzyme	20510337
Q10	20510337
significantly	20510337
decreased	20510337
the	20510337
cisplatin	20510337
-	20510337
induced	20510337
overexpression	20510337
of	20510337
inducible	20510337
nitric	20510337
oxide	20510337
synthase	20510337
,	20510337
nuclear	20510337
factor	20510337
-	20510337
kappaB	20510337
,	20510337
caspase	20510337
-	20510337
3	20510337
and	20510337
p53	20510337
in	20510337
renal	20510337
tissue	20510337
.	20510337

It	20510337
was	20510337
concluded	20510337
that	20510337
coenzyme	20510337
Q10	20510337
represents	20510337
a	20510337
potential	20510337
therapeutic	20510337
option	20510337
to	20510337
protect	20510337
against	20510337
acute	20510337
cisplatin	20510337
nephrotoxicity	20510337
commonly	20510337
encountered	20510337
in	20510337
clinical	20510337
practice	20510337
.	20510337
U87MG	20126413
decoded	20126413
:	20126413
the	20126413
genomic	20126413
sequence	20126413
of	20126413
a	20126413
cytogenetically	20126413
aberrant	20126413
human	20126413
cancer	20126413
cell	20126413
line	20126413
.	20126413

U87MG	20126413
is	20126413
a	20126413
commonly	20126413
studied	20126413
grade	20126413
IV	20126413
glioma	20126413
cell	20126413
line	20126413
that	20126413
has	20126413
been	20126413
analyzed	20126413
in	20126413
at	20126413
least	20126413
1	20126413
,	20126413
700	20126413
publications	20126413
over	20126413
four	20126413
decades	20126413
.	20126413

In	20126413
order	20126413
to	20126413
comprehensively	20126413
characterize	20126413
the	20126413
genome	20126413
of	20126413
this	20126413
cell	20126413
line	20126413
and	20126413
to	20126413
serve	20126413
as	20126413
a	20126413
model	20126413
of	20126413
broad	20126413
cancer	20126413
genome	20126413
sequencing	20126413
,	20126413
we	20126413
have	20126413
generated	20126413
greater	20126413
than	20126413
30x	20126413
genomic	20126413
sequence	20126413
coverage	20126413
using	20126413
a	20126413
novel	20126413
50	20126413
-	20126413
base	20126413
mate	20126413
paired	20126413
strategy	20126413
with	20126413
a	20126413
1	20126413
.	20126413
4kb	20126413
mean	20126413
insert	20126413
library	20126413
.	20126413

A	20126413
total	20126413
of	20126413
1	20126413
,	20126413
014	20126413
,	20126413
984	20126413
,	20126413
286	20126413
mate	20126413
-	20126413
end	20126413
and	20126413
120	20126413
,	20126413
691	20126413
,	20126413
623	20126413
single	20126413
-	20126413
end	20126413
two	20126413
-	20126413
base	20126413
encoded	20126413
reads	20126413
were	20126413
generated	20126413
from	20126413
five	20126413
slides	20126413
.	20126413

All	20126413
data	20126413
were	20126413
aligned	20126413
using	20126413
a	20126413
custom	20126413
designed	20126413
tool	20126413
called	20126413
BFAST	20126413
,	20126413
allowing	20126413
optimal	20126413
color	20126413
space	20126413
read	20126413
alignment	20126413
and	20126413
accurate	20126413
identification	20126413
of	20126413
DNA	20126413
variants	20126413
.	20126413

The	20126413
aligned	20126413
sequence	20126413
reads	20126413
and	20126413
mate	20126413
-	20126413
pair	20126413
information	20126413
identified	20126413
35	20126413
interchromosomal	20126413
translocation	20126413
events	20126413
,	20126413
1	20126413
,	20126413
315	20126413
structural	20126413
variations	20126413
(	20126413
>	20126413
100	20126413
bp	20126413
)	20126413
,	20126413
191	20126413
,	20126413
743	20126413
small	20126413
(	20126413
<	20126413
21	20126413
bp	20126413
)	20126413
insertions	20126413
and	20126413
deletions	20126413
(	20126413
indels	20126413
)	20126413
,	20126413
and	20126413
2	20126413
,	20126413
384	20126413
,	20126413
470	20126413
single	20126413
nucleotide	20126413
variations	20126413
(	20126413
SNVs	20126413
)	20126413
.	20126413

Among	20126413
these	20126413
observations	20126413
,	20126413
the	20126413
known	20126413
homozygous	20126413
mutation	20126413
in	20126413
PTEN	20126413
was	20126413
robustly	20126413
identified	20126413
,	20126413
and	20126413
genes	20126413
involved	20126413
in	20126413
cell	20126413
adhesion	20126413
were	20126413
overrepresented	20126413
in	20126413
the	20126413
mutated	20126413
gene	20126413
list	20126413
.	20126413

Data	20126413
were	20126413
compared	20126413
to	20126413
219	20126413
,	20126413
187	20126413
heterozygous	20126413
single	20126413
nucleotide	20126413
polymorphisms	20126413
assayed	20126413
by	20126413
Illumina	20126413
1M	20126413
Duo	20126413
genotyping	20126413
array	20126413
to	20126413
assess	20126413
accuracy	20126413
:	20126413
93	20126413
.	20126413
83%	20126413
of	20126413
all	20126413
SNPs	20126413
were	20126413
reliably	20126413
detected	20126413
at	20126413
filtering	20126413
thresholds	20126413
that	20126413
yield	20126413
greater	20126413
than	20126413
99	20126413
.	20126413
99%	20126413
sequence	20126413
accuracy	20126413
.	20126413

Protein	20126413
coding	20126413
sequences	20126413
were	20126413
disrupted	20126413
predominantly	20126413
in	20126413
this	20126413
cancer	20126413
cell	20126413
line	20126413
due	20126413
to	20126413
small	20126413
indels	20126413
,	20126413
large	20126413
deletions	20126413
,	20126413
and	20126413
translocations	20126413
.	20126413

In	20126413
total	20126413
,	20126413
512	20126413
genes	20126413
were	20126413
homozygously	20126413
mutated	20126413
,	20126413
including	20126413
154	20126413
by	20126413
SNVs	20126413
,	20126413
178	20126413
by	20126413
small	20126413
indels	20126413
,	20126413
145	20126413
by	20126413
large	20126413
microdeletions	20126413
,	20126413
and	20126413
35	20126413
by	20126413
interchromosomal	20126413
translocations	20126413
to	20126413
reveal	20126413
a	20126413
highly	20126413
mutated	20126413
cell	20126413
line	20126413
genome	20126413
.	20126413

Of	20126413
the	20126413
small	20126413
homozygously	20126413
mutated	20126413
variants	20126413
,	20126413
8	20126413
SNVs	20126413
and	20126413
99	20126413
indels	20126413
were	20126413
novel	20126413
events	20126413
not	20126413
present	20126413
in	20126413
dbSNP	20126413
.	20126413

These	20126413
data	20126413
demonstrate	20126413
that	20126413
routine	20126413
generation	20126413
of	20126413
broad	20126413
cancer	20126413
genome	20126413
sequence	20126413
is	20126413
possible	20126413
outside	20126413
of	20126413
genome	20126413
centers	20126413
.	20126413

The	20126413
sequence	20126413
analysis	20126413
of	20126413
U87MG	20126413
provides	20126413
an	20126413
unparalleled	20126413
level	20126413
of	20126413
mutational	20126413
resolution	20126413
compared	20126413
to	20126413
any	20126413
cell	20126413
line	20126413
to	20126413
date	20126413
.	20126413
A	16120104
single	16120104
-	16120104
nucleotide	16120104
polymorphism	16120104
in	16120104
the	16120104
5	16120104
'	16120104
-	16120104
untranslated	16120104
region	16120104
of	16120104
the	16120104
hPER2	16120104
gene	16120104
is	16120104
associated	16120104
with	16120104
diurnal	16120104
preference	16120104
.	16120104

The	16120104
PERIOD2	16120104
(	16120104
PER2	16120104
)	16120104
gene	16120104
is	16120104
a	16120104
key	16120104
component	16120104
of	16120104
the	16120104
molecular	16120104
mechanism	16120104
that	16120104
generates	16120104
circadian	16120104
rhythms	16120104
in	16120104
mammals	16120104
.	16120104

A	16120104
missense	16120104
mutation	16120104
in	16120104
the	16120104
human	16120104
PER2	16120104
gene	16120104
has	16120104
previously	16120104
been	16120104
linked	16120104
to	16120104
advanced	16120104
sleep	16120104
phase	16120104
syndrome	16120104
(	16120104
ASPS	16120104
)	16120104
.	16120104

We	16120104
have	16120104
investigated	16120104
three	16120104
other	16120104
single	16120104
-	16120104
nucleotide	16120104
polymorphisms	16120104
in	16120104
the	16120104
hPER2	16120104
gene	16120104
,	16120104
one	16120104
downstream	16120104
of	16120104
the	16120104
transcription	16120104
start	16120104
site	16120104
(	16120104
C	16120104
-	16120104
1228T	16120104
)	16120104
,	16120104
one	16120104
in	16120104
exon	16120104
2	16120104
in	16120104
the	16120104
5	16120104
'	16120104
-	16120104
untranslated	16120104
region	16120104
(	16120104
5	16120104
'	16120104
-	16120104
UTR	16120104
)	16120104
(	16120104
C111G	16120104
)	16120104
,	16120104
and	16120104
one	16120104
missense	16120104
mutation	16120104
(	16120104
G3853A	16120104
)	16120104
causing	16120104
a	16120104
glycine	16120104
to	16120104
glutamine	16120104
substitution	16120104
in	16120104
the	16120104
predicted	16120104
protein	16120104
.	16120104

Subjects	16120104
selected	16120104
from	16120104
a	16120104
group	16120104
of	16120104
484	16120104
volunteers	16120104
for	16120104
extreme	16120104
morning	16120104
or	16120104
evening	16120104
preference	16120104
,	16120104
or	16120104
intermediate	16120104
diurnal	16120104
preference	16120104
were	16120104
genotyped	16120104
with	16120104
regard	16120104
to	16120104
the	16120104
three	16120104
polymorphisms	16120104
(	16120104
n	16120104
=	16120104
35	16120104
for	16120104
each	16120104
group	16120104
)	16120104
.	16120104

Whereas	16120104
allele	16120104
frequencies	16120104
for	16120104
the	16120104
other	16120104
two	16120104
polymorphisms	16120104
did	16120104
not	16120104
differ	16120104
significantly	16120104
between	16120104
any	16120104
of	16120104
the	16120104
groups	16120104
,	16120104
the	16120104
111G	16120104
allele	16120104
frequency	16120104
was	16120104
significantly	16120104
higher	16120104
in	16120104
subjects	16120104
with	16120104
extreme	16120104
morning	16120104
preference	16120104
(	16120104
0	16120104
.	16120104
14	16120104
)	16120104
than	16120104
in	16120104
subjects	16120104
with	16120104
extreme	16120104
evening	16120104
preference	16120104
(	16120104
0	16120104
.	16120104
03	16120104
)	16120104
(	16120104
Fisher	16120104
'	16120104
s	16120104
exact	16120104
test	16120104
,	16120104
two	16120104
-	16120104
sided	16120104
P	16120104
value	16120104
=	16120104
0	16120104
.	16120104
031	16120104
,	16120104
odds	16120104
ratio	16120104
=	16120104
5	16120104
.	16120104
67	16120104
)	16120104
.	16120104

No	16120104
significant	16120104
difference	16120104
in	16120104
111G	16120104
allele	16120104
frequency	16120104
was	16120104
observed	16120104
between	16120104
either	16120104
of	16120104
these	16120104
groups	16120104
and	16120104
subjects	16120104
with	16120104
intermediate	16120104
diurnal	16120104
preference	16120104
.	16120104

Computer	16120104
prediction	16120104
indicated	16120104
that	16120104
the	16120104
C111G	16120104
polymorphism	16120104
,	16120104
which	16120104
occurs	16120104
12	16120104
bases	16120104
upstream	16120104
from	16120104
the	16120104
translation	16120104
start	16120104
codon	16120104
,	16120104
might	16120104
alter	16120104
the	16120104
secondary	16120104
structure	16120104
of	16120104
the	16120104
transcript	16120104
.	16120104

The	16120104
PER2	16120104
111G	16120104
allele	16120104
associates	16120104
with	16120104
morning	16120104
preference	16120104
and	16120104
is	16120104
a	16120104
potential	16120104
candidate	16120104
allele	16120104
for	16120104
ASPS	16120104
.	16120104
RNASEL	18189233
and	18189233
RNASEL	18189233
-	18189233
inhibitor	18189233
variation	18189233
and	18189233
prostate	18189233
cancer	18189233
risk	18189233
in	18189233
Afro	18189233
-	18189233
Caribbeans	18189233
.	18189233

BACKGROUND	18189233
:	18189233
Afro	18189233
-	18189233
Caribbeans	18189233
from	18189233
Tobago	18189233
are	18189233
at	18189233
high	18189233
risk	18189233
of	18189233
developing	18189233
prostate	18189233
cancer	18189233
.	18189233

This	18189233
elevated	18189233
risk	18189233
of	18189233
prostate	18189233
cancer	18189233
is	18189233
shared	18189233
by	18189233
populations	18189233
of	18189233
African	18189233
ancestry	18189233
living	18189233
in	18189233
diverse	18189233
environments	18189233
in	18189233
the	18189233
Western	18189233
hemisphere	18189233
.	18189233

Variation	18189233
in	18189233
the	18189233
ribonuclease	18189233
L	18189233
(	18189233
RNASEL	18189233
)	18189233
gene	18189233
has	18189233
recently	18189233
been	18189233
reported	18189233
to	18189233
be	18189233
associated	18189233
with	18189233
an	18189233
increased	18189233
risk	18189233
of	18189233
prostate	18189233
cancer	18189233
.	18189233

However	18189233
,	18189233
whether	18189233
RNASEL	18189233
variation	18189233
contributes	18189233
to	18189233
the	18189233
increased	18189233
risk	18189233
of	18189233
prostate	18189233
cancer	18189233
observed	18189233
in	18189233
populations	18189233
of	18189233
African	18189233
ancestry	18189233
remains	18189233
unclear	18189233
.	18189233

METHODS	18189233
:	18189233
We	18189233
resequenced	18189233
the	18189233
positional	18189233
candidate	18189233
gene	18189233
RNASEL	18189233
in	18189233
48	18189233
prostate	18189233
cancer	18189233
cases	18189233
and	18189233
genotyped	18189233
the	18189233
previously	18189233
reported	18189233
R462Q	18189233
and	18189233
D541E	18189233
polymorphisms	18189233
in	18189233
230	18189233
prostate	18189233
cancer	18189233
cases	18189233
and	18189233
458	18189233
controls	18189233
.	18189233

We	18189233
also	18189233
examined	18189233
the	18189233
inhibitor	18189233
of	18189233
RNASEL	18189233
(	18189233
ABCE1	18189233
)	18189233
for	18189233
variation	18189233
associated	18189233
with	18189233
prostate	18189233
cancer	18189233
risk	18189233
.	18189233

RESULTS	18189233
:	18189233
We	18189233
found	18189233
no	18189233
evidence	18189233
of	18189233
association	18189233
between	18189233
R462Q	18189233
and	18189233
D541E	18189233
polymorphisms	18189233
and	18189233
prostate	18189233
cancer	18189233
risk	18189233
in	18189233
our	18189233
case	18189233
/	18189233
control	18189233
analysis	18189233
.	18189233

A	18189233
novel	18189233
variant	18189233
(	18189233
K294E	18189233
)	18189233
was	18189233
identified	18189233
in	18189233
a	18189233
single	18189233
heterozygous	18189233
individual	18189233
with	18189233
prostate	18189233
cancer	18189233
.	18189233

We	18189233
also	18189233
observed	18189233
a	18189233
20	18189233
bp	18189233
insertion	18189233
/	18189233
deletion	18189233
polymorphism	18189233
1	18189233
,	18189233
109	18189233
bp	18189233
upstream	18189233
of	18189233
the	18189233
initiation	18189233
codon	18189233
,	18189233
but	18189233
this	18189233
variant	18189233
was	18189233
not	18189233
associated	18189233
with	18189233
prostate	18189233
cancer	18189233
.	18189233

We	18189233
identified	18189233
16	18189233
single	18189233
nucleotide	18189233
polymorphisms	18189233
in	18189233
the	18189233
ABCE1	18189233
gene	18189233
,	18189233
only	18189233
3	18189233
of	18189233
which	18189233
had	18189233
a	18189233
minor	18189233
allele	18189233
frequency	18189233
>	18189233
5%	18189233
.	18189233

A	18189233
common	18189233
A	18189233
/	18189233
G	18189233
transition	18189233
-	18189233
1	18189233
,	18189233
071	18189233
bp	18189233
from	18189233
the	18189233
transcriptional	18189233
start	18189233
site	18189233
was	18189233
genotyped	18189233
and	18189233
showed	18189233
no	18189233
evidence	18189233
of	18189233
association	18189233
with	18189233
prostate	18189233
cancer	18189233
.	18189233

CONCLUSIONS	18189233
:	18189233
Our	18189233
results	18189233
suggest	18189233
that	18189233
common	18189233
variation	18189233
in	18189233
the	18189233
putative	18189233
prostate	18189233
cancer	18189233
susceptibility	18189233
gene	18189233
,	18189233
RNASEL	18189233
,	18189233
or	18189233
its	18189233
inhibitor	18189233
does	18189233
not	18189233
contribute	18189233
significantly	18189233
to	18189233
prostate	18189233
cancer	18189233
risk	18189233
in	18189233
this	18189233
Afro	18189233
-	18189233
Caribbean	18189233
population	18189233
.	18189233
Hepatic	20801540
but	20801540
not	20801540
brain	20801540
iron	20801540
is	20801540
rapidly	20801540
chelated	20801540
by	20801540
deferasirox	20801540
in	20801540
aceruloplasminemia	20801540
due	20801540
to	20801540
a	20801540
novel	20801540
gene	20801540
mutation	20801540
.	20801540

BACKGROUND	20801540
_	20801540
#	20801540
38	20801540
;	20801540
AIMS	20801540
:	20801540
Aceruloplasminemia	20801540
is	20801540
a	20801540
rare	20801540
autosomal	20801540
recessive	20801540
neurodegenerative	20801540
disease	20801540
associated	20801540
with	20801540
brain	20801540
and	20801540
liver	20801540
iron	20801540
accumulation	20801540
which	20801540
typically	20801540
presents	20801540
with	20801540
movement	20801540
disorders	20801540
,	20801540
retinal	20801540
degeneration	20801540
,	20801540
and	20801540
diabetes	20801540
mellitus	20801540
.	20801540

Ceruloplasmin	20801540
is	20801540
a	20801540
multi	20801540
-	20801540
copper	20801540
ferroxidase	20801540
that	20801540
is	20801540
secreted	20801540
into	20801540
plasma	20801540
and	20801540
facilitates	20801540
cellular	20801540
iron	20801540
export	20801540
and	20801540
iron	20801540
binding	20801540
to	20801540
transferrin	20801540
.	20801540

RESULTS	20801540
:	20801540
A	20801540
novel	20801540
homozygous	20801540
ceruloplasmin	20801540
gene	20801540
mutation	20801540
,	20801540
c	20801540
.	20801540
2554	20801540
+	20801540
1G	20801540
>	20801540
T	20801540
,	20801540
was	20801540
identified	20801540
as	20801540
the	20801540
cause	20801540
of	20801540
aceruloplasminemia	20801540
in	20801540
three	20801540
affected	20801540
siblings	20801540
.	20801540

Two	20801540
siblings	20801540
presented	20801540
with	20801540
movement	20801540
disorders	20801540
and	20801540
diabetes	20801540
.	20801540

Complementary	20801540
DNA	20801540
sequencing	20801540
showed	20801540
that	20801540
this	20801540
mutation	20801540
causes	20801540
skipping	20801540
of	20801540
exon	20801540
14	20801540
and	20801540
deletion	20801540
of	20801540
amino	20801540
acids	20801540
809	20801540
-	20801540
852	20801540
while	20801540
preserving	20801540
the	20801540
open	20801540
reading	20801540
frame	20801540
.	20801540

Western	20801540
blotting	20801540
of	20801540
liver	20801540
extracts	20801540
and	20801540
sera	20801540
of	20801540
affected	20801540
patients	20801540
showed	20801540
retention	20801540
of	20801540
the	20801540
abnormal	20801540
protein	20801540
in	20801540
the	20801540
liver	20801540
.	20801540

Aceruloplasminemia	20801540
was	20801540
associated	20801540
with	20801540
severe	20801540
brain	20801540
and	20801540
liver	20801540
iron	20801540
overload	20801540
,	20801540
where	20801540
hepatic	20801540
mRNA	20801540
expression	20801540
of	20801540
the	20801540
iron	20801540
hormone	20801540
hepcidin	20801540
was	20801540
increased	20801540
,	20801540
corresponding	20801540
to	20801540
the	20801540
degree	20801540
of	20801540
iron	20801540
overload	20801540
.	20801540

Hepatic	20801540
iron	20801540
concentration	20801540
normalized	20801540
after	20801540
3	20801540
and	20801540
5months	20801540
of	20801540
iron	20801540
chelation	20801540
therapy	20801540
with	20801540
deferasirox	20801540
,	20801540
which	20801540
was	20801540
also	20801540
associated	20801540
with	20801540
reduced	20801540
insulin	20801540
demands	20801540
.	20801540

During	20801540
short	20801540
term	20801540
treatment	20801540
there	20801540
was	20801540
no	20801540
clinical	20801540
or	20801540
imaging	20801540
evidence	20801540
for	20801540
significant	20801540
effects	20801540
on	20801540
brain	20801540
iron	20801540
overload	20801540
.	20801540

CONCLUSIONS	20801540
:	20801540
Aceruloplasminemia	20801540
can	20801540
show	20801540
an	20801540
incomplete	20801540
clinical	20801540
penetrance	20801540
but	20801540
is	20801540
invariably	20801540
associated	20801540
with	20801540
iron	20801540
accumulation	20801540
in	20801540
the	20801540
liver	20801540
and	20801540
in	20801540
the	20801540
brain	20801540
.	20801540

Iron	20801540
accumulation	20801540
in	20801540
aceruloplasminemia	20801540
is	20801540
a	20801540
result	20801540
of	20801540
defective	20801540
cellular	20801540
iron	20801540
export	20801540
,	20801540
where	20801540
hepcidin	20801540
regulation	20801540
is	20801540
appropriate	20801540
for	20801540
the	20801540
degree	20801540
of	20801540
iron	20801540
overload	20801540
.	20801540

Iron	20801540
chelation	20801540
with	20801540
deferasirox	20801540
was	20801540
effective	20801540
in	20801540
mobilizing	20801540
hepatic	20801540
iron	20801540
but	20801540
has	20801540
no	20801540
effect	20801540
on	20801540
brain	20801540
iron	20801540
.	20801540
Aberrant	28468941
caveolin	28468941
-	28468941
1	28468941
-	28468941
mediated	28468941
Smad	28468941
signaling	28468941
and	28468941
proliferation	28468941
identified	28468941
by	28468941
analysis	28468941
of	28468941
adenine	28468941
474	28468941
deletion	28468941
mutation	28468941
(	28468941
c	28468941
.	28468941
474delA	28468941
)	28468941
in	28468941
patient	28468941
fibroblasts	28468941
:	28468941
a	28468941
new	28468941
perspective	28468941
on	28468941
the	28468941
mechanism	28468941
of	28468941
pulmonary	28468941
hypertension	28468941
.	28468941

A	28468941
heterozygous	28468941
caveolin	28468941
-	28468941
1	28468941
c	28468941
.	28468941
474delA	28468941
mutation	28468941
has	28468941
been	28468941
identified	28468941
in	28468941
a	28468941
family	28468941
with	28468941
heritable	28468941
pulmonary	28468941
arterial	28468941
hypertension	28468941
(	28468941
PAH	28468941
)	28468941
.	28468941

This	28468941
frameshift	28468941
mutation	28468941
leads	28468941
to	28468941
a	28468941
caveolin	28468941
-	28468941
1	28468941
protein	28468941
that	28468941
contains	28468941
all	28468941
known	28468941
functional	28468941
domains	28468941
but	28468941
has	28468941
a	28468941
change	28468941
in	28468941
only	28468941
the	28468941
final	28468941
20	28468941
amino	28468941
acids	28468941
of	28468941
the	28468941
C	28468941
-	28468941
terminus	28468941
.	28468941

Here	28468941
we	28468941
studied	28468941
how	28468941
this	28468941
mutation	28468941
alters	28468941
caveolin	28468941
-	28468941
1	28468941
function	28468941
,	28468941
using	28468941
patient	28468941
-	28468941
derived	28468941
fibroblasts	28468941
.	28468941

Transmission	28468941
electron	28468941
microscopy	28468941
showed	28468941
that	28468941
fibroblasts	28468941
carrying	28468941
the	28468941
c	28468941
.	28468941
474delA	28468941
mutation	28468941
form	28468941
typical	28468941
caveolae	28468941
.	28468941

Expression	28468941
of	28468941
mutated	28468941
caveolin	28468941
-	28468941
1	28468941
in	28468941
caveolin	28468941
-	28468941
1	28468941
-	28468941
null	28468941
mouse	28468941
fibroblasts	28468941
failed	28468941
to	28468941
induce	28468941
formation	28468941
of	28468941
caveolae	28468941
due	28468941
to	28468941
retention	28468941
of	28468941
the	28468941
mutated	28468941
protein	28468941
in	28468941
the	28468941
endoplasmic	28468941
reticulum	28468941
.	28468941

However	28468941
,	28468941
coexpression	28468941
of	28468941
wild	28468941
-	28468941
type	28468941
caveolin	28468941
-	28468941
1	28468941
with	28468941
mutated	28468941
caveolin	28468941
-	28468941
1	28468941
restored	28468941
the	28468941
ability	28468941
to	28468941
form	28468941
caveolae	28468941
.	28468941

Importantly	28468941
,	28468941
fibroblasts	28468941
carrying	28468941
the	28468941
mutation	28468941
showed	28468941
twofold	28468941
increase	28468941
in	28468941
proliferation	28468941
rate	28468941
associated	28468941
with	28468941
hyperphosphorylation	28468941
of	28468941
Smad1	28468941
/	28468941
5	28468941
/	28468941
8	28468941
.	28468941

This	28468941
mutation	28468941
impaired	28468941
the	28468941
antiproliferative	28468941
function	28468941
of	28468941
caveolin	28468941
-	28468941
1	28468941
.	28468941

Inhibition	28468941
of	28468941
type	28468941
I	28468941
TGFb	28468941
receptors	28468941
ALK1	28468941
/	28468941
2	28468941
/	28468941
3	28468941
/	28468941
6	28468941
responsible	28468941
for	28468941
phosphorylation	28468941
of	28468941
Smad1	28468941
/	28468941
5	28468941
/	28468941
8	28468941
reduced	28468941
the	28468941
hyperproliferation	28468941
seen	28468941
in	28468941
c	28468941
.	28468941
474delA	28468941
fibroblasts	28468941
.	28468941

These	28468941
results	28468941
demonstrate	28468941
the	28468941
critical	28468941
role	28468941
of	28468941
the	28468941
final	28468941
20	28468941
amino	28468941
acids	28468941
of	28468941
caveolin	28468941
-	28468941
1	28468941
in	28468941
modulating	28468941
fibroblast	28468941
proliferation	28468941
by	28468941
dampening	28468941
Smad	28468941
signaling	28468941
and	28468941
suggest	28468941
that	28468941
augmented	28468941
Smad	28468941
signaling	28468941
and	28468941
fibroblast	28468941
hyperproliferation	28468941
are	28468941
contributing	28468941
factors	28468941
in	28468941
the	28468941
pathogenesis	28468941
of	28468941
PAH	28468941
in	28468941
patients	28468941
with	28468941
caveolin	28468941
-	28468941
1	28468941
c	28468941
.	28468941
474delA	28468941
mutation	28468941
.	28468941
Mutations	28584052
in	28584052
N	28584052
-	28584052
acetylglucosamine	28584052
(	28584052
O	28584052
-	28584052
GlcNAc	28584052
)	28584052
transferase	28584052
in	28584052
patients	28584052
with	28584052
X	28584052
-	28584052
linked	28584052
intellectual	28584052
disability	28584052
.	28584052

N	28584052
-	28584052
Acetylglucosamine	28584052
(	28584052
O	28584052
-	28584052
GlcNAc	28584052
)	28584052
transferase	28584052
(	28584052
OGT	28584052
)	28584052
regulates	28584052
protein	28584052
O	28584052
-	28584052
GlcNAcylation	28584052
,	28584052
an	28584052
essential	28584052
and	28584052
dynamic	28584052
post	28584052
-	28584052
translational	28584052
modification	28584052
.	28584052

The	28584052
O	28584052
-	28584052
GlcNAc	28584052
modification	28584052
is	28584052
present	28584052
on	28584052
numerous	28584052
nuclear	28584052
and	28584052
cytosolic	28584052
proteins	28584052
and	28584052
has	28584052
been	28584052
implicated	28584052
in	28584052
essential	28584052
cellular	28584052
functions	28584052
such	28584052
as	28584052
signaling	28584052
and	28584052
gene	28584052
expression	28584052
.	28584052

Accordingly	28584052
,	28584052
altered	28584052
levels	28584052
of	28584052
protein	28584052
O	28584052
-	28584052
GlcNAcylation	28584052
have	28584052
been	28584052
associated	28584052
with	28584052
developmental	28584052
defects	28584052
and	28584052
neurodegeneration	28584052
.	28584052

However	28584052
,	28584052
mutations	28584052
in	28584052
the	28584052
OGT	28584052
gene	28584052
have	28584052
not	28584052
yet	28584052
been	28584052
functionally	28584052
confirmed	28584052
in	28584052
humans	28584052
.	28584052

Here	28584052
,	28584052
we	28584052
report	28584052
on	28584052
two	28584052
hemizygous	28584052
mutations	28584052
in	28584052
OGT	28584052
in	28584052
individuals	28584052
with	28584052
X	28584052
-	28584052
linked	28584052
intellectual	28584052
disability	28584052
(	28584052
XLID	28584052
)	28584052
and	28584052
dysmorphic	28584052
features	28584052
:	28584052
one	28584052
missense	28584052
mutation	28584052
(	28584052
p	28584052
.	28584052
Arg284Pro	28584052
)	28584052
and	28584052
one	28584052
mutation	28584052
leading	28584052
to	28584052
a	28584052
splicing	28584052
defect	28584052
(	28584052
c	28584052
.	28584052
463	28584052
-	28584052
6T	28584052
>	28584052
G	28584052
)	28584052
.	28584052

Both	28584052
mutations	28584052
reside	28584052
in	28584052
the	28584052
tetratricopeptide	28584052
repeats	28584052
of	28584052
OGT	28584052
that	28584052
are	28584052
essential	28584052
for	28584052
substrate	28584052
recognition	28584052
.	28584052

We	28584052
observed	28584052
slightly	28584052
reduced	28584052
levels	28584052
of	28584052
OGT	28584052
protein	28584052
and	28584052
reduced	28584052
levels	28584052
of	28584052
its	28584052
opposing	28584052
enzyme	28584052
O	28584052
-	28584052
GlcNAcase	28584052
in	28584052
both	28584052
patient	28584052
-	28584052
derived	28584052
fibroblasts	28584052
,	28584052
but	28584052
global	28584052
O	28584052
-	28584052
GlcNAc	28584052
levels	28584052
appeared	28584052
to	28584052
be	28584052
unaffected	28584052
.	28584052

Our	28584052
data	28584052
suggest	28584052
that	28584052
mutant	28584052
cells	28584052
attempt	28584052
to	28584052
maintain	28584052
global	28584052
O	28584052
-	28584052
GlcNAcylation	28584052
by	28584052
down	28584052
-	28584052
regulating	28584052
O	28584052
-	28584052
GlcNAcase	28584052
expression	28584052
.	28584052

We	28584052
also	28584052
found	28584052
that	28584052
the	28584052
c	28584052
.	28584052
463	28584052
-	28584052
6T	28584052
>	28584052
G	28584052
mutation	28584052
leads	28584052
to	28584052
aberrant	28584052
mRNA	28584052
splicing	28584052
,	28584052
but	28584052
no	28584052
stable	28584052
truncated	28584052
protein	28584052
was	28584052
detected	28584052
in	28584052
the	28584052
corresponding	28584052
patient	28584052
-	28584052
derived	28584052
fibroblasts	28584052
.	28584052

Recombinant	28584052
OGT	28584052
bearing	28584052
the	28584052
p	28584052
.	28584052
Arg284Pro	28584052
mutation	28584052
was	28584052
prone	28584052
to	28584052
unfolding	28584052
and	28584052
exhibited	28584052
reduced	28584052
glycosylation	28584052
activity	28584052
against	28584052
a	28584052
complex	28584052
array	28584052
of	28584052
glycosylation	28584052
substrates	28584052
and	28584052
proteolytic	28584052
processing	28584052
of	28584052
the	28584052
transcription	28584052
factor	28584052
host	28584052
cell	28584052
factor	28584052
1	28584052
,	28584052
which	28584052
is	28584052
also	28584052
encoded	28584052
by	28584052
an	28584052
XLID	28584052
-	28584052
associated	28584052
gene	28584052
.	28584052

We	28584052
conclude	28584052
that	28584052
defects	28584052
in	28584052
O	28584052
-	28584052
GlcNAc	28584052
homeostasis	28584052
and	28584052
host	28584052
cell	28584052
factor	28584052
1	28584052
proteolysis	28584052
may	28584052
play	28584052
roles	28584052
in	28584052
mediation	28584052
of	28584052
XLID	28584052
in	28584052
individuals	28584052
with	28584052
OGT	28584052
mutations	28584052
.	28584052
Cardiovascular	7468724
complications	7468724
associated	7468724
with	7468724
terbutaline	7468724
treatment	7468724
for	7468724
preterm	7468724
labor	7468724
.	7468724

Severe	7468724
cardiovascular	7468724
complications	7468724
occurred	7468724
in	7468724
eight	7468724
of	7468724
160	7468724
patients	7468724
treated	7468724
with	7468724
terbutaline	7468724
for	7468724
preterm	7468724
labor	7468724
.	7468724

Associated	7468724
corticosteroid	7468724
therapy	7468724
and	7468724
twin	7468724
gestations	7468724
appear	7468724
to	7468724
be	7468724
predisposing	7468724
factors	7468724
.	7468724

Potential	7468724
mechanisms	7468724
of	7468724
the	7468724
pathophysiology	7468724
are	7468724
briefly	7468724
discussed	7468724
.	7468724
Long	24055495
-	24055495
term	24055495
oral	24055495
galactose	24055495
treatment	24055495
prevents	24055495
cognitive	24055495
deficits	24055495
in	24055495
male	24055495
Wistar	24055495
rats	24055495
treated	24055495
intracerebroventricularly	24055495
with	24055495
streptozotocin	24055495
.	24055495

Basic	24055495
and	24055495
clinical	24055495
research	24055495
has	24055495
demonstrated	24055495
that	24055495
dementia	24055495
of	24055495
sporadic	24055495
Alzheimer	24055495
'	24055495
s	24055495
disease	24055495
(	24055495
sAD	24055495
)	24055495
type	24055495
is	24055495
associated	24055495
with	24055495
dysfunction	24055495
of	24055495
the	24055495
insulin	24055495
-	24055495
receptor	24055495
(	24055495
IR	24055495
)	24055495
system	24055495
followed	24055495
by	24055495
decreased	24055495
glucose	24055495
transport	24055495
via	24055495
glucose	24055495
transporter	24055495
GLUT4	24055495
and	24055495
decreased	24055495
glucose	24055495
metabolism	24055495
in	24055495
brain	24055495
cells	24055495
.	24055495

An	24055495
alternative	24055495
source	24055495
of	24055495
energy	24055495
is	24055495
d	24055495
-	24055495
galactose	24055495
(	24055495
the	24055495
C	24055495
-	24055495
4	24055495
-	24055495
epimer	24055495
of	24055495
d	24055495
-	24055495
glucose	24055495
)	24055495
which	24055495
is	24055495
transported	24055495
into	24055495
the	24055495
brain	24055495
by	24055495
insulin	24055495
-	24055495
independent	24055495
GLUT3	24055495
transporter	24055495
where	24055495
it	24055495
might	24055495
be	24055495
metabolized	24055495
to	24055495
glucose	24055495
via	24055495
the	24055495
Leloir	24055495
pathway	24055495
.	24055495

Exclusively	24055495
parenteral	24055495
daily	24055495
injections	24055495
of	24055495
galactose	24055495
induce	24055495
memory	24055495
deterioration	24055495
in	24055495
rodents	24055495
and	24055495
are	24055495
used	24055495
to	24055495
generate	24055495
animal	24055495
aging	24055495
model	24055495
,	24055495
but	24055495
the	24055495
effects	24055495
of	24055495
oral	24055495
galactose	24055495
treatment	24055495
on	24055495
cognitive	24055495
functions	24055495
have	24055495
never	24055495
been	24055495
tested	24055495
.	24055495

We	24055495
have	24055495
investigated	24055495
the	24055495
effects	24055495
of	24055495
continuous	24055495
daily	24055495
oral	24055495
galactose	24055495
(	24055495
200	24055495
mg	24055495
/	24055495
kg	24055495
/	24055495
day	24055495
)	24055495
treatment	24055495
on	24055495
cognitive	24055495
deficits	24055495
in	24055495
streptozotocin	24055495
-	24055495
induced	24055495
(	24055495
STZ	24055495
-	24055495
icv	24055495
)	24055495
rat	24055495
model	24055495
of	24055495
sAD	24055495
,	24055495
tested	24055495
by	24055495
Morris	24055495
Water	24055495
Maze	24055495
and	24055495
Passive	24055495
Avoidance	24055495
test	24055495
,	24055495
respectively	24055495
.	24055495

One	24055495
month	24055495
of	24055495
oral	24055495
galactose	24055495
treatment	24055495
initiated	24055495
immediately	24055495
after	24055495
the	24055495
STZ	24055495
-	24055495
icv	24055495
administration	24055495
,	24055495
successfully	24055495
prevented	24055495
development	24055495
of	24055495
the	24055495
STZ	24055495
-	24055495
icv	24055495
-	24055495
induced	24055495
cognitive	24055495
deficits	24055495
.	24055495

Beneficial	24055495
effect	24055495
of	24055495
oral	24055495
galactose	24055495
was	24055495
independent	24055495
of	24055495
the	24055495
rat	24055495
age	24055495
and	24055495
of	24055495
the	24055495
galactose	24055495
dose	24055495
ranging	24055495
from	24055495
100	24055495
to	24055495
300	24055495
mg	24055495
/	24055495
kg	24055495
/	24055495
day	24055495
.	24055495

Additionally	24055495
,	24055495
oral	24055495
galactose	24055495
administration	24055495
led	24055495
to	24055495
the	24055495
appearance	24055495
of	24055495
galactose	24055495
in	24055495
the	24055495
blood	24055495
.	24055495

The	24055495
increase	24055495
of	24055495
galactose	24055495
concentration	24055495
in	24055495
the	24055495
cerebrospinal	24055495
fluid	24055495
was	24055495
several	24055495
times	24055495
lower	24055495
after	24055495
oral	24055495
than	24055495
after	24055495
parenteral	24055495
administration	24055495
of	24055495
the	24055495
same	24055495
galactose	24055495
dose	24055495
.	24055495

Oral	24055495
galactose	24055495
exposure	24055495
might	24055495
have	24055495
beneficial	24055495
effects	24055495
on	24055495
learning	24055495
and	24055495
memory	24055495
ability	24055495
and	24055495
could	24055495
be	24055495
worth	24055495
investigating	24055495
for	24055495
improvement	24055495
of	24055495
cognitive	24055495
deficits	24055495
associated	24055495
with	24055495
glucose	24055495
hypometabolism	24055495
in	24055495
AD	24055495
.	24055495
Biophysical	28398555
and	28398555
functional	28398555
characterization	28398555
of	28398555
hippocalcin	28398555
mutants	28398555
responsible	28398555
for	28398555
human	28398555
dystonia	28398555
.	28398555

Dystonia	28398555
is	28398555
a	28398555
neurological	28398555
movement	28398555
disorder	28398555
that	28398555
forces	28398555
the	28398555
body	28398555
into	28398555
twisting	28398555
,	28398555
repetitive	28398555
movements	28398555
or	28398555
sometimes	28398555
painful	28398555
abnormal	28398555
postures	28398555
.	28398555

With	28398555
the	28398555
advent	28398555
of	28398555
next	28398555
-	28398555
generation	28398555
sequencing	28398555
technologies	28398555
,	28398555
the	28398555
homozygous	28398555
mutations	28398555
T71N	28398555
and	28398555
A190T	28398555
in	28398555
the	28398555
neuronal	28398555
calcium	28398555
sensor	28398555
(	28398555
NCS	28398555
)	28398555
hippocalcin	28398555
were	28398555
identified	28398555
as	28398555
the	28398555
genetic	28398555
cause	28398555
of	28398555
primary	28398555
isolated	28398555
dystonia	28398555
(	28398555
DYT2	28398555
dystonia	28398555
)	28398555
.	28398555

However	28398555
,	28398555
the	28398555
effect	28398555
of	28398555
these	28398555
mutations	28398555
on	28398555
the	28398555
physiological	28398555
role	28398555
of	28398555
hippocalcin	28398555
has	28398555
not	28398555
yet	28398555
been	28398555
elucidated	28398555
.	28398555

Using	28398555
a	28398555
multidisciplinary	28398555
approach	28398555
,	28398555
we	28398555
demonstrated	28398555
that	28398555
hippocalcin	28398555
oligomerises	28398555
in	28398555
a	28398555
calcium	28398555
-	28398555
dependent	28398555
manner	28398555
and	28398555
binds	28398555
to	28398555
voltage	28398555
-	28398555
gated	28398555
calcium	28398555
channels	28398555
.	28398555

Mutations	28398555
T71N	28398555
and	28398555
A190T	28398555
in	28398555
hippocalcin	28398555
did	28398555
not	28398555
affect	28398555
stability	28398555
,	28398555
calcium	28398555
-	28398555
binding	28398555
affinity	28398555
or	28398555
translocation	28398555
to	28398555
cellular	28398555
membranes	28398555
(	28398555
Ca2	28398555
+	28398555
/	28398555
myristoyl	28398555
switch	28398555
)	28398555
.	28398555

We	28398555
obtained	28398555
the	28398555
first	28398555
crystal	28398555
structure	28398555
of	28398555
hippocalcin	28398555
and	28398555
alignment	28398555
with	28398555
other	28398555
NCS	28398555
proteins	28398555
showed	28398555
significant	28398555
variability	28398555
in	28398555
the	28398555
orientation	28398555
of	28398555
the	28398555
C	28398555
-	28398555
terminal	28398555
part	28398555
of	28398555
the	28398555
molecule	28398555
,	28398555
the	28398555
region	28398555
expected	28398555
to	28398555
be	28398555
important	28398555
for	28398555
target	28398555
binding	28398555
.	28398555

We	28398555
demonstrated	28398555
that	28398555
the	28398555
disease	28398555
-	28398555
causing	28398555
mutations	28398555
did	28398555
not	28398555
affect	28398555
the	28398555
structure	28398555
of	28398555
the	28398555
protein	28398555
,	28398555
however	28398555
both	28398555
mutants	28398555
showed	28398555
a	28398555
defect	28398555
in	28398555
oligomerisation	28398555
.	28398555

In	28398555
addition	28398555
,	28398555
we	28398555
observed	28398555
an	28398555
increased	28398555
calcium	28398555
influx	28398555
in	28398555
KCl	28398555
-	28398555
depolarised	28398555
cells	28398555
expressing	28398555
mutated	28398555
hippocalcin	28398555
,	28398555
mostly	28398555
driven	28398555
by	28398555
N	28398555
-	28398555
type	28398555
voltage	28398555
-	28398555
gated	28398555
calcium	28398555
channels	28398555
.	28398555

Our	28398555
data	28398555
demonstrate	28398555
that	28398555
the	28398555
dystonia	28398555
-	28398555
causing	28398555
mutations	28398555
strongly	28398555
affect	28398555
hippocalcin	28398555
cellular	28398555
functions	28398555
which	28398555
suggest	28398555
a	28398555
central	28398555
role	28398555
for	28398555
perturbed	28398555
calcium	28398555
signalling	28398555
in	28398555
DYT2	28398555
dystonia	28398555
.	28398555
Primary	15649253
malignant	15649253
lymphoma	15649253
of	15649253
the	15649253
brain	15649253
:	15649253
frequent	15649253
abnormalities	15649253
and	15649253
inactivation	15649253
of	15649253
p14	15649253
tumor	15649253
suppressor	15649253
gene	15649253
.	15649253

Ten	15649253
primary	15649253
central	15649253
nervous	15649253
system	15649253
lymphomas	15649253
(	15649253
PCNSL	15649253
,	15649253
brain	15649253
lymphomas	15649253
)	15649253
were	15649253
examined	15649253
for	15649253
p14	15649253
gene	15649253
exon	15649253
1beta	15649253
deletion	15649253
,	15649253
mutation	15649253
and	15649253
methylation	15649253
by	15649253
Southern	15649253
blot	15649253
analysis	15649253
,	15649253
nucleotide	15649253
analysis	15649253
of	15649253
polymerase	15649253
chain	15649253
reaction	15649253
clones	15649253
and	15649253
Southern	15649253
blot	15649253
-	15649253
based	15649253
methylation	15649253
assay	15649253
.	15649253

In	15649253
Southern	15649253
blot	15649253
analysis	15649253
,	15649253
from	15649253
the	15649253
signal	15649253
densities	15649253
of	15649253
the	15649253
hybridized	15649253
bands	15649253
and	15649253
their	15649253
similarities	15649253
to	15649253
those	15649253
of	15649253
exons	15649253
2	15649253
and	15649253
3	15649253
in	15649253
our	15649253
previous	15649253
quantitative	15649253
study	15649253
,	15649253
we	15649253
found	15649253
that	15649253
exon	15649253
1beta	15649253
was	15649253
homozygously	15649253
deleted	15649253
in	15649253
four	15649253
cases	15649253
,	15649253
hemizygously	15649253
deleted	15649253
in	15649253
five	15649253
cases	15649253
and	15649253
not	15649253
deleted	15649253
in	15649253
one	15649253
case	15649253
.	15649253

Thus	15649253
,	15649253
the	15649253
same	15649253
deletion	15649253
patterns	15649253
covered	15649253
the	15649253
entire	15649253
p14	15649253
gene	15649253
for	15649253
all	15649253
cases	15649253
except	15649253
for	15649253
one	15649253
case	15649253
,	15649253
which	15649253
suggested	15649253
the	15649253
hemizygous	15649253
deletion	15649253
of	15649253
exons	15649253
1beta	15649253
and	15649253
2	15649253
and	15649253
homozygous	15649253
deletion	15649253
of	15649253
exon	15649253
3	15649253
.	15649253

In	15649253
addition	15649253
,	15649253
although	15649253
exon	15649253
1beta	15649253
mutation	15649253
is	15649253
rare	15649253
in	15649253
various	15649253
tumors	15649253
,	15649253
we	15649253
detected	15649253
a	15649253
missense	15649253
mutation	15649253
(	15649253
L50R	15649253
)	15649253
in	15649253
one	15649253
case	15649253
with	15649253
a	15649253
hemizygous	15649253
deletion	15649253
.	15649253

Methylation	15649253
of	15649253
the	15649253
5	15649253
'	15649253
CpG	15649253
island	15649253
of	15649253
the	15649253
p14	15649253
gene	15649253
was	15649253
not	15649253
suggested	15649253
for	15649253
any	15649253
case	15649253
without	15649253
homozygous	15649253
deletion	15649253
.	15649253

Our	15649253
observation	15649253
of	15649253
frequent	15649253
p14	15649253
gene	15649253
abnormalities	15649253
(	15649253
90%	15649253
)	15649253
and	15649253
inactivation	15649253
(	15649253
40	15649253
-	15649253
60%	15649253
)	15649253
was	15649253
in	15649253
striking	15649253
contrast	15649253
to	15649253
the	15649253
same	15649253
pathological	15649253
subtype	15649253
of	15649253
systemic	15649253
lymphoma	15649253
in	15649253
which	15649253
p14	15649253
gene	15649253
abnormalities	15649253
and	15649253
inactivation	15649253
were	15649253
infrequent	15649253
,	15649253
suggesting	15649253
a	15649253
difference	15649253
in	15649253
carcinogenesis	15649253
between	15649253
PCNSL	15649253
and	15649253
systemic	15649253
lymphoma	15649253
.	15649253
Learning	19631624
and	19631624
memory	19631624
deficits	19631624
in	19631624
ecstasy	19631624
users	19631624
and	19631624
their	19631624
neural	19631624
correlates	19631624
during	19631624
a	19631624
face	19631624
-	19631624
learning	19631624
task	19631624
.	19631624

It	19631624
has	19631624
been	19631624
consistently	19631624
shown	19631624
that	19631624
ecstasy	19631624
users	19631624
display	19631624
impairments	19631624
in	19631624
learning	19631624
and	19631624
memory	19631624
performance	19631624
.	19631624

In	19631624
addition	19631624
,	19631624
working	19631624
memory	19631624
processing	19631624
in	19631624
ecstasy	19631624
users	19631624
has	19631624
been	19631624
shown	19631624
to	19631624
be	19631624
associated	19631624
with	19631624
neural	19631624
alterations	19631624
in	19631624
hippocampal	19631624
and	19631624
/	19631624
or	19631624
cortical	19631624
regions	19631624
as	19631624
measured	19631624
by	19631624
functional	19631624
magnetic	19631624
resonance	19631624
imaging	19631624
(	19631624
fMRI	19631624
)	19631624
.	19631624

Using	19631624
functional	19631624
imaging	19631624
and	19631624
a	19631624
face	19631624
-	19631624
learning	19631624
task	19631624
,	19631624
we	19631624
investigated	19631624
neural	19631624
correlates	19631624
of	19631624
encoding	19631624
and	19631624
recalling	19631624
face	19631624
-	19631624
name	19631624
associations	19631624
in	19631624
20	19631624
recreational	19631624
drug	19631624
users	19631624
whose	19631624
predominant	19631624
drug	19631624
use	19631624
was	19631624
ecstasy	19631624
and	19631624
20	19631624
controls	19631624
.	19631624

To	19631624
address	19631624
the	19631624
potential	19631624
confounding	19631624
effects	19631624
of	19631624
the	19631624
cannabis	19631624
use	19631624
of	19631624
the	19631624
ecstasy	19631624
using	19631624
group	19631624
,	19631624
a	19631624
second	19631624
analysis	19631624
included	19631624
14	19631624
previously	19631624
tested	19631624
cannabis	19631624
users	19631624
(	19631624
Nestor	19631624
,	19631624
L	19631624
.	19631624
,	19631624
Roberts	19631624
,	19631624
G	19631624
.	19631624
,	19631624
Garavan	19631624
,	19631624
H	19631624
.	19631624
,	19631624
Hester	19631624
,	19631624
R	19631624
.	19631624
,	19631624
2008	19631624
.	19631624

Deficits	19631624
in	19631624
learning	19631624
and	19631624
memory	19631624
:	19631624
parahippocampal	19631624
hyperactivity	19631624
and	19631624
frontocortical	19631624
hypoactivity	19631624
in	19631624
cannabis	19631624
users	19631624
.	19631624

Neuroimage	19631624
40	19631624
,	19631624
1328	19631624
-	19631624
1339	19631624
)	19631624
.	19631624

Ecstasy	19631624
users	19631624
performed	19631624
significantly	19631624
worse	19631624
in	19631624
learning	19631624
and	19631624
memory	19631624
compared	19631624
to	19631624
controls	19631624
and	19631624
cannabis	19631624
users	19631624
.	19631624

A	19631624
conjunction	19631624
analysis	19631624
of	19631624
the	19631624
encode	19631624
and	19631624
recall	19631624
phases	19631624
of	19631624
the	19631624
task	19631624
revealed	19631624
ecstasy	19631624
-	19631624
specific	19631624
hyperactivity	19631624
in	19631624
bilateral	19631624
frontal	19631624
regions	19631624
,	19631624
left	19631624
temporal	19631624
,	19631624
right	19631624
parietal	19631624
,	19631624
bilateral	19631624
temporal	19631624
,	19631624
and	19631624
bilateral	19631624
occipital	19631624
brain	19631624
regions	19631624
.	19631624

Ecstasy	19631624
-	19631624
specific	19631624
hypoactivity	19631624
was	19631624
evident	19631624
in	19631624
the	19631624
right	19631624
dorsal	19631624
anterior	19631624
cingulated	19631624
cortex	19631624
(	19631624
ACC	19631624
)	19631624
and	19631624
left	19631624
posterior	19631624
cingulated	19631624
cortex	19631624
.	19631624

In	19631624
both	19631624
ecstasy	19631624
and	19631624
cannabis	19631624
groups	19631624
brain	19631624
activation	19631624
was	19631624
decreased	19631624
in	19631624
the	19631624
right	19631624
medial	19631624
frontal	19631624
gyrus	19631624
,	19631624
left	19631624
parahippocampal	19631624
gyrus	19631624
,	19631624
left	19631624
dorsal	19631624
cingulate	19631624
gyrus	19631624
,	19631624
and	19631624
left	19631624
caudate	19631624
.	19631624

These	19631624
results	19631624
elucidated	19631624
ecstasy	19631624
-	19631624
related	19631624
deficits	19631624
,	19631624
only	19631624
some	19631624
of	19631624
which	19631624
might	19631624
be	19631624
attributed	19631624
to	19631624
cannabis	19631624
use	19631624
.	19631624

These	19631624
ecstasy	19631624
-	19631624
specific	19631624
effects	19631624
may	19631624
be	19631624
related	19631624
to	19631624
the	19631624
vulnerability	19631624
of	19631624
isocortical	19631624
and	19631624
allocortical	19631624
regions	19631624
to	19631624
the	19631624
neurotoxic	19631624
effects	19631624
of	19631624
ecstasy	19631624
.	19631624
Variation	22051099
in	22051099
the	22051099
CXCR1	22051099
gene	22051099
(	22051099
IL8RA	22051099
)	22051099
is	22051099
not	22051099
associated	22051099
with	22051099
susceptibility	22051099
to	22051099
chronic	22051099
periodontitis	22051099
.	22051099

BACKGROUND	22051099
:	22051099
The	22051099
chemokine	22051099
receptor	22051099
1	22051099
CXCR	22051099
-	22051099
1	22051099
(	22051099
or	22051099
IL8R	22051099
-	22051099
alpha	22051099
)	22051099
is	22051099
a	22051099
specific	22051099
receptor	22051099
for	22051099
the	22051099
interleukin	22051099
8	22051099
(	22051099
IL	22051099
-	22051099
8	22051099
)	22051099
,	22051099
which	22051099
is	22051099
chemoattractant	22051099
for	22051099
neutrophils	22051099
and	22051099
has	22051099
an	22051099
important	22051099
role	22051099
in	22051099
the	22051099
inflammatory	22051099
response	22051099
.	22051099

The	22051099
polymorphism	22051099
rs2234671	22051099
at	22051099
position	22051099
Ex2	22051099
+	22051099
860G	22051099
>	22051099
C	22051099
of	22051099
the	22051099
CXCR1	22051099
gene	22051099
causes	22051099
a	22051099
conservative	22051099
amino	22051099
acid	22051099
substitution	22051099
(	22051099
S276T	22051099
)	22051099
.	22051099

This	22051099
single	22051099
nucleotide	22051099
polymorphism	22051099
(	22051099
SNP	22051099
)	22051099
seemed	22051099
to	22051099
be	22051099
functional	22051099
as	22051099
it	22051099
was	22051099
associated	22051099
with	22051099
decreased	22051099
lung	22051099
cancer	22051099
risk	22051099
.	22051099

Previous	22051099
studies	22051099
of	22051099
our	22051099
group	22051099
found	22051099
association	22051099
of	22051099
haplotypes	22051099
in	22051099
the	22051099
IL8	22051099
and	22051099
in	22051099
the	22051099
CXCR2	22051099
genes	22051099
with	22051099
the	22051099
multifactorial	22051099
disease	22051099
chronic	22051099
periodontitis	22051099
.	22051099

In	22051099
this	22051099
study	22051099
we	22051099
investigated	22051099
the	22051099
polymorphism	22051099
rs2234671	22051099
in	22051099
395	22051099
Brazilian	22051099
subjects	22051099
with	22051099
and	22051099
without	22051099
chronic	22051099
periodontitis	22051099
.	22051099

FINDINGS	22051099
:	22051099
Similar	22051099
distribution	22051099
of	22051099
the	22051099
allelic	22051099
and	22051099
genotypic	22051099
frequencies	22051099
were	22051099
observed	22051099
between	22051099
the	22051099
groups	22051099
(	22051099
p	22051099
>	22051099
0	22051099
.	22051099
05	22051099
)	22051099
.	22051099

CONCLUSIONS	22051099
:	22051099
The	22051099
polymorphism	22051099
rs2234671	22051099
in	22051099
the	22051099
CXCR1	22051099
gene	22051099
was	22051099
not	22051099
associated	22051099
with	22051099
the	22051099
susceptibility	22051099
to	22051099
chronic	22051099
periodontitis	22051099
in	22051099
the	22051099
studied	22051099
Brazilian	22051099
population	22051099
.	22051099
Disease	28883039
-	28883039
associated	28883039
mutations	28883039
in	28883039
human	28883039
BICD2	28883039
hyperactivate	28883039
motility	28883039
of	28883039
dynein	28883039
-	28883039
dynactin	28883039
.	28883039

Bicaudal	28883039
D2	28883039
(	28883039
BICD2	28883039
)	28883039
joins	28883039
dynein	28883039
with	28883039
dynactin	28883039
into	28883039
a	28883039
ternary	28883039
complex	28883039
(	28883039
termed	28883039
DDB	28883039
)	28883039
capable	28883039
of	28883039
processive	28883039
movement	28883039
.	28883039

Point	28883039
mutations	28883039
in	28883039
the	28883039
BICD2	28883039
gene	28883039
have	28883039
been	28883039
identified	28883039
in	28883039
patients	28883039
with	28883039
a	28883039
dominant	28883039
form	28883039
of	28883039
spinal	28883039
muscular	28883039
atrophy	28883039
,	28883039
but	28883039
how	28883039
these	28883039
mutations	28883039
cause	28883039
disease	28883039
is	28883039
unknown	28883039
.	28883039

To	28883039
investigate	28883039
this	28883039
question	28883039
,	28883039
we	28883039
have	28883039
developed	28883039
in	28883039
vitro	28883039
motility	28883039
assays	28883039
with	28883039
purified	28883039
DDB	28883039
and	28883039
BICD2	28883039
'	28883039
s	28883039
membrane	28883039
vesicle	28883039
partner	28883039
,	28883039
the	28883039
GTPase	28883039
Rab6a	28883039
.	28883039

Rab6a	28883039
-	28883039
GTP	28883039
,	28883039
either	28883039
in	28883039
solution	28883039
or	28883039
bound	28883039
to	28883039
artificial	28883039
liposomes	28883039
,	28883039
released	28883039
BICD2	28883039
from	28883039
an	28883039
autoinhibited	28883039
state	28883039
and	28883039
promoted	28883039
robust	28883039
dynein	28883039
-	28883039
dynactin	28883039
transport	28883039
.	28883039

In	28883039
these	28883039
assays	28883039
,	28883039
BICD2	28883039
mutants	28883039
showed	28883039
an	28883039
enhanced	28883039
ability	28883039
to	28883039
form	28883039
motile	28883039
DDB	28883039
complexes	28883039
.	28883039

Increased	28883039
retrograde	28883039
transport	28883039
by	28883039
BICD2	28883039
mutants	28883039
also	28883039
was	28883039
observed	28883039
in	28883039
cells	28883039
using	28883039
an	28883039
inducible	28883039
organelle	28883039
transport	28883039
assay	28883039
.	28883039

When	28883039
overexpressed	28883039
in	28883039
rat	28883039
hippocampal	28883039
neurons	28883039
,	28883039
the	28883039
hyperactive	28883039
BICD2	28883039
mutants	28883039
decreased	28883039
neurite	28883039
growth	28883039
.	28883039

Our	28883039
results	28883039
reveal	28883039
that	28883039
dominant	28883039
mutations	28883039
in	28883039
BICD2	28883039
hyperactivate	28883039
DDB	28883039
motility	28883039
and	28883039
suggest	28883039
that	28883039
an	28883039
imbalance	28883039
of	28883039
minus	28883039
versus	28883039
plus	28883039
end	28883039
-	28883039
directed	28883039
microtubule	28883039
motility	28883039
in	28883039
neurons	28883039
may	28883039
underlie	28883039
spinal	28883039
muscular	28883039
atrophy	28883039
.	28883039
Glucose	15630069
metabolism	15630069
in	15630069
patients	15630069
with	15630069
schizophrenia	15630069
treated	15630069
with	15630069
atypical	15630069
antipsychotic	15630069
agents	15630069
:	15630069
a	15630069
frequently	15630069
sampled	15630069
intravenous	15630069
glucose	15630069
tolerance	15630069
test	15630069
and	15630069
minimal	15630069
model	15630069
analysis	15630069
.	15630069

BACKGROUND	15630069
:	15630069
While	15630069
the	15630069
incidence	15630069
of	15630069
new	15630069
-	15630069
onset	15630069
diabetes	15630069
mellitus	15630069
may	15630069
be	15630069
increasing	15630069
in	15630069
patients	15630069
with	15630069
schizophrenia	15630069
treated	15630069
with	15630069
certain	15630069
atypical	15630069
antipsychotic	15630069
agents	15630069
,	15630069
it	15630069
remains	15630069
unclear	15630069
whether	15630069
atypical	15630069
agents	15630069
are	15630069
directly	15630069
affecting	15630069
glucose	15630069
metabolism	15630069
or	15630069
simply	15630069
increasing	15630069
known	15630069
risk	15630069
factors	15630069
for	15630069
diabetes	15630069
.	15630069

OBJECTIVE	15630069
:	15630069
To	15630069
study	15630069
the	15630069
2	15630069
drugs	15630069
most	15630069
clearly	15630069
implicated	15630069
(	15630069
clozapine	15630069
and	15630069
olanzapine	15630069
)	15630069
and	15630069
risperidone	15630069
using	15630069
a	15630069
frequently	15630069
sampled	15630069
intravenous	15630069
glucose	15630069
tolerance	15630069
test	15630069
.	15630069

DESIGN	15630069
:	15630069
A	15630069
cross	15630069
-	15630069
sectional	15630069
design	15630069
in	15630069
stable	15630069
,	15630069
treated	15630069
patients	15630069
with	15630069
schizophrenia	15630069
evaluated	15630069
using	15630069
a	15630069
frequently	15630069
sampled	15630069
intravenous	15630069
glucose	15630069
tolerance	15630069
test	15630069
and	15630069
the	15630069
Bergman	15630069
minimal	15630069
model	15630069
analysis	15630069
.	15630069

SETTING	15630069
:	15630069
Subjects	15630069
were	15630069
recruited	15630069
from	15630069
an	15630069
urban	15630069
community	15630069
mental	15630069
health	15630069
clinic	15630069
and	15630069
were	15630069
studied	15630069
at	15630069
a	15630069
general	15630069
clinical	15630069
research	15630069
center	15630069
.	15630069

Patients	15630069
Fifty	15630069
subjects	15630069
signed	15630069
informed	15630069
consent	15630069
and	15630069
41	15630069
underwent	15630069
the	15630069
frequently	15630069
sampled	15630069
intravenous	15630069
glucose	15630069
tolerance	15630069
test	15630069
.	15630069

Thirty	15630069
-	15630069
six	15630069
nonobese	15630069
subjects	15630069
with	15630069
schizophrenia	15630069
or	15630069
schizoaffective	15630069
disorder	15630069
,	15630069
matched	15630069
by	15630069
body	15630069
mass	15630069
index	15630069
and	15630069
treated	15630069
with	15630069
either	15630069
clozapine	15630069
,	15630069
olanzapine	15630069
,	15630069
or	15630069
risperidone	15630069
,	15630069
were	15630069
included	15630069
in	15630069
the	15630069
analysis	15630069
.	15630069

MAIN	15630069
OUTCOME	15630069
MEASURES	15630069
:	15630069
Fasting	15630069
plasma	15630069
glucose	15630069
and	15630069
fasting	15630069
serum	15630069
insulin	15630069
levels	15630069
,	15630069
insulin	15630069
sensitivity	15630069
index	15630069
,	15630069
homeostasis	15630069
model	15630069
assessment	15630069
of	15630069
insulin	15630069
resistance	15630069
,	15630069
and	15630069
glucose	15630069
effectiveness	15630069
.	15630069

RESULTS	15630069
:	15630069
The	15630069
mean	15630069
+	15630069
/	15630069
-	15630069
SD	15630069
duration	15630069
of	15630069
treatment	15630069
with	15630069
the	15630069
identified	15630069
atypical	15630069
antipsychotic	15630069
agent	15630069
was	15630069
68	15630069
.	15630069
3	15630069
+	15630069
/	15630069
-	15630069
28	15630069
.	15630069
9	15630069
months	15630069
(	15630069
clozapine	15630069
)	15630069
,	15630069
29	15630069
.	15630069
5	15630069
+	15630069
/	15630069
-	15630069
17	15630069
.	15630069
5	15630069
months	15630069
(	15630069
olanzapine	15630069
)	15630069
,	15630069
and	15630069
40	15630069
.	15630069
9	15630069
+	15630069
/	15630069
-	15630069
33	15630069
.	15630069
7	15630069
(	15630069
risperidone	15630069
)	15630069
.	15630069

Fasting	15630069
serum	15630069
insulin	15630069
concentrations	15630069
differed	15630069
among	15630069
groups	15630069
(	15630069
F	15630069
(	15630069
33	15630069
)	15630069
=	15630069
3	15630069
.	15630069
35	15630069
;	15630069
P	15630069
=	15630069
.	15630069
047	15630069
)	15630069
(	15630069
clozapine	15630069
>	15630069
olanzapine	15630069
>	15630069
risperidone	15630069
)	15630069
with	15630069
significant	15630069
differences	15630069
between	15630069
clozapine	15630069
and	15630069
risperidone	15630069
(	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
2	15630069
.	15630069
32	15630069
;	15630069
P	15630069
=	15630069
.	15630069
03	15630069
)	15630069
and	15630069
olanzapine	15630069
and	15630069
risperidone	15630069
(	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
2	15630069
.	15630069
15	15630069
;	15630069
P	15630069
=	15630069
.	15630069
04	15630069
)	15630069
.	15630069

There	15630069
was	15630069
a	15630069
significant	15630069
difference	15630069
in	15630069
insulin	15630069
sensitivity	15630069
index	15630069
among	15630069
groups	15630069
(	15630069
F	15630069
(	15630069
33	15630069
)	15630069
=	15630069
10	15630069
.	15630069
66	15630069
;	15630069
P	15630069
<	15630069
.	15630069
001	15630069
)	15630069
(	15630069
clozapine	15630069
<	15630069
olanzapine	15630069
<	15630069
risperidone	15630069
)	15630069
,	15630069
with	15630069
subjects	15630069
who	15630069
received	15630069
clozapine	15630069
and	15630069
olanzapine	15630069
exhibiting	15630069
significant	15630069
insulin	15630069
resistance	15630069
compared	15630069
with	15630069
subjects	15630069
who	15630069
were	15630069
treated	15630069
with	15630069
risperidone	15630069
(	15630069
clozapine	15630069
vs	15630069
risperidone	15630069
,	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
-	15630069
4	15630069
.	15630069
29	15630069
;	15630069
P	15630069
<	15630069
.	15630069
001	15630069
;	15630069
olanzapine	15630069
vs	15630069
risperidone	15630069
,	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
-	15630069
3	15630069
.	15630069
62	15630069
;	15630069
P	15630069
=	15630069
.	15630069
001	15630069
[	15630069
P	15630069
<	15630069
.	15630069
001	15630069
]	15630069
)	15630069
.	15630069

The	15630069
homeostasis	15630069
model	15630069
assessment	15630069
of	15630069
insulin	15630069
resistance	15630069
also	15630069
differed	15630069
significantly	15630069
among	15630069
groups	15630069
(	15630069
F	15630069
(	15630069
33	15630069
)	15630069
=	15630069
4	15630069
.	15630069
92	15630069
;	15630069
P	15630069
=	15630069
.	15630069
01	15630069
)	15630069
(	15630069
clozapine	15630069
>	15630069
olanzapine	15630069
>	15630069
risperidone	15630069
)	15630069
(	15630069
clozapine	15630069
vs	15630069
risperidone	15630069
,	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
2	15630069
.	15630069
94	15630069
;	15630069
P	15630069
=	15630069
.	15630069
006	15630069
;	15630069
olanzapine	15630069
vs	15630069
risperidone	15630069
,	15630069
t	15630069
(	15630069
33	15630069
)	15630069
=	15630069
2	15630069
.	15630069
42	15630069
;	15630069
P	15630069
=	15630069
.	15630069
02	15630069
)	15630069
.	15630069

There	15630069
was	15630069
a	15630069
significant	15630069
difference	15630069
among	15630069
groups	15630069
in	15630069
glucose	15630069
effectiveness	15630069
(	15630069
F	15630069
(	15630069
30	15630069
)	15630069
=	15630069
4	15630069
.	15630069
18	15630069
;	15630069
P	15630069
=	15630069
.	15630069
02	15630069
)	15630069
(	15630069
clozapine	15630069
<	15630069
olanzapine	15630069
<	15630069
risperidone	15630069
)	15630069
with	15630069
significant	15630069
differences	15630069
between	15630069
clozapine	15630069
and	15630069
risperidone	15630069
(	15630069
t	15630069
(	15630069
30	15630069
)	15630069
=	15630069
-	15630069
2	15630069
.	15630069
59	15630069
;	15630069
P	15630069
=	15630069
.	15630069
02	15630069
)	15630069
and	15630069
olanzapine	15630069
and	15630069
risperidone	15630069
(	15630069
t	15630069
(	15630069
30	15630069
)	15630069
=	15630069
-	15630069
2	15630069
.	15630069
34	15630069
,	15630069
P	15630069
=	15630069
.	15630069
03	15630069
)	15630069
.	15630069

CONCLUSIONS	15630069
:	15630069
Both	15630069
nonobese	15630069
clozapine	15630069
-	15630069
and	15630069
olanzapine	15630069
-	15630069
treated	15630069
groups	15630069
displayed	15630069
significant	15630069
insulin	15630069
resistance	15630069
and	15630069
impairment	15630069
of	15630069
glucose	15630069
effectiveness	15630069
compared	15630069
with	15630069
risperidone	15630069
-	15630069
treated	15630069
subjects	15630069
.	15630069

Patients	15630069
taking	15630069
clozapine	15630069
and	15630069
olanzapine	15630069
must	15630069
be	15630069
examined	15630069
for	15630069
insulin	15630069
resistance	15630069
and	15630069
its	15630069
consequences	15630069
.	15630069
Debrisoquine	1848636
phenotype	1848636
and	1848636
the	1848636
pharmacokinetics	1848636
and	1848636
beta	1848636
-	1848636
2	1848636
receptor	1848636
pharmacodynamics	1848636
of	1848636
metoprolol	1848636
and	1848636
its	1848636
enantiomers	1848636
.	1848636

The	1848636
metabolism	1848636
of	1848636
the	1848636
cardioselective	1848636
beta	1848636
-	1848636
blocker	1848636
metoprolol	1848636
is	1848636
under	1848636
genetic	1848636
control	1848636
of	1848636
the	1848636
debrisoquine	1848636
/	1848636
sparteine	1848636
type	1848636
.	1848636

The	1848636
two	1848636
metabolic	1848636
phenotypes	1848636
,	1848636
extensive	1848636
(	1848636
EM	1848636
)	1848636
and	1848636
poor	1848636
metabolizers	1848636
(	1848636
PM	1848636
)	1848636
,	1848636
show	1848636
different	1848636
stereoselective	1848636
metabolism	1848636
,	1848636
resulting	1848636
in	1848636
apparently	1848636
higher	1848636
beta	1848636
-	1848636
1	1848636
adrenoceptor	1848636
antagonistic	1848636
potency	1848636
of	1848636
racemic	1848636
metoprolol	1848636
in	1848636
EMs	1848636
.	1848636

We	1848636
investigated	1848636
if	1848636
the	1848636
latter	1848636
also	1848636
applies	1848636
to	1848636
the	1848636
beta	1848636
-	1848636
2	1848636
adrenoceptor	1848636
antagonism	1848636
by	1848636
metoprolol	1848636
.	1848636

The	1848636
drug	1848636
effect	1848636
studied	1848636
was	1848636
the	1848636
antagonism	1848636
by	1848636
metoprolol	1848636
of	1848636
terbutaline	1848636
-	1848636
induced	1848636
hypokalemia	1848636
.	1848636

By	1848636
using	1848636
pharmacokinetic	1848636
pharmacodynamic	1848636
modeling	1848636
the	1848636
pharmacodynamics	1848636
of	1848636
racemic	1848636
metoprolol	1848636
and	1848636
the	1848636
active	1848636
S	1848636
-	1848636
isomer	1848636
,	1848636
were	1848636
quantitated	1848636
in	1848636
EMs	1848636
and	1848636
PMs	1848636
in	1848636
terms	1848636
of	1848636
IC50	1848636
values	1848636
,	1848636
representing	1848636
metoprolol	1848636
plasma	1848636
concentrations	1848636
resulting	1848636
in	1848636
half	1848636
-	1848636
maximum	1848636
receptor	1848636
occupancy	1848636
.	1848636

Six	1848636
EMs	1848636
received	1848636
0	1848636
.	1848636
5	1848636
mg	1848636
of	1848636
terbutaline	1848636
s	1848636
.	1848636
c	1848636
.	1848636

on	1848636
two	1848636
different	1848636
occasions	1848636
:	1848636
1	1848636
)	1848636
1	1848636
hr	1848636
after	1848636
administration	1848636
of	1848636
a	1848636
placebo	1848636
and	1848636
2	1848636
)	1848636
1	1848636
hr	1848636
after	1848636
150	1848636
mg	1848636
of	1848636
metoprolol	1848636
p	1848636
.	1848636
o	1848636
.	1848636

Five	1848636
PMs	1848636
were	1848636
studied	1848636
according	1848636
to	1848636
the	1848636
same	1848636
protocol	1848636
,	1848636
except	1848636
for	1848636
a	1848636
higher	1848636
terbutaline	1848636
dose	1848636
(	1848636
0	1848636
.	1848636
75	1848636
mg	1848636
)	1848636
on	1848636
day	1848636
2	1848636
.	1848636

Blood	1848636
samples	1848636
for	1848636
the	1848636
analysis	1848636
of	1848636
plasma	1848636
potassium	1848636
,	1848636
terbutaline	1848636
,	1848636
metoprolol	1848636
(	1848636
racemic	1848636
,	1848636
R	1848636
-	1848636
and	1848636
S	1848636
-	1848636
isomer	1848636
)	1848636
,	1848636
and	1848636
alpha	1848636
-	1848636
hydroxymetoprolol	1848636
concentrations	1848636
were	1848636
taken	1848636
at	1848636
regular	1848636
time	1848636
intervals	1848636
,	1848636
during	1848636
8	1848636
hr	1848636
after	1848636
metoprolol	1848636
.	1848636

In	1848636
PMs	1848636
,	1848636
metoprolol	1848636
increased	1848636
the	1848636
terbutaline	1848636
area	1848636
under	1848636
the	1848636
plasma	1848636
concentration	1848636
vs	1848636
.	1848636

time	1848636
curve	1848636
(	1848636
+	1848636
67%	1848636
)	1848636
.	1848636

Higher	1848636
metoprolol	1848636
/	1848636
alpha	1848636
-	1848636
hydroxymetoprolol	1848636
ratios	1848636
in	1848636
PMs	1848636
were	1848636
predictive	1848636
for	1848636
higher	1848636
R	1848636
-	1848636
/	1848636
S	1848636
-	1848636
isomer	1848636
ratios	1848636
of	1848636
unchanged	1848636
drug	1848636
.	1848636

There	1848636
was	1848636
a	1848636
difference	1848636
in	1848636
metoprolol	1848636
potency	1848636
with	1848636
higher	1848636
racemic	1848636
metoprolol	1848636
IC50	1848636
values	1848636
in	1848636
PMs	1848636
(	1848636
72	1848636
+	1848636
/	1848636
-	1848636
7	1848636
ng	1848636
.	1848636
ml	1848636
-	1848636
1	1848636
)	1848636
than	1848636
EMs	1848636
(	1848636
42	1848636
+	1848636
/	1848636
-	1848636
8	1848636
ng	1848636
.	1848636
ml	1848636
-	1848636
1	1848636
,	1848636
P	1848636
less	1848636
than	1848636
.	1848636
001	1848636
)	1848636
.	1848636
(	1848636
ABSTRACT	1848636
TRUNCATED	1848636
AT	1848636
250	1848636
WORDS	1848636
)	1848636
Dexrazoxane	15897593
protects	15897593
against	15897593
myelosuppression	15897593
from	15897593
the	15897593
DNA	15897593
cleavage	15897593
-	15897593
enhancing	15897593
drugs	15897593
etoposide	15897593
and	15897593
daunorubicin	15897593
but	15897593
not	15897593
doxorubicin	15897593
.	15897593

PURPOSE	15897593
:	15897593
The	15897593
anthracyclines	15897593
daunorubicin	15897593
and	15897593
doxorubicin	15897593
and	15897593
the	15897593
epipodophyllotoxin	15897593
etoposide	15897593
are	15897593
potent	15897593
DNA	15897593
cleavage	15897593
-	15897593
enhancing	15897593
drugs	15897593
that	15897593
are	15897593
widely	15897593
used	15897593
in	15897593
clinical	15897593
oncology	15897593
;	15897593
however	15897593
,	15897593
myelosuppression	15897593
and	15897593
cardiac	15897593
toxicity	15897593
limit	15897593
their	15897593
use	15897593
.	15897593

Dexrazoxane	15897593
(	15897593
ICRF	15897593
-	15897593
187	15897593
)	15897593
is	15897593
recommended	15897593
for	15897593
protection	15897593
against	15897593
anthracycline	15897593
-	15897593
induced	15897593
cardiotoxicity	15897593
.	15897593

EXPERIMENTAL	15897593
DESIGN	15897593
:	15897593
Because	15897593
of	15897593
their	15897593
widespread	15897593
use	15897593
,	15897593
the	15897593
hematologic	15897593
toxicity	15897593
following	15897593
coadministration	15897593
of	15897593
dexrazoxane	15897593
and	15897593
these	15897593
three	15897593
structurally	15897593
different	15897593
DNA	15897593
cleavage	15897593
enhancers	15897593
was	15897593
investigated	15897593
:	15897593
Sensitivity	15897593
of	15897593
human	15897593
and	15897593
murine	15897593
blood	15897593
progenitor	15897593
cells	15897593
to	15897593
etoposide	15897593
,	15897593
daunorubicin	15897593
,	15897593
and	15897593
doxorubicin	15897593
+	15897593
/	15897593
-	15897593
dexrazoxane	15897593
was	15897593
determined	15897593
in	15897593
granulocyte	15897593
-	15897593
macrophage	15897593
colony	15897593
forming	15897593
assays	15897593
.	15897593

Likewise	15897593
,	15897593
in	15897593
vivo	15897593
,	15897593
B6D2F1	15897593
mice	15897593
were	15897593
treated	15897593
with	15897593
etoposide	15897593
,	15897593
daunorubicin	15897593
,	15897593
and	15897593
doxorubicin	15897593
,	15897593
with	15897593
or	15897593
without	15897593
dexrazoxane	15897593
over	15897593
a	15897593
wide	15897593
range	15897593
of	15897593
doses	15897593
:	15897593
posttreatment	15897593
,	15897593
a	15897593
full	15897593
hematologic	15897593
evaluation	15897593
was	15897593
done	15897593
.	15897593

RESULTS	15897593
:	15897593
Nontoxic	15897593
doses	15897593
of	15897593
dexrazoxane	15897593
reduced	15897593
myelosuppression	15897593
and	15897593
weight	15897593
loss	15897593
from	15897593
daunorubicin	15897593
and	15897593
etoposide	15897593
in	15897593
mice	15897593
and	15897593
antagonized	15897593
their	15897593
antiproliferative	15897593
effects	15897593
in	15897593
the	15897593
colony	15897593
assay	15897593
;	15897593
however	15897593
,	15897593
dexrazoxane	15897593
neither	15897593
reduced	15897593
myelosuppression	15897593
,	15897593
weight	15897593
loss	15897593
,	15897593
nor	15897593
the	15897593
in	15897593
vitro	15897593
cytotoxicity	15897593
from	15897593
doxorubicin	15897593
.	15897593

CONCLUSION	15897593
:	15897593
Although	15897593
our	15897593
findings	15897593
support	15897593
the	15897593
observation	15897593
that	15897593
dexrazoxane	15897593
reduces	15897593
neither	15897593
hematologic	15897593
activity	15897593
nor	15897593
antitumor	15897593
activity	15897593
from	15897593
doxorubicin	15897593
clinically	15897593
,	15897593
the	15897593
potent	15897593
antagonism	15897593
of	15897593
daunorubicin	15897593
activity	15897593
raises	15897593
concern	15897593
;	15897593
a	15897593
possible	15897593
interference	15897593
with	15897593
anticancer	15897593
efficacy	15897593
certainly	15897593
would	15897593
call	15897593
for	15897593
renewed	15897593
attention	15897593
.	15897593

Our	15897593
data	15897593
also	15897593
suggest	15897593
that	15897593
significant	15897593
etoposide	15897593
dose	15897593
escalation	15897593
is	15897593
perhaps	15897593
possible	15897593
by	15897593
the	15897593
use	15897593
of	15897593
dexrazoxane	15897593
.	15897593

Clinical	15897593
trials	15897593
in	15897593
patients	15897593
with	15897593
brain	15897593
metastases	15897593
combining	15897593
dexrazoxane	15897593
and	15897593
high	15897593
doses	15897593
of	15897593
etoposide	15897593
is	15897593
ongoing	15897593
with	15897593
the	15897593
aim	15897593
of	15897593
improving	15897593
efficacy	15897593
without	15897593
aggravating	15897593
hematologic	15897593
toxicity	15897593
.	15897593

If	15897593
successful	15897593
,	15897593
this	15897593
represents	15897593
an	15897593
exciting	15897593
mechanism	15897593
for	15897593
pharmacologic	15897593
regulation	15897593
of	15897593
side	15897593
effects	15897593
from	15897593
cytotoxic	15897593
chemotherapy	15897593
.	15897593
GATA4	18672102
mutations	18672102
in	18672102
486	18672102
Chinese	18672102
patients	18672102
with	18672102
congenital	18672102
heart	18672102
disease	18672102
.	18672102

Recent	18672102
studies	18672102
have	18672102
reported	18672102
germline	18672102
mutations	18672102
in	18672102
GATA4	18672102
gene	18672102
in	18672102
some	18672102
types	18672102
of	18672102
congenital	18672102
heart	18672102
disease	18672102
(	18672102
CHD	18672102
)	18672102
.	18672102

However	18672102
,	18672102
the	18672102
prevalence	18672102
of	18672102
GATA4	18672102
mutations	18672102
in	18672102
CHD	18672102
and	18672102
the	18672102
correlation	18672102
between	18672102
the	18672102
GATA4	18672102
genotype	18672102
and	18672102
CHD	18672102
phenotype	18672102
have	18672102
not	18672102
been	18672102
extensively	18672102
studied	18672102
.	18672102

We	18672102
screened	18672102
germline	18672102
mutations	18672102
in	18672102
the	18672102
coding	18672102
exons	18672102
and	18672102
the	18672102
flanking	18672102
intron	18672102
sequences	18672102
of	18672102
the	18672102
GATA4	18672102
gene	18672102
in	18672102
486	18672102
CHD	18672102
patients	18672102
by	18672102
denaturing	18672102
high	18672102
-	18672102
performance	18672102
liquid	18672102
chromatography	18672102
(	18672102
DHPLC	18672102
)	18672102
,	18672102
and	18672102
confirmed	18672102
the	18672102
mutations	18672102
by	18672102
sequencing	18672102
.	18672102

Nine	18672102
distinct	18672102
mutations	18672102
including	18672102
one	18672102
small	18672102
deletion	18672102
mutation	18672102
(	18672102
46delS	18672102
)	18672102
,	18672102
two	18672102
small	18672102
insertion	18672102
mutations	18672102
(	18672102
118	18672102
-	18672102
119insA	18672102
and	18672102
125	18672102
-	18672102
126insAA	18672102
)	18672102
,	18672102
and	18672102
six	18672102
non	18672102
-	18672102
synonymous	18672102
mutations	18672102
(	18672102
A6V	18672102
,	18672102
P163S	18672102
,	18672102
E359K	18672102
,	18672102
P407Q	18672102
,	18672102
S429T	18672102
and	18672102
A442V	18672102
)	18672102
were	18672102
identified	18672102
in	18672102
12	18672102
of	18672102
the	18672102
486	18672102
patients	18672102
(	18672102
nine	18672102
with	18672102
ventricular	18672102
septal	18672102
defect	18672102
,	18672102
two	18672102
with	18672102
Tetralogy	18672102
of	18672102
Fallot	18672102
,	18672102
and	18672102
one	18672102
with	18672102
endocardial	18672102
cushion	18672102
defect	18672102
)	18672102
.	18672102

Of	18672102
them	18672102
,	18672102
two	18672102
patients	18672102
carrying	18672102
E359K	18672102
mutation	18672102
were	18672102
from	18672102
two	18672102
generations	18672102
in	18672102
one	18672102
family	18672102
with	18672102
ventricular	18672102
septal	18672102
defect	18672102
(	18672102
VSD	18672102
)	18672102
.	18672102

Interestingly	18672102
,	18672102
a	18672102
nucleotide	18672102
insertion	18672102
of	18672102
c	18672102
.	18672102
1146	18672102
+	18672102
25insA	18672102
in	18672102
exon	18672102
6	18672102
was	18672102
detected	18672102
in	18672102
five	18672102
VSD	18672102
patients	18672102
,	18672102
but	18672102
not	18672102
in	18672102
486	18672102
normal	18672102
healthy	18672102
controls	18672102
.	18672102

Our	18672102
findings	18672102
are	18672102
useful	18672102
in	18672102
understanding	18672102
the	18672102
prevalence	18672102
of	18672102
GATA4	18672102
mutations	18672102
and	18672102
the	18672102
correlation	18672102
between	18672102
the	18672102
GATA4	18672102
genotype	18672102
and	18672102
the	18672102
CHD	18672102
phenotype	18672102
in	18672102
Chinese	18672102
patients	18672102
.	18672102
Two	20534762
novel	20534762
mutations	20534762
of	20534762
the	20534762
TSH	20534762
-	20534762
beta	20534762
subunit	20534762
gene	20534762
underlying	20534762
congenital	20534762
central	20534762
hypothyroidism	20534762
undetectable	20534762
in	20534762
neonatal	20534762
TSH	20534762
screening	20534762
.	20534762

CONTEXT	20534762
:	20534762
Patients	20534762
with	20534762
TSH	20534762
-	20534762
beta	20534762
subunit	20534762
defects	20534762
and	20534762
congenital	20534762
hypothyroidism	20534762
are	20534762
missed	20534762
by	20534762
TSH	20534762
-	20534762
based	20534762
neonatal	20534762
screening	20534762
.	20534762

OBJECTIVE	20534762
:	20534762
Our	20534762
objective	20534762
was	20534762
to	20534762
report	20534762
the	20534762
molecular	20534762
consequences	20534762
of	20534762
a	20534762
novel	20534762
splice	20534762
-	20534762
junction	20534762
mutation	20534762
and	20534762
a	20534762
novel	20534762
missense	20534762
mutation	20534762
in	20534762
the	20534762
TSH	20534762
-	20534762
beta	20534762
subunit	20534762
gene	20534762
found	20534762
in	20534762
two	20534762
patients	20534762
with	20534762
congenital	20534762
central	20534762
hypothyroidism	20534762
and	20534762
conventional	20534762
treatment	20534762
-	20534762
resistant	20534762
anemia	20534762
.	20534762

RESULTS	20534762
:	20534762
Patient	20534762
1	20534762
had	20534762
a	20534762
homozygous	20534762
G	20534762
to	20534762
A	20534762
nucleotide	20534762
change	20534762
at	20534762
the	20534762
5	20534762
'	20534762
donor	20534762
splice	20534762
site	20534762
of	20534762
exon	20534762
/	20534762
intron	20534762
2	20534762
.	20534762

This	20534762
resulted	20534762
in	20534762
a	20534762
silent	20534762
change	20534762
at	20534762
codon	20534762
34	20534762
of	20534762
the	20534762
mature	20534762
protein	20534762
.	20534762

In	20534762
vitro	20534762
splicing	20534762
assays	20534762
showed	20534762
that	20534762
the	20534762
mutant	20534762
minigene	20534762
dramatically	20534762
affected	20534762
pre	20534762
-	20534762
mRNA	20534762
processing	20534762
,	20534762
causing	20534762
exon	20534762
2	20534762
to	20534762
be	20534762
completely	20534762
skipped	20534762
.	20534762

The	20534762
putative	20534762
product	20534762
from	20534762
a	20534762
new	20534762
out	20534762
-	20534762
of	20534762
-	20534762
frame	20534762
translational	20534762
start	20534762
point	20534762
in	20534762
exon	20534762
3	20534762
is	20534762
expected	20534762
to	20534762
yield	20534762
a	20534762
nonsense	20534762
25	20534762
-	20534762
amino	20534762
-	20534762
acid	20534762
peptide	20534762
.	20534762

In	20534762
patient	20534762
2	20534762
,	20534762
sequence	20534762
analysis	20534762
revealed	20534762
a	20534762
compound	20534762
heterozygosis	20534762
for	20534762
the	20534762
already	20534762
reported	20534762
313delT	20534762
(	20534762
C105Vfs114X	20534762
)	20534762
mutation	20534762
and	20534762
for	20534762
a	20534762
second	20534762
novel	20534762
mutation	20534762
in	20534762
exon	20534762
3	20534762
,	20534762
substituting	20534762
G	20534762
for	20534762
A	20534762
at	20534762
cDNA	20534762
nucleotide	20534762
position	20534762
323	20534762
,	20534762
resulting	20534762
in	20534762
a	20534762
C88Y	20534762
change	20534762
.	20534762

This	20534762
cysteine	20534762
residue	20534762
is	20534762
conserved	20534762
among	20534762
all	20534762
dimeric	20534762
pituitary	20534762
and	20534762
placental	20534762
glycoprotein	20534762
hormone	20534762
-	20534762
beta	20534762
subunits	20534762
.	20534762

Data	20534762
from	20534762
in	20534762
silico	20534762
analysis	20534762
confirmed	20534762
that	20534762
the	20534762
C88Y	20534762
mutation	20534762
would	20534762
affect	20534762
subunit	20534762
conformation	20534762
.	20534762

Indeed	20534762
,	20534762
two	20534762
different	20534762
bioinformatics	20534762
approaches	20534762
,	20534762
PolyPhen	20534762
and	20534762
SIFT	20534762
analysis	20534762
,	20534762
predicted	20534762
C88Y	20534762
to	20534762
be	20534762
a	20534762
damaging	20534762
substitution	20534762
.	20534762

CONCLUSIONS	20534762
:	20534762
In	20534762
isolated	20534762
TSH	20534762
deficiency	20534762
,	20534762
the	20534762
exact	20534762
molecular	20534762
diagnosis	20534762
is	20534762
mandatory	20534762
for	20534762
diagnosis	20534762
of	20534762
isolated	20534762
pituitary	20534762
deficiency	20534762
,	20534762
delineation	20534762
of	20534762
prognosis	20534762
,	20534762
and	20534762
genetic	20534762
counseling	20534762
.	20534762

Moreover	20534762
,	20534762
diagnosis	20534762
of	20534762
central	20534762
hypothyroidism	20534762
should	20534762
be	20534762
considered	20534762
in	20534762
the	20534762
face	20534762
of	20534762
severe	20534762
infant	20534762
anemia	20534762
of	20534762
uncertain	20534762
etiology	20534762
.	20534762
Characterization	25054547
of	25054547
a	25054547
novel	25054547
BCHE	25054547
""""	25054547
silent	25054547
""""	25054547
allele	25054547
:	25054547
point	25054547
mutation	25054547
(	25054547
p	25054547
.	25054547
Val204Asp	25054547
)	25054547
causes	25054547
loss	25054547
of	25054547
activity	25054547
and	25054547
prolonged	25054547
apnea	25054547
with	25054547
suxamethonium	25054547
.	25054547

Butyrylcholinesterase	25054547
deficiency	25054547
is	25054547
characterized	25054547
by	25054547
prolonged	25054547
apnea	25054547
after	25054547
the	25054547
use	25054547
of	25054547
muscle	25054547
relaxants	25054547
(	25054547
suxamethonium	25054547
or	25054547
mivacurium	25054547
)	25054547
in	25054547
patients	25054547
who	25054547
have	25054547
mutations	25054547
in	25054547
the	25054547
BCHE	25054547
gene	25054547
.	25054547

Here	25054547
,	25054547
we	25054547
report	25054547
a	25054547
case	25054547
of	25054547
prolonged	25054547
neuromuscular	25054547
block	25054547
after	25054547
administration	25054547
of	25054547
suxamethonium	25054547
leading	25054547
to	25054547
the	25054547
discovery	25054547
of	25054547
a	25054547
novel	25054547
BCHE	25054547
variant	25054547
(	25054547
c	25054547
.	25054547
695T	25054547
>	25054547
A	25054547
,	25054547
p	25054547
.	25054547
Val204Asp	25054547
)	25054547
.	25054547

Inhibition	25054547
studies	25054547
,	25054547
kinetic	25054547
analysis	25054547
and	25054547
molecular	25054547
dynamics	25054547
were	25054547
undertaken	25054547
to	25054547
understand	25054547
how	25054547
this	25054547
mutation	25054547
disrupts	25054547
the	25054547
catalytic	25054547
triad	25054547
and	25054547
determines	25054547
a	25054547
""""	25054547
silent	25054547
""""	25054547
phenotype	25054547
.	25054547

Low	25054547
activity	25054547
of	25054547
patient	25054547
plasma	25054547
butyrylcholinesterase	25054547
with	25054547
butyrylthiocholine	25054547
(	25054547
BTC	25054547
)	25054547
and	25054547
benzoylcholine	25054547
,	25054547
and	25054547
values	25054547
of	25054547
dibucaine	25054547
and	25054547
fluoride	25054547
numbers	25054547
fit	25054547
with	25054547
heterozygous	25054547
atypical	25054547
silent	25054547
genotype	25054547
.	25054547

Electrophoretic	25054547
analysis	25054547
of	25054547
plasma	25054547
BChE	25054547
of	25054547
the	25054547
proband	25054547
and	25054547
his	25054547
mother	25054547
showed	25054547
that	25054547
patient	25054547
has	25054547
a	25054547
reduced	25054547
amount	25054547
of	25054547
tetrameric	25054547
enzyme	25054547
in	25054547
plasma	25054547
and	25054547
that	25054547
minor	25054547
fast	25054547
-	25054547
moving	25054547
BChE	25054547
components	25054547
:	25054547
monomer	25054547
,	25054547
dimer	25054547
,	25054547
and	25054547
monomer	25054547
-	25054547
albumin	25054547
conjugate	25054547
are	25054547
missing	25054547
.	25054547

Kinetic	25054547
analysis	25054547
showed	25054547
that	25054547
the	25054547
p	25054547
.	25054547
Val204Asp	25054547
/	25054547
p	25054547
.	25054547
Asp70Gly	25054547
-	25054547
p	25054547
.	25054547
Ala539Thr	25054547
BChE	25054547
displays	25054547
a	25054547
pure	25054547
Michaelian	25054547
behavior	25054547
with	25054547
BTC	25054547
as	25054547
the	25054547
substrate	25054547
.	25054547

Both	25054547
catalytic	25054547
parameters	25054547
Km	25054547
=	25054547
265	25054547
uM	25054547
for	25054547
BTC	25054547
,	25054547
two	25054547
times	25054547
higher	25054547
than	25054547
that	25054547
of	25054547
the	25054547
atypical	25054547
enzyme	25054547
,	25054547
and	25054547
a	25054547
low	25054547
Vmax	25054547
are	25054547
consistent	25054547
with	25054547
the	25054547
absence	25054547
of	25054547
activity	25054547
against	25054547
suxamethonium	25054547
.	25054547

Molecular	25054547
dynamic	25054547
(	25054547
MD	25054547
)	25054547
simulations	25054547
showed	25054547
that	25054547
the	25054547
overall	25054547
effect	25054547
of	25054547
the	25054547
mutation	25054547
p	25054547
.	25054547
Val204Asp	25054547
is	25054547
disruption	25054547
of	25054547
hydrogen	25054547
bonding	25054547
between	25054547
Gln223	25054547
and	25054547
Glu441	25054547
,	25054547
leading	25054547
Ser198	25054547
and	25054547
His438	25054547
to	25054547
move	25054547
away	25054547
from	25054547
each	25054547
other	25054547
with	25054547
subsequent	25054547
disruption	25054547
of	25054547
the	25054547
catalytic	25054547
triad	25054547
functionality	25054547
regardless	25054547
of	25054547
the	25054547
type	25054547
of	25054547
substrate	25054547
.	25054547

MD	25054547
also	25054547
showed	25054547
that	25054547
the	25054547
enzyme	25054547
volume	25054547
is	25054547
increased	25054547
,	25054547
suggesting	25054547
a	25054547
pre	25054547
-	25054547
denaturation	25054547
state	25054547
.	25054547

This	25054547
fits	25054547
with	25054547
the	25054547
reduced	25054547
concentration	25054547
of	25054547
p	25054547
.	25054547
Ala204Asp	25054547
/	25054547
p	25054547
.	25054547
Asp70Gly	25054547
-	25054547
p	25054547
.	25054547
Ala539Thr	25054547
tetrameric	25054547
enzyme	25054547
in	25054547
the	25054547
plasma	25054547
and	25054547
non	25054547
-	25054547
detectable	25054547
fast	25054547
moving	25054547
-	25054547
bands	25054547
on	25054547
electrophoresis	25054547
gels	25054547
.	25054547
The	16288199
promoter	16288199
of	16288199
inducible	16288199
nitric	16288199
oxide	16288199
synthase	16288199
implicated	16288199
in	16288199
glaucoma	16288199
based	16288199
on	16288199
genetic	16288199
analysis	16288199
and	16288199
nuclear	16288199
factor	16288199
binding	16288199
.	16288199

PURPOSE	16288199
:	16288199
Nitric	16288199
oxide	16288199
has	16288199
many	16288199
beneficial	16288199
functions	16288199
in	16288199
the	16288199
human	16288199
body	16288199
at	16288199
the	16288199
right	16288199
amounts	16288199
,	16288199
but	16288199
it	16288199
can	16288199
also	16288199
be	16288199
hazardous	16288199
if	16288199
it	16288199
is	16288199
produced	16288199
in	16288199
amounts	16288199
more	16288199
than	16288199
needed	16288199
and	16288199
has	16288199
therefore	16288199
been	16288199
studied	16288199
in	16288199
relation	16288199
to	16288199
several	16288199
neurological	16288199
and	16288199
non	16288199
-	16288199
neurological	16288199
disorders	16288199
.	16288199

In	16288199
vitro	16288199
and	16288199
in	16288199
vivo	16288199
studies	16288199
demonstrate	16288199
a	16288199
connection	16288199
between	16288199
the	16288199
inducible	16288199
form	16288199
of	16288199
Nitric	16288199
Oxide	16288199
Synthase	16288199
,	16288199
iNOS	16288199
,	16288199
and	16288199
the	16288199
neuropathological	16288199
disorder	16288199
glaucoma	16288199
,	16288199
one	16288199
of	16288199
the	16288199
major	16288199
causes	16288199
of	16288199
blindness	16288199
in	16288199
the	16288199
world	16288199
.	16288199

In	16288199
this	16288199
study	16288199
,	16288199
we	16288199
sought	16288199
to	16288199
establish	16288199
the	16288199
genetic	16288199
association	16288199
between	16288199
iNOS	16288199
and	16288199
primary	16288199
open	16288199
angle	16288199
glaucoma	16288199
,	16288199
POAG	16288199
,	16288199
and	16288199
to	16288199
find	16288199
the	16288199
functional	16288199
element	16288199
(	16288199
s	16288199
)	16288199
connected	16288199
with	16288199
the	16288199
pathogenesis	16288199
of	16288199
the	16288199
disease	16288199
.	16288199

METHODS	16288199
:	16288199
Two	16288199
microsatellites	16288199
,	16288199
1	16288199
insertion	16288199
/	16288199
deletion	16288199
,	16288199
and	16288199
8	16288199
single	16288199
nucleotide	16288199
polymorphisms	16288199
(	16288199
SNPs	16288199
)	16288199
in	16288199
the	16288199
regulatory	16288199
region	16288199
of	16288199
iNOS	16288199
were	16288199
genotyped	16288199
in	16288199
200	16288199
POAG	16288199
patients	16288199
and	16288199
200	16288199
age	16288199
-	16288199
matched	16288199
controls	16288199
.	16288199

Also	16288199
,	16288199
the	16288199
CCTTT	16288199
-	16288199
microsatellite	16288199
was	16288199
examined	16288199
for	16288199
its	16288199
protein	16288199
-	16288199
binding	16288199
capability	16288199
in	16288199
an	16288199
electrophoretic	16288199
mobility	16288199
shift	16288199
assay	16288199
,	16288199
EMSA	16288199
.	16288199

RESULTS	16288199
:	16288199
There	16288199
was	16288199
a	16288199
significant	16288199
difference	16288199
in	16288199
allele	16288199
distribution	16288199
of	16288199
the	16288199
CCTTT	16288199
-	16288199
microsatellite	16288199
,	16288199
between	16288199
patients	16288199
and	16288199
controls	16288199
.	16288199

(	16288199
CCTTT	16288199
)	16288199
14	16288199
,	16288199
which	16288199
has	16288199
been	16288199
reported	16288199
to	16288199
have	16288199
a	16288199
higher	16288199
activity	16288199
in	16288199
a	16288199
reporter	16288199
-	16288199
construct	16288199
,	16288199
was	16288199
significantly	16288199
more	16288199
abundant	16288199
in	16288199
POAG	16288199
patients	16288199
,	16288199
while	16288199
(	16288199
CCTTT	16288199
)	16288199
10	16288199
and	16288199
(	16288199
CCTTT	16288199
)	16288199
13	16288199
were	16288199
less	16288199
common	16288199
.	16288199

In	16288199
EMSA	16288199
,	16288199
the	16288199
(	16288199
CCTTT	16288199
)	16288199
14	16288199
allele	16288199
exhibited	16288199
specific	16288199
binding	16288199
of	16288199
nuclear	16288199
proteins	16288199
.	16288199

CONCLUSIONS	16288199
:	16288199
These	16288199
results	16288199
,	16288199
together	16288199
with	16288199
other	16288199
studies	16288199
on	16288199
this	16288199
gene	16288199
and	16288199
the	16288199
CCTTT	16288199
-	16288199
microsatellite	16288199
,	16288199
establish	16288199
,	16288199
for	16288199
the	16288199
first	16288199
time	16288199
,	16288199
a	16288199
genetic	16288199
association	16288199
of	16288199
iNOS	16288199
with	16288199
POAG	16288199
and	16288199
suggest	16288199
a	16288199
regulatory	16288199
function	16288199
for	16288199
the	16288199
microsatellite	16288199
.	16288199
Severe	15191352
form	15191352
of	15191352
thyroid	15191352
hormone	15191352
resistance	15191352
in	15191352
a	15191352
patient	15191352
with	15191352
homozygous	15191352
/	15191352
hemizygous	15191352
mutation	15191352
of	15191352
T3	15191352
receptor	15191352
gene	15191352
.	15191352

Resistance	15191352
to	15191352
thyroid	15191352
hormone	15191352
syndrome	15191352
(	15191352
RTH	15191352
)	15191352
is	15191352
a	15191352
rare	15191352
disorder	15191352
,	15191352
usually	15191352
inherited	15191352
as	15191352
an	15191352
autosomal	15191352
dominant	15191352
trait	15191352
.	15191352

Patients	15191352
with	15191352
RTH	15191352
are	15191352
usually	15191352
euthyroid	15191352
but	15191352
can	15191352
occasionally	15191352
present	15191352
with	15191352
signs	15191352
and	15191352
symptoms	15191352
of	15191352
thyrotoxicosis	15191352
or	15191352
rarely	15191352
with	15191352
hypothyroidism	15191352
.	15191352

Affected	15191352
individuals	15191352
are	15191352
usually	15191352
heterozygous	15191352
for	15191352
mutations	15191352
in	15191352
the	15191352
thyroid	15191352
hormone	15191352
receptor	15191352
beta	15191352
gene	15191352
(	15191352
TR	15191352
-	15191352
beta	15191352
)	15191352
.	15191352

We	15191352
present	15191352
a	15191352
patient	15191352
with	15191352
RTH	15191352
found	15191352
to	15191352
be	15191352
homo	15191352
-	15191352
/	15191352
hemizygous	15191352
for	15191352
a	15191352
mutation	15191352
in	15191352
the	15191352
TR	15191352
-	15191352
beta	15191352
gene	15191352
.	15191352

The	15191352
single	15191352
nucleotide	15191352
substitution	15191352
I280S	15191352
(	15191352
1123T	15191352
-	15191352
-	15191352
>	15191352
G	15191352
)	15191352
was	15191352
present	15191352
either	15191352
on	15191352
both	15191352
alleles	15191352
or	15191352
in	15191352
a	15191352
hemizygous	15191352
form	15191352
with	15191352
complete	15191352
deletion	15191352
of	15191352
the	15191352
second	15191352
allele	15191352
.	15191352

The	15191352
I280S	15191352
mutation	15191352
was	15191352
recently	15191352
reported	15191352
in	15191352
a	15191352
heterozygous	15191352
patient	15191352
.	15191352

The	15191352
severe	15191352
phenotype	15191352
with	15191352
seriously	15191352
impaired	15191352
intellectual	15191352
development	15191352
,	15191352
hyperkinetic	15191352
behaviour	15191352
,	15191352
tachycardia	15191352
,	15191352
hearing	15191352
and	15191352
visual	15191352
impairment	15191352
is	15191352
probably	15191352
due	15191352
to	15191352
the	15191352
dominant	15191352
negative	15191352
effect	15191352
of	15191352
the	15191352
I280S	15191352
mutant	15191352
protein	15191352
and	15191352
the	15191352
absence	15191352
of	15191352
any	15191352
functional	15191352
TR	15191352
-	15191352
beta	15191352
.	15191352
The	25550469
androgen	25550469
receptor	25550469
confers	25550469
protection	25550469
against	25550469
diet	25550469
-	25550469
induced	25550469
atherosclerosis	25550469
,	25550469
obesity	25550469
,	25550469
and	25550469
dyslipidemia	25550469
in	25550469
female	25550469
mice	25550469
.	25550469

Androgens	25550469
have	25550469
important	25550469
cardiometabolic	25550469
actions	25550469
in	25550469
males	25550469
,	25550469
but	25550469
their	25550469
metabolic	25550469
role	25550469
in	25550469
females	25550469
is	25550469
unclear	25550469
.	25550469

To	25550469
determine	25550469
the	25550469
physiologic	25550469
androgen	25550469
receptor	25550469
(	25550469
AR	25550469
)	25550469
-	25550469
dependent	25550469
actions	25550469
of	25550469
androgens	25550469
on	25550469
atherogenesis	25550469
in	25550469
female	25550469
mice	25550469
,	25550469
we	25550469
generated	25550469
female	25550469
AR	25550469
-	25550469
knockout	25550469
(	25550469
ARKO	25550469
)	25550469
mice	25550469
on	25550469
an	25550469
atherosclerosis	25550469
-	25550469
prone	25550469
apolipoprotein	25550469
E	25550469
(	25550469
apoE	25550469
)	25550469
-	25550469
deficient	25550469
background	25550469
.	25550469

After	25550469
8	25550469
weeks	25550469
on	25550469
a	25550469
high	25550469
-	25550469
fat	25550469
diet	25550469
,	25550469
but	25550469
not	25550469
on	25550469
a	25550469
normal	25550469
chow	25550469
diet	25550469
,	25550469
atherosclerosis	25550469
in	25550469
aorta	25550469
was	25550469
increased	25550469
in	25550469
ARKO	25550469
females	25550469
(	25550469
+	25550469
59%	25550469
vs	25550469
.	25550469

control	25550469
apoE	25550469
-	25550469
deficient	25550469
mice	25550469
with	25550469
intact	25550469
AR	25550469
gene	25550469
)	25550469
.	25550469

They	25550469
also	25550469
displayed	25550469
increased	25550469
body	25550469
weight	25550469
(	25550469
+	25550469
18%	25550469
)	25550469
,	25550469
body	25550469
fat	25550469
percentage	25550469
(	25550469
+	25550469
62%	25550469
)	25550469
,	25550469
and	25550469
hepatic	25550469
triglyceride	25550469
levels	25550469
,	25550469
reduced	25550469
insulin	25550469
sensitivity	25550469
,	25550469
and	25550469
a	25550469
marked	25550469
atherogenic	25550469
dyslipidemia	25550469
(	25550469
serum	25550469
cholesterol	25550469
,	25550469
+	25550469
52%	25550469
)	25550469
.	25550469

Differences	25550469
in	25550469
atherosclerosis	25550469
,	25550469
body	25550469
weight	25550469
,	25550469
and	25550469
lipid	25550469
levels	25550469
between	25550469
ARKO	25550469
and	25550469
control	25550469
mice	25550469
were	25550469
abolished	25550469
in	25550469
mice	25550469
that	25550469
were	25550469
ovariectomized	25550469
before	25550469
puberty	25550469
,	25550469
consistent	25550469
with	25550469
a	25550469
protective	25550469
action	25550469
of	25550469
ovarian	25550469
androgens	25550469
mediated	25550469
via	25550469
the	25550469
AR	25550469
.	25550469

Furthermore	25550469
,	25550469
the	25550469
AR	25550469
agonist	25550469
dihydrotestosterone	25550469
reduced	25550469
atherosclerosis	25550469
(	25550469
-	25550469
41%	25550469
;	25550469
thoracic	25550469
aorta	25550469
)	25550469
,	25550469
subcutaneous	25550469
fat	25550469
mass	25550469
(	25550469
-	25550469
44%	25550469
)	25550469
,	25550469
and	25550469
cholesterol	25550469
levels	25550469
(	25550469
-	25550469
35%	25550469
)	25550469
in	25550469
ovariectomized	25550469
mice	25550469
,	25550469
reduced	25550469
hepatocyte	25550469
lipid	25550469
accumulation	25550469
in	25550469
hepatoma	25550469
cells	25550469
in	25550469
vitro	25550469
,	25550469
and	25550469
regulated	25550469
mRNA	25550469
expression	25550469
of	25550469
hepatic	25550469
genes	25550469
pivotal	25550469
for	25550469
lipid	25550469
homeostasis	25550469
.	25550469

In	25550469
conclusion	25550469
,	25550469
we	25550469
demonstrate	25550469
that	25550469
the	25550469
AR	25550469
protects	25550469
against	25550469
diet	25550469
-	25550469
induced	25550469
atherosclerosis	25550469
in	25550469
female	25550469
mice	25550469
and	25550469
propose	25550469
that	25550469
this	25550469
is	25550469
mediated	25550469
by	25550469
modulation	25550469
of	25550469
body	25550469
composition	25550469
and	25550469
lipid	25550469
metabolism	25550469
.	25550469
Macular	19365571
corneal	19365571
dystrophy	19365571
in	19365571
a	19365571
Chinese	19365571
family	19365571
related	19365571
with	19365571
novel	19365571
mutations	19365571
of	19365571
CHST6	19365571
.	19365571

PURPOSE	19365571
:	19365571
To	19365571
identify	19365571
mutations	19365571
in	19365571
the	19365571
carbohydrate	19365571
sulfotransferase	19365571
gene	19365571
(	19365571
CHST6	19365571
)	19365571
for	19365571
a	19365571
Chinese	19365571
family	19365571
with	19365571
macular	19365571
corneal	19365571
dystrophy	19365571
(	19365571
MCD	19365571
)	19365571
and	19365571
to	19365571
investigate	19365571
the	19365571
histopathological	19365571
changes	19365571
in	19365571
the	19365571
affected	19365571
cornea	19365571
.	19365571

METHODS	19365571
:	19365571
A	19365571
corneal	19365571
button	19365571
of	19365571
the	19365571
proband	19365571
was	19365571
obtained	19365571
by	19365571
penetrating	19365571
keratoplasty	19365571
.	19365571

The	19365571
half	19365571
button	19365571
and	19365571
ultrathin	19365571
sections	19365571
from	19365571
the	19365571
other	19365571
half	19365571
button	19365571
were	19365571
examined	19365571
with	19365571
special	19365571
stains	19365571
under	19365571
a	19365571
light	19365571
microscope	19365571
(	19365571
LM	19365571
)	19365571
and	19365571
an	19365571
electron	19365571
microscope	19365571
(	19365571
EM	19365571
)	19365571
separately	19365571
.	19365571

Genomic	19365571
DNA	19365571
was	19365571
extracted	19365571
from	19365571
peripheral	19365571
blood	19365571
of	19365571
11	19365571
family	19365571
members	19365571
,	19365571
and	19365571
the	19365571
coding	19365571
region	19365571
of	19365571
CHST6	19365571
was	19365571
amplified	19365571
by	19365571
the	19365571
polymerase	19365571
chain	19365571
reaction	19365571
(	19365571
PCR	19365571
)	19365571
method	19365571
.	19365571

The	19365571
PCR	19365571
products	19365571
were	19365571
analyzed	19365571
by	19365571
direct	19365571
sequencing	19365571
and	19365571
restriction	19365571
enzyme	19365571
digestion	19365571
.	19365571

RESULTS	19365571
:	19365571
The	19365571
positive	19365571
reaction	19365571
to	19365571
colloidal	19365571
iron	19365571
stain	19365571
(	19365571
extracellular	19365571
blue	19365571
accumulations	19365571
in	19365571
the	19365571
stroma	19365571
)	19365571
was	19365571
detected	19365571
under	19365571
light	19365571
microscopy	19365571
.	19365571

Transmission	19365571
electron	19365571
microscopy	19365571
revealed	19365571
the	19365571
enlargement	19365571
of	19365571
smooth	19365571
endoplasmic	19365571
reticulum	19365571
and	19365571
the	19365571
presence	19365571
of	19365571
intracytoplasmic	19365571
vacuoles	19365571
.	19365571

The	19365571
compound	19365571
heterozygous	19365571
mutations	19365571
,	19365571
c	19365571
.	19365571
892C	19365571
>	19365571
T	19365571
and	19365571
c	19365571
.	19365571
1072T	19365571
>	19365571
C	19365571
,	19365571
were	19365571
identified	19365571
in	19365571
exon	19365571
3	19365571
of	19365571
CHST6	19365571
in	19365571
three	19365571
patients	19365571
.	19365571

The	19365571
two	19365571
transversions	19365571
resulted	19365571
in	19365571
the	19365571
substitution	19365571
of	19365571
a	19365571
stop	19365571
codon	19365571
for	19365571
glutamine	19365571
at	19365571
codon	19365571
298	19365571
(	19365571
p	19365571
.	19365571
Q298X	19365571
)	19365571
and	19365571
a	19365571
missense	19365571
mutation	19365571
at	19365571
codon	19365571
358	19365571
,	19365571
tyrosine	19365571
to	19365571
histidine	19365571
(	19365571
p	19365571
.	19365571
Y358H	19365571
)	19365571
.	19365571

The	19365571
six	19365571
unaffected	19365571
family	19365571
individuals	19365571
carried	19365571
alternative	19365571
heterozygous	19365571
mutations	19365571
.	19365571

These	19365571
two	19365571
mutations	19365571
were	19365571
not	19365571
detected	19365571
in	19365571
any	19365571
of	19365571
the	19365571
100	19365571
control	19365571
subjects	19365571
.	19365571

CONCLUSIONS	19365571
:	19365571
Those	19365571
novel	19365571
compound	19365571
heterozygous	19365571
mutations	19365571
were	19365571
thought	19365571
to	19365571
contribute	19365571
to	19365571
the	19365571
loss	19365571
of	19365571
CHST6	19365571
function	19365571
,	19365571
which	19365571
induced	19365571
the	19365571
abnormal	19365571
metabolism	19365571
of	19365571
keratan	19365571
sulfate	19365571
(	19365571
KS	19365571
)	19365571
that	19365571
deposited	19365571
in	19365571
the	19365571
corneal	19365571
stroma	19365571
.	19365571

It	19365571
could	19365571
be	19365571
proved	19365571
by	19365571
the	19365571
observation	19365571
of	19365571
a	19365571
positive	19365571
stain	19365571
reaction	19365571
and	19365571
the	19365571
enlarged	19365571
collagen	19365571
fibers	19365571
as	19365571
well	19365571
as	19365571
hyperplastic	19365571
fibroblasts	19365571
under	19365571
microscopes	19365571
.	19365571
